rank|status|study|conditions|interventions|study_type|phase|funder_type|outcome_measures|number_enrolled|nct_number|start_date
1|Recruiting|The Use of Integra in Coverage of Radial Forearm Free Flap Donor Site Defect||Device:IntegraplusSTSG;  Procedure:STSG|Interventional||Other|Donor site aesthetic quality on Vancouver Scar Scale;  Donor site functional outcomes as measured by hand strength and Range of Motion|100|NCT02980601|November 2015
2|Recruiting|Study of the Efficacy Safety &amp; Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury||Drug:Serlopitant;  Drug:Placebo|Interventional|Phase 2|Industry|ItchIntensity-NumericRatingScale;  ChangeinItchIntensity-NumericRatingScale|150|NCT02975271|November 2016
3|Recruiting|Study of the Efficacy Safety and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis||Drug:SerlopitantHighDose;  Drug:PlaceboOralTablet;  Drug:SerlopitantLowDose|Interventional|Phase 2|Industry|ItchIntensity-NumericRatingScale;  ChangeinItchIntensity-NumericRatingScale|450|NCT02975206|November 2016
4|Recruiting|DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis||Biological:BotulinumToxinsTypeA;  Biological:Placebos|Interventional|Phase 2|Industry / Other|Improvement in the American Orthopaedic Foot and Ankle Score (AOFAS);  Reduction in the visual analog pain score for the foot|60|NCT02973269|November 2016
5|Not yet recruiting|Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma||Other:LaboratoryBiomarkerAnalysis;  Other:Quality-of-LifeAssessment;  Drug:Simvastatin|Interventional||Other / NIH|Changeinfreelightchainratios;  Change in M-protein level measured using electrophoresis;  DOR;  Incidence of toxicities evaluated according to National Cancer Institute CTCAE version 4.0;  OR including stringent complete remission (CR) CR Partial Remission (PR) and very good PR;  Overallsurvival;  PFS;  QoL assessed using a survey designed by European Organization for Research and Treatment of Cancer (EORTC);  Response in patients who did and did not receive zoledronic acid with therapy;  Timetofirstresponse;  Timetonexttherapy;  TTP|35|NCT02971410|November 2016
6|Not yet recruiting|Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia||Procedure:BoneMarrowAspirationandBiopsy;  Drug:Cytarabine;  Drug:DaunorubicinHydrochloride;  Other:LaboratoryBiomarkerAnalysis|Interventional||Other / NIH|Change in incidence of cardiac toxicity defined as reduction in LVEF of &gt;= 10% compared to baseline LVEF and EF =&lt; 50% on the follow-up scan assessed using MRI;  Incidence of other unexpected toxicities measured by Common Terminology Criteria for Adverse Events version 4.0;  Proportion of patients who complete the infusion therapy;  Proportion of patients with study-related deviations;  Change in incidence of cardiac toxicity defined as reduction in LVEF of &gt;= 10% compared to baseline LVEF and EF =&lt; 50% on the follow-up scan assessed using ECHO;  ChangeinEFassessedbyMRIandECHO;  Change in incidence of cardiac toxicity defined as reduction in LVEF of &gt;= 10% compared to baseline LVEF and EF =&lt; 50% on the follow-up scan assessed using MRI and ECHO;  Change in left ventricular end diastolic volume assessed by MRI and ECHO;  Change in left ventricular end systolic volume assessed by MRI and ECHO;  Change in myocardial strain assessed by MRI and ECHO;  Disease-free survival for those patients who achieve remission;  Inductiondeathrate;  OverallresponseratedefinedasCR+CRi|40|NCT02971397|November 2016
7|Not yet recruiting|I HEAL for Breast Cancer Survivors With Diabetes||Behavioral: Diabetes Coping Skills Training (DCST)|Interventional||Other|Changeinphysicalsymptoms;  Changeinpsychologicaldistress;  Accessing change in Diabetes self-management behaviors via self reported medication adherence;  Accessing change in Diabetes self-management behavior via Barriers to taking medication;  Accessing change in Diabetes self-management behavior via Adherence to diabetes self-management behaviors;  Accessing change in Diabetes self-management behavior via Use of home blood glucose monitoring;  Improvedglycemiccontrol;  Changeinself-efficacy;  ChangeinPhysicalActivity;  AssessingchangeinPhysicalActivity|230|NCT02970344|January 2017
8|Not yet recruiting|Tranquil Moments II-CBT vs. Yoga for Worry||Behavioral:Cognitive-behavioraltherapy;  Behavioral:Yoga|Interventional||Other|PennStateWorryQuestionnaire;  PROMISAnxiety;  InsomniaSleepIndex|500|NCT02968238|May 2017
9|Recruiting|Psychosocial Stress and Aging in HIV||Behavioral:Breathe2Relax|Interventional|Phase 0|Other / NIH|Correlation of perceived stress with HIV virologic suppression;  Correlation of perceived stress with immune senescence;  Correlationofperceivedstresswithinflammation;  Correlation of perceived stress with frailty phenotype;  Feasibilityofastress-reductioncellphoneapp;  The effect of a cell phone app on stress-reduction;  Acceptability of a stress-reduction cell phone app|100|NCT02965469|May 2016
10|Not yet recruiting|A Study Promoting Critical Illness Recovery in the Elderly-- Pilot||Device:cycleergometry|Interventional||Other|Feasibility;  ShortPhysicalPerformanceBattery;  Handgripstrength;  Lengthofstay;  Healthcare utilization- ED visits and readmissions;  VentilatorFreeDays;  Mortality;  ShortForm-36;  MontrealCognitiveAssessment;  MuscleUltrasound--thicknesssizeechogenicity;  Myofibertypeandsize;  MuRF1levels;  NFkB|20|NCT02963558|November 2016
11|Not yet recruiting|Video-Enhanced Care Management for Medically Complex Veterans||Behavioral:Caremanagementviavideoconference;  Behavioral:Caremanagementviatelephonecalls|Interventional||U.S. Fed|Acceptability of care management program for medically complex Veterans with CI;  Perceived value of video-enhanced care management for medically complex Veterans with CI;  Feasibility of care management program for medically complex Veterans with CI;  Usability of video-enhanced care management for medically complex Veterans with CI|80|NCT02962687|February 2017
12|Recruiting|Pediatric Metabolism and Microbiome Repository|||Observational||Other / NIH|The measure of abnormal metabolism using a sample biorepository;  The measure of healthy metabolism using a sample biorepository|350|NCT02959034|September 2016
13|Recruiting|Brief Mood Enhancement Intervention||Behavioral:Reward;  Behavioral:Approach|Interventional||Other|Change in burnout as measured by the School Burnout Inventory total score;  Change in stress as measured by the Perceived Stress Scale total score;  Change in mastery as measured by the Pearlin Personal Mastery Scale total score;  Change in avoidance as measured by the Brief Experiential Avoidance Questionnaire total score;  Change in mood as measured by the Positive and Negative Affect Schedule total scores for Positive and Negative Affect;  Change in reward as measured by the Environmental Reward Observation Scale total score;  Change in behavioral activation as measured by the Activation sub-scale of the Behavioral Activation for Depression Scale;  Change in functional impairment as measured by the Modified Work and Social Adjustment Scale total score;  Change in quality of life as measured by the WHOQOL-BREF total score;  Change in depression symptoms as measured by the General Depression scale of the Inventory of Depression and Anxiety Symptoms;  Change in mastery as measured by the average of the daily Importance ratings of activities (0-10) on the Daily Activities Monitoring Form;  Change in avoidance as measured by the total score of the Avoidance/Rumination sub-scale of the Behavioral Activation for Depression Scale;  Change in environmental reward as measured by the average of the daily Pleasure ratings of activities (0-10) on the Daily Activities Monitoring Form|102|NCT02954965|November 2016
14|Recruiting|Mobile Health Application for Family and Behavioral Health Provider Communication||Behavioral:Connectdmobileapplication|Interventional||Industry / Other|Working Alliance Inventory (Short Form Therapist);  ParticipantTreatmentParticipation;  WorkingAllianceInventory(Client);  PTSDKnowledgeScale;  ZaritBurdenInterview;  DimensionsofAngerReactions;  Clinician-Administered PTSD Scale for DSM5 (CAPS 5)|120|NCT02954146|November 2016
15|Not yet recruiting|Exploring the Impact of Perioperative Galacto-Oligosaccharides (GOS) on Stress Anxiety and Cognition||Drug:Galacto-Oligosaccharide;  Drug:Maltodextrin(Placebo)|Interventional||Other|ChangeinWakingSalivaryCortisol;  Changesinpainperception;  Changesincognition;  Changesinperceivedstress;  Suicidalideationandbehavior|8|NCT02953691|November 2016
16|Recruiting|The Feasibility and Efficacy of an Extremely Brief Mindfulness Practice||Other:Thirty-SecondMindfulnessPractice;  Other:Three-MinuteMindfulnessPractice|Interventional||Other|Change in trait mindfulness as measured by the Five Facet Mindfulness Questionnaire (Baer et al. 2006);  Change in perceived stress as measured by the Perceived Stress Scale (Cohen Kamarck &amp; Mermelstein 1983);  Change in anxiety symptoms as measured by the GAD-7 Generalized Anxiety Disorder Scale (Spitzer Kroenke Williams &amp; L&#246;we 2006);  Change in mood as measured by the Positive and Negative Affect Schedule (Watson Clark &amp; Tellegen 1988);  Change in quality of life as measured by the Medical Outcomes Study 36-Item Short-Form Health Survey (Ware &amp; Sherbourne 1992);  Change in depression symptoms as measured by the PHQ-8 Patient Health Questionnaire - depression module (Spitzer Kroenke &amp; Williams 1999);  Group difference in intervention&apos;s acceptability as measured by qualitative questions;  Group difference in adherence as measured by frequency of daily brief mindfulness practice use;  Group difference in continued brief mindfulness practice use as measured by follow-up question;  Change in daily mood measured on a visual analogue scale;  Change in daily stress level measured on a visual analogue scale;  Change in empathy as measured by the Interpersonal Reactivity Index (Davis 1980) and four questions adapted from Hawk Fischer and Van Kleef (2011);  Change in perspective taking as measured by questions adapted from Hawk Fischer and Van Kleef (2011)|60|NCT02953444|November 2016
17|Recruiting|Probiotics in Occupational Shift Workers||DietarySupplement:Probiotic;  DietarySupplement:Placebo|Interventional||Other|VisceralFat;  Ratio of fat in the abdominal region vs. hip region;  BodyFat;  Leanbodymass|60|NCT02951689|September 2016
18|Recruiting|Protein Supplementation Post Bariatric Surgery||DietarySupplement:Protein|Interventional||Other|Number of patients reporting gastrointestinal effects during use of supplementation;  Number of shakes consumed out of the total number of shakes provided;  Bodyfat;  Leanbodymass;  Metabolism(restingmetabolicrate);  Functionalfitness(sittostandtest)|60|NCT02951663|October 2016
19|Recruiting|Pompe Telemedicine Developmental Study|||Observational||Other|Relationship between daily behaviors in school-aged children with Pompe disease and observed speech patterns as assessed by speech pathology.;  Document the developmental outcomes and cognitive function of individuals with Pompe disease treated with long-term ERT through school-age (ages 6-18) as assessed by PPVT-4.;  Document the developmental outcomes and language abilities of individuals with Pompe disease treated with long-term ERT through school-age (ages 6-18) as assessed by CELF-5.;  Document the developmental outcomes and cognitive function of individuals with Pompe disease treated with long-term ERT through school-age (ages 6-18) as assessed by Woodcock-Johnson Test of Achievement.;  Document the developmental outcomes and cognitive function of individuals with Pompe disease treated with long-term ERT through school-age (ages 6-18) as assessed by Leiter.;  Relationship between daily behaviors in school-aged children with Pompe disease and development as assessed by Conners.;  Relationship between daily behaviors in school-aged children with Pompe disease and development as assessed by BRIEF-P.;  Relationship between daily behaviors in school-aged children with Pompe disease and development as assessed by Child Behavior Checklist.|20|NCT02950298|December 2015
20|Not yet recruiting|Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations||Drug:Chemotherapy;  Biological:Immunotherapy;  Other:LaboratoryBiomarkerAnalysis;  Biological:Nivolumab;  Biological:Pembrolizumab;  Drug:TargetedMolecularTherapy;  Drug:TyrosineKinaseInhibitor|Interventional|Phase 2|Other / NIH|Objective response rate in patients with high PD-L1 expressing cancers after failure of targeted therapy defined as complete or partial response according to the investigator&apos;s assessment;  Incidence of adverse events measured using Common Terminology Criteria for Adverse Events version 4.0;  Incidence of mutations in secondary genes for patients with PD-L1 expression &lt; 50%;  Objective response rates for patients without high PD-L1 expressing cancers;  Objective response rates for the combined population to historical controls receiving second or third line targeted agents;  Overallsurvival;  Rate of tobacco use and mutation burden based on PD-L1 expression at time of progression;  Smokingstatusdefinedascurrentformernever|75|NCT02949843|December 2016
21|Not yet recruiting|Comparison of PIEB vs CEI for Labor Analgesia||Other:ProgrammedIntermittentEpiduralBolus;  Other:ContinuousEpiduralInfusion;  Drug:Ropivacaine;  Drug:Fentanyl|Interventional|Phase 4|Other|Volume of local anesthetic received through Patient Controlled Epidural Analgesia (PCEA) per hour-computerized information;  Total required local anesthetic required per hour- computerized information;  Time to first patient controlled epidural analgesia (PCEA) bolus- computerized information;  Laborpainscores-patientquestionnaire;  Degree of motor blockade measured as lowest recorded modified Bromage score;  Modeofdelivery;  Patient controlled epidural analgesia (PCEA) attempts-computerized information;  Patient controlled epidural analgesia (PCEA) ratio of successful attempts to unsuccessful attempts - computerized information;  Frequencyofhypotension-physiologicalparameter;  Durationoffirstandsecondstagesoflabor;  Level of patient satisfaction- patient questionnaire|120|NCT02949271|November 2016
22|Recruiting|Effects of IV-Administered Ca-DTPA and Zn-DTPA To Treat Patients With Gadolinium Deposition Disease||Drug:CalciumDTPA;  Drug:ZincDTPA|Interventional|Phase 1 / Phase 2|Other|Change from Baseline to Month 1 in Gd level from 24-hour urine samples following Calcium DTPA administration.;  Change from Baseline to Month 1 in Gd level from 24-hour urine samples following Zinc DTPA administration.;  Change from Baseline to Month 2 in Gd level from 24-hour urine samples following Calcium DTPA administration.;  Change from Baseline to Month 2 in Gd level from 24-hour urine samples following Zinc DTPA administration.;  Change from Baseline to Month 3 in Gd level from 24-hour urine samples following Calcium DTPA administration.;  Change from Baseline to Month 3 in Gd level from 24-hour urine samples following Zinc DTPA administration.;  ChangefrombaselinetoMonth1inthePainScore;  ChangefrombaselinetoMonth2inthePainScore;  ChangefrombaselinetoMonth3inthePainScore;  ChangefrombaselinetoMonth6inthePainScore;  Change from baseline to Month 12 in the Pain Score;  Change in American Chronic Pain Association (ACPA) Quality of Life (QOL) score from baseline to Month 1;  ChangeinACPAQOLscorefrombaselinetoMonth2;  ChangeinACPAQOLscoreatMonth3;  ChangeinACPAQOLscoreatMonth6;  ChangeinACPAQOLscoreatMonth12|20|NCT02947022|October 2016
23|Not yet recruiting|Optimal Volume Rate and Interval of Bolus Nerve Catheters for Shoulder Surgery||Drug:Ropivacaine|Interventional|Phase 4|Other|Optimal Volume of Ropivacaine 0.2% bolus via interscalene catheter;  Optimal Rate of Ropivacaine 0.2% administration bolus via interscalene cathter|99|NCT02946268|November 2016
24|Not yet recruiting|A MAD Study of TT301/MW189 in Healthy Volunteers||Drug:Cohort1-TT301/MW189;  Drug:Cohort2-TT301MW189;  Drug:Cohort3-TT301/MW189;  Other:Cohort1Placebo;  Other:Cohort2Placebo;  Other:Cohort3Placebo|Interventional|Phase 1 / Phase 2|Other|Adverseevents;  Pharmacokinetics-Cmax;  Pharmacokinetics-Tmax;  Pharmacokinetics-AUC;  Pharmacokinetics-T1/2;  Pharmacokinetics-Kel|24|NCT02942771|January 2017
25|Recruiting|Magnetic Resonance Imaging of Human Biometrics|||Observational||Industry|CollectHighQualityMRIData|30|NCT02942667|August 2016
26|Recruiting|Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer||Drug:anastrozole;  Drug:Palbociclib|Interventional|Phase 2|Other / Industry|Responserate|40|NCT02942355|November 2016
27|Recruiting|Collection of Biological and Environmental Samples and Clinical Data From Anonymous Adult Men and Women for Quality Control and Methods Development and Evaluation (ASCA)|||Observational||NIH|The samples and clinical data will be used to ascertain whether data and sample collection processing techniques and testing methods are sufficiently valid and precise to be used in specific epidemiologic studies.|5000|NCT02940015|October 2016
28|Not yet recruiting|Full-arch Monolithic Zirconia ISFDP Follow up||Device:Monolithiczirconiaprosthesis|Observational||Other|PercentIncidenceofProstheticComplications;  PercentIncidenceofBiologicalComplications;  Quantitativemeasurementofbonelevel;  Patientself-reportedOHIP-14satisfactionscores;  Patientself-reportedQoLFAST-10scores|60|NCT02931968|October 2016
29|Recruiting|Leukemia Stem Cell Detection in Acute Myeloid Leukemia||Procedure:AllogeneicHCT;  Drug:Consolidationchemotherapy|Interventional|Phase 3|Other|2yearrelapsefreesurvival(RFS);  1yearRFS;  RFS in favorable risk AML patients treated with consolidation chemotherapy;  RFS in intermediate risk AML patients treated with HCT;  RFS in favorable risk AML patients with detectable LSCs;  RFS in intermediate risk AML patients with undetectable LSCs;  Overallsurvival;  2 year RFS based on LSC detection at CR1 time point;  1 year RFS based on LSC detection at CR1 time point;  RFS in unfavorable risk AML patients based on LSC detection at CR1 time point;  comparison of RFS using different timepoints of the LSC assays in the transplant versus non-transplant populations;  ChangeinLSCstatus|400|NCT02927938|September 2016
30|Not yet recruiting|Neuroimaging Reward Behavioral Treatment and Smoking Cessation||Drug:NicotinePatch;  Drug: SPECTRUM Nicotine Research Cigarettes (.03 mg);  Behavioral:BehavioralActivation;  Behavioral:SupportiveCounseling|Interventional|Phase 1 / Phase 2|Other / NIH|Change in BOLD response to smoking and monetary reward;  DaystoRelapse|100|NCT02927847|November 2016
31|Recruiting|Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy||Drug:INCB054828|Interventional|Phase 2|Industry|Objective response rate (ORR) in subjects with FGFR2 translocations based on RECIST v1.1;  ORR in subjects with FGF/FGFR alterations other than FGFR2 translocations all subjects with FGF/FGFR alterations and subjects negative for FGF/FGFR alterations based on RECIST v1.1;  Progression-freesurvivalbasedonRECISTv1.1;  Safety and tolerability of INCB054828 as assessed by the frequency duration and severity of adverse events|100|NCT02924376|October 2016
32|Recruiting|Empowered With Movement to Prevent Obesity and Weight Regain||Behavioral:Weightloss;  Behavioral:Exercise;  Behavioral:Sitless|Interventional||Other|ChangeinBodyweight|180|NCT02923674|November 2016
33|Recruiting|Assessment of Infection Control Practice Efficiency and Health Economics of Sheathed Versus Standard Cystoscopy||Device:EndoSheathCST-5000Scope;  Device:OlympusViseraEliteOTV-S190Scope|Interventional|Phase 4|Other / Industry|TheChangeinBacteriuria|60|NCT02922868|March 2016
34|Not yet recruiting|Feasibility and Smokers&apos; Reactions to DNA Feedback||Behavioral:standardhealthinformation;  Behavioral: standard health information plus info. on DNA damage;  Behavioral: Subjects will review standard health information and information on DNA damage plus pictures of their DNA damage|Interventional||Other|Degree of participant understanding of materials to be measured by a survey;  Percentage of subjects who show up to the sessions;  Extent to which participants believe the feedback to be accurate;  Degree of participant understanding of materials to be measured by an interview;  Extent to which participants believe the feedback to be trustworthy;  Effect size of the changes in coherence between the control and biomarker arm from baseline to three months post-intervention on;  Effect size of the change in risk appraisals between the control and biomarker arm from baseline to three months post-intervention on;  Effect size of participant motivation to quit smoking between the control and biomarker arm from baseline to three months post-intervention on;  Effect size of plans to quit smoking between the control and biomarker arm from baseline to three months post-intervention on;  Effect size of mean levels of smoking between the control and biomarker arm at three months post-intervention;  Effect size of the number of quit attempts between the control and biomarker arm at three months post-intervention;  Effect size of the quit rate between the control and biomarker arm at three months post-intervention|100|NCT02922790|November 2016
35|Recruiting|An Evaluation of a Clinical Algorithm With Turbo-Power Following Treatment of Specific Morphologies||Device:LaserAtherectomy|Observational||Industry|Reductionofstenosis|60|NCT02921542|August 2016
36|Recruiting|Effects of Omega-3 Fatty Acids in Ambient Air Pollution Exposure in Healthy Adults||DietarySupplement:omega-3fattyacids|Observational||U.S. Fed|heartratevariability;  endothelialcellfunction;  diametersofretinalarteriesandveins;  pulmonaryfunctionindices;  bloodbiomarkers|60|NCT02921048|September 2016
37|Not yet recruiting|TMS Modulation of Insula-related Brain Networks.02||Device:transcranialmageneticstimulation|Interventional||Other|Change in functional connectivity strength measured with functional magnetic resonance imaging|60|NCT02919423|December 2016
38|Not yet recruiting|A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician&apos;s Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline a Taxane and Capecitabine||Drug:NKTR-102;  Drug:Eribulin;  Drug:Ixabepilone;  Drug:Vinorelbine;  Drug:Gemcitabine;  Drug:Paclitaxel;  Drug:Docetaxel;  Drug:Nab-paclitaxel|Interventional|Phase 3|Industry|OverallSurvival(OS)ofPatients;  Progression-Free Survival (Outside the Central Nervous System);  Progression-Free Survival in Brain Metastasis (PFS-BM);  To compare the Objective Response Rates (ORR) from NKTR-102 treatment with that of TPC;  TocomparetheClinicalBenefitRate(CBR);  TocomparetheDurationofResponse(DoR);  Compare Health-Related Quality of Life (HRQoL) using the European Organisation for Treatment of Cancer (EORTC) Quality of Life Core 30 (QLQ-C30) module with the brain neoplasms 20-question (BN-20) subscale.;  Compare Health-Related Quality of Life (HRQoL) using the the EuroQoL 5D (EQ-5D-5L&#8482;);  Compare Health-Related Quality of Life (HRQoL) using the Brief Fatigue Inventory (BFI);  MagnitudeofClinicalBenefit;  Maximum observed serum concentration (Cmax) of NKTR-102;  Time of maximum observed serum concentration (Tmax) of NKTR-102;  Area Under the serum Concentration time curve in the dosing interval (AUCtau) of NKTR-102;  Half-lifeof(t1/2)ofNKTR-102;  Number of participants with adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.3|350|NCT02915744|October 2016
39|Not yet recruiting|The Utility of NIOM During LITT for Refractory MTLE||Procedure:monitoringbydepthelectrode|Interventional||Other|fractional decrement in interictal epileptiform discharges (ID) from pre- to post-ablation;  Surgical complications associated with intraoperative monitoring electrodes and recording;  Epilepsysurgeryoutcome|20|NCT02913742|November 2016
40|Not yet recruiting|Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure||Drug:gammatocopherol;  Drug:Placebo|Interventional|Phase 2|Other / NIH|changeinsputum%PMNs|32|NCT02911688|September 2016
41|Not yet recruiting|Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder||Drug:Sulforaphane;  Drug:Placebo|Interventional|Phase 2|Other|Change in Social Responsiveness Scale-2 (SRS-2) total scores from baseline to weeks 4 8 12 and 16.;  Change in SRS-2 subscale scores (Social Awareness Social Cognition Social Communication Social Motivation and Restricted Interests/ Repetitive Behaviors) from baseline to weeks 4 8 12 and 16.;  Change in Aberrant Behavior Checklist (ABC) subscale scores (Social Withdrawal Hyperactivity Inappropriate Speech Stereotypy and Irritability) from baseline to weeks 4 8 12 and 16.;  Change in Clinical Global Impression-Severity (CGI-S) scores from baseline to weeks 4 8 12 and 16.;  Differences in Clinical Global Impression- Improvement (CGI-I) scores between treatment arms at weeks 4 8 12 and 16.;  Change in Repetitive Behavior Scale-Revised (RBSR) total scores from baseline to weeks 4 8 12 and 16.;  Complete Blood Count (CBC) with differential change in values from baseline to 12 weeks;  Liver function tests (alanine transaminase aspartate transaminase total bilirubin) change values from baseline to 12 weeks;  Serum chemistries (sodium potassium chloride bicarbonate Blood Urea Nitrogen creatinine calcium magnesium phosphorous glucose) change in values from baseline to 12 weeks.;  Thyroid Stimulating Hormone (TSH) change in values from baseline to 12 weeks.;  Vital signs (weight height blood pressure and heart rate) actual values at each time point measured and change in values from Baseline to Weeks 4 8 12 and 16.;  Change in the concentration of sulforaphane metabolites (dithiocarbamates) in overnight voided urine samples from baseline to week 12 the end of the active treatment phase.|54|NCT02909959|November 2016
42|Recruiting|A Pilot Study of Nocturnal Hypoglycemia Prevention in Type 1 Diabetes Using the Vigilant Diabetes Management Companion||Device:VigilantDiabetesManagementApplication|Interventional||Industry / Other|Reduction in the aggregate rate of nocturnal biochemical severe hypoglycemia in the Vigilant period versus the Baseline period as measured by meter or logged blood glucose values (mg/dL).;  Reduction in the aggregate rate of nocturnal hypoglycemia in the Vigilant period versus the Baseline period as measured by meter or logged blood glucose values (mg/dL).;  An aggregate (total study population) reduction in the rate of mild hypoglycemia (biochemical and logged) as measured by home blood glucose values &lt;70 mg/dL at 3 months compared to the monthly rate of hypoglycemia in the Baseline period.;  An aggregate reduction in the rate of biochemical severe hypoglycemia as measured by home blood glucose values &lt;40 mg/dL during months 1-3 compared to the monthly rate of biochemical severe hypoglycemia in the Baseline period.;  An aggregate reduction in average HbA1will be measured at baseline using DCA 2000 or equivalent NGSP- certified point-of-care method or local laboratory at 3 months compared to HbA1c levels obtained at study initiation.;  An aggregate reduction in the survey self-reported rate of use of; 1) Glucagon 2) Emergency medical services for hypoglycemia and 3) Hospital urgent care or clinic visits for hypoglycemia or associated with hypoglycemia care visits.;  An aggregate reduction in the mean glycemic variability as measured by monthly ADRR (Average Daily Risk Range) calculated based on downloaded meter download data;  An aggregate (total study population) reduction in the LBGI and HBGI as measured by percent of readings in and out of range calculated based on downloaded blood glucose meter download data.;  Reduction in reported fear of hypoglycemia as compared to baseline Fear of Hypoglycemia Fear Survey. The Hypoglycemia Fear Survey II (HSF II) will be used.;  Improvement in self-reported lost work productivity as a result of hypoglycemia. Individuals will complete a questionnaire about lost work days as a result of hypoglycemia at baseline and at 3 months.;  Improvement in self-reported psychosocial self-efficacy as compared to baseline measured using the Diabetes Empowerment Scale Short Form (DES-SF).|24|NCT02906891|May 2016
43|Not yet recruiting|Combination Nicotine Patch / Lorcaserin for Smoking Cessation||Drug:lorcaserin;  Drug:nicotinepatch;  Drug:placebolorcaserin|Interventional|Phase 2|Other / NIH|Time-to-lapse;  SmokingWithdrawal;  SmokingAbstinence;  Tolerability;  WeightGain;  6-monthSmokingAbstinence;  Percentage of Change in Ad libitum Smoking at End of Week 2;  Adherence|300|NCT02906644|September 2016
44|Enrolling by invitation|Goals for Reaching Optimum Wellness (GROWell)||Other:GROWell|Interventional||Other|FeasibilityoftheGROWellintervention;  AcceptabilityoftheGROWellintervention;  Efficacy- change in dietary components from Baseline to 37 Weeks Gestation|50|NCT02904473|October 2016
45|Recruiting|An Observational Study of Post-cesarean Delivery Respiratory Patterns Using a Non-invasive Minute Ventilation Monitor (Exspiron &#8482; System)|||Observational||Other / Industry|Changeinminuteventilation;  BerlinQuestionnaire;  STOP-BANGQuestionnaire;  EpworthSleepinessScale|100|NCT02903173|February 2015
46|Recruiting|Comparison of 1000 Hertz (Hz) Burst and Standard Spinal Cord Stimulation in Chronic Pain Relief||Device:Spinalcordstimulator|Interventional|Phase 4|Other|NPRS;  OswestryDisabilityIndex;  PatientsGlobalImpressionofChange;  PreferabilitySurvey|22|NCT02902796|September 2016
47|Not yet recruiting|VAL-1221 Delivered Intravenously in Ambulatory and Ventilator-free Patients With Late-Onset Pompe Disease||Drug:VAL-12211mg/kg;  Drug:VAL-12213mg/kg;  Drug:VAL-122110mg/kg|Interventional|Phase 1 / Phase 2|Industry|Incidencesoftreatment-emergentadverseevents;  Immunogenicity outcome measure - incidences of anti-VAL-1221 antibodies;  Immunogenicity outcome measure - incidences of GAA antibodies;  Pharmacokinetics Outcome Measure of VAL-1221 given IV;  Pharmacodynamics Outcome Measure of VAL-1221 given IV|12|NCT02898753|November 2016
48|Recruiting|Sleep Dysfunction and Neurocognitive Outcomes in Adolescent ADHD|||Observational||Other / NIH|Objectivesleepassessment;  Neurocognitiveassessment;  Executive functioning as measured by neurocognitive assessment|60|NCT02897362|August 2016
49|Recruiting|PrEP SMART Phase I Trial||Behavioral:PrEPSmart|Interventional|Phase 1|Other / Industry|Feasibility as measured by the average number of times per day participants initiate an interaction with PrEP Smart;  Feasibility as measured by the average number of times per day subjects respond to a prompt from PrEP Smart over the course of the four week period.;  Barriers to adherence following missed doses as measured by daily PrEP Smart assessment.;  Acceptability as measured by questionnaire that includes questions about satisfaction and likelihood of recommending to others on a Likert scale of 1 to 4.;  Acceptability as measured by an interview that will be conducted by the Principal Investigator.;  Barriers to adherence will be measured by the number of times it was taken outside of a 1 hour window;  Barriers to adherence will be measured by self-report via the PrEP Smart application.|20|NCT02895893|July 2016
50|Recruiting|Patient-Empowered Mobile Technology in Hospitalized Patients: Technology Resources to Understand Pain Assessment in Patients With Pain (TRU-PAIN)||Device:SMARTapp|Interventional||Other|time to discontinuation of the IV PCA with opioid medication;  timeofmovementduringhospitalization;  magnitudeofchangeinpainscores;  patient/family satisfaction scores as measured by feasibility survey|100|NCT02895841|August 2016
51|Not yet recruiting|Preparatory Work to Assess Adherence to Oral Chemotherapy|||Observational||Other|Patient Demographic and Health Behaviors Questionnaire;  BriefMedicationQuestionnaire(BMQ);  SingleItemAdherenceMeasure1;  SingleItemAdherenceMeasure2;  REALM-SF;  MedicationsAdherenceReasonsScale(MARS)|120|NCT02895542|October 2016
52|Recruiting|Lipiflow Versus Warm Compresses in Parkinson&apos;s Disease||Device:LipiFlowsystem;  Procedure:Warmcompresses|Interventional||Other|Meibomian gland assessment defined as assessment of 15 glands on the lower eyelid margin using a handheld instrument the Meibomian Gland Evaluator.;  Tearbreakuptime;  Assessment of dry eye symptoms with Ocular Surface Disease Index (OSDI) score before and after treatment;  Best spectacle-corrected visual acuity (BSCVA) with high-contrast Early Treatment Diabetic Retinopathy Study (ETDRS) logMAR chart using the ETDRS-Fast method under standard illumination;  CornealStaining;  SPEED Questionnaire assessment of dry eye symptoms before and after treatment|25|NCT02894658|August 2016
53|Recruiting|Effects of Exercise Training Intensity on Fitness and Insulin Sensitivity in African Americans||Behavioral: Moderate intensity exercise training (MOD-INT);  Behavioral: High Intensity exercise training (HI-INT)|Interventional||Other|Changeincardiorespiratoryfitness;  Changeinbodycomposition;  Changeinbodyweight;  Changeinwaistcircumference;  Changesinphysicalactivitylevels;  Changeindietarycomposition;  Changesinbloodlipidsconcentrations;  Changeinsystemicinflammation;  Changeininsulinsensitivity;  Changeinarterialstiffness;  Changeinqualityoflife;  Change in mitochondrial enzymes and protein content|60|NCT02892331|October 2016
54|Not yet recruiting|Hepatic Resection for Metastatic Pancreatic Adenocarcinoma|||Observational||Other|90-daymortality;  disease-freesurvival;  overallmortality;  surgicalsiteinfection;  bleedingpostoperatively;  pancreaticleak;  bloodclot;  reoperation;  readmissiontohospital;  tumorhistology;  marginstatus;  lymphnodestatus;  CA19-9levels;  timetostartoftherapyfromdiagnosis;  ORtime;  intraoperativetransfusion;  fluidadministrationintraoperatively;  estimatedbloodloss;  timetoendoftherapyfromdiagnosis;  useofextraoralfeeding;  useofneoadjuvanttherapy;  useofadjuvanttherapy|50|NCT02892305|September 2016
55|Completed|Evaluation of Go NAP SACC&apos;s Web-based Tools for Child Care||Behavioral:GoNAPSACC|Interventional||Other|Change in EPAO-SR Scores from Baseline to Post-intervention|102|NCT02889198|May 2014
56|Completed|Pokemon Go and Physical Activity|||Observational||Other|Averagenumberofstepsperday;  ChangeinnumberofstepsafterPokemonGo;  Greaterthan10000stepsperday|167|NCT02888314|August 2016
57|Not yet recruiting|SIMT Stereotactic Radiosurgery Outcomes Study||Radiation:Stereotacticradiosurgery|Interventional||Other / Industry|Proportion of patients who live longer than predicted according to the Graded Prognostic Assessment (GPA) score;  Proportion of patients that experience local brain recurrence within 1 year of SIMT SRS treatment.;  Proportion of patients who are dead within 1 year of SIMT SRS treatment due to neurologic reasons;  Proportion of patients that experience a new brain metastasis at a site different from the original brain metastasis site 1 year after SIMT SRS treatment;  Proportion of patients who experience grade 3 4 or 5 neurologic adverse events attributable to SIMT SRS|40|NCT02886572|October 2016
58|Recruiting|Pulmonary Embolism Short-term Clinical Outcomes Registry|||Observational||Other|ClinicalDeterioration;  Rightventriculardysfunction(RVD);  FunctionalOutcome;  PulmonaryEmbolismComplications|880|NCT02883491|August 2016
59|Recruiting|Spironolactone After Liver Transplant||Drug:Spironolactone|Interventional|Phase 4|Other|GFR|36|NCT02883400|December 2014
60|Recruiting|Curved Soft-Picks on Plaque Accumulation on Patients With Gingivitis||Device:Soft-PicksAdvanced;  Device:Floss|Interventional||Industry|ModificationoftheQuigley-HeinPlaqueIndex;  Performance of an assigned product based on user experience;  UNCModifiedGingivalIndex;  BleedingonProbing;  ProbingPocketDepth|44|NCT02883244|December 2016
61|Not yet recruiting|Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed Stage II-III Triple-Negative Breast Cancer||Drug:Atezolizumab;  Drug:Carboplatin;  Other:LaboratoryBiomarkerAnalysis;  Procedure:Lumpectomy;  Procedure:Mastectomy;  Drug:Paclitaxel|Interventional|Phase 2|NIH|Increase in TIL percentage measured by histopathologic assay;  IncreaseinpCRrate|60|NCT02883062|March 2017
62|Recruiting|Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial||Drug:Dasatinib+Quercetin|Interventional|Phase 1|Other|Reduction in the % of pro-inflammatory expressing cells|7|NCT02874989|August 2016
63|Not yet recruiting|Development of a Novel Transdiagnostic Intervention for Anhedonia||Behavioral:BehavioralActivation;  Behavioral:MindfulnessTreatment|Interventional||Other|Change from Baseline to Week 15 in Neural Activation;  Change from Baseline to Week 15 in Snaith-Hamilton Pleasure Scale Score|210|NCT02874534|December 2016
64|Recruiting|Acute Concussion Therapy Intervention Training in Healthy and Concussed Participants||Other:ACTIVETraining|Interventional|Phase 1 / Phase 2|Other|AverageDaystoRecovery;  AverageChangeinMentalStatus;  AverageChangedinBalance;  AverageChangeinCognition;  AverageChangeinNear-PointConvergence;  AverageChangeinConcussiveSymptoms|100|NCT02872480|August 2016
65|Recruiting|Prenatal Cocaine Nasal Oxytocin and Maternal Psychophysiology||Drug:Syntocinontreatment;  Other:Placebo|Interventional|Phase 1|Other|The effects of a 2-week trial of twice nasal oxytocin compared with placebo on maternal sensitivity;  The effects of a 2-week trial of nasal oxytocin compared with placebo on maternal reactivity to a social stressor indexed by change in vascular resistance from pre- to post-test nasal spray.;  The effects of a 2-week trial of nasal oxytocin compared with placebo on maternal reactivity to a social stressor indexed by change in plasma norepinephrine.;  The effects of a 2-week trial of nasal oxytocin compared with placebo on maternal reactivity to a social stressor indexed by self-reported affective ratings.|32|NCT02872467|May 2016
66|Recruiting|Valued EpiGenetic Glycemic ImprovEments Through Weight Loss||Behavioral:WeightLossGroup;  Behavioral:DelayedWeightLoss|Interventional||Other / Industry / NIH|Chang in Epigengene score (and related individual transcriptional and methylation measures);  changeinglucosetolerance;  change in homeostatic model assessment (HOMA) estimates of insulin resistance|200|NCT02869659|October 2016
67|Recruiting|Accelerated Invisalign Therapy in Conjunction With Acceledent Aura||Device:AcceleDentAura;  Device:AcceleratedInvisaligntherapy|Interventional|Phase 4|Other / Industry|Rate of orthodontic tooth movement [Little&apos;s Irregularity Index mm/day percent];  Activity of Bone Turnover Markers (BTMs) during Orthodontic Tooth Movement [Quantitative Polymerase Chain Reaction (qPCR) Cycle threshold values (Ct)];  Patient Discomfort [Visual Analog Scale in conjunction with Faces Pain Scale 1-10]|30|NCT02868554|August 2016
68|Recruiting|Resection Versus Microwave Ablation for Resectable Colorectal Cancer Liver Metastases||Device:Microwaveablation;  Procedure:Hepaticresection|Interventional||Other|Localdiseasecontrolatthesiteofintervention;  Overallsurvival;  Intrahepaticdisease-freesurvival;  Postoperativemorbidity;  Postoperativemortality|164|NCT02866344|August 2016
69|Completed|Mobile Technology and Online Tools to Track Adherence in Chronic Illness Patients||Behavioral:PlanetK|Interventional|Phase 2|Industry|KnowledgeofCKD;  End Stage Renal Disease-Adherence Questionnaire (ESRD-AQ);  PerceivedTreatmentBenefits;  STARxTransitionReadinessQuestionnaire;  ChronicKidneyDiseaseSelf-EfficacyInstrument;  Self-Management:Self-Efficacy for Managing Chronic Disease Scale;  Self-Management:PartnersinHealthScale;  QualityofLife|68|NCT02864641|July 2015
70|Not yet recruiting|Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens||Drug:5-dayTMZ;  Drug:21-dayTMZ;  Biological:PEP-CMV;  Drug:Tetanus-Diphtheriabooster;  Drug:TetanusPre-Conditioning|Interventional|Phase 1|Other / NIH|IncidenceofTreatment-relatedAdverseEvents;  ImmunologicResponse;  AntigenLoss|45|NCT02864368|December 2016
71|Active not recruiting|COMRADE: Collaborative Care Management for Distress and Depression in Rural Diabetes||Behavioral:IntegratedBehavioralCare|Interventional||Other / Industry|ChangeinGlycosylatedHemoglobin;  Change in Diabetes Related Distress measured by diabetes related distress scale (DDS-17)|139|NCT02863523|September 2014
72|Active not recruiting|Mobile Technology &amp; Online Tools to Track Adherence in Chronic Illness Patients||Behavioral:PlanetT1D|Interventional|Phase 2|Industry|KnowledgeofType1DiabetesDisease;  DiabetesManagementQuestionnaire(DMQ);  PerceivedTreatmentBenefits;  STARxTransitionReadinessQuestionnaire;  DiabetesSelf-Efficacyscale;  Self-Management: Self-Efficacy for Managing Chronic Disease Scale;  Self-Management:PartnersinHealthScale;  QualityofLife|200|NCT02861157|July 2015
73|Recruiting|Characterizing HIV-related Diastolic Dysfunction|||Observational||Other|persistent inflammation between HIV+/DD- and HIV+/DD+ subjects;  immune activation between HIV+/DD- and HIV+/DD+ subjects;  inflammation between HIV+/DD- and HIV+/DD+ subjects;  Perform phenomics of aggregate demographic data to define risk factor phenotype signatures and relate these to HIV+/DD- and HIV+/DD+ subjects;  myocardial fibrosis by magnetic resonance imaging between HIV+/DD- and HIV+/DD+;  serumlevelsofbiomarkers;  novel mechanisms underlying DD in HIV+ subjects as measured by proteomic and metabolomics panels;  the effect of DD on mechanics of the left atrium in HIV;  sub-clinicalnecrosisinHIV+/DD+subjects;  myocardialstressinHIV+/DD+subjects;  Perform phenomics of aggregate clinical data to define risk factor phenotype signatures and relate these to HIV+/DD- and HIV+/DD+ subjects;  Perform phenomics of aggregate biomarker data to define risk factor phenotype signatures and relate these to HIV+/DD- and HIV+/DD+ subjects;  Perform phenomics of aggregate electrocardiogram data to define risk factor phenotype signatures and relate these to HIV+/DD- and HIV+/DD+ subjects;  Perform phenomics of aggregate imaging data to define risk factor phenotype signatures and relate these to HIV+/DD- and HIV+/DD+ subjects|200|NCT02860156|November 2016
74|Not yet recruiting|CaREFREE Study (Calorie Restriction Environment and Fitness: Reproductive Effects Evaluation Study)||Behavioral:NEA;  Behavioral:DEA|Interventional|Phase 0|NIH|The primary outcome measure will be change in daytime LH pulse frequency following 5 days of neutral energy availability as compared to LH pulse frequency following 5 days deficient energy availability. LH pulse frequency will be derived from 2 ...;  Change in hormone measures (LH FSH estradiol and progesterone from daily urine samples and blood spots total cycle follicular and luteal phase length during the cycle following NEA or DEA;  Change in leptin ghrelin adiponectin insulin and glucose in response to standardized breakfast lunch and snack;  ChangeincortisolTSHTT3andfT4|50|NCT02858336|July 2016
75|Not yet recruiting|Human Biological Responses to Low Level Ozone||Other:Ozone;  Other:FilteredAir|Interventional||Other / U.S. Fed|Change in nasal % Polymorphonuclear Leukocyte (PMN);  RNAgeneexpressionprofiles;  ChangeinNasalImmunemediatorsofcytokines;  Changeinsputumcellcounts;  ChangeinFEV1;  ChangeinFlowmediateddilation;  Changeinheartratevariability(HRV);  Changeinleftventricularcontractility|16|NCT02857283|August 2016
76|Enrolling by invitation|Changes in Footwear Comfort and Performance in High School Football Players||Other:ModerateStiffnessFootwear;  Other:HighStiffnessFootwear|Interventional||Other|Footwear comfort rating using a 100mm visual analog scale;  Injuryincidence|100|NCT02856360|July 2016
77|Recruiting|Pre-hospital Advanced Therapies for Control of Hemorrhage - Pelvis||Device:PelvicBinder|Interventional||Other|MortalityRate;  PainScores-VisualAnalogScale;  SkinComplications;  Lengthofstayinhospital;  BloodTransfusions|75|NCT02855060|July 2016
78|Recruiting|Duke Scleroderma Clinic Patient Registry||Other:Registry|Observational||Other|Change in disease activity as measured by Rodnan Skin Score;  Change in disease activity as measured by patient reported Scleroderma Health Associated Questionnaire (SHAQ)|1000|NCT02851875|April 2016
79|Recruiting|Oral Psoriasis Treatment Adherence and Intervention Study||Behavioral:InternetSurvey|Interventional|Phase 3|Other / Industry|Adherence to prescribed oral Methotrexate treatment;  PatternsofMisuse;  Psoriasisseverityoutcomes;  RelationshiptoAdherence;  RelationshiptoSatisfaction|40|NCT02850900|April 2016
80|Recruiting|HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma||Procedure: Hyperthermic intraperitoneal chemotherapy;  Procedure:Openpancreaticoduodenectomy;  Drug:Gemcitabine|Interventional|Phase 2|Other|Peritonealdisease-freesurvival;  Overallsurvival;  Localdisease-freesurvival;  Postoperativemorbidity;  Postoperativemortality|10|NCT02850874|February 2016
81|Not yet recruiting|Geniculate Artery Embolization for the Treatment of Knee Pain||Device:GeniculateArteryEmbolization|Interventional||Other|Patientfunction(arbitraryunits);  Patientpain(mm);  ReductioninMedication(arbitraryunits)|20|NCT02850068|August 2016
82|Not yet recruiting|Evaluation of Tumor and Blood Immune Biomarkers in Resected Non-small Cell Lung Cancer|||Observational||Other|Quantity of functional tumor infiltrating lymphocytes (TILs) to determine tumor antigen-specific T cell re-activities.|30|NCT02848872|August 2016
83|Recruiting|Effects of E-cigarettes (ECIGs) on Pulmonary Inflammation and Behavior in HIV Infected Smokers||Other:ECIGS;  Behavioral:mobilecontingencymanagement(mCM);  Other:Usualbrand|Interventional||Other / NIH|Changesinsputumglutathioneconcentration;  Changeinsputum8-isoprostane;  Changeinnitrate/nitrite;  Changeinsputuminflammatorycytokines;  Change in withdrawal as measured by questionnaire;  Changeincravingasmeasuredbyquestionnaire;  Change in neurocognition as measured by questionnaire|20|NCT02848586|August 2016
84|Recruiting|An Open-Label Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration||Drug:Elamipretide|Interventional|Phase 1|Industry|TheincidenceandseverityofAdverseEvents;  Changeinfundushyperautofluorescence;  Change from Baseline in best-corrected low-luminance (LL) visual acuity;  Change from Baseline in mesopic light sensitivity by microperimetry;  Changeindarkadaptometry;  Change in drusen volume (&quot;retinal pigment epithelium - drusen complex&quot; as measured by automated segmentation) by SD-OCT;  Changeinfundusphotography;  Change in best-corrected visual acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study scale;  Changeisspeedreadingatstandardlight;  Changeisspeedreadingatlowlight;  Change in LL visual function by the Low-Luminance Questionnaire;  Change in National Eye Institute Visual Function Questionnaire-39 (VFQ-39) score;  Compliance of administration of subcutaneous elamipretide;  Number of home health visits necessary for subject or caregiver to learn how to inject elamipretide|40|NCT02848313|October 2016
85|Recruiting|Cord Blood Infusion for Children With Autism Spectrum Disorder||Biological:CordBloodInfusion;  Biological:Placebo|Interventional|Phase 2|Other|Changeinsocialcommunication;  ChangeinVinelandSocializationdomainrawscore;  Change in Vineland Socialization domain age equivalent;  Change in Pervasive Developmental Disorder Behavior Inventory (PDD-BI) composite standard score (parent questionnaire);  ChangeinCGI-S(clinicianassessment);  ChangeinCGI-I(clinicianassessment);  Change in Expressive One-Word Picture Vocabulary Test (clinician assessment);  Change in Vineland Adaptive Behavior Communication subscale standard score;  Change in Vineland Adaptive Behavior Daily Living subscale standard score;  ChangeinVinelandAdaptiveBehaviorComposite;  Change in individual subscales of the PDD-BI t scores;  Incidenceofinfusionreactions;  Severityofinfusionreactions;  Incidenceofproduct-relatedinfections;  Severityofproduct-relatedinfections;  Evidence of alloimmunization via anti-HLA and anti-RBC antibodies and nonspecific markers of systemic inflammation (ESR CRP);  Incidenceofgraftvs.hostdisease;  Severityofgraftvs.hostdisease;  Incidence of unexpected adverse events by relation to study product;  Severity of unexpected adverse events by relation to study product|165|NCT02847182|August 2016
86|Recruiting|Study on Smoking Cessation and Cost Outcomes in the Duke Smoking Cessation Program|||Observational||Other / NIH|Biochemically confirmed continuous 30-day abstinence from smoking;  Biochemically confirmed 7-day point prevalence abstinence from smoking;  Self-report 7-day point prevalence abstinence from smoking;  Smokingreduction;  Changesinstress;  Changesinanxiety;  Changesindepression;  Changesinrelapsepredictors;  Overall cost of treatment in dollars per participant;  cost of medical visits in dollars per abstinent participant;  costofmedicationsperabstinentsmoker;  cost of behavioral intervention per abstinent smoker;  costofprescribedmedicationsindollars|3000|NCT02845687|July 2016
87|Recruiting|A Volumetric Analysis of Soft and Hard Tissue Healing for Ridge Preservation and Socket Seal After Tooth Extraction||Biological:Xenograftbonesubstitute;  Biological:Collagendressing;  Biological:3D-collagenmatrix|Interventional|Phase 4|Other / Industry|Thicknessofthebuccalplate;  Heightofthealveolarridge;  Softtissuevolume;  Bonevolume;  Woundhealingassessment|24|NCT02844569|July 2016
88|Recruiting|Understanding of the Pathophysiology and Psychopharmacology of Binge Drinking||Drug:Naltrexone;  Drug:Bupropion|Interventional|Phase 2|Other|TolerabilityofNaltrexone/Buproprion;  ChangeinDrinkingBehavior;  ChangeinCraving|12|NCT02842073|September 2016
89|Enrolling by invitation|Study on Sit to Quit Phone Intervention||Drug:Nicotinepatches;  Behavioral:SittoQuit;  Behavioral:QuitforLife|Interventional|Phase 1|Other / Industry / NIH|Biochemically confirmed continuous 30-day abstinence from smoking;  Biochemically confirmed 7-day point prevalence abstinence from smoking;  Self-reported 7-day point prevalence abstinence rates;  Smokingreduction;  Changesinstress;  Changesinanxiety;  Changesindepression;  Changesinrelapsepredictors;  Feasibility:attendancerecords;  Feasibility:websiteusage;  Feasibility:courseevaluation;  Feasibility:demographics;  Feasibility:Behavioralinterventionused;  Feasibility:AttendanceatDSCPappointments;  Feasibility:ReferralroutestoDSCP;  Feasibility:Sideeffects;  Feasibility:medicationadherence;  Feasibility:mindfulnesspractices;  Feasibility:meditationtime|60|NCT02840435|September 2016
90|Completed|Dietary Nitrate Supplements and Ischemic Stroke Recovery||Drug:BeetitBeetrootjuice;  Drug:BeetItPlaceboBeetrootjuice|Interventional|Phase 2|Other|Adherencewithintervention;  Incidenceofadversetreatment-alteringevents;  Plasmanitratelevelsmicromoles/liter;  Plasmanitritelevelsmicromoles/liter;  Gaitspeed;  CerebralPerfusionimaging;  Upperextremitygripstrength;  MontrealCognitiveAssessment(MoCA)score;  ModifiedRankinScore|18|NCT02838901|June 2012
91|Not yet recruiting|The Relationship Between GOLD Risk Group and Clinical Outcomes in a Community-based COPD Cohort|||Observational||Other / Industry|ChangeinCompositeEndpoint;  ChangeinCOPDExacerbation;  ChangeinAll-CauseHospitalization;  ChangeinRespiratory-relatedHospitalization;  ChangeinAll-CauseMortality|850|NCT02838108|August 2016
92|Recruiting|The TREND Study: Tapered Reduction in Energy Intake as a Novel Approach to Dieting||Behavioral:TaperedLowCalorieDiet;  Behavioral:TraditionalLow-CalorieDiet|Interventional||Other|Ghrelin;  Leptin;  Glucagon-likepeptide-1(GLP1);  Body Composition (percent body fat percent lean mass);  RestingMetabolicRate(RMR);  Weight(kg);  Hunger;  Weight-relatedqualityoflife(IWQOL-Lite)|40|NCT02837211|August 2016
93|Not yet recruiting|Mobile Technology and Online Tools to Improve Asthma Control in Adolescents||Behavioral:CampAir;  Behavioral:InformationandReferral|Interventional|Phase 2|Industry / Other|NightWakeningsDuetoAsthma;  UrgentHealthUtilization;  AsthmaMorbidity;  Asthmaself-managementskills:AttackManagement;  Asthmaself-managementskills:SymptomPrevention;  Asthma self-management skills: Asthma Self-Efficacy;  Qualityoflife(QOL);  Asthmacontrol;  Useofmedication;  Self-Management subscale of the Asthma Management and Medication Scale (AMMS);  Interventionfeedback;  Softwareusage;  After-ScenarioQuestionnaire(ASQ);  Post-StudySystemUsabilityQuestionnaire(PSSUQ);  TechnologyAcceptanceModel(TAM);  CampAirEvaluation|70|NCT02835300|September 2016
94|Not yet recruiting|Selinexor With Induction Consolidation and Maintenance Therapy in Treating Older Patients With Acute Myeloid Leukemia||Drug:Cytarabine;  Drug:DaunorubicinHydrochloride;  Drug:Selinexor|Interventional|Phase 2|Other / NIH|Feasibility of combining selinexor with induction/consolidation/maintenance therapy assessed by percentage of patients eligible for maintenance therapy who complete at least 3 courses;  Incidence of adverse events assessed by Common Terminology Criteria for Adverse Events version 4.0;  Overallsurvival;  Progress-freesurvival;  Rateofallogeneicstemcelltransplantation;  Rateofcompleteremission|50|NCT02835222|August 2016
95|Not yet recruiting|Patient Function/Fitness and Psychosocial Health in Improving Health-Related Quality of Life in Patients With Stage I-IV Non-Small Cell Lung Cancer||Other:IntegratedFitnessAssessment;  Procedure:PsychosocialAssessmentandCare;  Procedure:Quality-of-LifeAssessment|Observational||Other / NIH|Patientfunction/fitness;  Patientwell-being|250|NCT02835066|July 2016
96|Recruiting|Teriflunomide&apos;s Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.|||Observational||Other / Industry|Percent Inhibition of activated/memory B-cells derived from RRMS patients.;  Change in Cytokine Secretion Profile of T-cells stimulated by teriflunomide treatment;  Measure the effect of oral teriflunomide on the cytokine secretion as measured in the ex-vivo obtained longitudinal samples from the treated patients.;  Measure the effect of oral teriflunomide on the B cell activation as measured in the ex-vivo obtained longitudinal samples from the treated patients.|46|NCT02833714|January 2016
97|Recruiting|Point of Care 3D Ultrasound for Various Applications: A Pilot Study|||Observational||Other|Experimental ultrasound diagnosis agreement with final reference standard diagnosis;  Durationofexperimentalultrasoundexam;  Experimentalultrasoundimagequality.|300|NCT02831556|July 2016
98|Enrolling by invitation|CALYPSO Pilot Study: Machine Learning Based Predictions of Surgical Complications||Other:CALYPSO;  Behavioral:StandardCare|Observational||Other|ThirtyDayOverallComplications;  ThirtyDayMortality;  WoundComplications;  CardiacComplications;  RespiratoryComplications;  Thromboticcomplications;  RenalComplications;  urinarytractinfections;  Neurologiccomplications;  Septiccomplications;  Unplannedreoperation;  unplannedreadmission;  bleedingcomplications|200|NCT02828475|June 2016
99|Not yet recruiting|Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer||Biological:Durvalumab;  Other:LaboratoryBiomarkerAnalysis;  Procedure:TherapeuticConventionalSurgery|Interventional||Other / NIH|Immune effector assessed in blood by flow cytometry and in tissue by immunohistochemistry;  Immune-regulatory miR responses as measured in plasma assessed by quantitative reverse transcriptase PCR (qRT-PCR);  Systemic immune response to HPV assessed by enzyme-linked immunosorbent assay (ELISA);  Regulatory responses assessed in blood by flow cytometry and in tissue by immunohistochemistry;  Immune-regulatory miR responses as measured in saliva assessed by quantitative reverse transcriptase PCR (qRT-PCR);  Immune-regulatory miR responses as measured in tumor tissue assessed by quantitative reverse transcriptase PCR (qRT-PCR);  Systemic immune response to tumor associated antigens assessed by enzyme-linked immunosorbent assay (ELISA);  Incidence of adverse events (AEs) as measured by CTCAE version 4.03;  Standardized Uptake Value (SUV) as measured by PET scans;  Tumor volume assessed using RECIST version 1.1 criteria|20|NCT02827838|August 2016
100|Recruiting|North Carolina Newborn Exome Sequencing for Universal Screening||Genetic:Wellinfantwholeexomesequencing;  Genetic:Diagnosedwholeexomesequencing|Interventional||Other / NIH|Parentaldecisionmakingusingdecisionaid.;  Sensitivity of whole exome sequencing in detecting conditions by comparing results of sequencing to the appropriate genes associated with the child&apos;s underlying condition.;  Participant characteristics and reactions to the study will be collected through surveys.|400|NCT02826694|June 2016
101|Recruiting|Adaptive Optics for Ophthalmic Technologies||Device:WF-AO-OCT|Interventional||Other|ImageQuality;  Peripheral Retina Structure Differences between Healthy Controls and participants with diabetic retinopathy.|100|NCT02826655|June 2016
102|Recruiting|A Pilot Study Investigating the Effect of Chemotherapy on the Tumoral Immunoprofile of Gynecologic Cancers|||Observational||Other / NIH|Change in number and type of tumor infiltrating lymphocytes;  Change in expression level of Inflammatory mediators;  ChangeintumorexpressionlevelofPD-L1;  ChangesinHLA-type|25|NCT02824328|June 2016
103|Not yet recruiting|Feasibility Study of Retinal Screening Using the RetinaVue 100 Camera in Outpatient Dialysis Centers||Device:RetinaVue100camera|Interventional||Other / Industry|UsabilityoftheRetinaVueHand-Held100Camera;  Percentage of diabetic dialysis subjects having prior retinal screening;  Percentage of diabetic dialysis subjects screened at study conclusion;  Percent change from baseline in diabetic dialysis subjects screened;  Rates of overall retinopathy in a dialysis population;  Patientsatisfaction|250|NCT02823600|July 2016
104|Recruiting|Effect of Urethral Analgesia on Voiding||Drug:lidocainegel;  Other:Plainaqueousgel|Interventional||Other|VoidingEfficiency;  Detrusorpressureatmaximumflow;  Presenceorabsenceofvoidingdysfunction;  Visual analog scale scores (measure of discomfort)|40|NCT02823431|July 2016
105|Not yet recruiting|Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil - WF 97116||Drug:Donepezil5mg;  Drug:Placebo|Interventional|Phase 3|Other|MemoryQuestion;  HVLT-RFormC1stlearningtrial;  Changes in Hopkins Verbal Learning Test-Revised (HVLT-R) Results;  Changes in Controlled Oral Word Association Test (COWA) Results;  Changes in Trail Making Test Parts A &amp; B (TMT-A TMT-B) Results;  Shipley Institute of Living Scale-Version 2 Vocabulary;  ChangesinPROMIS7-itemFatigueScaleResults;  PROMIS8-itemSleepDisturbanceScale;  Changes in Personal Health Questionnaire-9 Depression Scale Results;  DigitSpanTest-Backwards(DST-B);  Changes in Shipley Institute of Living Scale-Version 2 Vocabulary Results;  Changes in PROMIS 8-item Sleep Disturbance Scale Results;  Changes in Digit Span Test-Backwards (DST-B) Results;  ChangesinDigitSymbolCodingResults;  ChangesinFACT-Cognition(Version3)Results|276|NCT02822573|September 2016
106|Recruiting|Mobile Technology and Online Tools to Improve Asthma Control in Adolescents - Usability||Behavioral:CampAir|Interventional|Phase 2|Industry / Other|ProductEvaluation|25|NCT02816216|May 2016
107|Not yet recruiting|Safety of Anti-Depressant for Chronic Obstructive Pulmonary Disease (SAD-COPD)||Drug:Sertraline;  Drug:Placebo|Interventional||Other|Changein6MWdistance;  Change in dyspnea scores as measured by UCSD Medical Center Pulmonary Rehabilitation Program Shortness of Breath Questionnaire (UCSD-SOB);  Change in quality of life as measured by Ferrans &amp; Powers Quality of Life Index - Pulmonary version (QOL);  Change in perceived stress as measured by General Health Questionnaire-12 (GHQ-12);  Change in anxiety as measured by Hamilton Anxiety and Depression Scale (HADS);  Change in anxiety as measured by Anxiety Inventory for Respiratory Disease (AIR);  Change in depression as measured by Hamilton Anxiety and Depression Scale (HADS);  Tolerability|30|NCT02813447|June 2016
108|Recruiting|Recruiting African American Fathers/ Sons|||Observational||Other|Recruitment Strategy for the recruitment of African American father/son dyads|34|NCT02811848|April 2016
109|Recruiting|Intranasal Insulin and Post-stroke Cognition: A Pilot Study||Drug:IntranasalInsulin;  Drug:Intranasalsaline|Interventional||Other|Compositeofmemoryzscores;  Compositeofexecutivefunctionzscores|40|NCT02810392|April 2016
110|Recruiting|Do NSAIDS or Executing Exercise Decrease Local Erythema Site Swelling &amp; Pain After INoculation||Drug:Ibuprofen;  Behavioral:CompoundExerciseofPushups;  Drug:oralplacebo|Interventional||U.S. Fed|Pain;  serologicresponse;  erythema;  edema;  induration;  exercise|300|NCT02807623|September 2016
111|Not yet recruiting|To Enhance Breast Cancer Survivorship of Asian Americans||Behavioral: Technology-based information and coaching/support program|Interventional||Other|Changes in the needs for help measured using the Support Care Needs Survey-34 Short Form (SCNS-34SF);  Changes in physical and psychological symptoms measured using the Memorial Symptom Assessment Scale-Short Form (MSAS-SF);  Changes in quality of life measured using the Functional Assessment of Cancer Therapy Scale-Breast Cancer (FACT-B);  Changes in attitudes related to breast cancer survivorship measured using the Questions on Attitudes Self-Efficacy Perceived Barriers and Social Influences (QASPS);  Changes in self-efficacy related to breast cancer survivorship measured using the Cancer Behavior Inventory (CBI);  Changes in perceived barriers related to breast cancer survivorship measured using the subscale on perceived barriers of the QASPS;  Changes in social influences related to breast cancer survivorship measured using the subscale on social influences of the QASPS the Personal Resource Questionnaire (PRQ-2000) and the Perceived Isolation Scale (PIS)|330|NCT02803593|June 2016
112|Not yet recruiting|Respiratory Muscle Training in LOPD||Device:RMTtherapyusingmodifiedRMTdevice;  Device: Sham-RMT therapy using modified RMT device|Interventional||Other / NIH|Changeinrespiratorystrength;  Feasibility of sham-RMT as measured by program adherence;  Changeinmaximumexpiratorypressures(MEP);  Changein6-minutewalktest(6MWT);  Change in Gait Stairs Gower and Chair (GSGC) scale;  Changeinpeakcoughflow(PCF);  Change in Rasch-built Pompe-specific Activity Score (R-PAct)|28|NCT02801539|June 2016
113|Not yet recruiting|Hokusai VTE Pediatric Study||Drug:Edoxaban60mganddosingonmg/kgbasis;  Drug:WarfarindosedatINRlevelandmg/kgbasis;  Drug: Enoxaparin dosed at INR level and mg/kg basis;  Drug: Fondaparinux dosed at INR level and mg/kg basis;  Drug:Edoxaban45mganddosingonmg/kgbasis|Interventional|Phase 3|Industry|Composite and adjudicated endpoint: symptomatic recurrent VTE;  Composite and adjudicated endpoint: death as a result of VTE;  Composite and adjudicated endpoint: no change or extension of thrombotic burden;  Composite and adjudicated endpoints: major bleeding;  Composite and adjudicated endpoints: Clinically relevant non-major bleeding;  Composite and adjudicated endpoints of: symptomatic recurrent VTE death as a result of VTE and major and clinically relevant non-major bleeding.;  PharmacokineticsofEdoxaban-Cmax;  PharmacokineticsofEdoxaban-AUC;  PharmacokineticsofEdoxaban-CL/F;  PharmacokineticsofEdoxaban-V/F;  PharmacodynamicsofEdoxaban-PT;  PharmacodynamicsofEdoxaban-aPTT;  PharmacodynamicsofEdoxaban-Anti-FXa|274|NCT02798471|September 2016
114|Recruiting|Comparison of 3 Techniques for Recreation of Anterior Cruciate Ligament Anatomic Footprint||Procedure: Anterior Cruciate Ligament Reconstruction|Interventional||Other|3DreconstructedCTimaging;  International Knee Documentation Committee (IKDC) Subjective Knee Evaluation;  Knee injury and Osteoarthritis Outcome Score (KOOS);  KneeLaxity|30|NCT02795247|August 2016
115|Recruiting|Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea||Drug:Ivermectin;  Drug:Ivermectin(reference);  Drug:Placebo|Interventional|Phase 3|Industry|Mean percent change from baseline in the inflammatory (papules and pustules) lesion count;  Subjects with clinical success on the Investigator Global Assessment (IGA)||NCT02795117|
116|Recruiting|Optimizing Delivery of a Behavioral Cancer Pain Intervention Using a SMART||Behavioral:PainCopingSkillsTrainingFull;  Behavioral:PainCopingSkillsBrief|Interventional||Other|ChangeinPainintensity;  ChangeinPainIntensity;  PainInterference;  Practicalityasmeasuredbyaccrual;  Practicalityasmeasuredbyretention;  Practicalityasmeasuredbyadherence;  Pain Catastrophizing as measured by the 6-item pain catastrophizing subscale of the Coping Strategies Questionnaire;  Cost-Effectiveness|350|NCT02791646|November 2016
117|Not yet recruiting|Cardiovascular Injury Exercise Intolerance and Fatigue After Adjuvant Chemotherapy for Stage I-III Breast Cancer||Other:Observational;  Other:DataCollection;  Other:Assessments|Observational||Other|FACT-Fatigue;  ChangeinFACT-FatigueResults;  ChangeinMRIExamResults;  Changein6MinuteWalkResults;  Cohen&apos;s4-itemPerceivedStressScale(PSS);  ChangesinFACT-FatigueResults;  6MinuteWalkResults;  MOS36-itemShortFormHealthSurvey(SF-36);  Center for Epidemiological Studies Depression Scale (CESD-10);  GodinLeisure-TimeExerciseQuestionnaire(LTEQ);  PACEAdultSedentaryBehaviorsSurvey;  ChairStands-MeasuresLegStrength;  StandingBalanceTest;  GripStrength;  RangeofMotion|1000|NCT02791581|April 2017
118|Active not recruiting|Dose-Related Inflammatory Effects of Intravenous Endotoxin in Humans||Biological:Endotoxin;  Other:Placebo|Interventional|Phase 1|Other|Changeinheartrate;  Number of treatment emergent adverse events (TEAEs);  Changeinbloodpressure;  ChangeinECGparameters;  Changeinrespiratoryrate;  Changeinbodytemperature;  ChangeinPulseOximetry;  Dose-ResponseComparison;  ChangeinPatientHealthQuestionnaire(PHQ-9);  ChangeinAffectRatingScale;  Changeinplasmapro-inflammatorycytokines;  ChangeinRNA;  ChangeinhsC-reactiveprotein;  Changeincortisollevels;  Changeincompletebloodcount;  ChangeinWBCcounts;  Changeinlymphocytes;  Changeinmonocytes;  ChangeinmRNA|24|NCT02789241|August 2016
119|Recruiting|ICAN Symptoms Duke-NUS||Behavioral: Cognitive Behavioral Mult-Symptom management(CBT)|Interventional||Other|Feasibility as measured by study accrual by meeting recruitment goal;  Feasibility as measured by study attrition which will be assessed by patients who do not complete the post-assessment.;  Feasibility as measured by adherence to the study protocol by number of intervention sessions completed by the participant;  Acceptability as measured by Client Satisfaction Questionnaire 10-item version;  CulturalSensitivity;  Changeinanxietyanddepression;  Changeinpain;  Changeinfatigue;  ChangeinPain|40|NCT02787993|November 2016
120|Recruiting|Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generation||Other: Physical performance testing and patient-generated health data|Observational||Other|Proportion of patients being approached that agree to participate in the study;  Proportion of enrolled patients who complete CPET and 6MWD test without significant testing-related adverse events;  Proportion of recruited patients who wear Fitbit for at least 8 hours per day;  Proportion of patients for whom all data is successfully recorded within database;  Compare pre-treatment aerobic capacity (VO2max or 6MWD) with post-treatment average measured steps per day;  Compare pre-treatment clinician-rated performance status and aerobic capacity (VO2max or 6MWD) with post-treatment average steps per day;  Compare pre-treatment aerobic capacity (VO2max or 6MWD) and post-treatment average measured steps per day among the three cohorts (solid tumor hematologic malignancies hematopoietic cell transplantation);  Compare average measured steps per day and patient-reported symptomatic toxicities;  Compare resting heart rate trajectories (as measured by Fitbit) before and after chemotherapy;  Compare resting heart rates as measured from VO2max testing with resting heart rates as measured by Fitbit|45|NCT02786628|February 2016
121|Recruiting|A mHealth Behavioral Cancer Pain Protocol for Medically Underserved Communities||Behavioral:Device:smartphone|Interventional||Other|Change in pain severity will be assessed with the Brief Pain Inventory (BPI).;  Change in pain Interference will be assessed with the Brief Pain Inventory (BPI);  Change in self-efficacy for pain control will be assessed with the self-efficacy for pain management subscale of the Chronic Pain Self-Efficacy Scale.;  Change in pain catastrophizing will be assessed with the Coping Strategies Questionnaire.;  Change in Depressive Symptoms:(PROMIS )four-item Depression Scale a self-report measure of depressive symptoms.;  Changeinfatigue;  Change in mPCST Acceptability as measured by participants&apos; engagement;  changeinHealth-RelatedQualityofLife|20|NCT02783755|May 2016
122|Recruiting|Provider-Patient Communication Coaching||Behavioral:Communicationcoaching|Interventional||Other|Change in provider burnout as measured by questionnaire;  change in comfort addressing emotion as measured by questionnaire;  change in self-rated efficiency as measured by questionnaire|2400|NCT02783742|May 2016
123|Recruiting|A Randomized Controlled Trial Evaluating the Efficacy of Intralesional Triamcinolone in Hidradenitis Suppurativa.||Drug:TriamcinoloneAcetonide10mg/mL;  Drug:TriamcinoloneAcetonide40mg/mL;  Drug:NormalSaline|Interventional||Other|Number of days to lesion resolution in combined treatment arms compared to the placebo arm.;  Changeinpainfrombaselinetoday5;  Patient rating of impression of treatment at day 14|50|NCT02781818|June 2016
124|Recruiting|Culture of Circulating Tumor Cells Isolated From Cancer Patients With Metastatic Disease||Other:Blooddraw|Observational||Other|TheproportionofsuccessfulCTCculturegrowths.|30|NCT02781025|April 2016
125|Recruiting|Bedside Ultrasound to Measure Optic Nerve Sheath Diameter in Pediatric CSF Shunts|||Observational||Other|Compare the initial and final optic nerve sheath diameters measured by ultrasound in patients who are admitted for shunt failure;  Compare the optic nerve sheath diameter measurements of asymptomatic patients vs symptomatic patients who are not diagnosed with shunt failure vs those are diagnosed with shunt failure and admitted.|87|NCT02776085|May 2016
126|Recruiting|UCB Cimzia Pregnancy Follow-up Study|||Observational||Industry / Other|Percentage of newborns with major congenital malformations;  Percentage of pregnancy outcomes with major congenital malformations;  Numbersofmaternalpregnancy-relatedevents;  PercentageofVaginalandC-sectiondeliveries;  Gestationalageatbirth;  Birthweight;  Smallforgestationage;  Percentageofadverseeventsininfants;  Percentage of infants less than or equal to the 10th percentile for sex and age with respective to weight (based on the relevant population norm for the infant);  Percentage of infants less than or equal to the 10th percentile for sex and age with respective to height (based on the relevant population norm for the infant);  Percentage of infants less than or equal to the 10th percentile for sex and age with respective to head circumference (based on the relevant population norm for the infant);  Percentage of infants less than or equal to the 10th percentile for sex and age with respective to gross motor skills;  Percentage of infants less than or equal to the 10th percentile for sex and age with respective to fine motor skills;  Percentage of infants less than or equal to the 10th percentile for sex and age with respective to language;  Percentage of infants less than or equal to the 10th percentile for sex and age with respective to cognitive skills;  Percentage of infants less than or equal to the 10th percentile for sex and age with respective to social skills|360|NCT02775656|November 2016
127|Recruiting|Prehabilitation Using Aquatic Exercise||Behavioral:AquaticPrehab|Interventional||Other|ChangeinphysicalfunctionusingtheMAT-sf;  ChangeinphysicalfunctionusingtheeSPPB;  Change in physical function using the Postural Sway Force Plate|40|NCT02773745|April 2016
128|Recruiting|ARV Concentrations in Hair||Other:Hairanalysis|Observational||Other / NIH|IR-MALDESI response to ARVs to be validated by LC-MS/MS analysis in hair before and after treatment with bleach;  IR-MALDESI response to ARVs to be validated by LC-MS/MS analysis in hair before and after treatment with straighteners;  IR-MALDESI response to ARVs to be validated by LC-MS/MS analysis in hair before and after treatment with hair color|85|NCT02768779|April 2016
129|Recruiting|Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer||Drug:Pembrolizumab;  Drug:Cyclophosphamide|Interventional|Phase 2|Other|TheProgressionFreeSurvival(PFS)|36|NCT02768701|October 2016
130|Recruiting|A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium||Drug:Atorvastatin|Interventional|Phase 0|Other|Absolutedifferencescore|24|NCT02767362|November 2015
131|Withdrawn|Pharmacokinetics and Safety of MNK-155 in Postsurgical Adolescent Subjects With Moderate to Severe Acute Pain||Drug:MNK-155|Interventional|Phase 1|Industry|Timetoreachsteadystate;  Areaunderthecurve;  Peakexposure;  Half-life;  Timetopeakexposure|0|NCT02767349|January 2016
132|Recruiting|Using TMS to Increase Executive Function in Older Adults||Device:rTMS;  Device:ShamrTMS|Interventional||Other / NIH|Acute effect of a rTMS session on the performance for a working memory task as measured by reaction time of correct response (in ms);  change in cumulative effects of rTMS on the performance for a working memory task as measured by reaction time of correct response (in ms);  change in transfer of the effect of rTMS on other global cognition as measured by reaction time of correct response (in ms);  Acute effect of a rTMS session on the performance for a working memory task as measured by accuracy (in percentage);  change in cumulative effects of rTMS on the performance for a working memory task as measured by accuracy (in percentage);  change in transfer of the effect of rTMS on other global cognition as measured by accuracy (in percentage)|60|NCT02767323|January 2016
133|Not yet recruiting|Identification of Tongue Involvement in Late-Onset Pompe Disease||Other:Observationalstudy|Observational||Other / Industry|Maximal lingual (tongue) strength measured via manual muscle testing (MMT) measured via ordinal scale (see description);  Maximal lingual (tongue) strength measured via quantitative muscle testing (QMT) measured in kilopascals (KPA);  Maximal muscle thickness measured with ultrasound assessment in millimeters (mm);  Echo intensity measured with ultrasound assessment utilizing grayscale analysis|70|NCT02765828|May 2016
134|Recruiting|Aiming to Improve Readmissions Through InteGrated Hospital Transitions||Other:CHSTransitionServices|Interventional||Other|30-dayallcausereadmission;  30-dayallcauseCHSreadmission;  Observed\Expected ratio for all cause 30-day readmissions;  Lengthofstayupontheindexvisit;  Lengthofstayuponthereadmissionvisit;  Allcause60and90-dayreadmissionrate|1520|NCT02763202|February 2016
135|Not yet recruiting|Effect of Mentoring on Endotracheal Tube Exchange Using a New Device||Other:Expertmentoring;  Other:Self-study|Interventional||Other|ApneaTime;  Performancescore|20|NCT02763189|June 2016
136|Not yet recruiting|ABC294640 in Refractory / Relapsed Multiple Myeloma||Drug:ABC294640|Interventional|Phase 1 / Phase 2|Industry / Other / NIH|MaximumToleratedDose;  TreatmentResponse;  OverallSurvival;  DoseLimitingToxicity;  Correlativestudy:plasmaIL-6level.;  Correlative study: SK2 mRNA or activity sphingolipid metabolites c-Myc Mcl-1 and pS6) in bone marrow CD138+ myeloma cells.;  Pharmacodynamics: plasma sphingosine 1-phosphate level;  Pharmacokinetics:PlasmalevelsofABC294640|74|NCT02757326|September 2016
137|Recruiting|Pain Processing in Adults With Migraines||Other:Questionnaires;  Other: Quantitative Sensory Testing (QST) Pain Measurements|Interventional||Other|Heat Pain Intensity coefficient and intercept from stimulus response curve;  Heat Pain Unpleasantness coefficient and intercept from stimulus response curve;  PainCatastophizingscore;  DifficultyinEmotionsRegulationscore;  HeatPainThresholdTemperature;  Anxiety;  Depression;  Mindfulness;  Stress;  Hope;  Optimism;  SocialConnectedness;  Flourishing;  Resilience;  Sleep;  GlobalHealth|98|NCT02748577|January 2016
138|Recruiting|Qualitative Qualitative and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors||Biological:HepatitisAVaccine;  Other:LaboratoryBiomarkerAnalysis;  Biological:TetanusToxoidVaccine;  Biological:TrivalentInfluenzaVaccine|Observational||Other / NIH|Proliferative ability of lymphocytes by carboxyfluorescein diacetate succinimidyl ester assay;  The quantity of cells determined by flow cytometry;  Response of the tetanus toxoid vaccine-specific IgG antibody;  Vaccine-specific total antibody response after hepatitis A vaccination. In hepatitis A exposed patients hepatitis B will be used.|50|NCT02747407|May 2016
139|Not yet recruiting|Clinical Outcomes Maxilla: Buffered 1% Lidocaine vs. Non-buffered 2% Lidocaine||Drug:Lidocaine;  Drug:Epinephrine|Interventional||Other|Number of subjects with pulpal anesthesia maxillary molar;  Number of subjects with pulpal anesthesia maxillary canine|24|NCT02747186|May 2016
140|Not yet recruiting|Cytochrome P450 Epoxygenase Pathway Regulation of Macrophage Function|||Observational||NIH|The primary outcome measure will evaluate macrophage phagocytosis of fluorescein isothiocyanate (FITC)-labeled beads and bacteria (Streptococcus pneumoniae) in an ex vivo assay comparing alveolar macrophages from groups of individuals with and ...;  Macrophage phagocytosis of FITC-labeled beads and bacteria (S.pneumoniae) in an ex vivo assay comparing peripheral blood monocyte-derived macrophages from groupsof individuals with and without EPHX2 and CYP2J2 polymorphisms of interest|100|NCT02743468|April 2016
141|Recruiting|Pompe Disease QMUS and EIM||Device:Muscleultrasound;  Other:ElectricalImpedanceMyography|Interventional||Other / Industry|Percent change in muscle ultrasound echointensity as compared to baseline;  Percent change in muscle electrical impedance myography as compared to baseline;  Inter-rater reliability of muscle ultrasound and electrical impedance myography measures|25|NCT02742298|October 2016
142|Recruiting|Analgesic Benefit of PECS Blocks for Biceps Tenodesis Shoulder Surgery||Procedure: Interscalene plus PECS &quot;Pectoralis&quot; 1 and 2 Blocks;  Procedure:InterscaleneplusShamBlock|Interventional|Phase 4|Other|Post-operativeAxillaryPain;  NumericalRatingScalePainScoresatrest;  NauseaorVomiting;  TotalOpioidUsage;  TimetoReturnofAxillaryPain|40|NCT02741713|April 2016
143|Recruiting|Preoperative Pain Threshold and Rapid Recover Programs||Device:WagnerPainAlgometer;  Device:Dynamometer|Interventional||Other|Inpatientlengthofstayindays;  pain control average visual analogue scale 1 - 10 of hospital stay;  physical therapy performance on the first day after surgery;  dischargelocationplacement;  Outpatientnarcoticpillconsumption;  Outpatientnarcoticconsumptionrefillneeded;  Outpatient narcotic consumption multiple refills needed|200|NCT02740738|March 2016
144|Recruiting|The Effect of Reducing Posttraumatic Stress Disorder Symptoms on Cardiovascular Risk||Behavioral: Cognitive Processing Therapy - Cognitive|Interventional||Other|Changeinheartratevariability(HRV);  Changein24-hoururinarycatecholamine;  Change in inflammatory activity measured by high sensitivity C-reactive protein (hs-CRP);  Change in vascular endothelial function measured by brachial artery flow mediated dilation (FMD)|120|NCT02736929|April 2016
145|Active not recruiting|Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia||Drug:CX1739-300mg;  Drug:CX1739-600mg;  Drug:CX1739-900mg;  Drug:Placebo|Interventional|Phase 2|Industry / Other|Respiratorydepression;  Paintolerancethreshold;  Maintenanceofsedation;  The number of patients that experience an adverse drug reaction upon ingestion of CX1739 when used alone or in conjunction with remifentanil;  Changeinpupilsize|18|NCT02735629|March 2016
146|Not yet recruiting|Prospective Treatment Study of Catatonia Patients||Device:ElectroconvulsiveTreatment(ECT)|Interventional|Phase 1|Other|CatatoniaontheBush-FrancisScale(BFCRS);  DepressionontheHamiltondepressionscale;  Cognitive side effects on Montreal Cognitive Assessment (MoCA)|30|NCT02734498|May 2016
147|Recruiting|Implementation Research for Vulnerable Women in South Africa||Behavioral:Women&apos;sHealthCoOp(WHC)|Interventional||Other|Change in the perceived appropriateness of WHC intervention by interventionists;  Change in the perceived appropriateness of WHC intervention by interventionists and administrators;  Change in the perceived appropriateness of WHC intervention by clinicians community women and administrators;  AcceptabilityofWHCinterventionbypatients;  Change in the perceived acceptability of WHC intervention by interventionists (clinicians);  Change in the perceived acceptability of WHC intervention by setting (clinic);  Change in the perceived acceptability of WHC intervention by clinicians community women and administrators;  Adoption of WHC intervention by interventionists (clinicians);  AdoptionofWHCinterventionbysetting(clinic);  Change in the perceived adoption of WHC intervention by interventionists (clinicians) and administrators;  Change in the perceived adoption of WHC intervention by interventionists;  Start-upcostofWHCintervention;  OngoingcostofWHCintervention;  FeasibilityofWHCimplementation;  FeasibilityofWHCintervention;  FidelitytoWHCintervention;  PenetrationoftheWHCintervention;  SustainabilityoftheWHCintervention;  Change in the perceived sustainability of the WHC intervention;  SexualRisk;  Alcoholuse;  Substanceuse;  Victimization;  Communication;  RelationshipPower;  Medical evaluation initiation and treatment amongst HIV-positive women|432|NCT02733003|September 2014
148|Completed|The Efficacy of Cranial Electrostimulating Therapy for Depression and Anxiety Among Homeless Adults||Device:AlphaStimdevice;  Device:Shamdevice|Interventional||Other|DepressiveSymptoms;  Anxiety|10|NCT02732561|March 2016
149|Completed|Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis||Drug:InvestigationalOTCCream;  Other:CosmeticEczemaCream;  Drug:0.05%DesonideCream;  Other:PlaceboCream|Interventional|Phase 4|Industry|SCORAD(SeverityScoringofAtopicDermatitis)|53|NCT02732314|March 2016
150|Active not recruiting|Conventional Overdenture and Palateless Overdenture Oral Health Impact Comparison Study||Device:Overdenturetreatment|Observational||Other / Industry|OverallPatientsatisfactionOHIP49score;  Change in OHIP 49 score of initial edentulous condition to new interim denture;  Change in OHIP 49 score of new interim denture to implant retained interim denture;  Change in OHIP 49 score of implant retained interim denture to final palateless implant retained overdenture.|19|NCT02731703|April 2016
151|Not yet recruiting|Rejuvesol&#174; Washed RBC in Sickle Cell Patients Requiring Frequent Transfusions||Drug:Rejuvesol;  Procedure:Bloodtransfusion|Interventional|Phase 4|Other|Percenthemoglobin(HbA)decrement;  Actual HbA decrement (g/dl) with indexing to calculated circulating blood volume;  Actual HbA decrement (g/dl) without indexing to calculated circulating blood volume;  ChangeinRBCmicroparticles(MP)counts;  ChangeinRBC/RBC-MP-mediatedthrombingeneration;  Changeinp50pre-andpost-transfusion|4|NCT02731157|May 2016
152|Recruiting|Effect of High Protein Weight Loss for Seniors||Behavioral:WeightStableGroup|Interventional||Other|400MeterGaitWalkSpeed;  24-week body composition change at baseline 12-weeks and 24-weeks|124|NCT02730988|July 2015
153|Terminated|Take the Fight in Supporting and Empowering Patients With Cancer||Other:Quality-of-LifeAssessment;  Other:QuestionnaireAdministration;  Procedure:SupportiveCare|Interventional||Other / NIH|Change in patients self-reported outcomes using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life-Cancer 30 (QLQ-C30) questionnaire;  Change in strategists self-reported outcomes using Caregiver Quality of Life Index-Cancer (CQOLC McMillian 1996) scale|54|NCT02729883|February 2016
154|Recruiting|A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers||Drug:Pembrolizumab|Interventional|Phase 0|Other / Industry|FoldchangeintumorImmuneInfiltrates;  Toxicity Profile: Frequency and severity of adverse events as assessed by CTCAE|15|NCT02728830|June 2016
155|Not yet recruiting|Gabapentin as an Adjunct to Perioperative Pain Management Regimens for Uterine Aspiration||Drug:Gabapentin;  Drug:Placebo|Interventional|Phase 2|Other|Painscoreon11-pointVAS;  Painonthe100-mmVAS;  PerioperativenauseaasmeasuredbyVAS;  Perioperativevomiting;  Preoperative anxiety as measured by the preoperative state trait anxiety inventory;  Quantityofpainmedicationsused;  Sideeffects;  Pain(ona5-pointscale);  Nausea(ona5-pointscale);  Vomiting(ona5-pointscale);  SideEffects(ona5-pointscale);  General satisfaction with the procedure (on a 5-point scale)|96|NCT02725710|May 2016
156|Recruiting|Ventral Tegmental Area (VTA) Self-Activation in Attention Deficit Hyperactivity Disorder (ADHD)||Other: Real-Time functional Magnetic Resonance Imaging Feedback (RTFF)|Interventional||Other / NIH|PercentsignalchangeinVTABOLDactivation;  ChangeinVTABOLDsignalfollowingRTFF;  Change in goal-directed behavior as measured by the Effort discounting task;  Change in long-term memory formation as measured by memory trials;  Change in inhibitory control as measured by the Conners&apos; Continuous Performance Task (CPT);  Change in attention as measured by reaction time (RT) variability on the CPT|40|NCT02723708|August 2016
157|Recruiting|Magnetic Resonance Imaging (MRI) Solely For Liver Stereotactic Body Radiation Therapy (SBRT)|||Observational||Other|Measureaveragemotiontrajectories;  Imagequalityasmeasuredbyimagerating;  Imagequalityasmeasuredbytumorvolume;  Image quality as measured by tumor-to-live contrast to noise ratio;  Planningtargetvolume(PTV)|5|NCT02722395|August 2016
158|Enrolling by invitation|Application of a Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy in Patients With Eosinophilic Esophagitis (IDiET)||Behavioral: Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy|Interventional||Other / NIH|Histologic response (eosinophil counts at baseline and 6 weeks);  Absoluteesophagealeosinophilcount;  Endoscopyscore;  Dysphagiasymptomscore|16|NCT02722148|March 2016
159|Recruiting|Triggered Palliative Care for Advanced Dementia||Behavioral:SpecialtyPalliativeCare|Interventional||Other|Hospitaltransfers;  Comfort;  CaregiverStrain;  Accesstohospiceorpalliativecare;  POLST (Physician Orders for Life Sustaining Treatment);  PalliativeCareDomains;  Burdensometreatment|120|NCT02719938|March 2016
160|Recruiting|Comparison of Two Gingival Displacement Procedures||Device:AquasilUltraCordlessDentsply;  Device:UltrapakUltradentcord|Interventional|Phase 4|Other|Percentage of errors in impressions made for indirect restorations;  Timerequiredtomaketheimpression;  Patientdiscomfort|60|NCT02716727|October 2016
161|Recruiting|Arise: An Online Relapse Prevention Tool for Adolescent Substance Abusers||Behavioral:Arise|Interventional|Phase 2|Industry|Changefrombaselineinfrequencyofsubstance.;  Changefrombaselineincopingbehaviors.;  Change from baseline in knowledge of substance abuse recovery and relapse.;  Change from baseline in perceived benefits of substance use.;  Change from baseline in self-efficacy to avoid substance use.;  ChangefrombaselineinReadinessofChange.|125|NCT02715557|September 2014
162|Not yet recruiting|The Probiotic Study: Using Bacteria to Calm Your Mind||Drug:Lactobacillusrhamnosus|Interventional|Phase 2|Other|ChangeinChildAbdominalPainRating;  ChangeinChildAbdominalPainFrequency;  ChangeinChildAnxietySymptoms;  Feasibility:ratioofadherencetotreatment;  Change in relative quantities of taxa among groups relative to probiotic administration;  Changeinalphadiversity;  ChangeinBetadiversity(PCoA);  Change in trait-associated co-functional modules of organisms;  ChangeinSalivaryCortisol(ug/dL);  ChangeinHeartRate|40|NCT02711800|March 2016
163|Not yet recruiting|UltraShape Device for Non-Invasive Fat Reduction in the Male Breast (Pseudogynecomastia)||Device:UltraShapefocusedultrasounddevice|Interventional||Industry|Reduction in breast fat thickness after 3 treatments compared to baseline;  Reduction in breast fat thickness on treated side compared to control side;  Reduction in breast/chest circumference after 3 treatments compared to baseline;  Reduction in breast fat thickness compared to baseline|40|NCT02711605|May 2016
164|Recruiting|IL29 and IL28B Variants Associated With Periodontal Disease Pathogenesis||Procedure:Stent-inducedbiofilmovergrowth|Interventional||Other|Changeinpocketdepth(mm);  Changeinclinicalattachmentlevel(mm);  Changeinplaqueindex(0-3);  Changeinbleedingonprobing(Yes/No);  Change in gingival crevicular fluid interleukin-1 beta (GCF IL-1b);  Change in gingival crevicular fluid prostaglandin E2 (GCF PGE2);  Change in gingival crevicular fluid interleukin-29 (GCF IL-29);  Change in gingival crevicular fluid interleukin-28B (GCF IL-28B);  Changeingingivalindex(0-4);  Compositionofthemicrobiotaoralflora;  Change in gingival crevicular fluid interleukin-6 (GCF IL-6);  Change in interleukin-29 expression in dendritic cells at day 35;  Change in interleukin-28B expression in dendritic cells at day 35|220|NCT02710903|May 2016
165|Recruiting|HIRREM Developmental Study||Device:HIRREM|Interventional||Other|Heartratevariability;  BaroreflexSensitivity;  Center for Epidemiologic Studies Depression Scale (CES-D);  EQ-5D;  GeneralizedAnxietyDisorder-7(GAD-7);  InsomniaSeverityIndex(ISI);  PCL;  Rivermead Post-Concussion Symptoms Questionnaire (RPQ);  Dropstickreactiontime|250|NCT02709369|August 2011
166|Active not recruiting|ALS Reversals - Lunasin Regimen||Drug:LunasinRegimen;  Other:Historicalcontrol|Interventional|Phase 2|Other|Change in Revised ALS Functional Rating Scale (ALSFRS-R);  Changeinhistoneacetylation;  Percent agreement between the weights obtained by patients and study coordinator;  Enrollmentrate;  Retentionrate;  FrequencyofALSreversals;  ALSFRS-RAccuracy|50|NCT02709330|April 2016
167|Recruiting|Cefixime / Azithromycin pK Study||Drug:Cefixime;  Drug:Azithromycin|Interventional|Phase 1|NIH|Targetedclinicalevaluations;  Totalplasmaconcentrationsofcefixime;  Subjectreportedseriousadverseevents(SAEs);  AUCfrom0toinfinity[AUC0-infinity];  SubjectreportedAEs;  Individual plasma cefixime levels will be used to generate PK curves of cefixime levels versus time;  Averaged composite plasma cefixime levels will be used to generate PK curves of cefixime levels versus time;  Peakcefiximelevel(Cmax);  Total area under the curve (AUC from 0 hours to the time of next dosing [AUC0-t]);  Timetopeakdruglevel(Tmax);  Eliminationhalf-life(t1/2);  Eliminationrate(lambdaz);  Time that cefixime levels exceed four times the MIC of 0.5 mcg/mL (i.e. a plasma level of 2.0 mcg/mL);  Safetybloodtestresults;  Safetyurinanalysisresults|8|NCT02708992|April 2016
168|Active not recruiting|Clinical Outcomes of Buffered 1% Lidocaine vs. Non-buffered 2% Lidocaine||Drug:Lidocaine|Interventional||Other|Number of subjects with Pulpal anesthesia mandibular molar;  Number of subjects with Pulpal anesthesia mandibular canine|23|NCT02708433|March 2016
169|Not yet recruiting|Increasing Uptake of Behavioral Weight Loss Programs Among Primary Care Patients||Behavioral:MotivationalIntervention;  Other:ComparatorIntervention|Interventional||Other / NIH|Proportionofsubjectswhoinitiatetreatment;  Weight|60|NCT02708121|June 2017
170|Recruiting|Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection||Drug:Vorinostat;  Biological:AGS-004|Interventional|Phase 1|Other / NIH|Occurrence of at least one &#8805; Grade 3 adverse event including signs/symptoms lab toxicities and/or clinical events that is possibly or definitely related to VOR or AGS-004 any time from the first day of study treatment through the end of study.;  Change in the frequency of HIV infection per million resting CD4+T cells (RCI) from baseline to post-VOR/AGS.|12|NCT02707900|March 2016
171|Recruiting|TACE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma||Procedure:TransarterialChemoembolization;  Procedure:MicrowaveAblation|Interventional|Phase 4|Other|Intrahepaticdisease-freesurvival;  Overallsurvival;  Postoperativemorbidity;  Postoperativemortality|100|NCT02704130|March 2016
172|Recruiting|Prospective Data-collection System for the Comprehensive Appraisal of Cleft Care||Procedure:cleftliprepair;  Procedure:cleftpalaterepair;  Procedure:oronasalfistularepair;  Procedure:pharyngoplasty;  Procedure:gingivoperiosteoplasty;  Procedure:LeFort-1maxillaryrepositioning;  Procedure:rhinoplasty;  Procedure: myringotomy and tympanostomy tube placement;  Other:speechtherapy;  Procedure:orthodontia;  Procedure:presurgicalorthopedics|Observational||Other|Speech:intelligibility;  Speech:velopharyngealcompetence;  Speech:articulation;  Speech: patient-reported outcomes related to speech and speaking;  Hearing:puretoneaverage;  Dental:dmftandDMFTscores;  Dental: occlusion (Uses modifications of the GOSLON scale);  Dental: occlusion (Uses modifications of the Bauru scale);  Dental: patient-reported outcomes related to mastication;  Dental: patient-reported outcomes related to oral health;  Patient-reported outcomes related to eating/drinking;  Breathing: Patient-reported outcomes related to nasal and oral breathing;  Aesthetics: Patient-reported outcomes related to appearance;  Aesthetics: Clinical assessment of nasolabial and facial aesthetics|1000|NCT02702869|October 2016
173|Not yet recruiting|MRI and Cardio-Pulmonary Exercise Testing in Evaluating Exercise Intolerance in Patients With Stage I-III Breast Cancer After Chemotherapy Treatment||Other:CardiopulmonaryExerciseTesting;  Procedure:MagneticResonanceImaging|Observational||Other / NIH|A-VO2differences|32|NCT02702830|March 2016
174|Active not recruiting|Management of Coccydynia: A Prospective Observational Study of Coccygectomy||Other:Coccygectomy|Observational||Other|Painlevel;  PatientHealthStatus;  LowerBackDisability;  Complicationrates|77|NCT02701192|September 2007
175|Recruiting|Palliative Radiation Therapy in Reducing Pain in Patients With Bone Metastasis||Radiation:ExternalBeamRadiationTherapy;  Radiation:PalliativeRadiationTherapy;  Other:Quality-of-LifeAssessment;  Other:QuestionnaireAdministration|Interventional|Phase 2|Other / NIH|Change in narcotic use in daily oral morphine equivalents;  Change in pain intensity assessed using the Numerical Rating Pain Scale;  Change in quality of life measured using the quality of life questionnaire (QLQ) core(C)15-palliative (PAL) and QLQ-C30;  Re-treatmentrates|158|NCT02699697|May 2016
176|Recruiting|Risk Factors for Microscopic Colitis|||Observational||Other|MicroscopicColitis|1200|NCT02699333|May 2016
177|Recruiting|Mindfulness and Mechanisms of Pain Processing in Adults With Migraines||Other:MindfulnessBasedStressReduction;  Other:Migraine/stressEducation|Interventional||Other|Change in frequency of migraine days from baseline;  Change in migraine severity-pain intensity from baseline;  Change in migraine severity-pain unpleasantness from baseline;  Changeinmigrainedurationfrombaseline;  Change in experimental heat pain intensity from baseline;  Change in experimental heat pain unpleasantness from baseline;  Change in experimental heat pain threshold from baseline;  Changeinmindfulnessfrombaseline;  Changeinemotionregulationfrombaseline;  Changeinpaincatastrophizingfrombaseline;  Changeinpainacceptancefrombaseline;  Change in headache-related disability from baseline;  Changeinheadachedisabilityfrombaseline;  Change in headache-related quality of life from baseline;  Changeinperceivedstressfrombaseline;  Changeindepressionfrombaseline;  Changeinanxietyfrombaseline;  Changeinself-efficacyfrombaseline;  Changeinhopefrombaseline;  Changeinoptimismfrombaseline;  Changeinsleepfrombaseline;  Changeinglobalhealthfrombaseline;  Changeinsocialconnectednessfrombaseline;  Changeinflourishingfrombaseline;  Changeinresiliencefrombaseline|98|NCT02695498|March 2016
178|Recruiting|Dietary Acid Load Kidney Function and Disability in Elderly||Dietary Supplement: Oral bicarbonate supplementation;  DietarySupplement:Placebo|Interventional||Other|50% reduction in net acid excretion (NAE/Cr meq/g) by the kidney|80|NCT02691663|February 2016
179|Recruiting|Incentivizing Behavior Change Skills to Promote Weight Loss||Behavioral: incentives for dietary self-monitoring;  Behavioral:incentivesforinterimweightloss;  Behavioral:incentivesforboth|Interventional||Other / NIH|weight|96|NCT02691260|April 2016
180|Recruiting|Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy||Drug:pembrolizumabgemcitabineandcisplatin|Interventional|Phase 2|Other / Industry|Number of subjects that reach pathological downstaging to &lt;pT2 defined as pT0-T1N0M0 at the time of cystectomy;  Number of subjects that reach complete pathologic response (pT0) defined as pT0N0M0 at the time of cystectomy;  EventFreeSurvival;  Overallsurvival;  Number of adverse events and severity by grade (CTCAE).|39|NCT02690558|May 2016
181|Recruiting|Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL||Biological:ATLCAR.CD30cells|Interventional|Phase 1 / Phase 2|Other|Safe dose (ie number of cells/m^2) of ATLCAR.CD30 to infuse after conditioning chemotherapy and lymphodepletion with bendamustine in patients with CD30+ refractory/relapsed Hodgkin Lymphoma (HL) and non-Hodgkin Lymphoma (NHL);  Estimate 2 year progression free survival after infusion of ATLCAR.CD30;  Estimate 2 year overall survival (OS) after administration of ATLCAR.CD30;  Estimate objective response rate as defined by the Lugano Classification for CAR.CD30 transduced ATL;  Estimate duration of response after administration of CAR.CD30 transduced ATL;  Description of adverse events associated with CAR.CD30 transduced ATL;  Number of participants with adverse events as a measure of safety and tolerability of bendamustine as a lymphodepleting agent;  Measure the survival of ATLCAR.CD30 in vivo as assessed by quantitative polymerase chain reaction (PCR);  Estimate progression free survival in patients after administration of ATLCAR.CD30 and lymphodepletion using bendamustine|31|NCT02690545|April 2016
182|Recruiting|TMS Modulation of Insula-related Brain Networks||Device: repeated transcranial magnetic stimulation|Interventional||Other|Change in functional connectivity strength measured with functional magnetic resonance imaging|12|NCT02689323|March 2016
183|Recruiting|Predicting Understanding and Speeding Recovery After TKA||Drug:Gabapentin;  Drug:Placebo|Interventional|Phase 4|Other / NIH|Changes in daily worst-pain score after discharge from hospital|300|NCT02685735|February 2016
184|Active not recruiting|The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery||Drug:TranexamicAcid;  Drug:Placebo|Interventional|Phase 3|Other|AllogenicBloodTransfusions;  Peri-operativebloodloss;  ThromboembolicEvents;  Woundcomplications;  Cost|65|NCT02684851|October 2012
185|Recruiting|Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel||Drug:Pembrolizumab|Interventional|Phase 2|Other|Overallsurvival|105|NCT02684461|August 2016
186|Recruiting|Contrast-enhanced Ultrasound of the Kidney||Drug:Perflutrenlipidmicrosphere|Interventional|Phase 2|Other|Changeinradiologist&apos;slesionevaluation|75|NCT02684435|February 2016
187|Recruiting|Glycogen Storage Disease Type IV Database||Other:Nointervention|Observational||Other / Industry|Progressionofdisease|200|NCT02683512|December 2015
188|Recruiting|DPP4 Inhibition &amp; Beta Cell Function||Drug:ActiveComparator:Sitagliptin;  Drug:PlaceboComparator-NoSitagliptin|Interventional|Phase 1|Other / Industry|Arginine-stimulated insulin secretion with and without GLP-1 blockade (with Ex-9)|70|NCT02683187|September 2016
189|Recruiting|Physical Activity to Maintain Quality of Life and Physical Function in Women With Metastatic Breast Cancer: a Pilot Study||Behavioral:WalkwithEase|Interventional|Phase 1 / Phase 2|Other|changesinfatiguescores|30|NCT02682836|October 2015
190|Recruiting|Prospective Evaluation of Patient Reported Xerostomia After Whole Brain Radiation|||Observational||Other|Measureableacuteincreaseinxerostomia;  Association of degree of change in xerostomia score and the radiation dose received by the parotid glands;  Effect of whole brain radiation on the time course of xerosomia|60|NCT02682199|October 2015
191|Recruiting|NCCN Renal Cell Registry||Other:chartabstraction;  Other:EducationalProgram|Interventional||Other|Assignment of patient to appropriate firstline treatment based on Heng Risk criterion;  Percentage of increase in duration of treatment with appropriate first line therapy|120|NCT02677337|March 2016
192|Completed|Young Women&apos;s Health CoOp (Cooperative) in Cape Town||Behavioral:YoungWomen&apos;sHealthCoOp(YWHC);  Behavioral:HIVCounseling/Testing|Interventional||Other|Unprotectedintercourseamongwomen;  Alcoholuse;  Substanceuse;  Victimization|100|NCT02677025|May 2014
193|Completed|Safety Study of CN-105 Neuroprotective Peptide for Intracerebral Hemorrhage||Drug:CN-105;  Drug:Placebo|Interventional|Phase 1|Industry|The number and percentage of participants having study procedure-related suspected adverse reactions assessed by change from baseline in vital signs ECG and clinical labs.|48|NCT02670824|December 2015
194|Recruiting|Evaluation of Biomarkers in Human Synovial Fluid||Procedure:Arthroscopy;  Procedure:Arthroplasty|Observational||Other|Feasibility of biobank data collection as measured by percentage of patients with a complete data set one year post-operation;  Number of biomarkers worthy of study to aid in the diagnosis and progression of osteoarthritis;  Types of biomarkers worthy of study to aid in the diagnosis and progression of osteoarthritis;  Number of patients who responded to non-arthroplasty intervention based on biomarker analysis and measured with questionnaires;  Number of patients who did not respond to non-arthroplasty intervention based on biomarker analysis and measured with questionnaires|500|NCT02664870|January 2016
195|Recruiting|Conjoint Analysis of Patient Preferences in Joint Interventions||Other:Decisiontool;  Other:Standardtreatmentinformation|Interventional||Other|Patientpreferencessurvey-HipArthritis;  Patientpreferencessurvey-KneeArthritis;  Patient preferences survey - hip labral tears and FAI;  Patient preferences survey - Osteochondritis dissecans;  Patient preferences survey - Achilles tendon rupture;  Patient preferences survey - patellofemoral dislocation;  Patient preferences survey - distal radius fracture;  Patientpreferencessurvey-hipfracture;  Patientpreferencessurvey-anklefracture;  Patientpreferencessurvey-tibiafracture;  Patient preferences survey - proximal humerus fracture|2310|NCT02664337|February 2016
196|Recruiting|Administration of T Lymphocytes for Prevention of Relapse of Lymphomas||Drug:ATLCAR.CD30cells|Interventional|Phase 1|Other|Number of participants with adverse events as a measure of safety and tolerability of escalating doses of autologous activated T lymphocytes;  Measure the survival of ATLCAR.CD30 in vivo as assessed by quantitative PCR;  Estimate the progression free survival after infusion of ATLCAR.CD30;  Determine the overall survival after infusion of ATLCAR.CD30|18|NCT02663297|March 2016
197|Recruiting|Internet Surveys and Their Impact on Adherence to Brimonidine Topical Gel and QOL in Patients With Rosacea||Other:internetsurvey;  Drug:brimonidinetopicalgel0.33%|Interventional|Phase 4|Other|Change from baseline Disease severity measure: Clinician Erythema Assessment (CEA) to month 6.;  Change from baseline Disease severity measure: Patient Severity Assessment (PSA) to month 6.;  Change from baseline Disease severity measures: Investigator Visual Analogue Scale (VAS) to month 6.;  Change from baseline Disease severity measure: Lesion Count (Performed by investigator) to month 6.;  Change from baseline Subjective Symptom Improvement: Quality of Life Survey to month 6.;  Subject survey to identify factors that affect adherence to rosacea treatment|20|NCT02659670|January 2016
198|Recruiting|Efficacy of First Time Anterior Shoulder Decision Tool||Other:DecisionTool;  Other:InformationonShoulderDislocation|Interventional||Other|PatientPreferenceSurvey|210|NCT02656277|January 2016
199|Recruiting|Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy Temozolomide and BMX-001||Drug:BMX-001;  Radiation:RadiationTherapy;  Drug:Temozolomide|Interventional|Phase 1 / Phase 2|Industry / Other|Phase 1 - Maximum tolerated dose (MTD) of BMX-001 in combination with standard radiation therapy and temozolomide defined as the dose level that has an estimated dose limited toxicity (DLT) rate nearest to 0.25.;  Phase 2 - Median overall survival (time to death from randomization) for newly diagnosed HGG patients receiving BMX-001 plus standard radiation therapy and temozolomide.;  Safety and tolerability of BMX-001 in combination with standard radiation therapy and temozolomide in newly diagnosed high grade glioma patients will be assessed as the proportion of patients with a DLT.;  Median overall survival (time to death from the time protocol treatment is initiated).;  Progression-free survival (time between initiation of protocol treatment and the first recurrence of disease or death).;  Mean change between baseline and week 24 in normalized scores for cognition using standardized cognitive tests and computerized battery central nervous system (CNS) Vital Signs.;  Proportion of patients with radiographic response after treatment with BMX-001 in combination with standard radiation therapy and temozolomide in newly diagnosed high grade glioma patients.;  Peakplasmaconcentrations(Cmax)forBMX-001.;  Area under the plasma concentration versus time curve (AUC) for BMX-001.|66|NCT02655601|May 2016
200|Recruiting|STepped Exercise Program for Knee OsteoArthritis||Behavioral:SteppedExerciseProgram;  Behavioral:ArthritisEducation|Interventional||U.S. Fed|Western Ontario and McMaster Universities Osteoarthritis Index -modified short form (mSF-WOMAC);  ObjectivePhysicalFunction|345|NCT02653768|July 2016
201|Recruiting|Multidrug Resistant Gram-negative Bacilli Colonization and Infection in Burn||Other:MDR-GNB|Observational||Other|SpeciescausingMDR-GNBcolonization;  TimetoMDR-GNBcolonization;  Time to development of MDR and extreme drug resistant bacteria;  TimetoVAT/VAP;  TimetoMDR-GNBVAT/VAP|100|NCT02653157|October 2015
202|Recruiting|Effect of HPV Self-Collection on Cervical Cancer Screening in High Risk Women: My Body My Test 3||Other: Screening invitation (with brief education);  Other:Self-collectionforHPVtesting|Interventional||Other / NIH|Percent of participants that complete cervical cancer screening;  Levels of risk appraisal with regards to cervical cancer and screening;  Coststopayers;  Level of intention to complete cervical cancer screening;  Level of self-efficacy to complete cervical cancer screening;  Percentage of participants who schedule a clinic appointment to get cervical cancer screening|510|NCT02651883|April 2016
203|Enrolling by invitation|Controlled Trial to Compare Single Versus Two Portal Knee Arthroscopy Techniques||Procedure:SinglePortalKneeArthroscopy;  Procedure:TwoPortalKneeArthroscopy|Interventional||Other|IKDCSubjectiveKneeEvaluationFormScore;  PainLevelsandUseofPainMedication|110|NCT02648971|January 2016
204|Recruiting|Chronic Endometritis and IVF||Procedure:Endometrialbiopsy|Interventional||Other|Ongoingpregnancyrate;  Implantationrate;  Pregnancylossrate|60|NCT02646930|January 2016
205|Completed|Antiseptic Scrub Contamination and Transmission Trial||Other:Non-antisepticscrubs;  Other:Antisepticscrubs|Interventional||Other|The difference in total acquired contamination (Total CFU) on HCP clothing at the end of a 12-hour ICU shift.;  The presence or absence of individual specific pathogens: S. aureus (MRSA or MSSA) Enterococci (VRE or VSE) Acinetobacter spp. Pseudomonas spp. and Enterobacteriaceae of interest such as E. coli and Klebsiella spp.;  The proportion of positive cultures - overall and at each culture location;  The number of suspected and confirmed &quot;transmission events&quot;;  The proportion of suspected and confirmed &quot;transmission events&quot;;  Health care personnel perceptions of clothing as measured by survey|41|NCT02645214|June 2015
206|Completed|User Acceptability of P3L||Other:P3L;  Other:VUSE;  Other:CC|Interventional||Industry|Evaluation of the plasma concentration of nicotine and cotinine during the 1st ad libitum use session for the P3L the VUSE and subjects&apos; own brand of non-menthol CC;  Evaluation of the plasma concentration of nicotine and cotinine during the 2nd ad libitum use session for the P3L the VUSE and subjects&apos; own brand of non-menthol CC;  Evaluation of the plasma concentration of nicotine and cotinine during the 3rd ad libitum use session for the P3L the VUSE and subjects&apos; own brand of non-menthol CC;  Evaluation of nicotine withdrawal symptoms using the total score of the short version of the Questionnaire of Smoking Urges (QSU-brief) during the 1st ad libitum product use session;  Evaluation of nicotine withdrawal symptoms using the total score of the short version of the Questionnaire of Smoking Urges (QSU-brief) during the 2nd ad libitum product use session;  Evaluation of nicotine withdrawal symptoms using the total score of the short version of the Questionnaire of Smoking Urges (QSU-brief) during the 3rd ad libitum product use session|24|NCT02643693|December 2015
207|Active not recruiting|Efficacy of Neuro+ Attention Training||Behavioral:Neuro+AttentionTraining;  Other:TreatmentasUsual|Interventional||Industry|Change in ADHD symptoms with Quotient ADHD System assessment;  Change in assessment of ADHD symptoms with Conners 3-Parent rating scale;  Incidenceofadverseevents;  Self-reported convenience ratings of Neuro+ intervention|60|NCT02642055|December 2015
208|Recruiting|Antiretroviral Localization in Gut-Associated Lymphoid Tissue and Lower Female Genital Tract Tissue of HIV+ Subjects||Procedure:Bloodplasmacollection;  Procedure:CervicalandVaginalBiopsy;  Procedure: Colonoscopy with Ileal and Rectal Biopsy|Observational||Other|Antiretroviraltissuelocalization;  Quantitation of antiretroviral tissue concentrations by LC-MS/MS;  Immunohistochemical images of CD3 CD4 and CD8 distribution within tissue slices;  in-situ hybridization images of HIV RNA distribution within tissue slices;  Quantification of antiretroviral tissue concentrations by MSI|22|NCT02641444|April 2016
209|Recruiting|Safety of 4CMenB Exposure During Pregnancy||Biological:4CMenB|Observational||Industry|Majorcongenitalmalformation(MCM);  Pretermbirth;  Lowbirthweight(LBW)|30|NCT02640677|January 2016
210|Active not recruiting|The Compartmental Biology of HIV in the Male Genital Tract|||Observational||Other / NIH|SemenClearance(CL)ofTenofovir;  SemenClearance(CL)ofEmtricitabine;  SemenClearance(CL)ofTenofovirDiphosphate;  Semen Clearance (CL) of Emtricitabine Triphosphate;  Peripheral Blood Mononuclear Cell (PBMC) Clearance (CL) of Tenofovir Diphosphate;  Peripheral Blood Mononuclear Cell (PBMC) Clearance (CL) of Emtricitabine Triphosphate;  Tenofovir diphosphate/dATP ratio in seminal mononuclear cells;  Emtricitabine triphosphate/dCTP ratio in seminal mononuclear cells|24|NCT02638493|November 2015
211|Recruiting|Imaging Parameters and DME Treatment Response||Other:Nointervention|Observational||Other|Changes in disease state characteristics in response to therapy;  Changes in visual acuity using ETDRS visual acuity assessment|150|NCT02637245|May 2015
212|Recruiting|Exercise Intolerance in Elderly Patients With HFpEF(Heart Failure With Preserved Ejection Fraction)||Behavioral: dietary aerobic and resistance training;  Behavioral:dietaryandaerobicexercise|Interventional||Other / NIH|Peakexerciseoxygenconsumption(VO2);  Skeletalmusclemass;  Mitochondrialcontent;  Mitochondrialfunction;  Qualityoflife;  Musclestrength;  Musclequality;  Thighmusclecomposition|84|NCT02636439|August 2015
213|Recruiting|Stage Ib Trial of mSMART for Smoking Cessation Medication Adherence||Device:mSMART|Interventional||Other / Industry / NIH|Adherence to smoking cessation medication as assessed via Medication Event Monitoring System (MEMS);  Acceptability of mSMART based on responses to an exit interview;  Feasibility of mSMART based on frequency of participant use of the app;  Adherence to smoking cessation medication indicated by smoking abstinence;  Adherence to smoking cessation medication indicated by mSMART medication event data|60|NCT02635919|April 2016
214|Recruiting|The KNEEhabilitation Study: Improving Disability in Individuals With Knee Osteoarthritis||Device: Transcutaneous Electrical Nerve Stimulation;  Other:TherapeuticExercise;  Device: Sham Transcutaneous Electrical Nerve Stimulation|Interventional|Phase 1 / Phase 2|Other|Difference in the Change in self-reported disability as measured by the Western Ontario and McMasters Universities Index between groups;  Difference in Voluntary quadriceps activation as measured by the central activation ratio between groups;  Difference in Maximal quadriceps strength as measured by the maximal isometric voluntary contractions between groups;  Difference in Mean Internal Knee Extension Moment during Walking Gait measured in Nm/ kg*m between groups;  Mean Knee Flexion Angle during Walking Gait measured in degrees of knee flexion between groups|90|NCT02634814|October 2015
215|Recruiting|Walk With Ease Program For Patients With Systemic Lupus Erythematosus||Other:&quot;WalkWithEase&quot;|Interventional||Other|Change in Visual Analog Scale (VAS) Pain Score from Baseline to Six Weeks;  Change in VAS Stiffness Score from Baseline to Six Weeks;  Change in VAS Fatigue Score from Baseline to Six Weeks;  Change in FACIT-Fatigue Score from Baseline to Six Weeks;  ParticipantSatisfactionwithWalkWithEase|50|NCT02631005|March 2016
216|Recruiting|Motivated Behavior in Adults With and Without ADHD||Drug:methylphenidate;  Drug:Placebo|Interventional||Other|Changeinmotivatedbehavioronthebandittask|30|NCT02630017|February 2016
217|Recruiting|Reliability of Pupil Response to Acute Pain|||Observational||Other|ChangefromBaselineVerbalPainScores;  Percentageofchangeinpupildiameter|80|NCT02628314|July 2015
218|Recruiting|ICanSTEP : Increasing Physical Activity With Text Messaging||Other:DailySMStextmessaging|Interventional||Other|Feasibility as measured by the percentage of eligible patients who can be enrolled;  Feasibilityasmeasuredbyaccrualrate;  ChangeindailystepcountasmeasuredbyFitbit;  Change in minutes of weekly exercise as measured by Fitbit;  Changeinfatigueasmeasuredbyquestionnaire;  Change in depression as measured by questionnaire;  Change in general activity as measured by questionnaire;  Change in quality of life as measured by questionnaire;  Changeinbodymassindex(BMI);  Mean difference in daily step count as measured by Fitbit;  Mean difference in minutes of weekly exercise as measured by Fitbit;  Mean difference in fatigue as measured by questionnaire;  Mean difference in depression as measured by questionnaire;  Mean difference in general activity as measured by questionnaire;  Mean difference in quality of life as measured by questionnaire;  Meandifferenceinbodymassindex(BMI)|30|NCT02627079|February 2016
219|Recruiting|Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation Times||Drug:AminolevulinicAcid(ALA);  Device:EnvironCosmeticRoller;  Device:BLU-UIIlluminator|Interventional|Phase 4|Other|Efficacy-Percentage of treatment areas with &gt;75% reduction in lesion count as compared to baseline;  Efficacy-Percentage of treatment areas with 100% cure rate as compared to baseline|10|NCT02622594|October 2015
220|Recruiting|Clinical Outcomes of Buffered vs. Non-Buffered Lidocaine||Drug:Lidocaine|Interventional||Other|Lidocainebloodlevelspostinjection;  SumofPainIntensityScore;  Number of minutes to anesthesia symptoms of lower lip;  Topicalanesthesiaeffectcontralaterallowerlip|24|NCT02620683|December 2015
221|Recruiting|Prospective Subtalar Double or Triple Arthrodesis Study With CCS Screws||Device:AptusCCS5.0or/and7.0screws|Observational||Other|Therateofintraoperativecomplications.;  Therateofperioperativecomplications.;  Therateofdelayedosseousunionornon-union.;  The fixation of a double or triple arthrodesis neutral hindfoot alignment.;  The double or triple arthrodesis in substantial pain relief;  The double or triple arthrodesis will result in substantial functional improvement as measured by the American Orthopaedic Foot and Ankle Society (AOFAS) hindfoot score;  The double or triple arthrodesis will result in substantial functional improvement as measured by the Foot &amp; Ankle Disability Index (FADI) score;  The rate of secondary surgical procedures for any reason including hardware removal|50|NCT02619838|October 2015
222|Recruiting|A Quality Improvement Approach to the Management of Chronic Lymphocytic Leukemia||Other:EducationIntervention|Interventional||Other / Industry|Change in provider knowledge with management of Quality of Life Concerns for CLL patients as measured by survey;  Change in provider confidence with management of Quality of Life Concerns for CLL patients as measured by survey|50|NCT02619604|May 2016
223|Recruiting|Addressing Tobacco Use Disparities Through an Innovative Mobile Phone Intervention||Behavioral:ScheduledGradualReduction(SGR);  Behavioral:TextMessages|Interventional||Other / NIH|Proportion of Return Text Messages sent in Response to SGR Intervention;  Proportion of Support Messages Read by Participants;  Ratings of Usefulness of the Intervention Received;  QuitRateat3months;  QuitRateat6Months|100|NCT02613689|February 2016
224|Recruiting|LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer||Drug:Crizotinib|Interventional|Phase 2|Other / Industry|Overallresponserate;  Overallsurvival;  Progressionfreesurvival|46|NCT02612194|February 2016
225|Recruiting|A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy||Biological:Infusionofautologouscordblood;  Biological:Placebo|Interventional|Phase 2|Other|Survivalatoneyear;  Percentage of subjects with Bayley III scores in all three domains &gt; or equal to 85;  Mortalityrate;  Percentageofsubjectswhoexperienceseizures;  PercentageofsubjectswhorequireiNOuse;  PercentageofsubjectswhorequireECMO;  PercentageofsubjectswhorequireG-tubefeeding;  Percentage of subjects who are discharged on anti-epileptic meds|160|NCT02612155|January 2016
226|Recruiting|Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant||Drug:fostamatinib|Interventional|Phase 1|Other|Evaluate maximum tolerated dose of fostamatinib delivered following allogenic transplantation;  Incidence of chronic graft vs host disease (cGVHD);  Incidence of relapse of chronic graft vs host disease (cGVHD);  B-cellactivationrate;  B-celldeathrate;  NumberofB-cells|18|NCT02611063|January 2016
227|Completed|Evaluation of a Short Course of Gamma Tocopherol Supplementation in Adult Subjects||DietarySupplement:Gammatocopherol|Interventional||Other / NIH|Changeingammatocopherolserumlevels;  Changeingamma-CEHC;  Changein5-NO-gammatocopherol;  Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment|10|NCT02610829|November 2015
228|Recruiting|Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin||Drug:Pembrolizumab;  Radiation:IntensityModulatedRadiationTheapy|Interventional|Phase 2|Other / Industry|Progressionfreesurvival;  Overallsurvival|29|NCT02609503|February 2016
229|Recruiting|Static Magnetic Therapy for Carpal Tunnel Syndrome||Device:StrongMagneticWristband;  Device:WeakerMagneticWristband|Interventional||Other|Change in Boston Carpal Tunnel Questionnaire Score at 6 weeks;  Change in echogenicity (hyper or hypo) on the Median Nerve Ultrasound at 6 weeks;  Change in cross-sectional area as measured in mm2 on Median Nerve Ultrasound at 6 weeks;  Change in vascularity (normal or abnormal) as measured on Median Nerve Ultrasound at 6 weeks|22|NCT02609113|August 2015
230|Recruiting|Angiotensin Receptors and Age Related Mitochondrial Decline in HIV Patients||Drug:valsartan;  Other:Placebo|Interventional|Phase 2|Other|Changefrombaselinein400mwalk;  Changefrombaselineingripstrength;  Change from baseline in Quantity of AT1R and AT2R on monocytes;  Changefrombaselineinfrailtystatus|40|NCT02606279|July 2014
231|Recruiting|Vibratory Stimuli A Novel Rehabilitation Method for Preventing Post - Traumatic Knee Osteoarthritis||Device:Wholebodyvibration;  Device:Localmusclevibration|Interventional||Other|Change from baseline ground reaction force loading rate during walking gait immediately following vibration interventions;  Change from baseline quadriceps strength immediately following vibration interventions assessed by peak torque during maximal quadriceps activation;  Change from baseline knee proprioception immediately following vibration interventions assessed by joint reposition error|75|NCT02605876|November 2015
232|Recruiting|Celestone Versus Ketorolac Injection for the Treatment of DeQuervains Tenosyovitis||Drug:Celestone;  Drug:Ketorolac|Interventional|Phase 4|Other|Visualanalogscaleofpainwithfinklesteintest;  Visual analog scale of pain with tenderness over tendon;  Visual analog scale of pain on radial side of wrist;  The Disabilities of the Arm Shoulder and Hand Score (DASH);  Veterans-Rand12(VR-12);  PinchStrength;  GripStrength|64|NCT02604537|November 2015
233|Recruiting|Testosterone and Cortisol Levels in Infants|||Observational||Other / NIH|measurements of maternal and neonate/infant testosterone and cortisol (T&amp;C) levels from admission through 24-months of life to determine associations of T&amp;C with health outcomes of neonates and infants between genders;  video recorded interactions at 12- and 24-months to determine associations of testosterone and cortisol levels with quality of mother-infant interactions between genders during infancy;  standard infant testing at 12- and 24-months of age to determine associations of testosterone and cortisol levels with infant cognitive/motor/language development between genders during infancy|300|NCT02599545|October 2015
234|Recruiting|Pharmacokinetics and Pharmacodynamics of Apixaban in Nephrotic Syndrome||Drug:apixaban|Interventional|Phase 1 / Phase 2|Other|apixabanplasmalevels;  areaunderthecurve(AUC);  half-lifeofapixaban;  apixabananti-Xalevel;  thrombingeneration|30|NCT02599532|November 2015
235|Completed|Clinical Outcomes and Cost of Gram Negative Bacteremia|||Observational||Other / Industry|Mortality|2000|NCT02599220|January 2002
236|Active not recruiting|Assessment of the Safety of Allogeneic Umbilical Cord Blood Infusions in Children With Cerebral Palsy||Biological:siblingumbilicalcordblood|Interventional|Phase 1|Other|Assessment for infusion reactions infections graft versus host disease or any other adverse events;  Assessment for improvement in gross motor function;  Assessmentforimprovementinfinemotorfunction|15|NCT02599207|November 2015
237|Recruiting|Correlation of Spinopelvic Parameters and Acetabular Cup Orientation|||Observational||Other|Quantitative correlation between change functional anteversion and change in pelvic tilt using patient-specific measurements and computer models.;  Quantitative correlation between change functional anteversion and change in lumbar lordosis using patient-specific measurements and computer models.;  Presenceoflumbarpathology;  Previouslumbarsurgery-fusiontype;  Previouslumbarsurgery-lengthoffusion;  Totalhiparthroplastydislocation;  Othertotalhiparthroplastycomplication|84|NCT02598700|February 2016
238|Recruiting|Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer||Drug:Pertuzumab;  Drug:Trastuzumab|Interventional|Phase 1|Other|Safetyasmeasuredbyadverseevents;  Maximum tolerated dose as measure by dose limiting toxicity;  ResponserateasmeasuredbybrainMRI;  Cerebrospinal fluid (CSF) clearance of pertuzumab (mL/d/kg);  Cerebrospinal fluid (CSF) clearance of trastuzumab (mL/d/kg);  Serumclearanceofpertuzumab(mL/d/kg);  Serumclearanceoftrastuzumab(mL/d/kg);  Terminal half-life of pertuzumab in the cerebrospinal fluid (CSF) (days);  Terminal half-life of trastuzumab in the cerebrospinal fluid (CSF) (days)|36|NCT02598427|May 2016
239|Not yet recruiting|The Role of Nicotine and Non-Nicotine Alkaloids in E-Cigarette Use and Dependence||Other:E-cigarettes|Interventional||Other / NIH|Expired air carbon monoxide (CO) to assess recent smoking;  Mean volume of e-cigarette solution used per day to assess e-cigarette use.;  Cigarette use assessed by self-report in daily dairies;  E-cigarette use assessed by self-report in daily dairies|375|NCT02590393|March 2017
240|Recruiting|Trial of Acupuncture for Radiation-Induced Xerostomia in Head and Neck Cancer||Other:StandardOralHygiene;  Other:StandardOralHygiene+TrueAcupuncture;  Other:StandardOralHygiene+ShamAcupuncture|Interventional|Phase 3|Other|9ItemXerostomiaQuestionnaire|240|NCT02589938|February 2016
241|Active not recruiting|Foot and Ankle Clinic Application for Liposomal Related Anesthetic||Drug:Exparel|Interventional|Phase 4|Other / Industry|AmountofNarcoticUse;  VisualAnalogScaleofpain(0-10);  Anti-emeticuse;  Patient Satisfaction Questionnaire regarding post surgical pain relief;  Complications|36|NCT02586077|February 2014
242|Recruiting|Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC||Drug:AZD1775;  Drug:Cisplatin;  Radiation: Intensity Modulated Radiotherapy Treatments|Interventional|Phase 1|Other / Industry|Maximumtolerateddose;  Toxicity profile (Number of patients with adverse events);  ObjectiveResponseRate|24|NCT02585973|February 2016
243|Recruiting|Investigating the Impact of Obesity on Pubertal Development in Girls|||Observational||NIH|To determine the correlation between Tanner breast staging and breast maturation scores using breast ultrasound in girls;  To determine the contribution of peripheral aromatization to breast development in obese girls.|75|NCT02583646|October 2015
244|Recruiting|Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery||Other:LaboratoryBiomarkerAnalysis;  DietarySupplement:MuscadineGrapeSkinExtract;  Procedure:Quality-of-LifeAssessment|Interventional|Phase 1|Other / NIH|MTD of MGE defined as the dose level immediately below the dose level that induced a dose-limiting toxicity (DLT) in &gt;= 2 patients as assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;  Adherence to MGE treatment as measured by percent of pills taken at the end of every 4 week period;  Bestresponse;  Changeintotalphenoliclevelsinblood;  Change in quality of life and fatigue in cancer patients taking MGE as measured by FACT-G;  Changeinsystemiccytokinelevels;  Incidence of adverse events (AEs) assessed using NCI CTCAE version 4.0;  Overall response rate of MGE (complete response partial response and stable disease);  Overallsurvival(OS);  Progression-freesurvival(PFS);  Changeincomponentphenoliclevelsinurine;  Changeintotalphenoliclevelsinurine;  Changeincomponentphenoliclevelsinblood;  Change in quality of life and fatigue in cancer patients taking MGE as measured by PROMIS-Fatigue SF|30|NCT02583269|March 2016
245|Recruiting|Long-Working Distance OCT for Children||Device: Duke Biomedical Engineering&apos;s Long-working distance OCT|Interventional||Other|Percentofeyeswithsuccessfulresearchimaging.;  Percent of eyes with 5 substructures of retina capable of being determined as deformed containing cystoid spaces or abnormal (&gt; 50%) thickening or thinning of layers.;  Participant feedback as measured by questionnaire.;  Thetimeittakestogathertheresearchimages.|250|NCT02582164|June 2015
246|Recruiting|Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer||Other:LaboratoryBiomarkerAnalysis;  Drug:Paclitaxel;  Biological:Pembrolizumab|Interventional|Phase 2|Other / NIH|OverallResponseRate;  Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0;  ProgressionFreeSurvival|27|NCT02581982|March 2016
247|Recruiting|Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer||Drug:Carboplatin;  Other:LaboratoryBiomarkerAnalysis;  Drug:Paclitaxel;  Biological:Pembrolizumab;  Other:Quality-of-LifeAssessment|Interventional|Phase 2|Other / NIH|Durationofresponse;  Effectoftreatmentonimmunemarkers;  Objective response rate (ORR) assessed using RECIST;  Overallsurvival;  Progressionfreesurvival|20|NCT02581943|May 2016
248|Recruiting|Metabolic Changes in Blood Samples From Patients With Acute Myeloid Leukemia||Other:CytologySpecimenCollectionProcedure;  Other:LaboratoryBiomarkerAnalysis|Observational||Other / NIH|Glycolyticfluxrate;  Leveloffattyacidsynthasebywesternblot;  Number of mononuclear cells per sample determined by cell isolation;  Oxygenconsumptionrate;  Numberofviablesamples;  Levelofhexokinasebywesternblot;  Levelofphosphofructokinase-1bywesternblot;  Levelofphosphoglyceratemutasebywesternblot;  TotallevelofpyruvatekinaseM2bywesternblot;  Level of pyruvate kinase M2 for phospho-T105 by western blot;  Levelofphosphofructokinase-2bywesternblot|75|NCT02581917|July 2016
249|Not yet recruiting|The Effects of Mindfulness Meditation on Fibromyalgia-Related Pain||Behavioral:MindfulnessMeditationTraining;  Other:Wait-listControl/UsualCareGroup|Interventional||Other|ClinicalPain;  ExperimentalPain;  Fibromyalgia-associatedsymptoms;  Fibromyalgia-associatedanxiety;  HighFrequencyHeartRateVariability(HFHRV)|60|NCT02581332|October 2015
250|Recruiting|Efficacy of Ginseng for Patients on Regorafenib||Drug:Regorafenib;  DietarySupplement:Ginseng|Interventional|Phase 2|Other / Industry|SubjectFatigueAssessment;  SubjectCompliance;  CharacterizeAdverseEvents(AE);  SubjectRetention|90|NCT02581059|April 2016
251|Recruiting|Pharmacokinetics of Systemic Anti-Cancer Therapies in the Cerebrospinal Fluid (CSF) of Patients With Advanced Cancer|||Observational||Other|The concentration of drug metabolites of systemic anti-cancer therapies in the cerebrospinal fluid;  Ratio of serum to CSF concentration of systemic anti-cancer therapies as measured by concentration of drug metabolites in serum and in CSF|20|NCT02580045|October 2015
252|Active not recruiting|Reducing HIV Risk Among Adolescents: Evaluating Project HEART||Behavioral:SaferSex;  Behavioral:GrowthMindsets|Interventional||Other / NIH|6-itemself-reportofprogramacceptability;  7-item self-report of sexual communication self-efficacy;  3-item self-report of sexual communication intentions over next 3 months|222|NCT02579135|September 2015
253|Recruiting|Heart Rate Sensing and Response in Persons With Anorexia Nervosa||Behavioral:Onehoursupervisedexercisesession|Interventional||Other|Mean percentage of time in prescribed heart rate range during four bouts of interval exercise training|30|NCT02579018|March 2016
254|Completed|Evaluation of Cardiorespiratory Performance After Interval Exercise Training Prior to Hematopoietic Cell Transplantation||Behavioral:IntervalExerciseTraining(IET)|Interventional||Other|Of those patients with heart rate data number and percent of patients able to achieve 65-85% heart rate during one or more exercise sessions. Unit of measurement: number of patients and percent of patients with evaluable heart rate data.;  Number of adverse events as reported by patients and determined by study investigators. Unit of measurement: cumulative number of adverse events.;  Change in 6 minute walk distance based on pre- and post- intervention 6 minute walk distance testing. Unit of measurement: meters.;  Change in VO2peak based on pre- and post- intervention VO2peak measurement from cardiopulmonary exercise testing. Unit of measurement: ml/kg*min.|40|NCT02577939|June 2013
255|Recruiting|Clinical and Biological Outcomes of Human Milk and Formula Intake After Gastroschisis Repair||DietarySupplement:EnteralIntake-HumanMilk;  DietarySupplement:EnteralIntake-Formula|Interventional||Other|LengthofHospitalStay;  TimetoFullEnteralFeeds;  TimeonTotalParenteralNutrition|20|NCT02575846|September 2015
256|Recruiting|The Ability of Electronic Patient Symptom Reporting to Reduce Symptom Burden During Hospitalization for Chemotherapy||Other:Electronicsymptomsurvey;  Other:BlindedElectronicSymptomSurvey|Interventional||Other|Average peak symptom burden in the intervention group versus the control group|120|NCT02574897|July 2014
257|Recruiting|Behavioral Weight and Symptom Management for Breast Cancer Survivors and Partners||Behavioral: Couples-Based Behavioral Weight and Symptom Management|Interventional||Other / NIH|ChangeinWeight;  Changeinstepsperday;  Changein6minutewalkabilityscore;  Changein6minutewalkpainscore;  Change in Stanford Leisure-Time Activity Categorical Item (L-Cat);  ChangeinBingeEatingScale(BES);  ChangeinTheBriefPainInventory(BPI);  ChangeinPromisFatigueScale;  ChangeinProfileofMoodStates(POMS);  ChangeinFastinginsulin;  ChangeinIL-6;  ChangeinIL-8;  ChangeinTNF-alpha;  ChangeinAdiponectin;  ChangeinHeartRate;  TreatmentAcceptabilityQuestionnaire(TAQ);  ChangeinSessionattendancerate;  ChangeinUseofinterventionstrategies|100|NCT02574507|October 2015
258|Recruiting|Neuromodulation Enhanced Cognitive Restructuring: A Proof of Concept Study||Behavioral:CognitiveRestructuring;  Device:rTMS;  Device:ShamrTMS|Interventional||Other|Time to return to heart rate baseline during the regulation period during training;  Time to return to heart rate baseline during the regulation period at follow up;  Acceptability as measured by qualitative exit interview;  Feasibility as measured by qualitative exit interview;  Change in general psychological distress as measured by the Outcome Questionaire -45;  Change in general emotional distress as measured by daily mobile phone ratings 8 times/day of subjective units of distress)|65|NCT02573246|June 2016
259|Recruiting|Integrated Child Obesity Treatment Study: Bull City Healthy and Fit||Behavioral:BullCityHealthyandFit;  Behavioral:HealthyLifestylesClinic|Interventional||Other|ChangeinBodyMassIndex;  ChangeinHealthhabits;  ChangeinCardiovascularfitness;  ChangeinAdherencetoclinicappointments|100|NCT02573142|October 2015
260|Recruiting|Clinical Investigation of a New Bulk Fill Composite Resin in the Restoration of Posterior Teeth||Device:FiltekBulkFillPosterior;  Device:FiltekSupremeUltra|Interventional||Other / Industry|Percent success in Filtek Bulk Fill &amp; Filtek Supreme Ultra composite resin restorations at Year 2;  Percent success in Filtek Bulk Fill &amp; Filtek Supreme Ultra composite resin restorations at 6 months;  Percent success in Filtek Bulk Fill &amp; Filtek Supreme Ultra composite resin restorations at Year 1;  Percent success in Filtek Bulk Fill &amp; Filtek Supreme Ultra composite resin restorations at Year 3;  Percent success in Filtek Bulk Fill &amp; Filtek Supreme Ultra composite resin restorations at Year 5;  Wear for Filtek Bulk Fill &amp; Filtek Supreme Ultra composite resin restorations at 6 Months;  Wear for Filtek Bulk Fill &amp; Filtek Supreme Ultra composite resin restorations at Year 1;  Wear for Filtek Bulk Fill &amp; Filtek Supreme Ultra composite resin restorations at Year 2;  Wear for Filtek Bulk Fill &amp; Filtek Supreme Ultra composite resin restorations at Year 3;  Wear for Filtek Bulk Fill &amp; Filtek Supreme Ultra composite resin restorations at Year 5|50|NCT02572570|December 2015
261|Completed                  Has Results|Lazanda Fentanyl Nasal Spray Pre Radiofrequency Nerve Ablations(RFA) of Lumbar Facet Joints||Drug:Lazanda|Interventional|Phase 4|Other / Industry|Safety and Tolerability as Measured by the Number of Adverse Events;  Pain Score Differences Using the DVPRS (Defense and Veterans Pain Rating Scale) Tool.;  Patient Satisfaction Using a Likert Satisfaction Survey;  AdverseEvents;  SedationLevelAssessedbyPOSSTool|23|NCT02571634|May 2015
262|Recruiting|Battlefield Auricular Acupuncture During Adult Tonsillectomies and Effect of Post op Pain and Nausea||Other:Auricularacupuncture|Interventional||Other|PainscoresforsubjectsreceivingBFA;  Themorphineequivalentofopioiduse;  Returntodiet;  Nauseapostoperatively;  Vomitingpostoperatively|100|NCT02571075|November 2013
263|Recruiting|ImplemeNtation oF demOnstration pRoject for Health systeMs: Atrial Fibrillation (INFORM-AF) Part 1|||Observational||Other / Industry|Perceptions of using anticoagulation as a stroke prevention therapy in atrial fibrillation as measured by survey and interview;  Willingness to use anticoagulation as a stroke prevention therapy in atrial fibrillation as measured by survey and interview;  preferences for using anticoagulation as a stroke prevention therapy in atrial fibrillation as measured by survey and interview;  priorities for using anticoagulation as a stroke prevention therapy in atrial fibrillation as measured by survey and interview|110|NCT02569528|October 2015
264|Recruiting|Patient and Provider Confidence and Satisfaction With the Clinical Use of CYP Genetic Variability||Genetic:PainMedicationDNAInsight(TM)test|Interventional||Other / Industry|Provider Satisfaction Certainty and Confidence survey;  Providerperceptionofcaresurvey;  Providerglobalimpressionofchangesurvey;  Patient certainty confidence and satisfaction survey;  Patientperceptionofcaresurvey;  Patientglobalimpressionofchangesurvey;  PatientOutcomespainasassessedbytheDVPRS;  Patient Outcomes pain as assessed by BPI perception of pain relief item;  Patient Outcomes pain as assessed by the PROMIS Pain short form;  PatientOutcomesofdemographics;  Patient Outcomes of depression as assessed by the PROMIS depression short form;  Patient Outcomes of anxiety as assessed by the PROMIS anxiety short form|48|NCT02568618|July 2015
265|Recruiting|Platelets as Regulators of Inflammation in Cardiac Surgery||Procedure: coronary artery bypass grafting using cardiopulmonary bypass|Observational||Other|Acutekidneyinjury;  systemic inflammatory response activation as measured by serum TNFa levels;  systemic inflammatory response activation as measured by serum IL8 levels;  systemic inflammatory response activation as measured by serum Chymase levels;  systemic inflammatory response activation as measured by serum IL6 levels;  platelet activation as measured by p-selection levels;  platelet activation as measured by serum platelet factor 4 levels;  hospitallengthofstay;  Intensivecareunitlengthofstay;  majoradversecardiacevents|100|NCT02568410|October 2015
266|Recruiting|Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer That Cannot Be Removed by Surgery||Other:LaboratoryBiomarkerAnalysis;  Other:Quality-of-LifeAssessment;  Other:TargetedTherapy|Interventional||Other / NIH|Feasibility in terms of the ability to monitoring patient outcomes across separate treatment protocols and study teams.;  Proportion of patients enrolled on this protocol who are subsequently enrolled in a clinical trial based on the results of the genomic sequencing;  Proportion of patients enrolled on this protocol who have a clinical trial identified for them to be enrolled in based on the results of the genomic sequencing;  Proportion of patients with an actionable mutation;  Feasibility in terms of the ability to monitoring patient adverse events across separate treatment protocols and study teams.;  Change in patient-reported symptoms of cancer and cancer treatment as assessed by the MD Anderson Symptom Inventory;  Patient&apos;s perceived quality care as assessed by 3 items adapted from Arora et al;  Patient&apos;s satisfaction with treatment decision-making and decisional regret as assessed by an adapted Satisfaction with Decision scale;  Self-perceived burden as assessed by the Self-Perceived Burden Scale-Short form for measuring chronic disease patients&apos; feelings of being a burden on their caregivers;  Survival rate in patients who receive targeted treatment versus those who do not receive targeted treatment;  Treatment response rates in patients who receive targeted treatment versus those who do not receive targeted treatment|300|NCT02566421|October 2015
267|Recruiting|Community Hospital Identification of High CV Risk Patients During Cancer Treatment||Other:FastMRIandQuestionnaires|Interventional|Phase 3|Other|Change is being assessed of deteriorations in LVEF;  Change is being assessed of deteriorations in LVEF at 6 months;  Change is being assessed of deteriorations of CV function|30|NCT02566109|March 2016
268|Recruiting|Fitness in Allogeneic Stem Cell Transplantation||Behavioral: Interval Exercise Training/Motivational Accelerometry|Interventional||Other / NIH|Compare changes in VO2peak after a 5-12 week period of time prior to alloHCT in patients undergoing interval exercise training (IET) and motivational accelerometry (MA) vs patients receiving usual care (controls).;  Compare changes in 6 minute walk distance (6MWD) after a 5-12 week period of time prior to alloHCT in patients receiving IET/MA vs controls.;  Compare changes in peripheral blood p16INK4a after a 5-12 week period of time prior to alloHCT in patients receiving IET/MA vs controls.|60|NCT02564458|September 2015
269|Active not recruiting|North Carolina Prostate Cancer Comparative Effectiveness &amp; Survivorship Study (NC ProCESS)|||Observational||Other|PatientReportedOutcomes;  Disease-FreeSurvival;  Directly compare health care utilization among different treatment options for prostate cancer from review of medical records|1656|NCT02564120|January 2011
270|Recruiting|Pain Coping Skills Training for African Americans With Osteoarthritis||Behavioral:PainCopingSkillsTraining(CST)|Interventional||Other|Western Ontario and McMasters Universities Osteoarthritis (WOMAC) Pain Subscale;  WOMACPainSubscale;  WOMACTotalScore;  WOMACfunctionsubscale;  PatientHealthQuestionnaire8;  PatientGlobalAssessmentofChange;  CopingStrategiesQuestionnaire;  ArthritisSelf-EfficacyScale;  SF-12HealthRelatedQualityofLife;  PROMISPainInterference|248|NCT02560922|April 2016
271|Recruiting|MICU Recovery Clinic||Other: Questionnaires Physical and Cognitive Function|Observational||Other|PhysicalFunction;  CognitiveFunction;  Anxiety/DepressionScreening;  PostTraumaticStressDisorderScreening;  FunctionalStatus;  Resilience;  QualityofLife;  HospitalReadmissions;  Mortality|250|NCT02560129|July 2015
272|Active not recruiting|Contrast Echocardiography Cost Effectiveness for Left Ventricular Thrombus Assessment|||Observational||Other / Industry|Cost-effectiveness|500000|NCT02555527|September 2015
273|Recruiting|Effects of Smoking Environments on Craving and Smoking (CameraCue2.0)||Drug:NicotinePatch;  Drug:Varenicline;  Drug:PlaceboNicotinePatch;  Drug:PlaceboCapsule|Interventional||Other / NIH|ChangeincravingscoreduringCueExposuretask;  Change in latency to smoke during Cue Exposure task;  ChangeinsmokeintakeduringCueExposuretask|120|NCT02551692|January 2016
274|Recruiting|Incretin Action in Physiology and Diabetes||Drug:GIPinfusion;  Drug:GLP-1infusion;  Drug:Ex-9infusion|Interventional|Phase 1|Other / NIH|Betacellsensitivity|25|NCT02550548|April 2016
275|Enrolling by invitation|Oxytocin Treatment of Opioid Dependence||Drug:IntranasalOxytocinSpray;  Drug:Placebo|Interventional|Phase 1 / Phase 2|Other|Area Under the Curve (AUC) in Clinical Opiate Withdrawal Scale (COWS) Total Score on Days 1 to 5 Inclusive;  AUC in Subjective Opiate Withdrawal Scale (SOWS) Total Score on Days 1 to 5 Inclusive;  AUC in Visual Analog Scale (VAS) Score for Craving on Days 1 to 5 Inclusive|25|NCT02548728|February 2016
276|Recruiting|LCI-NOS-PAIN-001: A Prospective Pharmacogenomic-Driven Study of Pain Management in Oncology Outpatients||Genetic:PharmacogenomicTesting|Interventional|Phase 2|Other|Significant pain improvement as measured using the Edmonton Symptom Assessment Scale from baseline visit to day 30;  Number of subjects with treatment-related adverse events as assessed by CTCAE v4.03;  Morphine equivalent daily doses (MEDD) in milligrams;  Frequency of actionable genotypes defined as the presence of any mutation(s) that is (are) used to guide a drug/dose modification|78|NCT02542397|September 2015
277|Recruiting|Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma||Drug:Sym004|Interventional|Phase 2|Other / Industry|Six-monthprogression-freesurvival(PFS6);  Percentage of participants who experience grade 3 4 or 5 adverse events;  Radiographicresponse;  Medianprogression-freesurvival(PFS);  Medianoverallsurvival(OS)|61|NCT02540161|October 2015
278|Recruiting|Do Peanut Shaped Birthing Balls Reduce the Length of Labor in Patients With Epidural Analgesia?||Device:peanutshapedbirthingball|Interventional||Other|Lengthoflabor|240|NCT02539563|June 2015
279|Recruiting|Strengthening Instrumental Extinction to Prevent Smoking Relapse (VLNCCue)||Drug:NicotinePatch;  Drug: SPECTRUM Nicotine Research Cigarettes (0.07 mg);  Behavioral:MCE+;  Behavioral:MCE-|Interventional||Other / NIH|Change in Fagerstrom Test of Nicotine Dependence Score;  DaystoRelapse;  Change from Baseline in number of usual brand cigarettes smoked (EXT Engagement);  Change in number of cigarettes smoked per day (EXT Response);  Change in craving score during MCE task (MCE Response);  ChangeinPost-quitCue-reactivity;  ChangeinHeartRateduringCueReactivityTask|300|NCT02538042|September 2015
280|Completed|Impact of Skin to Skin Contact on Maternal Satisfaction Pain Scores and Narcotic Usage After Cesarean Delivery||Other:skintoskin|Interventional||Other|pain|70|NCT02533167|July 2015
281|Recruiting|TDN Manual Therapy and Exercise For the Management of Achilles Tendinopathy||Procedure:manualtherapyandexercise;  Procedure:triggerpointdryneedling|Interventional||Other|Change in Functional Activity Level from baseline with the Functional Ankle Ability Measure;  Change in Pain from Baseline with the Numeric Pain Rating Scale;  Change in Fear of Activity from baseline with the Tampa Scale of Kinesiophobia;  Change in Pain from baseline with the Global Rating of Change;  Change in Pain from baseline with the Pain Pressure Threshold Measure;  Change in strength from baseline with the Muscle Endurance Test for single leg heel raise;  Age;  Height;  Weight;  Gender;  DurationofPain|66|NCT02532595|May 2015
282|Recruiting|Comparative Volumetric Assessment of Alveolar Ridge Preservation Utilizing Different Bone Grafting Materials||Biological:AllograftMembrane;  Biological:AlloplastMembrane;  Biological:XenograftMembrane;  Biological:Membrane|Interventional||Other / Industry|Volumetric osseous changes using data from DICOM images acquired by Cone Beam Computed Tomography (CBCT) using 3D software;  Osseousdimensionalchanges;  Softtissuedimensionalchange|80|NCT02532543|April 2016
283|Recruiting|Chronic Lumbosacral Radiculopathy: Impact of an Analgesic Dietary Intervention on Pain &amp; Function||Other:DietA;  Other:DietB|Interventional||Other|Oswestry Disability Index--Primary clinical outcome;  17-Hydroxy Docosahexaenoic acid (DHA)--Primary biochemical outcome;  Painintensity;  Physicalactivity;  Sleepefficiency;  Sleepquantity;  Self-reportedhealth;  Redbloodcellfattyacids;  BorkovecandNauscale|52|NCT02531711|September 2015
284|Completed|Differential Biomechanical Effects of an ACL Injury Prevention Program in Women&apos;s Basketball and Soccer Players||Other:NeuromuscularPreventionProgram|Interventional||Other|Lower Extremity Angular Kinematics (hip flexion hip adduction hip internal rotation knee flexion abduction knee internal rotation knee external rotation);  Lower Extremity Kinetics (hip flexion hip adduction hip internal rotation knee flexion abduction knee internal rotation knee external rotation external moments);  TripleJumpDistance;  MaximalVerticalJumpHeight;  Agility|99|NCT02530333|May 2015
285|Recruiting|Nivolumab With DC Vaccines for Recurrent Brain Tumors||Drug:nivolumab;  Biological:DC|Interventional|Phase 1|Other / Industry|The safety of administering DC vaccines with nivolumab as measured by the percentage of patients who experience unacceptable toxicity during combination treatment;  Survival of subjects treated with any protocol treatment (i.e. nivolumab or DC vaccines).;  Progression Free Survival (PFS) of subjects treated with any protocol treatment (i.e. nivolumab or DC vaccines).|66|NCT02529072|January 2016
286|Recruiting|High Intensity Interval Training and Rheumatoid Arthritis||Behavioral:HIIT|Interventional||Other|ChangeinDiseaseActivityScores;  ChangeinPeakOxygenConsumption|26|NCT02528344|September 2015
287|Recruiting|Cognitive Behavioral Strategies and Transcranial Magnetic Stimulation in Obsessive-Compulsive Disorder: Open Label Study||Device:Transcranialmagneticstimulation;  Behavioral:Cognitivebehavioraltherapy|Interventional||Other|RemissionrateasmeasuredbyY-BOCS;  CompleteresponseasmeasuredbyY-BOCS;  PartialresponserateasmeasuredbyY-BOCS|5|NCT02528331|March 2016
288|Completed|Nutritional Supplement Efficacy on Cellular Protection and Skin Health in Generally Healthy Adults||DietarySupplement:NutritionalSupplement;  Radiation:MinimalErythemaDose(MED)|Interventional||Industry / Other|Cellularprotectionoftheskin;  SkinHealth|40|NCT02525224|July 2015
289|Recruiting|Optical Spectroscopy for Cutaneous Cancer||Other: No intervention; this is an observational study|Observational||Other|spectroscopic differences between tumor dysplasia and normal cutaneous tissue.|160|NCT02522793|May 2016
290|Recruiting|A Trial of RSL Versus WL for Malignant Breast Disease||Procedure:RadioactiveSeedLocalization;  Procedure:WireLocalization|Interventional||Other|SurgicalResectionMargins|400|NCT02522468|July 2015
291|Suspended|Conventionally vs. Digitally Fabricated Complete Dentures: Clinical Treatment Outcome Differences||Device:Completetraditionaldentures;  Device:CompleteCADCAMdentures|Interventional||Other|the overall comparison of functional assessment of digitally fabricated dentures to traditionally fabricated dentures;  comparison of functional assessment of digitally fabricated dentures to traditionally fabricated dentures;  comparison of patient satisfaction between digital dentures and traditional dentures;  bite force comparison between digital dentures and traditional dentures|16|NCT02521935|January 2017
292|Recruiting|IN Sub-Dissociative Ketamine vs IN Fentanyl||Drug:ketamine;  Drug:fentanyl;  Drug:ibuprofenoracetaminophen|Interventional|Phase 2|Other|Primary outcome: proportion of participants with minor side effects and significant adverse events;  Secondary outcome: total dose of opioid pain medication in morphine equivalents/kg/hour|80|NCT02521415|December 2015
293|Completed|Measuring Fatigue in Triage: A Pilot Study||Other:Survey|Observational||Other|Fatiguelevelasmeasuredbyquestionnaire|28|NCT02519205|October 2015
294|Recruiting|Exercise and Pharmacotherapy for Anxiety in Cardiac Patients||Drug:Lexapro;  Drug:Placebo;  Behavioral:SupervisedAerboicExercise|Interventional||Other|Change in Hospital Anxiety and Depression Scale Total Score;  ChangeinHeartRateVariabilitySDNN(msec);  ChangeinBaroreflexSensitivityms/mmHg;  Change in Vascular Endothelial Function % dilation;  Change in Inflammation (C-Reactive Protein ug/ml);  Change in Urinary Catecholamines (epinephrine and norepinephrine pg/ml);  Change in Lipids (total cholesterol LDL and HDL; mg/dL)|150|NCT02516332|December 2015
295|Enrolling by invitation|Mobile Contingency Management for Smoking Cessation in Returning US Veterans||Drug:Nicotinegum;  Behavioral:mobilecontingencymanagement;  Behavioral:Telephonecounseling;  Drug:Nicotinepatch;  Drug:Nicotinelozenge;  Device:Smartphone;  Device:Carbonmonoxidemonitor|Interventional||Other / U.S. Fed|smokingself-report;  salivacotinine|260|NCT02513069|November 2015
296|Completed|Examining the Role of Expressive Writing (EW) to Improve Resilience||Behavioral:6-weekWritingtoHealcourse|Interventional||Other|Connor-DavidsonResilienceScale(CD-RISC);  10-ItemPerceivedStressScale(PSS-10);  20-item Center for Epidemiological Studies Depression Scale (CES-D);  22-itemRuminationResponseScale(RRS)|39|NCT02510898|January 2016
297|Recruiting|SD-OCT Angiography||Device:AngioVueSD-OCT|Interventional||Other / Industry|ImageQuality|100|NCT02510885|July 2015
298|Completed|Addressing Tobacco Use Disparities in Rural Older Adults Through an Innovative Mobile Phone Intervention||Behavioral:SGR;  Behavioral:Supportmessageonly|Interventional||Other|Tobacco cessation defined as quit rate at 30 days as measured by self-reported abstinence from tobacco use;  Feasibility as measured by proportion of return text messages;  Acceptability as measured by percentage of participants who reported that they would recommend the program to a friend|40|NCT02510716|December 2015
299|Active not recruiting|Emotional Processing and Oxytocin Mechanisms in Premenstrual Dysphoric Disorder: A Pilot Study||Drug:Oxytocin;  Drug:Placebo|Interventional|Phase 2 / Phase 3|Other|Changeinpremenstrualsymptomseverity;  Neural response to cognitive-emotional processing tasks during functional magnetic resonance imaging (fMRI)|13|NCT02508103|July 2015
300|Recruiting|Point of Care 3D Ultrasound for Pediatric Appendicitis: a Pilot Study||Device:ultrasound|Observational||Other|Experimental ultrasound diagnosis agreement with final reference standard diagnosis;  Duration of experimental ultrasound exam (seconds);  Appendix visualized by experimental ultrasound (yes/no);  Experimentalultrasoundimagequality.|50|NCT02507674|October 2015
301|Recruiting|Vestibular Function After Cochlear Implantation Using Soft Surgery Techniques||Other:Vestibulartesting|Interventional||Other|Change in Vestibular function in Cochlear Implant Patients;  ChangeinQualityofLifebyquestionnaire|30|NCT02503592|April 2015
302|Recruiting|Autoimmune Paradoxical Reactions in IBD Longitudinal Cohort|||Observational||Other|Number of Participants with specific paradoxical Adverse Events Using Biologic therapies as a part of routine care for the treatment of IBD|400|NCT02503514|August 2015
303|Recruiting|Natural History Study of Factor IX Treatment and Complications||Other: Standard care with blood and urine sample collection|Observational||Other / Industry|Inhibitoryantibodies;  Annualizedbleedingrate;  Jointassessment;  Renaldisorders;  Hemophiliatreatmentadherence;  Healthrelatedqualityoflife;  Non-inhibitoryantibodies;  FactorIXusage;  Numberofhospitalizations;  Numberofsurgicalprocedures;  numberofdaysmissedfromschoolorwork|550|NCT02502409|July 2015
304|Not yet recruiting|Adaptive Pharmacotherapy for Tobacco Dependence||Behavioral:High-IntensityBehavioralTreatment;  Behavioral:Low-IntensityBehavioralTreatment;  Drug:Varenicline;  Drug:Bupropion;  Drug:Nicotinepatches|Interventional|Phase 2|Other / NIH / Industry|Biochemically confirmed continuous 30-day abstinence from smoking;  Biochemically confirmed 7-day point prevalence abstinence from smoking;  Self-report 24-hour point prevalence abstinence from smoking;  Self-report 7-day point prevalence abstinence from smoking;  Smokingreduction;  Changesinnicotinedependence;  Changesinstress;  Changesinanxiety;  Changesindepression;  Changesinrelapsepredictors;  Overallcostofmedication;  Costofmedicationperabstinentsmoker;  Costofprescribedmedication|600|NCT02501265|July 2016
305|Recruiting|Telephone-based Smoking Cessation||Behavioral:Behavioralmoodmanagement;  Other:Healtheducation|Interventional||U.S. Fed|Prolongedabstinencesurvey;  Pointprevalentabstinencesurvey;  PHQ-9PatientDepressionQuestionnaire;  BiochemicalVerification|350|NCT02500589|May 2016
306|Active not recruiting|Using Question Prompt Lists During Pediatric Asthma Visits to Increase Adolescent Involvement||Behavioral: Educational Video and Question Prompt List|Interventional||Other|AsthmaControl;  AdolescentAsthmaManagementSelfEfficacy;  AdolescentQualityofLife;  Number of Questions the Adolescent Asks about Asthma or Its Treatment during the audio-tape visits.;  Providers include adolescent input into the asthma management plan.;  AdolescentSatisfactionwiththeVisit;  AdherencetoAsthmaControlMedications;  Numberofparentreportedmedicineproblems;  Numberofadolescentreportedmedicineproblems;  Emergency Department (ED) asthma visits during the past 12 months;  Unscheduled physician visits during the past 12 months;  Lungfunction|360|NCT02498834|July 2015
307|Recruiting|Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery||Drug:BotulinumToxinTypeA;  Drug:Placebo|Interventional|Phase 1 / Phase 2|Other|Timetoin-hospitalPOAF;  Incidenceofin-hospitalPOAF;  Lengthofstay;  Adverseevents|130|NCT02498769|September 2015
308|Completed|The Use of Aging Biomarkers to Predict Adverse Outcomes After Cardiac Surgery|||Observational||Industry / Other|Development of stage 1 or higher postoperative AKI as defined by the AKIN classification (stage 1- &#8805; 0.5 mg/dL absolute or &#8805; 50% relative rise in peak SCr over the baseline);  Number of Participants who suffered postoperative stroke;  Number of Participants who suffered cognitive decline;  Number of Participants requiring prolonged mechanical ventilation (for longer than 24h);  Number of Participants with : cardiac arrest perioperative myocardial infarction and perioperative ventricular dysfunction.;  NumberofParticipantswithcardiacarrest;  Number of Participants with perioperative myocardial infarction;  Number of Participants with perioperative ventricular dysfunction.;  Number of Participants with postoperative deep sternal wound infection;  Number of Participants with postoperative thoracotomy infection;  NumberofParticipantswithpostoperativesepsis.;  Number of Participants in need for renal replacement therapy;  Number of Participants who progressed to end stage renal disease.;  Death|186|NCT02496234|July 2015
309|Completed|A Safety and PK Study of EC-18 in Healthy Subjects||Drug:EC-18;  Drug:Placebo|Interventional|Phase 1|Industry|The primary endpoint of the study will be the number and severity of treatment emergent adverse events (TEAEs) following single doses of EC-18 and placebo.;  To determine the composite pharmacokinetic (PK) parameters of EC-18 following sngle oral doses. AUC0-t AUC0-24 Cmax Tmax 48-hour time period.|33|NCT02496143|July 2015
310|Not yet recruiting|Electronic Nicotine Delivery Systems as a Smoking Cessation Treatment||Drug:Nicotinepatch;  Other:ENDS;  Other:Placebopatch;  Other:PlaceboENDS|Interventional|Phase 2|Other / NIH|Continuous four-week abstinence from smoking during treatment;  Continuous four-week abstinence from smoking after withdrawal of ENDS;  Continuous four-week abstinence from smoking after withdrawal of nicotine patches;  Seven-day point abstinence from smoking at 6 months post Quit Day|300|NCT02487953|January 2016
311|Recruiting|Rejuvenated Washed Packed Red Blood Cells in Pediatric Cardiac Surgery||Drug:Rejuvesol;  Procedure:Cardiacsurgery|Interventional|Phase 4|Other|Change in tissue oxygenation/perfusion during cardiac surgery measured by whole blood lactate concentration;  Change in ischemic organ injury during cardiac surgery measured by urinary neutrophil gelatinase associated lipocalin (NGAL);  Change in hemolysis during cardiac surgery as measured by plasma free hemoglobin levels|15|NCT02485366|June 2015
312|Recruiting|CIP-613 Cytarabine and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma||Drug:68-Bis(benzylthio)octanoicAcid;  Drug:Cytarabine;  Procedure:HematopoieticCellTransplantation;  Drug:MitoxantroneHydrochloride|Interventional|Phase 2|Other / NIH|Feasibility of administering CPI-613 in combination with high dose cytarabine and mitoxantrone during induction consolidation and maintenance therapies defined as percentage of patients eligible for maintenance therapy who complete at least 3 courses;  Completeresponse;  Early mortality (death within 60 days of beginning of treatment) to the observed rates in a historical cohort of subjects;  Frequency of toxicities experienced by the participants graded using the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0;  Overallsurvival;  Response rate (CR and CRi) assessed by standard criteria for AML|50|NCT02484391|September 2015
313|Recruiting|Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy||Drug:Rosuvastatin|Interventional|Phase 1|Other|Safetybyadverseevent;  Maximumtolerateddose;  Change in Ki-67 with rosuvastatin alone followed by rosuvastatin in combination with endocrine therapy;  progressionfreesurvival|12|NCT02483871|October 2015
314|Recruiting|Message Framing and Colorectal Cancer Screening||Behavioral:Educationalmaterials|Interventional||Other|CRCscreeningfollow-uprate;  Changes in attitudes towards CRC and CRC screening as measured by survey|750|NCT02483832|February 2015
315|Completed|Seeing the World Through Assorted Glasses||Device:AmberLenses;  Device:PlaceboLenses|Interventional||Other|Increasedim-lightmelatoninproduction;  Improvedsubjectiveself-reportedmood;  Improvedobjectivemeasuresofsleep;  Improvedsubjectiveself-reportedsleepquality|15|NCT02483559|June 2015
316|Enrolling by invitation|Feasibility of an Interval Exercise and Nutrition Intervention to Reduce Cardiovascular Disease Risk Factors||Other:Exercise&amp;DietarySupplement|Interventional||Other|Number of participants that complete exercise program;  Number of participants that complete nutrition program;  Numberofexercisesessionscompleted;  Numberofdaysnutritionprogramfollowed;  Change in Cardiorespiratory Fitness at 3 months 6 months and 12 months;  Change in fat mass at 3 months 6 months and 12 months;  Change in lean mass at 3 months 6 months and 12 months;  Change in blood lipids at 3 months 6 months 12 months;  Change in hemoglobin A1c at 3 months 6 months 12 months|15|NCT02482922|May 2015
317|Completed|Breakfast Meal Replacement||DietarySupplement:Mealreplacement|Interventional||Other|Change in Fat Mass measured from multi-compartment (4C) model;  Change in lean mass measured from multi-compartment (4C) model;  Change in percent body fat measured from multi-compartment (4C) model;  Change in resting metabolic rate using indirect calorimetry;  Change in respiratory exchange ratio using indirect calorimetry;  Change in total leptin concentrations from blood sample analysis;  ChangeinLDLfrombloodsampleanalysis;  Change in triglycerides from blood sample analysis;  Changeininsulinfrombloodsampleanalysis;  Changeinvisceralfatfromultrasonography;  Changeinsatietyviaquestionnaire|50|NCT02482545|June 2015
318|Recruiting|Study of Preoperative Boost Radiotherapy||Radiation:Singlefractionof10Gy|Interventional|Phase 2|Other|Radiation response in relative change from baseline and post radiation FAS (name of gene not an acronym) expression;  CosmesisEvaluations;  QualityofLife;  Compositereviewoflocalcontrol|100|NCT02482389|October 2015
319|Recruiting|Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer||Radiation:Stereotacticbodyradiotherapy(SBRT)|Interventional|Phase 2|Other|The rate of pathologic complete response to radiation at the time of surgery.;  Physician reported rates of good/excellent cosmesis.;  Patientreportedratesofgood/excellentcosmesis;  Theimpactofradiationongeneexpression;  Local control in the treated breast relative to historic controls|40|NCT02482376|October 2015
320|Active not recruiting|Interstitial Lung Diseases in the Veterans Administration|||Observational||U.S. Fed / Industry|Prevalence of Interstitial Lung Disease in the VISN6 Veterans Administration Patient Population;  Prevalence of Idiopathic Pulmonary Fibrosis in the VISN6 Veterans Administration Patient Population;  Accuracy of ICD-9 Codes for diagnosis of Interstitial Lung Disease;  Frequency of ICD-9 code diagnosis of Interstitial Lung Disease and clinic consultation with a pulmonary provider;  Prevalence of Co-morbid Diabetes Mellitus with Interstitial Lung Disease|3000|NCT02479126|July 2016
321|Recruiting|Longitudinal MR Imaging of Pulmonary Function in Patients Receiving Thoracic Radiation Treatment||Drug:Hyperpolarized129-Xenongas;  Device:MRI|Interventional|Phase 1|Other / NIH|Change in pulmonary function as measured by ventilation defect percentage (VDP);  Change in gas exchange defect percentage (EDP) following RT;  Change in perfusion defect percentage (PDP) following RT;  RBC:barrierratio|35|NCT02478255|February 2016
322|Enrolling by invitation|Addressing Real-world Anticoagulant Management Issues in Stroke|||Observational||Other / Industry|Prevalence of novel oral anticoagulants among patients with either acute ischemic stroke or intracerebral hemorrhage;  Number of Symptomatic intracranial hemorrhage events in ischemic stroke patients treated with tissue plasminogen activator (tPA);  Percentage of Symptomatic intracranial hemorrhage events in ischemic stroke patients treated with tissue plasminogen activator (tPA);  ModifiedRankinScale;  In-hospitalmortalityrate;  tPAtreatmentrate;  Number of intracerebral hemorrhage patients receiving anticoagulation reversal treatment;  Percentage of intracerebral hemorrhage patients receiving anticoagulation reversal treatment|10000|NCT02478177|September 2015
323|Completed|A Study to Assess the Tolerability of a Single Dose of AF-219 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)||Drug:AF-219|Interventional|Phase 2|Industry|EffectofAF-219onBP|6|NCT02477709|July 2015
324|Not yet recruiting|Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders||Drug:tolvaptan;  Other:Placebo|Interventional|Phase 4|Other|Changeinbodyweightat48hours;  Changes in congestion (patient reported and investigator assessed);  Changeinbodyweightatday8;  Clinicalcompositeofmorbidity|40|NCT02476409|July 2015
325|Recruiting|SMART Mobile Application Technology Utilization in the Treatment of Sickle Cell Disease Post Day Hospital Discharge||Device:SMARTapp|Interventional||Other|percentageofacutecareutilization;  percentage adherence to hydroxyurea (HU) administration;  percentage adherence to post-acute care out-patient follow up visit|100|NCT02475993|July 2015
326|Not yet recruiting|Rapid Acquisition of Pre- and Post-Incident Disaster Data|||Observational||NIH|Create a research registry comprised of disaster response workers who are rostered before or immediately after deployment to a disaster area.;  Gather sociodemographic health status occupational exposure and lifestyle information of the cohort before or immediately after deployment to a disaster area;  Collect process and store biological samples to allow estimations of disaster-related exposures of the disaster response worker cohort before or immediately after deployment to a disaster area;  Establish a well-characterized disaster response worker cohort that will allow for future analyses of associations between disaster exposures and health outcomes|500|NCT02473770|May 2015
327|Withdrawn|Pathways to Improving Functional Capacity in Older Patients With Chronic Kidney Disease and Cardiovascular Disease||DietarySupplement:FishOilandBicarbonate;  Dietary Supplement: Fish Oil and Bicarbonate Placebo;  Dietary Supplement: Fish Oil Placebo and Bicarbonate;  Dietary Supplement: Fish Oil Placebo and Bicarbonate Placebo|Interventional||Other|ChangefromBaselineofVO2peakat12weeks|0|NCT02473705|January 2016
328|Recruiting|Predictors of Opioid-Induced Respiratory Depression (OIRD)||Drug:Remifentanil;  Drug:Oxygen;  Drug:Carbondioxide|Interventional|Phase 1|Other|Hypercapnic Ventilatory Response (HCVR) gradient based upon ETCO2 and Minute Volume;  The proportion of subjects who are classified as low medium or high risk for Opioid Induced Respiratory Depression (OIRD).|20|NCT02473354|April 2015
329|Withdrawn|68-Bis(Benzylthio)Octanoic Acid Cytarabine and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia||Drug:68-Bis(benzylthio)octanoicAcid;  Drug:Cytarabine;  Drug:DaunorubicinHydrochloride|Interventional|Phase 1 / Phase 2|Other / NIH|MTD based on the number of observed dose-limiting toxicities as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I);  Rateofcompleteremission(PhaseII);  Incidence of adverse events as assessed by the CTCAE version 4.0 (Phase I/II);  Overallsurvival(OS)(PhaseII);  Progression-freesurvival(PhaseII);  Rate of allogeneic stem cell transplantation (Phase II)|0|NCT02472626|December 2015
330|Recruiting|Verizon mHealth Solution for Patients With Peripheral Artery Disease (PAD)||Other:FitbitPhysicalActivityMonitor;  Other:iHealthGlucometer;  Other:WithingsBloodPressure|Interventional||Other / Industry|Change score analysis of the average number of steps per week measured using a Fitbit activity tracker;  Change in cardiovascular fitness level measured by change score analysis of peak Volume of Oxygen (pVO2mL/kg/min) consumption measured during a cardiopulmonary exercise test (CPET).;  Change score analysis in Ankle Brachial Index (ABI) measurements;  Change score analysis in Body Mass Index measurements;  Change score analysis in Blood Glucose measurements;  Change in Medication Adherence scores as measured by the Morisky Medication Adherence Scale (MMAS-8);  Change in Quality of Life (QOL) scores on the Walking Impairment Questionnaire;  Change in Peripheral Artery Disease (PAD) Health Aptitude scores on the Health Aptitude Questionnaire;  Change in Smoking Habits scores on the PAD: Smoking Habit Questionnaire;  Change score analysis in Systolic and Diastolic Blood Pressure measurements;  Feasibility of this novel mobile health treatment strategy as measured by patient satisfaction survey;  Implementation of this novel mobile health treatment strategy as measured by patient satisfaction|45|NCT02472561|July 2015
331|Active not recruiting|Personalized Health Planning in Shared Medical Appointments for Individuals With Type II Diabetes Pilot Study||Behavioral: Personalized Health Planning Shared Medical Appointment|Interventional||Other|Feasibility measured using a patient satisfaction survey;  Change in patient activation measured using the patient activation measure;  Change in self-management of diabetes self-efficacy using the Diabetes Empowerment Scale;  Change in diabetes self efficacy using the 1-item diabetes self-efficacy scale;  ChangeinA1CusingtheA1Cbloodtest;  Change in depression screening score using the Patient Health Questionnaire (PHQ-9);  Change in functional health and well-being using the short form health survey;  Change in general self-rated health using the general self rated health survey (GSRH);  Change in health goal progress using a goal progress visual analog scale;  change in body mass index using weight and height measurements;  change in blood pressure using blood pressure measurement;  Change in low-density lipoprotein cholesterol (LDL) using LDL measurement|20|NCT02471794|December 2015
332|Not yet recruiting|Study of Exposure to Chemicals in Consumer Products|||Observational||NIH|Primary endpoint will be daily individual exposure estimates for each participant calculated through forward modeling of questionnaire data and environmental measurements and reverse modeling ofbiomarker data.;  To evaluate the accuracy of historical consumer product usage questionnaires.|200|NCT02471365|May 2015
333|Active not recruiting|Epigenetic Effect Modifications With Ozone Exposure on Healthy Volunteers||Other:Cleanair;  Other:Ozone|Interventional||U.S. Fed|Pulmonaryinflammation;  Changesinheartratevariability;  Forcedexpiratoryvolumein1second(FEV1);  Forcedvitalcapacity(FVC);  Indexofclotting/coagulationfactors;  Indexofinflammatoryfactorsfromblood|14|NCT02469428|December 2013
334|Recruiting|Acute Partner and Social Contact Referral: iKnow||Other:Notificationcards|Interventional||Other|the proportion of HIV-seropositive index participants with at least one newly diagnosed HIV-infected partner or social contact;  The proportion of HIV-seropositive index participants with at least one HIV-infected person referred who is not in care (newly diagnosed plus known diagnoses not in care);  Total HIV-infected persons including all subsequent referrals referred per first-wave index;  Total number of sexual partners referred (sexual partners or social contacts) per index;  Totalnumberofpersonsreferredperindex.|5975|NCT02467439|June 2015
335|Recruiting|Decisional Capacity and Informed Consent in Fragile X Syndrome||Other:Paper-BasedInformedConsent;  Device:Tablet-BasedConsent|Interventional||Other / NIH|Decisionalcapacityassessment|200|NCT02465931|October 2015
336|Active not recruiting|Pillars4Life Trial||Behavioral:Pillars4Life|Interventional||Other / Industry|Chronicpain;  Stress;  Anxiety|400|NCT02465892|May 2015
337|Completed|Macronutrient Regulation of Ghrelin and Peptide YY||Other:Highcarbohydratemeal;  Other:Highfatmeal|Interventional||Other / NIH|Changeinghrelinlevels;  ChangeinPYYconcentrations;  Fasting Insulin-like growth factor 1 (IGF-1) levels;  NeuropeptideY(NPY);  Gastricinhibitorypolypeptide(GIP);  Glucagon-likepeptide-1(GLP-1)|28|NCT02464514|January 2004
338|Recruiting|Systemic Steroids for Peripheral Nerve Blocks||Drug:Dexamethasone;  Drug:Bupivacaine;  Drug:Epinephrine;  Procedure:LumbarPlexusNerveBlock;  Drug:Saline|Interventional|Phase 4|Other|DurationofSensoryBlockade;  Timetofirstanalgesicrequest;  TotalOpioidConsumption;  VerbalNumericPainScoreComparisons|115|NCT02464176|June 2015
339|Completed|Macronutrient Effects on Alzheimer&apos;s Disease (MEAL-2)||Other:LowDiet;  Other:HighDiet|Interventional||Other|Change in cerebrospinal fluid levels of Alzheimer&apos;s disease biomarkers (CSF beta-amyloid 42);  Changesinbrainstructure;  Changes in adipose tissue distribution (Change in dual energy x-ray absorptiometry (DEXA) scan and CT measures of central and subcutaneous body fat);  Changes in cognition (Change in delayed memory and executive function composites);  ChangeinbrainfunctionasmeasuredbyMRI;  Changeinbrainperfusion|60|NCT02463084|March 2013
340|Recruiting|Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart||Drug:Insulinaspart;  Drug:Placebo|Interventional|Phase 1|Other / NIH / Industry|Changeincognition;  CSF and blood amyloid-beta tau protein and inflammatory markers;  MRI measure of cortical thinckness in AD-vulnerable regions|30|NCT02462161|May 2015
341|Recruiting|Perineural Steroids for Peripheral Nerve Blocks||Drug:Dexamethasone;  Drug:Bupivacaine;  Drug:Epinephrine;  Procedure:SaphenousPeripheralNerveBlock|Interventional|Phase 4|Other|DurationofSensoryNerveBlock;  VerbalPainScores;  RateofPostOperativeNauseaandVomiting;  NeurologicComplications;  PostOperativeOpioidUseandConsumption;  Timetofirstopioidanalgesicrequest|115|NCT02462148|July 2015
342|Active not recruiting|Testing the Efficacy of a Spousal Support Enhanced Weight Loss Program on Weight Loss Among African American Men||Behavioral:Attendswithpartner;  Behavioral:CouplesSkillTraining;  Behavioral:Facetofacegroupsessions;  Behavioral:SelfMonitor;  Other:Notebook;  Behavioral:Feedback|Interventional||Other|Weight;  WaistCircumference;  BMI;  Bloodpressure;  Behavior;  Psychosocialvariables;  SocialSupport;  Couple/FamilyVariables|104|NCT02458053|February 2016
343|Recruiting|Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis|||Observational||Other|Compliance rate of cancer and ALS patients using the device during a 14 week period.;  Numberofstepsperdayincancerpatients.;  Karnofskyperformancestatusincancerpatients.|50|NCT02457715|July 2015
344|Withdrawn|Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD||Drug:Aflibercept;  Drug:TriamcinoloneAcetonide;  Drug:Verteporfin|Interventional||Other / Industry|Percentage of individuals with resolution or major reduction in PDA;  Percentage of individuals with sustained visual acuity;  Averagenumberofafliberceptinjections;  Frequency of case with progressive disease on therapy;  Mean change in choroidal neovascularization lesion size by fluorescein angiography from baseline;  MeanchangeincentralfovealthicknessbySD-OCT;  Mean change in best-corrected ETDRS visual acuity from baseline;  Percentage of participants with 2-line ETDRS visual acuity gain;  Percentage of participants with 2-line ETDRS visual acuity loss|0|NCT02457026|January 2016
345|Recruiting|NIRTRAKS Post-Market Study (NIRTRAKS)||Device:Stentingprocedure|Interventional||Industry|TargetVesselFailure|131|NCT02455804|January 2016
346|Recruiting|Photodynamic Therapy for PDA in NV AMD||Other:NoIntervention|Observational||Other / Industry|PercentageofsubjectswithresolutionofPDA;  Mean change in best-corrected ETDRS visual acuity from baseline;  Percentage of subjects with 2-line ETDRS visual acuity gain from baseline;  Percentage of subjects with 2-line ETDRS visual acuity loss from baseline;  Mean change in central foveal thickness by SD-OCT from baseline;  Mean change in choroidal neovascularization lesion size by fluorescein angiography from baseline|100|NCT02452840|October 2014
347|Recruiting|Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist DUK-CPG-001 From Donors Following Allogeneic SCT||Biological:NKCellenriched-DLIonly;  Biological:NK-DLI+DUK-CPG-001|Interventional|Phase 2|Other / Industry|Progression-FreeSurvivalrate;  RateofUnacceptableToxicity;  Recovery of immune cell populations Pre and Post-Infusion;  Immune function Pre and Post-Infusion with antigen specific recovery as measured by Elispot assay;  Immune function Pre and Post-Infusion with antigen specific recovery as measured by Immunoscope assay;  Immune function Pre and Post-Infusion with antigen specific recovery as measured by flow-cytometric cytokine assay;  Immune function Pre and Post-Infusion with antigen specific recovery as measured by functional NK lysis assay|100|NCT02452697|June 2016
348|Recruiting|Investigation of Circulating Tumor Cells From Cancer Patients Undergoing Radiation Therapy||Other:Blooddraw|Observational||Other|To measure CTCs levels to evaluate the change pre- and post-treatment separately in patients with locally advanced head and neck cervical rectal lung prostate or oligometastatic solid malignancies undergoing radiotherapy with or without chemotherapy;  Change in CTC levels from Baseline to Post-RT treatment and the correlation with local tumor response or pathological evaluation depending on cohort|210|NCT02449837|May 2014
349|Recruiting|Novel Screening Tools For the Evaluation and Management of Malnourished Children in the Developing World||Other: Measurement of leptin and adiponectin obtained through blood sampling via venipuncture or finger/heelstick using novel screening tool|Observational||Other|Variation between results of novel screening tool and standard ELISA|20|NCT02449408|May 2015
350|Recruiting|Attitudes and Knowledge Regarding Clinical Trials in Underserved Populations Receiving Care at the Comprehensive Cancer Center of Wake Forest University||Other:MedicalChartReview;  Other:QuestionnaireAdministration;  Other:SurveyAdministration|Observational||Other / NIH|Attitudes towards and knowledge regarding clinical trials;  Cancer-relatedhealthneeds;  Perceivedqualityofcare;  Attitudes towards and knowledge regarding clinical trials by the elderly;  Cancer-relatedhealthneedsbyelderlypatients;  Cancer-relatedneeds;  Perceived quality of care received by elderly patients|315|NCT02444754|January 2016
351|Active not recruiting|Reducing Sedentary Behaviors Among Colorectal Cancer Survivors||Other:Brochureregardingsedentarybehavior|Interventional||Other|Feasibility of the print brochure as measured by Likert scale.;  Change in number of minutes per day of light to strenuous physical activity.;  Change in number of minutes per day of bouts of sedentary behaviors.;  Covariation between baseline use of an ActiGraph and self-reporting of sedentary behaviors|20|NCT02442583|May 2015
352|Recruiting|Interval Training Inflammation and Immune Function||Behavioral:HighIntensityIntervaltraining|Interventional||Other|Changeininflammatorymarkersinplasma;  Changeininflammatorymarkersinmuscle;  Changeinimmunemarkersinperipheralblood;  Changeinimmunemarkersinmuscle;  Change in Metabolic Syndrome risk factors composite score|30|NCT02441205|April 2015
353|Recruiting|Targeted Pain Coping Skills Training (PCST) for Prevention and Treatment of Persistent Post-Mastectomy Pain||Behavioral:PsychosocialIntervention|Interventional||Other|ChangeinPainBurden|60|NCT02439437|September 2015
354|Active not recruiting|Video Counseling for Effective Postpartum Contraception||Behavioral:LARCFirstVideo|Interventional||Other|Number of women who received an intrauterine device (IUD) or implant by 12 weeks postpartum;  Proportion of women using any contraceptive method at 12 weeks postpartum;  Proportion of women who attended a postpartum visit;  Proportion of women answering agree or strongly agree to the following statement &quot;I would recommend birth control counseling by video to a friend.&quot;|84|NCT02438800|May 2015
355|Recruiting|Patient Education to Improve Pain Management in Older Adults With Acute Musculoskeletal Pain: A Pilot Randomized Trial||Behavioral:Video;  Behavioral:Phonefollow-up|Interventional||Other|ChangeinPain;  SideEffects;  Averageoverallpainatonemonth;  Changeinphysicalfunction;  PainInterference|60|NCT02438384|September 2015
356|Recruiting|An Enhanced Protein (Dairy) Weight Loss Intervention for Dynapenic Obesity: Impact on Muscle Quality and Composition||Behavioral:WeightLoss;  DietarySupplement:DairyProtein;  Behavioral:Lowintensityexercise|Interventional||Other|Changeinmusclequality;  Changeinmuscleadiposeinfiltration;  ChangeinPhysicalFunction;  Changeinweight;  Changeinleanmass;  Changeinfatmass;  Changein6-minutewalktime;  Changein8-footupandgotime;  Changein30secondchairstands;  Changeindietaryproteinintake;  Changeincalorieintake;  ChangeinBoneMineralDensity;  Changeinsleep;  Changeindepression;  Changeinhandgripstrength;  Changeinphysicalactivity;  Changeinqualityoflife|70|NCT02437643|October 2015
357|Recruiting|Single Breath Hold Abdominal MRI||Device:Respiratory-triggeredT1wDISCOLAVA|Interventional||Other|Motionartifactscores;  Imagequalityscore|100|NCT02434471|January 2016
358|Withdrawn|Preoperative Antibiotic Dosing for Total Knee Arthroplasty||Device:NewIntraosseous;  Drug:Cefazolin|Interventional|Phase 4|Other|rateofacutesurgicalsiteinfection;  correlation of clinical comorbidities to acute infection rates;  numberofcomplications;  tourniquettime;  bloodloss|0|NCT02433704|May 2015
359|Terminated|The Effect of Feeding Infant Formula With Enriched Protein Fractions in the US||Other:Cow&apos;smilk-basedinfantformula;  Other: Cow milk-based infant formula with enriched protein fractions|Interventional||Industry / Other|SequenceRecallusing3-dimensionalprops;  Electroencephalogramresponsetostimuli;  InfantBehaviorQuestionnaireRevisedShort;  MacArthur-Bates Communication Development Inventory;  Bayley Scales of Infant and Toddler Development Third Edition;  AchievedWeight;  AchievedLength;  AchievedHeadCircumference;  FormulaIntake;  Medically-confirmedAdverseEvents|2|NCT02433600|August 2015
360|Completed|Eovist vs. Dotarem Healthy Volunteer MRI||Drug:gadoxetatedisodium;  Drug:gadoteratedimeglumine;  Drug:Saline|Interventional|Phase 4|Other|Subject breath hold capacity as measured by number of seconds a subject can hold his/her breath;  Subject-reported dyspnea a measured by questionnaire;  ChangesinO2saturation;  Changesinpulserate;  Presence of motion artifacts at arterial phase imaging;  Severity of motion artifacts at arterial phase imaging measured on a 1-5 scale|48|NCT02431598|June 2015
361|Recruiting|VIDA Mobile Health Cardiovascular Prevention Program||Behavioral:MobileHealthApplication|Interventional||Other / Industry|Change in Physical Activity as measured using a Fitbit;  Change in fitness (peak VO2mL/kg/min) as measured by cardiopulmonary exercise test (CPET).;  Change in Quality of Life (QOL) as measured by Seattle Angina Questionnaire (SAQ).;  Change in Medication Adherence as measured by Morisky Medication Adherence Scale (MMAS-8).;  ChangeinBodyMass;  ChangeinBodyMassIndex;  Changeinwaistcircumference;  Understand the feasibility and implementation of this novel mhealth treatment strategy.|40|NCT02431546|May 2015
362|Recruiting|Caregiver-Guided Pain Management Training in Palliative Care||Behavioral: Caregiver-guided pain management training (CG-PMT);  Behavioral:Enhancedtreatment-as-usual(TAU)|Interventional||Other / NIH|Change in caregiver self-efficacy for helping the patient manage pain;  Changeincaregiverstrain;  Changeincaregiversatisfaction;  Changeincaregiverpsychologicaldistress;  Changeincaregiverhealthbehaviors;  Changeincaregiverglobalhealthrating;  Changeinpatientpain;  Changeinpatientself-efficacy;  Changeinpatientpsychologicaldistress|472|NCT02430467|July 2015
363|Recruiting|Acid-Base Compensation in Chronic Kidney Disease||Drug:Sodiumbicarbonate;  Other:Controlleddiet|Interventional|Phase 1|Other / NIH|Changeinambulatorybloodpressure;  Changeinurinenetacidexcretion;  Changeinclinicbloodpressure;  Changeinplasmanitricoxidemetabolites|16|NCT02427594|April 2015
364|Enrolling by invitation|UNC Barrett&apos;s Esophagus and Esophageal Cancer Biorepository||Other:Esophagealbiopsies;  Other:Blood|Observational||Other|SpecimenBiorepository;  Data;  Collaborationwithotherinvestigators|500|NCT02427269|May 2015
365|Recruiting|Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3||Other:LaboratoryBiomarkerAnalysis;  Drug:PemetrexedDisodium;  Other:Quality-of-LifeAssessment|Interventional|Phase 2|Other / NIH|Change in QOL assessed by the EORTC Quality of Life Questionnaire Core-30 (QLQ-C30) and QLQ-Lung Cancer 13-item (LC13);  Timetotumorprogression;  Incidence of hematologic toxicity graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0;  Overallsurvival;  Responserate|30|NCT02426658|May 2015
366|Withdrawn|Methylprednisolone Sodium Succinate in Treating Patients With Acute Graft-versus-Host Disease of the Gastrointestinal Tract||Drug:Budesonide;  Drug:MethylprednisoloneSodiumSuccinate|Interventional|Phase 2|Other / NIH|Incidence of discontinuation of systemic GCs without acute GvHD flare and without disease progression/recurrence;  Proportionsofresponseamongsurvivingpatients;  Proportions of progression among surviving patients;  Rateofacute(and/orchronic)GvHD-freesurvival;  DailyandcumulativeGCdose;  Feasibility;  GvHD-freesurvival;  Incidence of acute GvHD &quot;flare&quot; after CR/PR requiring modification and/or additional agents (and/or 2.5 mg/kg/day of prednisone [or methylprednisolone equivalent of 2 mg/kg/day]) for systemic therapy;  IncidenceofchronicGvHD;  Incidence of National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 toxicities;  Incidenceofopportunisticinfections;  Non-relapsemortality(NRM);  NRM;  Overallsurvival|0|NCT02425813|October 2015
367|Recruiting|Efficacy of Ranolazine in Patients With Chronic Total Occlusions of Coronary Arteries||Drug:Ranolazine;  Drug:Placebo|Interventional|Phase 4|Other / Industry|CardiacMRI(CMR)strain;  Dobutaminewallmotionscoringindex(WMSI);  QualityofLife/burdenofangina;  TreadmillECGexercisedistance;  Time to ECG changes (ST depression) on exercise ECG|30|NCT02423265|June 2015
368|Suspended|Pharmacokinetics and Safety of PA-824 in Subjects With Mild Moderate and Severe Hepatic Impairment to Matched Non-Hepatically Impaired Subjects||Drug:PA-824|Interventional|Phase 1|NIH|The single-dose pharmacokinetics of PA-824. Serial blood samples for the measurement of the plasma levels of PA-824 will be collected prior to and following a single oral dose of 200 mg PA-824.;  Safety will be evaluated by a review of physical examinations vital signs assessments 12-Lead ECGs routine clinical laboratory tests (including chemistry hematology and urinalysis data) and adverse event (AE) assessments.|36|NCT02422524|September 2015
369|Completed|Effectiveness of Web-based Teaching to Traditional Patient Education in the Use of Injectable Fertility Medications||Other:videoinstruction;  Other:Nurseinstruction|Interventional||Other|Tthe level of knowledge after the intervention measured by a multiple choice post-test;  Satisfaction with education measured by the Likert scale survey|80|NCT02420964|June 2012
370|Recruiting|Tracking Outcomes in Pain Patients Using Fitness Devices||Procedure:Epiduralinjection|Observational||Other|Change in steps taken as measured by fitness devices;  ChangeinpainscoresasmeasuredbyVAS;  Change in minutes slept as measured by fitness device;  Changeinsurveymeasuresofpain|40|NCT02420457|March 2015
371|Completed|Uniting Couples In the Treatment of Eating Disorders (UNITE)||Behavioral:Psychotherapytreatment|Interventional||Other|Total score at Post-treatment of the Client Satisfaction Questionnaire-8 (CSQ-8)- Patient;  Total score at Post-treatment of the Client Satisfaction Questionnaire-8 (CSQ-8)- Partner;  Number of patients with binge-eating remission (0 objective binge episodes over last 28 days) at post-treatment determined by Eating Disorder Examination (EDE);  Number of patients with binge eating remission (0 objective binge-eating episodes in last 28 days) at 3-month follow-up determined by the Eating Disorder Examination (EDE);  Change from Baseline to Post-Treatment in the Eating Disorder Examination (EDE) Binge Eating Episode Frequency Score- Patient;  Change from Baseline to 3-Month Follow-up in the Eating Disorder Examination (EDE) Binge Eating Episode Frequency Score- Patient;  Change from Baseline to Post-Treatment in the Eating Disorder Examination (EDE) Number of Days Binge Eating Score- Patient;  Change from Baseline to 3-Month Follow-up in the Eating Disorder Examination (EDE) Number of Days Binge Eating Score- Patient;  Change from Baseline to Post-Treatment in the Binge Eating Scale (BES) Binge Eating Symptom Severity- Patient;  Change from Baseline to 3-Month Follow-up in the Binge Eating Scale (BES) Binge Eating Symptom Severity- Patient;  Change from Baseline to Post-Treatment in the Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (YBOCS-BE) Total Score- Patient;  Change from Baseline to 3-Month Follow-up in the Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (YBOCS-BE) Total Score- Patient;  Change from Baseline to Post-Treatment in the Eating Disorder Examination (EDE) Total Score- Patient;  Change from Baseline to 3-Month Follow-up in the Eating Disorder Examination (EDE) Total Score- Patient;  Change from Baseline to Post-Treatment in the Beliefs about Obese People Scale (BAOP) Total Score- Patient;  Change from Baseline to 3-Month Follow-up in the Beliefs about Obese People Scale (BAOP) Total Score- Patient;  Change from Baseline to Post-Treatment in the Attitudes Towards Obese People (ATOP) Total Score- Patient;  Change from Baseline to 3-Month Follow-up in the Attitudes Towards Obese People (ATOP);  Change from Baseline to Post-Treatment in the Beck Depression Inventory-II Scale (BDI) Total Score- Patient;  Change from Baseline to 3-Month Follow-up in the Beck Depression Inventory-II (BDI-II) Total Score- Patient;  Change from Baseline to Post-Treatment in the Beck Anxiety Inventory Scale (BAI) Total Score- Patient;  Change from Baseline to 3-Month Follow-up in the Beck Anxiety Inventory Scale (BAI) Total Score- Patient;  Change from Baseline to Post-Treatment in the Difficulties in Emotion Regulation Scale (DERS) Total Score- Patient;  Change from Baseline to 3-Month Follow-up in the Difficulties in Emotion Regulation Scale (DERS) Total Score- Patient;  Change from Baseline to Post-Treatment in the 12-Item Short Form Health Survey (SF-12) Physical Component Summary (PCS)- Patient;  Change from Baseline to 3-Month Follow-up in the 12-Item Short Form Health Survey (SF-12) Physical Component Summary (PCS)- Patient;  Change from Baseline to Post-Treatment in the 12-Item Short Form Health Survey (SF-12) Mental Component Summary (MCS)- Patient;  Change from Baseline to 3-Month Follow-up in the 12-Item Short Form Health Survey (SF-12) Mental Component Summary (MCS)- Patient;  Change from Baseline to Post-Treatment in the Dyadic Adjustment Scale (DAS) Total Score- Patient;  Change from Baseline to 3-Month Follow-up in the Dyadic Adjustment Scale (DAS) Total Score- Patient;  Change from Baseline to Post-Treatment in the Dyadic Adjustment Scale (DAS) Total Score- Partner;  Change from Baseline to 3-Month Follow-up in the Dyadic Adjustment Scale (DAS) Total Score- Partner;  Change from Baseline to Post-Treatment in the Communication Patterns Questionnaire Short Form (CPQ-SF) Total Score- Patient;  Change from Baseline to 3-Month Follow-up in the Communication Patterns Questionnaire Short Form (CPQ-SF) Total Score- Patient;  Change from Baseline to Post-Treatment in the Communication Patterns Questionnaire Short Form (CPQ-SF) Total Score- Partner;  Change from Baseline to 3-Month Follow-up in the Communication Patterns Questionnaire Short Form (CPQ-SF) Total Score- Partner;  Change from Baseline to Post-Treatment in the Marital Satisfaction Inventory-Revised (MSI-R) Problem Solving Communication (PSC)- Patient;  Change from Baseline to 3-Month Follow-up in the Marital Satisfaction Inventory-Revised (MSI-R) Problem Solving Communication (PSC)- Patient;  Change from Baseline to Post-Treatment in the Marital Satisfaction Inventory-Revised (MSI-R) Problem Solving Communication (PSC)- Partner;  Change from Baseline to 3-Month Follow-up in the Marital Satisfaction Inventory-Revised (MSI-R) Problem Solving Communication (PSC)- Partner;  Change from Baseline to Post-Treatment in the Marital Satisfaction Inventory-Revised (MSI-R) Affective Communication (AFC)- Patient;  Change from Baseline to 3-Month Follow-up in the Marital Satisfaction Inventory-Revised (MSI-R) Affective Communication (AFC)- Patient;  Change from Baseline to Post-Treatment in the Marital Satisfaction Inventory-Revised (MSI-R) Affective Communication (AFC)- Partner;  Change from Baseline to 3-Month Follow-up in the Marital Satisfaction Inventory-Revised (MSI-R) Affective Communication (AFC)- Partner;  Change from Baseline to Post-Treatment in the Accommodation and Enabling Scale for Eating Disorders (AESED)- Partner;  Change from Baseline to 3-Month Follow-up in the Accommodation and Enabling Scale for Eating Disorders (AESED)- Partner;  Change from Baseline to Post-Treatment in the Beliefs about Obese People Scale (BAOP) Total Score- Partner;  Change from Baseline to 3-Month Follow-up in the Beliefs about Obese People Scale (BAOP) Total Score- Partner;  Change from Baseline to Post-Treatment in the Attitudes Towards Obese People (ATOP) Total Score- Partner;  Change from Baseline to 3-Month Follow-up in the Attitudes Towards Obese People (ATOP) Total Score- Partner;  Change from Baseline to Post-Treatment in the Beck Depression Inventory-II Scale (BDI-II) Total Score- Partner;  Change from Baseline to 3-Month Follow-up in the Beck Depression Inventory-II Scale (BDI-II) Total Score- Partner;  Change from Baseline to Post-Treatment in the Beck Anxiety Inventory Scale (BAI) Total Score- Partner;  Change from Baseline to 3-Month Follow-up in the Beck Anxiety Inventory Scale (BAI) Total Score- Partner;  Change from Baseline to Post-Treatment in the Difficulties in Emotion Regulation Scale (DERS) Total Score- Partner;  Change from Baseline to 3-Month Follow-up in the Difficulties in Emotion Regulation Scale (DERS) Total Score- Partner|11|NCT02419326|September 2014
372|Completed|Integrated Population Program for Diabetic Kidney Disease||Behavioral:Telehealth|Interventional||Other / NIH|ChangeinBloodPressure;  Change in estimated Glomerular filtration rate (eGFR) for kidney function;  Change in dietary habits as measured by questionnaire;  Changeinweight;  Change in amount of physical activity as measured by questionnaire;  Changeintakingmedicineasprescribed|131|NCT02418091|March 2015
373|Completed|Effects of Smoking Environment on Craving and Smoking||Behavioral:6hoursmokingabstinence;  Behavioral:DelaytoSmokingTask(smokingcues);  Behavioral: Delay to Smoking Task (nonsmoking cues)|Interventional||Other / NIH|Change in self-report craving measured by the cue-exposure rating scale;  Difference in number of subjects who initiate smoking during the smoking cue Delay to Smoking Task compared to the nonsmoking cue Delay to Smoking Task;  Numberofminutestofirstpuff|41|NCT02416986|October 2014
374|Recruiting|PackHealth: Asthma Engagement Tool||Behavioral:Patientengagementtoolkit|Interventional||Other|Rateofasthmaexacerbations;  Rateofclinicaldeteriorationinasthmasymptoms;  Changeinasthmacontrol;  Changeinasthmarelatedqualityoflife;  Changeinpulmonaryfunctiontests;  Numberofurgentcarevisits;  Numberofemergencydepartmentvisits;  Numberofhospitalizations|50|NCT02413684|August 2015
375|Completed|Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Subjects Exhibiting Neuropsychiatric Disorders||Genetic:IDgenetixNeuropsychiatricTestPanel|Interventional||Industry / Other|Comparison of change in neuropsychiatric state between the two treatment arms measured by Neuropsychiatric Questionnaire (NPQ);  Comparison of change in responsiveness between the two treatment arms measured by Symbol Digit Coding (SDC) test;  Comparison of hospital utilization between the two treatment arms as measured by hospital admission and re-admission rates;  Comparison of adverse drug events between the two treatment arms over a 4-month period|220|NCT02411123|March 2015
376|Recruiting|Transcranial Direct Current Stimulation (tDCS) as a Treatment for Acute Fear||Device: NeuroConn Direct Current stimulator Multiple Channel -4|Interventional||Other|ChangeinVAS-Arating|30|NCT02410954|December 2015
377|Not yet recruiting|Inhaled Nanosilver Study|||Observational||NIH|To evaluate the impact of nanosilver exposure on ex vivo inflammatory response of bronchoscopy-derived cells (i.e. alveolar macrophage and epithelial cells) to challenge with a TLR agonist|60|NCT02408874|March 2015
378|Recruiting|Real Time In-Vivo Body Surface Dosimetry for External Beam Radiation Therapy||Other: Novel nano-scintillatorfiber-optic dosimeter ( nanoFOD)|Observational||Other|Dosimetric accuracy of the device with reference to a commercially available dosimeter;  Feasibility of clinical application of the nanaoFOD for dosimetric monitoring of external beam radiotherapy.|30|NCT02407977|May 2015
379|Recruiting|Determine the Prevalence and Severity of Asthma in HIV (Human Immunodeficiency Virus) Infected Patients|||Observational||Other|Asthma prevalence of HIV infected subjects currently followed at the Duke Infectious Disease (ID) Clinic compared to HIV uninfected asthma subjects identified at the Duke Asthma Allergy and Airway Center (DAAAC).;  Asthma phenotypic characteristics of HIV infected subjects compared to HIV uninfected asthma subjects and HIV infected non-asthmatic subjects.;  Prospective immunological phenotyping of Th1/Th2/Th17 cytokines and T cell subsets;  Retrospective immunological phenotyping (circulating cytokines) of HIV-infected patients utilizing available specimens in the Duke HIV Biorepository;  Retrospectively determine overall asthma prevalence among HIV-infected patients|93|NCT02405026|December 2014
380|Completed|Health Experiences &amp; Early Life Disadvantages||Behavioral:MeditationWorkshop|Interventional||Other / NIH|Change in meditation time (Self-reported meditation time recorded daily);  Leukocyte basal gene expression (evaluated through blood samples);  Levels of mistrust (Self-report questionnaire measure of hostility using 9-item Cooke-Medley scale);  Temporal Discounting (Monetary choice questionnaire to assess impulsive decision-making);  Cardiac vagal tone (Respiration and echocardiogram measured with respiration band and 2-lead electrode placement)|113|NCT02400593|August 2015
381|Completed|Integrated Coping and Awareness Training||Behavioral:I-CATTherapy|Interventional||Other / NIH|Change from Baseline Salivary Cortisol at Six Months;  Change from Baseline Urinary Oxidative Stress Level [Isoprostane] at Six Months;  Change from Baseline Positive and Negative Syndrome Scale (PANSS) Total Score at Six Months;  Change from Baseline Quality of Life Scale (QLS; Bilker et al. 2003) Total Score at Six Months;  Change from Baseline Heart Rate Variability (HRV) Measurement at Six Months;  Change from Baseline Modified Differential Emotions Scale (mDES) Positive Emotion Sub Scale Score at Six Months;  Change from Baseline Perceived Stress Scale (PSS) Total Score at Six Months;  Change from Baseline Brief COPE Scale (Assisted Format) Total Score at Six Months;  Change from Baseline Five Facet Mindfulness Questionnaire (FFMQ) Total Score at Six Months;  Change from Baseline Psychological Well-Being (PWB) Scale Total Score at Six Months|6|NCT02400502|March 2015
382|Not yet recruiting|Acthar for Treatment of Post-transplant FSGS||Drug:Acthar|Interventional||Other|numberofpatientswithproteinuria|20|NCT02399462|June 2016
383|Active not recruiting|Using Serum Parathyroid Hormones and Calcium to Improve Prostate Cancer Diagnosis||Other:Thisstudyhasnointervention|Observational||Other|To measure the relationship of calcium and PTH levels to PSA levels in patients receiving a prostate biopsy.|500|NCT02397629|May 2013
384|Active not recruiting|MBSR for Pain Catastrophizing in SCD||Behavioral:Mindfulness-basedStressReduction|Interventional||Other / NIH|Acceptability of MBSR as measured by semi-scripted telephone assessments;  Feasibility of MBSR as measured by recruitment attrition rates and practice logs;  Change in Pain Catastrophizing as measured by the Pain Catastrophizing Scale;  Change in Mindfulness as measured by the Mindful Attention Awareness Scale|60|NCT02394587|April 2015
385|Completed|ARC in Hemorrhagic Stroke||Other:Nointervention|Observational||Other|To describe the onset magnitude and change over time of ARC in patients with hemorrhagic stroke|80|NCT02386202|January 2015
386|Recruiting|Obstructive Sleep Apnea in Pregnancy||Device:ApneaLinkAir;  Behavioral:BerlinQuesionnaire;  Behavioral:EpworthSleepinessScale;  Behavioral:STOP-BANGquestionnaire;  Other:Physicalexam|Observational||Other|OSAscreeninginpregnancy;  Post-opminuteventilationfollowingc-section|150|NCT02383706|February 2015
387|Recruiting|Social Cognition and Interaction Training for Autism||Behavioral: Social Cognition and Interaction Training for Autism (SCIT-A);  Other:TreatmentasUsual(TAU)|Interventional||Other|Change in visual attention from baseline as measured by the Tobii Eye Tracking Paradigm;  Change in patient social skills as measured by the Social Responsiveness Scale (SRS);  Change in patient social cognition as measured by the Hinting Task;  Change in patient social cognition as measured by the Penn Emotion Recognition Task-40 (ER40)|100|NCT02382172|January 2015
388|Recruiting|Care2BWell: Worksite Wellness for Child Care||Behavioral:HealthyLifestyles;  Other:HealthyFinances|Interventional||Other / NIH|Change in moderate to vigorous physical activity (MVPA);  Changeindietaryintake;  Changeinsmoking/e-cigarettestatus;  Changeinsleepquality;  Changeinstress;  ChangeinBodyMassIndex;  Changeinwaistcircumference;  Changeincardiovascularfitness;  Changeinstrength;  Changeinendurance;  Changeinbalance;  Change in child care center worksite wellness environment;  Changeinteacherphysicalactivitypractices|416|NCT02381938|March 2015
389|Completed|Making Effective Human Papillomavirus (HPV) Vaccine Recommendations||Behavioral:Participatory;  Behavioral:Efficient|Interventional||Other / Industry|6 month % change in HPV vaccination (&#8805; 1 dose) control vs. each intervention arm (efficient or participatory) 11-12 year olds;  6 month % change in HPV vaccination (&#8805; 1 dose) efficient arm vs. participatory arm 11-12 year olds;  3 month % change in HPV vaccination (&#8805; 1 dose) control vs. each intervention arm 11-12 year olds;  3 month % change in HPV vaccine completion (3 doses) control vs. each intervention arm 11-12 year olds;  6 month % change in HPV vaccine completion (3 doses) control vs. each intervention arm 11-12 year olds;  3 month % change in tetanus diphtheria and acellular pertussis (Tdap) vaccination control arm vs. each intervention arm 11-12 year olds;  6 month % change in Tdap vaccination control arm vs. each intervention arm 11-12 year olds;  3 month % change in meningococcal vaccination (&#8805; 1 dose) control arm vs. each intervention arm 11-12 year olds;  6 month % change in meningococcal vaccination (&#8805; 1 dose) control arm vs. each intervention arm 11-12 year olds;  3 month % change in HPV vaccination (&#8805; 1 dose) control vs. each intervention arm 13-17 year olds;  6 month % change in HPV vaccination (&#8805; 1 dose) control vs. each intervention arm 13-17 year olds;  3 month % change in HPV vaccine completion (3 doses) control vs. each intervention arm 13-17 year olds;  6 month % change in HPV vaccine completion (3 doses) control vs. each intervention arm 13-17 year olds;  3 month % change in Tdap vaccination control arm vs. each intervention arm 13-17 year olds;  6 month % change in Tdap vaccination control arm vs. each intervention arm 13-17 year olds;  3 month % change in meningococcal vaccination (&#8805; 1 dose) control arm vs. each intervention arm 13-17 year olds;  6 month % change in meningococcal vaccination (&#8805; 1 dose) control arm vs. each intervention arm 13-17 year olds;  Change in clinician HPV vaccine knowledge efficient arm vs. participatory arm;  Change in clinician self-efficacy efficient arm vs. participatory arm;  Change in clinician recommendation quality efficient arm vs. participatory arm;  Change in clinician communication of routine use efficient arm vs. participatory arm;  Change in clinician communication of HPV vaccination as cancer prevention efficient arm vs. participatory;  3 month % change in HPV vaccination (&#8805; 1 dose) control vs. each intervention arm 11-12 year old females;  3 month % change in HPV vaccination (&#8805; 1 dose) control vs. each intervention arm 11-12 year old males;  6 month % change in HPV vaccination (&#8805; 1 dose) control vs. each intervention arm 11-12 year old females;  6 month % change in HPV vaccination (&#8805; 1 dose) control vs. each intervention arm 11-12 year old males;  3 month % change in HPV vaccine completion (3 doses) control vs. each intervention arm 11-12 year old females;  3 month % change in HPV vaccine completion (3 doses) control vs. each intervention arm 11-12 year old males;  6 month % change in HPV vaccine completion (3 doses) control vs. each intervention arm 11-12 year old females;  6 month % change in HPV vaccine completion (3 doses) control vs. each intervention arm 11-12 year old males;  3 month % change in HPV vaccination (&#8805; 1 dose) control vs. each intervention arm 13-17 year old females;  3 month % change in HPV vaccination (&#8805; 1 dose) control vs. each intervention arm 13-17 year old males;  6 month % change in HPV vaccination (&#8805; 1 dose) control vs. each intervention arm 13-17 year old females;  6 month % change in HPV vaccination (&#8805; 1 dose) control vs. each intervention arm 13-17 year old males;  3 month % change in HPV vaccine completion (3 doses) control vs. each intervention arm 13-17 year old females;  3 month % change in HPV vaccine completion (3 doses) control vs. each intervention arm 13-17 year old males;  6 month % change in HPV vaccine completion (3 doses) control vs. each intervention arm 13-17 year old females;  6 month % change in HPV vaccine completion (3 doses) control vs. each intervention arm 13-17 year old males|30|NCT02377843|March 2015
390|Recruiting|Does Physical Therapy Prevent Total Knee Arthroplasty in Patients With End Stage Osteoarthritis||Procedure:PhysicalTherapy|Interventional||Other|Preventionofsurgicalinterventionquestionnaire;  PROMIS-(Patient Reported Outcomes Measurement Information System) Lower Extremity Function Score|260|NCT02377102|February 2015
391|Completed|Evaluating CVD Medication Adherence Program in Low SES||Behavioral:m-health|Interventional||Other|Adherencetotheprogram&apos;sintervention;  Clinical effectiveness/impact of the program to pill refill adherence;  Clinicaleffectiveness/impactonBP;  Clinicaleffectiveness/impactonA1C;  Clinicaleffectiveness/impactoncholesterol|100|NCT02375737|January 2015
392|Suspended|Adherence Monitoring System in Managing Myelosuppression in Patients With Newly Diagnosed Malignant Gliomas Receiving Temozolomide and Radiation Therapy||Other:MedicalChartReview|Observational||Other / NIH|Development of a new adherence monitoring system within Epic that is functionally equivalent to the previously designed and validated system in the Cancer Center ORIS;  Frequency and timing of flags (laboratory date flags visit date flags and in-patient status flags) generated with the new system;  Non-adherentdaysgeneratedwiththenewsystem;  Expansion of both systems to other therapies that require compliance monitoring|50|NCT02375334|February 2015
393|Recruiting|Cilostazol After Lower Extremity Arterial Revascularization Trial||Drug:Cilostazol|Interventional|Phase 4|Other|Difference in quality of life in relation to use of cilostazol after lower extremity revascularization;  Patency of the graft/stent and re intervention rate after initial procedure|30|NCT02374957|February 2015
394|Active not recruiting|Website Application Based Education and Text Messaging in Improving Skin Wound Care in Patients Undergoing Mohs Surgery||Procedure:MohsSurgery;  Other:Internet-BasedIntervention;  Behavioral:Telephone-BasedIntervention;  Other:EducationalIntervention;  Behavioral:ExerciseIntervention;  Other: Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment;  Other:QuestionnaireAdministration;  Other:SurveyAdministration|Interventional||Other / NIH|Preoperativeanxietyscore;  Patientknowledgescore;  Medicationadherence;  Patientsatisfactionscore;  MobilityadherenceasmeasuredbyFitbitmonitor;  Incidenceofadverseevents|90|NCT02373722|March 2015
395|Recruiting|Treprostinil Sodium Inhalation for Patients At High Risk for ARDS||Drug:TreprostinilInhalationSolution;  Drug:Placebo|Interventional|Phase 2|Other / Industry|Change in the ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen (PaO2/FiO2 ratio) from day 0 to days 2 and 7;  Numberofventilator-freedaystoday28;  Number of subjects who required Bi-level Positive Airway Pressure (BiPAP) or Continuous Positive Airway Pressure (CPAP) via face mask from Day 0 to Day 28;  Change in the ratio of peripheral oxygen saturation to fraction of inspired oxygen (SpO2/FiO2) from day 0 to day 12;  Change in ARDS associated plasma biomarkers from day 0 to day 3 and day 7;  Change in the central venous oxygen saturation (SCVO2) from day 0 to day 3;  Change in central venous pressure (CVP) from day 0 to day 3;  Change in mean arterial pressure (MAP) from day 0 to day 7;  All-cause mortality from day 0 to day 28 for each treatment arm;  Proportion of subjects requiring intubation and mechanical ventilation from day 0 to day 28;  HospitalMortalityupto3months;  Individual plasma peak and trough treprostinil concentration;  Time to intubation and mechanical ventilation from day 0 to day 28|30|NCT02370095|February 2015
396|Completed|LycoRed 40051 Product as a Countermeasure to Exercise Stress||DietarySupplement:LycoRed(code40051)product;  DietarySupplement:Placebo|Interventional||Other / Industry|Changeinexercise-inducedoxidativestress;  Change in plasma carotenoids composite (lycopene phytofluene and phytoene);  Changeinexercise-inducedmuscledamagemarker;  Changeinexercise-inducedinflammation;  Change in exercise-induced inflammation composite;  Changeinoxidativecapacity|20|NCT02369666|November 2014
397|Recruiting|Transplant Social Worker Support for Live Kidney Donation in African Americans||Behavioral:TALKSSocialWorkerIntervention;  Other:FinancialAssistanceIntervention|Interventional||Other / NIH|Livekidneydonoractivation;  Potential recipient interest and pursuit of live donor kidney transplantation|570|NCT02369354|September 2015
398|Recruiting|Nutrition Education for Cardiovascular Disease Prevention in Spinal Cord Injury||Behavioral:Control;  Behavioral:EatRightLiveBetter|Interventional||Other|Nutrition Behavior and Knowledge measured by Likert scale;  BodyMassIndex;  WaistCircumference;  Laboratories-Fastinglipidpanel;  Laboratories-Fastingbloodglucose;  Laboratories - High Sensitivity C-reactive protein;  Diet quality as measured by Diet History Questionnaire (DHQ) II|200|NCT02368405|February 2015
399|Active not recruiting|Neovascular Morphology and Persistent Disease Activity Among Patients With NV AMD||Other:NoIntervention|Observational||Other / Industry|FrequencyofICGneovascularsubtypes;  Percentage of each neovascular subtype exhibiting persistent disease activity|75|NCT02367365|December 2014
400|Recruiting|Analysis of Procedural Times Using Colpassist for Robotic-Assisted Sacrocolpopexy; a Randomized Controlled Trial||Procedure:Traditionalvaginalpositioningdevice;  Procedure:Colpassistvaginalpositioningdevice|Interventional||Other / Industry|Comparison of duration of surgical steps during sacral colpopexy;  Surgeon and surgical-assistant satisfaction with the device|50|NCT02367235|January 2015
401|Completed|Effectiveness of Tortle Midliner Positioning System on the Prevention and Treatment of Cranial Molding Deformities in Preterm Infants||Device:TortleMidliner|Interventional||Other|Effectiveness of Tortle Midliner based on the cranial index measurements|32|NCT02366936|June 2015
402|Recruiting|DC Migration Study for Newly-Diagnosed GBM||Biological:GroupIunpulsedDCs;  Biological:GroupIITd;  Biological: Human CMV pp65-LAMP mRNA-pulsed autologous DCs;  Biological:111In-labeledDCs;  Drug:Temozolomide;  Drug:Saline;  Drug:GroupIIIbasiliximabandTd|Interventional|Phase 2|Other|OverallSurvival(OS);  ProgressionFreeSurvival(PFS);  Migration|116|NCT02366728|September 2015
403|Completed|Systolic Blood Pressure Measurement in Critically-ill Patients|||Observational||Other|blood pressure measurements collected under standard of care|12|NCT02366507|July 2014
404|Terminated                  Has Results|Hemodynamic Response During Goal Directed Fluid Therapy in the OR||Procedure:Initialboluspre-incision|Interventional||Industry|Dynamic Hemodynamic Response to Fluid Resuscitation|18|NCT02365688|September 2014
405|Recruiting|Hyperbaric Oxygen Therapy for Lung Transplantation||Drug:HyperbaricOxygenTherapy;  Procedure: Endobronchial Biopsy of Airway Epithelium|Interventional|Phase 2|Other|Need for airway stent placement as determined by transbronchial lung biopsy;  Rate of acute rejection as determined by transbronchial lung biopsy;  Developmentofairwaystenosis;  Needforballoonbronchoplasty;  Development of clinically significant lung infection;  Developmentofbronchitisobliteranssyndrome;  Bronchialepithelialgeneexpression|40|NCT02363959|February 2015
406|Recruiting|Perampanel in Seizure Patients With Primary Glial Brain Tumors||Drug:Perampanel|Interventional|Phase 4|Other|Percentage of patients with &#8805;50% seizure reduction during the maintenance period compared with seizure frequency before initiation of perampanel;  Percentage of patients who experience a adverse event possibly probably or definitely attributable to perampanel treatment|71|NCT02363933|February 2015
407|Recruiting|Active and Healthy Brotherhood: A Program for Chronic Disease Self-Management for Black Men||Behavioral:ActiveandHealthyBrotherhood(AHB)|Interventional||Other|Change activity behavior (minutes per week in Total physical activity (PA) and light moderate vigorous PA).;  Change sedentary behavior (minutes per week of sedentary behavior).;  Change dietary intake (Fruit and vegetable servings % fat sodium and fiber intake).;  Changestressmanagement.;  Change help-seeking behaviors (Medication adherence and doctor/ER visits).;  Changebloodpressure.;  Changebodyweight.;  Changebloodglucose.;  ChangeHbA1c.|440|NCT02362737|January 2015
408|Recruiting|STimulation to Improve Auditory haLLucinations||Device:tACS(alpha);  Device:tDCS|Interventional||Other / NIH|AuditoryHallucinationRatingScale(AHRS);  Electroencephalogram(EEG);  PositiveandNegativeSyndromeScale(PANSS);  Brief Assessment of Cognition in Schizophrenia (BACS) score|60|NCT02360228|May 2015
409|Completed|Evaluation of a Middle School Comprehensive Sexual Health Media Literacy Education Program||Behavioral:MediaAware-SexualHealth|Interventional||Other / NIH|Change in self-reported sexual activity assessed via questionnaire.;  Change in self-reported intentions to engage in sexual activity assessed via questionnaire.;  Change in self-reported attitude toward sexual activity assessed via questionnaire.;  Change in self-reported attitudes toward contraception assessed via questionnaire.;  Change in self-reported attitude toward sexual communication assessed via questionnaire.;  Change in self-reported perceived norms regarding sexual activity assessed via questionnaire.;  Change in self-reported perceived norms regarding contraception assessed via questionnaire.;  Change in self-reported perceived norms regarding sexual communication assessed via questionnaire.;  Change in self-reported self-efficacy to refusal sexual activity assessed via questionnaire.;  Change in self-reported self-efficacy to use contraception assessed via questionnaire.;  Change in self-reported self-efficacy for sexual communication assessed via questionnaire.;  Change in self-reported intentions for condom/contraception use assessed via questionnaire.;  Change in self-reported intentions for sexual communication assessed via questionnaire.|1017|NCT02359422|April 2014
410|Completed|Dose Proportionality of TFV-DP After a Single Dose of GS-7340 in Women||Drug:GS-7340|Interventional|Phase 1|Other / Industry|PlasmaDose-Proportionality;  TissueDose-Proportionality;  PBMCDose-Proportionality;  Intra-subject variability in intracellular deoxyadenosine triphosphate (dATP) in peripheral blood;  Inter-subject variability in intracellular deoxyadenosine triphosphate (dATP) in peripheral blood;  Intra-subject variability in intracellular deoxyadenosine triphosphate (dATP) in mucosal tissues;  Inter-subject variability in intracellular deoxyadenosine triphosphate (dATP) in mucosal tissues|24|NCT02357602|March 2015
411|Active not recruiting|Hyperbaric VO2max Study||Procedure: Hyperoxic hyperbaric interval exercise training;  Procedure: Normoxic normobaric interval exercise training;  Drug:Oxygen|Interventional|Phase 2|Other|Maximumaerobiccapacity(VO2max)change;  Mitochondrialmasschange;  Tfammuscleproteincontentchange;  Pgc-1acoactivatormuscleproteincontentchange;  COX-Igeneexpressionchange;  Ventilatorythreshold(VT)change;  Musclephenotypechange|25|NCT02356900|February 2015
412|Completed|Consumer-Based Activity Monitor in Evaluating and Measuring Activity of Older Patients With Abdominal Cancer Undergoing Surgery||Device: Management of Therapy Complications Fitbit Zip (portable pedometer device);  Other:QuestionnaireAdministration;  Other:Quality-of-LifeAssessment|Interventional||Other / NIH|Number of patients who self-report wearing the consumer-based activity monitor at least 16 days of the 21 day period|34|NCT02356471|March 2015
413|Recruiting|Improvement in Wound Healing With Negative Pressure Wound Therapy for Postoperative Total Hip Arthroplasty||Device:PREVENA|Interventional||Other / Industry|WoundHealingbytheASEPSIScriteria;  NumberofParticipantswithInfection|90|NCT02355691|May 2015
414|Recruiting|Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge&#174;) Abiraterone Acetate (Zytiga&#174;) or Enzalutamide (Xtandi&#174;) Undergoing Cardiopulmonary EXercise Testing||Drug:Enzalutamide;  Drug:Abirateroneacetate;  Drug:Sipuleucel-T|Observational|Phase 0|Other|Change in VO2peak from baseline with abiraterone enzalutamide or sipuleucel-T at week 21;  Compare VO2peak with patient- and physician reported functional status;  EvaluatethevariabilityofCPETinallarms|67|NCT02353715|May 2015
415|Terminated|Efficacy and Safety of Low Amplitude Electroconvulsive Therapy||Device:MECTASpectrum5000Q|Interventional||Other|ChangeinCaliforniaVerbalLearningTest-II|1|NCT02351843|February 2015
416|Recruiting|Liposomal Bupivacaine in Simultaneous Bilateral Total Knee Arthroplasty||Drug:Liposomalbupivacaine|Interventional|Phase 4|Other|AdverseEvents;  Plasmabupivacainelevels|15|NCT02349542|January 2015
417|Recruiting|Exercise Intervention for Cancer Survivors||Behavioral:ExerciseOEworkbook;  Behavioral:Dietworkbook|Interventional||Other|change in OE importance as measured by questionnaire;  change in OE accessibility as measured by questionnaire;  change in OE certainty as measured by questionnaire;  change in intentions to exercise as measured by questionnaire;  changeintotalweeklyminutesofexercise|68|NCT02348710|June 2015
418|Recruiting|Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies||Drug:ceritinib|Interventional|Phase 2|Other / Industry|OverallResponseRate(ORR);  ProgressionFreeSurvival(PFS)|24|NCT02343679|May 2015
419|Recruiting|A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)||Device:bevacizumabNovoTTF100Atemozolomide|Interventional|Phase 2|Other / Industry|Survivalat12months|46|NCT02343549|January 2015
420|Recruiting|Lifestyle Interventions in Treatment-Resistant Hypertension||Behavioral: Structured center-based lifestyle intervention;  Behavioral: Standard education and physician advice|Interventional||Other / NIH|Changeinclinicsystolicbloodpressure;  Change in 24-hour ambulatory systolic blood pressure;  Weight;  Aerobic capacity (Measured via an exercise treadmill stress test with VO2 collection);  DASH Diet adherence (Measured via food diary recall);  Change in Cardiovascular Disease (CVD) biomarker composite score|150|NCT02342808|June 2015
421|Withdrawn|Novel Therapies for Muco-Obstructive Lung Diseases: Testing the Transnasal Pulmonary Delivery Device in COPD/CB Subjects||Device:tPAD;  Device: 7% hypertonic saline (510K approved as a device)|Interventional|Phase 1|Other|MucociliaryClearanceRate(MCC60);  Symptomsurvey;  Spirometry|0|NCT02341183|May 2016
422|Recruiting|Transcranial alternatinG Current stimuLation for mAjor Depressive Disorder||Device:tACS(alpha);  Device:tACS(gamma)|Interventional||Other / NIH|The Montgomery-Asberg Depression Rating Scale (MADRS) will be the primary outcome measures for this study;  To compare alpha oscillation power from resting state EEG recordings on the first and last day of stimulation;  To compare alpha oscillation power from resting state EEG recordings on the first of stimulation to the 5 week follow up visit|90|NCT02339285|April 2015
423|Active not recruiting|Phase 1 Trial of Inactivated West Nile Virus Vaccine||Other:Placebo;  Biological:HydroVax-001|Interventional|Phase 1|NIH|Occurrence of any AE related to the study vaccine through day 57 after the second vaccination;  Occurrence of SAEs related to the study vaccine at any time during the study;  Occurrence of solicited local AE and reactogenicity signs and symptoms in the 14 days after each vaccination;  Occurrence of Grade 3 laboratory toxicities related to the study vaccine from first vaccination through day 15 after the second vaccination;  Occurrence of Grade 3 unsolicited adverse events related to the study vaccine from first vaccination through day 57 after the second vaccination;  Occurrence of solicited systemic AE and reactogenicity signs and symptoms in the 14 days after each vaccination;  The reverse cumulative distribution curve of PRNT50 titer on Days 15 and 29 after first vaccination and at days 15 29 57 180 and 365 after the second vaccination for each dose group and for all dose groups combined;  Geometric mean PRNT50 titer at days 15 and 29 after first vaccination and at days 15 29 57 180 and 365 following second vaccination;  Percentage of subjects achieving seroconversion in PRNT50 titer (fourfold or greater increase in titer from baseline) at day 29 after first vaccination and at day 57 after second vaccination|51|NCT02337868|March 2015
424|Recruiting|Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia||Drug:VincristineSulfateLiposome;  Other:LaboratoryBiomarkerAnalysis|Interventional|Phase 2|Other / NIH / Industry|Feasibility defined as 4 of the 1st 10 patients able to complete 2 or more courses of therapy regardless of dose modifications;  Responserate(CRCRiPRandMLFS);  Overallsurvival|39|NCT02337478|May 2015
425|Active not recruiting|Botanical Oils Study to Determine Genetic Differences in the Way Your Body Processes Fats in Edible Oils||DietarySupplement:soybeanoilandborageoil|Interventional||Other / NIH|Change in serum fatty acids from baseline as measured in mass and recorded as mg/dL|66|NCT02337231|June 2014
426|Completed|Lymph Node Counts in Endometrial Cancer Staging|||Observational||Other|Totalgrossnodeidentification;  Percentage of lymph nodes showing metastatic cancer (%NM)|120|NCT02335775|July 2008
427|Suspended|Role of Hyaluronic Acid in Causing Cancer Stem Cell Growth in the Bones of Patients With Breast Cancer||Other:CytologySpecimenCollectionProcedure;  Other:LaboratoryBiomarkerAnalysis|Observational||Other / NIH|HAS2expressionmeasuredbysingle-cellPCR;  CSCmarkerexpression|20|NCT02331212|March 2015
428|Active not recruiting|Our Year of Healthy Living (Formative Research &amp; Intervention)||Behavioral:HealthyMeHealthyWe|Interventional||Other / NIH|Changeinchildphysicalactivity;  Changeinchilddietquality;  Changeinchildweight;  Change in nutrition and physical activity environments in homes and child care centers|2160|NCT02330354|March 2015
429|Active not recruiting|Padres Efectivos (Parent Activation): Skills Latina Mothers Use to Get Healthcare for Their Children||Behavioral:activationcurriculum;  Behavioral:supportgroup|Interventional||Other|parentactivation;  caregiverdepression;  caregiverstress;  parentactivationqualitative;  Childserviceuseattendanceatvisits;  Childserviceusenoshows|302|NCT02329431|August 2013
430|Recruiting|Impact of Physical Activity on Biomarker of Aging and Body Composition Among Breast Cancer Survivors Age 65 and Older||Behavioral:WalkwithEaseProgram|Interventional||Other|To measure the change in level of p16 expression from baseline to end of chemotherapy to a control group;  To measure the changes in the level of p16 expression from baseline and end of chemotherapy.;  To measure changes in body compositional aspects of lean body mass (LBM);  To measure changes in body compositional aspects of fat tissue mass (FM);  To measure changes in body compositional aspects of percentage body fat (BF);  To measure change in physical activity over the course of the study;  To measure change in physical function over the course of the study;  To measure change in fatigue over the course of the study;  To measure change in quality of life over the course of the study;  To measure change in self-efficacy over the course of the study;  Tomeasureretentionduringthestudy;  Tomeasuresafetyofthewalkingprogram;  Tomeasureoverallsatisfactionwiththeprogram;  To average the number of daily and weekly steps per participant|100|NCT02328313|October 2014
431|Recruiting|FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions||Drug:FLTPET/MR|Observational||Other|Sensitivity and specificity of FLT-PET-MRI in distinguishing between recurrence and radiation necrosis with surgical biopsy as gold standard|15|NCT02328300|June 2014
432|Recruiting|LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer||Drug:carboplatinplusabraxane|Interventional|Phase 2|Other / Industry|Responserate(RR)|50|NCT02328105|December 2014
433|Recruiting|NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)|||Observational||NIH|The overall goal is to study the natural history of bacteria and its impact on asthma|200|NCT02327897|December 2014
434|Active not recruiting|Physical Activity for Older Adults Chronic Low Back Pain||Behavioral:PhysicalActivity;  Behavioral:CognitiveBehavioralTherapy|Interventional||U.S. Fed / Other|TimedGet-Up-AndGo;  PROMISHealthAssessmentQuestionnaire;  PatientSpecificFunctionalScale;  Roland-Morris Disease Specific Disability Questionnaire;  SatisfactionwithPhysicalFunctionScale|60|NCT02327325|May 2015
435|Recruiting|Novel Biomarker for Development of T2D|||Observational||Other|Relationship between 11&#946;-HSD1 and 5&#945;-reductase activity and measures of insulin resistance;  Genderandpubertalstatus;  Compare 11&#946;-HSD1 activity and 5&#945;-reductase activity among obese adolescents with T2D obese adolescents without T2D and normal weight controls;  Relationship between 11&#946;-HSD1 and 5&#945;-reductase activity and key metabolic signatures associated with insulin resistance;  Urine metabolic signatures associated with insulin resistance and type 2 diabetes;  Spoturineformetabolicprofiling|75|NCT02326129|February 2015
436|Recruiting|The Use of a Dynamic Compression Intramedullary Nail for Tibiotalocalcaneal Arthrodesis||Device:Procedure/Surgery:|Observational||Other|ChangeinPainAssessment;  ChangeinFunctionalAssessment;  FusionasmeasuredbyradiographandCTscan|30|NCT02324907|January 2015
437|Terminated|Esophageal Balloon Guided Weaning of the Morbidly Obese Patient||Device:EsophagealBalloon;  Other:Cstat|Interventional||Other|Numberofpatientsweanedbyday30;  Timetowean|25|NCT02323009|January 2011
438|Not yet recruiting|Phenotyping Acute Pain for Discovery Research and Directed Therapeutics||Other:questionnaires|Observational|Phase 4|Other|characterizechangesinacutepain|50|NCT02322996|September 2015
439|Completed|A Quantitative Optical Sensor to Monitor Vascular Physiology; A Healthy Volunteer Study|||Observational||Other / Industry|minimum contact pressure required for spectroscopic measurements|10|NCT02321995|June 2016
440|Recruiting|Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer||Drug:Gemcitabine/nab-Paclitaxel;  Radiation:Radiationtherapy;  Other:Sugicalresection;  Drug:Adjuvantchemotheapy|Interventional||Other|Feasibility of neoadjuvant gemcitabine/nab-paclitaxel and HIGRT in patients with potentially resectable pancreatic cancer.;  Grade&gt;/=2acutetoxicity;  Resectionrate;  R0resectionrate|25|NCT02318095|January 2015
441|Active not recruiting|Long-Term Follow-Up Safety Monitoring of Patients Dosed in the First-in-Man Phase I/II Study of TT-034.|||Observational||Industry|Long Term Safety as measured through an assessment of adverse events;  LongTermViralLoad|9|NCT02315638|November 2014
442|Completed|Meditation and Decision Making Study III||Behavioral:LovingkindnessMeditation(LKM);  Behavioral:MindfulnessMeditation|Interventional||Other / NIH|Change in positive emotions (as measured by the Modified Daily Emotions Scale);  Change in nonconscious incentive salience (as measured by the Affect Misattribution Procedure);  Changesinmeditationtime;  CardiacVagalTone|240|NCT02313779|December 2014
443|Recruiting|Causes of Comorbid Infertility Among Women With Rheumatoid Arthritis|||Observational||Other|OvarianReservebetweenwomenwithandwithoutRA;  Ovulation Frequency between women with and without RA;  Rates of Infertility between women with and without RA;  Number of Pregnancies between women with and without RA;  Age at attempted and actual conception between women with and without RA|150|NCT02313129|August 2015
444|Active not recruiting|Piedmont Aging Cognition &amp; Exercise Study-2||Behavioral:Exercise/Aerobic;  Behavioral:Exercise/Stretching|Interventional||Other|Change in cognitive performance from baseline following 6 month of high or low intensity exercise regimen;  Change from baseline in blood sugar concentration and cerebrospinal fluid glucose measures during an oral glucose tolerance test following 6 months of high or low intensity exercise|33|NCT02312843|March 2013
445|Active not recruiting|Physical Therapy Versus Internet-Based Exercise Training for Patients With Knee Osteoarthritis||Behavioral:InternetBasedExerciseTraining;  Behavioral:PhysicalTherapy|Interventional||Other|Change from baseline to month 4 and month 4 to month 12 in Western Ontario and McMasters Universities Osteoarthritis (WOMAC) Index score;  Change from baseline to month 4 and month 4 to month 12 in the Satisfaction with Physical Function Scale;  Change from baseline to month 4 and month 4 to month 12 in a grouping of tests to assess Objective Physical Function;  Change from baseline to month 4 and month 4 to month 12 in the Patient Health Questionnaire-8;  Change from baseline to month 4 and month 4 to month 12 in The Knee injury and Osteoarthritis Outcome Score (KOOS);  Change from baseline to month 4 and month 4 to month 12 in The PROMIS Sleep-related Impairment Instrument;  Change from baseline to month 4 and month 4 to month 12 in The PROMIS Fatigue Instrument;  Change from baseline to month 4 and month 4 to month 12 in the The Brief Fear of Movement Scale;  Change from baseline to month 4 and month 4 to month 12 in the Physical Activity Scale for the Elderly (PASE);  Change from baseline to month 4 and month 4 to month 12 in Additional Self-Report Physical Activity Items|350|NCT02312713|November 2014
446|Completed|Temperature Monitoring With InnerSense Esophageal Temperature Sensor/Feeding Tube After Birth Through Stabilization in VLBW Infants||Device: Philips InnerSense Esophageal Temperature Sensor/Feeding Tube;  Device:Standardofcarefeedingtube|Interventional||Other / Industry|meanaxillaryadmissiontemperature;  meanaxillarytemperature;  percentage of infants with hypothermic temperatures (&lt;36.5&#176; C);  relationship of minute to minute temperatures as measured by correlation coefficient|20|NCT02311972|November 2014
447|Recruiting|Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy||Drug:Belatacept;  Procedure:Handtransplant|Interventional|Phase 2|Other|Ability to use the tranplanted limb in activities of daily living at 18 months following transplantation measured by a quantitative functional test.;  Clinicalrejection;  Histologicalrejection|50|NCT02310867|March 2015
448|Recruiting|Cochlear Implantation After Labyrinthectomy or a Translabyrinthine Surgical Approach||Device:CochlearImplant|Interventional||Other / Industry|Speechperceptiontesting;  Soundlocalizationtesting;  Subjective questionnaires to indicate perceived benefits of cochlear implantation;  Speech perception testing in the aided condition (cochlear implant speech processor on) and unaided condition (cochlear implant speech processor off);  Sound localization testing in the aided condition (cochlear implant speech processor on) and unaided condition (cochlear implant speech processor off);  Subjective questionnaires drawing comparisons of aided benefit (cochlear implant speech processor on) to that of unaided (cochlear implant speech processor off)|10|NCT02309099|November 2014
449|Completed|PPV to Guide Fluid Management in the PICU||Device:AutomatedPulsePressureVariation|Interventional||Other|Totalfluid(mL/cc/day)given;  Numberofhoursonvasopressors;  Numberofdaysonventilatorysupport;  NumberofdaysinthePICU|100|NCT02308371|December 2014
450|Recruiting|The CARE Program: CAncer REhabilitation Pilot Study for Older Adults||Other:OccupationalandPhysicalTherapy|Interventional||Other|To measure the change in Nottingham Extended Activities of Daily Living (NEADL) score from baseline to three months.;  To measure the change in Activities of Daily Living from Baseline and 2 months;  To measure the change in Activities of Daily Living from Baseline and 3 months;  To measure the change in physical health from Baseline and 3 months;  To measure the change in physical health from Baseline and 2 months;  To measure the change in quality of life from Baseline and 2 months;  To measure the change in quality of life from Baseline and 3 months;  To measure the change in internalized occupational possibilities from Baseline and 3 months;  To measure the change in internalized occupational possibilities from Baseline and 2 months;  To measure the change in cognitive function from Baseline and 2 months;  To measure the change in cognitive function from Baseline and 3 months;  TomeasurethefeasibilityoftheCAREProgram;  To measure the change in balance over the course of the study;  To measure the change in upper extremity use and ability over the course of the study;  To measure the change in cognition over the course of the study;  To measure the change in dynamic gait ability over the course of the study;  TomeasuresatisfactionwiththeCAREProgram|82|NCT02306252|June 2014
451|Recruiting|Evaluation of Loratadine for G-CSF Induced Bone Pain in Patients With Hematologic Malignancies||Drug:Loratadine|Observational||Other|Incidence of bone pain following G-CSF administration|100|NCT02305979|December 2014
452|Active not recruiting|Intra-Arterial Microdosing: Proof-of-Concept in Humans||Drug:Insulin|Interventional|Phase 0|Other|GlucosePlasmaLevels;  18F-FDG Uptake as measured with Positron Emission Tomography (PET) imaging;  PotassiumPlasmaLevels;  LacticAcidPlasmaLevels|30|NCT02304211|December 2014
453|Recruiting|D2C7 for Adult Patients With Recurrent Malignant Glioma||Drug:D2C7-IT|Interventional|Phase 1|Other|Maximumtolerateddose(MTD)ofD2C7-IT;  Overallsurvival(OS);  Association between EGFRvIII and EGFRwt expression and PFS and OS.|45|NCT02303678|February 2015
454|Recruiting|Motion Immune Magnetic Resonance Imaging (MRI)||Device:MultiplexSensitivityEncoding(MUSE)|Observational||Other|Rating of image quality (based on 8 criteria) by multiple radiologists (blind to reconstruction method)|60|NCT02302521|May 2015
455|Active not recruiting|Qsymia as an Adjunct to Surgical Therapy in the Superobese||Drug:Phentermine/topiramate|Interventional||Other / Industry|RouxenYGastricBypass;  Percentweightloss;  Percentbodyfat;  RestingMetabolicRate|21|NCT02301416|December 2014
456|Completed|Optimal Timing of Double-Wire Technique For Biliary Cannulation at ERCP||Procedure: double-wire technique in patients undergoing ERCP with biliary cannulation;  Procedure: single-wire technique in patients undergoing ERCP with biliary cannulation|Interventional||Other|Successofbiliarycannulation;  Timetosuccessfulbiliarycannulation;  Post-ERCPpancreatitis|161|NCT02297750|August 2012
457|Recruiting|Intravesicular Onabotulinumtoxin A in Interstitial Cystitis||Drug:OnabotulinumtoxinA;  Procedure: injections upper aspect of trigone of urinary bladder;  Procedure: injections on posterior bladder wall excluding the trigone|Interventional|Phase 4|Other / Industry|The primary outcome will be assessing change in a measurement of subjective patient pain using the Pelvic Pain and Urinary Urgency Frequency (PUF) questionnaire and the O&apos;Leary-Sant Symptom and Problem Indexes.;  Secondary outcomes will be assessing change in patient performance in uroflowmetry.|40|NCT02297100|December 2014
458|Recruiting|Exercise and PTSD in Older Veterans||Behavioral: Exercise as an Adjuvant Therapy for Veterans with PTSD|Interventional||U.S. Fed|Feasibility;  PhysicalActivity;  PTSDSymptoms;  PhysicalFunction|40|NCT02295995|December 2015
459|Recruiting|Strength Testing After Nitrate Delivery (STAND) in ICU Patients||DietarySupplement:NitrateRichBeetrootJuice;  DietarySupplement:Placebo|Interventional|Phase 1|Other|physical function assessed using the Short Physical Performance Battery (SPPB);  PlasmaNitrateandNitriteLevels;  Skeletalmusclestrength;  HospitalLengthofStay|20|NCT02293616|June 2015
460|Completed|Thoracoabdominal Arortic CTA Study||Drug:Isovue|Interventional|Phase 4|Other|Radiationdose;  Noise;  Signaltonoiseratio;  Hounsfieldunitattenuationvalues;  Contrasttonoiseratio|150|NCT02291718|January 2014
461|Completed                  Has Results|Reducing Pain of Lidocaine Injection||Drug:1%Lidocaine;  Drug:1%Lidocaineplussodiumbicarbonate|Interventional|Phase 4|Other|Pain|88|NCT02288364|December 2014
462|Active not recruiting|Comparative Effectiveness of Rehabilitation Services for Survivors of Acute Ischemic Stroke||Other:retrospectiveanalysis|Observational||Other|Rehabilitationserviceuse;  Livingindependently;  Functionalstatus;  Depression;  Changeinworkstatus;  Diseaseself-management;  Qualityoflife;  Long-termcareplacement;  Hospitalreadmission;  Survival|275711|NCT02284165|May 2013
463|Recruiting|De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study||Radiation: Intensity Modulated Radiotherapy (IMRT);  Drug:Cisplatin(oralternative);  Procedure:Assessmentforsurgicalevaluation|Interventional|Phase 2|Other|2 year Progression Free Survival after de-intensified CRT in HPV-positive and/or p16 positive low-risk OPSCC;  Localcontrolrate;  Regionalcontrolrate;  Local-regionalcontrolrate;  Distantmetastasisfreesurvival;  Overallsurvivalrate;  Headandneckqualityoflifeassessments;  Speechandswallowingfunction|60|NCT02281955|August 2014
464|Active not recruiting|mHealth Messages to Sustain Recent Weight Loss - Phase 2||Behavioral:mHealthTextingforWeightLoss|Interventional||Other|Subject&apos;sweightloss;  Percentage of subjects who self-report weight to the clinic|100|NCT02279017|October 2014
465|Recruiting|The Impact of Early Follow-up on Readmission Rates in AMI Patients||Behavioral: Follow-up Appointment- early vs standard|Interventional||Other|hospitalreadmission|2000|NCT02276456|March 2014
466|Recruiting|Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC||Drug:Irinotecan;  Drug:Cisplatin|Interventional|Phase 2|Other|Estimate the median and three year survival rate of locally advanced NSCLC using the platinum doublet cisplatin and irinotecan;  Estimatetheprogression-freesurvival;  Compare the survival of patients treated with cisplatin/irinotecan with historical controls using cisplatin/etoposide.;  Measure toxicities and compliance of patients on this regimen|60|NCT02275806|October 2014
467|Recruiting|A Prospective Patient Registry of Patients Exposed to Bedaquiline||Drug:NoIntervention|Observational|Phase 4|Industry|Percentage of Participants with Medical Indication for Bedaquiline (BDQ) Treatment and Frequency of use of Expert Medical Consultation With BDQ;  Number of Participants With BDQ Susceptibility Based on Minimum Inhibitory Concentration (MIC);  MaximumDoseofBDQ;  TotalDurationofBDQTreatment;  Percentage of Participants with Different Drug Distribution Mechanisms Utilized for Drug Administration;  Number of Participants With Clinical and Microbiologic Patient Reported Outcomes;  Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs);  Comparison of Rate of Observed Outcomes With Nationally Available Reported Rates|300|NCT02274389|December 2013
468|Completed|Patient-Reported Preferences Affecting Revascularization Decisions||Other: Decision-making tool for coronary artery disease treatment|Interventional||Other / Industry|Concordance of patient preference with delivered treatment;  Knowledge;  Decisionalconflict;  Patientsatisfaction;  Informedvaluescongruence;  Angina;  Adhocpercutaneouscoronaryintervention|203|NCT02272062|November 2014
469|Completed|Dexamethasone and Pain Following Total Knee Arthroplasty||Drug:Dexamethasone;  Other:Placebo|Interventional|Phase 4|Other|ChangeinVisualanaloguepainscore;  ChangeinOpioidconsumption;  ChangeinChronicPain;  ChangeinFunctionalstatus;  ChangeinInterleukin6and10levels;  ChangeinMacrophageproliferation|45|NCT02271698|December 2014
470|Recruiting|Effect of Symptom Management on Inflammation and Survival in Metastatic Lung Cancer|||Observational||Other|OverallSurvival;  Percentage of patients who convert from c-reactive protein &apos;high&apos; (&gt; 10 mg/L) to &apos;low&apos; (&lt;10 mg/L);  Quality of Life (QOL) indicators per FACT-L score and the following at baseline 4 months and 10 months groups;  ChangeinVeriStratstatus|100|NCT02271581|October 2014
471|Completed|Effects of Neuromodulation on Verbal Fluency in Post-stroke Aphasia||Device:TNM(trademark)-thermoneuromodulation|Interventional||Industry / Other|Measure and quantify any improvements in verbal fluency at the end of a 3-month Tx period;  Mood;  gaitandposture;  heartratevariability;  durabilityofanygains;  QualityofLife|12|NCT02270866|October 2014
472|Completed|Utilizing Non-Invasive Fibroscan&#174; Technology to Identify Genetic Markers for Fatty Liver Progression|||Observational||Other|Liver stiffness measurement via transient elastography;  Liver fat measurement via Controlled Attenuation Parameter;  NAFLD-Fibrosisscore|53|NCT02267148|October 2014
473|Recruiting|Contingency Management Quitting Smoking and ADHD||Behavioral:ContingencyManagement(CM);  Drug: Transdermal nicotine skin patches (i.e. Habitrol);  Other:SupportiveCounseling|Interventional|Phase 1|Other / NIH|Change in motivation to quit smoking as measured by the Readiness to Change Questionnaire;  Change in motivation to quit smoking as measured by the Treatment Self-Regulation Questionnaire;  Change in motivation to quit smoking as measured by the Perceived Competence Scale for Cessation;  Change in motivation to quit smoking as measured by the Reasons For Quitting questionnaire;  Change in readiness to change behavior as measured by the Readiness to Change Questionnaire;  Change in readiness to change behavior as measured by the Treatment Self-Regulation Questionnaire;  Change in readiness to change behavior as measured by the Perceived Competence Scale for Cessation;  Change in readiness to change behavior as measured by the Reasons For Quitting questionnaire;  Comparison of populations in motivation to quit on the Reasons for Quitting Questionnaire;  ChangeinsmokingbehaviorinADHDpopulation;  Decreasingeffectsofquittingsmoking.|60|NCT02266784|October 2014
474|Enrolling by invitation|Optimizing Health Outcomes in Patients With Symptomatic Aortic Valve Disease|||Observational||Other|Mortality;  Stroke;  Discharged to home following the procedure (TAVR or SAVR);  days alive and out of the hospital during the first post-operative year|6484|NCT02266251|May 2014
475|Recruiting|Mobile Pain Coping Skills Training for Cancer Pain||Behavioral:PainCopingSkillsTraining|Interventional||Other|ChangeinPain|180|NCT02266017|October 2014
476|Completed                  Has Results|High Frequency Stimulation Trials in Patients With Precision Spinal Cord Stimulator System||Other:Highfrequencystimulation;  Other:Lowfrequencystimulation|Interventional|Phase 4|Other|NumericPainRatingScale(NPRS);  OswestryDisabilityIndexQuestionnaire(ODI).;  Patient&apos;sGlobalImpressionofChange(PGIC)|22|NCT02265848|October 2014
477|Completed|Relationship of Pulmonary Contusion to Pulmonary Inflammation and Incidence of Acute Respiratory Distress Syndrome|||Observational||Other|VolumeofPulmonaryContusiononCTscan;  Volume of serum inflammatory mediator levels in BAL fluid;  PresenceofTregsinBALfluid;  PresenceofactivatedneutrophilsinBALfluid;  Appearance of M2 macrophage phenotypes in BAL fluid|10|NCT02265198|September 2014
478|Recruiting|Novel Biomarkers for Risk Prediction of Contrast-Induced Acute Kidney Injury Post Coronary Angiography|||Observational||Industry / Other|Changes in serum creatinine levels (absolute and percentage);  Major Adverse Clinical Events (MACE a composite of all-cause mortality myocardial infarction or renal replacement therapy);  AdmissiontotheICU|200|NCT02263820|January 2015
479|Completed|Respiratory Viral Infections in Pediatric Transplantation|||Observational||Other|Incidenceofrespiratoryviralinfection;  All-cause mortality of respiratory viral infection|2669|NCT02260596|September 2014
480|Completed|Study to Determine the Safety Tolerability and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC||Drug:HPN-07;  Drug:NAC;  Drug:Placebo|Interventional|Phase 1|Industry|Safety and tolerability of single doses of HPN-07 alone and in co-administration with NAC: Adverse events;  Area under the curve (AUC) of single doses of HPN-07 alone and in co-administration with NAC;  Maximum observed plasma concentration (Cmax) of single doses of HPN-07 alone and in co-administration with NAC;  Half life (t1/2) of single doses of HPN-07 alone and in co-administration with NAC;  Volume of distribution (Vz) of single doses of HPN-07 alone and in co-administration with NAC;  Mean transit time (MTT) of single doses of HPN-07 alone and in co-administration with NAC;  Total clearance (CL) of single doses of HPN-07 alone and in co-administration with NAC|32|NCT02259595|October 2014
481|Recruiting|Radiation Induced Cardiopulmonary Injury in Humans||Procedure:SPECTLungPerfusionScan;  Procedure:SPECTHeartPerfusionScan;  Procedure:PulmonaryFunctionTests|Observational||Other|ChangesinRegionalLungFunction;  ChangesinRegionalHeartFunction;  Relating RT-Induced Changes in Regional injury to Global Cardiopulmonary Changes|80|NCT02259452|June 2008
482|Withdrawn|Flucelvax Pregnancy Registry||Biological:Flucelvax(cTIV)|Observational||Industry|majorcongenitalmalformation;  pretermbirth;  lowbirthweight|0|NCT02258178|September 2014
483|Recruiting|DHB Supplement Interaction Study|||Observational||NIH|Pharmacokinetic measures (AUC0 inf Cmax) of systemic drug exposure;  Geometric means estimates of treatment differences within-subject and between-subject treatment variance and the 95% confidence intervals around those estimates|50|NCT02257879|September 2014
484|Recruiting|Perimenopausal Effects of Estradiol on Reward Responsiveness||Drug:Estradiol;  Drug:Progesterone|Interventional|Phase 4|Other / NIH|Change in frontostriatal reactivity to reward during the MID fMRI task;  Change in neural connectivity measured during resting-state fMRI;  Change in response latency to reward versus non-reward during the MID fMRI task;  Change in Inventory of Depression and Anxiety Symptoms (IDAS) scores;  Change in the Positive and Negative Affect Schedule (PANAS);  Change in Mood and Anxiety Symptom Questionnaire--Anhedonic Depression subscale (MASQ-AD)|50|NCT02255175|October 2015
485|Recruiting|UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells||Biological:DUOC-01|Interventional|Phase 1|Other|EvaluateforInfusionalToxicity;  EvaluateforNeuroToxicity;  Efficacydetermination|12|NCT02254863|September 2014
486|Completed|The STRENGTH Study: Shapely Sisters Targeting Realistic Exercise and Nutrition Goals Through Healthy Habits||Behavioral:StandardWeightLossIntervention;  Behavioral: Stress-Focused Weight Loss Intervention|Interventional||Other|Weight;  PhysicalActivity;  Psychosocial&amp;BehavioralMeasures;  Walkability;  AerobicFitness|40|NCT02253641|April 2015
487|Recruiting|Oxytocin Treatment of Alcohol Dependence||Drug:IntranasalOxytocinSpray;  Drug:Placebo|Interventional|Phase 2|Other / NIH|Abstinent/Heavy drinking days during 12 weeks of test treatment;  Mean alcohol craving scores over 12 week test treatment period|50|NCT02251912|July 2015
488|Completed|Attention Deficit/Hyperactivity Disorder Internet Survey Study in a College Student Population|||Observational||Other|Compared measured adherence of Internet survey group to standard-of-care group;  Measured adherence by the MEMS&#174; cap in relation to the patient reported adherence via the Internet survey;  Changeindiseaseseverity|10|NCT02251080|September 2014
489|Recruiting|Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases||Drug:fludarabinephosphate;  Drug:busulfan;  Drug:cyclophosphamide;  Procedure: allogeneic hematopoietic stem cell transplantation;  Drug:tacrolimus;  Drug:mycophenolatemofetil|Interventional||Other / NIH|12monthdiseasefreesurvivalprobability;  RateofacuteGvHD;  RateofchronicGvHD;  Overallsurvival;  Relapse(ordeath);  Relapse-freemortality|24|NCT02248597|January 2015
490|Not yet recruiting|Impact of Family History and Decision Support on High-risk Cancer Screening||Behavioral:MeTree|Interventional||U.S. Fed|Provider referral for risk-appropriate colorectal cancer screening;  Patient uptake of risk-appropriate colorectal cancer screening;  Referralforgeneticconsultation|650|NCT02247336|January 2017
491|Completed|Exercise and Quality of Life in Leukemia Patients||Other:Exercise|Interventional||Other|Compare symptoms of fatigue in newly diagnosed acute leukemia patients;  Evaluate health-related quality of life changes over time;  Comparesymptomsofanxietybetweengroups;  Comparesymptomsofdepressionbetweengroups;  Comparesleepqualitybetweengroups;  Changesincardiovascularfunction;  Changesinmusclestrength;  Changesinbodycomposition;  Changesinfunctionalmobility;  Changesinmusclesize|18|NCT02246907|January 2014
492|Recruiting|Abstinence Reinforcement Therapy (ART) for Homeless Veteran Smokers||Drug:NicotinePatches;  Behavioral:mobilecontingencymanagement(mCM);  Behavioral:Smokingcessationcounseling;  Drug:Nicotinerescuemethod;  Drug:Bupropion|Interventional||U.S. Fed|Smokingabstinence;  Quality adjusted life year (QALY) resource utilization costs intervention delivery costs and participant time costs|165|NCT02245308|October 2014
493|Completed|Arthritis Pilot for Preserving Muscle While Losing Weight||Device:Vest;  Behavioral:Diet|Interventional||Other / Industry|Changeinbodyweight;  ChangeinbodycompositionmeasuredbyDXA;  Changesinphysicalfunction|37|NCT02239939|October 2014
494|Terminated|Acetabular Bone Vascularity in Metal-on-Metal Revisions|||Observational||Other|The depth (mm) of avascular bone from the acetabular surface per each patient;  Theratioofnecroticbonepereachpatient|7|NCT02239406|November 2014
495|Active not recruiting|Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)||Drug:Placebo(forMN-166);  Drug:MN-166|Interventional|Phase 2|Industry / Other|Evaluate safety and tolerability of MN-166 60 mg/d versus placebo when administered with riluzole in subjects with ALS;  The secondary objective is to evaluate the clinical endpoint responsiveness of MN-166 60 mg/d versus placebo when administered with riluzole in subjects with amyotrophic lateral sclerosis as measured by Functional Activity;  The secondary objective is to evaluate the clinical endpoint responsiveness of MN-166 60 mg/d versus placebo when administered with riluzole in subjects with amyotrophic lateral sclerosis as measured by Respiratory Function;  The secondary objective is to evaluate the clinical endpoint responsiveness of MN-166 60 mg/d versus placebo when administered with riluzole in subjects with amyotrophic lateral sclerosis as measured by Muscle Strength;  The secondary objective is to evaluate the clinical endpoint responsiveness of MN-166 60 mg/d versus placebo when administered with riluzole in subjects with amyotrophic lateral sclerosis as measured by Non-Invasion Ventilation (NIV)|120|NCT02238626|September 2014
496|Recruiting|Pain Management Using Mobile Technology in Veterans With PTSD and TBI||Device:NeuroSkyMindWaveMobile|Interventional||Other / NIH|Number of ten minute neurofeedback sessions completed on mobile platform;  Change in participant&apos;s self-reported pain score from 0-10 0 least amount of pain 10 highest|100|NCT02237885|August 2015
497|Recruiting|Natural History Study of Patients With Hypophosphatasia (HPP)|||Observational||Other|MedicalHistoryofHPPPatients;  long-termefficacyoftreatmentmodalities;  potential long term complications of the disease and/or treatment;  quality of life issues for patients living with hypophosphatasia|200|NCT02237625|September 2014
498|Active not recruiting|Function and Scoliosis Surgery|||Observational||Other|ChangeinLowerQuarterY-BalanceTest(YBT-LQ);  ChangeinFunctionalMovementScreen(FMS);  ChangeinTegnerActivityScale;  ChangeinMarxActivityScale;  ChangeinEQ-5D;  ChangeinSRS-22|15|NCT02237248|November 2014
499|Completed|The Effects of Potassium on Glucose Metabolism in African Americans||Drug:K+supplement;  Drug:Placebo|Interventional|Phase 2|Other|ChangeinGlucoseTolerance;  Changes in fasting 1-hour and 2-hour post-challenge glucose levels;  ChangesinInsulinSecretion;  ChangesinInsulinSensitivity|61|NCT02236598|January 2015
500|Recruiting|Study of an Emergency Department-based Intervention to Reduce Alcohol Misuse in Older Adults||Behavioral:BriefNegotiatedInterview;  Behavioral:GeneralHealthInformation|Interventional||Other / NIH|Alcoholmisuse;  Subgroup analysis of patients who met hazardous alcohol use criteria based on time-line follow back method of assessing alcohol consumption;  Function;  Alcoholconsumption;  Alcoholabuse;  GeneralHealth;  Risk-takingbehavior;  Trauma;  HealthcareUtilization|150|NCT02236494|October 2014
501|Terminated|A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)||Drug:Afuresertib;  Drug:Carfilzomib|Interventional|Phase 1|Industry|Part1: Number of participants with adverse events (AEs) as a measure of safety;  Part1: Safety assessed by monitoring the changes in vital signs;  Part1: Safety assessed by monitoring the changes in laboratory parameters;  Part1: Safety assessed by monitoring the changes in electrocardiograms (ECG);  Part2:ProgressionFreeSurvivial(PFS);  Part 1: Composite of PK parameters of afuresertib and carfilzomib alone or in combination with each other will be assessed following multiple afuresertib doses and following a single dose of carfilzomib;  Part1:Afuresertibconcentrations;  Part1:Overallresponserate(ORR);  Part1:PFS;  Part1:Overallsurvival(OS);  Part1:Durationofresponse(DOR);  Part2:ORR;  Part2:OS;  Part2:DOR;  Part 2: Number of participants with adverse events (AEs) as a measure of safety;  Part 2: Safety assessed by monitoring the changes in vital signs;  Part 2: Safety assessed by monitoring the changes in laboratory parameters;  Part 2: Safety assessed by monitoring the changes in ECG;  Part2:Afuresertibconcentrations|1|NCT02235740|November 2014
502|Recruiting|SDOCT-GMPE Software||Device:SDOCT-GMPEsoftware|Interventional||Other|RNFLthickness|200|NCT02235454|November 2014
503|Active not recruiting|Effects of Chemoradiation and Surgery on Cardiopulmonary Fitness and Tumor Neoplastic Phenotype in Gastrointestinal Malignancies||Other:CardiopulmonaryExerciseTest(CPET)|Interventional||Other|FeasibilityCompositeScore|25|NCT02235441|November 2014
504|Recruiting|Effect of Non-Alcoholic Steatohepatitis (NASH) on the Pharmacokinetics of 99mTechnetium-Mebrofenin||Radiation:Tc99mMEB|Interventional|Phase 1|Other / NIH|Hepaticexposure(AUC0&#8594;&#8734;);  Systemicexposure(AUC0&#8594;&#8734;);  Cmax(hepatic);  Tmax(hepatic);  Xurine;  CLuptake;  CLrenal|20|NCT02235233|April 2015
505|Enrolling by invitation|CBT for Aggression in Veterans||Behavioral:CognitiveBehavioralTherapy;  Behavioral:PresentCenteredTherapy|Interventional||U.S. Fed|Slope of the change in scores on the Conflicts Tactics Scale (CTS) over 4 time points;  Slope of the change in scores on the Dimensions of Anger Reactions Scale (DAR)over 4 time points;  Slope of the change in scores on the Classification of Violence Risk (COVR) over 4 time points;  Slope of the change in scores on the Novaco Anger Scale short form (NAS) over 4 time points;  Slope of the change in scores on the Community Reintegration of Service Members Computer Adaptive Test (CRIS-CAT) over 4 time points;  Slope of the change in scores on World Health Organization Disability Assessment Schedule Version 2.0 (WHO-DAS 2.0) over 4 time points;  Slope of the change in scores on the Inventory of Psychosocial Functioning (IPF) over 4 time points;  TheMcMasterFamilyAssessmentDevice(FAD)|60|NCT02233517|February 2015
506|Recruiting|CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery||Drug:68-bis(benzylthio)octanoicacid;  Drug:fluorouracil;  Other:pharmacologicalstudy;  Other:laboratorybiomarkeranalysis|Interventional|Phase 1|Other / NIH|MTD of 68-bis(benzylthio)octanoic acid in combination with fluorouracil based on the incidence of dose-limiting toxicities graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;  Incidence of toxicity of 68-bis(benzylthio)octanoic acid and fluorouracil combination graded according to NCI CTCAE version 4.0;  PK parameters (maximum observed concentration area under the curve half-life elimination rate constant drug clearance and volume of distribution) of 68-bis(benzylthio)octanoic acid in plasma samples;  Progression-freesurvival(PFS);  Overall response rate (ORR) (i.e. sum of complete response [CR] and partial response [PR]);  Disease control rate (DCR) (i.e. sum of CR PR and stable disease)|40|NCT02232152|December 2014
507|Recruiting|Molecular Mechanisms Underlying Prostate Cancer Disparities||Device:Biopsyorprostatectomy|Interventional||Other|Proportion of high and low expression of identified gene targets in Caucasian and African American specimens|198|NCT02229565|November 2014
508|Recruiting|Analysis of Post-Translational Modifications of a Critical Protein Implicated in Amyotrophic Lateral Sclerosis|||Observational||Other|Post-translational modifications (PTMs) of Cu/Zn superoxide dismutase 1|30|NCT02228915|August 2014
509|Completed|Can Quercetin Increase Claudin-4 and Improve Esophageal Barrier Function in GERD?||Drug:Quercetin|Interventional|Phase 1|Other / NIH|Expression of claudin-4 in esophageal squamous epithelium (ESE) of gastroesophageal reflux disease (GERD) in vivo;  Barrier function and acid resistance of esophageal squamous epithelium (ESE) as measured by epithelial resistance RT and fluorescein flux.|26|NCT02226484|August 2014
510|Recruiting|Surgery Prevention by Transforaminal Injection of Epidural Steroids for Cervical Radicular Pain||Drug:Lidocaine;  Drug:LidocainewithDexamethasone|Interventional|Phase 4|Other|avoidanceofnecksurgery;  Disability;  Pain;  PatientSatisfaction|60|NCT02226159|August 2014
511|Recruiting|Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry||Biological: Meningococcal quadrivalent CRM-197 conjugate vaccine|Observational||Industry|Majorcongenitalmalformation;  Pretermbirth;  Lowbirthweight;  Spontaneousabortions;  Stillbirths|100|NCT02223637|September 2014
512|Recruiting|Hyperpolarized Xenon-129 Magnetic Resonance Imaging and Spectroscopy of Brown Fat: Healthy Adult Volunteer Pilot Study||Drug:Xenon|Interventional|Phase 1|Other|Browadiposetissuevolume;  ChangeinBATtemperature|24|NCT02220426|September 2014
513|Active not recruiting|Fabrication of a Definitive Cad/Cam Titanium Abutment Prior to Guided Surgery: a Pilot Study.||Device:abutmentmargin.5mmsubgingival;  Device:abutmentmargin1.5mmsubgingival|Interventional||Other|Abutmentmarginexposure;  softtissueresponse|28|NCT02218541|November 2014
514|Completed|Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults||Drug:Raltegravir;  Drug:Dolutegravir;  Procedure:Colonoscopywithbiopsy|Observational|Phase 4|Other / Industry|HIV RNA and DNA in three gastrointestinal tract tissues (terminal ileum/ascending colon splenic flexure and rectum/sigmoid colon);  Raltegravir/Dolutegravir Drug Exposure in three gastrointestinal tract tissues (terminal ileum/ascending colon splenic flexure and rectum/sigmoid colon);  Local immunologic markers in three gastrointestinal tract tissues (terminal ileum/ascending colon splenic flexure and rectum/sigmoid colon)|20|NCT02218320|October 2014
515|Recruiting|Medical Home Care for Hematopoietic Stem Cell Transplantation Phase 2||Other:Patient-CenteredMedicalHome(PCMH);  Other:StandardCare|Interventional||Other|AcuteGraftVersusHostDisease(aGVHD);  RateofInfection;  DiseaseFreeSurvival(DFS);  OverallSurvival|180|NCT02218151|October 2014
516|Not yet recruiting|Pregnancy Eating Attributes Study|||Observational||NIH / Other / Industry|Bodyweight;  Dietaryintake|450|NCT02217462|October 2014
517|Completed|Improving Memory Performance by Applying Cognitive Training||Device:ActiveCognitiveTraining(ACT);  Device:Control(CON)|Interventional||Other|Changeinworkingmemory;  ChangeinDelaydiscounting|33|NCT02216591|August 2014
518|Unknown&nbsp;&#8224;|Comparative Efficacy and Safety of Two Ciprofloxacin 0.3% and Dexamethasone 0.1% Formulations in Subjects With Acute Otitis Externa||Drug:Ciprodex&#174;;  Drug: EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension|Interventional|Phase 3|Industry|ClinicalCureofAOE;  MicrobiologicalCure(MC)|500|NCT02216071|July 2014
519|Recruiting|Pasireotide in Prevention of GI Toxicity||Drug:Pasireotide+Chemo;  Drug:Pasireotide+TotalBodyIrradiation|Interventional|Phase 2|Other|Incidence of GI toxicity from the preparatory regimen and the GVHD prophylaxis in Stem Cell Transplantation (SCT) patients who are treated with pasireotide;  AcuteorchronicGVHD;  Citrulline and fecal calprotectin levels will be measured;  Evaluate GI toxicity assessment by video capsule endoscopy.|40|NCT02215070|February 2015
520|Recruiting|Treating Co-Occurring Substance Use and Mental Disorders Among Jail Inmates||Behavioral: Dual-diagnosis motivational interviewing (DDMI);  Behavioral:Integratedgrouptherapy(IGT);  Behavioral: Jail and community-based behavioral health services|Interventional|Phase 1 / Phase 2|Other|Acceptability;  Feasibility;  Fidelity;  Substanceuse;  Psychiatricsymptoms;  Healthstatus;  Serviceuse;  Externalizingbehaviors;  Qualityoflife;  Arrest;  Treatmentpreferences|72|NCT02214667|February 2015
521|Completed|The Effect of Prophylactic Antipyretics on Immune Responses and Fever After 2014-2015 and 2015-2016 Inactivated Influenza Vaccine||Drug:AcetaminophenArm;  Drug:PlaceboArm;  Drug:IbuprofenArm|Interventional|Phase 4|Other / U.S. Fed|Seroconversion;  Seroprotection;  GeometricmeanHAItiter|104|NCT02212990|September 2014
522|Completed                  Has Results|Comparison of Topical Skin Adhesive to Subcuticular Suture Closure of Implantable Port Incisions||Device:Octylcyanoacrylate;  Procedure:Suture|Interventional||Other|Number of Participants With Complication of Wound Dehiscence;  Number of Participants With Complication of Infection;  Healing-incision Cosmesis Score by Visual Analogue Scale;  ClosureTime;  ClosureMaterialsCost|109|NCT02212977|September 2014
523|Active not recruiting|Evidence-Based Tobacco Cessation Strategies in Patients With Cancer||Behavioral:smokingcessationintervention;  Other:surveyadministration;  Other:questionnaireadministration|Interventional||Other / NIH|Percentage of providers from the Piedmont Oncology Association (POA) reporting a need for training on evidence-based tobacco cessation strategies;  Percentage reporting feeling very confident in their ability to counsel smokers;  Percentage reporting they would be willing to participate in training on evidence-based tobacco cessation strategies;  Proportion of oncology patients willing to complete a survey in an oncology clinic;  Proportion of patients who report that their provider asked about tobacco use during their visit;  Proportion of current smokers who report that their provider advised them to quit during their visit and provided tobacco-cessation strategies|400|NCT02211196|February 2013
524|Active not recruiting|Electronic Medical Record Review in Monitoring the Effects of Adherence on Myelosuppression and Morbidity in Patients With Newly Diagnosed Brain Tumors Receiving Temozolomide and Radiation Therapy||Other:medicalchartreview|Observational||Other / NIH|Frequencyofnonadherence(retrospective);  Impact of nonadherence events on myelosuppression severity (retrospective);  Impact of nonadherence events on patient morbidity (retrospective);  Effect of an automated notification program on adherence rates (prospective)|240|NCT02208336|October 2010
525|Recruiting|A Validated Necrosis Assay to Determine the Need for Revision Surgery in Metal-on-metal Total Hip Arthroplasty|||Observational||Other|The number of patients with serum and synovial fluid biomarkers;  Thenumberofpatientswithtissuenecrosis|100|NCT02208271|August 2014
526|Completed|Heart Healthy Lenoir: Return of Results Study||Behavioral: Return of genomic results on cardiovascular disease risk|Interventional||Other / NIH|Changeinmotivation;  ChangeinEatingHabits;  ChangeinPhysicalActivity|135|NCT02208180|September 2014
527|Recruiting|Phase I Study of HIV 1 Antigen Expanded Specific T Cell Therapy||Biological:HXTCinfusion|Interventional|Phase 1|Other / NIH|Safety;  SecondarySafety|12|NCT02208167|January 2015
528|Completed|Variability in the Measurement of WBCT Between Blood Drawn From Indwelling Catheters and Direct Venipuncture||Drug: Blood drawn from indwelling catheters versus direct venipuncture|Interventional||Industry / Other|Whole blood clotting time results from blood drawn from indwelling catheters and direct venipuncture|10|NCT02207205|April 2014
529|Active not recruiting|The Interaction of Social Factors With Air Pollution||Other:CleanAir;  Other:Ozone|Interventional||U.S. Fed|Changesinheartratevariability;  Forcedexpiredvolumeinthefirstsecond(FEV1);  Indexofclotting/coagulationfactor;  ForcedVitalCapacity;  Indexofinflammatorymarkers;  Cortisol;  Cognitivefunctionperformance|40|NCT02206750|July 2014
530|Completed|Hydration Monitor Validation in Elderly||Device:HydrationMonitor|Observational||Industry / NIH / Other|To observe statistically significant changes in ultrasound velocity associated with normal daily variation of the individual hydration level of elderly|73|NCT02206633|November 2014
531|Completed|Using Hydration Monitor to Detect Changes in the Hydration Status Athletes||Device:HydrationMonitor|Observational||Industry / NIH / Other|To observe statistically significant changes in ultrasound velocity associated with acute dehydration|82|NCT02206581|October 2014
532|Completed|Trial of Naltrexone and Dextromethorphan for Gulf War Illness||Drug:naltrexone;  Drug:Dextromethorphan|Interventional|Phase 2|Other|SymptomsScores;  SF-36;  ConnorsContinuousPerformanceTest|60|NCT02206490|January 2012
533|Completed|Breast Health Education for Underserved Latino Women||Other:BreastHealthEducation|Interventional||Other|Change in baseline of breast cancer health literacy|250|NCT02205736|July 2014
534|Recruiting|Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer||Other:Biomarkeranalysis;  Drug:Administrationofradium-223|Interventional||Other / Industry|Change in proportion of patients who overexpress ALP in Circulating Tumor Cells (CTCs);  Change in biomarkers of epithelial plasticity and osteomimicry expressed in the CTCs and bone metastases of men with bone metastatic CRPC|20|NCT02204943|October 2014
535|Recruiting|Cochlear Implantation in Cases of Single-Sided Deafness||Device:CochlearImplant;  Other:ControlGroup|Interventional||Other / Industry|demonstrate effectiveness of cochlear implantation on speech perception;  demonstrate the effectiveness of cochlear implantation on localization;  demonstrate effectiveness of cochlear implantation on subjective benefit;  compare speech perception outcomes of cochlear implantation to that of current treatment options;  compare localization abilities of cochlear implantation to that of current treatment options;  compare subjective benefit of cochlear implantation to that of current treatment options|50|NCT02203305|October 2014
536|Recruiting|Multimodal Analgesia vs. Routine Care Pain Management for Lumbar Spine Fusion Surgery: A Prospective Randomized Study||Other:MultimodalAnalgesiaTreatment;  Other:StandardofCarePainManagementProtocol|Interventional|Phase 4|Other|Patient reported pain level using a verbal numeric pain scale (NPS);  Patientsatisfaction;  Narcoticconsumption;  Lengthofstay;  Dischargedestination;  OswestryDisabilityIndex(ODI);  TheVeteransRand12(VR-12)|124|NCT02202369|February 2015
537|Completed|Fatty Acids and Executive Function Development in 7-12 Year Olds|||Observational||Other|Error (count) and latency (in milliseconds) measures from executive function tasks;  Oxygenated and deoxygenated hemoglobin concentrations from near-infrared spectroscopy (NIRS);  Performance on the Maze as measured by Noldus Ethovision|79|NCT02199808|April 2014
538|Active not recruiting|Ankle Fracture vs Ankle Fracture-Dislocation|||Observational||Other|ChangeinFunctionalOutcome;  RadiographicOutcome|60|NCT02198768|September 2012
539|Completed|Pulsed Dye Laser in Treating Patients With Post Radiation Dysphonia||Procedure:lasertherapy;  Other:questionnaireadministration|Interventional||Other / NIH|Videostroboscopyrates;  ChangeinVoiceHandicapIndex(VHI)-10score;  Changeinjitter;  Voice quality using the patient self-assessment questionnaire;  Changeinshimmer;  Changeinnoisetoharmonicratio;  Changeinmeanphonatoryflow|9|NCT02198131|October 2009
540|Recruiting|Sex and Female Empowerment||Behavioral:Computer-adaptiveSAFE;  Behavioral:Face-to-faceSAFE;  Behavioral:UsualCare|Interventional||Other / NIH|InterventionSatisfaction;  ContraceptiveConsultationAppointment;  InterventionCompletion;  ContraceptiveMethodEffectiveness;  KnowledgeofReproduction;  KnowledgeofContraceptiveMethods;  ContraceptiveSelf-efficacyScale;  EffectiveContraceptiveBehavior;  Frequency of Use of Barrier Protection in past 30 days;  Number of Times Engaged in Unprotected Sex in past 30 days|90|NCT02197715|August 2014
541|Active not recruiting|Communication Effectiveness in Cancer Treatment||Other:questionnaireadministration;  Other:medicalchartreview|Observational||Other / NIH|Patient perceptions about the nature of their therapy and diagnosis;  Feasibilityasassessedbyaccrualrate;  Feasibilityasassessedbyparticipationrate;  Incidence of discrepancies between patient perceptions and the clinical record|100|NCT02197091|July 2014
542|Recruiting|IDH1 Peptide Vaccine for Recurrent Grade II Glioma||Biological:PEPIDH1Mvaccine|Interventional|Phase 1|Other|The proportion of patients with an unacceptable toxicity will be estimated.;  IFN&#947;ELIspotMeasurements|24|NCT02193347|December 2015
543|Terminated                  Has Results|TEA vs. PVB vs. PCA in Liver Resection Surgery||Device:thoracicepidural;  Device:continuousparavertebralcatheter;  Drug:Patient-ControlledAnalgesia|Interventional||Other|HighestVASPainScoreatRest;  HospitalLengthofStay;  GastrointestinalRecovery;  CumulativePostoperativeOpioidRequirement;  IncidenceofMajorPostoperativeComplication;  HighestVASPainScoresWithCoughing|10|NCT02192879|August 2014
544|Recruiting|The Effect of Walking on Fatigue After Chemotherapy in Patients 65 and Older||Behavioral:WalkWithEase|Interventional||Other|To measure change in fatigue scores between intervention and wait list control arms from baseline to three months.;  To measure change in fatigue scores between intervention and WLC arms from baseline to 3 months;  To report recruitment and retention in the study at 3 months;  To report recruitment and retention in the study at 6 months;  TomeasureimplementationofandadherencetoWWE;  Tocountthenumberofadverseevents;  To measure change in engagement of walking over time from baseline to three months.;  To measure change in physical function over time from baseline to three months.;  To measure change in quality of life over time from baseline to three months.;  To measure change in self-efficacy over time from baseline to three months.|150|NCT02191982|June 2014
545|Recruiting|Physical Activity Intervention for Older Patients During Chemotherapy for Colorectal Cancer||Behavioral:WalkWithEase|Interventional||Other|To measure the change in fatigue after three months between the intervention and control arm;  To measure changes in physical function at baseline between the intervention and control groups.;  To measure adherence to the physical activity intervention;  To measure the difference in p16INK4a levels before and after chemotherapy in the control and intervention groups;  To measure the change in muscle mass measurements before and after chemotherapy between the intervention and control arms;  To measure the association of p16INK4a and muscle mass with any differences in fatigue o physical function or QOL during chemotherapy;  To measure changes in Quality of Life at baseline between the intervention and control groups.;  To measure changes in ADLs at baseline between the intervention and control groups.;  To measure changes in Instrumental Activities of Daily Living at baseline between the intervention and control groups.;  To measure changes in Self-Efficacy at baseline between the intervention and control groups.|40|NCT02191969|June 2014
546|Recruiting|Technology to Enhance Treatment for Early Conduct Problems in Low Income Families||Behavioral:BehavioralParentTraining|Interventional||Other / NIH|Engagement;  Change in Disruptive Behavior from the start of treatment through 6 months after treatment ends;  TreatmentCost|102|NCT02191956|April 2013
547|Recruiting|Aromatherapy Using a Nasal Clip After Surgery||Other:Aromatherapyblend;  Other: Duration of effectiveness of the essential oil blend;  Other: Participant comfort using the nasal clip delivery system|Interventional||Industry / Other|Duration of effectiveness of the essential oil blend;  Participant comfort using the nasal clip delivery system|300|NCT02189980|June 2014
548|Active not recruiting|Improving Adherence to Recommended Surveillance in Breast Cancer Survivors||Behavioral:PsychosocialIntervention|Interventional||Other / NIH|Surveillanceadherence;  Gynecologicexamadherence;  Breastself-examadherence|100|NCT02189278|October 2013
549|Completed|Salivary Inflammatory Biomarkers: Predictors &amp; Comparative Effects of Sonicare/Elite-Flexcare in Stages of Perio Disease||Device:Sonicare/Elite-FlexcareToothbrush;  Device:ManualToothbrush|Interventional||Other / Industry|Change from baseline in (inflammatory biomarkers?) among a range of periodontal disease groups after using Sonicare Elite/Flexcare versus manual toothbrush for four weeks.;  Identification of salivary biomarkers that can distinguish between and among the 5 disease categories (health gingivitis and 3 levels of periodontal disease).|175|NCT02187185|April 2009
550|Completed|Effects of Wood Smoke Particles on Influenza-induced Nasal Inflammation in Normal Volunteers||Other:woodsmoke;  Other:cleanair|Interventional|Phase 0|Other / U.S. Fed / NIH|IL-13|39|NCT02183753|July 2014
551|Enrolling by invitation|Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor?||Drug:Acetaminophen;  Drug:Placebo|Interventional||Other|NeuraxialAnalgesicDrugconsumptionperhour;  rescuedoses;  maternaltemperature;  painscores;  patientsatisfaction|60|NCT02181387|September 2013
552|Enrolling by invitation|Sphenopalatine Ganglion Block for Post-Dural Puncture Headache||Drug:bupivacaine;  Drug:placebo|Interventional||Other|verbalpainscore;  epiduralbloodpatch;  patientsatisfaction;  painscore|30|NCT02181205|November 2014
553|Recruiting|Apixaban in Patients With Sickle Cell Disease||Drug:Apixaban;  Drug:Placebo|Interventional|Phase 3|Other / Industry|MeandailypainscoreinoutpatientswithSCD;  Change in thrombin generation from enrollment to 2 months following initiation of study drug.;  Comparison of daily pain scores while hospitalized between treatment arms;  Number of hospitalizations during each treatment period.|60|NCT02179177|January 2015
554|Enrolling by invitation|Outcome Study of Highly-cross Linked Polyethylene vs. Standard Polyethylene for Primary Posterior Stabilized (PS) Total Knee||Device:kneearthroplastystandardpolyethylene;  Device:kneearthroplastyXLPpolyethylene|Observational||Other / Industry|Number of Participants requiring revision or with Device Related Serious Adverse Events;  Radiographicosteolysis;  kneescores;  kneejointeffusion|500|NCT02178020|July 2009
555|Recruiting|Hepatitis C Alcohol Reduction Treatment||Behavioral:Briefalcoholcounseling;  Behavioral:GroupandIndividualTherapySessions|Interventional||Other / U.S. Fed|Alcohol abstinence rates at 6 months after consent;  Relapserateat12monthsafterconsent;  Otheralcoholuseindicators;  Illicitdruguse|230|NCT02176980|October 2014
556|Completed|Autologous Umbilical Cord Blood Infusion for Children With Autism Spectrum Disorder (ASD)||Biological:AutologousUmbilicalCordBlood|Interventional|Phase 1|Other / Industry|Number of participants with non-serious and serious adverse events.;  The primary efficacy measure will be change in the Vineland Adaptive Behavior Scale- II|25|NCT02176317|June 2014
557|Recruiting|Cutaneous Lupus Medication Experience Study||Drug:fluocinonide0.05%cream|Observational|Phase 0|Other|ChangeinAdherenceMeasures;  DiseaseSeverityMeasures|40|NCT02176148|December 2014
558|Recruiting|Comparison of the Sensitivity and Specificity of Acoustic Angiography to the Sensitivity and Specificity of Conventional Ultrasound||Device:AcousticAngiography|Interventional||Other / NIH|Sensitivityandspecificity(Percentage);  Area under the curve (AUC) of acoustic angiography;  Radiologistpreference;  Vesseltortuosity(Nounits);  Model-basedmalignancyscore(Arbitraryunits)|60|NCT02175628|June 2014
559|Terminated|CPI-613 Bendamustine Hydrochloride and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma||Drug:68-bis(benzylthio)octanoicacid;  Drug:bendamustinehydrochloride;  Biological:rituximab;  Other:laboratorybiomarkeranalysis|Interventional|Phase 1|Other / NIH|MTD of 68-bis(benzylthio)octanoic acid when used in combination with bendamustine hydrochloride and rituximab determined by dose-limiting toxicities graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE);  Response rate assessed by the modified IWG criteria;  Disease control rate assessed by the modified IWG criteria;  Overall survival assessed by the modified IWG criteria;  Progression free survival assessed by the modified IWG criteria;  Bonemarrowbiopsyanalysis;  Incidence of toxicities graded according to NCI CTCAE|1|NCT02168907|December 2014
560|Withdrawn|KeraStat Skin Therapy in Treating Radiation Dermatitis in Patients With Newly Diagnosed Stage 0-IIIA Breast Cancer||Procedure: dermatologic complications management/prevention;  Other:questionnaireadministration|Interventional||Other / NIH|Occurrence of any RT-induced EASR defined as a grade 4 or higher toxicity using the Modified Oncology Nursing Society Criteria for Radiation-Induced Acute Skin Toxicity|0|NCT02168179|December 2014
561|Recruiting|CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma||Drug:68-bis(benzylthio)octanoicacid;  Drug:bendamustinehydrochloride|Interventional|Phase 1|Other / NIH|MTD of 68-bis(benzylthio)octanoic acid when used in combination with bendamustine hydrochloride defined as the dose level immediately below the dose level that induced a dose-limiting toxicity in &lt; 2 patients;  RR derived from the modified IWG criteria and the International Cutaneous Lymphoma (Olsen criteria) for cutaneous lymphoma;  DCR derived from the modified IWG criteria and the International Cutaneous Lymphoma (Olsen criteria) for cutaneous lymphoma;  OS;  PFS;  Bonemarrowbiopsyassessment|14|NCT02168140|September 2014
562|Recruiting|The Impact of a Physical Activity Program on Biomarkers of Aging During Chemotherapy for Breast Cancer||Behavioral:WalkWithEase|Observational||Other|Compare the change in p16 from baseline to the end of chemotherapy for patients receiving a physical activity intervention to the historical value seen in a previous study;  Measure the association of change in physical activity levels with change in with p16 levels from baseline to end of chemo and baseline to 6-months post.;  Compare changes in p16 between patients who do and do not experience any grade 3/4 toxicities;  Predict changes in physical function fatigue and quality of life over;  Measure the association of change in physical activity levels with changes in physical function fatigue and quality of life measures;  Measure the association of change in p16 levels with changes in physical function fatigue and quality of life measures|48|NCT02167932|March 2014
563|Active not recruiting|Efficacy of Prostatic Artery Embolization (PAE) in Patients With Severe Benign Prostatic Hyperplasia (BPH)||Device:Microspheres|Interventional||Other|Prostatesize(grams);  Lowerurinarysymptoms(Arbitraryunits);  Procedure completion without complication (percentage);  SexualFunction(Arbitraryunits);  QualityofLife(Arbitraryunits)|15|NCT02167919|July 2014
564|Recruiting|Comparison of Combigan BID Versus Simbrinza TID||Drug:CombiganBID;  Drug:SimbrinzaTID|Interventional|Phase 4|Other / Industry|IntraOcularPressure;  Tolerability|40|NCT02167035|August 2014
565|Active not recruiting|APN401 in Treating Patients With Melanoma Kidney Cancer Pancreatic Cancer or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery||Biological: siRNA-transfected peripheral blood mononuclear cells APN401;  Other:laboratorybiomarkeranalysis|Interventional|Phase 1|Other / NIH|Maximum tolerated dose of siRNA-transfected peripheral blood mononuclear cells APN401 defined as the dose in which the number of patients with dose limiting toxicity is less than or equal to one out of six;  Incidence of adverse events of APN401 graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0;  Immune response measured by change in blood Th1-associated cytokines production in response to anti-CD3/28 stimulation or &gt;= tumor antigens post-therapy;  ClinicalresponseassessedbyRECIST;  Progression-freesurvival;  Overallsurvival|17|NCT02166255|December 2014
566|Recruiting|Cohort Study of Risk Reducing Salpingectomy||Procedure:Salpingectomy;  Procedure:Traditionalsterilization|Interventional||Other / Industry|PercentofwomenacceptingRRS;  PercentofwomenwithsuccessfulRRScompletion|50|NCT02165709|June 2014
567|Terminated|LCI-GU-BLA-SPEC-001: Aurora Kinase Expression in Muscle-Invasive Bladder Cancer|||Observational||Other|Correlation of pathologic response rate and aurora kinase expression|6|NCT02164942|June 2014
568|Recruiting|Comparison Study of Transversus Abdominal Plane Paravertebral and Epidural Blocks in Laparoscopic Colectomy||Procedure: Transversus Abdominis Plane (TAP) block with ropivacaine;  Drug:epiduralhydromorphone;  Procedure:ParavertebralBlock(PVB);  Drug:ropivacaine0.25%;  Drug:bupivacaine0.25%;  Drug: Midazolam up to 2 mg. Ppropofol 1-2.5 mg/kg. Dexamethasone 4 mg IV . Isevoflurane;  Drug:Acetaminophen1gIV|Interventional||Other|Postoperativeopioidconsumption;  Painscores;  Qualityofrecovery;  Complications;  Firstbowelmovement;  Opioidrelatedsideeffects;  Firstingestionofsolidfood|120|NCT02164929|December 2013
569|Active not recruiting|Effects of Exercise and Improved Nitric Oxide Bioavailability on Arteriovenous Fistula Maturation||Other:Handgriptraining;  Drug:Nitroglycerinointment|Interventional||Other / NIH|Improve rate of arteriovenous fistula (AVF) maturation;  Improvement in arteriovenous (AVF) patency rate at 3 months;  Improvement in rate of arteriovenous fistula (AVF) use for dialysis|11|NCT02164318|September 2014
570|Suspended|Study of Beet Juice for Patients With Sickle Cell Anemia||Drug:beetjuice(Unbeetable)|Interventional|Phase 2|Other / NIH|Total Number of Participants with Adverse Events as a Measure of Safety and Tolerability as a function of time;  Changes in Red blood cell properties as a function of time;  Changes in Platelet function as a function of time|24|NCT02162225|September 2014
571|Completed|Feasibility of Upright Bed Position in ARDS Patients||Other:InterventionArm|Interventional||Other|Number of participants with change in hemodynamic stability from baseline when placed in upright position;  Number of participants with change in Oxyhemoglobin Saturation from baseline when placed in upright position;  Number of participants with Change in Tidal Volume from baseline when placed in upright position;  Number of participants with change from baseline in Respiratory Rate when placed in upright position|10|NCT02160561|April 2013
572|Completed|Female Upper Genital Tract in HIV-infected Women||Procedure:Endometrialbiopsy|Observational||Other|Immunecharacteristics|26|NCT02160392|May 2010
573|Suspended|Effect of a Multimodal Pain Regimen on Pain Control Patient Satisfaction and Narcotic Use in Orthopaedic Trauma Patients||Drug:Gabapentin;  Drug:Acetaminophen;  Drug:Celecoxib;  Drug:Dexamethasone;  Drug:Oxycodone|Interventional|Phase 4|Other|Pain;  NarcoticUse;  PatientSatisfaction;  Patientfunction;  FractureUnion;  Adverseevents|160|NCT02160301|November 2017
574|Terminated                  Has Results|Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer||Drug:cisplatin;  Drug:Docetaxel;  Drug:Pegfilgrastim|Interventional|Phase 2|Other / Industry|InductionResponse;  Differential Gene Expression Between Responsive and Resistant Tumor Treated With Dose-dense Therapy;  NumberofGradeIII/IVHematologicAdverseEvents;  Number of Grade III/IV Non-hematologic Adverse Events;  Number of Patients Who Were Able to Maintain Hemoglobin Between 11-13 g/dL During Induction;  OverallSurvival|13|NCT02157116|May 2006
575|Completed|Omega 7 + 3 Combination and Systemic Inflammation||DietarySupplement:Omega7+3;  DietarySupplement:Omega3;  DietarySupplement:Placebo|Interventional||Other|Change in systemic inflammation as measured with CRP and cytokines;  Change in plasma lipoproteins (cholesterol triglycerides LDL-chol HDL-chol)|68|NCT02155816|May 2014
576|Recruiting|Pain Expectations in Subjects With Osteoarthritis||Drug:Modafinil;  Drug:Gabapentin;  Drug:Placebo|Interventional|Phase 4|Other|Restingpupildiameter|30|NCT02155257|July 2014
577|Completed|A Double-Blind Placebo-Controlled Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia||Drug:Armodafinil50-250mgpills|Interventional|Phase 2 / Phase 3|Other|ChangeinEpworthSleepinessScale;  Clinical Global Impressions change in severity of excessive daytime sleepiness (EDS);  Numberofnaps;  Numberofminutesnappedbasedonsleepdiary|27|NCT02151253|May 2011
578|Recruiting|Interleukin-2&#8212;Induced Cognitive/Affective/Sleep Symptoms|||Observational||Other|Participantenrollment;  Participantburnout|30|NCT02150369|February 2015
579|Completed|Trial of Two Techniques to Assess Postoperative Voiding Function||Procedure:ORretrogradefill|Interventional||Other|Comparison of the proportion of subjects who passed the voiding trial between the two groups;  Comparison of length of stay in post-anesthesia care unit between the two groups|59|NCT02150083|November 2011
580|Not yet recruiting|Limited Abdominal CT in ED Patients With Abdominal Pain||Other:noninterventionalstudy|Observational||Other|Diagnosistreatmentanddisposition;  radiationreduction|1000|NCT02146521|May 2016
581|Enrolling by invitation|Patient-centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research|||Observational||Other|Home-time(daysaliveandathome);  QualityofLife;  Death;  All-causereadmission;  Stroke/TIAreadmission;  Cardiovascularreadmission;  Bleedingreadmission|2000|NCT02146274|November 2013
582|Terminated|Low Pain Prediction in Cesarean Section Patients||Drug:duramorph;  Drug:placebo|Interventional||Other|pain;  itching;  nausea;  sedation|13|NCT02143141|November 2011
583|Terminated|Using Walk With Ease Walking Program With Men 65 and Older Being Treated for Prostate Cancer||Behavioral:WalkwithEase|Observational||Other|To measure the feasibility of implementing the WWE intervention among men age &gt;65 with a prostate cancer diagnosis;  Measuretherateofcompletionforstudysurveys|15|NCT02139774|October 2013
584|Not yet recruiting|Fentanyl Sublingual Spray for the Treatment of Acute Procedure-related Pain in a Monitored Setting||Drug:FentanylSublingualSpray(FSS);  Drug:PlaceboSublingualSpray(PSS)|Interventional|Phase 3|Industry|Pain scored on a scale from 0 to 10 where 0 = no pain and 10 = the most intense pain imaginable;  Sedation scored on a scale from 0 to 4 where 0 = awake/alert and 4 = unarousable|60|NCT02138409|June 2017
585|Recruiting|Correlation Study of Imaging Data Acquired During CABG With Data Acquired in the Cath Lab||Device:ComboMapXTGuidewire;  Procedure:&apos;SPY&apos;NIRFDuringOff-PumpCABG|Interventional||Other / Industry|CorrelationAnalysis|30|NCT02138305|December 2014
586|Withdrawn|Continuous Hemoglobin Monitoring: Detection of Acute Blood Loss - Accurate Timely and Cost-effective|||Observational||Other|Correlation of hemoglobin level measurement between continuous hemoglobin monitor and laboratory analysis|0|NCT02138175|January 2016
587|Completed|A Pilot Study of a Non-Invasive Neuromodulation Device for Treatment of Parkinson&apos;s Disease||Device: TNM (trade name) a form of Caloric Vestibular Stimulation|Interventional||Industry|Motor UPDRS score (Unified Parkinson&apos;s Disease Rating Scale);  EKGtorecordbeat-to-beat(R-R)intervaldata|6|NCT02134795|May 2014
588|Completed|Assessing Change in Short Term Therapy for Depression||Behavioral:self-systemtherapy;  Behavioral:cognitivetherapy|Interventional||Other|Change in Depressive symptoms - Beck Depression Inventory-II;  ChangeinAnxiety-BeckAnxietyInventory|56|NCT02134678|May 2011
589|Completed|Determining Relationships Among Maternity Stress &amp; Sleep|||Observational||Other|Feasibility of the study protocol during the prenatal phase. Feasibility will be defined by the successful completion of enrollment and stress testing lab visits in 13 out of the 15 participants designed per group.;  Feasibility with respect to the ability to retain participants / avoid attrition which will be defined as having at least 90% of participants who completed the prenatal phase of the study also complete one of the postpartum phone interviews.;  The investigators will test for group differences between women with or without depression histories in stress reactivity of cortisol [calculated using area under the curve (AUC)] to a mild psychosocial stressor paradigm.;  The investigators will test for group differences between women with or without depression histories in stress reactivity of adrenocorticotropic hormone ACTH [calculated using area under the curve (AUC)] to a mild psychosocial stressor paradigm.;  The investigators will use a two-group t-test or a Mann-Whitney-Wilcoxon test for non-normal distributions to test for group differences in prenatal depressive symptoms using the Endinburgh Postnatal Depression Scale (EPDS).;  The investigators will use a two-group t-test or a Mann-Whitney-Wilcoxon test for non-normal distributions to test for group differences in prenatal anxious symptoms using the Spielberger State-Trait Anxiety Inventory (STAI) trait version.;  The investigators will use a two-group t-test or a Mann-Whitney-Wilcoxon test for non-normal distributions to test for group differences in recent stressful life events (last 6 months) using the Life Events Scale (LES).;  The investigators will use a two-group t-test or a Mann-Whitney-Wilcoxon test for non-normal distributions to test for group differences in prenatal sleep quality (past 30 days) using the Pittsburgh Sleep Quality Index (PSQI).|17|NCT02133963|May 2014
590|Active not recruiting|Effects of Sequential Exposure to Nitrogen Dioxide and Ozone in Healthy Adult Human Volunteers.||Other:Ozone;  Other:Nitrogendioxide|Interventional||U.S. Fed|PulmonaryFunction;  HeartRateVariability|54|NCT02133586|January 2014
591|Recruiting|Use of Mobile Technology for Intensive Training in Medication Management||Behavioral:Videorecording;  Behavioral:MedicationAdministrationLog;  Behavioral:Education|Interventional||Other|Increaseadherencetomedicationregimen|50|NCT02133560|May 2014
592|Recruiting|Monocyte Phenotypic and Functional Differences||Biological:Blooddraw|Observational||Other|Variations in the intensity of cell surface receptor expression;  Diseaseprogression|90|NCT02132182|October 2014
593|Recruiting|Depression and Heart Failure Disease Progression|||Observational||Other|TimetoHospitalizationorDeath;  ChangeinQualityofLife;  ChangeinSelf-ManagementBehaviors;  ChangeinHeartFailureDiseaseBiomarkers|220|NCT02131428|November 2014
594|Completed|The Post-Vitrectomy Lenstatin&#8482; Study||DietarySupplement:Lenstatin;  Drug:Placebo|Interventional||Industry|PentacamNuclearDensityMeasurements|20|NCT02131194|June 2014
595|Withdrawn|Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide||Behavioral:Exercise|Interventional||Other|Change in lean mass between mCPRC patients undergoing a 12-week exercise intervention (intervention group) and mCPRC patients who do not undergo the exercise intervention (control group)|0|NCT02130947|April 2014
596|Completed|Examining the Effects of Neuromodulation on Glucose Metabolism in Type 2 Diabetes||Device:TNM(thermoneuromodulationdevice)|Interventional||Industry|Measurementofglycosylatedhemoglobin(A1c);  Measurementoflipidpanel;  Assessmentofqualityoflife;  Assessmentofmood;  Assessmentofdiabetesrelatedselfcare;  Feasibility and acceptability of the device as an intervention for the diabetes population|6|NCT02130401|June 2014
597|Recruiting|Stool Transplants to Treat Refractory Clostridium Difficile Colitis||Biological:fecalmicrobiota|Interventional|Phase 2|Other|RecurrentcolitisduetoClostridiumdifficile;  Tolerability of oral fecal microbiota transplantation;  Safetyoforalfecalmicrobiotatransplantation;  rate of repeat therapy for C. difficile colitis within 6 months of fecal microbiota transplantation.;  Rateofhospitalization;  Mortality;  Rateofadverseevents|10|NCT02127398|April 2016
598|Unknown&nbsp;&#8224;|Multivitamin Adherence Following Bariatric Surgery||Behavioral:WeeklyInternetsurveys|Interventional||Other|Adherencetomultivitamin|30|NCT02124889|April 2014
599|Completed|The Effect of Oral Carnitine Supplementation on MRS-derived Mitochondrial Function||Other:AcuteExercise|Interventional||Other / Industry|ChangeinAcylcarnitine/Carnitineratio;  ChangeinProteinacetylation;  ChangeinInsulinSensitivity;  ChangeinMitochondrialFunction|14|NCT02124590|June 2014
600|Not yet recruiting|Study to Assess Dopamine Receptor Modulation With Rotigotine to Enhance Morphine Analgesia in the Dental Model||Drug:Neupro&#174;transdermalpatch/placebo|Interventional|Phase 2|Other|Sumofpainintensitydifferencescores;  Analgesictabletstakenpostoperatively|50|NCT02123979|November 2015
601|Withdrawn|Exercise Heart Failure and Type 2 Diabetes||Behavioral:aerobicexercisetraining|Interventional||Other / NIH|exercisecapacity;  flow-mediateddilation;  nitritefluxduringexercise|0|NCT02122835|February 2012
602|Completed|Choline Dehydrogenase and Sperm Function: Effects of Betaine||Drug:Betainesupplement|Interventional|Phase 1|Other|Changeinspermmotilityfrombaseline;  Changeinspermcountfrombaseline;  Change in sperm mitochondrial function from baseline;  Changeinspermultrastructurefrombaseline;  Change in sperm choline dehydrogenase concentration from baseline;  Change in sperm betaine concentration from baseline;  Betaineintake;  Changeincompletebloodcountfrombaseline;  Changeinuricacidconcentrationfrombaseline;  Change in alkaline phosphatase concentration from baseline;  Change in aspartate transaminase concentration from baseline;  Change in lactic dehydrogenase concentration from baseline;  Changeinbilirubinconcentrationfrombaseline;  Change in blood urea nitrogen concentration from baseline;  Changeincreatinineconcentrationfrombaseline;  Changeinurinalysisparametersfrombaseline|6|NCT02122211|April 2014
603|Completed|Dynamics of the Microbiome in the Premature Infant|||Observational||Other|antigen identification of the infant microbiome over the first year of life|30|NCT02121938|April 2014
604|Recruiting|LNG-IUS at 2 Weeks Postpartum||Drug: Levonorgestrel Intrauterine System (LNG-IUS)|Interventional|Phase 4|Other|To report the acceptability of receiving an LNG-IUS two-weeks postpartum.;  To estimate the expulsion rate (complete or partial) at six months of LNG-IUS placed at two-weeks postpartum.;  To assess the pain experience of LNG-IUS insertion.|50|NCT02121067|September 2014
605|Completed|Comparative Effectiveness of Ambulatory Blood Pressure Monitoring vs Usual Care for Diagnosing and Managing Hypertension: A Pilot Study||Drug:Amlodipine;  Drug:Chlorthalidone;  Drug:Losartan|Interventional||Other|24 hour blood pressure average at the end of 4 month participation.|28|NCT02121041|May 2014
606|Withdrawn|A Randomized Comparison of AmnioClear&#8482; Human Allograft Amniotic Membrane vs. Moist Wound Dressing in the Treatment of Diabetic Wounds||Biological: AmnioClear&#8482; Human Allograft Amniotic Membrane|Interventional|Phase 4|Industry|ReductioninWoundSize|0|NCT02120755|
607|Active not recruiting|Feasibility of Heart Rate Variability Biofeedback With Impatient Pregnant Women at UNC-CH||Device: Heart Rate Variability Biofeedback emWave too;  Behavioral:useofemWaveTechnology(Heartmath)|Interventional||Other|Feasibility of using HRVB among hospitalized pregnant women;  Association between use of HRVB and maternal state anxiety;  AssociationbetweenHRVBandHigh-FrequencyHRVB;  Effectiveness of HRVB in women with varying levels of clinical depression and anxiety|30|NCT02119936|May 2014
608|Recruiting|Aneuploidy Rates in Advanced Maternal Age Patients Supplemented With Coenzyme Q10 (CoQ10) Versus Those That Are Not: a Pilot Study||DietarySupplement:CoQ10;  DietarySupplement:Placebo|Interventional||Other|EmbryomitochondrialDNA(mtDNA);  preimplantationchromosomalaneuploidy|30|NCT02119117|April 2014
609|Completed|Modulation of Insulin Sensitivity by Betaine Upregulation of FGF21||DietarySupplement:Betaine;  DietarySupplement:Dextrose|Interventional||Other|Plasma Fetal Growth Factor 21 (FGF21) concentration;  Plasmacholineconcentration;  Plasmabetaineconcentration;  Plasmaglucoseconcentration;  Plasmainsulinconcentration;  Plasmaadiponectinconcentration;  Typicaldietaryintake;  Typicalexercisehabits|23|NCT02118142|March 2014
610|Active not recruiting|Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer||Biological:PF-03446962;  Drug:Regorafenib|Interventional|Phase 1|Other / Industry|Recommended phase II dose (RPTD) for the combination of PF-03446962 plus regorafenib;  To evaluate the safety and tolerability of PF 03446962 administered in combination with regorafenib;  ResponserateofPF03446962plusregorafenib;  Progression free survival associated with PF 03446962 plus with regorafenib|24|NCT02116894|August 2014
611|Completed|Mobile Sensing of Smoking Behavior||Behavioral:48hoursmokingabstinence;  Other:Smartphone|Interventional||Other|Change in smoking behaviors as measured by an algorithm of social variables;  Change in smoking behaviors as measured by an algorithm of motion variables;  Change in smoking behaviors as measured by an algorithm of environmental variables;  Change in smoking behaviors as measured by an algorithm of device interaction variables;  Change in smoking behaviors as measured by an algorithm of positioning variables|2|NCT02116283|March 2014
612|Active not recruiting|Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma||Drug:Ipilimumab|Interventional|Phase 1|Other|Safetyandtolerability;  ResponseRate;  ProgressionFreeSurvival|44|NCT02115243|May 2014
613|Withdrawn|Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant||Biological:LMP2A-loadedconventionalDCvaccine;  Biological:DUK-CPG-001|Interventional|Phase 2|Other|Immuneresponse;  Number of patients with greater than grade 1 toxicity;  Duration of the presence of long term memory cells;  Durationofmulti-functionalCD8Tcellresponses;  Duration of Th1 Th2 and Th17 cluster of differentiation 4 (CD4) T cell responses as well as CD4+cluster of differentiation 25 (CD25)+Foxp3+ regulatory T cell (Treg) responses;  Diseasefreesurvival|0|NCT02115126|December 2016
614|Unknown&nbsp;&#8224;|A Family-Based Diabetes Intervention for Hispanic Adults in an Emerging Community||Behavioral: Experimental: Diabetes Self Management;  Behavioral:GeneralHealthEducation|Interventional||Other / NIH|HemoglobinA1C(HbA1C);  Behavioral outcomes of self-reported management of diabetes;  Health-relatedqualityoflife;  Diabetesknowledge;  Familysupport;  DiabetesSelf-efficacy|156|NCT02114814|November 2011
615|Completed|Improving Survivorship Care Through Enhanced Communication and Coordination: Pilot Study||Behavioral:SurvivorshipCarePlan(SCP);  Behavioral:CoordinatedPCPvisit|Interventional||Other|Number of participants with increased patient confidence about Survivorship Care;  PatientActivationScore;  Number of providers with increased confidence about survivorship|37|NCT02111616|December 2013
616|Completed                  Has Results|Non-Inferiority Study Comparing 3 Weekly Injections of SUPARTZ&#174; vs 3 Weekly Injections of Euflexxa&#174; for Knee OA||Device:Supartz;  Device:Euflexxa|Interventional|Phase 3|Industry|WOMAC VAS (0:None -100:Extreme) Pain Subscale Score Change From Baseline|421|NCT02110238|March 2014
617|Recruiting|Low-Dose Total Lymphoid Irradiation in Treating Patients With Refractory Chronic Graft-versus-Host Disease After Donor Stem Cell Transplant||Radiation:totalnodalirradiation;  Other:laboratorybiomarkeranalysis;  Other:questionnaireadministration|Interventional|Phase 1|Other / NIH|Incidence of adverse events scored as per Common Toxicity Criteria version 4.0;  Failure Free Survival (FFS) as assessed by scoring for chronic GvHD - specific core measures;  Immunomodulatory/immuno-suppressiveeffects|30|NCT02109809|July 2014
618|Completed|A 7-Day Cross-over Study of QD and BID TD-4208 in COPD||Drug:TD-4208;  Drug:Placebo|Interventional|Phase 2|Industry|Weightedmean(0-24)FEV1;  Adverseevents;  AUC FEV1 and derived weighted means for various timeframes;  SerialFEV1;  TroughFEV1;  Time to achieve 100 mL and 120 mL increase in FEV1 from baseline after the 1st dose;  Albuteroluse|64|NCT02109172|April 2014
619|Unknown&nbsp;&#8224;|Annex&#8482; Adjacent Level System for Treatment of Adjacent Level Disease||Device:Annex&#8482;AdjacentLevelSystem|Observational||Industry|% Improvement in Operative/Discharge parameters including surgical time and hospital stay;  Surgical Complication rate compared to retrospective chart review;  %PainreductiononVAS;  %ImprovementinDisabilityusingODI;  %ImprovementinQualityofLifeusingSF-36;  %PatientSatisfactionwithprocedure|60|NCT02108249|April 2014
620|Enrolling by invitation|Non-Endoscopic Surveillance for Barrett&apos;s Esophagus Following Ablative Therapy|||Observational||Other / NIH|CytospongeAcceptability;  CytospongePerformance|374|NCT02106910|October 2014
621|Completed|Clinical Evaluation of Total-Etch and Self-Etch Dental Adhesives - 6 Year Recall|||Observational||Other / Industry|Change from baseline to 6-year follow-up in retention.;  Change from baseline to 6-year follow-up in color match.|30|NCT02105896|November 2013
622|Active not recruiting|Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled LPS||Drug:GammaTocopherol700mgcapsules;  Drug:Placebo|Interventional|Phase 1 / Phase 2|Other / NIH|comparison of sputum PMNs associated with CCRE challenge as affected by gamma tocopherol;  Delta in MCC associated with CCRE challenge as affected by gamma tocopherol;  chronic eosinophilic airway inflammation as affected by gamma tocopherol;  DeltainMCCassociatedbygammatocopherol|15|NCT02104505|July 2014
623|Recruiting|A Risky Sex Prevention Intervention for Middle School Age Minority Girls||Behavioral: Education activities empowerment racial pride building;  Behavioral:GeneralHealtheducationactivities|Interventional||Other|RiskySexBehaviors;  HIVKnowledge;  Mother-DaughterCommunication/Bonding;  RacialPride;  Self-Esteem;  Empowerment;  SexualAssertiveness;  MotherSexualSelf-Efficacy|215|NCT02103218|November 2012
624|Completed|Anti-thrombin III (ATIII) vs Placebo in Children (&lt;7mo) Undergoing Open Congenital Cardiac Surgery||Drug:Anti-thrombinIII;  Other:Placebo|Interventional|Phase 2|Other / Industry|Decreased activation of the coagulation and fibrinolytic systems;  Totaldoseofheparinandprotamine;  Totalvolumeofbloodproducts;  Time from protamine administration to skin dressing;  Volumeofpostoperativebloodloss;  Volumeofbloodproducts;  Useofrecombinantfactor7a(VIIa);  Lengthofpostoperativeventilation;  SafetyprofileofATIIIdosing|40|NCT02103114|June 2014
625|Enrolling by invitation|Phenylephrine Dose and Mode of Administration for Spinal Anesthesia Induced Hypotension||Drug:Phenylephrine|Interventional||Other|Magnitudeofcardiacoutputchanges;  providerintervention;  vasopressorrequirement;  Emeticsymptoms;  hypertension;  hypotension;  bradycardia;  Anesthetictime|75|NCT02101047|August 2015
626|Recruiting|Efficacy of Intrathecal Oxytocin in Patients With Neuropathic Pain||Drug:oxytocin100micrograms;  Drug:NormalSaline(preservativefree)|Interventional|Phase 2|Other|Pain|40|NCT02100956|April 2014
627|Recruiting|Exhaled NO as a Biomarker of Gestational OSA and Persistence Postpartum|||Observational||Other|Difference in incidence of Obstructive Sleep Apnea (OSA)|65|NCT02100943|March 2014
628|Suspended|A Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI)||Drug:NNZ-2566;  Drug:Placebo|Interventional|Phase 2|Industry|Cognitive Function - Automated Neuropsychological Assessment Metrics (ANAM);  General Clinical Status - Clinical Global Impression of Severity and Improvement (CGI-S CGI-I);  Post-InjurySymptoms;  PosturalStability;  PsychologicalSequelae;  Change in subject&apos;s readiness and fitness to return to work as measured by the Return-to-Duty Assessment;  ResidualFunctionalDisability;  Safety;  Pharmacodynamic Measurements of Protein Biomarkers and micro-RNA;  Pharmacokinetic (PK) Measurements - maximum observed concentration (Cmax) trough concentration (Cmin)and area under the concentration-time curve (AUC) at steady-state|132|NCT02100150|September 2014
629|Completed|Older Cancer Caregiver Needs Post Hospital Discharge|||Observational||Other|Unmetcancercaregiverneeds;  Caregiverstrategiesassistingincaregivingrole;  Caregiver decision making in seeking assistance for cancer patient;  Caregiverneedsandpreferencesvarywithtime|23|NCT02099526|June 2014
630|Completed|The Mobile Health Platform||Device:TheMobileHealthPlatform|Interventional||Other|Change in the Acceptance and use of technology survey;  Perception of perceived usefulness attitudes and experiences|6|NCT02099513|March 2014
631|Completed|Trial of a Sugar-Sweetened Beverage Intervention in Overweight Mothers and Their Children Ages 3-5||Behavioral:SmartMomsIntervention|Interventional||Other|Change in child sugar-sweetened beverage consumption from baseline to 6 months;  Change in maternal caloric beverage consumption from baseline to 3 months;  Change in maternal weight from baseline to 6 months|51|NCT02098902|May 2014
632|Completed|Auditory Masking Effects on Speech Fluency in Aphasia and Apraxia of Speech||Behavioral:NormalAuditoryFeedback;  Behavioral:MaskedAuditoryFeedback;  Behavioral:AlteredAuditoryFeedback|Observational||Other / NIH|Disfluencydurationchangewithmaskingnoise;  Speechratechangewithmaskingnoise;  Speechsoundaccuracychangewithmaskingnoise|46|NCT02094014|March 2014
633|Completed                  Has Results|Health Coaching for Glaucoma Patients||Behavioral:HealthCoach|Interventional||Other|GlaucomaMedicationAdherence|9|NCT02090777|May 2014
634|Completed|Triceps Surae Trigger Point Size and Muscle Extensibility||Procedure:DryNeedling;  Procedure:Stretching|Interventional||Other|ChangeofAnkleDorsiflexionRangeOfMotion;  ChangeinAnkleDorsiflexionRangeofMotion;  ChangeinY-BalanceTestfortheLowerQuarter;  ChangeinYBalanceTestfortheLowerQuarter|30|NCT02087969|April 2014
635|Completed|Scapular Stabilization During Manual Horizontal Adduction Stretches and Its Effect on Increasing Posterior Shoulder Flexibility||Other: horizontal adduction stretch with scapular stabilization;  Other: Horizontal adduction stretch without scapular stabilization|Interventional||Other / Industry|ChangeinPosteriorShoulderTightness;  ChangeinInternalRotation|60|NCT02085200|June 2013
636|No longer available|Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use)||Biological: Enriched Hematopoetic Stem Cell Transplant|Expanded Access||Other|||NCT02084121|
637|Enrolling by invitation|Nonconvulsive Seizure Identification on Quantitative EEG by Neuro ICU Nurses|||Observational||Other|Sensitivity of nurses ability to detect recurrent NCS on QEEG;  Specificity of nurses ability to detect recurrent NCS on QEEG|30|NCT02082873|January 2015
638|Recruiting|Evaluating Quality of Life in Patients With Soft Tissue Sarcoma Presenting With Metastatic Lung Disease|||Observational||Other|Change in QoL score using patient-response questionnaire|100|NCT02080897|March 2014
639|Completed|Effects of a Cocoa Shot on the Human Brain 2||DietarySupplement:nocaffeine;  DietarySupplement:highcaffeine;  DietarySupplement:notheobromine;  DietarySupplement:lowtheobromine;  DietarySupplement:hightheobromine|Interventional|Phase 1|Other / Industry|ChangeinWorkingMemory(%correct);  ChangeinResponseTime(milliseconds);  ChangeinShortTermMemory(#correct);  ChangeinMood(changeinLikertscalescore);  ChangeinAttention(%accuracy);  ChangeinExecutiveFunction(#correct);  ChangeinBrainBloodFlow(ml/g/min);  %ChangeinHeartRate(beats/minute);  %ChangeinBloodPressure(mmHg);  ChangeinRespiration(breaths/minute)|24|NCT02080845|March 2014
640|Recruiting|Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)||Device: Mesenchymal-marker based ferrofluid (c-MET);  Device: Epithelial cell adhesion molecule (EpCAM) ferrofluid|Interventional||Other / Industry|Feasibility;  DifferenceinthemediannumberofCTCs;  Association of the number of detectable CTCs with baseline clinical and pathologic disease characteristics.;  Kinetics of CTCs over time during treatment with c-MET targeted therapies|85|NCT02080650|March 2014
641|Recruiting|Ambrisentan in Single Ventricle||Drug:Ambrisentan;  Other:Placebo|Interventional|Phase 2|Other|PlasmaconcentrationofAmbrisentan;  Amount and duration of chest tube drainage post Fontan Operation;  Changeinhemodynamicparameters;  Safety|20|NCT02080637|July 2015
642|Completed|Impact of Weight Loss on Physical Function||Behavioral:Moderateintensityweightloss;  Behavioral:Highintensitymedicalweightloss|Interventional||Other / Industry|Change in Short Physical Performance Battery (SPPB)|28|NCT02079051|February 2014
643|Completed|Efficacy of Belatacept in Reducing DSA||Drug:Belatacept|Interventional|Phase 4|Other|ReductionofDonorSpecificAntibodies(DSA);  AssessingSafety|3|NCT02078193|November 2013
644|Withdrawn|Heart Failure and Regional Specific Exercise Training Stimulus||Other:RegionalSpecificTraining(RSTS)|Interventional||Other|SubjectAdherence&amp;Compliance;  OneRepetitionMaximum(1RM);  SeniorFitnessTest|0|NCT02077426|June 2014
645|Completed|Effect of Compression Garments on Exercise Performance Following Acute High Intensity Exercise||Device:FarInfraredFabric;  Device:Spandex|Interventional||Other|Maximalvoluntarycontraction(MVC);  CreatineKinase|81|NCT02076334|February 2014
646|Recruiting|Integrated Approaches for Identifying Molecular Targets in Alcoholic Hepatitis|||Observational||Other / NIH|DiagnosisandSeverityofAlcoholicHepatitis;  MajorLiverComplications;  Death/Transplantation|700|NCT02075918|May 2014
647|Completed|Mushroom Blend on Oxygen Kinetics||DietarySupplement:MushroomBlend;  DietarySupplement:Placebo|Interventional||Other|Oxygenkinetics;  CriticalPower;  Lactate;  Cortisol;  MaximalOxygenConsumption|28|NCT02075892|August 2014
648|Recruiting|Evaluation of the Lung Nodule Sensitivity of Stationary Chest Tomosynthesis in Patients With Known Lung Nodules||Device:StationaryDigitalChestTomosynthesis|Interventional||Other|Specificity(percentage);  Specificityofs-DCT(percentage);  Readerpreference(arbitraryunits)_|100|NCT02075320|February 2014
649|Terminated                  Has Results|Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects||Biological:BVS857;  Other:placebo|Interventional|Phase 2|Industry|Number of Patients With Adverse Events as a Measure of Safety and Tolerability;  Efficacy Measure by Change in Lean Body Mass (LBM);  Serum Pharmacokinetics (PK) of BVS857: Cmax; The Observed Maximum Plasma (or Serum or Blood) Concentration Following Drug Administration;  Serum Pharmacokinetics (PK) of BVS857: Tmax; The Time to Reach the Maximum Concentration After Drug Administration;  Serum Pharmacokinetics (PK) of BVS857: AUClast; The Area Under the Plasma (or Serum or Blood) Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration;  Serum Pharmacokinetics (PK) of BVS857: AUCinf; The Area Under the Plasma (or Serum or Blood) Concentration-time Curve From Time Zero to Infinity;  Serum Pharmacokinetics (PK) of BVS857: T1/2; The Terminal Elimination Half-life;  Serum Pharmacokinetics (PK) of BVS857: CL; The Systemic (or Total Body) Clearance From Plasma (or Serum or Blood) Following Intravenous Administration;  Serum Pharmacokinetics (PK) of BVS857: Vz; The Volume of Distribution During the Terminal Elimination Phase Following Intravenous Administration;  Serum Pharmacokinetics (PK) of BVS857: Vss; The Volume of Distribution at Steady State Following Intravenous Administration;  Serum Pharmacokinetics (PK) of BVS857: Vz/F; The Apparent Volume of Distribution During the Terminal Elimination Phase Following Extravascular Administration;  Serum Pharmacokinetics (PK) of BVS857: CL/F; The Apparent Systemic (or Total Body) Clearance From Plasma (or Serum or Blood) Following Extravascular Administration|1|NCT02074995|February 2014
650|Enrolling by invitation|The Effect of Rivaroxaban in Sickle Cell Disease||Drug:rivaroxaban;  Drug:placebo|Interventional|Phase 2|Other / NIH|Change from baseline to 4 weeks in soluble vascular cell adhesion molecule-1 (VCAM-1) and interleukin-6 (IL-6);  Change from Baseline to Week 4 in other plasma markers of inflammation.;  Change from baseline to Week 4 in other markers of endothelial cell (EC) activation.;  Change from baseline to Week 4 in microvascular blood flow;  Change from baseline to Week 4 in markers of coagulation activation.|34|NCT02072668|February 2014
651|Completed|Mobile App Based Personalized Solutions and Tools for Medication Adherence of Rx Pills||Other:mSMARTsmartphoneapplication|Observational||Other / Industry / NIH|Percentage of alarms emitted by msmart app that subjects respond to.;  Likertresponsescore;  Percentageofstudyparticipantattrition.|11|NCT02072005|February 2014
652|Completed|Testing Methods of Self-persuasion Involving Cigarette Smoking||Behavioral:MotivationalInterviewing;  Behavioral:TailoredFeedback|Interventional||Other|Number of messages generated during in-person visit;  Qualityofmessages|48|NCT02069483|April 2014
653|Recruiting|BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent||Drug:Ciprofloxacin;  Drug:Placebo|Interventional|Phase 3|Other / NIH|(BK)Virusreplicationandshedding;  Salivaryfunction|20|NCT02068846|February 2014
654|Withdrawn|A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma||Drug:VemurafenibandTrientine|Interventional|Phase 1|Other|MaximumToleratedDose;  OverallResponse;  ProgressionFreeSurvival(PFS);  OverallSurvival(OS);  The change in phosphorylated Erk kinase activity relative to total Erk kinase activity;  The change in phosphorylated MEK kinase activity relative to total MEK kinase activity;  The change in the expression of the copper transporter CTR1;  Incidence of hyperproliferative skin lesions specifically cutaneous squamous cell carcinomas and keratoacanthomas|0|NCT02068079|April 2014
655|Recruiting|Reducing Lung Cancer Survivors&apos; Anxiety and Dyspnea (RELAX)||Device: Group A - Device guided breathing low dose;  Device: Group B - Device guided breathing high dose;  Device:GroupC-UsualBreathingControlGroup|Interventional||Other / NIH|Change from baseline HADS- Anxiety Assessed 4 weeks post-randomization;  Changefrom4weeksHADS-Anxietyat8weeks|75|NCT02063828|January 2015
656|Withdrawn|The Use of Thromboelastometry (ROTEM) to Evaluate the Changes in Coagulation With Two Different Doses of Oxytocin Following Cesarean Delivery||Drug:Oxytocin|Interventional||Other|coagulationasassessedbyROTEM;  cardiacoutputchangeswithoxytocin;  incidenceofnauseaandvomitingwithoxytocin;  estimated blood loss with different doses of oxytocin;  changesinbloodpressurewithoxytocin|0|NCT02063568|January 2015
657|Unknown&nbsp;&#8224;|Hispanic Community Health Study / Study of Latinos|||Observational||NIH|Prevalence of cardiovascular and pulmonary disease risk factors in Hispanics/Latinos|16400|NCT02060344|January 2006
658|Completed|Normal Eyelid Sensation Distribution||Device:Aesthesiometer|Interventional||Other|Eyelids&apos;sensationdistribution|30|NCT02059824|March 2014
659|Completed|Efficacy and Safety of the DASH Diet in Adults With Moderate Chronic Kidney Disease: Pilot Study||Other:DASHDiet;  Other:ControlDiet|Interventional||Other|Changeinofficesystolicbloodpressure;  Changeinserumpotassium|42|NCT02059811|February 2014
660|Withdrawn|Use of Recombinant Hyaluronidase Human is Effective for the Use of Local Blocks for Eyelid&apos;s Surgery||Drug:Hyaluronidase;  Other: 2 mL of lidocaine 2% with epinephrine 1:100000 without rHuPH20|Interventional||Other|Painsensation;  Anesthesiaduration|0|NCT02059694|
661|Terminated|Ammonia Levels and Cognitive Impairment|||Observational||Other|Changeinbloodammonialevel;  Changeinmini-statusexamination|17|NCT02059356|January 2014
662|Completed|Pharmacokinetics of Dexmedetomidine in Children During Cardiopulmonary Bypass (CPB)|||Observational||Other|Plasma pharmacokinetics (clearance volume of distribution area under the curve oxygenator extraction efficiency) of dexmedetomidine in children supported with cardiopulmonary bypass;  COMFORT behavioral score as a measure of dexmedetomidine pharmacodynamics;  Accessory sedative and analgesic use as a measure of dexmedetomidine pharmacodynamics|18|NCT02059343|March 2014
663|Recruiting|Intravenous Exenatide in Patients With Acute Brain Injury||Drug:Exenatide|Interventional|Phase 4|Other / Industry|Feasibility defined as the proportion of patients 1) experiencing severe hypoglycemia (&lt;40 mg/dL); 2) achieving glucose measurements within goal (110-180 mg/dL); and 3) experiencing nausea requiring discontinuation of exenatide therapy;  Mean glucose concentration during exenatide infusion;  Number of glucose measurements within goal (110-180 mg/dL)/total number of glucose measurements;  Mean time to reach glucose measurements within goal (110-180 mg/dL);  Glycemic variability defined as the standard deviation of glucose;  Meaninsulinuse(units/kgbodyweight);  Proportion of subjects requiring rescue insulin infusion protocol;  Number of hypoglycemic episodes (&lt;80 mg/dL)/total number of glucose measurements;  Number of subjects with &gt;1 episode of hypoglycemia (&lt;80 mg/dL)/total number of subjects;  Proportion of patients experiencing metabolic crisis defined as cerebral microdialysate glucose concentration &lt;0.7 mmol/L in combination with lactate pyruvate ratio &gt;40;  Mean daily intracranial and cerebral perfusion pressures;  Number of hypotensive episodes (SBP&lt;100 mmHg)/total number of blood pressure measurements;  Proportion of patients experiencing serious adverse events;  Pharmacokinetics of exenatide infusion defined as the correlation of exenatide concentrations with creatinine clearance|24|NCT02058940|August 2015
664|Recruiting|Botulinum Toxin for the Management of Chronic Orchialgia||Drug:BotoxInjection;  Procedure:Normalsalineinjection|Interventional|Phase 2|Other / Industry|VisualAnalogScaleforPainScore;  VisualAnalogScaleforPainscore;  QualityofLifeQuestionnaireScore;  UnitsofAnalgesicsUsedforTesticularPain|50|NCT02058836|November 2014
665|Recruiting|Impact of Oral Antibiotic Treatment on C. Difficile||Drug:Fidaxomicin;  Drug:Metronidazole;  Drug:Vancomycin|Observational|Phase 4|Other|Change in variation of the profile of C. difficile isolated from specific body sites of a patient with microbiology-proven CDAD;  Change in variation in the profile of C. difficile isolated from targeted surfaces in a hospital;  Extent and quantity of C. difficile shedding colonization and environmental contamination in patients who received oral fidaxomicin vs. oral metronidazole or vancomycin;  DurationofdiarrheathatwerepositiveforCDAD|30|NCT02057198|February 2014
666|Completed|Effects of Protein Supplementation on Lean Body Mass Recovery From Extreme Military Training||Dietary Supplement: Protein High-Protein and Control|Interventional||U.S. Fed|Change in lean body mass following SERE and recovery nutrition|71|NCT02057094|January 2014
667|Active not recruiting|HEART Pathway Implementation|||Observational||Other|Hospitalizationrate|14717|NCT02056964|November 2013
668|Recruiting|Treating NSCLC Minimal Stage IV With Curative Intent||Other: Induction chemotherapy and concurrent radiation;  Other: Consolidation: Radiation therapy to metastatic sites|Interventional|Phase 2|Other|Overallsurvival;  Newmetastaticdisease|20|NCT02054819|June 2013
669|Recruiting|Improving Diabetes Outcomes for Persons With Severe Mental Illness||Behavioral: Diabetes self-management and education|Interventional||Other|Changes in knowledge of diabetes self-management from baseline to six months as evidenced by scores on the Stanford Diabetes Self-Management Questionnaire.;  Changes in HBA1c values from baseline to six months.;  Changes in diabetes self-efficacy from baseline to six months as evidenced by scores on the Stanford Diabetes Self-Efficacy Questionnaire.;  Changes in eating self-efficacy from baseline to six months as evidenced by scores on a standardized measure of eating self-efficacy.;  Changes in exercise self-efficacy from baseline to six months as evidenced by scores on a standardized measure of exercise self-efficacy.;  Changes in healthy lifestyle activities from baseline to six months as evidenced by scores on a standardized measure of adult health behavior.;  Changes in health promoting activities from baseline to six months as evidenced by scores on a standardized measure of health promoting lifestyle activities.;  Changes in waist circumference from baseline to six months.;  Changes in triceps circumference from baseline to six months.;  Changes in subscapular skinfold measurement from baseline to 6 months.;  Changes in body mass index from baseline to six months.;  Changes in diastolic and systolic blood pressure from baseline to six months.|25|NCT02053714|December 2013
670|Completed                  Has Results|A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions||Drug:3%BenzoylPeroxide;  Drug:3%BenzoylPeroxidePlacebo;  Drug:NeutrogenaRapidClear&#174;|Interventional|Phase 4|Industry|To Assess the Percentage Change in Acne Lesion Swelling (Height) of the Target Lesion for 3% Benzoyl Peroxide (BPO) Gel Test Product Relative to the Vehicle Gel After 4 Once-daily Applications.;  To Assess the Percentage Change in Acne Lesion Swelling (Height) for the 3% Benzoyl Peroxide Gel Test Product and Positive Control Relative to the Vehicle Gel.;  To Assess the Change in Acne Lesion Redness (Erythema) for the 3% BPO Gel Test Product and Positive Control Relative to the Vehicle Gel.;  To Assess the Percentage Change in Acne Lesion Diameter (Size) for the 3% BPO Gel Test Product and Positive Control Relative to the Vehicle Gel.;  To Assess the Change in Facial Skin Clarity for the 3% BPO Gel Test Product and Positive Control Relative to the Vehicle Gel;  To Assess the Change in Perceptions of the Overall Appearance of Their Skin for the 3% BPO Gel Test Product and Positive Control Relative to the Vehicle Gel|90|NCT02052752|February 2014
671|Withdrawn|School Reintegration After Pediatric Hematopoietic Stem Cell Transplant|||Observational||Other|Psychosocialissues;  Culturalandenvironmentalissues|0|NCT02052570|January 2014
672|Completed                  Has Results|Study of Gralise to Treat Fibromyalgia Patients||Drug:GabapentinER|Interventional||Other / Industry|NumericPainRatingSystem(NPRS);  MedicalOutcomeStudy(MOS)SleepQuestionnaires;  SelfReportedSideEffects.;  FibromyalgiaImpactQuestionnaire(FIQ)|34|NCT02052414|July 2012
673|Completed|Novel Drug Delivery Technique Via Retroject Device||Device:RetrojectDeviceonly;  Device: Retroject device with ethacrynic acid injection;  Other:ethacrynicacidorbalancedsaltsolution|Interventional|Phase 1 / Phase 2|Other|Change in Intraocular pressures (IOP) lowering effect|9|NCT02051946|May 2014
674|Terminated|The Effect of Botulinum Toxin A Injections on Ankle Dorsiflexion Following Internal Fixation of Tibial Pilon Fractures||Drug:Botox;  Drug:Placebo|Interventional||Other|ChangeinAnkleDorsiflexionofInjuredExtremity;  ChangeinHealthRelatedQualityofLife;  ChangeinPain;  ChangeinfunctionalstatusoftheAnkle|8|NCT02051933|January 2013
675|Completed|Self-Reported Exercise Behavior and Short-Term Patient Outcomes in Women Undergoing Radiation Treatment for Operable Breast Cancer|||Observational||Other|To measure in composite the association between self reported exercise behaviour and patient reported outcomes of quality of life.;  To measure in composite the association between self-reported exercise behavior and acute radiation related toxicities.|45|NCT02050620|January 2014
676|Completed|Changes in Gut Hormones Body Composition and Energy Expenditure After Roux-en-Y||Other:RestingMetabolicRate(RMR);  Other:Duel-energyx-rayabsorptiometry(DEXA);  Other:VisualAnalogScale(VAS);  Other:MealStimulationTest|Interventional||Other|Difference in pre and post-prandial plasma Glucagon-like peptide-1 (GLP-1);  Difference in pre and post-prandial Peptide YY (PYY)|57|NCT02048501|January 2014
677|Active not recruiting|Comparing Types of Implementation of a Shared Decision Making Intervention||Other: Asthma Shared Decision Making (SDM) Toolkit|Interventional||Other|Patientperceptionofshareddecisionmaking;  Asthmaexacerbations;  Medicationadherence|1500|NCT02047929|August 2013
678|Not yet recruiting|Airway Inflammatory Response During Illness in Children With Respiratory Failure|||Observational||Other|Mean log transformed IL-10:IL-12p70 ratio in tracheal secretion bronchial secretion and serum within 48-hours of mechanical ventilation;  Blood oxygenation saturation and hemodynamic changes following non-bronchoscopic BAL;  Mean log transformed IL-10:IL-12p70 ratio in tracheal secretion bronchial secretion and serum between days 3-4;  Mean log transformed IL-10:IL-12p70 ratio in tracheal secretion bronchial secretion and serum between days 5-7|20|NCT02047877|April 2015
679|Recruiting|Adoptive Transfer of Haplo-identical DLI for AML and MDS||Drug:Idarubicin;  Drug:Cytarabine;  Biological:DLI|Interventional|Phase 1|Other|Numberofsubjectswithunacceptabletoxicity;  Diseasefreesurvival;  Overallsurvival;  RateofacuteGVHD;  Rateofunacceptabletoxicity;  RateofEfficacy;  RateofImmuneRecovery;  RateofHematopoieticrecovery|30|NCT02046122|July 2014
680|Terminated|Monitoring of Oral Human Papillomavirus Infection (HPV) in HPV-positive Oropharyngeal Squamous Cell Carcinoma (OPSCC)||Other:AssessmentofOralHPVInfection|Interventional|Phase 0|Other|Proportion of patients with HPV-positive OPSCC undergoing CRT who are clear of their oral HPV infection at each time-point;  Time to HPV clearance for patients with HPV-positive OPSCC undergoing CRT;  Number of aneuploidy cells as measured by FISH (Florescent in-situ hybridization) and the mRNA copy number for HPV E6 and HPV E7 at each time-point;  Clinical outcomes of interest (local control loco-regional control distant metastasis-free survival and overall survival (OS)) in patients with HPV-positive OPSCC undergoing CRT|1|NCT02045186|December 2013
681|Completed|Retinal Oxygen Function After Radiation Therapy|||Observational||Other|Abnormalities in regional retinal oxygen extraction after incidental irradiation of the retina.;  Prevalence of vision loss in patients with previous incidental irradiation of the retina;  Changes in retinal oxygen extraction compared to radiation dose;  Visionlossamountversusradiationdose.;  Changes in retinal oxygen extraction as compared to vision loss.|32|NCT02043470|March 2011
682|Terminated|Imaging Lens Deposits in Exfoliation Syndrome||Device:anteriorsegmentOCT|Observational||Other|Amount of exfoliation deposits on the lens as measured by AS-OCT|4|NCT02042703|February 2014
683|Completed|A Phase I/II Study to Evaluate the Immunologic Response and Virologic Impact of AGS-004||Biological:AGS-004|Interventional|Phase 1 / Phase 2|Other / Industry / NIH|CD8Tcellresponses;  Change in low level plasma HIV-1 RNA by single copy assay (SCA);  Change in frequency of HIV-1 infection of resting CD4+ T cells using the viral outgrowth assay|6|NCT02042248|March 2014
684|Completed|Who Contributes to the Ordering of CT Scans in Emergency Department Patients?|||Observational||Other|CTscansutilization;  Abnormalvs.normalCTscans|1500|NCT02040896|January 2014
685|Completed|Real Time In-Vivo Dosimetry For Gynecologic Brachytherapy||Device: Novel nano-scintillator fiber-optic dosimeter (nanoFOD)|Interventional||Other|Measure dosimetric accuracy of the device with reference to a commercially available dosimeter.;  Confirm feasibility of clinical application of the nanoFOD for dosimetric monitoring of brachytherapy with complex geometry implants.|16|NCT02040155|February 2014
686|Completed|Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases||Drug:RapidInfusionRituximab|Interventional||Other|Incidence of infusion related reactions with rapid infusion compared to standard infusion;  Reduction in chair time with rapid infusion compared to standard infusion|19|NCT02040116|February 2013
687|Recruiting|Long Term Follow Up Protocol for NiCord Patients||Genetic:NiCord|Observational||Industry|long term sustained engraftment of NiCord&#174; transplantation|50|NCT02039557|March 2014
688|Completed|A Feasibility Study to Assess Tenofovir and Maraviroc Protection Against HIV-1 in Cervical and Vaginal Explants||Drug:Tenofovir;  Drug:Maraviroc|Interventional|Phase 1|Other|Evidenceofexplantinfection|6|NCT02039323|February 2014
689|Recruiting|Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer||Drug:Sipuleucel-T;  Procedure:LymphNodeBiopsy|Interventional|Phase 1|Other|anti-PA2024andanti-PAPimmuneresponse;  Serumanti-PA2024antibodylevel;  serumanti-PAPantibodylevel|20|NCT02036918|March 2014
690|Completed|Protein and Recovery From Exercise-induced Muscle Damage||DietarySupplement:Proteinsupplement|Interventional||Other / Industry|Muscledamage;  Musclefunction;  Musclesoreness;  Inflammation;  Innateimmunefunction|30|NCT02034721|December 2013
691|Active not recruiting|A High Protein Weight Loss Intervention for Sarcopenic Obesity in Women||DietarySupplement:Proteinsupplementation;  Behavioral: Diet counseling and group education lessons|Interventional||Other|Physicalfunction;  LeanMass;  PhysicalFunction;  WeightLoss;  FatMass|80|NCT02033655|March 2014
692|Active not recruiting|Three Approaches to Glucose Monitoring in Non-insulin Treated Diabetes||Behavioral:SMBG|Interventional||Other|Change from baseline in Glycemic Control at 52 weeks;  Change from baseline Quality of Life scores at 52 weeks;  Change from baseline Problem Areas in Diabetes scores at 52 weeks;  Change from baseline Diabetes Symptom Checklist score at 52 weeks;  Change from baseline Summary of Diabetes Self Care Activities (SDCA) at 52 weeks;  Change from baseline Diabetes Treatment Satisfaction Questionnaire score at 52 weeks;  Change from baseline Diabetes-Specific Self-Efficacy at 52 weeks;  Change from baseline Patient-Provider Communication at 52 weeks;  HypoglycemiaFrequency;  Change from baseline Health Care Utilization at 52 weeks;  ChangeinTreatmentRegimen|450|NCT02033499|January 2014
693|Recruiting|TXA vs. Amicar in Total Knee and Hip Arthroplasty||Drug:Amicar;  Drug:TXA|Interventional|Phase 4|Other|BloodLoss;  NumberofTransfusions;  Preoperative and lowest postoperative hematocrit and hemoglobin;  Lengthofhospitalizationstay;  CostofHospitalization|400|NCT02030821|January 2015
694|Completed|The Use of Smart Scales for Weight Gain Prevention in African American Breast Cancer Survivors||Behavioral: Self-regulation plus activity monitoring;  Behavioral:Self-regulation|Interventional||Other|Proportion of participants with completed assessments at 6 months;  Weightchange;  Changeindietaryintake;  Changeinphysicalactivity;  Changeinwaistcircumference;  Changeinbloodpressure;  Changeincholesterol;  ChangeinhemoglobinA1c;  Changeintriglycerides;  Proportion of participants with completed assessments at 3 months|35|NCT02030353|January 2014
695|Terminated|Procedural Outcomes in Endobronchial Ultrasound - Transbronchial Needle Aspiration (EBUS-TBNA) With and Without Rapid On-Site Evaluation (ROSE)||Procedure:ROSE;  Device:22gaugeVizishotneedles|Interventional||Other|Timelapse;  Totalnumberofsampledlymphnodes;  Average number of needle aspirations per lymph node sampled;  Overalldiagnosticyield;  Proceduraltimeofthecytopathologist|37|NCT02028052|April 2012
696|Unknown&nbsp;&#8224;|Postoperative Pain and Skin Closure Methods After Cesarean Section||Procedure:Insorbstaplesskinclosure;  Procedure:Monocrylskinclosure;  Procedure:Vicrylskinclosure|Interventional||Other|Intravenousandanalgesicuse.;  Dailysubjectivepainscorewhilehospitalized;  6weekpostoperativesubjectivepainscore;  Scarcosmeticscore6weekspost-operatively.;  Woundcomplications;  Lengthofhospitalstay|150|NCT02028000|January 2012
697|Terminated|Phase I Rising-dose Study to Assess Tolerability Safety Pharmacokinetics Pharmacodynamics of AR09||Drug:AR09solution;  Drug:placebo|Interventional|Phase 1|Industry|Determine the maximum tolerated dose (MTD) of single IV doses of AR09;  Characterize the single dose pharmacokinetics (PK) of IV doses of AR09 and its predominate metabolite ADX892|17|NCT02027155|December 2013
698|Active not recruiting|RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)||Device: RNA extraction and amplification from biopsy specimens|Interventional||Other / Industry|Success rate for tumor RNA isolation and amplification|20|NCT02026960|March 2014
699|Unknown&nbsp;&#8224;|Evaluation of An Oral Fluid Collection Device|||Observational||Industry / Other|Presence of Nicotine in Collected Oral Fluid Samples|250|NCT02026440|December 2013
700|Recruiting|Phenylephrine Versus Ephedrine in Pre-eclampsia||Drug:Phenylephrine;  Drug:Ephedrine|Interventional|Phase 4|Other|Cerebraltissueoxygensaturation;  Cardiacoutput|40|NCT02025426|September 2012
701|Active not recruiting|Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method||Device: Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)|Interventional||Other / U.S. Fed / Industry|Feasibility as measured by successfully detecting at least one CTC in at least 2 out of 10 subjects comparing the non-detection rate over time.;  Comparison of the proportion of patients with no detectable CTCs between capture methods over time;  Changes in CTCs (using each method) over time during systemic therapy;  Change in correlation of CTC enumeration using each method with baseline clinical and pathologic disease characteristics (for example clinical stage site of metastatic disease Gleason sum for CRPC PSA for CRPC previous therapies);  Median number of CTCs detected by each method over time|80|NCT02025413|November 2011
702|Completed|Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude||Drug:Riociguat|Interventional|Phase 4|Other|ChangefromBaselineinPulmonaryArteryPressure;  ChangefromBaselineinRadialArterialPressure;  Change from Baseline in Arterial Oxygen Saturation (PaO2);  ChangefromBaselineinVentilationRate;  ChangefromBaselineinWorkRateatExhaustion;  ChangefromBaselineinCardiacOutput|28|NCT02024386|January 2014
703|Recruiting|Efficacy Study of NuCel&#174; in Patients Undergoing Fusion of the Lumbar Spine||Biological:NuCelwithAutograft|Interventional||Industry / Other|SpinalFusion;  Change from baseline pain using Visual Analogue Scale (VAS);  Change from baseline Oswestry Disability Index (Ver. 2.1);  X-raytocomparetobaselinepreoperativeX-ray|60|NCT02023372|December 2013
704|Terminated|Interactive Gentle Yoga in Improving Quality of Life in Patients With Stage I-III Breast Cancer Undergoing Radiation Therapy||Procedure:yogatherapy;  Other:internet-basedintervention;  Other:questionnaireadministration|Interventional||Other / NIH|Recruitment rates calculated as the number of women enrolled divided by the number of women who screened eligible for the study;  Retention rates calculated as the proportion of enrolled women who complete all study measures at each time point;  Adherence measured by the total number of yoga classes attended by each participant;  Participants&apos; acceptability of the intervention including ratings of ease/difficulty of use of the videoconferencing and participating in group classes from home using the device;  Feedback regarding the participants&apos; experience in the study;  ChangeindepressionasmeasuredbyHADS;  ChangeinanxietyasmeasuredbyHADS;  Change in fatigue as measured by visual analogue scale and Functional Assessment of Cancer Therapy-Fatigue;  Change in sleep quality as measured by Pittsburgh Sleep Quality Inventory|6|NCT02023008|May 2014
705|No longer available|Single Patient Expanded Access Protocol: Metabolic Boost||Biological: Enriched Hematopoetic Stem Cell Transplant|Expanded Access||Other|||NCT02021266|
706|Terminated|Clinical Evaluation of Direct Dorsal Column Stimulation||Device:Subduraltriallead;  Device:Epiduraltriallead|Interventional||Other|Feasibility as measured by interview and questionnaire|6|NCT02020460|June 2012
707|Active not recruiting|Combined Spinal-Epidural Temperature and Duration of Action||Drug:combinedspinalepidural|Interventional||Other|time;  analgesiaonset;  dermatomelevel|60|NCT02020304|September 2013
708|Recruiting|Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis||Drug:OralViscousBudesonide;  Drug:FluticasoneMDI;  Drug:Placeboslurry;  Drug:Placeboinhaler|Interventional||Other / NIH|Histologic effectiveness of viscous budesonide versus fluticasone MDI;  Symptomatic effectiveness of viscous budesonide versus fluticasone MDI;  Symptomrecurrence;  Histologicrecurrence|122|NCT02019758|October 2014
709|Recruiting|Effects of Tobacco Products on Live Attenuated Influenza Virus (LAIV) Infections in Human Volunteers||Biological:LAIV|Observational||Other / NIH / U.S. Fed|Change in nasal responses of nonsmokers (NS) cigarette smokers (CS) e-cigarette smokers (EC) hookah smokers (HS) and Little Cigar smokers (LCS) to live attenuated influenza virus;  Compare smoking (CS EC HS and LCS) and nonsmoking groups (NS) for changes in numbers and activation of inflammatory and immune cells in NLF at specific time points compared to baseline;  Compare smoking (CS EC HS and LCS) and nonsmoking groups (NS) for change in cytokines/chemokines and other mediators in NLF compared to baseline;  Compare smoking (CS EC HS and LCS) and nonsmoking groups (NS) for changes in influenza-specific antibody production in NLF and serum;  Compare smoking (CS EC HS and LCS) and nonsmoking groups (NS) for changes in mucus composition;  Compare smoking (CS EC HS and LCS) and nonsmoking groups (NS) for genomic signatures induced in epithelial cells;  Compare smoking (CS EC HS and LCS) and nonsmoking groups (NS) for epigenomic signatures induced in epithelial cells|100|NCT02019745|June 2014
710|Completed|Lung Transplant Subjects Using 19F MRI||Drug:perfluorinatedgas/oxygenmixture;  Device:MRI|Interventional|Phase 1|Other|obtain regional non-invasive images of pulmonary function in patient&apos;s post lung transplantation|6|NCT02019251|December 2013
711|Completed|Magnetic Resonance Imaging (MRI) in Motion|||Observational||Other|To evaluate the accuracy robustness and efficacy of MRI for tumor motion measurement.;  Tumorvolume;  Tumorcontrast-to-noiseratio(CNR);  TumorMotion|25|NCT02019199|November 2011
712|Completed|Effects of Shock Absorbing Insoles on Knee Pain and Walking in Persons With Knee Osteoarthritis||Other: Shock Absorbing Insole (SofSole Athletes Plus)|Interventional|Phase 2|Other|Kneepainwhilewalking;  GroundReactionForces;  Kneejointkineticsduringstancephaseofgait;  Gaitspeed|60|NCT02018380|August 2006
713|Recruiting|The Effect of Sponge Versus No-Sponge Placement of Mitomycin-C on the Outcomes of Trabeculectomy With Ex-PRESS Glaucoma Filtration Device||Procedure:Placementofthesponge;  Drug:Mitomycin-C|Interventional|Phase 2|Other|Changeincomplicationrates;  ChangeinIntraocularpressure|100|NCT02016898|March 2014
714|Recruiting|Vitamin D and Muscle Function Study||DietarySupplement:VitaminD;  DietarySupplement:Placebo|Interventional||Other / NIH|Change in percentage of type II (fast-twitch) muscle fibers over 4 months;  Change in lower extremity muscle power over 12 months;  Change in lower extremity muscle strength over 12 months;  Change in the expanded physical performance battery over 12 months;  Changeinposturalswayover12months;  Change in single muscle fiber contractility over 4 months;  Change in type I and type II denervated myofibers over 4 months;  Change in satellite cell differentiation over 4 months|200|NCT02015611|December 2013
715|Completed                  Has Results|Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone||Drug:Vilazodone|Interventional|Phase 3|Other|Change in Total MADRS Scores From Baseline to Week 8;  Change in the Discontinuation Emergent Signs and Symptoms Check List (DESS);  Change in Safety as Assessed by the Arizona Sexual Experience Scale (ASEX);  Change in Hamilton Anxiety Rating Scale (HAM-A) Total Scores;  ChangeinSheehanDisabilityScale(SDS);  Change in Clinical Global Impression-Improvement (CGI-I) Scale;  Change in Clinical Global Impression-Severity (CGI-S) Scale;  MADRSResponse;  MADRSRemission|70|NCT02015546|December 2012
716|Completed|Black Family Eating Behaviors Study|||Observational||NIH / Other|Eatingbehaviortraits;  HealthRiskAssessment(CHART);  Weighthistory;  LifeEventsCalendar|350|NCT02015078|November 2013
717|Suspended|Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer||Drug:Lucanthone;  Other:Placebo|Interventional|Phase 2|Other / Industry|Determine the efficacy of lucanthone when given during WBRT;  Evaluate the safety and toxicity of lucanthone when used in combination with standard doses of WBRT in the primary treatment of brain metastases secondary to non-small cell lung cancer|50|NCT02014545|January 2016
718|Recruiting|Muscle Ultrasound Signifies Condition Upgrade Leading Approach to Recovery||Procedure:MuscleUltrasoundandMuscleSample|Observational||Other|DaysofHospitalization|30|NCT02014285|November 2012
719|Recruiting|Nutrition for Migraine Prevention||Other:Diet|Interventional||Other / NIH|Primary metabolic outcome: 17-hydroxy docosahexaenoic acid (DHA);  Primary clinical outcome: Headache-specific Quality of Life (HIT-6);  Headache hours per day (headache frequency) are measured by a daily Headache Diary;  Patient-Reported Outcomes Measurement Information System-29 Profile;  17-hydroxyDHAtrajectory;  HIT-6|153|NCT02012790|July 2014
720|Recruiting|Bone Marrow Aspirate Concentrate (BMAC) Supplementation for Osteochondral Lesions||Procedure: ankle arthroscopy with debridement and microfracture of the OLT;  Other:BoneMarrowAspirateinjection|Interventional|Phase 4|Other|ChangeinPainAssessment;  ChangeinFunctionalAssessment;  MRIAssessment|30|NCT02011295|December 2013
721|Terminated|Bioelectrical Impedance Phase Angle in Predicting Treatment Outcome in Patients With Extensive Stage Small Cell Lung Cancer Receiving First-Line Chemotherapy||Procedure:bioelectricimpedanceanalysis|Interventional||Other / NIH|Progression-freesurvival;  Standardizedphaseanglemeasure;  Best overall response (complete partial progressive disease stable disease) using the Response Evaluation Criteria in Solid Tumors (RECIST);  Overallsurvival;  Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|1|NCT02011087|February 2014
722|Active not recruiting|Aerobic Training and Non-Exercise Physical Activity||Behavioral:AerobicExerciseTraining;  Behavioral:AerobicExercise+PhysicalActivity|Interventional||Other|Changeinwaistcircumference;  Changeinbodycomposition;  Changeinbodyweight;  Changeincardiorespiratoryfitness;  Changeinoralglucosetolerance(OGTT);  Changesinphysicalactivitylevels;  Changeindietarycomposition;  Changesinbloodlipids;  Changeinsystemicinflammation;  Change in oral glucose tolerance: Glucose and insulin AUC|45|NCT02010060|February 2014
723|Withdrawn|Evaluation of Safety and Efficacy of the EndoLift Liver Retractor||Device:EndoLiftLiverRetractor|Interventional||Other|Safety;  EffectiveuseoftheEndoLiftLiverRetractor|0|NCT02008409|November 2011
724|Recruiting|Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer||Biological:Panitumumab;  Drug:Cabozantinib|Interventional|Phase 1|Other / Industry|Recommended phase II dose (RPTD) for the combination of cabozantinib and panitumumab;  Objective response rate (ORR) of cabozantinib monotherapy in patients with prospectively identified MET amplified metastatic colorectal cancer;  Non-dose limiting toxicities of cabozantinib and panitumumab.;  Responserateofcabozantinibandpanitumumab;  Progression free survival associated with the cabozantinib and panitumumab regimen;  Overall survival associated with the cabozantinib and panitumumab regimen;  Progression free survival associated with cabozantinib monotherapy in patients with MET amplified colorectal cancer;  Overall survival associated with cabozantinib monotherapy in patients with MET amplified colorectal cancer;  To describe the safety and tolerability of cabozantinib monotherapy in patients with MET amplified colorectal cancer|30|NCT02008383|January 2014
725|Recruiting|Comparison of Stationary Breast Tomosynthesis and 2-D Digital Mammography in Patients With Breast Augmentation||Device:StationaryBreastTomosynthesis|Interventional||Other|Receiver Operative Curve (ROC) Area Under the Curve (AUC) (percentage);  Readerpreference-arbitraryunits;  Patientpreference-arbitraryunits|50|NCT02008032|December 2013
726|Withdrawn|ACTH Treatment of APOL1- Associated Nephropathy||Drug:Acthar|Interventional||Other|ChangeinproteinuriawithH.C.Acthargel;  ChangeineGFRwithH.C.Acthargel;  Percentchangeinproteinuria;  PercentchangeinCKD-EPIeGFR;  ChangeinCKD-EPIeGFR;  Duration of remission after H.C. Acthar gel treatment;  Changes in kidney fibrosis after H.C. Acthar gel treatment;  Cholesterol and lipoprotein profile before and after treatment with H.C. Acthar gel|0|NCT02006849|January 2014
727|Completed|Oxytocin Levels in Typically Developing Boys|||Observational||Other|PlasmaOxytocinLevels;  Inflammatorymarkers|60|NCT02006381|December 2013
728|Completed|Echinacea and Acute Respiratory Illness||DietarySupplement:QuickDefense|Interventional||Other|Commoncoldsymptoms|40|NCT02003651|November 2013
729|Active not recruiting|Radiation Adherence/Toxicity in Patients With Non-Ovarian Gynecological Cancers|||Observational||Other|Pre-treatmentI-ADLdependency;  Pooradherencetotreatment|15|NCT02003430|September 2013
730|Completed|A Randomized Controlled Trial of Inspiratory Muscle Training (IMT)in the ICU and CCU||Device:InspiratoryMuscleTrainer|Interventional||Other|Change in Maximum Inspiratory Pressure at baseline and before extubation.;  Completionofexcercisesession|10|NCT02003053|April 2013
731|Completed|The Role of Estrogen in Luteinizing Hormone Surge and Ovulation||Drug:Letrozole|Interventional|Phase 4|Other|IncreaseinProgesteronelevel;  ChangeinLHlevel;  FollicularDevelopment|10|NCT01999569|April 2007
732|Recruiting|LCI-HEM-SPEC-001: Tissue Collection for Genetic Analysis of Acute Myelogenous Leukemia|||Observational||Other|Number of participants with the mutation for acute myelogenous leukemia.|20|NCT01999556|November 2013
733|Completed                  Has Results|A Mixed Methods Approach to the Development and Testing of the Measure of Drug Self-Management (MeDS)|||Observational||Other / Industry|MeasureofMedicationSelf-Management(MeDS)|210|NCT01998269|November 2013
734|Recruiting|Efficacy of Spinal Oxytocin in Healthy Volunteers||Drug:Oxytocin15mcg;  Drug:Oxytocin150mcg;  Drug:Placebo|Interventional|Phase 2|Other|Hyperalgesia|36|NCT01996605|June 2014
735|Completed|Persistent Pain After CS Delivery|||Observational||Other|painriskfactors|575|NCT01996592|May 2013
736|Active not recruiting|Brain Connectivity in Age-Related Macular Degeneration|||Observational||Other / NIH|Cognitive Changes and Brain Connectivity in Age-Related Macular Degeneration|300|NCT01996215|April 2014
737|Active not recruiting|A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma||Drug:Ipilumimab;  Radiation:Radiation|Interventional|Phase 1|Other|Incidence of immune related adverse events associated with ipilimumab;  Incidenceofacuteandlateradiationtoxicities;  Overallresponserate(ORR);  6monthprogressionfreesurvival(PFS);  12monthprogressionfreesurvival(PFS);  Overallsurvival;  CD4+ and CD8+ reactivity to melanoma tumor antigens;  Cytokinesassociatedwithanti-tumorresponse|24|NCT01996202|November 2013
738|Recruiting|Wellness Intervention for Menstrual Mood Disorders||Behavioral:MindfulnessIntervention;  Behavioral:SocialSupportGroup|Interventional||Other / NIH|Change in Premenstrual Depression Symptomatology and Functional Impairment;  ChangeinColdPainSensitivity;  Change in premenstrual anxiety irritability and total symptom severity;  Change in sensitivity to the temporal summation of heat pain test|140|NCT01995916|August 2013
739|Recruiting|BABY STEPS II: SMS Scheduled Gradual Reduction Text Messages to Help Pregnant Smokers Quit||Behavioral: Scheduled Gradual Reduction Text Messages;  Behavioral:SupportTextMessages|Interventional||Other / NIH|biochemically validated seven-day point prevalence smoking abstinence;  prolongedsmokingabstinence;  biochemicallyvalidatedsmokingreduction;  biochemically validated postpartum smoking abstinence;  pretermbirth|522|NCT01995097|March 2014
740|Recruiting|Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care||Drug:Totalintravenousanesthesiawithpropofol;  Drug:Generalanesthesiawithisoflurane|Interventional|Phase 4|Other|Assess the correlation between perioperative change in CSF Markers of Alzheimers Disease and perioperative cognitive change.;  Continuouscognitiveindexscorechange;  AssessCSFMarkersofAlzheimersDisease;  PerioperativeCSFTau/Abetaratiochange|140|NCT01993836|November 2013
741|Enrolling by invitation|Pilot Study: Utilizing Manometry to Assess Radiation-Induced Changes in Esophageal Function|||Observational||Other|Utilizing manometry to assess radiation-induced changes to esophageal function;  Rate of radiation-induced changes in esophageal function|10|NCT01992068|September 2013
742|Completed|US Phase III Study of APD421 in PONV||Drug:APD421;  Drug:Placebo|Interventional|Phase 3|Industry|CompleteResponse(protectionfromPONV)|364|NCT01991860|August 2013
743|Completed|Use of Technological Advances to Prevent Smoking Relapse Among Smokers With PTSD||Drug:Bupropion;  Drug:nicotinereplacementtherapy;  Other:Smokingcessationcounseling;  Behavioral:mobilecontingencymanagement;  Other:StayQuitCoach|Interventional||Other|smokingself-report;  salivacotinine|15|NCT01990079|December 2013
744|Terminated|Home Based Exercise Program for Elderly Cancer Patients||Behavioral:HomeBasedExercise|Interventional||Other|ReductioninCancerRelatedFatigue(CRF);  QualityofLifeImprovement(QOL);  ReductioninPhysicalFunctionalDecline|8|NCT01990066|March 2014
745|Completed|Healthy Lifestyles Program for You (HLP4U): Augmenting Childhood Obesity Treatment.||Behavioral:Lifestylecounseling;  Behavioral:TextMessaging|Interventional||Other|FoodandActivityFrequencySurveyScore;  GeneralSelf-EfficacySurveyScore|101|NCT01989065|September 2014
746|Terminated|Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma||Drug:CTO;  Drug:Lomustine|Interventional|Phase 1|Other / Industry|Phase 1: Determine the maximum tolerated dose (MTD) of CTO when combined with lomustine;  Phase 2: Percentage of subjects who remain alive and progression-free at 6 months;  Phase 2: Percentage of subjects who experience a dose-limiting toxicity (DLT) during any cycle of protocol treatment;  Phase2:MedianOverallSurvival(OS);  Phase2:12monthOverallSurvival(OS);  Phase 2: Percentage of subjects with best overall response (BOR) of complete response (CR) and partial response (PR);  Phase2:MedianPFS|9|NCT01989052|May 2014
747|Recruiting|Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)||Drug:Atorvastatin;  Drug:Placebo|Interventional|Phase 2|Other / NIH|Determine if Atorvastatin (Lipitor) administration preserves LV Function;  Document the effect of atorvastatin on cognitive function;  Document effect of Atorvastatin on self-reported quality of life|250|NCT01988571|February 2014
748|Completed|Characterization of Dyslipidemia in Adolescent Obesity|||Observational||Industry|Comparisonofbiomarkerprofiles|50|NCT01988454|September 2011
749|Enrolling by invitation|Risk Factors and Biomarkers for Diagnosis and Treatment of EoE|||Observational||Other / NIH|RiskfactorsinEoEdiagnosis;  Inflammatoryserumbiomarkermeasures|800|NCT01988285|July 2011
750|Terminated                  Has Results|Epidural Analgesia Versus IV Analgesia in Lumbar Spine Fusions||Other:EpiduralCatheter-Dilaudid;  Drug:Dilaudid|Interventional|Phase 3|Other|Post-operative Pain as Assessed by Visual Analogue Scale (VAS);  PatientSatisfactionWithPerioperativeAnalgesia;  PatientSatisfactionWithOverallCare;  Number of Participants With Events of Special Interest;  Number of Participants With Adverse Events Related to the Study;  TotalPost-operativeOpioidConsumption;  NumberofParticipantsExperiencingDelirium;  Number of Participants Readmitted to Hospital Within 30 Days of Surgery;  LengthofHospitalStay;  WoundInfectionRates|17|NCT01986946|October 2013
751|Enrolling by invitation|Total Ankle Replacement for Ankle Arthritis|||Observational||Other|ChangeinVisualAnalogPainScale(VAS);  ChangeinShortFormHealthSurvey;  Change in Short Musculoskeletal Function Assessment (SMFA);  ChangeinAOFASHindfootScalequestionnaire;  ChangeinFootandAnkleDisabilityIndex(FADI);  Changes in Three dimensional kinematic and kinetic assessments during level walking|1000|NCT01986244|June 2007
752|Recruiting|Pacing in First-degree AV-block||Other:Pacing|Interventional||Other / Industry|Echocardiographic evidence of dyssynchrony (AV intra- or inter-ventricular)|20|NCT01985802|December 2015
753|Completed|Mobile Pain Coping Skills Training for Stem Cell Transplant Patients||Behavioral:MobilePainCopingSkillsTraining|Interventional||Other|Accrual;  Pain|72|NCT01984671|October 2013
754|Completed|Interaction Effects of Temperature and Ozone||Other:CleanAir;  Other:Ozone|Interventional||U.S. Fed|Forcedexpiredvolumeinthefirstsecond(FEV1);  Indexofclotting/coagulationfactor;  Indexofinflammatorymarkers;  ForcedVitalCapacity;  Changesinheartratevariability|16|NCT01981135|September 2011
755|Recruiting|Efficacy and Safety of High Dose Baclofen for Alcohol Dependence||Drug:Baclofen;  Drug:Placebo|Interventional|Phase 2|Other|Mean%HeavyDrinkingDays;  Mean%AbstinentDrinkingDays;  Anxiety level based on Spielberger Scale for State Anxiety|120|NCT01980706|November 2013
756|Withdrawn|Potassium Citrate Supplementation vs. Dietary Counseling||Dietary Supplement: Potassium Citrate Supplementation;  Other:DietaryEducation|Interventional|Phase 2|Other|Changein24-hoururineparameters|0|NCT01980004|November 2013
757|Enrolling by invitation|Jump Starting Shared Medical Appointments for Diabetes With Weight Management||Behavioral:Weightmanagement;  Behavioral:Sharedmedicalappointments(SMA)|Interventional||U.S. Fed|hemoglobinA1c;  hypoglycemicevents;  diabetesmedicationregimen;  weight;  costeffectiveness|308|NCT01973972|December 2014
758|Withdrawn|Pilot Study of NanoKnife for Ablation of Prostate Cancer in Low Risk Patients||Device:NanoKnifeProcedure|Interventional||Industry|Safety;  ProceduralEffects|0|NCT01972867|November 2013
759|Active not recruiting|Comparison of Transbronchial Cryoprobe and VATS Biopsy For the Diagnosis of Interstitial Lung Disease (ILD)||Procedure:Cryobiopsybiopsy;  Procedure:TransbronchialBiopsy;  Procedure:VATSbiopsy|Interventional||Other|Comparisonofbiopsytechnique|20|NCT01972685|June 2013
760|Completed|Neurocognitive Visual Reaction Training||Other:ReactionTimeTraining|Interventional||Other|Numberofcoloredballscorrectlyidentified;  Numberofballcatchesonalternateballtoss;  Reactiontimeondynavisionreactionboard|21|NCT01972581|October 2013
761|Recruiting|The Influence of Beta Blocker Therapy on the Hemodynamic Response to Inotrope Infusion in Patients With Acute Decompensated Heart Failure|||Observational||Other|Change in Fick Cardiac Index ( Fick CI) from baseline to maximum tolerated dose of inotrope therapy|57|NCT01971944|December 2010
762|Unknown&nbsp;&#8224;|High-resolution Relational Resonance-based Electroencephalic Mirroring (HIRREM) to Relieve Insomnia||Device:HIRREM|Interventional||Other|InsomniaSeverityIndex(ISI);  Dailysleepdiary|120|NCT01971567|October 2013
763|Completed|Effect of Tourniquet on Sensory Nerve Conduction Threshold (sNCT) and OxyNeuroGram (ONG) Index- A Volunteer Study||Device: tourniquet sensory nerve conduction abnormality|Interventional||Other|Changesinsensorynerveconduction;  Changesinoxyneurogramindex|10|NCT01970839|November 2014
764|Completed|Medication Therapy Management With Pharmacogenetic Testing||Other:MTMwithPGx|Interventional||Other|PatientsatisfactionwithMTMandPGx;  Change in clinical biomarkers associated with drug therapy;  Number of recommended drug selection/dosing adjustments;  PhysiciantimetoperformMTMandPGx|30|NCT01970774|November 2013
765|Completed                  Has Results|JUVEDERM&#174; Ultra XC vs. Belotero Balance&#174; for Perioral Lines||Device:JUVEDERM&#174;UltraXC;  Device:BeloteroBalance&#174;|Interventional||Industry|Percentage of Participants With at Least a 1 Point Improvement From Baseline on the Perioral Lines Severity Scale (POLSS);  Participant Assessed Procedural and Post-Procedural Pain Levels;  Subject&apos;s Global Assessment of Change in Appearance of Perioral Lines|138|NCT01970397|October 2013
766|Completed|The Role of Massage in Increasing Total Motile Sperm Count of IUI||Behavioral:Massage|Interventional|Phase 4|Other|TotalMotileSpermCount;  Pregnancy|40|NCT01969825|December 2005
767|Completed|Tolerability and Satisfaction With Evie||Device:EvieSlow-releaseInseminationDevice;  Other:TraditionalIntrauterineInsemination|Interventional|Phase 4|Other|Patienttolerabilityandsatisfaction;  Cramping;  PregnancyRates|20|NCT01969812|January 2014
768|Active not recruiting|NCGENES: North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing||Behavioral:Experimental|Interventional||Other / NIH|Extent of test-specific distress 2 weeks after return of results;  Change in test-specific distress at 3 and 6 months after return of results;  Extent of communication of test results with other people;  Extentofinformationseeking;  ExtentofDecisionRegret2weeksafterconsent;  Extent of Decision Regret 2 weeks after return of results;  Changeindecisionregret;  Extent of Healthcare Utilization 2 weeks after consent;  Extent of Healthcare Utilization 2 weeks after return of results;  ChangeinHealthcareUtilization;  Enactment of health-related lifestyle behaviors 2 weeks after consent;  Enactment of health-related lifestyle behaviors 2 weeks after return of results;  Change in enactment of health-related lifestyle behaviors;  Extent of psychological distress 2 weeks after consent;  Extent of psychological distress 2 weeks after return of results;  Changeinextentofpsychologicaldistress;  Extent of health-related Quality of Life 2 weeks after consent;  Extent of health-related Quality of Life 2 weeks after return of results;  Change in extent of health-related Quality of Life|645|NCT01969370|August 2012
769|Completed|PVI for Prediction of Spinal Induced Hypotension||Other:PVI|Observational||Other|Correlation between baseline PVI and change in SBP from baseline.;  Correlation between plethysmography variability index (PVI) change in response to passive leg raising (PLR) and change in SBP and pulse rate (PR) from baseline and need for vasopressors;  Correlation between intraoperative PVI change from baseline with change in SBP and PR from baseline and need for vasopressors.;  Correlation between baseline PVI and need for vasopressors.;  Correlation between baseline PVI and change in SBP and PR from baseline.;  Correlation between CO change in response to SLR with change in SBP and PR from baseline and need for vasopressors|38|NCT01967914|October 2013
770|Completed|Screening Brief Intervention and Referral to Treatment in Primary Care||Behavioral:ReferraltoTreatment;  Behavioral:BriefIntervention|Interventional||Other / NIH|Changeindrugusestatusorfrequency;  Change in treatment use status for drug use problems;  Change in cigarette smoking status and nicotine dependence;  Changeinalcoholusestatus;  Change in treatment use status for alcohol use problems;  Changeinmedicationadherence;  Rateofhealthcareservicesutilization;  Incidenceofmicro-andmacrovascularoutcomes;  Patient-reportedglobalhealthscalescores|134|NCT01966432|August 2013
771|Completed                  Has Results|Advancing the Standard of Care for Pin Site Care||Device:MediHoneyHCSdressing|Interventional||Other|TotalNumberofPinSites;  NumberofPatientsWithPinSiteInfection;  ChangeinSepsisRate|20|NCT01965665|October 2013
772|Completed|A Study to Evaluate a Skeletal-muscle Microbiopsy Technique With Dynamic Proteomic Measurement in Healthy Male Volunteers||Drug:DeuteratedWater;  Drug:Testosteroneenanthate;  Drug:Placebotomatchtestosteroneenanthate|Interventional|Phase 1|Industry|Change from Baseline in muscle derived protein synthesis rate;  Change from Baseline in lower extremity strength using the 1-repetition maximum (1-RM) leg strength FSRs from muscle proteins derived from muscle biopsies and serum samples;  Changes in FSR in muscle and serum derived muscle proteins;  Number of biopsy samples required to obtain desired collection weight;  Number of participants with biopsy-related adverse events|20|NCT01962454|May 2014
773|Active not recruiting|An Alternate Dosing Schedule for Pentavalent Rotavirus Vaccine (RotaTeq)||Biological:RV5(PentavalentRotavirusVaccine)|Interventional|Phase 4|Other / Industry|G1serum-neutralizingantibody;  G2serum-neutralizingantibody;  G3serum-neutralizingantibody;  G4serum-neutralizingantibody;  P[8]serum-neutralizingantibody|60|NCT01960725|February 2014
774|Unknown&nbsp;&#8224;|Study of Awareness and Detection of Familial Hypercholesterolemia|||Observational||Other|Promote awareness of FH to increase the number of identified FH patients reaching optimal level of disease management; target treatment levels for LDL cholesterol.|5000|NCT01960244|October 2013
775|Completed|Sexual Absorption of Vaginal Progesterone||Drug:Crinonevaginalprogesteronegel;  Drug:Placebovaginalgel|Interventional|Phase 4|Other|Malechangeinprogesterone;  Femalechangeinprogesterone|20|NCT01959464|November 2008
776|Completed|Hypoxia at Multiple Wavelengths of Light|||Observational||Industry|Assess the effect of progressive incremental hypoxia at multiple wavelengths of light|26|NCT01957891|September 2013
777|Completed|A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder||Drug:Ketamine;  Drug:Placebo|Interventional|Phase 2|Industry|Comparison of change from baseline to 4 hr post-dose on Day 1 in somatosensory evoked potential amplitudes (SEPs) between ketamine responders and ketamine non-responders.;  Comparison of change from baseline to 4 hr post-dose on Day 1 in motor evoked potential amplitudes (MEPs) between ketamine responders and ketamine non-responders.|13|NCT01957410|February 2014
778|Completed|Instaflex and Joint Pain in Community Adults||DietarySupplement:Instaflex;  DietarySupplement:Placebo|Interventional||Other / Industry|Jointpainandfunction;  Systemicinflammation;  Safety|110|NCT01956500|April 2013
779|Recruiting|Complementary Neurosteroid Intervention in Gulf War Illnesses (GWVI)||Drug:Pregnenolone;  Drug:Placebo|Interventional|Phase 2|U.S. Fed|Physical Component of the SF-36; assessing change between the baseline score (week 2) week 6 and week 10.;  Brief Pain Inventory; assessing change between the baseline score (week 2) week 6 and week 10;  Tower of London test of the Brief Assessment Checklist for Adolescents (BAC-A); assessing change between the baseline score (week 2) week 6 and week 10.;  Multidimensional Fatigue Inventory (MFSI); assessing change between the baseline score (week 2) week 6 and week 10.;  Global Severity Index of the Symptom Checklist-90-Revised (SCL-90R); assessing change between the baseline score (week 2) week 6 and week 10.|140|NCT01956279|October 2013
780|Completed|Single Subject Neratinib in Bladder Cancer (NRR)||Drug:Neratinib|Interventional||Other|Response|1|NCT01956253|July 2013
781|Unknown&nbsp;&#8224;|Establishment of a Human Tissue Bank for Studying the Microbial Etiology of Neurodegenerative Diseases|||Observational||Other|Create a bank of fecal and blood samples for the future investigation of the microbial etiology and pathophysiology of neurodegenerative diseases including but not limited to amyotrophic lateral sclerosis Parkinson&apos;s Diseases and multiple sclerosis.|300|NCT01954875|December 2009
782|Terminated|Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure||Drug:CTOandBevacizumab;  Drug:CTOalone|Interventional|Phase 1|Other / Industry|Phase 1: Determine the Maximum Tolerated Dose (MTD) of CTO when combined with standard dosing of bevacizumab;  Phase 2: Percentage of subjects who remain alive and progression-free at 6 months;  Phase 1: Number of subjects who experience a dose-limiting toxicity (DLT) during cycle 1;  Phase 2: Percentage of subjects who experience a dose-limiting toxicity (DLT) during any cycle of protocol treatment;  Phase2:MedianOverallSurvival(OS);  Phase2:6and12monthOverallSurvival(OS);  Phase 2: Percentage of subjects with best overall response (BOR) of complete response (CR) or partial response (PR);  Phase2:MedianPFS;  Phase2:12monthPFS|17|NCT01954030|October 2013
783|Active not recruiting|Are Serial Electrocardiograms Additive to SeriAl Second-generations Troponins in Predicting Acute CoronAry Syndromes in PatienTs With Undifferentiated cHest Pain||Device:SerialElectrocardiograms|Observational||Other|MajorAdverseCardiovascularEventsat30days;  Evidence of acute myocardial ischemia via objective cardiac testing performed during the index hospitalization|382|NCT01953276|January 2013
784|Not yet recruiting|Muscle Fiber Fragment Treatment for Urinary Incontinence||Other:AutologousMuscleFiberFragments|Interventional|Phase 1 / Phase 2|Other|Incidence of treatment-related serious adverse events;  ChangeinIncontinenceAssessmentbyPadTest|10|NCT01953263|November 2013
785|Withdrawn|Patient Satisfaction Efficacy and Compliance of Antiemetic Patch vs Pill in Malignant Glioma Patients||Drug:Granisetron;  Drug:Ondansetron|Interventional|Phase 2|Other / Industry|Satisfaction with Granisetron Transdermal Delivery System (GTDS) versus Ondansetron pill;  Complete response (CR) rate of Granisetron Transdermal Delivery System (GTDS) compared to Ondansetron pill;  Subject Compliance with Granisetron Transdermal Delivery System (GTDS) and Ondansetron pills;  Number of subjects experiencing a grade &#8805;3 treatment-related toxicity;  Patient satisfaction from the Treatment Satisfaction Questionnaire for Medication (TSQM-9 )|0|NCT01952886|
786|Completed|Sildenafil Citrate Before Surgery in Improving Kidney Function in Patients With Kidney Cancer||Drug:sildenafilcitrate;  Other:placebo;  Procedure:therapeuticconventionalsurgery|Interventional||Other / NIH|Accrualrate;  Retentionrate;  Participationrate;  ChangeinGFR;  Changeinproteinuria;  Estimatedbloodloss;  Hemoglobinconcentration;  Changesinbloodpressuremeasurements;  Vasopressor support requirements during the operative procedure;  Intravenous fluid requirements during the operative procedure;  Overallcomplicationrates;  Preliminary effect size of sildenafil citrate on change in GFR|30|NCT01950923|September 2013
787|Unknown&nbsp;&#8224;|Establishment of a Tissue Bank (Blood CSF) for the Understanding of the Disease Progression and Early Diagnosis of Motor Neuron Disease (MND)|||Observational||Other|LevelsofALSbiomarkersinCSF;  LevesofALSbiomarkersinblood|1000|NCT01950910|June 2007
788|Unknown&nbsp;&#8224;|Establishment of Phenotypic Profiles of Muscular Dystrophies for Understanding Disease Progression Diagnosis and Development of New Therapies|||Observational||Other|Immunohistochemistry for protein expression profiling of skeletal muscle tissue; initial analysis will be qualitative (positive or negative) or semi-quantitative (strong moderate weak or negative)|250|NCT01950897|September 2005
789|Active not recruiting|Evaluation of Serum Chemokines for Patients Undergoing Treatment With Boceprevir.|||Observational||Other / Industry|Level(ng/mL)ofserumchemokines.|60|NCT01949077|December 2011
790|Active not recruiting|Effects of Ranolazine and Exercise on Daily Physical Activity Trial||Drug:Ranolazine;  Behavioral:AerobicExercise;  Drug:Placebo|Interventional|Phase 4|Other / Industry|Changeinpeakoxygenconsumption;  Change in treatment satisfaction as measured by the seattle angina questionnaire;  Changeintotaldailyenergyexpenditure|38|NCT01948310|December 2013
791|Unknown&nbsp;&#8224;|Identification of Diagnostic And Prognostic Biomarkers From Amyotrophic Lateral Sclerosis (ALS) Skin and Adipose Samples|||Observational||Other|Abundance levels of the known messenger RNA transcriptome of skin and adipose tissue samples (measured by gene expression profiling);  Changes in abundance of or post-translational modification of proteins (measured by proteomics)|100|NCT01948102|July 2008
792|Completed|Pancreatic Resection Malnutrition and Readmission||Dietary Supplement: Nestle Impact Advanced Recovery nutritional supplement|Interventional||Other|Feasibility of implementing an evidence based perioperative nutritional plan for patients undergoing Whipple as measured by percentage of adherence to nutritional protocol;  ReadmissionRate;  Readmissioncause;  Length of stay for initial hospitalization and/or readmission;  Postsurgicalcomplications;  Nutritionalstatus|38|NCT01947166|December 2013
793|Completed|Clinical Immunization Safety Assessment (CISA) Project: Pilot Study to Assess the Effect of Prophylactic Antipyretics on Immune Responses and Fever After IIV||Other:Acetaminophen;  Other:Placebo|Interventional|Phase 4|Other / U.S. Fed|Completionofstudyprocedures;  ImmuneResponsetoIIV|41|NCT01946594|October 2013
794|Terminated                  Has Results|Acute Effects of Beet Juice Consumption on Exercise Capacity in Heart Failure||Drug:beetjuiceconcentrate;  Other:placebo|Interventional|Phase 1 / Phase 2|Other|ExerciseTolerance;  VascularFunction|2|NCT01946542|February 2014
795|Completed                  Has Results|A Retrospective Chart Review to Evaluate Diagnosis and Treatment of Chronic Migraine and Headache||Other:NoIntervention|Observational||Industry|Presence or Absence of Prophylactic Medication for Headache/Migraine;  Number of Unique Prophylactic Medications for Headache/Migraine Reported;  Number of Days With a Headache Recorded at the Visit With the Highest Number of Headaches;  Highest Number of Headache Days Per Month at a Qualifying Visit;  NumberofVisitsforHeadacheDiagnosis|459|NCT01946126|March 2014
796|Recruiting|Brain Imaging of Intranasal Oxytocin Treatment in Autism||Drug:Oxytocin|Interventional|Phase 1|Other / NIH|Aim1a.fMRIActivationAnalysis/Connectivity;  Aim 1b. Proportion of Time Attending to Social Stimuli (Eye Tracking);  PlasmaOxytocin(OT)levelsinaim1b.and2b.;  SalivaryOxytocin(OT)levelsforallaims.;  SRS-SocialResponsivenessScale;  Pervasive Developmental Disorders Behavior Inventory-Screening Version (PDDBI-SV);  ABC-lethargy/socialwithdrawalsubscale|28|NCT01945957|September 2014
797|Active not recruiting|Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy||Drug:Clenbuterol;  Drug:Placebo|Interventional|Phase 1 / Phase 2|Other|Change in creatine kinase (CK) reflecting worsening of muscle involvement;  Change in aspartate aminotransferase (AST) alanine transaminase (ALT) and bilirubin representing liver toxicity;  Change6minutewalktest;  Change in forced vital capacity in pulmonary function testing|17|NCT01942590|September 2013
798|Withdrawn|Microbiome Survey of Preterm Infants||Device:NoSting|Interventional||Other|ChangeinPretermInfantSkinMicrobiome;  Change in Preterm infant skin transepidermal water loss;  Changeinpretermskinph;  Change in preterm infant neonatal skin condition scores|0|NCT01942577|September 2013
799|Active not recruiting|Fatty Acid Levels and Memory in Breastfed Children|||Observational||Other|Relation between recognition memory and maternal FADS genotype;  Nutrient content of breastmilk as it relates to FADS genotype;  Nutrient content of breastmilk as it relates to recognition memory;  Relation between declarative memory and breastmilk nutrients;  Relation between declarative memory and concurrent nutrients|202|NCT01942434|January 2010
800|Recruiting|Health Education Intervention in Reducing Weight Gain in Patients With Newly Diagnosed Stage I-IV Breast Cancer Undergoing Chemotherapy||Other:educationalintervention;  Other:counselingintervention;  Behavioral:telephone-basedintervention;  Other:questionnaireadministration;  Procedure:quality-of-lifeassessment|Interventional||Other / NIH|Feasibility of conducting the weight gain prevention intervention measured as the percent of screened participants that are eligible and agree to participate;  Effectoftheinterventiononbodycomposition;  Effectoftheinterventiononself-efficacy;  Effectoftheinterventiononperceivedstress;  Effectoftheinterventiononfatigue;  Effect of the intervention on 6 minute walk distance;  Effect of the intervention on fruit vegetable and fat intake;  Effect of the intervention on physical activity participation;  Effect of the intervention on health-related quality of life;  Samplesizeforfuturelargertrials|20|NCT01941784|November 2013
801|Completed|Impact of Synergistic Sequential Treatment (SST)||Device:M22ResurFX;  Device:M22ResurFXandQS|Interventional||Industry|Improvement;  Blindedimprovement;  Skinresponse;  Downtime;  Improvementbysubject;  Comfort;  Biopsies;  AdverseEvents|17|NCT01940445|September 2013
802|Completed                  Has Results|Home Administration of FluMist by Parents/Caregivers||Biological:FluMist|Interventional||Other / Industry|Number of Subjects That Reported Successful Home Vaccination With no Adverse Events;  Number of Subjects That Reported Ability to Successfully Administer FluMist Vaccine at Home|41|NCT01938170|September 2014
803|Active not recruiting|Diffusion Weighted MR Imaging of the Breasts in Women at High Risk of Breast Cancer: A Pilot Study||Procedure:Diffusion-weightedMRimaging|Interventional||Other|Numberofidentifiedlesions;  A composite of the sensitivity specificity and AUC of contrast-enhanced MRI and diffusion MRI|100|NCT01938157|August 2013
804|Recruiting|Mothers and Others: Family-based Obesity Prevention for Infants and Toddlers||Behavioral:ObesityPreventionGroup;  Behavioral:InjuryPreventionGroup|Interventional||Other / NIH|Mean weight-for-length z-score at 15 months of age;  Proportion of infants ever breastfed and exclusively breastfed at 3 and 6 months of age;  Proportion of infants fed complementary foods before 4 or 6 months of age;  Infant dietary intake of fruits and vegetables whole grains desserts and sweets and salty snacks at 3 6 9 12 and 18 months of age;  Duration of infant sleep (hours of total daily sleep hours of nocturnal sleep and number of night awakenings) at 3 6 9 12 and 18 months of age;  Infant exposure to television and electronic media (number of hours of screen time per day proportion of infants with a T.V. or other media screen in bedroom) at 3 6 9 12 and 18 months of age|468|NCT01938118|October 2013
805|Active not recruiting|Novel Retinal Imaging Biomarkers in Early Alzheimer&apos;s Disease||Other: spectral-domain optical coherence tomography (SD-OCT)|Observational||Other|Nerve fiber layer/ganglion cell layer (NFL/GCL) abnormality score;  NFL/GCLabnormalityscore;  Drusen/plaquescore;  Totaldrusenarea|60|NCT01937221|September 2013
806|Completed|Determining the Barriers and Motivations to Clinical Trial Participation|||Observational||Other / Industry|Reasons why people choose to or not to participate in HIV Clinical Trials based on questionnaire responses|48|NCT01937091|August 2013
807|Active not recruiting|CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer||Drug:68-bis(benzylthio)octanoicacid|Interventional|Phase 1|Other / NIH|Tumor response rates defined as the proportion of patients who achieve complete response (CR) partial response (PR) stable disease (SD) or progressive disease (PD);  Progression-freesurvival(PFS);  Overallsurvival(OS)|20|NCT01931787|October 2013
808|Completed|A Transgenerational e-Intervention for Gestational Diabetics and Their Offspring||Behavioral:LifestyleCounseling|Interventional||Other / NIH|Changeinglycosylatedhemoglobin;  Changeinweightafterpregnancy|50|NCT01931280|September 2013
809|Recruiting|Impact of Fructose on Metabolism Energy Homeostasis and MR Biomarkers in NAFLD||Other:intravenousfructosechallenge|Interventional|Phase 1|Other|Changeinmetabolism;  Changeinenergyhomeostatic;  ChangeinMRBiomarkers|100|NCT01930123|October 2013
810|Completed|Evaluation of Efficacy and Accuracy of a Cordless Ultrasonic Dissection System|||Observational||Other / Industry|Placement of Sonicision Cordless Ultrasonic Dissection Device;  Efficacy of Sonicision Cordless Ultrasonic Dissection Device;  DeviceComplications|110|NCT01929928|January 2013
811|Completed|Evaluation of Efficacy and Accuracy of Aquamantys Device in General Surgery|||Observational||Other / Industry|EfficacyoftheAquamantysDevice;  PlacementofAquamantysDevice;  DeviceComplications|20|NCT01929902|July 2013
812|Completed|Study of Wellness Behaviors as a Function of Oxytocin vs Placebo||Drug:Oxytocin;  Drug:Placebo(foroxytocin);  Behavioral:LovingkindnessMeditation;  Behavioral:MindfulnessMeditation|Interventional|Phase 1|Other / NIH|Change in positive emotions (as measured by the Modified Daily Emotions Scale);  Change in nonconscious incentive salience (as measured by the Affect Misattribution Procedure).;  Changesinmeditationtime;  CardiacVagalTone|239|NCT01929161|September 2013
813|Enrolling by invitation|Fluid Intake Application to Reduce Kidney Stone Risks||Behavioral:iPhoneApplication;  Behavioral:AndroidApplication;  Device:iPhonecellular;  Device:Androidcellular|Interventional||Other|24-hoururinevolume;  Actual 24-hour urine volume vs. patient perceived urine volume;  Ease and interest in monitoring fluid intake based on survey data|50|NCT01928108|July 2013
814|Recruiting|Self-management Interventions for Advanced Breast Cancer||Behavioral:discussiongroup;  Behavioral:gentleexercise|Interventional||Other / NIH|Feasibility;  Acceptability;  Changeinpain;  Changeinfatigue;  Changeinsleepdisturbance;  ChangeinPsychologicaldistress;  Changeinfunctionalcapacity|60|NCT01927081|September 2014
815|Completed                  Has Results|Short-Term Effects &amp; Safety of an Accelerated Intravenous Iron Regimen in Patients With Heart Failure||Drug:Sodiumferricgluconate|Interventional|Phase 4|Other|SerumHemoglobinConcentration;  TransferrinSaturation;  SerumFerritinLevel|13|NCT01925703|April 2011
816|Completed|Effects of a Cocoa Shot on the Human Brain||DietarySupplement:HighCaffeine;  DietarySupplement:Lowcaffeine;  DietarySupplement:Hightheobromine;  DietarySupplement:lowtheobromine;  DietarySupplement:Notheobromine|Interventional|Phase 0|Other / Industry|ChangeinWorkingMemory(%correct);  ChangeinResponseTime(milliseconds);  ChangeinShortTermMemory(#correct);  ChangeinMood(changeinLikertscalescore);  ChangeinAttention(%accuracy);  ChangeinExecutiveFunction(#correct);  ChangeinBrainBloodFlow(ml/g/min);  %ChangeinHeartRate(beats/minute);  %ChangeinRespiration(breaths/minute);  %ChangeinBloodPressure(mmHg)|6|NCT01924481|September 2013
817|Completed|Development of Biomarkers of Effect From Chronic Tobacco Usage|||Observational||Industry|Urinary Tobacco Exposure Biomarkers: Nicotine (NIC) and nine metabolites Tobacco-specific nitrosamines polycyclic aromatic hydrocarbons aromatic amines mercapturic acid metabolites and thiocyanate.;  UrinaryTobaccoExposureBiomarkers:Tracemetals;  BuccalCellBiomarkers;  BloodBiomarkersofTobaccoExposure;  BloodBiomarkersofTobaccoEffect;  SalivaBiomarkers;  Urinary Tobacco Exposure Biomarkers: Nicotine (NIC) and nine metabolites.;  Health status scores from self-administered questionnaires on health nicotine dependence diet history tobacco product usage and perceived stress.|120|NCT01923402|June 2010
818|Completed                  Has Results|The Effect of Anticholinergics on Cognitive Function in the Elderly||Drug:TrospiumChloride;  Drug:Placebo|Interventional|Phase 4|Other|HopkinsVerbalLearningTest-Revised;  Mini-MentalStateExamination;  OveractiveBladderQuestionnaire|59|NCT01922115|June 2013
819|Completed|Child Care Wellness Study on Nutrition and Physical Activity||Behavioral:NAP-SACCChildCareWellnessProgram|Interventional||Other / U.S. Fed|Change in Nutrition and Physical Activity Policies;  Change in Nutrition and Physical Activity Behaviors|18|NCT01921842|January 2008
820|Terminated|Blood Pressure Heart Rate Variability &amp; Sleep in Veterans With PTSD||Behavioral: Cognitive-Behavioral Therapy for Insomnia (CBTI)|Interventional||U.S. Fed|BloodPressure;  HeartRateVariability|19|NCT01920451|August 2013
821|Recruiting|Anorexia Nervosa Genetics Initiative|||Observational||Other|Geneticdifferences|13000|NCT01916538|June 2013
822|Recruiting|The Effect of Scheduled Ripcord Removal on the Outcomes of Baerveldt 350 Implants||Procedure:Ripcordremoval|Interventional||Other|Incidenceofpost-operativecomplications;  Incidence of successful intraocular pressure control|50|NCT01915706|September 2013
823|Active not recruiting|Lymphedema in Endometrial Cancer|||Observational||Other|changeinincidenceoflower-extremitylymphedema;  changeinlymphedema-relatedmorbidity|100|NCT01914276|October 2013
824|Completed|Study of Exposure to Stress Postpartum Mood Adverse Life Events and Hormonal Function Among Latinas (SEPAH Latina)|||Observational||Other|Postpartumdepression|34|NCT01912833|August 2013
825|Completed                  Has Results|Pilot Study on Ambulatory Intraocular Pressure and Blood Pressure Monitoring in Glaucoma||Device:SensimedTriggerfish;  Device:BloodPressure|Interventional||Other / Industry|ArterialPressure;  IntraocularPressure;  MeanPerfusionPressure;  DiastolicPressure;  SystolicPressure|36|NCT01912599|July 2013
826|Completed|Preoperative Window Study of Metformin for the Treatment of Endometrial Cancer||Drug:Metformin|Interventional|Phase 0|Other / NIH|Change in Ki-67 mean levels between pre-metformin treatment endometrial biopsies and post-metformin treatment hysterectomy specimens|28|NCT01911247|May 2011
827|Enrolling by invitation|Adaptive Pet Study||Other:PET-CT|Interventional||Other|The number of subjects with benefit from an intra-treatment PET-CT;  Locoregionalcontrol.;  Freedomfromdistantmetastases;  Measureoverallsurvival(OS);  Measureacutetoxicities;  Measurelatetoxicities|320|NCT01908504|January 2012
828|Completed|Plasma and Urine TMAO Formation and Changes to Oxidized LDL After Ingestion of Different Amounts of Egg||Other:EggDose|Interventional||Other|Area under the plasma concentration versus time curve (AUC) of TMAO;  ConcentrationofTMAOinurine|6|NCT01906554|October 2012
829|Active not recruiting|The Role of S-nitrosohemoglobin in Regulating Systemic Blood Flow During Hypoxia and Normoxia||Drug:OralN-acetylcysteine|Interventional|Phase 0|Other|Forearmbloodflow|30|NCT01905696|March 2013
830|Recruiting|Negative Pressure Wound Therapy to Reduce Surgical Site Infection||Device:Conventionalwoundtherapy;  Device:Negativepressurewoundtherapy|Interventional||Other / Industry|IncidenceofSurgicalSiteInfection;  Characterizationofsurgicalsiteinfection;  Lengthofhospitalstay|126|NCT01905397|October 2013
831|Completed|Amphetamine-Enhanced Stroke Recovery||Drug:Dextroamphetamine;  Other:PhysicalTherapy;  Drug:Placebo|Interventional|Phase 2|Other|Mean Change in Fugl-Meyer Score from Baseline to 90 days Poststroke;  Mean Change in Ambulation Speed Score from Baseline to 90 Days Poststroke;  Mean Change in Ambulation Endurance Score from Baseline to 90 days Poststroke;  Mean Change in the Action Research Arm Test (ARAT) score from Baseline to 90 days Poststroke;  Mean Change in the Mobility Subscale of the Functional Independence Measure from Baseline;  Mean Change in the NIH Stroke Scale Score from Baseline;  MeanChangeinRankinScaleScorefromBaseline;  Mean Change in Mini-Mental State Examination Score|99|NCT01905371|April 2001
832|Recruiting|Auditory Brainstem Implantation in Young Children||Device: Auditory Brainstem Implantation in Children|Interventional|Phase 0|Other|SafetyandComplications;  SpeechPerception|10|NCT01904448|September 2012
833|Completed|Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant|||Observational||Other|CatalogueData|48|NCT01904175|August 2013
834|Completed|The Effect of Prophylactic FFP Administration on ECMO Circuit Longevity||Biological:Freshfrozenplasma|Interventional||Other|ECMOpumplongevity;  NumberofAdverseEvents|31|NCT01903863|July 2013
835|Recruiting|CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy||Drug:68-bis(benzylthio)octanoicacid|Interventional|Phase 2|Other / NIH|Response rate (RR) defined as the combined rate of complete remission (CR) marrow CR partial remission (PR) or stable disease (SD) as described by Cheson et al. (2006);  Safety profile of CPI-613 based on evaluation of symptoms vital signs ECOG performance status and survival clinical chemistry hematology and coagulation assessed by National Cancer Institute Common Terminology Criteria for Adverse Events v 4.0;  Progression-freesurvival(PFS);  Overallsurvival(OS);  Number of patients who achieve a reduction in blood transfusion requirements;  Number of patients who achieve hematologic improvement (HI) as defined by Cheson et al. (2006)|20|NCT01902381|August 2013
836|Recruiting|CPT and Smoking Cessation||Behavioral:CognitiveProcessingTherapy(CPT);  Drug:Bupropion;  Drug:nicotinereplacementtherapy(NRT);  Behavioral: Integrated Care for Smoking Cessation (ICSC);  Behavioral:smokefreeVET|Interventional|Phase 2 / Phase 3|U.S. Fed|smokingabstinence|50|NCT01901848|December 2013
837|Completed|Physical Activity to Reduce Joint Pain During Aromatase Inhibitor Therapy||Behavioral:WalkwithEase|Interventional||Other|Self-reportedjointpain;  Self-reportedwalking|78|NCT01900418|August 2013
838|Recruiting|Virtual Reality for Osteoarthritis Knee Pain Pilot||Procedure:VirtualRealityTrainingSession;  Device: 3D viewer with iPod Touch/iPhone (or similar smartphone)|Interventional||Other|FeasibilityofVirtualRealityinPainCoping;  Changeinselfreportedpain|30|NCT01899508|June 2015
839|Completed|Feasibility of Blood Oxygenation Level-Dependent Contrast (BOLD) Breast MRI Induced by Breath- Holding|||Observational||Other|The change in BOLD contrast of the breasts and / or chest wall tissue will be measured by comparing breath hold sequences to normal breathing.;  Feasibility as measured by a BOLD contrast signal in at least 30% of subjects|11|NCT01898533|September 2013
840|Completed|Triadic Expectations: Decision Making in the Context of Cancer Treatment|||Observational||Other|DecisionalRegret;  Decisional concordance or discordance among members of triads|38|NCT01898481|August 2013
841|Recruiting|Neurosteroids as Novel Therapeutic Agents for Chronic Pain in OEF/OIF Veterans||Drug:Pregnenolone;  Drug:Placebo|Interventional|Phase 2 / Phase 3|U.S. Fed|Painrating;  BriefPainInventory;  TowerofLondon;  DigitSequencingTask;  DavidsonTraumaScale|90|NCT01898013|September 2013
842|Completed|Quantifying the Presence of Lung Disease and Pulmonary Hypertension in Children With Sickle Cell Disease||Drug:Albuterol|Interventional|Phase 1|Other|Presence of obstructive or restrictive lung disease;  Presenceofpulmonaryhypertension|5|NCT01895998|August 2013
843|Completed|The Early Truancy Prevention Project||Behavioral:Teacherledintervention|Interventional||Other / U.S. Fed|Percentofstudentswhoaretruant;  Averagenumberofabsencesperclassroom|20|NCT01894464|August 2013
844|Completed                  Has Results|Shoe Lifts for Leg Length Inequality in Adults With Knee or Hip Symptoms||Device: Shoe lift correction for leg length inequality|Interventional||Other|ChangeinPainIntensity;  ChangeinLowerExtremityPhysicalFunction|46|NCT01894100|July 2013
845|Completed|Use of a Brief Phone Call After ED Discharge||Behavioral:EDDischarge&amp;MedicationCall;  Behavioral:PlaceboComparator|Interventional||Other|Time to the first occurrence of hospital readmission emergency department visit or death.;  Time elapsed from initial emergency department visit to Physician follow up;  Patientsatisfactionasreportedbyphonesurvey|2003|NCT01893931|August 2013
846|Completed|Observational Assessment of Baseline Asthma Control in African-American Children|||Observational||Other / U.S. Fed|Change in lung function assessed by spirometry over a period of 6-8 weeks;  AsthmaControlCompositeMeasure|25|NCT01891630|July 2013
847|Completed|Oral Peanut Immunotherapy for Peanut Allergic Patients||Drug:Peanutprotein|Interventional|Phase 0|Other|The percentage of peanut-allergic patients achieving clinical desensitization to peanut assessed after up to five years of OIT.;  Clinical desensitization will be measured with an oral peanut challenge conducted while on OIT therapy.;  Changes in number of antigen-specific lymphocytes.;  Changes in function of antigen-specific lymphocytes.|36|NCT01891136|April 2004
848|Completed|Thalidomide in the Treatment of Chronic Plaque Psoriasis.||Drug:Thalidomideoral|Interventional|Phase 2|Other|PsoriasisAreaandSeverityIndex(PASI)Score;  SubjectGlobalAssessment|21|NCT01891019|April 2003
849|Recruiting|The Prospective Collection Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen|||Observational||Other|Datafollowup|1000|NCT01890486|May 2001
850|Recruiting|Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer||Biological:AVX701|Interventional|Phase 1|Other / Industry|Numberofparticipantswithadverseevents|12|NCT01890213|November 2013
851|Completed|Bioequivalence Study of Isotretinoin Capsules 20 mg Under Fasting Condition||Drug:Isotretinoin|Interventional|Phase 1|Industry|Areaundercurve(AUC)|41|NCT01888341|August 2002
852|Completed|Bioequivalence Study of Isotretinoin Capsules 40 mg Under Fed Condition||Drug:Isotretinoin|Interventional|Phase 1|Industry|Areaundercurve(AUC)|26|NCT01888328|May 2001
853|Completed|Bioequivalence Study of Isotretinoin Capsules 40 mg Under Fasting Condition||Drug:Isotretinoin|Interventional|Phase 1|Industry|Areaundercurve(AUC)|35|NCT01888289|July 2001
854|Active not recruiting|Freezing of Gait in Parkinson&apos;s Disease||Device:TowerofHanoi;  Other:Placebogroup-nonuseofTowerofHanoi|Interventional||Other|DoubleLimbSupport(DLS)|60|NCT01887054|June 2013
855|Completed                  Has Results|A Clinical Trial Using Spy Elite System in Planning Tissue Advancement Flaps After Ventral Hernia Repair||Procedure:SPY-UnblindeduseofSPYElite;  Procedure:Control-BlindeduseofSPYElite|Interventional|Phase 1 / Phase 2|Other / Industry|WoundComplication|102|NCT01886963|November 2011
856|Active not recruiting|Safety and Efficacy of Albuterol on Motor Function in Individuals With Late-onset Pompe Disease Receiving Enzyme Replacement Therapy||Drug:Albuterol;  Drug:Placebo|Interventional|Phase 1 / Phase 2|Other|NumberofparticipantswithAdverseEvents.;  Change in forced vital capacity from pulmonary function tests at 30 weeks and 52 weeks.;  Changein6minutewalktest|16|NCT01885936|June 2013
857|Recruiting|Improving Resection Rates Among African Americans With NSCLC||Other:UsualCare;  Other:InterventionArm|Interventional||Other|ReceiptofLDTCI;  Receipt of Surgical and/or Radiation Oncology Consultation Confirmed by Medical Record Review;  Time to LDTCI (For Pts. Who Received LDTCI Only) Confirmed by Medical Record Review;  Satisfaction with Care Received Patient Satisfaction(REF) (28 items);  Time of Death Follow-up Survey Confirmed by Medical Record Review|200|NCT01885455|January 2015
858|Completed|Effect of ASEA on Energy Expenditure and Fat Oxidation in Humans||DietarySupplement:SaltWater;  DietarySupplement:ASEAwater|Interventional||Other|RestingEnergyExpenditure;  PlasmaHormones|15|NCT01884727|November 2012
859|Completed|Third Molar Clinical Trials: Pericoronitis Studies|||Observational||Other|QualityofLife;  inflammatorymediators|115|NCT01882270|January 2008
860|Available|Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants||Biological:CliniMACSCD34ReagentSystem|Expanded Access||Other / Industry|||NCT01881334|
861|Completed|Cardiopulmonary Responses to Exposure to Ozone and Diesel Exhaust||Other:ozone|Interventional||U.S. Fed|LungFunctionDecrement;  Heartratevariability|15|NCT01874834|August 2010
862|Completed|Traditional African Healing Ceremony in a U.S. Population||Behavioral:Movementtorhythm|Interventional||Other|Report from each participant as to whether they found the experience positive neutral or negative.;  writtennarrativeofexperience|17|NCT01873482|May 2014
863|Recruiting|Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia||Drug:gemtuzumabozogamicin;  Other:laboratorybiomarkeranalysis|Interventional||Other / NIH|Accesstogemtuzumabozogamicin;  Incidence of adverse events as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|30|NCT01869803|August 2013
864|Recruiting|Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia||Procedure:bioelectricimpedanceanalysis|Interventional||Other / NIH|Treatment related mortality defined as the percent of patients no longer alive at 60 days after registration;  Treatment related mortality defined as the percent of patients no longer alive at 30 days after registration;  Lengthofhospitalization;  Transfertointensivecareunitduringinduction;  Bonemarrowresponse;  Complete remission defined as less than 5% marrow blasts absolute neutrophil count &gt; 1000 platelet count &gt; 100000 and freedom from red cell transfusions;  Receiptofpost-remissiontherapy;  Overallsurvival|102|NCT01869777|July 2013
865|Recruiting|Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer||DietarySupplement:omega-3fattyacid;  Other:placebo;  Other:laboratorybiomarkeranalysis|Interventional|Phase 2|Other / NIH|PUFA levels in normal and metastatic breast tissue and in plasma and red blood cells;  Metabolites of omega-3 and omega-6 PUFA in malignant and normal breast tissue;  Proliferation and apoptosis in malignant breast tissue|60|NCT01869764|November 2013
866|Completed|Brief Intervention to Create Smoke-Free Homes Policies in Low-Income Households: North Carolina Effectiveness Trial||Behavioral: Educational print materials and coaching call|Interventional||Other / NIH|Presenceofatotalhomesmokingban;  Weeklysecondhandsmokeexposurefornon-smokers;  Cessationattempts(forsmokers);  Numberofcigarettessmoked(forsmokers);  Stageofchangetoquitsmoking(forsmokers);  Successfulcessation(forsmokers)|500|NCT01868672|June 2013
867|Recruiting|ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients||Drug:Cessationgroup;  Drug:Continuationgroup|Interventional||Other|Changeinbloodpressure;  Number of times vasopressors given to subject both intraoperatively and postoperatively;  Number of instances subjects transferred to Intensive Care Unit (ICU);  Number of instances that subject receives allogeneic blood;  Occurrenceofacutekidneyinjury|100|NCT01867047|June 2013
868|Active not recruiting|A Prospective Observational Study of Pregnancy Outcomes Among Women Exposed to Truvada for PrEP Indication|||Observational||Industry|Presence or absence of congenital malformations among infants born to HIV-1 uninfected women on FTC/TDF for PrEP;  Pregnancy outcomes in HIV-1 uninfected women who choose to continue or discontinue FTC/TDF for PrEP during their pregnancy as well as HIV-infected women treated with antiretrovirals|400|NCT01865786|January 2013
869|Active not recruiting|Microfinance and Health Intervention Trial for Youth in Dar es Salaam Tanzania||Behavioral:MicrofinanceandHealthLeadership|Interventional||Other / NIH|IncidenceofNewSexuallyTransmittedInfections;  Proportion of Men Reporting Perpetration of Physical Sexual or Psychological Partner Violence|2623|NCT01865383|July 2013
870|Completed|Interactive Web-Based Tool for Pelvic Organ Prolapse: Impact on Patient Understanding and Provider Counseling||Other:&quot;Usualpractice&quot;counseling;  Other: Standard &quot;usual practice&quot; clinical counseling with the pelvic organ prolapse web-based tool (iPad).|Interventional||Other|Change in patient reported satisfaction with understanding of bulge symptoms based on Likert scale scores.;  Change in patient reported anxiety with understanding of bulge symptoms based on Likert scale scores.;  Assessment of patient satisfaction after standard counseling (group 1) vs standard counseling with a web-based tool (ipad)(group 2).;  Change in provider satisfaction with knowledge and anxiety regarding counseling and satisfaction with the ability to counsel women regarding pelvic organ prolapse.;  Provider assessment: was the web-based tool easy to use would you implement this tool into your practice?|90|NCT01864408|May 2012
871|Completed|Albuterol in Individuals With Late Onset Pompe Disease (LOPD)||Drug:Albuterol|Interventional|Phase 1|Other|NumberofParticipantswithAdverseEvents;  Changeinforcedvitalcapacityat3months;  Changein6minutewalktestin6months.|8|NCT01859624|June 2012
872|Completed|Improved Patient Handoffs to Prevent Sentinel Events||Other:StructuredSignOutForm|Interventional||Other|Comparison of RRT&apos;s and unplanned transfers pre and post intervention matching aggregate numbers month to month;  Physician attitudes towards sign-out process pre and post intervention|4344|NCT01855646|
873|Completed|Sleep Apnea and Visual Perceptual Skill Learning||Other: Subject using usual positive airway pressure therapy while sleeping for one night|Interventional||Other|VDTlearningChangeScore;  ApneaHypopneaIndex(AHI)|14|NCT01852929|November 2009
874|Completed|An Evaluation of Neurofeedback Efficacy in Adults With ADHD||Other:Neurofeedback;  Other:ShamNeurofeedback|Interventional||Other|Attention Performance Index of the Test of Variables of Attention;  TestofVariablesofAttention|30|NCT01852357|April 2013
875|Completed|Enhancing Exercise in Breast Cancer Survivors||Behavioral: Newsletter about physical activity and breast cancer survivors;  Behavioral:Changingyourhabitsbrochure;  Behavioral: Tips for making exercise enjoyable and personally-valued;  Behavioral: Testimonials from breast cancer survivors|Interventional||Other|change in number of minutes of moderate to strenuous physical activity;  changes in joy and satisfaction with physical activity|81|NCT01849978|May 2014
876|Completed|Assessment of Ability of Breath Hold for Left-sided Breast Cancer Radiation Therapy to Reduce Side Effects to Heart||Other:CardiacSPECTperfusionscan|Observational||Other|Changesincardiacperfusion;  Wall-motionabnormalities|25|NCT01849614|March 2013
877|Recruiting|Superior Laryngeal Nerve Block For Awake Endotracheal Intubation Study||Procedure: Superior Laryngeal Nerve Block using the Thyrohyoid Membrane as an Anatomic Landmark|Observational||Other|The primary outcome measure is to assess the efficacy of blocking the superior laryngeal nerve by using cough at the vocal cords on a 4 point scale;  Timetoplacementofblock|95|NCT01848548|April 2013
878|Completed|Step by Step: A Tailored Walking Intervention for Breast Cancer Survivors||Behavioral:TailoredEmail;  Behavioral:TargetedEmail|Interventional||Other|Difference in weekly steps between intervention and comparison group at the end of the intervention (week 12).|90|NCT01845519|July 2013
879|Completed|Sulforaphane Supplementation in Atopic Asthmatics||DietarySupplement:AlphaSproutHomogenate;  DietarySupplement:SulforaphaneHomogenate|Interventional|Phase 1|Other|mRNA levels of NRF2 and NRF2-dependent phase II enzymes in nasal epithelial cells|16|NCT01845493|April 2013
880|Active not recruiting|Lipid Lowering Agents to Limit Lipid Oxidation and Activation of Clotting System in Nephrotic Syndrome||Drug:Pravastatin|Interventional|Phase 1|Other / NIH|Changes in Microparticle tissue factor (MP-TF) activity;  Changesinplasmacoagulationactivation|10|NCT01845428|May 2012
881|Unknown&nbsp;&#8224;|Omegaven&#174; in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury||Drug:Omegaven&#174;|Interventional|Phase 2|Other|Efficacy of parenteral administration of fish oil derived fat emulsion (Omegaven&#174;) to reverse established parenteral nutrition associated liver disease|20|NCT01845116|July 2010
882|Completed|Rethinking Eating and FITness for Men||Behavioral:REFITIntervention|Interventional||Other|Changeinweightfrombaselineto3months;  Changeinweightfrombaselineto6months;  Change in caloric intake between baseline and 3 months;  Change in physical activity between baseline and 3 months;  Self-efficacy for weight loss behaviors at 3 months;  Motivationforhealthyeatingat3months;  MotivationforPhysicalActivityat3months|107|NCT01843595|July 2013
883|Recruiting|Endogenous Pain Facilitation and Inhibition in Postpartum Women|||Observational||Other|Area of hyperalgesia will be the primary outcome measure;  Percent reduction in degree of pain to the 49 degrees Celsius stimulus during the time the foot is immersed in the cold water|80|NCT01843517|April 2013
884|Active not recruiting|Durham Connects RCT Evaluation II||Other:DurhamConnects|Interventional||Other / NIH|DSS Investigated and Substantiated Child Maltreatment Rates;  ChildEmergencyRoom(ER)PresentationRates;  ChildOvernightStaysinHospital;  MotherPostnatalWell-CareComplianceRates;  ChildPostnatalWell-CareComplianceRates;  MotherEmergencyRoom(ER)PresentationRates;  MotherOvernightStaysinHospital;  MotherMentalHealth;  Family Connections to Community Services/Resources;  MotherParentingBehaviors|1650|NCT01843036|January 2014
885|Unknown&nbsp;&#8224;|Prophylactic Modified McCall Culdoplasty During Total Laparoscopic Hysterectomy||Procedure:McCallculdoplasty|Interventional||Other|Feasibility;  Pelvicsupport;  Sexualfunction|50|NCT01840176|May 2013
886|Completed|Environments as Smoking Cues: Imaging Brain Substrates Developing New Treatments (CameraCue)||Behavioral:QuitSmoking6hours;  Behavioral:QuitSmoking24hours|Interventional||Other|Signal Change in Functional Magnetic Resonance Imaging (fMRI) BOLD Signal between Personal Environment Pictures Relative to Standard Environment Pictures|67|NCT01840111|December 2012
887|Active not recruiting|CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer||Drug:68-bis(benzylthio)octanoicacid|Interventional|Phase 1|Other / NIH|OverallSurvival;  Responserate;  ProgressionFreeSurvival;  Safety profile assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|10|NCT01839981|July 2013
888|Completed|chemQbiosciences:Manual Liquid Based Cytology||Procedure:Papsmear|Observational||Other|Compare cytologic outcomes using manual liquid based cytology to conventional|76|NCT01837303|May 2013
889|Active not recruiting|CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer||Drug:68-bis(benzylthio)octanoicacid;  Drug:oxaliplatin;  Drug:leucovorincalcium;  Drug:irinotecanhydrochloride;  Drug:fluorouracil;  Other:laboratorybiomarkeranalysis|Interventional|Phase 1|Other / NIH|MTD of 68-bis(benzylthio)octanoic acid when used in combination with mFOLFIRINOX determined by dose-limiting toxicities graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0|21|NCT01835041|April 2013
890|Completed|Translational Research Evaluating Neurocognitive Memory Processes|||Observational||Other / NIH|CaliforniaVerbalLearningTest-II|76|NCT01834677|April 2013
891|Terminated|Swept-Source Optical Coherence Tomography for Noninvasive Retinal Vascular Imaging||Device:Swept-SourceOpticalCoherenceTomography|Interventional||Other|OCT images and metrics derived from the OCT images|13|NCT01834196|August 2012
892|Recruiting|Use of a Mobile-based App for SCD Patients|||Observational||Other|Usability|100|NCT01833702|January 2015
893|Active not recruiting|Latinos Combating Diabetes||Behavioral:LifestyleWeightLoss;  Behavioral:Counseling|Interventional||Other / NIH|HemoglobinA1c;  BodyWeight;  BloodPressure;  FastingGlucose;  Lipids|225|NCT01831921|April 2013
894|Completed|A Comparison of Scalp Blood Flow and Hair Shaft In Premenopausal Women Versus Postmenopausal Women|||Observational||Other / Industry|Scalp/HairBiologicalStructural;  HairChemicalStructuralinformation;  HairChemicalStructure|50|NCT01831180|September 2013
895|Completed|Acute and Chronic Nicotine Modulation of Reinforcement Learning||Drug:Nicotinepolacrilex;  Drug:Placebo;  Other:satiety;  Other:abstinence|Interventional||Other|changeinbloodoxygenleveldependentsignal|48|NCT01830842|February 2014
896|Terminated                  Has Results|Effects of Sildenafil on Choroidal Thickness in AMD||Drug:Sildenafilcitrate|Interventional|Phase 2|Other|Change in Choroidal Thickness as Assessed on Enhanced-Depth Imaging Optical Coherence Tomography (EDI-OCT);  Change in Central Foveal Thickness as Assessed by Optical Coherence Tomography (OCT)|10|NCT01830790|March 2013
897|Completed|Comparative Study of Polymetric Clips (Hem-o-Lok) Versus Historical Endoscopic Staplers for Laparoscopic Appendectomy||Device:Polymetricclips;  Other:EndoscopicStaplers|Observational||Other|Lengthofstay;  TotalHospitalCharges;  Operativetime;  RatesofSurgicalOutcomes|26|NCT01830387|April 2013
898|Completed                  Has Results|Control of Tourniquet Pain With an Axillary Ring of Subcutaneous Local Anesthetic||Drug:BupivacainewithEpinephrine;  Drug:NormalSaline|Interventional|Phase 4|Other|TimeinMinutesThatTqRemainedInflated;  PainScoreatTimeofTqDeflation|24|NCT01829399|April 2013
899|Active not recruiting|Simultaneous Risk Factor Control Using Telehealth to slOw Progression of Diabetic Kidney Disease (STOP-DKD)||Behavioral:Pharmacisttelehealthintervention|Interventional||Other|Change in kidney function as measured by estimated glomerular filtration rate based on cystatin C(eGFRcys);  Change in blood pressure glucose/HbA1c and urine albumin|285|NCT01829256|May 2014
900|Completed                  Has Results|Milnacipran and Neurocognition Pain and Fatigue in Fibromyalgia : A 13-week Randomized Placebo Controlled Cross Over Trial||Drug:Milnacipran;  Drug:Placebo|Interventional|Phase 3|Other / Industry|VisualAnalogueScaleforPain;  ChangesinTheFatigueSeverityScale(FSS);  Composite Brief Assessment of Cognition (BAC) Score;  MATRICS Consensus Cognitive Battery Composite Score|26|NCT01829243|July 2011
901|Completed|Pelvic CT Imaging in Blunt Abdominal Trauma|||Observational||Other|IntrabdominalInjury;  RadiationExposure;  physicians&apos;pretestprobability|230|NCT01828749|February 2013
902|Active not recruiting|New Media Obesity Treatment in Community Health Centers||Behavioral:eHealthweightlossintervention|Interventional||Other|Weightchange;  The achievement and maintenance of &gt; 5% weight loss;  Diet;  Cardiometabolicriskmarkers;  GlobalFraminghamriskscore;  An evaluation of the intervention&apos;s impact and dissemination potential using the Reach Effectiveness Adoption Implementation Maintenance (RE-AIM) framework;  Physicalactivity|351|NCT01827800|June 2013
903|Withdrawn|Improving Medication Adherence in Hypertensive Patients||Behavioral:ElectronicIntervention|Interventional||Other|ProportionofDaysCovered(PDC)|0|NCT01826435|January 2014
904|Completed|Effects of a Double-Blind Single Dose of PER977 Administered Alone and Following a Single Dose of Edoxaban||Drug:PER977Placebo|Interventional|Phase 1|Industry|To evaluate the safety tolerability and plasma and urinary pharmacokinetics (PK) of a range of single intravenous (IV) doses of PER977;  Pharmacodynamicassessment|83|NCT01826266|July 2013
905|Completed|Duration of Antibiotic Therapy as Part of Maximal Medical Therapy for Chronic Rhinosinusitis||Drug:Doxycycline;  Drug:Azithromycin;  Drug:Augmentin|Interventional|Phase 4|Other|Number of patients recommended for sinus surgery after 3 weeks of antibiotic therapy;  Number of patients recommended for sinus surgery after 6 weeks of antibiotic therapy;  Change in Quality of Life after 3 weeks of antibiotics;  Change in Quality of Life after 6 weeks of antibiotics;  Change in Nasal endoscopy scores after 3 weeks of antibiotics;  Change in Nasal Endoscopy Score following 6 weeks of antibiotics;  ChangeinCTScoreafter3weeksofantibiotics;  ChangeinCTScoreafter6weeksofantibiotics;  Number of patients with antibiotic side effects after a 3 week course of antibiotics;  Number of subjects with antibiotic side effects after a 6 week course of antibiotics|37|NCT01825408|February 2013
906|Active not recruiting|Amniotic Membrane as an Adjunct Treatment for Hallux Rigidus||Procedure: Dorsal Cheilectomy without Amniotic Membrane Tissue Implantation;  Procedure: Dorsal Cheilectomy with Amniotic Membrane Tissue Implantation|Interventional|Phase 4|Other|American Orthopedic Foot and Ankle Society (AOFAS) score|60|NCT01825356|April 2013
907|Recruiting|Prospective Trial Comparing Two Different Polypropylene Meshes for Inguinal Hernias||Device:ULTRAPROMesh;  Device:3DMAX;  Other:Evaluation|Interventional||Other|To evaluate the clinical effectiveness of two currently used meshes for inguinal hernias;  To evaluate the ease of use and time it takes surgical residents to place the mesh and perform the surgery using these two different meshes.|511|NCT01825187|June 2014
908|Enrolling by invitation|Bone Metabolism After Bariatric Surgery|||Observational||Other|ChangesinBoneMineralDensity;  BiochemicalChangesinBoneMetabolism|40|NCT01824797|May 2013
909|Completed|Omega-6 to Omega-3 Fatty Acid Ratio and Higher Order Cognitive Function in 7-to 9-year-olds|||Observational||Other|Relation between executive function and n-6/n-3 fatty acid intake;  Temperament;  Socioeconomicstatus|70|NCT01823419|October 2010
910|Completed|Effect of Tyrosine on Behavioral Physiological and Nutritional Status During Survive Evade Resist Escape (SERE) School||Other:Tyrosine-ContainingBar;  Other:PlaceboBar|Interventional||U.S. Fed|change from baseline cognitive function compared to cognitive function as measured following treatment administration|73|NCT01823276|May 2013
911|Completed                  Has Results|Comparing Effectiveness of IV vs Oral Acetaminophen Given Perioperatively for Lap Choles for Pain Control||Drug: 2 capsules Oral Tylenol 2000 mg and IV &quot;salt water&quot;;  Drug: IV tylenol 1000mg and 2 oral capsule &quot;sugar pills&quot;|Interventional||Other|Pain;  Total Opioid Consumption From Time of First Waking to T24|67|NCT01823224|February 2013
912|Active not recruiting|Study on Visual Function Impairments in Dry Age-related Macular Degeneration|||Observational||Other / Industry|Changeinlowluminancevisualacuity;  Changeinconespecificcontrastsensitivity;  Changeincontrastsensitivity;  Changeinmacularsensitivityonmicroperimetry|210|NCT01822873|March 2013
913|Completed|Pistachios Performance Metabolomics||Other:Pistachios|Interventional||Other|Shiftsinmetabolites(metabolomics);  Inflammation;  ImmuneFunction;  OxidativeStress|40|NCT01821820|March 2013
914|Completed|Pelvic Ring Injury|||Observational||Other|Change in displacement on one or all of the standard radiographic views;  Changeinhealthrelatedqualityoflifeoutcomes|40|NCT01821339|March 2013
915|Active not recruiting|Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)||Drug:Ipilimumab;  Drug:PaclitaxelCisplatinCarboplatin|Interventional|Phase 2|Other|Percentage of subjects with detectable circulating T cells after treatment;  Feasibility and tolerability of neoadjuvant chemotherapy plus ipilimumab and surgery;  MedianDisease-FreeSurvival;  Number of subjects experiencing a metastasis by site of metastasis;  Patterns of pathologic response and response evaluation criteria in solid tumor (RECIST) response|30|NCT01820754|March 2013
916|Unknown&nbsp;&#8224;|Parents and Children Together Preventing Diabetes (PACT PD)||Behavioral:LifestyleIntervention;  Behavioral:StandardFamily-Basedintervention|Interventional||Other|BodyMassIndex;  WaistCircumference;  Physicalactivity;  DietaryIntake;  BloodPressure|72|NCT01819493|March 2013
917|Terminated|A Trial to Reduce Adhesions Following a Primary Cesarean Section||Device:Seprafilm|Interventional||Other|Adhesion formation following a primary C-section with and without adhesion barrier;  Correlation between adhesions and difficulty or delay in delivery of the infant(s)|29|NCT01819467|June 2014
918|Recruiting|Nicotine Non-Smokers With and Without ADHD and Genetics Study||Drug:Nicotinenasalspray;  Drug:Placebo|Interventional|Phase 1|Other / NIH|Changeincognitiveperformance.;  DifferencesinSubjectiveEffects.;  ChangeinPhysiologicalEffects.;  ChangeinEffectsofNicotineReinforcement.;  GeneticsEffectsonNicotineReinforcement.|150|NCT01819259|January 2013
919|Completed|High Yield Intraoperative Autologous Platelet Apheresis||Procedure:AphersisTreatmentArm;  Other:ControlArm|Interventional||Other / Industry|Numberofallogeneicplateletunitstransfused.;  Overallbloodproducttransfusion.|57|NCT01819246|January 2013
920|Completed|Adductor Canal Block for Medial Compartment Knee Arthroplasty||Procedure:Adductorcanalblock;  Procedure:Lumbarplexusblock|Interventional||Other|Verbal pain scores at 6 hours post nerve blockade.;  Opioidconsumption;  Timetofirstanalgesic;  Opioidrelatedsideeffects;  Quadricepsmotorstrength|150|NCT01818531|April 2013
921|Completed                  Has Results|Assessment of Fluticasone Propionate on Ocular Allergy Symptoms||Drug:Fluticasonepropionate;  Drug:Placebo|Interventional|Phase 3|Industry|Mean Change From Baseline in Reflective Total Ocular Symptom Score (rTOSS);  MeanChangeFromBaselineinAMrTOSS;  MeanChangeFromBaselineinPMrTOSS;  Mean Change From Baseline in Individual AM Reflective Ocular Symptom Scores for Eye Itching/Burning;  Mean Change From Baseline in Individual PM Reflective Ocular Symptom Scores for Eye Itching/Burning;  Mean Change From Baseline in Individual AM Reflective Ocular Symptom Scores for Eye Tearing/Watering;  Mean Change From Baseline in Individual PM Reflective Ocular Symptom Scores for Eye Tearing/Watering;  Mean Change From Baseline in Individual AM Reflective Ocular Symptom Scores for Eye Redness;  Mean Change From Baseline in Individual PM Reflective Ocular Symptom Scores for Eye Redness;  Mean Change From Baseline in AM Pre-dose Instantaneous Total Ocular Symptom Scores (iTOSS);  Mean Change From Baseline in Reflective Nasal Congestion Symptom Score (rNCSS);  End-of-treatment Assessment of Response to Therapy for Ocular Symptoms;  Mean Change in Objective Assessment of Conjunctival Redness;  Mean Changes From Baseline in Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) Scores;  Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Activities;  Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Practical Problems;  Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Nose Symptoms;  Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Eye Symptoms;  Mean Changes From Baseline in Individual MiniRQLQ Scores: Domain - Other Symptoms|626|NCT01817790|December 2012
922|Completed                  Has Results|Effect of CPAP on Postoperative Delirium||Device:CPAP|Interventional||Other|PresenceofPostoperativeDelirium|135|NCT01816685|June 2013
923|Unknown&nbsp;&#8224;|An Open-Label Single- and Multi-Dose Pharmacokinetic (PK) Study of Oral Diltiazem and Topical Diltiazem Hydrochloride||Drug: Diltiazem Hydrochloride Cream and Oral Diltiazem|Interventional|Phase 1|Industry|Single and multiple dose Pharmacokinetic parameters;  Safety as determined by nature severity and relationship of adverse events clinical labs physical exam findings vital signs and Electrocardiogram|12|NCT01816191|February 2013
924|Completed|Molecular Analysis of Microbial DNA in Infected Necrotizing Pancreatitis|||Observational||Other|Bacteria;  Cytokines;  GastrointestinalBacterialFlora|20|NCT01815489|July 2011
925|Withdrawn|Trial of Directed High-dose Nasal Steroids on Residual Smell Loss in Sinus Patients After Sinus Surgery||Drug:BudesonideRespules|Interventional|Phase 2|Other|ChangeinDegreeofOlfactoryFunction;  ChangeinHeadCTGrade;  ChangeinNasalEndoscopyGrade;  ChangeinQualityofLife;  Number of patients with steroid side effects after a 1-2 week course of steroids;  Number of patients with steroid side effects after a 8 week course of steroids|0|NCT01814618|March 2013
926|Recruiting|High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions||DietarySupplement:Docosahexaenoicacid;  Drug:Placebo|Interventional||Other|Number of days to return to full unrestricted athletic participation;  Number of days for balance and cognition to return to baseline|100|NCT01814527|July 2013
927|Completed|Mechanisms of Desensitization During Peanut Oral Immunotherapy||Drug:Peanutprotein|Interventional|Phase 2|Other / NIH|Percentage of subjects who develop desensitization;  Percentage of subjects who maintain desensitization once OIT is stopped|20|NCT01814241|April 2013
928|Completed|Conservative Management of Femoroacetabular Impingement||Other:Manualtherapyplusexercise;  Other:Adviceandhomeexercise|Interventional||Other|HipOutcomeScore;  NumericPainRatingScale;  FunctionalSquat;  GlobalRatingofChangeScale;  LowerExtremityFunctionalScale|18|NCT01814124|March 2013
929|Completed|Integrative Coping Group for Children||Behavioral:IntegrativeCopingGroup|Interventional||Other|The percentage of children who complete 80% of the intervention sessions;  ChangeinPsychologicalandSomaticSymptoms|28|NCT01813669|October 2012
930|Completed|Dexamethasone for Post-cesarean Delivery Pain||Drug:Dexamethasone;  Drug:Placebo|Interventional|Phase 4|Other|Morphineconsumptionat24hourspost-op;  Painscoresbetweenthegroupsat2hours.;  Time to first rescue analgesic request between the groups.;  Cumulative opioid consumption at 48 hours between the groups;  Painscoresbetweenthegroupsat24hours.;  Painscoresbetweenthegroupsat48hours.|48|NCT01812057|December 2012
931|Completed                  Has Results|Postoperative Subtenons Anesthesia for Postoperative Pain in Pediatric Strabismus Surgery||Drug: subtenons anesthetic - preservative-free bupivacaine 0.75%;  Drug: topical anesthetic - 0.5 cc of lidocaine 3.5% ophthalmic gel;  Drug: topical control - 0.5 cc of Hypromellose 0.3% gel;  Drug:subtenonscontrol-0.5ccofNormalSaline|Interventional||Other|Average Pain Score Over the First 30 Post-operative Minutes Using the CHEOPS Scale;  PeakPainScore;  TotalNarcoticUseDuringPost-operativeRecovery;  Negative Postoperative Behavior Score on the PHBQ (Post Hospitalization Behavioral Questionnaire);  AverageTimetoDischarge;  Number of Participants With Post Operative Nausea and Vomiting;  Number of Participants Who Required Anti-emetic Medication Post-operatively;  PeakPainScoreDuringFirst30Minutes|57|NCT01812044|March 2013
932|Active not recruiting|Total Knee Arthroplasty: Functional and Clinical Outcomes||Device:Zimmer;  Device:Stryker|Interventional||Other|Change in Lower Quarter Y-Balance Test (YBT-LQ) (Dynamic Balance);  ChangeinWalkingSpeed|100|NCT01811563|February 2013
933|Active not recruiting|Improving Biopsy Experiences Study for Women||Behavioral:GuidedMeditation;  Behavioral:Music;  Behavioral:SupportiveDialogue|Interventional||Other|ChangeinAnxiety;  Ratesofadherencetorecommendedfollow-upcare|243|NCT01811043|August 2012
934|Completed|The Most Effective Intervention for Reducing Posterior Shoulder Tightness Acutely in the Post-operative Population||Other:HorizontalAdductionStretchandPendulums;  Other:ModifiedSleeperStretchandPendulum|Interventional||Other|Inclinometric Measurement of Posterior Shoulder Tightness taken in side-lying;  GlobalRatingofChangeScore(GROC)|63|NCT01810211|September 2012
935|Completed                  Has Results|Does Oral Micronized Progesterone Shorten Time of Symptoms From Concussion||Drug:Progesterone;  Drug:Placebo|Interventional|Phase 4|Other|Time (in Days) That a Patient Reports Symptoms From Their Concussion.|25|NCT01809639|June 2013
936|Completed|Clinical Performance Evaluation of AQT90 FLEX BNP and NT-proBNP|||Observational||Industry|Determination of the clinical sensitivity and specificity of the AQT90 FLEX BNP and NT-proBNP assays at the clinical cut-off in heart failure patients|569|NCT01808872|March 2013
937|Active not recruiting|Oral Health Intervention Pilot Study for Individuals With Memory Problems||Behavioral:OralHealthIntervention|Interventional||Other|Changeinoralhealth;  Changesinsubjects&apos;self-efficacy|12|NCT01808235|July 2012
938|Recruiting|Pediatric Supracondylar Humerus Fracture NIRS Study||Device:NearInfraredSpectroscopyPads|Observational||Other|To establish the normal values of near infrared spectroscopy (NIRS) reading for pediatric forearms with and without supracondylar humerus fractures.;  To correlate NIRS readings with currently utilized methods of assessing perfusion in the upper extremity following supracondylar fractures (palpation of pulse Doppler vascular examination capillary refill and pulse oximetry).;  To assess the ability of NIRS measurements of forearm compartment perfusion to detect vascular injury associated with supracondylar fractures in children.|100|NCT01808183|February 2012
939|Completed|PLATFORM to Maximize Patient Knowledge of Health Goals After Acute Myocardial Infarction||Other:EducationalTool|Interventional||Other / Industry / U.S. Fed|Change in the effect of patient health goal and reminder tool on health outcomes;  Satisfactionandusefulnessofeducationtools;  Age-associated changes that modulate antiplatelet response;  Association between antiplatelet response and subsequent bleeding events;  Age-associated variation in platelet inhibitory response|192|NCT01807208|March 2013
940|Terminated|Automated MEdical Record Driven Implantable CArdioverter-defibrillator Heart Failure Trial (AMERICA-HF)||Other:AutomatedHF/EPReferral;  Other:Placebo(RegistryArm)|Interventional||Other|Rate of adherence (%) to ACC/AHA HF guideline recommended HF therapies among patients randomized to the registry compared to the intervention;  Adherence to ACC/AHA guideline recommended therapies by sex and race compared to standard referral processes among patients with ejection fraction (EF) &#8804; 35% and symptomatic HF.;  Repeated Measures Analysis of Adherence to ACC/AHA HF Guidelines|77|NCT01807130|September 2013
941|Active not recruiting|Lifestyle Intervention for Treatment of Diabetes||Behavioral:CommunityLifestyleWeightLoss(LWL);  Behavioral:DiabetesSelfManagement(DSM)|Interventional||Other / NIH|PredictedCardiovascularRisk;  HemoglobinA1c;  BloodPressure;  Lipids;  WeightChange|260|NCT01806727|April 2013
942|Completed|Empowering Rural African American Women and Communities to Improve Diabetes Outcomes||Behavioral:LifestyleCounseling;  Behavioral:EducationalControlArm|Interventional||Other|ChangeinHemoglobinA1c;  ChangeinWeight|200|NCT01806194|January 2012
943|Completed|Drug-Related Problems and Healthcare Utilization Post-Hospital Discharge||Other: RPh Counseling + Outpatient Med Dispensing at Discharge;  Other: Discharge Med Dispensing Plus Counseling - Current Practice|Interventional||Other|Drug-related problems (composite of adverse drug reactions drug interactions and failure to receive drugs) during the first 30 days post-hospital discharge;  Healthcareutilization;  Hospitalreadmissions;  Treatmentdelays|44|NCT01806038|March 2013
944|Completed|Breakfast Nutrition and Inpatient Glycemia||Other:ModifiedCarbohydrateBreakfast;  Other:ControlBreakfast|Interventional||Other|RelativechangeinBloodsugar|237|NCT01805414|September 2012
945|Active not recruiting|Mindfulness: a Novel Approach for the Management of Diabetes-related Distress||Behavioral:MindfulnessBasedStressReduction|Interventional|Phase 2 / Phase 3|Other|HgA1c;  DiabetesDistress;  SF36PhysicalHealthScore;  SF36MentalHealthScore;  Mean24hourambulatorysystolicbloodpressure;  Mean24hourdiastolicambulatorybloodpressure;  HOMA-IR;  Depression;  StateAnxiety;  TraitAnxiety;  SocialSupport;  CopingStyle;  GeneralStress;  Cortisol24hourareaunderthecurve;  CortisolAwakeningResponse;  IL-6;  SummaryofDiabetesSelf-CareActivities;  Average 24 hour glucose by continuous glucose monitor (cgm);  Averagenighttimeglucose;  Averagedaytimeglucose;  BlockFoodFrequencyQuestionnaire;  MeanDaySystolicAmbulatoryBloodPressure;  MeanDayDiastolicAmbulatoryBloodPressure;  MeanNightSystolicAmbulatoryBloodPressure;  MeanNightDiastolicAmbulatoryBloodPressure|90|NCT01805245|January 2012
946|Completed|Feasibility of Non-pharmacological Insomnia Therapy in People Living With HIV||Behavioral:CognitiveBehavioralTherapy;  Behavioral:BehavioralModification|Interventional||Other|SleepEfficiency;  AdherencetoHAART;  Fatigue|36|NCT01804907|March 2012
947|Completed|Do Common Physical Tests Predict Injury or Performance|||Observational||Other|injury;  performance|359|NCT01804894|March 2013
948|Active not recruiting|Gulf War Era Cohort and Biorepository|||Observational||U.S. Fed|The topics that will be measured by the survey are military service lifestyle behaviors physical and mental health and family (including family health).|1276|NCT01803854|September 2014
949|Completed|Using an Internet Study to Improve Adherence for Psoriasis Patients||Behavioral:InternetSurvey;  Drug:fluocinonide0.05%ointment|Interventional||Other|MeasuredMEMSAdherence;  MEMScaprelationtointernetsurvey;  DiseaseSeveritywithPASIandIGAassessment;  MEMscapdatacomparedtoPASIandIGAAssessment|40|NCT01802580|October 2012
950|Completed|Third Ventriculostomy Versus Shunt for Children With Hydrocephalus||Procedure:Endoscopicthirdventriculostomy(ETV);  Procedure:Ventricularshunt|Interventional||Other|TimeuntilneedforfurtherCSF-relatedsurgeries;  Total number of CSF-related surgeries needed within one year|8|NCT01801267|August 2013
951|Active not recruiting|PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)|||Observational||Other|Plexiform Neurofibroma Cohort: Difference in FDG-avidity between progressive and non-progressive lesions;  Optic Glioma Patients: Compare FDG-avidity between patients with progressive and non-progressive disease;  Report descriptive statistics for FDG-PET-MRI results;  Explore impact of FDG-PET-MRI surveillance on patient and family caregiver uncertainty and psychological distress|15|NCT01800032|January 2013
952|Completed|Cognitive De-Biasing and the Assessment of Pediatric Bipolar Disorder||Behavioral:DecisionMakingTutorial|Interventional||Other|Diagnosticaccuracy;  Clinicianattitudestowardintervention|240|NCT01799291|September 2012
953|Terminated|Nutritional Supplementation Effects on Rehabilitation Outcomes in Rotator Cuff Pathology||DietarySupplement:Placebo(maltodextrin);  DietarySupplement:Multi-nutrientBlend|Interventional|Phase 0|Other|Change in shoulder function pain strength and range of motion|5|NCT01798693|August 2013
954|Terminated                  Has Results|A Trial Examining the Efficacy of Escitalopram Oxalate Upon Depressive Symptoms and Fatigue in HIV Seropositive Women||Drug:Placebo;  Drug:Escitalopram|Interventional|Phase 4|Other|ReductioninDepressiveSymptoms|5|NCT01797380|January 2008
955|Recruiting|The Use of Biologic Mesh vs Bioabsorbable Mesh During Ventral Hernia Repair in At-risk Patients||Device:StratticeArm;  Device:Bio-AArm|Interventional||Other|HerniaRecurrence|96|NCT01794338|November 2012
956|Completed|Cognitive Rehabilitation in Sickle Cell Disease||Behavioral:Cogmed|Interventional||Other|Feasibility;  Efficacy|18|NCT01793740|October 2012
957|Terminated|A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects||Drug:GS-5737|Interventional|Phase 1|Industry|Area under the curve of MCC from Whole Lung Compartment;  Area under the curve of MCC from Central and Peripheral Lung|7|NCT01793649|October 2012
958|Recruiting|Transplantation and the Use of Raltegravir in HIV-Infected Patients|||Observational||Other / Industry|To examine raltegravir (RAL) in the management of HIV-infected persons listed for solid organ transplantation with a focus on mortality and graft survival;  Assess Raltegravir viability as a long term HIV treatment drug for patients undergoing transplant;  determine the viability of grafted organs in patients with HIV infections|10|NCT01793467|October 2012
959|Active not recruiting|Post-traumatic Arthritis Associated With Joint Injury||Procedure: Tissue sample collection at the time of surgery|Observational||Other / U.S. Fed|Markers of joint tissue degeneration following articular fracture;  KOOSquestionnaire|30|NCT01792791|October 2012
960|Active not recruiting|Sustained Effects of Hypertonic Saline on Mucociliary Clearance in Subjects With Chronic Bronchitis||Other:Inhaled7%HS(NaCl)hometreatment|Interventional||Other / NIH|Measure and compare the sustained effects on mucus clearance of two weeks of daily dosing of hypertonic saline versus a low salt control treatment for subjects with CB.;  We will also be collecting sputum and breath condensation to analyze for protein and inflammatory changes that might occur with exacerbations.|24|NCT01792271|February 2013
961|Unknown&nbsp;&#8224;|Targeted Fat Reduction of Pseudogynecomastia in the Male Breast Using the ZELTIQ Coolsculpting System||Device:ZeltiqCoolsculptingSystem|Interventional||Other|reductionofthefatlayer;  visualreductionofthefatlayer|12|NCT01791660|August 2012
962|Completed|Clinical Trial Comparing Standard Wound Closure Techniques Versus TissuGlu&#174; Surgical Adhesive||Device:TissuGluSurgicalAdhesive|Interventional|Phase 2 / Phase 3|Industry|NumberofPost-OperativeInvasiveTreatments;  SecondaryOutcomeMeasures|130|NCT01791504|March 2013
963|Recruiting|Carolina Alcohol and Drug Resources||Behavioral: Comprehensive substance abuse services|Interventional||Other|Changeinsubstanceuse;  Changeinmedicationadherence|690|NCT01791179|February 2013
964|Completed                  Has Results|Balance Training vs. Balance Training w/ STARS||Behavioral:BalanceTraining;  Behavioral:STARS|Interventional||Other|Balance;  Self-assessedDisability|24|NCT01790581|January 2013
965|Completed                  Has Results|Ultrasound in Muscle Biopsy||Procedure:Ultrasound|Interventional||Other|AmountofTissueObtained;  Number of Patients Receiving Diagnosis From Muscle Biopsy;  Number of Participants With Adverse Events Related to Muscle Biopsy;  Number of Times Biopsy Needle Was Inserted to Obtain Biopsy Tissue;  Number of Participants With Inadequate Biopsy Samples|40|NCT01790178|February 2013
966|Active not recruiting|Feasibility of an Evidence-based Walking Program in Cancer Pts 60+ During Chemotherapy||Behavioral:WalkWithEaseProgram;  Other:CollectBloodGAandOtherSurveyTools|Observational||Other|To measure the feasibility of implementing the WWE program among cancer patients age &#8805;60 as they undergo cytotoxic chemotherapy treatment.;  To measure the rate of completion of each of the following questionnaires/assessments at 3 different time points;  To measure relationships between physical activity levels and p16 levels.|29|NCT01789983|October 2012
967|Completed|Contingency Management for Smoking Cessation in Homeless Smokers||Drug:Bupropion;  Drug:Nicotinereplacementtherapy;  Behavioral:ContingencyManagement|Interventional||Other / U.S. Fed|Breathcarbonmonoxide;  Salivacotinine|25|NCT01789710|January 2013
968|Active not recruiting|Text Message Study||Other:cellulardevice/computers|Interventional||Other|ChangeinAnxiety;  ChangeinPain;  ChangeinSurgicalSite|194|NCT01789697|September 2012
969|Completed|Pilot Study To Assess Effect of Treatment and Adherence in PD Subjects||Radiation:GroupA-EarlyImaging;  Radiation:GroupB-DelayedImaging|Interventional|Phase 1|Other / Industry|Patientadherencetotreatmentplan;  UnifiedParkinsonDiseaseRatingScale(UPDRS);  LifeOrientationTest-Revised(LOT-R);  Marlowe-CrowneSocialDesirabilityScale(MCSD);  Obsessive-CompulsiveInventory(OCI);  ExpectationofGlobalResponse(EGCR)|20|NCT01788696|June 2012
970|Active not recruiting|Early Child Care and Risk of Obesity|||Observational||Other|Changeinchildadiposity|1000|NCT01788644|February 2013
971|Active not recruiting|Prevalence of Dysplasia of the Gastric Cardia|||Observational||Other / Industry|Presenceofdysplasiabeforeandafterablation|170|NCT01787864|February 2013
972|Completed|Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly (URGE)||Drug:FesoterodineFumarate|Interventional||Other / NIH|TreatmentBenefitScale|66|NCT01786967|September 2012
973|Completed                  Has Results|iCare vs Tonopen vs Goldmann Applanation Post-vitrectomy Surgery||Device:Icarereboundtonometry;  Device:Tonopenapplanation;  Device:Goldmannapplanation|Interventional||Other|MeasurementofIntraocularPressure;  AdverseEvents|68|NCT01786954|October 2012
974|Completed|Regulation of Branched-chain Amino Acid Metabolism in Pre-Diabetes||Other: Pre-Diabetes Group - 6-mo Aerobic and Resistance combined exercise training;  Other: GBP Group - Non-diabetics intending to undergo Gastric Bypass surgery|Interventional||Other / Industry|Changes in Branched-chain Amino Acid Metabolism in Pre-Diabetes at Baseline and post-intervention;  Changes in Insulin Sensitivity at Baseline and post-intervention|132|NCT01786941|June 2012
975|Completed|Neuromuscular Ultrasound in ALS||Other:Ultrasoundofnerveandmuscle|Observational||Other|Abnormalities at onset: Ultrasound vs. Electromyography;  UltrasoundPredictingOutcomeat1year|40|NCT01785550|February 2013
976|Completed                  Has Results|Dietary Nitrate and Exercise to Augment Exercise Training Benefits in Subjects With DM+PAD||Drug: Beetroot Juice (Beet-It Stamina Shot) and Exercise Training;  Other: Placebo Comparator Beverage (Beet-It Stamina Shot) &amp; Exercise Training|Interventional|Phase 2|Other / NIH|Change in Exercise Capacity - Maximal Oxygen Capacity (VO2peak);  Change in Exercise Capacity - Time to Exhaustion (TTE);  Change in Exercise Capacity - Claudication Onset Time (COT);  ChangeinFunctionalAbility;  ChangeInVascularFunction;  ChangeinAngiogenesis|18|NCT01785524|February 2013
977|Terminated|Bupivacaine for Benign Headache in the ED||Drug:0.5%bupivacaine;  Drug:StandardCare|Interventional|Phase 2|Other|Lengthofstay;  Incidence of immediate and post-discharge complications.;  Symptomaticreliefofheadache|24|NCT01785459|October 2013
978|Recruiting|Limb Girdle Muscular Dystrophy (LGMD) Natural History|||Observational||Other|Comprehensive clinical evaluation of individuals with GENETICALLY CONFIRMED LGMD according to the study protocol in order to evaluate disease progression|100|NCT01783509|November 2011
979|Completed|Hypercapnia: Cognitive Effects and Monitoring||Other:NOexerciseatdepth;  Other:exerciseatdepth|Interventional||Other|Is cognitive ability different while resting versus compared to cognitive ability while diving breathing different gas mixtures and while exercising?;  How does exhaled (end tidal) carbon dioxide compare with arterial carbon dioxide?|58|NCT01782625|January 2013
980|Completed|Pilot Testing a Patient and Provider Intervention for Managing Osteoarthritis in Hispanic Adults.||Behavioral:patientandproviderintervention|Interventional||Other|Change in Self-reported pain stiffness and function.;  ChangeinPhysicalfunction;  ChangeinDepressivesymptoms;  Changeinweight;  Participantsperceptionoftheintervention|16|NCT01782417|February 2013
981|Enrolling by invitation|Pilot Study of a Fluocinolone Acetonide Intravitreal Insert (FA-i) to Treat Intermediate- Posterior- or Panuveitis||Drug:FluocinoloneAcetonide|Interventional|Phase 1|Other|Changeinstatusofuveitisinstudyeye.;  Change in IOP (intraocular pressure) in study eye.;  Changeinlensstatusinstudyeye.;  Changeinendophthalmitisinstudyeye.;  Changeinvitreousstatusinstudyeye.;  Changeinretinalstatusinstudyeye.;  Changeinmacularthicknessinstudyeye.;  Change in Best Corrected Visual Acuity in the study eye.|18|NCT01781936|June 2012
982|Completed|Cognitive Remediation in 22q11DS||Behavioral:Cognitiveremediationprogram;  Behavioral:Smallgroupsocialskillstraining|Interventional||Other / NIH|Changeinsustainedattention;  Changeinexecutivefunction.;  Changeinverbalmemory.;  Socialskills;  Change in brain function and white matter structure.|38|NCT01781923|October 2010
983|Completed                  Has Results|Open-label Milnacipran for Persistent Knee Pain One Year After Total Knee Arthroplasty (TKA)||Drug:Open-labelflexiblydosedmilnacipran|Interventional|Phase 4|Other|ChangeinPainVisualAnalogueScale(VAS).;  ChangeinKneeSocietyScore(KSS).;  GlobalRatingofChange;  Change in Total Score of Multidimensional Fatigue Inventory (MFI-20);  ChangeintheBeckDepressionInventory(BDI-II);  Change in the Montgomery Asberg Depression Rating Scale;  Change in Total Score of State Trait Anxiety Inventory (STAI);  Change in Total Score of Short Form-36 (SF-36) Measuring Perceived Quality of Life|5|NCT01780389|October 2010
984|Completed|Study of Urethral Mobility in Male Stress Urinary Incontinence Pre- and Post- Placement of Transobturator Sling||Other:PreandPostSlingPelvicMRI|Observational||Other|Changeinurethralmobility|34|NCT01779323|March 2012
985|Completed                  Has Results|Advanced Comprehensive Diabetes Care for Veterans With Poorly-Controlled Diabetes||Behavioral: Home Telehealth with Behavioral Education Component|Interventional|Phase 0|U.S. Fed|DiabetesControl;  DiabetesSelfCare;  Self-reportedMedicationAdherence;  DepressiveSymptoms|50|NCT01778751|December 2013
986|Completed|Exploring Beliefs and Behaviors About Weight Loss in Couples||Behavioral:MentalContrasting-Individual;  Behavioral:MentalContrasting-Couple|Interventional||Other|weightloss;  dietarychanges;  numberofminutesofphysicalactivity|140|NCT01777711|October 2012
987|Active not recruiting|Helping Invested Families Improve Veterans Experiences Study||Behavioral: Helping Invested Families Improve Veterans Experiences Study - Control;  Behavioral: Helping Invested Families Improve Veterans Experiences Study - HI FIVES|Interventional||U.S. Fed|Patient days in the community (e.g. days not in emergency department inpatient or nursing home setting);  TotalcoststotheVA;  Satisfactionwithhealthcare;  Caregiverdepressivesymptoms|240|NCT01777490|February 2014
988|Recruiting|Study of Outcomes After Surgery/Treatment to Treat Bladder Cancer||Other:CollectBloodandSurveyInstruments|Observational||Other|To collect the number of changes in functional status surgical complications and survival status collected in a prospective database of patients undergoing a radical cystectomy with or without chemotherapy;  To measure associations between baseline measures with post-surgery and 90 day outcome measures;  To count changes over the course of treatment for components of the GA the FACT-Bl p16 and other clinical characteristics.|150|NCT01776138|April 2012
989|Completed|Polyphenols Exercise and Metabolomics||DietarySupplement:Nutrasorb;  DietarySupplement:Placebo|Interventional||Other / Industry|Metabolomics;changeinmetabolitesovertime;  Changeininflammation;  Changeinoxidativestress;  Changeinimmunefunction|34|NCT01775384|April 2012
990|Recruiting|Comparison of Stationary Breast Tomosynthesis and 2-D Digital Mammography in Patients With Known Breast Lesions||Device: Stationary Carbon Nanotube X-ray Digital Breast Tomosynthesis Scanner|Observational||Other / NIH|Receiver Operative Curve (ROC) Area Under the Curve (AUC) (percentage);  Readerpreference-arbitraryunits|100|NCT01773850|January 2013
991|Completed|Can a Rapid 2 Day Followup After Discharge From the ED Reduce Readmissions and Death for Patients 75 Years and Older?||Other:2-3dayreturnappointment|Interventional||Other|Mortality and readmissions to emergency department;  Mortality|26|NCT01769495|August 2013
992|Active not recruiting|CPI-613 Cytarabine and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia||Drug:CPI-613;  Drug:cytarabine;  Drug:mitoxantronehydrochloride;  Other:laboratorybiomarkeranalysis;  Other:pharmacologicalstudy|Interventional|Phase 1|Other / NIH|MTD of CPI-613 based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE 3.0);  Responserate(CRCRiandPR);  Overallsurvival|61|NCT01768897|January 2013
993|Active not recruiting|Caregiver Outlook: An Evidence-based Intervention for the Chaplain Toolkit||Behavioral:CaregiverIntervention|Interventional||Other|Feasibility and acceptability of a chaplain-led intervention;  Caregiver Outlook intervention qualitative discussion theme content and variation;  Interventionresponses;  Evaluate and establish effect sizes associated with Caregiver Outlook on caregiver anxiety depression anticipatory grief quality of life and burden.|33|NCT01768221|January 2013
994|Terminated|Cryosurgery and Radiation Therapy in Treating Patients With Painful Bone Metastases||Procedure:cryosurgery;  Radiation:radiationtherapy;  Procedure:quality-of-lifeassessment|Interventional||Other / NIH / Industry|ChangesinpainlevelasmeasuredbytheBPI;  Pain medication level assessed by changes in narcotic medication usage;  Adverse events graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;  Pain reduction after cryosurgery as measured by the BPI;  Survival|1|NCT01767935|July 2014
995|Completed|Immediate vs. Delayed Postpartum Etonogestrel Implant||Drug:Etonogestrelimplant|Interventional|Phase 4|Other|Continuationrate;  Rateofintercourse;  ContinuationRate|60|NCT01767285|January 2013
996|Completed|Altered Drug Disposition and Biomarkers for Diagnosis of Chronic Inflammatory Liver Disease||Other:Highfatmeal;  Drug:Morphine|Interventional|Phase 1|Other|Pharmacokinetic profile of morphine and its hepatically derived metabolites.;  Bileacidprofile;  FibroScan with Controlled Attenuation Parameter (CAP) Software|22|NCT01766960|November 2012
997|Recruiting|CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery||Drug:68-bis(benzylthio)octanoicacid|Interventional|Phase 1 / Phase 2|Other / NIH|Overallsurvival;  Response rate defined as proportion of patients with complete response (CR) partial response (PR) stable disease (SD) or progressive disease (PD) using based on the RECIST version 1.1;  Progression-freesurvival;  Adverse events based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0|13|NCT01766219|May 2013
998|Available|Treatment Use of 34-Diaminopyridine||Drug:34-diaminopyridine|Expanded Access||Other|||NCT01765140|
999|Recruiting|Carbohydrate Restriction and Prostate Cancer Growth||Behavioral:Lowcarbohydratediet|Interventional||Other / NIH / U.S. Fed|PSAdoublingtime(changeinPSAovertime)|60|NCT01763944|January 2013
1000|Completed|Physiologic Mechanisms in Pediatric Traumatic Brain Injury (TBI)|||Observational||Other / NIH|PresenceofapolipoproteinE(apo-E)allele;  Vasospasm detection by Transcranial Doppler Ultrasound (TCD)|60|NCT01763892|December 2012
1001|Active not recruiting|Neurophysiology of Postpartum Depression in an Experimental Model of Pregnancy and Parturition||Drug:LeuprolideAcetate;  Drug:Micronizedestradiol;  Drug:Progesterone|Interventional||Other / NIH|Blood-oxygen-level-dependent (BOLD) contrast during functional magnetic resonance imaging (fMRI);  Change in Inventory of Depression and Anxiety Symptoms (IDAS) scores;  Change in Edinburgh Postnatal Depression Scale (EPDS) scores|30|NCT01762943|August 2013
1002|Completed                  Has Results|Nonin 4 Wavelength Cerebral Oximeter Study||Device:Reductionofinspiredoxygen|Interventional||Other / Industry|AccuracyofSensor|23|NCT01762722|September 2009
1003|Unknown&nbsp;&#8224;|Evaluation of FeNO During and Following Acute COPD Exacerbation||Device:NIOXMINO&#174;|Observational||Other / Industry|ChangeinFeNOfromDay0totheendofthestudy;  Change in FEV1/FVC from Day 0 to the end of the study;  ChangeinFEV1fromDay0totheendofthestudy;  Change in FEF25-75 from Day 0 to the end of the study;  ChangeinPEFfromDay0totheendofthestudy;  Change in Inspiratory Capacity from Day 0 to the end of the study;  Change in Slow Vital Capacity (SVC) from Day 0 to the end of the study;  Change in FEV1/SVC from Day 0 to the end of the study;  Change in COPD Assessment Test (CAT) Responses from Day 0 to the end of the study|35|NCT01761006|March 2013
1004|Terminated|Prospective Case-Series of Ligasure Advance Pistol Grip and LigaSure Blunt Tip|||Observational||Other / Industry|Safety and Efficacy of the LigaSure Advance Pistol Grip and LigaSure Blunt Tip using the Force Triad Energy Platform during Roux-en-Y and gastric reduction procedures.;  Economic value of using LigaSure in gastric surgeries|51|NCT01759550|September 2011
1005|Terminated                  Has Results|Incisional Negative Pressure Wound Therapy||Device:Negativepressurewoundtherapy(NPWT)|Interventional||Other|Number of Participants With Post-operative Infection (NPWT)|19|NCT01759381|December 2012
1006|Active not recruiting|Hybrid PET/MR in the Therapy of Cervical Cancer||Procedure:FDGPET/MR|Observational||Other|Proportion of patients who successfully complete PET/MR scans at all study time-points;  Sensitivity of PET/MR for baseline disease assessment;  Specificity of hybrid PET/MR for baseline disease assessment;  Accuracy of hybrid PET/MR for baseline disease assessment;  Detection of disease with PET/MR at each time point|18|NCT01759355|October 2012
1007|Recruiting|Microvascular and Fibrosis Imaging Study||Other:AcousticRadiationForceImpulse(ARFI);  Other:LaserDopplerFlowmetry(LDF);  Other:LaserDopplerPerfusionImaging(LDI);  Other:OpticalCoherenceTomography(OCT);  Other: Orthogonal Polarization Spectral Imaging (OPSI);  Other:Nailfoldvideocapillaroscopy(NVC)|Observational||Other|Microvasculardensityinoralmucosaandskin;  MicrovascularPerfusioninoralmucosaandskin|220|NCT01758250|February 2013
1008|Active not recruiting|Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma||Drug:Bendamustine;  Drug:Pomalidomide;  Drug:Dexamethasone|Interventional|Phase 1 / Phase 2|Other / Industry|Maximumtolerateddoselevel;  ResponseRate;  Overallresponserate;  Timetoprogression;  Timetonexttherapy;  Progressionfreesurvival|56|NCT01754402|January 2013
1009|Completed|Predicting Tolerance to Radiation Therapy in Older Adults With Cancer|||Observational||Other|Association between pre-treatment loss of at least one independent activity of daily living (I-ADL) and poor tolerance to radiation therapy;  Association between pre-treatment loss of at least one independent activity of daily living (I-ADL) and the occurrence of any patient-reported toxicity from radiation therapy;  Association between pre-treatment loss of at least one independent activity of daily living and changes in Quality of Life measures;  Comparison of physician and patient-reported acute grade 3-5 toxicities;  Association between elevated p16Ink4&#945; gene expression and poor tolerance to and/or physician/patient-reported toxicity from radiation therapy;  Association between baseline components of the Comprehensive Geriatric Assessment and poor tolerance to or occurrence of patient-reported toxicity from radiation treatment|50|NCT01752751|November 2012
1010|Completed|EF5 in Melanoma Patients||Drug:EF5Hypoxia|Interventional|Phase 1|Other|Spatial comparison between marker proteins and hypoxia.|15|NCT01752257|July 2012
1011|Active not recruiting|A Prospective Pilot Study Evaluating Renal Lesions Through Contrast-enhanced Ultrasound (US) in Patients With Renal Cancer and in Those With a Risk Factor for Renal Malignancy||Procedure:Contrast-enhancedUltrasound;  Drug:Perflutrenlipid|Interventional||Other|Feasibility of using contrast-enhanced ultrasound in diagnosing renal malignancy in patients with known renal disease (Cohort 1) and in patients with a risk factor for renal malignancy diagnosed with suspicious or indeterminate lesions (Cohort 2);  Feasibility of comparing the sensitivity and specificity of contrast enhanced ultrasound to traditional imaging techniques (CT and MRI) in detecting renal lesions in patients already diagnosed with a renal malignancy|48|NCT01751529|May 2013
1012|Active not recruiting|PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study|||Observational||Other|Negative post-chemoradiation PET/MRI scan as correlated with surgical pathology;  Recurrence-freesurvival;  Disease-specificsurvival;  Overallsurvival|8|NCT01751516|October 2012
1013|Completed|Comparing Validity of Non-Invasive Hemoglobin Monitoring to Laboratory Results in Critically Ill Children||Other: Masimo Pronto Rad 7 Non-Invasive hemoglobin monitor;  Other: Standard Laboratory Blood Draw and Hemoglobin Analysis|Observational||Other|Comparison of standard hemoglobin monitoring vs. the MASIO non-invasive hemoglobin monitor|65|NCT01750463|January 2013
1014|Recruiting|Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis|||Observational||Other|Majoradversecardiacevents(MACE).;  all-causemortality;  cardiacmortality;  Pulmonarymortality;  PulmonaryTransplant;  CardiacTransplant;  ICD/PPMplacement;  AppropriateICDtherapy|400|NCT01745237|September 2002
1015|Completed|Effect of Beta-Alanine on Heart Rate Response||DietarySupplement:Placebo;  DietarySupplement:Beta-alanine|Interventional||Other|Physicalworkingcapacityatheartratethreshold|35|NCT01745016|January 2013
1016|Completed                  Has Results|Medication Adherence With Polyglot Meducation||Behavioral:educationintervention|Interventional||U.S. Fed|MedicationPossessionRatioatBaseline;  MedicationPossessionRatioat6Months;  BloodPressureatBaseline;  BloodPressureat6Months;  Cholesterol&amp;CreatinineLevelsatBaseline;  Cholesterol&amp;CreatinineLevelsat6Months;  WeightatBaseline;  Weightat6Months;  PulseatBaseline;  Pulseat6Months|23|NCT01744392|February 2013
1017|Completed|A Prospective Pharmacodynamic Study of Rivaroxaban||Drug:Rivaroxaban;  Other:noanticoagulation|Observational||Other||65|NCT01743898|October 2012
1018|Completed|Energy Expenditure and Substrate Utilization During Acute Under- and Over-feeding||Other:24-hourenergyexpenditure|Interventional||Other|EnergyExpenditure;  Wholebloodtranscriptomics;  Plasmametabolomics|7|NCT01740765|May 2012
1019|Recruiting|UCAN2: Uniting Couples in the Treatment of Anorexia Nervosa||Behavioral:UCAN+CBT;  Behavioral:CBT|Interventional||Other / NIH|Change in Body Mass Index (BMI) from baseline through 12 month follow-up;  Change in Global Eating Disorder Examination (EDE) Scores from baseline through 12 month follow-up;  Dropout (the percentage of individuals who withdrew participation from treatment);  Treatment satisfaction scores as measured with the Client Satisfaction Questionnaire (CSQ);  Relationship satisfaction as measured with the Dyadic Adjustment Scale (DAS) and DAS-4|100|NCT01740752|July 2012
1020|Active not recruiting|Bevacizumab Beyond Progression (BBP)||Radiation:RadiationTherapy;  Drug:Temozolomide;  Drug:Bevacizumab|Interventional|Phase 2|Other / Industry|OverallSurvival;  DescribeToxicity;  Progression-freeSurvival(PFS)|68|NCT01740258|January 2013
1021|Completed                  Has Results|Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients||Drug:Vorinostat;  Drug:Bevacizumab|Interventional|Phase 2|Other / Industry|Six-monthProgression-freeSurvival(PFS6);  RadiographicResponse;  Percentage of Participants Who Experience Grade 3 or Greater Treatment Related Non-hematologic Toxicities.;  MedianProgression-freeSurvival(PFS);  MedianOverallSurvival(OS)|48|NCT01738646|January 2013
1022|Enrolling by invitation|Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease||Drug:Atorvastatin;  Drug:Placeboforatorvastatin|Interventional|Phase 2|Other / NIH|Change from Baseline in Endothelial Function at 6 Weeks;  Change from baseline in plasma markers of endothelial activation at 6 weeks;  Change from baseline in heme oxygenase activity at 6 weeks;  Change from baseline in plasma levels of soluble fms-like tyrosine kinase-1 (sFLT-1) at 6 weeks.;  Change from baseline in monocyte activation at 6 weeks.;  Change from baseline in renal function at 6 weeks.;  Occurrenceofadverseevents.;  Abnormalphysicalfindings.;  Change from baseline in rho/rho kinase activity at 6 weeks;  Change from baseline in plasma levels of vascular endothelial growth factor (VEGF) at 6 weeks.;  Change from baseline in absolute cell counts at 6 weeks.;  Change from baseline in tissue factor (TF) expression at 6 weeks.;  Change from baseline in TF-mediated sFLT release from monocytes at 6 weeks.;  Change from baseline to Week 6 in Tricuspid regurgitant (TR) jet.|19|NCT01732718|September 2013
1023|Terminated|Partner-Assisted Interpersonal Psychotherapy or Antidepressant Medication for Antenatal Depression||Behavioral: Partner-Assisted Interpersonal Psychotherapy;  Other:TreatmentasUsual|Interventional|Phase 1 / Phase 2|Other|Hamilton Rating Scale for Depression-17 item version (HRSD-17);  DyadicAdjustmentScale(DAS)|2|NCT01732055|November 2012
1024|Completed|Imaging Lung Function Using Oxygen Enhanced MRI||Drug:MedicalGradeOxygen|Interventional|Phase 1|Other|ImageQuality|15|NCT01731015|January 2012
1025|Completed|Cerebrospinal Fluid (CSF) Biomarkers Alzheimer&apos;s Disease (AD) and Non-AD Dementias|||Observational||Other / Industry|RatioofCSFtautoA&#946;42(tau/A&#946;42)|40|NCT01730430|July 2012
1026|Completed|Phase I Study of the Safety Distribution and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG||Drug:nocarrieraddedmetaiodobenzylguanidine|Interventional|Phase 1|Other / NIH|Radiationdosimetry|12|NCT01730417|November 2009
1027|Completed|Comparative Study of the Optical Biometer for Measurements of the Eye|||Observational||Industry|AgreementandPrecisionEndpointsAnalyses;  Evaluation of Adverse Events Found During the Study|125|NCT01729962|December 2012
1028|Active not recruiting|Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma||Drug:Velcade;  Drug:Cyclophosphamide;  Drug:Revlimid|Interventional|Phase 2|Other / Industry|Overall response rate (ORR) during induction therapy;  Number of patients with any grade or severe adverse events as a measure of tolerability and safety;  Maximum depth of response during induction therapy;  Maximum depth of response during maintenance therapy;  Mediantimetoresponse;  Mediandurationofresponse;  Medianprogression-freesurvival;  Medianoverallsurvival;  Qualityoflife;  Functionality|17|NCT01729338|December 2012
1029|Completed                  Has Results|Study to Evaluate the Impact of FeNO Assessments on Asthma Management Decisions in Subject 7 to 60 Years of Age||Device:NIOXMINO&#174;Instrument(09-1100)|Observational||Industry|FeNOValuesbyACTScore;  FeNOCategoricalLevelsbyICSUse;  PhysicianAssessmentofAirwayInflammation;  Number of Participants Correctly Categorized by True Level of Airway Inflammation;  Asthma Management Changes After FeNO Results Were Considered|50|NCT01729247|October 2012
1030|Completed|Impact of Black Pepper on Energy Expenditure and Substrate Utilization||Other: 24-hour energy expenditure and substrate utilization|Interventional||Other|Energyexpenditureandsubstrateoxidation;  Gutpeptides|18|NCT01729143|April 2011
1031|Terminated                  Has Results|CO as a Stimulant for Mitochondrial Biogenesis in Human Cardiac Muscle||Drug:200ppmCOforonehour;  Other:Control|Interventional|Phase 1 / Phase 2|Other|Biochemical Markers for Mitochondrial Biogenesis (Blood and Right Atrial Tissue);  Compare Blood to Right Atrial Tissue Biochemical Markers of Mitochondrial Biogenesis|1|NCT01727167|February 2014
1032|Unknown&nbsp;&#8224;|Prediction of Methotrexate Response - A Pilot Study|||Observational||Other|||NCT01726959|December 2011
1033|Recruiting|LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations||Drug: BRAF inhibitor dabrafenib and MEK inhibitor trametinib|Interventional|Phase 2|Other / Industry|KinaseExpression;  BRAF and MEK inhibition associated with new functional mutations in the approximately 150 oncogenes;  Kinomesignaturepredictiveofresistance;  OverallResponseRate(ORR);  DurationofOverallResponseRate(ORR);  ProgressionFreeSurvival(PFS);  RateofOverallSurvival(OS)|20|NCT01726738|October 2012
1034|Completed|Does First Oral Intake After Emergence Predict the Incidence of Post-operative Vomiting in Children?||Other:AppleJuice;  Other:Water|Interventional||Other|Post-operativeVomiting|183|NCT01725399|October 2012
1035|Completed|Pilot Study to Evaluate Individualized Choice of Antidepressants in Patients With Cancer||Drug:Mirtazapine;  Drug:Citalopram|Interventional|Phase 2|Other|Feasibility;  DepressionScore|21|NCT01725048|January 2011
1036|Recruiting|A Controlled Study of Stem Cell Transplantation Medical Home Care Compared to Standard Hospital Care||Other:HomeCare|Interventional||Other|BowelMicrobiota;  Nutritional status using the PG-SGA assessment tool;  Incidence of acute Graft Versus Host Disease (GVHD);  Treatmentrelatedmorbiditiesandmortalities;  QualityOfLifeAssessment(QOL);  Costsofcare|90|NCT01725022|February 2012
1037|Terminated|Update and Biodistribution of [F-18]FMDHT pET/CT in Normal Healthy Volunteers and Patients With Metastatic Prostate Cancer - A First in Human Subject Study With [F-18] FMDHT||Drug: [F-18] fluorinated dihydrotestosterone (FDHT)|Interventional|Phase 0|Other|To map diffusion and clearance rates of this marker in normal and cancerous tissue.;  To determine if [F-18]FMDHT PET/CT uptake in the primary prostate tumor can be differentiated from normal surrounding prostate that will be confirmed with pathologic staining of biopsy or surgical specimens.|7|NCT01724619|November 2012
1038|Active not recruiting|Abstinence Reinforcement Therapy (ART) for Rural Veteran Smokers||Behavioral: Abstinence Reinforcement Therapy (ART);  Behavioral:TelephoneCounselingandNRT|Interventional||U.S. Fed|Primary outcome measure will be quality-adjusted life years (QALYs). The QALY is a standardized effectiveness measure that allows for the comparison of the value of a particular intervention to a broad range of other potential health care investments|300|NCT01723163|November 2013
1039|Recruiting|Nutritional Prevention of Exertional Muscle Dysfunction||DietarySupplement:Choline;  DietarySupplement:Placebo|Interventional||Other|CreatineKinase(CK)activity|30|NCT01722448|November 2012
1040|Completed|Ranolazine for the Treatment of Chest Pain in HCM Patients||Drug:Ranolazine|Interventional|Phase 4|Other / Industry|SafetyofRanolazinewithregardtoQTinterval;  Safety of Ranolazine with regard to adverse events;  Safety of Ranolazine with regard to drug tolerability;  Improvement in number of episodes of angina per week;  Improvementindyspnea;  Improvementinqualityoflife|14|NCT01721967|November 2012
1041|Recruiting|MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy||Procedure:magneticresonanceimaging|Interventional|Phase 1|Other / NIH|To correlate results of an automated MRI hardware/software platform for measuring left ventricular (LV) function with manual results.;  To test the ability of the pre- to post-anthracycline-based chemotherapy (Anth-bC) changes in our MRI platform generated measures of LV function to predict pre- to 24 month post-Anth-bC differences in LV function.|150|NCT01719562|January 2013
1042|Completed|The Effect of Phentermine and B12 on Weight Loss Among Obese Patients||Drug:PhentermineandB12;  Drug:Phentermine|Interventional|Phase 0|Other|WeightChange;  BloodPressure;  WaistCircumference;  Waisttohipratio|22|NCT01719185|September 2012
1043|Active not recruiting|Discharge Information and Support for Patients Receiving Outpatient Care in the Emergency Department||Behavioral:DISPOED|Interventional||U.S. Fed|repeatEDuse;  Satisfaction with health care and primary care provider;  TotalcoststotheVHA|513|NCT01717976|December 2013
1044|Terminated|Educational-Medical-Behavioral Treatment of Fecal Incontinence||Other:Education;  DietarySupplement:Fibersupplements;  Drug:Laxativesoranti-diarrheals;  Behavioral:Pelvicfloormuscleexercises;  Behavioral: Tips on how to prevent fecal incontinence;  Behavioral:Dailydiary;  Other:Protectivepadsorgarments|Interventional||Other / U.S. Fed|FecalIncontinenceSeverityIndex;  ZaritCaregiverBurdenInterview;  ManchesterHealthQuestionnaire;  Adequatereliefoffecalincontinence;  Fecalincontinencefrequency;  Urinaryincontinence;  Admissiontonursinghome;  Hospitalizations;  Emergencydepartmentvisits;  Outpatientclinicvisits;  FecalIncontinenceSeverityIndex(FISI)|31|NCT01717456|January 2013
1045|Completed|Optical Imaging and User Perception Study of Vaginal Gel||Other:vaginalgelimaging;  Behavioral:computeraidedselfinterview|Interventional||Other / NIH / Industry|numberandfrequencyofadverseevents;  extentofvaginalgelcoating;  uniformityofvaginalgelcoating;  subjectperceptionandpreferenceofvaginalgel|56|NCT01716000|January 2013
1046|Completed|Measuring Eating Activity and Strength: Understanding the Response -Using Protein||DietarySupplement:Proteinsupplementation;  Behavioral: Diet counseling and group education lessons|Interventional||Other|Change in Short Physical Performance Battery (SPPB);  Changeinleanbodymass|71|NCT01715753|September 2012
1047|Completed|Effect of Broccoli Sprouts Homogenate on SS RBC||Dietary Supplement: Broccosprouts&#174; (Brassica Protection Products LLC) homogenate|Interventional||Other|In vitro response of HbAA and HbSS erythroid cells to NRF2 activation by sulforaphane.;  Safety physiological effects and cellular effects of daily consumption of broccoli sprout homogenate in a cohort of Hb SS/SB0 thalassemia adult SCD patients|21|NCT01715480|March 2012
1048|Completed|Exploring Massage Benefits for Arthritis of the Knee for VA Healthcare Users||Other:SwedishMassage|Interventional||Other / NIH|Change in Western Ontario and McMaster Universities Osteoarthritis of the Knee and Hip Index (WOMAC);  ChangeinPain:TheVisualAnalogScale(VAS);  Change in Pain: PROMIS Pain Interference Questionnaire;  ChangeinJointFlexibility;  ChangeinPhysicalFunction|25|NCT01714869|November 2012
1049|Completed|Dental Implant Study Comparing Two Types of Metals Used for Dental Implants||Device:ZimmerTrabecularMetalTestCylinder;  Device:ZimmerTitaniumTestCylinder|Interventional|Phase 1|Other / Industry|Examination of the molecular pathways to compare osseous healing associated with trabecular metal vs. standard titanium.;  Gene expression profiles of trabecular metal verses titanium|42|NCT01714024|October 2012
1050|Withdrawn|Treatment of Acute Periprosthetic Total Hip Arthroplasty Infections||Procedure:opendebridementwithmodularexchange;  Procedure:onestageexchange|Interventional||Other|Success|0|NCT01712880|October 2012
1051|Completed|Evaluation of Regional Ventilation Using 19F MRI of Inert Perfluorinated Gases Mixed With Oxygen||Drug:perfluorinatedgas/oxygenmixture|Interventional|Phase 1|Other|MRI image quality of Perfluorinated Gas imaging of the lung|44|NCT01710449|September 2009
1052|Active not recruiting|Single-arm Study to Assess the Safety of Hydromorphone Hydrochloride by Intrathecal Administration||Drug:HydromorphoneHydrochloride|Interventional|Phase 3|Industry|Frequency of Adverse Events during a 12-month period of treatment with intrathecal hydromorphone.|350|NCT01709747|June 2013
1053|Recruiting|Safety and Efficacy Study of Hydromorphone Hydrochloride by Intrathecal Administration Using a Programmable Implantable Pump||Drug:HydromorphoneHydrochloride|Interventional|Phase 3|Industry|Superiority of intrathecal hydromorphone hydrochloride as compared to a control arm.;  FunctionalitybasedonaBriefPainInventory|250|NCT01709721|February 2013
1054|Recruiting|The MURDOCK Study Registry and Biorepository Horizon 1.5||Genetic:Biomarkerstudies|Observational||Other|The MURDOCK Study Registry and Biorepository Horizon 1.5|50000|NCT01708408|February 2009
1055|Completed|Effect Of Acute Inflammatory Mediators On Functional Limitations In Patients With Acute Respiratory Failure||Other:EarlyICUrehabilitationstrategies;  Other:UsualCare|Interventional|Phase 1 / Phase 2|Other|Hospitallengthofstaydays|100|NCT01707303|July 2007
1056|Completed|Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris||Drug:Taclonex|Interventional||Other / Industry|Thepatientpreference|20|NCT01707043|October 2012
1057|Active not recruiting|The Medication Experience Study||Other:InternetSurvey|Interventional||Other|The primary measure will be adherence as measured by pharmacy refills in each group.|186|NCT01702883|October 2012
1058|Completed|Almased Multi-Center Diabetes Intervention Trial||Dietary Supplement: Almased Meal Replacement Powder;  Behavioral:Group-BasedLifestyleIntervention|Interventional||Other|ChangeinHbA1c(%);  ChangeinHOMAIRIndex;  Changeinfastingbloodglucose(mg/dl)|240|NCT01702012|January 2013
1059|Completed|Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera|||Observational||Other / Industry|Compliancewithmealinstruction;  Evaluation of subjects&apos; attitudes toward contraception;  Association between caloric intake and virologic suppression;  Assessmentofmedicationadherence|33|NCT01701895|October 2012
1060|Completed|The Effects of Respiratory Muscle Strength Training (RMST) on Inspiratory and Expiratory Muscle Strength in Adults and Children With Pompe Disease||Other:respiratorymusclestrengthtraining|Observational||Other||11|NCT01701154|December 2010
1061|Completed                  Has Results|Time of Intravenous Acetaminophen Administration||Drug:Acetaminophen|Interventional|Phase 4|Other|ChangesinPostoperativePainScores;  PainMedicationConsumptionRates|126|NCT01699815|October 2012
1062|Recruiting|Reverse Shoulder Arthroplasty With or Without Concomitant Latissimus and Teres Major Transfer for Shoulder Pseudoparalysis With Teres Minor Dysfunction||Procedure:Transfergroup;  Procedure:Controlgroup|Interventional|Phase 4|Other|ADLERScore;  DASHScore;  ASESscore;  SF-12Score;  RangeofMotion;  X-RayMeasurements|42|NCT01697865|October 2012
1063|Completed|The CARRA Registry|||Observational||Other / NIH|EnrolledSubjects|9587|NCT01697254|August 2009
1064|Completed|Understanding and Discouraging Overuse of Potentially Harmful Screening Tests||Behavioral:QuantitativeInformationSheet;  Behavioral:QualitativeInformationSheet;  Behavioral:NarrativeInformationSheet;  Behavioral:FramedInformationSheet|Interventional||Other / U.S. Fed|Change from Baseline in Intent to Accept Screening Immediately Post-intervention;  Change from Baseline in Perceived Disease Risk Immediately Post-Intervention;  Change from Baseline in Perceived Disease Severity Immediately Post-Intervention;  Change from Baseline in Disease Specific Knowledge Immediately Post-Intervention;  Change from Baseline in Disease-Specific Screening Attitudes Immediately Post-Intervention;  Change from Baseline in Decisional Balance Immediately Post-Intervention;  Change from Baseline in Values Clarity Immediately Post-Intervention;  Change from Baseline in General Screening Knowledge Immediately Post-Intervention;  Change from Baseline in General Screening Attitudes Immediately Post-Intervention|775|NCT01694784|September 2012
1065|Unknown&nbsp;&#8224;|MRI to Assess the Effects of Dysautonomia and Chronic Nausea on Brain Transmitters|||Observational||Other|Assessment of the implication of dysautonomia on the brain and better evaluate its potential mechanistic process.|18|NCT01692561|August 2012
1066|Active not recruiting|The Effect of Hypovitaminosis D and Vitamin D Supplementation on Fracture Nonunion Rates||DietarySupplement:VitaminD;  DietarySupplement:Placebo|Interventional||Other|Healedfracture;  Nonunion|880|NCT01691833|February 2011
1067|Completed|MiraLAX Versus Placebo to Prevent Constipation Following Urogynecologic Surgery||Drug:MiraLax;  Drug:Placebo;  Drug:RescueLaxative|Interventional||Other|Timetofirstpostoperativebowelmovement;  Otherpostoperativemedicationuse;  Evaluation of symptoms and quality of life related to constipation;  SymptomsofOver-Effectiveness;  Evaluation of symptoms and quality of life related to constipation 6-weeks postoperatively|131|NCT01691742|September 2012
1068|Completed|Reliability of Hertel Exophthalmometer Measurements|||Observational||Other|Proptosis;  &quot;BaseMeasurement&quot;;  OrbitalDiseasestatus|85|NCT01691183|May 2012
1069|Completed                  Has Results|Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence||Drug:verylowdosenaltrexone;  Drug:extendedreleasenaltrexone;  Drug:buprenorphine/naloxone|Interventional|Phase 2|Other / Industry|RetentioninTreatment;  Withdrawal Intensity as Measured by the Clinical Opiate Withdrawal Scale (COWS);  Withdrawal Intensity as Measured by the Subjective Opiate Withdrawal Scale (SOWS);  Craving;  IllicitDrugUseMeasuredbyUrineDrugTesting;  Satisfaction With Treatment Measured by a Treatment Satisfaction Questionnaire;  Percentage of Participants Who Adhered to Study Visits.;  Percentage of Participants With Adherence to Medication (Naltrexone);  UseofAncillaryMedications.;  Number of Participants That Self Reported Illicit Drug Use|38|NCT01690546|September 2012
1070|Completed|Functional Modeling of the Pediatric Airway|||Observational||Other / NIH|Change in Functional computational model outcome parameters;  ValidationofComputationalmodel|39|NCT01690078|April 2011
1071|Completed|Environmental Polymorphisms Registry Health and Exposures Survey|||Observational||NIH||9000|NCT01688986|August 2012
1072|Completed|Mild Traumatic Brain Injury Registry|||Observational||Other|To determine which biomarkers and/or clinical variables correlate with long term symptoms of mild traumatic brain injury.|40|NCT01688869|April 2012
1073|Terminated|Platelet Rich Plasma vs. Corticosteroid Injection in the Treatment of Partial Rotator Cuff Tears||Biological:PlateletRichPlasma(PRP);  Drug:Corticosteroid|Interventional|Phase 1|Other|Percent change in Disabilities of the Arm Shoulder and Hand score. (DASH);  PercentchangeinVisualAnalogPainscale(VAS);  Percent change in American Shoulder and Elbow Surgeons (ASES) scale;  Sizeofrotatorcufftearsize.|12|NCT01688362|November 2012
1074|Active not recruiting|FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer (NRR)||Drug:FOLFIRINOX|Interventional|Phase 2|Other|Median overall survival (OS) of FOLFIRINOX in patients with unresectable locally advanced (ULA) pancreatic cancer;  Overall survival for borderline resectable patients;  Progressionfreesurvival(PFS);  Objectiveresponserate;  Diseasecontrolrate(DCR);  Rateofresectability(RR)|45|NCT01688336|January 2012
1075|Suspended|Finding Predictors of Side Effects to Chemoradiation Treatment in Elderly Patients With Head and Neck Cancer||Other:CollectBloodandSurveyInstruments|Observational||Other|Significant Change in Function from Baseline to Post-Treatment;  Explore Association between Baseline Measures and Decline in Living Status;  Explore Association of Baseline Measures with Grade 3 or Higher Toxicity;  Explore Association of Baseline p16 with Baseline GA Measures;  Explore Changes in p16 Expression GA Subscales and FACT-HN Scores Over Time.;  Explore Association between Baseline Measures and Changes in IADL Subscore|3|NCT01688323|July 2012
1076|Recruiting|Lung Cancer Surgery: Decisions Against Life Saving Care - The Intervention||Other:communicationintervention;  Other:RealTimeRegistryanddatafeedbackonly|Interventional||Other|Number of patients with stage I and II non-small cell lung cancer who receive surgery.|496|NCT01687738|August 2012
1077|Completed|Infection Rates of Myeloablative Allo SCT Recipients Receiving Neutropenic Diets Versus Non-Neutropenic Diets||Other:Non-neutropenicDiet|Interventional||Other|IncidenceofBacteremia;  AssessnutritionalstatususingPG-SGA|47|NCT01687231|April 2009
1078|Completed|LifeSkills Video Training in Patients About to Receive an Automatic Implantable Cardioverter-Defibrillator (AICD)||Behavioral: Video/workbook for patients about to receive an AICD;  Behavioral: LiveSkills Video/Workbook for patients about to receive an AICD|Interventional|Phase 1|Industry / Other|Whether patients understood the contents of the produced sections of the video/workbook and whether these contents were helpful. This will be determined by their comments during a focus group which will be held after they have watched the video.|37|NCT01686490|December 2007
1079|Completed                  Has Results|Nitrites Exercise and Peripheral Arterial Disease||Drug: Beetroot Juice (Beet-It Stamina Shot) &amp; Supervised Exercise Training;  Other: Placebo Comparator Beverage (Beet-It Stamina Shot) &amp; Exercise Training|Interventional|Phase 2|Other / NIH|Change in Exercise Capacity: VO2peak (Maximal Oxygen Consumption);  ChangeInTimeToExhaustion;  ChangeinFunctionalAbility;  ChangeInClaudicationOnsetTime;  ChangeInVascularFunction;  ChangeinAngiogenesis|32|NCT01684930|June 2012
1080|Completed|Intensive Dysarthria Sessions in Adults and Children With Down Syndrome||Behavioral:Speechsessions|Interventional||Other|Speechintelligibility|5|NCT01684670|February 2014
1081|Recruiting|EverFlex Post Approval Study||Device: EverFlex&#8482; Self-Expanding Peripheral Stent System|Interventional||Industry|PrimaryOutcome-Compositeendpoint|113|NCT01680835|September 2012
1082|Enrolling by invitation|The COX-2 Gene and the Immune System|||Observational||NIH|To determine whether 765&gt;C is associated with altered Th2 Th9 and Th17 differentiation in vivo;  To determine whether 8473T&gt;C is associated with altered Th2 Th9 and Th17 differentiation in vivo;  To determine whether 765G&gt;C is associated with altered prostaglandin and cytokine levels in vivo|117|NCT01678222|August 2012
1083|Unknown&nbsp;&#8224;|Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies||DietarySupplement:Microlipidandfishoil;  DietarySupplement:Microlipid|Interventional||Other|The serum biomarkers of oxidative stress and inflammatory cytokines;  The average enteral calorie (% of total calorie) intake before reanast;  The average weight gain (g/day) after reanastomosis|44|NCT01674478|October 2012
1084|Completed|Caregiver Outlook: An Intervention to Improve Caregiving in Serious Illness||Other:Preparationandlifecompletion;  Other:AttentionControl|Interventional||U.S. Fed|CaregiverAnxiety;  Spirituality;  Depression;  Anticipatorygrief;  Patientdaysathome;  Caregiverburden;  Caregivercompletionandpreparation;  ProlongedGrief|418|NCT01672294|June 2013
1085|Unknown&nbsp;&#8224;|Get Active and Eat Right: Moms at Work||Behavioral:Weightloss|Interventional||Other|Weightlossandchangeinbodycomposition;  Cholesterol|78|NCT01668316|July 2012
1086|Unknown&nbsp;&#8224;|Postpartum Etonogestrel Implant for Adolescents||Drug:Contraceptiveimplant|Interventional|Phase 4|Other|Continuationat1year;  Satisfaction;  Rapidrepeatpregnancy|96|NCT01666912|August 2012
1087|Recruiting|Pharmacokinetics of Micafungin in Children on Extracorporeal Membrane Oxygenation||Drug:Micafungin|Interventional|Phase 1|Other|Pharmacokineticprimaryendpoints;  Safety|50|NCT01666769|January 2013
1088|Completed|Advanced Image Guidance Utilized in Liver Surgery||Device:AdvancedImageGuidance|Interventional||Other|Successful insertion of ablation antenna into target lesion;  Ease of lesion targeting using Advanced Image Guidance (AIM)|13|NCT01666145|February 2012
1089|Active not recruiting|Imaging Correlates of Renal Cell Carcinoma Biological Features||Procedure:FDGPET/MR|Interventional||Other|Feasibility of FDG-PET-MRI making useful measurements that might be then used to globally assess tumor biological features|17|NCT01665703|August 2012
1090|Active not recruiting|Efficacy Evaluation of the HEART Pathway in Emergency Department Patients With Acute Chest Pain||Other:HEARTPathway|Interventional|Phase 3|Other|Objective cardiac testing (stress testing or cardiac imaging) within 30 days;  Cost length of stay recurrent ED visits and non-index hospitalization for chest pain.;  Objective cardiac testing (stress testing or cardiac imaging) cost length of stay and recurrent ED visits and non-index hospitalization for chest pain.;  Indexobjectivecardiactestingrate;  IndexHospitalAdmissionRate;  Earlydischargerate;  Composite of 30 day hospital admission and objective cardiac testing|282|NCT01665521|September 2012
1091|Recruiting|Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease||Other:Observational|Observational||Other / NIH|Clinical response to enzyme replacement therapy (ERT) using alglucosidase alfa (Myozyme);  ResponsetoImmuneToleranceInduction(ITI)|300|NCT01665326|September 2009
1092|Recruiting|Gene Expression Variation and Implant Wound Healing Among Smokers and Diabetics||Procedure:Dentalimplantsurgery|Observational||Other / NIH|FGF2methylationlevel;  FGF2mRNAexpressionlevel;  FGF2proteinlevel;  Implantstabilityquotient(ISQ);  Woundhealingindices(WHI)|44|NCT01663298|August 2010
1093|Completed                  Has Results|A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension||Drug:Hydrochlorothiazide;  Drug:Lisinopril;  Drug:Amlodipine;  Drug:metoprolol;  Drug:lisinopril/hydrochlorothiazide|Interventional||Other|Blood Pressure Control as Defined as Office BP Measurement of &lt;140 mmHg Systolic and &lt;90 mmHg Diastolic|17|NCT01658657|October 2012
1094|Enrolling by invitation|Surgical Outcomes Database For Faculty of Hepatopancreatic Biliary Surgery||Procedure:HPBSurgery|Observational||Other|SurgicalOutcome|300|NCT01657383|April 2012
1095|Completed                  Has Results|Stereotactic Radiation to Decrease Pancreatic Secretions||Radiation:StereotacticRadiation|Interventional||Other|DecreasedSecretions|1|NCT01656486|July 2012
1096|Active not recruiting|Negative Pressure Therapy in Preventing Infection After Surgery in Patients With Colon Rectal Pancreatic or Peritoneal Surface Cancer||Procedure:woundcaremanagement|Interventional||Other / NIH|Rate of incisional surgical site infection (SSI) which includes superficial incisional SSIs and deep incisional SSIs as defined by the Center of Disease Control and Prevention;  Rates of organ/space SSIs seromas hematomas incisional cellulitis and wound opening for any reason;  The cost of NPT and SSD as well as estimate additional costs associated with incisional SSIs in affected patients|264|NCT01656044|June 2012
1097|Active not recruiting                  Has Results|A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia||Drug:clofarabine;  Drug:cytarabine|Interventional|Phase 2|Other / NIH|Measure Patient Response to High-dose Cytarabine Followed by Clofarabine in Adult Patients With Relapsed or Refractory AML|39|NCT01656031|February 2005
1098|Recruiting|Positron Emission Tomography (PET) Study for Staging of Muscle Invasive Bladder Cancer||Procedure:FDGPET/MR|Interventional||Other|Sensitivity and specificity of the FDG-PET-MRI for staging of muscle-invasive bladder cancer;  Association of FDG-PET-MRI with RFS DSS and OS in patients with muscle-invasive bladder cancer|30|NCT01655745|August 2012
1099|Enrolling by invitation|Visceral (Kidney and Abdominal Organ) Function After Fenestrated and Branched Endovascular Aneurysm Repair (FEVAR/BEVAR) of Thoracoabdominal Aortic Aneurysms||Device: Endovascular repair of TAAA using branched stent graft|Interventional||Other / Industry|Change from baseline in renal function over time (up to two years) after endovascular aortic aneurysm repair various custom stent grafts;  Timetomorbidity;  Timetomortality;  Timetolossofstentgraftintegrity;  Timetomigration;  Endoleak;  BranchvesselEvents|160|NCT01654133|July 2012
1100|Completed|Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics||Drug:Liraglutide;  Drug:Insulin|Interventional|Phase 4|Other|ChangefrombaselineinHbA1catsixmonths;  Hypoglycemia;  TotalDailyInsulinDose(TDID);  Weight;  GlycoMark|36|NCT01654120|December 2011
1101|Completed|Evaluating a Novel Method of Generalizing Emotion Regulation||Behavioral:HabituationReminderTraining;  Behavioral:HabituationReminder;  Behavioral:Habituation|Interventional||Other / NIH|Reduction in emotional arousal or speed to recovery from emotional arousal following a stressor.;  Phoneusefeasibility|372|NCT01653548|August 2012
1102|Active not recruiting|Multisite Prevention of Conduct Problems (Fast Track)||Behavioral:FastTrack|Interventional||Other / NIH / U.S. Fed|Anti-SocialBehaviors;  SubstanceUsage;  SexualActivity;  PsychiatricDisorders;  AcademicAchievement|891|NCT01653535|March 1991
1103|Completed|ENLaCE Pilot Study||Behavioral:Meducationdevicetechniquevideo;  Other:Nutritionvideo|Interventional||Other|Change in inhaler turbuhaler and diskus technique;  Childinhalerself-efficacy;  AsthmaControl|92|NCT01641211|July 2012
1104|Recruiting|Imaging Regional Lung Defect Severity||Drug:PerfluorinatedGas/OxygenMixture;  Other:HighResolutionCToftheChest|Interventional|Phase 1 / Phase 2|Other|Gas trapping measured during washout of the perfluorinated gas mixture.;  Ventilation defect severity during wash-in of the perfluorinated gas mixture|250|NCT01640288|January 2013
1105|Completed|Markers of Alzheimers Disease After Propofol or Isoflurane Anesthesia||Drug:Propofol;  Drug:Isoflurane|Interventional|Phase 1|Other|Ratioofcerebrospinalfluidtautoamyloidbeta;  the relationship between anesthetic exposure and CSF biomarker changes;  the relationship between anesthetic exposure and CSF biomarker changes and demographics (age gender and race);  the relationship between CSF biomarker changes and serum markers of metabolic and/or inflammatory status;  the relationship between anesthetic exposure and biomarker changes and serum markers of metabolic and/or inflammatory status;  the relationship between anesthetic exposure and biomarker changes and neuroimaging results obtained as dictated by routine standard of care;  the relationship between anesthetic exposure and biomarker changes and depth of anesthesia based on average BIS (bispectral index) monitoring signal;  the relationship between anesthetic exposure and biomarker changes and the time of day that surgery is performed;  the relationship between anesthetic exposure and biomarker changes with genetic polymorphisms in ApoE (apolipoprotein E) and other genes related to inflammation metabolism brain function and/or Alzheimer&apos;s disease|105|NCT01640275|March 2012
1106|Completed|Pilot Study of Bone Marrow/Stem Cells in Grade IV Malignant Glioma||Biological:ALD-451|Interventional|Phase 1|Other|Numberofpatientswithunacceptabletoxicity;  Number of ALD-451 cells recovered from bone marrow of patients following radiation therapy and chemotherapy;  Neurocognition and patient-reported outcomes following ALD-451|11|NCT01639612|June 2012
1107|Completed                  Has Results|Reinfusion Drains vs Tranexamic Acid in Total Joint Arthroplasty||Procedure:Hemovacdrain;  Procedure:Re-infusiondrain;  Procedure:Tranexamicdrain|Interventional|Phase 4|Other|BloodTransfusion;  ChangeinHemoglobinLevel|204|NCT01636414|May 2012
1108|Completed|Behavioral Genetic and Epigenetic Implications of Dietary Supplementation With Alpha-linolenic Acid in Humans||DietarySupplement:Flaxseedoil;  DietarySupplement:cornoil|Interventional||Other|Changeindeclarativememoryperformance;  Changeinfattyacidlevelsinplasma;  Stability of methylation of promoter region of FADS2 gene|66|NCT01634776|February 2009
1109|Withdrawn|The Effects of Smoking Withdrawal On Resting State Functional Connectivity||Behavioral:Abstainfromsmokingfor24hours|Interventional||Other / NIH|Blood-oxygen-level-dependent(BOLD)signal|0|NCT01632384|February 2012
1110|Completed|Combination Gel and Vascular ND in Mild to Moderate Rosacea||Drug:Azelaicacid;  Device:Nd:Yaglaser|Interventional||Other / Industry|IGAofImprovement|10|NCT01631656|July 2010
1111|Active not recruiting|Molecular and Diagnostic Classification of Non-Small Cell Lung Cancer From Fine Needle Aspirates|||Observational||Other|Use of Ribonucleic acid-based molecular signature of tumor samples obtained by fine needle aspirate to discriminate subtypes of tumors relevant to treatment and outcomes.|103|NCT01630122|June 2012
1112|Completed|Neurostimulation Device for Treatment of Migraine Headache||Device:ThermoNeuroModulation(TNM)Device|Interventional||Other / Industry|Numberofmigraineheadachedays;  Severityofeachandofallheadaches;  TotalMonthlyHeadachePainScore|7|NCT01630044|May 2012
1113|Completed|Caloric Stimulation on Cerebral Blood Flow||Device:ThermoNeuroModulation(TNM)Device|Interventional||Other / Industry|Changesincerebralbloodflow;  AlterationsinEEGreadings;  Alterations in regional cerebral brain flow (rCBF)|10|NCT01629901|June 2012
1114|Active not recruiting|Integrated Dose Escalation for Advanced Localized Gynecologic Cancer (The IDEAL - GYN Trial)||Radiation:Boostradiation|Interventional||Other|Maximum tolerated dose of integrated boost radiation therapy administered with IMRT technique with concurrent chemotherapy (cisplatin).;  Local-regional control with integrated boost radiation therapy (TTLR);  Timetodistantrecurrence(TTDR);  Diseasefreesurvival(DFS).;  Overallsurvival(OS);  The number of acute dose limiting toxicities (DLT).;  Thenumberoflatedoselimitingtoxicities(DLT)|12|NCT01627288|June 2012
1115|Recruiting|Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant||Biological: Naive T Cell Depleted Donor Lymphocyte Infusion|Interventional|Phase 1|Other|MTDofNaiveTCDDLI;  ImmunologicalRecovery;  OverallIncidenceofAcuteGVHD;  OverallIncidenceofOpportunisticInfections;  OverallIncidenceofChronicGVHD|48|NCT01627275|June 2012
1116|Completed|HIV Prevention Among Latino MSM: Evaluation of a Locally Developed Intervention||Behavioral:HOLAenGrupos;  Behavioral: General Health intervention (comparison intervention )|Interventional||U.S. Fed|Increased self-reported consistent use of condoms during sexual intercourse;  Increased self-reported use of HIV and sexually transmitted disease (STD) counseling testing and treatment services|304|NCT01626898|August 2012
1117|Completed|Cathepsin Activatable Fluorescent Probe||Drug:LUM015|Interventional|Phase 1|Other|DoseofLUM015inmg;  Mean number of fluorescence counts per second per square centimeter;  To obtain PK/PD information regarding LUM015 when administered IV in patients.;  To analyze cathepsin protease expression in tumors.|15|NCT01626066|June 2012
1118|Completed|Effect of Sulforaphane-rich Broccoli Sprout Homogenate on Ozone Induced Inflammation Through Modulation of NRF2||DietarySupplement:Broccolisprouthomogenate;  DietarySupplement:alfalfasprouthomogenate|Interventional||Other / U.S. Fed|Change in % neutrophils in induced sputum comparing the 4 hr post O3 placebo v. SFN treatment periods.;  Spirometry (FEV1 FVC FEF25-75) for assessment of changes in lung function;  SFNlevels;  Cytokine concentration and flow cytometric assessment of surface markers in sputum supernatants;  mRNA expression of NRF2 and phase II antioxidant enzymes in nasal epithelial cells and in induced sputum macrophages|16|NCT01625130|October 2013
1119|Completed                  Has Results|Effects of Tai Chi Chuan on Psychobiological Indicators of Anxiety and Sleep Quality in Young Adults||Behavioral:AnxietyManagementEducation;  Behavioral:10weektaichiintervention;  Behavioral:Enhancedtaichiinstruction|Interventional||Other|Retention of Randomized Subjects During Intervention;  RetentionofRandomizedSubjectsforFollow-up;  AdherencetoOut-of-classPractice;  AdherencetoPracticeAftertheIntervention;  ChangeFromBaselineinStateAnxietyScores;  Change From Baseline in Pittsburgh Sleep Quality Index Scores|75|NCT01624168|January 2013
1120|Completed|The Effect of Nasal Continuous Positive Airway Pressure (N-CPAP) on Arterial pCO2 During Spinal Anesthesia||Other: Nasal Continuous Positive Airway Pressure (NCPAP)|Interventional||Other|Arterial Blood Gas (ABG) test to investigate the breathing effects on patients receiving CPAP treatment during spinal anesthesia for knee replacement.|40|NCT01622647|July 2012
1121|Recruiting|Anterior Capsulectomy vs. Repair in Direct Anterior THA||Procedure: Direct anterior approach with capsulectomy;  Procedure: Direct anterior approach without capsulectomy|Interventional||Other|Hipflexion;  Visualanalogscale-pain|72|NCT01621932|March 2012
1122|Completed|Ventilatory Heterogeneity in Participants With Asthma (MK-0476-513)||Drug:Montelukast;  Drug:Prednisone|Interventional|Phase 1|Other / Industry|Change from baseline in VH assessed by oxygen-enhanced 1H MRI (Oe 1H MRI) after two weeks of montelukast or prednisone treatment;  Change from baseline in VH assessed by 19F-perfluoropropane MRI (19F MRI) after two weeks of montelukast or prednisone treatment;  Change from baseline in VH assessed by Lung Clearance Index (LCI) after two weeks of montelukast or prednisone treatment;  Change from baseline in VH assessed by Conducting Airway Heterogeneity (Scond) after two weeks of montelukast or prednisone treatment;  Change from baseline in VH assessed by Forced Expiratory Volume in 1 second (FEV1) after two weeks of montelukast or prednisone treatment;  Comparison of VH assessed by Oe 1H MRI 19F MRI LCI Scond and FEV1 at baseline;  Short-term test-retest repeatability of VH by Oe 1H MRI and 19F MRI;  Mid-term test-retest repeatability of VH by Oe 1H MRI and 19F MRI|34|NCT01621386|January 2013
1123|Completed|Evaluation of DVD and Internet Decision Aids for Hip and Knee Osteoarthritis: Focus on Health Literacy||Behavioral:DVDDecisionAid;  Behavioral:InternetBasedDecisionAid|Interventional||Other|Change in the Facts about Osteoarthritis section of the Decision Quality Instrument - Knee Osteoarthritis (DQI-KOA; &#169; Massachusetts General Hospital 2010 46) at Baseline to post.;  Change in Decisional Conflict Scale at Baseline to post.;  Change in Decision Self-Efficacy Scale a Baseline to post.;  Change in the Facts about Osteoarthritis section of the Decision Quality Instrument - Knee Osteoarthritis (DQI-KOA; &#169; Massachusetts General Hospital 2010 46) at 30 days.;  Change in Decisional Conflict Scale at 30 days post.;  Measurement of the Acceptability and Usability Scale post viewing of the DAs.;  Semi-StructuredInterviews;  Time spent viewing different parts of the internet-based DA|155|NCT01618097|January 2012
1124|Unknown&nbsp;&#8224;|Tilt Table With Suspected Postural Orthostatic Tachycardia Syndrome (POTS) Subjects|||Observational||Other|AutonomicTestinginSuspectedPOTSSubjects;  Change in Heart Rate and Blood Pressure in Suspected POTS Subjects|48|NCT01617616|March 2012
1125|Completed|Study to Characterize the Durability of Hypertonic Saline to Enhance Mucociliary Clearance in Healthy Subjects||Drug:HypertonicSaline|Interventional|Phase 1 / Phase 2|Other / Industry|ChangeinmucociliaryClearance|12|NCT01617369|June 2012
1126|Completed|Lean Muscle Function|||Observational||Other|MuscleFiber;  MuscleStrength|24|NCT01616498|June 2012
1127|Unknown&nbsp;&#8224;|Management of Chronic Pain in Military Patients With Injuries Sustained During Active Duty||Device:Spinalcordstimulator|Interventional|Phase 4|Other / Industry|Changeinpainscore;  changeinrelatedpain;  changeinmeandailypainscore;  changeinmeanpainpertreatmentgroup;  changeinMPQpertreatmentgroup;  changeinspinerelatedpain;  changeinneuropathicpain;  analgesicefficacy;  painreliefusingacategoricalscale;  changeinmood;  changeinemotionalstatus;  changeinanxiety;  changeinqualityoflife;  effectivenessofintervention;  Functionaleffectivenessofintervention;  Functional effectiveness of interventions via activity scores;  changeinsleep;  urinedrugtests;  Effectofdemographiccharacteristics;  predictive value of the change in NPRS average pain scores;  Analgesicbenefit;  Safety and tolerability of analgesic interventions;  Tolerabilityofanalgesicinterventions|180|NCT01616342|December 2011
1128|Completed|Lose Now North Carolina Community Weight Loss Program||Behavioral: Group weight loss with companion internet|Interventional||Other|Weightchange;  Diet;  PhysicalActivity;  Lipids;  HemoglobinA1c;  BloodPressure|225|NCT01615471|June 2012
1129|Recruiting|Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery||Drug:Carboplatin;  Drug:Paclitaxel;  Drug:Lapatinib;  Drug:Cisplatin;  Radiation:IpsilateralRadiation;  Radiation:BilateralRadiation;  Procedure:TransoralSurgery|Interventional|Phase 2|Other / Industry|OverallResponseRate;  Feasibilityof3parttherapy;  PostInductionChemotherapyChangesinRiskLevel;  ProgressionFreeSurvivalandOverallSurvival;  VoiceandSwallowingFunction;  Numberofsubjectswhoexperienceadverseevents|40|NCT01612351|June 2012
1130|Withdrawn|Crossover Evaluation of Effect of Atorvastatin on PK of Irinotecan in CRC Patients Receiving FOLFIRI||Drug:FOLFIRI.;  Drug:Atorvastatin|Interventional|Phase 1|Other|Area under the plasma concentration versus time curve (AUC) of irinotecan.;  Area under the plasma concentration versus time curve (AUC) of SN-38.|0|NCT01605344|April 2012
1131|Completed|Improving Emergency Department Management of Adults With Sickle Cell Disease||Behavioral:QualityImprovement|Observational||Other|NumberofSCDpatientsmeetinghighusercriteria;  Change in clinical performance indicators and patient and clinician outcome measures|715|NCT01603160|September 2011
1132|Completed|Pharmacogenetic Testing in Primary Care|||Observational||Other / NIH|UseofPGxtesting;  Numberofadversedrugreactions|400|NCT01600846|December 2012
1133|Unknown&nbsp;&#8224;|Facilitating Completion of HPV Vaccination|||Observational||Other|HPVvaccinationuptake|200|NCT01600560|May 2012
1134|Completed|GooDMoMS: A Multimodel Pregnancy and Postpartum Intervention for Gestational Diabetics||Behavioral:lifestylecounseling|Interventional||Other|Changeinglycosylatedhemoglobin;  Changeinweightafterpregnancy|24|NCT01600534|May 2012
1135|Completed|Error Based Learning for Restoring Gait Symmetry Post-Stroke||Other:SameBeltSpeeds;  Other:DifferentBeltSpeeds|Interventional|Phase 1|Other / NIH|Change from baseline in spatiotemporal gait symmetry after 6 weeks of training;  Change from baseline in gait speed after 6 weeks of training;  Change from baseline in balance after 6 weeks of training;  Change from baseline in endurance after 6 weeks of training;  Change from baseline in quality of life after 6 weeks of training;  Change from baseline in metabolic efficiency after 6 weeks of training;  Change from baseline in community ambulation after 6 weeks of training;  Change from baseline in gait speed at 1 month follow-up;  Change from baseline in balance at 1 month follow up;  Change from baseline in endurance at 1 month follow up;  Change from baseline in quality of life at 1 month follow up;  Change from baseline in metabolic efficiency at 1 month follow up;  Change from baseline in community ambulation at 1 month follow up;  Change from baseline in spatiotemporal gait asymmetry at 1 month follow up|48|NCT01598675|January 2012
1136|Completed|A Study to Assess the Safety Tolerability and Pharmacokinetics of ACHN-975 in Healthy Volunteers||Drug:ACHN-975;  Drug:placebo|Interventional|Phase 1|Industry / Other|FrequencyofAEs;  SeverityofAEs;  PlasmaconcentrationsofACHN-975;  UrineconcentrationsofACHN-975|50|NCT01597947|May 2012
1137|Unknown&nbsp;&#8224;|Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding||Drug:Liraglutide;  Drug:Orlistat;  Drug:Liraglutide+Orlistat|Interventional|Phase 4|Other|Type2diabetesremission;  Wholebodyinsulinsensitivity;  GLP-1response;  FirstPhaseInsulinsecretion|9|NCT01597531|June 2012
1138|Withdrawn|Pharmacokinetics Pharmacodynamics and Cervicovaginal Lavage of Combined Oral Contraceptives and Raltegravir|||Observational||Other / Industry|Changeincervicovaginalfluidemilieu|0|NCT01597180|July 2012
1139|Active not recruiting|Bovine Lactoferrin in Reducing Taste Disturbances in Patients With Colorectal Cancer Receiving Oxaliplatin-Based Chemotherapy||Other:questionnaireadministration;  Procedure:quality-of-lifeassessment;  Other:laboratorybiomarkeranalysis;  Biological:bovinelactoferrin|Interventional||Other / NIH|Change in the Taste Visual Analog Scale (VAS) and taste and smell questionnaire responses;  Effect of bovine lactoferrin on lipid peroxidation byproducts in saliva as measured by the TBARs assay;  Malondialdehyde (MDA) concentrations before and after a ferrous iron oral rinse;  Quality of life as quantified by the Functional Assessment of Anorexia/Cachexia Treatment (FAACT) questionnaire|49|NCT01596634|January 2013
1140|Completed|A School Health Center Intervention to Increase Adolescent Vaccination||Behavioral:ModifiedVaccineConsentForm|Interventional||Other|Change from Baseline In The Number of Adolescent Vaccines;  Number of Returned Consent Forms Authorizing Vaccination|3417|NCT01595542|September 2011
1141|Completed|Mindful Movement and Breathing to Improve Outcomes of Gynecologic Surgery||Other:MindfulMovementandBreathingprogram;  Other:Questionnaireadministration;  Procedure:TheObserverMobilityScale;  Procedure:VolumetricIncentiveSpirometry|Interventional|Phase 0|Other|Feasibility of implementing and evaluating a Mindful Movement and Breathing Program among women undergoing gynecologic surgery for a suspected malignancy (recruitment retention adherence and program evaluation and acceptability rates);  Immediate effects of the Mindful Movement and Breathing program on reducing postsurgical pain psychological distress and lung function;  Collect data on measures that will be used to evaluate the efficacy of the Mindful Movement and Breathing program in a future larger randomized controlled trial|10|NCT01593657|May 2012
1142|Completed                  Has Results|Study of Anesthesia Techniques to Reduce Nausea and Vomiting After Jaw Corrective Surgery||Other:Antiemeticanesthesiaprotocol|Interventional||Other / NIH|Post-operativeNausea;  Post-operativeVomiting;  HospitalLengthofStay;  Post-dischargeNausea;  Post-dischargeVomiting|233|NCT01592708|June 2012
1143|Unknown&nbsp;&#8224;|Use of Parietex Plug and Patch Hernia System in Open Inguinal Hernia Repair||Procedure:Openinguinalherniarepairwithmesh|Observational||Other / Industry||50|NCT01590940|April 2012
1144|Completed|Supportive Intervention Programs Study||Procedure:Yogatherapy;  Other:questionnaireadministration;  Procedure:quality-of-lifeassessment;  Other:laboratorybiomarkeranalysis;  Other:assessmentoftherapycomplications;  Procedure:managementoftherapycomplications;  Other:educationalintervention|Interventional||Other|Feasibility of implementing a YST among patients undergoing chemotherapy (participating rate adherence and retention);  Preliminary efficacy of YST in terms of reducing fatigue;  TreatmentrelatedsymptomsandQOL;  Mediating variables (self efficacy response expectancies inflammatory biomarkers) intervention effect on fatigue treatment-related symptoms and QOL|15|NCT01590147|June 2011
1145|Active not recruiting|Palliative Care in Heart Failure||Behavioral: Usual heart failure care + interdisciplinary palliative care|Interventional|Phase 4|Other / NIH|Is there an impact on quality of life with the addition of a palliative care intervention?;  Is there an impact on depression and anxiety with the addition of a palliative care intervention?;  Is there an impact on caregiver satisfaction and perception of subject quality of life with the addition of a palliative care intervention?;  Is there an impact on spiritual well-being with the addition of a palliative care intervention?;  Is there an impact on cost and resource utilization with the addition of a palliative care intervention?|200|NCT01589601|August 2012
1146|Terminated|Pharmacokinetics and Safety of Ertapenem in the Postpartum Period||Drug:Ertapenem|Interventional|Phase 1|Other|MeasurefractionoftotalandunboundErtapenem.;  Correlation between plasma drug concentrations and safety outcomes|3|NCT01587495|March 2012
1147|Withdrawn|Adenovirus Vaccine Pregnancy Registry|||Observational||Industry / U.S. Fed|AdversePregnancyOutcomebyobservation|0|NCT01584037|December 2011
1148|Active not recruiting|Acoustic Radiation Force Impulse (ARFI) Ultrasound for Noninvasive Diagnostic Atherosclerosis Imaging|||Observational||Other / NIH|ARFIAUCscore;  ARFIsensitivity;  ARFIspecificity|25|NCT01581385|April 2012
1149|Completed|Bananas as an Energy Source During Exercise: a Metabolomics Approach||Dietary Supplement: Bananas versus 6% carbohydrate beverage|Interventional||Other / Industry|Performance and fuel substrate utilization as measured through metabolomics;  Exercise-inducedinflammation.|14|NCT01581190|September 2011
1150|Recruiting|Lenalidomide as Consolidation and Maintenance in Adults &gt;/= 60 Years of Age With AML Following Standard Induction||Drug:Lenalidomide|Interventional|Phase 1|Other / Industry|Determinetherateofdoselimitingtoxicities.;  Frequencyoftoxicity;  Durationoftoxicity;  Responserates|26|NCT01578954|June 2012
1151|Completed|Effects of Salpingectomy During Laparoscopic Hysterectomy on Ovarian Function||Procedure:Salpingectomy|Interventional||Other|Change from baseline in ovarian function as measured by Anti-Mullerian Hormone (AMH);  Patientdemographics;  Patientsurgicaloutcomes|30|NCT01578759|April 2012
1152|Completed|Mechanical Bowel Preparation Before Laparoscopic Hysterectomy and Laparoscopic Sacrocolpopexy: a Randomized Controlled Trial||Drug: Fleet Enema (sodium biphosphate and sodium phosphate)|Interventional||Other|Surgeon&apos;s assessment of surgical field visual quality;  Surgeonevaluationofpatientoutcomes;  Patientreportedsatisfaction|160|NCT01576965|April 2012
1153|Completed|Elders Preferences in Care Decisions||Behavioral:MakingADecisionAboutCRCScreening;  Behavioral:Drivers65Plus|Interventional||Other / U.S. Fed|Appropriatecolorectalcancerscreening;  Appropriatecolorectalcancerscreeningdecisions;  Appropriatescreeningandmediators;  Appropriatescreeningforhealthstrata;  Appropriatescreeningforstoolcards|424|NCT01575990|March 2012
1154|Active not recruiting|ENLIGHTEN: Exercise and NutritionaL Interventions for coGnitive and Cardiovascular HealTh ENhancement||Behavioral:AerobicExercise;  Behavioral:DASHdiet;  Other:Healtheducationcontrol|Interventional||Other|ChangeinExecutivefunction;  Bloodpressure;  Change in Visuospatial ability and lexical retrieval;  Inflammation;  FunctionalCapacity;  Flow-mediateddilationofthebrachialartery;  ArterialStiffness;  Intima-medialthickness;  Fastingglucose;  Cholesterol|160|NCT01573546|December 2011
1155|Recruiting|Bisphenol A Controlled Exposure Study||Other:deuterated-BisphenolA(d-BPA)|Interventional|Phase 1|NIH|Pharmacokinetics of d-BPA and d-BPA conjugates in blood and urine over 5 days.|60|NCT01573429|March 2012
1156|Completed|BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer||Drug:BKM120;  Drug:mFOLFOX6|Interventional|Phase 1|Other|Dose-limitingtoxicity(DLT);  MaximumToleratedDose(MTD);  Numberofsubjectsexperiencingadverseevents;  ProgressionFreeSurvival(PFS);  OverallSurvival(OS);  BiomarkersofClinicalBenefit|17|NCT01571024|May 2012
1157|Recruiting|Training Dual-Task Walking After Stroke||Behavioral:Gaittraining|Interventional||Other|Dual-taskcostongaitspeed;  Executivefunction;  Spontaneousphysicalactivity;  Kinematicsofgaitduringobstaclecrossing;  StrokeImpactScale|44|NCT01568957|September 2011
1158|Completed|To Compare the Safety Tolerability and Pharmacokinetics of QBX258 in Patients With Asthma||Drug:VAK694;  Drug:VAK694placebo;  Drug:QAX576;  Drug:QAX576placebo|Interventional|Phase 1|Industry|Numberofpatientswithadverseevents;  Concentrationofserumanti-VAK694antibodies;  Concentrationofserumanti-QAX576antibodies;  Area under the serum concentration curve for VAK694;  Area under the serum concentration curve for QAX576;  Changeininterleukinconcentrations|50|NCT01568762|October 2010
1159|Completed|Goals of Care: A Nursing Home Trial of Decision Support for Advanced Dementia||Behavioral:Goalsofcaredecisionsupport|Interventional||Other / NIH|Qualityofcommunicationanddecision-making;  Numberofpalliativecaredomainsincareplan;  Satisfactionwithcare;  Comfortindying;  Qualityoflife;  Qualityofdying;  Frequencyofcommunication;  Hospicereferral;  Hospitalizations|302|NCT01565642|May 2012
1160|Active not recruiting|Study of a Holistic Health Program for United Methodist Clergy||Behavioral:Holistichealth|Interventional|Phase 3|Other|MetabolicSyndrome;  Depression;  Stress|1167|NCT01564719|October 2010
1161|Completed|Bone Accrual and Hormones in Response to Lactation|||Observational||Other|The association of change in bone density and change in IGF-1 axis hormones during lactation and weaning;  The association of changes in bone density and change in bone turnover markers during lactation and weaning.|141|NCT01563094|January 2003
1162|Completed|Mild Cognitive Impairment Buddy Supported Exercise/ My Buddy Study||Behavioral:5-monthaerobicexerciseintervention|Interventional||Other|Adherence (number of sessions attended and exercise duration in targeted heart rate zone);  ChangeinscoreonDigitSymbolCodingTest;  Change in 400m walk time (from randomization to 5 months);  ChangeinTrailMakingTestpartBscore;  change in memory measured by Rey AVLT delayed recall score at 5 months|15|NCT01561820|November 2011
1163|Active not recruiting|Oxaliplatin Fluorouracil Erlotinib Hydrochloride and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction||Drug:erlotinibhydrochloride;  Drug:oxaliplatin;  Drug:fluorouracil;  Radiation:radiationtherapy;  Procedure:conventionalsurgery;  Other:immunohistochemistrystainingmethod;  Procedure:positronemissiontomography;  Procedure:computedtomography;  Procedure:laboratorybiomarkeranalysis;  Genetic:geneexpressionanalysis;  Radiation:fludeoxyglucoseF18|Interventional|Phase 1|Other / NIH|Toxicity rate of combination chemotherapy followed by surgery and erlotinib hydrochloride;  Timetoprogression;  Survival;  Specific characteristics that predict complete response rate (e.g. EGFR status EGFR amplification and cyclin D1 expression);  Test the predictive value of FDG-PET-CT imaging in identifying patients who will have a complete response|64|NCT01561014|April 2007
1164|Completed|Dental Plaque Removal Study||Device:ManualToothbrushonly;  Device:MTB+WaterpikUltraWaterFlosser&apos;High&apos;;  Device:MTB+Floss(MTB+Floss)|Interventional||Other / Industry|residual protein concentration in posterior sites following in-clinic use of MTB (Manual Toothbrush)+Waterpik Ultra Waterflosser &apos;high&apos; MTB+floss or MTB alone;  Modified Gingival Index Gingival Bleeding index Plaque Index and clinical attachment level).;  NumberofAdverseEventsandIntraoralExams|270|NCT01559987|February 2012
1165|Completed|Online Study of Colorectal Cancer and Prostate Cancer Screening Decision Making||Other:RatingandRankingTask;  Other:DiscreteChoiceTask;  Other:BalanceSheetTask|Interventional||Other|Participant-reported most important attribute from survey;  Participant-reported intent to undergo screening from survey;  Unlabeledscreeningtestoptions|1831|NCT01558583|July 2011
1166|Completed                  Has Results|Docetaxel Cisplatin Pegfilgrastim and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer||Drug:cisplatin;  Biological:pegfilgrastim;  Drug:erlotinibhydrochloride;  Other:laboratorybiomarkeranalysis;  Genetic:polymorphismanalysis;  Other:pharmacogenomicstudies;  Genetic:geneticlinkageanalysis;  Drug:docetaxel|Interventional|Phase 2|Other / NIH / Industry|TimetoProgression;  Response Rate Among Subgroups of Patients According to Molecular Profiles Including Tumor Characteristics and Genetic Polymorphisms From Peripheral Blood;  Median Survival Among Subgroups of Patients According to Molecular Profiles Including Tumor Characteristics and Genetic Polymorphisms From Peripheral Blood|45|NCT01557959|July 2007
1167|Completed                  Has Results|Postpartum Levonorgestrel-releasing Intrauterine System and Breastfeeding||Drug: Levonorgestrel-releasing intrauterine system|Interventional|Phase 4|Other|Breastfeeding;  LNG-IUSExpulsionorRemoval|61|NCT01555931|March 2012
1168|Withdrawn|Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation||Drug:TXA127|Interventional|Phase 2|Industry|Safety of TXA127 in subjects undergoing cord blood transplantation;  Effect of TXA127 on incidence severity and duration of aGVHD;  Effect of TXA127 on incidence severity and duration of mucositis;  EffectofTXA127onneutrophilengraftment;  EffectofTXA127onplateletrecovery;  EffectofTXA127onimmunereconstitution|0|NCT01554254|March 2012
1169|Completed|Healing Touch or Guided Imagery In Treating Pain Fatigue Nausea and Anxiety in Patients Undergoing Chemotherapy||Other:questionnaireadministration;  Procedure:therapeutictouch;  Behavioral:managementoftherapycomplications;  Procedure:standardfollow-upcare|Interventional||Other / NIH|Changescoresforeachpatientonpainscale;  Changescoresforeachpatientonfatiguescale;  Changescoresforeachpatientonnauseascale;  Changescoresforeachpatientonanxietyscale|244|NCT01553578|February 2012
1170|Completed                  Has Results|Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery||Drug:therapeuticangiotensin-(1-7);  Other:laboratorybiomarkeranalysis|Interventional|Phase 2|Other / NIH|Antitumor Activity as Assessed by Number of Patients Showing an Objective Tumor Response;  Number of Participants Who Experienced Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0;  TimetoDiseaseProgression;  OverallSurvival;  Plasma Levels of Angiogenic Peptides Including Placental Growth Factor (PlGF);  Plasma Levels of Angiogenic Peptides Including PIGF|20|NCT01553539|October 2009
1171|Completed|Comparison of Psyllium and Microcrystalline Cellulose on Glycemic Measures in Subjects With Impaired Fasting Glucose||DietarySupplement:psyllium;  DietarySupplement:MicrocrystallineCellulose|Interventional||Industry / Other|fastingserumglucose|18|NCT01549600|February 2012
1172|Completed                  Has Results|Once-Daily Asenapine for Schizophrenia||Drug:Asenapine10mgdailyintheevening;  Drug:Asenapine5mgtwicedaily|Interventional|Phase 4|Other / Industry|PatientAcceptance;  Change in Brief Psychiatric Rating Scale (BPRS) Total Score|30|NCT01549041|April 2012
1173|Completed|Cardiovascular Effects of Incremental Diesel Exhaust Inhalation in Middle-Aged Healthy GSTM1 Null Human Volunteers|||Observational||U.S. Fed||6|NCT01548625|July 2007
1174|Completed|Standard Percutaneous Nephrolithotomy Percutaneous Nephrolithotomy (PNL) Versus Tubeless PNL Versus Tubeless Stentless PNL||Procedure:StandardPercutaneousnephrolithotomy|Interventional|Phase 3|Other|Lengthofhospitalstay;  ChangeinCBCandChemistryPanel|60|NCT01548196|February 2008
1175|Recruiting|Remote Ischemic Preconditioning Mechanism Study||Device: Remote Ischemic Preconditioning Capsaicin UV-B|Interventional||Other|Areas of hyperalgesia and allodynia to mechanical stimuli.;  Pain intensity and unpleasantness to mechanical stimuli;  PresenceofparathesiaswhereRIPCwasused|24|NCT01541436|March 2012
1176|Completed|Intrauterine Lidocaine for Laminaria||Drug:Lidocaine;  Drug:NormalSaline|Interventional|Phase 1|Other|Patient self-report of pain score during laminaria insertion scored on a 100mm Visual Analog Scale;  Patient self-report of maximum recalled pain during interval between laminaria insertion and abortion procedure scored on a 100mm Visual Analog Scale|72|NCT01541293|September 2012
1177|Completed                  Has Results|Immediate Postplacental Insertion of IUDs at Time of Cesarean Delivery: A Randomized Clinical Trial||Device: Immediate Postplacental Placement of an IUD during cesarean delivery|Interventional|Phase 4|Other|IUDUse;  IUDExpulsion;  Women&apos;sSatisfactionWithIUDs|112|NCT01539759|March 2012
1178|Completed|The Effects of Antihistamines on Pre-Pulse Inhibition||Drug:Placebo;  Drug:Meclizine|Interventional|Phase 1|Other|ChangeinPPI;  Sedation|117|NCT01537471|January 2012
1179|Completed                  Has Results|Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking||Drug:memantinehydrochloride;  Drug:placebo|Interventional|Phase 2|Other / NIH|Retention;  Adherence;  NicotineDependence;  SmokingWithdrawal|130|NCT01535040|August 2012
1180|Completed                  Has Results|Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer||Drug:aprepitant;  Drug:gemcitabinehydrochloride;  Drug:capecitabine;  Drug:fluorouracil;  Procedure:radiationtherapy;  Other:questionnaireadministration;  Procedure:quality-of-lifeassessment;  Procedure:nauseaandvomitingtherapy;  Procedure:managementoftherapycomplications|Interventional||Other / NIH / Industry|Number of Patients With Gastrointestinal Toxicities (Grade 3 and 4 Nausea and Vomiting) Associated With Delivering Fluorouracil/Gemcitabine Hydrochloride-based Chemotherapy With Upper Abdominal Radiation;  Impact of Aprepitant/5HT-3 Antagonist Therapy on the Patient Quality of Life as Measured by the Number of Patients Using Anti Nausea Drugs;  Impact of Aprepitant/5HT-3 Antagonist Therapy on the Patient Quality of Life as Measured by the Number of Patients Taking Anti Nausea Drugs|22|NCT01534637|August 2006
1181|Recruiting|Belimumab (BENLYSTA&#174;) Pregnancy Registry||Drug:belimumab|Observational||Industry|Birthdefects;  Otherpregnancyoutcomes;  Infantoutcomes|500|NCT01532310|July 2012
1182|Completed|Mapping Multidimensional Illness Trajectories of Patients With End-stage Kidney Disease|||Observational||Other / NIH|Symptoms physical functioning psychosocial needs spiritual well-being cognitive functioning|227|NCT01530945|March 2012
1183|Completed                  Has Results|The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers||Drug:Aminophylline;  Drug:Ambrisentan;  Drug:Aminophyllineplusambrisentan|Interventional|Phase 1|Other|MeanNumberofAdverseEventsFollowingEachDose;  Plasma Halflife of Theophylline (Aminophylline) and Ambrisentan When Administered Alone or in Combination;  Time Until Maximum Plasma Concentration (Tmax) of Theophylline (Aminophylline) and Ambrisentan When Administered Alone or in Combination;  Maximum Plasma Concentration (Cmax) of Theophylline (Aminophylline) and Ambrisentan When Administered Alone or in Combination;  Area Under the Curve Within 24 Hours Post Dosing (AUC_0-24 Hours) of Theophylline (Aminophylline) and Ambrisentan When Administered Alone or in Combination;  Area Under the Curve Post Dosing (AUC_0-infinity) of Theophylline (Aminophylline) and Ambrisentan When Administered Alone or in Combination|18|NCT01530464|February 2012
1184|Recruiting|Prosocial Behavior and Volunteerism to Promote Physical Activity in Older Adults||Behavioral: Prosocial Behavior Physical Activity (PBPA);  Other:HealthyAging(HA)|Interventional||Other|physicalactivity;  physicalfunction|300|NCT01528761|February 2012
1185|Unknown&nbsp;&#8224;|A Prospective Study Evaluating The Utility of Transnasal Endoscopy With Roux en Y Gastric Bypass||Procedure:Endoscopy|Observational||Other|Anastomoticulceranddiameter;  Presenceofanastomoticstrictureanddiameter|20|NCT01526772|September 2011
1186|Active not recruiting|A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901||Biological:AVX901|Interventional|Phase 1|Other|Safety;  Immuneresponse|22|NCT01526473|February 2012
1187|Completed                  Has Results|Do Furanocoumarins Mediate the Fexofenadine-grapefruit Juice Interaction?||Drug:Fexofenadine|Interventional||Other|Primary Pharmacokinetic Measure: Area Under the Curve (AUC)|18|NCT01526213|September 2009
1188|Unknown&nbsp;&#8224;|EUS Prior to ERCP in the Positive Setting of Positive Intraoperative Cholangiogram (IOC) During Cholecystectomy|||Observational|Phase 0|Other|BileDuct;  Lesions;  Bileduct;  Diverticulum;  ERCP|40|NCT01525355|October 2010
1189|Enrolling by invitation|Blood Vessel Study|||Observational||NIH|Flow-mediated dilation (FMD; endothelium-dependent vasodilation) defined as the peak percent change in brachial artery diameter relative to baseline after reactive hyperemia as measured by ultrasound|155|NCT01524549|January 2012
1190|Completed|PRESENCE 2: Predicting Sedentary Entertainment Choices and Effects||Other:Motion-controlledvideogaming;  Other:Traditionalvideogaming;  Other:Televisionwatching|Interventional||Other|Energyintake;  Energyexpenditure|120|NCT01523795|October 2010
1191|Unknown&nbsp;&#8224;|Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout||Drug:levotofisopam|Interventional|Phase 2|Industry|Percentagereductioninserumurate;  Absolutereductioninserumuratefrombaseline|20|NCT01519687|January 2012
1192|Active not recruiting|Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy||Procedure:quality-of-lifeassessment;  Other:counselingintervention;  Behavioral:exerciseintervention;  Other:educationalintervention;  Procedure:standardfollow-upcare|Interventional||Other / NIH|Feasibility in terms of participation rates and barriers to recruitment and retention;  Magnitude and trajectory of changes in objective physical function;  Self-reported physical function using the SPPB PAT-D MAT-sf grip strength and lower extremity strength;  Self-reportedqualityoflife|70|NCT01519596|October 2012
1193|Suspended|Local Anesthetic Cream in Younger Patients Undergoing Lumbar Punctures||Drug:placeboadministration;  Drug:EMLA;  Drug:propofol;  Drug:fentanylcitrate|Interventional||Other / NIH|Total dose of propofol administered to each patient;  Level of movement (no movement minor movement major movement other) after EMLA cream or placebo cream administration;  Complications including any change in vital signs that requires intervention by the sedation team as well as post-LP headache and post-LP back pain from sedation with or without EMLA cream;  Traumatic lumbar punctures after EMLA cream or placebo cream administration|40|NCT01516684|January 2012
1194|Recruiting|Screening of Healthy Adults for Genetic Variations That Control Fatty Acid Processing|||Observational||Other / NIH|Determine the genotype at the rs174537 single-nucleotide polymorphism (SNP) in the fatty acid desaturate (FADS) gene cluster|800|NCT01516125|September 2011
1195|Completed|Effect of Blueberries on Cognition and Body Composition in Elderly With Mild Cognitive Decline||DietarySupplement:Freeze-driedblueberries;  DietarySupplement:DextrosePlacebo|Interventional|Phase 2|Other|Changeincognitivetestperformance;  Changeinbodymassdistribution;  Change in oxidative stress and inflammatory markers as measured in blood and urine|123|NCT01515098|January 2012
1196|Terminated|A Prospective Randomized Study Evaluating the Effect of Biliary Stenting on EAU-FNA in Patients With Suspected Malignant Biliary Obstruction||Procedure: EUS-FNA first followed by CRCP with bilinary stenting;  Procedure: ERCP with stent placement followed by EUS-FNA|Interventional|Phase 4|Other|Cytological yield (adequate versus inadequate for diagnosis) of EUS-FNA prior to stent placement vs post stent placement|8|NCT01514058|November 2011
1197|Completed|Eating Disorders in Type 1 Diabetes: Mechanisms of Comorbidity|||Observational||Other / NIH|BloodGlucoseValues;  Ecological Momentary Assessment of Emotional and Behavioral Outcomes|83|NCT01513746|December 2011
1198|Completed|Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fasting Condition||Drug:Lamotrigine;  Drug:Lamictal&#174;|Interventional|Phase 1|Industry|Areaundercurve(AUC)|20|NCT01513720|December 2002
1199|Completed|Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fed Condition||Drug:Lamotrigine;  Drug:Lamictal&#174;|Interventional|Phase 1|Industry|Areaundercurve(AUC)|20|NCT01513681|November 2002
1200|Enrolling by invitation|Study to Evaluate the Effect of RGMA001 on Patients With Non Alcoholic Fatty Liver Disease (NAFLD)||DietarySupplement:RGMA001;  DietarySupplement:SugarPill|Interventional||Industry|Efficacy;  Safety|40|NCT01511523|January 2012
1201|Recruiting|Double Push Acoustic Radiation Force (DP ARF) Ultrasound for Monitoring Degeneration in Duchenne Muscular Dystrophy|||Observational||Other / NIH|ChangeinDPARFmarginalpeakdisplacement;  Rate of change in DP ARF marginal peak displacement;  Change in quantitative muscle testing score of maximum voluntary isometric contraction (MVIC);  Change in time to rise from supine position to standing;  Changeindistancewalkedinsixminutes;  Changeintimetowalk30feet;  Rate of change in maximum voluntary isometric contraction (MVIC);  Rate of change in time to rise from supine to standing position;  Rateofchangeindistancewalkedinsixminutes;  Rateofchangeintimetowalk30feet;  Ageatlossofambulation;  Changeinpercentdegenerativemusclecomposition;  Changeinpercentnecrotictissuearea;  Changeinpercentfattissuearea;  Changeinpercentfibrotictissuearea|60|NCT01506518|January 2012
1202|Active not recruiting|Cognitive Assessments in Patients With Cancer Undergoing Chemotherapy||Procedure:cognitiveassessment;  Procedure:quality-of-lifeassessment|Observational||Other / NIH|Operational and logistical feasibility of administering cognitive assessment battery in medical oncology clinic environment during administration of chemotherapy.;  Changesincognitionovertime;  Association of cognitive performance with performance status and adverse events (AE)|25|NCT01506440|October 2011
1203|Active not recruiting|Prospective Randomized Evaluation of a Two and Three Piece Total Ankle Replacement||Device:Salto-TalarisTotalAnkleReplacement;  Device:STARTotalAnkleReplacement|Interventional||Other|To measure a change in one&apos;s pain following a Total Ankle Replacement using the Visual Analog Pain Scale (VAS)across multiple time points.;  To measure a change in one&apos;s functional health following a Total Ankle Replacement using Short Form Health Survey at multiple time points.;  To measure a change in one&apos;s physical limitations following a Total Ankle Replacement using the short musculoskeletal function assessment (SMFA)questionnaire at multiple time points.;  To measure a change in one&apos;s pain and function following a Total Ankle Replacement using the AOFAS Hindfoot Scale questionnaires at multiple time points.;  To measure a change in one&apos;s daily activity following a Total Ankle Replacement using the Foot and Ankle Disability Index (FADI) at multiple time points.;  Change in Three dimensional kinematic and kinetic assessment during level walking across time following total ankle replacement.|100|NCT01504438|October 2011
1204|Completed|Effect of Samples on Acne Treatment With Epiduo&#174; Gel||Drug:Adapalene+benzoylperoxidesamples;  Drug: Adapalene + benzoyl peroxide from standard tube|Interventional||Other / Industry|AdherencetoStudyMedication;  ChangeinAcneGlobalAssessment;  ChangeinAcneLesionCount|20|NCT01504204|December 2011
1205|Completed|Mederma to Reduce Appearance of Post Surgical Scars||Other:MedermaN&amp;I;  Other:MedermaUltraGel|Interventional||Industry|Investigator assessment of post-surgical scar appearance (indices are erythema softness texture and overall appearance). This assessment is accompanied by photography and dermaspectrophotometry.|20|NCT01504061|January 2012
1206|Terminated                  Has Results|Neurostimulation in Temporomandibular Disorders (TMD) Patients||Device:CaloricVestibularNeurostimulation;  Device:placebo|Interventional||Other|Change From Baseline in Visual Analog Score (VAS) in Days 1-7 Post Treatment;  Mean Percentage of Time Spent in Pain From Days 1-7;  Number of Participants With Signs and Symptoms of Temporomandibular Disorder Based on Outcomes of Research Diagnostic Criteria (RDC) Exam|5|NCT01502709|December 2011
1207|Terminated                  Has Results|Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma||Drug: Rituximab BortezomibY90 ibritumomab tiuxetan|Interventional|Phase 2|Other / Industry|Response Rate (Complete Response + Partial Response);  Number of Participants With Progression Free Survival;  OverallSurvivalat1Year;  OverallSurvivalat5Year|5|NCT01497275|February 2012
1208|Completed|Implementation of a Personalized Medicine (Pharmacogenomics) Service in a Community Pharmacy||Other: Pharmacogenomics testing for clopidogrel responsiveness|Interventional|Phase 1|Other / Industry|Feasibility of Pharmacogenomics testing in a Community pharmacy|48|NCT01495845|December 2011
1209|Completed|Evaluation of a Dry Powder Aerosol Dispersion Mechanism by Radiolabeling Techniques||Device:modifiedHandihalerDPI;  Device:standardHandihalerDPI|Interventional||Other|Fractionaldeliveryofdrypowdertothelung|6|NCT01495442|December 2011
1210|Withdrawn|Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma||Drug:Vorinostat;  Drug:Bortezomib;  Drug:pegylatedliposomaldoxorubicin|Interventional|Phase 2|Other / Industry|Estimatetheoverallresponserate.;  Evaluate the quality of life measures in patients.;  Assessthesafetyandtolerability.;  Estimatetheoverallsurvival.;  EstimateProgression-freesurvival|0|NCT01492881|April 2012
1211|Completed|Epigenetic Effects of Diesel Exhaust and Ozone Exposure||Other:Ozoneexposure;  Other:Dieselexhaust;  Other:Ozone18;  Other:CleanAir|Interventional||U.S. Fed|Airwayresponses;  Cardiovascularresponses;  Solublefactors|42|NCT01492517|May 2010
1212|Recruiting|PVSRIPO for Recurrent Glioblastoma (GBM)||Biological:PVSRIPO|Interventional|Phase 1|Other / NIH|MaximumToleratedDoseorOptimalDose;  ProgressionFreeSurvival;  OverallSurvival;  RadiographicResponse|65|NCT01491893|January 2012
1213|Active not recruiting|IIT CTI Bendamustine Rituximab Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin&apos;s Lymphoma||Drug:Bendamustine+Rituximab+Pixantrone|Interventional|Phase 1 / Phase 2|Other / Industry|MaximumToleratedDose;  OverallResponse;  Progressionfreesurvival;  Toxicity (number of participants with adverse events);  Overallsurvival|33|NCT01491841|November 2011
1214|Terminated|Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia||Drug:Eltrombopag|Interventional|Phase 1|Other / Industry|ToleratedEltrombopagDose;  Efficacy|1|NCT01491594|April 2012
1215|Completed|Evaluation of Allergenicity of Hypoallergenic Peanut Product in Peanut Allergic Subjects||Other:Epicutaneousskinpricktesting|Observational||Other|Size of wheal with epicutaneous testing using non-hypoallergenic extracts.|22|NCT01489514|December 2011
1216|Active not recruiting|Strength Training for ARthritis Trial||Behavioral:HighIntensityStrengthTraining;  Behavioral:LowIntensityStrengthTraining;  Behavioral:AttentionControl|Interventional|Phase 2|Other / NIH|Pain;  KneeCompressiveForces;  Function;  Mobility;  InflammatoryMarkers;  ThighComposition|375|NCT01489462|March 2012
1217|Active not recruiting|Patient Preferences for Breast Reconstruction After Mastectomy|||Observational||Other / NIH|TreatmentConcordance;  BodyImage;  SatisfactionwithDecisions;  QualityofLife;  Knowledge|145|NCT01488357|June 2012
1218|Completed|Stabilimax Investigational Device Exemption (IDE) Clinical Investigation Patient Followup Study|||Observational||Industry|VisualAnalogScale(VAS)forLegPain;  ZurichClaudicationQuestionnaire(ZCQ);  MajorDeviceRelated(MDR)Complications;  RevisionReoperationorRemoval;  OswestryDisabilityIndex(ODI);  Presence (control) or Absence (Stabilimax)of fusion;  AdverseEvents(AE);  PhysicianSatisfactionScale|43|NCT01485289|August 2011
1219|Active not recruiting|Dose Escalation Study of Pazopanib Plus TH-302||Drug:PazopanibandTH-302|Interventional|Phase 1|Other / Industry|Maximaltolerateddose;  Doselimitingornondoselimitingtoxicities|50|NCT01485042|December 2011
1220|Completed|Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia||Drug:cefepimehydrochloride|Interventional|Phase 1|Other / NIH|Defervescence(withouthypothermia);  Clinicalsuccessorfailure;  Needforadditionalantimicrobials;  Mortality(in-house);  Timetodefervescence;  Hospitallengthofstay;  Successfultreatmentofbaselineinfection|70|NCT01484015|February 2011
1221|Terminated                  Has Results|Treatment of Vasopressor-induced Ischemia With Botulinum Toxin A||Drug:InjectionofbotulinumtoxinA|Interventional||Other|Perfusion (as Determined by Laser Doppler Measurements);  DigitalAmputations|2|NCT01483209|March 2012
1222|Active not recruiting|Vascular and Cognitive Assessments in Patients With Breast Cancer Undergoing Chemotherapy After Surgery||Procedure:ultrasoundimaging;  Other:questionnaireadministration;  Procedure:assessmentoftherapycomplications;  Procedure:quality-of-lifeassessment;  Procedure:magneticresonanceimaging|Interventional||Other / NIH|Participationrate;  Retentionrate;  Changes in flow-mediated dilation and aortic dilation that occur after adjuvant chemotherapy for breast cancer;  Correlation between the presence of brain circulation and vascular changes and performance on neuropsychological testing and the FACT-Cog|30|NCT01483196|January 2012
1223|Withdrawn|Pre and or Post Operative Blood Pressure Control With Clevidipine (Cleviprexm Medicines Company) in Aortic Aneurysm / Dissection||Drug:Clevidipine|Interventional||Other / Industry|The use of Clevidipine to maintain clinically acceptable blood pressure.;  Theincidenceofhypotension|0|NCT01480531|December 2011
1224|Completed|New Therapy for Patients With Severe Tinnitus||Other:SoundBasedandEducationalTherapies;  Other: Integrated Medicine Therapies and Sound Based Education Therapies;  Other:IntegratedMedicineTherapiesandSBE|Interventional||Other / NIH|TinnitusHandicapInventory|40|NCT01480193|September 2011
1225|Completed|Physiological Changes in Adults With Metabolic Syndrome Exposed to Ultrafine Air Particles||Other:UltrafineAirPollutionParticulateMatter;  Other:FilteredAir|Interventional||U.S. Fed|ChangesinVascularFunction;  Changesinheartratevariability|48|NCT01475968|December 2004
1226|Completed|Trivalent Influenza Vaccine in Preventing Flu in Patients With Central Nervous System Tumors||Biological:trivalentinfluenzavaccine;  Other:laboratorybiomarkeranalysis|Observational|Phase 0|Other / NIH|Efficacy of influenza vaccination in patients with central nervous system tumors as defined by a four-fold increase in HI titers from the pre-vaccination baseline;  Efficacy of influenza vaccination in patients with central nervous system tumors as defined by a serum post-vaccination HI titer of at least 1:40;  Relationship between a variety of clinical factors and seroconversion following influenza vaccination;  Relationship between serologic markers of immune function and response to vaccination|38|NCT01474174|September 2011
1227|Completed|Mila Blooms Intervention Study||Behavioral:MilaBlooms|Interventional||Other / NIH|Feasibility of the Mila Blooms Intervention at changing health behaviors.|21|NCT01473342|April 2011
1228|Terminated                  Has Results|Milnacipran (Savella) in Irritable Bowel Syndrome (IBS)||Drug:Milnacipran;  Drug:Placebo|Interventional|Phase 2|Other / Industry|PainResponse;  QualityofLife(IBS-QOL);  SubjectSelfReportedAdequateReliefofPain;  TreatmentEfficacyQuestionnaire(TEQ);  Dose Related Incremental Benefit in Pain Reduction Based on VAS|2|NCT01471379|April 2012
1229|Recruiting|Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis||Drug:Fluocinonidecream|Interventional||Other / Industry|Change in Investigator&apos;s Global Assessment of atopic dermatitis;  ChangeinActigraphyMovementCountperHour;  ChangeinEczemaAreaandSeverityIndexScore;  ChangeinBodySurfaceAreaofatopicdermatitis;  ChangeinVisualAnalogScaleforitch;  SubjectGlobalAssessmentofatopicdermatitis;  AdherencetoFluocinonideCream|10|NCT01469767|November 2011
1230|Completed|Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212||Drug:GSK1120212|Interventional||Other / Industry|the number and type of kinases in participant tissue sample prior to administration of drug compared to post-treatment.;  the number and type of kinases that produce a compensatory response to MEK inhibitor;  thenumberofparticipantswithadverseevents|15|NCT01467310|January 2012
1231|Completed                  Has Results|Study of Donepezil in Female Breast Cancer Survivors With Cognitive Dysfunction||Drug:donepezilhydrochloride;  Drug:Placebo|Interventional|Phase 2|Other / NIH|Retention;  Compliance;  HVLT-IR;  Fatigue|62|NCT01466270|April 2012
1232|Completed                  Has Results|Clinical Evaluation Of A New Two-Component Self-Etch Universal Adhesive||Procedure: Adhesive: OptiBond XTR; Composite: Herculite Ultra;  Procedure: Adhesive: OptiBond FL; Composite: Herculite Ultra|Interventional||Other|Retention;  ColorMatch;  CavosurfaceMarginDiscoloration;  SecondaryCaries;  AnatomicForm;  MarginalAdaptationand/orIntegrity;  PostOperativeSensitivity|24|NCT01464996|December 2011
1233|Completed|Vasospasm in Pediatric Traumatic Brain Injury|||Observational||Other|Vasospasm detection by Transcranial Doppler Ultrasound;  Detection of biomarkers in pediatric traumatic brain injury|6|NCT01461902|September 2011
1234|Completed|Obesity in HIV After Antiretroviral Therapy||Drug:antiretroviraltherapy|Observational||Other / Industry|Change in BMI from baseline after 12 months of initial antiretroviral therapy;  Change in the inflammatory marker high-sensitivity C-reactive protein from baseline after 12 months of antiretroviral therapy;  Change in the prothrombotic marker D-dimer from baseline after 12 months of initial antiretroviral therapy|200|NCT01461876|November 2009
1235|Completed|Comparing Cardiac Output Measurements in Critically Ill Children Using USCOM and Transthoracic ECHO||Device: Ultrasonic Cardiac Output Monitor (USCOM).|Observational||Other|CardiacIndex|22|NCT01460329|October 2011
1236|Completed                  Has Results|Comparing Virtual Reality Exposure Therapy to Prolonged Exposure||Behavioral:ProlongedExposureTherapy(PE);  Behavioral: Virtual Reality Exposure Therapy (VRET);  Behavioral:Waitlist|Interventional||U.S. Fed / Other|Clinician-AdministeredPTSDScale(CAPS);  PTSDChecklist-Civilian(PCL-C);  PrimaryCarePTSDScreen(PC-PTSD);  BeckDepressionInventory-II(BDI-II);  Inventory of Attitudes Toward Seeking Mental Health Services (IASMHS);  PerceivedStigmaMeasure(PSS);  SuicideRiskAssessment;  BeckAnxietyInventory(BAI);  Behavior and Sympton Identification Scale (BASIS-24);  IntenttoAttend;  SubjectiveUnitsofDistress(SUDs);  SideEffectsQuestionnaire;  BASIS-24;  PTSDChecklist(PCL-C)|162|NCT01459705|October 2011
1237|Unknown&nbsp;&#8224;|Assessment of Muscle Function and Size in Older Adults With Rotator Cuff Tear|||Observational||Other|Shoulderstrength|50|NCT01459536|September 2011
1238|Completed|GSK1349572 Exposure in Blood Seminal Fluid and Rectal Fluid and Tissue in Healthy Male Subjects||Drug:dolutegravir|Interventional|Phase 1|Other / Industry|Area under the concentration versus time curve (AUC) in blood plasma after a single dose;  Peak concentration (Cmax) in blood plasma after a single dose;  Area under the concentration versus time curve (AUC) in blood plasma at steady state;  Peak concentration (Cmax) in blood plasma at steady state;  Area under the concentration versus time curve (AUC) in seminal fluid after a single dose;  Peak drug concentration (Cmax) in seminal fluid after a single dose;  Area under the concentration versus time curve (AUC) for seminal fluid at steady state;  Peak drug concentration (Cmax) for seminal fluid at steady state;  Area under the concentration versus time curve (AUC) for rectal fluid after a single dose;  Peak drug concentration (Cmax) in rectal fluid after a single dose;  Area under the concentration versus time curve (AUC) for rectal fluid at steady state;  Peak drug concentration (Cmax) for rectal fluid at steady state;  Area under the concentration versus time curve (AUC) for rectal tissue after a single dose;  Peak drug concentration (Cmax) for rectal tissue after a single dose;  Area under the concentration versus time curve (AUC) for rectal tissue at steady state;  Peak drug concentration (Cmax) for rectal tissue at steady state;  Area under the concentration versus time curve ratios after a single dose;  Area under the concentration time curve ratios at steady state;  Accumulationratio|14|NCT01459315|November 2011
1239|Terminated|This Study is to Determine if Degenerative Spinal Pain and Disorders Cause the Levels of Substance P to Change in a Patients Saliva Blood and/or Cerebrospinal Fluid.||Other:treatmentplan|Observational||Other|Substance P Neuropeptide Levels in Saliva And Serum in Patients with Spinal Disease: A Pilot Study|53|NCT01458938|July 2009
1240|Completed|Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer||Other:questionnaireadministration;  Procedure:quality-of-lifeassessment;  Other:counselingintervention;  Other:internet-basedintervention;  Behavioral:telephone-basedintervention;  Other:educationalintervention;  Drug:nicotinereplacementtherapy|Interventional|Phase 1|Other / NIH|Participation of patients with lunch cancer in the outpatient oncology setting;  Accrual of patients with lung cancer in the outpatient oncology setting;  Participantretention;  Participant acceptance of the enhanced quitline-based smoking cessation intervention;  Protocolfidelity;  Abstinencerateinbothgroups;  Comparison of changes in quality of life stress and depressive symptoms between groups|6|NCT01457469|January 2011
1241|Recruiting|Development of a Tumor Molecular Analyses Program and Its Use to Support Treatment Decisions|||Observational||Other|Number and type of genetic mutations found in each patient&apos;s tumor sample;  ProgressionFreeSurvival|5000|NCT01457196|September 2011
1242|Completed|Study to Assess the Effects of Daily Administration of Pioglitazone on Brain Hemodynamics in Healthy Elderly Participants||Drug:Pioglitazone;  Drug:Placebo|Interventional|Phase 1|Industry|Change from Baseline in BOLD fMRI Signal Related to Pioglitazone in Regions of the Brain Related to Cognition.|61|NCT01456117|November 2011
1243|Completed                  Has Results|Tick-borne Illness and Clothing Study||Other:PermethrinImpregnatedUniforms|Interventional||Other|WorkRelatedTickBites;  SeroconversionAgainstaTick-borneIllness|159|NCT01454414|October 2010
1244|Recruiting|Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide||Drug:Aprepitant;  Drug:Ondansetron|Interventional|Phase 2|Other / Industry|Proportion of patients achieving an acute and delayed complete response (CR);  Proportion of patients achieving complete control (CC);  Patient&apos;s global satisfaction with the antiemetic regimen;  Timetotreatmentfailure|136|NCT01450826|December 2012
1245|Completed                  Has Results|Suppressive Therapy With Oral Antibiotics for Prevention of Postoperative Urinary Tract Infection (UTI)||Drug:Nitrofurantoin;  Drug:Placebo|Interventional|Phase 4|Other|UrinaryTractInfections;  OtherRiskFactorsforUTI|163|NCT01450800|August 2011
1246|Completed                  Has Results|The Use of the Prevena&#8482; Incision Management System on Post-Surgical Cesarean Section Incisions||Device: Prevena&#8482; Incision Management System (PIMS);  Device:Standard-of-careDressing|Interventional|Phase 4|Industry|Incidence of Postoperative Surgical Site Occurrences (SSOs) up to Day 42 (+/- 10 Days) Post Cesarean Section Surgery.;  Incidence Rate of Surgical Incision Intervention (SII) up to Day 42 (+/- 10 Days) Post Cesarean Section Surgery.|92|NCT01450631|February 2012
1247|Terminated                  Has Results|Right Ventricular (RV) Pacing in Early Post-operative Continuous Flow Left Ventricular Assist Device (LVAD)||Device: Implantable Cardioverter-Defibrillator (subject&apos;s pre-existing ICD)|Interventional|Phase 4|Other / Industry|LengthofHospitalization;  Post-operative Need for Hemodynamic / Respiratory Support;  RightVentricularFunction;  FunctionalCapacityandSymptoms|3|NCT01446796|September 2011
1248|Suspended|Safety and Feasibility Study of Umbilical Cord Blood Cells for Infants With Hypoplastic Left Heart Syndrome||Biological:AutologousUmbilicalCordBlood|Interventional|Phase 1|Other|Adverse event rates occurring in the pilot study population. The investigators will compare infusion outcomes of infants infused with frozen cells and infants infused with non-frozen cells.;  Feasibilityandpreliminaryefficacy|20|NCT01445041|September 2011
1249|Completed|Development and Validation of a Quality of Life Instrument for Actinic Keratosis||Other:AKRQquestionnaire;  Other:Skindex-16DLQISkinHealthCalculator|Interventional||Other|Difference in questionnaire score in patients with Actinic keratosis and with out actinic keratosis;  CorrelationbetweenAKRQandDLQIscores;  The correlation between AKRQ and Skindex-16 scores;  The correlation between the AKRQ and Skin Health Calculator scores.|150|NCT01444989|September 2011
1250|Completed|Study of Birth Control Use After Childbirth||Behavioral:LARCScript|Interventional||Other|Self-reporteduseofLARCmethod;  Self-reportedinterestinuseofaLARCmethod;  Self-reporteduseofanycontraceptivemethod;  Self-reported reasons for not using the contraceptive method of choice|800|NCT01443533|May 2011
1251|Completed|Cardioprotective Effects of Omega-3 Fatty Acids Supplementation in Healthy Older Subjects Exposed to Air Pollution Particles||DietarySupplement:Fishoil;  DietarySupplement:Oliveoil|Interventional||U.S. Fed|Heartratevariabilitychanges;  endothelial function changes measured by flow-mediated dilation of the brachial artery|29|NCT01442480|June 2009
1252|Unknown&nbsp;&#8224;|Longitudinal Study of Multi-Analyte Profile for Dyslipidemia||Drug:Pravastatin|Interventional||Other|Comparison of 29 specific cardiovascular related lab assays from baseline through a period of 6 months in a control population with dyslipidemia vs a study group with dyslipidemia receiving an FDA approved Statin (Pravastatin).;  Limited time-course of different stages of disease regression|40|NCT01441908|June 2011
1253|Terminated|Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants||Drug:rifampin|Interventional|Phase 1|Other / NIH|Area under the plasma concentration versus time curve 0-24 hours for rifampin;  Peakplasmaconcentrationofrifampin;  Clearanceofrifampin;  Volumeofdistributionatsteadystate;  Halflifeofrifampin;  Number of subjects with adverse events as a measure of safety and tolerability.|2|NCT01441206|September 2011
1254|Completed                  Has Results|Nurse Education in Subjects With Psoriasis Undergoing Treatment With Adalimumab||Behavioral:Standardnurseeducation;  Behavioral:Additionalnurseeducation|Interventional||Other|ChangeinPsoriasisAreaSeverityIndex(PASI-75);  Investigator&apos;s Global Assessment (IGA) of Psoriasis;  AdherencetoAdalimumabTreatment|7|NCT01435265|January 2010
1255|Completed|Patient and Provider Interventions for Managing Osteoarthritis in Primary Care||Behavioral: Patient Behavioral Intervention for OA;  Behavioral:ProviderInterventionforOA;  Behavioral: Combined Patient and Provider Interventions for OA|Interventional||Other / NIH|Change in the Western Ontario and McMasters Universities Osteoarthritis Index (WOMAC) from Baseline to 12-months.;  Change in the Western Ontario and McMasters Universities Osteoarthritis Index (WOMAC) at 18-months post Baseline.;  Change in the Western Ontario and McMasters Universities Osteoarthritis Index (WOMAC) at 24-months post Baseline.;  Change in the Short Physical Performance Test Protocol from Baseline to 12-months.;  Change in the Patient Health Questionnaire (PHQ-8) from Baseline to 12-months.|537|NCT01435109|July 2011
1256|Active not recruiting|Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients||Drug:NicotineReplacementPatch|Interventional||Other / NIH|Evaluate a smoking cessation intervention among cancer patients|146|NCT01434342|October 2011
1257|Completed|Heart-Healthy Lenoir Lifestyle Study||Behavioral:MaintenanceofWeightLoss--Control;  Behavioral: Maintenance of Weight Loss--Experimental|Interventional|Phase 3|Other / NIH|Cohort study: fruit and vegetable intake at 6 months;  Embedded randomized trial: maintenance of weight loss;  Physicalactivity;  Bloodpressure;  Bloodlipids;  A1c;  Fruitandvegetableintakeat6months;  Weight;  Healthrelatedqualityoflife;  Genomicpredictorsoflifestylechange|339|NCT01433484|September 2011
1258|Completed|Touch and Attention MRI Study|||Observational||Other||10|NCT01432288|August 2011
1259|Completed                  Has Results|Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants||Drug:gadofosveset|Interventional||Other / Industry|ImagingQualityScore;  QuantitativeAnalysisNoiseRatios|30|NCT01431300|August 2011
1260|Completed|Measuring Adherence to Medication for Depression and Attention-deficit Hyperactivity Disorder|||Observational||Other|Adherence to Standard-of-Care Medication for Depression or ADHD|20|NCT01430767|September 2011
1261|Active not recruiting|Mindfulness-based Personalized Health Planning for Reducing Risk of Heart Disease and Diabetes||Behavioral: Mindfulness-based Personalized Health Planning;  Other:Structured&amp;GuidedEducation|Interventional|Phase 3|Other / NIH|Fastingglucose;  Severityofdepressivesymptoms;  Reductioninrestingbloodpressure;  Changesininflammation|140|NCT01430221|May 2011
1262|Completed|Improving Care for Patients With High Blood Pressure||Behavioral: Complex quality improvement intervention|Interventional||Other / NIH|systolicbloodpressure;  Bloodlipids;  GeneralCardiovascularDiseaseRisk;  Genomicpredictorsofbloodpressurechange|535|NCT01425515|September 2011
1263|Completed|Testing the Efficacy of an Online Social Network Intervention to Increase Social Support for Physical Activity||Behavioral: online social network enrollment plus education and self monitoring;  Behavioral:Webeducationcontrol|Interventional||Other|Mean perceived social support for physical activity scores on the Peer/Friend Support for Healthy Eating and Physical Activity Scale.;  Physical activity in kilocalories on the Paffenbarger Physical Activity Questionnaire/College Alumnus Questionnaire|134|NCT01421758|December 2010
1264|Completed                  Has Results|Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo||Drug:Placebo;  Drug:Dalteparin|Interventional|Phase 2|Other / Industry|ChangeinD-dimer;  ChangeinClinicalPainScores;  Change in Thrombin Generation Assay - Endogenous Thrombin Potential|34|NCT01419977|May 2011
1265|Suspended|Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies||Device: Enriched Hematopoetic Stem Cell Transplantation|Interventional|Phase 1 / Phase 2|Other|ProportionofHemoglobinAandS;  EnrichedHematopoeticStemCellEngraftment|30|NCT01419704|May 2011
1266|Completed|Accuracy of the O2 MedTech PMS-3000 Monitor||Device: O2 MedTech cerebral oximeter (Oxygen desaturation)|Interventional|Phase 2|Industry / Other|Accuracy of device to measure cerebral tissue oxygen saturation|42|NCT01418079|August 2011
1267|Completed|A Pilot Study of Intra-arrest Therapeutic Hypothermia in Patients Suffering Non-Traumatic Out of Hospital Cardiac Arrest||Drug:4degreechilledsaline|Interventional||Other|Survivaltohospitaldischarge;  Number of patients who achieve prehospital return of spontaneous circulation;  Totalvolumeofchilledsalineinfused|363|NCT01413399|August 2011
1268|Active not recruiting|Neural Markers and Rehabilitation of Executive Functioning in Veterans With Traumatic Brain Injury and Posttraumatic Stress Disorder||Behavioral:CognitiveRehabilitationIntervention;  Behavioral: Cognitive Rehabilitation Control Intervention|Interventional||Other|ExecutiveFunction;  Impulsivity;  InterpersonalConflict|100|NCT01410721|January 2012
1269|Completed|Improving Vitamin D Status in Home-bound Elders||DietarySupplement:VitaminD3;  DietarySupplement:VitaminE|Interventional||Other|Changein25-hydroxyvitaminDlevels;  Numberoffalls;  Measurecompliancetointervention|68|NCT01410084|October 2010
1270|Active not recruiting|Early Brain Development in Twins|||Observational||Other / NIH|BrainGrayMatterVolume;  Brainwhitemattertractintegrity;  MullencompositeScore|600|NCT01409746|April 2004
1271|Completed|Genetic Susceptibility to Radiation-Induced Skin Reactions in Racial/Ethnic Groups of Patients With Breast Cancer||Genetic:DNAanalysis;  Genetic:geneexpressionanalysis;  Other:enzyme-linkedimmunosorbentassay;  Other:flowcytometry;  Other:laboratorybiomarkeranalysis;  Other:questionnaireadministration;  Procedure:adjuvanttherapy;  Procedure:assessmentoftherapycomplications;  Procedure:quality-of-lifeassessment;  Radiation: 3-dimensional conformal radiation therapy;  Radiation:breastirradiation;  Radiation:externalbeamradiationtherapy;  Radiation:hypofractionatedradiationtherapy;  Radiation:intensity-modulatedradiationtherapy;  Radiation:wholebreastirradiation|Observational||Other / NIH|Occurrence of RT-induced early adverse skin reaction (EASR);  Qualityoflife|1000|NCT01407770|September 2011
1272|Active not recruiting|Durham Connects RCT Evaluation||Other:DurhamConnects|Interventional||Other / NIH|DSS Investigated and Substantiated Child Maltreatment Rates;  ChildEmergencyRoom(ER)PresentationRates;  ChildOvernightStaysinHospital;  ChildPostnatalWell-CareComplianceRates;  Child Social-Emotional Competence and Behavior Problems;  MotherMentalHealth;  Family Connections to Community Services/Resources;  MotherParentingBehaviors|2329|NCT01406184|July 2009
1273|Completed|GSK1349572 Exposure in Blood Cervicovaginal Fluid and Cervical and Vaginal Tissue in Healthy Female Subjects||Drug:GSK1349572(dolutegravir)|Interventional|Phase 1|Other / Industry|Area under the concentration time curve in blood plasma after a single dose;  Peak Concentration (Cmax) after a single dose in blood plasma;  Area under the concentration time curve in cervicovaginal fluid after a single dose;  Area under the concentration time curve in cervical and vaginal tissue after a single dose;  Peak Concentration (Cmax) after a single dose in cervicovaginal fluid;  Peak Concentration (Cmax) after a single dose in cervical and vaginal tissue;  Area under the concentration time curve for cervicovaginal fluid at steady state;  Area under the concentration time curve in cervical and vaginal tissue at steady state;  Peak concentration (Cmax) in cervicovaginal fluid at steady state;  Peak concentration (Cmax) in blood plasma at steady state;  Area under the concentration time curve in blood plasma at steady state;  Area under the concentration time curve ratios after a single dose;  Area under the concentration time curve ratios at steady state|10|NCT01404806|August 2011
1274|Completed|Evaluate the Efficacy of a Silk-Like Fabric for the Prevention of Pressure Sores in a Long Term Care Setting||Device:DermaTherapy&#174;Linenandunderpads.|Interventional||Other / U.S. Fed|Prevention and reduction in the incidence of pressure ulcers;  Reductionofbacterialcontamination|75|NCT01403272|September 2010
1275|Enrolling by invitation|Agricultural Health Study Follow-up|||Observational||NIH||89656|NCT01399411|June 2011
1276|Unknown&nbsp;&#8224;|Comparison of Meal Replacements Versus Protein Supplements and Utilizing the Protein Digestibility Corrected Amino Acid Score (PDCAAS) Method||DietarySupplement:Group1MealReplacement;  DietarySupplement:Group2ProteinSupplement;  DietarySupplement:Group3|Interventional|Phase 4|Other|ProteinAbsorption;  PatientCompliancewithProteinSupplement;  Patient tolerability and satisfaction of protein supplement|60|NCT01399333|January 2010
1277|Completed|Epigenetics DNA Methylation Patterns and Periodontal Disease|||Observational||Other / NIH|DNA methylation patterns of selected candidate genes;  IdentificationofmiRNAspecies|98|NCT01399034|October 2007
1278|Completed|Neuromuscular Ultrasound for Focal Neuropathies|||Observational||Other|OverallNeuropathySumScore|120|NCT01394822|September 2011
1279|Completed|Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia||Drug:IntranasalOxytocinSpray|Interventional|Phase 1|Other / NIH|Change in social cognition scores from baseline to 6 and 12 week time points;  Change in social functioning measures from baseline to 6 and 12 week time points;  Change in PANSS total and subscale scores from baseline to 6 and 12 week time points.|68|NCT01394471|July 2011
1280|Recruiting|Pain and Function After Orthopedic Surgery||Other:Observational|Observational||Other|Self-reportedpainintensity|75|NCT01390298|July 2011
1281|Active not recruiting|Titrated Disease Management for Patients With Hypertension||Behavioral:Booster/lowresource;  Behavioral:Medium/Level1resourceintensity;  Behavioral:High/Level2resourceintensity|Interventional||U.S. Fed|Changeinsystolicbloodpressure;  HypertensionControl;  CostEffectiveness;  MedicationAdherence|400|NCT01390272|July 2012
1282|Active not recruiting|Pediatric Atopic Dermatitis (AD) Internet Survey||Behavioral:WeeklyInternetsurvey;  Drug:TopicalTriamcinolone|Interventional||Other|Adherencetotopicaltriamcinolone;  EczemaAreaSeverityIndex;  Investigator&apos;sGlobalAssessment|40|NCT01385527|June 2011
1283|Completed|Feasibility of a Stigma Reduction Intervention for Human Immunodeficiency Virus (HIV)-Infected Women||Behavioral:Ipodvideo|Interventional||Other / NIH|Feasibility of implementing a stigma reduction intervention among Human Immunodeficiency Virus (HIV)-infected women;  Acceptability of the use of a portable device to deliver a video intervention among Human Immunodeficiency Virus(HIV)-infected women;  Utility of the use of a portable media device to deliver stigma-reduction intervention among Human Immunodeficiency Virus(HIV)-infected women;  Change from baseline in levels of internalized stigma;  Change from baseline in levels of coping self-efficacy;  Changeinsafedisclosurebehaviorsfrombaseline|99|NCT01385241|July 2011
1284|Completed|Strategies for Enhancing Mucosal Immunity to Influenza Vaccine||Drug:Fluzone|Interventional|Phase 0|Other|Change in hemagglutinin antibody titers from baseline to Day 28 in serum and mucosal secretions.;  Numberofsubjectswithadverseevents.;  Comparison of hemagglutinin antibody titers between intranasal and intramuscular route of administration from baseline to Day 28.|60|NCT01385215|April 2011
1285|Recruiting|Remote Ischemic PreConditioning Effect on Postsurgical Pain||Device: Thigh Tourniquet (VBM Single Use Tourniquet Cuff Items 20-34-722SLZ-1);  Device:ShamRIPC|Interventional||Other|Comparison of pain intensity and unpleasantness postoperatively;  Opioidconsumption;  Consumptionofnonopioidanalgesics|80|NCT01383317|June 2011
1286|Completed|Family Partners for Health||Behavioral: Nutrition and exercise education and coping skills training|Interventional||Other / NIH|Change in body mass index in adults and body mass index percentile in children.;  Change in adiposity for adults and children as measured by change in waist circumference triceps and subscapular skinfold measures.;  Change in health behaviors as measured by nutrition and exercise in adults and children.;  Change in self-efficacy in adults and children as measured by belief that they can improve their eating and exercise behaviors.|718|NCT01378806|April 2007
1287|Completed|Personalized Diabetic Kidney Disease Risk Info to Initiate and Maintain Health Behavior Changes|||Observational||Other|Blood pressure and /or Estimated Glomerular Filtration Rate (eGFR)|19|NCT01377688|October 2011
1288|Completed|Ankle Block Versus Popliteal Fossa Block as Primary Anesthesia for Forefoot Surgical Procedures||Procedure:electiveforefootsurgery|Interventional|Phase 4|Other|Conversion to general anesthesia following either a single shot popliteal fossa block or ankle block;  VisualAnalogPainScale(VAS);  PatientSatisfaction;  LengthofPostAnesthesiaCareUnit(PACU)stay;  NarcoticUse|202|NCT01376960|June 2011
1289|Completed|Anatomic Reconstruction of the Patellofemoral Joint||Procedure: Measured Resection of patellofemoral joint;  Procedure:Measuredresectionofpatella|Interventional|Phase 4|Other|AnteriorkneePain;  Knee Injury and Osteoarthritis Outcome Score (KOOS);  RangeofMotionofknee|52|NCT01375231|June 2011
1290|Completed|Efficacy and Satisfaction Comparing Two Braces in the Treatment of Developmental Dysplasia of the Hip (DDH) in Infants||Other:PavlikBrace;  Other:PlastizoteBrace|Interventional|Phase 4|Other|Resolutionofinstability|30|NCT01375218|June 2011
1291|Completed|Racial Disparity in Barrett&apos;s Esophagus|||Observational||Other / NIH|To examine the association between BE and environmental factors;  To investigate the association between BE and genetic and epigenetic status of Cdx1/Cdx2|255|NCT01374074|March 2011
1292|Active not recruiting|Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance||Drug:Liquidpeanutextract(PeanutSLIT)|Interventional|Phase 1 / Phase 2|Other / NIH|Percentage of subjects on peanut SLIT who pass the final double blind placebo controlled food challenge to assess tolerance after the randomized tolerance period.;  Number of participants with treatment-related adverse events as assessed by CTCAE v3.0;  Change from baseline in peanut skin prick testing at 48 months and at the final avoidance DBPCFC.;  Change from baseline in peanut basophil activation at 48 months and at the final avoidance DBPCFC.;  Change from baseline in peanut-specific IgE at 48 months and at the final avoidance DBPCFC.;  Change from baseline in peanut-specific IgG4 at 48 months and at the final avoidance DBPCFC.;  Change from baseline in peanut-specific IgA at 48 months and at the final avoidance DBPCFC.;  Change from baseline in TH1 cytokine levels (IFN-gamma TNF-alpha) at 48 months and at the final avoidance DBPCFC.;  Change from baseline in TH2 cytokine levels (IL-4 IL-5 IL-13 IL-10) at 48 months and at the final avoidance DBPCFC.;  Change from baseline in regulatory T-cell cytokines (IL-10 TGF-beta) at 48 months and at the final avoidance DBPCFC.;  Change from baseline in regulatory T-cells at 48 months and at the final avoidance DBPCFC.;  Correlation of baseline subject characteristics (age race sex weight height baseline peanut skin test baseline peanut IgE) with successful desensitization as well as with the maintenance of desensitization after treatment avoidance.|49|NCT01373242|June 2011
1293|Completed|Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)||Drug:Lenalidomide+Plerixafor(+Rituximab)|Interventional|Phase 1|Other / Industry|MaximumToleratedDose;  Response(CR/PR);  Progression-freesurvival(PFS);  Overallsurvival(OS);  ReductioninseverityofBsymptoms;  Reduction in the frequency of blood and platelet transfusions;  ReductioninthenumberofB-symptoms|21|NCT01373229|January 2012
1294|Completed|Is the Neosquamous Epithelium &quot;Normal&quot; Following Endoscopic Ablation of Dysplastic Barrett&apos;s Esophagus?|||Observational||Other|To characterize reflux symptomatology before and after radiofrequency ablation in subjects with dysplastic Barrett&apos;s Esophagus (BE).;  To characterize the physiological and morphological properties of the neosquamous epithelium (NSE);  Correlate the physiologic and morphologic changes in the neosquamous epithelium (NSE) after ablation with the frequency and type of refluxate seen on pH-Impedance.|99|NCT01373125|June 2011
1295|Completed|Guilford Genomic Medicine Initiative (GGMI)|||Observational|Phase 4|Other|Evaluate effectiveness of family history collection and decision support for increasing appropriate referrals to genetic counselors for patients at risk of hereditary cancer syndromes;  Evaluate effectiveness of family history collection and decision support for increasing appropriate screening for breast colon and ovarian cancer;  Evaluate effectiveness of family history collection and decision support for appropriate risk-based management of thrombosis;  Measure patient-related outcomes associated with using the MeTree tool;  Measure physician experience with the MeTree system;  ImplementationparametersforMeTree|1184|NCT01372553|October 2009
1296|Active not recruiting|Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders||Biological:FCRxinfusion|Interventional|Phase 1 / Phase 2|Other|Production of missing enzyme at levels greater than or equal to 10% of normal;  EnrichedHematopoeticStemCellEngraftment|30|NCT01372228|April 2011
1297|Completed|Families and Pediatric Cardiac Surgery Multidisciplinary Teams: How Well Do We Communicate|||Observational||Other|Peri-operativeriskinformation;  Informeddecisions;  Trustinthemedicalteam;  Desire for disclosure of peri-operative complications|23|NCT01371864|August 2011
1298|Completed|Pedal@Work: A Worksite Wellness Program||Behavioral:Pedal@WorkWorksiteWellness;  Behavioral:Pedal@Work|Interventional||Other|StepWatch-PhysicalActivityMinutes;  CardiometabolicRisk|40|NCT01371084|June 2011
1299|Completed|NAC-003 P.L.U.S. Program (Progress Through Learning Understanding &amp; Support)||Other:CerefolinNAC&#174;|Observational||Industry|To determine if CerefolinNAC&#174; affects a subject&apos;s quality of life as measured by the Quality of Life-Alzheimer&apos;s Disease Scale (QOL-AD);  To determine overall patient satisfaction with CerefolinNAC&#174; using a 9-point satisfaction scale|204|NCT01370954|May 2011
1300|Completed|Effect of Interleukin-1 Receptor Antagonist on Inhalation of 20000 EU Clinical Ctr Reference Endotoxin in Normal Volunteers||Drug:Anakinra;  Drug:Placebo|Interventional|Phase 1|Other / NIH|blockade of IL-1 &#946; will suppress neutrophil response to challenge with 20000 EU CCRE|17|NCT01369017|October 2011
1301|Completed|The WEIGH Study: Weighing to Improve and Gain Health||Behavioral: Daily Self-weighing + weekly feedback+ weekly lessons|Interventional||Other|PercentWeightLoss;  ChangesinCaloricIntake;  ChangesinEnergyExpenditurefromExercise;  ChangesinSelf-efficacyforEatingBehaviors;  Changesinself-efficacyforexercisebehaviors;  Changes in Weight Control Strategies (diet and exercise);  ChangesinMotivation;  Changes in Dietary Hunger Restraint and Disinhibition;  ChangesinBingeEatingsymptoms;  Changesindepressivesymptoms;  ChangesinBodyShapeConcerns;  Changes in cognitions related to disordered eating|91|NCT01369004|February 2011
1302|Terminated|CONSERVE Plus Post-Approval Study (PAS)|||Observational||Industry|ClinicalsuccessatMonth120;  Radiographicoutcomes;  MetalIon(serum);  AssessmentforAdverseEvents;  MeasurementofPatientSatisfaction|199|NCT01367899|November 2010
1303|Completed|Technology-Enhanced Helping the Noncompliant Child||Behavioral:HelpingtheNoncompliantChild(HNC);  Behavioral: Technology-Enhanced Helping the Noncompliant Child (TE-HNC)|Interventional|Phase 1|Other / NIH|Retention;  Engagement;  ChildExternalizingDisorders;  Cost-Effectiveness;  ConsumerSatisfaction|22|NCT01367847|September 2010
1304|Unknown&nbsp;&#8224;|Effect of Growth Hormone on Early Brain Development in Girls With Turner Syndrome||Drug:somatotropin|Interventional||Other / Industry|Totalbrainvolume;  Volumeofbrainlobes;  Whitemattertracts|25|NCT01367834|May 2010
1305|Terminated|INBONE Total Ankle Arthroplasty(TAA)Using Calcaneal Stem Fixation||Device: Radiographic evaluation of previously implanted patients|Observational||Industry / Other|RadiographicEvaluation|24|NCT01366989|October 2010
1306|Terminated|Safety and Efficacy Study of Ethanol Locking to Prevent Central Line Infection in Premature Neonates||Drug:Ethanollock;  Drug:Heparinizedsaline|Interventional||Other|Incidence of PICC-related sepsis in infants with ethanol-treated vs. Placebo treated lines;  Evaluation of PICC colonization following ethanol locking;  Whether the primary and secondary endpoints differ by birthweight strata;  To determine whether ethanol lock treatment impacts incidence of clinical evaluations for suspected sepsis;  To determine whether antibiotic use for any indication (including non-bacteremia) alters the incidence of PICC-related infection or colonization as defined in the primary and secondary endpoints;  Determine side effects of ethanol locking in premature babies;  To determine effect of ethanol locking on neonatal PICC lines|10|NCT01365312|February 2010
1307|Completed|Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment|||Observational||Other|Pre-PostTreatmentDifferencesbetweenGroups|25|NCT01364818|September 2011
1308|Completed                  Has Results|Maintenance After Initiation of Nutrition TrAINing||Behavioral:Maintenanceintervention|Interventional||U.S. Fed|Weight;  EstimatedDailyCaloricIntake;  EstimatedMetabolicMinutesofWalkingPerWeek;  Estimated Metabolic Minutes of Moderate Physical Activity Per Week|222|NCT01357551|August 2012
1309|Completed|Effects of TT301 on Cytokine Levels Post Endotoxin Challenge||Drug:TT301;  Drug:Placebo|Interventional|Phase 1|Industry|CytokinelevelspostLPSchallenge|18|NCT01357421|May 2011
1310|Unknown&nbsp;&#8224;|Silk-Like Fabric for the Prevention of Pressure Sores in a Long Term Care Setting||Device:DermaTherapy&#174;Linenandunderpads.|Interventional||Other / U.S. Fed|Prevention and reduction in the incidence of pressure ulcers;  Reductionofbacterialcontamination|75|NCT01355666|September 2010
1311|Completed|Improving Money Management Skills for Veterans With Psychiatric Disabilities||Behavioral:$AFE|Interventional||Other / U.S. Fed|Employment;  Financialsavings;  FinancialDebt;  Homelessness|183|NCT01352624|April 2011
1312|Active not recruiting|Dietary Intervention for Visceral Adiposity||DietarySupplement:Benefiber;  DietarySupplement:TrueLemon|Interventional||Other|ChangeinabdominaladipositymeasuredbyCT;  Changeinmetabolicriskfactors|30|NCT01350518|February 2011
1313|Completed|Facebook-based Physical Activity Intervention for Young Adult Cancer Survivors: the FITNET Randomized Pilot Study||Behavioral:Facebook-basedMessages/Website;  Behavioral:Facebook-basedSelf-helpComparison|Interventional|Phase 0|Other|Primary study outcome measures at the participant level will be minutes of moderate-intensity physical activity per week and exercise in MET-hrs/week.;  Qualityoflife;  Psychosocialfactors;  Utilizationofprogramcomponents/activities;  Perceptionsofprogramcomponents/activities;  Communicationfactors|97|NCT01349153|April 2011
1314|Completed|Pilot Study of Using Copeptin to Predict Response to Tolvaptan||Drug:tolvaptan|Interventional|Phase 4|Other / Industry|Urineoutput;  Bodyweight|21|NCT01346072|April 2011
1315|Withdrawn|A Pilot Study of Tumor-Derived Exosomes as Diagnostic and Prognostic Markers in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy|||Observational||Other|To characterize protein surface markers and RNA profiles in tumor derived exosomes from breast cancer patients undergoing neoadjuvant chemotherapy|0|NCT01344109|February 2011
1316|Completed|Stress Reduction Training to Improve Sleep Quality Stress Physiology &amp; Cardiovascular Disease (CVD) Risk Markers||Behavioral: Mindfulness Based Stress Reduction (MBSR);  Behavioral: Mindfulness-Based Stress Reduction (MBSR)|Interventional||Other / NIH|Sleepquality;  Stressphysiology;  Mindfulness;  Health-relatedqualityoflife;  NegativeAffect;  Cognitivefunctioning;  Emotionregulation;  Stress-relatedphysicalsymptoms|87|NCT01343810|September 2010
1317|Terminated|Direct Noise Reduction in the Intensive Care Units (ICU) Using Earplugs and Noise Canceling Headphones||Device:FoamEarplugs;  Device:NoiseCancelingHeadphones|Interventional|Phase 2 / Phase 3|Other|DaysFreeofDeliriumorcoma;  NoiseAttenuation;  SleepEfficiencyandArchitecture;  Amountofsedativeuse;  Amountofanalgesicuse|12|NCT01343095|May 2011
1318|Completed|Neuroactive Steroids and Traumatic Brain Injury (TBI) in OEF/OIF Veterans||Drug:Pregnenolone;  Drug:Placebo|Interventional|Phase 2|U.S. Fed|CAPS (Cluster D symptoms) - PRIMARY BEHAVIORAL OUTCOME MEASURE;  Tower of London (Subscale test of BAC-A) - PRIMARY COGNITIVE OUTCOME MEASURE;  BeckDepressionInventory-II(BDI-II);  BAC-A;  CAPSTotalScores;  Connor-DavidsonResilienceScale(CD-RISC)|82|NCT01336413|October 2013
1319|Completed|Curcumin Biomarkers||Drug:CurcuminC3tablet|Interventional|Phase 1|Other|Geneexpression;  Ribonucleicacid(RNA)level;  Apoptosis;  NumberofParticipantswithAdverseEvents|40|NCT01333917|November 2010
1320|Completed|Nitric Oxide Mediated Vasodilatory Response to Hawthorn Standardized Extract||DietarySupplement:Hawthorn;  DietarySupplement:Placebocapsule|Interventional|Phase 1|Other|FMDMax;  BP|24|NCT01331486|May 2010
1321|Completed|Curcumin Pharmacokinetics||Drug:curcumin|Interventional|Phase 1|Other|AUC;  Cmax;  Tmax;  Ke;  T1/2;  Vd;  Testofbioequivalence;  bioequivalenceoftissuecurcuminconcentration|12|NCT01330810|March 2011
1322|Completed|Study of Intracranial Pressure (ICP) Monitoring in Critically Ill|||Observational||Other||30|NCT01330264|July 2009
1323|Completed|Pharmacokinetics of Tenofovir Emtricitabine Maraviroc and Raltegravir in Cervical Vaginal and Rectal Tissues and Secretions||Other:PharmacokineticSampling|Interventional|Phase 1|Other|DoseProportionality|49|NCT01330199|February 2012
1324|Terminated|Early Intervention for Morbidly Obese Patients After Roux-en-Y Gastric Bypass (RYGB) Surgery||Behavioral:Lifestylecounseling|Interventional||Other|First quartile excess weight loss(0-11% EWL)at one month predicted first quartile EWL at 12-month and 36-month follow-up.|8|NCT01329692|December 2010
1325|Completed|The Effects of a Self-management Intervention on Low Literacy Patients With Chronic Obstructive Pulmonary Disease (COPD)||Behavioral:Self-ManagementIntervention|Interventional||Other|change in Inhaler use technique scores from baseline to follow-up;  timespentinself-managementactivities;  change in COPD-related knowledge from baseline to follow-up;  change in smoking status from baseline to follow-up|99|NCT01327456|January 2008
1326|Completed|Single Dose Truvada in HIV-negative Men and Women||Drug:tenofovir+emtricitabine|Observational|Phase 4|Other / Industry|TFV TFV-DP FTC FTC-TP in blood CVF cervical and vaginal and rectal tissue over 14 days|12|NCT01326221|October 2008
1327|Withdrawn|Daily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis||Drug:tadalafil|Interventional|Phase 4|Other / Industry|improvement in Gastric Emptying Study residual tracer amount|0|NCT01326117|April 2011
1328|Terminated|Patient Positioning in Lumbar Fusion Surgery and Its Impact on Spinal Sagittal Balance and Surgeon Satisfaction||Other:HyperlordoticPositioning|Interventional||Other|To assess if the specific intra-operative positioning affects post-operative sagittal alignment;  Surgeon satisfaction with operative patient positioning|7|NCT01326091|March 2011
1329|Completed|Study to Characterize the Pharmacokinetics of Raltegravir in the Gastrointestinal (GI) Tract of Healthy Male Volunteers||Drug:Raltegravir|Interventional|Phase 1|Other / Industry|AUC = Area under the concentration versus time curve of raltegravir;  Cmax=maximumconcentrationofraltegravir;  Tmax = time to maximum concentration of raltegravir;  C12 = concentration at 12 hours after dose of raltegravir;  t1/2=half-lifeofraltegravir|15|NCT01325051|April 2011
1330|Completed|Family PALS (PArtners in Lifestyle Support)||Behavioral: Adult diabetes family-based weight loss intervention|Interventional||Other / NIH|Changeinbodyweight;  EffectonHemoglobinA1c;  Lifestylebehaviors;  Bloodpressurechange;  Changeinpsychosocialfactors|108|NCT01324011|January 2011
1331|Completed|Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.||Drug:Adalimumab|Interventional||Other / Industry|Percentage change in endothelial function compared to baseline.;  Changesincytokineprofilecomparedtobaseline|17|NCT01320293|March 2011
1332|Completed|The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART||Drug:Vorinostat|Interventional|Phase 1 / Phase 2|Other / NIH / Industry|To compare RCVL in HIV-infected patients on stable ART before and after a single exposure to VOR after a pair of exposures to VOR and after multiple exposures to VOR.;  To compare the change in HIV RNA expression per million resting CD4 + cells after multiple (10) VOR doses.;  ChangesonplasmaHIV-1RNA;  To assess safety tolerability and PK profile of VOR;  To assess the alterations in global histone acetylation within resting lymphocytes;  To compare the frequency of resting CD4+ T cell infection (RCI) after multiple (10) repeated short interval dosing with VOR|37|NCT01319383|March 2011
1333|Completed                  Has Results|Measurement of Kidney Blood Flow and Oxygen Levels by MRI||Drug:Furosemide;  Other:Placebo|Interventional||Other|Measurement of Renal Blood Flow of the Kidney by Both the PAH Method and by MRI;  MeasurementofRegionalBloodOxygenationbyMRI|10|NCT01318967|October 2010
1334|Completed|A Study of Immediate and Delayed Closure of Type II and IIIa Open Tibia Fractures||Procedure:delayedclosure;  Procedure:immediatewoundclosure|Interventional||Other|infectionrate;  hospitalreadmissions;  tibialfracturehealing|451|NCT01315392|July 2000
1335|Completed|Perimenopausal Estrogen Replacement Therapy Study||Drug:Estradiol;  Drug:Placebo|Interventional|Phase 2 / Phase 3|Other / NIH|Change in Depressive Symptoms as Indicated by The Center for Epidemiologic Studies Depression Scale (CES-D);  Change in Psychiatric Diagnosis as Assessed by the Structured Clinical Interview for DSM Disorders I/NP;  Change in Stress Reactivity during Laboratory Session including Trier Social Stress Test;  Change in Functional Well-being as Assessed by the Medical Outcomes Study 36-item Short form (SF-36);  ChangeinMetabolicrisk;  ChangeinFlowMediatedVasodilatation;  ChangeinBaroreceptorsensitivity|350|NCT01308814|October 2010
1336|Completed|A Study of Oxytocin in Children and Adolescents With Autistic Disorder||Drug:Oxytocin;  Drug:Placebo|Interventional|Phase 2|Other|Tolerability;  Biomarkers;  AdverseeffectsofOxytocinNasalSpray;  Satisfaction;  Socialreciprocity;  ADOSSeverityScore;  ABC-SocialWithdrawal;  Pervasive Developmental Disorder Behavior Inventory (PDD-BI)|25|NCT01308749|March 2011
1337|Completed|A Study Comparing the Interproximal Plaque and Gingivitis Effects of Three Interdental Cleaning Modalities||Device: Sonicare Interproximal (IP) Cleaning Prototype|Interventional|Phase 3|Other / Industry|residualproteinconcentrationinposteriorsites;  GBIandMGI|80|NCT01307358|February 2011
1338|Unknown&nbsp;&#8224;|Early Provision of Enteral Microlipid and Fish Oil to Infants With Enterostomy||DietarySupplement:MicroLipidandfishoil|Interventional|Phase 3|Other|Average duration of exposure to PN (including Intralipid IL) between the initial feeding and bowel reanastomosis;  Average weight gain (g/day)from initiating feeding to reanastomosis;  Average level of conjugated bilirubin and ostomy output of infants receiving ML/FO to the group receiving usual care between the initial feeding after placement of ostomy and reanastomosis;  Dietary fat and protein absorption from initiating feeding to reanastomosis;  Expression of four key genes that play a crucial role in intestinal adaptation;  Neurodevelopment outcomes and growth in the infants receiving ML/FO vs. in the infants receiving usual care at the 18-24 month of age.|40|NCT01306838|October 2009
1339|Unknown&nbsp;&#8224;|Study of the P16 Gene as a Predictor of Myelosuppression in Breast Cancer Patients|||Observational||Other|Determine if p16INK4a Expression at Baseline is Related to Nadir Neutrophil Counts in Women with Breast Cancer Receiving Chemotherapy;  Define the Association Between p16INK4a Expression and Physical Activity Smoking and Alcohol Consumption in Women with Breast Cancer Receiving Chemotherapy;  Explore the Associations between p16INK4a Expression at Baseline and Other Chemotherapy-Related Toxicities including Nausea and Vomiting Neuropathy Fatigue and Other Grade 3 and 4 Toxicities;  Explore Associations between p16INK4a Expression at Baseline Chemotherapy Regimen and its Effect on Patient Function|100|NCT01305954|December 2010
1340|Completed                  Has Results|Low Dose Naltrexone for Glioma Patients||Drug:LDN;  Drug:Placebo|Interventional|Phase 2|Other|Effects of Low-dose Naltrexone Versus Placebo on Change in Quality of Life (QoL) in High-grade Glioma Patients Undergoing Standard Chemoradiation From Baseline;  Effects of Low-dose Naltrexone Versus Placebo on Change in Functional Capacity From Baseline;  Effects of Low-dose Naltrexone Versus Placebo on Change in Neurocognitive Function From Baseline|110|NCT01303835|May 2011
1341|Completed                  Has Results|TissueLink Study During Multi-Level Spine Surgery||Device:Tissuelinkdevice|Interventional|Phase 4|Other / Industry|HemoglobinMeasurementg/dl|60|NCT01300559|April 2006
1342|Completed                  Has Results|Open Label Use Of RiaStap During Aortic Reconstruction||Drug:RiaSTAP|Interventional|Phase 4|Other / Industry|FibrinogenLevelChange;  PackedRedBloodCellTransfusion;  FreshFrozenPlasmaTransfusion;  PlateletTransfusion;  CryoprecipitateTransfusion|23|NCT01300286|December 2010
1343|Active not recruiting|Long-Acting Reversible Contraception||Drug:DMPA;  Drug:oralcontraceptives;  Drug:Implanon&#174;;  Drug:ParaGard&#174;;  Drug:Mirena&#174;|Interventional|Phase 4|Other|Contraceptivemethoddiscontinuation;  Unintendedpregnancy;  ParticipantattitudestoLARCvsSARC|916|NCT01299116|December 2011
1344|Completed|Steps to Health: Targeting Obesity in the Health Care Workplace||Behavioral:StepstoHealth;  Behavioral:StepstoHealthPlus!|Interventional||Other|Weightloss;  Improvementinlevelofphysicalactivity;  Relativeimpactofthedifferentprograms;  Relativecostofdifferentprograms;  Improvementinnutrition|550|NCT01299051|January 2011
1345|Completed|Use of a Soy-based Meal Replacement Weight Loss Intervention to Impact Ectopic Fat||Dietary Supplement: Medifast meal replacement products|Interventional||Other|ProtocolCompliance;  ChangeinBodyComposition;  ChangeinCardiometabolicHealth;  ChangeinPhysicalFunction;  Number of participants with adverse events as a measure of safety and tolerability|24|NCT01298817|March 2011
1346|Completed|High Pain Intervention in Cesarean Sections||Drug:Duramorph;  Drug:Acetaminophen|Interventional||Other|Severityofacutepain;  IncidenceofdepressionandPersistentPain;  Pain;  analgesicconsumption|60|NCT01298778|August 2010
1347|Completed                  Has Results|Sweet Preference and Alcohol Craving||Drug:Naltrexone;  Behavioral:BrendaTherapySessions;  Drug:Placebo|Interventional|Phase 2|Other / NIH|PercentHeavyDrinkingDays;  PercentDaysAbstinent|80|NCT01296646|January 2010
1348|Terminated|Structural Analysis of Human Tissue|||Observational||Other||35|NCT01293864|April 2007
1349|Completed|Open-label Normal Healthy Volunteer Clinical Trial of a Novel Ondansetron Formulation||Drug:Ond-PR1;  Drug:Ond-PR1+MPh-IR;  Drug:Ond-PR2;  Drug:Ond-PR2+_MPh-IR|Interventional|Phase 1|Other|The release profile of Ondansetron Pulsatile Release (Ond-PR) in the human gastrointestinal (GI) tract matches the one predicted from test tube dissolution experiments.;  To determine drug-drug interactions of Ond-PR with a simultaneously-administered MPh-IR.|6|NCT01290276|December 2010
1350|Recruiting|Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia||Drug:Interleukin-2|Interventional|Phase 2|Other|Event-freesurvival;  Patientresponse|14|NCT01289678|July 2006
1351|Completed|Clinical Assessment of Nonin 7600 Near Infrared Spectroscopy (NIRS) Tissue Oximetry During Cardiovascular Surgery|||Observational||Industry|Percent of time Regional Oxygen Saturation (rSO2) values are registered during open heart surgery.;  Correlation between delirium outcome scale and Regional Oxygen Saturation (rSO2) values.|50|NCT01289470|January 2011
1352|Completed|A Global Imatinib and Nilotinib Pregnancy Exposure Registry||Drug:Tasigna;  Drug:Gleevec|Observational||Industry|Monitor pregnancies exposed to Imatinib or Nilotinib to estimate prevalence of birth defects;  Assess impact on maternal CML disease when treatment is interrupted;  Assess post 12 month post-delivery data on maternal and infant status|4|NCT01289054|January 2011
1353|Active not recruiting|Gulf Long-Term Follow-Up Study|||Observational||NIH|To investigate potential short- and long-term health effects associated with oil spill clean-up activities/exposures surrounding the Deepwater Horizon Disaster.;  To investigate biomarkers of potentially adverse biological effect in relation to oil spill clean-up activities/exposures.;  To create a resource for additional collaborative research on focused hypotheses or subgroups.;  To create a resource to better understand the short and long-term human health effects of oil and oil dispersants in the environment.|55000|NCT01287000|January 2011
1354|Recruiting|Pharmacokinetics of Off Label Pediatric Medications|||Observational||Other|pharmacokinetics|400|NCT01286519|July 2010
1355|Completed|Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures|||Observational||Industry|Phase I: The number of accurate liver surface registrations obtained in the laparoscopic environment providing the surgeon with a comfort level of adding the registration procedure to the scheduled laparoscopic surgical ablation procedure.;  Phase II: The number of surgical oblation procedures that present data showing equivalent location of the ablation probe when compared to the US and Pathfinder Guidance System 3D image data.|30|NCT01286428|January 2011
1356|Terminated|Home Hypnotherapy for Refractory Functional Chest Pain: A Pilot Study||Behavioral:HomeHypnotherapy;  Behavioral:Educational|Interventional||Other / NIH|Globalchangeinchestpainatthe12weeks;  Globalchangeinchestpainat4weeks;  Globalchangeinchestpainat6weeks;  Changeinsymptomscoreat3months;  Changeinpsychometricscoreat3months;  ChangeinHRQOLscoresat3months|8|NCT01284179|February 2011
1357|Recruiting|Hyperpolarized 129Xe MRI for Imaging Pulmonary Function||Drug:Xenon|Interventional|Phase 1|Other|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|160|NCT01280994|January 2011
1358|Withdrawn|Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab||Drug:Standardofcaretreatment;  Drug:eculizumab|Interventional|Phase 2|Other / Industry / NIH|BirminghamVasculitisActivityScore(BVAS);  Complementlevelselevation;  BirminghamVasculitisActivityScore(BVAS);  Normalisationofcomplementactivation;  Changeincomplementlevels;  changeincomplementlevels2;  BirminghamVasculitisActivityScore(BVAS)2|0|NCT01275287|May 2011
1359|Withdrawn|Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens||Drug:Retinoicacid;  Drug:Standardofcare|Interventional|Phase 2|Other / NIH|change in leukocyte Myeloperoxidase (MPO) and Proteinase 3 (PR3) message;  BirminghamVasculitisActivityScore(BVAS)|0|NCT01275274|January 2012
1360|Terminated|Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults||Drug:Peanutflour|Interventional|Phase 1 / Phase 2|Other|To treat peanut-allergic subjects with POIT and to determine whether this protocol lowers their risk of anaphylactic reactions and causes long-term tolerance.;  To determine the effect that POIT has on the peanut-specific cellular and humoral response in peanut-allergic subjects.|5|NCT01274429|December 2010
1361|Completed|Acceptance-Based Separated Family Treatment for Adolescent Anorexia Nervosa||Behavioral:AcceptanceandCommitmentTherapy;  Behavioral:ParentSkillsTraining|Interventional||Other|BodyMassIndex;  EatingDisorderExamination(16.0D)|75|NCT01274416|May 2009
1362|Recruiting|Trial of CMV Specific DLIs From 3-6/6 HLA Matched Family Member Following Nonmyeloablative Allo SCT||Biological: CMV Specific T Cell donor lymphocyte infusion|Interventional|Phase 1|Other|Safety of CMV Specific T cell infusion following Stem Cell Transplant;  Efficacy of CMV-specific T cell infusion in terms of response progression free survival and overall survival;  Evaluate the recovery of immune function post engraftment with this regimen.|20|NCT01274377|February 2011
1363|Completed                  Has Results|Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies||Drug:deferasirox;  Other:laboratorybiomarkeranalysis;  Other:enzyme-linkedimmunosorbentassay|Interventional||Other / NIH|Changes in Mean Neutrophil Values (as Measured by Lab) for Arm 1 (Other Arms Were Used for Calibration Only);  Need for Hospitalization Ventilator Support Exchange Transfusion/Apheresis or Treatment With Antifungals or Antibiotics;  Cumulative Incidence of Documented Bacterial Fungal and Viral Infections|16|NCT01273766|January 2011
1364|Completed|Effects of Sulforaphane (SFN) on Immune Response to Live Attenuated Influenza Virus in Smokers and Nonsmokers||DietarySupplement:Broccolisprouthomogenate;  DietarySupplement:Alfalfasprouthomogenate|Interventional||Other / NIH|Interleukin 6 (IL-6) in NL after LAIV inoculation (expressed as area under curve for ratio of IL-6 to baseline) in smokers;  change in nasal cells-cytokines chemokines natural killer cell activation; tolerance of homogenate; nasal biopsy Nrf2 cytokine and phase II enzyme mRNA; serum antibodies; blood cell response to influenza antigen|51|NCT01269723|December 2010
1365|Completed                  Has Results|Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study|||Observational||Other|ChangeinWeight(inLbs.);  ChangeinGlucoseLevels(mg/dL);  ChangeinTotalCholesterol(mg/dL);  ChangeinTriglycerides(mg/dL);  ChangeinLDL(mg/dL)|4|NCT01269710|October 2009
1366|Unknown&nbsp;&#8224;|Pilot Study of Topical Steroid for Prevention of Chronic Lung Disease in Extremely Premature Infants.||Drug:Infasurf;  Drug:Pulmicort;  Other:Sham|Interventional|Phase 2|Other|To measure the effect of surfactant with and without Budesonide on the development of BPD in ELBW infants.;  To measure the effect of surfactant with and without Budesonide on the inflammatory cytokines in tracheal aspirates.|45|NCT01268215|July 2010
1367|Completed|Bioavailability Study Comparing Tolvaptan Administered Via Nasogastric Tube to Tolvaptan Tablets Swallowed Intact||Drug:Tolvaptan|Interventional|Phase 1|Other / Industry|Area under the plasma drug concentration-time curve from time 0 to infinity (AUC);  Area under the plasma drug concentration-time curve from time 0 to the last quantifiable point (AUC(0-t));  Maximumplasmaconcentration(Cmax);  Timetomaximalconcentration(Tmax)|29|NCT01261481|January 2011
1368|Completed|A PK/PD Study of Fospropofol Disodium Compared With Propofol Injectable Emulsion||Drug:Fospropofoldisodiumpropofol|Interventional|Phase 4|Industry|&#8226; The primary objective of the study is to characterize the PK and PD properties of 3 dose levels of fospropofol disodium in comparison with 3 estimated equivalent dose levels of propofol|36|NCT01260142|November 2010
1369|Completed|Telephone Psychotherapy for Late-Life Generalized Anxiety Disorder (GAD)||Behavioral:psychotherapy|Interventional|Phase 2|Other / NIH|PennStateWorryQuestionnaire(PSWQ-A);  HamiltonAnxietyRatingScale(HAM-A);  BeckDepressionInventory(BDI);  PepperCenterToolforDisability(PCT-D);  ShortForm(36)HealthSurvey(SF-36);  InsomniaSeverityIndex(ISI);  GAD-7|141|NCT01259596|January 2011
1370|Completed|A Representational Intervention to Promote Preparation for End-of-life Decision Making||Behavioral:theSPIRITintervention|Interventional||Other / NIH|changes from baseline in dyad preparedness for end-of-life decision making over 12 months;  changes from baseline in surrogate psychosocial morbidities over 6 months;  surrogate perspectives on decision making experience|420|NCT01259011|March 2010
1371|Completed|Efficacy and Patient Satisfaction With AQUACEL&#174; Ag Surgical Dressing Compared to Standard Surgical Dressing||Procedure:PostopDressing|Interventional||Other / Industry|The incidence of postoperative severe skin reactions (defined as blisters) around the surgical incision site;  Patient pain and satisfaction (1-100 visual analog scale)|300|NCT01258270|December 2010
1372|Completed|Effect of Calcium Polycarbophil on Type II Diabetes Mellitus Control: a Randomized Double-blind Study||Drug:Placebo;  Drug:Calciumpolycarbophil|Interventional||Other|ChangeinHemoglobinA1cfrombaseline;  Weight;  BloodPressure;  Number and dosage of medications for DM HTN and hyperlipidemia;  SerumLDLHDLtriglyceridestotalcholesterol;  Adverseoutcomes|48|NCT01252524|October 2010
1373|Completed|Endothelial Cell Loss and Induced Astigmatism After Wound-directed and Wound-assisted IOL Injection||Procedure:Lensinsertionduringcataractsurgery|Interventional||Other|Surgicallyinducedastigmatism;  Endothelialcellloss;  Bestcorrectedvisualacuity;  Finalincisionsize|72|NCT01250964|April 2010
1374|Completed|Human Cytochrome P450 4F Enzymes and Drug Interactions||Drug:Warfarin;  Drug:Placebo;  Drug:Lovastatin|Interventional|Phase 1|Other / NIH|Pharmacodynamics;  Pharmacokinetics|19|NCT01250535|December 2010
1375|Terminated|Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability||Device:SteenSolution&#8482;;  Other:ConventionalLungTransplant|Interventional||Other / Industry|30DayMortality;  PrimaryLungGraftDysfunction(PGD);  ICULengthofStay;  Day7Ventilator/ECMOStatus;  Recipientmortalityat12months.|103|NCT01241942|December 2010
1376|Completed|A Study of FolateScan in Patients With Knee Osteoarthritis||Drug:99mTc-EC20|Observational||Other / Industry|Frequencyofkneeuptakeof99mTc-EC20;  Intensityandlocationofuptakeof99mTc-EC20;  Correlation of knee symptoms and knee uptake of 99mTc-EC20;  Correlationof99mTc-EC20uptakeandbiomarkers;  Correlation of knee radiographic OA and knee uptake of 99mTc-EC20|25|NCT01237405|October 2010
1377|Terminated                  Has Results|Benazepril Hydrochloride Lisinopril Ramipril or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors||Drug:lisinopril;  Drug:losartanpotassium;  Other:laboratorybiomarkeranalysis;  Drug:benazeprilhydrochloride;  Drug:ramipril|Interventional|Phase 2|Other|Changes in Ang1-7 Levels Among Patients After ACE-I/ARB Treatment Measured in Picogram/Milliliter;  ChangeinAngIIVEGFPlGFandACELevels|6|NCT01234922|February 2011
1378|Terminated|Yoga Therapy in Treating Patients With Malignant Brain Tumors||Procedure:yogatherapy;  Other:questionnaireadministration;  Procedure:quality-of-lifeassessment|Interventional||Other / NIH|Estimate the participation rate accrual adherence and retention to a yoga trial in patients with malignant brain tumors;  Self-reportedfatigue;  Depressivesymptoms;  Distress;  Health-relatedqualityoflife;  Preliminary estimates of the efficacy of a yoga intervention in patients with malignant brain tumors on the outcomes of fatigue distress and cognitive function;  Standardize the cancer-specific yoga protocol for use with brain tumor patients|9|NCT01234805|December 2010
1379|Completed|Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI||Drug:Risperidone;  Drug:Olanzapine|Interventional||Other|NeurocognitiveAssessmentProcedure;  fMRIactivationTasks;  Performance accuracy on Visual-auditory target detection task;  Performance accuracy on Auditory oddball target detection task|34|NCT01234454|January 2002
1380|Completed|Efficacy and Tolerability Study of Device RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults||Device:RD047-26|Interventional|Phase 2|Industry|InvestigatorGlobalAssessment;  InvestigatorPruritusAssessment;  SubjectItchAssessment;  AdverseEvents|17|NCT01232985|October 2010
1381|Completed|We Can Prevent Diabetes: A Behavioral Intervention to Reduce Diabetes Risk in African Americans||Behavioral: Mindfulness-based diabetes prevention education group;  Behavioral: Conventional diabetes prevention education group|Interventional|Phase 1 / Phase 2|Other / NIH|insulin resistance as measured by the homeostatic model assessment-insulin resistance (HOMA-IR);  Salivarycortisol;  InsulinresistanceasmeasuredbytheHOMA-IR|74|NCT01227473|February 2010
1382|Recruiting|TGF-(Beta) and Susceptibility to RSV|||Observational||NIH||200|NCT01224691|October 2010
1383|Completed|Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fasting Conditions||Drug:Risperidone|Interventional||Industry|Bioequivalence evaluation of Risperidone 1 mg Orally-disintegrating tablets|44|NCT01222975|October 2004
1384|Completed|Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fed Conditions||Drug:Risperidone|Interventional||Industry|Bioequivalence evaluation of risperidone 1 mg ODT tablets|40|NCT01222923|October 2004
1385|Recruiting|Thymus Transplantation Safety-Efficacy||Biological:ThymusTissueforTransplantation;  Procedure:BloodDraw;  Drug:Rabbitanti-thymocyteglobulin;  Drug:Cyclosporine;  Drug:Tacrolimus;  Drug:MethylprednisoloneorPrednisolone;  Drug:Basiliximab;  Drug:Mycophenolatemofetil|Interventional|Phase 1 / Phase 2|Other / NIH|Survival;  DescriptiveStudy-ImmuneOutcomes;  NaiveCD4TCellCount;  DescriptiveStudy-GVHD;  DescriptiveStudy-Infections;  DescriptiveStudy-AutoimmuneDisease;  DescriptiveStudy-PersistentRashes;  DescriptiveStudy-ThymusDonorTCellPresence;  DescriptiveStudy-OtherAdverseEvents|50|NCT01220531|December 2010
1386|Completed|Treatment of Palmar Plantar Erythrodysesthesia (PPE) With Topical Sildenafil||Drug:sildenafilcitrate|Interventional|Phase 1|Other|Grade of hand foot syndrome over time as measured by NCI CTC version 4.0 PPE syndrome criteria;  Assessment of patient reported pain at rest and when making a fist using a 1-10 score.;  Assessment of severity of erythema and desquamation or blistering as measured on 0-4 score from photographs.|10|NCT01219023|June 2010
1387|Completed|Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling||Drug:InterferonAlfa-2b|Interventional|Phase 1|Other / Industry|Protein quantification of interferon stimulated genes (ISG)|22|NCT01217359|May 2010
1388|Terminated|Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma||Biological: Vaccination with RNA-transfected mature autologous DC|Interventional|Phase 1|Other|Number of Participants with Adverse Events as a Measure of Safety and Tolerability;  Cellular anti-melanoma immune responses will be assessed|2|NCT01216436|January 2010
1389|Completed                  Has Results|Prevention of Intraoperative Nausea and Vomiting During Cesarean Section||Drug:Metoclopramide;  Drug:Phenylephrineinfusion;  Drug:CombinationGroup|Interventional||Other|IntraoperativeNauseaandVomiting;  PostoperativeNauseaandVomiting(PONV);  Pruritus;  Satisfaction;  MaternalHemodynamics|306|NCT01216410|December 2008
1390|Completed|Discharge Planning for Elderly Patients in the Emergency Department: Use of a Brief Phone Call After Discharge to Improve Medication Utilization and Physician Follow-up||Other:Phonecallfollow-up;  Other:Satisfactionsurvey;  Other:Controlgroup---nointervention|Interventional||Other|Whether patient obtained medications prescribed at their discharge from ED;  Whether patient is using medications that were prescribed at their ED discharge correctly;  Whether the patient arranged a follow-up appointment with their primary care provider;  Whether patient attended visit with their primary care provider after discharge from the ED;  Patient&apos;ssatisfactionwithEDvisit;  ReturntotheEDwithin30daysofinitialvisit;  Costoftheintervention|157|NCT01207180|September 2010
1391|Active not recruiting|Systolic Blood Pressure Intervention Trial||Other:IntensivecontrolofSBP;  Other:StandardBParm|Interventional||NIH / Other|First occurrence of a myocardial infarction (MI) acute coronary syndrome (ACS) stroke heart failure (HF) or CVD death;  All-causemortality;  Declineinrenalfunction;  Developmentofendstagerenaldisease(ESRD);  Dementia;  Declineincognitivefunction;  Smallvesselcerebralischemicdisease|9361|NCT01206062|October 2010
1392|Withdrawn|Optimizing Ovulation Induction in the Poor Responder||Drug:Estradiol;  Drug:OralContraceptivePills(OCP)|Interventional||Other|Follicularresponseandsynchrony;  IVFoutcomes|0|NCT01200537|October 2010
1393|Withdrawn|Apremilast for Chronic Plaque Psoriasis (CPP) Patients Who Have Failed One Course of Biologic Therapy||Drug:apremilast|Interventional|Phase 2|Other|Safety/efficacy of apremilast in CPP pts that have failed 1 course of biologic therapy;  Mechanistic studies performed to assess efficacy of apremilast to inhibit inflammatory responses in non-involved mildly traumatized skin.|0|NCT01200264|September 2010
1394|Completed|Study of Bimatoprost Gel on Eyelash Growth||Drug:Bimatoprosteyelashgel|Interventional|Phase 3|Other|eyelashlength;  eyelashpigment;  eyelashthickness;  eyelashamount;  eyelashsideeffects|20|NCT01200251|February 2007
1395|Terminated|Paricalcitol Fluorouracil and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery||Drug:paricalcitol;  Radiation:radiationtherapy;  Other:laboratorybiomarkeranalysis;  Drug:fluorouracil|Interventional|Phase 1|Other / NIH|Toxicity and tolerability of the paricalcitol regimen as measured by calcium levels;  Biologic effects of oral paricalcitol with oral fluorouracil chemoradiation on vitamin D receptor staining MIB-1 caspase 3 p 21 and bax protein expression;  Patterns of gene expression in tumor samples of patients who receive chemoradiation with and without paricalcitol|2|NCT01197664|August 2010
1396|Completed|Ehealth: Second Life Impacts Diabetes Education &amp; Self-Management||Behavioral: eHealth program in the Virtual Environment (VE) platform Second Life|Interventional||Other|PerceivedUsefulness;  PerceivedEaseofUse;  Processdata;  Demographics;  MetabolicIndicators;  Diabetesknowledge|20|NCT01186965|January 2011
1397|Active not recruiting                  Has Results|Gliadel XRT Temodar Avastin Followed by Avastin Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)||Drug:Gliadel;  Radiation:RadiationTherapy;  Drug:Avastin;  Drug:Temodar|Interventional|Phase 2|Other / Industry|21-monthOverallSurvival;  MedianOverallSurvival;  MedianProgression-freeSurvival;  Unacceptable Toxicity Related to the Treatment Regimen|41|NCT01186406|April 2011
1398|Completed|Understanding of Genetic Risk Information for Type 2 Diabetes||Behavioral: Receiving results via genetic counselor|Interventional||Other / NIH|Accurate understanding of genetic risk information;  Impactonbehaviorchange|300|NCT01186354|July 2010
1399|Completed|Post-traumatic Stress Disorder (PTSD) Addiction and Virtual Reality||Behavioral:ProlongedExposureTherapy;  Behavioral:ProlongedExposuretherapy+VR/ER|Interventional||Other / U.S. Fed|Acceptability/feasibility (e.g. retention) of the novel intervention;  ChangeinPTSDsymptoms;  Changeinsubstanceuse;  Biochemicalmeasures|38|NCT01186315|December 2008
1400|Withdrawn|Statin Therapy To Limit Cognitive Dysfunction After Cardiac Surgery||Drug:atorvastatin|Interventional||Other / Industry|NeurocognitiveDysfunction|0|NCT01186289|October 2010
1401|Terminated|Trisenox&#174; in Women With Metastatic Endometrial Cancer||Drug:Arsenictrioxide|Interventional|Phase 2|Other / Industry|Objective response (CR+PR) rate of subjects given Trisenox;  SafetyofTrisenox&#174;;  Progression free survival and overall survival in patients treated with Trisenox&#174;;  Durationofresponse;  Associations between markers of angiogenesis (e.g. VEGF) with response|5|NCT01184053|March 2010
1402|Completed|Distal Locking Using an Electromagnetic Field Guided Computer Based Real Time System for Orthopaedic Trauma Patients||Procedure:free-hand;  Procedure:Wandtechnique|Interventional||Other / Industry|Reducedoperativetime.;  ReducedC-armexposure;  Reducesinadvertentnailmisses.;  Nocomplications|55|NCT01183078|August 2010
1403|Terminated|Incidence of Respiratory Depression in Cesarean Section|||Observational||Other|RESPIRATORYDEPRESSION|100|NCT01181843|July 2010
1404|Completed|Pivotal Trial of Dermagraft(R) to Treat Diabetic Foot Ulcers||Device:Dermagraft;  Other:Comparator|Interventional|Phase 3|Industry|Completewoundclosure;  Timetoreachcompletewoundclosure;  Percentofwoundclosurebystudyend|314|NCT01181453|December 1998
1405|Completed|Tenofovir Emtricitabine Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population||Drug: tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV);  Drug:tenofovir/emtricitabine(TDF/FTC);  Drug:Atazanavir(ATV);  Drug:Ritonavir;  Procedure:Phlebotomy|Observational||Other / NIH|Clearance estimates for each drug adjusted for age and frailty|85|NCT01180075|May 2010
1406|Completed|Vitamin D Supplementation and Physical Function in Older Adults||DietarySupplement:calcium;  DietarySupplement:VitaminDpluscalcium|Interventional||Other / NIH|ChangeinPhysicalperformance;  Skeletalmusclegeneexpression;  ChangeinexpandedSPPBbalancetasktime;  Changeinnarrow4mwalktestofbalancetime;  Changein400mwalktesttime;  Changeinkneeextensorpower|16|NCT01179503|January 2010
1407|Completed|The Effectiveness of Personalized Stroke Risk Communication||Other:PersonalizedHeartAttackandStrokeRisk;  Other:StandardEducation|Interventional||U.S. Fed|Impactofpersonalizedriskinformation;  Evaluateimpactonmedicationadherence|90|NCT01178060|September 2008
1408|Completed|Inuniv and Working Memory||Drug:extendedreleaseguanfacine|Interventional|Phase 4|Other / Industry|CentralNervousSystem-VitalSigns(CNS-VS);  Wide Range Assessment of Memory and Learning(WRAML)|18|NCT01177306|July 2010
1409|Completed                  Has Results|A Novel Method to Improve Acne Outcomes||Behavioral:Internetsurvey;  Drug:Benzoylperoxide5%gel|Interventional||Other|AdherencetoStudyMedication;  The Change (Dynamic Assessment) in the Acne Global Assessment From Baseline to End of Study.;  The Change (Dynamic Assessment) From Baseline to End of Treatment in Lesion Counts.;  The Measured Adherence by the MEMS Cap in Relation to the Patient Reported Adherence Via the Internet Survey.;  The Measured Adherence by the MEMS Cap in Relation to the Change (Dynamic Assessment) in the Acne Global Assessment.|20|NCT01176955|May 2009
1410|Terminated|A 5 Year Follow-up on Newly Diagnosed Breast Cancer Patients|||Observational||Other||20|NCT01176838|November 2008
1411|Withdrawn|Dermal Fillers Patient Satisfaction|||Observational||Other|Satisfactionwithresultsofdermalfiller|0|NCT01176812|May 2009
1412|Completed|Reusable Versus Disposable Draping System in Breast Reconstruction Surgery||Other:CultureSwabsRodacPlateCultures|Interventional||Other|Infection rates of reusable versus disposable draping system in the operating room|107|NCT01176786|September 2009
1413|Terminated|Use of Palliative Performance and Symptom Distress Scales in Older Patients With Advanced Ovarian Cancer||Other: Palliative Performance Scale version 2 (PPSv2);  Other:McCorkleSymptomDistressScale(SDS);  Other:GeriatricAssessment;  Other:MedicalRecordsAbstraction|Observational|Phase 1|Other / NIH|Changes in scale score after surgery and/or chemotherapy|11|NCT01175967|June 2010
1414|Completed                  Has Results|PROspective Multicenter Imaging Study for Evaluation of Chest Pain||Procedure:CoronaryAngiography;  Procedure:StressEchocardiogram;  Procedure:NuclearStressTest;  Procedure:ExerciseElectrocardiogram|Interventional||Other / NIH|TimetoPrimaryEndpoint;  Time to Death Myocardial Infarction (MI) Unstable Angina Hospitalization;  TimetoDeathorMyocardialInfarction(MI);  Time to Major Complications From Cardiovascular (CV) Procedures;  Time to Death Myocardial Infarction (MI) Unstable Angina (UA) Complications No Coronary Artery Disease (CAD);  Percentage of Invasive Cardiac Catheterization Events Without Obstructive Coronary Artery Disease Within 90 Days Following Participant Randomization;  MedicalCost;  Quality of Life (QOL) as Measured by Duke Activity Status Index;  Quality of Life (QOL) as Measured by Seattle Angina Scale Anginal Frequency Subscale;  Quality of Life (QOL) as Measured by Seattle Anginal Quality of Life Subscale;  Quality of Life (QOL) as Measured by Complete Resolution of Symptoms That Led to the Initial Testing;  CumulativeRadiationExposureWithin90Days|10003|NCT01174550|July 2010
1415|Completed|Effectiveness of a Cancer Center Based Physical Activity Intervention||Behavioral:Physicalactivitycounseling|Interventional||Other|Effectiveness of a cancer center based physical activity intervention for increasing physical activity in breast cancer survivors.;  Effectiveness of a cancer center based physical activity counseling intervention on increasing quality of life in breast cancer survivors.|20|NCT01173861|March 2010
1416|Completed|Computer-Assisted Tailored Cue-card Health [CATCH] Study||Behavioral:TailoredCueCards|Interventional|Phase 1|Other / NIH|Sexrisk;  Injectionrisk|122|NCT01170741|June 2010
1417|Completed                  Has Results|Sildenafil in Single Ventricle Patients||Drug:Sildenafilbyinjection|Interventional|Phase 1|Other|MaximumSildenafilPlasmaConcentration;  HemodynamicSafetyandEfficacy|21|NCT01169519|April 2011
1418|Completed                  Has Results|Cerebral Perfusion Pressure Using Precedex and Other Sedatives||Drug:Standard-of-CareplusDexmedetomidine;  Other:Standard-of-Care|Interventional|Phase 3|Other / Industry|VariabilityofIntracranialPressure(ICP);  ChangeinPressureReactivityIndex(PRx);  Amount of Sedative/Analgesic Used During Treatment in Patients With Secondary Brain Injury;  Cerebral Perfusion Pressure Changes in Patients With Secondary Brain Injury;  Mean Arterial Blood Pressure (MAP) Variability in Patients With Secondary Brain Injury|89|NCT01169467|October 2009
1419|Terminated|Ventriculostomy in Subarachnoid Hemorrhage (SAH): Intracranial Pressure (ICP) Open or Not?|||Observational||Other / Industry|Cerebralarteryvasospasm|60|NCT01169454|March 2009
1420|Active not recruiting|Pharmacokinetics/Pharmacodynamics (PK/PD) of Fluconazole in Children on Extracorporeal Membrane Oxygenation (ECMO)||Drug:Fluconazole|Interventional|Phase 1|Other|Pharmacokinetics/Pharmacodynamics|21|NCT01169402|July 2010
1421|Terminated|PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias||Drug:Clofarabine|Interventional||Other / Industry|Define human intra-patient bioavailability of clofarabine; Compare the pharmacokinetics of intravenously-administered clofarabine when administered alone with the pharmacokinetics of clofarabine when co-administered with cimetidine an OCT2 inhibitor.;  Examine safety of orally-administered clofarabine; Examine the safety of a combined intravenous and oral clofarabine regimen;  Examine efficacy of orally-administered clofarabine;  Explore the influence of OCT2-encoding single nucleotide polymorphisms on clofarabine pharmacokinetics and pharmacodynamics|13|NCT01169012|September 2010
1422|Recruiting|Evaluation of Continuous Saphenous Nerve Block to Supplement a Continuous Sciatic Nerve Block After Ankle Surgery||Drug:0.2%ropivacaine;  Drug:saline|Interventional||Other / Industry|Verbalpainscores;  Opioiduse;  nausea;  vomiting;  sleepdisturbance;  Reductionofquadricepsstrength|74|NCT01167907|July 2010
1423|Recruiting|Lactation Education Study in Mothers of Very Low Birth Weight Infants||Other:Instructionaldigitalvideodisc(DVD)|Interventional||Other|Maternal breast milk proportion of enteral feeding.;  Volume of daily maternal milk intake in relation to infant weight.;  Maternal lactation and breast milk expression knowledge.|40|NCT01167517|July 2010
1424|Completed|Development of a Questionnaire to Measure Hypervigilance for Visceral Pain|||Observational||Other / Industry||157|NCT01166802|February 2008
1425|Completed|Lubiprostone Effects on Visceral Pain Sensitivity||Drug:Lubiprostone;  Drug:Placebo|Interventional|Phase 1|Other / Industry|Painthreshold|62|NCT01166789|February 2008
1426|Terminated|Esophagoscopy in Evaluating Treatment in Patients With Stage I-IV Head and Neck Cancer Who Are Undergoing Radiation Therapy and/or Chemotherapy||Procedure:endoscopicprocedure;  Other:questionnaireadministration|Interventional||Other|Abnormalendoscopicesophagealexamination;  Severityofself-ratedswallowingdysfunction|6|NCT01164566|December 2010
1427|Completed|Telephone Physical Activity Intervention in Obese Youth||Behavioral:physicalactivity|Interventional||Other|physicalactivity;  BMI|60|NCT01162512|July 2010
1428|Completed|Nutrition for Chronic Daily Headache||Other:Lowomega-6plushighomega-3diet;  Other:Lowomega-6diet|Interventional|Phase 1 / Phase 2|Other|HeadacheImpactTest;  Omega-3 and omega-6 fatty acids in RBCs and plasma|67|NCT01157208|July 2009
1429|Completed                  Has Results|Considering Patient Diet Preferences to Optimize Weight Loss||Behavioral:Choice;  Behavioral:Control|Interventional||U.S. Fed|BodyWeight;  Diet Adherence as Measured by Block Food-frequency Questionnaire (Absolute Percentage Deviation From the Goal Macronutrient Intake--&lt;30% Fat for Low-fat Diet or &lt;10% Carbohydrate for Low-carbohydrate Diet);  Obesity-specific Health-related Quality of Life as Measured by Impact Of Weight On Quality Of Life-Lite (IWQOL-Lite) Questionnaire|207|NCT01152359|May 2011
1430|Completed|Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors||Drug:pioglitazone;  Drug:Pioglitazone|Interventional|Phase 1|Other|Best tolerated dose of 2 different doses of orally administered pioglitazone;  Toxicitiesassociatedwithbothdoselevels;  To evaluate the effect of pioglitazone on glycemic levels and hemoglobin A1c values when pioglitazone is used as a cytoprotective agent concurrent with radiotherapy in normoglycemic patients.|18|NCT01151670|August 2010
1431|Completed                  Has Results|Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan in the Premier Perspective Database||Drug:Alvimopan|Observational||Industry|PercentageofPatientsWhoDied;  Percentage of Patients With Reported In-hospital Postoperative Gastrointestinal (GI) Morbidity;  Percentage of Patients With In-hospital Cardiovascular Morbidity;  Percentage of Patients With In-hospital Cerebrovascular Morbidity;  Percentage of Patients With In-hospital Pulmonary Morbidity;  Percentage of Patients With In-hospital Infection Morbidity;  Percentage of Patients With In-hospital Thromboembolic Morbidity;  Percentage of Patients With In-hospital Other Morbidity;  Percentage of Patients Who Were Readmitted Within 15 Days of Discharge;  Percentage of Patients Who Were Readmitted Between 16 and 30 Days After Discharge;  Percentage of Patients Who Were Readmitted Within 30 Days of Discharge;  Percentage of Patients Discharged to Various Locations;  IntensiveCareUnitLengthofStay;  PostoperativeLengthofHospitalStay|7050|NCT01150760|April 2010
1432|Completed|Can E-cadherin Found in Tissue/Blood be Valuable in Identifying &amp; Monitoring Patients With Post-proton Pump Inhibitor (PPI)-Responsive Heartburn||Drug:Dexlansoprazole|Interventional|Phase 4|Other|Dexlansoprazole|40|NCT01149395|June 2010
1433|Completed|A Randomized Study of Autologous Umbilical Cord Blood Reinfusion in Children With Cerebral Palsy||Biological: Autologous Umbilical Cord Blood or Placebo|Interventional|Phase 2|Other|The primary measure of efficacy will be improvement of standardized measures of neurodevelopmental function.;  A secondary objective is to determine effects on quality of life in these children.;  A secondary objective is to describe functional and morphologic changes on brain MRI in these children.;  A secondary objective is to ask whether there is a correlation between clinical response and RNA expression of neural endotheial and inflammatory cytokines measured by RNA arrays in cord blood cells given to these patients.|63|NCT01147653|June 2010
1434|Completed|Botanical Oil Supplementation in Diabetic and Metabolic Syndrome Subjects||DietarySupplement:borage/echiumoilcombination;  DietarySupplement:fishoil;  DietarySupplement:cornoil|Interventional|Phase 1 / Phase 2|Other|fastinginsulin;  hsCRP;  leptin;  serumfattyacids;  proandanti-inflammatorycytokines;  fastingglucose;  hemoglobin1Ac;  adiposederivedcytokines;  circulating blood lipids and blood cell components;  PBMCgeneexpression;  SNPsinDNAofselectedgenes;  PBMCleukotrienestimulation|80|NCT01145066|May 2009
1435|Completed|Evaluation of Factors II VII IX X and Proteins C and S Following High-dose Vitamin K Supplementation||DietarySupplement:VitaminK20mg|Interventional||Other|Change in levels and activities due to vitamin K supplementation|8|NCT01143831|November 2009
1436|Suspended|Study of the Effect of SNPs in p53 and p53 Response Elements on the Inflammatory Response to DNA Damage|||Observational||NIH||105|NCT01143519|May 2010
1437|Enrolling by invitation|The Role of Glucocorticoid Receptor SNPs in Receptor Function and Metabolic Disease|||Observational||NIH||278|NCT01143493|May 2010
1438|Enrolling by invitation|Study of the Effect of Innate on the Inflammatory Response to Endotoxin|||Observational||NIH||67|NCT01143480|May 2010
1439|Completed                  Has Results|Cardiovascular Intervention Improvement Telemedicine Study||Behavioral:PharmacistCVD|Interventional||U.S. Fed|Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent);  MeanSystolicBloodPressure;  MeanDiastolicBloodPressure;  MedicationNon-adherence;  CholesterolLDL;  BodyMassIndex;  HBA1CinDiabeticPatients|428|NCT01142908|November 2011
1440|Completed|Pounds Off Digitally (POD): The Use of Podcasting and Mobile Media to Promote Weight Loss||Behavioral:Podcasting+mobilemedia|Interventional|Phase 1|Other|Weightloss|96|NCT01139255|June 2010
1441|Completed|Biomarkers in Blood Samples From Older Breast Cancer Survivors||Genetic:geneexpressionanalysis;  Genetic: reverse transcriptase-polymerase chain reaction;  Other:laboratorybiomarkeranalysis;  Other:medicalchartreview;  Other:questionnaireadministration|Observational|Phase 1|Other / NIH|p16INK4aexpressionbetweencohort2vscohort3;  p16INK4aexpressionbetweencohort1vscohort2;  p16INK4a expression between cohorts 1 2 and 3 vs cohort 4|246|NCT01138345|January 2010
1442|Recruiting|Antiretroviral Pregnancy Registry (APR)-Risk of Birth Defects||Drug:AnyAntiretroviralTherapy|Observational||Industry / Other|A birth defect is defined as any congenital malformations according to modified (by APR) classification of Centers for Disease Control and Prevention (CDC)&apos;s Metropolitan Atlanta Congenital Defects Program (MACDP) criteria|1|NCT01137981|February 1993
1443|Recruiting|Tissue Blood and Body Fluid Sample Collection From Patients With Hematologic Cancer||Other:biologicsamplepreservationprocedure;  Other:cytologyspecimencollectionprocedure|Observational|Phase 1|Other / NIH|Tissue blood and body fluid samples collection for ongoing diagnostic prognostic or immune-monitoring studies;  Development of a centralized quality-controlled quality-assured facility for the procurement processing storage and distribution of normal and malignant tissue specimens and corresponding blood specimens|15000|NCT01137643|July 2009
1444|Enrolling by invitation|Prenatal Exposure Effects Psychophysiology Study|||Observational||Other|Determine the effect of prenatal cocaine exposure on the neonatal brain. ventricular volumes|150|NCT01134770|July 2008
1445|Completed|Personalized Cardiovascular Risk Information to Initiate and Maintain Health Behavior Changes||Behavioral:Web-BasedIntervention|Interventional||Other|Cardiovascular Disease (CVD) Risk Knowledge Assessment|98|NCT01134458|December 2010
1446|Enrolling by invitation|A Follow-up of the Early Pregnancy Study Cohort.|||Observational||NIH|Recalloftimetopregnancy.;  Distribution of gestational age in naturally conceived pregnancies.|221|NCT01132924|April 2010
1447|Completed|Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving Chemotherapy||Other:enzyme-linkedimmunosorbentassay;  Other:laboratorybiomarkeranalysis;  Other:medicalchartreview|Observational|Phase 1|Other / NIH|Levelsofcirculatingtissuefactor(TF);  Alterationincoagulationparameters;  Correlation of TF with markers of coagulation activation and endothelial activation;  Incidenceofvenousthromboembolism|18|NCT01132833|December 2008
1448|Completed|Bioequivalence Study of Lamotrigine 25 mg Chewable Tablets of Dr.Reddy&apos;s Under Fed Condition||Drug:Lamotrigine|Interventional|Phase 1|Industry|BioequivalencebasedonCmaxandAUCparameters|26|NCT01131975|January 2003
1449|Completed|Bioequivalence Study of Lamotrigine 25 mg Chewable Tablets of Dr.Reddy&apos;s Under Fasting Condition||Drug:Lamotrigine|Interventional|Phase 1|Industry|BioequivalencebasedonCmaxandAUCparameters|26|NCT01131949|January 2003
1450|Completed|Bioequivalency Study of Amlodipine Besylate Tablets 10 mg of Dr. Reddy&apos;s Under Fed Conditions||Drug:Amlodipine|Interventional|Phase 1|Industry|BioequivalencebasedonCmaxandAUCparameters|24|NCT01131936|August 2002
1451|Completed|Bioequivalency Study of Amlodipine Besylate Tablets 10 mg of Dr. Reddy&apos;s Under Fasting Conditions||Drug:Amlodipine|Interventional|Phase 1|Industry|BioequivalencebasedonCmaxandAUCparameters|26|NCT01131923|October 2002
1452|Completed                  Has Results|Patient and Provider Interventions for Managing Osteoarthritis in Primary Care||Behavioral:OsteoarthritisIntervention|Interventional||U.S. Fed|Western Ontario and McMasters Universities Osteoarthritis Index (WOMAC);  ShortPhysicalPerformanceTestProtocol;  PHQ-8|300|NCT01130740|August 2011
1453|Completed|Resistance Training in Lung Cancer Patients on Chemotherapy||Behavioral:Exercise|Interventional||Other|Systemic inflammation measured by c-reactive protein.;  Chemotherapycompletion|15|NCT01130714|January 2010
1454|Completed|Effects of 2 Different Broccoli Sprout Containing Supplements on Nasal Cells in Healthy Volunteers||Dietary Supplement: Supplement A followed by Supplement B;  Dietary Supplement: Supplement B followed by Supplement A|Interventional||Other / NIH|the change in nasal cell HO-1 expression induced by two different preparations of sulforaphane (SFN)-containing nutritional supplements;  serumSFNlevel|11|NCT01129466|May 2010
1455|Completed|Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)||Behavioral:HIPECOrientation;  Behavioral: Consultation with Survivorship Navigator;  Other:Questionnaires|Interventional||Other|Assess feasibility of instituting an orientation program brief follow up care and phone calls in this patient population;  Reducepre-treatmentdistressandanxiety;  Improvepre-treatmentself-efficacy;  ProvideeducationalmaterialdeliveredbytheSRB;  Improve overall post-operative QOL ratings at 3 months relative to discharge|10|NCT01126346|May 2010
1456|Active not recruiting|Memory Study of Youngest Women Enrolled in the Women&apos;s Health Initiative Hormone Therapy (HT) Arm|||Observational||Other|All-causedementia;  MildCognitiveImpairment|1362|NCT01124773|June 2009
1457|Completed|Neuroimaging of Smokers With and Without Attention Deficit Hyperactivity Disorder (ADHD)|||Observational||Other / NIH|To evaluate the effects of smoking abstinence on response inhibition brain function in smokers with and without ADHD.|101|NCT01123668|July 2009
1458|Completed|&quot;Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction&quot;||Drug:fondaparinuxsodiuminjection|Interventional|Phase 1|Other / Industry|Blood samples to measure specific Arixtra&#174; concentration;  Frequency of bleeding events and new thrombotic events|9|NCT01121770|May 2010
1459|Terminated                  Has Results|Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma||Drug:azacitidine;  Drug:lenalidomide|Interventional|Phase 2|Other / Industry|Response Predicted by Molecular Signatures Compared to True Response;  OverallResponse;  Number of Participants With Grade 3 and 4 Toxicities|11|NCT01121757|April 2010
1460|Completed|Intraosseous Versus Intravenous Vascular Access During Cardiac Arrest||Device:IntravenousaccessduringOHCA;  Device:HumeralIOinsertion;  Device:TIbialIOinsertion|Interventional||Other|First attempt success rate between the tibial IO humeral IO and peripheral IV.;  TimetofirstACLSmedication;  Timetovascularaccess;  Fluid flow rates as measured by total volume infused during resuscitation.|182|NCT01119807|May 2010
1461|Completed                  Has Results|Stroke Education Intervention Trial - Pilot||Behavioral:strokeeducation|Interventional||Other|Feasibility of Intervention (Ability to Reach Patients at 3 Months);  FollowupAppointmentWithMD|30|NCT01115660|January 2010
1462|Withdrawn|A Panobinostat Presurgery||Drug:panobinostat|Interventional|Phase 2|Other / Industry|Anti-tumor Activity as Measured by Percentage of Patients Who Remain Progression-free after Six Months;  SafetyEvaluationofPanobinostat;  Evaluation of Intratumoral Pharmacokinetics and Pharmacodynamics of Panobinostat;  EvaluationofSystemicPharmacokinetics|0|NCT01115036|April 2010
1463|Completed                  Has Results|Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection||Drug:Mucinex;  Drug:Placebo|Interventional|Phase 2|Industry|Percent of Inhaled Radioactive Tracer Particles Cleared From Lungs;  GuaifenesinAUC(0-3);  Assess Sputum Properties (Objective Measures) and Symptoms (Subjective Measures) After Treatment With Mucinex or Placebo.|38|NCT01114581|April 2010
1464|Completed|Prospective Aerobic Reconditioning Intervention Study||Behavioral:Exercise;  Behavioral:Control|Interventional||Other / NIH|Peakexercisecapacity;  Qualityoflife|201|NCT01113840|July 1993
1465|Completed                  Has Results|Improving Decision Making About Feeding Options for Dementia||Other:FeedingOptionsinDementiaDecisionAid|Interventional||Other / NIH|DecisionalConflictScale;  PercentWithTreatmentDecisions|256|NCT01113749|May 2007
1466|Active not recruiting|Breast Cancer Rehabilitation Program in Improving Quality of Life in Breast Cancer Survivors||Other:questionnaireadministration;  Behavioral:exerciseintervention;  Procedure:quality-of-lifeassessment;  Other:surveyadministration;  Procedure:managementoftherapycomplications;  Procedure:psychosocialassessmentandcare|Interventional||Other|Ability to recruit breast cancer survivors into a six-month breast cancer rehabilitation program;  BMI;  Muscularstrength;  Rangeofmotion;  Qualityoflife;  Proportion of screened women who are eligible for the study and the proportion of eligible women who agree to participate;  Proportion of women who complete the study and the average number of weeks of participation|25|NCT01113554|June 2010
1467|Completed                  Has Results|AMG 102 and Avastin for Recurrent Malignant Glioma||Drug:AMG102;  Drug:Avastin|Interventional|Phase 2|Other / Industry|RadiographicResponse;  MedianOverallSurvival(OS);  Six-monthProgression-freeSurvival(PFS6);  Percentage of Participants Who Experience Treatment-related Grade 2 or Greater CNS Hemorrhage or Grade 4 or Greater Non-hematologic Toxicities|36|NCT01113398|August 2010
1468|Completed|Fast Spectral Imaging Device for Tumor Margin Mapping|||Observational||Other / NIH|To perform a critical evaluation of the device in a practical clinical setting|54|NCT01107080|September 2009
1469|Completed|Study Evaluating Heated Lidocaine/Tetracaine Patch in Patients With Pain Associated With Myofascial Trigger Points||Drug:Heatedlidocaine/tetracainepatch|Interventional|Phase 2|Industry|Painintensity;  Pain interference with activities (eg general normal work sleep)|20|NCT01106989|June 2010
1470|Completed                  Has Results|L-Arginine Supplementation With or Without Enzyme Inhibitors Treating Erectile Function of Prostate Cancer Survivors||Drug:Placebo;  DietarySupplement:OralL-Arginine|Interventional|Phase 2|Other / NIH|ErectileFunction;  Retention;  Adherence;  QualityofLife|140|NCT01105130|October 2010
1471|Terminated|Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma||Drug:erlotinibhydrochloride;  Drug:isotretinoin;  Other:laboratorybiomarkeranalysis;  Genetic:proteinexpressionanalysis|Interventional|Phase 1|Other / NIH|Recommended phase II doses of erlotinib hydrochloride and isotretinoin;  Toxicity as assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0;  Progression-freesurvival;  Overallsurvival;  Responserates(completeorpartialresponse);  EGFRvIII PTEN cyclin D1 cyclin E and RARbeta1 expression in tumor samples|5|NCT01103375|May 2010
1472|Terminated|A Pilot Trial in a Sleep Laboratory Setting to Observe Night Time Bladder Function of Subjects With Overactive Bladder (OAB)||Procedure:cystometry(CMG);  Procedure:polysomnography(PSG)|Observational||Industry|Averagenocturiaindividualvolumevoid;  Nocturnalfunctionalbladdercapacity;  Totalurineproduction;  Total wake time from lights out until getting out of bed in the morning;  Averageurgencyrating;  Numberofnocturiaswithurgency&#8805;3;  Percentageofsubjectswith&#8805;2nocturias;  TimefromawakeningtovoidonCMG/PSG;  Numberofawakenings;  Waketimeaftersleeponset;  Sleeponsetlatency;  For DO+ subjects number of nocturias associated with DO+|15|NCT01099345|July 2010
1473|Completed                  Has Results|Clopidogrel Pharmacogenomics Project||Drug:clopidogrel75mg;  Drug:Clopidogrel150mg|Interventional|Phase 2|Other|Clopidogrel Resistance Defined by P2Y12 Reaction Units (PRU)Value &gt;230|50|NCT01097343|March 2010
1474|Completed|Do Acid Sensing Ion Channels Contribute to Heartburn?||Drug:Amiloride;  Drug:Placebo|Interventional|Phase 1|Other|Bernstein test to measure Initial Onset of Heartburn Symptoms;  Bernstein test to measure onset of Heartburn Symptoms after receipt of medication or placebo|24|NCT01095133|March 2010
1475|Enrolling by invitation|Haufen Diagnostic Biomarkers of BK Renal Disease||Procedure:RenalAllograftBiopsy|Interventional||Other / Industry|Correlate Haufen urine and plasma data with the clinical presentation and - in selected cases - with renal biopsy findings.|10|NCT01094691|November 2008
1476|Completed|Cell Phone Intervention in Young Adults||Behavioral:Behavioralweightlossintervention|Interventional|Phase 2|Other / NIH|Changeinbodyweight|365|NCT01092364|November 2010
1477|Completed|Efficacy of Retrograde Fill Vs Spontaneous Fill to Assess Voiding Function||Procedure:VoidingTrial|Interventional||Other|Presenceofurinaryretention|50|NCT01091844|December 2009
1478|Unknown&nbsp;&#8224;|Correlation of Oropharyngeal Pepsin and Gastroesophageal (GE) Reflux|||Observational||Other / Industry|Positive correlation between GE reflux events and oropharyngeal pepsin concentrations;  Compare oropharyngeal pepsin concentrations in patients with GE reflux to a. patients with normal pH/MII and isolated oral aspiration on MBS b. healthy controls.;  Non-acid GE reflux events are positively correlated with increasing levels of oropharyngeal pepsin.;  Patients with isolated oral aspiration (without GE reflux) will have no oropharyngeal pepsin.|170|NCT01091805|December 2008
1479|Completed                  Has Results|Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure||Drug:MAP0004;  Drug:IVPlacebo(Saline);  Drug:PlaceboInhaler;  Drug:IVDihydroergotamineMesylate(DHE)|Interventional|Phase 1|Industry|AUC(0-2hrs) of Pulmonary Arterial Systolic Pressure (PASP) Over Time Post 1st Dose;  Percent of Subjects With an Increase in PASP Greater Than 10mmHg From Baseline to 2 Hours From the First Dose;  Maximum Change in PASP From Baseline to the Two Hour Period Following the First Dose;  AUC(0-4hrs) of Pulmonary Arterial Systolic Pressure (PASP) From the Start of the First Dose to Two Hours After the Second Dose;  Change in Blood Pressure From Baseline After the Two 2-hour Post Dosing Periods;  Change From Baseline in QTc Interval at 14 Minutes After the 1st and 2nd Dose|24|NCT01089062|March 2010
1480|Recruiting|Sample Collection Registry for Quality Control of Biological and Environmental Specimens and Assay Development and Testing|||Observational||NIH|To generate a pool of biological or environmental samples with which to develop and test specific laboratory assays.;  Characterizevascularagerelated-other|10000|NCT01087307|February 2010
1481|Completed                  Has Results|Study of Propranolol as Anti-Adhesive Therapy in Sickle Cell Disease (SCD)||Drug:Propranolol;  Drug:Placebo|Interventional|Phase 2|Other / NIH|SS RBC Adhesion (Epi -1d/cm2- vs. Sham) by Treatment;  SS RBC Adhesion (Epi -2d/cm2- vs. Sham) by Treatment;  SS RBC Adhesion (Epi -3d/cm2- vs. Sham) by Treatment;  OverallChangeofPlasmaLevelsofsE-selectin;  OverallChangeofPlasmaLevelsofsP-selectin;  OverallChangeofPlasmaLevelsofsICAM-1;  OverallChangeofPlasmaLevelsofsVCAM-1;  OverallChangeofHemoglobin(Hgb)Levels;  OverallChangeofHematocrit(Hct)Levels;  Overall Change of Lactate Dehydrogenase (LDH) Levels;  Overall Change of Oxygen Saturation (02Sat) Levels;  OverallChangeofSystolicBloodPressureLevels;  OverallChangeofDiastolicBloodPressureLevels|31|NCT01077921|June 2010
1482|Terminated                  Has Results|Apremilast in the Treatment of Moderate to Severe Acne||Drug:apremilast|Interventional|Phase 2|Other / Industry|Proportion of Patients With a Success Rate (Based on the Researcher&apos;s Global Assessment (RGA) Sum of Clear (0) or Almost Clear (1));  Proportion of Patients With a Minimum 2-grade Improvement in the Researcher Global Assessment (RGA) From Baseline to Week 12.;  Mean Percentage Reduction From Baseline in Individual Lesion Counts (Total Inflammatory Non-inflammatory) at Week 12;  Proportion of Patients Achieving a Clear or Almost Clear PGA at 16 Weeks;  The Absolute Change in Lesion Counts (Total Inflammatory Non-inflammatory) From Baseline to Week 12;  Safety of Apremilast 20 Mgs BID for 12 Weeks Will be Assessed by Evaluating Adverse Events (AEs) Vital Signs Laboratory Evaluations and Withdrawals From the Study|3|NCT01074502|February 2010
1483|Recruiting|The Cymbalta Pregnancy Registry||Drug:duloxetine|Observational||Industry / Other|To estimate the risk of major congenital anomalies among pregnancies exposed to Cymbalta;  To estimate risk of recognized spontaneous abortions stillbirths elective terminations minor congenital anomalies and any serious adverse pregnancy outcomes among pregnancies exposed to Cymbalta and their live births during the first year of life;  To examine any potential impact of Cymbalta use while breastfeeding on the infant during the first year of life;  To compare the risk of major congenital anomalies among pregnancies exposed to Cymbalta to an appropriate comparator(s) such as the Centers for Disease Control and Prevention (CDC) Metropolitan Atlanta Congenital Defects Program (MACDP)|484|NCT01074151|July 2009
1484|Completed|Effect of Yoga on Objective and Subjective Menopausal Hot Flashes||Behavioral:Yoga|Interventional|Phase 2|Other / NIH|SubjectiveHotFlashes;  Objectivehotflashes;  Hotflashinterference|54|NCT01073397|January 2010
1485|Completed|Serine Proteases in Gastrointestinal Function and Irritable Bowel Syndrome (IBS)|||Observational||Other / NIH|fecalserineproteaseactivity;  intestinalpermeability|60|NCT01072916|February 2009
1486|Completed|The Role of Intestinal Inflammation in Irritable Bowel Syndrome (IBS)|||Observational||Other / NIH||78|NCT01072903|January 2009
1487|Completed|Comparison of Non-nutritive Suck (NNS) Measures to Clinical Estimates of Suck and Feeding Readiness in Preterm Infants|||Observational||Industry|To describe NNS pressure waveforms and NNS-STI values in normal premature infants with gestational ages 30 to 36 weeks during the first week of life.;  To describe the progression of NNS waveform pattern and NNS-STI values in normal premature infants as they mature to term postmenstrual age.|70|NCT01069731|January 2008
1488|Completed|Evaluating Patterned Oral Somatosensory Entrainment Stimulation Using the NTrainer on Oral Feeding Performance|||Observational||Industry|Postmenstrual age at the time of full oral feedings;  Postmenstrual age at the time of hospital discharge|24|NCT01069718|March 2008
1489|Completed                  Has Results|Topical Cyclosporine Suspension for the Treatment of Brittle Nails||Drug: topical cyclosporine ophthalmic suspension 0.05%;  Drug:vehicle|Interventional|Phase 2|Other / Industry|&#8226; Number of Patients Receiving at Least a 1-grade Improvement in the Physicians Global Improvement Assessment (PGIA) of Two Target Nails.;  Patients Assessment of Satisfaction With Length of Fingernails|21|NCT01064830|February 2010
1490|Completed|Combined Spinal/Epidural (CSE) Saline Duration/Spread||Other:Sterilenormalsaline0mls;  Other:15mlssterilenormalsaline|Interventional||Other|Highest sensory blockade level to pinprick and to cold;  timetoonsetofanalgesia;  Duration of analgesia (time to request additional analgesia)|60|NCT01062893|August 2009
1491|Recruiting|A Trial of AMG 479 Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer||Drug:AMG479EverolimusPanitumumab|Interventional|Phase 1|Other / Industry|To define the maximal tolerated dose (MTD) and/or recommended phase II dose (RPTD) for the doublet AMG 479 in combination with everolimus in subjects with advanced solid tumors.;  To define the maximal tolerated dose (MTD) and/or recommended phase II dose (RPTD) for the triplet AMG 479 in combination with everolimus and panitumumab in subjects with advanced solid tumors.;  To describe the toxicity profile seen with these combinations.;  To describe any signs of clinical activity including response rate and progression free survival associated with these regimens.|100|NCT01061788|April 2010
1492|Completed|Evaluation of the Media Detective Program for Elementary School-Aged Children to Prevention Substance Use||Behavioral:MediaDetective|Interventional||Other|Intenttoalcoholortobaccoproducts;  Understanding of the persuasive intent of advertising;  Mediadeconstructionskills;  Interestinalcohol-brandedmerchandise;  Self-efficacy to refuse offers to use alcohol or tobacco products|679|NCT01060852|March 2006
1493|Active not recruiting|The Genetics of Chiari Type I Malformation|||Observational||Other|Genetic factors contributing to Chiari Type I malformation|2000|NCT01060800|June 2009
1494|Completed                  Has Results|Genetic Testing for Type 2 Diabetes||Genetic:genetictestingfortype2diabetes;  Behavioral:Conventionalriskcounseling;  Behavioral:eyediseasecounseling|Interventional||U.S. Fed / Other|Weight;  InsulinResistance(HOMA2-IR);  PerceivedLifetimeRiskofType2Diabetes;  DailyCaloricIntake;  ModerateIntensityPhysicalActivity|601|NCT01060540|August 2010
1495|Active not recruiting|Transoral Robotic Surgery (TORS) for Oral and Laryngopharyngeal Lesions Using Da Vinci Robotic Surgical System||Device: Da Vinci Robotic Transoral Robotic Surgical System|Interventional|Phase 0|Other|In order to evaluate the feasibility of TORS the investigators will report the number and percent of all evaluable patients who have successfully undergone TORS at each interim analysis.;  Secondary outcome measures are operative time blood loss and complications to assess the learning curve for TORS by measuring the efficiency and accuracy of the procedures and to assess the quality of life of the patients undergoing TORS.|60|NCT01059357|June 2010
1496|Completed                  Has Results|Group Physical Therapy for Knee Osteoarthritis||Other:GroupPhysicalTherapyforKneeOA;  Other:IndividualPhysicalTherapyforKneeOA|Interventional||U.S. Fed|Western Ontario and McMasters Universities Osteoarthritis Index (WOMAC);  ShortPerformancePhysicalBattery(SPPB)|320|NCT01058304|February 2011
1497|Completed|Neurobiology of Nicotine and Non-nicotine Components of Tobacco Addiction||Behavioral:Quitsmoking;  Drug:Nicotinepatch;  Drug:PlaceboPatch|Interventional|Phase 1|Other / NIH|Measure cue reactivity while subjects undergo a functional magnetic resonance imaging (fMRI).;  Measure continuous working memory while subjects are scanned in a functional magnetic resonance imaging (fMRI).|147|NCT01056926|March 2009
1498|Completed                  Has Results|Supplemental Nicotine Administration for Smoking Cessation in Posttraumatic Stress Disorder (PTSD)||Drug:nicotinepatch;  Drug:placebopatch|Interventional||Other|Participants Self-reporting Abstinence During 6 Weeks Post Quit;  Abstinence as Measured by Exhaled Carbon Monoxide (CO)|69|NCT01055886|November 2009
1499|Completed|Safety Study of Bevacizumab Everolimus and LBH589 (BEL) for Advanced Solid Tumors||Drug:BevacizumabEverolimusandLBH589|Interventional|Phase 1|Other / Industry|To define the maximal tolerated dose (if any) and the recommended phase II dose for the triplet combination of everolimus plus LBH589 plus bevacizumab in subjects with advanced solid tumors;  To describe any dose limiting toxicities of this combination and to describe any non-dose limiting toxicities of this combination.;  To describe pharmacokinetic characteristics of everolimus and LBH589 when the two drugs administered in combination.;  To describe the effect of this treatment combination on blood based biomarkers for tumor angiogenesis and tumor growth factors.;  To describe any signs of clinical activity of this treatment combination including response rate time to progression and duration of response.|14|NCT01055795|March 2010
1500|Withdrawn|To Evaluate the Characteristics of a Breast Cancer||Drug:EF5;  Procedure:PartialorTotalMastectomy|Interventional|Phase 0|Other / NIH|Toevaluatetumorcharacteristics;  Intra and Interpatient correlations with tumor hypoxia|0|NCT01055678|January 2010
1501|Withdrawn|Milk-only Lactation Study for Patients on Eltrombopag||Drug:eltrombopag|Interventional|Phase 4|Industry|Breast milk eltrombopag concentrations collected from nursing mothers taking eltrombopag;  AEs in infant reported during the 24 hour breast milk collection period;  Plasma eltrombopag concentrations from infant as data permit (optional)|0|NCT01055600|March 2013
1502|Active not recruiting                  Has Results|Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer||Other:laboratorybiomarkeranalysis;  Procedure:quality-of-lifeassessment;  Other:questionnaireadministration;  Drug:cinacalcethydrochloride|Interventional|Phase 2|Other / NIH|RateofRiseofSerumPSA|20|NCT01054079|September 2011
1503|Completed|Managing Chronic Kidney Disease in Eastern North Carolina||Behavioral:ChronicKidneyDiseaseEducation|Interventional||Other|To determine the effect of CKD education on the behavior of the primary care physician in underserved areas in Eastern North Carolina.;  To assess the rate of reduction of CKD in patients in Eastern North Carolina.|1257|NCT01054066|August 2008
1504|Terminated|Effects of Swallowing Exercises on Patients Undergoing Radiation Treatment for Head and Neck Cancer||Behavioral:exerciseintervention;  Other:questionnaireadministration;  Procedure:quality-of-lifeassessment|Interventional|Phase 3|Other|M.D. Anderson Dysphagia Inventory (MDADI) swallowing quality of life score;  Penetration Aspiration Scale (PAS) as assessed via FEES;  Diet level (Dysphagia Outcome and Severity Scale (DOSS)) as assessed via FEES;  Feedingtubeduration(days);  Eating Assessment Tool (EAT) quality of life score;  Lingualstrengthasassessedbylingualmanometry;  Percentweightloss;  Percentweightrecovery|156|NCT01053546|November 2010
1505|Active not recruiting|Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer||Procedure:massagetherapy;  Other:questionnaireadministration;  Procedure:quality-of-lifeassessment;  Other:interventionbycaregiver;  Procedure:standardfollow-upcare|Interventional||Other / NIH|Feasibility and acceptability of conducting a massage intervention with childhood cancer patients and their primary caregivers;  Effectiveness of caregiver massage to reduce child and caregiver distress and promote child health-related quality of life|80|NCT01053494|April 2010
1506|Completed|Do Motion Metrics Lead to Improved Skill Acquisition on Simulators?||Other:skillstraining|Interventional||Other / Industry|Laparoscopic suturing performance in the animal operating room;  inadvertentinjuriesintheanimalOR;  training duration required by novices to reach proficiency in laparoscopic suturing based on speed motion efficiency or a combination of these metrics|42|NCT01052168|November 2009
1507|Active not recruiting|A Pilot C11-Choline PET-CT Imaging Study in Patients With Locally Advanced Esophageal Cancer||Drug:C11-Choline|Interventional|Phase 1|Other|To evaluate our ability to obtain reliable and meaningful 11C-Choline PET-CT images of esophageal cancer (pre- and post- chemotherapy).;  Perform semi-quantitative analysis of tracer uptake using standard uptake values (SUV) and qualitative analysis using pure visual analysis.|22|NCT01051479|March 2010
1508|Terminated|Rosuvastatin in Treating Women With Cardiovascular Complications Who Are Undergoing Chemotherapy For Breast Cancer||Drug:rosuvastatin;  Other:placebo;  Other:surveyadministration;  Procedure:managementoftherapycomplications|Interventional|Phase 1|Other / NIH|Whether the rate of statin adherence for patients taking chemotherapy is comparable to the rate of adherence found in prior studies (i.e. JUPITER study);  Changes in fasting cholesterol and other patient level characteristics (such as heart rate blood pressure etc);  Ratesofside-effectsinthetwogroups|70|NCT01051401|January 2010
1509|Completed|Improving Muscle for Functional Independence Trial||Behavioral:ResistanceTraining;  Behavioral:ResistanceTraining+Diet|Interventional||Other|Skeletal muscle function (muscle quality and muscle power) and overall physical function (SPPB score);  single-fiber contractile force and power intramyocellular lipid (IMCL) muscle gene and protein expression of interleukin-6 (IL-6) and tumor necrosis factor alpha.|126|NCT01049698|February 2010
1510|Completed|The Effects of Music Therapy on Women&apos;s Anxiety Before and During Cesarean Delivery||Other:Musicgroup;  Other:Nonmusicgroup|Interventional||Other|The intervention of patient-selected music before and after Cesarean delivery will decrease anxiety levels in a patient population undergoing Cesarean delivery.|50|NCT01049477|September 2008
1511|Completed                  Has Results|A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis||Drug:FluocinonideCream0.1%|Interventional|Phase 4|Other / Industry|Change in Investigator Global Assessment of Atopic Dermatitis Severity From Baseline to Day 2/3.;  Change in Investigator Global Assessment of Atopic Dermatitis Severity From Baseline to Day 14.|20|NCT01049243|March 2009
1512|Completed|Investigating Fitness Interventions in the Elderly (INFINITE)||Behavioral:ExerciseOnly;  Behavioral:Exercise+Diet|Interventional||Other|maximal aerobic capacity (VO2max) and functional endurance (400 m walk time);  changes in specific CVD risk factors (inflammatory markers blood lipids blood pressure and glucose tolerance)|180|NCT01048736|October 2009
1513|Completed                  Has Results|Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris||Drug: clindamycin phosphate 1.2% and tretinoin 0.025%;  Drug:clindamycin1%gel;  Drug:tretinoin0.025%cream|Interventional|Phase 4|Other / Industry|Measured Adherence to ZIANA Gel or Generic Topical Clindamycin 1% Gel Each Morning Plus Generic Topical Tretinoin 0.025% Cream Each Evening in Subjects With Mild to Moderate Acne;  The Change (Dynamic Assessment) From Baseline to Week 12 (or End of Treatment) in Total Acne Lesion Count|26|NCT01047189|March 2009
1514|Unknown&nbsp;&#8224;|Pilot Study of Lovaza (Omega 3 Fatty Acids) to Improve Cardiac Antioxidant/Anti-inflammatory Profile Before Cardiac Surgery||Drug:Lovazagroup|Interventional|Phase 4|Other / Industry|Specific Aim 1: To determine if Lovaza treatment reduces markers of inflammation and improves mitochondrial function in atrial myocardium;  Specific Aim 2: To determine if Lovaza treatment alters the biophysical and biochemical organization of cardiac mitochondrial membranes. The following questions will be addressed using the blood and cardiac tissue samples collected as described above:|24|NCT01046604|January 2010
1515|Completed                  Has Results|Reducing Donor Specific Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients (DSA Study)||Drug:MyforticEscalation|Interventional|Phase 4|Other / Industry|Percent Change in Mean Fluorescence Index (MFI) of Donor Specific Antibodies (DSA) With Increasing Doses of Enteric-Coated Mycophenolate Sodium (EC-MPS);  To Assess the Rate of Rejection Infection and Renal Function as Mycophenolic Acid Dose is Increased.|32|NCT01044303|January 2010
1516|Completed                  Has Results|Outlook Quality of Life Intervention Study||Other:LifeCompletion;  Other:AttentionControl|Interventional||U.S. Fed|QUAL-E-PreparationSub-scale;  QUAL-ELifeCompletionSub-scale;  POMSAnxietySub-scale;  CES-D;  FACIT-SP;  FACT-G-SocialSub-scale|221|NCT01044290|January 2011
1517|Completed|Teen CHAT: Improving Physician Communication With Adolescents About Healthy Weight||Behavioral: Web-based intervention targeting MD communication; Summary Report|Interventional||Other / NIH|Physiciancommunication;  SummaryReport;  Adolescent Nutrition Physical Activity and BMI Z-score|684|NCT01040975|September 2009
1518|Completed|En Pareja: A Latino Couples Intervention to Help Expectant Fathers Quit Smoking||Behavioral: couple-based counseling for smoking cessation plus self-help smoking cessation guide;  Behavioral: Guia -a self help smoking cessation guide|Interventional||Other / NIH|seven-daypointprevalencesmokingabstinence;  continued abstinence (no smoking at all in between and including all follow-ups);  prolonged abstinence (continued abstinence after two week grace period with failures counting as smoking seven days in a row or one day in two consecutive weeks)|705|NCT01040949|September 2008
1519|Completed                  Has Results|A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream 2% Formulations||Drug:ButoconazoleNitrateVaginalCream;  Drug:Placebo;  Drug:Gynazole1vaginalcream|Interventional||Industry|The Test of Equivalence Between the Test and Reference Products Was Based on the Therapeutic Cure Rates at Visit 3/Test-of-Cure.;  ClinicalCure;  MycologicalCure|611|NCT01039584|February 2008
1520|Completed|Care Transitions for Complex Patient - Cycle 1 and Cycle 2||Other:Reports;  Other:ReportsandNotices;  Other:Usualcare|Interventional||Other|Emergency department encounter rates among patients in the study population.;  Emergency department encounter rates for low severity diagnoses among all patients.;  Total emergency department encounter rates among patients for whom intervention was appropriate.;  Total emergency department encounter rates among all patients.;  Hospitalization rates among patients for whom intervention was appropriate.;  Hospitalizationratesamongallpatients.;  Hospital readmission rates within 30 days after hospitalization among patients for whom intervention was appropriate.;  Hospital readmission rates within 30 days after hospitalization among all patients.;  Primary care visit rates among patients following an emergency department encounter or hospitalization for whom intervention was appropriate.;  Primary care visit rates among all patients following an emergency department encounter or hospitalization.;  Rates of completion of medically-indicated post hospitalization studies or procedures among patients for whom intervention was appropriate.;  Rates of completion of medically-indicated post hospitalization studies or procedures among all patients.;  Total medical costs among patients for whom intervention was appropriate.;  Totalmedicalcostsamongallpatients.;  Emergency department costs among patients for whom intervention was appropriate.;  Emergencydepartmentcostsamongallpatients.;  Hospitalization costs among patients for whom intervention was appropriate.;  Hospitalizationcostsamongallpatients.;  Outpatient costs among patients for whom intervention was appropriate.;  Outpatientcostsamongallpatients.;  Patient satisfaction among patients for whom intervention was appropriate.;  Patient-reported quality of life among patients for whom intervention was appropriate.;  Provider satisfaction among providers with contact with patients for whom intervention was appropriate.|8422|NCT01039324|December 2009
1521|Completed|p16 Methylation for Smoking Cessation||Behavioral: p16 Methylation and Lung Cancer Education|Interventional||Other / U.S. Fed|To determine patient interest in finding out whether through the testing of p16 methylation in their sputum whether they are at increased or average risk for developing cancer;  To determine the percentage of patients who return their sputum for p16 methylation analysis;  To determine the percentage of patients who complete the 1-month phone interview;  To determine the percentage of patients who complete the 3-month interview;  To determine the percentage of patients who have a positive result for p16 methylation in their sputum indicating they are at higher risk for developing lung cancer|35|NCT01038492|April 2009
1522|Terminated                  Has Results|Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease||Drug:Warfarin;  Drug:Placebo|Interventional|Phase 2|Other / NIH|Effect of Anticoagulation on Pulmonary Artery Systolic Pressure Was Obtained by Doppler Echocardiography;  6-minuteWalkTest;  ThrombinGeneration;  PlateletActivation;  EndothelialActivation;  All-causeMortality;  MajorandMinorBleedingComplications|3|NCT01036802|December 2009
1523|Completed                  Has Results|Randomized Investigation of Chest Pain Diagnostic Strategies||Other: Clinical decision unit care coupled with cardiac MRI|Interventional||Other / NIH|The Composite of Revascularization Re-hospitalization and Recurrent Cardiac Testing Through 90 Days.;  LengthofStay;  AcuteCoronarySyndrome;  Mortality;  StressTesting-relatedAdverseEvent|105|NCT01035047|January 2010
1524|Completed|Study to Evaluate Safety Tolerability Maximum Tolerated Dose (MTD) Efficacy and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies||Drug:CPI-613|Interventional|Phase 1|Other|To determine the safety and MTD of CPI-613 when administered 2x weekly for 3 consecutive weeks.;  To determine PKs of CPI-613 following IV administration.|26|NCT01034475|March 2010
1525|Completed|Mechanisms Underlying Drug-Diet Interactions||Drug:warfarinvitaminKmidazolam|Interventional||Other|AUC;  Cmax|19|NCT01034124|January 2007
1526|Terminated                  Has Results|Memantine and Postoperative Pain||Drug:Memantine;  Drug:Placebo|Interventional|Phase 4|Other|24hrOpioidConsumption;  PainScores;  OpioidRelatedSideEffects;  OpioidRelatedSideEffects:Pruritus;  Hyperalgesia;  PatientSatisfaction;  ChronicPost-surgicalPain|77|NCT01032759|December 2009
1527|Completed|Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors||Drug:Armodafinil;  Other:placebo|Interventional|Phase 2|Other / NIH|Estimate accrual adherence retention and participation of primary brain tumor patients undergoing partial or whole-brain RT who are randomized to receive armodafinil.;  Toxicity as measured by the CTEP active version of the CTCAE;  Fatigue as measured by the FACIT-F and Brief Fatigue Inventory;  Overall quality of life and brain-specific quality of life;  SleepinessasmeasuredbytheEpworthSleepScale;  Cognitive function as measured by the Wake Forest Cognitive Function Battery|54|NCT01032200|August 2010
1528|Completed                  Has Results|Effect of Hypertonic Saline on Mucus Clearance in Children Ages 5-12 With Cystic Fibrosis||Drug:HypertonicSaline;  Drug:Placebo|Interventional||Other / NIH|ChangeinMucociliaryClearanceRate;  FEV1(Spirometry)Change|23|NCT01031706|September 2009
1529|Completed|Quitting Caffeine for Better Glucose Metabolism||Behavioral:Caffeineabstinence|Interventional|Phase 1|NIH|Caffeineabstinence;  HbA1c|25|NCT01030796|December 2009
1530|Completed|Early Childhood Follow-up of Congenital Diaphragmatic Hernia Survivors|||Observational||Other|Persistent medical morbidities and/or neurodevelopmental impairment at school age (ages 4-6).|16|NCT01029665|September 2008
1531|Completed|Multicomponent Cognitive Behavioral Therapy(CBT) for Posttraumatic Stress Disorder (PTSD) and Substance Abuse||Behavioral:CBTandexposuretherapyforPTSD;  Other:TreatmentasUsual|Interventional|Phase 1|Other|ClinicianAdministeredPTSDScale;  AddictionSeverityIndex|45|NCT01029197|August 2009
1532|Completed|Pilot Trial in Sleep Laboratory Setting to Compare the Physiology of Night Time Bladder Function in Subjects With Overactive Bladder (OAB) Versus Subjects That Have Insomnia and Healthy Normal Subjects||Procedure:cystometry;  Procedure:polysomnography|Observational|Phase 4|Industry|Number and proportion of voids associated with urgency;  Number and proportion of voids associated with Detrusor Overactivity episodes within 10 minutes prior to the polysomnography (PSG) awakenings;  TimefromPSGawakeningtoeachvoidinminutes|26|NCT01029015|November 2006
1533|Terminated|Open Label of Thalidomide in Treatment of Women With Chronic Pelvic Pain Associated With Endometriosis||Drug:Thalidomide|Interventional|Phase 1|Other / Industry|painreport|9|NCT01028781|October 2006
1534|Unknown&nbsp;&#8224;|Oxytocin Treatment of Schizophrenia||Drug:intranasaloxytocinspray;  Other: formulated solution containing all ingredients as Syntocinon Spray except for oxytocin|Interventional||Other|PANSStotalandsubscores;  Social cognition skill task performance and ratings of social functioning|80|NCT01028677|November 2009
1535|Terminated|Thermal Ablation Combined With External Beam Radiation Therapy for Patients With Inoperable Non-Small Cell Lung Cancer &gt; 3.5 cm in Size||Radiation: thermal ablation with external beam radiation|Interventional|Phase 1|Other|Assess the initial safety of the combination of interventional ablation and external beam radiotherapy including acute and late toxicity (90 days).|1|NCT01028612|February 2010
1536|Active not recruiting|Time to Conceive: A Study of Fertility||Other:Nointervention|Observational||Other / NIH|Conception|850|NCT01028365|April 2008
1537|Withdrawn|Impact of Maternal-infant Therapeutics on Safety Mortality and Disability|||Observational||Other||0|NCT01028183|August 2010
1538|Completed|Intensive Computerized Brain Training (ICBT) in Youth With Early Onset Psychosis (EOP)||Other:ICBTProgram|Interventional||Other / NIH|Feasibility Tolerability and Acceptability of Intensive Computerized Brain Training (ICBT) in youth with EOP.|35|NCT01027962|October 2009
1539|Active not recruiting|Donor Lymphocyte Infusion After Alternative Donor Transplantation||Biological:Infusionofdonorlymphocytes|Interventional|Phase 1 / Phase 2|Other|Immunerecoveryfollowingtransplantation;  IncidenceandseverityofGVHD;  Determine incidence of infection and EBV-related post-transplant lymphoproliferative disease (PTLD)|38|NCT01027702|August 2009
1540|Completed|Impact of Host Iron Status and Iron Supplement Use on Erythrocytic Stage of Plasmodium Falciparum||DietarySupplement:IronSupplement|Interventional||Other||45|NCT01027663|November 2009
1541|Recruiting|The Savella Pregnancy Registry|||Observational||Other / Industry|The primary objective is to estimate the prevalence of major congenital anomalies among off-springs of women exposed to Savella during pregnancy.;  Estimate the prevalence of spontaneous abortions stillbirths induced abortions minor congenital anomalies and adverse pregnancy outcomes.|350|NCT01026077|November 2009
1542|Completed|Dietary Patterns and Cardiovascular (CVD) Risk in Spinal Cord Injury (SCI) Factors In Individuals With Chronic Spinal Cord Injury|||Observational||Other||100|NCT01025609|September 2009
1543|Completed                  Has Results|A Trial Comparing Mini-posterior Approach and Direct Anterior Approach||Procedure: Mini-Posterior surgical approach for total hip arthroplasty;  Procedure: Direct Anterior surgical approach for total hip arthroplasty|Interventional||Other|NumberofDaysforDiscontinueAssistiveDevices;  HarrisHipScore;  Western Ontario and McMaster Universities Arthritis Index (WOMAC);  AbductionAngle;  AnteversionAngle;  WOMAC|66|NCT01024309|November 2009
1544|Completed|Safety Metabolism and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis C||Drug:silymarin;  DietarySupplement:greenteaextract(EGCG)|Interventional|Phase 1 / Phase 2|Other / NIH|To assess the safety and tolerability of coadministered silymarin and green tea extract at different doses in patients with chronic hepatitis C.;  To characterize the antioxidant effects of silymarin and EGCG administered alone or in combination.|60|NCT01018615|November 2009
1545|Completed|Trial of a Water Beverage Intervention for Promoting Modest Weight Reduction in Free Living Adults||Behavioral:DietarysubstitutionA;  Behavioral:DietarySubstitutionB;  Behavioral:HealthyChoices|Interventional||Other|Weightchange;  urinespecificgravity;  fastingglucose|318|NCT01017783|March 2008
1546|Terminated                  Has Results|Panitumumab and Irinotecan for Malignant Gliomas||Drug:Irinotecan;  Drug:Panitumumab|Interventional|Phase 2|Other / Industry|6-monthProgression-freeSurvival(PFS);  One-YearOverallSurvival;  Safety of Panitumumab in Combination With Irinotecan;  Effect of Panitumumab in Combination With Irinotecan on Corticosteroid Dose;  Relationship Between Epidermal Growth Factor Receptor (EGF-R) Mutational Analysis and Efficacy or Toxicity;  ObjectiveResponseRate;  MedianOverallSurvival(OS)|16|NCT01017653|February 2010
1547|Completed                  Has Results|Optimal Planning Target Volume With Stereotactic Radiosurgery||Radiation:StereotacticRadiosurgery|Interventional||Other|12-monthLocalControlRate;  RateofRadionecrosisatSRSTreatmentSite;  12MonthRateofDistantBrainMetastases;  MedianOverallSurvival;  Quality of Life at 3 Months After SRS as Measured by the Functional Assessment of Cancer Therapy-Brain (FACT-Br);  Cognition at 3 Months After SRS as Measured by the Mini-Mental State Exam (MMSE);  Cognition at 3 Months After SRS as Measured by the Trail Making Test (TMT);  RateofDeathDuetoNeurologicCauses|49|NCT01017497|December 2009
1548|Terminated                  Has Results|Vyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivity Disorder (ADHD) and Obesity||Drug:Lis-dexamphetamine|Interventional|Phase 4|Other / Industry|Pre and Post Study Fasting Blood Sugar and Two Hour Post Prandial.|14|NCT01017263|December 2009
1549|Completed                  Has Results|Radiosurgery and Avastin for Recurrent Malignant Gliomas||Radiation:StereotacticRadiosurgery(SRS);  Drug:Bevacizumab|Interventional||Other / Industry|CentralNervousSystem(CNS)Toxicity;  Progression-freeSurvival(PFS);  RadiographicResponseatMonth2;  OverallSurvival(OS);  Change in Quality of Life From Baseline to 2 Months After Stereotactic Radiosurgery (SRS);  Cognition at 2 Months After Stereotactic Radiosurgery (SRS)as Measured by the Mini-Mental State Exam ( MMSE);  Cognition at 2 Months After Stereotactic Radiosurgery (SRS) as Measured by the Trail Making Test (TMT);  Performance Status at 2 Months After Stereotactic Radiosurgery (SRS);  Steroid Usage After Stereotactic Radiosurgery (SRS);  Dynamic Contrasted-enhanced MRI (DCE-MRI) Perfusion Indices at 1 Week After Stereotactic Radiosurgery (SRS): K-trans;  Dynamic Contrasted-enhanced MRI (DCE-MRI) Perfusion Indices at 2 Months After Stereotactic Radiosurgery (SRS): K-trans;  Dynamic Contrasted-enhanced MRI (DCE-MRI) Perfusion Indices at 1 Week After Stereotactic Radiosurgery (SRS): AUC;  Dynamic Contrasted-enhanced MRI (DCE-MRI) Perfusion Indices at 2 Months After Stereotactic Radiosurgery (SRS): AUC;  Dynamic Contrasted-enhanced MRI (DCE-MRI) Perfusion Indices at 1 Week After Stereotactic Radiosurgery (SRS): EVF;  Dynamic Contrasted-enhanced MRI (DCE-MRI) Perfusion Indices at 2 Months After Stereotactic Radiosurgery (SRS): EVF;  Dynamic Contrasted-enhanced MRI (DCE-MRI) Perfusion Indices at 1 Week After Stereotactic Radiosurgery (SRS): ADC;  Dynamic Contrasted-enhanced MRI (DCE-MRI) Perfusion Indices at 2 Months After Stereotactic Radiosurgery (SRS): ADC|15|NCT01017250|December 2009
1550|Terminated                  Has Results|Dexmedetomidine Sedation With Third Molar Surgery||Drug:Dexmedetomidine;  Drug:Midazolam;  Drug:Ketamine|Interventional|Phase 4|Other|Amnesia: Lack of Picture Recall Shown Prior to Sedation.;  Amnesia: Lack of Recall One Day After Surgery of The Picture That Was Shown Prior to Sedation.;  Amnesia: Lack of Picture Recall Following Dexmedetomidine Infusion Plus Midazolam.;  Amnesia: Lack of Recall One Day After Surgery of The Picture That Was Shown Following Dexmedetomidine Infusion Plus Midazolam.;  Amnesia: Lack of Picture Recall Shown 15 Minutes Into Surgery;  Amnesia: Lack of Recall One Day After Surgery of The Picture That Was Shown 15 Minutes Into Surgery.;  Amnesia: Lack of Picture Recall Shown 30 Minutes Into Surgery;  Primary Title: Amnesia: Lack of Recall One Day After Surgery of The Picture That Was Shown 30 Minutes Into Surgery.;  Amnesia: Lack of Picture Recall at Surgery End Time.;  Amnesia: Lack of Recall One Day After Surgery of The Picture That Was Shown at Surgery End Time.;  RespiratoryParameters:RespiratoryRate;  RespiratoryParameters:OxyhemoglobinSaturation;  RespiratoryParameters:End-tidalCarbonDioxide;  MeanArterialBloodPressure;  HeartRate;  SurgeonSatisfactionWithSedationTechnique;  PatientSatisfactionWithSedationTechnique;  RamseySedationScaleScore;  BispectralIndexScore(BIS)|18|NCT01017237|July 2009
1551|Terminated                  Has Results|Moderate to Persistent Asthma in the Obese Subject||Drug:Montelukast;  Other:Sugarpill|Interventional|Phase 4|Other|Determine the Effect of Montelukast / Moderate Dose ICS Versus High Dose ICS on Asthma Control as Measured by the Asthma Control Questionnaire.;  Serum Adiponectin Leptin Tumor Necrosis Alpha (TNF-&#945;) and Interleukin 6 (IL6) Levels;  Post Bronchodilator Forced Expiratory Volume in 1 Second (FEV1);  Change in Trends in Asthma Control Questionnaire (ACQ ACTQ) Scores Over Duration of the Study;  AsthmaExacerbation;  SputumCellCountsandDifferentials|38|NCT01016847|January 2010
1552|Completed|Muscadine Grape Seed Supplementation and Vascular Function||Dietary Supplement: Muscadine grape seed supplement|Interventional||Other|BrachialArteryFlowmediateddilation;  Plasma markers of inflammation and anitoxidant capacity|50|NCT01011517|June 2007
1553|Terminated|Study of Immunotoxin MR1-1||Biological:MR1-1|Interventional|Phase 1|Other / NIH|Maximumtolerateddoseanddoselimitingtoxicity;  DiseaseProgression|9|NCT01009866|November 2006
1554|Terminated|The Effect of Levocetirizine on Inflammatory Mediators in Dermatographism||Drug:levocetirizineorplacebo|Observational||Other / Industry|To evaluate the inhibitory effect of levocetirizine in the induction of dermatographism. To assess the levels of key inflammatory mediators and proteases in the skin during dermatographic reaction using microdialysis.|11|NCT01008592|April 2009
1555|Unknown&nbsp;&#8224;|Wound Healing of Incisional Wounds for Bilateral Hernia Repair||Drug:Dermabond;  Drug:HydrogenPeroxideOxygenproducinggel|Interventional|Phase 1|Other|Wound infection wound dehiscence allergic reaction to gel components width elevation color marks and general appearance measured at clinic visits.|40|NCT01008111|October 2009
1556|Withdrawn|TRAUMA HELP: Healing and Analgesia With Propranolol||Drug:Propranolol;  Drug:PropranololER;  Drug:Sugarpills|Interventional|Phase 2|Other|Daily average pain score (0-10 numeric rating pain score recorded daily from patient) after study drug initiation.;  Sleepquality;  Anxietysymptoms|0|NCT01007084|October 2009
1557|Active not recruiting|Tetracaine Combined Spinal Epidural (CSE) Versus Bupivacaine CSE||Drug:Tetracaine;  Drug:Bupivacaine|Interventional||Other|Spinalanalgesicduration|60|NCT01005459|August 2009
1558|Active not recruiting                  Has Results|Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma||Drug:Bevacizumab;  Drug:Temozolomide;  Radiation:RadiationTherapy(XRT);  Drug:Topotecan|Interventional|Phase 2|Other / Industry|6-monthProgression-freeSurvival;  OneandTwoYearOverallSurvival;  MedianOverallSurvival;  Number of Patients Experiencing a Central Nervous System (CNS) Hemorrhage or a Systemic Hemorrhage;  Number of Patients Experiencing a Greater Than or Equal to Grade 4 Hematologic or a Greater Than or Equal to Grade 3 Non-hematologic Toxicity;  MedianProgression-freeSurvival|80|NCT01004874|December 2009
1559|Completed|Physiological Effects of Yogurt With Bb12 in Subjects With GI Symptoms Strointestinal Symptoms||Other:Aprobioticyogurtwithinulin;  Other:Acidifieddairysnack|Interventional||Other / Industry|The primary outcome measures will be the whole gut (WGTT) and colonic transit time (CTT) as assessed by SmartPill&#8482;;  Secondary outcome measures (a) Stool frequency (b) Stool consistency (c) Gastric emptying and small bowel transit time|40|NCT01004484|June 2009
1560|Terminated|Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen||Drug:Baclofen;  Drug:PlaceboComparator:Placebo|Interventional|Phase 4|Other|Efficacy of baclofen vs. placebo on dysfunctional voiding as measured with uroflometry and EMG; patients&apos; symptoms score questionnaires and diaries.;  Efficacy of baclofen vs. placebo on the external anal sphincter muscle dysfunction via patient symptoms and questionnaire.;  The safety of baclofen in patients with dysfunctional voiding (urinary and defecatory).|12|NCT01003249|September 2009
1561|Active not recruiting|Bariatric Outcomes Longitudinal Database (BOLD)|||Observational||Other|Improvementofcomorbidities;  Mortalityweightlosssurgicalcomplications|600000|NCT01002352|June 2007
1562|Active not recruiting|Nipple Sparing Mastectomy - Cosmetic Outcomes||Procedure:NippleSparingMastectomy|Interventional||Other|CosmeticAppearance;  PatientSatisfaction;  Presence of tumor in nipple areolar complex frozen section;  Presence of tumor in nipple areolar complex permanent histology;  Complications;  LocalRecurrence|75|NCT01002014|January 2009
1563|Completed                  Has Results|Internet-Based Smoking Cessation for Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) Veterans||Behavioral:Internet-based;  Behavioral:StandardClinic-Based|Interventional||U.S. Fed|The Impact of an Internet Intervention on Rates of Abstinence From Cigarettes (Self-reported 7-day Point Prevalent Abstinence)|413|NCT01001546|May 2010
1564|Unknown&nbsp;&#8224;|Identifying Changes in Blood (Potential Biomarkers) in Individuals With Drug-Induced Liver Injury|||Observational||Other||25|NCT01000766|September 2009
1565|Unknown&nbsp;&#8224;|Establishment of Cell Culture Systems From Discarded Operating Room Tissue|||Observational||Other / U.S. Fed||1000|NCT01000077|February 2009
1566|Completed|Shoulder Injury Prevention Program in Swimmers||Procedure:ShoulderStrengthening|Interventional|Phase 2|Other|ShoulderandScapularStabilizerStrength;  ScapularKinematics;  ShoulderROM;  PosturalAssessment;  Widthofsubacromialspace|48|NCT00998777|September 2009
1567|Completed|Study of Parenting Intervention to Prevent Child Obesity||Behavioral:ParentingProgram|Interventional||Other / NIH|Child percent body fat after the 8-month intervention period controlling for baseline percent body fat. Percent body fat will be calculated using Dezenberg&apos;s equation which takes into account child height weight gender race and tricep skinfolds.;  Child BMI and Child BMI z-score based on measured child height weight and parent-reported date of birth;  ParentBMIbasedonmeasuredheightandweight;  Parent and child dietary intake measured with 3 unannounced dietary recalls collected via telephone interview (will not include foods eaten by child while outside of parent&apos;s care);  Parent and child physical activities assessed via 7-days of accelerometer monitoring (using the AciGraph GT3X monitor programed with 60-s epochs for adults and 15-s epochs for children);  Parenting-related stress assessed with the Parental Stress Index - Short Form (Abidin 1995);  Autonomous motivation to change behaviors (parenting practices feeding practices and physical activity practices) will be assessed using modified versions of the Treatment Self-Regulation Questionnaire (Williams GC 1996);  Self-efficacy for general parenting will be assessed with the Parenting Sense of Competence Scale (Johnston C 1989);  Self-efficacy for implementing healthy nutrition and physical activity practices will be assessed with an instrument recently developed by the PI.;  Parents&apos; perceived social support and connectedness with regard to positive parenting and healthy feeding and physical activity practices will be assessed using modified versions of the Social Provisions Scale (Cutrona 1987);  The Alabama Parenting Questionnaire - Preschool Revision (Clerkin 2007)will be used to assess general parenting practices specifically the use of positive parenting inconsistent parenting and punitive parenting;  Difficulties in Emotion Regulation (Gratz 2004) will be used to assess parental skills at regulating their own emotions;  Coping with Children&apos;s Negative Emotions (Fabes 1990) will be used to assess parental skill at helping the child deal with and manage his/her negative emotions;  Confusion Hubbub and Order Scale (Matheny 1995) will be used to assess the degree of order versus confusion in the home environment;  The Parenting Convergence Scale (Ahrons 1981) will be used to assess parental skill with coparenting;  The Caregiver Feeding Style Questionnaire (Hughes SO 2005) will be used to assess the two dimensions of parenting: demandingness and responsiveness as they relate to feeding practices;  The Parental Feeding Style Questionnaire (Wardle 2002) will be used to assess parents&apos; use of emotional feeding instrumental feeding encouraging to eat and control over eating;  Nine subscales from the Comprehensive Feeding Practices Questionnaire (Musher-Eizenman 2007) will be used to assess child control encouraging balance/variety involvement modeling monitoring pressure to eat restriction for health or weight control;  One sub-scale from the Preschooler Feeding Questionnaire (Baughcum 2001) will be used to assess structure during feeding interactions;  Two items slightly modified from the Child Feeding Questionnaire (Birch 2001) will be used to determine parent perceptions of child weight and concern about child becoming overweight;  A variety of newly developed items drawn from the literature will be used to assess parent practices around child physical activity|324|NCT00998348|July 2009
1568|Completed|Study to Evaluate the Effect of a Very Low Carbohydrate Diet on Gastroesophageal Reflux Disease||Other:Diet-verylowcarborlowfat|Interventional||Other / Industry|Change in distal esophageal acid exposure after initiating a very low carbohydrate diet compared to the decrease seen after initiating a low fat diet;  The change in serum levels of pro-inflammatory cytokines after initiating a very low carbohydrate diet compared to a traditional low fat diet as measured with blood samples.|40|NCT00998244|September 2009
1569|Completed|A Pilot Study of Early Postpartum Intrauterine Contraception||Device:MirenaIntrauterineContraceptiveSystem|Interventional|Phase 4|Other|IUDexpulsion;  Feasibilityofenrollment|40|NCT00997932|June 2009
1570|Completed                  Has Results|Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers||Drug:PA32540|Interventional|Phase 3|Industry|Number of Subjects Monitored for Long-term Safety of PA32540;  Most Frequent Treatment Emergent Adverse Events Leading to Study Drug Discontinuation|380|NCT00995410|October 2009
1571|Completed|Yoga or Educational Wellness Class for Women With Stage I Stage II or Stage III Breast Cancer Undergoing Chemotherapy||Behavioral:Yoga;  Behavioral:Education|Interventional|Phase 2|Other / NIH|Studyparticipationrate;  Fatigueatbaselineandatweeks510and14;  Depressive symptoms at baseline and at weeks 5 10 and 14;  Sleep quality at baseline and at weeks 5 10 and 14;  Distressatbaselineandatweeks510and14;  Treatment-related symptoms at baseline and at weeks 5 10 and 14;  Quality of life at baseline and at weeks 5 10 and 14;  Feedback on the yoga intervention from patients and yoga teachers|40|NCT00994279|October 2009
1572|Withdrawn|Adjunctive Pregnenolone in Post-Traumatic Stress Disorder (PTSD) and Depression in Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) Veterans||Drug:pregnenolone;  Drug:placebo|Interventional|Phase 2|U.S. Fed|ClinicianAdministeredPTSDScale(CAPS)|0|NCT00993629|January 2010
1573|Completed|A Program to Increase Physical Activity Among Blacks||Behavioral:Faith-based;  Behavioral:Non-faith-based|Interventional||Other / NIH|Comparing the efficacy of faith-based vs non-faith-based to a control condition in increasing daily physical activity measured as steps/day.|496|NCT00991731|July 2009
1574|Completed|The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage||Drug:Topicaloxygen;  Drug:placebo|Interventional|Phase 2|Industry|skingradingevaluationofphotodamage;  stratumcorneumhydration(skincapacitance);  bioinstrumental assessment of skin &quot;melanin&quot; lightening and lesional erythematous sites;  bioinstrumental assessment of skin texture scaliness (desquamation);  punch biopsy histopathologic examination (H&amp;E and immunohistochemistry for Aquaporin 3 and Filaggrin);  RT-PCR collagenase  and hypoxia-inducible factor-1 alpha;  productperformance|49|NCT00991198|September 2009
1575|Completed                  Has Results|Cerebrospinal Fluid (CSF) Pharmacokinetics of Antimicrobials in Children|||Observational||Other|CSF:SerumRatioofVancomycin|8|NCT00991185|July 2009
1576|Completed                  Has Results|The Effect of Depth of Anesthesia as Measured by Bispectral Index (BIS) on Emergence Agitation in Children||Other:Depthofanesthesia|Interventional||Other|Peak Pediatric Assessment of Emergence Delirium (PAED) Score Within the First 30 Minutes of Reaching the Recovery Room (Post-Anesthesia Care Unit);  TimetoEmergenceFromAnesthesia;  Pain Score: Faces Legs Activity Cry and Consolability (FLACC)|40|NCT00990769|September 2009
1577|Completed|Feasibility and Effects of Preventive Home Visits for Older Adults||Behavioral:Preventivehomevisit;  Behavioral:minimalintervention|Interventional||Other|functionalability;  lifesatisfaction|110|NCT00985283|January 2008
1578|Completed|Effects of Aliskiren on Patient With Heart Failure and a Normal Ejection Fraction||Drug:aliskiren;  Drug:placebo|Interventional|Phase 4|Other / Industry|The primary objective of this study is to determine whether treatment with aliskiren (300 mg) compared to placebo will improve treadmill exercise time in older (age &#8805; 55 years) patients with heart failure and normal ejection fraction (HFNEF).;  Determine whether aliskiren (300mg) compared to placebo will improve other measures of exercise performance including peak exercise oxygen consumption (VO2peak) ventilatory anaerobic threshold (VAT) and 6-minute walk distance.;  Determine whether treatment with aliskiren (300 mg) compared to placebo will improve left ventricular diastolic function assessed via tissue Doppler imaging (early diastolic mitral annular velocity);  Evaluate the safety and tolerability of aliskiren in older patients with HFNEF|52|NCT00982033|July 2009
1579|Completed|Centers for Education on Research and Therapeutics - Heart Failure: Targeted Intervention Study||Behavioral:Intensivequalityimprovementtools|Interventional||Other / U.S. Fed|Improvement in the overall opportunity-based composite of measures eligible for intervention (absolute score difference compared to the control arm) based on the existing Get With the Guidelines Heart Failure Achievement Measures and Quality Measures.;  Improvement in Defect Free (all or none) score based on the combined Get With the Guidelines Heart Failure Achievement and Quality Measures;  Improvement in scores of each individual Get With the Guidelines Heart Failure Achievement and Quality Measure;  Improvement in length of stay and in-patient mortality.|147|NCT00979264|March 2010
1580|Completed|Clinical Decision Support for Medication Management and Adherence||Other:MedicationManagementreport;  Other:Caremanageremailnotices|Interventional||Other / U.S. Fed|Rates of aggregate adherence by study group to all applicable pharmacotherapy rules during the study period.;  Rates of adherence to pharmacotherapy rules for a specific therapeutic drug class;  Rates of adherence to pharmacotherapy rules for a specific IOM priority condition.;  Rates of adherence to applicable pharmacotherapy rules 6 months after an intervention was first initiated or could have been initiated for the control arm.;  Rates of adherence by drug class to applicable pharmacotherapy rules 6 months after an intervention was first initiated or could have been initiated for the control arm.;  Rates of adherence by IOM condition to applicable pharmacotherapy rules 6 months after an intervention was first initiated or could have been initiated for the control arm.;  The proportion of email notices that were followed up by a documented care management encounter within 30 days.;  The proportion of email notices that were followed up by a completed clinic encounter within 60 days.;  Resource use and medical costs associated with the interventions and their delivery as well as direct healthcare costs (inpatient and outpatient).;  Provider satisfaction measured using standard usability survey instruments.;  Outpatientencounterrates.;  Emergencydepartmentencounterrates.;  Inpatienthospitalizationrates.|5000|NCT00979225|September 2009
1581|Completed|Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma||Drug:AC480|Interventional|Phase 1|Other / Industry|Intratumoral and plasma pharmacokinetics of AC480 will be obtained on surgical tissue specimens from 5 patients treated pre-operatively with AC480.;  Anti-proliferativeeffectofAC480byFDG-PET;  IntratumoralandplasmapharmacodynamicsofAC480;  6-monthprogression-freesurvival(PFS);  Radiographicresponse;  Adverseeventandtoxicitymonitoring|5|NCT00979173|November 2009
1582|Completed|The Arthritis Diet and Activity Promotion Trial||Behavioral:DietaryWeight-loss;  Behavioral:Exercise|Interventional||Other|self-reportedphysicalfunction(WOMACscale);  6-minutewalkingdistance;  timedstairclimbing;  weight-loss;  self-reportedpain;  progression of knee osteoarthritis measured radiographically;  chronic inflammation measured according to CRP IL-6 IL-6 soluble receptor TNF-alpha TNF alpha receptors 1 and 2;  totalmortality|318|NCT00979043|November 1997
1583|Completed                  Has Results|Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme||Drug:Avastin;  Drug:Temozolomide;  Drug:Irinotecan|Interventional|Phase 2|Other / Industry|ResponseRate;  Incidence and Severity of Central Nervous System (CNS) Hemorrhage and Systemic Hemorrhage;  Incidence of Grade &#8805; 4 Hematologic and &#8805; Grade 3 Non-hematologic Toxicities;  MedianProgression-freeSurvival(PFS);  MedianOverallSurvival(OS)|41|NCT00979017|November 2009
1584|Completed|Duke Urology Database and Specimen Bank|||Observational||Other||87820|NCT00978991|January 1988
1585|Completed|Tailored Case Management for Diabetes and Hypertension||Behavioral: Tailored telephone-based case management;  Behavioral:NurseEducation|Interventional||Other / NIH|BloodPressure;  HemoglobinA1c|377|NCT00978835|May 2008
1586|Terminated                  Has Results|Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)||Drug:RAD001;  Drug:LBH589;  Drug:Doublet(RAD001andLBH589)|Interventional|Phase 2|Other / Industry|OverallResponseRate;  Assessment of Association Between Observed Response to RAD001 and LBH589 and the Response Predicted by Molecular Signatures Developed in Our Pre-clinical Model;  SummaryofAdverseEvents(AEs);  Distribution of Change Across Time of mTOR and HDAC-I Inhibition From Baseline Until After the 1st 2 Cycles of Study Drug in Patients Who Received LBH and RAD.;  Evaluate the Association of Observed Response to the Doublet With the Response Predicted by Molecular Signatures for Activated B Cell Like (ABC) DLBCL and for Germinal Center B Cell Like (GCB) DLBCL.|50|NCT00978432|February 2012
1587|Terminated                  Has Results|Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome||Drug:Droxidopa|Interventional|Phase 2|Industry|PatientGlobalImpressionofImprovement|3|NCT00977171|July 2010
1588|Completed|Standardized Rehabilitation for Intensive Care Unit (ICU) Patients With Acute Respiratory Failure||Other:StandardizedRehabilitation;  Other:UsualCare|Interventional||Other|To determine whether standardized rehabilitation therapy will decrease hospital length of stay.|300|NCT00976833|October 2009
1589|Completed|Lowering Salt Intake in Chronic Kidney Disease: A Pilot Randomized Crossover Trial||DietarySupplement:LowSaltDiet;  DietarySupplement:UsualSaltDiet|Interventional||Other|Primary Outcome: Change in volume status (intracellular extracellular volume and total body water) as measured by BIA using both whole body and segmental techniques|35|NCT00974636|May 2009
1590|Completed|Herbal Therapy for Subcutaneous Injection Site Reactions in Multiple Sclerosis||Other:Bach&apos;sRescueRemedyCream;  Other:PlaceboCream|Interventional||Other / Industry|Significant decrease in time and size of redness based on daily measure of skin site reactions using herbal cream compared to placebo cream.;  Participants will indicate how the herbal cream has made a difference to their quality of life based on a qualitative description of effects of skin site reactions before herbal cream and following use of herbal cream|60|NCT00972062|June 2009
1591|Active not recruiting|T-cell Depleted Alternative Donor Transplantation||Device:CliniMACS&#174;(Tcelldepletion)|Interventional|Phase 2|Other|DeterminerateofsevereGVHD.;  Evaluatetherateofengraftment;  Evaluatepost-transplantinfections;  Evaluate rate of EBV-related post transplant lymphoproliferative disorder (PTLD);  Evaluatepost-transplantleukemiarelapse;  Evaluatetransplant-relatedmortality;  Evaluatetransplant-relatedtoxicities;  Evaluateoverallsurvival;  Monitor device performance: purity of selected product yield of CD34+ cells CD3+ cell depletion viability and sterility.|53|NCT00968864|August 2009
1592|Completed|A Comparison of Different Ventilation Strategies in Children Using the Proseal&#8482; Laryngeal Mask Airway||Procedure:Spontaneousventilation;  Procedure:PressuresupportVentilation;  Procedure:Pressurecontrolventilation|Interventional||Other|Differences in end-tidal carbon dioxide and tidal volume compared between the spontaneous ventilation and pressure support ventilation groups.;  Differences in respiratory rates between spontaneous ventilation and pressure support ventilation groups.;  Mean values of respiratory rate compared between the spontaneous ventilation and pressure control ventilation groups.;  Mean values of respiratory rate compared between pressure support ventilation and pressure control ventilation groups.|33|NCT00966433|August 2009
1593|Unknown&nbsp;&#8224;|Breastfeeding and Exercise for Healthy Infants and Postpartum Moms Too!||Other:Exerciseandweightlossintervention|Interventional||Other|BoneMineralDensity;  BodyComposition|44|NCT00966381|October 2008
1594|Completed|Translating Dietary Trials Into the Community||Behavioral:DASHdiet;  Behavioral:DelayedIntervention|Interventional||Other / NIH|Dietarychangefrombaseline.;  Participation;  Bloodpressure|25|NCT00964483|January 2010
1595|Completed|Exercise Dose-Response Effects in Prediabetes||Behavioral:AerobicExercise;  Behavioral:ExerciseandDiet|Interventional||Other / NIH|FastingPlasmaGlucose;  MeasuresofGlucosecontrol|288|NCT00962962|July 2009
1596|Completed                  Has Results|A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers||Drug:PA32540;  Drug:ECAspirin325|Interventional|Phase 3|Industry|Number of Participants With Gastric Ulcer Confirmed by Endoscopy(EC) Aspirin 325 mg;  The Number of Participants With Gastric and/or Duodenal Ulcers;  TheNumberofSubjectsWith&quot;TreatmentSuccess&quot;;  The Number of Participants Discontinuing From the Study Due to NSAID-Associated Upper GI Adverse Events;  The Number of Participants With Heartburn Resolution at 6 Months ie no Heartburn Symptoms During the Last 7 Days Prior to the Visit|530|NCT00961350|October 2009
1597|Completed|Evaluating the Pharmacokinetics of 400 mg Oral Dose of Raltegravir in HIV-Infected Pre-Menopausal Women|||Observational||Other / Industry|To describe the pharmacokinetics of raltegravir in cervicovaginal secretions as compared to blood plasma at steady-state in six HIV-positive women.|6|NCT00961272|July 2009
1598|Completed                  Has Results|Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE)||Drug:inhaled/swallowedbudesonide;  Drug:viscous/swallowedbudesonide|Interventional||Other / Industry|TissueEosinophilCounts;  AdrenalInsufficiency|25|NCT00961233|October 2009
1599|Completed                  Has Results|Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers||Drug:PA32540;  Drug:EC-Aspirin325mg|Interventional|Phase 3|Industry|Number of Participants With Gastric Ulcer Confirmed by Endoscopy;  The Number of Participants With Gastric and/or Duodenal Ulcers;  TheNumberofSubjectsWith&quot;TreatmentSuccess&quot;;  The Number of Participants Discontinuing From the Study Due to NSAID-Associated Upper GI Adverse Events;  The Number of Participants With Heartburn Resolution at 6 Months i.e. no Heartburn Symptoms During the Last 7 Days Prior to the Visit|519|NCT00960869|October 2009
1600|Active not recruiting|Exercise Intolerance in Elderly Patients With Diastolic Heart Failure||Behavioral:Exercise;  DietarySupplement:DietaryIntervention;  Behavioral:Dietandexercise;  Other:AttentionControl|Interventional||Other / NIH|Exercisecapacity;  Body and thigh muscle composition Quality of Life|100|NCT00959660|February 2009
1601|Completed|Comparison of Three Cannulas for Hysterosalpingography||Procedure:HSGwithacorn-tippedcannula;  Procedure:HSGwithcervicalvacuumcup;  Procedure:HSGwithballooncatheter|Interventional||Other|painscores;  thetotaldurationoftheprocedure;  directfluoroscopictime;  ratesofvasovagalreaction;  diagnosticqualityofimagesobtained|114|NCT00956774|February 2009
1602|Completed|Assessment of Postural Orientation and Equilibrium In Early Amyotrophic Lateral Sclerosis (ALS)|||Observational||Other|SOTequilibriumscoresonconditions1-6.;  MSS on conditions 1-6 Weight Symmetry Score on conditions 1-6 DGI score TUG score POMA-B score|35|NCT00956501|February 2009
1603|Completed|Supported Treadmill Ambulation Training (STAT) for Patients Diagnosed With Amyotrophic Lateral Aclerosis||Behavioral:TreadmillExercise|Interventional|Phase 1 / Phase 2|Other|TwentyFiveFootWalkTest(25FWT);  TheSix-MinuteWalkTest(6MWT);  Fatigueseverityscale(FSS);  Musclestrength;  ALSfunctionalratingscale(ALSFRS-R);  VitalCapacity;  BeckDepressionInventory(BDI)|9|NCT00956488|September 2008
1604|Completed                  Has Results|Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)||Drug:bevacizumabandCPT-11andCarboplatin|Interventional|Phase 2|Other|6MonthProgression-freeSurvival;  ObjectiveResponseRate;  MedianProgressionFreeSurvival(PFS);  MedianOverallSurvival(OS);  Safety of Bevacizumab (Avastin) in Combination With Irinotecan and Carboplatin|104|NCT00953121|September 2009
1605|Completed|Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer||Biological:dHER2+AS15ASCI;  Drug:Lapatinib|Interventional|Phase 1 / Phase 2|Other / Industry|The safety of dHER2+AS15 ASCI when administered in combination with Lapatinib measured by dose limiting toxicity.;  The specific humoral and cellular immune response induced by the dHER2+AS15 ASCI upon co-administration of Lapatinib|12|NCT00952692|July 2009
1606|Completed                  Has Results|A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion||Device: fluocinolone acetonide (Retisert Implant Bausch and Lomb)|Interventional||Other / Industry|Change From Baseline in Visual Acuity Using Early Treatment Diabetic Retinopathy Study (ETDRS) Charts;  Improvement in Macular Edema on Optical Coherence Tomography and Color Photos|29|NCT00952614|October 2002
1607|Completed|Targeted Feedback Reports to Improve Acute Coronary Syndromes (ACS) Care||Behavioral:TargetedFeedbackReports;  Behavioral:TargetedFeedbackReport|Interventional||Other / U.S. Fed|The primary outcome is improvement in the overall composite of all metrics eligible for intervention regardless of their selection as targets.;  The secondary outcome is improvement in the composite of targeted metrics.|149|NCT00952250|February 2009
1608|Completed                  Has Results|Safety and Efficacy Study of Duet TRS||Device:DuetTRS|Interventional||Industry|IncidenceofAdverseEvents.;  OperatingRoom(OR)Time;  LengthofHospitalStay;  IncidenceofStapler&apos;Misfires&apos;|29|NCT00950872|November 2009
1609|Terminated                  Has Results|Motorized Continuous Cold Therapy Versus Standard Post-op Icing Protocol for Two Foot and Ankle Procedures||Device:Iceman&#174;ColdTherapyunit(djOrtho);  Other:Ice|Interventional|Phase 4|Other / Industry|VisualAnalogScale(VAS)PainScores;  NarcoticPainMedicationUsage;  PatientSatisfaction;  SurgicalComplications;  PostoperativeComplications|36|NCT00950183|February 2007
1610|Completed|Chronic Insertional Achilles Tendonitis Treated With or Without Flexor Hallucis Longus Tendon Transfer||Procedure:Achillesdecompression&amp;debridement;  Procedure: Achilles decompression and debridement with FHL transfer|Interventional|Phase 4|Other|ankle plantar flexion strength measured using a handheld dynamometer;  American Orthopaedic Foot and Ankle Society(AOFAS) Ankle-Hindfoot score;  Visualanalogpainscale(VAS);  Hallux plantarflexion strength using the dynamometer;  PatientSatisfaction;  Surgicalcomplications;  Postoperativecomplications|52|NCT00950053|December 2008
1611|Withdrawn|Comparison Study of Biofoam Porous Metal Versus Allograft to Treat Adult Acquired Flatfoot||Device:Biofoam;  Other:IliacCrestAllograftwithlockedplate|Interventional|Phase 4|Other / Industry|The degree of correction as measured by talonavicular coverage angle which is used to quantify the degree of deformity. Degree of correction is defined as the difference between the preoperative and postoperative talonavicular coverage angle.;  American Orthopaedic Foot and Ankle Society (AOFAS) Ankle-Hindfoot Score;  FootFunctionIndex(FFI)Score;  PainVisualAnalogScale(VAS);  Implantfailure|0|NCT00949897|March 2009
1612|Completed                  Has Results|Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension||Drug:SPARC0912;  Drug:Reference0912|Interventional|Phase 3|Industry|Change in Intraocular Pressure From Baseline to Week 12|578|NCT00947661|July 2010
1613|Completed                  Has Results|Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension||Drug:SPARC0913|Interventional|Phase 3|Industry|NumberofSubjectsWithAEs;  Mean Change in IOP From Baseline to Visit 7 (End of Evaluations Visit)|161|NCT00945958|November 2010
1614|Active not recruiting|Single Dose Partial Breast Radiotherapy||Radiation:Radiosurgery|Interventional|Phase 1|Other|MaximumToleratedDose;  Localcontrol;  Cosmeticoutcome;  MagneticResonanceImages(MRI);  Acquiretissue|32|NCT00944528|January 2010
1615|Completed                  Has Results|An Open Label Study to Describe the Pharmacokinetics of Daptomycin in Infants||Drug:Daptomycin|Interventional|Phase 1|Other|PKofDaptomycin;  AdverseEventsWillbeMonitored.|20|NCT00942149|January 2010
1616|Active not recruiting|Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer||Radiation:SBRTProstate|Interventional|Phase 2|Other|Toxicity;  Diseasefreesurvival;  QualityofLife|60|NCT00941915|November 2009
1617|Completed                  Has Results|Evaluate Inflammation Caused by Gingivitis in Adults||Drug:Triclosan/Copolymer/fluoridetoothpaste;  Drug:sodiummonofluorophosphatetoothpaste|Interventional|Phase 4|Industry|Level of Gingival Crevicular Fluid Interleukin - 1 (GCF IL-1) at 2 Hours;  Level of Gingival Crevicular Fluid Interleukin - 6(GCF IL-6) at 2 Hours|49|NCT00941668|January 2007
1618|Completed                  Has Results|Suberoylanilide Hydroxamic Acid (SAHA) Bevacizumab Daily Temozolomide for Recurrent Malignant Gliomas||Drug:Vorinostst/Bevacizumab/Temozolomide|Interventional|Phase 1 / Phase 2|Other / Industry|Phase I: Determination of the Maximum Tolerated Dose (MTD);  PhaseII:6-monthProgression-freeSurvival(PFS);  PhaseII:RadiographicResponse.;  PhaseII:MedianProgression-freeSurvival(PFS);  PhaseII:MedianOverallSurvival(OS);  Phase II: Number of Patients With Grade 2 or Greater Treatment-related Toxicities|48|NCT00939991|October 2009
1619|Completed|Outlook: An Intervention to Improve Quality of Life in Serious Illness||Other:OutlookAttentionControl;  Other:OutlookIntervention|Interventional||Other / NIH|QUAL-E subscale describing preparation for death (Quality of Life at End of Life Steinhauser et al. 2004);  Remaining subscales of the QUAL-E instrument (Quality of Life at End of Life Steinhauser et al. 2004)|154|NCT00939146|February 2010
1620|Completed|Community Based Obesity Prevention Among Blacks||Behavioral:Adaptivesteprecommendation;  Behavioral:10000step/dayrecommendation|Interventional||Other|Adherence to the pedometer-based physical activity regimen;  Changeinphysicalactivity;  ChangeinBMI|50|NCT00939081|May 2010
1621|Completed|Enhanced Self-Efficacy Training||Other:Self-EfficacyTrainingforCaregivers;  Other:ComparisonConditionsforCaregivers|Interventional||Other / NIH|Self-efficacyinsymptommanagement;  Psychologicalwell-being;  Managementofpsychologicaldistress;  QualityofLife|358|NCT00938769|August 2009
1622|Completed|Community Based Obesity Prevention Among Black Women||Behavioral:ObesityPrevention|Interventional||Other|Change in BMI. We have set a target of BMI maintenance among those randomized to the intervention condition.;  Changeinobesityriskbehaviors;  Measuresofbodycomposition;  Psychosocialmediators;  Obesityrelatedbiomarkers|194|NCT00938535|November 2009
1623|Completed|Treatment for Periodontal Disease in Dialysis Patients||Procedure:PeriodontalScalingandRootPlaning|Interventional||Other / Industry|SerumAlbuminIL-6CRP;  HbA1cperiodontalprobing|60|NCT00937976|August 2008
1624|Completed|Treatment of Patients With Nocturia||Drug:SER120;  Drug:Placebo|Interventional|Phase 3|Industry|numberofnocturicepisodes;  proportion of nights with less than or equal to one nocturic episode|301|NCT00937859|June 2009
1625|Completed|Xience V at Wake Forest University Baptist Medical Center (WFUBMC)|||Observational||Other / Industry|Composite of non-fatal myocardial infarction death or stent thrombosis;  Targetlesion/vesselrevascularization|59|NCT00937573|July 2009
1626|Unknown&nbsp;&#8224;|Low Dose Extended-release Epidural and Lumbar Plexus Block Compared to Lumbar Plexus Block for Total Hip Resurfacing||Drug:ExtendedReleaseEpiduralMorphine(EREM);  Drug:Placebo|Interventional||Other / Industry|Lengthofhospitalstayaftersurgery;  Totalopioidconsumption;  Patientsatisfactionscore;  Verbalpainscores;  Distancewalked|60|NCT00934661|January 2010
1627|Completed                  Has Results|Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease||Drug:Lucinactantfirst;  Drug:Placebofirst|Interventional|Phase 2|Other / Industry|ChangeinMucociliaryClearance;  Spirometry|16|NCT00934362|October 2008
1628|Terminated|Functional Imaging of Tumor and Normal Tissue||Procedure:MRIandPETimaging|Observational||Other|Permeability perfusion diffusion and glucose metabolism;  Relationships between baseline and treatment induced changes in vascular permeability perfusion interstitial space glucose metabolism and saliva production to identify prognostic and predictive parameter(s) for treatment|21|NCT00933114|October 2009
1629|Active not recruiting|Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study||Drug:LowDosePeanutProtein;  Drug:HighDosePeanutProtein|Interventional|Phase 1 / Phase 2|Other|To treat peanut-allergic subjects with PMIT and to determine whether this protocol lowers their risk of anaphylactic reactions and causes long-term tolerance.;  To determine the effect that PMIT has on the peanut-specific cellular and humoral response in peanut-allergic subjects.|60|NCT00932828|June 2009
1630|Completed                  Has Results|Continuous Cardiac Arrhythmia Monitoring in Hemodialysis Patients||Device: continuous cardiac monitoring device (REVEAL Medtronic)|Observational||Other / Industry|Number of Participants With a Significant Arrhythmia Detected;  Number of Participants Experiencing a Peridialytic or Intradialytic Arrhythmias|8|NCT00932659|June 2009
1631|Completed|Tailored Intervention Protocol for Oral Chemotherapy Adherence||Behavioral:NurseCoaching|Interventional||Other / NIH|AdherencetoOralChemotherapyMedication|48|NCT00932490|August 2009
1632|Completed|Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy||Drug:PeanutOralImmunotherapy;  Drug:Omalizumab|Interventional|Phase 1 / Phase 2|Other / Industry|The percentage of subjects who pass the 20gm peanut flour (~50% peanut protein) oral food challenge following the desensitization phase of the study;  Incidence of side effects during initial escalation and build up phase|11|NCT00932282|July 2009
1633|Completed|UCAN: Uniting Couples in the Treatment of Anorexia Nervosa||Behavioral:CBCT;  Behavioral:FamilySupportiveTherapy|Interventional||Other / NIH|Eatingdisorderbehavior;  CoupleSatisfaction|40|NCT00928109|April 2008
1634|Not yet recruiting|Evaluation of a Nasal Allergen Challenge Procedure Using Dust Mite Extract||Biological:dustmiteinhalation|Interventional|Phase 1|Other / NIH|Successful nasal allergen challenge without serious adverse event.;  analyze and compare cells of the airway and serum for a variety of inflammatory markers relevant to innate immunity.|15|NCT00927329|October 2016
1635|Completed                  Has Results|Continuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD)||Drug:ContinuousOC(EE/DROS);  Drug:IntermittentOC(EE/DROS);  Drug:placebo|Interventional|Phase 4|Other / NIH|Pre-PostChangeinPremenstrualSymptomSeverity|67|NCT00927095|July 2008
1636|Completed|The Use of a Language Toolkit for Toddlers||Behavioral:Languagetoolkit;  Behavioral:Safetycounseling|Interventional||Other|Language/Wordsacquisition|40|NCT00926510|August 2009
1637|Completed|Improving Representative Payeeship for People With Psychiatric Disabilities and Their Families||Behavioral: Steps for Achieving Financial Empowerment (SAFE)|Interventional||Other / U.S. Fed|employment;  empowerment;  familysupport|303|NCT00924976|May 2008
1638|Completed|A Study of Inhalation of 20000 EU CCRE and Mucociliary Clearance (MCC) in Otherwise Healthy Individuals Who Are Current Cigarette Smokers||Biological:20KEUCCRE|Interventional|Phase 1|Other|Increaseinsputumneutrophils;  Mucociliaryclearancerates|12|NCT00924768|May 2009
1639|Completed|Colon Cancer Prevention Study||Other:BehavioralMessages;  Other:GenericMessages|Interventional||Other|Elaboration using the Elaboration Likelihood Scale;  Behavioral Intention to Engage in Colorectal Cancer Screening or Physical Activity|207|NCT00924690|June 2009
1640|Active not recruiting|Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies||Radiation:EsophagealsparingIMRT|Interventional|Phase 1|Other|Maximumtolerateddose(MTD)ofIMRT;  TheoccurrenceofRT-inducedacuteesophagitis;  To determine if biological predictors of esophagitis can identify patients who develop severe esophageal toxicity during radiation therapy|25|NCT00921739|August 2009
1641|Completed                  Has Results|Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C||Drug:interferonalfa-2b;  Drug:peginterferonalfa-2b;  Drug:ribavirinUSP;  Device:externaldruginfusionpump|Interventional|Phase 2|Industry|Viral Load: Incidence of Sustained Virologic Response (SVR);  Safety/Tolerability;  RapidVirologicResponse(RVR);  EarlyVirologicResponse(EVR);  End-of-treatmentResponse(EOT);  Pharmacokinetics;  Pharmacodynamics;  Functional Health Depression Score and Fatigue Level;  ViralDecay|116|NCT00919633|June 2009
1642|Completed|Preventing Postpartum Return to Smoking||Behavioral:TailoredCounselingInterventionArm|Interventional||Other / NIH|To assess the efficacy of an intervention in preventing or delaying postpartum smoking resumption among women who stop smoking during pregnancy.;  To determine the association of baseline risk assessment variables with time to resumption.|386|NCT00917943|April 2008
1643|Unknown&nbsp;&#8224;|Neuradiab&#174; Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme||Drug: Neuradiab in combination with Bevacizumab (Avastin)|Interventional|Phase 2|Industry|The safety of Neuradiab&#174; when followed by Avastin therapy will be assessed based on Investigator reported symptomatic toxicity findings on physical exam and Adverse Events.;  Overall survival (OS). Data will be reported based on a dataset of 60 patients.;  Time to progression (TTP). Data will be reported based on a dataset of 60 patients.|60|NCT00906516|May 2009
1644|Completed                  Has Results|Optima: Optimizing Prograf Therapy in Maintenance Allografts II||Drug:cyclosporine;  Drug:Prograf(Tacrolimus)|Interventional|Phase 4|Other / Industry|Renal Function in Patients Converted From Cyclosporine to Prograf;  Optimal Dose/Blood Level of Prograf in Long-term Maintenance Kidney Transplant Patients;  Change in Risk Factors for Cardiovascular Morbidity and Chronic Graft Dysfunction as Evidenced by Blood Levels of Homocysteine and Transforming Growth Factor Beta (TGF-B)|63|NCT00905515|August 2003
1645|Completed|Impact of Myfortic on Gastrointestinal (GI) Prophylaxis in Maintenance Renal Transplant Patients||Drug:GImedication|Interventional|Phase 4|Other / Industry|To determine the success (% of patients) in discontinuing GI medications over the 90-day period or also % of patients able to maintain reduced doses of GI medications over the 90-day period.;  To evaluate the cost effectiveness of discontinuing GI medications in transplant recipients.|61|NCT00905242|March 2006
1646|Recruiting|Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure||Drug: Intravenous Bolus Furosemide and Oral Metolazone;  Drug:IntravenousContinuousInfusionFurosemide|Interventional|Phase 4|Other|Dailynetfluidoutput;  PatientGlobalAssessmentScale;  Daily urine output (mL urine out per mg furosemide received);  Need for additional or alternative diuretic (crossover) or IV vasoactive therapy (study failure);  Death rehospitalization and unscheduled visit for HF to an emergency department or outpatient clinic;  Critically low potassium (&lt; 3.5 mmol/L) and magnesium (&lt; 1.6 mg/dL) concentrations;  Changeinbloodureanitrogenorcreatinine;  Number of hypotensive episodes defined as systolic blood pressure below 85 mmHg or greater than 10 mmHg below baseline (whichever is greater);  Total number of times antihypertensive doses are held due to low blood pressure|160|NCT00904488|October 2008
1647|Completed|Genotype-Guided Warfarin Therapy Trial||Other:Genotype-guideddosedetermination;  Other:Non-genotypeguidedwarfarindosing|Interventional||Other|Timeintherapeuticrange(TTR);  Numberofanticoagulationvisits;  ProportionofINRs&gt;4;  Majorbleedingevents;  Minorbleedingevents;  Thromboemboliccomplications;  All-causemortality;  Timetotherapeuticdose;  Emergencydepartmentvisits;  Hospitalizations;  Costsandcost-effectiveness|109|NCT00904293|August 2008
1648|Completed|Mucus Dehydration and Evolution of Chronic Obstructive Pulmonary Disease (COPD) Lung Disease||Other:7%hypertonicsaline|Observational||Other / NIH|Mucociliaryclearanceofinhaledtc99m;  Identification of bacterial and viral communities in mucus samples; analysis of biochemical and biophysical properties of mucus|100|NCT00903955|September 2006
1649|Completed|Effect of Antipsychotics on Appetite Regulation|||Observational||Other / NIH|ghrelinareaunderthecurve;  PYYareaunderthecurve;  glucoseareaunderthecurve;  insulinareaunderthecurve;  bodycomposition;  subjectiveappetiteratings|45|NCT00903916|August 2007
1650|Completed|Evaluating the Effect of Mucinex&#174; 1200 mg on Mucociliary and Cough Clearance From the Human Lung||Drug:Mucinex1200mg;  Drug:Placebo|Interventional|Phase 1|Other / Industry|Difference between drug and placebo in the percentage of particles cleared from the lung.;  Difference between drug and placebo as an estimate of small airway clearance.;  Difference between drug and placebo between study days.;  Blood will be drawn to determination of guaifenesin in the serum.|12|NCT00902707|May 2009
1651|Completed                  Has Results|A Controlled Laboratory Study of the Effects on Cue-Induced Craving in Dependent Smokers||Device:ActiverTMSCondition;  Device:rTMSLocationControlCondition;  Device:rTMSFrequencyControlCondition|Interventional|Phase 2|Other|Change in Craving for Cigarettes After Smoking Cues Versus Neutral Cues Using a Repeated Measure Design.;  Change in Craving for Cigarettes After Controlled Smoke Presentations.|21|NCT00901459|May 2009
1652|Completed                  Has Results|Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant||Drug:G-CSFplusPlerixafor|Interventional|Phase 2|Other / Industry|Number of Participants Who Achieved &gt; or Equal to 2 X 10(6)CD34+ Cells/kg Within 3 Days of Apheresis After Receiving Plerixafor With G-CSF.;  Number of Participants Experiencing a Grade III/IV Toxicity;  NumberofSubjectsExperiencingGraftFailure;  DaystoAbsoluteNeutrophilCount&gt;500;  Number of Subjects Experiencing Durability of Engraftment;  PlateletEngraftment|21|NCT00901225|May 2009
1653|Completed                  Has Results|Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide||Drug:Palonosetron(PALO)|Interventional|Phase 2|Other / Industry / NIH|Safety and Tolerability of Palonosetron as Determined by the Number of Participants Who Experience Unacceptable Toxicity;  CompleteResponse;  Change in the Functional Living Index - Emesis (FLIE) Score From Baseline to Each Week of Radiation (XRT) and Temozolomide (TMZ) Treatment;  Percentage of Participants With a Osoba Nausea Module Maximum Standardized Score of Zero for Each Week of Radiation (XRT) and Temozolomide (TMZ);  Percentage of Participants With a Osoba Vomiting/Retching Module Maximum Standardized Score of Zero for Each Week of Radiation (XRT) and Temozolomide (TMZ)|57|NCT00900757|August 2009
1654|Recruiting|Cervical Cancer Detection Using Optical Spectroscopy||Device:OpticalSpectroscopyBench-TopSystem;  Device:PortableOpticalSpectrometer;  Device:Transvaginalcolposcope|Interventional||Other|Identification of optical signatures of cervical tissue|310|NCT00900575|May 2006
1655|Withdrawn|Antibiotic Therapy After Incision and Drainage for Abscess||Procedure:Incisionanddrainage;  Drug:Trimethoprim/Sulfamethoxazole(Bactrim);  Drug:Placebo|Interventional||Other|Resolutionofabscess|0|NCT00900510|May 2009
1656|Recruiting|Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors||Other:biologicsamplepreservationprocedure;  Other:medicalchartreview|Observational||Other / NIH|Tissue and cell repository for Wake Forest University Comprehensive Cancer Center investigators|2500|NCT00900471|May 2004
1657|Completed|Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants||Other:immunologictechnique;  Other:laboratorybiomarkeranalysis;  Other:massspectrometry|Observational||Other / NIH|Presence of bone morphogenetic protein antagonist regulated in cancer (BARC) in urine and serum samples;  BARCexpressionlevels;  Correlation of changes in serum markers of iron metabolism with changes in BARC expression;  Feasibility of an enzyme-linked immunosorbent assay to detect BARC levels as a diagnostic procedure|40|NCT00900276|June 2006
1658|Terminated|TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension||Drug:Placebo;  Drug:TC-5214|Interventional|Phase 1 / Phase 2|Industry|Mean difference between TC-5214 and placebo in change at 3 hours from baseline SBP;  Safety and tolerability of TC-5214 in patients with refractory hypertension and obtain preliminary dose-response estimates|1|NCT00899977|May 2009
1659|Terminated|Gene Expression in Normal Tissue and Tumor Tissue From Patients Who Have Undergone Surgery For Kidney Cancer|||Observational||Other / NIH|Expression levels of novel genes and proteins (HFARP HAMGR28 HE9NG77) in frozen normal tissue and tumor tissue;  Correlation of gene and protein expression levels with disease stage tumor size and pathology reports;  Comparison of proteomic screening of potential biomarkers using plasma and/or urine samples from patients with renal cell cancer or breast cancer stored in the CCCWFU Tumor Tissue Core with tissue samples from patients enrolled in this study|30|NCT00899860|September 2003
1660|Active not recruiting|Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants||Other:immunologicaldiagnosticmethod;  Other:physiologictesting|Observational||Other / NIH|Cellkillingability(positiveornegative);  Percentageofcellskilled|48|NCT00899496|September 2005
1661|Terminated|Tamoxifen Resistance in Women With Stage I Stage II Stage IIIA or Stage IIIB Breast Cancer||Drug:tamoxifencitrate;  Genetic:geneexpressionanalysis;  Genetic:proteinexpressionanalysis;  Other:immunoenzymetechnique;  Other:laboratorybiomarkeranalysis|Observational||Other / NIH|Evaluation of the mechanisms of tamoxifen citrate (TAM) resistance in breast cancer;  Change in expression levels of protein biomarkers of TAM resistance as measured periodically for 3 years or until relapse whichever comes first;  Retrospective data on the predictive value of resistance-inducing genes|2|NCT00899197|May 2007
1662|Active not recruiting|Prevalence of Sleep Disturbances in Psoriasis|||Observational||Other|Measured prevalence of poor sleep quality in psoriasis subjects as compared to sex- age- and BMI-matched subjects without psoriasis defined as the control population will be assessed by the Pittsburgh Sleep Quality Index (PSQI).;  Measured prevalence of poor sleep quality in control subjects using the PSQI in order to compare against psoriasis subjects.;  Measured prevalence of insomnia in both groups assessed by the Insomnia Severity Index.;  Measured prevalence of hypersomnia in both groups assessed by the Epworth Sleepiness Scale.;  Measured prevalence of pruritus in both groups assessed by Itch Severity Scale (ISS).;  Measured prevalence of depression in both groups assessed by Patient Health Questionnaire (PHQ-9).;  Measure prevalence of sleep disordered breathing in both groups assessed by Snore Outcome Survey (SOS).;  Measured prevalence of pruritus depression and sleep disordered breathing in those with impaired sleep.;  Measured prevalence of depression in subjects with pruritus and sleep-disordered breathing.|80|NCT00895375|October 2009
1663|Completed                  Has Results|Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype||Drug:NicotinePatches;  Drug: Nicotine patches then bupropion &amp; nicotine patches (Pre-Quit);  Drug: Nicotine patches then varenicline (Pre-Quit);  Drug: Nicotine patches then nicotine patches (Pre-Quit);  Drug: Nicotine patches then bupropion &amp; nicotine patches (Post-Quit);  Drug: Nicotine patches then varenicline (Post-Quit);  Drug: Nicotine patches then nicotine patches (Post-Quit)|Interventional|Phase 3|Other / Industry|Continuous 4-week Abstinence From Smoking Between Weeks 8-11 After the Quit Date (Through the End of Treatment);  Abstinence(7Days)at6Months.;  Continuous Abstinence From Smoking at 6 Months Post Quit.|606|NCT00894166|May 2009
1664|Completed|Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme||Biological:BTSCmRNA-loadedDCs|Interventional|Phase 1|Other / NIH|Feasibilityandsafety;  Humoralandcellularimmuneresponses|50|NCT00890032|September 2009
1665|Completed                  Has Results|Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)||Drug:Methylphenidatetransdermalsystem;  Drug:Lisdexamfetaminedimesylate;  Drug: Osmotic-release oral system methylphenidate (OROS MPH);  Drug:Mixedamphetaminesaltsextendedrelease|Interventional|Phase 4|Other / NIH|Dichotomized Clinical Global Impression-Effectiveness (CGI-E) Scale;  Clinical Global Impressions-Improvement (CGI-I) Scale;  Clinical Global Improvements-Acceptability (CGI-A) Scale|228|NCT00889915|April 2009
1666|Completed|Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors||Drug:CNTO95andavastin|Interventional|Phase 1|Other / Industry|To define a recommended phase II dose for the combination of CNTO 95 plus bevacizumab in subjects with advanced solid tumors.;  To evaluate dose limiting as well as non-dose limiting toxicities of this combination.;  To explore the effect of the combination versus each agent individually on dermal wound angiogenesis in a skin biopsy the clinical activity of this combination and the association between blood- and urine-based biomarkers and clinical outcome.|13|NCT00888043|March 2009
1667|Completed                  Has Results|Treatment Effects of Escitalopram (Lexapro&#174;) on Generalized Anxiety Disorder in Patients With HIV and AIDS||Drug:Escitalopram|Interventional|Phase 3|Other / Industry|Change From Randomization to End of Treatment in Scores on the Hamilton Anxiety Rating Scale (HAM-A);  Changes From Randomization to End of Treatment in Scores on the Beck Depression Inventory;  Change From Randomization to End of Treatment in Scores for the Clinical Global Impression(CGI-S and CGI-I);  Change From Randomization to End of Treatment for Trail Making Tet (TMT);  Changes From Randomization to End of Treatment in Scores on the Mini Mental State Examination (MMSE);  Changes From Randomization to End of Treatment in Scores on the Sheehan Disability Scores (SDS)|30|NCT00887679|May 2009
1668|Completed|Mindfulness Emotional Well-being and Sleep Quality||Behavioral: Mindfulness-Based Stress Reduction (MBSR)|Interventional||Other / NIH|Mindfulness;  Sleepquality;  Cognitiveperseveration;  Emotionregulation;  Spirituality;  Health-relatedqualityoflife|372|NCT00887614|July 2009
1669|Completed|Spinal Cord Stimulator Implant Study||Behavioral:CopingSkillsTraining;  Behavioral:Education|Interventional||Other|Improvements in pain psychological distress and physical disability;  Patients will learn a repertoire of coping skills which can be applied to other challenges in life.|101|NCT00887419|November 2008
1670|Unknown&nbsp;&#8224;|Metabolics of Roux-en-Y Gastric Bypass (RYGB) With Gastrostomy|||Observational||Other / Industry||120|NCT00887302|May 2009
1671|Unknown&nbsp;&#8224;|The Effect of Gum Chewing on Postoperative Ileus||Device:Motionsicknesswristband;  DietarySupplement:ChewingGum|Interventional|Phase 3|Other|Timetoresolutionofpost-operativeileus.|60|NCT00879294|
1672|Completed|Reliability of Point-of-care INR Measurements in Patients With Antiphospholipid-antibody Syndrome Treated With Warfarin||Device: INR by point-of-care instruments and venopuncture|Observational||Other / Industry||63|NCT00878137|March 2009
1673|Completed|Nurture: A Program for Mothers With Histories of Disordered Eating||Behavioral:NurtureSupportGroupTherapy;  Behavioral:Grouptherapy|Interventional||Other / NIH|Parentingself-efficacy|28|NCT00877994|April 2008
1674|Completed|Sex Differences in Early Brain Development; Brain Development in Turner Syndrome|||Observational||Other / NIH|BrainvolumesonMRI;  BrainvolumesandDTIparameters|295|NCT00877942|October 2006
1675|Completed|Efficacy and Tolerability of Baclofen for Alcohol Dependence||Drug:baclofen;  Drug:placebo;  Behavioral:BRENDAcounseling|Interventional|Phase 2 / Phase 3|Other|%heavydrinkingdays;  %relapse;  %abstinentdays;  depressionsymptoms;  anxietysymptoms|80|NCT00877734|April 2005
1676|Active not recruiting|Prospective Studies of the Pathogenesis of Schizophrenia|||Observational||Other / NIH|magnetic resonance images (structural and functional);  Cognitivedevelopment|600|NCT00877552|August 2002
1677|Unknown&nbsp;&#8224;|Corneal Endothelium Delivery Instrument||Device: EndoSaver&#8482; Corneal Endothelium Delivery Instrument|Interventional|Phase 2|Industry / Other|6-monthpost-operativeendothelialcelldensity;  12-monthpost-operativeendothelialcelldensity|100|NCT00874835|March 2009
1678|Completed                  Has Results|Safety Study of Transvenous Limb Perfusion in Human Muscular Dystrophy||Other: Retrograde high pressure transvenous perfusion with normal saline|Interventional|Phase 1|Other / NIH|MuscleNerveorVascularDamage|16|NCT00873782|March 2009
1679|Completed|Erectile Dysfunction Study||Other:aerobicexercise;  Other:wait-listcontrol|Interventional||Other / NIH|To determine the effects of supervised aerobic exercise training versus usual care on incidence of ED among men undergoing radical prostatectomy for clinically localized prostate cancer.;  To determine the effects of aerobic exercise training versus wait-list control on changes in patient symptoms and the number of men receiving phosphodiesterases type-5 (PDE-5) inhibitor therapy as well as therapy dose.;  To determine the effects of aerobic exercise training versus wait-list control on changes in postulated biologic mechanisms that may underlie the relationship between exercise training and ED.|64|NCT00873665|December 2008
1680|Completed                  Has Results|Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Drug:perifosine|Interventional|Phase 2|Other / Industry|OverallResponse;  OverallSurvival;  Event-freeSurvival|16|NCT00873457|August 2009
1681|Completed|Coping Skills and Heart Failure: Outcomes and Mechanisms||Behavioral:Copingskillstraining|Interventional||Other / NIH|Quality of Life Heart Failure Disease Biomarkers and Clinical Outcomes|190|NCT00873418|March 2009
1682|Completed|Study of Massage Therapy Within a Brain Tumor Setting||Behavioral:MassageTherapy|Interventional||Other|To assess the feasibility and acceptability of massage therapy provided to primary brain tumor patients. This assessment will integrate data about patient eligibility rates patient participation rates patient adherence rates and adverse events.;  To examine the effects of massage therapy on psychological outcomes related to stress distress anxiety and depression in this population and to explore whether psychological outcomes are associated with changes in patient reported QoL.|10|NCT00873184|September 2008
1683|Withdrawn|BTC Neuropsychological Database|||Observational||Other|Bivariate correlational analyses will be conducted to examine associations between neuropsychological depression demographic medication data tumor-related treatment  and QoL variables.;  In exploratory analyses FACT-BR scale scores will be regressed on candidate neurocognitive predictors while controlling for other potentially confounding variables using hierarchical regression analyses.|0|NCT00873132|April 2009
1684|Completed|Helping African American Prostate Cancer Survivors and Their Partners Cope With Challenges After Surgery for Prostate Cancer||Behavioral:telephone-basedintervention;  Other:educationalintervention;  Other:partner-assistedcopingskillstraining;  Other:questionnaireadministration;  Procedure:psychosocialassessmentandcare;  Procedure:quality-of-lifeassessment|Interventional||Other / NIH|Symptom distress in survivors as assessed by the Sexual Urinary and Bowel Bother subscales of the Prostate Cancer Index Composite (EPIC) (16) at baseline 2 months and 5 months;  Depressed mood in survivors and partners as assessed by the depression subscale of the Profile of Mood States-SF (POMS-SF 95) at baseline 2 months and 5 months;  Quality of life of survivors as assessed by the Physical Well-being Functional Well-being and Prostate Cancer subscales of FACT-P (127) at baseline 2 months and 5 months;  Caregiver strain in partners as assessed by the Caregiver Strain Index (CSI) at baseline 2 months and 5 months;  Self-efficacy for symptom control in survivors and partners as assessed by the Self-Efficacy for Symptom Control Inventory; EPIC; and CSI at baseline 2 months and 5 months;  Relationship functioning in survivors and partners as assessed by the Dyadic Adjustment Scale (129) and the Miller Social Intimacy Scale (130) at baseline 2 months and 5 months;  Coping skills in survivors and partners as assessed by the Coping Strategies Social Problem Solving Scale-Revised and La Trobe Communication Questionnaires at baseline 2 months and 5 months|112|NCT00869739|August 2008
1685|Completed|Efficacy Evaluation of Observation Unit Cardiac Magnetic Resonance Imaging (MRI) in Patients With Intermediate Risk Acute Chest Pain||Other:OU-CardiacMRI;  Other:OU-ConventionalCareTesting|Interventional||Other|Therapeuticefficacy:Lengthofstay;  Therapeutic efficacy: Correct cardiovascular admission decision;  Therapeutic efficacy: Non-therapeutic cardiac catheterizations;  Diagnostic thinking efficacy: change in diagnostic certainty;  Costofindexhospitalization|124|NCT00869245|March 2009
1686|Unknown&nbsp;&#8224;|Direct Tumor Injection KLH-Pulsed Dendritic Cells in Unresectable Pancreatic Cancer||Biological: KLH-pulsed autologous dendritic cell vaccine|Interventional|Phase 2|Other|OverallSurvival|35|NCT00868114|July 2006
1687|Completed|The Teachable Moment: Screening and Brief Intervention for Admitted Trauma Patients||Behavioral:QuantityFrequencyModel;  Behavioral:TargetsSubjectiveDrunkenness|Interventional|Phase 2|Other|Trauma recidivism after discharge as measured by a review of computerized ED recordsNC Trauma databasethe Forsyth County EMS registryNC EMS registry and self-reports at a 6-month telephone follow-up of alcohol-related injuries and changes in alcohol;  Patient satisfaction ratings of the BIthe response to the BI as rated by the interviewerreported citations for driving under the influence(to be obtained from the NC State Department of Motor Vehicles) and 3 surveys of trauma service staff|333|NCT00865774|January 2009
1688|Completed|Single Dose Two-Way Crossover Fasted Bioequivalence Study of Nabumetone 750 mg Tablets in Healthy Volunteers||Drug:Nabumetone750mgtabletssingledose|Interventional|Phase 1|Industry|RateandExtendofAbsorption|40|NCT00864968|February 2007
1689|Completed|Single Dose Two-Way Crossover Fed Bioequivalence Study of Nabumetone 750 mg Tablets in Healthy Volunteers||Drug:Nabumetone750mgtabletssingledose|Interventional|Phase 1|Industry|RateandExtendofAbsorption|30|NCT00864604|April 2007
1690|Completed|A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Fasting Conditions||Drug: Cetirizine Hydrochloride 10 mg tablets single dose;  Drug:Zyrtec&#174;10mgtabletssingledose|Interventional|Phase 1|Industry|RateandExtendofAbsorption|26|NCT00864279|August 2006
1691|Completed|A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Non-fasting Conditions||Drug: Cetirizine Hydrochloride 10 mg tablets single dose;  Drug:Zyrtec&#174;10mgtabletssingledose|Interventional|Phase 1|Industry|RateandExtendofAbsorption|26|NCT00863902|August 2006
1692|Completed|Pilot Study for VeinoPlus to Improve Symptoms of Postthrombotic Syndrome||Device:VeinOPlus|Interventional|Phase 2|Other|Estimate the optimal electrical stimulation intensity level at which patients using the portable electrical muscle stimulator (VeinoPlus&#174;) have the largest benefit for relief of symptoms.;  Estimate whether use of the device was a &quot;clinical success&quot; as defined by the patient reporting benefit by the improvement of symptoms after having used the device plus an interest and willingness to continue using the device.;  Estimate the extent to which the portable electrical muscle stimulator (VeinoPlus) improves the quality of life and objective findings of postthrombotic syndrome.;  Compute information needed to power a future cross-over study.|12|NCT00858130|March 2009
1693|Unknown&nbsp;&#8224;|Physical Activity Program for Older Renal Transplant Candidates||Other:PhysicalActivity|Interventional||Other|The Short Physical Performance Battery SPPB) score a brief and simple bedside performance-based instrument.;  Health-relatedquality-of-lifescores;  Self-reporteddisabilityscores;  Re-hospitalization;  Inter-current illness including cardiovascular events or falls;  Endurance;  BodycompositionbybothDEXAandthighCT;  Gripstrength;  Legstrength;  ADLdisability|25|NCT00857974|July 2007
1694|Terminated|Yoga in Relieving Fatigue in Patients Undergoing Chemotherapy for Ovarian Cancer||Behavioral:Homeyogapractice;  Procedure:yogaclasses|Interventional||Other / NIH|Self-reportedfatigue;  Self-reported distress depression and sleep quality;  Pre- and post-yoga class change in symptom/distress ratings;  Yogainterventionadherence|2|NCT00856453|May 2009
1695|Completed|Hemostatic Textile to Control Bleeding at Donor Graft Sites||Device:Stasilon|Observational|Phase 4|Other|To compare the efficacy of a new hemostatic textile named Stasilon&#8482; against standard wound dressings in controlling burn patient donor graft site bleeding.|20|NCT00855569|June 2008
1696|Completed                  Has Results|Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia||Drug:acyclovirsodium|Interventional|Phase 3|Other / NIH|Number of Participants Experiencing Incidence of Nephrotoxicity Defined as a Serum Creatinine &#8805; 2 Times the Patient&apos;s Baseline|112|NCT00855309|November 2008
1697|Completed|Study in Healthy Males to Measure Darunavir and Etravirine in Blood Seminal Fluid and Rectal Tissue||Drug:darunavir;  Drug:Ritonavir;  Drug:Etravirine|Interventional|Phase 1|Other / Industry|To generate individual pharmacokinetic parameters for darunavir ritonavir and etravirine in seminal plasma after single and multiple dosing;  To generate composite pharmacokinetic parameters for darunavir ritonavir and etravirine in rectal tissue after single and multiple dosing;  To generate matrix:blood plasma ratios of darunavir ritonavir and etravirine in semen and rectal tissue after single and multiple dosing|13|NCT00855088|July 2009
1698|Completed                  Has Results|A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis||Drug:Olux-EFoam;  Drug:Clobexlotion|Interventional|Phase 4|Industry|At Least a One Grade Improvement for the Target Psoriasis Lesion on the Elbow or Knee (Psoriasis Grading Scale);  At Least 1 Grade Improvement Psoriasis Grading Scale;  At Least a 2 Grade Improvement Psoriasis Grading Scale;  At Least a 3 Grade Improvement Psoriasis Grading Scale;  At Least 1 Grade Improvement in the Psoriasis Global Assessment;  At Least a 2 Grade Improvement in the Psoriasis Global Assessment;  At Least a 3 Grade Improvement in the Psoriasis Global Assessment;  At Least 1 Grade Improvement in Subject&apos;s Global Assessment;  At Least a 2 Grade Improvement in Subject&apos;s Global Assessment;  At Least a 3 Grade Improvement in Subject&apos;s Global Assessment;  MedianChangeinPsoriasisGradingScale;  Dermatology Quality of Life - Symptoms and Feelings;  DermatologyQualityofLife-DailyActivities;  DermatologyQualityofLife-Leisure;  DermatologyQualityofLife-WorkandSchool;  Dermatology Quality of Life - Personal Relationships;  DermatologyQualityofLife-Treatment;  TotalDermatologyLifeQualityIndex(DLQI)Score;  DermatologyLifeQualityIndex(DLQI)Categories|34|NCT00852761|March 2009
1699|Terminated                  Has Results|Validation of Brain Oxygenation Monitor on Pediatric Patients||Device:CASNIRSFORE-SIGHToximeter|Interventional||Other / Industry|Accuracy of NIRS Sensor to Estimate Flank Tissue Oxygen Saturation;  Accuracy of NIRS Sensor to Estimate Intestine Tissue Oxygen Saturation;  Accuracy of NIRS Sensor to Estimate Hepatic Tissue Oxygen Saturation;  Correlation Between Somatic StO2 and Cerebral SctO2 Oxygen Saturation;  Correlation Between NIRS Derived Estimate of Hemoglobin Concentration and Measured Arterial Blood Hemoglobin Concentration.|72|NCT00849940|February 2009
1700|Terminated|Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases||Procedure: Nonmyeloablative allogeneic stem cell transplant|Interventional|Phase 1|Other|Engraftment;  GraftversusHostDisease;  Toxicity;  Mortality;  ResponseRate;  ImmuneFunctionPost-engraftment;  ProgressionFreeSurvival;  OverallSurvival|4|NCT00849745|January 2003
1701|Completed|Phase I Trial of Inhaled Nitric Oxide to Treat Acute Pulmonary Embolism||Drug:nitricoxide|Interventional|Phase 1|Other|Borgscore;  vitalsigns|25|NCT00848731|February 2009
1702|Completed|Compatibility of a Mild Moisturizing Hand Cleanser for Patients With Mild to Moderate Hand Dermatitis||Other:mildmoisturizinghandcleanser|Interventional||Other|Efficacy of mild moisturizing hand cleaner for improvement of hand dermatitis from frequent hand washing|46|NCT00843466|May 2007
1703|Completed|Bronchoscopy Assisted Sampling of Cells and Fluid From the Lower Respiratory Tract of Human Subjects|||Observational||Other|The goal of this project is to define the effect of smoking on key aspects of airway biology. These studies will also provide crucial &amp; novel definition of airway biology in smokers against which COPD &amp; CF patients will be compared.|30|NCT00840723|February 2009
1704|Active not recruiting|Genetic Susceptibility TO Ozone-induced Airway Inflammation in Humans||Other:ozone|Interventional||Other / U.S. Fed / NIH|Airwayneutrophilicresponsetoozoneexposure;  expression of specific genes of interest in a subset of ozone-responsive and ozone-non-responsive subjects|200|NCT00840528|February 2002
1705|Completed|Effect Of Obesity On Ozone-Induced Airway Inflammation||Other:ozone0.4ppm|Interventional||Other / NIH / U.S. Fed|Methacholinereactivity(primaryendpoint);  Breathingandlungfunctionvariables;  inducedsputummarkers|40|NCT00839943|May 2006
1706|Completed|Effect of a 10000 EU Dose of Endotoxin in Allergic and Mildly Asthmatic Adults||Biological: Clinical Center Reference Endotoxin (CCRE)|Interventional|Phase 1|Other / NIH|Magnitude of change in neutrophil content of induced sputum after inhalation of 10000 EU CCRE;  change in PFT&apos;s vital signs and symptom score after inhalation of 10000 EU of CCRE|11|NCT00839189|October 2002
1707|Completed|A Study of Inhalation of 20000 EU CCRE in Normal Volunteers Compared to Allergic Asthmatic Individuals||Biological: Clinical Center Reference Endotoxin (CCRE)|Interventional|Phase 1|Other / NIH|The primary objective of this study is to test the hypothesis that persons with allergic asthma will have an increased neutrophil response to challenge with 20000 EU CCRE compared to normal volunteers;  Secondary objectives include post CCRE comparison between AA&apos;s and NV&apos;s with regard to changes in airway cells and blood as well as changes in mucociliary clearance (MCC) in response to inhalation of 20000 EU CCRE.|32|NCT00839124|January 2009
1708|Terminated|Response of Airway Cells to 20000 EU of Endotoxin in Normal Adults||Biological: Clinical Center Reference Endotoxin (CCRE)|Interventional|Phase 1|Other / NIH|Neutrophil response (influx of PMNs to the airways as determined in sputum) after inhalation of CCRE (20000 EU);  changesinPFT&apos;sandvitalsigns|26|NCT00838851|August 2003
1709|Completed|In Vitro Basophil Responsiveness to Allergen Challenge After Gamma-tocopherol Supplementation in Allergic Asthmatics||DietarySupplement:gamma-tocopherol|Interventional|Phase 1|Other / NIH|We intend to examine the effect of once daily oral doses 1200 mg of gamma tocopherol (2 capsules of the gamma tocopherol enriched vitamin E preparation) on in vitro basophil activation with D. farinae challenge.;  Circulating antioxidant levels(tocopherols and metabolites) in-vitro basophil activation to IgG anti-IgE and to N-formyl-methionyl-leucyl-phenylalanine.|25|NCT00836368|December 2008
1710|Completed|Improving Neurologic Outcomes in People With Diabetes Who Are Undergoing Heart Surgery||Behavioral:IntensiveGlucoseManagement;  Behavioral:TraditionalGlucoseManagement:|Interventional|Phase 3|NIH|Proportion of participants with identifiable brain lesions detected by magnetic resonance imaging (MRI);  Proportion of participants with new neuropsychological deficits (20% decline on two or more neuropsychological tests);  NumberoflesionsasmeasuredbyMRI;  SizeoflesionsasmeasuredbyMRI;  Genetic analysis (i.e. predictive utility of haplotype assignment on primary outcomes);  Neuropsychological deficits (i.e. predictive utility of neuropsychological performance on presence number and volume of lesions)|133|NCT00836329|December 2008
1711|Completed                  Has Results|Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes||Drug:Metformin;  Drug:Insulin|Interventional|Phase 2|Other|BloodGlucoseMeasurements;  NumberofPatientsWithObstetricComplications;  MaternalWeightGain;  NumberofBabiesWithNeonatalHypoglycemia;  Glycosylated Hemoglobin (HbA1c) by Pregnancy Trimester;  Percent of Glucose Values at or Below Fasting Goal (&lt;95 mg/dL);  Percent of Glucose Values at or Below Postprandial Goal (&lt;130 mg/dL);  NumberofEpisodesMaternalHypoglycemia;  NumberofBabiesWithAdverseNeonatalOutcomes|31|NCT00835861|August 2008
1712|Terminated                  Has Results|A Safety Study of Eptifibatide in Patients With Sickle Cell Disease||Drug:Eptifibatide;  Drug:Placebo|Interventional|Phase 1 / Phase 2|Other|1)MajorBleedingEpisodes;  ChangeinPlateletCount;  Effect of Eptifibatide on Duration of Acute Pain Episodes;  Effect of Eptifibatide on Duration of Hospitalization|13|NCT00834899|January 2009
1713|Recruiting|An Observational Study of Pregnancy And Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin Perjeta In Combination With Herceptin or Kadcyla During Pregnancy or Within 7 Months Prior To Conception (MotHER)|||Observational|Phase 4|Industry||100|NCT00833963|December 2008
1714|Completed|Extinction Based Treatment for Nicotine Dependence||Drug:NicotinePatchesDenicotinizedCigarettes|Interventional|Phase 1|Other|To test two quit smoking therapies and to study brain function while each therapy is being used.|257|NCT00831155|January 2009
1715|Completed                  Has Results|Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma||Drug:RhuMab-E25|Interventional|Phase 3|Other / Industry|Change in Exhaled Nitric Oxide From Baseline to Week 12|20|NCT00829179|October 2002
1716|Completed|Lenalidomide and Decitabine in High Grade Myelodysplastic Syndromes||Drug:LenalidomideDecitabine|Interventional|Phase 1|Other / Industry|Maximally tolerated dose (MTD)as defined by the protocol;  responseduration;  effectoncytogeneticabnormalities|15|NCT00828802|March 2009
1717|Completed|An Open-Label Study of an Ophthalmic Solution to Reduce Intraocular Pressure in Patients With Ocular Hypertension||Drug:C-KADOphthalmicSolution|Interventional||Industry|Meanchangeinintraocularpressurefrombaseline|12|NCT00825396|April 2007
1718|Completed|Rapid Administration of Insulin in Sepsis||Drug:GIK|Interventional|Phase 1|Other|Absolutesafetyendpoint(explicitdefinitions);  ChangeinSOFAscoremicrocirculatoryflow|20|NCT00823108|March 2009
1719|Completed|Cholesterol Hypertension and Glucose Education Study||Behavioral: Tailored cardiovascular risk management (Nurse-administered )|Interventional||Other|Change in the outcome (SBP Hb A1c or LDL) from baseline to the 12 month evaluation.;  Changes in CVD related health behaviors (e.g. aspirin use medication adherence exercise and diet) as well as changes in stroke and CHD risk as assessed by the UPKDS risk engine|362|NCT00815789|December 2008
1720|Completed|Prevention and Treatment of Immersion Pulmonary Edema||Drug:Sildenafil|Interventional|Phase 0|Other|Pulmonary artery pressure during cold water immersion|10|NCT00815646|January 2008
1721|Completed                  Has Results|Validation of Brain Oxygenation Monitor||Device:Desaturation|Interventional||Other / Industry|AccuracyofSensor|18|NCT00815490|June 2008
1722|Completed                  Has Results|Study of Sorafenib/Cetuximab in Head and Neck Cancer||Drug:Sorafenib;  Drug:Cetuximab|Interventional|Phase 1 / Phase 2|Other / Industry|Phase 1 - Maximum Tolerated Dose (MTD) of Sorafenib Administered With Cetuximab (400 mg/m2 Loading Dose Followed by 250 mg/m2 Weekly);  TumorControlRate;  MedianSurvival;  MedianProgression-FreeSurvival(PFS);  Phase 2 - Mean Change From Baseline in Quality of Life - Functional Assessment of Cancer Therapy - Head and Neck (FACT-H&amp;N)|31|NCT00815295|January 2008
1723|Terminated|Coping With High Grade Glioma||Behavioral:copingskillsinterventiontraining;  Behavioral:usualcare|Interventional||Other|To explore the effects of a coping skills training (CST) intervention on distress self-efficacy and other related outcomes among caregivers of high grade glioma patients.|14|NCT00815152|December 2008
1724|Active not recruiting|Oral Immunotherapy (OIT) for Peanut Allergy||Drug:Peanut;  Drug:OatFlour|Interventional|Phase 2|Other|To treat peanut-allergic subjects with peanut OIT and to determine whether this protocol lowers their risk of anaphylactic reactions and causes long-term tolerance.;  To determine the molecular-level effect that peanut OIT has on the peanut-specific cellular and humoral activity/response in peanut-allergic subjects.|60|NCT00815035|April 2009
1725|Terminated                  Has Results|Stereotactic Radiosurgery After Surgery in Treating Patients With Brain Metastases||Behavioral:MMSE;  Behavioral:QOLviaFACT-Br;  Procedure:MRI;  Radiation:Post-operativeSRS|Interventional|Phase 2|Other / NIH|Recurrence Rate at the Surgical Site as Measured by MRI;  Rate of Salvage Whole-brain Radiotherapy Stereotactic Radiosurgery (SRS) or Surgery;  Rate of New Brain Metastases Outside of the Adjuvant SRS Site;  Quality of Life as Measured by the FACT-Br Subscales;  Preservation of Neurocognitive Function as Measured by the Mini-Mental State Exam;  Clinical Significance (if Any) of Locally Recurrent Brain Metastasis at the Time of Their Occurrence (Mass Effect Cognitive Functioning and Other Symptoms);  RateofDeathDuetoNeurologicCauses;  OverallSurvival|1|NCT00814463|August 2008
1726|Terminated                  Has Results|Stereotactic Radiosurgery in Treating Patients With Brain Metastases||Procedure:therapeuticconventionalsurgery;  Radiation:stereotacticradiosurgery|Interventional|Phase 2|Other / NIH|Number of Patients With Local Recurrence at the Surgical Site Within 12 Months After Stereotactic Radiosurgery (SRS);  Number of Patients Receiving Salvage Whole-brain Radiotherapy Stereotactic Radiosurgery (SRS) or Surgery;  Volume of Adjacent Normal Brain Parenchyma Irradiated;  Number of Patients With New Brain Metastases Outside of the Pre-operative Stereotactic Radiosurgery (SRS) Site;  Quality of Life After Stereotactic Radiosurgery (SRS) as Measured by the Functional Assessment of Cancer Therapy-Brain (FACT-Br);  Preservation of Neurocognitive Functioning as Measure by the Mini-Mental State Exam (MMSE);  Clinical Significance of Locally Recurrent Brain Metastases;  Number of Patients Who Died Due to Neurological Causes;  OverallSurvival(OS)|6|NCT00811655|October 2008
1727|Recruiting|Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease|||Observational||Other / NIH|Thisisnotaninterventionalstudy|1800|NCT00807482|January 2004
1728|Active not recruiting|Genetic Modifiers of Cystic Fibrosis (CF) Liver Disease|||Observational||Other / NIH|Thisisnotaninterventionalstudy|154|NCT00804583|March 2004
1729|Completed|C-11 Choline PET-CT Scan in Finding Metastases in Patients With Newly Diagnosed High-Risk Prostate Cancer||Procedure:needlebiopsy;  Drug: PET-CT scans supplemented with 11C-Choline tracer|Interventional|Phase 1|Other / NIH|Determination of utility of 11C-Choline in enhancing efficacy of Pet-CT scans|18|NCT00804245|August 2008
1730|Terminated|Amantadine and Temporal Discrimination in Patients With Traumatic Brain Injury (TBI)||Drug:amantadine|Interventional||Other|The primary outcome measure is the Interval Bisection Timing Task.;  The secondary efficacy measure is the Barrett Impulsiveness Scale (BIS-11).|16|NCT00800514|January 2009
1731|Completed|Pharmacokinetics (PK) Study of a Fluconazole Loading Dose in Infants and Toddlers||Drug:FluconazoleLoadingDose;  Drug:FluconazoleLoadingDose&amp;HighDose|Interventional|Phase 1|Other|PlasmaconcentrationofFluconazole|13|NCT00797420|November 2008
1732|Completed|Pharmacokinetics of NRL972 in Patients With Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD)||Drug:NRL972|Interventional|Phase 2|Industry|The primary efficacy variable is the NRL972 fractional retention ratio for 10 and 30 minutes post-dose (C30/C10) for different populations with NAFLD.;  Approximate overall clearance and t&#189; within 60 minutes of dosing with NRL972. Cmax AUC(0-&#8734;) and mean residence time derived from a non-compartmental analysis.|125|NCT00794716|June 2008
1733|Terminated|Does Dietary and Lifestyle Counseling Prevent Excessive Weight Gain During Pregnancy? A Randomized Controlled Trial||Behavioral:Dietaryandlifestylecounseling|Interventional||Other|The investigators primary outcome is the rate of adherence to the IOM guidelines between our study groups.;  The investigators secondary outcomes will include the effect of weight gain on mode of delivery rate of operative vaginal delivery infant weight and the incidence of preeclampsia GDM vaginal/perineal lacerations and shoulder dystocia.|100|NCT00792480|October 2005
1734|Completed|Voriconazole Pharmacokinetics in Children With Gastrointestinal Graft Versus Host Disease||Drug:voriconazole|Interventional|Phase 1|Other / NIH|Reduced bioavailability of oral voriconazole in pediatric patients status post stem cell transplantation with gastrointestinal graft versus host disease;  Pharmacokinetics(including clearance maximum concentration area under the time concentration curve and half life) of voriconazole in pediatric patients status post hematopoietic stem cell transplantation.|5|NCT00792246|December 2008
1735|Completed                  Has Results|Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema||Drug:Pegaptanib|Interventional||Other|ImprovementinVAETDRS&gt;/=15Letters;  Proportion of Patients Experiencing &gt; 0 Letter Vision Gain and a &lt; 15 Loss;  Decrease in CME as Evidenced by Imaging (Fluorescein Angiography and 50 Micron Change in OCT);  A Decrease in Anterior Chamber Cells or Vitreous Cells or Haze in Injected Eye;  Change in Immunomodulatory Medications (Topical Periocular or Systemic) After the Initiation of Macugen Therapy|5|NCT00790803|March 2009
1736|Completed|Development &amp; Validation of Utilities for Health States Relevant to Cervical Cancer Patients||Other: Discussion &amp; scoring of health states related to the treatment of cervical cancer|Observational||Other|The development and validation of a comprehensive set of quality of life related utility scores for the treatment of cervical cancer.;  To incorporate these utility scores into a previous decision model which will allow for outcomes costs and quality of life to be analyzed in the treatment of cervical cancer patients.|60|NCT00788216|September 2008
1737|Completed|A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma||Drug:Everolimus(RAD001);  Drug:Sunitinib(Sutent)|Interventional|Phase 1|Other / Industry|To determine the maximum tolerated dose (MTD)/recommended Phase 2 regimen of 2+1 dosing with Sunitinib and daily RAD001 in patients with advanced renal cell carcinoma.;  To determine the safety and tolerability of 2+1 dosing of Sunitinib and daily RAD001 in patients with advanced RCC;  To more fully evaluate the safety and tolerability of 2+1 dosing of Sunitinib and daily RAD001 at the MTD/recommended Phase 2 dose in patients with advanced RCC;  Describe the non-dose limiting toxicities associated with combination therapy using 2+1 dosing Sunitinib and daily RAD001.;  Describe the pharmacokinetics of Sunitinib and RAD001 and evaluate any association with disease response;  To estimate objective response rate (partial or complete) seen in patients with advanced RCC in a dose expansion cohort treated at the MTD or recommended Phase 2 dose regimen;  To estimate the overall survival of RCC patients treated with Sunitinib and RAD001;  To estimate the time to disease progression of RCC patients treated with Sunitinib and RAD001|5|NCT00788060|October 2008
1738|Completed                  Has Results|Bipolar Disorder in Late Life||Drug:ValproicAcid|Observational||Other|Boyko DWM Hyperintensity Value &gt;2 in Subjects Who Received Acute Treatment for Mania;  Boyko DWM Hyperintensity Value &gt;2 in Subjects Who Received Continuation Treatment;  Boyko Subcortical (SC) Hyperintensity Value &gt;2 in Subjects Who Received Continuation Treatment;  fa LOFC in Subjects Who Received Continuation Treatment;  fa ROFC in Subjects Who Received Continuation Treatment|19|NCT00787930|October 2005
1739|Completed|Impact of GBS on CVD in Type 2 Diabetes Mellitus||Other:DiabetesSupportandEducation;  Procedure:gastricbypasssurgery;  Other:TissueControlGroup|Interventional||Other / NIH|To determine whether surgically induced weight loss decreases the risk of CVD in morbidly obese subjects with Type 2 Diabetes Mellitus (T2DM);  To elucidate the mechanisms by which surgically induced weight loss reduces over time the risk of CVD in morbidly obese subjects with T2DM.|84|NCT00787670|November 2008
1740|Completed                  Has Results|Phase 2 Study of Efficacy Tolerability and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting||Drug:Intranasalgranisetron|Interventional|Phase 2|Industry|PercentageofPatientsWithCompleteControl;  PercentageofPatientsWithCompleteResponse;  PercentageofPatientsWithTotalResponse;  Percentage of Patients With Major Control of Emesis;  Percentage of Patients With Minor Control of Emesis;  PercentageofPatientsWithFailure;  PercentageofPatientsUsingRescueMedications;  TimetoFirstEmeticEpisode;  TimetoFirstRescueMedication;  TimetoTreatmentFailure;  NumberofEmeticEpisodes;  Severity of Nausea Measured by a 4 Categorical Scale;  Patient Global Satisfaction With Antiemetic Therapy Measured by a VAS|68|NCT00787566|October 2008
1741|Completed|Diet Imaging and Energy Balance Trial (DIET)||Behavioral: Low Carbohydrate Ketogenic Diet (LCKD);  Behavioral:LowFatDiet(LFD)|Interventional||Other|Compared to individuals in the LFD group individuals placed on an LCKD will exhibit decreased brain responses to high-carbohydrate food cues.;  In addition to these questions we will also examine relations between food consumption acquired from the diaries genetic factors and brain function.|51|NCT00787280|August 2008
1742|Completed                  Has Results|Transfusions and Nitric Oxide Level in Preterm Infants|||Observational||Other|SNOHgBLevels;  Oxygen Saturation and Measures of Perfusion Pre and Post-transfusion.|8|NCT00787124|September 2008
1743|Completed                  Has Results|Ventriculostomies in SAH: ICP Open or Not?|||Observational||Other|CerebralArteryVasospasm;  ExternalVentricularDrain(EVD)Complications;  CerebrospinalFluid(CSF)OutputPerDay|37|NCT00787020|November 2008
1744|Completed|Community Cancer Centers Pilot Patient Survey|||Observational||NIH|EvaluationofNCCCPPilotProgram;  Gain an understanding of the patients&apos; perspective on the NCCCP Pilot Program and to assess how well health care and informational needs are being met.|6000|NCT00786656|November 2008
1745|Completed                  Has Results|Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)||Drug:Placebo;  Drug:Dalteparin|Interventional|Phase 3|Other / NIH|NumberofArterialThromboembolicEvents;  MajorBleeding;  Number of Subjects With Death Acute Myocardial Infarction Deep Vein Thrombosis or Pulmonary Embolism;  NumberofParticipantsWithMinorBleeding|1884|NCT00786474|July 2009
1746|Completed                  Has Results|Outlook Quality of Life Intervention||Other:Lifecompletionandpreparation;  Other:AttentionControl|Interventional||U.S. Fed|QualityofLife-Preparation;  QUAL-ECompletionSub-scale;  FunctionalStatusADL;  Center for Epidemiology Studies - Depression Scale (CES-D);  POMSAnxietySub-scale|36|NCT00784095|December 2008
1747|Completed|Comparative Bioavailability and Effect of Food on CMX001 in Healthy Volunteers||Drug:CMX001|Interventional|Phase 1|Industry / NIH|AUCandCmaxofCMX001andcidofovir;  Clinical and laboratory endpoints and adverse events|24|NCT00780182|October 2008
1748|Completed|Epidural Neostigmine for Labor Pain||Drug:Neostigmine;  Drug:Bupivacaine;  Drug:fentanyl|Interventional||Other|Amount of drug consumed per hour in each group(Arm)|157|NCT00779467|October 2008
1749|Terminated                  Has Results|Utility of Intravitreal Methotrexate in Diabetic Macular Edema Resistant to Conventional Therapies||Drug:Methotrexateintravenous25mg/ml|Interventional||Other|Primary Would be 30% Decrease in One Subfield Thickness on Optical Coherence Tomography (OCT) 4 Weeks After the Last Intraocular Injection;  Secondary Would be Increase in Visual Acutiy (VA) Two Lines or More at the End of One Month After the Last Intraocular Injection.;  Secondary Would be Significant Clinical Improvement (Judged at the Slit Lamp Exam Using a 90D Lens) in Macular Edema at the End of One Month After the Last Intraocular Injection.|2|NCT00779142|September 2011
1750|Completed|Bioequivalence Study of Benazepril HCl / Hydrochlorothiazide 20 mg/ 25 mg Tablets Under Fasting Conditions||Drug: Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets|Interventional||Industry|Bioequivalence|42|NCT00778726|September 2004
1751|Completed|Bioequivalence Study of Benazepril HCl / Hydrochlorothiazide 20 mg/ 25 mg Tablets Under Fed Conditions||Drug: Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets|Interventional||Industry|Bioequivalence|30|NCT00778674|October 2004
1752|Completed|Bioequivalecne Study of Minocycline 100mg Tablets Under Fed Conditions||Drug:Minocycline100mgTablets|Interventional||Industry|Bioequivalence|24|NCT00777413|November 2002
1753|Completed|Bioequivalence Study of Minocycline 100mg Tablets Under Fasting Conditions||Drug:Minocycline100mgTablets|Interventional||Industry|Bioequivalence|28|NCT00776542|October 2002
1754|Completed|Digital Breast Tomosynthesis Preference Study||Device:DigitalBreastTomosynthesisExam|Interventional||Other / Industry|ReaderPreference|51|NCT00776126|October 2008
1755|Completed|Bioequivaelnce Study of Doxycycline Monohydrate 100mg Tablets Under Fed Conditions||Drug:Doxycyclinemonohydrate100mgtablets|Interventional||Industry|Bioequivalence|32|NCT00775918|June 2005
1756|Completed|Bioequivalence Study of Atenolol 100mg Tablets Under Fasting Conditions||Drug:Atenolol100mgTablets|Interventional||Industry|Bioequivalence|36|NCT00775580|May 2005
1757|Completed|Study in Healthy Males to Measure Maraviroc in Blood Saliva Seminal Fluid and Rectal Tissue||Drug:Maraviroc|Interventional|Phase 1|Other / Industry|To generate individual maraviroc pharmacokinetic parameters in seminal plasma after single and multiple dosing;  To generate composite maraviroc pharmacokinetic parameters in rectal tissue after single and multiple dosing;  To generate matrix:blood plasma ratios of maraviroc in semen and rectal tissue after single and multiple dosing|14|NCT00775294|May 2008
1758|Completed|Bioequivalence Study of Doxycycline Monohydrate 100mg Tablets Under Fasting Conditions||Drug:Doxycyclinemonohydrate100mgtablets|Interventional||Industry|Bioequivalence|32|NCT00775177|June 2005
1759|Completed|Pharmacist-Administered Injections for Contraception||Other:Pharmacist-administered;  Other:clinic-administeredinjections|Interventional||Other / Industry|Compliance in returning for 3 month and 6 month injections;  Attitudesaboutclinicalsetting|50|NCT00775047|August 2006
1760|Completed|Media Effects Study on Health-Related Content||Behavioral:electronichealthinformation|Interventional|Phase 0|Other|Physiologicalresponse;  Psychosocialresponse|40|NCT00775008|October 2008
1761|Completed                  Has Results|Once Weekly Subcutaneous Ports for the Administration of Anticoagulants||Device:Insuflon|Interventional||Other / Industry|AverageSubcutaneousAnti-XaBloodLevels;  Percent Difference of Each Participant&apos;s Subcutaneous Anti-Xa Levels;  Percent Difference of Each Participant&apos;s Anti-Xa Levels Without Port and Day One of Using the Port;  Percent Difference of Each Participant&apos;s Anti-Xa Blood Levels Between Day 1 and Day 7;  Standard Deviation of Participant&apos;s Own Glomerular Filtration Rate (GFR)|21|NCT00774748|August 2008
1762|Completed|A Pilot Study to Characterize the Pharmacokinetics of Raltegravir in the Cervicovaginal Fluids of HIV-infected Women||Drug:Raltegravir(Isentress&#174;)|Observational||Other / Industry|To characterize the pharmacokinetics of raltegravir in cervicovaginal fluids of HIV-infected women and compare this to the blood plasma pharmacokinetics being obtained in the main study CID 0706.|1|NCT00774683|August 2008
1763|Completed|Vascular Improvement With Olmesartan Medoxomil Study||Drug: olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure;  Drug: atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure|Interventional|Phase 4|Industry|Subcutaneous gluteal fat arteriole measurements prior to and after 52 weeks of therapy;  Resultsofvascularfunctiontests;  Measurement of serum lipid and markers of atherosclerosis;  Retinalarteriolemeasurements;  Calculationofinsulinsensitivitymeasurement;  24 hour urine creatinine and thromboxane B2 measurements;  Calculation of albumin-to-creatinine ratio and sodium-to-creatinine ratio|100|NCT00772499|November 2002
1764|Completed|Pounds Off Digitally Study: A Podcasting Weight Loss Intervention||Behavioral:podcasting|Interventional|Phase 1|Other|weight;  elaboration|94|NCT00771095|January 2008
1765|Withdrawn|Molecular Markers of Human Sperm Function|||Observational||NIH||0|NCT00767611|October 2008
1766|Unknown&nbsp;&#8224;|A Study to Evaluate the Efficacy of Silk - Like Bedding Fabric as Used in a Standard Pillow Case in the Treatment of Acne Vulgaris||Device:silk-likefabricstandardpillowcase;  Device:pillowcasemadeof100%cotton|Interventional||Other|The primary outcome is Investigator Global Assessment of Improvement measuring reduction in inflammatory lesions from Baseline to Week 12.;  The secondary outcome is patient assessment of facial acne vulgaris assessment.|40|NCT00767104|October 2008
1767|Completed|The Effect of Pregnancy on the Pharmacokinetics of the Kaletra Tablet||Drug:Kaletra|Interventional|Phase 1|Other|To compare the C12h and AUC0-12h of protein bound and unbound blood plasma lopinavir (LPV) using standard doses during the second and third trimesters of pregnancy.;  To compare the C12h and AUC0-12h of protein bound and unbound blood plasma LPV between standard doses (400mg/100mg BID) and increased doses (500/125mg BID) of Kaletra&#174; during the third trimester of pregnancy.;  To compare the C12h and AUC0-12h of protein bound and unbound blood plasma ritonavir (RTV) using standard doses during the second and third trimesters of pregnancy.|12|NCT00766818|January 2007
1768|Completed|Studying Urine and Blood Samples in Women With Newly Diagnosed Breast Cancer||Genetic:DNAanalysis;  Genetic:mutationanalysis;  Genetic:polymorphismanalysis;  Other:laboratorybiomarkeranalysis;  Other:medicalchartreview;  Other:questionnaireadministration;  Procedure:evaluationofcancerriskfactors|Observational||Other / NIH|Association between the genotype for 4 metabolic enzymes (e.g. CYP1A1 GSTM GSTT and GSTP) that play key roles in the metabolism of environmental human carcinogens and the risk of breast cancer development|1104|NCT00766454|November 1998
1769|Completed|Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury||Drug:TopicalKetoprofen10%Cream;  Drug:TopicalPlaceboCream|Interventional|Phase 3|Industry|Assess the efficacy of ketoprofen 10% cream in subjects with acute pain associated with mild to moderate acute soft tissue injury (acute sprain or strain) of upper and lower extremities on the day 3 visit.;  Assess the safety tolerability and other parameters of ketoprofen 10% cream in subjects with acute pain associated with mild to moderate acute soft tissue injury of upper and lower extremities.|364|NCT00765700|September 2008
1770|Terminated|Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)||Drug:RegadenosonDobutamine|Interventional|Phase 4|Other / Industry|Durationofprocedures;  Ease of Administration of regadenoson versus intravenous dobutamine.|40|NCT00763035|January 2009
1771|Completed                  Has Results|Compare Anti-inflammatory Dentifrices||Drug:Triclosan/Copolymer/fluoridetoothpaste;  Drug:Sodiummonofluorophosphatetoothpaste|Interventional|Phase 4|Industry|GingivalIndex(GI);  ProstaglandinE2(PGE2);  Interleukin-1Beta(IL-&#223;);  Interleukin-6(IL-6);  NuclearFactorKappaBLigand(RANK-L);  8-iso-prostaglandinF2&#945;(8-iso-PGF2&#945;);  DentalPlaqueIndex(PI);  BleedingonProbing(BOP)|49|NCT00762528|February 2009
1772|Terminated                  Has Results|A Pilot Study of the Provant Therapy System in Subjects With Diabetic Foot Ulcers||Device:TheProvantTherapySystem|Interventional||Industry|TheIncidenceofWoundsReachingCompleteClosure|8|NCT00761176|July 2008
1773|Completed|Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients||Drug:bivalirudin|Interventional|Phase 4|Industry|Plateletcounts|150|NCT00759083|September 2008
1774|Terminated|Range of Neutrophil Response to 20000 EU of Clinical Center Reference Endotoxin in Otherwise Healthy Smokers||Biological:CCREinhalation|Interventional|Phase 1|Other / NIH|To identify a dose of inhaled CCRE that is well tolerated and that induces measurable increases in neutrophil content of induced sputum that can be employed to screen large populations for susceptibility to the inflammatory effect of inhaled endotoxin.|2|NCT00753870|August 2008
1775|Unknown&nbsp;&#8224;|Prosocial Behavior and Exercise Among Older Adults||Behavioral: Prosocial Behavior Physical Activity (PBPA);  Behavioral:PhysicalExercise(PE)|Interventional||NIH|Self-reportedphysicalactivity;  Physicalfunctionhealth-relatedqualityoflife|80|NCT00747019|December 2008
1776|Completed                  Has Results|Randomized Control Trial to Assess Postoperative Pain After Sling Placement||Drug:0.125%Marcaine|Interventional||Other|Difference in Postoperative Pain Using a Visual Analog Scale at 2 Hours.;  Difference in Postoperative Pain Using a Visual Analog Scale at 6 Hours.;  Difference in Postoperative Pain Using a Visual Analog Scale at 24 Hours.;  In-hospitalMedicationAmounts;  Difference in Successful Voiding Trial Prior to Discharge Following Placement of Mid-urethral Sling Via the Suprapubic Approach.|42|NCT00746863|January 2007
1777|Completed|Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women.||Drug:Raltegravir|Interventional|Phase 1|Other|DruglevelsinCVFandbloodplasma|7|NCT00746499|September 2008
1778|Active not recruiting|Examining the Relationship Between Hormone Therapy and Cognitive Function (The WHIMS-ECHO Study)|||Observational||Other|All-causedementia;  Mildcognitiveimpairment|2922|NCT00745056|August 2008
1779|Completed                  Has Results|Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders||Biological: Unrelated Umbilical Cord Blood Transplant;  Drug:ReducedIntensityConditioning|Interventional|Phase 1|Other|Determine the Feasibility of Attaining Acceptable Rates of Donor Cell Engraftment (&gt;25% Donor Cells at 180 Days) Following RIC Regimens in Children &lt; 21 Years Receiving UCBT for Non-malignant Disorders.;  ToDescribethePaceofNeutrophilRecovery;  ToEvaluatethePaceofImmuneReconstitution.;  To Determine the Overall Survival at day180 Post-transplant;  To Describe Incidence of Acute Graft Versus Host Disease (GVHD) (II - IV);  To Describe the Incidence of Grade 3-4 Organ Toxicity;  To Evaluate Long-term Complications Such as Sterility Endocrinopathy and Growth Failure;  To Evaluate the Incidence of Late Graft Failures at 2 Years Post-transplant;  ToDescribethePaceofPlateletRecovery|22|NCT00744692|October 2008
1780|Terminated|Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb&#174; Compared to Placebo Control||Drug:Pancrelipase|Interventional|Phase 4|Industry / Other|Peak levels of three enzymes - lipase amylase and protease - each measured in U/ml will be outcomes|3|NCT00744250|August 2008
1781|Terminated                  Has Results|Effect on Bleeding When Using FloSeal Matrix&#8482; in Subjects Undergoing Endoscopic Vein Harvest (EVH)||Biological:FloSealMatrix|Interventional|Phase 4|Other / Industry|NumberofParticipantsWithDecreasedBleeding|50|NCT00742313|June 2009
1782|Completed                  Has Results|Reproducibility of 6 Minute Walk Tests for Oxygen Desaturation|||Observational||Other|Kappa Statistic for Correlation of the Oxygen Saturation Across 3 Serial 6 Minute Walk Tests (6MWT)|97|NCT00740220|September 2006
1783|Completed|Evaluating the Effects of Hormone Replacement Therapy on Brain Function (The WHIMS-MRI Study)|||Observational||NIH / Other|Prevalence of silent infarcts in women assigned to HRT versus women assigned to placebo|1426|NCT00739869|May 2004
1784|Active not recruiting|Non-invasive Blood Pressure (BP) Monitoring Compared to A-Line BP Monitoring|||Observational||Other|Correlation between NIBP and IABP. NIBP is measured in both upper arms both wrists both thighs and both ankles.|200|NCT00739700|June 2007
1785|Terminated|Presep and Vascath Interaction Study|||Observational||Other|changeinSvO2|100|NCT00739089|August 2008
1786|Completed|Does Echocardiographically Guided Ventriculo-Ventricular Optimization Yield a Sustained Improvement in Echocardiographic Parameters in Cardiac Resynchronization Therapy Patients? (DEVISE CRT)||Other: &quot;Sequential Arm&quot; (Promote  model # 2207-36 or Atlas HF  model # V-343);  Other: &quot;Simultaneous Arm&quot; (Promote  model # 2207-36 or Atlas HF  model # V-343)|Interventional||Other / Industry|To determine if a sustained hemodynamic benefit of increased Cardiac Output is maintained in patients who undergo ECHO guided optimization of V-V timing following CRT implantation when compared to patients simultaneously biventricularly paced.;  Assessment for improvements in 1)6 minute walk 2)ECHO parameters 3)symptoms as assessed by the Minnesota Quality of Life Score.|40|NCT00737490|June 2005
1787|Terminated|Recombinant Human Growth Hormone (RH-GH) For Accelerating Immune Reconstitution Post Unrelated Cord Blood Transplant||Drug: Genotropin (Recombinant Human Growth Hormone)|Interventional|Phase 1|Other / Industry|To define the safety of recombinant human growth hormone (rh-GH Genotropin) in a population of patients undergoing allogeneic transplantation;  To evaluate the incidence of mortality due to opportunistic infections in the first 6 months.;  To evaluate the incidence and severity of infectious complications.;  To assess laboratory parameters of post-transplant immune recovery in patients on GH therapy.;  To determine the probability and time of neutrophil and platelet recovery on GH therapy.|14|NCT00737113|September 2008
1788|Terminated                  Has Results|Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)||Drug:Glucophage(Metformin);  Drug:Placebo|Interventional|Phase 4|Other|Study Endpoints Will Include Measurements of Insulin Sensitivity Hepatic Insulin Clearance and Altered Parameters of Lipid Metabolism Changes in the Histological Features That Define NAFLD and Quantitative Measurements of Visceral and Peripheral Fat.;  Tests the Postulate That Metformin Will Improve Insulin Sensitivity in NAFLD. Also Test the Postulate That Improving IR (Insulin Resistance) With an Insulin Sensitizing Agent Will Improve Biochemical and Histological Features of NAFLD.;  Determine if Metformin Improves the Altered Parameters of Lipid Metabolism as Compared to Placebo.;  Measure the Differential Effects of IR and Lipid Metabolism on Peripheral Mononuclear Cell (PBMC) Inflammatory Response and the Associated Hepatocyte Mitochondrial Ultrastructure and Measures of Oxidative Stress|11|NCT00736385|April 2009
1789|Completed                  Has Results|Attention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study||Drug: Lis-dexamphetamine (LDX; Vyvanse) and Transdermal Nicotine Patch;  Drug:Placeboandtransdermalnicotinepatch|Interventional||Other / Industry|The Number of Subjects in Each Treatment Group Exhibiting Sustained 4-week Smoking Abstinence Defined as CO Levels &lt; 4 Ppm for Each Post-quit Study Visit.;  SmokingRates;  Continuous Performance Test (CPT) Commission Errors;  Continuous Performance Test (CPT) Reaction Time Standard Error;  ADHDCAARSSelf-ReportandObserverShortForms;  CognitiveFunctioning;  Clinician Rated Clinical Global Impressions of Improvement Scale (CGI-I)|32|NCT00736255|December 2007
1790|Completed|Memory and Picture Viewing Study|||Observational||Other / NIH|brainreactivity|116|NCT00736203|July 2008
1791|Completed                  Has Results|A Study to Determine if Carbon Dioxide Lavage During Total Knee Surgery Reduces Intraoperative Embolic Events||Device:pulsatilesalinelavage;  Device:carbondioxidelavage|Interventional|Phase 2|Industry / U.S. Fed|The Number of Cerebral Emboli During Surgery as Measured by Transcranial Doppler (TCD);  Number of Patients With Emboli in the High Category;  ChangesinNeurocognitiveTestsFollowingSurgery;  DeliriumDuringHospitalStay;  ChangesinPulmonaryandRenalFunction;  CardiacInjury;  SystemicInflammatoryResponse(SIRS)Markers;  BiomarkersofNeuronalDamage|20|NCT00736125|December 2007
1792|Completed                  Has Results|A Trial of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis||Drug:aprepitant;  Drug:Placebo|Interventional||Other / Industry|Number of Post-ERCP Pancreatitis Cases in Participants Who Are Administered Aprepitant and Placebo Prior to ERCP and One Day After ERCP:Assess the Total Number of Incidents of Post-ERCP Pancreatitis in Each Group (Treatment and Control).;  Incidence of Pain Post-ERCP Within 48 Hours of ERCP and at 1 Week Post-ERCP; Unrelated to Pancreatitis;  Number of Participants Who Were Hospitalized Within 7 Days Post-ERCP for Abdominal Pain That Did Not Meet Criteria for Acute Pancreatitis|73|NCT00736073|August 2007
1793|Completed|PARTNER Recruitment and Brief Intervention Pilot Study||Behavioral:Counseling|Interventional|Phase 1 / Phase 2|Other|The trial will compare the effectiveness of using an onsite behavioral health specialist for screening intervention and referral with basic written information and staff recommendations typically provided in primary care offices.;  Assessments and early intervention of identifying alcohol abuse in minors.|300|NCT00735956|September 2008
1794|Terminated                  Has Results|A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)||Drug:Gliadel/Avastin/CPT-11|Interventional|Phase 2|Other / Industry|24-weekOverallSurvival;  24-weekProgression-freeSurvival(PFS);  MedianProgression-freeSurvival(PFS);  MedianOverallSurvival(OS);  Incidence and Severity of Central Nervous System (CNS) Hemorrhage;  Incidence of Grade &#8805; 4 Hematologic and &#8805; Grade 3 Non-hematologic Toxicities|18|NCT00735436|December 2008
1795|Completed                  Has Results|Phase I/II Trial of Radiation Avastin and Tarceva for Pancreatic Adenocarcinoma||Drug:Avastin;  Drug:Tarceva;  Radiation:RadiationTherapy|Interventional|Phase 1|Other / Industry|TarcevaMaximumToleratedDoseinmg;  NumberofDoseLimitingToxicities;  OneYearOverallSurvivalFromTimeofDiagnosis|12|NCT00735306|July 2008
1796|Completed                  Has Results|Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer||Device:HyperthermiaSystem;  Drug:MitomycinC|Interventional|Phase 0|Other|SafetyandTolerability;  MedianRecurrenceFree-survival|15|NCT00734994|April 2008
1797|Recruiting|An Optical Assay System for Intra Operative Assessment of Tumor Margins in Patients||Device:49-channelopticalspectrometer|Interventional||Other / NIH|Identification of the optical signatures of breast tissue.|530|NCT00734955|May 2006
1798|Completed                  Has Results|Aprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having Craniotomy||Drug:Aprepitant+Dexamethasone;  Drug:Ondansetron+Dexamethasone|Interventional|Phase 4|Other / Industry|CumulativeIncidenceofEmesis;  IncidenceofNausea;  IncidenceofVomiting;  UseofRescueAntiemetics;  Number of Participants With a Complete Response Rate;  AverageNauseaScore;  NumberofVomitingEpisodes;  TimetoFirstVomiting;  Number of Participants Who Rated Their Satisfaction With Antiemetic Management as &quot;Very Satisfied&quot;|115|NCT00734929|September 2007
1799|Withdrawn|Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma||Drug:enzyme-inducinganti-epilepticdrugs|Interventional|Phase 1|Other / Industry|ToxicityassessedusingCTCAEv.3.0;  Progressionfreeandoverallsurvival;  Radiographic response (modified MacDonald Criteria)|0|NCT00734864|June 2009
1800|Completed|Optical Spectroscopy During Breast Cancer Surgery and Core Needle Biopsy||Device:HighResolutionMicroendoscope;  Device:Bench-topopticalspectrometer|Interventional||Other|Opticalsignatures|132|NCT00734838|January 2006
1801|Completed                  Has Results|Treating Co-Morbid Sleep Difficulties in Veterans With Posttraumatic Stress Disorder (PTSD): A Pilot Study||Behavioral:SleepInterventionforPTSD(SIP).|Interventional||U.S. Fed|InsomniaSeverity;  NightmareFrequency|22|NCT00734799|January 2008
1802|Completed                  Has Results|Concurrent Nicotine Patch / Denicotinized Cigarette Therapy for Smoking Cessation II||Drug:NicotinePatch|Interventional|Phase 3|Other|Continuous Abstinence From Smoking at Ten Weeks Post-quit|479|NCT00734617|August 2007
1803|Completed|Partner-Assisted Emotional Disclosure for GI Cancer||Behavioral:Partner-assistedemotionaldisclosure;  Behavioral:CancerEducation|Interventional||Other|Patient&apos;spsychologicaladjustment;  Patient&apos;sphysicalandfunctionalwell-being;  Communication quality between the patient and partner (i.e.level of disclosure helpfulness of disclosure and perceived empathy from the partner and decreased partner avoidance and criticism).;  Partners&apos; psychological well-being and caregiver strain;  Gender and marital satisfaction as moderators of the effects of partner-assisted ED.|300|NCT00734513|January 2003
1804|Completed                  Has Results|Anidulafungin PK in Infants and Toddlers||Drug:Anidulafungin|Interventional|Phase 1|Other|The Pharmacokinetics (Area Under the Curve) of Anidulafungin in Infants and Toddlers Less Than 24 Months of Age With Suspected Serious Infection.;  Safety (Participants With Adverse Events) of Anidulafungin in Infants and Toddlers Less Than 24 Months of Age With Suspected Serious Infection.|15|NCT00734500|January 2008
1805|Completed                  Has Results|Combining Objective and Subjective Sedation Assessment Tools||Device:BispectralIndex(BIS)Monitor|Interventional||Other / Industry|MeanSedativeUse;  UnplannedSelf-deviceRemovalEvents;  MeanDaysonMechanicalVentilation|300|NCT00734409|May 2008
1806|Completed                  Has Results|Bortezomib With Melphalan and Prednisone for Multiple Myeloma||Drug:Bortezomib;  Drug:Melphalan;  Drug:Prednisone|Interventional|Phase 2|Other|Response;  Number of Patients With Any Grade or Severe Adverse Event;  MedianDurationofResponse|45|NCT00734149|July 2004
1807|Completed|Lung Mucus Hypersecretion and NQO1|||Observational||NIH|AirwayMucociliaryClearance;  Bronchial Epithelial Cells obtained by bronchoalveolar lavage.|60|NCT00729352|August 2008
1808|Completed|Functional Implications of TNF||Drug: Etanercept inhibition of ozone-induced airway hyper-responsiveness.|Observational||NIH|biologic response to ozone exposure: bronchoalveolar lavage fluid analyzed for inflammatory cytokines cell differentials and activated alveolar macrophages.;  Alveolar macrophages (collected in lung lavage fluid) will be studied ex vivo for activation state and pro-inflammatory cytokine secretion.|10|NCT00729131|August 2008
1809|Active not recruiting|Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia||Drug:DietarySupplement:Pregnenolone;  DietarySupplement:Placebo|Interventional|Phase 2|U.S. Fed|MATRICSConsensusCognitiveBattery(MCCB);  University of California Performance-based Skills Assessment (UPSA);  Brief Assessment of Cognition in Schizophrenia (BACS);  Scale for the Assessment of Negative Symptoms(SANS);  The Calgary Depression Scale for Schizophrenia (CDSS) Positive and Negative Syndrome Scale (PANSS)Clinical Global Impressions (CGI) Scale;  PositiveandNegativeSyndromeScale(PANSS);  ClinicalGlobalImpressions(CGI)Scale|88|NCT00728728|December 2009
1810|Terminated|Aerobic Exercise in Patients Receiving Chemotherapy for Cancer||Behavioral:exerciseintervention|Interventional||Other / NIH|Percentageofpatientsenrollinginthestudy;  Percentageofpatientscompletingthestudy;  V02peakbeforeandafterchemotherapy|1|NCT00728429|June 2008
1811|Completed|Pregnant Women&apos;s CoOp||Behavioral:Woman-focusedintervention;  Behavioral:TreatmentasUsual|Interventional|Phase 1|Other / NIH|To compare the relative efficacy of the woman-focused intervention in reductions in substance abuse and sexual risk behaviors maintain retention in drug treatment reduce violence and improve prenatal care and ARV treatment adherence (as needed).;  To explore the intervention&apos;s potential mechanisms of action and moderating factors that may influence response to the treatment.|100|NCT00722670|June 2007
1812|Active not recruiting|Docetaxel Cisplatin and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer||Biological:cetuximab;  Drug:cisplatin;  Drug:docetaxel;  Drug:fluorouracil;  Procedure:computedtomography;  Procedure:positronemissiontomography;  Procedure:quality-of-lifeassessment;  Radiation: 3-dimensional conformal radiation therapy;  Radiation:intensity-modulatedradiationtherapy|Interventional|Phase 2|Other / NIH|Progression-freesurvival;  Objectiveresponserate;  Bestoverallresponserate;  Overallsurvivalandlocal-regionalcontrol;  Incidenceofdistantmetastasis;  Accuracy of PET/CT scan in evaluating objective response; in detecting residual disease at primary sites and nodes; in guiding the recommendation for salvage surgery or for neck dissection; and in early detection of recurrent or metastatic disease;  Acuteandchronictoxicities;  Qualityoflifeandswallowing|46|NCT00721513|September 2008
1813|Completed|Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer||Drug:aprepitant;  Drug:cyclophosphamide;  Other:placebo|Interventional||Other / NIH|Effect of aprepitant on cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics as measured by plasma AUC|19|NCT00719173|August 2005
1814|Completed                  Has Results|A Multicenter Randomized Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy Safety and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Major Abdominal Surgery||Drug:Oralsufentanil;  Drug:Placebo|Interventional|Phase 2|Industry|SPID-12;  Proportion of Patients Who Responded Very Good or Excellent in Patient Global Evaluation of Pain Relief|88|NCT00718081|August 2008
1815|Completed                  Has Results|Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease||Drug: cyclosporine ophthalmic emulsion 0.05% artificial tears|Observational||Industry|Ocular Surface Disease Index (OSDI) Total Score at Baseline|781|NCT00717418|September 2004
1816|Completed                  Has Results|Controlled Study of the Effect of Xenaderm&#174; Ointment Vehicle Versus White Petrolatum on Healing||Drug:XenadermVehicle;  Other:Placebocomparator|Interventional|Phase 2|Industry|CompleteWoundClosure|25|NCT00713349|June 2008
1817|No longer available|Therasphere&#174; for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer||Device:yttriumY90microspheres(Therasphere&#174;)|Expanded Access||Other|||NCT00701168|
1818|Completed                  Has Results|Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery||Drug:LoteprednolEtabonate;  Drug:VehicleofOphthalmicLoteprednolEtabonate|Interventional|Phase 3|Industry|Participants With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0;  ParticipantsWithGrade0(no)Pain;  Participants With Complete Resolution of Anterior Chamber Cells and Flare at Each Visit.;  Mean Change From Baseline to Each Follow-up Visit in Anterior Chamber Cells and Flare|400|NCT00699153|June 2008
1819|Terminated|Effects of Capsaicin on the Structure Distribution and Function of Cutaneous Small Nerve Fibers in Psoriatic Skin||Drug:Capsaicin|Interventional|Phase 4|Other|To assess the effect of capsaicin on small nerve fiber function in psoriasis|12|NCT00697034|June 2006
1820|Completed|Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population||Drug:Fluorouracil0.5%|Interventional|Phase 4|Other|Adherence to Carac&#174; in subjects with moderate to severe actinic keratosis.|20|NCT00696488|April 2007
1821|Unknown&nbsp;&#8224;|Analysis of Adherence in Subjects Undergoing Differin Gel 0.1% Treatment of Moderate to Severe Acne Vulgaris||Drug:Adapalene|Interventional|Phase 4|Other|Percent change from baseline in total lesions counts;  GlobalAssessmentofimprovementfrombaseline.|80|NCT00696449|June 2006
1822|Completed|Comprehensive Investigation of Opiates Neuropeptides Barrier Function Scratching and Sleep Physiology|||Observational||Other|To assess whether there are differences in dermal and serum opiate levels and neuropeptides involved in atopic dermatitis between day and night|31|NCT00696397|March 2006
1823|Completed|Clinical Trial to Evaluate Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy||Drug:Biafine|Interventional|Phase 4|Other|The change of the target lesions from Baseline to or end of treatment in the IGA|20|NCT00695578|October 2006
1824|Unknown&nbsp;&#8224;|Adherence to Topical Hydrocortisone 17-Butyrate 0.1% (Locoid&#174;) Using Different Vehicles in Adults With Atopic Dermatitis||Drug: hydrocortisone 17-butyrate 0.1% preparation ointment;  Drug: hydrocortisone 17-butyrate 0.1% preparation cream;  Drug: hydrocortisone 17-butyrate 0.1% preparation lipocream|Interventional|Phase 4|Other|ThechangeovertreatmentintheIGA.|30|NCT00693693|November 2006
1825|Unknown&nbsp;&#8224;|Comparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Itch in Adult Hemodialysis Patients||Drug:Sarna;  Drug:Cetaphil|Interventional|Phase 4|Other|The primary outcome is investigator assessment of pruritus score and response to treatment using an itch questionnaire;  The secondary outcome is the effect of treatment on skin moisturization and quality of life at baseline and end of treatment.|30|NCT00693654|November 2006
1826|Terminated                  Has Results|Effect of Spinal Ketorolac After Acute Opioid Exposure||Drug:ketorolac;  Drug:placebo;  Drug:remifentanil;  Drug:Capsaicin|Interventional|Phase 2|Other / NIH|Hyperalgesia;  Cerebrospinal Fluid (CSF) Prostaglandin E2 (PGE2) Concentration|30|NCT00693160|December 2007
1827|Completed|Evaluation of Recovery From Drug-Induced Lymphopenia Using Cytomegalovirus-specific T-cell Adoptive Transfer||Biological:CMV-ALT+CMV-DCs;  Biological:CMV-ALT+Saline|Interventional|Phase 1|Other|To evaluate if vaccinating adult patients with newly-diagnosed GBMs using CMV-DCs during recovery from therapeutic TMZ-induced lymphopenia with ALT in patients that are seropositive for CMV enhances the T-cell response.;  To evaluate the safety of ALT with CMV pp65-activated T-cells in adult patients with newly-diagnosed GBMs during recovery from therapeutic TMZ-induced lymphopenia.|23|NCT00693095|September 2008
1828|Terminated|Polycystic Ovarian Syndrome: Impact of Flaxseed Supplementation||DietarySupplement:flaxseed|Interventional|Phase 2|Other|To explore the effects of flaxseed supplementation on women with clinically confirmed PCOS.|4|NCT00693082|August 2007
1829|Completed|Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells||Biological:ALDHbrUmbilicalCordBloodCells|Interventional|Phase 1|Other / Industry|To assess the safety of infusing ex vivo cytokine-primed ALDHbr cells isolated from banked unrelated umbilical cord blood (CB) into patients also receiving a standard unmanipulated unrelated CB transplant delivering &gt;2.5x10e7 nucleated cells per kg.;  To describe the biological effect of ex vivo cytokine-primed ALDHbr cells in these patients on neutrophil and platelet engraftment and immune reconstitution.;  To describe the clinical outcomes in these patients: - incidence of infections -Non relapse mortality -incidence of acute and chronic graft-vs-host disease -overall survival at 180 days|37|NCT00692926|October 2005
1830|Completed                  Has Results|Neuroimaging Attentional Impairment During Abstinence||Behavioral:SmokingAbstinence|Interventional||Other / NIH|Percent Signal Change in fMRI BOLD Signal Between RVIP Task and Control Task in Inferior Frontal Gyri (IFG) During Sustained Attention Task on Satiated Day;  Percent Signal Change in fMRI BOLD Signal Between RVIP Task and Control Task in Inferior Frontal Gyri (IFG) During Sustained Attention Task on Abstinent Day;  Percent Signal Change in fMRI BOLD Signal Between RVIP Task and Control Task in Middle Frontal Gyri (MFG) During Sustained Attention Task on Satiated Day;  Percent Signal Change in fMRI BOLD Signal Between RVIP Task and Control Task in Middle Frontal Gyri (MFG) During Sustained Attention Task on Abstinent Day;  Percent Signal Change in fMRI BOLD Signal Between RVIP Task and Control Task in Angular Gyrus (AnG) During Sustained Attention Task on Satiated Day;  Percent Signal Change in fMRI BOLD Signal Between RVIP Task and Control Task in Angular Gyrus (AnG) During Sustained Attention Task on Abstinent Day;  Percent Signal Change in fMRI BOLD Signal Between RVIP Task and Control Task in Cuneus (Cun) During Sustained Attention Task on Satiated Day;  Percent Signal Change in fMRI BOLD Signal Between RVIP Task and Control Task in Cuneus (Cun) During Sustained Attention Task on Abstinent Day|80|NCT00692406|June 2005
1831|Active not recruiting|Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia|||Observational||Other|To evaluate the expression of Fas protein in skin biopsies of participants with central centrifugal scarring alopecia (CCSA) lichen planopilaris (LP) and discoid lupus erythematosus (DLE) and in healthy controls.;  To evaluate the expression of Fas protein in skin biopsies of participants with central centrifugal scarring alopecia before and after treatment with intralesional and topical steroids.|25|NCT00691769|April 2006
1832|Completed                  Has Results|Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy||Drug:LenalidomideInduction;  Drug:SequentialMaintenanceTherapy|Interventional|Phase 2|Other / Industry|ProgressionFreeSurvival;  TimetoResponse;  OverallSurvival;  TimetoProgression;  DurationofResponse|18|NCT00691704|August 2008
1833|Completed|Comprehensive Investigation of Heart Rate Variability as a Measure of the Autonomic Nervous System in Atopic Dermatitis|||Observational||Other||45|NCT00691366|March 2007
1834|Unknown&nbsp;&#8224;|A Multi-center Study to Evaluate the Safety of Etanercept in the Treatment of Lichen Planus||Drug:etanercept|Interventional|Phase 2|Other|The percentage of patients achieving a response in mucosal disease (or cutaneous disease if no mucosal disease) at 12 weeks.;  The percentage of patients achieving a response in cutaneous or mucosal disease at 24 weeks.|5|NCT00691106|March 2007
1835|Withdrawn|Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis||Drug:adalimumab|Interventional|Phase 2|Other|ChangeinPGAscore.;  Number of complete responders partial responders minimal responders and non-responders|0|NCT00690911|
1836|Withdrawn|Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum||Drug:adalimumab|Interventional|Phase 2|Other|Meanchangeinthenumberofulcers.|0|NCT00690846|
1837|Completed|Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis||Drug:topicaldesonidehydrogel0.05%|Interventional|Phase 4|Other|The change from Baseline to Week 4 (or end of treatment) in the IGA|41|NCT00690833|August 2007
1838|Active not recruiting|Evaluation of Scalp and Hair Shaft With Biologic Markers in African American and Caucasian Hair|||Observational||Other|Observe comparators of African American and Caucasian women&apos;s hair|60|NCT00690664|April 2007
1839|Unknown&nbsp;&#8224;|Seniors Health and Activity Research Program-Pilot||Behavioral:PhysicalActivityTraining(PAT);  Behavioral:CognitiveTraining(CT);  Behavioral:HealthyAgingEducation(HAE)|Interventional||NIH|Composite of five executive functioning and four episodic memory measures that have been previously validated;  Speed of processing visuospatial skills and verbal fluency;  Perceived cognitive functioning problems and quality of life;  Domain scores [executive function (five tests); immediate memory (two tests); delayed memory (two tests)]|100|NCT00688155|May 2008
1840|Completed|A Randomized Controlled Trial (RCT) of Carbon Dioxide Versus Air Insufflation During Endoscopic Retrograde Cholangiopancreatography (ERCP)||Other:CO2insufflation;  Other:Roomairinsufflation|Interventional||Other / Industry / NIH|Abdominalpain(VAS).;  TheextentofCO2retention.|74|NCT00685386|June 2008
1841|Completed|The Women&apos;s Health Initiative Memory Study (The WHIMS Study)||Drug:Estrogenhormonetherapy;  Drug:Estrogenplusprogesteronehormonetherapy;  Drug:Placebo|Observational||NIH / Other|All-causedementia;  Mildcognitiveimpairment|7525|NCT00685009|January 1996
1842|Recruiting|Studies of the Variable Phenotypic Presentations of Rapid-Onset Dystonia Parkinsonism and Other Movement Disorders|||Observational||Other / NIH|RDPSeverity;  Presenceofneuropsychiatricdisease;  MagneticResonanceImaging(MRI)|130|NCT00682513|April 2008
1843|Completed|Sex Differences in Vascular Markers of Stroke Risk|||Observational||Other / NIH|Carotid intimal medial thickness (IMT) and 10-year cardiovascular risk assessment. The primary analysis will focus on gender differences.;  Brachial artery flow mediated dilation (BAFMD) and ankle-brachial index (ABI)|117|NCT00681681|February 2008
1844|Completed|Mindfulness vs. Support Groups for Irritable Bowel Syndrome||Behavioral:Mindfulnesstraining;  Behavioral: Psycho-educational support group for women with IBS|Interventional||Other / NIH|IBS-S;  VisceralSensitivityIndex;  Work Productivity and Activity Impairment for IBS (WPAI:IBS);  RecentPhysicalSymptomsQuestionnaire(RPSQ);  BriefSymptomInventory(BSI);  StateTrait-AngerExpressionInventory(STAXI);  CopingStrategiesQuestionnaire(CSQ);  IBSQOL;  DailySymptomDiary|75|NCT00680693|October 2006
1845|Completed|Supplemental Choline and Brain Development in Humans||DietarySupplement:Phosphatidylcholine;  DietarySupplement:Cornoilplacebo|Interventional||Other|Infantworkingmemory;  Breastmilkcholineconcentration;  Plasmacholineconcentrations|150|NCT00678925|December 2004
1846|Completed                  Has Results|Cost Comparison of Cardiac Magnetic Resonance Imaging (MRI) Use in Emergency Department (ED) Patients With Chest Pain||Other: Observation unit care coupled with cardiac MRI|Interventional||Other|CostofIndexHospitalization;  Correct Admission Decision Based Upon the Reference Standard of Acute Coronary Syndrome (ACS) at 30 Days;  The Number of Participants Randomized to the OU and Were Able to Complete CMR Imaging;  Number of Participants Who Utilized the Indicated Health Care Procedures;  Adverse Events During Magnetic Resonance Imaging (MRI) Scanning|110|NCT00678639|January 2008
1847|Completed|Study of Cancer Peptides Vaccine Plus GM-CSF as Adjuvant Treatment for High Risk (TXN2-3M0) or Metastatic Breast Cancer With No Evidence of Disease||Biological:OCPMImmunotherapeuticVaccine|Interventional|Phase 1|Other / Industry|Safety/tolerability: Number of subjects with dose limiting toxicity after 3 immunizations.;  Immunologic response: Number of subjects with tumor antigen specific immune response after 3 immunizations.|13|NCT00674791|June 2007
1848|Completed|Correlation of Location of Abdominal Tenderness With Acute CT Abnormalities in Emergency Department Patients||Device:radio-opaqueadhesiveskinmarkers|Observational||Other|sensitivity and specificity of a hypothetical limited CT restricted to the region of abdominal tenderness for detection of acute pathology on CT on the entire abdomen.;  the percentage decrease in radiation exposure which could be achieved by performing a CT restricted to the region of abdominal tenderness compared with CT of the entire abdomen|102|NCT00673374|May 2008
1849|Completed|Early Detection of Lung Cancer Via Bi-plane Correlation Chest Imaging||Device:bi-planechestradiography|Interventional|Phase 0|Other|The technique is effective in diagnosing early lung tumors.;  The relative performance of BCI with respect to chest radiography and CT for lung cancer detection.|86|NCT00673283|April 2007
1850|Completed                  Has Results|Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched) T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies||Biological:haplo/cordtransplant|Interventional|Phase 1 / Phase 2|Other / Industry|The Number of Participants Reaching Primary Endpoint of Absolute Neutrophil Count (ANC) of 500/uL (Engraftment).;  180DaySurvival;  Non-RelapseMortalityat180DaysPostTransplant;  Platelet Engraftment (Untransfused and Platelet Count &gt; 50000);  IncidenceofPrimaryandSecondaryGraftFailure;  Number of Participants With Acute or Chronic Graft-versus-host Disease (GVHD);  RatesofLeukemicRelapse;  Number of Participants With Donor Cells at 100 Days Post-transplant|3|NCT00673114|August 2007
1851|Completed|Group Parent Training for Adolescent Eating Disorders||Behavioral:GroupParentTraining;  Behavioral:MaudsleyFamilyTherapy|Interventional||Other|BodyMassIndex;  Eatingdisordersymptomsotherthanbodyweight.|124|NCT00672906|July 2005
1852|Completed|Self System Therapy and Chronic Low Back Pain Trial||Behavioral:Self-SystemTherapy;  Behavioral:Education;  Other:StandardCare|Interventional|Phase 4|Other|Depressionlevels|137|NCT00672880|October 2003
1853|Completed                  Has Results|&#946;-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients||Drug:PreemptiveTherapywithAnidulafungin;  Drug: Empiric antifungal therapy based on physician discretion.|Interventional||Other / Industry|Clinical Utility of Biweekly &#946;-D-glucan (BDG) Testing in At-risk Intensive Care Unit (ICU) Patients.;  Safety and Tolerability of Preemptive Anidulafungin;  Validate Gene Expression Signatures Predictive of IC;  Incidence of Proven or Probable Invasive Fungal Infection (IFI)|64|NCT00672841|June 2008
1854|Completed|Adherence to Hydroxyurea in Children With Sickle Cell Anemia||Behavioral:Bloodsmeareducation;  Other:standardeducation|Interventional||Other / NIH|treatmentadherence|31|NCT00672789|April 2008
1855|Completed|Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells||Biological: Proteasome siRNA and tumor antigen RNA-transfected dendritic cells|Interventional|Phase 1|Other|For this Phase I study subjects will be evaluated both clinically and with laboratory testing for any signs of toxicity associated with vaccination.;  For each subject the induction of anti-melanoma immune responses will be assessed by in vitro testing.;  For each subject clinical responses to vaccination will also be assessed.|12|NCT00672542|January 2008
1856|Terminated|Rhubarb and Angiotensin Converting Enzyme Inhibitor||DietarySupplement:rhubarbextract;  DietarySupplement:placebo|Interventional||Other / NIH|albuminuria;  rateofdeclineofGFR|8|NCT00672451|January 2008
1857|Completed                  Has Results|Neuroimaging Decision Making and Response Inhibition During Smoking Abstinence||Behavioral:SmokingAbstinence|Interventional||Other / NIH|Signal Change in Functional Magnetic Resonance Imaging (fMRI) BOLD Signal Between Response Inhibition Trials and Control Trials in Right Inferior Frontal Cortex (rIFC) During Task on Satiated Day;  Signal Change in fMRI BOLD Signal Between Response Inhibition Trials and Control Trials in Right Inferior Frontal Cortex (rIFC) During Task on Abstinent Day;  Signal Change in fMRI BOLD Signal Between Response Inhibition Trials and Control Trials in Presupplementary Motor Area (Pre-SMA) During Task on Abstinent Day;  Signal Change in fMRI BOLD Signal Between Response Inhibition Trials and Control Trials in Presupplementary Motor Area (Pre-SMA) During Task on Satiated Day|62|NCT00672256|January 2007
1858|Completed                  Has Results|Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme||Drug:Erlotinib+sirolimus|Interventional|Phase 2|Other / Industry|6-monthProgression-freeSurvival(PFS);  MedianProgressionFreeSurvival(PFS);  MedianOverallSurvival(OS);  BestRadiographicResponse;  Number of Participants Experiencing a &#8805; Grade 3 Treatment-related Non-hematologic Toxicity.|32|NCT00672243|April 2007
1859|Terminated                  Has Results|Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic Recurrent or Unresectable Renal Cell Cancer (RCC)||Radiation:Stereotacticbodyradiation|Interventional|Phase 1 / Phase 2|Other / Industry|Number of Participants With Overall Complete and Partial Response (CR+PR)|1|NCT00672178|March 2008
1860|Terminated|A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation||Biological:WT1derivedpeptides|Interventional|Phase 1|Other|SafetyandFeasibility;  ImmuneResponse;  Efficacy(PFSandOS)|8|NCT00672152|June 2007
1861|Completed                  Has Results|Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)||Drug:BevacizumabandErlotinib|Interventional|Phase 2|Other / Industry|6MonthProgression-freeSurvival;  RadiographicResponse;  PharmacokineticsofErlotinib:Cmax;  PharmacokineticsofErlotinib:AUC;  Association of Biomarkers and One-year Survival - Epidermal Growth Factor (EGFR);  Association of Biomarkers and One-year Survival - EGFR vIII;  Association of Biomarkers and One-year Survival - Phosphatase and Tensin Homologue (PTEN);  Association of Biomarkers and One-year Survival - Phosphorylated Protein Kinase B (pAKT);  Association of Biomarkers and One-year Survival - Phosphorylated Mitogen-activated Protein Kinase (pMAPK);  Association of Biomarkers and One-year Survival - Vascular Endothelial Growth Factor (VEGF);  Association of Biomarkers and One-year Survival - VEGFR-2|57|NCT00671970|February 2007
1862|Completed|Role of TLR4 in Environmental Asthma||Biological:Lipopolysaccharideendotoxin|Interventional|Phase 1|Other|Ascertain individuals homozygous and heterozygous for mutant TLR4 genotype along with wild types by recruitment of healthy screening subjects in the community.;  Assess the effect of TLR4 genotype on LPS endotoxin induced immune responses and assess the association of the LPS-induced immune response with LPS-induced airway responses.|855|NCT00671892|September 2001
1863|Terminated|Differential Gene Expression in Lung and Peripheral Blood After Inhaled Allergen Challenge||Biological:HouseDustMite;  Biological:Diluent|Interventional|Phase 1|Other|Identify genes in airway epithelial and BAL cells that are differentially expressed following inhalation of house dust mite allergen among study subjects with allergic asthma and normal phenotypes.|40|NCT00671593|October 2006
1864|Completed|Nitric Oxide LPS and the Pathogenesis of Asthma Phase 1|||Observational||NIH / Other||420|NCT00671229|May 2003
1865|Completed|An Evaluation of the Cosmetic Appearance of Metronidazole Gel (MetroGel&#174;) 1%||Drug:MetronidazoleGel|Observational||Industry|AssessmentofCosmeticAppearancebyInvestigator;  AssessmentofCosmeticAppearancebySubject;  ErythemaSeverity;  InvestigatorGlobalSeverityScore;  Tolerability Assessments and incidence of adverse events|30|NCT00668655|February 2008
1866|Completed                  Has Results|Efficacy of Cantharidin in Molluscum Contagiosum||Drug:cantharidin&apos;svehicle;  Drug:Cantharidin0.7%|Interventional||Other / NIH|Patients Experiencing Complete Clearance of All Molluscum Lesions.;  Mean Change in Each Group Measured by Lesion Count.|29|NCT00667225|January 2008
1867|Completed|Sex Aging and Antiretroviral Pharmacokinetics||Drug:ARVregimenchosenbytreatingphysician|Observational||Other / NIH|To measure and compare steady state blood plasma pharmacokinetics of antiretroviral therapies in post- and pre-menopausal HIV-infected women.;  To longitudinally quantify and compare genital tract antiretroviral drug exposure in post- and pre-menopausal HIV-infected women;  To determine and compare sexual HIV infectivity in post- and pre-menopausal HIV-infected women by measuring HIV RNA dynamics in blood plasma and genital tract secretions before and after the initiation of highly active antiretroviral therapy.|11|NCT00666055|March 2008
1868|Completed|Measuring Stress in Women With Newly Diagnosed Stage I Stage II or Stage III Breast Cancer or Ductal Carcinoma In Situ of the Breast||Other:laboratorybiomarkeranalysis;  Other:questionnaireadministration;  Other: study of socioeconomic and demographic variables;  Procedure:assessmentoftherapycomplications;  Procedure:psychosocialassessmentandcare;  Procedure:therapeuticconventionalsurgery|Observational||Other / NIH|Diurnalcortisolrhythm;  Consistency of diurnal salivary cortisol levels over two days;  Changes in diurnal cortisol rhythm pattern and night-time urinary epinephrine excretion pre- to post-surgery;  Correlation of the diurnal cortisol rhythm and the night-time urinary excretion with the measures of psychosocial and behavioral stress responses|24|NCT00665782|March 2008
1869|Completed                  Has Results|Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis||Drug:PN400(VIMOVO);  Drug:celebrex;  Other:Placebo;  Drug:RescueAntacid|Interventional|Phase 3|Industry|Change in Western Ontario and McMaster Universities (WOMAC) Pain Questionnaire Subscore From Baseline;  Change in Western Ontario and McMaster Universities (WOMAC) Function Questionnaire Subscore From Baseline;  Change in Patient Global Assessment (PGA) Subscore From Baseline;  Mean Change From Baseline in American Pain Society Patient Outcome Questionnaire (APS-POQ)Total Interference Caused by Pain.;  AntacidTabletUse;  ModifiedSeverityofDyspepsiaAssessment(mSODA);  Percent of Days With no Heartburn (Heartburn Resolution);  Number of Participants Reporting Pre-specified Non-steroidal Antiinflammatory Drug-associated Upper Gastrointestinal (UGI) Symptoms;  The Number of Subjects Who Discontinued From the Study Due to Any Pre-specified Non-steroidal Antiinflammatory Drug-associated Upper Gastrointestinal Adverse Event|610|NCT00665431|April 2008
1870|Completed|Craniosacral Therapy in Migraine: A Feasibility Study||Other:Craniosacraltherapy;  Procedure:Lowstrengthstaticmagnets|Interventional||Other / NIH|HIT-6;  Headachefrequency|66|NCT00665236|September 2006
1871|Completed|Diet Exercise Metabolism and Obesity in Older Women||Behavioral:CaloricRestriction;  Behavioral: Caloric Restriction + Low-Intensity aerobic exercise;  Behavioral: Caloric Restriction plus High-intensity aerobic exercise|Interventional||Other|Abdominalvisceralfatvolume;  HDL cholesterol Triglyceride concentrations Glucose tolerance|112|NCT00664729|November 2002
1872|Terminated|Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia||Drug:Terameprocol(EM-1421)|Interventional|Phase 1|Industry|Safety maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of Terameprocol (EM-1421) given as intravenous infusion three times a week in patients with leukemia;  Pharmacokinetics (PK) of Terameprocol (EM-1421) given as intravenous infusion three times a week in patients with leukemia;  Toaccessanti-tumoractivity|16|NCT00664677|August 2007
1873|Completed                  Has Results|Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis||Drug:PN400(VIMOVO);  Drug:celebrex;  Drug:Placebo;  Drug:RescueAntacid|Interventional|Phase 3|Industry|Change in Western Ontario and McMaster Universities (WOMAC) Pain Questionnaire Subscore From Baseline;  Change in Western Ontario and McMaster Universities (WOMAC) Function Questionnaire Subscore From Baseline;  Change in Patient Global Assessment (PGA) Subscore From Baseline;  American Pain Society Patient Outcome Questionnaire (APS-POQ)Total Interference Caused by Pain.;  AntacidTabletUse;  ModifiedSeverityofDyspepsiaAssessment(mSODA);  Percent of Days With no Heartburn (Heartburn Resolution);  Number of Participants Reporting Pre-specified Non-steroidal Antiinflammatory Drug-associated Upper Gastrointestinal (UGI) Symptoms;  The Number of Subjects Who Discontinued From the Study Due to Any Pre-specified Non-steroidal Antiinflammatory Drug-associated Upper Gastrointestinal Adverse Event|614|NCT00664560|April 2008
1874|Unknown&nbsp;&#8224;|The Analysis of Skin Temperature by Long Wave Infrared Imaging to Determine Its Effectiveness as a Predictor of Tissue Injury|||Observational||Industry|Each time a pattern of injury is identified by the device we will correlate this occurrence with the Braden scale to see whether or not it suggested an injury potential.;  It is our hypothesis that the pattern of injury will develop without warning from the Braden scores.|100|NCT00664235|February 2008
1875|Completed|The Effect of Visual Stimuli on Itch Perception Intensity in Healthy and Atopic Dermatitis Patients|||Observational||Other||25|NCT00660127|October 2007
1876|Completed|Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis||Drug:PAC113|Interventional|Phase 2|Industry|Eliminating or reducing clinical signs and symptoms of oral Candida infections.;  To evaluate the microbiological response of Candida to different concentrations of PAC-113.|223|NCT00659971|January 2008
1877|Completed|Measuring Adherence in Subjects With Acne Vulgaris in a Clinic Population Subtitle: Topical Benzoyl Peroxide for Acne||Drug:BenzoylPeroxide|Interventional|Phase 4|Other|Adherence;  Efficacy|20|NCT00658112|July 2006
1878|Completed|Ethnic Differences in Response to Topical Capsaicin: A Psychophysical Study on Healthy Subjects||Drug:Capsaicin|Interventional|Phase 4|Other|To assess ethnic differences in burning pain induced by topical capsaicin;  To assess ethnic differences on the effects of topical capsaicin on thermal sensory thermal thresholds|40|NCT00655811|February 2008
1879|Completed                  Has Results|Long-Term One Year Use of Alefacept (Amevive&#174;) in Moderate to Severe Chronic Plaque Type Psoriasis||Drug:Alefacept|Interventional|Phase 4|Other|Efficacy of Continuous Use of Alefacept as Defined as a 75% Reduction in Psoriasis Area and Severity Index (PASI);  Safety of Alefacept Using CD4 Counts and Adverse Event Reporting|15|NCT00655564|May 2008
1880|Completed|Fixation of Unstable Distal Radius Fractures||Device: Intramedullary Radius Fixation (Micronail);  Procedure:VolarPlateFixation|Interventional||Other / Industry|MichiganHandOutcomesQuestionnaire;  Disabilities of the Arm Shoulder and Hand Questionnaire|59|NCT00654615|May 2008
1881|Unknown&nbsp;&#8224;|Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit||Drug:tacrolimusointment|Interventional|Phase 4|Other|Measured adherence to topical therapy in children via MEMS cap in a &quot;real-life&quot; clinic population;  The change from Baseline to Week 4 (or end of treatment) in the IGA.;  The change from Baseline to Week 4 (or end of treatment) in the calculated EASI score.|30|NCT00654355|April 2008
1882|Completed|Inhalation of 20000 Endotoxin Units(EU) of Clinical Center Reference Endotoxin in Healthy Volunteers||Biological:ClinicalCenterReferenceEndotoxin|Interventional|Phase 1|Other / NIH|To determine the inflammatory response to 20000 endotoxin units (EU) of CCRE (Clinical Center Reference Endotoxin) inhalation in a cohort of healthy volunteers.|20|NCT00654134|October 2005
1883|Completed|The Effect of Yogurt Containing BB12 on Children&apos;s Health and Child Care Absenteeism||Other:YogurtdrinkwithprobioticbacteriaBB12;  Other:Placebo|Interventional||Other / Industry|Days of illness symptoms number duration and severity of illness episodes day care absenteeism and parental work absenteeism;  Health care utilization and illness related costs as measured by number of physician visits ER visits hospitalizations and antibiotics use. Also child growth and quality of life. Exploratory biomarker outcomes in stool.|181|NCT00653705|January 2007
1884|Completed                  Has Results|An Effectiveness Trial of Project ALERT||Behavioral:ProjectALERT|Interventional||Other|Self-reported30-dayUseofAlcohol;  Self-reported30-dayUseofCigarettes;  Self-reported30-dayMarijuanaUse;  Self-reported30-dayInhalantUse;  Self-reportedLifetimeAlcoholUse;  Self-reportedLifetimeCigaretteUse;  Self-reportedLifetimeMarijuanaUse;  Self-reportedLifetimeInhalantUse|8338|NCT00650585|May 2004
1885|Completed                  Has Results|Clinical Evaluation of the Photoallergy Potential of Xenaderm Ointment||Other:OintmentVehicle;  Drug:Xenaderm|Interventional|Phase 1|Industry|FrequencyDistributionofSkinIrritationScores|59|NCT00645164|March 2008
1886|Terminated|Genetics of Asthma - Bronchoscopy Studies||Biological:Endotoxin-lipopolysaccharide(LPS)|Interventional|Phase 1|Other|Identify Genes in airway epithelial and Bronchoalveolar Lavage (BAL)that are differentially regulated following inhalation of LPS endotoxin.;  Identify mediators in airway epithelial and BAL cells that are differentially regulated following LPS inhalation.|17|NCT00644514|September 2007
1887|Active not recruiting|Omega-3 Fatty Acids and Post Traumatic Stress Disorder (PTSD)||Drug:Omega-3FattyAcid;  Drug:Placebo|Interventional||U.S. Fed|Our primary outcome measures will be the Clinician-Administered PTSD Scale (CAPS) and the Brief Assessment of Cognition in Affective Disorders (BAC-A);  Secondary outcome measures include the Quick Inventory of Depressive Symptomatology (QIDS)  the Connor Davidson Resilience Scale the Continuous Performance Test (CPT) and Trail Making A+B|18|NCT00644423|September 2008
1888|Terminated|Mirror-Box Training in Adults With Chronic Hemiparesis Secondary to Stroke||Behavioral:motortraining|Interventional||Other|Fugl-Meyer Test of Motor Recovery Upper Extremity;  ArmMotorAbilityTest|3|NCT00643864|February 2006
1889|Terminated                  Has Results|Rapid Switch From Flolan to Remodulin in the Outpatient Clinic||Drug:treprostinilsodium|Interventional|Phase 4|Industry|ChangeinSixMinuteWalkDistance;  ChangeinWHOFunctionalClassification;  Change in Borg Dyspnea Score Immediately After Six Minute Walk;  Change in Score on Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR);  Change in Score on Treatment Satisfaction Questionnaire for Medication;  Change in Total Weekly Time Spent With the Specific Activities Associated With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol;  ChangeinPAHSignsandSymptoms-Fatigue;  ChangeFrominSignsandSymptomsofPAH-Edema;  ChangeinSignsandSymptomsofPAH-Dyspnea;  ChangeinSignsandSymptomsofPAH-Orthopnea;  ChangeinSignsandSymptomsofPAH-Dizziness;  ChangeinSignsandSymptomsofPAH-Syncope;  ChangeinSignsandSymptomsofPAH-ChestPain;  PatientImpressionofChangeQuestionnaire|7|NCT00643604|March 2008
1890|Terminated|Nitric Oxide LPS and the Pathogenesis of Asthma Phase II||Biological:LPSendotoxin|Interventional|Phase 1|Other|Differential response to inhaled LPS based on NOS2 inhibition.;  Physiologicmeasurements|70|NCT00643058|April 2003
1891|Completed                  Has Results|Group Physical Therapy for Knee Osteoarthritis||Other:GroupPhysicalTherapy|Interventional||U.S. Fed|Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)|24|NCT00642772|March 2008
1892|Active not recruiting|Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme||Biological:tetanustoxoid;  Biological: therapeutic autologous dendritic cells;  Biological:therapeuticautologouslymphocytes|Interventional|Phase 1|Other|Feasibility and safety of vaccination with cytomegalovirus pp65-LAMP mRNA-loaded dendritic cells (DCs) with or without autologous lymphocyte transfer;  Humoralandcellularimmuneresponses;  Timetoprogression;  Differential ability of indium In-111-labeled DCs to track to the inguinal lymph nodes under different skin preparative conditions;  Differential ability of indium In-111-labeled DCs to track to lymph nodes on the tumor bearing and non-tumor bearing side of the cervical lymph nodes;  Immunologiccellinfiltrateinrecurrenttumors;  Evidence of antigen-escape outgrowth in recurrent or progressive tumors|16|NCT00639639|January 2006
1893|Terminated|Severity Postoperative Pain Prediction|||Observational||Other / NIH|To determine the predictive value of a simple to perform preoperative evaluation in assessing level of anxiety anticipated pain and the intensity rating of an audio tone to predict level of postoperative pain after surgery.|300|NCT00638404|August 2007
1894|Completed|Comparison of Loss of Resistance Techniques||Procedure:Air;  Procedure:Saline|Interventional||Other|To compare whether air or saline makes a difference in the success and quality of labor pain relief when the combined spinal epidural is used to treat labor pain relief.|350|NCT00638274|July 2005
1895|Withdrawn|The Gene Expression Studies of the Role of Tumor Microenvironments in Tumor Progression|||Observational||Other||0|NCT00638040|September 2009
1896|Completed                  Has Results|Rapid Sternal Closure System (TALON)||Device:RapidSternalClosureSystem;  Device:Conventionalwireclosure|Interventional|Phase 4|Other|Percentage Change of Preoperative Incentive Spirometry (IS) Volume Achieved;  Number of Participants With Sternal Wound Infection or Sternal Instability/Non-union|51|NCT00638014|March 2008
1897|Completed|Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer||Drug:docetaxel;  Drug:ixabepilone;  Drug:paclitaxel;  Drug: paclitaxel albumin-stabilized nanoparticle formulation;  Drug:paricalcitol|Interventional|Phase 1|Other / NIH|Clinicalfeasibilityoftherapyadministration;  Dose of paricalcitol that maintains a normal calcium level when given in combination with a taxane or ixabepilone;  Correlation of baseline levels of 25-hydroxycholecalciferol and parathyroid hormone with time to treatment failure;  Measurement of effect of combination of paricalcitol and a taxane or ixabepilone on parathyroid hormone levels failure|24|NCT00637897|March 2008
1898|Completed|Early Detection of Breast Cancer Using Tomosynthesis Imaging||Radiation:Mammographyandtomosynthesisimaging|Interventional||Other|Radiologist ROC (receiver operating characteristic) area under curve (AUC)|385|NCT00637598|November 2004
1899|Recruiting|Insulin Resistance in Nonalcoholic Fatty Liver Disease: A Case Control Study|||Observational||Other|Measure Insulin Resistance (IR) and clearance its effects on lipid metabolism inflammatory response and oxidative stress using intravenous glucose tolerance testing in patients with NAFLD as compared to matched controls.;  Determine if IR is associated with altered parameters of lipid metabolism as compared to matched controls;  Measure the differential effects of IR and lipid metabolism on peripheral mononuclear cell (PBMC) inflammatory response and the associated hepatocyte mitochondrial ultrastructure and measures of oxidative stress.|80|NCT00637520|July 2007
1900|Terminated                  Has Results|Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab||Drug:Palonosetron(Aloxi)andDexamethasone|Interventional|Phase 2|Other / Industry / NIH|Acute CINV (Chemotherapy Induced Nausea and Vomiting) CR (Complete Response) Rate;  Acute Chemotherapy-Induced Nausea and Vomiting (CINV) Complete Response (CR) Rate by Corticosteroid Use at Baseline;  Acute Chemotherapy-Induced Nausea and Vomiting (CINV) Complete Response (CR) Rate by Anticoagulant Use at Baseline;  Delayed Chemotherapy-Induced Nausea and Vomiting (CINV) Complete Response (CR) Rate;  Percentage of Patients With &#8805; Grade 3 Treatment-related Toxicities;  Overall Mean Change in the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score From Baseline to Day 5 of the First Week of Chemotherapy;  Overall Mean Change in the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score From Baseline to Day 5 of the First Week of Chemotherapy by Acute Chemotherapy-Induced Nausea and Vomiting (CINV) Complete Response (CR)|63|NCT00636805|May 2008
1901|Completed|CONNECT for Quality: A Study to Reduce Falls in Nursing Homes||Behavioral:FallsQI;  Behavioral:Connect|Interventional||Other / NIH|Fallrelatedprocessmeasures;  Fallrates;  Staffinteractionmeasures;  ProbabilityofRecurrentFalls|1350|NCT00636675|September 2009
1902|Completed|Feasibility of Exercise With Post-Op Lung Cancer Patients||Behavioral:Exercise|Interventional||Other|ECGstresstest;  Safety;  adherencelevels;  Treatment compliance and toxicity and quality of life;  Inflammation|21|NCT00636571|March 2006
1903|Completed|Fluocinolone Acetonide Implant for Retinal Vein Occlusion (RVO)||Device:fluocinoloneacetonide(RetisertImplant)|Interventional|Phase 0|Other / Industry|Change from baseline in visual acuity using Early Treatment Diabetic Retinopathy Study (ETDRS) charts;  Amount of macular edema on optical coherence tomography and color photos;  Elevations in Intraocular Pressure (IOP) requiring anti-glaucoma medication or increase in number of medications required or need for drainage surgery to maintain IOP within clinically satisfactory levels.;  Quality of life scores using the Visual Functioning (VF)-25 and SF-36 surveys;  Ocular adverse events (vitreous hemorrhage retinal detachment cataract endophthalmitis drug toxicity)|30|NCT00636493|October 2002
1904|Terminated                  Has Results|Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer||Drug: Doxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC)|Interventional|Phase 2|Other / U.S. Fed|Pathologic Complete Response (pCR) Rate in Patients With HER2-negative Early-stage Breast Cancer;  Probabilities of Being Sensitive to AC and TC as Determined by the Patient&apos;s Genomic Signatures;  Percentage of Patients Who Had Breast-conserving Surgery With Negative Margins;  To Percentage of Patients Who Had Breast-conserving Surgery at First Attempt.;  ClinicalResponseUsingWHOCriteria;  Disease-freeSurvival;  SitesofRecurrence;  OverallSurvival;  Economic Impact of Using Genomic Assessment to Guide Management.;  Patients&apos; Perceptions of Participating in a Clinical Trial Evaluating Cancer Genomics for PST of Early-stage Breast Cancer.|56|NCT00636441|April 2008
1905|Completed|Inattention in Childhood Cancer Survivors||Behavioral:AttentionTraining;  Behavioral:Placebo|Interventional||Other / NIH|Memory;  Feasibility|23|NCT00636337|December 2007
1906|Recruiting|Genetics of Spina Bifida and Anencephaly|||Observational||Other / NIH|genetic factors associated with neural tube defects|10000|NCT00636233|May 1993
1907|Terminated                  Has Results|EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma||Drug:cenersensodium;  Drug:Rituximab;  Drug:Cyclophosphamide;  Drug:Fludarabine|Interventional|Phase 2|Other / Industry|Number of Patients With an Overall Response (Complete Response + Partial Response);  ProgressionFreeSurvival;  OverallSurvival|20|NCT00636155|February 2008
1908|Completed|Molecular Genetic and Genomic Assessments From Patients Treated With RAD001|||Observational||Other / U.S. Fed|Functional extent of mTOR inhibition in the phosphorylation status of S6K and CA IX protein in prostate tumors from patients treated with RAD001.;  To determine by comparative genomic hybridation (CGH) loss of heterozygosity (LOH) patterns of the 10q23 locus (to assess PTEN status) and other sites of chromosomal alterations associated with pathologic response to mTOR inhibition.;  To identify expression profiles associated with AKT activation and RAD001 treatment effect.;  To identify candidate plasma markers of glycolysis that reflect tumor AKT activity.|35|NCT00636090|January 2007
1909|Completed|Guided Imagery for Military Sexual Trauma-Related Posttraumatic Stress Disorder (PTSD)||Behavioral:GuidedImageryAudio;  Behavioral:MusicAudio|Interventional||Other / NIH / U.S. Fed|PTSD Severity - Clinician Administered PTSD Scale (CAPS);  NeuroactiveSteroidassay|40|NCT00635635|October 2007
1910|Terminated                  Has Results|Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases||Drug:paricalcitol;  Other:immunoenzymetechnique;  Other:laboratorybiomarkeranalysis;  Procedure:dualx-rayabsorptometry;  Procedure:quality-of-lifeassessment|Interventional|Phase 2|Other / NIH|Biochemical Markers (i.e. Serum Parathyroid Hormone [PTH] Bone-specific Alkaline Phosphatase and Osteocalcin) That Are Surrogates for Fracture Risk and Are Associated With Increased Bone Pain Morbidity and Mortality From Prostate Cancer|2|NCT00634582|January 2009
1911|Completed|Healthy Living Partnership to Prevent Diabetes||Behavioral: Group-Based Lifestyle Intervention (Phases 1 and 2);  Other:IndividualEducationProgram(AllPhases);  Behavioral:Self-DirectedMaintenance(Phase3);  Behavioral:ExtendedGroupMaintenance(Phase3)|Interventional|Phase 3|Other / NIH|FastingGlucose;  WeightLoss;  WaistCircumference;  DietaryIntake;  PhysicalActivity|301|NCT00631345|August 2007
1912|Unknown&nbsp;&#8224;|Women&apos;s Health Initiative Study of Cognitive Aging|||Observational||Other|Does HT protect against age-associated memory and cognitive longitudinal decline in women age 65 and older as measured over time by a series of cognitive tests administered annually?;  To determine the long-term effects of HT on changes in memory other cognitive functions and affect; and to investigate predictors of the transitions between normal aging and mild cognitive impairment and mild cognitive impairment and dementia.|2303|NCT00631332|July 1999
1913|Completed|Effect of Gamma Tocopherol Supplementation on Neutrophil Response to 20000 EU of Clinical Center Reference Endotoxin in Normal Adults||Drug:gammatocopherol|Interventional|Phase 1|Other / NIH|The primary goal of this study is to determine the effect of &#947;T on endotoxin-induced airway inflammation in non-allergic non-asthmatic subjects.|18|NCT00631085|May 2008
1914|Completed|Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells||Other:IFNbeta-1b|Interventional|Phase 1|Other|Determine the effect of IFN-B-1b-induced SOCS3 upregulation in DCs&apos; on their maturation and the capacity to present;  Characterize the effect of IFN-1b-induced SOCS3 expression in DCs on Th1/Th2 cell differentiation and T-cell cytokine transcription.|56|NCT00630721|September 2007
1915|Terminated|Safety Study of 20000 EU of Clinical Center Reference Endotoxin in Allergic Adults With and Without Mild Asthma||Biological:ClinicalCenterReferenceEndotoxin|Interventional|Phase 1|Other / NIH|Increased sputum neutrophils with no adverse events|4|NCT00630461|May 2008
1916|Terminated                  Has Results|Feasibility Study of Vessel Analysis for Noninvasive Diagnosis of Malignancy in Breast Tumors||Other: Magnetic Resonance Angiography (MRA) of the Breast|Interventional||Other|Amount of Blood Vessel Tortuosity in Breast With Known Cancer|6|NCT00630292|March 2008
1917|Completed                  Has Results|RAD001 in Patients With Metastatic Hormone-Refractory Prostate Cancer||Drug:RAD001|Interventional|Phase 2|Other / Industry|BiochemicalResponseRate;  PathologicResponse;  ProgressionFreeSurvival;  MolecularResponse;  ClinicalResponse|35|NCT00629525|August 2005
1918|Completed|Innohep for Prophylaxis of Venous Thromboembolism in Brain Tumor Patients||Drug:Innohep|Interventional||Other / Industry|Neurologic evaluation CBC Coagulation test (PT w/ INR aPTT)Karnofsky performance status Thrombosis panel Adverse events assessment;  Bonedensitometrystudy(DEXA-Scan)d|40|NCT00629447|February 2004
1919|Terminated|Computerized Cognitive Training for Childhood Cancer Survivors||Behavioral:Captain&apos;sLogComputerProgram|Interventional||Other|Computerprogramresults|9|NCT00629395|June 2007
1920|Completed                  Has Results|Coronary Heart Disease as Measured by Coronary Calcium Score Among Individuals With Chronic Traumatic Spinal Cord Injury|||Observational||Other|Percent Agreement Between Coronary Calcium Score (CCS) and National Cholesterol Education Program (NCEP) Guidelines;  AdherencetoNCEPCriteria|45|NCT00628446|September 2007
1921|Completed                  Has Results|A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children||Drug:NoIntervention|Observational|Phase 4|Industry / Other|FluMist Use in Participants up to 59 Months of Age;  Vaccinating Physician Specialty: Pediatrician or Pediatric Specialist;  Vaccinating Physician Specialty: General/Family Practitioner;  VaccinatingPhysicianSpecialty:Other;  VaccinatingPhysicianSpecialty:Unknown;  GeographicRegion:Northeastern;  GeographicRegion:NorthCentral;  GeographicRegion:Southern;  GeographicRegion:Western;  NumberofOutpatientVisits:0;  NumberofOutpatientVisits:1;  NumberofOutpatientVisits:2orMore;  Number of Days With a Respiratory Claim in 28 Days Prior to Vaccination: 0;  Number of Days With a Respiratory Claim in 28 Days Prior to Vaccination: 1;  Number of Days With a Respiratory Claim in 28 Days Prior to Vaccination: 2 or More|321697|NCT00626808|October 2007
1922|Active not recruiting|Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia||Biological:RNA-loadeddendriticcellvaccine;  Drug:basiliximab|Interventional|Phase 1|Other / NIH|Functional capacity of CD4+CD25+ CD127- T-regulatory cells;  Safety|18|NCT00626483|March 2007
1923|Completed|Chemotherapy Radiation Therapy and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery||Biological:PEP-3-KLHconjugatevaccine;  Biological:daclizumab;  Drug:temozolomide;  Other:placebo;  Biological:PEP-3-KLH|Interventional|Phase 1|Other / NIH|Functional suppressive capacity of CD4+CD25+CD127- T-regulatory cells;  Comparison of proliferative T-cell response to phytohemagglutinin (PHA) among treatment groups (with versus without daclizumab/basiliximab)|16|NCT00626015|March 2007
1924|Completed                  Has Results|Nicotine Patch Pretreatment for Smoking Cessation in PTSD||Drug:Nicotine;  Behavioral: Cognitive Behavioral Therapy for Smoking Cessation;  Drug:BupropionSustainedRelease(SR);  Drug:Placebopatch|Interventional|Phase 0|U.S. Fed|SmokingAbstinenceSelf-reported;  CarbonMonoxideMonitoring;  SmokingCraving|87|NCT00625131|May 2008
1925|Completed|Efficacy and Safety of A Collagen Bupivacaine Implant in Women Following Abdominal Hysterectomy||Drug:BupivacaineCollagenSponge(CollaRx&#174;);  Drug:placebo|Interventional|Phase 2|Industry|Totaluseofopioidrescueanalgesia;  PainintensityratingonaVisualAnalogScale;  Painintensityratingona4-pointLikertscale;  Timetofirstuseofopioidrescueanalgesia;  Treatmentemergentadverseevents;  Vital signs - heart rate respiration rate systolic and diastolic blood pressure and body temperature|54|NCT00624910|December 2007
1926|Completed|IV vs. IA tPA (Activase) in Acute Ischemic Stroke With CTA Evidence of Major Vessel Occlusion||Drug:IVtpa(Alteplase)vsIAtpa(Alteplase)|Interventional||Other / Industry|Feasibility of enrolling 12 subjects with major vessel occlusion within 1 year and random 1:1 assignment to treatment with IV (N=6) and IA (N=6) IA Activase using the following criteria: Time to clinical and radiological assessments;  TimetoIAActivasetreatment;  Preliminary safety assessment: 24 hour symptomatic ICH;  Resources utilized and risk-benefit of IA Activase treatment.;  90-day efficacy outcome including NIHSS modified Rankin Scale and Barthel&apos;s Index.;  24-hrecanalization(TIMI2/3)onMRAorCTA;  Major extracranial bleed (defined under section 3.3.3) and asymptomatic intracranial hemorrhage.|7|NCT00624000|March 2004
1927|Completed                  Has Results|Adjunctive Pregnenolone in Veterans With Mild TBI||Drug:Pregnenolone;  Drug:Placebo|Interventional||U.S. Fed|Brief Assessment of Cognition in Affective Disorders (BAC-A);  ClinicianAdministeredPTSDScale(CAPS);  Quick Inventory of Depressive Symptomatology (QIDS)|30|NCT00623506|January 2008
1928|Completed|Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression||Drug:Carbamazepine;  Drug:Placebo|Interventional||Other / U.S. Fed|Neuropsychiatric Inventory Irritability Domain (frequency and severity) completed by observer;  Neuropsychiatric Inventory Aggression Domain (frequency severity and caregiver distress) completed by the observer and person with brain injury;  Neuropsychiatric Inventory Irritability Domain (caregiver distress) completed by the observer and the Neuropsychiatric Inventory Irritability Domain (frequency severity and distress) completed by person with brain injury;  GlobalImpressionofChange;  STAXI-2byobserver;  STAXI-2completedbypersonwithbraininjury;  CliniciansGlobalImpressionofChange|74|NCT00621751|February 2008
1929|Completed                  Has Results|Cephalon Decitabine Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome||Drug: Decitabine Arsenic Trioxide and Ascorbic Acid|Interventional|Phase 2|Other / Industry|Number of Patients With an Overall Response of Complete Response (CR) or Partial Response (PR);  Duration of a Complete or Partial Response Based on Number of People Who Responded.;  NumberofPatientsWithanUnacceptableToxicity|7|NCT00621023|November 2007
1930|Withdrawn|Exercise Training Among Men With Prostate Cancer||Behavioral:Exercise|Interventional||Other|Cardiorespiratory Fitness will be determined using a incremental treadmill test with 12-lead ECG monitoring.;  Fastinglipidswillbeassessed.|0|NCT00620932|January 2008
1931|Completed                  Has Results|The Role of Intra-Operative Intracapsular Blocks in Post-Operative Pain Management Following Total Knee Arthroplasty||Other:Placebosalineinjection;  Drug:Ropivicaine0.5%|Interventional|Phase 4|Other / Industry|NumericPainScore;  Total Fentanyl Patient-Controlled Anesthesia (PCA) Narcotic Consumption;  Postoperative Day 1 Physical Therapy Outcome - Ambulation Distance;  Postoperative Day 1 Physical Therapy Outcome- Knee Extension and Flexion;  Postoperative Day 1 Physical Therapy Outcome - Straight Leg Raise|67|NCT00620828|May 2007
1932|Completed|Myfortic Conversion Trial in OLT Recipients With GI Intolerance||Drug:MycophenolicAcid(Myfortic)|Observational||Other / Industry|Evaluation of GI symptoms using GSRS GIQLi and SF-12 after conversion to Myfortic|31|NCT00619216|March 2008
1933|Completed                  Has Results|Study of Aripiprazole to Treat Children and Adolescents With Autism||Drug:aripiprazole|Interventional|Phase 2|Other / Industry|Change From Baseline in Aberrant Behavior Checklist-Irritability at 12 Weeks;  Clinical Global Impressions Scale - Severity Score (CGI-S);  Change From Baseline in the Aberrant Behavior Checklist -Lethargy/Social Withdrawal Subscale at 12 Weeks|30|NCT00619190|January 2006
1934|Completed|Efficacy of Probiotic Bacteria in Subjects With IBS or Functional Diarrhea/ Bloating||Dietary Supplement: Probiotics - Lactobacillus and bifidobacterium;  DietarySupplement:Placebo|Interventional||Other / Industry|The primary outcome measure will be the global relief of GI symptoms as assessed by Global Symptom Assessment (GSA) of relief of functional GI symptoms.;  Assess the improvement of specific functional bowel disorders (FBD) related symptoms and Health Related Quality of Life (HRQOL).|56|NCT00618904|December 2005
1935|Completed|Preventing Falls Through Enhanced Pharmaceutical Care||Behavioral:PharmaceuticalCare;  Other:WrittenMaterials|Interventional||Other|Timetofirstfall;  Proportionofparticipantswhofall;  Useofhigh-riskmedications|200|NCT00618800|August 2004
1936|Completed|Efficacy of Yogurt Containing BB12 in Subjects With GI Symptoms||Dietary Supplement: Probiotic BB12 - Bifidobacterium lactis;  DietarySupplement:Placebo|Interventional||Other / Industry|The global relief of functional GI symptoms as assessed by Global Symptom Assessment (GSA) of relief of functional GI symptoms.;  The satisfaction with treatment as assessed by Satisfaction Survey.|63|NCT00618488|February 2007
1937|Completed                  Has Results|Open Label Seroquel (Quetiapine) Study for Treatment Resistant Functional Bowel Disorder||Drug:Quetiapine(50mg/day-100mg/day)|Interventional||Other / Industry|AdequateReliefinPainScoreDuringTreatment|25|NCT00617396|February 2008
1938|Completed                  Has Results|Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth||Drug:metformin;  Drug:placebo|Interventional|Phase 2|Other|Change From Baseline to Week 24 in Body Mass Index (BMI);  ChangeFromBaselinetoWeek24inWeight;  ChangeFromBaselinetoWeek24inFatMass;  ChangeFromBaselinetoWeek24inInsulinLevel;  Change From Baseline to Week 24 in Cholesterol Level;  ChangeFromBaselinetoWeek24inTriglycerides;  IncidenceofMetabolicSyndrome|9|NCT00617240|January 2007
1939|Completed|Effects of Diesel Exhaust Followed by Administration of Nasal Spray Flu Vaccine on Individuals With &amp; Without Allergies||Other: live attenuated influenza virus (LAIV) with clean air;  Other:LAIVanddieselexhaustparticles|Interventional||Other / NIH / U.S. Fed|Change in IL-13 and ECP in nasal lavage fluids (NLF) compared to pre-virus baseline;  Duration/quantityofvirusshedding;  Change in inflammatory cells in NLF at specific time points compared to baseline;  Change in inflammatory cytokines/chemokines and other mediators (PGE2 tryptase MPO adenosine) in NLF at specific time points compared to baseline;  Post LAIV change in overall &quot;oxidative stress&quot; in nasal epithelial cells;  Post LAIV change in epithelial gene expression profiles for innate immune and oxidant/antioxidant network arrays in nasal epithelial biopsies;  Change in levels and activities of circulating white blood cells including eosinophils basophils monocytes and lymphocytes;  Outcomes for GSTM1 null vs. sufficient genotype individuals|54|NCT00617110|January 2008
1940|Terminated                  Has Results|Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone Aripiprazole and Clozapine||Drug:metformin;  Behavioral:healthylifestyleintervention|Interventional|Phase 2|Other|PercentChangeinBMI;  AbsoluteChangeinWeight;  PercentChangeinFatMass;  PercentChangeinWeight;  PercentChangeinInsulinLevels;  PercentChangeinTotalCholesterol;  PercentChangeinTriglycerides;  IncidenceofMetabolicSyndrome;  PercentChangeinGlucoseLevels;  PercentChangeinHDL;  PercentChangeinLDL|1|NCT00617058|March 2007
1941|Completed                  Has Results|Effects of a Very Low Carbohydrate Diet on Symptoms of Irritable Bowel Syndrome (IBS)||Other:Verylowcarbohydratediet|Interventional|Phase 0|Other|Number of Subjects Reporting &quot;Adequate Relief&quot; From IBS Symptoms for the Previous Week. Adequate Relief Was a &quot;True/False&quot; Item.;  Impact of Very Low Carbohydrate Diet on Stool Frequency;  SicknessImpactProfile|17|NCT00616200|August 2009
1942|Completed|Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-003)||Drug:Difluprednate;  Other:Placebo|Interventional|Phase 3|Industry|The proportion of subjects with an anterior chamber cell grade of &quot;0&quot; and a flare grade of &quot;0&quot; on Day 14 compared between difluprednate and placebo groups;  The proportion of subjects with an anterior chamber cell grade of &quot;0&quot; and a flare grade of &quot;0&quot; on Day 7 compared between difluprednate and placebo groups.|120|NCT00616070|December 2007
1943|Completed|Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide||Drug:TemodarandIrinotecan|Interventional|Phase 2|Other / Industry|Progression-freesurvival;  Toxicityassessment|41|NCT00616005|November 2005
1944|Suspended|American Norditropin Studies - Registry of Growth Hormone (GH) Patients||Drug:NorditropinGrowthHormone|Observational||Other / Industry||79|NCT00615953|May 2007
1945|Completed                  Has Results|Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)||Drug:ImatinibMesylate&amp;Hydroxyurea|Interventional|Phase 2|Other / Industry|12-monthProgressionFreeSurvival(PFS);  MedianProgression-freeSurvival;  MedianOverallSurvival(OS);  ObjectiveResponseRate;  Safety and Tolerability of Gleevec + Hydroxyurea in Patients With Low-grade Gliomas|64|NCT00615927|February 2006
1946|Completed|Genetics of Peripheral Artery Genomics|||Observational||Other|Discover novel gene expression pattern in peripheral arterial disease|122|NCT00615121|June 2004
1947|Terminated                  Has Results|MK-0518 Intensification And HDAC Inhibition In Depletion Of Resting CD4+ T Cell HIV Infection||Drug:Raltegravir;valproicacid|Interventional|Phase 2|Other / NIH / Industry|AChangeintheNumberofHIVInfectedCells.|6|NCT00614458|April 2007
1948|Completed|Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas||Drug:VandetanibandEtoposide|Interventional|Phase 1|Other / Industry|Safety tolerability biologic activity &amp; pharmacokinetic profile of vandetanib when used in combo w etoposide|49|NCT00613223|February 2008
1949|Completed|Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG||Drug:GleevecRAD001andHydroxyurea|Interventional|Phase 1|Other / Industry|To determine MTD &amp; DLT &amp; Imatinib mesylate &amp; RAD001 when combined w Hydroxyurea among pt w GBM;  To further evaluate safety &amp; tolerability &amp; Imatinib mesylate in combo w RAD001 &amp; Hydroxyurea;  To evaluate PK on Imatinib mesylate when administered w RAD001 among GBM pt who are on &amp; not on EIAEDs|78|NCT00613132|May 2005
1950|Completed|Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma||Drug:TemodarandO6-Benzylguanine(BG)|Interventional|Phase 2|Other / Industry / NIH|Radiographicevidenceoftumorresponse;  6monthprogression-freesurvival;  Relationship between tumor AGT at original diagnosis &amp; response to Temozolomide + O6-BG|67|NCT00613093|October 2002
1951|Completed|Ph I Zactima + Imatinib Mesylate &amp; Hydroxyurea for Pts w Recurrent Malignant Glioma||Drug:ZactimaGleevecHydroxyurea|Interventional|Phase 1|Other / Industry|To determine MTD &amp; dose-limiting toxicity (DLT) &amp; Zactima when combo w Imatinib mesylate &amp; Hydroxyurea among pt w Recurrent MG;  To further assess safety &amp; tolerability of Zactima &amp; Imatinib mesylate &amp; Hydroxyurea|27|NCT00613054|November 2007
1952|Completed                  Has Results|Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan||Drug:Temo+Avastin;  Drug:VP-16+Avastin|Interventional|Phase 2|Other / Industry|The Primary Outcome Measure is 6 Month Progression-free Survival.;  RadiographicResponse;  MedianProgression-freeSurvival(PFS);  MedianOverallSurvival(OS);  Grade 3 or Greater Treatment Related Non-hematologic Toxicities.|23|NCT00613028|April 2008
1953|Completed|Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM||Drug:TemodarandO6-Benzylguanine|Interventional|Phase 1|Other / Industry|Doselimitingtoxicity;  Progression-freesurvival|42|NCT00612989|February 2005
1954|Completed                  Has Results|Treatment of Mood and Marriage Study (TOMMS)||Behavioral:Weeklymaritaltherapy;  Drug: As indicated: Sertraline bupropion venlafaxine mirtazepine nortriptyline tranylcypromine lithium augmentation etc.|Interventional|Phase 1 / Phase 2|Other / NIH|HamiltonDepressionRatingScale(HDRS);  DyadicAdjustmentScale(DAS);  Frequency&amp;AcceptabilityofPartnerBehavior;  ConflictTacticsScale;  SCIDMoodDisorders;  PersonalAssessmentofIntimacyinRelationships;  BeckAnxietyInventory|42|NCT00612807|July 2006
1955|Completed|PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 &amp; 4 Malignant Gliomas||Drug:TemodarandSCH66336|Interventional|Phase 1|Other / Industry|Dose-limitingtoxicity;  Progression-freesurvival|37|NCT00612651|October 2005
1956|Completed|Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas||Drug:TemodarO6-BGandIrinotecan|Interventional|Phase 1|Other / Industry|Incidenceoftoxicities;  Responserate&amp;progression-freesurvival|96|NCT00612638|January 2005
1957|Completed                  Has Results|A Multicenter Randomized Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy Safety and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Elective Unilateral Total Knee Replacement||Drug:SufentanilNanoTab;  Drug:PlaceboNanoTab|Interventional|Phase 2|Industry|SPID-12|94|NCT00612534|March 2008
1958|Completed                  Has Results|Ph II Bevacizumab + Etoposide for Pts w Recurrent MG||Drug:BevacizumabandEtoposide|Interventional|Phase 2|Other / Industry|6MonthProgression-FreeSurvival(PFS);  ObjectiveResponseRate;  SafetyofStudyTreatmentRegimen;  MedianProgression-FreeSurvival;  MedianOverallSurvival(OS)|59|NCT00612430|March 2007
1959|Completed                  Has Results|Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas||Drug:AvastinandTemozolomide|Interventional|Phase 2|Other / Industry|ResponseRate|41|NCT00612339|August 2007
1960|Completed|Ph I SU011248 + Irinotecan in Treatment of Pts w MG||Drug:SU011248&amp;Irinotecan|Interventional|Phase 1|Other / Industry|Determine MTD &amp; DLT of SU011248 + Irinotecan in pts w RMG not on EIAEDs;  Demographic&amp;baselinecharacteristics;  Efficacyobservations&amp;measurements;  Safetyobservations&amp;measurements;  PKmeasurements|25|NCT00611728|March 2008
1961|Terminated|CMV pp65 Specific T Cell Adoptive Immunotherapy in Allogeneic Stem Cell Transplantation for Malignant Disease||Biological:CMVpp65SpecificTCells|Interventional|Phase 1|Other / NIH|Number of CMV pp65 specific CD8+ T cells produced.;  Development of grade III-IV GVHD or major organ toxicity.;  PresenceofCMVinperipheralblood.;  Percentage of CD8+ T cells that are CMV pp65 specific.|2|NCT00611637|August 2005
1962|Completed                  Has Results|Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma||Drug:Avastin;  Drug:Bortezomib|Interventional|Phase 2|Other / Industry|6-monthProgression-freeSurvival(PFS);  MedianProgressionFreeSurvival(PFS);  MedianOverallSurvival(OS);  RadiographicResponseRate;  Number of Patients With Grade 3 or Greater Treatment-related Non-hematologic Toxicities|56|NCT00611325|May 2008
1963|Completed|Everolimus Fluorouracil Leucovorin Panitumumab and Oxaliplatin in Treating Patients With Solid Tumors That Did Not Respond to Treatment||Biological:panitumumab;  Drug:everolimus;  Drug:fluorouracil;  Drug:leucovorincalcium;  Drug:oxaliplatin|Interventional|Phase 1|Other / NIH|Maximum tolerated dose of everolimus in combination with sequential fluorouracil (5-FU) and leucovorin calcium panitumumab modified 5-FU leucovorin calcium and oxaliplatin (mFOLFOX6) and mFOLFOX6 with panitumumab;  Toxicity as assessed by CTC version 3.0 at the beginning of each treatment course;  Tumorresponse;  Correlation of response with S6-phosphorylation and AKT-phosphorylation in archived tumor samples|74|NCT00610948|March 2008
1964|Completed|Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS)||Drug:ParoxetineCR;  Drug:Placebo|Interventional|Phase 4|Other / Industry|Change from baseline in: Changes in Mean composite pain scores (on IVRS);  Change from baseline in Associated symptoms of IBS (diarrhea constipation incomplete emptying etc.) scores IBS Quality of Life scores Clinical Global Impression scores of 1 or 2 Beck Depression Inventory II Beck Anxiety Inventory;  Recording of spontaneous adverse events throughout the screening run-in and treatment phases of the study Conducting the DOTES at defined points during the study|60|NCT00610909|January 2002
1965|Completed|Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas||Drug:OralTopotecanandTemodar|Interventional|Phase 1|Other / Industry|maximumtolerateddose;  Safety&amp;efficacy|62|NCT00610571|April 2004
1966|Completed|Escitalopram (Lexapro&#174;) In Patients With Major Depression With Atypical Features||Drug:Escitalopram|Interventional|Phase 3|Other / Industry|changes in HAM-D-29 scores from baseline to end of treatment.;  changes in 8-atypical items on the HAM-D-29 SDS and ESQ from baseline to end of treatment. Response will be defined as 50% or greater reduction in HAM-D-29 scores from baseline to end of treatment.|15|NCT00610506|October 2005
1967|Completed|Ph I Dasatinib + Erlotinib in Recurrent MG||Drug:ErlotinibandDasatinib|Interventional|Phase 1|Other / Industry|To determine MTD &amp; DLT of Dasatinib when combined w Erlotinib among pts w Recurrent MG;  To further evaluate safety &amp; tolerability of Dasatinib + Erlotinib;  To evaluate the PK of Dasatinib when administered w Erlotinib among Recurrent MG pts who are on &amp; not on EIAEDs;  To evaluate for anti-tumor activity w this regimen in this pt population|47|NCT00609999|January 2008
1968|Completed                  Has Results|Ciprofloxacin for the Prevention of Postoperative Endoscopic Recurrence in Crohn&apos;s Disease||Drug:Ciprofloxacin;  Drug:Placebo|Interventional|Phase 2|Other / NIH|SafetyandTolerabilityofCiprofloxacin;  Endoscopic Recurrence Under Postoperative Treatment With Study Medication at 6 Months|33|NCT00609973|May 2008
1969|Completed|GIOP Prevention Among People With Rheumatoid Arthritis||Behavioral:TailoredMaterials;  Behavioral: Tailored Materials Plus Physician Feedback;  Behavioral:GenericMaterials;  Behavioral:NoInformation|Interventional||Other|CalciumIntake;  VitaminDIntake;  BoneMineralDensityTesting;  Use of prophylactic medications (e.g. bisphosphonates)|273|NCT00609830|July 2001
1970|Completed|Diagnostic Yield of Vitreous Biopsy in Sarcoid Uveitis||Procedure:DiagnosticVitrectomy|Interventional||Other|To determine the diagnostic yield of vitreous biopsy in patients with suspected sarcoid uveitis|150|NCT00609687|January 2007
1971|Completed|Functional MRI Evaluation of the Effect of Citalopram in Autism Spectrum Disorders||Drug:Citalopram;  Drug:Placebo|Interventional|Phase 1|Other / NIH|FunctionalMagneticResonanceImaging;  CliniciansGlobalImprovementScale;  ChildrensYale-BrownObsessiveCompulsiveScale|12|NCT00609531|January 2007
1972|Completed|Brain Imaging of Psychotherapy for Depression||Behavioral: Brief Behavioral Activation Treatment for Depression|Interventional||Other|HamiltonDepressionInventory;  FunctionalMagneticResonanceImaging|27|NCT00609453|October 2006
1973|Completed|A Randomized Trial of Remote Monitoring of Implantable Cardioverter Defibrillators Versus Quarterly Device Interrogations in Clinic||Other:MethodsformonitoringpatientswithICD&apos;s|Interventional||Other / Industry|Re-hospitalization and ED visits for cardiac causes unscheduled clinic visits for device-related issues medications patient logs patients&apos; level of satisfaction with their device care at baseline 6 months and 12 months.;  Health-related quality of life at baseline 6 months and 12 months. Health utilization costs incurred during the study period.|151|NCT00606567|December 2006
1974|Terminated|An Open Label Double-blind Discontinuation Study of Quetiapine Extended Release(XR)||Drug:QuetiapineXR;  Drug:Placebo|Interventional|Phase 0|Other|Kaplan Meier survival of Clinical Global Impression of Improvement (CGI-I);  PercentageofCGI-IBSPSSPIN|55|NCT00606541|January 2008
1975|Completed|Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants||Procedure: Total Body Irradiation with Fludarabine in UCB Transplants|Interventional|Phase 1|Other|The primary objective will be to measure the time to and rate of hematologic engraftment following transplant and the frequency of treatment-related mortality.;  The secondary objective will be to estimate the proportion of patients developing acute and chronic graft-versus-host disease 100 day treatment-related mortality and to measure disease-free survival.;  The tertiary objective will be to measure the time to immunologic reconstitution as defined by normal numbers of T and B cells normal T-cell proliferative responses normal natural killer (NK) cell function and normal immunoglobulin synthesis.|40|NCT00606437|September 2005
1976|Completed                  Has Results|U-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod||Drug: U-500 Insulin delivered by Omnipod (disposable insulin pump)|Interventional|Phase 4|Other|Improvement in Glycemic Control as Assessed by Change in Hemoglobin A1c (HbA1c);  PercentageofTimeSpentinHypoglycemia;  Patient Satisfaction With Insulin Delivery Method Via Insulin Delivery Rating System Questionnaire (IDRSQ)|21|NCT00606034|December 2007
1977|Completed|Study to Determine the Phototoxity of Atralin (Tretinoin) Gel 0.05%||Drug:Atralin(tretinoin)Gel0.05%|Interventional|Phase 1|Industry|UVinducedskinsensitization|60|NCT00604032|January 2008
1978|Completed|Testing the Effectiveness of the Interactive Tutorial of the Home Macular Perimeter (HMP)||Device:ForeseeHome|Observational||Industry|Proportion of subjects who manage to use the device as in a daily testing|25|NCT00603850|January 2008
1979|Completed|Clinical Evaluation of the Photoallergy Potential of Atralin Gel||Drug:Atralin(tretinoin)gel0.05%|Interventional|Phase 1|Industry|UVInducedskinirritation|40|NCT00603772|January 2008
1980|Active not recruiting|Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery||Drug:erlotinibhydrochloride;  Genetic:proteinanalysis;  Genetic:westernblotting;  Other:immunohistochemistrystainingmethod;  Other:laboratorybiomarkeranalysis;  Other:liquidchromatography;  Other:massspectrometry;  Procedure:neoadjuvanttherapy;  Procedure:therapeuticconventionalsurgery|Interventional|Phase 0|Other / NIH|Identify tissue biomarkers of EGFR activation and inhibition for which initial values and changes after treatment with erlotinib hydrochloride would best correlate with the objective response of the tumor measured clinically and radiologically;  Objectiveresponse;  Tumor cell metabolic response measured by PET scan at 4-6 days after beginning of treatment and correlation with tumor response evaluated at the end of treatment by CT scan PET scan and direct tumor measurements;  Role of PET/CT scan in evaluating response to short-term treatment with erlotinib hydrochloride and comparison with the same response evaluation performed by CT scan;  Incidenceofriskfactorsforrelapse;  Incidence of adverse effects or significant laboratory changes;  Any treatment-induced delay of the established date for definitive surgical treatment|24|NCT00601913|March 2008
1981|Completed|Social Cognition and Interaction Training for Improving Social Functioning in People With Schizophrenia||Behavioral: Social cognition and interaction training (SCIT);  Behavioral:Treatmentasusual(TAU)|Interventional|Phase 1|Other / NIH|FaceEmotionIdentificationTask(FEIT);  FaceEmotionDiscriminationTask(FEDT);  TheHintingTask;  TheAwarenessofSocialInferenceTest(TASIT);  Ambiguous Intentions Hostility Questionnaire(AIHQ);  &quot;BeadsintheJar&quot;Task;  QualityofLifeScale(QLS);  PositiveandNegativeSyndromeScale(PANSS);  SocialSkillsPerformanceAssessment(SSPA);  SchizophreniaCognitionRatingScale(SCoRS);  OvertSocialCognition:ARatingScale(OSCARS);  LecomteSelf-EsteemScale;  NumberofHospitalAdmissions|66|NCT00601224|June 2007
1982|Completed|DNA/RNA Analysis of Blood and Skeletal Muscle in Patients Undergoing Cardiac Resynchronization Therapy (CRT)|||Observational||Other|Shift of the muscle transcriptome away from Apoptosis/Inflammation. Reversal of active apoptosis in skeletal muscle.Quality of life assessment(Minn.HF Ques) Exercise capacity (6 min walk).;  Improved LV synchrony as determined by TDI Decrease in blood markers of inflammation and Oxidative stress and catabolism.|30|NCT00600392|January 2006
1983|Withdrawn|Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer||Drug:Bevacizumab;  Drug:Carboplatin;  Radiation:RadiationTherapy|Interventional|Phase 2|Other / Industry|To determine the safety of the proposed treatment in this patient population.;  ProgressionFreeSurvival|0|NCT00600210|January 2008
1984|Completed|A Study of Sublingual Immunotherapy in Peanut-allergic Children||Drug:PeanutSLIT;  Drug:PlaceboSLIT|Interventional||Other / NIH|Determine if peanut-specific SLIT will cause clinical desensitization to develop in peanut-allergic young children.;  Determine if peanut-specific SLIT will cause tolerance to develop in peanut-allergic young children.;  Determine if the development of the desensitized state and tolerance to peanut is associated with the down-regulation of mast cells and basophils.;  Determine the effect of peanut-specific mucosal and systemic humoral immune responses on oral tolerance and peanut SLIT.;  Delineate the mechanism of the T-cell response to allergen-specific T-cells during peanut SLIT - (regulatory T cells).;  Delineate the mechanism of the T-cell response to allergen-specific T-cells during peanut SLIT - (TH2/TH1 cytokines).;  Delineate the mechanism of the T-cell response to allergen-specific T-cells during peanut SLIT - (oligonucleotide microarrays).|33|NCT00597727|January 2008
1985|Completed                  Has Results|Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant||Drug:Non-myeloablativeStemCellTransplantation|Interventional|Phase 2|Other|DiseaseFreeSurvival;  ImmuneRecovery;  ProgressionFreeSurvival;  OverallSurvival;  GraftFailure|264|NCT00597714|February 2008
1986|Completed                  Has Results|Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus||Drug:Bevacizumab;  Drug:Everolimus|Interventional|Phase 2|Other / Industry|OverallResponse;  ProgressionFreeSurvival(PFS)|50|NCT00597506|October 2007
1987|Completed                  Has Results|Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM||Drug:SorafenibandTemozolomide|Interventional|Phase 2|Other / Industry|6MonthProgressionFreeSurvival(PFS);  SafetyandToxicityofCombination;  Pharmacokinetics:C-max;  Pharmacokinetics:T-max;  Pharmacokinetics:AUC-24|32|NCT00597493|September 2007
1988|Terminated|Phase I Study of Umbilical Cord Blood Transplantation Followed by Third Party Thymus Transplantation||Biological: Thymic Transplantation for Recipients of UCB transplant|Interventional|Phase 1|Other|Toxicity of thymus transplantation following unrelated umbilical cord blood transplantation. Emphasis will be placed on adverse events that are not typically associated with umbilical cord blood transplantation.;  To determine whether engraftment of a third party thymus allograft is feasible in patients who have undergone unrelated UCBT. Thymic engraftment will be determined by biopsy of the thymus allograft and immunohistochemical evidence of thymopoiesis.;  To assess thymic function by measuring the number of naive T cells and the number of T cell receptor rearrangement excision circles (TRECS) and by assessing the diversity of the T cell receptor beta chain.|6|NCT00597441|November 2005
1989|Completed                  Has Results|Avastin in Combination With Radiation (XRT) &amp; Temozolomide Followed by Avastin Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas||Drug:Avastin;  Drug:Temozolomide;  Radiation:RadiationTherapy(XRT);  Drug:Irinotecan|Interventional|Phase 2|Other / Industry|16-monthOverallSurvival(OS);  12-monthProgression-freeSurvival(PFS);  Number of Patients Experiencing a Central Nervous System (CNS) Hemorrhage or a Systemic Hemorrhage;  Number of Patients Experiencing a Grade &#8805; 4 Hematologic or Grade &#8805; 3 Non-hematologic Toxicity|125|NCT00597402|July 2007
1990|Unknown&nbsp;&#8224;|Chronic Hepatitis Intervention Project for Drug Users||Behavioral:Motivationalinterviewing;  Behavioral:Educationalintervention|Interventional|Phase 3|NIH|Reduction/cessationofalcoholuse;  Reductions in direct and indirect needle and syringe sharing;  Reductionsinunprotectedsexualbehavior|851|NCT00596843|September 2003
1991|Terminated                  Has Results|Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec||Drug:PN400(VIMOVO);  Drug:Diclofenac/Misoprostol|Interventional|Phase 3|Industry|Number of Participants With Gastric Ulcer Confirmed by Endoscopy;  Number of Participants With Duodenal Ulcers Confirmed by Endoscopy;  Number of Participants With Upper Gastro-intestinal Injury Grade 4 as Measured by Lanza (1991) Score|20|NCT00594854|September 2007
1992|Completed                  Has Results|Enhancing Fitness in Older Pre-diabetic Veterans||Behavioral:PhysicalActivityCounseling|Interventional|Phase 2 / Phase 3|U.S. Fed|FastingInsulin;  3MonthFastingInsulin;  12MonthFastingInsulin;  FastingGlucose;  3MonthFastingGlucose;  12MonthFastingGlucose;  PhysicalActivityEndurance|302|NCT00594399|October 2008
1993|Terminated|Alcohol in the Treatment of Obesity||Other:whitewine|Interventional||Other|An outcome measure for the study is an increase weight loss or no change in the wine group of .05% over the 4 weeks of the study;  Participants will also be asked to complete a visual satiety scale each day before and after lunch and dinner.|18|NCT00594074|April 2007
1994|Active not recruiting|Cord Blood for Neonatal Hypoxic-ischemic Encephalopathy||Biological:infusionofautologouscordblood;  Other:Neurodevelopmentaloutcomes|Interventional|Phase 1|Other|Adverse event rates occurring in the pilot study population will be compared between the cord blood cell recipients and historical controls.;  Secondary endpoints of this pilot study will include preliminary efficacy as measured by neurodevelopmental function at 4 - 6 months and 9 - 12 months of age;  neuroimaging results will be collected and compared with available results from prior trials of therapies in this population and from a previously collected set of images from normal term newborns through the first year of life.|52|NCT00593242|January 2008
1995|Terminated|Trisenox Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma||Drug: Arsenic Trioxide Ascorbic Acid and Bortezomib|Interventional|Phase 1|Other / Industry|Toxicity;  Response|25|NCT00590603|July 2008
1996|Completed|Coping in African American Prostate Cancer Survivors||Behavioral:CopingSkillsTraining;  Behavioral:ProstateCancerEducation|Interventional||Other / U.S. Fed|Symptomdistress;  Emotionalfunctioning;  Physicalfunctioning;  Self-efficacyforsymptommanagement|62|NCT00589966|May 2007
1997|Completed|Relapse Prevention for Suicidal Dually Diagnosed Youths||Behavioral: CBT-RP (relapse prevention) + Enhanced TAU;  Behavioral:EnhancedTAUAlone|Interventional|Phase 1|Other|suicideideationandbehavior;  depression severity alcohol/cannabis abuse impairment|13|NCT00589641|July 2005
1998|Completed                  Has Results|Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis||Drug:infliximab|Interventional|Phase 4|Other|Effects of Infliximab on Uveitis Disease Activity.|13|NCT00589628|September 2007
1999|Completed                  Has Results|Safety Trial of NK Cell DLI 3-5/6 Family Member Following Nonmyeloablative ASCT||Device:NK-CD56|Interventional|Phase 1|Other|Toxicity;  Efficacy-OverallSurvival|21|NCT00586703|April 2005
2000|Completed                  Has Results|Safety Trial of NK DLI From 6/6 HLA Matched Family Member Following Nonmyeloablative ASCT||Device: NK Cell infusion using CD56 monoclonal antibody;  Procedure:DonorApheresis|Interventional|Phase 1|Other|Toxicity;  Efficacy-ProgressionFreeSurvival;  Efficacy-OverallSurvival;  Efficacy-DiseaseProgression|47|NCT00586690|May 2005
2001|Completed|Evaluation of Parenting Interventions to Decrease Family Risk for Child Maltreatment||Behavioral:Parent-ChildInteractionTherapy;  Behavioral:HealthandSafety;  Behavioral:EarlyRelationships|Interventional||Other|Durham County North Carolina Department of Social Services accepted reports of child maltreatment|123|NCT00586677|May 2005
2002|Completed|Developing Computer Based Treatments for Addiction||Behavioral:I/GDC+VR/CER;  Behavioral:I/GDC|Interventional||Other / NIH|Urinalyses;  Physiological measures: skin conductance heart rate and skin temperature;  Interview measures: Structured Clinical Interview for DSM-IV Axis I (SCID-I) Addiction Severity Index;  Self-report measures of Substance use [e.g. TLFB; Minnesota Cocaine Craving Questionnaire (MCCS); Cocaine Craving Questionnaire (CCQ)];  HIVRiskBehaviors|216|NCT00586534|January 2007
2003|Completed|BEP Study Phase I (Bevacizumab Everolimus Panitumumab)||Drug:bevacizumabeverolimuspanitumumab|Interventional|Phase 1|Other / Industry|To determine the MTD/recommended phase II regimen and evaluate safety of panitumumab added to RAD001 plus bevacizumab in adult patients with advanced solid tumors.;  To preliminarily describe any clinical activity (PR CR or duration of SD) associated with this regimen|56|NCT00586443|November 2007
2004|Terminated|A Research Pilot Study in Healthy Volunteers to Evaluate Biomarkers for Novel Anticancer Treatments||Other:punchbiopsy|Interventional||Other|To refine techniques needed to describe the expected values and variability of multiple angiogenic and tumor growth factor levels in blood and urine using ELISA and other evolving protein and gene expression and cell capture technologies.;  To describe the expected values and variability of multiple angiogenic and tumor growth factor levels in blood and urine including VEGF bFGF PDGF PDEGF TGF&#946; TSP1 and MMP2 and MMP9. Other angiogenic and tumor growth factors may also be evaluated.|61|NCT00586417|January 2007
2005|Completed|A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid Tumors||Drug:bevacizumabABT-510|Interventional|Phase 1|Other / Industry|To determine the recommended Phase II dose for the combination of ABT-510 plus bevacizumab;  To collect preliminary data on the clinical activity of this combination (tumor response rate progression-free survival rate of stable disease &gt; 6 months).|45|NCT00586092|September 2005
2006|Completed|Effect of Discontinuation of Sugar Sweetened Beverages||Behavioral: discontinuation of sugar sweetened beverages|Interventional||Other|HemoglobinA1c;  Fastingglucose|5|NCT00585897|January 2007
2007|Completed                  Has Results|Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath||Drug:CampathPurgedNon-myeloablativeASCT;  Procedure:DonorApheresis|Interventional|Phase 2|Other / Industry|Toxicity;  OverallSurvival(OS);  Response|176|NCT00580034|February 2003
2008|Active not recruiting|Thymus Transplantation With Immunosuppression||Biological:ThymusTissueforTransplantation|Interventional|Phase 1|Other / NIH|Safety &amp; tolerability of Thymoglobulin and cyclosporine followed by thymus transplantation: Survival at 1 year post-transplantation.;  Use of additional post transplant immunosuppression after that listed in the protocol.;  Allograftbiopsyusedtoevaluategraftrejection;  CD3count;  Thymopoiesis;  CD4count;  CD8count;  naiveCD4count;  naiveCD8count|15|NCT00579709|July 2002
2009|Active not recruiting|Phase I/II Thymus Transplantation With Immunosuppression #950||Biological:ThymusTissueforTransplantation;  Other: Thymus Tissue and Parental Parathyroid Transplantation;  Procedure:BloodDraw;  Drug:Rabbitanti-thymocyteglobulin;  Drug:Cyclosporine;  Drug:Tacrolimus;  Drug:MethylprednisoloneorPrednisolone;  Drug:Daclizumab;  Drug:Mycophenolatemofetil|Interventional|Phase 1 / Phase 2|Other / NIH|Safety/toxicity of 3 immunosuppression regimens in subjects undergoing thymus transplantation. Assessment will be survival at 1 year; incidence of fatal severe moderate and disseminated infections; and incidence of Grade 3 and 4 toxicities.;  Thymopoiesis: assessment will be done by evaluating thymus graft biopsy tissue post transplantation;  Development of T cell numbers and function post thymus transplantation using the 3 regimens tested.;  Efficacy of parental parathyroid transplantation. Number of subjects who are off both calcium and calcitriol supplementation. The time at which calcium supplementation needs to be resumed post parathyroid transplant will also be recorded.|28|NCT00579527|March 2006
2010|Completed|Evaluation of a Home Visiting Program for First Time Parents||Behavioral:HealthyFamiliesDurham;  Behavioral:YearlyCheckup|Interventional||Other / NIH|Durham County North Carolina Department of Social Services reports of child maltreatment|343|NCT00579449|March 2005
2011|Terminated|Exenatide Pregnancy Registry - Type 2 Diabetes in Pregnancy|||Observational|Phase 4|Industry|PrimaryOutcome;  SecondaryOutcomeMeasure|7|NCT00579150|January 2009
2012|Completed                  Has Results|Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath||Drug:CampathPurgedNon-myeloablativeASCT|Interventional|Phase 2|Other / Industry|Toxicity;  OverallSurvival(OS);  Response|48|NCT00578942|May 2005
2013|Completed                  Has Results|African American Knowledge Optimized for Mindfully Healthy Adolescents||Behavioral:MotivationalInterviewingActive|Interventional||Other / NIH|Attendance at First Depression Treatment Appointment|16|NCT00578318|June 2007
2014|Completed                  Has Results|Phase I/II Study of Panitumumab Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer||Drug:Panitumumab;  Drug:Capecitabine;  Drug:Oxaliplatin;  Radiation:RadiationTherapy(RT)|Interventional|Phase 1 / Phase 2|Other / Industry|Panitumumab Maximum Tolerated Dose in Milligrams (mg);  Number of Participants With Dose-limiting Toxicities (DLTs);  Overall Survival Rates for the Patients Studied on This Protocol.;  Pathological Complete Response Rates Associated With This Regimen.|29|NCT00578071|December 2007
2015|Completed|Community and Clinician Partnership for Prevention||Other:ActiveIntervention;  Other:PassiveIntervention;  Other:Nointervention|Interventional||Other / U.S. Fed|The number of referrals from the practices to the community resources;  Numberofreferralsreceivedbyeachresource;  The proportion of patients with unhealthy behaviors who were referred from the practices to community resources;  Practice attitudes and practice regarding referral to community resources|9|NCT00577759|February 2008
2016|Terminated|Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia||Drug:clofarabine;  Drug:gemtuzumabozogamicin|Interventional|Phase 1|Other / NIH / Industry|Maximumtolerateddoseofclofarabine;  Rate of complete response and/or partial complete response with incomplete platelet recovery;  Durationofremission;  Frequency of patients proceeding to allogeneic or autologous blood or bone marrow stem cell transplantation|21|NCT00577694|November 2007
2017|Active not recruiting                  Has Results|Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma||Drug:cyclophosphamide;  Drug:etoposide;  Drug:rituximab;  Drug:cytarabine;  Drug:doxorubicin;  Drug:tositumomab|Interventional|Phase 2|Other / Industry|1YearProgression-freeSurvivalRate;  Disease-free Survival in Patients With a Complete Response (CR or CRu);  OverallSurvival;  OverallResponse;  SecondaryMalignancies|39|NCT00577629|June 2005
2018|Completed|Duke Conte Center for the Neuroscience of Depression in Late Life|||Observational||Other|Each of the projects in the Duke Conte Center has its own aims and primary outcomes|795|NCT00576875|August 2006
2019|Active not recruiting|Thymus Transplantation Dose in DiGeorge #932||Biological:ThymusTissueforTransplantation;  Other:ParathyroidTissueforTransplantation|Interventional|Phase 2|Other / NIH|Regression analyses used to correlate dose to immunologic parameters: T cell proliferative response; na&#239;ve T cells; and T cell variability.;  Thymus transplantation efficacy: survival is recorded. Immune reconstitution efficacy: T cell phenotypic and functional parameters are evaluated. This is evaluated in descriptive fashion.;  Parental parathyroid transplantation efficacy: number of subjects who are off calcium and calcitriol supplementation. The time that calcium supplementation needs to be resumed is recorded.;  Safety. Particular attention on oligoclonal T cell development; pulmonary complications; infections; and autoimmune diseases. Dose is correlated with number of subjects who get rashes lasting &gt;1 week with development of wheezing or oxygen requirement.;  Correlations between dose and other immune parameters and factors which might affect outcome including HLA matching and thymus donor heart defect. Evaluate whether HLA-DR matching results in increased total CD4 T cell numbers.|28|NCT00576836|February 2006
2020|Active not recruiting|Thymus Transplantation in DiGeorge Syndrome #668||Biological:ThymusTissueforTransplantation|Interventional|Phase 2|Other / NIH|Survivalrateatoneyearpost-transplantation.;  Tcellproliferativeresponsetotetanustoxoid|26|NCT00576407|November 2001
2021|Completed                  Has Results|Responses of Myocardial Ischemia to Escitalopram Treatment||Drug:Escitalopram;  Drug:Placebo|Interventional|Phase 4|Other / NIH|Percentage of Participants With an Absence of Mental Stress-induced Myocardial Ischemia (MSIMI) During the 3 Mental Stressors;  Percentage of Participants With Overall Mental Stress-induced Myocardial Ischemia (MSIMI);  Mental Stress Induced Change of Systolic Blood Pressure;  Mental Stress Induced Change of Diastolic Blood Pressure;  PercentageofParticipantsWithAdverseEvents;  BeckDepressionInventory;  MentalStressInducedChangeinHeartRate;  5HTTSerotoninTransporterProtein;  PlateletSerotoninBindingAffinityKd_100;  PerceivedStressScale;  Cook-MedleyHostility(Ho)Scale;  Cook-Medley Hostility (Ho) Hostile Affect Sub-scale;  Spielberger State-Trait Anxiety Inventory Scales (STAI);  Exercise Stressed-induced Myocardial Ischemia (ESIMI)|127|NCT00574847|September 2006
2022|Completed|Pathogenesis and Genetics of Environmental Asthma Ozone Study|||Observational||NIH|Pathogenesis and genetics of environmental asthma ozone study|170|NCT00574158|July 2005
2023|Completed|Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors||Drug:carboplatin;  Drug:cisplatin;  Drug:etoposide;  Drug:pemetrexeddisodium;  Drug:sorafenibtosylate|Interventional|Phase 1|Other / NIH|Recommended phase II dose and maximum tolerated dose of sorafenib tosylate when administered in combination with cisplatin and etoposide or carboplatin and pemetrexed disodium;  Toxicity;  Efficacy of treatment as measured by RECIST criteria or by tumor markers;  Pharmacokinetics of sorafenib tosylate in combination with etoposide (samples are no longer being collected and studies are no longer being performed as of 1/8/09)|31|NCT00573690|September 2007
2024|Completed                  Has Results|A Randomized Double-Blind Study Testing the Effects of Pregabalin on Diabetic Neuropathy||Drug:Pregabalin;  Drug:Placebo|Interventional|Phase 4|Other / Industry|Assessing the Change in Resting Blood Pressure Upon Treatment of Pregabalin vs. Placebo in Patients With Diabetes and Peripheral Neuropathy.;  Assessing the Change in Heart Rate by Means of the LifeShirt System Upon Treatment of Pregabalin vs. Placebo in Patients With Diabetes and Peripheral Neuropathy.;  Assessing the Change in Heart Rate Variability by Means of the LifeShirt System Upon Treatment of Pregabalin vs. Placebo in Patients With Diabetes and Peripheral Neuropathy.;  Assessing the Change of Parameters of Autonomic Nerve Function Such as Heart Rate Variability by Means of the LifeShirt System Upon Treatment of Pregabalin vs. Placebo in Patients With Diabetes and Peripheral Neuropathy.;  To Assess the Change of Pain Symptoms Upon Treatment of Pregabalin in Comparison to Placebo.;  To Assess the Change of Anxiety Symptoms Upon Treatment of Pregabalin in Comparison to Placebo.;  To Assess the Change of Depressive Symptoms Upon Treatment of Pregabalin in Comparison to Placebo.;  To Assess the Change in Disability Scale Upon Treatment of Pregabalin in Comparison to Placebo.|40|NCT00573261|March 2006
2025|Terminated                  Has Results|A Pilot Study of Daptomycin for Antimicrobial Prophylaxis||Drug:daptomycin6mg/kgIV|Interventional|Phase 4|Other / Industry|Rate of Patients Receiving Antimicrobial Prophylaxis Within the Appropriate Timeframe Before Incision|11|NCT00572260|January 2008
2026|Completed|ENCORE: Exercise and Nutritional Interventions for Cardiovascular Health||Behavioral:DASHdiet;  Behavioral:DASHdietplusWeightloss|Interventional||Other / NIH|Bloodpressure;  Ambulatory blood pressurevascular functionleft ventricular geometry glucose tolerancebody composition quality of life|144|NCT00571844|October 2003
2027|Completed|Estimating Volume Using LiDCO|||Observational||Other|Strokevolumevariation|34|NCT00571441|December 2007
2028|Unknown&nbsp;&#8224;|Isolation and Culture of Circulating Tumor Cells From Peripheral Blood|||Observational||Industry||500|NCT00571389|November 2007
2029|Completed|Retisert and Cataract Surgery in Patients With Severe Uveitis||Device:Retisert(fluocinoloneacetonideimplant)|Interventional||Other|Preoperative and postoperative ocular inflammation;  visualacuity|21|NCT00570830|September 2006
2030|Active not recruiting|Neurocognitive Outcomes of Depression in the Elderly|||Observational||Other / NIH|Change in Depression status (measured by Montgomery Asberg Depression Rating Scale);  Change in Cognitive impairment (as measuring using cognitive tests including those found in the CERAD battery);  Development of dementia (Determined by Clinical Consensus Conference);  Change in Cognition (as measured by tests including those in the CERAD battery) Change in Brain MRI markers (e.g. volume of white matter and gray matter lesions);  Change in Impairment in Instrumental or Basic Activities of Daily Living;  Packing density of prefrontal cortex neurons with pyramidal morphology in post-mortem neuroanatomical studies|795|NCT00570583|December 1995
2031|Terminated|Utility of Exercise-induced N-terminal (NT) Pro-brain Natriuretic Peptide Levels in Predicting Prognosis in Asymptomatic Aortic Stenosis||Other:NT-pro-BNPlevels|Interventional||Other|development of symptomatic aortic stenosis (new/progressive angina or dyspnea pre-syncope/syncope hospitalization for cardiac chest pain or heart failure drop in LV ejection fraction cardiovascular or sudden death valve replacement surgery)|110|NCT00567437|December 2007
2032|Active not recruiting|Parathyroid and Thymus Transplantation in DiGeorge #931||Biological:Thymus/ParathyroidTransplantation|Interventional|Phase 1|Other / U.S. Fed / NIH|Efficacy parameter: use of calcium/calcitriol at 1 year post-transplantation.;  Efficacyparameters:ionizedcalcium;  Efficacyparameters:CD3count;  Efficacyparameters:CD4count;  Efficacyparameters:CD8count;  Efficacyparameters:naiveCD4count;  Efficacyparameters:naiveCD8count;  Efficacy parameters: proliferative response to phytohemagglutinin;  Efficacy parameters: proliferative response to tetanus toxoid;  Efficacy parameters: spectra typing at 1 year post transplantation|25|NCT00566488|January 2005
2033|Terminated                  Has Results|Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer||Drug:Dasatinib|Interventional|Phase 2|Other / Industry|ResponseRate;  SafetyandTolerabilityofNeoadjuvantDasatinib;  Gene Expression Profile Activation of Src Pathways;  SafetyandTolerabilityofAdjuvantDasatinib|2|NCT00564876|November 2007
2034|Completed|Synera&#8482; for Epidural Needle Insertion||Drug:Synera(TM);  Other:Placebopatch|Interventional|Phase 4|Other|Subject VRS (0 - 11) with epidural needle insertion;  AnesthesiaproviderperceivedVRS;  Needfordeepinfiltrationwithlocalanesthesia|33|NCT00564785|February 2007
2035|Completed                  Has Results|Pilot Study of Pregnenolone Augmentation Targeting Cognitive Symptoms in Persistently Symptomatic Patients With Schizophrenia||Drug:Pregnenolone;  Drug:Placebo|Interventional||U.S. Fed|Mean Score on the Scale for the Assessment of Negative Symptoms (SANS) p=0.048;  Mean Change of Z-scores on the Brief Assessment of Cognition in Schizophrenia (BACS);  Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS);  Mean Score Change in Calgary Depression Scale for Schizophrenia (CDSS);  ClinicalGlobalImpressionScale(CGI-I);  Mean Score on the Positive and Negative Symptom Scale (PANSS)|28|NCT00560937|June 2005
2036|Completed|Targeting Cognition in PTSD: Pregnenolone Augmentation of SSRIs||Drug:PregnenoloneorPlacebo|Interventional||U.S. Fed|CAPSBAC-A;  PCLCD-RISCCGIBDI-II|27|NCT00560781|April 2006
2037|Active not recruiting|Schizophrenia and PTSD Project: Health Interventions and Risk/Resilience Evaluation(SAPPHIRE Study)|||Observational||U.S. Fed|Brief Assessment of Cognition in Schizophrenia (BACS)|400|NCT00560677|March 2007
2038|Completed                  Has Results|Secondary Prevention With Paroxetine vs. Placebo in Subthreshold Posttraumatic Stress Disorder (PTSD)||Drug:Paroxetine;  Drug:Placebo|Interventional|Phase 4|U.S. Fed|ClinicianAdministeredPTSDScale(CAPS);  ShortPTSDRatingInterview;  ConnorDavidsonResilienceScale;  HospitalAnxietyandDepressionScale;  Clinical Global Impressions of Severity and of Improvement Scales;  SymptomChecklist90;  SheehanDisabilityScale(SDS)|12|NCT00560612|January 2006
2039|Completed|Effectiveness Study of a Computer-Based Colorectal Cancer Screening Decision Aid||Behavioral:CHOICEdecisionaid;  Behavioral:YourMedspatienteducationprogram|Interventional||Other|Receiptofcolorectalcancerscreening;  Change in participants&apos; readiness to be screened (Stage of Change);  Self-reported intent to discuss colorectal cancer screening with healthcare provider;  Provider ordering a colorectal cancer screening test;  Participant completion of computer program without assistance;  Participantacceptanceofcomputerprogram;  Number of polyps and cancers found by screening tests performed|350|NCT00558233|November 2007
2040|Completed                  Has Results|Efficacy Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation||Drug: PSD502 contains a mixture of lidocaine and prilocaine;  Drug:Placebo|Interventional|Phase 2 / Phase 3|Industry|Mean Intravaginal Ejaculatory Latency Time (IELT): Change From Baseline to During 3 Month Double Blind-treatment;  Index of Premature Ejaculation (IPE): Change From Baseline to End of Month 3;  Percentage of Subjects With Mean Intravaginal Ejaculatory Latency Time (IELT) &gt; 1 Minute and &gt;2 Minutes During the 3 Months of Double-blind Treatment;  Change in Mean Intravaginal Ejaculatory Latency Time (IELT) From Baseline to Month 3;  Change in the Index of Premature Ejaculation (IPE) Domains of Ejaculatory Control Distress and Sexual Satisfaction From Baseline to Month 1;  SubjectPEPatMonth1;  Change in the Index of Premature Ejaculation (IPE) Domains of Ejaculatory Control Distress and Sexual Satisfaction From Baseline to Month 2;  Subject Premature Ejaculation Profile (PEP) at Month 2;  Subject Premature Ejaculation Profile (PEP) at Month 3;  Partner Premature Ejaculation Profile (PEP) at Month 3|256|NCT00556478|October 2007
2041|Completed|Physical Activity in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy||Behavioral:exerciseintervention|Interventional||Other / NIH|Percentage of adults 50 years of age or older admitted for induction or reinduction chemotherapy for acute myeloid leukemia (AML) who are eligible for the study;  Percentage of eligible patients recruited into the study;  Number and frequency of reported barriers to eligibility and enrollment;  Percentage of study participants who successfully completed the physical and the psychosocial measures;  Record barriers to completion of the physical activity program;  Physical function as measured by the Short Physical Performance Battery (SPPB);  Quality of Life as measured with the Distress Thermometer|26|NCT00554489|July 2007
2042|Completed|Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)||Drug:Rezular15mg;  Drug:Placebo;  Drug:Rezular|Interventional|Phase 3|Other|AdequateRelief|711|NCT00552565|September 2007
2043|Unknown&nbsp;&#8224;|Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis||Drug:rituximab|Interventional|Phase 2|Other / Industry|Evaluate symptomatic physiologic and radiographic effects of therapy;  Evaluate the overall tolerability of therapy and the requirement for therapeutic whole-lung lavage|10|NCT00552461|January 2007
2044|Completed                  Has Results|Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment||Drug:0.59mgFluocinoloneAcetonideimplant|Interventional|Phase 4|Other / Industry|NumberofEyesWithInflammationRecurrence;  Percentage of Eyes With Improvement in Visual Acuity;  Number of Participant&apos;s Eye Requiring Adjunctive Therapy;  Number of Eyes With Increased Intraocular Pressure|21|NCT00543296|March 2004
2045|Completed|Using Magnetic Resonance Imaging to Predict People Who Are Likely to Develop Flash Pulmonary Edema (The PREDICT Study)|||Observational||Other / NIH|Association between MRI stress measures of cardiovascular stiffness and cardiovascular events|579|NCT00542503|June 2007
2046|Recruiting|Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer||Drug: Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin;  Procedure:DefinitiveSurgery;  Radiation:Radiotherapy|Interventional|Phase 2|Other|1)Pathologicresponse;  1) Clinical response 2) Disease free survival (DFS) 3) Overall Survival (OS)|30|NCT00542191|July 2007
2047|Unknown&nbsp;&#8224;|MiniArc Study: Long-Term Effectiveness Trial for AMS Sling Systems||Device:MiniArc|Observational|Phase 4|Industry|Evaluation of long-term effectiveness after implantation of MiniArc sling via qualitative(i.e.UDI-6 and IIQ-7) and quantitative measurement (i.e.pad weight test and cough stress test) in females for treatment of SUI in general post-market use.;  Evaluation of procedural variables of the implantationoutcomesand long-term safety.These outcomes will be measured via questionnaires procedural data and report of adverse events.|188|NCT00541151|September 2007
2048|Completed|Behavioral Insomnia Therapy With Chronic Fatigue Syndrome||Behavioral:CognitiveBehavioralTherapy;  Other: Usual Care for Chronic Fatigue Syndrome (Active Control Group)|Interventional|Phase 1 / Phase 2|Other / NIH|totalwaketime;  totalsleeptime;  sleepefficiency;  beliefsaboutsleep;  sleephabits;  actigraphy(measurementofactivity);  scores on measures of fatigue mood anxiety quality of life chronic fatigue syndrome symptoms fibromyalgia symptoms medication usage|24|NCT00540254|September 2007
2049|Completed                  Has Results|Precedex Versus Propofol-Awakening for Reducing Brain Injury Expansion||Drug:Dexmedetomidine;  Drug:Propofol|Interventional|Phase 1 / Phase 2|Other / Industry|Lactate/Pyruvate(L/P)Ratio|8|NCT00538616|January 2008
2050|Terminated|Combining Observational and Physiologic Sedation Assessment Tools||Other:RamsayScale;  Device:Bispectralindexmonitor|Interventional|Phase 4|Other / Industry|Howmuchsedativewasinfused;  Howquicklythesubjectrecoveredfromsedation;  Thenumberofundersedationevents|67|NCT00538369|November 2006
2051|Completed|Ultrasound Guided Arthrocentesis||Procedure:Ultrasoundguidedarthrocentesis|Interventional||Other|Successrateforarthrocentesis;  Reductioninaspirationattempts|132|NCT00537589|December 2004
2052|Completed|A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing Malignancies||Biological:AVX701|Interventional|Phase 1 / Phase 2|Industry / Other|determine the safety of immunization with CEA(6D) VRP;  evaluate CEA-specific immune response to immunizations|28|NCT00529984|September 2007
2053|Completed                  Has Results|How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis||Drug:doxercalciferol|Interventional|Phase 4|Other / Industry|ChangeinEndothelialCellFunction|24|NCT00528788|September 2007
2054|Completed                  Has Results|A 12-month Phase 3 Open-label Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)||Drug:PN400(VIMOVO);  Drug:PN400(VIMOVO)|Interventional|Phase 3|Industry|Number of Subjects Monitored for Long-term Safety of PN 400|239|NCT00527904|March 2007
2055|Completed                  Has Results|Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen||Drug:PN400(VIMOVO);  Drug:Naproxen|Interventional|Phase 3|Industry|Number of Participants With Gastric Ulcer Confirmed by Endoscopy;  The Number of Participants With Pre-Specified NSAID-Associated Upper GI Adverse Events or Duodenal Ulcers;  The Number of Participants Discontinuing From the Study Due to NSAID-Associated Upper GI Adverse Events or to Duodenal Ulcer;  The Number of Participants Developing Duodenal Ulcers Throughout 6 Months of Treatment;  Heartburn Symptom Resolution ie no Heartburn Symptoms During the Last 7 Days Prior to the Visit;  Improvement From Baseline in Upper Abdominal Pain and Discomfort Scores at 6 Months Based on the Overall Treatment Evaluation for Dyspepsia Questionnaire;  Mean Change From Baseline on Pain Intensity of the Severity of Dyspepsia Assessment (SODA) Subscales;  Mean Change From Baseline on Non-Pain Symptoms of the Severity of Dyspepsia Assessment (SODA) Subscales;  Mean Change From Baseline on Satisfaction of the Severity of Dyspepsia Assessment (SODA) Subscales|434|NCT00527787|September 2007
2056|Completed|Evaluation of Walk With Ease in Arthritis||Behavioral:WalkwithEase-Group;  Behavioral:WalkwithEase-Self|Interventional|Phase 3|U.S. Fed / Other|PhysicalActivityLevel;  6-minutewalk;  Walkingbehaviors;  Exerciseself-efficacy;  Health-relatedQualityofLife(SF36);  HealthAssessmentQuestionnaire;  ArthritisSymptoms;  SeniorFitnessTest(function)|468|NCT00526435|October 2007
2057|Terminated                  Has Results|DepoCyt for Active Lymphomatous or Leukemic Meningitis||Drug:cytarabineliposomeinjection|Interventional|Phase 2|Other / Industry|ResponseRate;  TimetoNeurologicProgression|4|NCT00523939|June 2006
2058|Completed|Hydroxyurea in Young Children With Sickle Cell Anemia||Drug:hydroxyurea|Interventional||Other|Transcranialdopplerultrasoundvelocity;  Magneticresonanceimaging/angiography;  GlomerularFiltrationRate;  QualityofLife;  Neurocognitiveoutcomes;  Growthparameters;  Hematologicalparameters|14|NCT00519701|April 2002
2059|Completed|Pharmacogenomics of Antidepressant Response in Children and Adolescents|||Observational||Other / NIH|Suicidal Event(120 patients) Behavioral Activation(120 patients) Co-occurring Suicidal Event + Behavioral Activation (120 patients) Tolerant controls (at a control to case ratio of 3:1) no evidence of Suicidal Events or Behavioral Activation|211|NCT00516932|May 2007
2060|Recruiting|Duke Autoimmunity in Pregnancy Registry|||Observational||Other||500|NCT00513591|August 2007
2061|Recruiting|Duke Lupus Registry|||Observational||Other||1000|NCT00512694|July 2007
2062|Completed|Fluorescence Bronchoscopy and Molecular Characterization of Abnormal Bronchial Lesions: Novel Approaches for Early Detection of Lung Cancer in High Risk Patients|||Observational||NIH||200|NCT00512642|July 1999
2063|Terminated                  Has Results|Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma||Drug:Bortezomib;  Drug:Rituximab;  Drug:Fludarabine;  Drug:Mitoxantrone;  Drug:Dexamethasone|Interventional|Phase 2|Other / Industry|CompleteandPartialResponse;  DurationofResponse;  Percentage of Subjects Experiencing Progression Free Survival;  Percentage of Subjects Experiencing Overall Survival;  Number of Participants With a Grade 3-4 Hematologic Toxicity.;  NumberofParticipantsWithNeuropathyAnyGrade|14|NCT00510887|January 2007
2064|Terminated                  Has Results|Sorafenib in Myelodysplastic Syndrome||Drug:Sorafenib|Interventional|Phase 2|Other / Industry|Number of Subjects Achieving Hematological Response;  NumberofSubjectsRequiringDoseReductions;  TimetoProgression;  OverallSurvival;  ChangeinMicrovesselDensity|19|NCT00510289|July 2006
2065|Terminated                  Has Results|NICardipine Neuroprotection in AortiC Surgery (NICNACS)||Drug:Nicardipine;  Drug:0.9%saline|Interventional|Phase 2|Other|Duration From Initiation of Cardiopulmonary Bypass (CPB) to Electrocerebral Silence (ECS) Defined as no Discernable Electroencephalographic Activity at an Amplification of 2 Micro Volts (&#956;V)/mm Confirmed for 3 Minutes;  TemperatureatWhichECSOccurs;  TemperatureatWhichAblationof(SSEP)Occurs;  TimePointsofEEGPatterns;  Time Points for SSEP Latency and Amplitude Changes;  BispectralIndexScores(BIS);  CerebralOximetryMeasurements;  TranscranialDopplerMeasurements|7|NCT00508118|January 2008
2066|Terminated                  Has Results|Combined Patching-Atropine for Residual Amblyopia||Device:Patching;  Drug:Atropine|Interventional|Phase 3|Other / NIH|Distribution of Amblyopic Eye Visual Acuity at 10 Weeks;  Mean (SD) Distribution of Visual Acuity at 10 Weeks;  Distribution of Amblyopic Eye Visual Acuity Change From Baseline to 10 Weeks;  Mean (SD) Change in Visual Acuity in the Amblyopic Eye at the 10 Week Primary Outcome Exam|55|NCT00506675|October 2007
2067|Completed                  Has Results|Ketamine In Thoracic Surgery (KITS) Trial||Drug:Ketamine;  Drug:0.9%saline|Interventional|Phase 2|Other|InterleukinLevelsat24Hours;  C-reactiveProtein(CRP)SerumLevels;  VerbalPainScores|40|NCT00504725|July 2007
2068|Unknown&nbsp;&#8224;|Creation of a PBRN to Study Healthcare Delivery to a Transitioning Community|||Observational||U.S. Fed|||NCT00503555|June 2006
2069|Withdrawn|Vitamin D and Carboxy PTH Fragments in Coronary Calcification||Drug:Doxercalciferoladministration;  Drug:Doxercalciferoladministeredby1-84-7-84|Interventional|Phase 4|Other|Percent Change in Hounsfield units of coronary calcification between baseline and after one year of therapy;  Mean dose of Vitamin D2 administered over 12 months|0|NCT00502268|February 2008
2070|Completed                  Has Results|Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma||Drug:Bevacizumab;  Drug:MetronomicTemozolomide|Interventional|Phase 2|Other / Industry|6-MonthProgression-freeSurvival;  ResponseRate;  Incidence and Severity of CNS Hemorrhage and Systemic Hemorrhage;  Incidence of Grade &#8805; 4 Hematologic or Grade &#8805; 3 Non-hematologic Toxicity|32|NCT00501891|July 2007
2071|Completed|Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed Progressive or Recurrent Primary Malignant Brain Tumors|||Observational||Other / NIH|assess any changes in standard semen/sperm analysis parameters|16|NCT00499798|August 2004
2072|Completed|Physical and Mental Assessment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia|||Observational||Other / NIH|feasibility of administering a functional assessment in clinical situation|11|NCT00499785|June 2007
2073|Completed|Individualized Exercise Programs for Patients Receiving Chemotherapy for Newly Diagnosed Acute or Relapsed Myeloid Leukemia or Lymphoblastic Leukemia||Behavioral:Restingvitals;  Behavioral:BodyComposition;  Behavioral:TimedGet-upandGotest(TGUG).;  Behavioral:Cardiorespiratoryassessment;  Behavioral:Handgripevaluation;  Behavioral:Dynamicmuscularendurance|Interventional||Other / NIH|Effects of an individualized prescriptive exercise intervention;  Number of subjects experiencing fatigue depression and quality of life issues|10|NCT00499759|February 2006
2074|Active not recruiting                  Has Results|Radiofrequency Ablation and External-Beam Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery||Procedure:radiofrequencyablation;  Radiation:radiationtherapy|Interventional|Phase 2|Other / NIH|TwoYearProgressionFreeSurvivalRate;  Rate of Acute and Late Treatment-related Toxicity (Per CTCAE v3.0) Related to Specific Symptoms|13|NCT00499447|May 2007
2075|Completed                  Has Results|Vitamin D and Soy Supplements in Treating Patients With Recurrent Prostate Cancer||DietarySupplement:cholecalciferol;  DietarySupplement:genistein;  DietarySupplement:soyisoflavones;  Genetic:polymerasechainreaction;  Genetic:proteinexpressionanalysis;  Other:immunologictechnique;  Other:laboratorybiomarkeranalysis|Interventional|Phase 2|Other / NIH|Number of Participants Showing a 50% Reduction in Serum Prostate Specific Antigen(PSA) During Treatment;  ChangesinPSASlope;  ChangesinPSADoublingTime|26|NCT00499408|April 2007
2076|Completed|Fludeoxyglucose F 18-PET Imaging for Early Detection of Residual Disease in Patients Undergoing Radiofrequency Ablation of Liver Metastases From Colorectal Cancer||Procedure:positronemissiontomography;  Procedure:radiofrequencyablation|Interventional||Other / NIH|Sensitivity and specificity of fludeoxyglucose F 18 (FDG)-PET imaging in early diagnosis of residual disease;  Findingsonday7afterRFAusingFDG-PETimaging|4|NCT00499395|July 2005
2077|Completed|Risk of Life-threatening Heart Rhythm Disturbances in Siblings||Device:ICD|Observational||Other|ICDDischarge|2047|NCT00498524|July 2007
2078|Completed|Magnetic Resonance Imaging of Atrial Septal Defects|||Observational||Other||44|NCT00498446|July 2002
2079|Completed                  Has Results|Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery||Drug:StandardCare;  Drug:nepafenac|Interventional|Phase 4|Other|Central Macular Thickness (Difference in Mean Pre-post Changes by the Two Treatment Groups);  Pre-operativeBestCorrectedVisualAcuity(BCVA);  FovealThickness;  Macular Volume (Difference in Mean Pre-post Changes by the Two Treatment Groups);  Post-operative Best Corrected Visual Acuity (BCVA)|82|NCT00494494|June 2007
2080|Completed                  Has Results|Aripiprazole Augmentation of Antidepressants in PTSD||Drug:Aripiprazole;  Drug:Placebo|Interventional|Phase 2|U.S. Fed|ClinicianAdministeredPTSDScale(CAPS);  Brief Assessment of Cognition in Affective Disorders (BAC-A);  PositiveandNegativeSymptomsScale(PANSS);  Connor-DavidsonResilienceScale(CD-RISC);  Beck Depression Inventory Second Edition (BDI-II)|14|NCT00489866|March 2007
2081|Completed|Visceral Lymphatic Mapping Using Isosulfan Blue in Patients With Cancer of the Pancreas Colon Stomach Small Intestine or Gallbladder|||Observational||Other / NIH|Safety as determined by the number of adverse events resulting from procedure;  Ability of surgically defined sentinel lymph nodes to predict whether other lymph nodes are involved with the tumor|115|NCT00489515|February 1999
2082|Terminated|Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids||Biological:efalizumab|Interventional||Other / NIH|Numberofsubjectsexperiencingadverseevents;  Feasibilityofdigitalimaging;  Feasibilityofserialskinbiopsies;  Overallcompleteresponserate|2|NCT00489216|December 2006
2083|Recruiting|Strength and Range of Motion in Women Undergoing Surgery for Breast Cancer||Other:physiologictesting|Observational||Other / NIH|Collection of data before surgery at each follow-up visit and at 2 years after surgery;  Changes in physical activity participation measures of body composition shoulder range of motion grip strength and arm strength over time;  Differences in changes in physical activity and indices of fitness according to type of surgery and adjuvant therapy;  Relationships between exercise participation fitness and body composition over time;  Correlation of data with an ongoing randomized exercise trial that includes strength and flexibility assessments with no pre-surgery measures|275|NCT00489125|March 2005
2084|Completed|Low Antioxidant Diet in Controlling Cachexia in Patients With Oropharyngeal Cancer Receiving Chemotherapy and Radiation Therapy||Other:ADD;  Other:Placebo|Interventional|Phase 1|Other / NIH|Numberofpeoplewithadverseevents|4|NCT00486304|February 2006
2085|Completed|Use of Bicarbonate to Reduce the Incidence of Acute Renal Failure After Cardiac Surgery||Other:Sodiumbicarbonate;  Other:Normalsaline;  Other:Bicarbonate;  Other:Placebo|Interventional||Other|Maximum change in serum creatinine level (SCr) over the 72 hour post-operative period;  Maximum change in GFR over 72 hours post operatively;  Lengthofhospitalstay;  Incidence of need for dialysis for treatment of acute renal failure;  Mortality|123|NCT00484354|May 2006
2086|Withdrawn|Pharmacokinetic Study of Fondaparinux in Outpatients With Renal Dysfunction||Drug:fondaparinux|Interventional||Other / Industry|PK parameters (half-life area-under-the curve and peak serum concentration);  Anti-factor Xa levels and assessment for bleeding(complete blood count)|0|NCT00483600|August 2007
2087|Completed|Oxaliplatin Capecitabine and Cetuximab in Treating Patients With Advanced Liver Cancer||Biological:cetuximab;  Drug:capecitabine;  Drug:oxaliplatin|Interventional|Phase 2|Other / NIH|DiseaseResponseRate;  Numberofsubjectsexperiencingadverseevents;  OverallSurvival;  Timetoprogression|33|NCT00483405|October 2006
2088|Completed|Written Educational Information and Phone Calls in Increasing Follow-Up Care in Hispanic Women With Abnormal Pap Smears||Other:educationalintervention;  Other:questionnaireadministration;  Other: study of socioeconomic and demographic variables;  Other:surveyadministration|Interventional||Other / NIH|Reasonsfornonadherencetofollow-up;  Effect of written educational information and phone calls on follow-up rate|238|NCT00483288|May 2005
2089|Recruiting|Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome|||Observational||Other|characterize genetic risk factors associated with the development of familial antiphospholipid antibody syndrome.|2800|NCT00482794|June 2006
2090|Completed|Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)||Drug:PanzemNCD;  Drug:Temozolomide|Interventional|Phase 2|Industry|6-month progression free survival and median overall survival for patients receiving at least one dose|15|NCT00481455|April 2007
2091|Completed                  Has Results|Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer&apos;s Disease||Drug:Aricept(donepezilSR23mg);  Drug:Aricept(donepezilIR10mg)|Interventional|Phase 3|Industry|Change From Baseline to Week 24 in SIB Total Score;  Overall Change From Baseline in Modified CIBIC+ to Week 24;  Change From Baseline to Week 24 in ADCS-ADL Total Score;  Change From Baseline to Week 24 in MMSE Total Score|1467|NCT00478205|June 2007
2092|Completed|Angiotensin-(1-7) in Treating Patients With Metastatic or Unresectable Solid Tumors||Biological:therapeuticangiotensin-(1-7)|Interventional|Phase 1|Other / NIH|Maximumtolerateddose;  Toxicity;  Response rate (complete or partial response) as measured by RECIST criteria|18|NCT00471562|March 2007
2093|Unknown&nbsp;&#8224;|Randomized Controlled Trial of Bladder Flap vs.None||Procedure:bladderflapduringcesareansection|Interventional||Other|operative time: start of surgery to delivery of infant;  estimatedbloodloss;  bladderinjuries;  otherintra-operativecomplications;  intra-operativetransfusions;  post-operativecomplications;  medicationuse:antibioticsandnarcotics;  durationofpost-ophospitalization;  readmisisonpostdischarge|123|NCT00470288|October 2005
2094|Completed|Improving Care for Primary Care Patients With Diabetes and Poor Literacy and Numeracy Skills||Behavioral: Literacy/Numeracy oriented educational intervention;  Behavioral:ControlGroup|Interventional|Phase 4|Other / Industry|A1C;  Patientself-managementbehaviors;  Patientknowledge;  Patientsatisfaction|110|NCT00469105|December 2006
2095|Unknown&nbsp;&#8224;|Safety and Efficacy Study of Re-treatment With Rituximab (MabThera/Rituxan) in Patients With Active Rheumatoid Arthritis Who Respond Poorly to Anti-TNF&#945; Therapies||Drug:Rituximab|Interventional|Phase 3|Industry|The primary endpoint is the proportion of patients with an ACR20 response achieved by re-treatment at any time.;  The proportion of patients achieving an ACR50 and ACR70 response at any time following treatment.|341|NCT00468377|March 2004
2096|Completed|Visibility of Lesion Characteristics With Phase Contrast Mammography||Other:PhaseContrastMammography|Interventional||Other|Measure: Lesion Visibility Comparison of Phase Contrast Mammography with X-Ray Mammography.|53|NCT00467727|April 2007
2097|Completed|Effect of Burn Size on Cytomegalovirus Reactivation and Correlates of T Cell Immune Function in Burned Patients|||Observational||Other|CMVIgGandviralloadPCR|60|NCT00467532|March 2007
2098|Completed|Effect of House Dust Mite Allergen Challenge in Persons Using 1200 mg Gamma Tocopherol Supplements||Drug:GammaTocopherol|Interventional|Phase 1|Other|Post-treatment change in concentration of house dust mite-induced eosinophils in nasal lavage fluid (NLF) compared to pre-treatment baseline.;  (a)NLF inflammatory mediators including eicosanoid products inflammatory cytokines relevant to innate immunity and allergic inflammation cells other than eosinophils total protein (b)safety outcomes of cbc and coagulation factors|8|NCT00466596|March 2007
2099|Completed                  Has Results|Metabolic Signatures and Biomarkers in Schizophrenia||Drug:Aripiprazole;  Drug:Risperidone;  Other:Healthyvolunteers|Interventional|Phase 1|Other / Industry|TotalPlasmalogenLevelsintheLipidProfile|71|NCT00466310|February 2007
2100|Completed                  Has Results|A Study of Zolpidem Tartrate Sublingual Tablet in Adult Patients With Insomnia||Drug:zolpidemtartratesublingualtablet;  Drug:Placebo|Interventional|Phase 3|Industry|Latency to Sleep Onset After Middle-of-the-Night Awakening at Baseline;  Latency to Sleep Onset After Middle-of-the-Night Awakening During Double-blind Treatment;  Subjective Total Sleep Time Following Middle-of-the-Night Awakening at Baseline;  Subjective Total Sleep Time Following Middle-of-the-Night Awakening During Double-blind Treatment;  Subjective Number of Awakenings Following Middle-of-the-Night Awakening at Baseline.;  Subjective Number of Awakenings Following Middle-of-the-Night Awakening During Double-blind Treatment;  Subjective Wake Time After Sleep Onset Following Middle-of-the-Night Awakening at Baseline;  Subjective Wake Time After Sleep Onset Following Middle-of-the-Night Awakening During Double-blind Treatment;  Morning Sleepiness Rating Following Dosing Post Middle-of-the-Night Awakening at Baseline;  Morning Sleepiness Rating Following Dosing Post Middle-of-the-Night Awakening During Double-blind Treatment|295|NCT00466193|May 2007
2101|Completed                  Has Results|The Treatment of Insomnia in Patients With HIV Disease||Drug:Doxepin;  Drug:Temazepam;  Drug:Placebo|Interventional|Phase 4|Other|Response: Change in Insomnia Severity Rating Scale at 3 Months.;  ChangeinPiperFatigueScaleat3Months|44|NCT00465972|March 2007
2102|Completed|Development and Evaluation of a Medical Intervention for Early Childhood Caries||Behavioral:Continuingmedicaleducation|Interventional||Other|Rate of preventive dental services provision per 100 well-child visits.;  Percent of practices providing 20 or more preventive dental visits.|120|NCT00464009|February 2001
2103|Completed|Randomized Controlled Trial of Hyperbaric Oxygen in Patients Who Have Taken Bisphosphonates||Device:hyperbaricoxygen;  Device:non-treatedcontrolgroup|Interventional|Phase 1|Other|Clinical outcome assessments. Effect of HBO as an adjunct to the routine treatment of ONJ will be evaluated by physical exam and pain scores;  Quality of life measurements by the Duke Health Profile;  Laboratorymeasuresofboneturnover;  Molecular indicators of osteoclast activation (RANK RANKL OPG pAKt)|54|NCT00462098|August 2006
2104|Completed|Intraperitoneal Hyperthermic Perfusion With Oxaliplatin in Treating Patients With Stage IV Peritoneal Cancer Due to Appendix Cancer or Colorectal Cancer||Drug:oxaliplatin|Interventional|Phase 1|Other / NIH|Maximumtolerateddose;  Pharmacokinetics;  Change in the phenotypic expression of proteins involved in the apoptotic and heat-stress inducible pathways|16|NCT00458809|March 2007
2105|Terminated|Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer||Drug:Carboplatin;  Drug:Abraxane|Interventional|Phase 2|Other / Industry|OverallResponseRate;  DurationofResponse;  ProgressionFreeSurvival(PFS);  Numberofindividualswithadverseevents|30|NCT00454324|April 2006
2106|Completed|Bacteria Entering the Blood Stream From Tooth Extractions and Tooth Brushing||Drug: Effect of Amoxicillin on bacteremia following a single-tooth extraction|Interventional|Phase 2|Other / NIH|Overallincidenceofbacteremiainthreegroups|290|NCT00454285|January 2003
2107|Completed                  Has Results|Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases||Procedure:allogeneicbonemarrowtransplantation;  Procedure: allogeneic hematopoietic stem cell transplantation;  Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;  Procedure: peripheral blood stem cell transplantation|Interventional|Phase 2|Other|Treatment-related Mortality Within the First 6 Months After Transplantation;  CompleteResponse;  OverallSurvival;  Disease-freeSurvival;  Graft-versus-hostDisease;  IronStatusattheTimeofTransplantation;  QualityofLifeattheTimeofTransplantation;  Treatment-related Mortality at 100 Days After Transplantation|66|NCT00453206|February 2007
2108|Terminated                  Has Results|5% Lidocaine Ointment in the Treatment of Vulvar Vestibulitis||Drug:5%topicallidocaineointment;  Drug:Placebocream|Interventional|Phase 2|Other|Number of Participants Who Report the Ability to Have Intercourse;  Change in Visual Analog Scale (VAS) Scores With Intercourse From Baseline to Week 8;  SF-12QualityofLifeScores;  ModifiedGracelyPainScale|14|NCT00450242|December 2006
2109|Unknown&nbsp;&#8224;|Phase II Trial of Pulsed Taxol With Concurrent Thoracic Radiotherapy &amp; Adjuvant Chemo in Stage III NSCLC||Drug:Taxol(paclitaxel);  Procedure:Radiotherapy;  Drug:Carboplatin;  Drug:Gemcitabine|Interventional|Phase 2|Other|TumorresponseusingRECISTcriteria;  Locoregionalcontrol;  Distantfailure;  Progressionfreesurvival|30|NCT00449657|February 2007
2110|Completed|Study of Dust Mite Inhalation in Humans||Biological:inhaledallergenchallenge|Interventional|Phase 1|Other / NIH|Effect of allergen challenge procedure on the following:changes in airway monocytes cell surface marker expression and changes in airway PMN and Eosinophil numbers;  changesinsymptomscores;  changeslungfunction|13|NCT00448851|February 2007
2111|Completed|Cigarette Smoke and Susceptibility to Influenza Infection|||Observational||Other / NIH|Nasal responses of healthy adult volunteers not routinely exposed to SHS vs responses of smokers to live attenuated influenza virus.;  Compare replication of live attenuated influenza virus (LAIV) in nasal epithelium of seronegative healthy adult volunteers not routinely exposed to SHS vs. smokers.;  In the setting of LAIV infection compare markers of oxidant stress and mucosal inflammation in nasal epithelium of healthy adult volunteers not routinely exposed to SHS vs. smokers|138|NCT00448617|July 2006
2112|Completed|Development and Evaluation of A Mailed Arthritis Self-Management Program||Behavioral: Mailed Arthritis Self-Management Education|Interventional||Other / U.S. Fed|Health-related Quality of Life (Self-reported Health Pain Disability Fatigue Activity Limitation Health Distress);  HealthCareUtilization;  Self-ManagementBehaviors;  Self-EfficacyforArthritisSelf-Management|900|NCT00448474|November 2005
2113|Active not recruiting|Fludarabine and PK-Directed Busulfan With or Without ATG Followed By Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases||Biological:rabbitanti-thymocyteglobulin;  Biological:therapeuticallogeneiclymphocytes;  Drug:busulfan;  Drug:fludarabinephosphate;  Drug:tacrolimus;  Procedure: allogeneic hematopoietic stem cell transplantation;  Procedure: peripheral blood stem cell transplantation;  Drug:methotrexate|Interventional|Phase 1 / Phase 2|Other / NIH|One-year disease-free survival (DFS) rate at the maximum tolerated dose identified during phase I of the trial (target AUC 6912);  Overallanddisease-freesurvival;  Dose-limitingtoxicitiesofbusulfan;  Capacity of test dosing of busulfan that would result in the desired area under the curve concentration exposure of patients receiving a full-dose busulfan regimen;  To assess the incidence of graft vs host disease and DNA chimerism in patients between one month and two years post transplant|60|NCT00448357|October 2005
2114|Completed                  Has Results|Family-supported Smoking Cessation for Chronically Ill Veterans||Behavioral:Family-supported;  Behavioral:StandardTelephonecounseling|Interventional||U.S. Fed|The Impact of a Family-supported Intervention on Rates of Abstinence From Cigarettes Compared to a Standard Intervention;  The Impact of a Family-supported Intervention on Abstinence at 12-month Follow-up|471|NCT00448344|February 2008
2115|Active not recruiting|Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease||Biological:anti-thymocyteglobulin;  Biological:sargramostim;  Biological:therapeuticallogeneiclymphocytes;  Drug:busulfan;  Drug:fludarabinephosphate;  Drug:methotrexate;  Drug:tacrolimus;  Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;  Procedure: peripheral blood stem cell transplantation|Interventional|Phase 2|Other / NIH|Treatment-relatedmortality;  Complete response at 6 and 12 months post-transplant;  Complete or mixed donor chimerism at 30 60 and 90 days post-transplant;  5-yeardisease-freesurvival;  Graft-vs-hostdiseaseat6monthspost-transplant|70|NCT00448201|November 2003
2116|Completed|Zylet vs TobraDex in Blepharokeratoconjunctivitis||Drug: Loteprednol etabonate and tobramycin ophthalmic suspension;  Drug: Tobramycin and dexamethasone ophthalmic suspension|Interventional|Phase 4|Industry|The primary efficacy endpoint for this study is the change from baseline to Day 15 in the signs and symptoms composite score;  The distribution of Investigator global assessment at each visit.;  The percentage of eyes that were considered improved or cured at each visit based on the Investigator global assessment.;  The change from baseline to Day 7 (Visit 3) and to Day 3 (Visit 2) in the signs and symptoms composite score.;  The change from baseline to each visit in the signs composite score and the symptoms composite score.;  The change from baseline to each visit in the Blepharitis signs composite score the conjunctivitis signs composite score and the Keratitis signs composite score.;  The change from baseline to each visit in individual signs and symptoms.;  VA Biomicroscopy and IOP assessments at each visit;  AdverseEvents|276|NCT00447577|January 2007
2117|Completed|Benefits of Tanning in Fibromyalgia Patients||Procedure:UltravioletLight|Interventional||Other|A 30% improvement in reported pain will be considered a treatment &quot;success.&quot; As a secondary outcome we will compare post-treatment pain scores between the UV and non-UV exposures given on the first day the dose is given (A vs. B in table 4).;  A treatment &quot;success&quot; in Phase 2 will be defined as a 30% reduction in pain relative to the baseline reported at screening on the 11-point pain scale.;  Detailedpainassessment;  Mood;  Qualityoflife;  Tanningblind|19|NCT00447083|May 2005
2118|Completed|PCOS Twin Study - Environmental Factors in the Development of Polycystic Ovary Syndrome Phase 2|||Observational||NIH|||NCT00444288|February 2007
2119|Completed|An Open-Label Randomized Comparative 3-Way Cross-Over Study to Evaluate the Effect of Food on the 24-Hour Intragastric pH at Day 5 After Twice Daily Oral Administration of PN 200 (Omeprazole/Naproxen) in Healthy Volunteers||Drug:PN200|Interventional|Phase 1|Industry|To compare the pharmacodynamic efficacy of PN 200 in controlling intragastric pH (percent time pH &gt; 4.0);  To evaluate the effect of different dosing times of PN 200 on the pharmacokinetic properties of omeprazole|24|NCT00442208|January 2007
2120|Completed|Oral Bacteria and Allergic Disease in Children|||Observational||NIH||60|NCT00438646|February 2007
2121|Completed|A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian Tubal or Peritoneal Cancer||Biological:tumorpeptidevaccine|Interventional|Phase 1|Other / Industry|Date of first objective finding will be used to define the date of relapse|8|NCT00437502|March 2007
2122|Completed|Analysis of Adherence &amp; Associated Factors in Teenagers Undergoing Treatment of Acne Vulgaris With Differin&#174; Gel 0.1%||Other:Morefrequentthannormalofficevisits;  Other: Electronic reminders (voice e-mail text messages);  Other: Parenteral involvement / intervention reminders;  Other:Nointerventionorreminders|Interventional|Phase 4|Industry|Efficacy - Percent adherence calculated from MEMS Caps readings;  Efficacy - lesion counts; percent adherence as calculated by product weights and by Subject&apos;s Diary; Global Severity Assessment; Global Assessment of Improvement; Subject questionnaire;  Safety-tolerabilityandadverseeventreporting|61|NCT00437151|June 2006
2123|Completed                  Has Results|Life 2: Improving Fitness and Function in Elders||Behavioral: Multi-component physical activity counseling program|Interventional||U.S. Fed|UsualGaitSpeed;  RapidGaitSpeed;  Physical Activity Frequency (CHAMPS Questionnaire);  SelfRatedHealth;  Sf-36PhysicalFunctionSubscale;  2MinuteWalk|400|NCT00435188|November 2004
2124|Completed|Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction||Drug:Bivalirudin;  Drug:Unfractionatedheparin;  Device:Baremetalstent;  Device:Paclitaxel-elutingstent|Interventional|Phase 3|Other / Industry|PharmacologyArm-Primary;  StentArm-PrimaryEfficacy;  StentArm-PrimarySafety;  PharmacologyArm-MajorSecondary;  StentArm-MajorSecondary|3604|NCT00433966|March 2005
2125|Completed|Immunotherapy for Peanut Allergy||Procedure:Sublingualimmunotherapy|Interventional||Other|A negative double-blind placebo controlled food challenge at the completion the two years of the study.;  A change in the cytokine level between the baseline and each selected time point during the two years of the study.|7|NCT00429429|April 2006
2126|Unknown&nbsp;&#8224;|FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease||Drug:FGF-1|Interventional|Phase 1|Industry|Safety|24|NCT00424866|December 2014
2127|Completed|Changes in Cerebral Blood Flow in Patients Treated With Spinal Cord Stimulation for Low Back and Leg Pain||Other: Precision Spinal Cord Stimulation and PET Scan|Interventional|Phase 4|Industry|Cumulative frequency of adverse events and events per subject;  Cerebral blood flow and VAS with optimal paresthesia coverage compared with SCS off;  Cerebral blood flow and VAS with partial paresthesia coverage and subthreshold stimulation compared with optimal coverage and with SCS off|15|NCT00418301|January 2007
2128|Unknown&nbsp;&#8224;|Safety and Efficacy of an Ambulatory Biofeedback Device for Primary Insomnia||Device:PortableBiofeedback|Interventional||Industry|Sleeplatencyat4weekfollow-up;  wake time after sleep onset (WASO) at 4 week follow-up;  totalawaketime(SOL+WASO)at4weekfollow-up;  Shifting from moderate/severe insomnia to mild/no insomnia (Insomnia Severity Index)at 4 week follow-up;  Daytimefunctioningat4weekfollow-up|132|NCT00415714|September 2006
2129|Completed|Lifestyle Modification for Obesity-Related Type 2 Diabetes||Behavioral:Lowcarbohydrateketogenicdiet;  Behavioral: Low glycemic index reduced calorie diet|Interventional|Phase 4|Other|HemoglobinA1c;  Bodyweight;  Serumlipoproteins|90|NCT00415688|July 2004
2130|Completed|Levetiracetam in Post-Traumatic Stress Disorder||Drug:levetiracetam;  Drug:Placebo;  Drug:Levetriracetam|Interventional|Phase 2 / Phase 3|Other / Industry|ClinicalGlobalImpressions-Improvement(CGI-I);  DavidsonTraumaScale(DTS);  HospitalAnxietyandDepressionScale(HADS);  Connor-DavidsonResilienceScale(CD-RISC);  36-itemShortFormHealthSurvey(SF-36);  PittsburghSleepQualityIndex;  Work Productivity and Activity Improvement Questionnaire (WPAI);  SheehanDisabilityInventory(SDI)|16|NCT00413296|November 2005
2131|Terminated|Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.||Drug:Tucotuzumabcelmoleukin(EMD273066)|Interventional|Phase 2|Industry||140|NCT00408967|December 2006
2132|Completed|Overcoming Psychiatric Barriers to the Treatment of Hepatitis C||Behavioral:psychosocialintervention|Interventional||Other / Industry|Whether or not the patient is deemed an appropriate candidate for interferon therapy at the end of the 9-month intervention.|101|NCT00407732|January 2007
2133|Completed|Systemic Pharmacokinetics of BOL-303224-A||Drug:BOL-303224-A|Interventional|Phase 1|Industry|Assessment of systemic pharmacokinetics following a single dose and steady-state pharmacokinetics after multiple TID dosing;  Investigator ratings of ocular discharge and bulbar conjunctival injection Visual Acuity ophthalmoscopy findings and Adverse event collection|24|NCT00407589|October 2006
2134|Completed|Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implants||Drug:fluocinoloneacetonideintravitrealimplant;  Drug:Fluocinoloneacetonide2.1mg|Interventional|Phase 2 / Phase 3|Industry|Recurrence of uveitis before and after implantation.;  Post-implantation rate of uveitis recurrence within patient comparison of implanted vs fellow eyes.;  Post-implantation time to recurrence of uveitis within patient comparison of implanted vs fellow eyes.;  The need for adjunctive uveitis treatment for the study eye within patient comparison (pre- versus post-implantation);  Reduction in the area of cystoid macular edema (CME) within patient comparison of responding eyes (implant vs fellow eyes);  Results of QOL surveys pre- versus post-implantation;  Visual acuity within patient comparison of responding eyes (implant vs fellow eyes);  Time to recurrence between treatment group comparison;  Post implantation uveitis rate between treatment group comparison|278|NCT00407082|December 2000
2135|Completed|Exercise Intervention Study for Early-Stage Breast Cancer Patients Receiving Neoadjuvant Therapy.||Behavioral:ExerciseTraining;  Behavioral:Chemoonly|Interventional|Phase 1 / Phase 2|Other / U.S. Fed|Determine effects of endurance exercise training on cardiopulmonary fitness via a stress test;  Adherencetofitnessprogram;  Quality of life as determined by the (Functional Assessment of Cancer Therapy-Breast) FACT-B scale.;  Determine and define feasibility for an adequately powered Phase III study.;  Determine effects of exercise training on tumor vascularity systemic response and tumor response.|23|NCT00405678|September 2006
2136|Completed|Aspirin Use and Postoperative Bleeding From Dental Extractions in a Healthy Population||Drug:Aspirin|Interventional|Phase 2|Other|Oralbleedingtime;  Report of bleeding at phone follow-up at 3-7 (first follow-up) and 40-55 hours (second follow-up)|36|NCT00405613|May 2003
2137|Completed|Sorafenib in Treating Patients Undergoing Surgery for Stage II Stage III or Stage IV Kidney Cancer||Drug:sorafenibtosylate|Interventional||Other / NIH|Number of subjects experiencing adverse events while taking sorafenib prior to nephrectomy;  Feasibility of neoadjuvant systemic therapy prior to nephrectomy;  Responseinprimaryrenaltumors;  Effects of sorafenib tosylate therapy on gene expression protein expression and metabolic profile|30|NCT00405366|November 2006
2138|Recruiting|Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women.|||Observational|Phase 4|Other / Industry||1600|NCT00404989|January 1989
2139|Completed|Hydroxyurea to Prevent Stroke in Children With Sickle Cell Anemia and Elevated TCD Flow Velocity||Drug:Hydroxyurea|Interventional|Phase 2|Other|ChangeinTCDflowvelocity;  Stroke|50|NCT00402480|April 2003
2140|Completed|Staccato&#174; Fentanyl Pharmacokinetics in Healthy Volunteers||Drug:StaccatoFentanyl;  Drug:Staccatoplacebo|Interventional|Phase 1|Industry|To establish the plasma PK profile of fentanyl following single and multiple Staccato Fentanyl doses;  To assess Staccato Fentanyl absolute bioavailability and dose proportionality;  SafetyandTolerabilityofStaccatoFentanyl|51|NCT00402350|April 2006
2141|Terminated                  Has Results|Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS)||Drug:Octreotide;  Drug:Placebo|Interventional||Other / NIH / Industry|Number of Participants With Decrease in Fasting Total Ghrelin;  Number of Participants With Decrease in Weight From Baseline to 6 Months;  Number of Participants With Decreased BMI Z-score From Baseline to 6 Months;  Number of Participants With Decreased Skin-fold Measurements From Baseline to 6 Months;  Number of Participants With Decrease in Hunger and Food Intake;  Number of Participants With Improved Insulin Regulation From Baseline to 6 Months;  Number of Participants With Improved Adiponectin Regulation From Baseline to 6 Months;  Number of Participants With Improved Leptin Regulation From Baseline to 6 Months;  Number of Participants With Improved Peptide YY (PYY) Regulation From Baseline to 6 Months;  Number of Participants With Decreased Body Composition From Baseline to 6 Months by BOD POD&#174;;  Number of Participants With Decreased Body-composition From Baseline to 6 Months by DEXA|5|NCT00399893|December 2006
2142|Terminated                  Has Results|Azacitidine Darbepoetin Alfa and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes||Drug: Azacitadine and Hematopoietic Growth Factors|Interventional||Other / NIH|NumberofParticipantsWithCompleteResponse;  RateofMajorHematologicalImprovement;  MinorHematologicalImprovements;  Time to Progression to Acute Myeloid Leukemia (Blast &#8805; 20%) or Death;  OverallSurvival;  ChangeinBoneMarrowApoptosis;  Expressionofp53andp21|3|NCT00398047|September 2006
2143|Recruiting|Immune Cell Response to Stimuli|||Observational||NIH||2040|NCT00397280|November 2006
2144|Completed|Video-Based Coping Skills Training for Caregivers||Behavioral: Video-based coping skills training with telephone coaching|Interventional|Phase 2|Industry / NIH|Center for Epidemiological Studies Depression scale;  SpielbergerState-TraitAngerandAnxietyScales;  PerceivedStressScale;  PittsburghSleepQualityIndex;  Heart rate and blood pressure at rest and during recall of caregiver situation;  Salivary cortisol upon awakening 30 minutes later and prior to going to bed at night|116|NCT00396825|January 2007
2145|Terminated                  Has Results|AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin&apos;s Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone||Drug:G-CSFplusplerixafor|Interventional|Phase 2|Industry|Number of Patients Who Achieved &#8805;2*10^6 CD34+ Cells/kg Following Treatment With Plerixafor 240 &#181;g/kg and G-CSF for up to 3 Consecutive Days;  OverallParticipantsCountsofAdverseEvents;  The Fold Increase in Peripheral Blood CD34+ Cells Following the First Dose of Plerixafor;  Number of Days to Polymorphonuclear Leukocyte (PMN) Engraftment;  NumberofDaystoPlatelet(PLT)Engraftment;  Graft Durability at 12 Months After Transplantation|5|NCT00395967|April 2005
2146|Completed|Antidepressant Safety in Kids Study||Drug: Selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) medications|Observational|Phase 4|Other / NIH|Score on the Clinical Global Impression Improvement scale (CGI-I);  Clinician Patient Access to Electronic Records System;  CAPTN Serious Adverse Events (SAE)/Harm-related adverse events form;  Score on the Clinical Global Impression Severity scale (CGI-S);  Score on the Children&apos;s Global Assessment Scale (CGAS);  ParentCopingStrategiesQuestionnaire(CSQ);  YouthCopingStrategiesQuestionnaire(CSQ)|569|NCT00395213|May 2007
2147|Completed|The Influence of Breast Cancer Risk and Risk Perception on Lifestyle Behaviors Among Women With a Family History: A Mixed Method Approach|||Observational||NIH||40|NCT00393406|October 2006
2148|Completed                  Has Results|Sleep Specialty Consultation: Improving Management of Sleep Disorders||Behavioral:SleepSpecialtyConsultation|Interventional||U.S. Fed|Provider Adherence to Sleep Specialist Recommendations;  DiarySleep:TotalWakeTimeandTotalSleepTime;  SleepEfficiency;  SleepQuality;  Sleepiness|156|NCT00390572|January 2007
2149|Completed|Improving Medication Use in Patients With Hypertension||Behavioral:Pharmacistintervention|Interventional||Other / NIH|Adherencetobloodpressuremedications;  Bloodpressurecontrol;  Health-relatedqualityoflife;  Exacerbationofsymptoms;  Patientsatisfaction;  Directcosts|492|NCT00388817|January 2002
2150|Completed|Improving Drug Use for Elderly Heart Failure Patients||Behavioral:Pharmacistintervention|Interventional||Other / NIH|Medicationadherence;  Exacerbationofheartfailure;  Health-relatedqualityoflife;  Patientsatisfaction;  Healthcareutilization;  Directcosts|314|NCT00388622|February 2001
2151|Completed|PET Scans and CT Scans in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy|||Observational||Other / NIH|Prognostic value of positron emission tomography-computed tomography imaging in predicting clinical response at baseline at weeks 2 and 4 and at week 6 post chemoradiotherapy|19|NCT00388024|February 2006
2152|Completed|Imatinib Mesylate Vatalanib and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma||Drug:hydroxyurea;  Drug:imatinibmesylate;  Drug:vatalanib|Interventional|Phase 1|Other / NIH|Maximum tolerated dose and dose-limiting toxicity of imatinib mesylate and vatalanib when administered with hydroxyurea;  Safety;  Tolerability;  Pharmacokinetic;  Antiangiogeniceffects|37|NCT00387933|July 2005
2153|Completed|Safety Study of a Vitamin E Supplement in Normal Volunteers and Those With Both Allergy and Asthma||Drug: Vitamin E supplement rich in gamma tocopherol|Interventional|Phase 1|Other / NIH|serum levels of gamma tocopherol and its metabolites after eight days of supplementation;  latency between the first dose and peak levels of gamma tocopherol;  effect of gamma tocopherol supplementation on other antioxidants;  effect of supplementation with gamma tocopherol on changes on cell surface marker expression on circulating monocytes and macrophages and on these cells&apos; response to ex vivo LPS challenge|16|NCT00386178|October 2006
2154|Completed|Improving Employment in Patients Who Have Survived Cervical Cancer Uterine Cancer or Ovarian Cancer||Other:counselingintervention;  Other: study of socioeconomic and demographic variables|Interventional||Other / NIH|Developmentofastructuredinterviewinstrument;  Recruitmentstrategy|70|NCT00383279|February 2006
2155|Completed|Evaluation of an Investigational Multi-Purpose Disinfecting Solution for Care of Soft Contact Lenses||Device: FID 107027 Multi-Purpose Disinfecting Solution;  Device: ReNu MultiPlus Multi-Purpose Solution No Rub Formula|Interventional||Industry|Lens Cleanliness - Residual lens lysozyme (HPLC) at Day 90 on Group IV lenses;  AverageLensWearingTime|252|NCT00382681|July 2004
2156|Completed|Risk Assessment of Long-Haul Truck Drivers|||Observational||Other / NIH|The prevalence of hepatitis B hepatitis C hypertension hyperlipidemia diabetes and obesity HIV N. gonorrhoeae and C. trachomatis|294|NCT00381992|September 2005
2157|Completed|Intensive Diet and Exercise for Improving Knee Osteoarthritis in Obese and Overweight Older Adults||Behavioral:Diet;  Behavioral:Exercise|Interventional|Phase 2|Other / NIH / Industry|Inflammatorybiomarkers;  Kneejointloads;  Bonemarrowlesions;  Articularcartilage;  Function;  Pain;  Mobility;  Change in quadriceps&apos; strength and disease progression as a function of knee alignment|454|NCT00381290|October 2006
2158|Active not recruiting|Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer||Drug:Erlotinib;  Procedure:RadicalCystectomy|Interventional|Phase 2|Other / NIH|PathologicalCompleteResponseRate;  Disease Recurrence and Progression rates after cystectomy;  OverallSurvivalRate;  Numberofsubjectsexperiencingadverseevents|27|NCT00380029|May 2006
2159|Completed|Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer||Drug:lapatinibditosylate;  Genetic: TdT-mediated dUTP nick end labeling assay;  Genetic:geneexpressionanalysis;  Genetic:microarrayanalysis;  Other:immunohistochemistrystainingmethod;  Procedure:biopsy;  Radiation:radiationtherapy|Interventional|Phase 1|Other / NIH|ToxicityasassessedbyNCICTCAEv3.0;  Inhibition of receptor and downstream signal transduction pathway activation in tumor tissue as assessed by IHC;  Efficacy;  Correlation of response with inhibition of downstream signaling;  Geneexpression|20|NCT00379509|April 2006
2160|Completed|Confirmation of Self-Reported Incident ALS Cases in the AARP-Diet and Health (AARP-DH) Cohort|||Observational||NIH||21|NCT00377351|September 2006
2161|Completed|Zinc Supplements in Lowering Cadmium Levels in Smokers||DietarySupplement:zincoxide|Interventional|Phase 2|Other / NIH|Reductionofcadmiumlevels;  Serum levels of cotinine zinc and cadmium at 3 pre-supplementation visits and at 6 supplementation visits;  Correlation of increased cadmium levels with decreased mismatch repair;  Reversal of cadmium-induced inhibition of mismatch repair|61|NCT00376987|December 2003
2162|Completed|Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases||Procedure:musictherapy|Interventional||Other / NIH|State anxiety as measured by the State-Trait Anxiety Inventory (STAI) questionnaire;  Perceived pain level as measured by the Visual Analogue Scale;  Patient satisfaction as measured by a post-procedure questionnaire|65|NCT00376922|June 2006
2163|Completed|Effects of an Alternative Treatment for Military Sexual Trauma on PTSD Symptoms Neurosteroids and Brain Function||Behavioral:GuidedImageryforTrauma(GIFT)|Interventional||Other / U.S. Fed||34|NCT00374738|November 2006
2164|Terminated|Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer&apos;s Disease Patients||Drug:RazadyneER;  Drug:Aricept|Interventional|Phase 4|Other / Industry|Brain activity patterns as collected via functional magnetic resonance imaging (fMRI) at rest and associated with task performance after 4 weeks of low-dose treatment and after 8-weeks of higher-dose treatment.;  Differences in cognitive testing and functional status at pre-treatment baseline and after completion of the 12-week treatment trial.|4|NCT00369603|October 2006
2165|Completed|Breath Analysis Technique to Diagnose Pulmonary Embolism||Device:BreathScreenPE|Interventional|Phase 2 / Phase 3|NIH / Industry|Evaluating the safety and effectiveness of the BreathScreen PE as an adjunct to the use of the D-dimer in evaluating patients clinically suspected of having pulmonary embolism|475|NCT00368836|March 2006
2166|Completed|Parkinson&apos;s Genes and Environment Study|||Observational||NIH||9000|NCT00367900|February 2006
2167|Completed                  Has Results|Study of the Insomnia in Patients With Low Back Pain||Drug:Eszopiclone;  Drug:Placebo|Interventional|Phase 4|Other / Industry|Mean Subjective Sleep Diary Derived Total Sleep Time (TST);  VisualAnalogScalePainRatings(VAS);  MeanSleepOnsetLatency(SOL);  WakeTimeAfterSleepOnset;  NumberofAwakenings;  SleepQualityRatings;  InsomniaSeverityIndex(ISI);  PatientGlobalImpressionofPainRatings;  RolandMorrisLowBackPainInventory(RMLBPI);  HamiltonDepressionRatingScale(HAM-D-24);  ShortForm36HealthSurveyQuestionnaire(SF-36);  State-TraitAnxietyInventory(STAI)|58|NCT00365976|August 2006
2168|Completed|Showing Health Information Value in a Community Network||Other:Computer-basedclinicaldecisionsupport.|Interventional||Other|Emergency department utilization rates and hospitalization rates;  EDencounterratesforlowseverityconditions;  EDencounterratesforasthma;  EDencounterratesfordiabetes;  Hospitalizationrates;  Hospitalizationratesforasthma(alsoPQI);  Hospitalizationratesfordiabetes(alsoPQI);  Glycemiccontrol(hemoglobinA1c);  Medicationcontraindications;  HEDIS-Preventiveservices;  HEDIS-#WCCvisits;  AHRQPreventionQualityIndicators;  HEDIS-Asthmaanddiabetes;  #ofmessagestriggeredforhealthrisks;  #ofmessagestriggeredforbarrierstocare;  Missedappointmentrates;  Primarycareappointmentrates;  F/Uratespost-partum;  Patientsatisfactioninstruments(CHAPS);  EuroQoL;  Provideropinionsurveys;  CostsofEDutilizationforallcauses;  CostsofEDuseforasthma;  CostsofEDusefordiabetes;  CostsofEDuseforlowseverityvisits;  Hospitalizationcostsforallcauses;  Hospitalizationcostsforasthma;  Hospitalizationcostsfordiabetes;  Reimbursementforlabs+otherancillaryservices;  Primarycarereimbursement;  EDratesforrecurrentEDencounters|20108|NCT00365885|August 2006
2169|Completed|Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme||Drug: Gliadel wafers in combination with O6-benzylguanine|Interventional|Phase 2|Other / NIH|6-monthoverallsurvival;  Oneyearoverallsurvival;  2yearoverallsurvival;  Medianoverallsurvival;  Toxicityprevalence|52|NCT00362921|April 2004
2170|Completed                  Has Results|Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma||Drug:hydroxyurea;  Drug:imatinibmesylate|Interventional|Phase 2|Other / NIH / Industry|Progression-freeSurvivalat6Months;  MedianProgression-freeSurvival(PFS);  MedianOverallSurvival(OS);  ObjectiveResponseRate|21|NCT00354913|May 2005
2171|Terminated                  Has Results|Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer Fallopian Tube Cancer or Peritoneal Cavity Cancer||Drug:capecitabine;  Drug:docetaxel|Interventional|Phase 2|Other / NIH|ObjectiveTumorResponse;  TimetoProgression;  Number of Participants With Grade 3 or Higher Toxicity;  QualityofLife|2|NCT00354601|January 2006
2172|Completed|Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma||Drug:imatinibmesylate;  Drug:temozolomide;  Other:pharmacologicalstudy|Interventional|Phase 1|Other / NIH|Maximumtolerateddose;  Dose-limitingtoxicity;  Safetyandtolerability;  Pharmacokinetics;  Anti-tumoractivity|65|NCT00354068|July 2004
2173|Completed|Organochlorine Exposure in Relation to Timing of Natural Menopause|||Observational||NIH|Organochlorine&amp;amp;Nat.Menopause;  Rateofchangeoforganochlorinelevels|600|NCT00353171|November 2002
2174|Completed|Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma||Drug:bevacizumab;  Drug:irinotecan;  Procedure: dynamic contrast-enhanced magnetic resonance imaging|Interventional|Phase 2|Other / NIH|Correlation of the acute permeability and blood flow response (24-48 hours) with progression-free survival (PFS);  OverallSurvivalandTumorResponse;  Incidence and severity of central nervous system (CNS) hemorrhage and systemic hemorrhage|20|NCT00352521|April 2006
2175|Completed|Effect of Revival Soy on Weight Loss and Skin Hair and Nails in Premenopausal Women||Behavioral:RevivalSoyDietarySupplement|Interventional|Phase 4|Industry / Other|Investigator assessed appearance of skin (roughness wrinkling dyspigmentation and redness) at baseline and after 3 and 6 months;  Investigator assessed appearance of hair (roughness dullness lack of manageability and scalp flaking) at baseline and after 3 and 6 months;  Investigator assessed appearance of finger nails (roughness ridging flaking and splitting) at baseline and after 3 and 6 months.;  Bodyweightatmonthlyintervals;  Body mass index (BMI) at the baseline and study completion;  Subject-perceived changes in appearance of skin hair and finger nails at baseline and after 3 and 6 months|40|NCT00352157|July 2006
2176|Completed|Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy||Drug:CyclosporineRefreshPlus|Interventional|Phase 4|Industry|DryEyeSymptoms;  Dryeyesigns|93|NCT00349440|September 2006
2177|Completed|Effect of Conjugated Linoleic Acid Supplement on Body Composition||Drug: Tonalin Conjugated linoleic acid (dietary supplement)|Interventional||Other / Industry|Changeinbodyfatmassat12weeks;  Changeinleanbodymassat12weeks;  Changeinbodymassindexat12weeks;  Changeinbodyweightat12weeks;  Changeinenergyexpenditureat12weeks;  Changeinlipidprofileat6weeksand12weeks;  Change in clinical laboratory values at 6 weeks and 12 weeks (safety)|60|NCT00347373|August 2004
2178|Terminated|Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer||Biological:filgrastim;  Biological:pegfilgrastim;  Drug: lyso-thermosensitive liposomal doxorubicin(Thermodox);  Procedure:hyperthermiatreatment|Interventional|Phase 1|Other / NIH|Maximum tolerated dose of temperature-sensitive liposomal doxorubicin (ThermoDox&#8482;) in combination with hyperthermia;  Pharmacokinetics|29|NCT00346229|April 2006
2179|Active not recruiting|Soy Supplements in Treating Patients Undergoing Surgery for Localized Prostate Cancer||DietarySupplement:soyisoflavones;  DietarySupplement:soyproteinisolate;  Other:placebo|Interventional|Phase 2|Other / NIH|Correlation of pretreatment ER-&#946; expression with response to soy supplementation|62|NCT00345813|October 2003
2180|Completed|UCB Antiepileptic Drugs (AED) Pregnancy Registry (Formerly the Keppra&#174; Pregnancy Registry)|||Observational|Phase 4|Industry|The number of birth defects reported and confirmed by a teratologist|516|NCT00345475|December 2004
2181|Completed|TC-WYRE: TAXUS Express Stent vs. Cypher Stent - What&apos;s Your Real Life Experience?||Device:TAXUSStentandCypherStent|Interventional||Industry||2500|NCT00344630|May 2006
2182|Completed|Soy-Based Meal Replacement in Helping Women With Stage I Stage II or Stage III Breast Cancer in Complete Remission Lose Weight||Behavioral:behavioraldietaryintervention;  Behavioral:exerciseintervention;  DietarySupplement:soyisoflavones;  DietarySupplement:soyproteinisolate;  Other:counselingintervention;  Other:educationalintervention;  Procedure:psychosocialassessmentandcare;  Procedure:quality-of-lifeassessment|Interventional||Other / NIH||25|NCT00343434|January 2005
2183|Terminated|AMEVIVE&#174; Pregnancy Registry||Drug:Ameviveexposure|Observational||Industry|Evaluate pattern or increase in major birth defects in children of women w/ psoriasis who were exposed to AMEVIVE&#174; at any time within the 8 wks prior to conception or at any time during pregnancy where outcome of the pregnancy is unknown prospectively;  To evaluate the number of live born infants versus fetal loss in pregnant women exposed to AMEVIVE&#174;;  To evaluate gestational age body weight gender head circumference and body length in live born infants exposed to AMEVIVE&#174;;  To evaluate appearance pulse grimace activity and respiration (APGAR) scores at 1 and 5 minutes of age in live born infants exposed to AMEVIVE&#174;;  To evaluate hospitalizations for infection in live born infants exposed to AMEVIVE&#174;;  To evaluate clinically significant infections with unusual organisms not requiring hospitalization in live born infants exposed to AMEVIVE&#174;;  To evaluate malignancies in live born infants exposed to AMEVIVE&#174;|3|NCT00342862|December 2003
2184|Completed|Pesticide Exposure and Health Status in North Carolina African American Male Farmers and Farm Workers|||Observational||NIH||389|NCT00341965|January 1999
2185|Completed|Postpartum Uterine Regression|||Observational||NIH|Monitorfibroids|400|NCT00341848|December 2001
2186|Completed|Cockroach Allergen Reduction by Extermination Alone in Low-Income Urban Homes: A Randomized Control Trial||Behavioral:EffectofCockroachAllergen|Interventional|Phase 1|NIH||65|NCT00341445|August 2004
2187|Completed|Prevention of Tumor Spread Due to Lung Cancer Surgery|||Observational||NIH|Determine the effect of initial venous versus arterial ligation during resection for NSCLC on the risk of distant metastases within two years of follow-up|120|NCT00341380|September 2002
2188|Completed|Genetic Measurements in Blood Cells of Children Taking Adderall or Methylphenidate|||Observational||NIH||84|NCT00341029|December 2005
2189|Completed|NIEHS/UNC Environmental Polymorphism Study|||Observational||NIH||485|NCT00340886|October 2001
2190|Completed|Diet and Genetic Damage|||Observational||NIH|to determine if eating certain foods and other dietary constituents will ameliorate the short-term damaging effects associated with fried meat consumption.|16|NCT00340743|April 2004
2191|Completed|Fibroid Growth Study|||Observational||NIH||300|NCT00340288|June 2001
2192|Completed|Hormonal Changes in Early Pregnancy|||Observational||NIH||80|NCT00340028|January 2005
2193|Completed|Exposure to Neurotoxins as Risk Factors for Amyotrophic Lateral Sclerosis|||Observational||NIH||0|NCT00339976|August 2002
2194|Completed|Johnston County ADHD Study: Environmental Reporductive and Familial Risk Factors for Attention-Deficit Hyperactivity Disorder (ADHD)|||Observational||NIH||8000|NCT00339729|May 1997
2195|Completed|Dust Mite Allergen Reduction Study||Other:MITE-T-FASTtestkit|Interventional|Phase 2|NIH|The primary outcome is the change in the log-transformed (Der f 2 + Der p 2) allergen concentrations for the child s bed and bedroom floor.;  Data from each of the six sampled locations (child s bed child s bedroom floor living room floor parent s bed and parent s floor) are analyzed separately and changes are compared between the treatment and control groups.;  Data from the questionnaire and observation form will be used toaddress the secondary study objective to determine if use of an in-home test kit results in a change in dust mite reduction attitudes and behaviors.|100|NCT00339690|June 2005
2196|Completed|National Survey of Lead and Allergen Hazards in Housing|||Observational||NIH||2000|NCT00339573|June 1998
2197|Active not recruiting|Yoga in Controlling Symptoms and Reducing Stress in Women With Ovarian Cancer or Breast Cancer||Procedure:yogatherapy|Interventional||Other / NIH|FatigueasmeasuredbytheFACT-Fatiguesubscale;  Psychological distress as measured by the Center for Epidemiologic Studies-Depression Scale and the State-Trait Anxiety Inventory;  Positive affect as measured by the Positive and Negative Affect Schedule;  Quality of life as measured by Functional Assessment of Cancer Therapy (FACT-O) for patients with ovarian cancer or FACT-B for patients with breast cancer|106|NCT00337233|January 2004
2198|Withdrawn|Effect of Dexmedetomidine Upon Sleep Postoperatively||Drug:Dexmedetomidine;  Drug:Propofol;  Drug:Midazolam;  Drug:Fentanyl;  Drug:Isoflurane|Interventional|Phase 4|Other|Measurements of sleep quality during postoperative period:Epworth Sleepiness Scale;  Completionofsleeplog;  Subjects will also be asked to complete Visual Analogue Scales (VAS) of sleep and daytime sleepiness.;  The quality of postoperative recovery (QoR) and the presence of fatigue (Brief Fatigue Inventory);  Subjects will also be asked to complete Visual Analogue Scale (VAS) of fatigue.|0|NCT00333632|June 2006
2199|Completed|Study to Prevent Cartilage Damage Following Acute Knee Injury.||Drug:Anakinra|Interventional|Phase 1 / Phase 2|Other|pain;  chondropathyscore|10|NCT00332254|March 2006
2200|Completed                  Has Results|Pilot Study of Duloxetine in Psychological Resilience||Drug:Duloxetine|Interventional|Phase 2|Other|Change in Connor Davidson Resilience Scale (CD-RISC) From Baseline to 8 Weeks|18|NCT00331799|April 2007
2201|Completed|Exercise Training Versus Drug Therapy for Treating Depression in Older Adults||Behavioral:SupervisedExercise;  Behavioral:Home-BasedExercise;  Drug:Sertraline(Zoloft);  Drug:PlaceboPill|Interventional|Phase 3|Other / NIH|Measured at Week 16 and Months 6 and 12 post-treatment: Post-treatment recovery from MDD;  Post-treatment depression scores on the Hamilton Depression Rating Scale;  Measured at Week 16 and Months 6 and 12 post-treatment: Quality of life (MOS SF 36);  Anxiety(StateTraitAnxietyInventory);  Cognitive Functioning (selected subtests from the Wechsler Memory Scale-R and WAIS-III; Digit Vigilance; Trail Making Test; Finger Tapping Test; Controlled Oral Word Association);  Cardiovascular biomarkers including flow mediated dilation heart rate variability and baroreflex sensitivity|457|NCT00331305|August 1999
2202|Active not recruiting|Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation||Drug:Alemtuzumab;  Drug:Anti-ThymocyteGlobulin|Interventional|Phase 4|Other|Patientsurvival;  Graftsurvival;  AcuteRejection;  Hematologicadverseevents;  Infectiousadverseevents;  Otheradverseevents;  Cost;  Healthstatusandqualityoflife|275|NCT00331162|February 2005
2203|Completed|Comparison of Two Programs to Encourage Physical Activity in Individuals With Chronic Obstructive Pulmonary Disease||Behavioral:LifestyleActivityProgram;  Behavioral:ExerciseProgram|Interventional|Phase 3|NIH|Amount of time engaged in moderate physical activity each week;  Healthrelatedqualityoflife;  Self-reporteddisability;  Physicalfunction;  Exercisecapacity|318|NCT00328484|January 2002
2204|Completed|Levetiracetam for Cramps Spasticity and Neuroprotection in Motor Neuron Disease||Biological:Levetiracetam|Interventional|Phase 2|Other / Industry|Safetyandtolerabilityat9monthsoftreatment.;  Cramps scores spasticity scores FVC ALSFRS MMT|20|NCT00324454|May 2006
2205|Completed                  Has Results|Study of an Intervention to Improve Use of Life-saving Medications for Heart Disease||Behavioral: oral education &amp; written tips for remembering medications;  Device:pillbox;  Device:pocketmedicationcard;  Behavioral: sharing information with community pharmacist;  Behavioral: Medication use evaluations by community pharmacist;  Behavioral: informing physician if patient has stopped a medication;  Behavioral:Routinedischargecounseling;  Other:Lettertophysician/dischargesummary|Interventional||Other / Industry / U.S. Fed|Patient-reported Adherence to Triple Therapy (Aspirin/Antiplatelet; Beta Blocker; and Statin) at 6 Months;  Percent of Patients Adherent to Beta-blocker and Statin Via Refill Records;  Percent of Patients Adherent to Beta-blocker Via Refill Records;  Percent of Patients Adherent to Statin Via Refill Records;  Death in Intervention Patients Compared to Usual Care|143|NCT00323258|June 2006
2206|Completed|Healing Touch in Treating Patients Receiving Chemotherapy for Acute Myeloid Leukemia or Acute Lymphocytic Leukemia||Procedure:therapeutictouch|Interventional||Other / NIH|Feasibility of recruiting and retaining patients for a randomized controlled trial to study healing touch (HT) as supportive care;  Effectiveness of healing touch on reducing psychological stress and fatigue|40|NCT00321880|February 2006
2207|Completed                  Has Results|A Patient-Spouse Intervention for Self-Managing High Cholesterol||Behavioral:spouse-assistedintervention|Interventional||U.S. Fed|Low-densityLipoproteinCholesterol;  CaloricIntake;  SaturatedFat(Grams/Day);  TotalFat(Grams/Day);  CholesterolIntake;  FiberIntake;  FrequencyofModerateIntensityPhysicalActivity;  DurationofModerateIntensityPhysicalActivity;  TotalFat(%);  SaturatedFat(%);  NumberofParticipantsWithGoalLDL-C;  Number of Participants Prescribed Cholesterol Medication|255|NCT00321789|September 2007
2208|Completed|Cognitive Behavioral Insomnia Therapy for Individuals With Fibromyalgia||Behavioral: Cognitive behavioral therapy for insomnia;  Behavioral:Pseudo-desensitizationprocedure;  Other:Usualcare|Interventional|Phase 2 / Phase 3|Other / NIH|Totalwaketime;  Totalsleeptime;  Sleepefficiency;  Sleeponsetlatency;  Waketimeaftersleeponset;  Scoreonaninsomniaratingscale;  Scoreonafatigueratingscale;  Scoreonamoodratingscale;  Subjectivepainratings;  Scoreonahealth-relatedqualityoflifescale|111|NCT00321451|May 2006
2209|Completed|Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors||Drug:erlotinibhydrochloride;  Drug:pemetrexeddisodium;  Drug:vinflunine|Interventional|Phase 1|Other / NIH|Maximum tolerated dose (MTD) of vinflunine and pemetrexed disodium;  Maximum tolerated dose (MTD) of vinflunine and continuously dosed erlotinib;  Maximum tolerated dose (MTD) of vinflunine and intermittently dosed erlotinib|41|NCT00320073|August 2006
2210|Completed|Virulence Determinants in S Aureus Bacteremia||Other:Nointervention|Observational||Other / NIH|Curevs.recurrenceofStaphinfectionvs.death|1354|NCT00319826|March 2004
2211|Completed|Examining the Link Between Trace Elements and Cardiovascular Disease Risk Factors in Young Adults|||Observational||Other / NIH|CVDriskfactors|4362|NCT00318734|May 2006
2212|Completed|Betaseron Pregnancy Registry|||Observational|Phase 4|Other / Industry||113|NCT00317564|April 2006
2213|Completed|The Impact of Patient Involvement in Decision-Making About Heart Disease Prevention||Device:Heart-to-HeartDecisionAid|Interventional||Other|DiscussionwithprovideraboutCHDriskreduction;  StatedplansforCHDriskreduction;  KnowledgeaboutCHDprevention;  PerceptionofCHDrisk;  Interestinparticipatingindecision-making|120|NCT00315978|June 2003
2214|Completed                  Has Results|Optimizing Body Composition for Function in Older Adults||Drug:Pioglitazone;  Behavioral: Resistance exercise training to maximize muscle power;  Behavioral:Hypocaloricdiet;  Drug:Placebo|Interventional|Phase 4|Other / Industry|AppendicularNon-boneLeanMass;  LeanBodyMass|88|NCT00315146|April 2006
2215|Completed                  Has Results|A Pilot Study of Dronabinol for Adult Patients With Primary Gliomas||Drug:Dronabinol|Interventional|Phase 1|Other / Industry|TolerabilityRate;  UnacceptableToxicityRate;  Mean Change From Baseline in Quality of Life -- FACT-Br;  Mean Change From Baseline in Quality of Life -- FLIE;  Mean Change From Baseline in Quality of Life -- MMSE|33|NCT00314808|April 2006
2216|Completed|Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage||Drug:imiquimod|Interventional|Phase 4|Other|histologicclearanceofbasalcellcarcinoma|15|NCT00314756|March 2005
2217|Completed|Post-Hospitalization Nursing Effectiveness (PHONE) Study||Procedure: Care coordination by telephone contacts with a nurse|Interventional|Phase 3|Other|Bayley Scales of Infant Development-Second Edition;  Growththroughoneyearofage;  Rehospitalizationsinthefirstyearoflife;  VinelandAdaptiveBehavioralScales|150|NCT00314431|May 1996
2218|Withdrawn|Using Magnetic Resonance Spectroscopy With MRI to Non-invasively Determine Breast Cancer Extent of Disease||Procedure:MagneticResonanceSpectroscopy|Interventional||Other||0|NCT00312637|March 2005
2219|Completed|Acupuncture for the Prevention of Postdates Pregnancy||Procedure:Acupuncture;  Procedure:Shamcomparator|Interventional|Phase 2|Other|preventionofinpatientinductionoflabor;  rateofcesareandelivery;  ratesofchorioamnionitis;  lengthofmaternalhospitalstay;  ratesofassisteddelivery;  neonataloutcomes|89|NCT00312585|February 2005
2220|Terminated|Study of Valproic Acid to Treat HIV Infected Adults||Drug:Enfuvirtide;  Drug:Valproicacid|Interventional|Phase 1|Other|Frequencies of replication-competent HIV detected in resting CD4 cells;  Changeinintegratedproviralgenomes;  GenitaltractproviralDNAandviralload;  Detectable viral load during VPA therapy and if it remains undetectable after VPA is discontinued;  HIV-specificantibodychangesandCTLresponses;  Change in replication-competent HIV detected in resting CD4 cells in study participants after intensified HAART and after extended VPA therapy with or without intensified HAART;  Changes in viral load after intensification of HAART with or without VPA|14|NCT00312546|June 2006
2221|Completed|Umbilical Cord Blood Stem Cell Transplantation in Adults With Advanced Blood Disorders or Cancer||Procedure:StemCellTransplantation|Interventional|Phase 1 / Phase 2|Other / NIH|SurvivalRates|34|NCT00312429|January 2002
2222|Terminated|A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)||Drug:Pegaptanibsodium|Interventional|Phase 4|Industry||262|NCT00312351|April 2006
2223|Active not recruiting|Extracranial Stereotactic Radiosurgery in Treating Patients With Solid Tumors||Procedure:Radiosurgery|Interventional|Phase 1 / Phase 2|Other / NIH|Maximum tolerated dose for up to 90 days after completion of study treatment;  Minimum dose required for local control as assessed by RECIST one-dimensional criterion and volumetric analysis for 90 days after completion of study treatment;  Median time to progression of treated tumor for up to 2 years;  Toxicity as assessed by NCI Common Toxicity Criteria (CTC) version 2.0 for up to 90 days after completion of study treatment;  Cause of death as assessed by medical records and autopsy at time of death|48|NCT00311597|June 2002
2224|Completed|A Church Based Intervention to Improve Diabetes Care||Behavioral:SpecialIntervention;  Behavioral:DelayedIntervention|Interventional||Other / U.S. Fed|MeanHemoglobinA1c;  MeanDietaryrecallsaturatedfatconsumption;  Median number of minutes per day engaged in physical activity|201|NCT00311324|February 2001
2225|Completed|Gefitinib Docetaxel and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer||Drug:docetaxel;  Drug:gefitinib;  Other:laboratorybiomarkeranalysis;  Radiation:radiationtherapy|Interventional|Phase 1|Other / NIH|To determine the feasability of daily ZD1839 delivered with concurrent 3-dimensional planned thoracic radiation|45|NCT00310154|November 2003
2226|Completed                  Has Results|Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix Cancer||Drug:thalidomide;  Procedure:surgery|Interventional|Phase 2|Other / NIH|ProgressionFreeSurvival;  Toxicity|29|NCT00310076|October 2002
2227|Completed|Acupressure in Preventing Nausea and Vomiting in Young Cancer Patients Receiving Chemotherapy||Procedure:acupressuretherapy;  Procedure:shamintervention|Interventional||Other / NIH|reductionofchemotherapyrelatednausea|28|NCT00310063|April 2005
2228|Terminated|Pemetrexed Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer||Drug:pemetrexeddisodium|Interventional|Phase 1|Other / NIH|determine maximum tolerated dose of Premetrexed wehen given concurrently with gemcitabine|4|NCT00310050|October 2005
2229|Completed|Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine in Treating Patients With Advanced Metastatic Solid Tumors||Drug:gemcitabinehydrochloride;  Drug: paclitaxel albumin-stabilized nanoparticle formulation|Interventional|Phase 1|Other / NIH|DoseLimitingToxicity(DLT);  MaximumToleratedDose(MTD);  RadiographicResponsetoTreatment|18|NCT00307255|August 2006
2230|Completed|Graduated Recovery Intervention Program for Enhancing Treatment for First-Episode Psychosis||Behavioral: Graduated Recovery Intervention Program (GRIP);  Behavioral:Treatmentasusual(TAU)|Interventional||Other / NIH|RoleFunctioningScale;  Heinrichs-CarpenterQualityofLifeScale(QLS);  Multidimensional Scale of Perceived Social Support (MSPSS);  GlobalFunctioningScale;  Brief Evaluation of Medication Influences and Beliefs;  PositiveandNegativeSyndromeScale(PANSS);  CalgaryDepressionScaleforSchizophrenia(CDSS);  BriefTraumaQuestionnaire(BTQ);  PTSDChecklist(PCL);  AlcoholUseScaleandDrugUseScale(AUS/DUS);  Numberofhospitaladmissions;  Ambiguous Intentions Hostility Questionnaire (AIHQ);  Goalattainmentratings;  ScalesofWellbeing;  SocialSkillsPerformanceAssessment(SSPA);  TreatmentComplianceScale(TCS)|46|NCT00307216|April 2006
2231|Completed|Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma||Drug:PanzemNanocrystalColloidalDispersion|Interventional|Phase 2|Industry|6 month progression free survival and median overall survival|27|NCT00306618|January 2006
2232|Completed|Bilateral Refractive Amblyopia Treatment Study||Device:Spectacles|Observational|Phase 3|Other / NIH|Visualacuityof20/25orbetterinbotheyes|113|NCT00305955|August 2004
2233|Completed|Weight Management and Coping Skills Training For Patients With Knee Osteoarthritis||Behavioral: Lifestyle Behavioral Weight Management Program;  Behavioral:Pain-CopingSkillsTraining;  Other:StandardCare|Interventional||Other / NIH|Psychologicalimpairment;  Physicaldisability;  Jointstiffness;  Activitylevel;  Physicalactivities;  Physiologicalmeasuresofdiseaseactivity;  Gaitmeasures|412|NCT00305890|January 2004
2234|Completed|Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors||Drug:RAD001(everolimus);  Drug:PTK787(vatalanib)|Interventional|Phase 1|Other / Industry|Maximum tolerated dose (MTD) of vatalanib and everolimus;  Safetyandtolerability;  Safety and tolerability at the MTD in patients with metastatic renal cell carcinoma (RCC);  Nondose-limitingtoxicity;  Pharmacokinetics;  Changes in the phosphorylation status of S6K protein in peripheral blood mononuclear cells;  ClinicalresponseinpatientswithmetastaticRCC;  OverallsurvivalofpatientswithRCC;  TimetoprogressionofpatientswithRCC|37|NCT00303732|December 2004
2235|Completed                  Has Results|Exercise to Treat Depression in Individuals With Coronary Heart Disease||Behavioral:SupervisedAerobicExercise;  Drug:Sertraline;  Drug:PlaceboPill.|Interventional|Phase 3|Other / Industry|HamiltonDepressionRatingScale;  HeartRateVariability(HRV);  PercentChangeinFlowMediatedDilation(FMD);  C-reactiveProtein(CRP);  PlateletFactor4;  BaroreflexSensitivity(BRS);  Interleuken6(IL-6)|101|NCT00302068|July 2006
2236|Completed                  Has Results|Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma||Drug:IVZometa|Interventional|Phase 2|Other / Industry / NIH|Percent of Patients With Change in Combined Bone Mass Density T-score &lt;= -0.5.;  Skeletal-relatedComplications;  MeanChangeinBoneMassDensity(BMD)|60|NCT00301873|May 2006
2237|Terminated|Augmentation Study of Levetiracetam in Obsessive Compulsive Disorder||Drug:Sertraline;  Drug:Levetiracetam;  Drug:Placebo|Interventional|Phase 2 / Phase 3|Other / Industry|ClinicalGlobalImpression-improvement(CGI-I);  Yale-BrownObsessive-CompulsiveScale(YBOCS);  HospitalAnxietyandDepressionScale;  SheehanDisabilityScale(SDS)|12|NCT00299611|November 2005
2238|Terminated|Reducing Farmworkers Exposure to Agricultural Chemicals||Behavioral:LayHealthAdvisor|Interventional||NIH||400|NCT00298649|July 2002
2239|Withdrawn|Daptomycin or Vancomycin in Treating Bacteria in the Blood in Patients With Neutropenia Caused By Chemotherapy||Drug:daptomycin;  Drug:vancomycin|Interventional||Other / NIH|determine the efficacy of daptomycin to treat gram positive infections;  determine the safety of daptomycin in neutropenic patients|0|NCT00296049|July 2005
2240|Active not recruiting|Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia||Drug:clofarabine;  Drug:cytarabine|Interventional|Phase 1|Other / NIH|Responserate;  Safetyprofileandtolerability|53|NCT00295841|February 2005
2241|Completed|Study of BEMA&#8482; Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects||Drug:BEMA&#8482;Fentanyl|Interventional|Phase 3|Industry|SummaryofPainIntensityDifferences|152|NCT00293033|February 2006
2242|Terminated                  Has Results|Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)||Drug:Imatinibtablets;  Drug:Hydroxyureacapsules|Interventional|Phase 2|Industry|Percentage of Patients With an Objective Overall Response (OOR);  DurationofObjectiveOverallResponse(OOR);  PercentageofPatientsWhoHadClinicalBenefit;  Percentage of Patients With Progression-free Survival at Months 6 and 12;  Percentage of Patients Surviving at Months 6 12 and 24;  NumberofPatientsWithatLeast1AdverseEvent|231|NCT00290771|February 2006
2243|Completed                  Has Results|Identifying Patients With Dementia in Primary Care||Other:Nointerventiondelivered.|Observational||U.S. Fed|PerformanceCharacteristics|630|NCT00289471|October 2009
2244|Completed                  Has Results|Self-Management of Osteoarthritis||Behavioral:HealthEducation;  Behavioral:OsteoarthritisSelf-Management|Interventional||U.S. Fed|Pain;  AIMS2PhysicalFunction;  AIMS2Affect;  ArthritisSelfEfficacy|523|NCT00288912|October 2006
2245|Completed|NC Enhanced WISEWOMAN Project||Behavioral:Lifestylebehaviorchangeprogram;  Behavioral:Pamphlets|Interventional||Other / U.S. Fed|physicalactivity;  fruitintake;  vegetableintake;  fatintake;  Biomarkers of dietary intake (red blood cell membrane fatty acids carotenoids);;  CVD risk factors (total and HDL cholesterol blood pressure);;  Psychosocialvariables|258|NCT00288327|March 2003
2246|Completed|North Carolina WISEWOMAN: Weight-Wise Pilot Study||Behavioral:Weightlossintervention|Interventional||Other / U.S. Fed|bodyweight|151|NCT00288301|February 2005
2247|Completed|Measuring Cholesterol in the Fasting and Postmeal State in Patients With Type 2 Diabetes|||Observational||Other / Industry||30|NCT00287404|October 2005
2248|Completed|Sleep Disorders and Gastroesophageal Reflux Disease (GERD)||Drug:Rabeprazole|Interventional|Phase 4|Other / Industry|The percentage of: subjects with non-OSA sleep disturbances who demonstrate esophageal reflux night-time arousals which are accompanied by a reflux event.|20|NCT00287391|September 2004
2249|Terminated|Effect of Ozone on Airway Inflammation in Allergic Asthmatics Treated With Omalizumab||Drug:omalizumab|Interventional||Other / NIH / Industry|The primary efficacy endpoint (increase in airway neutrophils) will be assessed by comparison of the differences between sputum neutrophil influx after ozone (adjusted for post air challenge neutrophils) between omalizumab and placebo treated volunteers;  Differences in ozone induced changes in FEV1 and FVC between omalizumab and control groups;  Differences in mucociliary clearance and airway deposition between omalizumab and control groups;  Differences in ozone induced changes in sputum eosinophils between omalizumab and control groups|1|NCT00287378|March 2006
2250|Completed|Genetic Susceptibility to Ozone in Mild Asthmatic Volunteers||Drug:ozone|Interventional||Other / U.S. Fed|post ozone change in lung function (FEV1) between subjects with GSTM1 null genotype compared to GSTM1 sufficient subjects;  Secondary endpoints include post ozone airway PMN influx between subjects with GSTM1 null genotype compared to GSTM1 sufficient subjects;  % decrease in FVC between subjects with GSTM1 null genotype compared to GSTM1 sufficient subjects|52|NCT00287365|January 2006
2251|Completed|Study of Amantadine for Weight Stabilization During Olanzapine Treatment||Drug:OlanzapineAmantadine;  Drug:Olanzapineandplacebo|Interventional|Phase 1|Other / Industry|To compare time to clinical significant weight gain in the amantadine + olanzapine group with the placebo + olanzapine group.;  We will determine if the amantadine + olanzapine group has a lower % body fat compared to the placebo + olanzapine group at 16 weeks;  We will determine if the amantadine +olanzapine group has a higher RQ signifying better fat utilization compared to the placebo + olanzapine group at 16 weeks;  We will determine if the amantadine + olanzapine group has significantly better metabolic profile at 16 weeks as compared to the placebo + olanzapine group.|40|NCT00287352|May 2005
2252|Completed                  Has Results|The Utility of Nexium in Chronic Cough and Reflux Disease||Drug:Esomeprazole;  Drug:Placebo|Interventional|Phase 4|Other / Industry|Change in Cough-Specific Quality of Life Questionnaire|40|NCT00287339|September 2005
2253|Terminated|Comparison of Low-dose Epidural With Intravenous Narcotic Versus Intravenous Narcotic Alone||Drug:BupivacaineClonidineMorphine|Interventional|Phase 3|Other|24 hour recording of pain sedation narcotic usage and satisfaction.|40|NCT00287326|January 2006
2254|Completed|Daily Vitamin K in Patients on Warfarin With Unstable INRs||Drug:VitaminK|Interventional||Other|Number of warfarin adjustments required in each phase;  Time in therapeutic sub- and supra-therapeutic range;  Variance/SDofINRsforeachpatient;  Adherence assessed by pill counts and pharmacy record review;  Thrombotic/bleedingepisodes|15|NCT00287313|October 2005
2255|Completed|Randomized Controlled Trial in Liver Transplant Recipients Treated in Steroid Sparing Regimen||Drug:Neoral;  Drug:Tacrolimus|Interventional|Phase 1|Other / Industry|compare timing &amp; severity of recurrent chronic HCV disease Neoral versus Prograf;  compare the effectiveness of Neoral with Prograf as primary immunotherapy|40|NCT00286871|February 2006
2256|Completed                  Has Results|Rituximab in the Treatment of Patients With Bullous Pemphigoid||Drug:Rituximab|Interventional|Phase 1 / Phase 2|Other / Industry|PrimarySafetyEndpoint;  NumberofDaystoCessationofNewBlister;  Systemic Corticosteroid Dose of 25% of Starting Dose or 10 mg/Day by Week 24;  IgG Anti Bullous Pemphigoid (BP) 180 Measured in Units by ELISA at Week 24.;  BCellNumberatWeek24|8|NCT00286325|March 2005
2257|Completed|Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Patients||Drug:Prochymal(TM)|Interventional|Phase 2|Industry|Primaryefficacyendpoint;  -ResponsebyDay28;  Secondaryefficacyendpoints;  Improvement of GVHD by day 28 in one or more organs;  involvedwithGVHDsymptomsatday1;  TimetobestoverallGVHDgrade;  Beststageofeachinvolvedorganbyday28;  Time to improvement or resolution of GVHD in one or;  moreorgans;  SafetyEndpoints;  Adverseevents;  Infusionaltoxicity;  Overallrelapseofunderlyingdisease;  Overallsurvival;  Formationofectopictissuefoci;  Incidenceofinfection|15|NCT00284986|November 2005
2258|Completed|Combination Chemotherapy and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer||Drug:capecitabine;  Drug:carboplatin;  Drug:paclitaxel;  Radiation:radiationtherapy|Interventional|Phase 1|Other / NIH||13|NCT00281788|September 2003
2259|Completed|Secondary Prevention of Osteoporotic Fractures in Residents of Long-Term Care Facilities||Behavioral: Long-term care facilities in the intervention arm will receive education and feedback audit on performance|Interventional|Phase 2 / Phase 3|Other|Number of new prescriptions for FDA-Approved osteoporosis medications.;  Secondary Outcome Measures: Changes in number of bone mineral density test ordered change in the number of hip protectors issued change in the number of prescriptions for calcium and vitamin D changes in the rate of new osteoporotic fractures.|64|NCT00280943|January 2005
2260|Completed|Induction Chemotherapy Using Paclitaxel Carboplatin CPT-11 With Pegfilgrastim||Drug:Paclitaxel;  Drug:Carboplatin;  Drug:CPT-11;  Drug:Pegfilgrastim;  Radiation:Conformalradiotherapy|Interventional|Phase 2|Other / Industry|Numberofsubjectsexperiencingtoxicity;  Efficacy of 2 cycles of induction paclitaxel/carboplatin/irinotecan;  ProgressionFreeSurvival|24|NCT00280787|November 2003
2261|Recruiting|Biomarkers in Patients With Rectal Cancer Undergoing Chemotherapy and Radiation Therapy||Drug:capecitabine;  Drug:5-fluorouracil;  Procedure:SurgicalResection;  Radiation:Radiationtherapy|Observational||Other / NIH|Activation of NF-kappa B in response to treatment with external beam radiotherapy;  Correlation of NF-kappa B pathway activation with therapeutic outcomes;  Downstream events induced by NF-kappa B activation;  Global gene expression profiles at baseline and during chemoradiotherapy;  Correlation of changes in gene expression with patient outcomes;  Downstream events related to activation of p53 in response to treatment with radiotherapy;  Correlation of p53 pathway-mediated events with clinical outcomes|60|NCT00280761|December 2003
2262|Completed|Carboplatin and Docetaxel After Surgery in Treating Patients With Stage I Stage II or Stage III Non-Small Cell Lung Cancer||Drug:carboplatin;  Drug:docetaxel;  Procedure:adjuvanttherapy|Interventional|Phase 2|Other / NIH|Feasibility of administering of carboplatin/docetaxel as adjuvant therapy in resected stage I-IIIA NSCLC;  Numberofsubjectswithtoxicity|75|NCT00280735|May 2004
2263|Completed|A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors||Drug:STA-5312|Interventional|Phase 1|Industry||30|NCT00276913|June 2004
2264|Completed|Bevacizumab Everolimus and Erlotinib in Treating Patients With Advanced Solid Tumors||Biological:bevacizumab;  Drug:erlotinibhydrochloride;  Drug:everolimus|Interventional|Phase 1|Other / NIH|MaximumToleratedDose;  Safety|65|NCT00276575|March 2005
2265|Completed                  Has Results|Zonisamide for Weight Reduction in Obese Adults||Drug:Zonisamide|Interventional||Other / NIH|ChangeinBodyWeight;  ProportionsofPatientsWith5%WeightLoss;  ProportionsofPatientsWith10%WeightLoss;  WaistCircumference;  InflammatoryMarkers;  Lipids;  QualityofLife;  PsychologicalMeasures;  BloodPressure|225|NCT00275834|January 2006
2266|Completed|Effects of Resistance and Aerobic Exercise on Cardiovascular Health||Behavioral:ResistanceTraining;  Behavioral:AerobicExercise;  Behavioral:Combo;  Behavioral:ContinuedSedentarylifestyle|Interventional|Phase 2|Other / NIH|Major Cardiometabolic Risk Factors: lipoproteins; Ectopic Fat (Visceral Fat Liver fat); body composition (fat mass lean body mass; and Insulin Sensitivity;  Metabolic Syndrome (ATP III defined); Maximal Oxygen consumption; muscle biopsy measures (oxidative enzymes capillary density myofiber diameter)|261|NCT00275145|May 2004
2267|Completed|Efficacy of Amiloride and Hypertonic Saline in Cystic Fibrosis||Drug:7%NaCl;  Drug:AmilorideHCl|Interventional|Phase 2|Other|FEV1;  Mucociliaryclearancerate;  QualityofLife;  FVC;  FEF25-75;  Coughclearancerate|24|NCT00274391|July 2001
2268|Unknown&nbsp;&#8224;|Frequent Hemodialysis Network: Nocturnal Trial||Behavioral:Nocturnalhomehemodialysis|Interventional|Phase 2 / Phase 3|NIH|composite of 12 month mortality and the change over 12 months in left ventricular mass by cine-MRI;  a composite of 12 month mortality and the change over 12 months in the SF-36 RAND physical health composite;  cardiovascular structure/funct (change in LV mass over 12 mos) health-related QoL/phys funct (change over 12 mos in PHC);  depression/dis burden (change over 12 mos in Beck Depression Inv.)nutrition (change over 12 mos in serum albumin cognitive funct (change over 12 mos in TrailMaking Test B)mineral metabolism (change over 12 mos in aveg pre-dialysis serum phosphorus);  clinevents(rateofnon-accesshospitalordeath;  hypertensionanemia|150|NCT00271999|January 2006
2269|Completed|Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas||Biological:bevacizumab;  Drug:irinotecanhydrochloride|Interventional|Phase 2|Other / NIH|Safety;  Activityintermsofprogression-freesurvival|68|NCT00268359|May 2005
2270|Active not recruiting|Vaccine Therapy Trastuzumab and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer||Biological:sargramostim;  Biological: therapeutic autologous dendritic cells;  Biological:trastuzumab;  Drug:vinorelbineditartrate|Interventional|Phase 2|Other / NIH|Efficacy;  Generationoffunctionalantigen-specificTcells|26|NCT00266110|December 2005
2271|Completed|Oxaliplatin Gemcitabine Erlotinib and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer||Drug:erlotinibhydrochloride;  Drug:gemcitabinehydrochloride;  Drug:oxaliplatin;  Radiation:radiationtherapy;  Drug:Oxaliplatin|Interventional|Phase 1|Other / NIH|Maximum tolerated dose (MTD) of oxaliplatin and gemcitabine hydrochloride (Part 1);  Maximum Tolerated Dose (MTD) of erlotinib hydrochloride and gemcitabine hydrochloride (Part 2)|23|NCT00266097|August 2004
2272|Completed|Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients||Drug:EN3267|Interventional|Phase 3|Industry|The Study Objective is to evaluate the long-term safety and effectiveness of EN3267 in treating breakthrough pain episodes in opioid tolerant cancer patients who are using stable doses of opioid medication.|97|NCT00263575|January 2005
2273|Completed|An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs Syndrome||Drug:Rotigotine|Interventional|Phase 3|Industry|Safety and tolerability will be assessed by adverse events changes in laboratory tests changes in vital signs physical and neurological examination changes in menstrual and sexual function global subject rating;  To obtain data on changes in severity in RLS symptoms and quality of life over a one year maintenance period.|279|NCT00263068|December 2005
2274|Completed|Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.||Drug:EN3267|Interventional|Phase 3|Industry|||NCT00262678|December 2005
2275|Completed|Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer||Drug:octreotideacetate|Interventional|Phase 2|Other / NIH|Mediansurvival;  numberofsubjectswithtoxicities|31|NCT00257426|July 2005
2276|Completed|Policosanol for the Treatment of Hypercholesterolemia||Drug: Policosanol supplement (oral capsule) vs. placebo|Interventional||Other|PrimaryOutcomeVariables:;  Percent change in LDL-C between baseline and 8 weeks in the policosanol and placebo arms.;  SecondaryOutcomeVariables:;  Percent change between baseline and 8 weeks in both study arms for the following parameters:;  &#8226;totalcholesterolHDL-Candtriglycerides;  &#8226;hs-CRP;  &#8226;LDLParticleconcentration;  &#8226;ALT;  &#8226;Adverseeffectsprofile|40|NCT00255216|January 2005
2277|Completed|Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors||Drug:capecitabine;  Drug:imatinibmesylate|Interventional|Phase 1|Other / NIH||25|NCT00253565|August 2003
2278|Unknown&nbsp;&#8224;|Improving Sleep and Psychological Functioning in People With Depression and Insomnia||Drug:Eszopiclone;  Drug:Fluoxetine;  Drug:Placebo|Interventional|Phase 4|Other / NIH|&quot;Role Functioning&quot; and &quot;Relation to Self/Others&quot; Basis-32 subscale ratings;  Quality of life ratings as measured by the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q);  Subjective sleep symptoms (perceived sleep onset latency perceived total sleep time number of awakenings final rising time and the presence and duration of any naps the prior day);  Insomnia symptoms as measured by the Insomnia Severity Index (ISI)|96|NCT00247624|October 2005
2279|Unknown&nbsp;&#8224;|Trial for the Use of Pretest Probability to Reduce Unnecessary Testing for Low-Risk Patients With Chest Pain||Device:PREtestConsult|Interventional|Phase 3|Industry|Documentedmyocardialinfarction(ESCcriteria);  Death thought to be from ACS (autopsy not required);  Need for revascularization (stent or surgical) within 45 days;  Cardiaccatheterizationdemonstrating;  Percentage of patients deemed very low risk (pretest probability less than 2%) by the physician or the PREtest Consult ACS platform during the index visit;  Percentage of patients discharged without admission to the hospital or emergency department chest pain unit during the index visit;  Length of stay for the index visit to the emergency department;  Incidence of stress testing cardiac imaging and cardiac catheterization during the index visit and in the 45 days following the index visit;  Hospital charges billed to each patient or their insurance provider for the index visit;  Rate of reimbursement to the hospital for the index visit of each patient;  Patient satisfaction as recorded by a survey instrument during a phone interview seven (7) days post-index visit|400|NCT00243516|October 2005
2280|Completed|A Trial To Assess Switching From Ropinirole Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson&apos;s Disease||Drug:Rotigotine|Interventional|Phase 3|Industry|Tolerability of rotigotine as determined by the total number of subjects completing the trial.;  Effectonsymptomsandothervariables.;  Safety.||NCT00242008|December 2004
2281|Completed|3-D Transcranial Ultrasound Analysis Study||Device:3-Dultrasoundscanner;  Drug: Perflutren Protein-Type A Microspheres for injection|Interventional||Other|Phaseaberrationcorrectionofskullbone|28|NCT00239525|May 2006
2282|Completed                  Has Results|Hypertension Intervention Nurse Telemedicine Study (HINTS)||Behavioral: Nurse Behavioral intervention with Home BP Telemonitoring;  Behavioral: Nurse Medication Management with Home BP Telemonitoring;  Behavioral: Nurse Combined intervention with Home BP Telemonitoring|Interventional||U.S. Fed|Estimated Percentage of Participants in Blood Pressure Control at Baseline;  Estimated Percentage of Participants in Blood Pressure Control at 6 Months;  Estimated Percentage of Participants in Blood Pressure Control at 12 Months;  Estimated Percentage of Participants in Blood Pressure Control at 18 Months;  BloodPressureAveragesSystolic&amp;Diastolic|591|NCT00237692|May 2006
2283|Completed|Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer||Drug:PS-341;  Drug:Doxil;  Drug:Velcade|Interventional|Phase 1 / Phase 2|Other / NIH|Maximum tolerated dose (MTD) of PS-341 in combination with Doxil (Phase I);  Response rate of the combination of Velcade and Doxil in patients with metastatic breast cancer|107|NCT00237627|May 2001
2284|Completed|A Trial to Assess the Efficacy and Safety of SPM 927 in Subjects With Painful Distal Diabetic Neuropathy||Drug:SPM927|Interventional|Phase 2 / Phase 3|Industry|To investigate the efficacy of 200 400 and 600 mg/day of lacosamide compared with placebo in reducing pain in subjects with painful distal diabetic neuropathy.;  To investigate the effect of lacosamide on subjects&apos; perception of pain sleep activity quality of life as well as to investigate the pharmacokinetics and safety of lacosamide.|496|NCT00235469|April 2004
2285|Completed|Molecular Marker Profiling of Axillary Lymph Nodes in Predicting Response in Patients With Locally Advanced or Metastatic Breast Cancer Who Are Undergoing Chemotherapy Followed By Surgery||Procedure:PET(positronemissiontomography)|Interventional|Phase 2|Other / NIH|Improved breast conservation rates in neoadjuvant patients|15|NCT00233974|May 2002
2286|Completed|Treatment of Bacterial Vaginosis With Oral Tinidazole||Drug:Tinidazole|Interventional|Phase 3|Industry|Therapeuticefficacy;  Safety;  Clinicalefficacy;  Microbiologicalefficacy|200|NCT00229216|January 2005
2287|Completed                  Has Results|Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation||Drug:valganciclovir;  Other:Placebo|Interventional|Phase 3|Other / Industry|IncidenceofCMVEndOrganDisease;  IncidenceofCMVSyndrome;  AnyCMVInfection;  BiopsyProvenAcuteLungRejection;  Non-CMVInfection;  SeverityofViremia;  GanciclovirResistance|136|NCT00227370|July 2003
2288|Terminated|Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme||Drug:erlotinibhydrochloride|Interventional|Phase 1|Other / NIH|Progression-freesurvival;  Correlation between presence of the EGFRvIII mutation with treatment outcomes|10|NCT00227032|September 2005
2289|Completed|Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase||Drug:SPM907|Interventional|Phase 2|Industry|||NCT00220389|June 2003
2290|Completed|Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome||Drug:SPM907|Interventional|Phase 3|Industry|||NCT00220376|April 2004
2291|Completed|DBT Compared to I/GDC for the Treatment of Opiate Addiction in Emotionally Dysregulated Patients. - 1||Behavioral:DBT;  Behavioral:I/GDC|Interventional||Other / NIH|Psychologicalassessmentinterview;  Urinalysis;  Pre- and post-session therapist and client questionnaires|39|NCT00218595|August 2004
2292|Completed|Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence||Drug:DepotRisperidoneMicrosphere(Consta)|Interventional|Phase 4|Other / Industry||64|NCT00215579|April 2004
2293|Completed|Quetiapine in Social Anxiety Disorder||Drug:quetiapine|Interventional|Phase 2 / Phase 3|Other / Industry|BriefSocialPhobiaScale(BSPS);  ClinicalGlobalImpressionsofSeverity(CGI-S);  Clinical Global Impressions of Improvement (CGI-I);  SocialPhobiaInventory(SPIN);  HospitalAnxietyandDepressionScale(HADS);  ConnorDavidsonResilienceScale(CD-RISC);  SheehanDisabilityInventory(SDI);  BarnesAkathisisScale(BAS);  Simpson-AngusScale(SAS)|15|NCT00215254|March 2004
2294|Completed|Effects of Duloxetine vs. Escitalopram on Heart Rate Variability in Depression||Drug:duloxetinevs.escitalopram|Interventional|Phase 2 / Phase 3|Other / Industry|Effectoftreatmentonheartratevariability;  Effect of treatment on affective variables (depression anxiety stress reactivity);  Effect of treatment on neurotransmitter transporter occupancy|26|NCT00215228|July 2005
2295|Completed                  Has Results|Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder||Drug:escitalopram;  Drug:Placebo(sugarpill)|Interventional|Phase 2|Other / Industry|YaleBrownObsessiveCompulsiveScale|14|NCT00215137|October 2004
2296|Completed|Promoting Postpartum Weight Loss in Overweight Women||Behavioral: moderate exercise and healthy low-fat diet|Interventional||Other / NIH|BMI change from baseline to 12 months post-intervention (24 months postpartum) will be assessed via self-report and validated by in-person weight measurement. The proportion of women who lose 10% of baseline BMI;  Change in BMI from pre-pregnancy to 12 months post-intervention; proportion below their pre-pregnancy weight at 1 6 and 12 months post-intervention; and BMI change from baseline to 1 a|450|NCT00212251|August 2004
2297|Completed|Enhanced Internet Behavior Therapy for Treating Obesity||Behavioral: internet behavioral weight loss program|Interventional||NIH|weightchangefrom0to12months;  patternsofweightchange(0-33-66-12months);  changeinwaistcircumference;  changeinphysicalactivity;  changeindietaryintake;  changeinsocialsupport|100|NCT00212238|September 2003
2298|Completed|Lay Health Advisors for Sexually Transmitted Disease Prevention||Behavioral: HoMBReS: A lay health advisor approach to STD prevention|Interventional|Phase 1 / Phase 2|U.S. Fed|ReducedSTDmorbidity;  Reducedriskbehavior;  Improvedaccesstoservices|354|NCT00207506|October 2004
2299|Completed|Comparing ASHC and CDSMP Outcomes In Arthritis||Behavioral:ArthritisSelfmanagementprogram;  Behavioral: Chronic Disease Self Management Program|Interventional||U.S. Fed / Other|Health related quality of life measured at 4 and 12 months;  Health care utilization measured at 4 and 12 months;  Self management behaviors measured at 4 and 12 months;  Self efficacy for arthritis management measured at 4 and 12 months|416|NCT00207441|April 2003
2300|Completed|Study of Expectorant Activity of Oral N-Acetylcystein (NAC) in Patients With Stable Chronic Bronchitis||Drug:OralN-acetycystein(NAC)|Interventional|Phase 2|Other / Industry|Acuteexacerbations;  Clinicalassessments;  Functionalexercisecapacity;  Relationship between mucus physical and transport properties|240|NCT00205647|January 1997
2301|Unknown&nbsp;&#8224;|Macrolide Antibiotic Therapy for Patients With Cystic Fibrosis||Drug:Biaxin(clarithromycin)|Interventional||Other / Industry|PulmonaryFunctionTesting-FEV1;  QualityofLife;  decrease in neutrophil-dominated airway inflammation;  decrease in Pseudomonas alginate production in vitro and in the airway|50|NCT00205634|December 2000
2302|Terminated|Effects of a New Antimicrobial Dressing on Wound Healing and Incidence of Sternal Wound Infections||Device:TELFA&#8482;A.M.D.Islanddressing|Interventional||Industry|Decreased cumulative incidence rate of superficial surgical site infections localized at the sternal incision in the treatment group as compared to the control group.;  Reduction of microbial log counts at the incisional site in the treatment group compared to the control group; Decreased cumulative incidence of mediastinitis in the treatment group as compared to the control group|1100|NCT00203541|February 2004
2303|Completed|Interventions to Improve Hypertension Control and Reduce Cardiovascular Disease Risk||Behavioral: Lifestyle interventions to lower blood pressure for patients;  Behavioral:MDCQI-typeintervention|Interventional|Phase 2|Other / NIH|Changeinsystolicbloodpressure;  ChangeindiastolicBP;  ChangeinBPat18months;  PatientandMDadherencetointervention|574|NCT00201136|February 2004
2304|Completed|Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer||Drug:Gemcitabine;  Drug:Carboplatin;  Drug:Paclitaxel|Interventional|Phase 2|Industry|Pathological complete response rate in previously untreated patients with clinical Stage I and II non-small cell lung cancer (NSCLC).;  Response rate disease free survivaltoxicities including pulmonary toxicity operative mortality and quality of life.|77|NCT00191256|June 2001
2305|Completed|Gemcitabine/Platinum Containing Regimens as Preoperative Chemotherapy for Patients With Non Small Cell Lung Cancer||Drug:gemcitabine;  Drug:carboplatin;  Drug:cisplatin|Interventional|Phase 2|Industry|Completepathologicalresponse;  Response rate disease free survival toxicity including pulmonary toxicityoperative mortality and quality of life.|70|NCT00191230|September 2001
2306|Active not recruiting|Radiation Therapy During Surgery in Treating Older Women With Invasive Breast Cancer||Procedure:surgery;  Procedure:therapy;  Radiation:radiationtherapy|Interventional|Phase 2|Other / NIH|Rates of good/excellent cosmesis as measured by the RTOG cosmetic rating scale;  Incidenceofgrade3/4toxicity;  Association of nuclear p53 expression in tumor and normal tissue before and after IORT;  Association of nuclear NFkB expression in tumor and normal tissue before and after IORT;  Association of phosphorylated EGFR HER2 p44/42 MAPK and Akt in breast tumors and normal tissue before and after IORT;  Ipsilateral breast recurrence (tumor bed recurrence versus elsewhere in breast|89|NCT00182728|February 2003
2307|Completed|Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)||Drug:BG9418(interferonbeta-1a)|Observational||Industry|Record and analyze birth defects and spontaneous fetal losses;  Recordandanalyzepregnancyoutcomes|329|NCT00168714|February 2004
2308|Completed|Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures||Drug:SPM927|Interventional|Phase 2 / Phase 3|Industry|Evaluate the safety and tolerability of lacosamide when given as iv infusions in subjects who are receiving oral lacosamide in addition to up to 3 concomitant AEDs for partial seizures. The primary variables are adverse events;  Seizure counts trough and measured maximum concentration for lacosamide as well as the O-desmethyl-metabolite.|160|NCT00151879|February 2005
2309|Completed|EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis||Drug:Avonex/Zocor|Interventional|Phase 4|Other|The primary objective of this study is to determine whether combination therapy with IFNb-1a plus simvastatin when compared to IFNb-1a plus placebo decreases or delays additional clinical or MRI activity.;  Wewillusethefollowingoutcomemeasures:;  Relapse rates Time to first relapseNumber of new T2 lesions Number of new Gd-enhancing lesions|30|NCT00146068|September 2004
2310|Completed|The Role of Vitamins E and C in Maintaining Lung Health in People With Asthma||DietarySupplement:Vitamin|Interventional|Phase 1|Other / NIH|Sputum cell ascorbate and alpha-tocopherol levels; measured bi-weekly and at Week 12;  Methacholine reactivity; measured at Weeks 6 and 12;  Lung function and symptom scores; measured weekly and at Week 12|16|NCT00142610|August 2005
2311|Completed                  Has Results|Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer||Radiation:Chemoradiotherapy;  Drug:Cisplatin;  Drug:Bevacizumab;  Drug:Erlotinib|Interventional|Phase 0|Other / Industry|TumorResolution;  LocalRegionalControl;  FailureFreeSurvival|28|NCT00140556|August 2005
2312|Completed|Using the Healthcare Visit to Improve Contraceptive Use||Behavioral:Contraceptivecounseling|Interventional||U.S. Fed / Other|Contraceptiveuse;  Chlamydiainfection;  Pregnancy|747|NCT00140296|March 2003
2313|Completed|EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis||Drug:Rebif|Interventional||Other|To determine the effects of IFNb-1a plus atorvastatin versus IFNb-1a plus placebo on the gene expression in peripheral blood mononuclear cells (PBMCs) derived from patients with isolated clinical syndrome suggestive of MS;  To identify markers of therapeutic response and to predict patients&apos; clinical response based on their in vitro response to this combination therapy measured by the gene expression levels in activated PBMCs;  evaluate safety and efficacy of combination therapy with Rebif and Lipitor in patients with clinicayy isolated syndrome suggestive of MS.|30|NCT00137176|October 2004
2314|Completed|Comparing Paroxetine and Duloxetine on Cardiovascular Measures||Drug:paroxetineversusduloxetine|Interventional|Phase 2 / Phase 3|Other / Industry|R-Rintervalchangewithdeepbreathing;  Respiratorysinusarrhythmia;  Montgomery-AsbergDepressionRatingScale(MADRS);  HospitalAnxietyandDepressionScale;  SpielbergerState-TraitAnxietyInventory;  Connor-DavidsonResilienceScale;  Norepinephrinereceptoroccupancy;  Serotoninreceptoroccupancy|40|NCT00136383|March 2005
2315|Completed|Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome||Drug:Rotigotine|Interventional|Phase 3|Industry|IRLS sum score and CGI Item 1 score severity of illness;  IRLS Responder: A responder is a subject with a decrease of &#8805;50% in IRLS sum score;  CGI Item 1 Responder: A responder is defined as a subject with a decrease of &#8805;50% in CGI Item 1;  Changes in CGI Items 2-3 (continuous) during the Maintenance Period; Change from Baseline in RLS-6 Rating Scales at the end of the Maintenance Period|811|NCT00135993|May 2005
2316|Completed|Addition of Naltrexone to Methadone Taper||Drug:Naltrexone;  Drug:Placebocomparator;  Drug:naltrexone|Interventional|Phase 2|NIH|Withdrawalintensity;  Retentionintreatment|174|NCT00135759|April 2005
2317|Completed|Trial to Assess the Efficacy and Safety of SPM 927 (200 400 and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy||Drug:SPM927|Interventional|Phase 3|Industry|To investigate the efficacy of 200 400 and 600mg/day of lacosamide compared with placebo in reducing pain in subjects with painful distal diabetic neuropathy.;  To investigate the effect of lacosamide on subjects&apos; perception of pain sleep activity and quality of life as well as to investigate the pharmacokinetics and safety of lacosamide.|654|NCT00135109|October 2004
2318|Completed|A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide &#169;) and/or Weekly Paclitaxel||Drug:cyclophosphamide;  Drug:doxorubicin;  Drug:paclitaxel|Observational||Other / NIH|Treatment-induced myelosuppression (e.g. neutropenia);  Incidenceofperipheralneuropathy;  Response (relapse in adjuvant setting) for 10 years after completion of study treatment|94|NCT00131963|October 2003
2319|Completed|Biofeedback for Dyssynergic Constipation||Behavioral:Biofeedback;  Drug:Diazepam;  Behavioral:Pelvicfloorretraining|Interventional||NIH|Proportion of subjects reporting adequate relief per treatment group;  Demonstrate association of improvement in quality of life with treatment outcome;  Identify predictors of successful treatment outcome;  Describe physiological mechanism of treatment effects|117|NCT00127257|September 1999
2320|Completed|Biofeedback for Fecal Incontinence||Behavioral:Biofeedback;  Behavioral:Kegelexercises|Interventional||NIH|Proportion of subjects reporting adequate relief per treatment group;  Demonstrate association of improvement in quality of life with treatment outcome;  Identify predictors of successful treatment outcome|165|NCT00124904|September 1999
2321|Completed                  Has Results|PIE II: Pharmacological Intervention in the Elderly II||Drug:Spironolactone;  Drug:Placebo|Interventional|Phase 3|Other / NIH|ExerciseIntolerance;  QualityofLife;  ConcentricLeftVentricularRemodeling;  LeftVentricularDiastolicStiffness|80|NCT00123955|April 2005
2322|Completed|Comparison of Two Programs to Improve Blood Pressure Treatment Adherence||Behavioral:Nurseadministered;  Device:BPMonitor|Interventional||Other / NIH / Industry|BPmeasurement;  Satisfactionwithcare;  Riskassociatedwithhypertension;  Selfreportedadherence;  Efficacywithtreatment|777|NCT00123058|June 2003
2323|Completed|Study of Escitalopram in the Treatment of Specific Phobia||Drug:Escitalopram|Interventional|Phase 2 / Phase 3|Other / Industry|Response based on a criterion of 50% or greater reduction in the Marks Main Phobia Questionnaire and Marks Fear Questionnaire from baseline;  ResponsebasedonCGI-Icategory|12|NCT00121069|September 2002
2324|Terminated|To Determine the Effects of Avosentan on Doubling of Serum Creatinine End Stage Renal Disease and Death in Diabetic Nephropathy||Drug:SPP301|Interventional|Phase 3|Industry|To determine the effect of each dose of avosentan on time to doubling of serum creatinine end stage renal disease (ESRD) or death when administered on top of standard treatment in subjects with type 2 diabetes mellitus and diabetic nephropathy.;  To determine the effect of each dose of avosentan on: cardiovascular mortality;  non-cardiovascularmortality;  coronary or peripheral vascular revascularisations including amputations (except where due to trauma);  non-fatalacutemyocardialinfarction;  stroke;  congestiveheartfailure;  unstableangina|2364|NCT00120328|July 2005
2325|Completed|Health eCommunities - The Impact of Listservs on Cancer Patients||Behavioral:ParticipationontheACORListserv|Observational||Other||3360|NCT00119951|September 2003
2326|Completed|St. John&apos;s Wort for the Treatment of Generalized Social Anxiety Disorder (GSAD)||Drug:Hypericumperforatum(St.John&apos;swort)|Interventional|Phase 2 / Phase 3|NIH|Clinical Global Impression (CGI) designed to assess global severity of illness and change in the clinical condition over time;  BriefSocialPhobiaScale(BSPS);  LiebowitzSocialAnxietyScale;  SocialPhobiaInventory(SPIN);  Self-RatingDepressionScale(SDS);  HospitalAnxietyandDepressionScale(HADS)|56|NCT00118833|August 2002
2327|Recruiting|Ribavirin Pregnancy Registry|||Observational|Phase 4|Other / Industry|To evaluate association between ribavirin and birth defects;  Estimate risk of birth defects in exposed pregnancies|600|NCT00114712|January 2004
2328|Completed                  Has Results|Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout||Biological:Pegloticase|Interventional|Phase 2|Other / Industry|Reduction in Plasma Uric Acid to Less Than 6 mg/dL.;  Clinical Response: Number of Swollen and Tender Joints;  In a Subset of Subjects Who Volunteer Separately Change in Uric Acid Pool Size Will be Assessed by a Method That Involves Infusion of Uric Acid Labeled With N15 a Stable (Nonradioactive) Isotope of Nitrogen.;  Reduction of the Ratio of Uric Acid:Creatinine in Urine;  DevelopmentofAntibodiestoPEG-uricase;  Infusion1:MaximumConcentration(Cmax)Value;  Infusion1:MinimumConcentration(Cmin)|30|NCT00111657|December 2004
2329|Completed|Effectiveness of an Internet-Based Curriculum in Increasing Health Care Providers&apos; Knowledge of Herbs and Dietary Supplements||Behavioral: Complementary and alternative medicine education|Interventional||NIH|Changes in participant knowledge confidence and communication practices regarding herbs and dietary supplements;  Impact of comfort with using technology on the primary outcomes|1500|NCT00110539|February 2004
2330|Completed                  Has Results|A Low-Carbohydrate Ketogenic Diet Versus Orlistat for Weight Loss||Behavioral:Lowcarbohydrateketogenicdiet;  Drug:Orlistat;  Behavioral:Low-fatdiet|Interventional||U.S. Fed|ChangeFromBaselineinBodyWeightat48Weeks;  Change From Baseline in Risk Factors for Heart Disease (e.g. Lipid Profiles) at 48 Weeks;  ChangeFromBaselineinBloodSugarat48Weeks|146|NCT00108524|July 2004
2331|Completed|Tumor RNA Transfected Dendritic Cell Vaccines||Biological:TumorRNAtransfecteddendriticcells|Interventional|Phase 1|U.S. Fed|||NCT00108264|
2332|Completed|Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast Cancer||Drug:Abraxane|Interventional|Phase 1|Industry|Safety/tolerabilityendpoints:;  incidence of treatment-emergent/related adverse events and serious adverse events;  laboratoryabnormalities;  nadirofmyelosuppression;  incidence of patients experiencing dose modifications dose interruptions and/or premature discontinuation of study drug|30|NCT00107094|March 2005
2333|Completed|Behavioral Insomnia Therapy in Primary Care||Behavioral:Cognitive-BehavioralTherapy|Interventional||U.S. Fed|Objective (actigraphic) and subjective (sleep log) sleep measures at 6 weeks and 6 months;  Mood and quality of life at 6 weeks and 6 months; healthcare utilization at 6 months|100|NCT00105872|March 2002
2334|Completed|Psychiatric Advance Directives for Improved Mental Health Care||Procedure: Psychiatric Advance Directives intervention|Interventional||U.S. Fed|Rate of involuntary commitment (12 months) perceived coercion (baseline 1 6 12 and rehospitalization) and treatment adherence (baseline and 12 months and record review);  Satisfaction with inpatient care (baseline rehospitalization) treatment motivation working alliance psychiatric symptoms PAD completion PAD content PAD consulted (hospital record review) psychiatric ER use (12 month record review).|360|NCT00105794|March 2004
2335|Completed|Study to Lower Veterans BP: Patient/Physician Intervention||Behavioral:Telephonebehavioraleducation;  Behavioral:Computerbehavioraleducation|Interventional||U.S. Fed|BP control at primary care visit; Systolic and diastolic BPs as recorded at each primary care provider visit during 24 month enrollment period.;  Knowledge and perceived risks associated with hypertension and ability to continue hypertension regimen will be assessed at baseline and via telephone 6 and 24 months after baseline; Medication adherence will be assessed from pharmacy records|544|NCT00105716|March 2002
2336|Terminated|Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes||DietarySupplement:cholecalciferol;  Drug:arsenictrioxide|Interventional|Phase 2|Other / NIH|Completeresponserate;  toxicityassessmentaftertherapy|5|NCT00104806|November 2004
2337|Completed|Genistein in Preventing Breast or Endometrial Cancer in Healthy Postmenopausal Women||DietarySupplement:Genistein;  DietarySupplement:Placebo|Interventional|Phase 1|Other / NIH|EfficacyofgenisteinonDNAandapoptosis|30|NCT00099008|March 2004
2338|Terminated|Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer||Drug:sorafenibtosylate;  Biological:recombinantinterferonalfa;  Other:laboratorybiomarkeranalysis|Interventional|Phase 2|NIH|Overall response rate (CR+PR) using RECIST criteria;  Grade 3+ toxicities assessed using NCI CTCAE version 3.0;  Progression-freesurvival;  Overallsurvival;  Durationofresponse|40|NCT00098618|October 2004
2339|Terminated|FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer||Drug:romidepsin;  Other:laboratorybiomarkeranalysis|Interventional|Phase 2|NIH|Radiographic response rate (complete response &amp; partial response);  Progression-free survival (PFS) according to RECIST;  Frequency of treatment related grade 1-4 toxicities and cardiac toxicities as assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0;  Correlation of changes in gene expression profile in dermal granulation tissue pre- and post-treatment with gene expression profile;  Correlation of wound vascular scores pre- and post-treatment with gene/protein changes;  Toxicity;  Changesingeneexpressionprofile;  Changes in levels of p21 and thymidine kinase expression and tubulin acetylation using Western blotting;  Changes in gene expression profile in dermal granulation tissue;  ChangeinplasmaandurineTGFBlevels|20|NCT00098527|October 2004
2340|Completed|MOTOR: Maternal Oral Therapy to Reduce Obstetric Risk||Other: multi-center randomized controled periodontal therapy|Interventional|Phase 3|Other / NIH|Birthatlessthan37weeksgestationalage|1800|NCT00097656|February 2004
2341|Completed|An Observational Study of the Use and Safety of Raptiva During Pregnancy (FOLLOW)|||Observational|Phase 4|Industry||18|NCT00097240|January 2005
2342|Completed|MRI Sarcoma Non Invasive Thermometry||Drug:doxorubicinhydrochloride;  Drug:ifosfamideandmesna;  Procedure: hyperthermia treatment with an MRI Compatible Radiofrequency Extremity Hyperthermia Applicator;  Radiation:radiationtherapy|Interventional|Phase 1 / Phase 2|Other / NIH|TemperatureRisefromBaseline;  OverallSurvival|15|NCT00093509|November 1999
2343|Completed|A Safety Study of ABI-007 for In-Stent Restenosis||Drug:PaclitaxelNanoparticleAlbuminBound|Interventional|Phase 2|Industry|Incidence of treatment-emergent adverse events and serious adverse events.;  Major Adverse Cardiac Events at 2 months following the stent procedure.;  SafetyandtolerabilityforABI-007;  Evaluationofrestenosisat6months.|76|NCT00093223|September 2001
2344|Completed|Safety of KAI-9803 for Injection With Angioplasty Following Heart Attack||Drug:KAI-9803forInjection;  Drug:Placebo|Interventional|Phase 1 / Phase 2|Industry|Numberofparticipantswithadverseevents;  Number of participants with major cardiac events (death congestive heart failure recurrent myocardial infarction repeat target vessel revascularization);  Creatinekinase-myocardialband(CK-MB);  ST-segmentelevation;  Angiographyvesselflow;  Infarct size by single photon emission computed tomography (SPECT);  Echocardiographic left ventricular ejection fraction (LVEF)|154|NCT00093197|September 2004
2345|Completed|Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma||Drug:ABI-007|Interventional|Phase 2|Industry|Determine anti-tumor activity of ABI-007 in patients with metastatic melanoma.;  Evaluate number of cycles required before patients achieve maximum response|33|NCT00093119|January 2004
2346|Completed|Vaccine Therapy Trastuzumab and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer||Biological: therapeutic autologous dendritic cells;  Biological:trastuzumab;  Drug:vinorelbineditartrate|Interventional|Phase 2|Other / NIH|Responserate;  Immuneresponse|55|NCT00088985|January 2004
2347|Completed|Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer||Drug:erlotinibhydrochloride;  Drug:celecoxib;  Other:laboratorybiomarkeranalysis|Interventional|Phase 1|NIH|Clinical tolerable dose of celecoxib as measured by NCI CTCAE v3.0|45|NCT00088959|December 2003
2348|Terminated                  Has Results|Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer||Drug:cisplatin;  Procedure:hyperthermiatreatment;  Radiation:brachytherapy;  Radiation:externalbeamradiationtherapy|Interventional|Phase 3|Other / NIH|Primary Tumor Response Rate at 4-6 Weeks Post Treatment;  Five-yearFailure-freeSurvival;  Five-YearLocalRecurrence-FreeSurvival;  Five-YearOverallSurvival|101|NCT00085631|March 2003
2349|Terminated|Docetaxel and Carboplatin in Treating Patients With Recurrent Stage IVB Squamous Cell Carcinoma (Cancer) of the Cervix||Drug:carboplatin;  Drug:docetaxel|Interventional|Phase 1|Other / NIH|Maximumtolerateddoseofdocetaxel|15|NCT00084890|November 2003
2350|Unknown&nbsp;&#8224;|High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2||Biological:aldesleukin|Interventional|Phase 2|Other|||NCT00080977|June 1998
2351|Completed|Painful HIV Neuropathy and Alpha-Lipoic Acid||Drug:Alpha-LipoicAcid|Interventional|Phase 1 / Phase 2|NIH||60|NCT00079807|September 2003
2352|Completed                  Has Results|Antidepressant Medication Treatment for Depression in Individuals With Chronic Heart Failure||Drug:Sertraline;  Drug:Placebo|Interventional|Phase 2 / Phase 3|Other / NIH|Symptoms of Depression in Congestive Heart Failure Patients With Clinical Depression After Treatment With Sertraline or Placebo;  Percentage of Cardiac Events and Morbidity / Mortality Including Rehospitalization in Congestive Heart Failure Patients With Depression After Treatment With Sertraline or Placebo.|469|NCT00078286|November 2003
2353|Completed|National Registry of Veterans With Amyotrophic Lateral Sclerosis and DNA Bank|||Observational||U.S. Fed / Other|Help studies using dates and DNA collected to determine possible genetic factor.|2121|NCT00076154|January 2003
2354|Terminated|Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy||Drug:celecoxib|Interventional|Phase 2|Other / NIH|EffectofCOX-2inhibitorsonPSAlevel;  Diseaseprogressionrate|37|NCT00073970|April 2003
2355|Completed|Assessing the Results of Lip Surgery in Patients With Cleft Lip and Palate||Procedure:Liprevisionsurgery|Observational|Phase 2 / Phase 3|Other / NIH|Facialmovement/animation;  LipForce;  EMG;  Lipsensation|127|NCT00070811|August 2001
2356|Completed|Cholecalciferol in Treating Patients With Myelodysplastic Syndrome||DietarySupplement:cholecalciferol|Interventional|Phase 2|Other / NIH|||NCT00068276|July 2003
2357|Terminated|A Study of the Pharmacokinetics of Black Cohosh||Drug:Blackcohosh|Interventional|Phase 1|NIH||12|NCT00068185|August 2003
2358|Completed|HIV Symptom Management Program for African American Mothers||Behavioral:HIVSymptomEducationProgram|Interventional|Phase 3|NIH|||NCT00065819|September 1996
2359|Completed                  Has Results|Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)||Drug:Atorvastatin;  Drug:Placeboatorvastatin|Interventional|Phase 3|Other|ChangeinMean-MeanCommonCarotidIMT(CIMT);  ChangeinMean-MaxCIMT;  ChangeinMean-MeanCIMT;  ChangeinMean-MaxCommonCIMT;  ChangeinMean-MaxInternalCIMT;  ChangeinMean-MeanInternalCIMT;  ChangeinMean-MaxBifurcationCIMT;  ChangeinMean-MeanBifurcationCIMT;  ChangeinMean-MaxFarWallCIMT;  ChangeinMean-MeanFarWallCIMT;  ChangeinMean-MaxNearWallCIMT;  ChangeinMean-MeanNearWallCIMT;  ChangeinNaturalLogofmg/LforhsCRP;  ChangeinTotalCholesterol;  ChangeinHDLCholesterol;  ChangeinLDLCholesterol;  ChangeinTriglycerides;  ChangeinLipoproteinA;  ChangeinHomocysteine|221|NCT00065806|September 2003
2360|Completed|Botanical/Drug Interactions in HIV: Glucuronidation||Drug:silymarin|Interventional|Phase 1|NIH||60|NCT00065741|September 2003
2361|Completed|High Intensity Light Therapy in Alzheimer&apos;s Disease||Device:high-intensitylighttherapy|Interventional|Phase 3|NIH||107|NCT00065689|March 2003
2362|Completed|Human Requirements for the Nutrient Choline||Other:Estrogenpluscholinedepletiondiet;  Other:Placebopluscholinedepletiondiet;  Other: Pre-menopausal women with SNPs given a low choline diet|Interventional||Other / NIH|Evidence of liver or muscle dysfunction (based on elevations in CPK AST ALT) or increased liver fat (measured by liver MRI)|43|NCT00065546|June 2007
2363|Completed|Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma||Drug:IL13-PE38QQR;  Procedure:targetedfusionproteintherapy;  Procedure:surgery|Interventional|Phase 1|Industry||18|NCT00064779|July 2003
2364|Completed|Study of Karenitecin (BNP1350) in Patients With Brain Tumors||Drug:Karenitecin(BNP1350)|Interventional|Phase 2|Industry|ObjectiveTumorResponseRate;  OverallSurvival;  OverallSafety|40|NCT00062478|October 2001
2365|Terminated|Inhaled Nitric Oxide in Prevention/Treatment of Ischemia-Reperfusion Lung Injury Related to Lung Transplantation||Drug:nitricoxideforinhalation;  Drug:Placebo|Interventional|Phase 3|Industry|arterialandmixedvenousbloodgases;  pulmonaryvascularpressures;  cardiacoutput;  systemichemodynamics;  NO2andNOconcentrations|84|NCT00060450|August 2001
2366|Completed|Reduced Manipulation of the Aorta and Neurobehavioral Outcome Trial||Procedure: single aorta clamp with retrograde cardioplegia;  Procedure: multiple aorta clamps with antegrade cardioplegia|Interventional|Phase 3|NIH||300|NCT00059319|January 1999
2367|Completed|Vaccine Therapy in Treating Patients With Refractory Stage IV Cancer||Biological:CEApeptide1-6D|Interventional|Phase 1|Other / NIH|Safety;  Immuneresponse|4|NCT00057915|September 2003
2368|Completed|Genetic Study of Familial Factors in Patients With Colon Cancer||Genetic:cytogeneticanalysis;  Genetic:genemapping;  Genetic:microarrayanalysis|Observational||Other / NIH||600|NCT00055848|December 2001
2369|Completed|Cognitive Therapy for Binge-Eating Disorder||Procedure:CBT|Interventional||Other / NIH||60|NCT00050037|April 2001
2370|Completed|EF5 Compared With Other Methods of Detecting Oxygen Levels in Tumor Cells of Patients With Head and Neck Cancer||Drug:EF5;  Other:bioluminescence;  Other:flowcytometry;  Other:immunohistochemistrystainingmethod;  Procedure:biopsy|Interventional|Phase 2|Other / NIH|Heterogeneity of hypoxia as measured by EF5 binding at completion of accrual;  Heterogeneity of CA9 expression by immunohistochemistry at completion of accrual;  Heterogeneity of glucose and lactate by bioluminescence imaging at completion of accrual;  Spatial coordination as measured by EF5 binding at completion of accrual;  Compare spatial coordination between the location of CA9 and hypoxia and/or lactate concentration at completion of accrual|8|NCT00049140|August 2002
2371|Unknown&nbsp;&#8224;|A Rollover Study to Provide Chronic T-1249 to Patients Who Completed Study T1249-102||Drug:T-1249|Interventional|Phase 1 / Phase 2|Industry|||NCT00048217|
2372|Completed|The Sister Study: Genetic and Environmental Risk Factors for Breast Cancer|||Observational||NIH||50884|NCT00047970|August 2003
2373|Completed|Phase 1 Study OF CDC-501 in Patients With Solid Tumors||Drug:Lenalidomide|Interventional|Phase 1|Industry|To identify the MTD and safety of CDC-501 when given in a 6-wk cycle of daily administration of CDC-501 for 4 wks followed by a 2-wk rest in doses of 5 mg/day up to 25 mg/day in pts with solid tumors that are refractory after standard treatment.|24|NCT00046735|June 2002
2374|Completed|Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer||Drug:ABI-007|Interventional|Phase 3|Industry||460|NCT00046527|June 2001
2375|Completed|ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer||Drug:ABI-007|Interventional|Phase 2|Industry||100|NCT00046514|June 2001
2376|Completed|A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies||Drug:ABI-007|Interventional|Phase 1|Industry||20|NCT00046423|April 2000
2377|Completed|Diet and Exercise-Based Counseling Program Compared With a Standard Counseling Program in Patients With Early-Stage Prostate Cancer||Procedure:nutritionalsupport;  Procedure:quality-of-lifeassessment|Interventional||Other / NIH|||NCT00044980|July 2002
2378|Completed|Combined Behavioral/Pharmacological Therapy for Insomnia||Behavioral: Cognitive-Behavioral Therapy for Insomnia;  Drug:zolpidemtartrate(Ambien);  Drug:Placebo|Interventional|Phase 2|Other / NIH||162|NCT00044629|September 2001
2379|Completed|Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT First Inning)||Drug:bivalirudin|Interventional|Phase 3|Industry|Majorbleedingevents|50|NCT00043940|April 1999
2380|Completed|SYNERGY: Open Study of Enoxaparin Versus Unfractionated Heparin in Patients With Acute Coronary Syndromes||Drug:enoxaparin|Interventional|Phase 3|Industry|To measure the composite endpoint of all-cause mortality or the first clinical events committee (CEC)-adjudicated nonfatal myocardial infarction;  Tomeasuretheincidenceofmajorbleeding.;  Incidenceofminorandallbleeding;  To evaluate the combined and individual incidence of all-cause mortality clinical events committee (CEC)-adjudicated nonfatal MI stroke or recurrent ischemia that required revascularization;  Toevaluatetheincidenceofall-causemortality;  To evaluate the combined incidence of all-cause mortality or CEC-adjudicated nonfatal MI|8000|NCT00043784|August 2001
2381|Completed|Work and Health Disparities Among Rural Women|||Observational||NIH||150|NCT00042419|March 2002
2382|Unknown&nbsp;&#8224;|Screening Adolescents for Type 2 Diabetes Mellitus in a Community Clinic||Behavioral:Familybasededucationalprogram|Interventional||NIH / Other||400|NCT00042042|
2383|Completed                  Has Results|Effects of Magnesium on Individuals Undergoing Coronary Artery Bypass Graft Surgery||Drug:Magnesium;  Drug:0.9%saline|Interventional|Phase 2|Other / NIH|CognitiveFunction|389|NCT00041392|December 2001
2384|Completed|Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery||Drug:imatinibmesylate;  Other:placebo;  Other:laboratorybiomarkeranalysis|Interventional|Phase 3|NIH|Recurrence-freesurvival(RFS);  Safety as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0;  Relationship between genetic and phenotypic characteristics of GIST and clinical outcomes|732|NCT00041197|June 2002
2385|Active not recruiting|Gene Modifiers of Cystic Fibrosis Lung Disease|||Observational||Other|Thisisnotaninterventionalstudy.|600|NCT00037765|September 2001
2386|Completed|Study of Health Promotion in Patients With Early-Stage Breast or Prostate Cancer||Procedure:fatigueassessmentandmanagement;  Procedure:nutritionalsupport;  Procedure:physicaltherapy;  Procedure:psychosocialassessmentandcare;  Procedure:quality-of-lifeassessment|Interventional||Other / NIH|||NCT00037024|April 2002
2387|Completed|Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder||Drug:DuloxetineHydrochloride|Interventional|Phase 3|Industry|||NCT00036309|May 2002
2388|Completed|Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer||Drug:megestrolacetate;  Radiation:radiationtherapy|Interventional|Phase 3|Other / NIH|||NCT00031785|September 2000
2389|Completed|Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome||Drug:thalidomide|Interventional|Phase 2|Other / NIH|||NCT00030550|September 2001
2390|Completed|Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer||Biological:epoetinalfa;  Drug:carboplatin;  Drug:paclitaxel;  Radiation:radiationtherapy|Interventional|Phase 3|Other / NIH|||NCT00028938|January 2002
2391|Completed|Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer||Biological:TRICOM-CEA(6D)|Interventional|Phase 1|Other / NIH|Safety;  Immuneresponse|14|NCT00027534|January 2002
2392|Unknown&nbsp;&#8224;|Linkage and Identification of (a) Candidate Gene(s) for Tooth Disorders|||Observational||NIH|||NCT00026026|
2393|Completed|Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase in the Treatment of Classical Infantile Pompe Disease||Drug: recombinant human acid alpha-glucosidase (rhGAA)|Interventional|Phase 2|Industry||8|NCT00025896|May 2001
2394|Completed|Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery||Drug:imatinibmesylate;  Other:laboratorybiomarkeranalysis|Interventional|Phase 2|NIH|Determination whether patients with completely resected high-risk primary GIST who undergo adjuvant treatment with imatinib mesylate have prolonged survival compared to historical controls;  Prevalenceofrecurrencefreesurvival;  Prevalenceofrecurrence;  Overallsurvival;  Toxicities graded according to the National Cancer Institute Common Toxicity Criteria|89|NCT00025246|September 2001
2395|Completed|Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease||Procedure:CABGsurgeryplusMED;  Drug:ActiveMedicationAlone;  Procedure:CABGplusMEDandSVR|Interventional|Phase 3|Other / NIH|H01-Total mortality; H02-Long-term survival free of cardiac hospitalization;  Cost-effectiveness;  Qualityoflife;  Exercisecapacity;  Treatment-specific prediction of primary endpoints by baseline measurements of myocardial ischemia and viability and by baseline and post-treatment measurements of LV size and function and neurohormonal and pro-inflammatory cytokine levels|2136|NCT00023595|January 2002
2396|Completed|Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission||Drug:Erythromycin;  Drug:Nevirapine;  Drug:Ampicillinsodium;  Drug:Metronidazole|Interventional|Phase 3|NIH||3720|NCT00021671|
2397|Completed|Treatment to Quit Smoking||Drug:Mecamylamine;  Drug:NicotinePatch;  Behavioral:Cigarettebrandswitching|Interventional|Phase 2|U.S. Fed|||NCT00018161|January 1997
2398|Completed|The Genetics of Environmental Asthma||Biological:LPSendotoxinsalineHDM|Interventional||NIH|BAL and endobronchial brush biopsy are measured and cell samples are analyzed to identify the genes in airway epithelia and inflammatory cells that are differentially expressed in response to LPS and dust mite antigen.RNA is isolated for gene expression.;  postbronchoscopysymptomfollowup|176|NCT00018096|June 2001
2399|Unknown&nbsp;&#8224;|Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen||Drug:rifabutin;  Drug:isoniazid;  Drug:efavirenz|Interventional||NIH / U.S. Fed|||NCT00018083|
2400|Completed|ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse||Drug:gefitinib|Interventional|Phase 2|Other / NIH|||NCT00016991|June 2001
2401|Completed|An Integrated Model of Primary Care in Mental Health||Procedure:Integratedmodelofprimarycare|Interventional||U.S. Fed||271|NCT00013260|
2402|Completed|Health Services Implications of a Teledermatology Consult System||Procedure:Teledermatology|Interventional||U.S. Fed||260|NCT00013234|
2403|Completed|Gemcitabine and Radiation Therapy in Treating Patients With Cancer of the Pancreas||Drug:gemcitabinehydrochloride;  Procedure:adjuvanttherapy;  Radiation:radiationtherapy|Interventional|Phase 2|Other / NIH|||NCT00010166|December 2000
2404|Terminated|Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer||Biological: therapeutic autologous dendritic cells|Interventional|Phase 1|Other / NIH||3|NCT00010127|November 2000
2405|Completed|Gemcitabine in Treating Patients With Advanced Colorectal Cancer||Drug:gemcitabinehydrochloride|Interventional|Phase 2|Other / NIH|||NCT00007943|September 2000
2406|Completed|Amyotrophic Lateral Sclerosis (ALS) Gulf War Study|||Observational||U.S. Fed / Other|Probability of ALS among veterans both deployed and non-deployed to the Gulf Region(8/2/1990-7/31/1991)|135|NCT00007722|July 2000
2407|Completed|To Determine the Prevalence of HIV and Other Related Infections Such as Hepatitis C Along With Associated Risk Behaviors in Patients With Severe Mental Illness (SMI).|||Observational||U.S. Fed|||NCT00007709|January 1998
2408|Completed|Finding Diabetes Mellitus Among Veterans|||Observational||U.S. Fed||1276|NCT00007696|April 1998
2409|Completed|The Identification of Prognostic Factors of Late Stage Disease Particularly Those That Are Modifiable That Might Explain the Worsened Prognosis With Colorectal Cancer Among Veterans.|||Observational||U.S. Fed|||NCT00007618|January 1998
2410|Completed|To Explore Racial Differences in Potential Risk Factors for Developing Prostate Cancer in the VA Population.|||Observational||U.S. Fed|||NCT00007579|February 1998
2411|Completed|Study of the Pharmacokinetics of Mycophenolate Mofetil in Patients Who Have Undergone Orthotopic Liver Transplantation||Drug:mycophenolatemofetil|Interventional||NIH / Other||20|NCT00007059|June 1998
2412|Completed|Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer||Drug:megestrolacetate;  Procedure:quality-of-lifeassessment|Interventional|Phase 3|Other / NIH|||NCT00006799|October 2000
2413|Completed|Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed Recurrent or Progressive Anaplastic Glioma||Drug:O6-benzylguanine;  Drug:temozolomide;  Procedure:conventionalsurgery|Interventional|Phase 1|Other / NIH|||NCT00006474|March 2001
2414|Unknown&nbsp;&#8224;|Phase I/II Trial of Doxil and Hyperthermia for Breast Cancer Patients With Chest Wall Recurrence or Stage IV Disease With Locally Advanced Breast Cancer||Drug:Doxil;  Procedure:heattreatment|Interventional|Phase 2|NIH|||NCT00006433|January 2000
2415|Completed|Acute Glycemic Effects of a Very Low Fat Diet in Type 2 Diabetes||Procedure:verylowfatdiet|Interventional||NIH / Other / Industry|||NCT00006432|January 2000
2416|Unknown&nbsp;&#8224;|Active Immunotherapy Of Metastatic Renal Cell Carcinoma Using Autologous Dendritic Cells Transfected With Autologous Total Tumor RNA||Biological:DCRCC-RNA|Interventional|Phase 1|NIH / Other|||NCT00006431|
2417|Unknown&nbsp;&#8224;|A Safety and Feasibility Study of Active Immunotherapy in Patients With Metastatic Prostate Carcinoma Using Autologous Dendritic Cells Pulsed With Antigen Encoded in Amplified Autologous Tumor RNA||Biological: Autologous dendritic cells transfected with amplified tumor RNA|Interventional|Phase 1|NIH / Other|||NCT00006430|
2418|Completed|Effectiveness of AZT and Nevirapine in Preventing HIV Transmission From Ugandan Mothers to Their Newborns||Drug:Nevirapine;  Drug:Zidovudine|Interventional|Phase 3|NIH||1500|NCT00006396|
2419|Completed|Genetic Study in Patients Receiving Treatment for Hodgkin&apos;s Disease or Childhood Brain Tumor||Genetic:chromosomaltranslocationanalysis;  Genetic:generearrangementanalysis;  Genetic:mutationanalysis|Observational||Other / NIH||19|NCT00006342|January 1997
2420|Completed|Hormonal Birth Control and the Risk of Acquiring HIV||Drug:Ethinylestradiol/levonorgestrel;  Drug:Medroxyprogesteroneacetate|Interventional||NIH||6360|NCT00006324|December 1999
2421|Completed|Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa|||Observational||NIH||125|NCT00006298|
2422|Completed|The Safety of Nevirapine When Given to Breast-Feeding Babies From Birth to Age 6 Months||Drug:Nevirapine|Interventional|Phase 1|NIH||75|NCT00006279|
2423|Completed|Safety and Tolerability of the Vaginal Gel PRO 2000/5||Drug:PRO2000|Interventional|Phase 1|NIH / Industry||60|NCT00006207|
2424|Completed|Capecitabine Paclitaxel and Trastuzumab in Treating Patients With Metastatic Breast Cancer||Biological:trastuzumab;  Drug:capecitabine;  Drug:paclitaxel|Interventional|Phase 1 / Phase 2|Other / NIH|||NCT00006108|August 1999
2425|Completed|A Study of Chlorhexidine in the Prevention of HIV-1 Transmission From Mothers to Their Babies||Drug:Chlorhexidinegluconate|Interventional|Phase 2|NIH||150|NCT00006075|
2426|Completed|Biological Therapy in Treating Patients With Advanced Cancer||Biological: HER-2/neu intracellular domain protein;  Biological: therapeutic autologous dendritic cells|Interventional||Other / NIH|Safety|3|NCT00005956|February 2000
2427|Completed|Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors||Drug:temozolomide|Interventional|Phase 2|Other / NIH|||NCT00005955|August 2000
2428|Completed|Temozolomide in Treating Patients With Brain Metastases||Drug:temozolomide|Interventional|Phase 2|Other / NIH|||NCT00005954|August 2000
2429|Completed|Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors||Biological:filgrastim;  Drug:temozolomide;  Procedure: peripheral blood stem cell transplantation|Interventional|Phase 1 / Phase 2|Other / NIH|Overallresponseat12months;  Disease-freesurvivalat12months;  Toxicity by NCI Common Toxicity Criteria v. 3.0 at 12 months;  Engraftment related to autologous marrow or peripheral blood stem cell transplantation at 12 months|30|NCT00005952|August 2000
2430|Completed|Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma||Drug:irinotecanhydrochloride;  Drug:temozolomide|Interventional|Phase 1|Other / NIH|||NCT00005951|August 2000
2431|Withdrawn|Genistein in Treating Patients With Stage II Stage III or Stage IV Prostate Cancer||DietarySupplement:genistein|Interventional|Phase 1|Other / NIH||0|NCT00005827|December 1999
2432|Completed|Vaccine Therapy in Treating Patients With Stage III or Stage IV Kidney Cancer||Biological: therapeutic autologous dendritic cells;  Procedure:conventionalsurgery|Interventional|Phase 1|Other / NIH||15|NCT00005816|February 2000
2433|Completed|Genetic Study of Patients With Primary Ciliary Dyskinesia|||Observational||NIH / Other||180|NCT00005650|February 2000
2434|Unknown&nbsp;&#8224;|Paclitaxel and Capecitabine in Treating Women With Metastatic Breast Cancer||Drug:capecitabine;  Drug:paclitaxel|Interventional|Phase 2|Industry|||NCT00005649|July 1998
2435|Active not recruiting|University of North Carolina Alumni Heart Study||Other:Thereisnointervention|Observational||Other / NIH|CoronaryHeartDisease|6340|NCT00005398|May 1996
2436|Completed|Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma||Drug:O6-benzylguanine;  Drug:carmustine|Interventional|Phase 2|Other / NIH|||NCT00005081|August 2000
2437|Unknown&nbsp;&#8224;|Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment||Drug:Ritonavir;  Drug:Abacavirsulfate;  Drug:Amprenavir;  Drug:Efavirenz;  Drug:Lamivudine;  Drug:Stavudine|Interventional|Phase 4|Industry||300|NCT00005017|
2438|Completed|Vitamin Therapy for Prevention of Stroke||Drug:pyridoxine;  Drug:cyanocobalamin;  Drug:folicacidmultivitamin|Interventional|Phase 3|NIH|||NCT00004734|September 1996
2439|Completed|Biological Therapy in Treating Patients With Metastatic Cancer||Biological:CEARNA-pulsedDCcancervaccine|Interventional|Phase 1|Other / NIH|Safety;  Immuneresponse|24|NCT00004604|February 1997
2440|Completed|Phase I/II Randomized Study of Hydroxyurea With or Without Clotrimazole in Patients With Sickle Cell Anemia||Drug:clotrimazole;  Drug:hydroxyurea|Interventional|Phase 1 / Phase 2|Other||20|NCT00004492|October 1999
2441|Completed|Randomized Study of Alendronate in Adult Patients With Cystic Fibrosis Related Osteoporosis||Drug:alendronatesodium;  Drug:calciumcarbonate;  Drug:cholecalciferol|Interventional||Other||60|NCT00004489|October 1998
2442|Suspended|Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis||Drug:bromocriptine;  Drug:sertralinehydrochloride|Interventional|Phase 2|NIH / Other||40|NCT00004300|
2443|Completed|Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer||Biological:PSARNA-pulseddendriticcellvaccine|Interventional|Phase 1 / Phase 2|Other / NIH||17|NCT00004211|July 1999
2444|Completed|DTGM Fusion Protein in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia||Biological:DTGMfusionprotein|Interventional|Phase 1 / Phase 2|Other / NIH|||NCT00003840|October 2000
2445|Completed|Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg||Drug:isolatedlimbperfusion;  Drug:melphalan;  Biological: recombinant tumor necrosis factor family protein;  Other:pharmacologicalstudy;  Other:laboratorybiomarkeranalysis|Interventional|Phase 3|NIH|CRproportion;  Incidence of adverse events graded according to NCI CTC version 2.0;  Localprogression-freesurvival;  Overallsurvival|216|NCT00003789|March 1999
2446|Completed|Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors||Drug:carmustine;  Drug:irinotecanhydrochloride;  Procedure:surgicalprocedure;  Radiation:iodineI131monoclonalantibody81C6|Interventional|Phase 1|Other / NIH||21|NCT00003484|September 1997
2447|Completed|Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors||Procedure:conventionalsurgery;  Radiation:iodineI131monoclonalantibody81C6;  Radiation:radiationtherapy|Interventional|Phase 1 / Phase 2|Other / NIH||10|NCT00003478|October 1997
2448|Completed|Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma||Drug:carmustine;  Drug:polifeprosan20withcarmustineimplant;  Procedure:surgicalprocedure|Interventional|Phase 2|Other / NIH||68|NCT00003467|January 1998
2449|Completed|Temozolomide in Treating Patients With Anaplastic Oligodendroglioma||Drug:temozolomide|Interventional|Phase 2|Other / NIH||60|NCT00003465|March 1998
2450|Completed|Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme||Drug:temozolomide;  Radiation:radiationtherapy|Interventional|Phase 2|Other / NIH||50|NCT00003464|September 1997
2451|Completed|Intrathecal Busulfan in Treating Patients With Recurrent Refractory or Metastatic Leptomeningeal Tumors||Drug:busulfan|Interventional|Phase 1|Other / NIH||20|NCT00003462|April 1998
2452|Completed|Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors||Procedure:surgicalprocedure;  Radiation: astatine At 211 monoclonal antibody 81C6|Interventional|Phase 1 / Phase 2|Other / NIH|||NCT00003461|February 1998
2453|Withdrawn|Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood Transplantation in Treating Patients Who Are HIV Positive and Have Hematologic Cancer||Biological:anti-thymocyteglobulin;  Drug:melphalan;  Procedure:antiviraltherapy;  Procedure: bone marrow ablation with stem cell support;  Procedure: peripheral blood stem cell transplantation;  Procedure:umbilicalcordbloodtransplantation;  Radiation:radiationtherapy|Interventional|Phase 1|Other / NIH||0|NCT00003435|May 1998
2454|Terminated|Biological Therapy in Stage I Stage II or Stage III Surgically Resected Pancreatic Cancer||Biological:carcinoembryonicantigenpeptide1;  Biological:hepatitisBantigenpeptide|Interventional|Phase 1|Other / NIH|ProgressionFreeSurvival|8|NCT00003434|June 1998
2455|Completed|Immunotherapy in Treating Patients With Resected Liver Metastases From Colon Cancer||Biological: carcinoembryonic antigen RNA-pulsed DC cancer vaccine|Interventional|Phase 1 / Phase 2|Other / NIH|||NCT00003433|June 1998
2456|Terminated|Immunotherapy in Treating Patients With Metastatic Breast Cancer||Biological: carcinoembryonic antigen RNA-pulsed DC cancer vaccine|Interventional|Phase 1 / Phase 2|Other / NIH|Evaluate the ability of active immunotherapy with carcinoembryonic antigen (CEA) RNA pulsed dendritic cells to induce CEA specific T cells in patients with metastatic breast cancer in complete remission following peripheral blood stem cell transplant.;  Determine the clinical efficacy in terms of overall and recurrence free survival of immunotherapy with CEA RNA pulsed dendritic cells in this patients population.|4|NCT00003432|June 1998
2457|Completed|Flt3L in Treating Patients With Metastatic Colorectal Cancer||Biological:recombinantflt3ligand|Interventional|Phase 1|Other / NIH|||NCT00003431|June 1998
2458|Completed|Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain||Drug:O6-benzylguanine;  Drug:carmustine|Interventional|Phase 1|Other / NIH||56|NCT00003348|May 1998
2459|Completed|Gemcitabine Plus Radiation Therapy or Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer||Drug:cisplatin;  Drug:gemcitabinehydrochloride;  Radiation:radiationtherapy|Interventional|Phase 1 / Phase 2|Other / NIH|&#8226;Determine the maximum tolerated dose of twice-weekly gemcitabine when delivered concurrently with thoracic radiotherapy;  assess the efficacy of dose of twice-weekly gemcitabine when delivered concurrently with thoracic radiotherapy|40|NCT00003202|January 1998
2460|Completed|Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma||Drug:carmustine;  Drug:irinotecanhydrochloride|Interventional|Phase 1|Other / NIH||36|NCT00002988|April 1997
2461|Completed|Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced or Metastatic Cancer of the Esophagus||Drug:cisplatin;  Drug:fluorouracil;  Drug:paclitaxel;  Procedure:surgicalprocedure;  Radiation:radiationtherapy|Interventional|Phase 1 / Phase 2|Other / NIH|MaximumToleratedDose;  Numberofsubjectsexperiencingadverseevents;  Efficacyoftreatment|26|NCT00002984|March 1997
2462|Completed|Carboplatin Etoposide Cyclophosphamide and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer||Drug:carboplatin;  Drug:cyclophosphamide;  Drug:etoposide;  Procedure:autologousbonemarrowtransplantation|Interventional|Phase 2|Other / NIH|To investigate the response rate High Dose Carboplatin Etoposide Cyclophosphamide and Autologous Transplantation;  evaluate toxicity of High Dose Carboplatin Etoposide Cyclophosphamide and Autologous Transplantation|11|NCT00002943|February 1993
2463|Completed|Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer||Procedure:autologousbonemarrowtransplantation;  Procedure: peripheral blood stem cell transplantation|Interventional|Phase 3|Other / NIH||136|NCT00002942|June 1996
2464|Completed|High-Intensity Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia||Biological:filgrastim;  Drug:cyclophosphamide;  Drug:cytarabine;  Drug:dexamethasone;  Drug:doxorubicinhydrochloride;  Drug:etoposide;  Drug:ifosfamide;  Drug:leucovorincalcium;  Drug:mesna;  Drug:methotrexate;  Drug:therapeutichydrocortisone;  Drug:vincristinesulfate;  Radiation:low-LETcobalt-60gammaraytherapy;  Radiation:low-LETphotontherapy|Interventional|Phase 2|Other / NIH|response rate for patients with relapsed or refractory acute lymphoblastic leukemia after brief high intensity chemotherapy;  evaluate adverse events after brief high intensity chemotherapy|25|NCT00002865|April 1995
2465|Unknown&nbsp;&#8224;|Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer||Biological:aldesleukin;  Biological:recombinantinterferonalfa;  Procedure:conventionalsurgery|Interventional|Phase 2|Other||14|NCT00002847|September 1995
2466|Unknown&nbsp;&#8224;|Interleukin-2 in Treating Patients With Metastatic or Recurrent Kidney Cancer||Biological:aldesleukin;  Procedure:conventionalsurgery|Interventional|Phase 2|Other||14|NCT00002846|September 1995
2467|Unknown&nbsp;&#8224;|Interleukin-2 in Treating Patients With Metastatic Melanoma||Biological:aldesleukin|Interventional|Phase 2|Other||20|NCT00002845|September 1995
2468|Completed|Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors||Biological:monoclonalantibodyMe1-14F(ab&apos;)2|Interventional|Phase 1|Other / NIH||6|NCT00002754|February 1993
2469|Completed|Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas||Radiation:iodineI131monoclonalantibody81C6|Interventional|Phase 1|Other||6|NCT00002753|November 1991
2470|Completed|Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers||Radiation:iodineI131monoclonalantibody81C6|Interventional|Phase 1 / Phase 2|Other|||NCT00002752|February 1993
2471|Completed|Monoclonal Antibody Therapy in Treating Patients With Brain Metastases||Biological:monoclonalantibodyMe1-14F(ab&apos;)2|Interventional|Phase 1 / Phase 2|Other||6|NCT00002751|July 1989
2472|Completed|Melphalan in Patients With Neoplastic Meningitis||Drug:melphalan|Interventional|Phase 1|Other||6|NCT00002750|December 1992
2473|Completed|A Study of Amprenavir in Patients With Protease Inhibitor-Related Complications||Drug:Amprenavir|Interventional||Industry|||NCT00002417|
2474|Completed|A Study of Amprenavir in HIV-Infected Patients||Drug:Amprenavir|Interventional||Industry|||NCT00002405|
2475|Completed|The Safety and Effectiveness of Retrovir in HIV-Infected Patients Who Have Problems Related to the Nervous System||Drug:Zidovudine|Interventional||Industry|||NCT00002288|
2476|Completed|A Study of Retrovir in the Prevention of HIV Infection in Health Care Workers Accidentally Exposed to the Virus||Drug:Zidovudine|Interventional||Industry|||NCT00002287|
2477|Completed|A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients||Drug:Zidovudine|Interventional||Industry|||NCT00002286|
2478|Completed|A Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients With AIDS||Drug:Zidovudine|Interventional||Industry|||NCT00002285|
2479|Completed|An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen||Drug:Abacavirsulfate;  Drug:Amprenavir|Interventional||Industry|||NCT00002205|
2480|Completed|A Study of 1592U89 in HIV-Infected Adults||Drug:Abacavirsulfate|Interventional||Industry|||NCT00002200|
2481|Completed|A Study of 1592U89 and Ethanol When Given Together to HIV-Infected Patients||Drug:Abacavirsulfate|Interventional|Phase 1|Industry|||NCT00002198|
2482|Completed|A Study of 1592U89 in HIV-Infected Children||Drug:Abacavirsulfate|Interventional||Industry||250|NCT00002197|
2483|Completed|A Prospective Double-Blind Study of Retrovir in Early HIV Infection||Drug:Zidovudine|Interventional||Industry|||NCT00002045|
2484|Completed|A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases||Drug:Zidovudine|Interventional||Industry|||NCT00002044|
2485|Completed|An Oral Dose-Ranging Finding Study in Patients With HIV Disease CDC Classification Groups IIB III and IV-C2||Drug:Zidovudine|Interventional||Industry|||NCT00002023|
2486|Completed|A Treatment IND for 566C80 Therapy of Pneumocystis Carinii Pneumonia||Drug:Atovaquone|Interventional||Industry|||NCT00001991|
2487|Completed|An Open-Label Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral Pentamidine||Drug:Atovaquone|Interventional||Industry|||NCT00001990|
2488|Completed|A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons||Biological: HIV-1 C4-V3 Polyvalent Peptide Vaccine|Interventional|Phase 1|NIH / Industry||30|NCT00001060|
2489|Completed|A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes||Drug:Zidovudine;  Drug:Aldesleukin|Interventional|Phase 1|NIH||30|NCT00001005|
2490|Completed|A Study of Zidovudine in the Prevention of HIV Infection in Individuals Exposed to the Virus||Drug:Zidovudine|Interventional||NIH|||NCT00000993|
2491|Completed|A Study of Nonoxynol-9 (N-9) and HIV Infection||Drug:Nonoxynol-9|Interventional|Phase 3|NIH||4400|NCT00000926|
2492|Completed|A Treatment IND for Retrovir Brand Zidovudine (AZT) Therapy of Pediatric Patients With HIV Disease||Drug:Zidovudine|Interventional||NIH / Industry|||NCT00000662|
2493|Completed|Behavioral Insomnia Therapy for Fibromyalgia||Behavioral:Behavioralinsomniatherapy|Interventional||Other / NIH||106|NCT00000397|July 1999
2494|Recruiting|iOmit: Reducing Intentional Insulin Misuse in Type 1 Diabetes||Behavioral:TherapywithMobileAppEnhancement;  Device:RecoveryRecord(RR)Mobileapp|Interventional||Other / NIH|MetabolicControl(ChangeinHbA1c);  MobileTechnologyEngagement(FrequencyofUse);  AdequateInsulinDosing(Frequency);  Medical Utilization: Total Number of Primary Care Visits;  Medical Utilization: Total Number of Emergency Department Care Visits;  Participant Engagement in Treatment as evidenced by attendance/treatment completion;  Improvement in Metabolic Control; CGM Continuous Glucose Monitoring;  Decrease in Diabetes-Specific Eating Disorder symptomatology;  Decrease in Overall Eating Disorder symptomatology|60|NCT02980627|March 2016
2495|Recruiting|Virtual vs. Traditional Physical Therapy Following Total Knee Replacement||Device: Virtual physical therapy rehabilitation program;  Other:Nointervention|Interventional||Other / Industry|Costdifference;  Knee Injury and Osteoarthritis Outcome Score (KOOS);  Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health Score;  Numberoffalls;  Re-hospitalization|300|NCT02914210|November 2016
2496|Not yet recruiting|Abuse Liability of Reduced Nicotine Content Cigarettes in the Context of Concurrent E-Cigarette Use||Drug: Smoking research cigarettes with e-cigarette|Interventional||Industry / NIH / U.S. Fed|Mean number of research cigarettes smoked per day as primary index of abuse liability;  Nicotine discrimination tests to determine detection recognition and difference thresholds;  Extent of e-cigarette use based on self-report and cotinine levels|320|NCT02870218|January 2017
2497|Recruiting|Tourniquet Pressure in Primary Total Knee Arthroplasty||Procedure:TourniquetCuffPressure|Interventional||Other|PostoperativePain;  EstimatedBloodLoss;  RangeofMotion;  Intra-operativeBloodlessness;  WoundHealingIssues;  NeedforRevisionofTotalKneeArthroplasty;  AbilitytoAmbulate;  QuadricepsStrength;  NeedforManipulationUnderAnesthesia|146|NCT02830087|June 2016
2498|Recruiting|Phase I Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of NTM-1632||Biological:NTM-1632;  Other:Placebo|Interventional|Phase 1|NIH|The occurrence of Adverse Events from administration of NTM-1632;  The occurrence of changes from baseline in clinical safety laboratory values following administration of NTM-1632;  The occurrence of changes from baseline in ECG parameters post administration of NTM-1632;  The occurrence of changes from baseline in physical examination following administration of NTM-1632;  The occurrence of changes from baseline in vital signs following administration of NTM-1632;  The occurrence of Serious Adverse Events following administration of NTM-1632;  The assessment of area-under-the-curve for concentration vs time (AUC(0-t)) for each of the three monoclonal antibodies of NTM-1632;  The assessment of maximum plasma titer/concentration (Cmax) for each of the three monoclonal antibodies of NTM-1632;  The assessment of time to maximum concentration (Tmax) for each of the three monoclonal antibodies of NTM-1632;  The presence of human anti-human antibodies in 0.165 mg/kg and 0.33 mg/kg dosing cohorts;  The presence of human anti-human antibodies in all dosing cohorts|24|NCT02779140|August 2016
2499|Active not recruiting|Stress and Coping in Caregivers of Younger Patients With Cancer||Other:LaboratoryBiomarkerAnalysis;  Other:PhysiologicTesting;  Other:QuestionnaireAdministration|Observational||Other / NIH|Level of Caregiver Distress as measured by multiple regressions analysis|163|NCT02725385|March 2014
2500|Recruiting|Technology Enhanced Behavioral Activation Treatment for Substance Use||Behavioral:LETSACT;  Behavioral:LETSACT-SE;  Behavioral:TreatmentasUsual|Interventional|Phase 2|Other / NIH|TimelineFollowback(TLFB);  Psychiatric Research Interview for Substance and Mental Disorders (PRISM-5);  ShortFormHealthSurvey(SF-12);  BehavioralActivationforDepressionScale(BADS);  DailyGoalsForm;  RewardProbabilityIndex(RPI);  Texas Christian University (TCU) HIV/AIDS Risk Assessment Form;  DrugUseHistoryQuestionnaire(DUQ);  Urinalysis;  Breathalyzer;  BeckDepressionInventory-II(BDI-II)|300|NCT02707887|January 2016
2501|Recruiting|To Determine the Measurement Properties of the ACT in an African American Adolescent Population With Persistent Asthma|||Observational||Other|Cohen&apos;skappa;  SensitivityofACTQuestionnaire|80|NCT02671643|October 2014
2502|Recruiting|To Determine the Validity of the ACT in an Adolescent Population With Persistent Asthma||Other:ValidationofAsthmaControlQuestionnaire|Observational||Other|Cohen&apos;skappa;  SensitivityofACTQuestionnaire;  SpecificityofACTQuestionnaire|80|NCT02662413|January 2016
2503|Recruiting|Ibrutinib in Treating Patients With Refractory Stage IV Cutaneous Melanoma||Drug:Ibrutinib;  Other:LaboratoryBiomarkerAnalysis;  Other:PharmacogenomicStudy|Interventional|Phase 2|NIH|Antitumor response defined as the sum of complete response and partial response evaluated by RECIST criteria 1.1;  OS;  PFS|32|NCT02581930|August 2016
2504|Recruiting|Human Prostate Tissue Model to Maintain and Study Prostate Cancer Stem Cells||Other:CytologySpecimenCollectionProcedure;  Other:LaboratoryBiomarkerAnalysis|Observational||Other / NIH|Percentofviableinjectedcells;  Abilitytomakespheres(clusterofcells);  Ratioofspherestotheamountofinjectedcells;  Numberofalivecells(usingflowcytometry);  Percentage of the TROP2 positive cells (using flow cytometry);  Ability of cells to make glandular structures by observing the structure under microscope and performing immunostaining for epithelial markers like E-Cadherin beta-catenin;  NumberofCSCs|60|NCT02425800|March 2015
2505|Completed|A Study of a Self-Administered Memory Screening Test With Automated Reporting (SAMSTAR) in Participants With Mild Cognitive Impairment||Other:SAMSTAR;  Other:RAVLT|Observational|Phase 0|Industry|Cognitive Evaluation by Self-administered memory screening test with automated reporting (SAMSTAR);  Cognitive Evaluation by Rey Auditory Verbal Learning Test (RAVLT);  AssessthefeasibilityofSAMSTAR|153|NCT02419183|May 2015
2506|Recruiting|Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection||Drug:DTG/3TC/ABCFDC|Interventional||Other / Industry / NIH|Viralloadmeasurementof&lt;200copies/mL;  Occurrence of Grade 3 or higher adverse event (AE);  Virologic efficacy of DTG/3TC/ABC FDC given once daily to participants with acute HIV as determined by the proportion of treated participants with HIV-1 RNA to &lt;50 copies/mL;  Rate of virologic decline in the first 24 weeks of treatment|40|NCT02384395|September 2015
2507|Completed|Biomarkers of Aging as Predictors of Kidney Transplant Function||Other:Notreatment|Observational||Industry / Other|Slow graft function (SGF; decline in serum creatinine &gt;20% within 24h after transplant no dialysis);  Delayed graft function (DGF; need for dialysis during first week after transplant);  Long-term graft function measured by change in serum creatinine (delta1-12eGFR);  Long-term graft function measured by change in serum creatinine (delta1-6eGFR)|35|NCT02335333|January 2015
2508|Recruiting|Effect of Feedings on Caffeine in Premature Infants||Drug:Caffeine|Observational||Other|Clearance(CL)ofcaffeineatsteadystate;  Volume of distribution (V) of caffeine at steady state;  Caffeine metabolizing enzyme activity using urinary metabolic ratios;  Fold change in caffeine clearance due to hypoxia hypotension and infections|50|NCT02293824|December 2014
2509|Withdrawn|Ciprofloxacin Compared to Placebo in Diagnosing Prostate Cancer in Patients Undergoing Prostate Biopsy||Drug:ciprofloxacin;  Other:placebo;  Other:quality-of-lifeassessment;  Other:laboratorybiomarkeranalysis|Interventional|Phase 2|Other / NIH|Prostatecancerdetectionrates;  ChangeinPSA;  Rates of post-biopsy complications (including duration of hematuria hematochezia hematospermia fever &gt; 101&#176;F and hospital admission rates related to biopsy sepsis and pain)|0|NCT02252978|December 2015
2510|Recruiting|Detection of Brown Adipose Tissue by Magnetic Resonance Imaging|||Observational||Other|Averagedicesimilaritycoefficient|24|NCT02237872|September 2014
2511|Completed|Nicotinamide Safety Study||Drug:Nicotinamide|Interventional|Phase 1|Other|Measurement of safety of vitamin B3-amide (nicotinamide) 500mg dietary supplementation during expectant management of EOP (early onset preeclampsia);  Measurement of safety of vitamin B3-amide (nicotinamide) 1000mg dietary supplementation during expectant management of EOP|10|NCT02213094|October 2013
2512|Withdrawn|Cortical Metrics in Intervention Trials With Autism Spectrum Disorders||Drug:Dextromethophan|Interventional|Phase 2 / Phase 3|Other|The difference in the Cortical Metric before and after acute exposure to dextromethorphan (DXM);  Changeinthecorticalmetric;  TheCorticalMetric;  AberrantBehaviorChecklist(ABC)TotalScore;  Pervasive Developmental Disorders Behavior Inventory - Screening Version Score (PDDBI-SV) Social Deficit Score;  Social Responsiveness Scale Version 2 Total Score (SRS)|0|NCT02212275|August 2015
2513|Completed|Integrative Health Coaching in Community Settings||Behavioral:IntegrativeHealthCoaching|Interventional||Other|Subjectattritionrate;  Duration(inminutes)ofcoachingsessions.;  Subject and site personnel process evaluation (reach effectiveness adoption implementation and maintenance (RE-AIM)) following intervention completion;  Changeinpatientactivation;  Change in subject perception of interpersonal support;  Changeinbodymassindex|74|NCT02186327|August 2014
2514|Terminated|Comparison of Combination Therapy vs Single Agent Therapy for Treatment of Urge Incontinence.||Drug:Oxybutyninextendedrelease;  Device:PosteriorTibialNerveStimulation;  Drug:Placebo|Interventional|Phase 4|Other|ChangeinmeannumberofUUIepisodesperday;  Changein24hrpadweight|36|NCT02176642|August 2014
2515|Recruiting|Respiratory Event-Related Potentials in Patients With Spinal Cord Injury|||Observational||Other|Event-RelatedPotentials;  GeneralHealthStatus|40|NCT02163551|June 2014
2516|Completed|EF5 in Measuring Tumor Hypoxia in Patients With Stage I-III Non-Small Cell Lung Cancer||Drug:EF5;  Other:LaboratoryBiomarkerAnalysis;  Procedure:TherapeuticConventionalSurgery;  Other:TissueOxygenMeasurement|Interventional|Phase 2|NIH|Frequency and degree of hypoxia using a polarographic needle electrode;  Serum/plasmamarkersofhypoxia;  Tissuemarkersofhypoxia;  Tumor perfusion using dynamic positron emission tomography|28|NCT02154399|May 2002
2517|Completed|A Public Health Program to Reduce Risk of Antepartum Depression||Behavioral: Insight-Plus Cognitive Behavioral Intervention|Interventional||Other / NIH|Mean change in Edinburgh Postpartum Depression Scale (EPDS) Scores from baseline to post intervention and 1-month follow-up;  Mean change in antepartum Beck Depression Inventory (BDI-II) Scores from baseline to post intervention and 1-month follow-up|146|NCT02144844|December 2010
2518|Active not recruiting|H.O.P.E: Helping Ovarian Cancer Patients Cope||Other:StructuredPalliativeCare;  Other:UsualCare|Interventional||Other|QualityofLife|50|NCT02090582|April 2014
2519|Recruiting|Feeling and Body Investigators||Behavioral: Feeling and Body Investigators with Functional Abdominal Pain;  Behavioral:TreatmentStrategies|Interventional||Other|PercentageofParticipantsWhoCompleteTreatment;  Percentage of Participants Completing Homework Assignment|126|NCT02075437|March 2014
2520|Completed|Study Evaluating the Digestibility of Serum-Derived Bovine Immunoglobulin Protein Isolate in Healthy Adults||Other: Serum-derived bovine immunoglobulin protein isolate (SBI);  Other:MatchingPlacebo|Interventional||Industry|AminoAcidMetabolism;  BovineIgGPlasmaConcentration;  BovineIgGConcentrationinStool|42|NCT02017405|December 2013
2521|Completed|Patient Self-management and Gene Guided Therapy for Chronic Hepatitis C|||Observational||Other|ChangeinSelfManagement|20|NCT02006823|March 2012
2522|Terminated                  Has Results|A Study To Evaluate The Safety And Effects On The Body Of An Investigational Drug Using An Endotoxin-Induced Inflammatory Response Model||Drug:PF-06282999;  Drug:Placebo;  Other:LPS|Interventional|Phase 1|Industry|Peak Myeloperoxidase (MPO) Activity Following Inflammatory Stimulus;  MPO Activity (Area Under the Concentration-time Profile From 0.5 to 2 Hours [AUC0.5-2hrs]) Following Inflammatory Stimulus;  MPO Activity (Area Under the Concentration-time Profile From 0 to 2 Hours [AUC0-2hrs]) Following Inflammatory Stimulus;  Number of Participants With Treatment-emergent Adverse Events (TEAEs) Serious Adverse Events (SAEs) and Withdrawals Due to TEAEs;  Number of Participants With Laboratory Test Abnormalities;  Number of Participants With Change From Baseline and Absolute Values in Vital Signs Meeting Categorical Summarization Criteria;  Number of Participants With Electrocardiogram (ECG) Values Meeting Categorical Summarization Criteria;  Number of Participants With Abnormal Urinary Biomarker Values;  Concentrations of TNF-alpha IL-1 Beta IL-6 IL-8 and hsCRP;  Peak (AUC0.5-2hours and AUC0-2hours) of MPO Activity/MPO Mass;  Maximum Plasma Concentration (Cmax) of PF-06282999;  Area Under the Concentration-time Profile From Time 0 to End of Dosing Interval Tau (AUCtau) of PF-06282999;  TimetoCmax(Tmax)ofPF-06282999|23|NCT01965600|March 2014
2523|Completed                  Has Results|Transcranial Current Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia||Device:tDCS;  Device:Shamstimulation|Interventional||Other|Change in Auditory Hallucination Rating Scale (AHRS)Score From Baseline to Day 5;  PersistenceofDecreaseinAHRSScoreOverTime|26|NCT01963676|January 2014
2524|Recruiting|Adolescent Vaccination in Pharmacies||Drug:HPVvaccine|Observational||Other / Industry|Parents&apos; willingness to get their adolescent children HPV vaccine in pharmacy;  Parents&apos; satisfaction with HPV vaccine vaccine administration in the pharmacy|1704|NCT01960088|July 2015
2525|Recruiting|Muscle Progenitor Cell Therapy for Urinary Incontinence||Biological:AutologousMuscleProgenitorCells|Interventional|Phase 1 / Phase 2|Other|Incidence of treatment-related serious adverse events and the incidence of protocol defined treatment or procedure related adverse events;  changeinIncontinenceAssessmentbypadtest;  change in Number of incontinence episodes and pads used per day;  changeinUrogenitaldistressandqualityoflife|10|NCT01953315|January 2014
2526|Completed|Therapeutic Plasma Exchange in MG||Other:Skinbiopsy;  Other:SingleFiberElectromyography|Observational||Other / Industry|Immunoglobulinlevels;  Lymphocytesubpopulations;  SFEMG;  Vaccination/protectiveantibodies;  ClinicalOutcomesAssessments|11|NCT01927692|July 2013
2527|Completed|Human Papilloma Viruses (HPV) Vaccine Adherence Community Clinic Study||Behavioral:HPVVaccineElectronicReminders|Interventional||Other|Vaccine Adherence as measure by receiving the 3 recommended doses withing a 6 month time period.;  HPV Knowledge as measured by a 20% increase in knowledge about HPV and HPV vaccine among the intervention group.|522|NCT01908517|August 2013
2528|Completed|Statin Therapy to Improve Medication Adherence||Genetic: Genetic testing and reporting for SLCO1B1*5 allele|Interventional|Phase 1|Other|ChangeinBeliefsaboutMedicines;  ChangeinMedicationadherence;  Percentage of patients who meets their National Cholesterol Education Program (NCEP) low-density lipoprotein cholesterol (LDLc)goals;  Numberofnewstatinprescriptionswritten;  Patient reported medication utilization as a surrogate for medication adherence|63|NCT01894217|May 2011
2529|Active not recruiting|Functional Movement Retraining After Hip Replacement||Behavioral:FunctionalMovementRetraining|Interventional||U.S. Fed / Other|Change in Hip disability and osteoarthritis outcomes score (HOOS);  Change in Satisfaction with physical function questionnaire;  Globalassessmentofhipsymptomchange;  Change in Objective functional test: Timed get up-and-go;  ChangeinObjectivefunctionaltest:Sittostand;  Change in Objective functional test: Walking speed;  Change in Objective functional test: Stair climbing;  Change in University of California Los Angeles (UCLA) activity questionnaire;  ChangeinHarrishipscore(HHS);  ChangeinLowerquarterY-balancetest(YBT-LQ)|15|NCT01878175|May 2014
2530|Completed|Keys to Healthy Family Child Care Homes||Behavioral: Keys to Healthy Family Child Care Homes|Interventional||Other / NIH|ChangeinChildPhysicalActivity;  ChangeinChildDietaryIntake;  ChangeinChildBodyMassIndex;  ChangeinProviderPhysicalActivity;  ChangeinProviderDietaryIntake;  ChangeinProviderBodyMassIndex;  Change in Provider Motivation for Providing Children with Physical Activity and Healthy Eating Opportunities;  Change in Provider Self-Efficacy for Physical Activity and Healthy Eating;  ChangeinProviderSocialSupport;  Change in Physical Activity- and Nutrition-Related Environmental Characteristics of Family Child Care Home;  ChangeinChildWaistCircumference|805|NCT01814215|April 2013
2531|Completed|Optimizing Outcomes in Women With Gestational Diabetes Mellitus and Their Infants||Behavioral:Intervention|Interventional||Other / NIH|fastingbloodglucose;  weight(bodymassindex);  oralglucosetolerancetest;  insulinlevels;  homeostasismodelassessment;  hemoglobinA1c;  completelipidpanel;  bloodpressure;  adiposity;  healthbehaviors;  self-efficacy;  infantweightstatus;  breastfeeding|200|NCT01809431|May 2012
2532|Completed|Characterizing and Comparing the Profile of Microorganisms From Specific Body Sites and Environmental Surfaces in Newly Disinfected Patient Rooms||Other:Nointervention|Observational||Other / U.S. Fed|Changes in the Profile of Epidemiologically-Important Organism;  Time to Change in the Profile of Epidemiologically Important Organism|80|NCT01803100|January 2013
2533|Completed|A Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude||Drug:Aminophylline400mg;  Drug:Ambrisentan5mg;  Other:Placebo|Interventional|Phase 1|Other / U.S. Fed|The safety of combined or single-dose aminophylline and ambrisentan at simulated high altitude in resting human subjects;  The safety of combined or single-dose aminophylline and ambrisentan at simulated altitude in exercising human subjects;  The efficacy of combined aminophylline and ambrisentan to improve exercise capacity under simulated high altitude;  The influence of simulated high altitude on pharmacokinetic profiles and drug interaction of aminophylline and ambrisentan|92|NCT01794078|September 2013
2534|Completed|Parent Treatment for Child Social Adjustment||Behavioral:SSGRIN-ParentGuide|Interventional||Other / NIH|Children&apos;ssocialskills;  Parental child and dyadic behavioral observations|240|NCT01765166|January 2010
2535|Completed                  Has Results|Cholesterol Medication Packaging Study||Behavioral:packaging|Interventional||U.S. Fed|CholesterolMedicationAdherence;  Change in LDL Cholesterol Level as Measured at Baseline 6months 12months|240|NCT01744977|December 2012
2536|Active not recruiting|Donepezil Compared to Placebo in Patients With Chronic Neuropathic Pain||Drug:Donepezil;  Drug:Placebo|Interventional|Phase 4|Other / NIH|PainIntensity|33|NCT01743976|December 2012
2537|Completed|FITShop: Promoting Physical Activity in Black Barbershops||Behavioral:YourMove(physicalactivity);  Other:YourMoney(financialempowerment)|Interventional||Other|Changeinphysicalactivitymeasures;  Changeinsmokingstatus;  Changeinweight/BMI;  Changeinwaistcircumference;  Changeinrestingheartrate;  Changeinbloodpressure;  Changeinaerobicfitnesslevel;  Changeinpsycho-socialvariables;  Changeinbarber-customerinteractions;  Changeinbarbershopcharacteristics|628|NCT01699321|July 2012
2538|Active not recruiting|Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet||Drug:(FDC)ELV/COBI/FTC/TDF|Interventional|Phase 3|Other|viral load measurement of &lt;200 copies/mL at week 24;  virologic efficacy of the fixed dose combination (FDC) ELV/COBI/FTC/TDF given once daily to participants with acute HIV infection as determined by the proportion of treated participants with HIV-1 RNA to &lt;50 copies/mL at week 48|30|NCT01694420|September 2012
2539|Completed|Internet-Based Osteoarthritis Pain Coping Skills Intervention||Behavioral:PainCOACH|Interventional|Phase 3|Other / NIH|Changeinpainintensity;  Changeinpain-relatedanxiety;  Change in pain-related interference with functioning;  Changeinbodilyrelaxation;  Changeinproblemsolvingskills;  Changeinemotionaladjustment;  ProgramUsability;  Numberofparticipantsrecruited;  Numberofparticipantswhocompletethestudy;  Number of participants who adhere to study protocol;  Medication type and frequency of use during the past week;  Changeinanduseofpaincopingstrategies;  Personality;  Changeinself-efficacyforpainmanagement;  Changeinsocialsupport|113|NCT01638871|October 2012
2540|Completed                  Has Results|Use of FeNO to Identify Eosinophilic Inflammation in Patients Age 40 Years and Above With Chronic Obstructive Airways Disease||Device:NIOXMINO&#174;Instrument(09-1100)|Observational||Industry|SpirometryResults:FEV1(L);  SpirometryResults:FVC(L);  SpirometryResults:FEV1(%Predicted);  SpirometryResults:FEF50%(L/Sec);  SpirometryResults:FEF25-75(L/Sec);  SpirometryResults:PEF(L/Min);  FeNOLevelsbyGOLDStageofSeverity;  FeNOLevelsbyInhaledCorticosteroidUse;  FeNOLevelsbySmokingStatus;  FeNOLevelsbyICD9CodeCategory;  MeanFeNOLevelsbyICD9CodeCategory|200|NCT01634620|June 2012
2541|Suspended|Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability||Procedure: Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution&#8482;;  Device:STEENSolution&#8482;|Interventional|Phase 2|Other / NIH / Industry|30DayMortalityandGraftSurvival;  PrimaryLungGraftDysfunction(PGD);  ICULengthofStay;  Day7Ventilator/ECMOStatus;  Recipientmortalityat12months.;  Bronchiolitis Obliterans Syndrome (BOS) free graft survival.|10|NCT01615484|September 2013
2542|Terminated                  Has Results|Tailored Smoking Cessation Treatment for LIVE FOR LIFE&#174; Participants||Drug:varenicline(Chantix);  Drug:bupropion(Zyban);  Drug:nicotinepatches|Interventional|Phase 2 / Phase 3|Other / Industry|Cost-effectiveness of the Adaptive Treatment Approach to Smoking Cessation;  QuitSuccessGenotypeScore|19|NCT01560507|May 2012
2543|Completed|Examining Adolescent Assessment Feedback Incentive and Exchange (AFIX) in North Carolina||Other: Assessment  Feedback Incentives and eXchange Program|Interventional||Other|Change in Vaccination Rate: HPV vaccine initiation among 11-12 year olds;  Change in Vaccination Rate: HPV vaccine initiation among 13-18 year olds;  Change in Vaccination Rate: Tdap vaccine among 11-12 year olds;  Change in Vaccination Rate: Tdap vaccine among 13-18 year olds;  Change in Vaccination Rate: Meningitis vaccine among 11-12 year olds;  Change in Vaccination Rate: Meningitis vaccine among 13-18 year olds;  Change in Vaccination Rate: HPV vaccine completion among 11-12 year olds;  Change in Vaccination Rate: HPV vaccine completion among 13-18 year olds|91|NCT01544764|April 2011
2544|Active not recruiting|Safety Efficacy and Dosing of Stereotactic Radiosurgery for Hepato-cellular Carc/Colo-rectal Liver Metastases||Radiation: Stereotactic Radiosurgery using the CyberKnife System.|Interventional|Phase 1|Other|Tolerable Doses of Radiation in Patients with Liver Cancer or Metastases to the Liver in Patients with Good vs. Compromised Liver Function.;  Tumor Response to Doses of Radiation in Patients with Liver Cancer or Metastases to the Liver in Patients with Good vs. Compromised Liver Function.|30|NCT01528878|April 2009
2545|Completed|Engaging Latino Families in Eating Disorders Treatment||Behavioral:CognitiveBehavioralTherapy;  Behavioral: Cognitive Behavioral Therapy with Family Enhancement|Interventional||Other / NIH|Change from Baseline in Eating Disorder Examination (EDE) Scores at End of Treatment;  Change from Baseline in Beck Depression Inventory-Revised (BDI-R) score at Week 6 of Treatment;  Change from Baseline in Beck Depression Inventory-Revised (BDI-R) score at End of Treatment;  Change from Baseline in Beck Depression Inventory-Revised (BDI-R) score at 3 Month Follow-up;  Change from Baseline in the Symptom Checklist-36 (SCL-36) score at Week 6 of Treatment;  Change from Baseline in Symptom Checklist-36 (SCL-36) score at End of Treatment;  Change from Baseline in Symptom Checklist-36 (SCL-36) score at 3 Month Follow-up;  Change from Baseline in Family Support Questionnaire score at End of Treatment;  Change from Baseline in Family Support Questionnaire score at 3 Month Follow-up;  Change from Baseline in Family Cohesion (FC) score at End of Treatment;  Change from Baseline in Family Cohesion (FC) score at 3 Month Follow-up;  Change from Baseline in Family Burden Interview Scale (FBIS) score at End of Treatment;  Change from Baseline in Family Burden Interview Scale (FBIS) score at 3 Month Follow-up;  Change from Baseline in Family Score (FS) at End of Treatment;  Change from Baseline in Family Score (FS) at 3 Month Follow-up;  TreatmentAdherenceasofEndofTreatment;  Change from Baseline in Eating Disorder Examination Questionnaire (EDE-Q) score at Week 6 of Treatment;  Change from Baseline in Eating Disorder Examination Questionnaire (EDE-Q) score at End of Treatment;  Change from Baseline in Eating Disorder Examination Questionnaire (EDE-Q) score at 3 Month Follow-up|25|NCT01470508|August 2010
2546|Completed|Mechanistic Evaluations of Pre-Cessation Therapies for Smoking Cessation||Drug:Varenicline;  Drug:Bupropion;  Drug:Nicotinepatches;  Other:Placebovarenicline;  Other:Placebobupropion;  Other:Placebopatch|Interventional|Phase 3|Other / NIH|The amygdala and ventral anterior cingulate gyrus (vACG) scans will be compared to evaluate significant differences;  Days to First Cigarette Following Quitting Smoking|282|NCT01406223|July 2011
2547|Completed|Mother Sibling Interactions Following Very Low Birth Weight (VLBW) Infant Homecoming|||Observational||Other / NIH|Differences in level of maternal worry in mothers of very low birthweight (VLBW) infants compared to mothers of full-term infants;  Differences in mother-sibling interaction between two groups;  Differences in internalizing and externalizing behaviors between two groups;  Effects of maternal worry anxiety depression and Post-Traumatic Stress Disorder (PTSD) on two groups;  Change in mother-sibling interactions between groups|300|NCT01385254|January 2010
2548|Completed|Peripheral Intravenous Catheter Complication Rate Comparison of Two Different Catheter-Stabilization Systems|||Observational||Industry|PIVCathetercomplicationrates;  Costeffectiveness|682|NCT01382524|June 2011
2549|Completed                  Has Results|Study of Biotene OralBalance Gel for Oral Care in Critically-Ill Mechanically Ventilated Neonates||Other:BioteneOralBalance&#174;gel;  Other: Sterile Water moisten cotton tipped applicator|Interventional||Other|Feasibility;  DurationofMechanicalVentilation|41|NCT01314742|May 2010
2550|Terminated                  Has Results|Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN||Drug:Panitumumab;  Procedure:Surgery;  Procedure:RadiationTherapy|Interventional|Phase 2|Other / Industry|Change in Tumor (Primary Tumor and Lymph Node) Response and Progression Between Pre- and Post- Panitumumab Therapy;  Nine(9)MonthProgressionFreeSurvival(PFS);  Nine(9)MonthOverallSurvival(OS)|6|NCT01305772|January 2011
2551|Recruiting|Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer||Drug:BMK120;  Drug:Capecitabine;  Drug:BYL719;  Drug:Trastuzumab;  Drug:Lapatinib|Interventional|Phase 1|Other / Industry|MaximumToleratedDose;  Doselimitingtoxicity(DLT);  ObjectiveResponse;  BestOverallResponse|84|NCT01300962|August 2011
2552|Completed                  Has Results|Improving the Efficacy of Anti-Nicotine Immunotherapy||Biological:NIC002inAluminumhydroxide(Alum);  Biological:PlaceboVaccine-Aluminumhydroxide|Interventional|Phase 2|Other / Industry|Vaccine-Induced Percent Change in Brain Nicotine Area Under Curve (AUC) After Single or Multiple (7) Puffs;  Vaccine-Induced Percent Change in Brain Nicotine Maximum Concentration After Single or Multiple (7) Puffs;  Vaccination-Induced Percent Change in T1/2 of Brain Nicotine Accumulation After Single or Multiple (7) Puffs;  Vaccination-Induced Percent Change in Initial Slope of Brain Nicotine Accumulation After a Single Puff|52|NCT01280968|December 2010
2553|Enrolling by invitation|Title: Comparative Effectiveness of Asthma Interventions Within an AHRQ PBRN||Behavioral:electronicmedicalrecord;  Other:IntegratedApproachtoCare;  Other:usualcare;  Other:SharedDecisionMaking;  Other:schoolbasedcare|Interventional||Other|Reducing Hospitalizations and Emergency Department Visits;  ImprovingAdherencetoMedication;  ImproveQualityofLife;  ReducedSchoolAbsenteeism;  ImprovedSelf-Efficacy;  ImprovedSchoolPerformance|1040|NCT01280500|March 2011
2554|Completed|Acupuncture in Menopause||Procedure:Acupuncture|Interventional|Phase 2|Other / NIH|SubjectiveHotFlashes;  ObjectiveHotFlashes;  OtherSymptoms;  QualityofLife|200|NCT01276028|April 2011
2555|Completed|Young Women&apos;s CoOp Study||Behavioral:YoungWomen&apos;sCoOp;  Behavioral:StayingHealthyandEatingWell|Interventional||Other / U.S. Fed|Changes in behaviors including condom use substance use and violence prevention|237|NCT01224184|May 2010
2556|Completed                  Has Results|Oxytocin Treatment of Alcohol Withdrawal||Drug:intranasaloxytocinspray;  Other:intranasalspraywithoutoxytocin|Interventional|Phase 1|Other|TotalLorazepamDosage(inMilligrams);  CIWA-ArScores|14|NCT01212185|July 2010
2557|Terminated|Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma Bone Sarcoma or Soft Tissue Sarcoma||Drug:temsirolimus;  Drug:valproicacid(VPA)|Interventional|Phase 1|Other / NIH|Maximum tolerated dose (MTD) of temsirolimus in combination with valproic acid;  Objectiveresponserate;  Progression-freesurvival;  Temsirolimus pharmakokinetic parameters (Maximum plasma concentration)|7|NCT01204450|November 2009
2558|Completed|A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation in Subjects With Chronic Non-Malignant Pain||Drug:Methylnaltrexonebromide;  Drug:OralPlacebo|Interventional|Phase 3|Industry|Proportionofsubjectswithrescue-freelaxation|700|NCT01186770|September 2010
2559|Active not recruiting|Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer||Radiation:stereotacticbodyradiationtherapy|Interventional|Phase 2|Other|Progression-freesurvival;  To assess physical function for this cohort of patients|45|NCT01185639|August 2010
2560|Terminated                  Has Results|Pacing Affects Cardiovascular Endpoints in Patients With Right Bundle-Branch Block (The PACE-RBBB Trial)||Device:VVI-40;  Device:RVDDD-40;  Device:BiVDDD-40|Interventional||Other|The Primary Endpoint of the Trial Will be a Comparison of the Proportion of Patients in Each of the Three Treatment Groups Who Demonstrate Positive LV Remodeling Defined as a Decrease in LV End Systolic Diameter of &gt;5mm.;  SecondaryEchocardiographicEndpoints;  ArrhythmicEvents;  MinnesotaQualityofLifeQuestionnaire;  6-minuteWalkDistance;  NYHAFunctionClass;  LeftVentricularEjectionFraction(LVEF);  LeftVentricularEnd-diastolicSize|16|NCT01169493|January 2011
2561|Unknown&nbsp;&#8224;|Collaborative Study Of Neurofeedback Training Of 6-18 Year Olds With Autism||Behavioral:Neurofeedbacktraining|Interventional|Phase 1|Other / NIH|Level of normalization of brainwaves based upon QEEG|30|NCT01154777|July 2011
2562|Completed|Project POWER Adapting Project SAFE: Reducing STD/HIV Risk in Women Prisoners||Behavioral: Project POWER HIV Risk-reduction Intervention;  Behavioral:NCDOCStandardofCareforSTIs|Interventional||Other / U.S. Fed|STIInfectionRate;  Number of unprotected sex acts as a measure of enacting sexual protective practices.|598|NCT01111721|March 2009
2563|Completed                  Has Results|FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders||Drug:Aripiprazole|Interventional|Phase 4|Other / NIH|Baseline and Week 8scores on Children&apos;s Yale-Brown Obsessive Compulsive Scale - Pervasive Developmental Disorder Version;  TotalRepetitiveBehaviorScale-Revised(RBS_R)|13|NCT01028820|August 2009
2564|Active not recruiting|Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery||Drug:doxorubicinhydrochloride;  Drug:mitomycinC;  Drug:sorafenibtosylate;  Other:laboratorybiomarkeranalysis;  Other:pharmacologicalstudy|Interventional|Phase 1|Other / NIH|Safety and toxicity as assessed by NCI CTCAE v3.0 criteria;  Overallsurvival;  Correlativestudies|11|NCT01011010|July 2009
2565|Active not recruiting|Fetal Umbilical Cord Blood (UCB) Transplant for Lysosomal Storage Diseases||Biological:ALD-601|Interventional|Phase 1|Other / Industry|To determine whether immune tolerance and donor cell engraftment can be achieved through first trimester injection of donor cells to fetus&apos;s diagnosed with lethal LSDs.;  Safetyandfeasibilityoffetalintrap.;  Donor chimerism for neonate at birth and 7 days post delivery.;  Establishment of threshold enzyme levels in neonate at birth and 7 days post delivery.;  Donor chimerism for mother post delivery and 1 year post date of birth.|12|NCT01003912|October 2009
2566|Recruiting|Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior||Other:biologicsamplepreservationprocedure;  Other:laboratorybiomarkeranalysis;  Procedure:biopsy|Observational||Other / NIH|Generation of a biorepository for current and future correlative research studies|1000|NCT01000883|December 1998
2567|Completed|Wheeled Mobility in Everyday Life||Other: Wheeled Mobility in Everyday Life:Effects of Wheelchair Type on Mobility Performance of Elders in Public Environments|Interventional||Other|Speed(inmeters/second);  Self Report of exertion pain fatigueand device preference|59|NCT00981344|October 2008
2568|Completed|Stress Management and Biomarkers of Risk in Cardiac Rehabilitation||Behavioral:SMT-enhancedCardiacRehabilitation;  Behavioral:StandardCardiacRehabilitation|Interventional||Other / NIH|StressScores;  Major Adverse Cardiovascular Events (MACE) - All cause death MI cardiac revascularization and cardiovascular hospitalization.;  Biomarkers|164|NCT00981253|September 2009
2569|Completed|Treatment of Acute HIV With Emtricitabine Tenofovir and Efavirenz (CID 0805)||Drug:Atripla|Interventional|Phase 4|Other / Industry|To determine the safety and tolerability and the virologic and immunologic efficacy of FTC/TDF and efavirenz or the fixed-dose combination of efavirenz/FTC/TDF (Atripla) given once daily to patients with acute HIV infection.;  To assess impact of once daily therapy combined with a standardized adherence program on treatment adherence virologic suppression and rate of viral load decline in blood and infectious fluids (cerebrospinal fluid semen and vaginal secretions).;  To define the prevalence of genotypic and phenotypic resistance to antiretroviral agents among persons diagnosed with acute HIV infection in the Southeastern United States.|90|NCT00924898|January 2005
2570|Completed                  Has Results|Educational Videos to Improve Patient Decision Making and Race Disparities in Implantable Cardioverter Defibrillator Use|||Observational||Other / Industry|DecisiontoReceiveanICD;  DecisionalConflictScale;  ReceiptofanICD|59|NCT00918125|November 2010
2571|Completed|The Effects of One-Time Pregnenolone Dehydroepiandrosterone (DHEA) or Placebo Administration On Withdrawal Symptoms Mood Craving And Cigarette Evaluation Ratings In Male Smokers||DietarySupplement:dehydroepiandrosterone(DHEA);  DietarySupplement:pregnenolone;  Drug:Placebo|Interventional|Phase 2|Other|The administration of DHEA or pregnenolone will reduce smoking withdrawal symptoms.;  The administration of DHEA or pregnenolone will reduce the subjective rewarding effects of nicotine inhaled in cigarette smoke.;  The administration of DHEA or pregnenolone will reduce stress-induced changes in mood and craving for cigarettes.|22|NCT00900900|July 2009
2572|Completed|Study to Evaluate HIV Viremia and Persistence in Acutely HIV-Infected ARV Na&#239;ve Patients Treated With Darunavir/Ritonavir and Etravirine||Drug:Darunavir/RitonavirandEtravirine|Interventional|Phase 4|Other / Industry|To measure virologic and immunologic response in AHI with DRV/R &amp; ETR (absolute values and change from baseline plus slope of change).;  To measure drug levels in various compartments with replication in cellular compartments and immunological outcome.|15|NCT00855413|March 2009
2573|Completed|Effect of Type 2 Diabetes Genetic Risk Information on Health Behaviors and Outcomes||Other:StandardizedRiskAssessment|Interventional||Other / Industry|Percentageofweightloss;  Change in perceptions of personal risk for Type 2 diabetes;  Change in HOmeostasis Model Assessment of Insulin Resistance (HOMA-IR)|450|NCT00849563|April 2009
2574|Completed                  Has Results|Cognitive Effects of Inhalational Versus Intravenous General Anesthesia in the Elderly||Drug: inhalation anesthesia with isoflurane vs. TIVA with propofol|Interventional||Other / U.S. Fed|ChangeinNeurocognitivePerformance(Z-score)|200|NCT00788008|November 2008
2575|Terminated|Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis||Drug:sorafenibtosylate|Interventional|Phase 1|Other / NIH|Correlation between hepatic retention and clearance of technetium Tc 99m mebrofenin (MEB) and technetium Tc 99m sestamibi (MIBI) and clearance (and other pharmacokinetic parameters) of sorafenib tosylate;  Tolerabledoseofsorafenibtosylate;  Correlation between the pharmacokinetics of MEB and MIBI and the dose-limiting toxicity of sorafenib tosylate;  Conjugated or unconjugated bilirubin increase in response to sorafenib tosylate;  Correlation between increased bilirubin and decreased clearance of MEB and/or MIBI;  Correlation between survival and MRI characteristics associated with high tumor VEGF levels;  Correlation between clearance of sorafenib tosylate and expression levels of hepatic transport proteins;  Correlation between survival and activation of the RAF/MEK/ERK pathway at baseline;  Medianoverallsurvival|6|NCT00767468|October 2008
2576|Withdrawn|Cardio Risk of Acute Schizophrenia Olanzapine Duke||Drug:Olanzapine;  Drug:Metformin;  Drug:Simvastatin|Interventional|Phase 4|Other|To compare added metformin and/or added simvastatin versus no intervention in reducing or eliminating increased cardiovascular risk (as estimated by elevation in non-HDL cholesterol levels) during the treatment of schizophrenia with olanzapine.;  To compare added metformin and/or added simvastatin versus no intervention in reducing or eliminating increased cardiovascular risk during the treatment of schizophrenia with olanzapine.|0|NCT00672464|April 2008
2577|Completed|Raltegravir as Early Therapy in African-Americans Living With HIV Study||Drug:Raltegravir+Truvada|Interventional|Phase 4|Other / Industry|Assess Raltegravir tolerability acceptability and adherence among African-American men and women initiating HIV therapy. 2. Determine the pharmacokinetics of Raltegravir in African-American men and women.;  Determine the pharmacokinetics of Raltegravir in African-American men and women.|43|NCT00667433|June 2008
2578|Completed|A Couples Approach to Enhance Breast Cancer Survivorship||Behavioral: Cancer-Focused Relationship Enhancement;  Behavioral:Couple&apos;sCancerEducation|Interventional||Other / NIH|Relationship Functioning Individual Functioning Cancer Related Physical Functioning;  Observational coding of couples social support and decision making conversations|163|NCT00665899|July 2004
2579|Terminated|Intensity-Modulated Radiation Therapy Pemetrexed and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer||Drug:erlotinibhydrochloride;  Drug:pemetrexeddisodium;  Procedure:quality-of-lifeassessment;  Radiation:intensity-modulatedradiationtherapy|Interventional|Phase 1 / Phase 2|Other / NIH|Maximum tolerated dose of erlotinib hydrochloride (Phase I);  Progression-free survival (PFS) at 1 year (Phase II)|27|NCT00573989|March 2008
2580|Completed                  Has Results|Feasibility of Cocooning Immunization Strategy With Influenza Vaccine||Biological: Trivalent inactivated influenza vaccine|Interventional||Other / U.S. Fed|Influenza Vaccine Coverage (Percent) for New Mothers of Newborns;  Influenza Vaccine Coverage (Percent) for New Fathers of Newborns;  Influenza Vaccine Coverage (Percent) for All Household Contacts of Newborns|544|NCT00570037|October 2007
2581|Completed|KAN-DO: A Family-based Intervention to Prevent Childhood Obesity||Behavioral:KAN-DO|Interventional||Other / NIH|BMI z-score (via measured weight and height) of preschooler;  Mother&apos;s measured weight as well as eating and physical activity behavioral targets (brief measures) in both mother and child|832|NCT00563264|October 2007
2582|Completed|Erythropoietin Resistance in Anemia of Chronic Kidney Disease|||Observational||Other||32|NCT00526747|August 2007
2583|Terminated|Vinflunine and Cetuximab as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer||Biological:cetuximab;  Drug:vinflunine|Interventional|Phase 2|Other / NIH|Overall tumor response rate as assessed by RECIST criteria;  Durationofresponse;  Overallsurvival;  Progression-freesurvival|18|NCT00519831|August 2007
2584|Completed|Evaluating a Web-Based Educational Program for Adults at Risk for Coronary Heart Disease (The Heart to Heart Feasibility Study)||Behavioral: Heart to Heart (Web-Based Decision Aid);  Behavioral:PhysicianEducationSession|Interventional||Other / NIH|Feasibility of subject recruitment; feasibility of delivery of the CHD intervention and surveys in a busy practice setting; feasibility of measuring study outcomes;  Self-reported use of any new CHD risk reduction strategy; global CHD risk; blood pressure; serum total cholesterol and HDL-c levels; smoking status; aspirin use; self-reported plans for CHD risk reduction; self-efficacy for CHD risk reduction|186|NCT00494052|June 2007
2585|Completed                  Has Results|Oxaliplatin Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma||Drug: capecitabine (Xeloda) oxaliplatin and bevacizumab (Avastin)|Interventional|Phase 2|Other / Industry|MedianProgression-FreeSurvival(PFS);  To Assess the Safety and Tolerability of the Combination of Bevacizumab Oxaliplatin and Capecitabine in Patients With Previously Untreated Metastatic Esophagogastric Adenocarcinoma;  ResponseRate;  MedianSurvival|60|NCT00447330|February 2007
2586|Completed|The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months||Drug:SumatriptanandNaproxensodium|Interventional|Phase 3|Industry|ENDPOINTS;  Adverse events physical examination findings vital signs and clinical laboratory findings will be evaluated.|500|NCT00442221|May 2004
2587|Completed|A Study of the Cost Effectiveness of Generalist Care Managers for Depression Treatment in Medicaid Recipients||Procedure:GeneralistCareManagervsUsualCare|Interventional||Other|Baseline 3 and 6-month Patient Health Questionnaire (PHQ9) scores;  Baseline and 6-month Short Form (SF)-12 scores Medicaid claims data; patient perception of treatment by self-report; review of GCM case notes physician and office staff time study; physician and office staff focus groups|300|NCT00373477|July 2003
2588|Completed                  Has Results|Clonidine-induced Spinal Acetylcholine Release: Normal Volunteers vs. Neuropathic Pain||Drug:clonidine|Interventional|Phase 2|Other / NIH|Acetylcholine Concentration in Cerebrospinal Fluid|43|NCT00350532|September 2004
2589|Completed                  Has Results|Clonidine Versus Adenosine to Treat Neuropathic Pain||Drug:clonidine;  Drug:adenosine;  Drug:placebo|Interventional|Phase 2|Other / NIH|NumberMeetingSuccessCriterion|24|NCT00349921|August 2004
2590|Completed|Lupus Nephritis: Role of Environmental and Occupational Exposures|||Observational||NIH||0|NCT00342329|April 2001
2591|Completed|Can Immune Parameters Predict Acute and Chronic Rejection in Lung Recipients?|||Observational||NIH||400|NCT00340951|June 2005
2592|Completed|Mechanisms of Lung Allograft Rejection|||Observational||NIH||120|NCT00340418|June 2005
2593|Completed|Prospective Lung Transplant Database for Genetic Research|||Observational||NIH||400|NCT00339209|June 2005
2594|Terminated|Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal||Drug:Antipsychotic/RisperidoneConsta|Interventional|Phase 4|Other / Industry||30|NCT00314613|April 2006
2595|Completed|Exercise and Dietary Counseling in Improving Physical Activity Nutrition and Quality of Life in Older Long-Term Cancer Survivors Who Are Overweight||Behavioral: behavioral dietary and exercise intervention|Interventional|Phase 2|Other / NIH|Physical function as assessed by Short-Form Health Survey (SF-36) with physical function subscale and late effects lower body subscales at baseline and years 1 and 2 following study completion;  Quality of life as assessed by SF-36 at baseline and years 1 and 2 following study completion;  Physical activity as assessed by Community Healthy Activities Model Program for Seniors (CHAMPS) at baseline and years 1 and 2 following study completion;  Dietary intake as assessed by 2-day dietary recalls at baseline and years 1 and 2 following study completion;  Body weight status as assessed by body mass index at baseline and years 1 and 2 following study completion;  Depression and/or anxiety as assessed by Hospital Anxiety Depression Scale at baseline and years 1 and 2 following study completion;  Self-efficacy for exercise and dietary change assessed by self-efficacy algorithms at baseline and years 1 and 2 following study completion;  Stage of readiness for exercise and dietary change as assessed by the stage of change algorithms at baseline and years 1 and 2 following study completion|641|NCT00303875|December 2003
2596|Completed                  Has Results|Capecitabine Cetuximab Oxaliplatin and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery||Biological:bevacizumab;  Biological:cetuximab;  Drug:capecitabine;  Drug:oxaliplatin|Interventional|Phase 2|Other / NIH|Response Rate (Percentage of Participants With Partial or Complete Response);  SafetyandTolerability;  Progression-freeSurvival;  OverallSurvival|30|NCT00290615|January 2006
2597|Completed|Whole-Brain Radiation Therapy and Pemetrexed in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer||Drug:pemetrexeddisodium;  Radiation:radiationtherapy|Interventional|Phase 2|Other / NIH|Response of intracranial metastases (complete and partial response);  Numberofsubjectsexperiencingadverseevents|10|NCT00280748|May 2005
2598|Completed|Docetaxel Androgen Ablation Therapy and External-Beam Radiation Therapy in Treating Patients With High-Risk Localized Prostate Cancer||Drug:docetaxel;  Drug:leuprolideacetate;  Radiation:radiationtherapy|Interventional|Phase 1 / Phase 2|Other / NIH|Progression-freesurvival;  Survival|23|NCT00225420|August 2005
2599|Terminated|Testing Pharmacological Therapies for Pregnant Smokers||Behavioral: Motivational interviewing for smoking cessation;  Behavioral:Cognitivebehaviorstherapy;  Drug:CBT+NRT|Interventional|Phase 4|Other / NIH|Biochemically-validatedsmokingcessation|181|NCT00224419|June 2003
2600|Completed                  Has Results|Geodon for the Treatment of Refractory Social Anxiety Disorder||Drug:Ziprasidone;  Drug:Sertraline|Interventional|Phase 2|Other / Industry|BriefSocialPhobiaScale(BSPS)|51|NCT00215150|November 2004
2601|Terminated|Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer||Drug:romidepsin|Interventional|Phase 2|NIH|Responserate;  ToxicityasassessedbyCTCAEversion3.0;  Timetoprogression;  Survival|51|NCT00091195|September 2004
2602|Completed|Sensory Re-Training Following Facial Surgery for Correction of Facial Skeletal Disharmony||Behavioral:SensoryRe-training;  Behavioral:SensoryRetraining;  Behavioral:OpeningExercises|Interventional|Phase 3|Other / NIH|Perceptionofalteredsensation;  Perceptionofalteredfunction;  Two-pointthreshold;  Twopointdiscrimination;  Contactdetection|186|NCT00078507|December 2001
2603|Unknown&nbsp;&#8224;|Self-Injury: Diagnosis and Treatment||Drug:Naltrexonehydrochloride;  Procedure: Transcutaneous sensory nerve stimulation|Interventional|Phase 3|NIH||37|NCT00065936|July 1997
2604|Completed|Coping Skills Training for Early Rheumatoid Arthritis||Behavioral:ComprehensiveCopingSkillsTraining;  Behavioral:ArthritisEducationSessions;  Behavioral:StandardCare|Interventional||Other / NIH|Pain;  Psychologicaldisability;  Physicaldisability;  Erythrocytesedimentationrate;  Jointtendernesscount;  Gripstrength;  Physicianassessmentofdiseaseactivity;  Creactiveprotein|105|NCT00056394|February 2003
2605|Completed|EF5 in Assessing Tumor Response to Anticancer Therapy in Patients With Stage I Stage II or Stage III Non-Small Cell Lung Cancer||Drug:EF5;  Other:flowcytometry;  Other:immunohistochemistrystainingmethod|Interventional|Phase 2|Other / NIH|Frequency and degree of hypoxia as measured by EF5 binding at 24 to 48 hrs. after study drug infusion;  Correlation of hypoxia with serum/plasma markers of hypoxia tissue markers of hypoxia tumor angiogenesis apoptosis tumor perfusion and microvessel density at 24 to 48 hrs. after study drug infusion;  Longevity of EF5 adducts as measured by EF5 binding|60|NCT00041028|May 2002
2606|Completed|Multimodality Treatment for Women With Stage II Stage III or Stage IV Breast Cancer||Biological:trastuzumab;  Drug:cyclophosphamide;  Drug:doxorubicinhydrochloride;  Drug:paclitaxel;  Procedure:conventionalsurgery;  Radiation:RadiationTherapy|Interventional|Phase 2|Other|To determine the cardiac and other toxicity of weekly Taxol given with weekly Herceptin when delivered immediately following four cycles of standard dose AC;  To identify whether the addition of Taxol&#174; with or without Herceptin&#174; further decreases tumor size and the number of positive axillary lymph nodes beyond that achieved by conventional breast cancer adjuvant therapy (4AC).;  To determine the 10 year DFS and OS in patients receiving and not receiving Herceptin&#174; and determine whether the initial pathologic response in Neoadjuvant patients correlates with the eventual 5-year DFS or OS|85|NCT00006110|December 1998
2607|Completed|A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients||Drug:Nelfinavirmesylate;  Drug:Lamivudine;  Drug:Filgrastim;  Drug:Stavudine;  Drug:Cyclophosphamide|Interventional|Phase 1|NIH||10|NCT00000899|
2608|Recruiting|Mobile Mindfulness to Improve Psychological Distress After Critical Illness||Behavioral:mobilemindfulness;  Behavioral:standardmindfulness;  Behavioral:education|Interventional||Other / NIH|Percent of participants who provide consent among all who either consent or refuse;  ClientSatisfactionQuestionnaire(CSQ)score;  SystemUsabilityScale(SUS);  Percent of participants who provide informed consent who are randomized;  Percent of randomized participants who drop out of study;  Percent of participants who have neither dropped out nor died who complete telephone interviews;  Percent of participants in the self-directed MBT group who complete weekly surveys;  Percentage of self-directed MBT sessions attended by eligible participants;  Visualanalogsatisfactionscale;  Numberofparticipantclicksonstudywebsite;  Usability themes developed from semi-structured participant interviews;  Psychological distress symptoms as measured by the Patient Health Questionnaire (PHQ) scale;  Physicalsymptoms;  Cognitive and Affective Mindfulness Scale-Revised (CAMS-R);  Psychological distress symptoms as measured by the Generalized Anxiety Disorder (GAD) scale;  Psychological distress symptoms as measured by the Post-Traumatic Stress Scale (PTSS);  AvoidancedomainoftheBriefCoping(COPE)scale|90|NCT02701361|March 2016
2609|Recruiting|ExpressGraft-C9T1 Skin Tissue as a Treatment of Diabetic Foot Ulcers||Biological:ExpressGraft-C9T1SkinTissue|Interventional|Phase 1|Industry / NIH|Safety and tolerability of ExpressGraft-C9T1 skin tissue evaluated by adverse events clinically significant vital signs blood chemistry safety laboratory values and incidence of treatment site infection through study completion.|6|NCT02657876|May 2016
2610|Active not recruiting|Understanding Adaptive Challenges Associated With Male-factor Infertility|||Observational||Other|Feasibility as measured by the percentage of eligible subjects agreed to participate;  Feasibilityasmeasuredbyretentionpercentage;  Change in level of global infertility stress as measured by questionnaire;  Change in quality of life as measured by questionnaire;  Concordance between men and partners with respect to levels of global infertility stress as measured by questionnaire;  Concordance between men and partners with respect to quality of life as measured by questionnaire;  Feasibility as measured by percentage of participants who used text messaging to complete their study questionnaires|24|NCT02607098|November 2015
2611|Recruiting|Effects of Nicotine Reduction on Smoking Behavior in ADHD Smokers||Other:Verylownicotinecontentcigarettes;  Other:Conventionalnicotinecontentcigarettes|Interventional||Other / NIH / U.S. Fed|Numberofcigarettessmokedperday;  Composite measure of influence of reduced nicotine content on ADHD symptoms measured by ADHD Rating Scale and Clinical Global Impressions Scale along with related measures of cognition measured by the N-Back Task and the Continuous Performance Test;  Composite measure of outcomes associated with acceptability; withdrawal measured by the MNWS and compliance measured by Time-Line Follow-Back questionnaire and daily self-report cigarette use;  Measures of discomfort/dysfunction; withdrawal and depression;  Measures of other health&#8208;related behaviors; dependence measures|350|NCT02599571|January 2016
2612|Recruiting|Bupropion Hydrochloride or Patient&apos;s Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy||Drug:BupropionHydrochloride;  Other:LaboratoryBiomarkerAnalysis;  Drug:NicotineReplacement;  Other:Quality-of-LifeAssessment;  Other:QuestionnaireAdministration;  Drug:Varenicline|Interventional||Other / NIH|Proportionofpatientswhoarenotsmoking;  Levels of depression and anxiety as measured by Hamilton Rating Scale-Depression questionnaire;  Proportion of patients who are not smoking at 6 months post RT or CRT;  Proportion of patients who develop mucositis and mucositis-related pain evaluated by Common Terminology Criteria for Adverse Events;  Proportion of patients who experience smoking relapse among patients who quit smoking;  QOLasmeasuredbyMDAndersonInventory|60|NCT02582008|January 2016
2613|Recruiting|PeRiodontal Treatment to Eliminate Minority InEquality and Rural Disparities in Stroke||Procedure:Intensivedentaltreatment;  Procedure:Standarddentaltreatment;  Drug:Arestin|Interventional|Phase 3|Other|IschemicStroke;  Transientischemicattack(TIA);  Myocardialinfarction(MI);  CardiovascularDeath;  ProgressionofAtherosclerosis;  VascularCognitiveImpairment;  BloodPressure;  hs-CRP;  hemoglobinA1c;  FastingLipids|400|NCT02541032|December 2015
2614|Recruiting|Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography||Device:DigitalBreastTomosynthesis;  Device:Full-FieldDigitalMammogram|Interventional||Industry|Cancer Status (Sites&apos; diagnosis of cancer status (positive/negative);  Cancer Characteristics (composite of cancer characteristics will be collected)|200|NCT02540083|August 2015
2615|Recruiting|PK and Safety Study of XARTEMIS&#174; XR (7.5 mg Oxycodone HCl/325 mg APAP) in Postsurgical Adolescent Subjects With Moderate to Severe Acute Pain||Drug:XARTEMISXR|Interventional|Phase 4|Industry|Timetoreachsteadystate;  Areaunderthecurve;  Peakexposure;  Half-life;  Timetopeakexposure|60|NCT02508935|June 2015
2616|Recruiting|Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma||Biological: Allogeneic Hematopoietic Stem Cell Transplantation;  Drug:Carmustine;  Drug:Cytarabine;  Drug:Etoposide;  Drug:IxazomibCitrate;  Other:LaboratoryBiomarkerAnalysis;  Drug:Melphalan;  Drug:Methotrexate;  Biological: Peripheral Blood Stem Cell Transplantation;  Other:Quality-of-LifeAssessment;  Drug:Tacrolimus|Interventional|Phase 1|Other / NIH|Incidence of grade III-IV acute (or overlap) GvHD and ixazomib related grade III-IV toxicity;  Transplantrelatedmortality(TRM);  Incidence of discontinuation of ixazomib maintenance therapy;  Overallsurvival;  Progression-freesurvival;  Proportion of patients who are eligible to start ixazomib maintenance therapy;  Responserates(CRVGPRandPR);  Time to engraftment (defined by ANC &gt; 500 and platelets &gt; 20000)|24|NCT02504359|July 2015
2617|Recruiting|Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis||Drug:Hyperpolarized129-Xenongas;  Device:MRI|Interventional|Phase 1|Other / NIH|Change in lung function as measured by ventilation defect percentage (VDP);  Change in lung function as measured by gas exchange defect percentage (EDP)|79|NCT02478268|May 2015
2618|Recruiting|The Effect of Walking on Fatigue During Radiotherapy in Breast Cancer Patients 65 and Older||Behavioral:WalkWithEaseArmA|Interventional|Phase 2|Industry / Other|Compare the change in treatment related fatigue from baseline to last week of radiotherapy between patients in the WWE intervention and usual care arms using the Fatigue Symptom Index (FSI).;  Compare the change in treatment related fatigue from baseline to 1-4 months post-radiotherapy between patients in the WWE intervention and usual care arms using the FSI.;  ChangeinTreatmentRelatedFatigueSymptomIndex;  ChangeinPhysicalFuncionalityIndex|50|NCT02434367|August 2014
2619|Active not recruiting|Cord Blood Infusion for Ischemic Stroke||Biological:allogeneicumbilicalcordblood|Interventional|Phase 1|Other|NumberofAdverseEvents;  IncidenceofGraftversusHostDisease;  ChangeinmodifiedRankinScore;  ChangeinInfarctVolumes|10|NCT02397018|May 2015
2620|Recruiting|The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia Study|||Observational||Other|Neo-BAT score (Neo-BAT: Neonatal Bleeding Assessment Tool);  Numberofthromboticevents|72|NCT02371330|April 2015
2621|Recruiting|PROMComplete for Determination of Rupture of Fetal Membranes||Other:non-interventionstudy|Observational||Industry|accuracy of Pro-mcomplete vs conventional testing for ruptured fetal membranes;  Occurrenceofdiscordantexamination|600|NCT02369601|August 2015
2622|Recruiting|FARE Peanut SLIT and Early Tolerance Induction||Drug:LiquidPeanutExtract;  Drug:PlaceboGlycerinSLIT|Interventional|Phase 2|Other / NIH|Percentage of participants desensitized to peanut using peanut SLIT as an early intervention in subjects ages 1 to 4 years;  ThechangeinpeanutspecificIgElevels;  ThechangeinpeanutspecificIgGlevels;  ThechangeinpeanutspecificIgG4levels;  Thechangeinpeanutspecificbasophilactivation;  The change in responses of mast cell as measured by prick skin testing to peanut;  ThechangeinspecificT-cellcytokineresponses;  ThechangeinTregulatorycellactivation|50|NCT02304991|December 2014
2623|Recruiting|Double-Blind 2-Site Randomized Clinical Trial of Neurofeedback for ADHD||Device:Neurofeedbacktreatment|Interventional||Other / NIH|Scores of Teacher and Parent Rated Inattentive Symptoms|140|NCT02251743|June 2014
2624|Active not recruiting|TDAP Safety in Pregnant Women|||Observational||Other / U.S. Fed|Rates of injection-site and systemic reactions post Tdap administration.;  Rates of preterm and small for gestational age (SGA) births in women who received Tdap prenatally;  Differences in injection-site and systemic reactions in pregnant women who received Tdap before the current pregnancy versus women who are receiving their first Tdap dose;  Rates of additional obstetrical and infant outcomes in pregnant women receiving Tdap;  Health outcomes and growth parameters among infants born to women who received Tdap during pregnancy|375|NCT02209623|May 2014
2625|Completed                  Has Results|Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.||Drug:PF-04937319IRMST;  Drug:PF-04937319MR1;  Drug:PF-04937319MR2;  Drug:PF-04937319MR3|Interventional|Phase 1|Industry|Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUCinf];  Change From Reference in Weighted-Mean-Daily-Glucose (WMDG) on Day 1;  Maximum Observed PF-04937319 Plasma Concentration (Cmax);  PF-04937319 Plasma Concentration at 5 Hours After Morning Dose (C5);  PF-04937319 Plasma Concentration at 16 Hours After Morning Dose (C16);  PF-04937319 Plasma Concentration at 24 Hours After Morning Dose (C24);  Ratio of Maximum to Approximate Trough PF-04937319 Concentration (Cmax/C24);  Time to Reach Maximum Observed PF-04937319 Plasma Concentration (Tmax);  Area Under the Curve From Time Zero to Last Quantifiable PF-04937319 Concentration (AUClast);  TerminalEliminationHalf-Life(t1/2);  Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)|39|NCT02206607|September 2014
2626|Completed                  Has Results|Kinematic Analysis: Posterior Stabilized Fixed Bearing Total Knee Arthroplasty With Attune Knee System||Device: DePuy Attune posterior stabilizing fixed bearing knee system|Observational||Other / Industry|Femoro-tibial Kinematics - Translation and Lift-off for Deep Knee Bend;  Femoro-tibial Kinematics: Translation and Lift-off for Gait;  Femoro-tibial Kinematics: Translation and Lift-off for Ramp Down;  Femoro-tibialKinematics-DeepKneeBend;  Femoro-tibialKinematics-Gait;  Femoro-tibialKinematics-RampDown;  MaxGroundReactionForce-DeepKneeBend;  MaxGroundReactionForce-Gait;  MaxGroundReactionForce-RampDown|5|NCT02204748|November 2014
2627|Recruiting|Weekly Carboplatin Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN||Drug:Cetuximab;  Drug:Paclitaxel;  Drug:Carboplatin|Interventional|Phase 2|Other|Overallsurvival;  ProgressionFreeSurvival;  OverallResponseRate;  Toxicityevaluation;  QualityofLife|38|NCT02124707|April 2014
2628|Completed                  Has Results|Evaluation of Videoconferencing Versus Telephone Genetic Counseling||Other:VideoconferencingGeneticConsultation;  Other:TeleconferencingGeneticConsultation|Interventional||U.S. Fed|Assessment of Knowledge Retention of Genetic Counseling Information Via 8-Question Pre- and Post-Counseling Assessment;  Satisfaction With Genetic Counseling Session Using the Genetic Counseling Satisfaction Scale;  Qualitative Assessment of Genetic Counseling Experience Barriers and Facilitators by PATIENTS;  Qualitative Assessment of Genetic Counseling Experience Barriers and Facilitators by GENETIC COUNSELORS;  CostAnalysis|38|NCT02108977|April 2014
2629|Recruiting|Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients||Drug:Metformin|Interventional||Other|Responserate;  adverseeventmeasurement|30|NCT02035787|March 2014
2630|Terminated|Safety Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia||Drug:SG2000|Interventional|Phase 1 / Phase 2|Industry|MaximumToleratedDose(MTD)ofSG2000.;  safetyprofile;  areaundertheconcentration-timecurve(AUC);  Maximumplasmaconcentration(Cmax);  timetoreachCmax;  terminalhalflife(T1/2);  hematologyandserumchemistry;  Physicalexamination;  Vitalsigns;  bonemarrowaspirate;  pulseoximetry;  electrocardiogram|6|NCT02034227|April 2012
2631|Recruiting|Prader-Willi Syndrome Macronutrient Study||Other:LowCarbohydratediet;  Other:LowFatdiet|Interventional||Other|Suppressionofghrelin;  Changesinsatiety;  Improvementsininsulinsensitivity|13|NCT02011360|May 2014
2632|Completed|Socio-Economic Survey in Uganda|||Observational||Other|Immediate social-economic impact of orthopedics trauma as measured by socio-Economic Questionnaire|30|NCT01971697|September 2013
2633|Enrolling by invitation|Accountability for Cancer Care Through Undoing Racism and Equity||Other:ACCURENavigator;  Other:UsualCarebyCancerCenterCareTeam|Interventional||Other / NIH|Lung Cancer - Lung Resection Surgery within 4 months of diagnosis or stereotactic radiation Breast Cancer - Completion of surgery radiation if surgery is breast conserving and adjuvant chemotherapy (when indicated) within 6 months of diagnosis;  Adherencetoscheduledappointments|300|NCT01954641|April 2013
2634|Active not recruiting|Bovine Lactoferrin Supplement in Improving Taste in Patients With Cancer Receiving Chemotherapy||Biological:bovinelactoferrinsupplement;  Other:questionnaireadministration;  Procedure:quality-of-lifeassessment;  Other:laboratorybiomarkeranalysis|Interventional|Phase 2|Other / NIH|Change in taste disturbances using the visual analogue scale (VAS) and the Smell and Taste Questionnaire;  Change in smell disturbances using the VAS and the Smell and Taste Questionnaire;  Effect of bovine lactoferrin supplement on lipid peroxidation byproducts as measured by the TBARs assay;  Malondialdehyde (MDA) concentrations before and after a ferrous iron oral rinse;  Smelling loss as quantified by the Brief Smell Identification Test (B-SIT);  Quality of life as quantified by the Functional Assessment of Anorexia/Cachexia Treatment (FAACT) and Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) questionnaires|30|NCT01941810|February 2014
2635|Recruiting|Cardiac Magnetic Resonance Imaging Strategy for the Management of Patients With Acute Chest Pain and Detectable to Elevated Troponin||Procedure:CardiacMRI;  Other:ACC/AHAGuidelineadherentcare|Interventional|Phase 3|Other / NIH|Reduction in composite death nonfatal myocardial infarction (MI) cardiac related readmission and cardiac related ED visits;  Reductionininvasiveangiography.;  Reductionincoronaryrevascularization.;  Reductioninrecurrentcardiactesting.|312|NCT01931852|September 2013
2636|Unknown&nbsp;&#8224;|Clinical Trial of PeriZone PerioPatch in Subjects With Chronic Periodontitis||Device:PeriZonePerioPatch;  Procedure:Scalingandrootplaningalone|Interventional||Industry|Changeinpocketdepth(PD)fromBaseline;  Change in clinical attachment level (CAL) from Baseline;  Change in percent bleeding on probing (BOP) from Baseline;  ChangeinGingivalIndex(GI)fromBaseline;  ChangeinPlaqueIndex(PI)fromBaseline|80|NCT01808703|March 2013
2637|Recruiting|Genes Associated With Bronchopulmonary Dysplasia and Retinopathy of Prematurity|||Observational||NIH|Bronchopulmonary dysplasia; retinopathy of prematurity|3600|NCT01780155|November 2012
2638|Completed|A Test of Different Degrees of Cost Sharing on Program Uptake and Attendance||Behavioral:Differentlevelsofcostsharing|Interventional||Other|Uptake;  Efficacy|1239|NCT01756066|January 2013
2639|Completed|Multidetector Computed Tomography (MDCT) Tailored Protocol|||Observational||Industry|DiagnosticQuality|1493|NCT01737333|October 2012
2640|Active not recruiting|Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer||Drug:Capecitabineandaflibercept|Interventional|Phase 1 / Phase 2|Other / Industry|Recommended Phase II dose (RPTD) for the capecitabine and aflibercept doublet combination;  Progression free survival associated with the regimen;  Frequencyofbestresponse;  Overallsurvival|64|NCT01661972|August 2012
2641|Completed|Evaluation of Behavioral Intervention for HIV Positive Prisoners in NC and TX||Behavioral: Text reminders counseling and link coordination;  Behavioral:Standardofcare-controlarm|Interventional||Other / NIH|HIVRNAlevel(ViralLoad)|381|NCT01629316|March 2012
2642|Active not recruiting|Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)||Drug:Saline;  Drug:Insulindetemir;  Drug:Insulin|Interventional|Phase 2|Other|VerbalMemoryComposite;  GlucoseTolerance;  CerebralBloodFlow;  CerebralSpinalFluid(CSF)BiomarkersofAD;  PlasmaBiomarkersofAD;  ExecutiveFunctionComposite;  FunctionalAbility;  The Alzheimer&apos;s Disease Assessment Scale-Cognitive [ADAS-Cog/Alzheimer&apos;s Disease Cooperative Study (ADCS)] - MCI revision|36|NCT01595646|November 2011
2643|Enrolling by invitation|Intraoperative OCT Guidance of Intraocular Surgery|||Observational||Other / NIH|Test and provide feedback on the intraoperative system both in laboratory and then in the operating room.|802|NCT01588041|September 2009
2644|Completed|Strengthening Exercise and Quadriceps Force During Walking||Other:StrengthTraining|Interventional||Other|Change from baseline in peak quadriceps force during walking at 12 weeks;  Change from baseline in quadriceps power and work during walking at 12 weeks;  Change from baseline in knee compressive force during walking at 12 weeks|30|NCT01538407|March 2012
2645|Recruiting|Alpha 1 Anti-Trypsin in Treating Patients With Acute Graft-Versus-Host Disease||Biological:Alpha-1-ProteinaseInhibitorHuman;  Other:LaboratoryBiomarkerAnalysis;  Other:PharmacologicalStudy|Interventional|Phase 1 / Phase 2|Other / NIH|Number (percentage) of patients at each dosing cohort who experience no toxicity and in whom GVHD is stable or improved;  Number (percentage) of patients at each dosing cohort experiencing an unexpected severe adverse event;  Number (percentage) of patients at each dosing cohort who experience one or more suspected serious adverse reactions or serious adverse reactions;  Number (percentage) of patients at each dosing cohort who experience one or more thrombotic or thrombo-embolic events;  Number (percentage) of patients at each dosing cohort with occurrence of infections;  Number (percentage) of patients at each dosing cohort with progression of GVHD;  Plasma concentrations of alpha-1-proteinase inhibitor human at each dosing cohort;  Pro-inflammatory cytokine levels at the messenger ribonucleic acid (by polymerase chain reaction) and protein (by enzyme-linked immunosorbent assay) levels at each dosing cohort|24|NCT01523821|November 2013
2646|Active not recruiting|School Support as Structural HIV Prevention for Adolescent Orphans in Kenya||Behavioral:SchoolSupportIntervention|Interventional|Phase 2|Other / NIH|Droppedoutofschool;  Change from baseline in ever had sexual intercourse at 1 year;  Change from baseline in ever had sexual intercourse at 2 years;  Change from baseline in ever had sexual intercourse at 3 years;  HIVIncidence;  HSV-2Incidence;  Evermarriedoreverpregnant;  Health-relatedqualityoflife|835|NCT01501864|July 2011
2647|Completed|WHC+ (Women&apos;s Health CoOp PLUS)||Behavioral: Test Treat Retain(TTR) + Women&apos;s Health CoOp (WHC);  Biological:TestTreatRetain(TTR)only|Interventional|Phase 1|Other|Unprotectedintercourseamongwomen;  Medical evaluation initiation amongst HIV-positive;  Treatment initiation and retention amongst HIV-positive women;  HIV viral load among HIV-positive women who meet criteria for antiretroviral treatment (ART) and who produce medical records with HIV viral loads;  Alcoholuse;  Victimization|641|NCT01497405|May 2012
2648|Completed                  Has Results|Preventing Hypotension in Parturients With an Elevated Body Mass Index (BMI)||Drug:Phenylephrinebolus;  Drug:phenylephrineinfusion|Interventional|Phase 4|Other|IncidenceofNauseaandVomiting;  IncidenceofHypotension;  NeonatalAcidosis|170|NCT01481740|November 2010
2649|Recruiting|Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer||Drug:Dasatinib|Interventional|Phase 2|Other / Industry|Change in Ki-67 in Breast Tissue of High-Risk Women|66|NCT01471106|January 2014
2650|Completed|New Biomarkers Evaluating Ovarian Cancer|||Observational||Industry|Evaluate novel biomarkers for patients with an adnexal mass|280|NCT01466049|December 2011
2651|Terminated|A Clinical Trial to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain||Drug:SSR411298;  Drug:Placebo(forSSR411298)|Interventional|Phase 2|Industry|Change from baseline in average Numeric Rating Scale (NRS) pain intensity score;  Change from baseline in Brief Pain Inventory Short-Form (BPI-SF) scores;  Responderrates;  Breakthroughpainfrequency;  Opioid consumption expressed as the morphine-equivalent dose per day;  Rescue medication consumption expressed as the number of rescue medication doses per day;  Mood disorders as measured by the Hospital Anxiety &amp; Depression Scale (HADS);  Change in nausea as measured by Visual Analog Scale (VAS);  Constipation as measured by the Bowel Function Index (BFI);  Healthcareutilization;  Patientsatisfactionofpainrelief;  Quality of life as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) version 3;  Overviewofadverseevents(AE);  SSR411298plasmaconcentration|5|NCT01439919|January 2012
2652|Recruiting|A Novel Optical Spectral Imaging System for Imaging Breast Tumor Margins||Device:miniaturespectralimagingsystem;  Device:Bench-topopticalspectrometer;  Device:Highresolutionmicroendoscope|Interventional||Other / NIH|Sensitivity and specificity of optical spectral imaging system;  Identification of the optical signatures of breast tissue|210|NCT01372631|April 2011
2653|Completed                  Has Results|Deplin&#174; P.L.U.S. Program (Progress Through Learning Understanding &amp; Support)||Other:Deplin&#174;|Observational||Industry|Change in Depression Severity as Measured by the 9-item Patient Health Questionnaire (PHQ-9);  Proportion of Patients Reporting Difficulty in Daily Functioning Due to Depressive Symptoms;  Change in Overall Patient Satisfaction With Deplin&#174; Using a 9-point Satisfaction Scale|554|NCT01369030|November 2010
2654|Active not recruiting|Neoadjuvant Pazopanib in Renal Cell Carcinoma||Drug:Pazopanib|Interventional|Phase 2|Other / Industry|Responserate;  RecurrenceFreeSurvival(RFS);  Altered surgical approach after treatment with pazopanib;  Numberofparticipantswithadverseevents;  Predictive molecular markers in response to treatment with pazopanib;  Exploratory Analysis of Objective Response and Recurrence Free Survival rates|21|NCT01361113|May 2011
2655|Completed|Tadalafil for Sarcoidosis Associated Pulmonary Hypertension||Drug:Tadalafil|Interventional|Phase 2 / Phase 3|Other / Industry|Changein6minutewalkdistance|6|NCT01324999|March 2011
2656|Active not recruiting|Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects||Drug:Bavituximab|Interventional|Phase 1|Other / Industry|Measure number of severe side effects seen during first cycle of therapy;  Progressionfreesurvival|25|NCT01323062|May 2011
2657|Active not recruiting                  Has Results|Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant||Drug:Plerixafor|Interventional|Phase 1 / Phase 2|Other / Industry|TimetoNeutrophilRecovery;  TimetoPlateletRecovery;  Plerixafor-associatedAdverseEvents;  Transplant Related Mortality Calculated at Day +100;  ImmunologicalReconstitution;  PlasmaCytokines/Chemokines;  Incidence of Grade II/IV Acute Graft Versus Host Disease|43|NCT01280955|December 2011
2658|Completed|Family Treatment for Adolescents With Anorexia Nervosa||Behavioral: Acceptance-based separated family treatment|Interventional|Phase 1|Other|BodyMassIndex(BMI;  EatingDisorderExamination(16.0D)|26|NCT01280799|May 2009
2659|Completed                  Has Results|Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab||Drug:Pazopanib|Interventional|Phase 2|Other / Industry|DiseaseControlRate;  Combined Response Rate (CR + PR) of Pazopanib According to RECIST v1.1;  ProgressionFreeSurvival;  OverallSurvival|15|NCT01262820|December 2010
2660|Terminated                  Has Results|Study Of Abraxane&#174; And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer||Drug:Abraxane;  Drug:Carboplatin|Interventional|Phase 2|Other / Industry|PFS;  To Assess the Safety and Tolerability of a Combination Regimen of Weekly Abraxane&#174; and Carboplatin to Treat Women With &quot;Triple Negative&quot; Stage IV Metastatic Breast Cancer|10|NCT01207102|August 2011
2661|Active not recruiting|Study of Novel Approaches for Prevention||Behavioral:Self-regulationtheory|Interventional||Other / NIH|WeightGain;  Weightgainlessthan1pound;  Weightgaindifferences;  Behavior;  Cardiovasculardiseaseriskfactors;  DemographicandPsychologicalVariables;  Mediatorsoftheeffectoftheintervention;  Obesity|599|NCT01183689|August 2010
2662|Completed|Engaging Motivation for the Prevention of Weight Regain||Behavioral: Mindfulness Based Weight Loss Maintenance (MBWLM);  Behavioral: Behavioral: Standard Behavioral Weight-Loss Maintenence|Interventional|Phase 2|Other / NIH|WeightLossMaintenance;  BodyMassIndex;  Waistcircumference;  PercentBodyFat;  Psychologicaloutcomesandlifestylebehavior;  Biologicalmarkersofappetite;  Glucosemetabolism;  Biologicalmarkersofinflammation|95|NCT01169428|July 2007
2663|Completed|Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA||Biological:AD5CEAVaccine|Interventional|Phase 1 / Phase 2|Industry / Other|The primary objective of this protocol is to determine the safety of immunization with Ad5 [E1- E2B-]-CEA(6D) in patients with advanced or metastatic CEA-expressing malignancies including Maximum Tolerated Dose (MTD).;  The secondary objectives of this protocol are to evaluate CEA-specific immune responses to the immunizations and to obtain preliminary data on clinical response rate.|35|NCT01147965|June 2010
2664|Completed|Improved Detection of Neonatal Sepsis Using a Targeted Biomarker Assay|||Observational||Other|Cytokineresponse;  Heartratecharacteristics|250|NCT01120678|February 2009
2665|Completed|Preoperative Radiation Therapy for High Risk Prostate Cancer||Radiation:Radiation;  Procedure:RadicalProstatectomy|Interventional|Phase 1|Other|post-operativemorbidity;  continence;  erectilefunction;  biochemicalrecurrence|15|NCT01041326|April 2005
2666|Completed|Intervention Study of Communication in Oncologist-Patient Encounters||Behavioral:CHESS;  Behavioral:COPE;  Behavioral:CHESS/COPE|Interventional||Other / NIH|Patientexpressionofemotion;  Patients randomized to the COPE only arm will have lower levels of negative affect and an increased number of requests for emotional support as compared to patients in the Internet only arm.;  Patients randomized to the CHESS only arm will have lower levels of negative affect as compared to patients in the Internet only arm.;  Patients randomized to the CHESS+COPE arm will have an increased number of expressions of emotional concerns and lower levels of negative affect as compared to patients in either the COPE only or CHESS only arms.|659|NCT00994578|November 2010
2667|Completed|Magnetic Seizure Therapy (MST) for the Treatment of Major Depression||Device:MagstimTheta;  Device:ThymatronSystemIV|Interventional|Phase 2|Other|Hamilton Rating Scale for Depression (HRSD) 24 item;  BeckDepressionInventory;  Neuropsychological testings to assess the acute short term long term memory effects of the treatments|20|NCT00973934|April 2002
2668|Completed|CP-868596 And CP-868596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors||Drug:CP-868596;  Drug:Docetaxel;  Drug:AG-013736|Interventional|Phase 1|Industry|First-cycleDoseLimitingToxicities;  Determine the safety and tolerability of the combination of daily CP&#8209;868596 and docetaxel on an every 3&#8209;week schedule;  Determine the safety and tolerability of the combination of daily CP&#8209;868596 plus daily AG&#8209;013736 plus docetaxel on an every 3&#8209;week schedule;  To evaluate the pharmacokinetics (PK) of CP&#8209;868596 and docetaxel when given in combination;  To evaluate the pharmacokinetics (PK) of CP&#8209;868596 AG&#8209;013736 and docetaxel when given in combination;  Conduct biomarker investigations on plasma/serum samples to explore critical events in pharmacodynamic response to CP&#8209;868596 (eg VEGF phospho&#8209;SHP etc.);  To explore the relationship between polymorphisms in genes involved in the metabolism and transport of CP&#8209;868596 and pharmacokinetic/pharmacodynamic parameters;  To explore the effects of CP&#8209;868596 on tumor blood flow and permeability via DCE&#8209;MRI;  To assess any preliminary clinical evidence of anti&#8209;tumor activity using RECIST|50|NCT00949624|December 2005
2669|Active not recruiting|Lidocaine For Neuroprotection During Cardiac Surgery||Drug:Lidocaine;  Drug:Placebo|Interventional||Other / NIH / Industry|Changeincognitivefunctionfrombaseline;  Platelet and white blood cell activation gradients;  Change in quality of Life as measured by questionnaires;  Change in neurological function as measured by neurological assessment scores|476|NCT00938964|July 2009
2670|Completed                  Has Results|Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase&#174;||Behavioral:Neurobehavioraltesting;  Other:Visualandauditoryassessments|Observational||Industry|Number of Participants Who Were Screened For The Follow-On Study With an Investigational Agent;  Number of Participants With a Score of at Least 90 on The General Conceptual Ability (GCA) Sub-Scale of The Differential Ability Scale (DAS)|33|NCT00937794|July 2009
2671|Completed|Relationship Between Natural Killer Cells&apos; Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2||Other:flowcytometry;  Other:immunologictechnique;  Other:laboratorybiomarkeranalysis|Observational||Other / NIH|Correlation of in vitro lysis of autologous pre-treatment acute myeloid leukemia (AML) blasts with relapse-free survival;  Correlation of expression of inhibitory and activating ligands on AML blast cells with relapse-free survival;  Correlation of expression of activating and inhibitory natural killer (NK) receptors on interleukin-2-expanded cells with relapse-free survival;  Comparison of the susceptibility to autologous NK cell lysis of leukemic blasts obtained at diagnosis with those blasts obtained at relapse|451|NCT00896701|January 2004
2672|Terminated                  Has Results|Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer||Drug:Temsirolimus;  Drug:Diphenhydramine|Interventional|Phase 2|Other|Change in Circulating Tumor Cell (CTC) Counts in Men With Metastatic Treatment-refractory Castration-resistant Prostate Cancer.;  Percent Change in CTC Count From Baseline to 12 Weeks of Treatment.;  Mean Percent of N-cadherin Expression at Baseline and 8 Weeks of Treatment.;  PercentChangeinLDH;  MedianProgression-FreeSurvival(PFS);  Maximum Rate of Change of Prostate-Specific Antigen (PSA).;  TimetoPSAProgression;  Time to Second PSA Progression After Addition of Anti-androgen Therapy;  ChangeOverTimeinCTCGeneExpressionProfile;  SafetyandTolerabilityofTemsirolimus|11|NCT00887640|July 2009
2673|Completed|Online Cognitive Behavioral Therapy for Bulimia Nervosa||Behavioral:CognitiveBehavioralGroupTherapy|Interventional||Other / NIH|Abstinencefrombinge/purgeepisodes;  Reductionofbinge/purgeepisodes;  Maintenanceofbehaviorchange|196|NCT00877786|April 2008
2674|Completed                  Has Results|Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema||Drug:Dexamethasone|Interventional|Phase 2|Industry|Change From Baseline in Central Retinal Thickness in the Study Eye;  Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye;  Percentage of Patients With at Least 10 Letters of Improvement in BCVA From Baseline in the Study Eye;  Percentage of Patients With Fluorescein Leakage as Measured by Fluorescein Angiography (FA) in the Study Eye|56|NCT00799227|January 2009
2675|Completed|Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas||Biological:GAA/TT-peptidevaccineandpoly-ICLC|Interventional|Phase 0|Other / Industry|InductionofGAA-specificT-cellresponse;  The incidence and severity of adverse events associated with the vaccine regime will be assessed with an early stopping rule based on the frequency of Regimen Limiting Toxicity (RLT).;  Clinical Response: Radiological response will be determined using the standard WHO response criteria. Based on serial magnetic resonance imaging (MRI) scans 2-year progression-free survival (PFS) will be evaluated in an exploratory manner.;  Biopsy/resection will be encouraged for patients who develop progression. Whenever post-vaccine tumor tissues are available they will be analyzed for GAA expression status and infiltration of GAA-specific T-cells.;  Influence of RT on induction of GAA-specific immune response: we will compare the rate and magnitude of GAA-specific immune responses in Cohorts 1 and Cohort 2 using IFN-gamma-enzyme-linked immuno-spot (ELISPOT) and tetramer assays.|13|NCT00795457|January 2009
2676|Completed                  Has Results|Placebo-controlled Trial of Transdiscal Radiofrequency Annuloplasty||Device: The Transdiscal Radiofrequency Annuloplasty|Interventional|Phase 1|Industry|PhysicalFunction;  Pain;  Disability|64|NCT00750191|September 2007
2677|Completed|Coping Skills for Patients With Chronic Obstructive Pulmonary Disease (COPD) and Their Caregivers||Behavioral: Telephone-based Enhanced Coping Skills Training (CST);  Other: Usual Medical Care and COPD education and symptom monitoring (UMC)|Interventional||Other / NIH|Composite measure of psychological quality of life composite index of all cause mortality and COPD-related hospitalization.;  Compositemeasureofsomaticqualityoflife|746|NCT00736268|August 2008
2678|Completed                  Has Results|Evaluating the Effectiveness of a Stepped-Care Approach to Long-Term Weight Loss (The Step-Up Study)||Behavioral: Standard Behavioral Weight Loss Program;  Behavioral:Stepped-CareWeightLossProgram|Interventional||Other / NIH|WeightLoss;  PhysicalActivity;  EnergyIntake;  CardiovascularFitness;  BodyComposition|363|NCT00714168|March 2008
2679|Terminated                  Has Results|Phase 2 Study of Safety Efficacy and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia||Drug:daptomycin;  Drug:vancomycin|Interventional|Phase 2|Industry|Number of Participants With Treatment-emergent Creatine Phosphokinase (CPK) Elevations;  Number of Participants With Elevated Serum Creatinine;  Number of Participants With Treatment Cure at End of Therapy (EOT) Visit;  Number of Participants With Treatment Cure at Test of Cure (TOC)/Safety Visit|38|NCT00695903|September 2008
2680|Completed|Physical Activity Following Surgery Induced Weight Loss||Behavioral:PhysicalActivity|Interventional||Other|Insulin sensitivity intramyocellular lipid total body fat total lean mass;  Intra-muscular adipose tissue abdominal fat mitochondria content fat oxidation|128|NCT00692367|December 2007
2681|Completed                  Has Results|Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy||Drug:SunitinibMalate|Interventional|Phase 2|Other / Industry|Change in Apoptotic Indices Before and After Treatment;  Change in Proliferation Indices Before and After Treatment;  Number of Patients Experiencing Grade &#8805;4 Hematologic or Grade &#8805;3 Non-hematologic Toxicity;  ChangeinPathologic(MicrovesselDensity).;  Change in Systemic Parameters Before and After Sunitinib Malate Treatment.;  Protein Levels and Activation Status of PDGFR in Prostate Cancer Tissue.;  Difference in Gene Expression Patterns Using Microarray Analysis;  InterstitialFluidPressure(IFP)|30|NCT00672594|July 2006
2682|Withdrawn|A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma||Drug:buthioninesulfoximine;  Drug:melphalan;  Genetic:microarrayanalysis;  Other:highperformanceliquidchromatography;  Other:laboratorybiomarkeranalysis;  Other:pharmacologicalstudy;  Procedure:biopsy|Interventional|Phase 1|Other / NIH|Maximum tolerated dose of melphalan when administered as an isolated limb infusion in combination with a systemic infusion of buthionine sulfoximine (BSO);  Dose-limiting toxicity of regional melphalan when administered with systemic BSO;  Clinicalresponse;  Effectiveness of systemic BSO in decreasing tumor glutathione (GSH) levels and its effect on GST activity and GST expression;  Correlation between tumor GSH levels and GSH levels in peripheral blood mononuclear cells to determine if the latter can serve as a surrogate marker for tumor GSH depletion;  Pharmacokinetics;  mRNAexpressionsignatureofmelphalanresistance;  Efficacy as defined by the RECIST criteria modified for cutaneous lesions;  Correlation of baseline mRNA expression signature of melphalan resistance with treatment efficacy|0|NCT00661336|April 2008
2683|Active not recruiting                  Has Results|Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme||Biological:PEP-3vaccine;  Biological:sargramostim;  Drug:Temozolomide|Interventional|Phase 2|Other / NIH|HumoralandCellularImmuneResponse;  Clinical Efficacy of Vaccination in Terms of Progression-free Survival (PFS);  ResponsetoVaccination;  ToxicitytoPEP-3VaccineImmunization|40|NCT00643097|September 2007
2684|Completed|DAMES: Daughters And MothErS Against Breast Cancer||Behavioral:StandardizedMaterialsGroup;  Behavioral:IndependentTailoredIntervention;  Behavioral: Partner-Assisted Tailored Intervention|Interventional||Other / NIH|OverallAccrual|482|NCT00630591|February 2008
2685|Terminated|Effect of Spinal Ketorolac on Mechanical Hypersensitivity After a Total Hip Replacement||Drug:ketorolactromethamineopthalmicsolution;  Drug:placebo|Interventional|Phase 2|Other / NIH|The primary outcome measure area of hypersensitivity to mechanical stimuli surrounding the wound 48 hr after surgery remains the same and is only a surrogate measure for developing chronic pain.;  A secondary purpose of this study is to determine the predictive value of 3 simple preoperative tests for severity of acute pain following surgery|62|NCT00621530|March 2008
2686|Terminated|Three Way Interaction Between Gabapentin Duloxetine and Donepezil in Patients With Diabetic Neuropathy||Drug:donepezil;  Drug:duloxetine;  Drug:donepezil2.5mgandduloxetine30mg;  Drug:placebo;  Drug:gabapentin|Interventional||Other / NIH|Pain intensity measurements will be recorded twice daily using McGill short form pain questionnaire on the PDA. The Visual Analog Pain Scale (VAS) will serve as the primary outcome measure.|22|NCT00619983|February 2008
2687|Completed|Paroxetine-CR (Paxil-CR) in the Treatment of Patients With Fibromyalgia Syndrome||Drug:ParoxetineCR;  Drug:Placebo|Interventional|Phase 4|Other / Industry|Twenty five percent change from baseline in Fibromyalgia Impact Questionnaire (FIQ) total scores;  Change from baseline in FIQ Number of tender points Beck Depression Inventory II Beck Anxiety Inventory Visual Analog Scale for pain;  Recording of spontaneous adverse events throughout the screening run-in and treatment phases of the study|120|NCT00610610|January 2002
2688|Active not recruiting|Education Intervention in Encouraging Health Providers to Talk With Cancer Patients About the Use of Complementary and Alternative Medicine||Other:educationalintervention;  Other:questionnaireadministration|Interventional|Phase 3|Other / NIH|Proportion of patients who report that the health provider discussed complimentary and alternative medicine (CAM) use;  Frequency with which health providers ask about CAM use and referral for CAM use by health providers;  Relationship between personal CAM use among health providers and frequency of asking patients about CAM use;  Frequency and type of CAM use among patients diagnosed with cancer|1360|NCT00608933|June 2008
2689|Unknown&nbsp;&#8224;|Statin Therapy Versus Placebo Prior to Prostatectomy||Drug:Simvastatin;  Other:Placebo|Interventional||U.S. Fed / Other|Measure the effect of pre-operative simvastatin versus placebo on the mevalonate pathway synthesis and target activation in benign and malignant prostate tissue.;  Compare the effect of pre-operative simvastatin versus placebo on prostate cancer cell apoptosis and its mediators in men undergoing planned prostatectomy.|44|NCT00572468|December 2007
2690|Completed                  Has Results|A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults||Drug:VI-0521;  Drug:topiramate;  Drug:phentermine|Interventional|Phase 3|Industry|PercentWeightLossFromBaselinetoWeek28;  Percentage of Subjects With at Least 5% Weight Loss at Week 28 With LOCF|756|NCT00563368|December 2007
2691|Completed|Magnetic Seizure Therapy (MST) for Severe Mood Disorder||Device:Thymatron;  Device:MagstimTheta|Interventional|Phase 3|Other|Clinical improvement (Hamilton Rating Scale for Depression);  Clinical improvement (Inventory of Depressive Symptomatology - Clinician-Rated)|75|NCT00488748|June 2007
2692|Completed|To Compare the Gastroprotective Effects and Pharmacokinetic Profile of PA Versus Enteric-Coated Aspirin||Drug:aspirin;  Drug:omeprazole|Interventional|Phase 1|Industry|To compare the gastroprotective effects of a once-daily dose of PA 325;  To evaluate the safety and GI tolerability including ulcerogenic potential the pharmacokinetic profile and the effect on gastric pH of PA 325|80|NCT00442052|November 2006
2693|Completed|A Parallel Group Study to Compare the Gastroprotective Effects of PA 325 Versus 81 mg Enteric Coated Aspirin||Drug:aspirin;  Drug:omeprazole|Interventional|Phase 1|Industry|The primary endpoint is the occurrence of gastric and/or duodenal bulb lesions meeting Grade 3 or Grade 4 Lanza (1988) scores for the stomach and duodenal bulb (combined).;  Secondary endpoints include the incidence of gastric and/or duodenal ulcers total number of gastric and/or duodenal erosions gastric pH and any other GI tolerability issues.|80|NCT00441519|February 2007
2694|Completed|To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane Headaches||Drug:sumatriptan;  Drug:naproxensodium|Interventional|Phase 3|Industry|Trexima will be evaluated for efficacy as an acute treatment for migraine based on its superiority over placebo at 2 hours for: a) pain relief (no or mild pain) b) incidence of photophobia c) incidence of phonophobia and d) incidence of nausea.;  a) sustained pain relief over 24 hours b) sustained photophobia-free over 24 hours c) sustained phonophobia-free over 24 hours and d) sustained nausea-free over 24 hours.|1200|NCT00434083|July 2004
2695|Completed|A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG||Drug:(MC-1)Pyridoxal5&apos;-phosphate|Interventional|Phase 3|Industry|combined incidence of cardiovascular death or nonfatal myocardial infarction on days up to and including post-operative day (POD) 30;  lengthofhospitalstayforindexhospitalization;  length of stay in intensive care unit (ICU) or coronary care unit (CCU) for index hospitalization;  incidence of cardiovascular death up to and including POD 90|3000|NCT00402506|November 2006
2696|Completed                  Has Results|Study of Campral (Acamprosate) for Alcohol Dependence in a Family Medicine Clinic||Drug:Acamprosate(Campral)|Interventional|Phase 4|Other|%Dropout;  PercentDaysAbstinent;  Retention;  PercentWithCompleteAbstinence;  %HeavyDrinkingDaysDuringTrial;  ClinicalGlobalImpressionScale;  %CompliantWithMedication|100|NCT00381043|August 2006
2697|Completed|Estrogen Receptor Gene Mutations|||Observational||NIH||0|NCT00342498|January 1994
2698|Completed|Environmental Factors in the Development of Polycystic Ovary Syndrome|||Observational||NIH|||NCT00341731|December 2000
2699|Terminated|Comparison Of Molecular Targets In Mild To Severe Asthmatics And Healthy Subjects||Procedure:Bronchoscopsy;  Procedure:Prednisolone|Interventional|Phase 1|Industry|compare key drug targets across 4 asthma phenotypes and healthy subjects;  evaluate changes in target expression in response to a 2 week course of corticosteroids across the 4 asthma phenotypes;  Histopathologyonbronchialbiopsies;  Cytospins;  targetproteinexpression;  targetexpressionintheblood;  inflammatorymarkers;  lungfunction;  RadiologicalParameters;  Qualityoflife(QoL)andsymptomscores;  Changesinmedication;  Measuresofpulmonaryinflammation;  Assessmentsoflungstructure;  activationstateofasignallingpathway;  WholeBloodTaqManand/ortranscriptomicanalysis;  newtargetsandbiomarkers;  TaqMan and/or Differential Gene Expression and Proteomics;  Pharmacogenomicsfrombloodsamples|58|NCT00331058|February 2006
2700|Completed                  Has Results|Can Group Visits Improve Outcomes of Veterans With Diabetes||Other:DiabetesGroupManagementVisits|Interventional|Phase 3|U.S. Fed|HemoglobinA1c;  SystolicBloodPressure;  Cost-effectiveness Proportion of Patients With LDL &lt; 100 Health Services Utilization Quality of Life (as Measured by DQoL) Patient Empowerment (as Measured by DES).|239|NCT00286741|June 2006
2701|Completed|Bortezomib Fluorouracil and External-Beam Radiation Therapy in Treating Patients With Stage II Stage III or Stage IV Rectal Cancer||Drug:bortezomib;  Drug:fluorouracil;  Radiation:radiationtherapy|Interventional|Phase 1|Other / NIH|Maximumtolerateddose;  Dose-limitingtoxicity;  Dose-effect relationship of bortezomib on NF-kappa B activation induced by chemoradiotherapy;  Downstream events induced by NF-kappa B activation;  Downstream events related to activation of p53 in response to treatment with chemoradiotherapy and bortezomib;  Rateofcompletepathologicremission;  Gene expression pattern of tumors as assessed by cDNA microarray analysis pre- and post-treatment|11|NCT00280176|April 2003
2702|Completed|Computer Program in Improving Communication Between Doctors and Patients With Stage IV Cancer||Behavioral:communicationlecture;  Behavioral:lectureplusCD-ROM|Interventional||Other / NIH|Number of empathic statements and responses to patients&apos; expressions of negative emotion|800|NCT00276627|February 2003
2703|Terminated                  Has Results|Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia||Drug:GemcitabineHydrochloride;  Drug:MitoxantroneHydrochloride|Interventional|Phase 2|Other / NIH|CompleteResponseRate;  DurationoftheFirstCompleteResponse;  Disease-freeandOverallSurvival;  LaboratoryCorrelates:Immunohistochemistry;  WhiteBloodCellCountatTimeofRelapse;  Percentage of Patients Making it to Bone Marrow Transplant.|24|NCT00268242|January 2006
2704|Completed|Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)||Device: CoStar Paclitaxel Drug Eluting Coronary Stent System;  Device: TAXUS&#8482; Express2&#8482; Paclitaxel-Eluting Coronary Stent|Interventional|Phase 3|Industry|MACE defined as a composite of target vessel revascularization new myocardial infarction (MI) or cardiac death;  In-segmentlatelumenloss;  Devicelesionandproceduresuccess;  IncidenceofMACE;  Coronaryangiographyintheangiographiccohort;  Targetlesionrevascularization|1701|NCT00165035|May 2005
2705|Completed|Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients||Drug:GW786034;  Drug:lapatinib|Interventional|Phase 1|Industry|Changes in pre and post treatment lab values and monitoring/reporting AES.AE&apos;s throughout study;  Labseverywkfirstcycle:day1subsequentcycles;  find max conc of drugs in blood and time it occurs find out if drugs are taken up by the body how much/for how long find out if drugs affect the size of the tumor. Blood taken day 15 22 or 37 and tumor assessed every 8 wks|65|NCT00158782|September 2004
2706|Completed|MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)||Drug:(MC-1)Pyridoxal-5&#8217;-phosphate|Interventional|Phase 2|Industry|Combined incidence of cardiovascular death nonfatal myocardial infarction and nonfatal cerebral infarction on days up to and including post-operative day 30.;  Combined incidence of cardiovascular death nonfatal myocardial infarction and nonfatal cerebral infarction up to and including post-operative day (POD) 90;  Incidence of cardiovascular death up to and including POD 4 POD 30 POD 90;  Incidence of nonfatal myocardial infarction up to and including POD 4 POD 30 POD 90;  Incidence of all cause morality up to and including POD 4 POD 30 POD 90;  Global disability as measured by the Modified Rankin scale at POD 30 and POD 90;  MMSEscoreatPOD30andPOD90;  Among patients with a confirmed cerebral infarction severity of stroke as measured by the National Institutes of Health Stroke Scale (NIHSS) at the time of stroke diagnosis and at subsequent study visits up to and including POD 90;  Psychometric testing results as measured by a short battery of tests at POD 4 POD 30 and POD 90 on a subset of approximately 150 volunteers per treatment arm;  CK-MBAUC(0-24hours)|900|NCT00157716|April 2004
2707|Completed|Anti-CD20 Antibody Therapy for Sjogren&apos;s Syndrome||Drug:Rituximab|Interventional|Phase 1|NIH / Other|Grade 3 4 or 5 toxicity related to rituximab administration|12|NCT00101829|April 2004
2708|Terminated|Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer||Drug:MotexafinGadoliniumInjection|Interventional|Phase 1|Industry||18|NCT00080028|
2709|Completed|Akathisia (Restless Legs Syndrome) in People With Schizophrenia and Mental Retardation|||Observational|Phase 3|NIH|||NCT00065286|December 1996
2710|Completed|GW786034 in Treating Patients With Advanced Solid Tumors||Drug:pazopanibhydrochloride|Interventional|Phase 1|Other / NIH|Safety and toxicity assessed weekly during treatment;  Diseaseresponseevery9weeks||NCT00060151|December 2002
2711|Completed|The DIAMOND Study: Distensibility Improvement And Remodeling in Diastolic Heart Failure||Drug:ALT-711|Interventional|Phase 2|Industry||20|NCT00043836|July 2002
2712|Completed|A Study of DPC 817 in HIV-Infected Males||Drug:DPC817|Interventional|Phase 1|Industry||30|NCT00040274|
2713|Completed|Treatment of Functional Bowel Disorders||Drug:Desipramine;  Behavioral:CognitiveBehavioralTreatment|Interventional|Phase 3|NIH||300|NCT00006157|July 1996
2714|Completed|Temozolomide in Treating Patients With Progressive Low-Grade Glioma||Drug:temozolomide|Interventional|Phase 2|Other / NIH|Responserate;  Activityoftemozolomide|100|NCT00003466|March 1998
2715|Completed|Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal||Biological:aldesleukin;  Biological:gp100antigen;  Biological:tyrosinasepeptide|Interventional|Phase 1 / Phase 2|Other / NIH|||NCT00003229|July 1997
2716|Completed|LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases||Biological:LMB-7immunotoxin|Interventional|Phase 1|Other / NIH||24|NCT00003020|September 1997
2717|Completed|Chemotherapy in Treating Patients With Recurrent Malignant Glioma||Drug:carmustine;  Drug:topotecanhydrochloride|Interventional|Phase 1|Other||36|NCT00002986|February 1997
2718|Completed|Carboplatin in Patients With Progressive Gliomas||Drug:carboplatin|Interventional|Phase 2|Other||25|NCT00002749|February 1993
2719|Withdrawn|A Study of Zidovudine in HIV-Infected Patients With Kidney Problems||Drug:Zidovudine|Interventional|Phase 1|NIH||0|NCT00000685|
2720|Completed|Treatment of Obsessive-Compulsive Disorder (OCD) in Children||Behavioral:CognitiveBehaviorTherapy;  Behavioral:EducationalSupport;  Drug:Sertraline|Interventional|Phase 3|Other / NIH|||NCT00000384|May 1997
2721|Recruiting|Weight Loss and Exercise for Communities With Arthritis in North Carolina||Behavioral:Diet&amp;Exercise;  Behavioral:AttentionControl|Interventional|Phase 3|Other / NIH|Change in knee pain in overweight and obese adults with knee Osteoarthritis compared to an attention-control group measured by WOMAC Pain Scale.;  Change in knee function in overweight and obese adults with knee Osteoarthritis compared to an attention-control group measured by WOMAC Function Scale.;  Change in Health Related Quality of Life in overweight and obese adults with knee Osteoarthritis compared to an attention-control group measured by SF-36.;  Change in mobility in overweight and obese adults with knee Osteoarthritis compared to an attention-control group measured by six minute walk.;  Measurement of the cost-effectiveness of the implemented strategies for the diet/exercise intervention and budget impact analysis.|820|NCT02577549|January 2016
2722|Completed|Alternate Dosing Schedules Study for HPV Vaccine (ADS)||Biological:Both2ndand3rddosesontime;  Biological:2nddoselateand3rddoseontime;  Biological:2nddoseontimeand3rddoselate;  Biological:Bothdoseslate|Observational|Phase 4|Other / U.S. Fed|HPV6GMT;  HPV11GMT;  HPV16GMT;  HPV18GMT|331|NCT02280642|March 2009
2723|Active not recruiting|Short Messaging Service for Optimizing Hemoglobin A1C Management in Low-Income Diabetics||Other:Texting|Interventional||Other|ChangefrombaselineA1C;  Adherencetomedicalappointments;  Change in A1C based on age gender race type and duration of diabetes;  Timenecessarytocompleteserviceimplementation|170|NCT02049359|January 2014
2724|Completed|Carolina-ColoWrap&#174; in Colonoscopy Performance and Outcomes Study||Device:ColoWrap|Interventional||Industry / Other|Meancolonoscopicinsertiontime;  Frequencyofuseofancillarymaneuvers;  Frequencyofprolongeddifficultcases;  DrugandDosageRequiredtoCompleteProcedure;  ColonoscopyCompletionRate;  Timetopatientdischarge;  Operatorperceptionofpatientdiscomfort;  Patient Pain Bloating and Satisfaction at Discharge;  Operator&apos;sAssessmentofProceduralDifficultly;  Assistant/Technician&apos;s Assessment of Musculoskeletal Pain Following Procedure|350|NCT02025504|April 2014
2725|Completed                  Has Results|Evaluation of Moclobemide a Reversible MAO-A Inhibitor as an Adjunct to Nicotine Replacement Therapy in Female Smokers||Drug:NicotinePatch;  Drug:Moclobemide|Interventional|Phase 2|Other / Industry / NIH|ContinuousFour-weekAbstinenceFromSmoking;  Point Abstinence From Smoking at Six Months Post Quit;  ContinuousTenWeekAbstinenceFromSmoking;  Percentage of Change in Smoking Withdrawal Symptoms;  Percentage of Change in Expired Air Carbon Monoxide (CO) During the First Week of Nicotine Patch Treatment.|76|NCT01926626|September 2013
2726|Completed|Vitamin D2 Muscle Damage NASCAR Pitcrew||DietarySupplement:VitaminD2mushroompowder;  Other:Placebo|Interventional||Other / Industry|Muscledamage;  MuscleFunction;  SerumvitaminDconcentration;  ImmuneFunction|33|NCT01825616|October 2012
2727|Active not recruiting|Serial Collection of Primary Progressive Multiple Sclerosis Participants in the MURDOCK Study||Other: generation of &apos;omic markers of disease progression|Observational||Other|Generation of &apos;omic markers of disease progression|100|NCT01776060|January 2013
2728|Active not recruiting|Cooperative Lifestyle Programs (CLIP-II)||Behavioral:Caloricrestriction;  Behavioral:AerobicTraining;  Behavioral:ResistanceTraining|Interventional||Other|400-MwalktestandLowerLegStrength;  CTScan|273|NCT01547182|March 2012
2729|Completed|Telemonitoring Study - for Chronic Myeloid Leukemia (CML)||Behavioral:noaccesstoeMedonline;  Behavioral:eMedonlineaccess|Interventional||Other / Industry|eMedonline will be used to measure non-compliance in taking oral drug regimens.|14|NCT01490983|April 2009
2730|Recruiting|Cosmetic Evaluation of Lumpectomy Versus Oncolytic Mammoplasty With Bilateral Breast Reduction for Early Stage Breast Cancer|||Observational||Other / NIH|Evaluation of cosmetic results as judged by the patient surgeon and radiation oncologist at stated follow-up intervals that will judge cosmesis by serial photography and quality of life (QOL) forms.;  Ipsilateral breast recurrence rate. Disease status will be evaluated at routine patient follow-up appointments including routine mammography.;  Contralateral breast cancer rate. This will be monitored according to routine protocol including yearly mammograms and clinical breast exams.|84|NCT01400399|August 2010
2731|Completed|PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin&#174;)(OND003IND)||Drug:OND-PR002andMPh-IR;  Other: Placebo: Two dextrose capsules for Ond-PR002 and MPh-IR|Interventional|Phase 2|Other / NIH|Efficacy of combined Ond-PR002 and MPh-IR treatment;  SafetyofcombinedMPh-IR+Ond-PR002treatment;  Changes in the PK parameters of Ond-PR002 PK after 14-day treatment;  Changes in the PK parameters of MPh-IR PK after 14-day treatment;  Tolerability of combined MPh-IR + Ond-PR002 treatment|30|NCT01377662|August 2011
2732|Active not recruiting|Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma||Radiation:RadiationTherapy|Interventional||Other|To determine if high rates of local control can be maintained after a reduction in the RT dose and volume after 4 to 6 cycles of rituximab containing chemotherapy.;  Progression-freesurvival;  OverallSurvival;  Toexaminepatternsoffailure|62|NCT01186978|October 2010
2733|Completed                  Has Results|Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection||Drug:Etravirine(Intelence);  Drug:Truvada|Interventional|Phase 2|Other / Industry|The Antiretroviral Activity of Etravirine 400 mg Given Once Daily With Fixed-dose Truvada Once Daily Among Treatment-na&#239;ve HIV-1 Infected Adults as Measured by the Percentage of Participants With HIV RNA &lt; 50 Copies/mL at Week 24;  The Proportion of Participants With HIV RNA &lt;50 Copies/mL at Week 48 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine;  The Proportion of Participants With HIV RNA &lt;50 Copies/mL at Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine;  The Proportion of Participants With HIV RNA &lt;200 Copies/mL at Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine;  The Proportion of Participants With HIV RNA &lt;200 Copies/mL at Week 48 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine;  The Proportion of Participants With HIV RNA &lt;200 Copies/mL at Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine;  Change in CD4+ Cell Count From Baseline to Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine;  Change in CD4+ Cell Count From Baseline to Week 48 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine;  Change in CD4+ Cell Count From Baseline to Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine;  Resistance Mutations in the Subset of Patients With Confirmed Virologic Failure Who Have HIV RNA &gt;500 Copies/mL and Genotype Resistance Results;  Tolerability of Etravirine in HIV-1 Infected Adults Initiating Antiretroviral Therapy;  Probability of Remaining Free of a Safety/Tolerability Event at 96 Weeks;  Change in the Lipid Profile and Glucose Metabolism in a Subgroup of up to 40 Participants From Baseline to Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine;  Change in Glucose Metabolism (Insulin Resistance) in a Subgroup of up to 40 Participants From Baseline to Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine;  Change in the Lipid Profile and Glucose Metabolism in a Subgroup of up to 40 Participants From Baseline to Week 48 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine;  Change in Glucose Metabolism (Insulin Resistance) in a Subgroup of up to 40 Participants From Baseline to Week 48 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine;  Change in the Lipid Profile and Glucose Metabolism in a Subgroup of up to 40 Participants From Baseline to Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine;  Change in Glucose Metabolism (Insulin Resistance) in a Subgroup of up to 40 Participants From Baseline to Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine;  Change in Limb and Trunk Fat Distribution as Measured by DEXA Scan in the Same Subgroup of up to 40 Participants (as in Aim 8) From Baseline to Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine;  Change in Limb and Trunk Fat Distribution as Measured by DEXA Scan in the Same Subgroup of up to 40 Participants (as in Aim 8) From Baseline to Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine;  Change in Fat Mass Ratio as Measured by DEXA Scan in the Same Subgroup of up to 40 Participants (as in Aim 8) From Baseline to Week 24 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine;  Pharmacokinetics of Etravirine in Genital Secretions of up to 10 Men and up to 10 Women at Week 4 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine;  Change in Fat Mass Ratio as Measured by DEXA Scan in the Same Subgroup of up to 40 Participants (as in Aim 8) From Baseline to Week 96 of Treatment With Etravirine and Fixed-dose Tenofovir/Emtricitabine;  Population Pharmacokinetics of Etravirine 400 mg Once Daily in Combination With Fixed-dose Emtricitabine-tenofovir Among Treatment-na&#239;ve HIV-1 Infected Adults;  Population Pharmacokinetics of Etravirine 400 mg Once Daily in Combination With Fixed-dose Emtricitabine-tenofovir Among Treatment-na&#239;ve HIV-1 Infected Adults: Etravirine AUC-24 Hours at Steady State|80|NCT00959894|September 2009
2734|Recruiting|Augmentation of Screening Colonoscopy With Fecal Immunochemical Testing||Device:FecalImmunochemicalTesting|Interventional||Other|rate of significant colon neoplasia among those who enter a screening or surveillance program with FIT testing added at yearly intervals vs. that of &quot;usual care&quot; patients in the same patient population.;  the pathology found at repeat colonoscopy in each group.|4100|NCT00892593|May 2009
2735|Completed                  Has Results|Alternate Dosing Schedules Study for HPV Vaccine||Biological:ReceivedHPVvaccinefirst;  Biological:Receivedconcomitantvaccinesfirst|Interventional|Phase 4|Other / U.S. Fed|PainFollowingHPVVaccine|72|NCT00862810|March 2009
2736|Terminated                  Has Results|Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC||Drug:Dasatinib|Interventional|Phase 2|Other / Industry|TumorResponse;  OverallSurvival;  Grade 3-5 Toxicity Associated With Dasatinib Treatment;  Describe Change in Serum Levels of C-terminal Cross-linked Collagen I Between Pre-treatment and 6 Weeks After Starting Dasatinib.;  Determine Relationship Between K-ras Gene Mutation and Response to Dasatinib.|37|NCT00787267|September 2008
2737|Terminated|A Phase I/Expansion Study of Dasatinib||Drug:gemcitabine;  Drug:dasatinib|Interventional|Phase 1|Other / Industry|To determine the MTD/Recommended Phase II Dose (RPTD) of gemcitabine plus dasatinib once daily and twice daily dosing in patients with advanced solid tumors;  To describe any dose limiting toxicities for these regimens;  To describe and non-dose limiting toxicities for these regimens;  To preliminarily describe markers of efficacy for gemcitabine plus dasatinib in patients with previously untreated metastatic pancreatic cancer: response rate progression free survival overall survival.;  To preliminarily describe changes in blood and urine based biomarkersat baseline compared to first restaging and at progression for patients with previously untreated metastatic pancreatic cancer treated on the expanded cohorts at the MTD/RPTD.|30|NCT00598091|April 2007
2738|Terminated|PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma||Drug:PTK787|Interventional|Phase 2|Other / Industry|Response;  Safety|20|NCT00511043|November 2005
2739|Completed|Effects of Anti-HIV Therapy on Red Blood Cells of HIV-infected Mothers and Their Infants|||Observational||NIH||0|NCT00342082|June 2004
2740|Completed|Gemcitabine Paclitaxel and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium||Drug:cisplatin;  Drug:gemcitabinehydrochloride;  Drug:paclitaxel;  Procedure:conventionalsurgery|Interventional|Phase 2|Other / NIH|Response;  Responseduration;  Freedomfromprogression;  Overallsurvival;  Toxicity|71|NCT00310011|June 1998
2741|Completed|Combination Chemotherapy Bev RT and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer||Biological:bevacizumab;  Drug:carboplatin;  Drug:erlotinibhydrochloride;  Drug:paclitaxel;  Radiation: 3-dimensional conformal radiation therapy|Interventional|Phase 1 / Phase 2|Other / NIH|Maximum dose of erlotinib when given together with carboplatin paclitaxel and thoracic conformal radiotherapy (Phase I [closed to accrual as of 1/3/2008]);  Safety and toxicity profile of combining both bevacizumab and erlotinib hydrochloride with carboplatin paclitaxel and thoracic conformal radiotherapy (Phase I [closed to accrual as of 1/3/2008]);  CombinationChemotherapyBevRTandErlotinib;  Overalltoxicityprofile(PhaseII);  Response rate to induction therapy (Phase I [closed to accrual as of 1/3/2008] and II);  Toxicity profile of induction therapy (Phase I [closed to accrual as of 1/3/2008] and II);  Overall response rate and survival profile (Phase I [closed to accrual as of 1/3/2008] and II);  Feasibility and tolerability of administering consolidation therapy after induction therapy and chemoradiotherapy (Phase I [closed to accrual as of 1/3/2008] and II)|48|NCT00280150|January 2006
2742|Completed|Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy||Drug:lapatinibditosylate|Interventional|Phase 2|Other / NIH|Proportion of patients with early hormone refractory prostate cancer experiencing decrease in measurable disease after treatment with lapatinib (GW572016).;  Numberofpatientsexperiencingadverseevents;  TimetoPSAprogression;  Predictive molecular markers in response to treatment with lapatinib (GW572016)|35|NCT00246753|October 2005
2743|Completed|Exercise and Weight Loss for Improving Mobility in Older Adults Who Are Obese||Behavioral:Exercise;  Behavioral:WeightLoss;  Behavioral:HealthEducationControl|Interventional||Other / NIH|400meterwalk|288|NCT00119795|August 2005
2744|Not yet recruiting|A Collaborative Palliative and Oncology Care Model for Patients With Acute Myeloid Leukemia||Other:StandardLeukemiaCare;  Other:PalliativeCare|Interventional||Other|Comparison Of The Change In Patients&apos; FACT-Leukemia Score From Baseline To Week-2 Between Study Arms;  Compare Change In FACT-Leukemia Scores From Baseline To Months 1 3 And 6 And Longitudinally Between The Study Arms.;  Compare Rates of Patients&apos; Depressive Symptoms (as per HADS) and Major Depressive Syndrome (as per PHQ-9) at Baseline Week-2 Months 1 3 and 6 and Longitudinally Between the Two Arms;  Compare Change In Patients&apos; Fatigue Scores (as per FACT-fatigue) From Baseline To Week-2 Baseline To Months 1 3 And 6 And Longitudinally Between Study Arms.;  Compare Symptom Burden (as per ESAS) At Baseline Week-2 Months 1 3 And 6 And Longitudinally Between Study Arms.;  Compare Rates Of Patient-Reported PTSD (as per PCL) At Week-2 Months 1 3 And 6 And Longitudinally Between Study Arms.;  Compare Patient-Report Of Discussion EOL Care Preferences Between Study Arms;  Compare Rates Of Documentation Of EOL Care Preferences (i.e. code status yes documented vs. no) In The Electronic Health Record Between The Two Study Arms Within 30 Days Of Death;  Compare Rates Of Chemotherapy Administration Within 3 7 14 And 30 Days Of Death Between The Two Study Arms;  Compare Rates Of Hospitalizations Within 3 7 14 And 30 Days Of Death Between The Study Arms;  Compare Rates Of Hospice Utilization And Length-Of-Stay In Hospice At The EOL Between The Study Arms.|160|NCT02975869|December 2016
2745|Not yet recruiting|Internet-Delivered Positive Affect Program in Managing Emotion in Young Adult Cancer Survivors||Other:Internet-BasedIntervention;  Procedure:Quality-of-LifeAssessment;  Other:QuestionnaireAdministration;  Behavioral:Telephone-BasedIntervention|Interventional||Other / NIH|Acceptability;  Accrual;  Adherence;  Refusal;  Retention|60|NCT02832154|August 2016
2746|Recruiting|MEtformin and Lorcaserin for WeighT Loss in Schizophrenia||Drug:Lorcaserin;  Drug:Metformin;  Drug:Placebo|Interventional|Phase 4|Other / NIH|Mean Difference in Body Weight Change Between Participants Assigned to lorcaserin/metformin combination treatment and placebo;  Mean Difference in Body Weight Change Between Participants Assigned to lorcaserin monotherapy treatment and placebo;  Change in HDL Cholesterol From Baseline to 52 Weeks;  Change in LDL Cholesterol From Baseline to 52 Weeks;  ChangeinTriglyceridesFromBaselineto52Weeks;  Change in Total Cholesterol From Baseline to 52 Weeks;  Change in Hemoglobin A1c From Baseline to 52 Weeks;  Change in Fasting Glucose From Baseline to 52 Weeks|110|NCT02796144|September 2016
2747|Recruiting|High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML||Drug:pembrolizumab|Interventional|Phase 2|Other / Industry|The rate of CR for age-adjusted HiDAC followed by pembrolizumab 200mg on day 14.;  Rateofunacceptabletoxicity|37|NCT02768792|August 2016
2748|Recruiting|A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas||Drug:Alisertib|Interventional|Phase 1|Other / Industry|Maximumtolerateddose(MTD);  Toxicity;  RateofResponse;  Progressionfreesurvival|24|NCT02700022|July 2016
2749|Not yet recruiting|A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD||Drug:AptensioXR;  Drug:Placebo|Interventional|Phase 4|Industry|ADHD-RS-IVTotalScore;  CGI-Iscore;  CGI-Sscore|150|NCT02683265|March 2016
2750|Not yet recruiting|A 12-Month Open Label Safety Study of Aptensio XR&#174; in Children Ages 4-5 Years Diagnosed With ADHD||Drug:AptensioXR|Interventional|Phase 4|Industry|Treatment-emergentadverseevents(TEAEs);  ColumbiaSuicideSeverityRatingScale(C-SSRS);  Vitalsigns;  12-leadelectrocardiogram;  ADHD-RS-IVPreschoolVersion;  Clinical Global Impressions-Severity Scale (CGI-S);  Connors Early Childhood Behavior-Parent Short [ConnorsEC BEH-P(S)]|120|NCT02677519|September 2016
2751|Recruiting|Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma||Other:LaboratoryBiomarkerAnalysis;  Biological:Nivolumab;  Other:PharmacogenomicStudy|Interventional|Phase 2|NIH|Durationofresponse;  Incidence of adverse events of nivolumab graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0;  Tumor response evaluated using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors guideline (version 1.1);  Effectsoftreatment;  HTLV-1clonality;  HTLV-1specificCT&apos;s;  Immunecellnumbers;  Timeontheviralloadmeasurements|20|NCT02631746|June 2016
2752|Not yet recruiting|Selinexor Carfilzomib and Dexamethasone Versus Placebo Carfilzomib and Dexamethasone in Multiple Myeloma||Drug:Selinexor;  Drug:Placebo(forselinexor);  Drug:carfilzomib;  Drug:Dexamethasone|Interventional|Phase 2|Industry|ProgressionFreeSurvival(PFS);  OverallResponseRate(ORR)|90|NCT02628704|December 2015
2753|Recruiting|Evaluation of Intracoronary Hyperoxemic Oxygen Therapy in Anterior Acute Myocardial Infarction Patients (IC-HOT)||Device:SSO2Therapy|Interventional||Industry|NetAdverseClinicalEvents(NACE)|100|NCT02603835|December 2015
2754|Recruiting|Targeted Electrotherapy for Aphasia Stroke Rehabilitation (TEASER) - Phase II Multi-Center Study||Device:HD-tDCS(SoterixMedicalActive);  Device:HD-tDCS(SoterixMedicalSham)|Interventional|Phase 2|Industry / NIH / Other|Effect size of HD-tDCS for the adjunctive treatment of anomia in chronic aphasia after stroke;  Determinealternateoutcomemeasures|58|NCT02540109|July 2015
2755|Recruiting|Optimal Management of Pain in Hospitalized Patients - Opioid Tolerant Populations.||Other:NewClinicalPathway|Interventional||Other|HospitalreadmissionorERvisit;  Amountofreductioninopioiddose;  Lengthofstay|1200|NCT02470728|January 2016
2756|Recruiting|Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD||Drug:MethylphenidateHClERCapsules|Interventional|Phase 4|Industry|Cmax;  AUC(0-t);  AUC(0-inf);  AUC/D;  CL/F;  V(dss)/F;  Cmax/dose;  Tmax;  T1/2;  Eliminationrateconstant(Kel)|60|NCT02470234|February 2016
2757|Enrolling by invitation|Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD||Drug:VitaminD3|Interventional|Phase 2|Other|Change from baseline in lung cathelicidin level at 8 weeks;  Change from baseline in blood cathelicidin at 8 weeks;  Change from baseline in blood vitamin D binding protein at 8 weeks|40|NCT02464059|June 2015
2758|Recruiting|Optimizing Drug Doses in Critically Ill||Other:NoIntervention|Observational||Other|To examine whether ARC compromises renally eliminated drug therapeutic serum concentrations in patients with TBI (urine collections/ two levetiracetam serum concentrations to measure creatinine clearance and therapeutic drug concentrations);  To estimate the optimal dose needed to achieve therapeutic serum concentrations of the probe medication levetiracetam in patients with TBI|40|NCT02437838|August 2015
2759|Not yet recruiting|Prospective Comparative Assessment of Alveolar Bone Augmentation Using GUIDOR&#174; Membrane in the Bound Edentulous Space||Biological:GUIDOR&#174;membranewithFDBA;  Biological:GUIDOR&#174;membrane;  Biological:Bio-Gide&#174;membranewithFDBA|Interventional||Other / Industry|Dimensionalbonechangesat6months;  Inflammation;  Infection;  Membraneexposure|60|NCT02387008|October 2016
2760|Recruiting|A Study of the Safety and Efficacy of 514G3 in Subjects Hospitalized With Bacteremia Due to Staphylococcus Aureus||Biological:514G3;  Drug:Placebo;  Drug:StandardIVantibiotictherapy|Interventional|Phase 1 / Phase 2|Industry|DeterminationoftheMaximumToleratedDose;  Time to sterile culture from date of randomization;  Determinationoftheserumhalf-lifeof514G3;  DurationofFever;  Lengthofhospitalization|52|NCT02357966|May 2015
2761|Terminated|A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders||Biological:ProHema-CBTransplant|Interventional|Phase 1|Industry|Safety profile assessed primarily by neutrophil engraftment|1|NCT02354443|June 2015
2762|Completed|Oral Water Hydration to Prevent Post-Vaccination Presyncope||Other:OralWaterHydration|Interventional||Other / U.S. Fed|Presyncope;  Acceptability of oral water hydration in the intervention group assessed by qualitative reports in the post-vaccination observation period and response to a survey about whether they liked getting water.;  Syncope;  AlternativeCaseDefinitionofPresyncompe|1820|NCT02353390|March 2015
2763|Unknown&nbsp;&#8224;|Clinical Evaluation of GENEX&#174; DS in Instrumented Posterolateral Fusion||Device:genexbonegraftwithbonegraft;  Other:autogenousbonegraft|Observational||Industry|Fusion;  Complications|30|NCT02317185|December 2014
2764|Recruiting|Glioma Modified Atkins-based Diet in Patients With Glioblastoma||Other:Dietmodification|Interventional||Other|Feasibility of intermittent modified Atkins diet in patients with GBM assessed by percent of patients able to remain on the diet and achieve nutritional goals;  Biologic activity measured by pre- and post-study cerebral glutamate and glutamine concentrations assessed by MRS.;  Tolerability assessed by percent of patients who have an adverse reaction of any grade attributed to the diet of possible probable or definite;  DietaryActivity|25|NCT02286167|November 2014
2765|Completed|Evaluate SAGE-547 in Female Patients With Severe Postpartum Depression||Drug:SAGE-547|Interventional|Phase 2|Industry|Safety and tolerability of SAGE-547 measured by mean changes from baseline in clinical laboratory measures vital signs and ECGs; physical examination; and concomitant medication usage;  Pharmacokinetic (PK) profile of SAGE-547 as measured by AUC Cmax Tmax Css Cavg.;  Effects of SAGE-547 on patient symptom response evaluated by changes from baseline in Hamilton Rating Scale for Depression-17 (HAM-D-17) and individual Clinical Global Impression-Improvement (CGI-I) Scale scores|4|NCT02285504|September 2014
2766|Completed|Evaluate SAGE-547 in Patients With Essential Tremor||Drug:SAGE-547;  Drug:Placebo|Interventional|Phase 2|Industry|SafetyandtolerabilityofSAGE-547;  Effect of SAGE-547 on patient response as measured by accelerometer (transducer measurement of tremor amplitude);  Effect of SAGE-547 on patient response as measured globally by The Essential Tremor Rating Scale (TETRAS);  Pharmacokinetic (PK) profile of SAGE-547 as measured by AUC Cmax Tmax Css and Cavg|24|NCT02277106|September 2014
2767|Recruiting|EXTEND Exercise Trial||Drug:Enzalutamide;  Drug:Androgendeprivationtherapy;  Behavioral:Supervisedexercisetraining|Interventional|Phase 2|Other|Change in VO2peak in usual care versus exercise training arms;  Change in physical function/functional capacity over time between the usual care and exercise training arms;  Change in one repetition maximum (1RM) in upper and lower extremity muscular strength over time between the usual care and exercise training arms as well as the muscular cross sectional area (CSA) of the dominant thigh using MRI;  Change in the effect on metabolic outcome over time between the usual care and exercise training arms.;  Change in the effect on patient reported outcomes (PROs) of interest over time between the usual care and exercise training arms.;  Changeineligibilityrate;  Changeinacceptancerate;  Changeinadherencerate;  Changeinattritionrate;  Changeinadverseeventrate|56|NCT02256111|April 2015
2768|Completed|Impact of Graphic Cigarette Warnings||Other:SurgeonGeneral&apos;sWarning;  Other:GraphicWarning|Interventional||Other / NIH|Quitattempts;  Changeinquitintentions;  SuccessfulQuitting;  Changeinforgoingacigarette;  Changeinpositivereinforcementattitudes;  Changeinnegativereinforcementattitudes;  Changeinperceivedlikelihood;  Change in frequency of conversations about warning labels;  Fear;  Cognitiveelaboration|2149|NCT02247908|October 2014
2769|Recruiting|Treatment for Teens With Alcohol Abuse and Depression||Behavioral:MET/CBT-12;  Behavioral:CBT-D;  Other:D-TAU|Interventional||Other / NIH|Alcohol use frequency assessed with the Alcohol Consumption Questionnaire;  Severity of depression as measured on the Children&apos;s Depression Rating Scale-Revised (CDRS-R);  Alcohol use quantity assessed with the Alcohol Consumption Questionnaire;  Cannabis use frequency assessed with the Drug Checklist;  Diagnosis;  Teen-AddictionSeverityIndex(T-ASI);  Suicidal Ideation Questionnaire-Jr. High Version (SIQ-Jr);  Children&apos;s Global Assessment of Functioning (CGAS);  Clinical Global Impression-Improvement in Depression (CGI-I)|170|NCT02227589|January 2015
2770|Enrolling by invitation|Diagnosis and Monitoring of Eosinophilic Esophagitis Using the Cytosponge|||Observational||Other|Cytospongeaccuracyandutility;  Cytospongesafetyandacceptability|100|NCT02114606|July 2015
2771|Recruiting|Point-of-Care RBC Washing to Prevent Transfusion-Related Pulmonary Complications||Biological: Point-of-care washed red blood cell transfusion.;  Biological: Standard of care red blood cell transfusion.|Interventional|Phase 1 / Phase 2|Other|Biomarkers associated with Transfusion-Related Acute Lung Injury and Transfusion Associated Circulatory Overload.;  Numberof&quot;off-protocol&quot;transfusions;  Changeinrecipienthemoglobin;  ChangeinrecipientCellFreeHemoglobin;  Changeinhaptoglobin;  Durationofmechanicalventilation;  Durationofoxygensupplementation;  SOFAscore;  HospitalLengthofStay|170|NCT02094118|January 2016
2772|Recruiting|Efficacy and Safety of Expandable Spacer in the Treatment of Degenerative Disc Disease Using the Minimally Invasive Transforaminal Lumbar Interbody Fusion Surgical Approach||Device:CALIBER|Interventional|Phase 4|Industry / Other|Fusionanddischeightmaintenance;  PatientSelfAssessment|75|NCT02075554|July 2012
2773|Recruiting|Diabetes Self-Management &amp; Support LIVE||Behavioral:LIVE;  Behavioral:Website|Interventional||Other / NIH|ChangeinDietaryIntake;  ChangeinPhysicalActivity;  ChangeinHbA1Clevel;  ChangeinBMI;  ChangeinWaistCircumference;  ChangeinBloodPressure;  ChangeinLipidLevels|300|NCT02040038|July 2014
2774|Completed|Internet Enhanced Patient-Centered Orthopedic Care: A Prospective Randomized Controlled Pilot Trial||Other:eRehab;  Other:FormalPhysicalTherapy|Interventional|Phase 1|Other|Outcome scores for knee (KOOS) and shoulder (DASH);  NRS-11painscores|24|NCT02025400|July 2012
2775|Completed                  Has Results|Cardioneuroablation for Neurocardiogenic Syncope||Procedure:Cardioneuroablation;  Device: Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter|Interventional||Other / Industry|SyncopeRecurrenceRate;  IncidenceofSeriousAdverseEvents|3|NCT02009982|December 2013
2776|Suspended|Phase II of Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma||Drug:Doxorubicin;  Drug:Methotrexate;  Drug:Leucovorin;  Biological:Hydroxyurea;  Drug:Zidovudine;  Procedure:UrineAlkalization|Interventional|Phase 2|Other|OverallSurvivalRateofSubjects|26|NCT01964755|April 2011
2777|Completed|Cognitive ADHD Videogame Exploratory Study||Device: Neuro-typical controls and ADHD will receive EVO game play.|Interventional||Industry|Demonstrate a difference in EVO cognitive measures between neuro-typicals and ADHD subjects;  EvaluateEVOsafety;  EVOgameplayfeasibility|85|NCT01943539|September 2013
2778|Active not recruiting|High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors||Biological:trivalentinfluenzavaccine;  Other:laboratorybiomarkeranalysis|Interventional|Phase 1|Other / NIH|Estimation of geometric mean titer (GMT) seroconversion defined as the percentage of patients with at least a four-fold increase in hemagglutinin inhibition (HI) antibodies;  Estimation of GMT seroconversion defined as the percentage of patients with at least a four-fold increase in HI antibodies;  GMT;  Seroconversion;  Seroprotection rate defined as the percentage of patients with a serum HI antibody of at least 1:40|60|NCT01941758|November 2013
2779|Recruiting|Valproic Acid for the Prevention of Post-Amputation Pain||Drug:ValproicAcid;  Other:CherrySyrup|Interventional|Phase 2|Other / U.S. Fed|Efficacy of Valproic Acid in reducing the Incidence of chronic neuropathic and post-amputation pain.;  Neuropathic limb or post-amputation pain and the incidence of pain sub-types;  Effectonanalgesicrequirement;  Qualitativecharacterizationofpainsub-types|224|NCT01928849|December 2013
2780|Completed|Study of the Effects of Supplements on Eye Disease in Participants From the Age-Related Eye Disease Study|||Observational||NIH|Vision loss outcome measure is mean change in visual acuity by Early Treatment Diabetic Retinopathy (ETDRS) score.|52|NCT01915238|July 2013
2781|Completed|Mechanisms and Functional Outcomes of Exercise Progression Models in the Elderly||Other:RegionalSpecificTrainingStimulus(RSTS);  Other:AerobicExerciseRegimen(AE)|Interventional||Other / NIH|ChangeInExerciseCapacity;  ChangeinMaximalStrength;  ChangeinFunctionalAbility;  ChangeInVascularFunction;  ChangeinSkeletalMusclePhysiology|108|NCT01899586|September 2009
2782|Completed|Genetically Guided Statin Therapy||Genetic: Reporting for SLCO1B1*5 allele at randomization;  Genetic: Reporting for SLCO1B1*5 allele at the end;  Genetic:GenetictestingforSLCO1B1*5allele|Interventional||Other / U.S. Fed|ChangeinMedicationadherence;  Change in Low density lipoprotein cholesterol (LDLc);  Medicationpossessionratio(MPR);  Newstatinprescriptions;  ChangeinBriefPainInventory(BPI);  ChangeinSF-12HealthSurvey;  Physicalactivity;  ChangeinBeliefsaboutmedications(BMQ)|167|NCT01894230|July 2013
2783|Completed|Young Hearts Strong Starts||Other:Intervention;  Other:Control|Interventional|Phase 4|Other|Summary composite measure of practice performance and exposure;  Measures of guideline adherence for BMI blood pressure and tobacco use and exposure|32|NCT01893593|November 2011
2784|Completed|Effect of Lung Cancer Diagnoses on Family Behaviors|||Observational||NIH|The primary aim of the analyses is to identify for whom genetic testing for lung cancer susceptibility may be a teachable moment to promote behavior change.|600|NCT01862770|December 2012
2785|Active not recruiting|A Prospective Evaluation of the Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Patients With Solid Tumors.||DietarySupplement:curcumin;  Drug:Irinotecan|Interventional|Phase 1|Other|Maximumtolerateddose(MTD);  Pharmacokinetics|23|NCT01859858|June 2013
2786|Enrolling by invitation|Deployment Related Mild Traumatic Brain Injury (mTBI)|||Observational||U.S. Fed / Other|OvertimechangeinConcussivesymptoms;  ChangeinWorkRelatedIssues;  Automated Neuropsychological Assessment Metrics (ANAM);  ChangeinSocialInteraction;  Alcoholandcaffeineuse;  HealthUtilization|1500|NCT01847040|September 2009
2787|Recruiting|Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia||Drug:Clofarabine;  Drug:Mitoxantrone|Interventional|Phase 1 / Phase 2|Other|DetermineMTD;  ResponseRate;  MonitorforMinimalResidualDisease|55|NCT01842672|March 2013
2788|Recruiting|Randomized Controlled Trial of Group Prevention Coaching||Behavioral:ProblemSolving|Interventional|Phase 3|U.S. Fed|Riskoffatalcoronaryeventornon-fatalMI;  InternationalPhysicalActivityQuestionnaire;  BlockBrief2000FoodFrequencyQuestionnaire;  PatientActivationMeasure|400|NCT01838226|August 2014
2789|Active not recruiting|Will Veterans Engage in Prevention After HRA-guided Shared Decision Making?||Behavioral: Shared decision making with a Prevention Coach|Interventional||U.S. Fed|Enrollmentinpreventionservices;  PatientActivationMeasures;  FraminghamRiskScore|450|NCT01828567|October 2014
2790|Completed|Feasibility Study: Evaluation of the Treatment of Striae Using Ultherapy&#174; in Combination With Laser Treatment||Device:Ultherapy&#174;treatmentonly;  Device: Ultherapy&#174; treatment and CO2 laser treatment;  Device:CO2Lasertreatmentonly|Interventional||Industry|Change from baseline in overall skin texture and appearance of abdominal striae;  90DayPatientSatisfaction;  180DayPatientSatisfaction;  Change from baseline in overall aesthetic appearance of abdominal striae at 90 days;  Change from baseline in overall aesthetic appearance of abdominal striae at 180 days;  Change from baseline in skin striae texture and depth at 90 Days;  Change from baseline in skin striae texture and depth at 180 Days|14|NCT01810484|January 2013
2791|Active not recruiting|Severe Asthma Research Program - Wake Forest University|||Observational||Other / NIH|Changeinpulmonaryfunctionovertime;  Frequencyofsevereasthmaexacerbations|700|NCT01750411|December 2012
2792|Completed|Gastrin-Releasing Peptide and Bronchopulmonary Dysplasia|||Observational||Other|urineGRPlevels;  infantpulmonaryfunctiontests|260|NCT01748565|May 2012
2793|Active not recruiting|Aerobic Training in Metastatic Breast Cancer||Behavioral:ProgressiveStretchingGroup;  Behavioral:NonlinearAerobicTraining;  Other:Blooddraw;  Other:CardiopulmonaryExerciseTesting(CPET)|Interventional||Other|safetyofaerobictraining;  feasibilityofaerobictraining|27|NCT01725633|December 2010
2794|Completed|Decisionmaking for Abnormal Uterine Bleeding (AUB)||Other:AdaptiveConjointAnalysis|Interventional||Other|Differences in patient-reported satisfaction between treatment groups;  Differences in decision regret between treatment groups|380|NCT01721304|May 2009
2795|Active not recruiting|RITHM - Resonance Imaging Trial for Heart Biomarkers in Adolescent/Young (AYA) Cancer Survivors|||Observational||Other|To determine if aortic stiffness or myocardial wall strain is increased in childhood cancer survivors who received anthracycline chemotherapy;  To determine if aortic stiffness changes during treatment with anthracycline chemotherapy in childhood cancer patients|115|NCT01719094|August 2012
2796|Completed|Combination Treatment Study for Memory Impairment and Depression||Drug:Donepezil;  Drug:Placebo|Interventional|Phase 4|Other / NIH|SelectiveRemindingTest(SRT);  ADAS-Cog|86|NCT01658228|September 2011
2797|Completed|Procleix&#174; Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican Blood Donors - American Red Cross||Device:ProcleixDengueVirusAssay|Observational||Industry|Qualitative detection of ribosomal RNA from Dengue Virus in plasma specimens from individual human donors including volunteer donors of whole blood and blood components and other living donors.|35035|NCT01656174|August 2012
2798|Completed|Symptomatic Pulmonary Arterial Hypertension After Mitral Valve Surgery|||Observational||Other / Industry|Prevalenceofpulmonaryhypertension|100|NCT01646541|July 2012
2799|Completed|EnSite NavX-Guided Coronary Sinus Mapping During CRT Implant||Other:EnSiteNavXSystem|Interventional||Industry|Determine feasibility of CS mapping with EnSite NavX during CRT implant|16|NCT01615835|April 2007
2800|Active not recruiting|Examining The Role of CGM in T2DM||Other: Continuous Glucose Monitoring with treatment algorithm|Interventional||Other / Industry|change in glycosylated hemoglobin using intensive periodic CGM monitoring vs traditional monitoring;  change in fasting plasma glucose between two groups;  comparison of change of the area under the curve for CGM results for both treatment arms;  qualityoflifedataevaluation|90|NCT01614262|June 2012
2801|Completed|Feasibility Study: Ulthera&#174; System for the Treatment of Moderate to Severe Facial Acne||Device:UltheraSystemTreatment|Interventional||Industry|Changefrombaselineinfacialacne;  Changefrombaselineinskinclarity;  Reductionofsebumproduction;  PatientSatisfactionat60days;  PatientSatisfactionat180days|24|NCT01591304|August 2011
2802|Recruiting|Pilot Study Evaluating Safety &amp; Efficacy of a DCBT: NiCord&#174; &amp; UNM CBU to SCD Patients After Myeloablative Therapy||Drug:NiCord|Interventional|Phase 1 / Phase 2|Industry|Safety and Tolerability will be measured by acute NiCord&#174; infusional toxicity.;  Assessment of cumulative incidence of donor-derived neutrophil engraftment.;  Proportionoftransplant-relatedmortality.;  Event-freesurvival.;  Overallsurvival.|10|NCT01590628|April 2012
2803|Completed|Single-Dose Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild Moderate and Severe Hepatic Impairment and Normal Hepatic Function||Drug:BardoxoloneMethyl|Interventional|Phase 1|Industry|Areaundertheplasmaconcentration-timecurve;  Timetomaximumobservedconcentration;  Oralclearance;  Terminalhalf-life;  Terminalrateconstant|34|NCT01563562|April 2012
2804|Completed|Sensory-Targeted Ankle Rehabilitation Strategies (STARS)||Other:AnkleJointMobilization;  Other:FootMassage;  Other:CalfStretching|Interventional|Phase 2|Other / NIH|FootandAnkleAbilityMeasure;  GaitInitiation;  TimetoBoundary;  Weight-bearingLungeTest;  CutaneousSensation;  Single Limb Balance Error Scoring System Assessment|80|NCT01541657|December 2011
2805|Completed|New Use of the ViKY Device for Uterus Positioning||Device:ViKYUP|Interventional||Industry|Effectiveness;  AdverseEvents;  surgerycharacterization|30|NCT01531504|December 2011
2806|Completed|The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer||Drug:tasquinimod;  Drug:tasquinimod0.25mg;0.5mg;  Drug:tasquinimod0.25mg;0.5mg;1.0mg|Interventional|Phase 1|Other|The primary objective is to determine the recommended dose of tasquinimod in combination with cabazitaxel and prednisone based on safety and tolerability in men with chemorefractory metastatic castration-resistant prostate cancer (CRPC).;  Evaluationofprogressionfreesurvival;  Preliminary evidence of efficacy will be determined by several criteria one of which is PSA declines;  Preliminary evidence of efficacy will be determined by several criteria one of which is circulating tumor cell changes over time;  Measurement of the rates of radiographic response along with duration of responses.|25|NCT01513733|January 2012
2807|Active not recruiting|Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib) Therapy||Behavioral:noaccesstoeMedonline;  Behavioral:eMedonlineaccess|Interventional||Other|eMedonline will be used to measure non-compliance in taking oral drug regimens.|48|NCT01490775|April 2009
2808|Completed                  Has Results|Safety Study of Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS)||Drug:AztreonamLysineforInhalation(AZLI);  Procedure:StatusPostLungTransplant|Interventional|Phase 4|Other / Industry|Change in Pulmonary Function as Measured by Serial Forced Expiratory Volume in 1 Second (FEV1) on Spirometry;  Change in Global Health Related Quality of Life Measured by Serially Self-administered Short Form 36 Health Survey Questionnaire (SF-36) at Baseline (Prior to AZLI First Dose) and During AZLI Therapy at Month 1;  Change in Global Health Related Quality of Life Measured by Serially Self-administered Short Form 36 Health Survey Questionnaire (SF-36) at Baseline (Prior to AZLI First Dose) and During AZLI Therapy at Month 1 and Month 5.;  Change in Respiratory-specific Health Related Quality of Life Measured by Serially Self Administered St. George&apos;s Respiratory Questionnaire (SGRQ) at Baseline (Prior to AZLI First Dose) and During AZLI Therapy at Month 1;  Change in Respiratory-specific Health Related Quality of Life Measured by Serially Self Administered St. George&apos;s Respiratory Questionnaire (SGRQ) at Baseline (Prior to AZLI First Dose) and During AZLI Therapy at Month 5.;  Change in Pulmonary Function as Measured by Serial Forced Expiratory Flow (FEF25-75) on Spirometry at Baseline (Prior to AZLI First Dose) and During AZLI Therapy at Month 5.;  Change in Pulmonary Function as Measured by Serial Forced Expiratory Flow (FEF25-75) on Spirometry at Baseline (Prior to AZLI First Dose) and During AZLI Therapy at Month 1;  ChangeinFEV1OffAZLITherapy;  ChangeinHRQOLOffAZLITherapy.;  Among Patients Colonized With Pseudomonas Aeruginosa Change in Infection Burden as Measured by the Culture Final Report (01+ 2+ 3+ 4+) of in Pseudomonas Aeruginosa Sputum or Bronchoalveolar Fluid.;  Bronchoalveolar Lavage Fluid (BALF) Neutrophilia After Treatment When Performed as Part of Clinical Care (SOC).|30|NCT01469364|March 2013
2809|Active not recruiting|Prevention of Postpartum Weight Retention in Low Income WIC Women||Behavioral:Onlinepostpartumweightcontrol|Interventional||Other|Weight;  Psychosocialmeasures|430|NCT01408147|July 2011
2810|Completed|Milnacipran for Migraine Pain||Drug:Milnacipran;  Drug:Placebo|Interventional||Other|EvaluatingHeadachePainReduction;  EvaluatingtheimprovementofQualityofLife;  MigrainePrevention;  SleepandEnergy;  AnxietyandDepression|37|NCT01393522|June 2011
2811|Active not recruiting|Pazopanib Docetaxel Prednisone Prostate||Drug:Pazopanib;  Drug:Docetaxel;  Drug:Prednisone;  Drug:Pegfilgrastim|Interventional|Phase 1|Other / Industry|Number and Percent of Participants with Adverse Events as a Measure of Safety and Tolerability; Number and Percent of participants who have disease progression;  Establishthemaximumtolerateddose;  Measurement of pazopanib and docetaxel drug levels in participants.;  Relationship between genetic variants and drug levels (Cmax Tmax AUC CL Vd).;  Establishtheoptimaldosingschedule|36|NCT01385228|June 2011
2812|Completed                  Has Results|Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma||Drug:Active;  Drug:Placebo|Interventional|Phase 1 / Phase 2|Industry|Measurement of Change in Methacholine PC20 From Baseline Compared With Placebo 24 Hours After Dosing;  Measurement of Change in Methacholine PC20 From Baseline Compared With Placebo 8 Hours After Dosing;  To Assess the Safety and Tolerability of Single Dose Administration of N6022 in Patients With Mild Asthma.|14|NCT01316315|March 2011
2813|Completed|A Novel Diet-Phenotype Interaction Affecting Body Weight||Behavioral:Dietarycounselling|Interventional||Other|Percent body fat by dual-energy x-ray absorptiometry (DXA);  Triglyceride;  HDLcholesterol;  LDLcholesterol;  C-reactiveprotein;  PlasminogenActivatorInhibitor-1;  Fastingbloodglucose;  Insulinresistance;  Bloodpressure;  Trunkfat|155|NCT01303757|February 2011
2814|Completed|Dose-Proportionality and Intra-Individual Variability of Intracellular TFV-DP and FTC-TP in Healthy Volunteers||Drug:Emtricitabine/tenofovir|Interventional|Phase 1|Other|Assessdose-proportionality;  Comparison of intra-individual variability--days 28 and 35;  Determine relationship between pre-dose and decaying concentrations;  Determinedifferencesbetweenmenandwomen;  Safetyprofiles|32|NCT01276600|January 2011
2815|Completed|Decision Support Interventions (DESI) for Prostate Cancer Screening and Treatment - Study 2||Behavioral:ProstatecancertreatmentDESI|Interventional||Other / NIH|Comparison of Active treatment vs. Watchful waiting/active surveillance at 3 and 6 months;  DESIviewing;  Healthcareutilization|218|NCT01244568|December 2010
2816|Unknown&nbsp;&#8224;|Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL||Drug:Revlimid|Interventional|Phase 1 / Phase 2|Other / Industry|Stage 1 - Safety (type frequency severity and relationship of adverse events to study treatment) and tolerability;  Stage1-Overallresponserate(CRPRSD);  Stage 2 - Proportion of patients with a stem cell collection of at least 3x106 CD34+ cells prior to ASCT;  Stage 3 - Overall response rate (CR PR SD) and complete response rate and conversion to higher quality of response during maintenance (e.g. from PR to CR);  Stage 2 &#8226; Incidence of DLT for determination of MTD to be used in Stage II conversion to higher quality of response during maintenance (e.g. from PR to CR);  TimetoResponse;  Stage2-1and2yearOverallSurvival(OS)|67|NCT01241734|June 2010
2817|Completed|Decision Support Interventions (DESI) for Prostate Cancer Screening - Study 1||Behavioral:DESIforhomeviewing;  Behavioral: DESI for viewing at Shared Medical Appointment;  Behavioral:OptionofSMAandDESIorDESIonly|Interventional||Other / NIH|PSAtestvs.NoPSAtest;  Healthcareutilizationandcosts;  DESIviewing;  Decisionspecificknowledge;  Discussionwithprovider|2521|NCT01241656|January 2011
2818|Completed|Pilot Study Evaluating Safety &amp; Efficacy of DCBT: NiCord&#174; &amp; UNM CBU to Patients With Hematological Malignancies||Drug:NiCord&#174;|Interventional|Phase 1 / Phase 2|Industry|Safety and Tolerability: will be measured by acute NiCord&#174; infusional toxicity and assessment of the proportion of patients with neutrophil engraftment;  Proportion of non-relapse mortality development of acute GvHD|11|NCT01221857|November 2010
2819|Completed|Cognitive Behavioral Treatments for Depression in Chronic Illness||Behavioral: Conventional cognitive behavioral therapy;  Behavioral: Religious cognitive behavioral therapy|Interventional||Other|BeckDepressionInventory;  DukeSocialSupportIndex(abbreviated);  DukeSocialSupportIndex|132|NCT01208428|April 2011
2820|Terminated|L-Carnitine Administration in Early Sepsis||Drug:L-Carnitine;  Drug:NormalSaline|Interventional|Phase 1|Other|Reductioninorganfailure;  Microcirculation;  ICUandhospitallengthofstay;  All-causemortality;  Changeininflammatorymarkers|31|NCT01193777|September 2010
2821|Unknown&nbsp;&#8224;|Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer||Biological:bevacizumab;  Biological:cetuximab;  Drug:FOLFIRIregimen;  Drug:FOLFOXregimen;  Drug:capecitabine;  Drug:fluorouracil;  Drug:irinotecanhydrochloride;  Drug:leucovorincalcium;  Drug:mitomycinC;  Drug:oxaliplatin;  Procedure:therapeuticconventionalsurgery|Interventional|Phase 3|U.S. Fed / NIH|Overallsurvival(OS);  Progression-freesurvival(PFS);  Qualityoflife;  Toxicityburden;  Circulatingtumorcells;  Comparison of OS and PFS according to patients&apos; peritoneal surface tumor genotype for the NAD(P)H|340|NCT01167725|August 2010
2822|Terminated|Peripheral Blood Biomarkers in Idiopathic Interstitial Pneumonias|||Observational||Other / NIH||269|NCT01151527|April 2010
2823|Completed|Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR||Drug:Ablavar|Observational||Industry|IncidenceofNephrogenicSystemicFibrosis;  Incidence of Severe Adverse Events (SAEs) &amp; Adverse Events (AEs)|2|NCT01135316|October 2009
2824|Completed                  Has Results|Durability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic Fibrosis||Drug:sodiumchloride(7%)|Interventional|Phase 1|Other / Industry|Change in Average Mucociliary Clearance (0-90 Minutes) at 1 and 4 Hrs Post Dose (MCC4hr - MCCbaseline; MCC1hr - MCCbaseline)|16|NCT01094704|November 2009
2825|Completed                  Has Results|Rivastigmine Study in Adolescents With Down Syndrome||Drug:Rivastigmine;  Other:LiquidPlacebo|Interventional|Phase 1 / Phase 2|Other|Vineland Adaptive Behavior Scales Second Edition (Survey Interview Form);  Behavior Rating Inventory of Executive Function-Preschool (BRIEF-P)|42|NCT01084135|November 2009
2826|Active not recruiting|Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer||Drug:cisplatin;  Drug:carboplatin;  Other:questionnaireadministration|Observational|Phase 2|Other / NIH|Use of the Frailty Index and/or the geriatric assessment in prediction of toxicity|50|NCT01026467|January 2010
2827|Terminated                  Has Results|Paclitaxel Carboplatin and Panitumumab in Treating Patients With Metastatic Breast Cancer||Biological:panitumumab;  Drug:paclitaxel;  Drug:carboplatin;  Procedure:laboratorybiomarkeranalysis;  Procedure:immunohistochemistrystainingmethod|Interventional|Phase 2|Other|Antitumor Activity as Assessed by Objective Tumor Response According to RECIST Criteria;  ToxicityAccordingtoCTCAEv3.0;  TimetoProgression;  Survival;  ExpressionofEGFRandOtherProteinMarkers|14|NCT01009983|March 2010
2828|Recruiting|Lymphedema Following Hand/Wrist Surgery in Women Post Axillary Node Dissection||Procedure:TourniquetUse|Interventional|Phase 4|Other|Lymphedema15%changefrompre-postingirth;  Wound assessmentPatient Satisfaction (on a scale of 0-10Surgical and postoperative complications|206|NCT00984269|September 2009
2829|Suspended|Evaluation of the CloSys Closure System as an Adjunct to Standard Compression||Device:CloSysHemostaticDevice(HD);  Procedure:Standardcompression|Interventional||Industry|Timetohemostasis;  Timetoambulation;  Adverseevents|130|NCT00963690|August 2009
2830|Completed|Safety of Intramuscular Injections (IM) of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia (CLI)||Biological:PLX-PAD|Interventional|Phase 1|Industry|Adverse events; Amputation incidence Death incidence &amp; Rehospitalization incidence;  Immunologicalreaction|12|NCT00951210|August 2009
2831|Completed                  Has Results|Increasing Patching for Amblyopia in Children 3 to &lt; 8 Years Old||Device:EyePatch|Interventional|Phase 3|Other / NIH|Distribution of 10-week Amblyopic Eye Visual Acuity;  Mean10-weekAmblyopicEyeVisualAcuity;  Distribution of the Change in Amblyopic Eye Visual Acuity at 10 Weeks From Randomization;  Mean Change in Amblyopic Eye Visual Acuity at 10 Weeks From Randomization;  Compliance With Prescribed Patching by Treatment Group at 10 Weeks;  Average Compliance With Prescribed Patching by Treatment Group;  Treatment Group Comparison of the Proportion of Participants Who Have Improved by 2 or More logMAR Visual Acuity Lines at 10 Weeks Since Randomization;  Treatment Group Comparison of 10-week Interocular Difference;  Distribution of Baseline Characteristics at the 10-week Outcome;  Mean Amblyopic Eye Visual at Randomization According to Baseline Characteristics for 10-week Outcome;  Treatment Comparison of Mean Amblyopic Eye Visual Acuity Change at 10-weeks According to Baseline Characteristics;  Distribution of Amblyopic Eye Visual Acuity at Visit of Best Post-randomization Visual Acuity;  Mean Amblyopic Eye Visual Acuity at Visit of Best Post-randomization Visual Acuity;  Distribution of the Change in Best Post-randomization Visual Acuity in the Amblyopic Eye;  Mean Change in Amblyopic Eye Visual Acuity Since Randomization at Visit of Best Post-randomization Visual Acuity;  Treatment Group Comparison of the Proportion of Participants Who Have Improved by 2 or More logMAR Visual Acuity Lines Based on Visual Acuity at Best Post-randomization Visit;  Distribution of Best Fellow Eye Visual Acuity at 10-week Outcome;  Mean Best Fellow Eye Visual Acuity at 10-week Outcome;  Distribution of Best Fellow Eye Visual Acuity at Final Visit;  MeanBestFellowEyeVisualAcuityatFinalVisit;  Distribution of Change in Best Fellow Eye Visual Acuity Since Randomization at 10 Weeks;  Mean Change in Best Fellow Eye Visual Acuity Since Randomization at 10 Weeks;  Distribution of Change in Best Fellow Eye Visual Acuity Since Randomization at Final Visit;  Mean Change in Best Fellow Eye Visual Acuity Since Randomization at Final Visit;  Distribution of Randot Preschool Stereoacuity Scores at Randomization;  Distribution of Randot Preschool Stereoacuity Scores at 10 Weeks;  Change in Randot Preschool Stereoacuity Level at 10-week Outcome Since Randomization;  Distribution of Randot Preschool Stereoacuity Scores at Randomization for Participants With Anisometropic Amblyopia;  Distribution of Randot Preschool Stereoacuity Scores at 10 Weeks for Participants With Anisometropic Amblyopia;  Change in Randot Preschool Stereoacuity Level at 10-week Outcome Since Randomization for Participants With Anisometropic Amblyopia|169|NCT00945100|August 2009
2832|Completed                  Has Results|Augmenting Atropine Treatment for Amblyopia in Children 3 to &lt; 8 Years Old||Drug:Atropine;  Device:Planolens|Interventional|Phase 3|Other / NIH|Distribution of 10-week Amblyopic-Eye Visual Acuity;  Mean10-weekAmblyopic-EyeVisualAcuity;  Distribution of the Change in Amblyopic-Eye Visual Acuity;  Mean Change in Amblyopic-Eye Visual Acuity at 10 Weeks From Randomization;  Treatment Group Comparison of the Proportion of Participants Who Achieved 20/25 or Better Visual Acuity at 10 Weeks Since Randomization;  Treatment Group Comparison of the Proportion of Participants Who Have Improved by 2 or More logMAR Visual Acuity Lines at 10 Weeks Since Randomization;  Spectacle Compliance at 10 Weeks by Treatment Group;  AverageSpectacleCompliancebyTreatmentGroup;  Atropine Compliance at 10 Weeks by Treatment Group;  AverageAtropineCompliancebyTreatmentGroup;  Distribution of Interocular Difference at 12-week Exam;  MeanInterocularDifferenceat12-weekExam;  Distributionof12-weekFellow-EyeVisualAcuity;  MeanFellow-EyeVisualAcuityat12-weekExam;  Distribution of Change in Fellow-Eye Visual Acuity at 12 Weeks From Randomization;  Mean Change in Fellow-Eye Visual Acuity at 12 Weeks From Randomization;  Distribution of Baseline Characteristics at the 10-week Outcome;  Mean Amblyopic Eye Visual at Randomization According to Baseline Characteristics for 10-week Outcome;  Treatment Comparison of Mean Amblyopic Eye Visual Acuity Change at 10-weeks According to Baseline Characteristics;  Distribution of Amblyopic-Eye Visual Acuity at Best Outcome Visit;  Mean Amblyopic-Eye Visual Acuity at Best Outcome Visit;  Distribution of Change in Amblyopic-Eye Visual Acuity From Randomization to Best Outcome Visit;  Mean Change in Amblyopic-Eye Visual Acuity at Best Outcome Visit;  Treatment Group Comparison of the Proportion of Participants Who Have Improved by 2 or More logMAR Visual Acuity Lines Based on Visual Acuity at Best Outcome Visit;  Distribution of Randot Preschool Stereoacuity Score at 12 Weeks;  Distribution of Randot Preschool Stereoacuity Scores at 12 Weeks for Participants With Anisometropic Amblyopia|73|NCT00944710|August 2009
2833|Completed                  Has Results|Efficacy and Safety Study of the Misoprostol Vaginal Priming Insert (MVPI) Prior to Hysteroscopy||Drug:misoprostol;  Drug:placebo|Interventional|Phase 2|Industry|Change in Diameter of the Internal Cervical os From Baseline (Pre-treatment) to Just Prior to the Hysteroscopy Procedure (Post-treatment).;  Percent of Women Requiring Further Dilatation in Order to Allow Uterine Access;  Total Procedure Time From Insertion of the First Hegar Dilator to Completion of the Hysteroscopy Procedure;;  Physician Assessment of Ease of Cervical Dilation;;  PercentageofParticipantsWithAdverseEvents|51|NCT00925938|January 2010
2834|Completed|XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib||Drug:dasatinib;  Drug:bevacizumab;  Drug:Oxaliplatin;  Drug:Capecitabine|Interventional|Phase 1|Other / Industry|To determine the maximum tolerated dose(MTD)/recommended phase II dose (RPTD) of capecitabine/oxaliplatin/bevacizumab/dasatinib for patients with advanced solid tumors.;  To further describe dose-limiting and non-dose-limiting toxicities associated with this regimen.;  To describe clinical activity (partial response (PR) complete response (CR) or stable disease (SD)&gt;6 months time to progression and overall survival) associated with this regimen for patients with previously untreated metastatic and/or re;  To explore any correlation between blood urine and paraffin biomarkers and clinical outcomes|22|NCT00920868|May 2009
2835|Active not recruiting|Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic Castrate-resistant Prostate Cancer||Drug:Docetaxel;  Drug:Prednisone;  Drug:177Lu-J591|Interventional|Phase 1|Other|Determine the maximum tolerated dose of fractionated 177Lu-DOTA-J591 administered concurrently with three-weekly docetaxel for the treatment of patients with metastatic castrate-resistant prostate cancer.;  Determine the toxicity profile of concurrent docetaxel with fractionated 177Lu-DOTA-J591|30|NCT00916123|May 2009
2836|Completed|Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid Leukemia||Genetic:microarrayanalysis;  Genetic:polymerasechainreaction|Observational||Other / NIH|Correlation of increased or decreased expression of same transcripts with disease outcome;  Minimum number of genes that can be used for precise diagnosis of each of the three subtypes of acute myeloid leukemia;  Identification of individual genes that are differentially expressed between the subtypes of AMLs;  Correlation of the patterns of expression of the translocation-specific transcripts with age sex race response to treatment survival and with other known mutations|96|NCT00897182|May 2008
2837|Completed|Evaluation of Limb-Girdle Muscular Dystrophy|||Observational||Other|The measurement of growth factors (TGF-B IGF-II) and cytokines (IL18 IL1A and IL1B) between the different types of LGMD and BMD.;  The difference in the growth factors (TGF-B IGF-II) and cytokines (IL18 IL1A and IL1B) pre-evaluation and post-evaluation.;  Evaluation of surrogate and clinically relevant outcome measures in LGMD.;  Quality of life questionnaires to correlate patient- perceived limitations in daily activities with the quantitative strength measurements and functional ability with timed testing.;  Evaluation of patient understanding in their diagnosis and genetic etiology of their diagnosis.|60|NCT00893334|April 2009
2838|Recruiting|Metacognitive Training to Enhance Strategy Use in Blast-Related TBI||Behavioral:GoalManagementTraining|Interventional|Phase 1 / Phase 2|U.S. Fed|computerizedTOLBRIEF-ADkefs|54|NCT00857207|October 2013
2839|Completed                  Has Results|Contralateral Comparison of Three Excimer Laser Systems in Performing LASIK||Device:ExcimerLaser;  Device:AMO/VISXCustomVue&#8482;;  Device:LADARVision4000excimerlaser|Interventional|Phase 4|Other / Industry|1 Day Postoperative Lasik Uncorrected Visual Acuity;  1 Week Postoperative Lasik Uncorrected Visual Acuity;  1MonthPostoperativeLasikVisualAcuity|40|NCT00821236|January 2009
2840|Completed                  Has Results|Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension||Drug:TimololMaleateinSorbate;  Drug:Timololhemihydrate;  Drug:Timololmaleategelformingsolution|Interventional|Phase 4|Industry|StingingonInstillation;  ConjunctivalHyperemia;  TearFilmBreak-upTime;  CornealStainingGrade;  CornealStainingCount;  IntraoclularPressure;  BasicSchirmer&apos;s;  ConjunctivalStaining-NasalGrade;  ConjunctivalStaining-NasalCount;  ConjunctivalStaining-TemporalGrade;  ConjunctivalStaining-TemporalCount;  VisualAcuity|30|NCT00804648|November 2008
2841|Terminated                  Has Results|Quetiapine XR for Cognitive and Functional Disability in Clinically Stable Patients With Bipolar Disorder||Drug:QuetiapineXR;  Drug:Placebo|Interventional|Phase 4|Other|The Continuous Performance Test-Identical Pairs Version;  Brief Assessment of Cognition for Affective Disorders (BAC-A)|32|NCT00746421|January 2010
2842|Completed                  Has Results|Study to Compare Marginal Bone Loss Around Implants From Two Dental Implant Systems.||Device: ASTRA TECH Implant System; Fixture ST: &#216; 4.5 cm in lengths of 9 11 and 13 mm.;  Device: 3i Osseotite&#174; implant: &#216; 4.0 in lengths of 8.5 10 11.5 and 13 mm|Interventional||Industry|MarginalBoneLevelChanges|36|NCT00746187|December 2002
2843|Completed                  Has Results|A 3-arm Multi-center Randomized Controlled Study Comparing Transforaminal Corticosteroid Transforaminal Etanercept and Transforaminal Saline for Lumbosacral Radiculopathy||Drug:etanercept;  Drug:methylprednisolone;  Drug:normalsaline|Interventional|Phase 2 / Phase 3|Other / U.S. Fed|NumericalRatingLegPainScore;  OswestryDisabilityScore;  GlobalPerceivedEffect;  MedicationReduction|84|NCT00733096|August 2008
2844|Unknown&nbsp;&#8224;|The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy||Drug:MilkProteinExtractImmunotherapy;  Drug:MilkPowderImmunotherapy|Interventional|Phase 1 / Phase 2|Other / Industry|The primary endpoint is clinical response to treatment defined as (1) tolerating ten times the initial oral food challenge threshold dose OR (2) tolerating the maximum oral food challenge dose at the oral food challenge at completion of immunotherapy.;  The proportion of patients who maintain a clinical response after withdrawal of treatment for one week.;  The proportion of patients who maintain a clinical response after withdrawal of treatment for six weeks.;  Incidence of all serious adverse events during the study;  Incidenceofalladverseeventsduringthestudy.|30|NCT00732654|August 2008
2845|Completed                  Has Results|An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease||Biological:AlglucosidaseAlfa;  Drug:Methotrexate;  Drug:Rituximab|Interventional|Phase 4|Industry|Change From Baseline in Number of Patients With Anti-Recombinant Human Acid Alfa-glucosidase (Anti-rhGAA) Immunoglobulin G (IgG) Antibody at End of Study;  Number of Patients With Recombinant Human Acid Alfa-glucosidase (rhGAA) Inhibitory Antibody at End of Study;  NumberofPatientsWhoSurvivedatEndofStudy;  Number of Patients With Normal/Abnormal Left Ventricular Mass (LVM) Z-Score and LVM Index at End of Study;  Number of Patients With Ventilator Use at End of Study;  Gross Motor Disability Assessed by Gross Motor Function Measure-88 (GMFM-88) at End of Study;  Motor Development Status Assessed by Alberta Infantile Motor Scale (AIMS) at End of Study;  Disability Index Assessed by the Pompe Pediatric Evaluation of Disability Inventory (Pompe PEDI) at End of Study|4|NCT00701129|October 2009
2846|Completed|FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey||Drug:FazaClo(clozapineUSP)ODT|Observational||Industry|Clinical changes in body weight in patients with treatment-resistant schizophrenia after initiating treatment with FazaClo;  Clinical changes in salivation in patients with treatment-resistant schizophrenia after initiating treatment with FazaClo;  Changes in Clinical Global Impression (CGI) scale when compared to baseline||NCT00683891|
2847|Completed|PH I SRC Kinase Dasatinib Combo Paclitaxel &amp; Carboplatin in Pts w Ovarian Peritoneal &amp; Tubal Cancer||Drug:DasatinibPaclitaxelandCarboplatin|Interventional|Phase 1|Other|To determine maximal tolerated dose (MTD) of dasatinib in combination with paclitaxel and carboplatin during the first cycle of treatment;  To describe the toxicity of this combination of therapy;  To describe the pharmacokinetics and pharmacodynamics parameters related to this combination;  To describe the clinical activity as defined as the response rate (complete and partial response rate) and progression-free survival &gt; 6 months;  To compare the SRC pathway microarray signature in pre and post-treatment cancer specimens;  To evaluate SRC pathway downstream substrates FAX paxcillin and CRK-L in pre and post-treatment cancer specimens|11|NCT00672295|August 2007
2848|Completed|Partnership for Glaucoma||Other:ComputerTablet;  Other:ContinuingEducationCourse;  Other:Continuingeducation|Interventional||Other|To determine if innovative technology will improve process quality of care &amp; important outcomes of care by optometrists in a cost-efficient manner while simultaneously empowering &amp; including patients as part of the care process.|721|NCT00672048|October 2007
2849|Completed                  Has Results|Escitalopram Treatment of Night Eating Syndrome||Drug:Escitalopram;  Drug:Placebo|Interventional||Other|NightEatingQuestionnaire;  Change in Beck Depression Inventory II (BDI-II) Score;  Change in Coping Inventory for Stressful Situations (CISS);  ChangeinPerceivedStressScale(PSS);  Change in Three Factor Eating Questionnaire (TFEQ);  Number of Participants With a Clinical Global Impression - Improvement (CGI-I) Score &#8804; 2;  ChangeinLipidPanel;  ChangeinBeckAnxietyInventory(BAI)Score;  ChangeinGlucose;  ChangeinWeight;  Number of Participants Who no Longer Meet the NESHI Criteria;  Number of Participants Who Had a 50% Reduction in NEQ Scores|40|NCT00636649|October 2008
2850|Completed|Mucosal Immunotherapy for Peanut Allergy||Biological:Peanutflour;  Biological:Oat|Interventional|Phase 2|Other|An outcome measure will be determined by a comparison of the result of the double blind placebo controlled food challenges (DBPCFC)at the starting point and at the end of the study for each of the subjects.;  Other outcome measures will be the changes seen in the pre and post peanut skin tests and the pre and post IgE levels to peanut|10|NCT00597675|March 2007
2851|Completed                  Has Results|Treatment of Egg Allergy in Children Through Oral Desensitization (EGG OIT)||Drug:Eggwhiteprotein|Interventional||Other|Negative Double-blind Placebo-controlled Food Challenge (DBPCFC) to Egg After Egg OIT Treatment;  Subjects on OIT Will Have a Decrease in Wheal Size of an Egg Protein Skin Prick Test Placed at the End of the Study on OIT Compared With Wheal Size of Egg Protein Skin Test at Entry.;  Subjects on OIT Will Have a Decrease in Serum CAP-FEIA to Egg Over the Course of the Study.|13|NCT00597558|February 2003
2852|Withdrawn|Treatment of Advanced Renal Cell Carcinoma With Quinacrine||Drug:quinacrine|Interventional|Phase 2|Industry|Tumorresponse;  Timetotumorprogression|0|NCT00574483|November 2007
2853|Completed|Nutrient Levels Alter Transplant Outcome||DietarySupplement:Arginineandcanolaoil;  DietarySupplement:CoromegaandArginine|Interventional||Other / NIH|Plasmaandredbloodcelllipidprofiles;  Plasmaaminoacidprofiles|54|NCT00560014|September 1997
2854|Completed|Glucose/Insulin Responses:Subjects With Type 2 Diabetes Consuming Diabetes-Specific vs Standard Nutritional Formulas||Other:Adultenteralformula|Interventional|Phase 3|Industry|Adjusted area under the curve (adj-AUC) of glucose response;  Adjusted peak for glucose and insulin response;peak time for glucose and insulin response; Adj-AUC for insulin response; change in glucose and insulin; subjective gastrointestinal tolerance|54|NCT00540488|August 2002
2855|Recruiting|Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion||Biological: Kidney and hematopoietic stem cell transplant/novel platform technology|Interventional|Phase 2|Other|EnrichedHematopoeticStemCellEngraftment|60|NCT00497926|March 2008
2856|Completed|Determination of the Prevalence and Prognostic Importance of Unrecognized Non-Q-wave Myocardial Infarction by MRI|||Observational||Other||185|NCT00493168|January 1998
2857|Unknown&nbsp;&#8224;|Repetitive Behavior Disorders in People With Severe Mental Retardation||Drug:sertraline|Interventional|Phase 3|NIH|||NCT00491478|September 1992
2858|Completed|Arthritis Self-Management Education Program||Behavioral:ArthritisQuickStart;  Other:Delayedtreatmentintervention|Interventional||Other / U.S. Fed|Self-Efficacy;  Self-reportedhealth|690|NCT00467064|October 2006
2859|Completed|A Randomized Double-Blind Placebo-Controlled Study of Oral Milk Immunotherapy for Cow&apos;s Milk Allergy||Drug:cow&apos;smilkpowder|Interventional|Phase 1 / Phase 2|Other|The percentage of patients who can tolerate four times the initial OFC threshold dose or the maximum OFC dose of 8 grams after therapy.;  Incidence of protocol-defined severe hypersensitivity reactions during the study;  Incidence of all serious adverse events during the study;  Incidenceofalladverseevents;  To assess for any changes in milk-IgE milk-IgG4 and skin test reactivity during OIT and as milk allergy persists or resolves.|20|NCT00465569|August 2006
2860|Active not recruiting                  Has Results|Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain||Drug:Donepezil|Interventional||Other / NIH|Neurocognitive Function as Measured by the Neurocognitive Battery at 24 Weeks|14|NCT00452868|June 2006
2861|Completed|To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches||Drug:sumatriptan;  Drug:naproxensodium|Interventional|Phase 3|Industry|Trexima will be evaluated for efficacy as an acute treatment for migraine based on its superiority over placebo at 2 hours for: a) pain relief (no or mild pain) b) incidence of photophobia c) incidence of phonophobia and d) incidence of nausea.;  a) sustained pain relief over 24 hours b) sustained photophobia-free over 24 hours c) sustained phonophobia-free over 24 hours and d) sustained nausea-free over 24 hours.|1400|NCT00433732|August 2004
2862|Completed                  Has Results|Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder||Drug:GTS21/Placebo|Interventional|Phase 1 / Phase 2|Industry|To Assess the Safety and Tolerability of GTS21 (25 mg Tid 75 mg Tid 150 mg Tid).|37|NCT00419445|February 2007
2863|Completed                  Has Results|Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy||Drug:Azacitidine|Interventional|Phase 2|Other / Industry|RateofDiseaseFreeSurvivalatOneYear;  OverallSurvival(OS);  NumberofParticipantsWithAdverseEvents|24|NCT00387647|August 2006
2864|Completed|Organizational Skills Training for Children With Attention Deficit Hyperactivity Disorder||Behavioral:OrganizationalSkillsTraining;  Behavioral:Contingencymanagement(CM)|Interventional||Other / NIH|Children&apos;sOrganizationalSkillsScale(COSS);  AcademicPerformanceRatingScale(APRS);  HomeworkProblemsChecklist;  FamilyEnvironmentScale;  BehaviorAssessmentSystemforChildren|157|NCT00381407|September 2006
2865|Completed|Biomarkers in Patients Undergoing Transrectal Ultrasound Prostate Biopsy||Genetic:proteomicprofiling;  Other:immunologicaldiagnosticmethod;  Other:laboratorybiomarkeranalysis;  Other:massspectrometry;  Procedure:biopsy;  Procedure:ultrasoundimaging|Observational||Other / NIH|Unique proteins or peptides associated with prostate cancer|60|NCT00373035|February 2006
2866|Active not recruiting|Agriculture Health Study|||Observational||NIH / U.S. Fed||90500|NCT00352924|April 1993
2867|Completed|Influence of Social and Environmental Factors on Women&apos;s Reproductive Function in a Maya Community of Guatemala|||Observational||NIH||0|NCT00340782|April 2006
2868|Completed|Effect of Brain Lesion Severity on Treatment Response in Late-Life Depression||Drug:Sertraline|Interventional||Other / NIH|Measured at Week 12: Montgomery-Asberg Depression Scale (MADRS);  Measured at Week 12: Hamilton Depression Rating Scale (Ham-D);  ClinicalGlobalImpression(CGI);  QualityofLifeAssessment;  DisabilityAssessment|131|NCT00339066|August 2001
2869|Completed|Bortezomib Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade Follicular or Mantle Cell Non-Hodgkin&apos;s Lymphoma||Biological:rituximab;  Drug:bortezomib;  Radiation:yttriumY90ibritumomabtiuxetan;  Radiation:Indium111ibritumomabtiuxetan|Interventional|Phase 1|Other / NIH|Maximumtolerateddoseofbortezomib;  Dose-limitingtoxicity;  Responserate|12|NCT00334438|July 2006
2870|Suspended|GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II Stage III or Stage IV Diffuse Large B-Cell Lymphoma||Drug: autologous immunoglobulin idiotype-KLH conjugate vaccine;  Drug:cyclophosphamide;  Drug:doxorubicinhydrochloride;  Drug:prednisone;  Drug:rituximab;  Drug:sargramostim;  Drug:vincristine;  Procedure:Intervention/procedure;  Procedure:antibodytherapy;  Procedure:biologicaltherapy;  Procedure:chemotherapy;  Procedure:colony-stimulatingfactortherapy;  Procedure:cytokinetherapy;  Procedure:monoclonalantibodytherapy;  Procedure:non-specificimmune-modulatortherapy;  Procedure:therapeuticprocedure;  Procedure:tumorcellderivativevaccine;  Procedure:vaccinetherapy|Interventional|Phase 3|Industry|Disease-free survival as measured by the Kaplan-Meier method at 3 years;  Disease-free survival as measured by the Kaplan-Meier method at 2 years;  Duration of response (complete or partial response);  Overalldisease-freesurvival|480|NCT00324831|
2871|Completed|Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema||Drug:VEGFTrap-Eye|Interventional|Phase 1|Industry|To assess the ocular and systemic safety and tolerability of a single intravitreal (IVT) injection of VEGF Trap-Eye in patients with diabetic macular edema (DME);  To obtain a preliminary assessment of the effect of a single dose of VEGF Trap-Eye on central retinal thickness (CRT) at the center point as determined by optical coherence tomography (OCT);  To obtain a preliminary assessment of the effect of a single IVT administration of VEGF Trap-Eye on visual acuity|5|NCT00320814|April 2006
2872|Unknown&nbsp;&#8224;|Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Metastatic Kidney Cancer or Aplastic Anemia||Biological:anti-thymocyteglobulin;  Biological:filgrastim;  Biological:graft-versus-tumorinductiontherapy;  Biological:therapeuticallogeneiclymphocytes;  Drug:busulfan;  Drug:cyclophosphamide;  Drug:fludarabinephosphate;  Drug:methotrexate;  Drug:mycophenolatemofetil;  Drug:tacrolimus;  Procedure:allogeneicbonemarrowtransplantation;  Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;  Procedure: peripheral blood stem cell transplantation|Interventional||Other / NIH||35|NCT00295997|May 2005
2873|Completed|Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome Leukemia Bone Marrow Failure Syndrome or Severe Immunodeficiency Disease||Biological:anti-thymocyteglobulin;  Biological:therapeuticallogeneiclymphocytes;  Drug:fludarabinephosphate;  Drug:thiotepa;  Procedure:allogeneicbonemarrowtransplantation;  Procedure: allogeneic hematopoietic stem cell transplantation;  Procedure: in vitro-treated peripheral blood stem cell transplantation;  Radiation:total-bodyirradiation|Interventional|Phase 1|Other / NIH|Engraftment at 4 weeks post bone marrow transplantation through 100 days;  Survival assessed monthly for 6 months every 3 months for 2 years every 6 months for 1 year and then yearly for 5 years post transplantation;  Disease-free survival and infection assessed monthly for 6 months every 3 months for 2 years every 6 months for 1 year and then yearly for 5 years post transplantation;  Graft-versus-host disease assessed monthly for 6 months every 3 months for 2 years every 6 months for 1 year and then yearly for 5 years post transplantation;  CD4countinblood&lt;100/mm&#179;at12weeks|21|NCT00295971|April 2005
2874|Completed|Breast Cancer Screening Via Computer V. Phone||Behavioral: Tailored interactive intervention for mammography screening|Interventional|Phase 3|Other / NIH|Toincreaseannualmammographyadherence;  Cost-effectivenessofDVDversustelephonesurvey|1686|NCT00287040|September 2007
2875|Completed|GM-CSF and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Colon Cancer||Biological:sargramostim;  Drug:fluorouracil;  Drug:leucovorincalcium;  Drug:oxaliplatin;  Procedure:adjuvanttherapy;  Procedure:conventionalsurgery;  Procedure:neoadjuvanttherapy|Interventional|Phase 2|Other|Proportion of patients with a change in tumor-associated macrophage VEGF expression;  Disease-freeandoverallsurvival|50|NCT00262808|March 2004
2876|Completed|To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients||Drug:GW572016oraltablets|Interventional|Phase 1|Industry|To characterize the effect of repeat oral dose of lapatinib treatment on the pharmacokinetics of a single oral and single intravenous dose of midazolam in adult cancer patients.;  To assess the safety and tolerability of chronic oral lapatinib therapy in cancer patients.|16|NCT00258050|November 2005
2877|Completed|Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)||Drug:Rosiglitazone(Avandia);  Drug:Adalimumab(Humira)|Interventional|Phase 1|Other|Safetyandtoleranceofmedications;  Reductioninproteinuria|21|NCT00193648|July 2005
2878|Completed                  Has Results|Early Intervention With Fluoxetine in Autism||Drug:Fluoxetine;  Drug:Placebo|Interventional|Phase 2|Other / NIH|RateofRecruitment;  RateofAttrition;  Change From Baseline to 12 Months in Total Score on Caregiver Strain Questionnaire;  Change From Baseline to Month 12 in Aberrant Behavior Checklist Irritability Subscale Score (ABC-I)|18|NCT00183339|July 2005
2879|Terminated|UMD rPA Regimen Trial in Adults||Biological: Anthrax vaccine absorbed made from Bacillus anthracis (AVA);  Biological: Recombinant protein antigen (rPA) made from Bacillus anthrax;  Biological: Recombinant protein antigen (rPA) made from Escherichia coli|Interventional|Phase 2|NIH||270|NCT00133484|
2880|Completed|Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer||Biological:denileukindiftitox;  Biological: recombinant fowlpox-CEA(6D)/TRICOM vaccine;  Biological: therapeutic autologous dendritic cells|Interventional|Phase 1|Other / NIH|Safety as measured by rate of adverse events during study drug treatment;  Rate of immune response as measured by ELISPot at week 10|24|NCT00128622|September 2005
2881|Terminated|Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Moderate to Severe Cancer Pain||Drug:FentanylTransdermalMatrixPatchZR-02-01|Interventional|Phase 3|Industry|Numberofparticipantswithadverseevents;  Painintensity;  GlobalSatisfactionsatisfied)|24|NCT00126789|August 2005
2882|Completed|Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)||Drug:BotulinumtoxintypeB(Myobloc);  Procedure:Injectionofsalivaryglands|Interventional|Phase 2 / Phase 3|Other|Global impression of change by subject at eight weeks post injection;  Patient&apos;ssubjectiveassessmentofbenefit;  Change in volume of saliva produced over five minutes (measured with funnel and tube);  ALSFunctionalRatingScale(ALSFRS);  Caregiver&apos;ssubjectiveassessmentofbenefit;  Change in anticholinergic medication doses and number of times per day suction is used;  SEQOL-DW;  Durationofbenefit;  Assessment of treatment assignment (final visit only);  Globalassessmentofchangebyinvestigator|20|NCT00125203|July 2003
2883|Completed                  Has Results|Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder||Drug:ContinuedParoxetineCR;  Drug:Quetiapine;  Drug:Placebo|Interventional|Phase 4|Other|Hamilton Anxiety Scale (HAM-A) Score at Study Endpoint.;  Remission(HAM-A&#8804;7);  Response Clinical Global Impression of Improvement (CGI-I);  Depressive Symptoms Montgomery-Asberg Depression Rating Scale (MADRS);  The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q).|50|NCT00113295|February 2004
2884|Terminated|Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies||Drug:CAMPATH(alemtuzumab)|Interventional|Phase 1|Industry||24|NCT00113048|December 2003
2885|Completed|Trial to Evaluate 2 Hours of Daily Patching for Amblyopia in Children||Device:Eyepatch;  Device:Spectacles|Interventional|Phase 3|Other / NIH|maximalimprovementinvisualacuity|268|NCT00091923|February 2004
2886|Completed|Pain and Stress Management for People With Rheumatoid Arthritis||Behavioral:Copingskillstraining;  Behavioral:Writtenemotionaldisclosure;  Behavioral:Arthritiseducation;  Behavioral:Healthbehaviorwriting|Interventional|Phase 2|Other / NIH|Jointcount;  Psychologicalimpairment;  Pain;  Physicaldisability;  C-reactiveprotein;  Fatigue|280|NCT00088764|February 2005
2887|Completed|Acupuncture for the Treatment of Chronic Daily Headaches||Procedure:Acupuncture|Interventional||NIH||74|NCT00086021|February 2002
2888|Completed|Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors||Biological:SS1(dsFv)-PE38immunotoxin|Interventional|Phase 1|NIH|||NCT00066651|July 2003
2889|Unknown&nbsp;&#8224;|Increased Access to Emergency Contraceptive Pills||Behavioral: Increased access to emergency contraceptive pills|Interventional||NIH||1490|NCT00060463|October 2002
2890|Completed|Bevacizumab Fluorouracil and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer||Biological:bevacizumab;  Drug:fluorouracil;  Radiation:externalbeamradiationtherapy;  Procedure:therapeuticconventionalsurgery;  Other:laboratorybiomarkeranalysis|Interventional|Phase 1|NIH|Maximum tolerated dose of bevacizumab when administered concurrently with 5-fluorouracil (5-FU) and external beam radiation therapy (EBRT) in patients with cT3 and T4 rectal cancer prior to surgery;  Pathological response rate after preoperative bevacizumab 5-FU EBRT and surgery;  Progression-freesurvival;  Localcontrol;  Overallsurvival|32|NCT00052559|August 2002
2891|Completed|Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584||Drug:PTK787/ZK222584|Interventional|Phase 2|Industry|Evaluateefficacy;  Evaluate changes in dynamic contrast enhanced magnetic resonance imaging;  To explore the correlation of the pharmacokinetics;  To assess changes in surrogate markers of angiogenesis|11|NCT00052013|February 2003
2892|Completed|Treatment Outcome of Vascular Depression||Drug:Sertraline|Observational||Other / NIH||208|NCT00045773|April 2001
2893|Completed|Study Evaluating rhIL-11 in Active Crohn&apos;s Disease||Drug:RecombinantHumanInterleukin-11(rhIL-11)|Interventional|Phase 2|Industry|||NCT00040521|April 2002
2894|Completed|Meditation-Based Treatment for Binge Eating Disorder||Behavioral:Meditation|Interventional|Phase 2 / Phase 3|NIH||160|NCT00032760|March 2002
2895|Completed|Oltipraz in the Prevention of Lung Cancer in People Who Smoke||Drug:oltipraz|Interventional|Phase 1|Other / NIH|||NCT00006457|August 2000
2896|Unknown&nbsp;&#8224;|Decompression Coring Versus Conservative Therapy in Patients With Avascular Necrosis of the Hip Related to Sickle Cell Disease||Procedure:Coredecompression|Interventional||NIH / Other||50|NCT00006130|June 1999
2897|Completed                  Has Results|Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies &amp; Bone Marrow Failure Syndromes||Drug:CampathChemoand/orTBIAlloSCT|Interventional|Phase 2|Other|NumberofPatientsWithNeutrophilEngraftment;  NumberofPatientsWithPlateletEngraftment;  Number of Patients With Grade 3-4 Acute Graft Versus Host Disease (GVHD);  Number of Participants With Grade 3-4 Unexpected Adverse Events;  Number of Participants With Transplant-related Mortality;  OverallSurvival|2|NCT00004143|September 1999
2898|Completed|Tretinoin Cytarabine and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia||Drug:tretinoin;  Drug:daunorubicinhydrochloride;  Drug:cytarabine;  Drug:mercaptopurine;  Drug:methotrexate;  Drug:arsenictrioxide|Interventional|Phase 3|NIH|Responserates;  Distributionsofevent-freesurvival;  Disease-freesurvival;  Survival;  Toxicities for the various therapies graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0|420|NCT00003934|June 1999
2899|Completed|Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas||Drug:carmustine;  Drug:irinotecanhydrochloride;  Drug:polifeprosan20withcarmustineimplant;  Procedure:surgicalprocedure|Interventional|Phase 1|Other / NIH|||NCT00003463|July 1998
2900|Completed|A Study of Foscarnet in the Treatment of HIV Infection in Patients Who Have Taken Zidovudine for a Long Time||Drug:Zidovudine;  Drug:Foscarnetsodium|Interventional|Phase 1|NIH||12|NCT00001002|
2901|Completed|A Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients||Drug:Pyrimethamine;  Drug:Leucovorincalcium;  Drug:Zidovudine|Interventional|Phase 1|NIH / Industry||26|NCT00000973|
2902|Completed|A Phase I Evaluation of Azidothymidine (AZT) in Children With Acquired Immune Deficiency Syndrome (AIDS) or AIDS Related Complex (ARC)||Drug:Zidovudine|Interventional|Phase 1|NIH||12|NCT00000701|
2903|Recruiting|A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients||Behavioral: multi-domain rehabilitation intervention;  Behavioral:AttentionControl|Interventional||Other / NIH|Change in Short Physical Performance Battery (SPPB);  All-Causerehospitalization|360|NCT02196038|September 2014
2904|Active not recruiting|Omega 3 for Treatment of Depression in Patients With Heart Failure||Drug:400/200EPA/DHAfishoil2grams;  Drug:AnalmostpureEPA2grams;  Other:Matchedplacebocornoilcapsules|Interventional|Phase 3|Other / NIH|Change in Hamilton Depression Rating Scale (HDRS) score;  ChangeinRedBloodCell/PlasmaEPA|200|NCT02057406|May 2014
2905|Active not recruiting|Abiraterone Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer||Drug:Abirateroneacetate;  Drug:Androgendeprivation;  Radiation:RadiationTherapy;  Drug:Prednisone|Interventional|Phase 2|Other / Industry|RateofundetectablePSA(&lt;0.1ng/ml);  PSAnadirvalue;  TimetoPSAnadir;  Biochemicalprogression-freesurvival;  Metastasisorsystemictherapy;  Testosteronerecovery;  PSA &lt; 1.5ng/ml in setting of non-castrate testosterone;  Safetyandtolerability|37|NCT01717053|September 2013
2906|Active not recruiting|Metformin for the Treatment of Endometrial Hyperplasia||Drug:Metformin|Interventional|Phase 0|Other|ResponseRate;  Toxicityevaluation;  PatientCompliance;  Potential molecular markers in response to treatment with Metformin|18|NCT01685762|September 2012
2907|Completed|Efficacy and Safety of Activated Recombinant Human Factor VII in Refractory Haemorrhagic Cystitis||Drug:activatedrecombinanthumanfactorVII|Interventional|Phase 2|Industry|Reduction of hematuria that failed 24-hour standard therapy evaluated by change of urine color;  Reduction of hematuria that failed 24-hour standard therapy evaluated by urine haemoglobin content;  Reduction of hematuria that failed 24-hour standard therapy evaluated by urocrit;  Symptomsofvenousorarterialthrombosis|7|NCT01561352|September 2001
2908|Active not recruiting|Rehabilitation and Exercise Training After Hospitalization||Behavioral:Usualcare;  Behavioral:Rehabilitationintervention|Interventional|Phase 0|Other|6minutewalktest;  SPPB|27|NCT01508650|October 2011
2909|Terminated                  Has Results|Esmolol for Treatment of Perioperative Tachycardia||Drug:Esmolol|Interventional|Phase 3|Other / Industry|Percentage of Intraoperative Case Time With Heart Rate (HR) &lt;60 or &gt;80 Bpm;  Percentage of Postoperative First Three Hours With Heart Rate (HR) &lt;60 or &gt;80 Bpm;  Percentage of Postoperative Hours 4 to 12 With Heart Rate (HR) &lt;60 or &gt;80 Bpm.;  Percentage of Intraoperative Case Time With Systolic Blood Pressure &lt;95 mmHg;  Percentage of Postoperative First Three Hours With Systolic Blood Pressure &lt;95 mmHg;  Percentage of Postoperative Hours 4 to 12 With Systolic Blood Pressure &lt;95 mmHg|76|NCT01208402|September 2010
2910|Recruiting|Infant Immunity Comparison of Breastfed and Bottlefed Infants||Procedure:bloodsample/stoolsample|Observational||Other|Molecular profile of human IgG and IgA by pyrosequencing.;  Vaccineresponse;  Antibodyactivity;  Plasma level of B cell activating factor and/or a proliferation-inducing ligand|80|NCT02568579|January 2015
2911|Completed|Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients||Drug:Paclitaxel|Interventional||Industry / NIH|Treatmentsafety;  Technicalsuccess;  Airwaypatencyimprovements;  QualityofLife|20|NCT02066103|January 2014
2912|Active not recruiting|Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)||Drug:enzalutamide;  Drug:AndrogenDeprivation;  Radiation:RadiationTherapy|Interventional|Phase 2|Other / Industry|Twoyearprogression-freesurvival;  PSAlessthan0.1;  Threeyearprogression-freesurvival;  Biochemicalprogression-freesurvival;  PSAnadir;  Lengthoftimetotestosteronerecovery;  Number of patients with adverse events related to combination enzalutamide ADT and XRT|38|NCT02057939|April 2014
2913|Completed|Improving Colon Cancer Screening for Diverse Populations||Behavioral:Decisionaidandnavigation|Interventional||Other|Colorectalcancerscreeningcompletion;  Colorectalcancerscreeningknowledge;  Colorectalcancerscreeningrelatedself-efficacy;  Colorectalcancerscreeningrelatedintent|265|NCT02054598|January 2014
2914|Recruiting|Baby NAP SACC Intervention Study||Behavioral:BabyNAPSACC;  Behavioral:BacktoSleep|Interventional||Other / NIH|changeinweight-for-lengthz-score;  changeinskinfoldthickness;  change in child physical activity via accelerometer;  changeinchilddietaryintake;  changeinchildcarepoliciesandpractices|960|NCT01890681|August 2013
2915|Suspended|Early Mobility for the Critically Injured Burn Patient||Other:StandardizedRehabilitationTherapy|Interventional||Other / U.S. Fed|Hospitallengthofstay;  Functional Status &amp; Health Related Quality of Life|150|NCT01866735|May 2013
2916|Active not recruiting|Military Continuity Project||Behavioral:TAU;  Behavioral:CCVT+TAU|Interventional||Other / U.S. Fed|ScaleforSuicideIdeation-Current(SSI-C);  SuicideAttemptSelf-InjuryCount(SASI-Count);  InterpersonalNeedsQuestionnaire(INQ);  TreatmentHistoryInterview(THI);  ReasonsforTermination-Client(RT-C);  ClientSatisfactionQuestionnaire(CSQ)|800|NCT01829620|April 2013
2917|Completed                  Has Results|Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction||Drug:Placebo;  Drug:Avanafil100mg;  Drug:Avanafil200mg|Interventional|Phase 4|Industry|Per-subject Proportion of Sexual Attempts That Had an Erectogenic Effect Within Approximately 15 Minutes Following Dosing|440|NCT01698684|September 2012
2918|Completed|Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure||Drug:Tolvaptan;  Drug:Placebo|Interventional|Phase 3|Other|Dyspnea improvement measured by Likert scale at 8 and 24 hours;  Renalfunction;  Bodyweight;  FluidLoss;  Breathing;  Hospitalstay;  worseningheartfailure|257|NCT01644331|October 2012
2919|Completed|A Safety Study of TTP4000 in Subjects With Alzheimer&apos;s Disease||Drug:TTP4000;  Drug:Placebo|Interventional|Phase 1|Industry|Numberofparticipantwithadverseevents;  Evaluation of participant plasma TTP4000 concentrations|8|NCT01548430|October 2011
2920|Completed                  Has Results|Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma||Drug:Everolimus;  Drug:Pasireotide|Interventional|Phase 2|Other / Industry|TimetoProgression(TTP);  NumberofIndividualsExperiencingToxicity;  OverallSurvival(OS);  ObjectiveResponseRate(ORR)|24|NCT01488487|December 2011
2921|Terminated|Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer&apos;s Disease||Drug:HPP854;  Drug:Placebo|Interventional|Phase 1|Industry|NumberofParticipantAdverseEvents;  Evaluation of participant plasma HPP854 concentrations;  Change in cerebrospinal fluid concentration of Amyloid-Beta|7|NCT01482013|October 2011
2922|Completed                  Has Results|Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults||Biological:GSKBiologicals&apos;FluLaval&#174;;  Biological:Placebo(saline);  Biological: GSK Biologicals&apos; investigational H1N1 Influenza Vaccine - GSK2340274A;  Biological: GSK Biologicals&apos; investigational H1N1 Influenza Vaccine - GSK2340273A|Interventional|Phase 1|Industry|Number of Seroconverted Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.;  Number of Seroprotected Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.;  Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.;  Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.;  Titers for Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.;  Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/California/7/2009 (H1N1)V-like Virus-homologous Vaccine Strain.;  Number of Seroconverted Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.;  Number of Seroprotected Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.;  Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.;  Number of Seropositive Subjects for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.;  Titers for Hemagglutination Inhibition (HI) Antibodies Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.;  Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Titers Against A/Brisbane/59/2007 (H1N1) Virus-heterologous Vaccine Strain.;  Number of Influenza-specific Cluster of Differentiation 4 (CD4) T-cells Producing Two or More Markers Within Cluster Differentiation 40 Ligand (CD40L) Interleukin-2 (IL-2) Interferon-&#947; (IFN-&#947;) and Tumor Necrosis Factor-&#945; (TNF-&#945;).;  Number of Subjects Reporting Any and Related Potential Immune-mediated Disease (pIMDs).;  Number of Subjects Reporting Any and Related Medically Attended Adverse Events (MAEs).;  NumberofSubjectsReportingUnsolicitedAEs.;  Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs).;  Case Descriptions for Subjects Experiencing Reverse Transcription-polymerase Chain Reaction (RT-PCR) and Culture-confirmed Influenza.;  Number of Subjects Reporting Solicited Local Symptoms.;  Number of Subjects Reporting Solicited General Symptoms.;  Number of Subjects Reporting Clinical Laboratory Abnormalities in Haematological Parameters Assessed With Respect to Normal Laboratory Ranges.;  Number of Subjects Reporting Clinical Laboratory Abnormalities in Biochemistry Parameters Assessed With Respect to Normal Laboratory Ranges.|133|NCT01059617|February 2010
2923|Completed|A Study of CDX-1307 in Patients With Incurable Breast Colorectal Pancreatic Ovarian or Bladder Cancer (CDX 1307-01)||Biological:CDX1307|Interventional|Phase 1|Industry|To establish the safety and tolerability profile of CDX-1307 in patients with incurable breast colorectal pancreatic ovarian or bladder cancer alone and in combination with adjuvants.;  To evaluate dose-limiting toxicities immune response and clinical activity (tumor response and time to progression)|48|NCT00709462|March 2004
2924|Completed|Phase I Study of CDX-1307 hCG-B Vaccine for Patients With Incurable Locally Advanced or Metastatic Breast Colorectal Pancreatic Bladder or Ovarian Cancer||Biological:CDX-1307|Interventional|Phase 1|Industry|To establish safety and tolerability profile of CDX1307 alone and with adjuvant in patients with breast colorectal pancreatic bladder and ovarian cancer;  Investigateclinicalactivity|36|NCT00648102|January 2006
2925|Completed|Automated Chest Physiotherapy to Improve Outcomes in Neuro||Other:ChestPhysiotherapy|Observational||Other|Intracranialpressure|40|NCT00571623|September 2007
2926|Completed                  Has Results|Phase II Dasatinib Study in Advanced Breast Cancer||Drug:Dasatinib|Interventional|Phase 2|Other / Industry|Estimation of the Proportion of Progression-free Patients at 16 Wks.;  To Measure Response to Protocol Therapy Per RECIST Criteria;  Characterization and Comparison of SRC (A Protein Tyrosine Kinase)Dysregulation at Baseline (All Patients) After 4 Weeks of Dasatinib Treatment (All Patients) and at Progression (Only Patients Who Progress After Documented Response);  Correlate SRC Dysregulation Results With Response to Dasatinib Therapy;  To Explore the Association Between Each Patient&apos;s SRC Signature and Their Time to Progression.;  To Explore the Association Between Dasatinib and Osteoclastic Bone Resorption|31|NCT00546104|October 2007
2927|Completed|Confirmation of Systemic Autoimmune Diseases in the Agricultural Health Study|||Observational||NIH||700|NCT00341198|April 2002
2928|Completed|Incidence and Mortality of Childhood Cancer Among Children of Farmer Pesticide Applications|||Observational||NIH||21985|NCT00339378|June 2000
2929|Unknown&nbsp;&#8224;|Observational Study of Sepsis and Pneumonia to Develop Diagnostic Tests|||Observational||Other / NIH / U.S. Fed / Industry|Death;  SepticShock;  SevereSepsis;  Timetodeath;  Timetoseveresepsis;  Severesepsis;  Timetosepticshock;  Septicshock;  Cryptic shock (ScvO2&lt;65 or Lactate &gt;2.5 and MAP &gt;65 mmHg [&gt;18 years of age] or SBP &gt;90 [&lt;18 years of age]);  Time to Cryptic shock (ScvO2&lt;65 or Lactate &gt;2.5 and MAP &gt;65 mmHg [&gt;18 years of age] or SBP &gt;90 [&lt;18 years of age]);  Hospitalization;  Lengthofhospitalstay;  ICUadmission;  LengthofICUadmission;  Disposition;  Renaldysfunction;  Respiratorydysfunction;  Hematologydysfunction;  Metabolicdysfunction;  RenalSOFAscore;  LungSOFAscore;  CoagulationSOFAscore;  LiverSOFAscore;  CVSSOFAscore;  TimetorespiratorySOFAScore;  TimetocoagulationSOFAscore;  TimetoliverSOFAscore;  TimetoCVSSOFAscore;  TimetoRenalSOFAscore;  DICscore&gt;5(modifiedISTHscoringsystem);  TimetoDICscore&gt;5;  DevelopmentofALI;  DevelopmentofARDS;  TimetoALI;  TimetoARDS;  Ventilator;  Ventilatordays;  MELDscore;  Effect of early goal directed therapy on primary and secondary end-points;  Effect of Activated Protein C on primary and secondary end-points;  Effect of stress-dose corticosteroids on primary and secondary end-points;  Effect of intensive glycemic control on primary and secondary end-points;  APACHEIIscore;  PRISMIIIscore;  SOFAscore;  CAPmortality;  CAPandseveresepsis;  CAPandsepticshock;  SevereCAP(ATScriteria);  SevereCAP(BTScriteria);  Pneumococcalsepsis;  Staphylococcusaureussepsis;  Gramnegativerodsepsis;  Fungalsepsis;  SeptiFastresult;  Microbiologiccultureresult;  Urinarylegionellaantigen;  Microbiologicculture;  CAPtimetodeath;  CAPmortality;  CAPtimetoseveresepsis;  CAPseveresepsis;  CAPtimetosepticshock;  CAPsepticshock;  TimetosevereCAP(ATSandBTScriteria);  SevereCAP(ATSandBTScriteria);  CAPmechanicalventilation;  CAPtimetomechanicalventilation;  CAPlengthofmechanicalventilation;  CAPSOFArespiratoryscore&gt;2;  CAP respiratory component of severe sepsis criteria;  CAPhospitalized;  CAPlengthofhospitalization;  CAPICUadmission;  CAPlengthofICUstay;  CAPDisposition;  CAPALI;  CAPARDS;  CAPtimetoARDS;  CAPtimetoALI;  CAPPORTscore|1200|NCT00258869|December 2005
2930|Completed|Low-Fat Diet and/or Flaxseed in Preventing Prostate Cancer||DietarySupplement:dietaryintervention;  DietarySupplement:flaxseed|Interventional|Phase 2|Other / NIH|Prostatic Carcinoma Proliferation Rate by MIB-1 assay at time of prostatectomy;  Prostatic Carcinoma Apoptotic Index by TUNEL assay at time of prostatectomy;  Prostate-specific antigen by Hybritech assay at baseline and follow-up;  Total testosterone sex hormone binding globulin insulin-like growth factor (IGF) and IGF-binding protein-3 total cholesterol and low-density lipoprotein cholesterol by ELISA assays at baseline and follow-up|161|NCT00049309|January 2003
2931|Active not recruiting|Serum Levels of Bupivacaine in Autotransfusion Drains Following Total Joint Arthroplasty||Drug: periarticular bupivicaine and liposomal bupivicaine|Observational||Other|Change in blood serum levels of bupivocaine from baseline|10|NCT02276040|October 2014
2932|Completed                  Has Results|Proof-Of-Concept Investigation With a Neurosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate||Drug:Ganaxolone;  Drug:NicotinePatch|Interventional|Phase 2|Other / NIH|Percentage of Change in Expired Air Carbon Monoxide (CO) at End of Week 2;  Percentage of Change in Expired Air Carbon Monoxide (CO) at End of Week 4|36|NCT01857531|June 2013
2933|Completed                  Has Results|Combination Bupropion / Varenicline for Smoking Cessation in Male Smokers||Drug:Chantix;  Drug:Zyban;  Drug:Nicotinepatches|Interventional|Phase 2|Other / NIH / Industry|Number of Participants Completing Continuous Four-week Abstinence From Smoking Between the 8-week and 11-week Post Quit Day Visits;  Number of Participants Completing Seven-day Point Abstinence From Smoking at 6 Months Post Quit Day;  Number of Participants Completing Continuous Abstinence From Smoking Between Quit Day and 11-week Post Quit Day Visit|376|NCT01806779|March 2013
2934|Completed                  Has Results|Meclizine as a Potential Smoking Cessation Treatment||Drug:Meclizine;  Drug:NicotinePatch;  Drug:Placebo|Interventional|Phase 2|Other / Industry|Percentage of Change in Expired Air Carbon Monoxide (CO) at End of Week 1;  Percentage of Change in Expired Air Carbon Monoxide (CO) at End of Week 3;  Number of Participants Completing the Continuous 4 Week Abstinence From Smoking;  Percentage of Change of CO at End of Week 1 When Comparing Abstinent Smokers Versus Non-abstinent Smokers;  Percentage of Change of CO at End of Week 3 When Comparing Abstinent Smokers Versus Non-abstinent Smokers|146|NCT01443858|August 2011
2935|Completed                  Has Results|Concurrent Bupropion / Varenicline for Smoking Cessation||Drug:Varenicline;  Drug:Bupropion;  Drug:Nicotinepatches;  Drug:NicotineInhaler|Interventional|Phase 3|Other / NIH / Industry|Four-week Continuous Abstinence From Cigarette Smoking;  SevenDayPointAbstinenceFromCigaretteSmoking;  ContinuousCigaretteAbstinenceFromQuitDate|702|NCT01303861|March 2011
2936|Completed|Efficacy Study of LIQUICURE&#8482; to Treat Toe Nail Fungus||Device:LIQUICURE|Interventional||Industry|Freedom from major product-related adverse events for the duration of the feasibility phase.;  Clearance of fungal nail infection defined by negative culture and improvement in visual nail characteristics;  Timetoclearanceofinfection|63|NCT00960089|July 2008
2937|Completed|Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting||Other:VaccinationProgram|Observational||Other / U.S. Fed|Implementation and measurement of a health services intervention in community or private Ob/Gyn practices to improve the delivery of standard clinical care to vaccinate women against human papillomavirus influenza &amp; pertussis.|3988|NCT00828555|November 2008
2938|Completed|Shared Decision Making for Prostate Cancer Screening: a Practice-Based Randomized Controlled Trial||Other:YouDecide;  Other:ReducingYourRisksintheCrash|Interventional||Other|Men&apos;s understanding that prostate cancer screening requires a decision;  Men&apos;s knowledge about prostate cancer and prostate cancer screening;  Men&apos;s participation in the decision about prostate cancer screening with their clinician at their preferred level;  Thepresenceofashareddecision;  men&apos;sintenttobescreenedforprostatecancer;  Selfreportedscreening;  Actualscreeningbychartreview|128|NCT00630188|March 2005
2939|Completed|Telemedicine vs. Face-to-Face Cancer Genetic Counseling||Other:Telemedicine;  Other:Face-to-Face|Interventional||Other|Patientsatisfaction;  Cost-effectiveness|130|NCT00609505|August 2008
2940|Completed                  Has Results|Phase II Study With Abraxane Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer||Drug:Abraxane;  Drug:Bevacizumab;  Drug:Carboplatin|Interventional|Phase 2|Other / Industry|Best Clinical Response Expressed as Percentage of Participants Treated With Combination Regimen of Weekly Abraxane&#174; and Carboplatin Plus Biweekly Bevacizumab to Treat Women With Stage IV or Inoperable Stage III &quot;Triple Negative&quot; Metastatic Breast Cancer.;  Median Proportion Progression-free as Estimated by Kaplan-Meier Methods;  To Evaluate Sequential Plasma Samples for Presence of Selected Angiogenic Markers;  to Determine if Apolipoprotein Alleles (Apo-E) Correlate With Treatment-related Neuropathy;  to Determine if SPARC Expression in Breast Tumors Predicts Progression-free Survival (PFS)|41|NCT00479674|May 2007
2941|Active not recruiting|Carboplatin Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers||Biological:bevacizumab;  Drug:carboplatin;  Drug:erlotinibhydrochloride;  Drug:pemetrexeddisodium|Interventional|Phase 2|Other / NIH|Progression-freesurvival;  Overallsurvival;  Subjectsexperiencingtoxicity|40|NCT01344824|November 2010
2942|Completed|Survival TRaining for ENhancing Total Health (STRENGTH)||DietarySupplement:Calcium-RichDiet;  Other:Arm2:Exercise+Calcium-RichDiet;  Other: Exercise + Fruit &amp; Vegetable Low Fat + Calcium Diet|Interventional|Phase 2|Other / NIH|Distance Medicine Based Diet Exercise Program Within the Cooperative Group Setting|39|NCT00068458|September 2003
2943|Completed                  Has Results|Trial of Collaborative Depression Care Management for HIV Patients||Other: Measurement-Based Care collaborative depression management;  Other:EnhancedUsualCare|Interventional||Other / NIH|AntiretroviralMedicationAdherence;  DepressiveSymptoms;  HealthCareCosts;  AppointmentAdherence;  Number of Participants With Viral Load Below Detection;  QualityofLife;  SelfReportedAdherence;  Self-reportedAdherence;  SafetyEndpoint;  Depression-freeDays|304|NCT01372605|April 2010
2944|Completed|Informing Decisions in Chronic Critical Illness: A Randomized Control Trial (RCT)||Behavioral:SupportiveInformationTeamGroup|Interventional||Other / NIH|HospitalAnxietyandDepressionScale;  ImpactofEventsScale-Revised;  Discussion of Preferences for Patients Goals of Care;  QualityofCommunication;  Family Satisfaction in the Intensive Care Unit (ICU) Survey;  Modified Center for Gerontology and Health Care Research (CHCR) Tool;  LimitationofIntensiveCareUnit(ICU)Therapy;  HospitalLengthofStay;  Mortality;  Physician-SurrogateDiscordanceScore|622|NCT01230099|October 2010
2945|Terminated|Vorinostat Bortezomib and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma||Drug:bortezomib;  Drug: pegylated liposomal doxorubicin hydrochloride;  Drug:vorinostat|Interventional|Phase 1|Other / NIH|Maximumtolerateddoseofvorinostat;  Overallresponserate;  Durationofresponse|32|NCT00744354|October 2008
2946|Completed|Quit Smoking Program for Lung Cancer Patients&apos; Families (The Family Ties Project)||Behavioral: Coping-focused counseling telephone calls|Interventional||Other / NIH|7-day point-prevalence abstinence at 2 weeks and 6 month follow-up;  7-day point-prevalence abstinence at the 12-month follow-up and prolonged abstinence|496|NCT00345891|June 2004
2947|Recruiting|Environmental Polymorphisms Registry|||Observational||NIH||20000|NCT00341237|November 2003
2948|Recruiting|DiRectional AthErectomy + Drug CoAted BaLloon to Treat Long CalcifIed FemoropopliTeal ArterY Lesions||Device:MedtronicHawkOne&#174;orTurboHawk&#8482;;  Device:MedtronicIN.PACT&#174;Admiral&#174;DCB;  Device: Medtronic Spider&#8482; Distal Protection Device (DPD);  Device:VolcanoVisions&#174;PV.014&quot;IVUScatheter;  Device:NitinolStentPlacement|Interventional||Other / Industry|PrimaryPatency;  FreedomfromMAE;  DeviceSuccess;  ProceduralSuccess;  IVUS;  PACCS scoring and related procedural complications;  DirectionalAtherectomy;  MajorAdverseEventsthru24months;  PostprocedureTVR;  CD-TLRpostprocedure;  TimetoCD-TLRthru24monthspostprocedure;  Majortargetlimbamputationpostprocedure;  Thrombosis-targetlesionpostprocedure;  Primarysustainedclinicalimprovement;  Secondarysustainedclinicalimprovement|150|NCT02850107|June 2016
2949|Recruiting|Operative and Non-operative Treatment of Traumatic Arthrotomies|||Observational||Other|Costoftreatments;  Superficialwoundinfection;  Pain;  Returntoworkorpreviouslevelofactivity|100|NCT02841644|April 2015
2950|Recruiting|Clinical Study to Evaluate the Effectiveness Safety and Tolerability of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects||Drug:OxymorphoneHCl;  Drug:Placebo|Interventional|Phase 3|Industry|Cumulative total amount of morphine rescue medication required for analgesia in the active treatment group versus placebo group.;  Safety will be measured by incidence of Abnormal Laboratory Values Vital Sign Values and/or Adverse Events that are related to treatment.;  Assessment of pain using the age appropriate scale Face Legs Activity Cry Consolability (FLACC) or the Neonatal Infant Pain Scale (NIPS).;  Pharmacokinetic variable: Volume of Distribution (Vd);  Pharmacokineticvariable:Clearance(CL)|100|NCT02687451|February 2016
2951|Recruiting|Safety and Feasibility of SurModics SurVeil (TM) Drug Coated Balloon||Device:SurVeilDrugCoatedBalloon;  Procedure:Angioplasty|Interventional||Industry|Peakpaclitaxelplasmaconcentration;  Areaunderthedrugconcentrationtimecurve;  Technicalsuccess;  Devicesuccess;  Proceduresuccess;  Restinganklebrachialindex;  ChangeinRutherfordclassification;  Changein6-minutewalktest;  Primarypatency;  Peak systolic velocity ratio (PSVR) as measured by Duplex ultrasound;  Latelumenloss;  ChangeinWalkingImpairmentQuestionnaire;  EvidenceofPaclitaxeltoxicity;  Majorvascularcomplications;  Thrombolysis in Myocardial Infarction (TIMI)-defined major and minor bleeding;  Majoradverseevents;  All-causedeath;  Indexlimbabovetheankleamputation;  Indexlimbbelowtheankleamputation;  Clinically-drivenTLR;  Clinically-driven target vessel revascularization (TVR);  Arterial thrombosis of the treated segment on angiography;  Emboliceventsoftheindexlimb|15|NCT02648620|April 2016
2952|Recruiting|Safety Study of MGD009 in B7-H3-expressing Tumors||Biological:MGD009|Interventional|Phase 1|Industry|Numberofparticipantswithadverseevents;  Peakplasmaconcentration;  Number of participants that develop anti-drug antibodies;  Changeintumorvolume|114|NCT02628535|September 2015
2953|Recruiting|American Trial Using Tranexamic Acid in Thrombocytopenia||Drug:TranexamicAcid;  Drug:Placebo|Interventional|Phase 3|Other / NIH|Bleedingwithin30days;  Numberofplatelettransfusions;  Number of days alive and without WHO grade 2 bleeding|360|NCT02578901|June 2016
2954|Completed|Pharmacokinetic Safety Tolerability and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis||Drug:Umeclidinium;  Drug:Vehicle|Interventional|Phase 2|Industry|Plasma concentration after repeat dosing of umeclidinium;  CmaxandCtauafterrepeatdosingofumeclidinium;  Tmaxandt1/2afterrepeatdosingofumeclidinium;  Terminal plasma elimination rate constant after repeat dosing of umeclidinium;  AUC(0-t) and AUC(0-tau) after repeat dosing of umeclidinium;  Composite of population pharmacokinetic profile after repeat dosing of umeclidinium;  Numberofreportedadverseevents;  Electrocardiogram (ECG) assessment as a measure of safety and tolerability;  Laboratoryassessmentsasameasureofsafety;  Bodytemperatureassessment;  Bloodpressureassessment;  Pulserateassessment;  Degreeofapplicationsiteirritation;  Change from baseline in amount (in milligram) of sweat produced at Day 14;  Number of subjects with cut-points for percent change from baseline in sweat production at Day 14;  Change in Hyperhidrosis Disease Severity Scale (HDSS) score from baseline to Day 14.;  Number of subjects with 2-point decrease from baseline to Day 14 in HDSS score|28|NCT02563899|November 2015
2955|Recruiting|Clinical Outcomes Study of the Nexel Total Elbow||Device:NexelTotalElbow|Interventional||Industry|Survivorship|120|NCT02469662|June 2015
2956|Completed|Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT&#174; DISKUS&#174; and ADVAIR&#174; DISKUS&#174; in Patients With Persistent Asthma 12 Years of Age and Older||Drug:TreatmentA:FpMDPI;  Drug:TreatmentB:FSMDPI;  Drug:TreatmentCFlovent;  Drug:TreatmentD:Advair|Interventional|Phase 1|Industry|AUC0-tPlasmadrugconcentration;  CmaxPlasmadrugconcentration;  AUC0-&#8734;Plasmadrugconcentration;  AUC%extrapPlasmadrugconcentration;  tmaxPlasmadrugconcentration;  t&#189;Plasmadrugconcentration;  &#955;zPlasmadrugconcentration;  CL/FPlasmadrugconcentration;  Vz/FPlasmadrugconcentration|43|NCT02437604|May 2015
2957|Recruiting|Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors||Drug:CRLX301|Interventional|Phase 1 / Phase 2|Industry|Determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of CRLX301 in Phase 1;  Number of Participants with Adverse Events as a Measure of Safety and Tolerability;  Evaluate the pharmacokinetic (PK) profile of CRLX301 in blood and/or urine specimens of patients receiving at least 1 dose;  ExplorepreliminarysignsofefficacyofCRLX301|60|NCT02380677|April 2015
2958|Recruiting|Data Collection Registry of the HeRO Graft for End Stage Renal Disease Patients Receiving Hemodialysis||Device:HeROGraftimplantfordialysisaccess|Observational||Industry|Mortality;  Adequacyofdialysis(Kt/V);  Infectionrate|300|NCT02164175|May 2014
2959|Recruiting|First in Human Dose Escalation Study of TEW-7197 in Subjects With Advanced Stage Solid Tumors||Drug:TEW-7197|Interventional|Phase 1|Industry / Other|Maximum tolerated dose (MTD) based on the number of subjects experiencing at least 1 DLT;  Dose-dependency of toxicity based on: dose limiting toxicities; frequency type grade and seriousness and causality of treatment-emergent adverse events and laboratory assessments.|50|NCT02160106|June 2014
2960|Active not recruiting|Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease||Biological:HAVG|Interventional|Phase 1|Industry|HAVGgraftassessment;  HAVGpatencyrate;  AdverseEvents;  HAVGgraftinterventions;  ChangefrombaselineinPanelReactiveAntibody;  DevelopmentofIgGantibodies;  Graftinterventions;  HAVGpatencyrates|20|NCT01840956|May 2013
2961|Active not recruiting                  Has Results|Safety and Efficacy of Valiant Mona LSA Stent Graft System||Device:ValiantMonaLSAStentGraftSystem|Interventional||Industry|Primary Safety Observation - Rate of Major Adverse Events (MAEs);  PrimaryEffectivenessObservation|9|NCT01839695|April 2013
2962|Completed|Clinical Performance Study of the Ultra Influenza A&amp;B Test Using Nasal Swabs for Identifying Subjects Who Are Infected With the Influenza Virus Strain Type A or Type B||Device:FluSymptoms|Observational||Industry|Identify subjects who are infected with the virus strain type A or type B;  Demonstrate the ability of untrained intended users to effectively run and read the Ultra Influenza A&amp;B Test with insignificant risk of erroneous results.|677|NCT01753531|November 2012
2963|Recruiting|BIBF 1120 in Bevacizumab Resistant Persistent or Recurrent Epithelial Ovarian Cancer||Drug:BIBF1120|Interventional|Phase 2|Other / Industry|ProgressionFreeSurvival;  ObjectiveTumorResponseviaRECIST1.1;  DurationofProgression-FreeSurvival;  Objective Tumor Response Based on GCIG CA-125 Criteria;  VEGFLevelsCorrelatedWithTreatmentOutcome;  Additional Growth Factor Correlation with Treatment Response;  Coagulation and Endothelial Cell Activation Markers;  AdverseEventFrequencyandSeverity|56|NCT01669798|February 2013
2964|Active not recruiting|Managing Childhood Abdominal Pain||Behavioral: Cognitive Behavioral Therapy &amp; Social Learning;  Behavioral:EducationandSupport|Interventional||Other|AbdominalPainIndex;  Adults&apos;ResponsestoChildren&apos;sSymptoms;  PainResponseInventory;  PainBeliefsQuestionnaire;  PainCatastrophizingScale|300|NCT01620606|September 2011
2965|Active not recruiting|Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix||Drug:mitomycinC;  Drug:oxaliplatin;  Procedure:therapeuticconventionalsurgery;  Other:quality-of-lifeassessment;  Drug:hyperthermicintraperitonealchemotherapy|Interventional|Phase 2|Other / NIH|Difference in the rate of grade 3 or 4 hematologic toxicities (leukopenia thrombocytopenia and neutropenia) between the mitomycin C and oxaliplatin treatments;  Comparison of disease-free survival between the two treatment arms;  Comparison of overall survival between the two treatment arms;  QualityoflifeasassessedbyFACT-G|116|NCT01580410|May 2009
2966|Active not recruiting|Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck||Drug:Cetuximab;  Drug:Nab-paclitaxel;  Drug:Carboplatin|Interventional|Phase 2|Other / Industry|Clinical Response Rate Following Induction Chemotherapy;  Rate of Complete Response following Induction Chemotherapy;  ProgressionFreeSurvivalandOverallSurvival;  Toxicityevaluation;  QualityofLife|40|NCT01412229|February 2012
2967|Active not recruiting|BKM120 in Metastatic Castration-resistant Prostate Cancer||Drug:BKM120|Interventional|Phase 2|Other / Industry|Progression free survival (PFS) as determined radiographically based on Prostate Cancer Working Group 2 (PCWG2) criteria or based on the onset of a skeletal related event.;  Define radiologic response rates using Response Evaluation Criteria In Solid Tumors(RECIST) 1.1.;  Number and Percent of Participants with Adverse Events as a Measure of Safety and Tolerability;  ProstateSpecificAntigen(PSA)response;  Determinetheoverallsurvivalofparticipants.;  Evaluate baseline circulating tumor cell (CTC) levels and changes in CTC.;  Determine the time to new metastatic disease from the baseline visit.;  Correlation of baseline genomic profile from targeted metastatic biopsy with PFS evaluating known oncogenic signatures particularly the PI3 kinase signature and presence or absence of phosphatase and tensin homolog (PTEN) and PI3K activation.;  Post&#8208;treatment day 28 (optional) metastatic biopsy to assess inhibition of the PI3K/Akt pathway correlated with a day 28 serum pharmacokinetic assessment;  Circulating tumor cell collection with measurements of CTC gene expression to assess mechanisms of resistance to BKM120;  Post&#8208;treatment day 28 (optional) metastatic biopsy gene expression profile to assess mechanisms of resistance to BKM120|66|NCT01385293|August 2011
2968|Active not recruiting|Administration of T Lymphocytes for Hodgkin&apos;s Lymphoma and Non-Hodgkin&apos;s Lymphoma (CART CD30)||Drug:CAR.CD30Tcells|Interventional|Phase 1|Other|Number of participants with adverse events as a measure of safety and tolerability of escalating doses of autologous activated T lymphocytes;  MeasurethesurvivalofCAR.CD30invivo;  Measure the response of the subjects tumor to the CAR.CD30 transduced ATL|18|NCT01316146|December 2011
2969|Completed|Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100||Biological:VGX-3100|Interventional|Phase 1|Industry|Safety and tolerability of a fourth dose of VGX-3100;  HumoralandcellularimmuneresponsestoVGX-3100|14|NCT01188850|July 2010
2970|Completed|Safety and Efficacy of LCL161 in Patients With Solid Tumors||Drug:LCL161|Interventional|Phase 1|Industry|Occurrenceofdose-limitingtoxicities;  Frequencyandtypeofadverseevents;  Comparison of amount of LCL161 that gets into blood stream from tablet formulation versus liquid formulation (bioavailability);  Blood assessments to determine how much LCL161 gets into the blood stream (pharmacokinetic parameters);  Pharmacodynamic measurements to determine how LCL161 interacts with proteins related to cancer such as cIAP cytokines and cell death markers; hair skin and tumor samples will be evaluated for target inhibition;  Solid tumor response criteria will be used to identify any anti-tumor activity|71|NCT01098838|November 2008
2971|Completed                  Has Results|A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase&#174;||Other:Control;  Drug:IdursulfaseIT(1mg);  Drug:IdursulfaseIT(10mg);  Drug:IdursulfaseIT(30mg)|Interventional|Phase 1 / Phase 2|Industry|NumberofSeriousAdverseEvent(SAE);  NumberofTreatmentEmergentAdverseEvent(AE);  Safety Changes in Cerebrospinal Fluid (CSF)- White Blood Cells (WBC);  Safety: Development of Anti-idursulfase Antibodies (CSF);  Safety: Development of Anti-idursulfase Antibodies (Serum);  Clinically Significant ECG Findings at Any Time During the Study.;  Change From Baseline in CSF Glycosaminoglycans [GAGs] at Week 27;  Level of Idursulfase in the CSF Compartment Resulting From Monthly Idursulfase IT Administrations;  Concentration of Idursulfase in Serum After Single Administration (Week 3) in Conjunction With Elaprase;  Concentration of Idursulfase in Serum After Repeated Doses of Intrathecal Idursulfase-IT Given in Conjunction With Elaprase;  %ChangeFromBaselineinUrinaryGAG|16|NCT00920647|November 2009
2972|Terminated                  Has Results|Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer||Drug:Nilutamide;  Drug:Dasatinib|Interventional|Phase 2|Other / Industry|ProgressionFreeSurvival(PFS);  Overall Response Rate of Men With High AR Activity;  OverallResponseRateofMenWithLowARActivity|57|NCT00918385|May 2009
2973|Completed                  Has Results|Learning Impairments Among Survivors of Childhood Cancer||Drug:Methylphenidate|Interventional|Phase 4|Other / NIH|Brain White Matter Volume for Patients Versus Sibling Controls;  Brain White Matter Volume for Patients With Acute Lymphoblastic Leukemia Versus Brain Tumors;  Brain White Matter Volume for Treatment Intensity Groups and Sibling Controls;  Change From Methylphenidate (MPH) Home Maintenance Phase Baseline to Completion of Phase as Measured by Conners&apos; Teacher Rating Scale (CTRS: ADHD T Score);  Change From Maintenance Phase Baseline to Completion of Phase as Measured by Conners&apos; Teacher Rating Scale (CTRS: Cognitive Problem T Score);  Change From Maintenance Phase Baseline to Completion of Phase as Measured by Conners&apos; Parent Rating Scale (CPRS: ADHD T Score);  Change From Maintenance Phase Baseline to Completion of Phase as Measured by Conner&apos;s Parent Rating Scale (CPRS: Cognitive Problem T Score);  Change From Maintenance Phase Baseline to Completion of Phase as Measured by Social Skill Rating System (SSRS-P);  Change From Maintenance Phase Baseline to Completion of Phase as Measured by Wechsler Individual Achievement Test (WIAT) Reading: Composite Standard Score;  Change From Maintenance Phase Baseline to Completion of Phase as Measured by Wechsler Individual Achievement Test (WIAT) Spelling: Standard Score;  Change From Maintenance Phase Baseline to Completion of Phase as Measured by Wechsler Individual Achievement Test (WIAT) Math: Composite Standard Score;  Best Weekly Score Measured by Conners&apos; Parent Rating Scale (CPRS: ADHD T Score) During the 3-week Home Crossover Phase.;  Effectiveness of MPH in Enhancing Classroom Attentiveness Academic Productivity and Social Behavior Measured by The Conners&apos; Parent Rating Scale (CPRS) Cognitive Problem/Inattention Scale.;  Effectiveness of MPH in Enhancing Classroom Attentiveness Academic Productivity and Social Behavior Measured by The Conners&apos; Parent Rating Scale (CPRS) Hyperactivity Scale.;  Effectiveness of MPH in Enhancing Classroom Attentiveness Academic Productivity and Social Behavior Measured by The Conners&apos; Parent Rating Scale (CPRS) ADHD Index.;  Effectiveness of MPH in Enhancing Classroom Attentiveness Academic Productivity and Social Behavior Measured by The Conners&apos; Teacher Rating Scale (CTRS) Cognitive Problem/Inattention Scale.;  Effectiveness of MPH in Enhancing Classroom Attentiveness Academic Productivity and Social Behavior Measured by The Conners&apos; Teacher Rating Scale (CTRS) Hyperactivity Scale.;  Effectiveness of MPH in Enhancing Classroom Attentiveness Academic Productivity and Social Behavior Measured by The Conners&apos; Teacher Rating Scale (CTRS) ADHD Index.;  Effectiveness of MPH in Enhancing Classroom Attentiveness Academic Productivity and Social Behavior Measured by Social Skills Rating System - Parent (SSRS-P) - Social Skill.;  Effectiveness of MPH in Enhancing Classroom Attentiveness Academic Productivity and Social Behavior Measured by Social Skills Rating System - Parent (SSRS-P) - Problem Behavior.;  Effectiveness of MPH in Enhancing Classroom Attentiveness Academic Productivity and Social Behavior Measured by Social Skills Rating System - Teacher (SSRS-T) - Social Skill.;  Effectiveness of MPH in Enhancing Classroom Attentiveness Academic Productivity and Social Behavior Measured by Social Skills Rating System - Teacher (SSRS-T) - Problem Behavior.;  Establish the Effectiveness of MPH on Laboratory Measures of Sustained Attention Reaction Time and Impulsivity Using Conner&apos;s Continuous Performance Test (CPT) for Omission Errors.;  Establish the Effectiveness of MPH on Laboratory Measures of Sustained Attention Reaction Time and Impulsivity Using Conner&apos;s Continuous Performance Test (CPT) for Commission Errors.;  Establish the Effectiveness of MPH on Laboratory Measures of Sustained Attention Reaction Time and Impulsivity Using Conner&apos;s Continuous Performance Test (CPT) for Hit Reaction Time.;  Establish the Effectiveness of MPH on Laboratory Measures of Sustained Attention Reaction Time and Impulsivity Using Conner&apos;s Continuous Performance Test (CPT) for d&apos; (Sensitivity).;  Establish the Effectiveness of MPH on Laboratory Measures of Sustained Attention Reaction Time and Impulsivity Using Conner&apos;s Continuous Performance Test (CPT) for Beta (Risk Taking).;  Establish the Effectiveness of MPH on Laboratory Measures of Learning and Recall Using California Verbal Learning Test (CVLT) Over Five Learning Trials.;  Establish the Effectiveness of MPH on Laboratory Measures of Learning and Recall Using California Verbal Learning Test (CVLT) for Short Delay Free Recall.;  Establish the Effectiveness of MPH on Laboratory Measures of Learning and Recall Using California Verbal Learning Test (CVLT) for Long Delay Free Recall.;  Establish the Effectiveness of MPH on Laboratory Measures of Interference Impulsivity Cognitive Flexibility and Selective Attention Using the Stroop Word-Color Association Test (Stroop) for Word Naming Time.;  Establish the Effectiveness of MPH on Laboratory Measures of Interference Impulsivity Cognitive Flexibility and Selective Attention Using the Stroop Word-Color Association Test (Stroop) for Color Naming Time.;  Establish the Effectiveness of MPH on Laboratory Measures of Interference Impulsivity Cognitive Flexibility and Selective Attention Using the Stroop Word-Color Association Test (Stroop) for Ink Color Naming Time.;  Establish the Effectiveness of MPH on Laboratory Measures of Interference Impulsivity Cognitive Flexibility and Selective Attention Using the Stroop Word-Color Association Test (Stroop) for Interference Score.|469|NCT00576472|January 2000
2974|Completed|The Von Willebrand Disease (VWD) International Prophylaxis Study||Drug:VWF/FVIIIproducts|Interventional||Other / Industry|von Willebrand Disease associated bleeding frequency;  Optimal treatment regimens for joint bleeding GI bleeding epistaxis and menorrhagia|105|NCT00557908|June 2007
2975|Completed|Tolerability of Inhaled Hypertonic Saline in Infants With Cystic Fibrosis||Drug:inhaled7%hypertonicsaline(HS)|Interventional||Other|The proportion of infants who are intolerant of single and repeated doses of HS according to protocol-defined criteria;  New or increased cough increased qualitative breathing rate new or increased noisy breathing or new or increased emesis at home as noted by parents on the daily symptom report;  Change in respiratory rate oxygen saturation or cough frequency between the baseline measurement and measurements obtained after HS administration;  Change in respiratory rate oxygen saturation or cough frequency between the baseline value at the enrollment visit and the value at the final study visit;  Unanticipatedadverseevents;  Adherence as measured by (1) the number of doses of HS administered per the home symptom report and (2) returned study drug vials|19|NCT00546663|September 2007
2976|Completed|Comparing the Effectiveness of Two Family-based Therapies in Treating Young Children With Obsessive-Compulsive Disorder||Behavioral:CognitiveBehaviorTherapy;  Behavioral:RelaxationTherapy|Interventional|Phase 3|Other / NIH|Children&apos;sYale-BrownObsessiveCompulsiveScale;  ClinicalGlobalImprovement|127|NCT00533806|October 2007
2977|Completed|Phase 1 Study of EZN-2968 Weekly in Adult Patients With Advanced Solid Tumors or Lymphoma||Drug: Intravenous EZN-2968 (anti-HIF-1&#945; LNA AS-ODN)|Interventional|Phase 1|Industry|Determine the maximum tolerated dose (MTD) of EZN-2968.;  Determine the pharmacokinetic (PK) profile; Determine the PD profile.|52|NCT00466583|March 2007
2978|Completed|Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic|||Observational||NIH||0|NCT00340769|April 2001
2979|Completed                  Has Results|Randomized Fixed Bearing vs Mobile Bearing Cruciate Substituting TKA||Device:TotalKneeArthroplasty;  Device:Totalkneereplacement|Interventional||Industry|KneeSocietyScore;  Complications;  Revisions;  MedicalImaging;  SF-12PatientOutcomes|149|NCT00289107|April 2001
2980|Completed|Study of the Efficacy Safety and Tolerability of Oral CEP-701 in Patients With Severe Psoriasis||Drug:CEP-70120mg;  Drug:CEP-70140mg;  Drug:CEP-70160mg;  Drug:CEP-70180mg|Interventional|Phase 2|Industry|PhysiciansStaticGlobal(PSGA)Score;  PSGAChangefromBaseline;  PsoriasisAreaandSeverityIndex(PASI)|46|NCT00236119|June 2005
2981|Terminated|Efficacy of Seprapack Sinus Dressing Versus No Dressing in the Prevention of Intranasal Adhesions Following Sinus Surgery||Device:SeprapackSinusDressing|Interventional||Industry|reduction in post-operative scarring when compared to use of no sinus packing||NCT00140608|June 2003
2982|Completed                  Has Results|Treatment of Obsessive Compulsive Disorder in Children||Drug:Serotoninreuptakeinhibitorsmanagement;  Behavioral: Cognitive behavioral therapy by a psychologist;  Behavioral: Instructional cognitive behavioral therapy by a psychiatrist|Interventional|Phase 3|Other / NIH|Children&apos;s Yale-Brown Obsessive Compulsive Scale (CY-BOCS);  ChildObsessive-CompulsiveImpactScale(COIS);  ChildDepressionInventory;  PediatricAdverseEventRatingScale(PAERS)|124|NCT00074815|September 2003
2983|Completed|Study of Systemic and Spinal Chemotherapy Followed by Radiation for Infants With Brain Tumors||Drug: Induction therapy (Regimen 1 Course 1 Cycle A1;  Drug: Regimen 1 Course 1 Cycle A2 (Days 22 - 42);  Drug:CycleB;  Drug:Regimen1Course2;  Drug:IntrathecalMafosfamide;  Drug:Regimen1Course2ITmafosfamide;  Drug:Regimen2Course1;  Drug:Regimen2Course1CycleC1;  Drug:Regimen2Course2;  Radiation:radiationtherapy|Interventional||Other|To evaluate the feasibility including expected disease progression of delivering 20 weeks of systemic chemotherapy plus (IT) mafosfamide.;  To evaluate the safety and feasibility of a limited dose escalation schedule of IT mafosfamide in children &lt; 3 years of age.|119|NCT00042367|April 2000
2984|Recruiting|Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors||Biological:MEDI9090;  Biological:Durvalumab|Interventional|Phase 1|Industry|Number of subjects reporting infusion related reactions;  Number of subjects that develop changes in detectable antidrug antibodies to MEDI9090;  IndividualMEDI9090concentrations;  Numberofsubjectsreportingadverseevents;  Number of subjects reporting serious adverse events;  Number of subjects with vital sign abnormalities reported as adverse events;  Number of subjects with ECG abnormalities reported as adverse events|36|NCT02900157|August 2016
2985|Recruiting|Comparative Effectiveness of Microprocessor Controlled and Carbon Fiber Prosthetic Feet in Transtibial Amputees||Device:Kinnex;  Device:PacificaLP|Interventional||Industry|Amputee Mobility Predictor with Prosthesis (AMPPRO);  L-FunctionalTest(L-Test)Baseline;  5timesSit-to-Stand(5timesSTS)Baseline;  6minuteTimedWalkTest(6mTWT)Baseline;  PhysiologicalCostIndex(PCI)Baseline;  HillAssessmentIndex(HAI)Baseline;  2 Dimensional Video Motion Analysis (2D Video Analysis) Baseline;  L-FunctionalTest(L-Test)after4weeks;  5timesSit-to-Stand(5timesSTS)after4weeks;  6minuteTimedWalkTest(6mTWT)after4weeks;  PhysiologicalCostIndex(PCI)after4weeks;  HillAssessmentIndex(HAI)after4weeks;  2 Dimensional Video Motion Analysis (2D Video Analysis) after 4 weeks;  OrthoticProstheticUserSurvey(OPUS);  Prosthesis Evaluation Questionnaire - Mobility Subscale (PEQ-MS);  ProsthesisLimbUserSurveyofMobility(PLUS-M);  Activities-Specific Balance Confidence Scale (ABC);  SocketComfortScore(SCS)|30|NCT02864693|June 2016
2986|Recruiting|Tolerability Safety and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)||Drug:Naloxegol;  Drug:Placebo|Interventional|Phase 4|Other / Industry|AdverseEvents;  Numerical Rating Scale (NRS) for Pain change from Baseline;  DailyOpioidUsechangefromBaseline;  Adverse Events associated with Blood Laboratory result changes from Baseline;  Electrocardiogram (ECG) Interval and Rate Change from Baseline;  VitalSignschangesfromBaseline;  RescueFreeBowelMovements(RFBM)ResponderRate;  TimetoFirstPost-doseRescueFreeLaxation;  BristolStoolScale(BSS)Score;  Patient Assessment of Constipation Symptoms (PAC-SYM);  Patient Assessment of Constipation Quality of Life (PAC-QOL);  Degree of Straining question with each Bowel Movement;  Complete Evacuation question with each Bowel Movement|44|NCT02839889|September 2016
2987|Recruiting|A Study of CA-170 (Oral PD-L1 PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas||Drug:CA-170|Interventional|Phase 1|Industry|The number of patients with a dose-limiting toxicity (DLT) in the first treatment cycle;  Maximumtolerateddose(MTD)ofCA-170;  RecommendedPhase2Dose(RP2D)ofCA-170;  MaximumConcentration(Cmax);  AreaUndertheCurve(AUC);  Exploratory Outcome Measure: Preliminary clinical efficacy based on RECIST;  Exploratory Outcome Measure: Preliminary clinical efficacy based on irRECIST;  Exploratory Outcome Measure: Preliminary clinical efficacy based on Cheson|300|NCT02812875|May 2016
2988|Recruiting|Safety of Simultaneous Tdap and IIV in Pregnant Women||Biological: Tetanus Diphtheria and Pertussis Vaccine;  Biological: 2016-2017 Quadrivalent Inactivated Influenza Vaccine|Interventional|Phase 4|Other / U.S. Fed|Proportion of Injection-site Reactions post Tdap and Flu administration;  Proportions of Systemic Reactions post Tdap and Flu administration;  Pertussis Serum Antibody Levels as measured by Geometric mean titers;  Diphtheria Serum Antibody Levels as measured by the proportion of subjects with seroprotection (defined as &gt; 0.1 IU/mL);  Tetanus Serum Antibody Levels as measured by the proportion of subjects with seroprotection (defined as &gt; 0.1 IU/mL);  Flu Serum Antibody Levels as measured by proportion of subjects with seroprotection (pre- and post-immunization) and seroconversion (4-fold rise from baseline);  feasibility as measured by number of participants recruited;  feasibility as measured by participant retention (percentage of participants who complete all visits);  feasibility reported as percentage of adequate data collected;  feasibility reported as percentage of adequate biospecimens collected;  feasibility reported as percentage of timely collected biospecimens;  feasibility reported as percentage of timely collected data;  Proportion of adverse maternal outcomes based on medical record review;  Proportion of adverse infant outcomes based on medical record review;  Proportionofclinicalchorioamnionitis;  Proportion of histologic chorioamnionitis on surgical pathology examination of placental tissue;  feasibility as measured by percentage of blood samples in testable condition;  feasibility as measured by percentage of blood samples in with sufficient volume for testing;  feasibility as measured by percentage of testable blood samples completed|50|NCT02783170|September 2016
2989|Recruiting|Initial and Chronic Methicillin Resistant Staphylococcus Aureus (MRSA) Infection in Cystic Fibrosis (CF)||Other:InterventionN/A.Observationalstudy|Observational||Other|Changes in presence of hypermutable MRSA isolates post-therapy compared to pre-therapy.;  OtherMRSAcharacteristicsinsputum;  Clinicalimprovementwiththerapy|100|NCT02684422|July 2015
2990|Completed|A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma||Drug:FluticasonePropionateMDPI;  Drug:FluticasonePropionate/SalmeterolMDPI;  Drug:Fluticasonepropionate/salmeterol|Interventional|Phase 1|Industry|Maximumobservedplasmadrugconcentration(Cmax);  Area under the plasma drug concentration-time curve (AUCO-t);  Time to maximum observed plasma drug concentration (tmax)|20|NCT02680561|April 2016
2991|Completed|Homecoming Line: Telephone Support for Veterans||Behavioral:TelephoneCaseMonitoring;  Behavioral:TreatmentasUsual|Interventional||U.S. Fed|PTSDChecklist(PCL)Slope;  PTSDpsychotherapyvisits-interventionperiod;  Othermentalhealthvisits-interventionperiod;  Depressionslope;  Alcoholproblemsslope;  Drugproblemsslope;  Aggressionslope;  QualityofLifeslope;  PTSDpsychotherapyvisits--follow-upperiod;  Othermentalhealthvisits--follow-upperiod;  Selective serotonin reuptake inhibitor refills (medication possession ratio);  Prazosinrefills(medicationpossessionratio)|358|NCT02655991|March 2008
2992|Suspended|UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch||Other:BiospecimenCollection|Observational||Other|Proportion of subjects who receive NGS and have a personalized report generated with potential treatment options;  Collection of tissue and blood samples from subjects receiving treatment for urothelial cancer;  Proportion of subjects whose personalized NGS report includes targeted therapy treatment options;  Proportion of subjects whose personalized NGS report includes potential clinical trial options;  Proportion of subjects who receive targeted therapy;  Collect comprehensive demographic data for all subjects enrolled in this clinical trial;  Collect comprehensive treatment histories for all subjects enrolled in this clinical trial;  Collect comprehensive clinical outcomes for all subjects enrolled in this clinical trial;  Research projects resulting from biospecimen and data repository|200|NCT02643043|May 2016
2993|Recruiting|Evaluation of The MetaNeb&#174; System to Reduce Postoperative Pulmonary Complications||Device:MetaNeb&#174;System|Interventional||Industry|Significant Postoperative Pulmonary Complication Incidence;  Requirement for invasive mechanical ventilation &gt; 48 hours post-operatively;  Requirementforrespiratorysupport&gt;48hours;  LengthofICUstay;  Lengthofhospitalstay;  Readmission to ICU and transfers to elevated level of care for pulmonary complications;  Readmissiontohospital;  TimeonMechanicalVentilation|400|NCT02627742|March 2016
2994|Recruiting|Sustained Acoustic Medicine for Chronic Low Back Pain Secondary to Herniated Nucleus Pulposus or Other Conditions||Device:SustainedAcousticMedicine(SAM);  Device:ShamDevice|Interventional||Industry|Brief Pain Inventory-Short Form (BPI-SF): Pain Severity;  BPI-SF:PainInterference;  OswestryDisabilityIndex;  ActiGraphActivityMonitor;  NumericRatingScale:PainonFlexion;  NumericRatingScale:PainonExtension|100|NCT02609854|November 2015
2995|Recruiting|Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed/Refractory Acute Leukemia or High-Risk MDS||Drug:FT-1101|Interventional|Phase 1|Industry|MaximumToleratedDose(MTD);  DoseLimitingToxicities(DLT);  RecommendedPhase2Dose(RP2D);  Area under the plasma concentration versus time curve (AUC);  PeakPlasmaConcentration(Cmax);  Timeofpeakplasmaconcentration(TMax);  Time for half of the drug to be absent in blood stream following dose (T 1/2);  Rate at which drug is removed from blood stream (CL/F);  Rate of drug distribution within the blood stream (Vd/F);  Observe patients for any evidence of anti-leukemic or anti-myelodysplastic activity of FT-1101|78|NCT02543879|September 2015
2996|Completed|HEMOBLAST Pilot Clinical Investigation||Device:HEMOBLASTBellows|Interventional|Phase 2 / Phase 3|Industry|The primary endpoint of this clinical investigation is the mean paired Kappa statistic for the assignment of SBSS scores by 2 Investigators.;  Proportion of subjects achieving hemostasis within 6 minutes of HEMOBLAST&#8482; Bellows application;  Proportion of subjects achieving hemostasis within 10 minutes of HEMOBLAST&#8482; Bellows application;  Proportion of subjects achieving hemostasis within 3 minutes of HEMOBLAST&#8482; Bellows application;  Incidence of adverse events through final follow-up|27|NCT02502019|August 2015
2997|Recruiting|Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty (TKA) Using the SPRINT System||Device: SPRINT Peripheral Nerve Stimulation (PNS) System|Interventional||Industry|Mean knee pain while walking as measured by the Brief Pain Inventory during first 4 weeks of treatment compared to historical controls;  Devicerelatedadverseeventrates;  Average knee pain as measured by the Brief Pain Inventory during first 4 weeks of treatment compared to historical controls;  Average knee pain at rest as measured by the Brief Pain Inventory during first 4 weeks of treatment compared to historical controls;  Cumulative analgesic usage as noted by subject in daily diary compared to historical controls;  Opioid related side effects as measured by side effect checklist compared to historical controls;  Range of motion as measured by degrees of active and passive knee flexion and extension compared to historical controls;  Timed Up and Go (TUG) Test time compared to historical controls;  6 Minute Walk Test distance compared to historical controls;  Fixed Distance Walk Test time compared to historical controls;  Western Ontario McMaster University Osteoarthritis Index (WOMAC) score compared to historical controls;  Knee pain interference with activities of daily living as measured by the Brief Pain Inventory compared to historical controls;  Patient Global Impression of Change score compared to historical controls;  Pain Catastrophizing Scale score compared to historical controls;  Time to meet recovery milestones compared to historical controls;  Subject satisfaction with the study and therapy as measured by a Subject Satisfaction Survey|36|NCT02468934|September 2015
2998|Enrolling by invitation|Comfort Talk and Economic Outcomes in MRI||Behavioral:ComfortTalk&#174;Training|Interventional||Industry / Other|Non-completionrate;  SedationRate;  PatientSatisfaction;  Noshowrate|12|NCT02427737|April 2015
2999|Withdrawn|Evaluation of the Short and Long Term Performance and Clinical Outcomes of the Crux Vena Cava Filter System|||Observational||Industry|PreventionofPulmonaryEmbolism|0|NCT02420626|January 2016
3000|Recruiting|Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy||Drug:Palbociclib|Interventional|Phase 2|Other / Industry|ProgressionFreeSurvival;  Progression Free Survival (PFS) and Overall Survival (OS);  ResponseRate(RR);  Numberofparticipantswithadverseevents|40|NCT02334527|March 2015
3001|Active not recruiting|A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10||Drug:TopicalRoseBengal0.005%|Interventional|Phase 2|Industry|Change in the immunologic structural and hyperproliferative state of the skin in the target plaque and evidence of cellular atypia following PH-10 application;  Psoriasis Severity Index (PSI) changes from pre-treatment;  PlaqueResponsechangesfromDay1pre-treatment;  Pruritus Self-Assessment score changes from Day 1 pre-treatment;  Correlation of PSI changes with observed histopathologic and immunohistopathologic changes in the skin of the target plaque;  Incidenceofadverseexperiences;  Incidence of adverse changes in clinical laboratory tests;  Incidence of adverse changes in weight or vital signs;  Correlation of adverse experiences with observed histopathologic and immunohistopathologic changes in the skin|30|NCT02322086|January 2015
3002|Enrolling by invitation|An Observational Longitudinal Prospective Long-Term Registry Of Patients With Hypophosphatasia (HPP)|||Observational||Industry|Patient-reportedOutcomes|500|NCT02306720|December 2014
3003|Completed|Study of A Cell-Phone System to Improve Health of Youth With Diabetes||Behavioral: health coaching with technology support|Interventional||Other / NIH|ChangefromBaselineinHbA1cat4months;  Change from Baseline in Quality of Life measures at 4 months|74|NCT02280564|March 2011
3004|Terminated|Pharmacokinetics and Clinical Response of Tolvaptan in Neurocritical Care Patients||Drug:Tolvaptan|Observational||Other / Industry|Maximum observed plasma concentration (Cmax) and time to maximum observed plasma concentration (Tmax) of tolvaptan over 36 hours post-dose;  The elimination rate constant (ke) of tolvaptan over 36 hours post-dose;  Area under the plasma concentration time curve (AUC) of tolvaptan from time zero to 36 hours post-dose;  The clinical response of tolvaptan administered through the nasogastric tube in acute brain injured patients;  The safety of tolvaptan administered via a nasogastric tube in acute brain injured patients|1|NCT02215148|November 2014
3005|Recruiting|Single Agent Regorafenib in Refractory Advanced Biliary Cancers||Drug:Regorafenib|Interventional|Phase 2|Other / Industry|OverallSurvival(OS)at6Months;  DiseaseControlResponse(DCR);  ProgressionFreeSurvival(PFS)|39|NCT02115542|April 2014
3006|Active not recruiting|Renal Denervation in Patients With Uncontrolled Hypertension - SYMPLICITY HTN-4||Device: Renal Denervation using the Symplicity Renal Denervation System;  Other:ShamRenalDenervation;  Device:RenalAngiography|Interventional|Phase 3|Industry|ReachingBPGoal;  Incidence of Major Adverse Events through 1 month post-procedure (Renal artery stenosis measured at 6 months)|44|NCT01972139|October 2013
3007|Terminated                  Has Results|A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy||Drug:Droxidopa;  Drug:Placebo|Interventional|Phase 3|Industry|Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1)|61|NCT01927055|November 2013
3008|Recruiting|The Pathogenesis of Hepatitis C Virus Vertical Transmission|||Observational||Other / Industry|To evaluate for the presence of HCV Core protein HCV RNA and SPP in the placenta and fetal membranes using paraffin-embedded sections and post-delivery specimens respectively.|50|NCT01921400|January 2013
3009|Active not recruiting|Efficacy and Safety of Beta-adrenoceptor Inverse Agonist Nadolol in Mild Asthma||Drug:Nadolol;  Drug:Placebo|Interventional|Phase 2|Industry|The change in methacholine provocative concentration causing a 20% fall (PC20) based on forced expiratory volume in 1 second (FEV1) between baseline visit and final dose dispensing visit.|60|NCT01804218|March 2013
3010|Terminated                  Has Results|Radial Reload Open LAR Case Series||Device: Covidien Radial Reload Stapler with Tri-Staple Technology|Interventional||Industry / Other|StapleLine;  DistalMargins;  Usability:Visibility;  Usability:Access;  Usability:Manueverability|8|NCT01717014|May 2013
3011|Enrolling by invitation|Enhanced Algorithm for Crohn&apos;s Treatment Incorporating Early Combination Therapy||Other:EnhancedTreatmentAlgorithm;  Other:ConventionalStep-careAlgorithm|Interventional|Phase 4|Other|Risk of CD-related complications at one-year measured at the practice level;  RiskofCD-relatedcomplicationsat6months.|1200|NCT01698307|March 2014
3012|Completed|Clinical Evaluation of the APTIMA&#174; HPV 16 18/45 Genotype Assay on the PANTHER&#174; System||Device:APTIMAHPVAssay|Observational||Industry||2200|NCT01694875|October 2012
3013|Recruiting|Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer||Drug:PLX3397;  Drug:Eribulin|Interventional|Phase 1 / Phase 2|Other / Industry|Maximum tolerated dose of PLX3397 given in combination with with standard dose eribulin in patients with metastatic breast cancer (Phase 1b);  Percentage of patients with chemotherapy pre-treated triple negative metastatic breast cancer treated with PLX3397 in combination with eribulin who are progression free at 12 weeks (Phase 2);  Serum concentrations for the combination of PLX3397 and eribulin (Phase 1b);  Safetyoftreatment(Phase1b&amp;2);  Immuneresponse(Phase1b&amp;2);  Efficacy of drug combination including response rate and duration of response (Phase 2)|80|NCT01596751|July 2012
3014|Completed|NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness||Drug:Natalizumab(Tysabri)|Interventional|Phase 4|Other / Industry|Change in parameters of sleep as measured by polysomnography and multi-sleep latency test over 6 months of Natalizumab treatment.;  Change in neurocognition parameters over 6 months of Natalizumab treatment and correlation with changes in sleep efficiency.;  Change in subjective measures of fatigue sleepiness and mood over 6 months of Natalizumab treatment and correlation with changes in sleep efficiency.|37|NCT01591551|March 2012
3015|Withdrawn|Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia||Drug:AFX-2|Interventional|Phase 1|Industry|Safety and tolerability will be assessed based on the incidence duration and intensity of adverse events;  Safety and tolerability will also be determined by assessing any changes in study test results from baseline values;  Qualityoflifeindices;  Maximum tolerated dose and/or dose-limiting toxicity;  Biologicalandimmuneresponses|0|NCT01456182|December 2011
3016|Terminated|Pilot Study of Model Based Iterative Reconstruction Using 64-Slice|||Observational||Industry|Evidence for reduced x-ray radiation exposure for applicable patient indications|92|NCT01431378|September 2011
3017|Completed|APTIMA HPV 16 18/45 Genotype Assay on the TIGRIS DTS System in Women With ASC-US or Negative Pap Test Results|||Observational||Industry|Sensitivity of the assay to detect HPV genotypes 16 18 and/or 45;  Specificity of the assay to give a positive signal only in HPV 16 18 and/or 45 positive samples|1260|NCT01384370|June 2011
3018|Completed|Weight Management Demonstration Project: HEALTH||Behavioral:RCT1;  Behavioral:RCT2;  Behavioral:RCT3|Interventional||Other / U.S. Fed|BodyMassIndexBMI;  BMI;  BloodPressure|2395|NCT01307280|August 2006
3019|Active not recruiting|AMG 319 Lymphoid Malignancy FIH||Drug:AMG319|Interventional|Phase 1|Industry|Clinically significant or &gt; or = to Grade 3 CTCAE changes in safety laboratory tests physical exams ECGs or vital signs;  PKparameters;  Clinical/radiological response rate for CLL subjects;  Treatment-emergentadverseevents;  Phospho-AKTlevelincirculatingCLLcells;  Number of patients with clinical/radiological response|28|NCT01300026|April 2011
3020|Completed                  Has Results|Safety Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults||Biological:BioThrax;  Biological:AV7909Formulation1;  Biological:AV7909Formulation2;  Biological:AV7909Formulation3;  Biological:AV7909Formulation4;  Drug:Control|Interventional|Phase 1|Industry / NIH / U.S. Fed|Incidence of Injection Site Reactions From Subject Diary Cards by Injection and Severity (Mild Moderate or Severe) Following the First Vaccination (Day 0);  Percentage of Subjects With Injection Site Reactions From Subject Diary Cards by Injection and Severity (Mild Moderate or Severe) Following the First Vaccination (Day 0);  Incidence of Injection Site Reactions From Subject Diary Cards by Injection and Severity (Mild Moderate or Severe) Following the Second Vaccination (Day 14);  Percentage of Subjects With Injection Site Reactions From Subject Diary Cards by Injection and Severity (Mild Moderate or Severe) Following the Second Vaccination (Day 14);  Incidence of Systemic Reactions From Subject Diary Cards by Injection and Severity (Mild Moderate or Severe) Following the First Injection (Day 0);  Percentage of Subjects With Systemic Reactions From Subject Diary Cards by Injection and Severity (Mild Moderate or Severe) Following the First Injection (Day 0);  Incidence of Systemic Reactions From Subject Diary Cards by Injection and Severity (Mild Moderate or Severe) Following the Second Injection (Day 14);  Percentage of Subjects With Systemic Reactions From Subject Diary Cards by Injection and Severity (Mild Moderate or Severe) Following the Second Injection (Day 14);  Incidence of Hematology Serum Chemistry and Urinalysis Abnormalities Reported as Adverse Events;  Percentage of Subjects With Hematology Serum Chemistry and Urinalysis Abnormalities Reported as Adverse Events;  Peak TNA NF50 GMT for All Subjects in the Immunogenicity Population and by Gender After IM Administration of Investigational Product on Days 0 and 14.;  Median Time to Peak TNA NF50 GMT for All Subjects in the Immunogenicity Population and by Gender After IM Administration of Investigational Product on Days 0 and 14.;  TNA NF50 GMTs Across Study Days After IM Administration of Investigational Product on Days 0 and 14.|105|NCT01263691|December 2010
3021|Completed                  Has Results|A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)||Biological:PRM-151;  Other:Placebo|Interventional|Phase 1|Industry|SafetyandTolerability;  Cmax;  Tmax;  AUC48;  TerminalEliminationHalfLife;  TotalBodyClearance;  Vss;  FVC (Forced Vital Capacity) Change From Baseline to Day 57;  FVC (Forced Vital Capacity) % Predicted Change From Baseline;  DLCO (%) (Diffusing Capacity of Carbon Monoxide) Change From Baseline;  FEV1 (Forced Expiratory Volume 1sec )(%) Change From Baseline;  6MWT (6 Minute Walk Test) Distance Walked Change From Baseline;  SGRQ (St. George&apos;s Respiratory Questionnaire) Total Score Change From Baseline|21|NCT01254409|January 2011
3022|Terminated|Toxicity and Safety Evaluation of an Omega-3 Fatty Acid and a Multivitamin and Antioxidant Nutritional Preparation|||Observational||Industry / Other||200|NCT01221714|October 2010
3023|Active not recruiting|Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma||Drug:Lenalidomide|Interventional|Phase 0|Other / Industry|To evaluate the feasibility of lenalidomide maintenance therapy in patients with relapsed Hodgkin lymphoma after ASCT as measured by dropout rate.;  Overall survival event free survival and progression free survival.;  Adverseeventprofile;  Conversion of partial response/stable disease post-ASCT to complete response.;  Evaluateimmuneresponse|28|NCT01207921|April 2011
3024|Terminated                  Has Results|Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy||Drug:Photodynamictherapy;  Drug:Imiquimod|Interventional|Phase 4|Other / Industry|ActinicKeratosisCount;  CompleteClearance;  CosmeticAppearance|21|NCT01203878|September 2010
3025|Completed                  Has Results|Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention||Drug:10%FBRcontainingbioadhesivegel;  Drug:placebogel|Interventional|Phase 1 / Phase 2|Other / NIH|Light Microscopic Histologically Scored Diagnoses Pretreatment to Post Treatment;  ChangesinLesionalSizes;  Treatment Changes in Loss of Heterozygosity Events|41|NCT01192204|October 2010
3026|Completed|Predictors of Response to Augmentation With Ziprasidone (Geodon&#174;) in Major Depressive Disorder||Drug:ziprasidone;  Drug:Sugarpill|Interventional|Phase 4|Other|The primary outcome of this study is to determine if predictors of response can select a population of patients with MDD that is effectively treatable by augmentation with ziprasidone.|64|NCT01168674|February 2010
3027|Completed|Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)||Drug:asfotasealfa|Interventional|Phase 2|Industry|Effect of asfotase alfa on reduction in plasma inorganic pyrophosphate (PPi) and plasma pyridoxal-5&apos; phosphate (PLP);  SafetyandTolerabilityofasfotasealfa;  Change in bone mineral content and density as measured by dual-energy X-ray absorptiometry (DXA);  Change in walking ability as measured by the Six-Minute Walk Test (6MWT);  Change in HPP-related osteomalacia as measured by trans-iliac crest bone biopsy|19|NCT01163149|June 2010
3028|Terminated|A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid Tumors||Drug:AMG780|Interventional|Phase 1|Industry|To assess the safety and tolerability of AMG 780 in subjects with advanced solid malignancies (including adverse event rate incidence of dose-limiting toxicities and determination of maximum tolerated dose);  To evaluate the pharmacokinetic (PK) parameters of AMG 780 including but not limited to Cmax AUC and accumulation ratio;  To evaluate tumor response using RECIST criteria (measured by CT/MRI);  To evaluate changes in tumor volume (measured by volumetric CT/MRI);  To evaluate changes in tumor vascularity and to estimate the relationship between dose/pharmacokinetics and vascular response (measured by DCE-MRI);  To evaluate the incidence of anti-AMG 780 antibody formation|44|NCT01137552|June 2010
3029|Active not recruiting|Interactive Cancer Communication System (ICCS) Directed Physical Activity Enhancement for Colon Cancer Survivors||Behavioral:SurvivorshipCHESS;  Other:Control|Interventional||Other|Changeinlevelofphysicalactivity|34|NCT01133132|February 2010
3030|Completed|Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion||Drug:Temozolomide|Interventional|Phase 1|Other / Industry|Safety Profile of intra-arterial temozolomide and maximum tolerated dose of temozolomide;  To define tumor response in field in patients treated with temozolomide|29|NCT01127594|July 2010
3031|Completed                  Has Results|Study of Recurrent Prostate Cancer With Rising Prostate Specific Antigen (PSA)||Drug:Disulfiram|Interventional||Other|Proportion of Subjects With a Demethylation Response at Each Dose Level;  ClinicalResponse|19|NCT01118741|May 2010
3032|Terminated|Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)||Drug:Nilotinib;  Drug:NilotinibwithImatinib|Interventional|Phase 2|Other / Industry|Progressionfreesurvival;  ResponsebyChoiCriteria|5|NCT01089595|February 2009
3033|Completed                  Has Results|Oxygen Saturation Alarms in the Neonatal Intensive Care Unit|||Observational||Industry|Detection of Oxygen Alarms That Resulted in Clinicians Changing the Care of the Infant.|50|NCT01085539|January 2010
3034|Completed|Collection and Extraction of Respiratory Specimens|||Observational||Industry|PresenceofInfluenzaVirus|600|NCT01083511|March 2010
3035|Active not recruiting|Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal Radiotherapy||Drug:aprepitant;  Drug:Ondansetron|Interventional|Phase 2|Other|Complete Response rate (no vomiting and no rescue anti-emetic therapy);  CompleteResponserate;  Proportionofpatientswhodidnotvomit;  No Significant Nausea: The proportion of patients who did not experience any nausea &#8805; 3 on 0 - 10 scale;  No Nausea: The proportion of patients who did not experience any nausea. Nausea = 0 on 0 - 10 scale;  Complete Protection: The proportion of patients who did not vomit require rescue therapy or have nausea &#8805; 3 on 0 - 10 scale;  Total Protection: The proportion of patients who did not vomit require rescue therapy or have any nausea (Nausea = 0 on 0 - 10 scale).;  Vomiting frequency: The frequency of vomiting (# episodes per week) in patients who did vomit at least once.;  Nausea frequency: The frequency of nausea (Nausea &gt; 0 in a given week/ number of weeks during overall period of radiation treatment);  Significant Nausea frequency: The frequency of significant nausea (Nausea &#8805; 3 in a given week/ number of weeks during overall period of radiation treatment);  Frequency of rescue medication use: The number of days in which rescue medication was taken / number of days of radiotherapy;  Time to Failure: The time period in days from the start of radiation until the first vomiting episode or use of rescue medication for all patients and for the subset of patients who do not have a Complete Response.;  All adverse events that occur during radiation treatment with assessment of severity (CTC v.3) and relationship to study drug.|52|NCT00970905|October 2009
3036|Withdrawn|Accuracy of the Pima&#8482; CD4 Test for Enumeration of CD4+ T-Cell Counts|||Observational||Other / Industry||0|NCT00951795|September 2009
3037|Completed                  Has Results|Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations||Biological:InactivatedH1N1Vaccine|Interventional|Phase 2|NIH|Number of Participants Reporting Vaccine-associated Serious Adverse Events (SAEs);  Number of Participants Reporting Solicited Local Reactions Based on the Functional Grading Scale After the First Vaccination;  Number of Participants Reporting Solicited Local Reactions Based on the Functional Grading Scale After the Second Vaccination;  Number of Participants Reporting Measured Injection Site Reactions of Swelling and Redness After the First Vaccination;  Number of Participants Reporting Measured Injection Site Reactions of Swelling and Redness After the Second Vaccination;  Number of Participants Reporting Solicited Systemic Reactions Based on the Functional Grading Scale After the First Vaccination;  Number of Participants Reporting Solicited Systemic Reactions Based on the Functional Grading Scale After the Second Vaccination;  Number of Participants Reporting Fever After the First Vaccination;  Number of Participants Reporting Fever After the Second Vaccination;  Number of Participants in the 18-64 Year Age Stratum With 4-fold or Greater HAI Antibody Titer Increases Against Influenza H1N1 2009 Virus at 8-10 Days Following 1 Dose of Vaccine;  Number of Participants in the 65 Years and Older Age Stratum With 4-fold or Greater HAI Antibody Titer Increases Against Influenza H1N1 2009 Virus at 8-10 Days Following 1 Dose of Vaccine;  Number of Participants in the 18-64 Year Age Stratum With 4-fold or Greater HAI Antibody Titer Increases Against Influenza H1N1 2009 Virus at 21 Days Following 1 Dose of Vaccine;  Number of Participants in the 65 Years and Older Age Stratum With 4-fold or Greater HAI Antibody Titer Increases Against Influenza H1N1 2009 Virus at 21 Days Following 1 Dose of Vaccine;  Number of Participants in the 18-64 Year Age Stratum With a Serum Hemagglutination Inhibition (HAI) Antibody Titer of 1:40 or Greater Against Influenza H1N1 2009 Virus Prior to and at 8-10 Days Following 1 Dose of H1N1 Vaccine;  Number of Participants in the 65 Years and Older Age Stratum With a Serum Hemagglutination Inhibition (HAI) Antibody Titer of 1:40 or Greater Against Influenza H1N1 2009 Virus Prior to and at 8-10 Days Following 1 Dose of H1N1 Vaccine;  Number of Participants in the 18-64 Year Age Stratum With a Serum Hemagglutination Inhibition (HAI) Antibody Titer of 1:40 or Greater Against Influenza H1N1 2009 Virus at 21 Days Following 1 Dose of H1N1 Vaccine;  Number of Participants in the 65 Years and Older Age Stratum With a Serum Hemagglutination Inhibition (HAI) Antibody Titer of 1:40 or Greater Against Influenza H1N1 2009 Virus at 21 Days Following 1 Dose of H1N1 Vaccine;  Number of Participants in the 18-64 Year Age Stratum With 4-fold or Greater HAI Antibody Titer Increases Against Influenza H1N1 2009 Virus at 8-10 and 21 Days Following 2 Doses of H1N1 Vaccine;  Number of Participants in the 65 Years and Older Age Stratum With 4-fold or Greater HAI Antibody Titer Increases Against Influenza H1N1 2009 Virus at 8-10 Days Following 2 Doses of H1N1 Vaccine;  Number of Participants in the 65 Years and Older Age Stratum With 4-fold or Greater HAI Antibody Titer Increases Against Influenza H1N1 2009 Virus at 21 Days Following 2 Doses of H1N1 Vaccine;  Number of Participants in the 18-64 Year Age Stratum With a Serum Hemagglutination Inhibition (HAI) Antibody Titer of 1:40 or Greater Against Influenza H1N1 2009 Virus at 8-10 and 21 Days Following 2 Doses of H1N1 Vaccine;  Number of Participants in the 65 Years and Older Age Stratum With a Serum Hemagglutination Inhibition (HAI) Antibody Titer of 1:40 or Greater Against Influenza H1N1 2009 Virus at 8-10 Days Following 2 Doses of H1N1 Vaccine;  Number of Participants in the 65 Years and Older Age Stratum With a Serum Hemagglutination Inhibition (HAI) Antibody Titer of 1:40 or Greater Against Influenza H1N1 2009 Virus at 21 Days Following 2 Doses of H1N1 Vaccine|406|NCT00943631|August 2009
3038|Terminated                  Has Results|Study of orBec&#174; With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)||Drug:oralbeclomethasone1721-dipropionate;  Drug:Placebo|Interventional|Phase 3|Industry|The Proportion of Subjects With GVHD Treatment Failure;  CumulativeExposuretoPrednisone;  SurvivalStatus|140|NCT00926575|October 2009
3039|Completed|Transition From Hospital to Home in Solid Organ Transplant (SOT)|||Observational||Other|Determine the influences of care coordination and discharge teaching on readiness for discharge in solid organ transplant recipients;  Determine the relationship of parent readiness for hospital discharge with coping utilization of healthcare resources medication adherence and parent adjustment following hospital discharge|37|NCT00907023|January 2009
3040|Unknown&nbsp;&#8224;|Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension||Drug:Ambrisentan|Interventional|Phase 2 / Phase 3|Other / Industry|Changein6minutewalkdistance.|24|NCT00851929|November 2008
3041|Completed|Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.||Drug: capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)|Interventional|Phase 1|Other / Industry|To determine the MTD/RPTD of capecitabine/oxaliplatin/bevacizumab/everolimus (XELOX-A-Ev) for subjects with advanced solid tumors.;  Describe dose-limiting and non-dose-limiting toxicities;  preliminarily investigate the response rate and PFS|32|NCT00849550|July 2009
3042|Unknown&nbsp;&#8224;|Early Versus Late Bronchoscopy in Bone Marrow Transplantation (BMT) Patients||Procedure: Variation in the time for performing bronchoscopy|Interventional|Phase 4|Other|Change in therapy due to results obtained from bronchoscopy.;  In-Hospitalandthreemonthmortality;  Durationofantibiotictherapy|100|NCT00846352|January 2009
3043|Completed|A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of People With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab||Biological:Cetuximab;  Drug:Irinotecan;  Biological:IMC-A12(cixutumumab)|Interventional|Phase 2|Industry / Other|ProgressionFreeSurvival;  Objective Response Rate (ORR) (Complete Response plus Partial Response);  OverallSurvival;  Progression Free Survival (PFS) over entire duration;  Resection Rate the number of patients who had a complete resection/ablation of metastases with no evidence of disease remaining;  Toxicity of the irinotecan + cetuximab + IMC-A12 regimen;  Post-treatment serum levels of IMC-A12 in patients receiving IMC-A12;  Change in Behavioral and Health Outcomes [BAHO] Quality of Life Questionnaire;  SerumAnti-IMC-A12AntibodyAssessment|4|NCT00845039|May 2009
3044|Completed|BN83495 in Prostate Cancer||Drug:BN83495(Cohort1);  Drug:BN83495(Cohort2);  Drug:BN83495(Cohort3)|Interventional|Phase 1|Industry|Absolute and percentage change in levels of hormones from baseline to D28/29 at 6 timepoints;  Tolerance (Physical Exam ECOG Performance Status Electrocardiogram biochemistry/haematology Urinalysis Adverse Events Concomitant Medications disease progression);  Pharmacokinetic assessments/Pharmacodynamic assessments|17|NCT00790374|January 2009
3045|Completed|Study of IMC-1121B in Patients With Advanced Solid Tumors Not Responding To Standard Therapy||Biological:IMC-1121B;  Biological:1121B|Interventional|Phase 1|Industry|NumberofparticipantswithAdverseEvents(AEs);  MaximumToleratedDose;  Maximum concentration (Cmax) cohorts 1 2 3 4 and 5;  Minimum concentration (Cmin) cohorts 1 2 3 4 and 5;  Area under concentration (AUC) cohorts 1 2 3 4 and 5;  Half-life(t1/2)cohorts1234and5;  Clearance (Cl) rate drug is completely removed cohorts 1 2 3 4 and 5;  Volume of distribution (Vss) at steady state cohorts 1 2 3 4 and 5;  Serum Anti-IMC-1121B Antibody Assessment (immunogenicity);  ChangeintumorsizefromBaselineMeasurement|25|NCT00786383|February 2006
3046|Terminated|Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)||Drug:FG-3019|Interventional|Phase 1|Industry|Safety and tolerability of FG-3019 as measured by AEs SAEs physical exams lab tests and the Treatment Satisfaction Questionnaire for Medications;  StandardplasmaandurinaryPKparameters;  Change from baseline in urinary protein/creatinine albumin/creatinine albumin excretion rate estimated glomerular filtration rate (eGFR) 24 hour urinary protein and fasting serum lipids|12|NCT00782561|April 2008
3047|Completed|Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies||Device: Enriched Hematopoetic Stem Cell Transplant|Interventional|Phase 1 / Phase 2|Other|Level of Donor Chimerism from Enriched Hematopoietic Stem Cell Engraftment|9|NCT00777231|January 2005
3048|Completed|Design &amp; Evaluation of a Medication Therapy Management Program to Improve Patient Safety in Medicare Beneficiaries||Behavioral:Basicmedicationtherapymanagement;  Behavioral: Enhanced medication therapy management|Interventional||Other / U.S. Fed|AdverseDrugEvents;  Emergencydepartmentvisits;  Hospitalizations;  Drugrelatedproblems;  Discrepancies in medication list intervention arms compared with best possible medication history;  Patientsatisfactionwithcare.|637|NCT00773942|November 2007
3049|Completed|Study of Efficacy of Bowel Preparation Before Colonoscopy||Drug:FM-602;  Drug:MarketedBowelCleanser|Interventional|Phase 2|Industry|Effectiveness of bowel cleansing assessed by the examining physician|148|NCT00771485|September 2008
3050|Unknown&nbsp;&#8224;|TRIAD - Treatment of Insomnia and Depression||Drug:Antidepressant;  Behavioral:DesensitizationTherapyforInsomnia;  Behavioral: Cognitive Behavioral Therapy for Insomnia|Interventional|Phase 2 / Phase 3|Other|Rateofdepressionremission;  RateofInsomniaremission|216|NCT00767624|December 2008
3051|Completed                  Has Results|Effect of Orlistat in Body Composition||Drug:Orlistat;  Drug:Placebo|Interventional|Phase 4|Industry|Change From Baseline to Week 24 in Abdominal VAT Mass;  Change From Baseline to Week 12 in Abdominal VAT Mass;  ChangeFromBaselinetoWeek24inBodyWeight;  ChangeFromBaselinetoWeek24inTotalFatMass;  Change From Baseline to Week 24 in Percentage Body Fat;  Change From Baseline to Week 24 in Waist Circumference;  Change From Baseline to Week 24 in Percentage Liver Fat;  ChangeFromBaselinetoWeek24inLiverFat;  Change From Baseline to Week 24 in Total Calories Expended for Physical Activity;  Change From Baseline to Week 24 in Quality of Life (QoL) Scores.;  SelectivityIndexatWeek24|131|NCT00752726|September 2008
3052|Completed|Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP)||Biological:AsfotaseAlfa|Interventional|Phase 1|Industry|To determine the safety and tolerability of Asfotase Alfa given intravenously and given subcutaneously.;  To assess the pharmacokinetics (PK) of Asfotase Alfa given intravenously and subcutaneously;  To assess the bioavailability of the subcutaneous Asfotase Alfa|6|NCT00739505|August 2008
3053|Withdrawn|FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma||Device:SIR-Spheresmicrospheres;  Drug:FOLFOX6cycles1-3;  Drug:FOLFOX6cycles4onwards;  Drug:Bevacizumabcycles3onwards|Interventional|Phase 2 / Phase 3|Industry|Toxicityandsafety|0|NCT00735241|July 2008
3054|Completed                  Has Results|A Preference Study Comparing Kristalose&#174; and Liquid Lactulose||Drug:lactulose(Kristalose&#174;);  Drug:liquidlactulose|Interventional|Phase 4|Industry|Patient Preference in Terms of Overall Preference and Preference of Taste Consistency and Portability.|50|NCT00712543|June 2009
3055|Completed                  Has Results|Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet||Biological:Entercept;  Other:Placeboinjections|Interventional|Phase 1 / Phase 2|Other / Industry|The Number of Subjects Who Achieve a 50% Reduction in the Palmoplantar Psoriasis Severity Index at 12 Weeks|20|NCT00585650|May 2007
3056|Completed                  Has Results|Minimizing Harm From ADEs by Improving Nurse-Physician Communication|||Observational||U.S. Fed|IncidentRateforCommunicationEvents;  OverallInvolvementinConversationbyRoles|39|NCT00574990|January 2008
3057|Active not recruiting|Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis||Drug:Dasatinib;  Drug:ZoledronicAcid|Interventional|Phase 1 / Phase 2|Other / Industry|Maximum Tolerated Dose (MTD) for Dasatinib in Combination with Zoledronic Acid;  Response Rate of Dasatinib in Combination with Zoledronic Acid|28|NCT00566618|November 2007
3058|Completed                  Has Results|Topotecan Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer||Drug:Topotecan;  Drug:Cisplatin;  Drug:Bevacizumab|Interventional|Phase 2|Other / Industry|Anti-tumor Activity as Measured by Surviving Progression-free;  OverallSurvival;  Frequency of Response as Measured by RECIST Criteria (Imaging);  Correlate Patterns of Gene Expression as Assessed by Microarrays;  Correlate Hypoxia Inducible Factor 1 (HIF-1) and Hypoxia Induced Gene Expression as Measured by Laboratory Studies|27|NCT00548418|February 2007
3059|Completed|A Prospective Study to Evaluate the Specificity of the Cobas TaqScreen MPX Test for Use on the Cobas s 201 System for Screening Plasma Pools From Source Plasma Donors for the Presence of HBV DNA HCV RNA and HIV-1 RNA||Device:cobass201TaqScreenMPXTest|Interventional||Industry|Source plasma donors were screened for the presence of HIV-1 RNA HBV DNA and/or HCV RNA|100000|NCT00520273|August 2007
3060|Terminated|Evaluation and Optimization of PB127 Myocardial Perfusion Echocardiography on Ultrasound Systems||Drug:PB127forInjectableSuspension|Interventional|Phase 2|Industry|Determination of optimal machine settings and imaging parameters for myocardial perfusion for a variety of ultrasound imaging systems to be used in upcoming clinical trials|40|NCT00487903|September 2007
3061|Terminated                  Has Results|Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction||Drug:naratriptanHCl|Interventional|Phase 4|Other / Industry|HeadacheDays;  HeadacheImpactTest-6(HIT-6)Score;  Mental Efficiency Workload Test (MEWT) Performance Index Score;  OverallSatisfactionWithMedicationScore;  QualityofLifeScores;  SustainedTreatmentEffect|12|NCT00487578|October 2006
3062|Completed|A Prospective Safety Follow Up Study Of Subjects Enrolled In Study A4321001 And Who Have Received Drug Product||Other:ObservationalTrial|Observational||Industry|follow up for ocular safety and clinical features of ocular siderosis;  ERGchanges;  Anteriorsegmentandfundalphotography|16|NCT00471224|June 2007
3063|Completed                  Has Results|Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma||Drug:UltratraceIobenguane(MIBG)I131|Interventional|Phase 1 / Phase 2|Industry|MTDofUltratraceIobenguaneI131|24|NCT00458952|April 2007
3064|Completed|Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in Allergic Conjunctivitis||Drug: Ketotifen with a Contact Lens (generic name not yet established)|Interventional|Phase 3|Industry|Ocularitching;  Conjunctival ciliary and episcleral redness; chemosis and mucous discharge; tearing and lid swelling|120|NCT00432757|January 2007
3065|Completed|Project CHEER (Comprehensive Headache Evaluation Education Relief)||Behavioral: Service delivery through a Headache Management Program|Interventional||Other / U.S. Fed / Industry|MIDAS simple and accurate five-question survey that measures days lost to headache disability during the last 3 months and also headache pain on a 10-point scale.;  The measure is taken by telephone at the screening interview and by mailed survey at basel;  CATI headache diagnostic survey is administered by telephone at the screening interview to obtain a diagnosis of headache type.;  SF-36 Quality of Life Survey is administered by mailed survey at baseline and at 6 and 12 months;  Health Care Utilization Measures will include self-report by patients on the mailed surveys at baseline and at 3 6 and 12 months.;  Patients are asked about their use of outpatient inpatient and emergency room services as well as use of alternative therapies (e.g. accupuncture massage therpay herbalists) and prescription and nonprescription drugs.;  Patient reports will be validated by administrative utilization data and by a limited chart review at each site.|828|NCT00417742|June 2002
3066|Completed|Pharmacokinetic Study Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis||Drug:tigecycline|Interventional|Phase 1|Industry|To assess the pharmacokinetics (PK) of tigecycline in subjects with cholestatic hepatic dysfunction.;  To assess the safety and tolerability of single doses of tigecycline in subjects with cholestatic hepatic dysfunction.|8|NCT00406237|December 2006
3067|Completed|Xylitol Adult Caries Trial (X-ACT)||DietarySupplement:xylitol;  DietarySupplement:inactivelozenge|Interventional|Phase 3|Other / NIH|combined root and coronal D2FS (dental caries) increment;  combined root and coronal D12FS (dental caries) increment;  separate root and coronal D12FS (dental caries) increments;  association of lozenge use with D12FS (dental caries) in control group only|709|NCT00393055|January 2007
3068|Active not recruiting|Sorafenib Tosylate in Treating Patients With Metastatic Locally Advanced or Recurrent Medullary Thyroid Cancer||Other:LaboratoryBiomarkerAnalysis;  Other:PharmacologicalStudy;  Drug:SorafenibTosylate|Interventional|Phase 2|NIH|Objective response rate of sorafenib tosylate in metastatic medullary thyroid carcinoma in setting of inherited tumor syndromes as well as in setting of sporadic medullary thyroid cancer;  Calcitoninlevels;  CEAlevels;  DCE-MRIdata;  Degree of Ras-MAPK signaling inhibition in the tumor;  DegreeofVEGFexpressioninthetumor;  FludeoxyglucoseF-18PETdata;  Incidence of toxicity graded using the revised National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0;  RETgenedefectsinthetumor;  Selected polymorphisms of genes influencing sorafenib tosylate metabolism and/or resistance genes that may predict response or toxicity|50|NCT00390325|October 2006
3069|Completed|Enhancing the Prospective Prediction of Psychosis|||Observational||Other / NIH|Information on the natural history of basic symptoms of psychosis;  Factors that may affect the improvement or persistence of basic symptoms of psychosis|268|NCT00291200|August 2003
3070|Active not recruiting|Ampligen in Chronic Fatigue Syndrome||Drug:PolyI:PolyC12U(Rintatolimod)|Interventional|Phase 3|Industry|Safety;  QualityofLifeAssessments|100|NCT00215813|March 1997
3071|Completed|Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis||Drug:MEDI-507|Interventional|Phase 2|Industry|Analyses of categorical data will be performed and analysis of continuous data will be performed using a one-way analysis of variance (ANOVA) with traetment group as a factor.;  Percentage of subjects with at least 75% improvement and those with at least 50% improvement will be compared.|120|NCT00192452|March 2001
3072|Completed|A Study of Pemetrexed in Small Cell Lung Cancer Which Has Returned||Drug:Pemetrexed|Interventional|Phase 2|Industry|To assess the antitumor activity for patients with both sensitive and refractory small cell lung cancer patients as measured by tumor response rate. To characterize the toxicities of pemetrexed in this patient population;  To better understand any side effects of pemetrexed|80|NCT00191750|July 2004
3073|Completed|Civilian Post-Traumatic Stress Disorder Risperidone Clinical Trial||Drug:SertralineandRisperidone|Interventional|Phase 1 / Phase 2|Other / Industry|Remissionofsymptomsafter16weeks|65|NCT00133822|April 2004
3074|Completed                  Has Results|Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma||Drug:Erlotinibhydrochloride|Interventional|Phase 1 / Phase 2|Other|Number of Participants With Dose-limiting Toxicity (DLT);  MaximumToleratedDose(MTD)ofErlotinib;  ProgressionFreeSurvival(PFS);  CmaxofErlotinibandItsMetaboliteOSI-420;  ErlotinibTmax;  AUC Time 0-infinite (AUCinf) of Erlotinib and Its Metabolite OSI-420;  Number of Positive Mutations of EGFR and Downstream Pathways;  AbilityofErlotinibtoInhibitEGFRSignaling;  Correlation Between Standard Magnetic Resonance Imaging and Investigational Radiologic Techniques in Assessing Tumor Response to This Treatment;  To Prospectively Investigate the Technical Factors Involved in Planning and Administering Conformal Fractionated RT as Outlined in This Study and to Correlate RT Dosimetry With Patterns of Failure Standard and Investigational Imaging and Toxicity;  PlasmaandCSFLevelsofVEGFbFGFandSDF1;  Number of Participants Experiencing Grade 3 or 4 Toxicity Events|62|NCT00124657|March 2005
3075|Unknown&nbsp;&#8224;|Trial to Reduce Antimicrobial Prophylaxis Errors (TRAPE)||Behavioral:Qualityimprovementstrategies|Interventional||U.S. Fed / Other|Change in performance between hospitals in the intervention and hospitals in the control group on the proportion of prophylaxis administered within the recommended timeframes.;  Change in performance on appropriate selection of drug appropriate duration appropriate number of doses pre-op appropriate use of beta-lactams in patients with allergies.||NCT00114036|August 2002
3076|Completed|AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme||Drug:AEE788;  Drug:everolimus|Interventional|Phase 1 / Phase 2|Industry|Maximum tolerated dose and dose-limiting toxicity of AEE788;  Safety;  Tolerability;  Single-dose and repeated-dose pharmacokinetic profile;  Efficacy (response rate progression-free survival and overall survival);  Antiangiogeniceffects|16|NCT00107237|October 2003
3077|Unknown&nbsp;&#8224;|Nicotine Treatment of Mild Cognitive Impairment (MCI)||Drug:Transdermalnicotinepatch;  Drug:Placebotransdermalpatch|Interventional|Phase 1|NIH|Safetyoftransdermalnicotinepatch;  Changeincognitiveperformance;  Changeinglobalfunctioning|75|NCT00091468|September 2003
3078|Terminated|Treatment of Diabetic Nephropathy||Drug:celecoxib|Interventional||NIH||30|NCT00065559|April 2003
3079|Completed|BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma||Drug:forodesinehydrochloride|Interventional|Phase 1 / Phase 2|Industry|||NCT00061880|February 2003
3080|Completed|Vitamin B Therapy for Hyperlactatemia||Drug:Thiaminehydrochloride;  Drug:Riboflavin|Interventional||NIH||225|NCT00031057|
3081|Completed|Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis||Drug:anti-thymocyteglobulin;  Drug:cyclophosphamide|Interventional|Phase 2|Other||20|NCT00016458|June 2000
3082|Completed|Computerized Guidelines Enhanced by Symptoms and History: Clinical Effects||Behavioral:Computerreminders|Interventional||U.S. Fed||1000|NCT00013039|
3083|Completed|Safety of the Candidate Vaccine C4-V3 Alone or With Interleukin-12 (IL-12) in HIV-Infected Patients Receiving Effective Anti-HIV Drug Therapy||Drug:Interleukin-12;  Biological: HIV-1 C4-V3 Polyvalent Peptide Vaccine|Interventional|Phase 1|NIH||12|NCT00005779|
3084|Completed|A Study of Azithromycin in the Prevention of Mycobacterium Avium Complex Disease (MAC) in HIV-Infected Patients||Drug:Azithromycin|Interventional||Industry|||NCT00002309|
3085|Recruiting|Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use||Drug:Eluxadoline;  Drug:Placebo|Interventional|Phase 4|Industry|PercentageofPrimaryCompositeResponders;  PercentageofStoolConsistencyResponders;  PercentageofPainResponders;  PercentageofMonthlyCompositeResponders|340|NCT02959983|October 2016
3086|Not yet recruiting|A Study to Assess the Effect of AZD5634 on Mucociliary Clearance Safety Tolerabilitiy and Pharmacokinetic Parameters in Patients With Cystic Fibrosis||Drug:Placebo-AZD5634;  Drug:AZD5634-Placebo|Interventional|Phase 1|Industry|Percentage of average whole lung particle clearance between 0 and 60 minutes after administration of aerosolized radiolabelled particles;  Percentage of average central clearance between 0 and 60 minutes after administration of aerosolized radiolabelled particles;  Percentage of average peripheral clearance between 0 and 60 minutes after administration of aerosolized radiolabelled particles;  Percentage of average tracheobronchial clearance between 0 and 60 minutes after administration of aerosolized radiolabelled particles;  Percentageofparticleclearanceat6-hour;  Percentage of average whole lung cough clearance between 60 minutes and 90 minutes after administration of aerosolized radiolabelled particles;  Percentage of average central cough clearance between 60 minutes and 90 minutes after administration of aerosolized radiolabelled particles;  Percentage of average peripheral cough clearance between 60 minutes and 90 minutes after administration of aerosolized radiolabelled particles;  Percentage of average tracheobronchial cough clearance between 60 minutes and 90 minutes after administration of aerosolized radiolabelled particles;  Maximumobservedplasmaconcentration(Cmax);  Area under the concentration-time curve from time zero extrapolated to infinity (AUC);  Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC 0-last);  Area under the plasma concentration-time curve from time zero to 6 hours post-dose (AUC 0-6);  Observedlastquantifiableconcentration(Clast);  Timeoflastquantifiableconcentration(tlast);  Time to reach maximum plasma concentration (t max);  Terminaleliminationrateconstant(&#955;z);  Terminaleliminationhalf-life(t1/2&#955;z);  Apparentclearance(CL/F);  Apparent volume of distribution at terminal phase (Vz/F);  Cumulative amount of AZD5634 excreted in urine from time zero to 6 hours (Ae 0-6);  Cumulative percentage of dose excreted unchanged in urine from time zero to 6 hours (fe(0-6)%);  Renal clearance estimated by dividing Ae(0-t) (CLR);  Safety of subjects by evaluating the incidence of adverse events (AEs);  Safety of subjects by evaluating the systolic and diastolic blood pressure;  Safetyofsubjectsbyevaluatingthepulserate.;  Safety of subjects by evaluating spirometry results;  SafetyofsubjectsbyevaluatingtheECGresults;  Safetyofsubjectsbythephysicalexamination;  Safety of subjects by evaluating the respiratory rate.;  Safety of subjects by evaluating fractional excretion of potassium (FEK);  Safety of subjects by evaluating urine sodium/potassium (Na/K) ratio;  Safety of subjects by evaluating the pulse oximetry;  Safety of subjects by evaluating the clinical laboratory test results for biochemistry;  Safety of subjects by evaluating the clinical laboratory test results for urinalysis;  Safety of subjects by evaluating the clinical laboratory test results for hematology|12|NCT02950805|December 2016
3087|Recruiting|Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma||Drug:nab-Paclitaxel;  Drug:Gemcitabine|Interventional|Phase 2|Other|ResponseRate;  ProgressionFreeSurvival(PFS);  Occurrence of Study Treatment Related Adverse Events|72|NCT02945800|October 2016
3088|Recruiting|Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)||Drug:veliparib;  Drug:nivolumab;  Drug:carboplatin;  Drug:pemetrexed;  Drug:paclitaxel|Interventional|Phase 2|Industry|Recommended Phase 2 dose (RPTD) of veliparib (ABT-888) in combination with nivolumab and platinum doublet chemotherapy in participants with metastatic or advanced Non-Small Cell Lung Cancer (NSCLC).;  Progression-freesurvival(PFS);  OverallSurvival(OS);  ObjectiveResponseRate(ORR);  DurationofOverallResponse(DOR);  Maximum observed plasma concentration (Cmax) for veliparib;  TimetoCmax(peaktimeTmax)forveliparib;  Area under the plasma concentration-time curve (AUC) for veliparib;  Maximum observed plasma concentration (Cmax) for pemetrexed;  Tmaxforpemetrexed;  AUCforpemetrexed;  Maximum observed serum concentration (Cmax) of nivolumab anti-drug antibody (ADA);  Tmaxfornivolumab;  AUCfornivolumab|184|NCT02944396|November 2016
3089|Recruiting|A Multicenter 2 Part Study to Assess the Efficacy and Safety of H.P. Acthar&#174; Gel in Subjects With Rheumatoid Arthritis||Drug:Acthar;  Drug:Placebo|Interventional|Phase 4|Industry|Proportion of subjects with Disease Activity Score with 28 joint count and Erythrocyte Sedimentation Rate (DAS28-ESR);  ProportionofsubjectswhomaintainedDAS28-ESR|232|NCT02919761|October 2016
3090|Not yet recruiting|Phase I Trial of Apalutamide Plus Abiraterone Acetate Docetaxel and Prednisone in Patients With mCRPC||Drug:Apalutamide;  Drug:Abirateroneacetate;  Drug:Docetaxel;  Drug:Prednisone|Interventional|Phase 1|Other / Industry|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.|24|NCT02913196|September 2016
3091|Enrolling by invitation|Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder||Drug:Nelotanserin|Interventional|Phase 2|Industry|Long-term safety and tolerability will be evaluated based on incidence of adverse events (AEs) and significant changes in physical examinations vital signs ECGs and clinical laboratory assessments over time during treatment.;  Long-term effectiveness will be evaluated based on change in the frequency and severity of visual hallucinations (as recorded by patient&apos;s caregiver) and/or REM sleep behaviors (based on a clinical evaluator) over time during treatment.|80|NCT02871427|August 2016
3092|Recruiting|Peripheral Registry of Endovascular Clinical Outcomes &quot;The PRIME Registry&quot;|||Observational||Other / Industry|Amputationfreesurvivalrates;  Accesssiteandproceduralcomplications;  Targetlesionrevascularization;  Targetvesselrevascularization;  Proceduralsuccess|5000|NCT02786173|December 2012
3093|Active not recruiting|Feasibility Study in Subjects With Mild to Moderate Alzheimer&apos;s Disease||Drug:T3D-959|Interventional|Phase 1 / Phase 2|Industry|The effect of treatment with T3D-959 on changes in 18F-FDG-PET measurements of the cerebral metabolic rate for glucose (CMRgl) in an empirically pre-specified statistical region of interest (sROI) that is preferentially affected by AD.;  The effect of treatment with T3D-959 on changes in resting state Blood Oxygen Level Dependent (BOLD) signal in functional Magnetic Resonance Imaging (fMRI) of the brain areas associated with cognitive tasks.;  Change from Baseline in the score of the Digit Symbol Substitution Test;  Comparison of the response to treatment of T3D-959 based on ApoE genotype;  Change from Baseline in the plasma metabolome profile after 2 week treatment with T3D-959 using mass spectrometry.;  Change from Baseline in the total score of the 11-item Alzheimer&apos;s Disease Assessment Scale - Cognitive Subscale|36|NCT02560753|July 2015
3094|Recruiting|Efficacy of iLid Cleanser (Avenova) Versus Vehicle on Ocular Skin Flora||Device:iLidCleanser|Interventional||Industry|Microbiologicalefficacy;  OcularSigns|100|NCT02455895|May 2015
3095|Recruiting|Study of Orofacial Pain and PropRANOlol||Drug:PropranololER;  Drug:Placebo|Interventional|Phase 2|Other / Industry / NIH|Change in the weekly mean pain index after 5 weeks of treatment;  Change in the weekly mean pain index after 9 weeks of treatment;  Change in the weekly mean pain intensity after 5 weeks of treatment;  Change in the weekly mean pain intensity after 9 weeks of treatment;  Change in the weekly mean pain duration after 5 weeks of treatment;  Change in the weekly mean pain duration after 9 weeks of treatment;  Change in the SF-McGill Pain Questionnaire total score after 5 weeks of treatment;  Change in the SF-McGill Pain Questionnaire total score after 9 weeks of treatment;  Change in the SF-McGill Pain Questionnaire current facial pain intensity after 5 weeks of treatment;  Change in the SF-McGill Pain Questionnaire current facial pain intensity after 9 weeks of treatment;  Change in the SF-McGill Pain Questionnaire weekly average facial pain intensity after 5 weeks of treatment;  Change in the SF-McGill Pain Questionnaire weekly average facial pain intensity after 9 weeks of treatment;  Change in the SF-McGill Pain Questionnaire weekly average facial pain duration after 5 weeks of treatment;  Change in the SF-McGill Pain Questionnaire weekly average facial pain duration after 9 weeks of treatment;  Change in the Graded Chronic Pain Scale (GCPS) Characteristic Pain Intensity (CPI) after 5 weeks of treatment;  Change in the Graded Chronic Pain Scale (GCPS) Characteristic Pain Intensity after 9 weeks of treatment;  Change in the Graded Chronic Pain Scale (GCPS) Disability Days after 5 weeks of treatment;  Change in the Graded Chronic Pain Scale (GCPS) Disability Days after 9 weeks of treatment;  Change in the Graded Chronic Pain Scale (GCPS) Disability Score after 5 weeks of treatment;  Change in the Graded Chronic Pain Scale (GCPS) Disability Score after 9 weeks of treatment;  Change in the Jaw Functional Limitation Scale (JFLS) global score after 5 weeks of treatment;  Change in the Jaw Functional Limitation Scale (JFLS) global score after 9 weeks of treatment;  Change in the Headache Impact Test (HIT-6) global score after 5 weeks of treatment;  Change in the Headache Impact Test (HIT-6) global score after 9 weeks of treatment;  Change in the Pittsburgh Sleep Quality Index (PSQI) global score after 5 weeks of treatment;  Change in the Pittsburgh Sleep Quality Index (PSQI) global score after 9 weeks of treatment;  Change in the Patient Global Impression of Change (PGIC) after 5 weeks of treatment;  Change in the Patient Global Impression of Change (PGIC) after 9 weeks of treatment;  Change in the Perceived Stress Scale (PSS) global score after 5 weeks of treatment;  Change in the Perceived Stress Scale (PSS) global score after 9 weeks of treatment;  Change in the Hospital Anxiety and Depression Scale (HADS) anxiety score after 5 weeks of treatment;  Change in the Hospital Anxiety and Depression Scale (HADS) anxiety score after 9 weeks of treatment;  Change in the Hospital Anxiety and Depression Scale (HADS) depression score after 5 weeks of treatment;  Change in the Hospital Anxiety and Depression Scale (HADS) depression score after 9 weeks of treatment;  Change in the Symptom Checklist 90-Revised (SCL-90R) Somatization Scale after 5 weeks of treatment;  Change in the Symptom Checklist 90-Revised (SCL-90R) Somatization Scale after 9 weeks of treatment;  Change in the SF-12 Health Survey v2 (SF-12v2) Physical Component Summary (PCS) after 5 weeks of treatment;  Change in the SF-12 Health Survey v2 (SF-12v2) Physical Component Summary (PCS) after 9 weeks of treatment;  Change in the SF-12 Health Survey v2 (SF-12v2) Mental Component Summary (MCS) after 5 weeks of treatment;  Change in the SF-12 Health Survey v2 (SF-12v2) Mental Component Summary (MCS) after 9 weeks of treatment;  Change in thermal pain threshold after 5 weeks of treatment;  Change in thermal pain threshold after 9 weeks of treatment;  Change in thermal pain tolerance after 5 weeks of treatment;  Change in thermal pain tolerance after 9 weeks of treatment;  Change in pressure pain threshold at temporalis muscle after 5 weeks of treatment;  Change in pressure pain threshold at temporalis muscle after 9 weeks of treatment;  Change in pressure pain threshold at masseter muscle after 5 weeks of treatment;  Change in pressure pain threshold at masseter muscle after 9 weeks of treatment;  Change in pressure pain threshold at temporomandibular joint after 5 weeks of treatment;  Change in pressure pain threshold at temporomandibular joint after 9 weeks of treatment;  Change in pressure pain threshold at trapezius muscle after 5 weeks of treatment;  Change in pressure pain threshold at trapezius muscle after 9 weeks of treatment;  Change in pressure pain threshold at lateral epicondyle after 5 weeks of treatment;  Change in pressure pain threshold at lateral epicondyle after 9 weeks of treatment|200|NCT02437383|August 2015
3096|Completed|Ultherapy&#174; for Treating the Face and Neck Using Standard Versus Simulines Transducers||Device:UltheraTreatmentatEL2;  Device:UltheraTreatmentatEL4|Interventional||Industry|Comfort level of standard transducers versus simulines transducers during Ultherapy&#174; treatment;  Brow lift obtained using simulines versus standard transducers;  Improvement in overall lifting and tightening of skin;  PatientSatisfaction;  Efficiency of simulines versus standard transducers|42|NCT02416076|December 2014
3097|Recruiting|Smartphone Ophthalmoscope of Lens Vascularity to Estimate Gestational Age|||Observational||Other|Anterior lens capsule vascularity estimated gestational age|420|NCT02346214|July 2016
3098|Completed|Study to Evaluate the Janssen Autism Knowledge Engine in Children and Adults With Autism Spectrum Disorder||Other:NoIntervention|Observational|Phase 0|Industry|Stage 1: Usability of the Janssen Autism Knowledge Engine (JAKE) in Measuring Clinical Symptoms of Autism Spectrum Disorder (ASD);  Stage 2: Usability of the Janssen Autism Knowledge Engine (JAKE) in Measuring Clinical Symptoms of ASD;  Utility of JAKE Symptom Tracker in Measuring Clinical Symptoms of ASD;  Correlation Between Key Biosensors and ASD Symptoms;  Ease of use and Utility of JAKE for use in Prospective Clinical Trials;  Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|34|NCT02299700|September 2014
3099|Recruiting|Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer||Drug:Radium-223|Interventional|Phase 2|Other|painresponse;  ChangesinBoneAlkalinephosphatase(ALP);  Changesinotherbonemarkers:|63|NCT02278055|October 2014
3100|Active not recruiting|A Prospective Longitudinal Breast Cancer Study||Device:CA15-3Assay|Observational||Industry|MeasureCA15-3inBreastCancerPatients|130|NCT02270931|May 2014
3101|Recruiting|SCCI Tissue and Data Repository Protocol|||Observational||Other / U.S. Fed|Collectingprocessingandarchivinghumantissue|5000|NCT02182180|November 2014
3102|Completed|A Two Arm Multi-Site Clinical Evaluation of the ARIES HSV 1&amp;2 Assay in Symptomatic Patients|||Observational||Industry|Diagnostic accuracy will be expressed in terms of clinical sensitivity (or positive agreement) and specificity (or negative agreement).|1963|NCT02092233|January 2014
3103|Suspended|Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome||Drug:Cytarabine;  Drug:DaunorubicinHydrochloride;  Drug:Etoposide;  Drug:IdarubicinHydrochloride;  Other:LaboratoryBiomarkerAnalysis;  Drug:Pomalidomide|Interventional|Phase 1|NIH|MTD of pomalidomide defined as the highest dose at which 0 or 1 dose-limiting toxicities (DLT) are observed in 6 patients according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0;  Overallsurvival;  Progression-freesurvival(PFS);  ProportionofpatientsachievingCRCRiorPR;  Proportion of toxicities in the expansion cohort graded according to NCI CTCAE version 4.0|28|NCT02029950|December 2013
3104|Active not recruiting|Literacy-Adapted Psychosocial Treatments for Chronic Pain --- &quot;Learning About Mastering/My Pain&quot;||Behavioral:PainEd;  Behavioral:CBTforPain;  Other:UsualCare|Interventional||Other|BriefPainInventory-Intensity(BPI-Intensity);  Brief Pain Inventory-Interference (BPI-Interference);  PatientHealthQuestionnaire-9(PHQ-9);  PatientGlobalImpressionofChange(PGIC)|299|NCT01967342|May 2013
3105|Terminated                  Has Results|Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277&#174;||Drug:DiaPep277&#174;|Interventional|Phase 3|Industry|HypoglycemicEvents;  Change From Baseline in Glucagon-stimulated C-peptide AUC at Early Termination Visit|38|NCT01898286|October 2013
3106|Completed|HPTN 073 Black Men Who Have Sex With Men (MSM) Pre-Exposure Prophylaxis (PrEP)||Drug:FTC/TDF|Interventional|Phase 4|Other|InitiationofPrEP;  AdherencetoPrEP;  Adverseevents;  STIs;  Changesinsexualrisk-takingbehavior;  InitiateordeclinePrEP;  IncidentHIV-seroconversions/characteristics;  Participantperceptionofcareandreferralplan|225|NCT01808352|August 2013
3107|Completed|Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee||Drug:OLT1177Gel;  Other:Placebogel|Interventional|Phase 2|Industry|ChangeinWOMACkneepainsubscale(scale0-20);  ChangeinCurrentKneePain(100-mmVAS);  Mean group rating of Relative Knee Pain (5-point scale);  ChangeinWOMACkneepainsubscale;  ChangeinPainonMovement(100-mmVAS);  ChangeinGlobalRatingofDisease;  ChangeinGlobalEvaluationofTreatment;  ChangeinWOMACStiffnesssubscale(Scale0-8);  ChangeintheuseofRescueMedication;  ChangeinthetimetouseofRescueMedication;  Proportion of subjects experiencing an improvement in WOMAC knee pain subscale;  Proportion of subjects whose WOMAC knee pain subscale is less than the PASS;  Proportion of subjects experiencing an improvement in Pain on Movement;  Proportion of subjects whose POM is less than the PASS|79|NCT01768975|January 2013
3108|Terminated|Evaluation of the VEGA Knee System&#174; Range of Motion|||Observational||Industry|WOMAC;  Healthrelatedqualityoflife|7|NCT01768871|January 2013
3109|Active not recruiting|Prospective Observational Study of Erythropoietin-Iron Interaction in Anemia of Renal Disease||Other:Specimencollection|Observational||Other / NIH|HemoglobinConcentration(g/dL);  ReticulocytePercentage(%);  ReticulocyteHemoglobinEquivalentRetHe(pg)|120|NCT01719146|January 2013
3110|Active not recruiting|Predicting Caries Risk in Underserved Toddlers in Primary Healthcare Settings|||Observational||Other / NIH|Presence of any caries at baseline and incidence and/or progression of any caries lesions at follow up examinations;  Presenceofanycariesatbaseline;  Incidence and/or progression of any caries lesions at the follow-up examinations.;  countsofthenumberofcarioussurfaces|1326|NCT01707797|November 2012
3111|Terminated|Effect of Including Synera&#174; in Discussions on Dialysis Access Conversion in Patients With Needle Phobias||Other:EnhancedNeedlePhobiaIntervention;  Other:StandardNeedlePhobiaIntervention|Interventional|Phase 4|Industry|Proportion of patients achieving a score of 3 or 4 on the stages of change questionnaire;  Proportion of patients for whom the intervention was successful|10|NCT01623583|April 2014
3112|Completed|Contour 3D&#174;/TriAd&#174; Tricuspid Annuloplasty Ring Post-Market Clinical Trial||Device: Contour 3D&#174; or Tri-Ad&#174; implant for tricuspid valve repair|Observational|Phase 4|Industry|Evaluate the hemodynamic performance of the tricuspid valve following implantation of a tricuspid annuloplasty ring in a post-market environment;  1. Evaluate the effect of TV repair with the study ring on right atrial size and right ventricular function;  2. Characterize the patient population for which an annuloplasty ring is chosen to repair TV insufficiency and assess the effect of TV repair with the study ring on the tricuspid valve functional status|64|NCT01585779|May 2012
3113|Completed|Exploring Massage Benefits for Arthritis of the Knee||Procedure:MassageTherapy|Interventional|Phase 2|Other / NIH|Change in Western Ontario and McMaster Universities Osteoarthritis of the Knee and Hip Index (WOMAC);  ChangeinPain:TheVisualAnalogScale(VAS);  Change in Pain: PROMIS Pain Interference Questionnaire;  ChangeinJointFlexibility;  ChangeinPhysicalFunction|222|NCT01537484|June 2012
3114|Completed|Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer||Drug:Gemcitabine;  Drug:BAY80-6946;  Drug:Cisplatin;  Drug:NaCl;  Drug:BAY80-6964fixeddose|Interventional|Phase 1|Industry|Adverseeventcollection;  Maximum tolerated dose measured by adverse event profile;  Maximum drug concentration in plasma (Cmax) of Copanlisib with gemcitabine or cisplatin plus gemcitabine;  The time of the maximum concentration (Tmax) of Copanlisib with gemcitabine or cisplatin plus gemcitabine;  Area under the curve (AUC) of Copanlisib with gemcitabine or cisplatin plus gemcitabine;  Area under the concentration time curve (AUC (0-tn)) of Copanlisib with gemcitabine or cisplatin plus gemcitabine;  Half life (t1/2) of Copanlisib with gemcitabine or cisplatin plus gemcitabine;  Biomarker evaluation including analysis of pathway activation in tumor tissue and blood/plasma;  TumorResponseasmeasuredbyRECIST1.1criteria|50|NCT01460537|November 2011
3115|Completed|Clinical Evaluation of the APTIMA&#174; HPV Assay Using the PANTHER&#8482; System|||Observational||Industry|HPV Assay result Agreement between TIGRIS and PANTHER Systems|11816|NCT01446198|March 2012
3116|Completed|Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies||Drug:BAY1000394|Interventional|Phase 1|Industry|Number of subjects with Adverse Events as a measure safety;  Maximum tolerated dose: Measured by adverse event profile;  Biomarkers evaluation measured by Enzyme-linked immunosorbent assay (ELISA);  Tumor Response evaluation measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1);  PeakPlasmaConcentration(Cmax)ofBAY1000394;  Pharmacokinetics parameters will be measured using Peak Plasma Time (tmax) of BAY1000394;  Area under the plasma concentration versus time curve from 0 to tn (AUC(0 tn)) of BAY1000394;  Area under the plasma concentration versus time curve (AUC) of BAY1000394;  Half-lifeofBAY1000394|10|NCT01335256|December 2010
3117|Terminated|Radiographic and Clinical Outcomes of PureGen in Posterior Lumbar (PLIF) and Transforaminal Interbody Fusion (TLIF)||Biological: PureGen Osteoprogenitor Cell Allograft|Observational||Industry|Fusion|6|NCT01293981|February 2011
3118|Completed                  Has Results|Metronidazole Pharmacokinetics (PK) in Premature Infants||Drug:Metronidazole|Interventional|Phase 1|Other / NIH / Industry|AreaUndertheCurveatSteadyState;  LoadingDoseMaximumConcentration;  LoadingDoseMinimumConcentration;  MultipleDoseMaximumConcentration;  MultipleDoseMinimumConcentration;  Clearance;  VolumeofDistribution|24|NCT01222585|January 2011
3119|Unknown&nbsp;&#8224;|Megadyne Ace Incision/Dissection Study||Device:E-ZCleanACEBlade|Interventional|Phase 4|Industry|EvaluateWoundHealing/ScarFormation;  Evaluate patient satisfaction relating to wound healing|52|NCT01175889|August 2010
3120|Completed|Detection of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activity in Rectal Tissues From Human Subjects|||Observational||Other|To develop and improve techniques to detect mature CFTR protein at the rectal cell membrane by performing rectal biopsies and ex-vivo Intestinal Current Measurement (ICM).;  To estimate the range of detectable CFTR activity among human rectal tissue of subjects with and without cystic fibrosis.|57|NCT01078740|October 2009
3121|Completed|Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas||Drug:Debio1143(AT-406)|Interventional|Phase 1|Industry|MaximallyToleratedDose;  Pharmacokinetic;  Pharmacodynamic;  Efficacy;  Correlation of Efficacy to Pharmacokinetic and/or Pharmacodynamic Effects of Debio 1143 (AT-406)|51|NCT01078649|February 2010
3122|Withdrawn|Pilot Study of Bevacizumab (Avastin) in Patients With Septic Shock||Drug:Bevacizumab;  Drug:Placebo|Interventional||Other|The change in Sequential Organ Failure Assessment score (SOFA) to assess reduction in organ failure;  Inflammation signaling: the change in circulating levels of IL-6 and TNF-alpha level as the primary;  Endothelial cell signaling/activation: change in E-selectin ICAM-1 and sFLT;  VEGF signaling: measurement of VEGF levels in response to the study drug or placebo and determine if there is a reduction in overall VEGF signaling.;  OverallsafetyofBevacizumab;  Mortality|0|NCT01063010|February 2010
3123|Active not recruiting|The FIRSTT: Comparing MRgFUS(MR-guided Focused Ultrasound) Versus UAE (Uterine Artery Embolization)for Uterine Fibroids.||Procedure:Focusedultrasound(MRgFUS);  Procedure:Uterinearteryembolization(UAE)|Interventional|Phase 4|Other / NIH|Symptomatic outcomes measured by validated instruments;  Adverseeventsfollowingtreatment;  Biologicpredictorsofoutcome|180|NCT00995878|October 2009
3124|Completed|A Phase 1 Study of the HSP90 Inhibitor STA-9090 in Subjects With Acute Myeloid Leukemia Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia||Drug:STA-9090(ganetespib)|Interventional|Phase 1|Industry|To assess efficacy in subjects with AML ALL and blast-phase CML based on standard response criteria;  To characterize the safety and tolerability of once-weekly STA-9090 (ganetespib) in subjects with AML ALL and blast-phase CML|29|NCT00964873|August 2009
3125|Completed                  Has Results|Treatment of Androgenic Alopecia in Males||Device:HairMaxLaserComb;  Device:Controldevice|Interventional||Industry|Changes in Terminal Hair Count at 16 and 26 Weeks Compared to Baseline in Men Diagnosed With Androgenetic Alopecia|79|NCT00947219|July 2009
3126|Completed                  Has Results|A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo)||Drug:Acyclovir|Interventional|Phase 1|Other / NIH|Clearance(CL);  VolumeofDistribution(V);  Half-life(T1/2);  MaximumSteadyStateConcentration(Cmaxss);  Steady State Concentration at 50% of the Dosing Interval (C50ss);  MinimumSteadyStateConcentration(Cminss)|32|NCT00942084|September 2011
3127|Terminated|Atkins Diet and Prostate Cancer Clinical Trial||Behavioral:AtkinsDiet|Interventional|Phase 2|Other / U.S. Fed|The primary end-point will be differences in insulin sensitivity between the arms;  Measures will include other cardiac risk factors overall body morphometrics body composition as assessed by dual energy x-ray absorptiometry (DXA) and cancer control (PSA levels)|45|NCT00932672|June 2009
3128|Completed|Axillary Lymph Node Preservation Surgery in Reducing Lymphedema in Patients With Breast Cancer||Procedure:axillarylymphnodedissection;  Drug:isosulfanbluebasedlymphaticmapping;  Procedure:quality-of-lifeassessment;  Other:Questionnaireadministration|Interventional|Phase 1 / Phase 2|Other / NIH|Percentage of patients with arm lymphatics above at or below the axillary vein (Pilot);  Percentage of patients with positive axillary reverse mapping (ARM) identified nodes;  Incidenceoflymphedema;  Surgical related quality of life measured using Short Form (SF)-8 Quality of Life Survey Instrument;  Tumor status of blue lymph nodes as tumor bearing or non-tumor bearing (Pilot);  Predictors of lymphedema including patient age body mass index tumor characteristics and location of arm lymphatics|19|NCT00932035|June 2009
3129|Completed                  Has Results|Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease||Drug:GMI-1070|Interventional|Phase 1 / Phase 2|Industry|Safety as Measured by the Number of Participants With Adverse Events;  TotalPlasmaClearance;  VolumeoftheCentralCompartment;  IntercompartmentalClearance;  VolumeofthePeripheralCompartment|15|NCT00911495|May 2009
3130|Completed|Establishing a Standard for Peri-operative Implantable Cardioverter Defibrillator (ICD) Patient Education||Behavioral:Intervention|Interventional||Other / Industry|Score on measure assessing construct of quality of life;  Scoreonmeasureassessingdepression;  score on measure assessing construct of patient acceptance of device;  scoreonmeasureassessinganxiety|62|NCT00845234|July 2008
3131|Active not recruiting|Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma||Drug:Everolimus|Interventional|Phase 2|Other / Industry|To prospectively validate the expression of phospho-Akt and phospho-S6 as predictive biomarkers of responsiveness to everolimus.;  To estimate the progression-free survival in patients with advanced RCC treated with everolimus.;  To determine the objective response rate to everolimus in patients with advanced RCC.;  To assess in an exploratory fashion the predictive value of PML phospho-TSC (S664) phospho-PRAS40 eIF4E and FOXO expression with respect to response to everolimus.|40|NCT00827359|March 2009
3132|Completed                  Has Results|Prometra&apos;s Utilization in Mitigating Pain (PUMP)||Device:InfusionPump(Prometra)|Interventional||Industry|Demonstrate That Prometra Programmable Pump System Accurately and Safely Delivers Medication in the Intrathecal Space as Programmed.|110|NCT00817596|January 2007
3133|Terminated                  Has Results|Multimodality Phase II Study in Prostate Cancer||Drug:Docetaxel;  Drug:Sunitinib;  Radiation:EBXRT|Interventional|Phase 2|Other / Industry|The Rate of Progression Free Survival (PFS) at 24 Months;  Proportion of Biochemical Progression (bPFS Proportion) at 2 and 3 Years.;  RateofLocalRecurrenceat2and3Years;  Metastasis-free Survival (MFS) Rates at 2 and 3 Years.;  ChangeinQualityofLife(QoL)After1Year;  ChangeinQualityofLife(QoL)After3Month;  Comparison of RNA Expression Profile From Original Prostate Radical Prostatectomy Specimen Among Those With PSA Relapse at 2 and 3 Years as Compared to Those Without PSA Relapse at the Primary Endpoint.|36|NCT00734851|December 2008
3134|Completed|Pediatric Locking Nail for the Treatment of Femoral Fractures in Children||Device:PediatricLockingNail|Observational||Industry|limbalignment;  length of healing weight-bearing time (time to full weight bearing) and length of hospital stay and absence of complications|33|NCT00725894|November 2007
3135|Completed|A Study Of the Effectiveness Of Pomegranate Pills in Men With Prostate Cancer Before Prostatectomy||DietarySupplement:Pomegranatepill;  DietarySupplement:Pomegranatepillplacebo|Interventional||Other|Pomegranateoxidativestress|25|NCT00719030|February 2009
3136|Completed|Study to Evaluate the Safety Pharmacokinetics Tissue Distribution Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents||Drug:123-I-MIP-1072;  Drug:123-I-MIP-1095|Interventional|Phase 1|Industry|To examine the pharmacokinetics and organ radiation dosimetry of 123-I-MIP-1072 and 123I-MIP-1095 in patients with prior histological diagnosis of prostate cancer with evidence of recurrent metastatic disease.;  To examine whole body excretion and metabolism of 123-I-MIP-1072 and 123-I-MIP-1095 in patients with recurrent metastatic prostate cancer.;  To evaluate the safety of administering a 10.0 mCi dose of 123-I-MIP-1072 and 123-I-MIP-1095 to patients with recurrent metastatic prostate cancer.;  Optimizeimagingparameters|12|NCT00712829|May 2008
3137|Completed|Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH||Drug:Activetreatment;  Drug:Placebo|Interventional|Phase 1|Industry|Urine6-&#946;-hydroxycortisol:cortisolratio;  Adverse event monitoring physical examinations sitting vital sign measurements (blood pressure and pulse rate) 12-lead ECGs laboratory safety assessments.;  PK for CP-945598 and its primary circulating metabolite;  BreathID&#174;tests(methacetinandoctanoate);  Solubleandexploratorybiomarkers|9|NCT00706537|July 2008
3138|Completed|Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors||Behavioral: Writing A (Experimental informative writing);  Behavioral: Writing B (Experimental noninformative writing);  Behavioral: Writing C (Control informative writing);  Behavioral: Writing D (Control noninformative writing)|Interventional||Other|PsychologicalAdjustment;  QualityofLife|315|NCT00701844|July 2007
3139|Terminated|ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases||Biological:ALD-101|Interventional|Phase 3|Industry|To assess the efficacy of adjuvant therapy of ALD-101 in accelerating platelet engraftment in patients also receiving a standard unrelated UCBT for treatment of inherited metabolic diseases;  To assess the efficacy of ALD-101 in accelerating neutrophil engraftment;  To assess the safety of adjuvant therapy of ALD-101 in infusional toxicity adverse events and primary graft failure.|40|NCT00654433|March 2008
3140|Active not recruiting|Tissue Expander/Implant Reconstruction: A Single-Blinded Randomized Controlled Trial||Procedure:AllodermQuestionnaires;  Procedure:WithoutALLODERMQuestionnaires|Interventional|Phase 3|Other|whether using Alloderm to create the inferior-medial portion of the expander pocket will decrease patient-reported pain in both the immediate post-operative period and during the expansion phase.;  To examine if the use of Alloderm will decrease patient-reported sensory morbidity in both the immediate post-operative period and during the expansion phase.;  To evaluate whether the use of Alloderm in tissue expander/implant reconstruction affects the rate of postoperative expansion and in-hospital narcotic use.;  To examine if the use of Alloderm will impact both chronic breast pain and sensory morbidity.;  To evaluate patient satisfaction following postmastectomy tissue expander-implant reconstruction with and without the use of Alloderm.;  To examine the effect of Alloderm on the overall aesthetic outcome including the formation of capsular contracture following tissue expander/implant reconstruction.|98|NCT00639106|March 2008
3141|Unknown&nbsp;&#8224;|Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)||Drug:REGIMEN;  Drug:REGIMENB|Interventional|Phase 2|Other / Industry|The primary endpoint of this trial is improvement in 3-year progression-free survival from 30% to 50% under the study regimen.|21|NCT00632827|June 2008
3142|Completed|Treatment for Bipolar Depression: Acute &amp; Prophylactic Efficacy With Citalopram||Drug:citalopram+moodstabilizer;  Procedure:FDGPETscans;  Procedure:MRIstructuralscans;  Procedure:Genotyping;  Procedure:BloodDraw;  Drug:placebo+moodstabilizer|Interventional|Phase 2 / Phase 3|Other / NIH|In acute treatment citalopram will be more effective than placebo for depressive symptoms in bipolar disorder;  In acute treatment citalopram will be associated with a greater risk of acute hypomania mixed-states or mania than placebo.;  In maintenance treatment the total number of affective episodes and their rate (episodes/study time) as well as time to intervention with other medications and time to first episode will be lower in the placebo than in the citalopram group.;  Antidepressant response or remission in depressed bipolar patients will be associated with changes in cortical and paralimbic regions consistent with SRI antidepressant response in unipolar depressed patients.;  Polymorphic variation at the 5HTTLPR gene will alter the risk of acute mania or increased mood-cycling with citalopram vs. placebo treatments|120|NCT00562861|November 2007
3143|Completed|Effectiveness of an Anger and Stress Management Program on Reducing Blood Pressure Levels in Youth||Behavioral: Williams LifeSkills Stress and Anger Management Workshop;  Behavioral:Highschoolclasses|Interventional|Phase 2|NIH / Industry|Reduction in day-time ambulatory systolic blood pressure|259|NCT00508612|April 2007
3144|Completed|A Phase 1 Double-Blind Randomized Single Dose Escalation Safety Study of Intra-articular OP-1 in Subjects With Osteoarthritis of the Knee||Drug: Intra-articular Injection of OP-1 to affected knee|Interventional|Phase 1|Industry|Determine safety and tolerability as well as dose limiting toxicity (DLT) and maximal tolerated dose (MTD) of intraarticular OP-1;  Determine the proportion of patients with 20% 50% and 70% improvement in the Western Ontario and McMaster (WOMAC) pain and function subscales at 4 8 12 and 24 weeks.;  Determine the change from baseline to 4 8 12 and 24 weeks in the pain other symptoms function in daily living function in sports and recreation and knee related quality of life subscales of the Knee and Osteoarthritis Outcome Score (KOOS) survey.;  Determine the change from baseline to 4 8 12 and 24 weeks in the patient&apos;s global assessment and disease status and physician&apos;s global assessment and disease status using the 100-mm visual-analogue scale (VAS).;  Quality of life measured by the Short Form (SF)-36 at baseline and 4 812 and 24 weeks;  Amount of rescue medications required at 4 8 12 and 24 weeks;  Knee cartilege and surrounding saft tissue changes by magnetic resonance imaging (MRI) of the index knee and proteoglycan content by delayed gadolinium enhanced MRI of cartilage (dGEMRIC);  Analysis of efficacy data using the Outcome Measures in Arthritis Clinical Trials -Osteoarthritis Research Society (OMERACT-OARSI) Responder Index;  BloodlevelsofOP-1|33|NCT00456157|March 2007
3145|Completed|A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)||Drug:Brivanib|Interventional|Phase 1|Industry|To determine the effect on pharmacokinetics of BMS-540215 the active metabolite of brivanib alaninate when administered following a high fat meal versus administration in a fasted state;  To assess safety and tolerability of Brivanib alaninate when administered in a fasted state or following a high fat meal|29|NCT00437437|May 2000
3146|Completed                  Has Results|Home-based Telehealth Stroke Care: A Randomized Trial for Veterans||Behavioral:TRintervention;  Behavioral:In-homemessagingdevice.;  Behavioral:Usualcare|Interventional|Phase 2|U.S. Fed|Physical Function as Measured by Telephone Version of FIM|48|NCT00384748|November 2008
3147|Completed|Clinical Trial of the Optimal Endpoint of Early Sepsis Resuscitation||Procedure:ModifiedEGDT;  Procedure:StandardEGDT|Interventional||NIH|Mortality|300|NCT00372502|January 2007
3148|Active not recruiting|Combination Of Lapatinib With Carboplatin Paclitaxel and Trastuzumab In Metastatic Breast Cancer||Drug:lapatinib;  Drug:carboplatin;  Drug:trastuzumab;  Drug:paclitaxel|Interventional|Phase 1|Industry|Adverseeventsandsafetyevaluations;  Tumor response by RECIST: complete (CR) partial (PR) stable (SD) progressive (PD);  Durationofresponse:;  Prog.freesurvival:|31|NCT00367471|December 2006
3149|Completed|A Multi-Center Trial of Botox for Severe Urge Urinary Incontinence||Drug:Botox;  Drug:Placebo|Interventional||Other|Bladder diary number of daily incontinence episodes;  Number of pads used quality-of-life questionnaires|40|NCT00345332|October 2005
3150|Completed                  Has Results|Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy||Drug:Bevacizumab;  Drug:Docetaxel|Interventional|Phase 2|Other / Industry|Endorectal MRI Response After Completion of 6 Cycles of Neoadjuvant Therapy;  PSA Response After Completing 6 Cycles of Neoadjuvant Chemotherapy.|42|NCT00321646|June 2006
3151|Completed                  Has Results|Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children||Drug:Atomoxetine;  Drug:Placebo;  Behavioral:ParentTraining|Interventional|Phase 4|Other / NIH|ChangeinADHD-IVRatingScaleTotalScore;  ChangeinTotalADHD-IVTeacher|93|NCT00254462|October 2005
3152|Terminated|Holmium Laser Ablation of the Prostate (HoLAP) Versus KTP Laser Vaporization of the Prostate||Other: Comparison study between KTP and HoLAP for BPH|Observational||Other / Industry|operative parameters short and long-term results and complications associated with HoLAP and KTP laser vaporization of the prostate|18|NCT00169767|May 2005
3153|Completed|Conservative Versus Liberal Red Cell Transfusion in Myocardial Infarction Trial: The CRIT Pilot||Procedure:PackedRedBloodCellTransfusion|Interventional|Phase 4|Other / U.S. Fed|In-hospitaldeath;  Recurrentmyocardialinfarction(MI);  Neworworseningheartfailure;  CriticalCareUnit(CCU)lengthofstay;  Lengthofhospitalization;  Death or recurrent MI at hospital discharge and 30 days;  Death or recurrent MI or new or worsening congestive heart failure (CHF) at 30 days;  Deathat30days;  In-hospitalrecurrentischemia;  In-hospital death or recurrent MI or new or worsening CHF or recurrent ischemia;  Acute renal insufficiency (increase in serum creatinine of &#8805; 0.5mg/dL);  Numberoftransfusionsreceivedperpatient;  Proportion of patients receiving at least one transfusion;  Meandailyhematocrit;  Transfusion-relatedreactions|45|NCT00126334|April 2003
3154|Unknown&nbsp;&#8224;|FibroScan in Patients With Hepatitis B and C Presenting for Liver Biopsy||Device:FibroScan|Interventional|Phase 3|Other / Industry|To diagnose cirrhosis in patients with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV);  To determine correlation of FibroScan measurement with Metavir fibrosis scores by differentiating no/mild (F0/F1) from severe fibrosis (F2 - F4)|300|NCT00125762|March 2005
3155|Completed|Guidelines for Drug Therapy of Hypertension: Multi-Site Implementation||Behavioral: ATHENA Decision Support System An Automated Clinical Decision Support System for Health Care Providers;  Behavioral:Profilingperformance|Interventional|Phase 3|U.S. Fed|Primary care clinicians adherence to hypertension guidelines and blood pressure control in their panels of patients.|190|NCT00122161|
3156|Completed                  Has Results|Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi&apos;s Sarcoma||Drug:valganciclovir|Interventional||Other / NIH|TumorResponseRateEvery4Weeks|6|NCT00096538|April 2004
3157|Completed|Safety and Tolerability of Pegylated Interferon (PEG-IFN) Alfa-2a in HIV Infected People||Drug:Pegylatedinterferonalfa-2a|Interventional|Phase 2|NIH|CD4count;  CD8count;  Laboratoryandclinicaladverseeffects|12|NCT00078442|May 2006
3158|Completed|Medical and Surgical Treatment of Esophageal Reflux|||Observational||NIH||175|NCT00061724|
3159|Terminated|506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment||Drug:Compound506U78|Interventional|Phase 1|Other / NIH|Maximumtolerateddose|10|NCT00004239|December 1999
3160|Completed|A Study of 141W94 in Combination With Other Anti-HIV Drugs||Drug:Indinavirsulfate;  Drug:Amprenavir;  Drug:Nelfinavirmesylate;  Drug:Saquinavir|Interventional|Phase 1|Industry||48|NCT00002372|
3161|Completed|A Multi-Center Open-Label Ascending Multiple Oral Dose Safety Tolerance and Pharmacokinetic Study of 3&apos;-Deoxy-3&apos;-Fluorothymidine (FLT) in Patients With Acquired Immune Deficiency Syndrome (AIDS) or AIDS-Related Complex (ARC)||Drug:Alovudine|Interventional||Industry|||NCT00002254|
3162|Recruiting|PREA PK And Safety PASS Study Of IV Pantoprazole In Pediatric Subjects||Drug:ivpantoprazole|Interventional|Phase 4|Industry|time to peak plasma concentration (Tmax) of iv pantoprazole;  peak plasma concentration (Cmax) of iv pantoprazole;  area under the concentration-time curve from time zero to last concentration (AUClast) of iv pantoprazole;  area under the concentration-time curve from time zero to extrapolated infinite time (AUCinf) of iv pantoprazole;  steady state volume of distribution (Vss) of iv pantoprazole;  terminal phase half-life (T1/2) of iv pantoprazole;  clearance(CL)ofivpantoprazole;  CYP2C19genotyping|24|NCT02401035|December 2016
3163|Active not recruiting|Telephone-Based Intervention in Increasing Adherence to Adjuvant Hormonal Therapy in Patients With Breast Cancer||Behavioral:Telephone-BasedIntervention;  Other:SurveyAdministration;  Other:LaboratoryBiomarkerAnalysis|Interventional||Other|Optimal usage of AHT (includes initiation continuation and adherence);  Acceptance assessed via medical records of receiving a prescription for AHT and filling it;  Continuation assessed via self-report of taking at least one dose per week;  Adherence assessed via self-report of taking the prescribed dose at least 6 of 7 days per week;  Changeinbiomarkers;  Patient and physician responses to the intervention and study participation|39|NCT02400060|March 2014
3164|Completed|Improving Psychological Distress Among Critical Illness Survivors and Their Caregivers||Behavioral:copingskillstraining;  Other:educationprogram|Interventional||Other|Hospitalanxietyanddepressionscalescore;  Impactofeventsscale-revised(IES-R)score|417|NCT01983254|October 2013
3165|Active not recruiting|Improving Decision Making for Patients With Prolonged Mechanical Ventilation||Behavioral:Decisionaid;  Other:Usualcare|Interventional||Other / NIH|Clinician-surrogateconcordancescalescore;  Hospital anxiety and depression scale (HADS) score;  post-traumaticstresssyndromeinventory;  totalhealthcarecosts;  patient-centerednessofcarescale;  Medicalcomprehensionscalescore;  Qualityofcommunicationscalescore|421|NCT01751061|January 2013
3166|Completed|A Prospective Non-concurrent Controlled Evaluation of Open and MAS&#174; PLIF||Procedure: Open PLIF (posterior lumbar interbody fusion);  Procedure:MASPLIF|Observational||Industry|Complications;  ClinicalOutcomes;  RadiographicOutcomes|67|NCT01640977|June 2012
3167|Completed|CONcussion Treatment After Combat Trauma (CONTACT)||Behavioral: Individualized Scheduled Telephone Support (ISTS);  Other:UsualCare(UC)|Interventional||Other / U.S. Fed|RivermeadPostConcussionSymptomsQuestionnaire;  Brief Symptom Inventory - 18 Global Severity Index;  Effects on functioning quality of life pain sleep depression posttraumatic stress resilience work activity and health services usage.;  EffectofISTSindemographicsubgroups;  Satisfaction with ISTS by participants and significant others|366|NCT01387490|June 2011
3168|Completed                  Has Results|CONNECT for Better Falls Prevention in VA Community Living Centers||Behavioral:CONNECTeducationalintervention;  Behavioral:FALLSeducationalintervention|Interventional|Phase 3|U.S. Fed / Other|Fall-relatedProcessMeasures;  ChangeinFacilityFallRates|689|NCT00836433|February 2010
3169|Completed|First Line Chemotherapy Treatment of Advanced NSCLC||Drug:enzastaurin;  Drug:pemetrexed;  Drug:docetaxel;  Drug:carboplatin|Interventional|Phase 2|Industry|Timetoprogressivedisease;  Assessment of biomarkers relevant to pemetrexed carboplatin enzastaurin and disease state and their correlation to clinical outcome;  Assessment of smoking history and hormone replacement therapy and the correlation to clinical outcome;  Comparisonsofsafetybetweeneachtreatmentarm;  Comparisons of patient reported outcomes using the FACT-Lung and FACT-Taxane;  Overallsurvival;  Durationofresponse;  Timetotreatmentfailure|217|NCT00308750|March 2006
3170|Terminated|The Efficacy of Crotaline Fab Antivenom for Copperhead Snake Envenomations||Biological: Crotaline Polyvalent Immune Fab (ovine) (active initial and maintenance therapy);  Biological: Crotaline Immune Fab (ovine) (active initial therapy; placebo maintenance therapy);  Biological:Placebo|Interventional|Phase 4|Other|Limb function: AMA disability rating score of envenomated limb time to recovery of 100% of premorbid function Kaplan-Meier analysis;  Limb function: AAOS Normative Outcome Study scoring for envenomated limb;  Limb function: AAOS Normative Outcome Study scoring for envenomated limb time to recovery of 100% of premorbid function Kaplan-Meier analysis;  Pain:visualanalogscore;  Painmedicationuse:Mgofmorphineequivalents;  Swelling: percentage (%) of limb spread proximal from bite site;  Swelling: % increase in volume compared to contralateral (non-envenomated) limb;  Limbfunction:returntowork;  Limb function: physical or occupational therapy sessions attended;  Hematological: Clotting studies and platelet counts;  Complicationsoftherapy|25|NCT00303303|April 2005
3171|Completed|Evaluation of a Powered Stapler System on Surgical Interventions Required During Laparoscopic Sleeve Gastrectomy||Device:ECHELONFLEX&#8482;PoweredPlusStapler|Observational||Industry|Surgical interventions (type quantity frequency rationale) required during LSG;  Procedureduration;  Lengthofstay;  Estimatedbloodloss|100|NCT02358785|January 2015
3172|Enrolling by invitation|Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients||Device:GORE&#174;HybridVascularGraft;  Device:Non-heparinbondedsyntheticgraft|Interventional||Industry|Prevalence of a positive poly-specific enzyme immunoassay (EIA) at Day 7 and/or Day 14 time points|200|NCT02165761|July 2014
3173|Completed|Southeastern Diabetes Initiative Clinical Intervention||Other:ExtensionofCare|Interventional||Other / U.S. Fed / Industry|Mortality;  Rateofhealthservicesutilization;  ChangeinMedicationAdherence;  ChangeinHbA1c;  Changeinbloodlipids;  Changeinbloodglucose;  Changeinbloodpressure;  Incidence of micro- and macro-vascular complications;  Changeinpatient-reportedoutcomes|648|NCT01965639|April 2013
3174|Completed|The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)||Drug:AZD1722;  Drug:Placebo|Interventional|Phase 2 / Phase 3|Industry|Percent Complete Spontaneous Bowel Movement responders vs placebo|371|NCT01923428|August 2013
3175|Recruiting|Reducing Suicidal Ideation Through Insomnia Treatment||Drug:Zolpidem-CR;  Drug:Placebo|Interventional|Phase 4|Other / NIH|SuicideSeverityIndex(SSI);  DysfunctionalBeliefsandAttitudesAboutSleep;  Disturbing Dreams and Nightmares Severity Index (DDNSI);  BeckHopelessnessScale(BHS);  HamiltonRatingScaleforDepression(HAM-D);  InsomniaSeverityIndex(ISI)|138|NCT01689909|September 2012
3176|Unknown&nbsp;&#8224;|Study of Low Adherent Dressing Versus the Standard of Care for the Management of Skin Grafts Over Thermal Burns||Device:P6LowAdherentDressing;  Other:StandardofCare(SOC)|Interventional||Industry / U.S. Fed|Management of skin grafts as determined by investigator&apos;s visual assessment of percent graft take;  Theincidenceofpost-operativegraftinfections;  Assessment of patient&apos;s pain / discomfort using a visual analog scale.;  Costsofstudyburnsitewounddressingregimens.;  Ease of use and clinician preference of the study burn site wound dressing regimens;  Statistical robustness of visual graft take assessments in-person and from digital photographs;  Progression of percent graft take with time for both P6 and SOC.;  Assessment of the incidence and severity of SAEs and wound specific AEs including local reactions.|80|NCT01654094|October 2012
3177|Completed|Uncertainty Management Intervention||Other:UncertaintyManagementIntervention;  Other:ComparisonConditionsforLiverTransplant|Interventional||Other / NIH|UncertaintyManagement;  Symptomcontrol;  Qualityoflife;  Psychologicaldistress|288|NCT00938795|February 2010
3178|Completed                  Has Results|Burn Healing and Analgesia With Propranolol||Drug:Propranolol;  Drug:Placebo;  Drug:Propanolol|Interventional|Phase 2|Other|OverallPainTrajectorySlopes;  SleepQuality;  ItchSymptoms;  AnxietySymptoms|45|NCT00934947|July 2009
3179|Terminated                  Has Results|Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated Suspension||Drug: Megestrol acetate concentrated suspension 110 mg/mL;  Drug: Megestrol acetate concentrated suspension 60 mg/mL;  Drug:Placebo|Interventional|Phase 3|Industry|Average Daily Caloric Intake Over the Course of the 8-week Double-blind Phase;  Change in Weight Over the Course of the 8-week Double-blind Phase;  Changes in Body Composition as Measured by Bioelectric Impedance Analysis (BIA) at Week 4 and Week 8 Relative to Baseline;  Change in Appetite Over the 8-week Double-blind Phase as Measured by a VAS Appetite Scale|4|NCT00637806|June 2006
3180|Terminated                  Has Results|A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain||Drug:Bevacizumab;  Drug:Docetaxel;  Drug:CPT-11;  Drug:Paclitaxel;  Drug:VinorelbineTartrate;  Drug:Gemcitabine|Interventional|Phase 2|Other / Industry|Safety and Tolerability Will be Assessed According to Standard (CTCAE Version 3.0) Toxicity Reporting Criteria.;  Determining the Safety and Tolerability of Adding Avastin to Single Agent Chemotherapy to Treat Patients With Brain Metastasis Originating From Breast Cancer;  Assess the Activity of Avastin When Added to Single Agent Chemotherapy as Measured by Radiographic Response RateProgression Free Survival and Overall Survival.;  To Assess the Quality of Life During Treatment With This Therapeutic Approach|16|NCT00476827|May 2007
3181|Completed|Risk of Developing Antibodies to Heparin-PF4 After Heart Surgery||Drug:Heparin|Observational||Other|ThromboticeventscompatiblewithHIT;  antibody positibe status post operative day 5 and day 30|1015|NCT00237328|June 2006
3182|Completed|Telephone Enhancement Procedure for Continuing Care - 1||Behavioral:BehaviorTherapy|Interventional|Phase 3|Other|Treatmentcompliancedrugandalcoholastinence|339|NCT00067171|January 2003
3183|Not yet recruiting|A Study of Autologous Neo-Kidney Augment&#8482; (NKA) in Type 2 Diabetics With Chronic Kidney Disease||Biological:Neo-KidneyAugment(NKA)|Interventional|Phase 2|Industry / Other|ChangeinRenalFunction;  Treatmentemergentadverseevents|50|NCT02836574|August 2016
3184|Recruiting|Novel Therapeutics in Posttraumatic Stress Disorder (PTSD): A Randomized Clinical Trial of Mifepristone||Drug: Mifepristone (600 mg/day) or placebo (sugar pill)|Interventional|Phase 2|U.S. Fed|Presence or absence of a clinical response defined as a 30% or greater reduction in total CAPS (past week symptom status);  Changes in CAPS (past week symptom status) score from baseline to weeks 1 4 and 12 to capture time by treatment interaction the proportion of clinical responders at 12 weeks for deciding sustainability the time to addition of rescue medication to det|90|NCT01739335|November 2012
3185|Terminated|PureGen: A Radiographic Analysis of Rate and Quality of Fusion in Patients Undergoing Anterior Cervical Discectomy and Fusion (ACDF)||Biological: PureGen Osteoprogenitor Cell Allograft|Observational||Industry|Fusion|50|NCT01291134|February 2011
3186|Completed|Assessment of Acute Disease to Reduce Imaging Costs||Device:PilotPhase;  Device: Intervention group receive the numeric PTP estimate;  Device:NoIntervention|Interventional||Other / U.S. Fed|Primary measurements will test if the webtool works properly(observational): A. Technical reliability B. Accurate low PTP C. Calibration;  A. Quality: B. Effectiveness: C. Efficiency: D. Safety: E. Patient satisfaction:|850|NCT01059500|January 2010
3187|Active not recruiting|Chemoradiotherapy With Elective Low Dose Nodal Radiation for Locally Advanced Head and Neck Cancer||Drug:Cisplatin;  Radiation:ElectiveNodalIrradiation(ENI)|Interventional|Phase 2|Other / NIH|To assess the actuarial elective nodal failure (ENF) rate for patients with locally advanced HNSCC treated with chemoRT including very low dose elective nodal IMRT and concurrent weekly cisplatin.;  ToassessactuarialLRCDFSandOSrates.;  Toevaluatepatients&apos;qualityoflife(QOL).;  To evaluate grade 3-5 toxicity by CTCAE v4.0 with special attention to swallowing function feeding tube dependence and xerostomia.|76|NCT01372111|March 2011
3188|Completed|Heart to Health: A Combined Lifestyle and Medication Intervention to Reduce Cardiovascular Disease (CVD) Risk||Behavioral:Lifestyleandmedicationintervention|Interventional||Other / U.S. Fed|Predicted10-yearCHDrisk;  Useofandadherencetocardiovascularmedicines;  DietaryIntake;  Physicalactivity;  Bloodpressure;  TotalHDLanddirectLDLcholesterol;  Smokingstatus;  Adverseevents;  AcceptabilityoftheIntervention;  Cost-effectiveness|489|NCT01245686|February 2011
3189|Completed|Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy||Drug:fluorouracil;  Drug:leucovorin;  Drug:oxaliplatin|Interventional|Phase 1|Other / NIH|Achievement of targeted AUC using pharmacokinetic (PK)-guided 5 fluorouracil as part of mFOLFOX6 therapy;  Toxicity differences between PK-guided therapy versus non-PK-guided therapy|76|NCT01164215|February 2010
3190|Completed                  Has Results|Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression||Drug:Asenapine5-20mgdaily;  Drug:Placebo1-4tabletsdaily|Interventional|Phase 4|Other / Industry|ChangeinMADRSTotalScore;  StudyCompletionRate;  ClinicalResponseRate;  ClinicalRemissionRate;  RatesofSustainedRemission|46|NCT01670019|October 2012
3191|Recruiting|Early Weight Bearing on Supracondylar Distal Femur Fractures in Elderly Patients||Other:NonWeightbearing;  Other:EarlyWeightBearing|Interventional||Other|Fracture Healing in Early Weight Bearing assessed by radiographs;  VisualAnalogScaletoassesspain;  OxfordKneeScoretomeasurekneefunction;  SF12tomeasurereturntofunction|200|NCT02475941|June 2015
3192|Completed|Open-Label Study of OTO-201 for Middle Ear Effusion Evaluating Trans-Tympanostomy Tube Administration||Drug:OTO-201|Interventional|Phase 3|Industry|Safety: Adverse events otoscopic exams and tympanometry;  Feasibility of Administration (Questionnaire on the feasibility of trans-tympanostomy tube administration)|33|NCT02350998|January 2015
3193|Completed|Feasibility Testing of the Quality-monitoring Tool Qdact for the Palliative Care Research Cooperative|||Observational||Other / U.S. Fed|Feasibility of qdact.pcrc as measured by number of issues/comments on qualitative surveys|40|NCT02411305|February 2015
3194|Recruiting|Permanent Versus Absorbable Colpopexy Trial||Device: polytetrafluoroethylene Gore-Tex permanent suture;  Device: 2-0 polydioxanone PDS delayed absorbable monofilament suture|Interventional|Phase 4|Other|vaginalmeshandsutureexposurerates|200|NCT02277925|December 2014
3195|Active not recruiting|De-intensification of Radiation and Chemotherapy for Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Carcinoma||Radiation: Intensity Modulated Radiotherapy (IMRT);  Drug:Cisplatin;  Procedure:Limitedsurgicalevaluation|Interventional|Phase 2|Other|Complete pathological response rate after de-escalated CRT in HPV-positive and/or p16 positive OPSCC.;  Localcontrolrate;  Regionalcontrolrate;  Local-regionalcontrolrate;  Cause-specificsurvivalrate;  Overallsurvivalrate;  Headandneckqualityoflifeassessments;  Speechandswallowingfunction|43|NCT01530997|November 2011
3196|Recruiting|Predictive Models for Spine and Lower Extremity Injury After Discharge From Rehab|||Observational||U.S. Fed|InjuryOccurrence;  Injury-RelatedHealthcareUtilization|480|NCT02776930|January 2016
3197|Recruiting|Kinematic Analysis: Posterior Stabilized Fixed Bearing Total Knee Arthroplasty With Attune Knee System - Phase 2||Device: DePuy Attune posterior stabilizing fixed bearing knee system|Observational||Other / Industry|Femoro-tibialKinematics-DeepKneeBend;  Femoro-tibialKinematics-Gait;  Femoro-tibialKinematics-RampDown;  MaxGroundReactionForce-DeepKneeBend;  MaxGroundReactionForce-Gait;  MaxGroundReactionForce-Rampdown|30|NCT02613338|November 2015
3198|Recruiting|A See and Treat Paradigm for Cervical Pre-cancer||Device:transvaginaldigitalcolposcope(TVDC);  Other:Standardofcarescreening|Interventional||Other|Concordance of the TVDC to standard of care as measured by weighted kappa statistic|200|NCT02477124|September 2015
3199|Completed|Stratifying Risk in Barrett&apos;s Esophagus: A Pilot Study for Biomarker-based Patient Management|||Observational||Other|RiskStratification|111|NCT02075905|March 2014
3200|Completed|Common Recreational Diving Practices: A Randomized Control Trial Using Pre-Dive Checklist||Other:Apre-divechecklist|Interventional||Other|Mishaps;  Majormishaps;  MinorMishaps|1116|NCT01960738|June 2012
3201|Terminated|Active Surveillance Post-Approval Atudy of the Stelkast Surpass Acetabular System||Device: Stelkast Surpass Acetabular System implant|Observational||Industry|Survivorship|347|NCT01672086|August 2012
3202|Completed|Clinician JUdgment Versus Risk Score to Predict Stroke outComes: The JURASSIC Clinical Trial||Other:Clinicalscenarios|Interventional||Other|30 Day Mortality or Disability (mRS &gt;3) at discharge;  Deathat30days;  Deathorinstitutionalizationatdischarge|111|NCT01657279|July 2012
3203|Completed|Analysis of Standard Versus Barbed Sutures in Primary Total Knee Arthroplasty.|||Observational||Other|Intraoperative closure time in total knee arthroplasty.;  Cost analysis in terms of operative time and material costs of closure in total knee arthroplasty.|363|NCT01320371|January 2011
3204|Terminated|Study to Investigate the Safety Pharmacokinetics Pharmacodynamics and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.||Drug:GSK2126458andGSK1120212|Interventional|Phase 1|Industry|To characterize the safety of GSK2126458 and GSK1120212 dosed orally in combination through adverse event assessment and changes in safety assessments including laboratory parameters vital signs and ECG parameters.;  To characterize the tolerability of GSK2126458 and GSK1120212 dosed orally in combination through adverse event assessment and changes in safety assessments including laboratory parameters vital signs and ECG parameters.;  To determine the recommended Phase II regimen(s) of GSK2126458 and GSK1120212 dosed orally in combination based on safety tolerability PK and PD markers (e.g. changes from baseline in biomarkers of pathway inhibition).|69|NCT01248858|December 2010
3205|Completed                  Has Results|A Study of Influenza Virus Vaccines in Children and Adults||Biological: 2009-2010 Trivalent Influenza Virus Vaccine;  Biological: 2008-2009 Trivalent Influenza Virus Vaccine;  Biological:QuadrivalentInfluenzaVirusVaccine|Interventional|Phase 2|Industry|Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With Quadrivalent Influenza Vaccine or Fluzone&#174; Trivalent Influenza Vaccines.;  Geometric Mean Titers (GMTs) Against Influenza B Strains After Vaccination With Fluzone&#174; Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccine in Adult Participants.;  Geometric Mean Titers (GMTs) Against Influenza A Strains After Vaccination With Fluzone&#174; Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccine in Adult Participants.|600|NCT00988143|October 2009
3206|Completed                  Has Results|Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma||Drug:Lenalidomide;  Drug:Rituximab|Interventional|Phase 2|Other / NIH|Disease-freeSurvivalat1Year;  Disease-freeSurvivalat2Years;  NumberofPatientsWithEachWorst&#8208;GradeToxicity|44|NCT00765245|October 2008
3207|Completed                  Has Results|Study to Compare Survival for ASTRA TECH Implant System OsseoSpeed&#8482; Implants Following Immediate Loading in Extraction Sockets Versus Immediate Loading in Healed Ridges||Device:ASTRATECHImplantSystemOsseoSpeed&#8482;|Interventional||Industry|ImplantSurvival|132|NCT00710944|April 2005
3208|Completed|Pertussis Vaccine in Healthy Pregnant Women||Drug:Placebo;  Biological: Tetanus toxoid reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|Interventional|Phase 1|NIH|Incidence of injection site and systemic reactions following injections.;  Frequency of vaccine-associated adverse events (AEs).;  Frequency of vaccine-associated serious adverse events (SAEs).;  Infant growth measurements (fronto-occipital circumference [FOC] length and weight).;  BayleyIIIdevelopmentalscreeningofinfants.;  Incidence of pertussis infection captured by surveillance for adverse events (AEs) and serious adverse events (SAEs).;  Concentrations of immunoglobulin G (IgG) for pertussis toxin (PT) pertactin (PRN) fimbrial proteins (FIM) filamentous hemagglutinin (FHA) tetanus toxoid (TT) and diphtheria toxoid (DT).|80|NCT00707148|January 2009
3209|Completed|Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3||Biological:VGX-3100|Interventional|Phase 1|Industry|Safety and tolerability of escalating doses of VGX-3100 administered by IM injection with EP to adult female subjects post surgical or ablative treatment of grade 2 or 3 CIN.;  Humoral and cellular immune responses to VGX-3100 in blood samples obtained from study subjects after each dose of a 3-dose series of VGX-3100 containing 0.6 2 or 6 mg of DNA/dose.|18|NCT00685412|May 2008
3210|Completed                  Has Results|Efficacy and Safety Study of Lidocaine Vaginal Gel for Recurrent Dysmenorrhea (Painful Periods)||Drug:Lidocaine;  Drug:Placebo|Interventional|Phase 2|Industry|The Primary Efficacy Variable Will be the Time-weighted Average Pain Intensity Over 4 Treatment Days Using the 4 Point Categorical Scale.;  Treatment-emgergentAdverseEvents;  Evaluate Electrocardiograms (ECGs) for Potentially Significant QT Changes at Approximate Peak Lidocaine Plasma Concentration After 4 Days of Dosing|81|NCT00651313|August 2007
3211|Completed|Early Life Factors and Respiratory Health in Mexico City Children|||Observational||NIH||6800|NCT00342758|October 2001
3212|Completed|Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma||Procedure:conventionalsurgery;  Radiation: iodine I 131 monoclonal antibody TNT-1/B|Interventional|Phase 2|Industry||60|NCT00004017|February 2000
3213|Enrolling by invitation|Influenza Vaccine Feasibility Study in Children With Persistent Asthma||Drug:ccIIV4;  Drug:IIV4|Interventional|Phase 4|Other / U.S. Fed|To assess the feasibility of conducting a randomized prospective safety study of LAIV4 versus IIV4 during the 42 days after vaccination in children aged 5-11 years with persistent asthma of varied severity (ccIIV4 will be used as a surrogate for LAIV4);  Local and Systemic reactogenicity events during the 14 days post-vaccination;  UnsolicitedandSeriousAdverseEvents;  Proportionsofasthmaexacerbations|50|NCT02967393|October 2016
3214|Recruiting|Long-term Safety and Effectiveness of AUGMENT&#174; Bone Graft Compared to Autologous Bone Graft||Device:AUGMENT&#174;BoneGraft;  Procedure:StandardofCare|Observational||Industry|DemonstrationofbridgingboneviaCT;  Subject function as determined by pain on weight bearing;  Subject function as determined by AOFAS - AHS score;  Subject function as determined by Foot Function Index|150|NCT02879149|August 2016
3215|Recruiting|Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP)||Drug:Asfotasealfa|Interventional|Phase 2|Industry|Change in PPi from Baseline to pre-3rd dose in Week 9;  Change in PLP from Baseline to pre-3rd dose in Week 9|27|NCT02797821|June 2016
3216|Completed|A Study in Participants With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Lucentis&#174; Prefilled Syringe||Drug:LucentisPFS|Interventional|Phase 3|Industry|NumberofParticipantsWithPFSUsageErrors|35|NCT02698566|February 2016
3217|Recruiting|Reference Database Development for the Quotient&#174; System iPad Test||Device:Quotient&#174;SystemiPadTest|Interventional||Industry|Range of measured head motion of typically developing subjects while taking the attention test as determined on the dimensions of total number of motions &gt;1mm/sec during the 15-minute test;  Duration of motion free periods in seconds during the 15-minute test;  Area of head motion covered in centimeters during the total 15-minute test.;  Total length of movement in meters during the total 15-minute test.;  Range of attentive responses to a 15-minute go/no-go attention task (assessed simultaneously with the motion assessment) in terms of accuracy in % correct response during the 15-minute test;  Average response time to stimulus items in milliseconds during the 15-minute test;  Total errors of omission in % of total targets during the 15-minute test;  Total errors of commission in % of total non-targets during the 15-minute test;  Variability reported as the standard deviation of all responses from mean response time reported in milliseconds during the 15-minute test|1600|NCT02693275|April 2016
3218|Terminated|Safety Tolerability and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years With Normal Cytology ASCUS or LSIL||Drug:GTL001+;  Drug:Aldara|Interventional|Phase 1|Industry|Incidence of local and systemic reactions recorded on diary cards as a measure of safety and tolerability;  Level of anti-CyaA serum as a measure of cellular and humoral Immunogenicity;  Percentage of subjects with anti-CyaA serum antibody response as a measure of cellular and humoral immunogenicity;  Specific responses to HPV 16 and HPV 18 E7 Ag stimulation as a measure of cellular and humoral Immunogenicity;  Percentage of subjects with positive specific response to HPV 16 and/or HPV 18 E7 stimulation as a measure of cellular and humoral Immunogenicity|13|NCT02689726|August 2015
3219|Recruiting|HER2+ Breast Cancer Neo-Adjuvant Coordination of Care Program||Other:chartabstraction|Observational||Other|CoordinationofCareeffortsevaluationscore|30|NCT02616133|January 2016
3220|Completed|A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)||Drug:Rociletinib;  Drug:Trametinib|Interventional|Phase 1 / Phase 2|Industry|Incidenceoftreatment-emergentadverseevents;  ObjectiveResponseRate(ORR);  Cmax of rociletinib and trametinib at steady state;  Tmax of rociletinib and trametinib at steady state;  AUCofrociletinibandtrametinibatsteadystate;  Cmin of rociletinib and trametinib at steady state;  t1/2ofrociletinibatsteadystate;  Duration of Response (DR) According to RECIST Version 1.1;  Disease Control Rate (DCR) According to RECIST Version 1.1;  Progression Free Survival (PFS) According to RECIST Version 1.1;  OverallSurvival(OS);  Longitudinal changes in blood based biomarkers (i.e. mutations in EGFR) in ctDNA;  Cmaxofrociletinibmetabolitesatsteadystate;  Tmaxofrociletinibmetabolitesatsteadystate;  AUCofrociletinibmetabolitesatsteadystate;  Cminofrociletinibmetabolitesatsteadystate|7|NCT02580708|September 2015
3221|Recruiting|Indomethacin PK and PD Therapy in Pregnancy|||Observational||Other / NIH|Delivery&lt;34weeksgestation;  Pretermdelivery&lt;3732and28weeksgestation;  Prolongation of pregnancy by 48 hours after enrollment (for sPTL);  Gestationalageatdelivery;  Chorioamnionitis;  Pretermprematureruptureofmembranes;  Oligohydramnios;  Modeofdelivery;  Postpartumhemorrhage;  Venousthromboembolism;  Pulmonaryedema;  MaternalDeath;  Birthweight;  Apgarscores;  Fetalorneonataldeath;  AdmissionandlengthofstayintheNICU;  Provenneonatalsepsisbyculture;  Respiratorydistresssyndrome;  Patentductusarteriosus;  Necrotizingenterocolitis;  Bronchopulmonarydysplasia;  Periventricularleukomalacia;  Intraventricularhemorrhage|300|NCT02451228|May 2015
3222|Recruiting|PTC596 in Patients With Advanced Solid Tumors||Drug:PTC596|Interventional|Phase 1|Industry|Dose-limitingtoxicities|60|NCT02404480|March 2015
3223|Recruiting|Inovio TRT-001: Telomerase DNA Immunotherapy in Breast Lung and Pancreatic Cancers||Biological:INO-1400;  Biological:INO-9012|Interventional|Phase 1|Industry / Other|Adverse events graded in accordance with &quot;Common Terminology Criteria for Adverse Events (CTCAE)&quot; NCI version 4.03;  Injection site reactions including but not necessarily limited to local skin erythema induration pain and tenderness at administration site [;  Changes in safety laboratory parameters from baseline;  Timetoprogression;  Antigenspecificcellularimmuneresponses;  AntigenspecificELISA;  H&amp;E stain; immunohistochemistry for CD45 CD3 CD8 FoxP3; and TCRbeta molecular analysis of baseline/archival tumor tissue and relapsed tumor tissue when possible.|54|NCT02327468|December 2014
3224|Recruiting|Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung Biliary and Bladder Cancer||Drug:NC-6004;  Drug:Gemcitabine|Interventional|Phase 1 / Phase 2|Industry|DeterminethemaximumtolerateddoseofNC-6004;  Overallresponserate|85|NCT02240238|May 2014
3225|Recruiting|eStimCycle: Early Rehabilitation in Critical Care||Device:FES-Cycling;  Other:StandardCare|Interventional||Other|Musclemassandcrosssectionalarea;  MuscleStrength;  NeuropsychologicalBatteryofTests;  Biomarkeranalyses;  Hours of mechanical ventilation ICU hours and ICU readmission;  ConfusionAssessmentMethodforICU(CAM-ICU);  MontrealCognitiveAssessment(MoCA);  Activities of Daily Living and Instrumental Activities of Daily Living;  Physicalfunction;  Informant Questionnaire on Cognitive Decline in the Elderly short form (IQCODE-SF);  HospitalAnxietyandDepressionScale;  ImpactofEventsScale-Revised(IES-R)|154|NCT02214823|July 2012
3226|Recruiting|Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer||Behavioral:Telephonesurveysystem|Observational||Other / U.S. Fed|Proportionofpainpalliationresponders;  Clinicalsignificanceofpainscorechanges;  Prevalence and trajectory of pain progression and pain palliation;  Quantifyinganalgesicmedicationuse;  Frequencyofpainreporting;  Web-avidityofpatients|220|NCT02008058|December 2013
3227|Completed|Safety and Efficacy Study of Single Doses of TT-034 in Patients With Chronic Hepatitis C||Drug:TT-034|Interventional|Phase 1 / Phase 2|Industry|The primary objective is to assess the safety and tolerability of single escalating doses of TT-034 administered IV as a single infusion to subjects with CHC.;  To assess the activity of TT-034 on the viral load of subjects with CHC receiving single escalating doses of TT-034|9|NCT01899092|January 2014
3228|Completed|A Study to Evaluate the Safety Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis||Biological:ABT-122;  Biological:Placebo|Interventional|Phase 1|Industry|NumberofparticipantswithAdverseEvents;  Changeinphysicalexamincludingvitalsigns;  Changeinclinicallabtestresults;  ChangeinElectrocardiogram(ECG)results;  Determinationofpharmacokinetic(PK)parameters;  Measurement of anti-drug anti-bodies (ADA) of ABT-122|19|NCT01853033|July 2013
3229|Withdrawn|The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study||Other:Regressionoffibrosis;  Other: Specific risk factors related to hepatocellular carcinoma|Observational||Other|Hepatocellularcarcinoma;  Riskfactorsforhepatocellularcarcinoma;  Profile with lowest risk for hepatocellular carcinoma|0|NCT01831037|July 2015
3230|Completed|RESULT (REflux Surgery in Lung Transplantation) Preliminary Study Protocol|||Observational||Other / NIH|BALaspirationmarkers;  Death;  BOS;  FEV-1;  AcuteRejection|647|NCT01406210|September 2011
3231|Completed|Patient Understanding (Cognitive Debriefing) of a Daily Diary of Gastroparesis Symptoms|||Observational||Industry|Qualitative Content Analysis of Cognitive Debriefing Data|40|NCT01316484|March 2011
3232|Completed|Study of SCY-635 Pegasys and Copegus in Hepatitis C||Drug:Placebo;  Drug:SCY-635;  Drug:peginterferonalfa2a;  Drug:Ribavirin|Interventional|Phase 2|Industry|UndetectableHCVRNA;  Partialearlyvirologicresponse;  Incidence and severity of treatment emergent adverse events and changes in laboratory values as measures of Safety and tolerability;  PharmacokineticassessmentofSCY-635;  Pharmacokinetics of peginterferon alfa 2a and Ribavirin (trough concentrations)|11|NCT01265511|November 2010
3233|Active not recruiting|Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme||Drug:VB-111;  Drug:Bevacizumab|Interventional|Phase 1 / Phase 2|Industry|OverallSurvival;  ProgressionFreeSurvival|75|NCT01260506|December 2010
3234|Unknown&nbsp;&#8224;|Tesetaxel as First-line Therapy for Metastatic Breast Cancer||Drug:Tesetaxelonceevery3weeks;  Drug:Tesetaxelonceweekly|Interventional|Phase 2|Industry|Responserate(revisedRECIST);  Diseasecontrolrate;  Progression-freerate;  Durableresponserate;  Durationofresponse;  Timetoprogression;  Adverseevents|81|NCT01221870|November 2010
3235|Completed|Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors||Drug:TKI258|Interventional|Phase 1|Industry|Determine the relative bioavailability of the final market image form of TKI258 (monohydrate tablets) as compared to the clinical service form of TKI258 (anhydrate capsules);  Determine the effect of food on the bioavailability of TKI258;  Characterize the safety and tolerability of TKI258 including acute and chronic toxicities.;  Evaluate preliminary evidence of anti-tumor activity of TKI258 in patients with advanced solid tumors.|63|NCT01155713|July 2010
3236|Enrolling by invitation|Molecular Phenotypes for Cystic Fibrosis Lung Disease|||Observational||Other / NIH||200|NCT01116414|July 2009
3237|Active not recruiting|Electrical Stimulation for the Treatment of Post-Stroke Shoulder Pain||Device:TheSPRSystem|Interventional||Industry|PainIntensity(TrialStageSuccess);  DeviceRelatedAdverseEvents;  PainIntensity(ImplantStageSuccess);  PainInterference;  Pain-FreePassiveRangeofMotion;  QualityofLife;  EconomicImpactofShoulderPain;  EmotionalFunctioning;  UserSatisfaction;  GlobalImpactofStimulationTherapy|45|NCT01094301|April 2010
3238|Completed                  Has Results|Evaluation of PillCam&#8482; Colon 2 in Visualization of the Colon||Device: PillCam&#8482; (Capsule Endoscopy) Colon 2 capsule|Interventional|Phase 3|Industry|Sensitivity of Capsule Endoscopy for Indicated Polyps;  Specificity of Capsule Endoscopy for Indicated Polyps;  PercentofParticipantsWithScoringIndex3or4|51|NCT01087528|July 2009
3239|Completed|A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma||Drug:brentuximabvedotin;  Drug:doxorubicin;  Drug:vinblastine;  Drug:dacarbazine;  Drug:bleomycin|Interventional|Phase 1|Industry|Incidence of adverse events and laboratory abnormalities;  Brentuximabvedotinconcentrationinblood;  Antitherapeuticantibodiesinblood;  Bestclinicalresponse|51|NCT01060904|January 2010
3240|Completed|Ziprasidone in Early Onset Schizophrenia Spectrum Disorders||Drug:Ziprasidone|Interventional|Phase 2|Other / Industry / NIH|The primary outcome measure will be responder status defined as a CGI improvement score of 1 or 2 plus a 20 % reduction in the baseline PANSS score at week 8.;  A correlational analysis will be done to examine the potential relationship between dose and treatment response and reduction in positive and negative symptoms.;  Subsequent analyses will examine the ZEOSS week 0 visit scores to assess for further improvement in symptoms and ability to sustain response/prevent relapse in subjects who responded to but could not tolerate the prior antipsychotic.|40|NCT01006551|December 2002
3241|Completed|Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma||Biological:ACE-041|Interventional|Phase 1|Industry|To evaluate the safety and tolerability of ACE-041 in patients with advanced solid tumors or relapsed/refractory multiple myeloma by monitoring adverse events clinical laboratory tests vital signs physical examinations and anti-drug antibody tests.;  To evaluate the pharmacokinetic effect of ACE-041 through the collection of blood samples and to evaluate the preliminary anti-tumor activity of ACE-041 through tumor response evaluation collection of blood biomarkers and imaging techniques.|37|NCT00996957|October 2009
3242|Completed|GE Healthcare VolumeRAD Lung Nodule Detection Study||Device:ChesttomosynthesisandX-ray|Observational||Industry|Multi-reader multi-case Receiver Operating Characteristics (ROC) methodology.;  Actionability classification accuracy of all modalities|187|NCT00963651|August 2009
3243|Completed                  Has Results|Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases||Radiation:FluorineF18SodiumFluoride|Interventional|Phase 2|NIH|Changesin18F-fluoridePET(SUV)-TumorBone;  Changesin18F-fluoridePETSUV-NormalBone;  Changesin18F-fluorideKi-TumorBone;  Changesin18F-fluorideKi-NormalBone;  Changes in 18F-fluoride Transport (by Patlak Flux) - Tumor;  Changes in 18F-fluoride Transport (by Patlak Flux) - Normal|18|NCT00936975|September 2009
3244|Completed                  Has Results|Clinical Study of Aldurazyme in Patients With Mucopolysaccharidosis (MPS) I||Biological: rhIDU (recombinant human-Alpha-L-Iduronidase);  Biological:Placebo|Interventional|Phase 3|Industry|Overall Change From Baseline to Week 26 in Percent Predicted Forced Vital Capacity (FVC);  Overall Change From Baseline to Week 26 in Six Minute Walk Test (6MWT);  Overall Change From Baseline to Week 26 in Apnea/Hypopnea Index (AHI);  Overall Percent Change From Baseline to Week 26 in Liver Volume;  Overall Change From Baseline to Week 26 in Child Health Assessment Questionnaire/Health Assessment Questionnaire (CHAQ/HAQ) Disability Index Score;  Overall Change From Baseline to Week 26 in Active Joint Range of Motion (ROM);  Overall Percent Change From Baseline to Week 26 in Urinary Glycosaminoglycan (GAG) Levels|45|NCT00912925|December 2000
3245|Completed|Evaluation of the PillCam&#8482; Colon Capsule Endoscopy (PCCE) Preparation and Procedure|||Observational||Industry|ColoncleansinglevelscoreforPCCE;  Grading of visual interference from bubbles in the colon for PCCE;  Numberofcoloncapsulesexcretedovertime;  Capsule transit time from ingestion to entrance into the cecum &amp; through the colon;  Numbertypeandseverityofadverseevents;  Accuracy parameters (sensitivity specificity NPVPPVLR) of PCCE in detecting polyps equal to or larger than 10mm as compared to colonoscopy;  Accuracy parameters (sensitivity specificity NPVPPVLR) of PCCE in detecting polyps equal to or larger than 6mm as compared to colonoscopy;  The diagnostic yield of PCCE in detecting a variety of colonic lesions|40|NCT00885235|October 2008
3246|Active not recruiting|Study Comparing Appearance and Function of Three Different Dental Implant Designs When Placed in Front Region of Upper Jaw||Device:OsseoSpeed&#8482;;  Device:NobelSpeedy&#8482;Replace&#174;;  Device:NanoTite&#8482;Certain&#174;PREVAIL&#174;|Interventional||Industry|Buccalsofttissue(gum)changes|144|NCT00820235|February 2009
3247|Terminated                  Has Results|NAVISTAR&#174; THERMOCOOL&#174; Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation- Treatment Use Study||Device:RadiofrequencyAblation|Interventional|Phase 3|Industry|Percentage of Subjects Who Exhibited no Documented Symptomatic Paroxysmal Atrial Fibrillation (PAF) Episodes From Study Day 91 Through Day 361.;  The Percentage of Subjects Who Experienced Incidences of Early Onset (Within 7 Days of Ablation Procedure) Catheter-related Adverse Events.;  PercentageofSubjectsWhoAchievedAcuteSuccess;  24-hourHolterData;  TTMData;  Percentage of Subjects Who Responded to Quality of Life Assessment|10|NCT00721149|September 2008
3248|Completed|Global&#174; AP&#8482; Total Shoulder Arthroplasty||Device:Global&#174;AP&#8482;Totalshoulderarthroplasty|Interventional||Industry|ConstantShoulderScore;  SF-12;  Penn/ASES;  RadiographicData;  QualityofLifeSurvey|64|NCT00719771|January 2008
3249|Completed                  Has Results|Pharmacokinetics of Ceftaroline in Subjects 12 to 17 Years of Age||Drug:ceftaroline|Interventional|Phase 1|Industry|The Maximum Plasma Concentration (Cmax) of Ceftaroline After Administration of Ceftaroline Fosamil at a Dose of 8 mg/kg up to a Maximum Dose of 600 mg Via IV Infusion Over 60 Minutes.;  Number of Adverse Events (AEs) Reported After Starting Study Drug Administration (Treatment Emergent Adverse Events TEAEs) by Relationship to Ceftaroline (Related or Unrelated).|9|NCT00633126|March 2008
3250|Completed|Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies||Drug:SNX-5422|Interventional|Phase 1|Industry|adverseeventsandothersafetyassessments;  disease response specific to the hematological malignancy|25|NCT00595686|January 2008
3251|Active not recruiting|Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy||Drug:imatinibmesylate;  Genetic:geneexpressionanalysis;  Genetic:mutationanalysis;  Genetic:polymerasechainreaction;  Other:flowcytometry;  Procedure:biopsy|Interventional|Phase 2|Other / NIH|Progression-free survival for patients less than 60 years of age;  Progression-free survival for patients 60 years of age and older;  ToxicityasmeasuredbyNCICTCv.3.0;  Correlation of c-kit expression with multidrug resistance gene expression (MDR1 MRP1 LRP and BCRP) and AF1q expression|32|NCT00509093|December 2008
3252|Completed|Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients||Drug:Atazanavir/Ritonavir;  Drug:Atazanavir/Ritonavir+Famotidine;  Drug: Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine|Interventional|Phase 4|Industry|Atazanavirplasmadrugconcentrations;  Ritonavirplasmadrugconcentrations;  Safetymeasures:Physicalexaminations;  ECGs;  laboratory tests including liver and renal function;  CD4count;  HIVviralload|40|NCT00384904|December 2006
3253|Completed|Prochymal&#8482; Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn&apos;s Disease||Drug: Prochymal&#8482; adult human mesenchymal stem cells;  Drug:adulthumanmesenchymalstemcells|Interventional|Phase 2|Industry|Crohn&apos;sdiseaseactivityindex;  Inflammatory bowel disease quality-of-life questionnaire;  Crohn&apos;sdiseaseendoscopicindexofseverity;  Crohn&apos;sremission|10|NCT00294112|February 2006
3254|Completed|Affect Recognition: Enhancing Performance of Persons With Acquired Brain Injury (ABI)||Behavioral:FacialAffectRecognitionTraining;  Other:StoriesofEmotionalInference|Interventional|Phase 2 / Phase 3|Other / U.S. Fed|Diagnostic Assessment of Nonverbal Affect-Adult Faces (DANVA2-AF);  EmotionalInferenceFromStoriesTest;  InterpersonalReactivityIndex;  NeuropsychiatricInventory|71|NCT00283153|October 2008
3255|Completed|Clinical and Molecular Studies in Families With Glaucoma and Related Diseases|||Observational||NIH|Statisticallysignificantlinkage|1|NCT00272363|December 2005
3256|Completed|Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD)||Drug:Risperidone|Interventional|Phase 1 / Phase 2|Other / NIH||100|NCT00166595|February 2003
3257|Completed|The LIFE Study: Lifestyle Interventions and Independence for Elders Pilot||Behavioral:PhysicalActivity|Interventional|Phase 1 / Phase 2|NIH|Combined outcome of ability to walk 400 m without the use of an assistive device or adjudicated evidence of inability to walk 400 m or death;  Drop-indrop-outandlosstofollow-uprates;  Established Populations for Epidemiologic Studies of the Elderly (EPESE) physical performance score;  4mgaitspeed;  400mgaitspeed;  Self-reporteddisabilityscale;  Onset of self- or proxy-reported and objectively assessed disability in activities of daily living (ADLs);  Seriousfallinjuries;  Combinedcardiovascularevents;  Acute care hospitalizations and nursing home admissions;  Cognitive function measures; Health-related quality of life (HRQL) as reflected by depressive symptoms anxiety energy and fatigue level sleep and pain; Nursing home and acute-care hospitalization length of stay; Cost-effectiveness|424|NCT00116194|April 2004
3258|Completed|Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias||Drug:laromustine;  Drug:temozolomide|Interventional|Phase 1|Industry||25|NCT00098436|September 2004
3259|Completed|Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)||Drug:AP23573|Interventional|Phase 1|Industry||11|NCT00087451|July 2004
3260|Completed                  Has Results|Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)||Drug:Risperidone;  Drug: Olanzapine (enrollment closed in this treatment);  Drug:Molindone|Interventional|Phase 4|Other / NIH|Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at 8 Weeks;  Change From Baseline in PANSS Positive Symptom Subscale Score at 8 Weeks.;  Change From Baseline in PANSS Negative Symptom Subscale at Week 8;  ChangeFromBaselineinWeightatWeek8;  Change From Baseline in Barnes Akathisia Scale at Week 8;  Change From Baseline in Body Mass Index Change kg/m2 at Week 8|116|NCT00053703|February 2002
3261|Completed                  Has Results|Effects of Treating Obstructive Sleep Apnea in Epilepsy||Device: continuous positive airway pressure (CPAP);  Device:Placebo-CPAP|Interventional|Phase 2|Other / NIH|CPAP Adherence/Tolerance as Measured by Proportion of Nights Used;  Number of Patients That Were Able to be Blinded to CPAP or Placebo CPAP;  Number of Patients Requiring Only One Night of Baseline Sleep Study to Detect Sleep Apnea|68|NCT00047463|September 2002
3262|Completed|Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer||Drug:bryostatin1;  Drug:paclitaxel|Interventional|Phase 2|NIH||46|NCT00005028|May 2000
3263|Completed|Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer||Drug:arzoxifenehydrochloride|Interventional|Phase 2|Industry|||NCT00003670|October 1998
3264|Not yet recruiting|Risk Evaluation and Education for Alzheimer&apos;s Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN)||Behavioral:Alzheimer&apos;sDiseaseRiskDisclosure;  Behavioral: Amyloid Brain Imaging and Alzheimer&apos;s Disease Risk Disclosure|Interventional||Other / NIH|Change in baseline neuropsychological performance compared to 6 weeks and 6 months post-disclosure;  Change in baseline measure scores on scales and questionnaires of psychological distress compared to 6 weeks and 6 months post-disclosure.;  Change in baseline measures of health behaviors compared to 6 weeks and 6 months post-disclosure to determine the type and frequency of behavior changes in response to learning risk information.|270|NCT02959489|November 2016
3265|Recruiting|Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer||Drug:MRZ;  Drug:TMZ;  Radiation:RT|Interventional|Phase 1|Industry|Determine MRZ maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) for both concomitant treatment (MRZ + TMZ + RT) and adjuvant treatment (MRZ + TMZ);  To confirm the MRZ RP2D for concomitant and adjuvant treatment in an expanded group of patients;  Assess adverse events during concomitant and adjuvant treatment;  Evaluate the activity (overall survival [OS]) of MRZ + TMZ + RT;  Evaluate the activity (progression-free survival [PFS]) of MRZ + TMZ + RT;  MRZ pharmacokinetics - Maximum Serum Concentration (Cmax);  MRZ pharmacokinetics - Elimination Half-Life (t1/2);  MRZ pharmacokinetics - Area Under the Blood Concentration-Time Curve (AUC0-t AUC0-inf);  MRZpharmacokinetics-Clearance(CL);  MRZ pharmacokinetics - Volume of Distribution (Vd);  TMZserumconcentration;  Assess neurological coordination using the Scale for the Assessment and Rating for Ataxia (SARA)|48|NCT02903069|August 2016
3266|Recruiting|Engineering an Online STI Prevention Program||Behavioral:Knowledgealone;  Behavioral:Self-efficacyalone;  Behavioral:Perceivedbenefitsalone;  Behavioral:Perceivedbenefitsandself-efficacy;  Behavioral:Injunctivenorms;  Behavioral:Injunctivenormsandself-efficacy;  Behavioral: Injunctive norms and perceived benefits;  Behavioral: Injunctive norms perceived benefits and self-efficacy;  Behavioral:Descriptivenormsalone;  Behavioral:Descriptivenormsandself-efficacy;  Behavioral: Descriptive norms and perceived benefits;  Behavioral: Descriptive normsperceived benefitsself-efficacy;  Behavioral:Descriptiveandinjunctivenorms;  Behavioral: Descriptive norms injunctive normsself-efficacy;  Behavioral: Descriptive and injunctive norms benefits;  Behavioral: Descriptive and injunctive norms benefitsefficacy;  Behavioral:Expectanciesalone;  Behavioral:Expectanciesandself-efficacy;  Behavioral:ExpectanciesandPerceivedBenefits;  Behavioral: Expectancies perceived benefits self-efficacy;  Behavioral:Expectanciesandinjunctivenorms;  Behavioral: Expectancies injunctive norms and self-efficacy;  Behavioral: Expectancies injunctive norms benefits;  Behavioral: Expectancies injunctive norms benefits efficacy;  Behavioral:Expectanciesanddescriptivenorms;  Behavioral: Expectancies descriptive norms and self-efficacy;  Behavioral: Expectancies descriptive norms and benefits;  Behavioral: Expectanciesdescriptive norms benefits efficacy;  Behavioral: Expectancies descriptive and injunctive norms;  Behavioral: Expectancies descr&amp; injun norms efficacy;  Behavioral: Expectancies desc &amp; injun norms benefits;  Behavioral: Expectanciesdesc &amp; injun normsbenefitsefficacy|Interventional||Other|Descriptive norms about the intersection of alcohol and sex collected via an online questionnaire.;  Injunctive norms about the intersection of alcohol and sex collected via an online questionnaire.;  Expectancies about the intersection of alcohol use and sex collected via an online questionnaire.;  Perceived benefits about using protective behavioral strategies collected via an online questionnaire.;  Self-efficacy to use protective behavioral strategies collected via an online questionnaire.;  Binge drinking behavior collected via an online questionnaire;  Unprotected sex behavior at most recent sex collected via an online questionnaire;  Penetrative sex at most recent hookup collected via an online questionnaire|13773|NCT02897804|August 2016
3267|Recruiting|A Study of LY3041658 in Participants With Skin Diseases||Drug:LY3041658;  Drug:Placebo|Interventional|Phase 1|Industry|Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration;  Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3041658;  Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) During Dosing Interval at Steady State (AUCss) of LY3041658;  Pharmacokinetics (PK): Time to Maximum Concentration (Tmax) of LY3041658|60|NCT02896868|November 2016
3268|Recruiting|Analyzing Retinal Microanatomy in ROP||Device:SweptSourceOCT;  Other:MagneticResonanceImaging;  Other:Scavengedbloodcollection|Observational||Other / NIH|Initiate ICN research imaging with the novel ultralight hand piece and high speed SSOCT (Aim 1A);  Number of infants with reproducible imaging of the peripheral vascular-avascular junction (Aim 1B);  Number of microns of retinal thickness and distance from foveal to ellipsoid zone band as seen on retinal vascular imaging using infant specific automated image processing;  Number of microns of retinal thickness and distance from foveal to ellipsoid zone band as seen from multi-layer segmentation using infant specific automated image processing (1C);  Retinal microanatomy grading from Swept Source Optical Coherence Tomography (SSOCT);  BrainMRIgrading;  Visualacuityscores;  Neurodevelopmentalscores;  Peripheralretinalmicroanatomygrading;  ROPseveritygradeofretinalmicroanatomybyOCT;  Maximum ROP stage as determined during clinical evaluation;  Neuroinflammatorymarkerscores;  Presenceofnon-ROPocularconditions;  ROPspecificsfromclinicalexamination;  ROPspecificsfromOCTimaging;  Clinician&apos;sdecisiontotreat|160|NCT02887157|March 2016
3269|Recruiting|sEphB4-HSA in Treating Patients With Kaposi Sarcoma||Other:LaboratoryBiomarkerAnalysis;  Other:PharmacologicalStudy;  Behavioral:Quality-of-LifeAssessment;  Biological:RecombinantEphB4-HSAFusionProtein|Interventional|Phase 2|Other / NIH / Industry|Proportion of participants experiencing clinical response;  Proportion of participants experiencing unacceptable toxicity;  Pharmacodynamic parameters of recombinant EphB4-HSA fusion protein;  Trough levels of recombinant EphB4-HSA fusion protein|42|NCT02799485|November 2015
3270|Completed|Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System||Drug: Aripiprazole + IEM (Ingestible Event Marker)|Interventional|Phase 2|Industry|NumberofInboundandOutboundCallsbyhelptype|49|NCT02722967|March 2016
3271|Recruiting|AGEN-1884 an Anti-CTLA-4 Antibody in Advanced Solid Cancers||Drug:AGEN1884|Interventional|Phase 1|Industry|Doselimitingtoxicities(DLTs)ofAGEN1884.;  MaximumtolerateddoseMTD.;  Concentration of AGEN1884 on Day 1 at 2 6 and 24 hours and on Day 8 Day 15 and Day 22.;  Objectiveresponserate(ORR);  Durationofresponse(DOR);  Progression-freesurvival(PFS);  Overallsurvival(OS);  Changeinimmunecellpopulations|48|NCT02694822|April 2016
3272|Not yet recruiting|&quot;Solana&#8482; Trichomonas Assay Field Study&quot;||Device:SolanaTrichomonasAssayTesting|Observational||Industry|TrichomonasTestResult|1000|NCT02566447|October 2015
3273|Completed|Pilot Mammography Reader Study to Assess Breast Cancer Detection in FFDM Plus DBT Versus FFDM Alone||Device:FFDMPlusDBT;  Device:FFDM|Interventional|Phase 1|Industry|PerSubjectAreaUnderCurve(AUC)|100|NCT02511730|June 2015
3274|Recruiting|A Trial of Comparing the Pathology Status of Lymphoseek&#174;-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection||Drug:Tc99mtilmanocept|Interventional|Phase 2|Industry|Per-subjectfalsenegativerate;  Per-subjectsensitivity;  Per-subjectnegativepredictivevalue;  Per-subjectaccuracy;  Proportion of lymph nodes identified intraoperatively by a dye that are also identified by Lymphoseek;  Number of lymph nodes per-subject identified by Lymphoseek;  Number of lymph nodes per-subject identified by other dyes;  Per-subjectconcordance;  Per-subjectreverseconcordance;  Number of pathology positive lymph nodes per-subject identified by Lymphoseek;  Number of pathology positive lymph nodes per-subject identified by dyes;  Incidenceofadverseevents|40|NCT02509585|January 2016
3275|Recruiting|A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation||Drug:VX-661/ivacaftor;  Drug:ivacaftor;  Drug:VX-661/ivacaftormatchingplacebo;  Drug:ivacaftormatchingplacebo|Interventional|Phase 2|Industry|Absolutechangeinmucociliaryclearance(MCC);  Absolute change in percent predicted forced expiratory volume in 1 second (ppFEV1);  AbsolutechangeingastrointestinalpH;  Absolutechangeinsweatchloridetest;  Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|45|NCT02508207|February 2016
3276|Recruiting|A Trial of Tocilizumab in ALS Subjects||Drug:Tocilizumab;  Other:Placebo|Interventional|Phase 2|Other / Industry|SafetyandTolerability;  EfficacySVC;  EfficacyALSFRS-R;  EfficacyHHD;  Target engagement ( change in PBMC pro-inflammatory gene expression);  Target engagement (change in CSF sIL-6 receptor concentrations);  Target engagement (changes in cytokine levels in the serum and CSF)|24|NCT02469896|November 2015
3277|Recruiting|Regorafenib in Metastatic Colorectal Cancer||Drug:Regorafenib|Interventional|Phase 2|Other / Industry|Number of subjects who experience grade 3-5 toxicity as a measure of safety and tolerability.;  Number of subjects who respond to study treatment.;  Association of adverse events with the Comprehensive Geriatric Assessments.;  Subject&apos;s quality of life as assessed by the Comprehensive Geriatric Assessment form while receiving study treatment.|60|NCT02466009|March 2015
3278|Completed|Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients||Drug:Ceftolozane/Tazobactam|Interventional|Phase 4|Other / Industry|CeftolozaneClearance;  CeftolozaneVolumeofDistribution;  TazobactamClearance;  TazobactamVolumeofDistribution;  CeftolozaneProbabilityofTargetAttainment;  Safety and Tolerability (changes in serum chemistry hematology and hepatic lab values as well as reported adverse events)|20|NCT02421120|September 2015
3279|Recruiting|Cytosponge Adequacy Study Evaluation II|||Observational||Industry|AcceptabilityoftheProcedure;  Adequacy;  Operatingcharacteristics;  MucosalAbrasion;  Ongoingsafetymeasures|175|NCT02395471|August 2015
3280|Completed|AFIX to Improve HPV Vaccination||Other:AFIXin-personconsultation;  Other:AFIXwebinarconsultation|Interventional||Other|HPVvaccination(&#8805;1dose)11-12yearolds;  HPVvaccination(3doses)11-12yearolds;  Tetanus diphtheria and acellular pertussis (Tdap) vaccination 11-12 year olds;  Meningococcal vaccination (&#8805;1 dose) 11-12 year olds;  HPVvaccination(&#8805;1dose)13-17yearolds;  HPVvaccination(3doses)13-17yearolds;  Tdapvaccination13-17yearolds;  Meningococcal vaccination (&#8805;1 dose) 13-17 year olds;  Tdapvaccination11-12yearolds|225|NCT02370459|April 2015
3281|Recruiting|The DIVINE Study: DIetary Management of Glucose VarIability iN thE ICU||Other:PeptamenBariatric;  Other:Replete|Interventional||Industry|Glucose variability - Number of glycemic events outside the serum glucose range of 110-150 mg/dl;  Glucose variability - Number of glycemic events between 80-110 mg/dl and 150-180 mg/dl;  Glucose variability - Number of episodes of hypoglycemia (glucose &lt; 80 mg/dl);  Glucose variability - Number of episodes of hyperglycemia (glucose &gt; 180 mg/dl);  Glucosevariability-Averageglucoselevels;  Needforexogenousinsulinadministration;  Needforexogenousglucoseadministration;  Nursingtime|208|NCT02337556|November 2014
3282|Completed|A Novel Intervention Promoting Eating Disorder Treatment Among College Students||Behavioral: Promoting Eating Disorder Treatment among College Students|Interventional|Phase 1|Other / NIH|Help-seeking behavior (Use of services (e.g. counseling/therapy) for eating and body image issues);  Predictors of help-seeking behavior (e.g. perceived need/urgency knowledge attitudes intentions to seek help)|1149|NCT02284685|January 2015
3283|Active not recruiting|PK Study With Pantoprazole in Obese Children and Adolescents||Drug:Pantoprazole|Interventional|Phase 1|Other / Industry|Pharmacokinetic Analysis in obese children after one single oral dose of Pantoprazole. The PK parameters for pantoprazole will be measured from Cmax Tmax Ka Kel AUC VDss/F &amp; CL/F;  The CYP2C19 genotype and its association with CYP2C19 phenotype (PK) will be measured with the analysis of a blood sample|40|NCT02186652|July 2014
3284|Active not recruiting|Evaluating the Impact of Year Long Augmented Diabetes Self Management Support||Other:diabetesselfmanagementsupport|Interventional||Other / Industry|Change from baseline HbA1c at 3 9 15 and 27 months;  Change from baseline blood pressure at 3 9 15 and 27 months;  Change from baseline cholesterol at 3 9 15 and 27 months;  Change from baseline BMI at 3 9 15 and 27 months;  Change from baseline weight at 3 9 15 and 27 months;  Change from baseline fasting glucose at 3 9 15 and 27 months;  Change from baseline patient credential at 3 9 15 and 27 months;  Change from baseline depression at 3 9 15 and 27 months;  Change from baseline food security at 3 9 15 and 27 months|449|NCT02160639|January 2015
3285|Recruiting|Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma||Drug:Ibrutinib;  Other:LaboratoryBiomarkerAnalysis;  Drug:Palbociclib;  Other:PharmacologicalStudy|Interventional|Phase 1|NIH|Recommended phase II dose of the combination of ibrutinib and palbociclib defined as the highest dose level at which no more than 1/6 patients present with a dose limiting toxicity (DLT);  CR rate evaluated according to the revised response criteria of the International Working Group;  Incidence of toxicities assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0;  ORR evaluated according to the revised response criteria of the International Working Group;  Partial response rate evaluated according to the revised response criteria of the International Working Group;  PFS;  RD|28|NCT02159755|May 2014
3286|Unknown&nbsp;&#8224;|22-gauge ProCore Needle v. Standard 22-gauge (P00030500)||Other:22-gaugeStandardNeedle;  Other:22-gaugeProCoreNeedle|Interventional||Other / Industry|Ease of use of 22-gauge ProCore EBUS needles and the standard 22-gauge needles.;  Quality of tumor obtained (measured by cell block and ability to perform mutational analysis);  Quantity of tissue obtained (measured by number of unstructured fragments)|200|NCT02154698|June 2014
3287|Completed                  Has Results|ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis||Drug:ACT01;  Drug:Comp01;  Drug:Comp02;  Drug:Comp03;  Drug:Comp04|Interventional|Phase 2|Industry|TreatmentSuccessatEndofStudyVisit;  IrritationScore|100|NCT02126670|April 2014
3288|Completed|The Tobacco Alcohol Prescription Medication and Other Substances Tool||Other:Tabletadministration;  Other:Intervieweradministration|Interventional||Other / NIH|Diagnostic and Statistical Manual-5 Substance Use Disorder Diagnosis;  SeverityofSubstanceUseProblems;  DaysofSubstanceUse;  SeverityofAlcoholUse;  Severityofcigarettesmokingproblems;  Severityofsmokelesstobaccoproblems;  SubstanceUse|2000|NCT02110693|March 2014
3289|Recruiting|Sickle Cell Clinical Research and Intervention Program|||Observational||Other|Relationship between treatment plan and health outcomes in participants with sickle cell disease (SCD);  Relationship between genetic properties of biological samples and health outcomes in participants with sickle cell disease|1300|NCT02098863|March 2014
3290|Recruiting|Immunotherapy Study for Patients With Stage IV Melanoma||Drug:HyperAcute&#174;-Melanoma(HAM)Immunotherapy;  Drug:Ipilimumab;  Drug:Pembrolizumab;  Drug:Nivolumab|Interventional|Phase 2|Industry|Safety;  ClinicalResponseRate;  ClinicalActivity;  Anti-tumorImmuneResponse;  ImmuneActivation;  Anti-TumorMechanism|100|NCT02054520|June 2014
3291|Enrolling by invitation|Comparison of Continuous Sternal ECG Patch Monitors (Carnation and Zio) Trial|||Observational||Industry|ECGsignalquality;  Devicecomfort|50|NCT02031484|July 2016
3292|Recruiting|Comparison of Depression Identification After Acute Coronary Syndrome: Quality of Life and Cost Outcomes||Other:CognitiveBehavioralTherapy(CBT);  Drug:AntidepressantMedication;  Other:StandardCare;  Other:Depressivesymptomscreener;  Other:Nointervention|Interventional||Other / NIH|QualityAdjustedLifeYears;  Costofhealthcareutilization;  Depression-freedays|1500|NCT01993017|November 2013
3293|Recruiting|Regeneration of Pulp-Dentin Development in Teeth With Necrotic Pulps and Immature Roots||Drug:TripleAntibioticPaste;  Other:StandardTreatment|Interventional|Phase 1|Other|ToothSurvival;  Positivepulpalresponse|120|NCT01976065|September 2014
3294|Recruiting|A Novel &quot;Pediatric-Inspired&quot; Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia||Drug:Daunorubicin;  Drug:Vincristine;  Drug:Prednisone;  Drug:PEG-Asparaginase;  Drug:Methotrexate;  Drug:6-MP(6-Mercaptopurine);  Drug:Cyclophosphamide;  Drug:Cytarabine;  Drug:Leucovorin;  Drug:Dexamethasone;  Other:Blooddraw;  Device:CT/PETscans|Interventional|Phase 2|Other / Industry|rateofmolecularremission;  completeremission(CR);  overallsurvival(OS);  event-freesurvival(EFS);  diseasefreesurvival(DFS)rates;  minimalresidualdisease(MRD)status;  safety|39|NCT01920737|August 2013
3295|Active not recruiting|Integrating ENGagement and Adherence Goals Upon Entry iENGAGE to Control HIV||Behavioral: Based on behavioral motivational interviewing (MI) technique|Interventional||Other|Viral load suppression (&lt;200c/ml)among patients newly initiating outpatient HIV medical care;  Viremiacopyyears(VCY)|371|NCT01900236|December 2013
3296|Terminated|Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)||Drug:ONO-2952;  Drug:Placebocomparator|Interventional|Phase 2|Industry|Change in pain intensity rating during rectal distention by using a numeric pain rating scale;  Safety assessed through adverse events and clinical laboratory values|39|NCT01887002|June 2013
3297|Active not recruiting|Zimmer POLAR - Total Knee Arthroplasty (TKA)||Device:ZimmerPersonaTotalKneeSystem|Interventional||Industry|KneeSocietyScores;  EQ-5D|300|NCT01859130|April 2013
3298|Completed|Mindfulness and Acceptance Applied in Colleges Through Web-Based Guided Self-Help||Behavioral:Web-BasedGuidedSelf-Help|Interventional|Phase 1|Industry|SystemUsabilityScale;  ProgramKnowledgeQuestionnaire;  DepressionAnxietyandStressScale;  FiveFacetMindfulnessQuestionnaire;  PersonalValuesQuestionnaire;  AcceptanceandActionQuestionnaire-II;  SatisfactionWithLifeScale|113|NCT01808404|February 2013
3299|Enrolling by invitation|Symptom Clusters in Children With Leukemia|||Observational||Other||400|NCT01708421|November 2012
3300|Completed                  Has Results|Primary Care Providers Use of a Gene Expression Test in Coronary Artery Disease Diagnosis|||Observational||Industry|Change in Clinicians&apos; Treatment Decision After Gene Expression Testing|251|NCT01594411|April 2012
3301|Completed|Evaluating the Pharmacokinetics of High-Dose Rifapentine When Given as a Single Dose or in Divided Doses to Healthy Adults||Drug:Rifapentine(RPT)|Interventional|Phase 1|NIH|RPT PK parameter: area under the curve over 24 hours (AUC 0 to 24h);  RPTPKparameter:AUC0to24h;  Grade 2 or higher signs and symptoms observed while on study beginning with the first dose of study drug and continuing through the follow-up period;  RPT PK parameter: maximum observed plasma concentrations (Cmax);  Cmin(trough)values;  Metabolizer status of human genetic variants/polymorphisms in gene SLCO1B1 and possibly other genes that are thought to affect PK of RIF;  RPT PK parameter: minimum observed plasma concentration (Cmin);  RPTPKparameter:oralclearance(CL/F);  RPTPKparameter:eliminationhalf-life(T1/2);  RPT metabolite desacetyl-rifapentine (desRPT) PK parameter: AUC 0 to 24h;  RPTmetabolitedesRPTPKparameter:Cmax;  RPTmetabolitedesRPTPKparameter:Cmin;  RPTmetabolitedesRPTPKparameter:CL/F;  RPTmetabolitedesRPTPKparameter:T1/2;  RPTPKparameter:Cmax;  RPTPKparameter:Cmin;  RPTPKparameter:CL/F;  RPTPKparameter:T1/2;  RPTmetabolitedesRPTPKparameter:AUC0to24h;  RPT and its metabolite desRPT PK parameter AUC 0 to 24h at steady state when given at a dose of 20 mg/kg once daily (Group 1) and at a dose of 15 mg/kg once daily (Group 2 );  RPT and its metabolite desRPT PK parameter Cmax at steady state when given at a dose of 20 mg/kg once daily (Group 1) and at a dose of 15 mg/kg once daily (Group 2 );  RPT and its metabolite desRPT PK parameter Cmin at steady state when given at a dose of 20 mg/kg once daily (Group 1) and at a dose of 15 mg/kg once daily (Group 2 );  RPT and its metabolite desRPT PK parameter CL/F at steady state when given at a dose of 20 mg/kg once daily (Group 1) and at a dose of 15 mg/kg once daily (Group 2 );  RPT and its metabolite desRPT PK parameter T1/2 at steady state when given at a dose of 20 mg/kg once daily (Group 1) and at a dose of 15 mg/kg once daily (Group 2 );  RPT and its metabolite desRPT PK parameter area under the curve extrapolated to infinity (AUC 0 to inf);  RPTanditsmetabolitedesRPTPKparameterCL/F;  RPTanditsmetabolitedesRPTPKparameterT1/2;  RPT and its metabolite desRPT PK parameter AUC 0 to 24h|44|NCT01574638|June 2012
3302|Terminated|Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation||Drug:standardtherapy;  Drug:placebo;  Drug:activatedrecombinanthumanfactorVII|Interventional|Phase 2|Industry|Effect on bleeding defined as change in bleeding score;  Transfusionrequirements;  Bleedingevaluation;  Adverseevents;  Changesinsafetycoagulationparameters|11|NCT01564563|June 2002
3303|Completed                  Has Results|A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers||Drug:MM-121;  Drug:Irinotecan;  Drug:Cetuximab|Interventional|Phase 1|Industry|Dose Escalation: To Evaluate the Safety and Tolerability of Escalating Doses of the MM-121 Plus Cetuximab and the MM-121 Plus Cetuximab Plus Irinotecan Combination;  To Further Determine the Safety Parameters of the MM-121 + Cetuximab and MM-121 + Cetuximab + Irinotecan Combination by Determining the Recommended Phase 2 Dose (RP2D) of the Combination(s) (Via Recording of Maximum Tolerated Dose (MTD)): MM-121 Doses;  To Further Determine the Safety Parameters of the MM-121 + Cetuximab and MM-121 + Cetuximab + Irinotecan Combination by Determining the Recommended Phase 2 Dose (RP2D) of the Combination(s): Cetuximab and Irinotecan;  ObjectiveResponseRate;  Pharmacokinetics;  PharmacokineticParametersofMM-121;  Immunogenicity|48|NCT01451632|October 2011
3304|Completed|Study to Evaluate TRV120027 on Renal Pharmacodynamics in Patients With Heart Failure and Renal Dysfunction||Drug:TRV120027;  Drug:NormalSaline|Interventional|Phase 1|Industry|ChangefromBaselineGlomerularFiltrationRate;  Change from Baseline in Vital Signs (Blood pressure heart rate)|17|NCT01444872|August 2011
3305|Recruiting|Post Admission Cognitive Therapy (PACT) for the Inpatient Treatment of Military Personnel With Suicidal Behaviors||Behavioral: Post Admission Cognitive Therapy (PACT)|Interventional||Other / U.S. Fed|RepeatSuicideAttempts;  Depression;  Hopelessness;  SuicideIdeation;  Post-TraumaticStressSymptoms;  AcceptabilityofTreatment;  RepeatPsychiatricHospitalizations|218|NCT01359761|February 2011
3306|Completed|Study to Assess the Safety Tolerability and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer||Drug:AMP-224|Interventional|Phase 1|Industry|Numberofparticipantswithadverseevents.;  Number of participants with dose-limiting toxicities.;  Number of participants with changes in laboratory values vital signs physical exam and electrocardiogram.;  Determine Maximum Tolerated Dose based on the occurrence of dose-limiting toxicities.;  Determine Recommended Phase 2 Dose following analysis of adverse events pharmacokinetics and changes in laboratory evaluations.;  Evaluate pharmacokinetics including area under the plasma concentration versus time curve (AUC) peak plasma concentration (Cmax) and clearance of AMP-224 following single and repeat doses of AMP-224.;  Evaluate Overall Response Rate (ORR) including Complete Response (CR) Partial Response (PR) Stable Disease (SD) and Progression-Free Survival (PFS).;  Characterization of the effects of AMP-224 on its receptor PD-1 in peripheral T cells via flow cytometry and correlate with response to treatment.;  Evaluation and correlation between response to treatment and expression of PD-1 on tumor infiltrating T cells or in available malignant pleural effusions via flow cytometry and/or immunohistochemistry.;  Evaluation and correlation between response to treatment and expression of B7-H1 on tumors via immunohistochemistry.;  Identification of peripheral patient selection and pharmacodynamic markers from blood samples that predict and/or correlate with response to treatment.|44|NCT01352884|March 2011
3307|Completed                  Has Results|A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval||Drug:lapatinib;  Drug:placebomatchinglapatinib|Interventional|Phase 4|Industry|Treatment Difference in Duration of Cardiac Ventricular Depolarization and Repolarization Interval (QT) in Fridericia-corrected QT Interval (QTcF) Values Between Placebo and Lapatinib 2000mg;  Change From Baseline in the Holter ECG Parameters of QT Interval Corrected QT Interval (QTc) Bazett Corrected QTc Interval (QTcB) Individual-corrected QT Interval (QTcI) RR Interval PR Interval and QRS Duration at Indicated Time Points;  Number of Participants With 12-lead Holter ECG Findings at the Indicated Time Points;  Number of Participants With the Worst-case Post-Baseline 12-lead Holter ECG Findings With Significant ST T Wave and U Wave Abnormalities;  Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE);  Mean Albumin and Hemoglobin at the Indicated Time Points;  Mean Alkaline Phosphatase (ALP) Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) at the Indicated Time Points;  Mean Direct Bilirubin Total Bilirubin and Creatinine at the Indicated Time Points;  Mean Calcium Chloride Carbon Dioxide (CO2) Potassium Sodium Magnesium and Urea at the Indicated Time Points;  Mean Total Neutrophils (ANC [Absolute Neutrophil Count]) Platelets and Leukocyte Count at the Indicated Time Points;  Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points;  Change From Baseline in Heart Rate at the Indicated Time Points;  Number of Participants With 12-lead ECG Findings at Indicated Time Points;  Mean Area Under the Plasma Drug Concentration-time Curve (AUC) From Time Zero (Pre-dose) to the Last Time of Quantifiable Concentration (AUC[0-t]) and From Time Zero (Pre-dose) to 24 Hours Post Dose (AUC[0-24]) for Lapatinib;  Mean Maximum Plasma Concentration (Cmax) and Observed Plasma Concentration at 24 Hours Post-dose (C24) of Lapatinib;  Median Time to Cmax (Tmax) and the Time Prior to the First Quantifiable (Non-zero) Lapatinib Plasma Concentration (Tlag) Following the Last (3rd) Lapatinib Dose|58|NCT01328054|December 2011
3308|Completed                  Has Results|Evaluation of the Spectra Optia&#174; Mononuclear Cell Collection Procedure||Device:SpectraOptiaApheresisSystem|Interventional||Industry|Days Until Neutrophil Recovery Following Peripheral Blood Stem Cell Transplant Minus the Historical Median Day Until Recovery.;  DaysUntilPlateletRecovery;  CD34+CellCollectionEfficiency.;  MononuclearCel(MNC)CollectionEfficiency;  PlateletCollectionEfficiency;  HematocritofMNCProduct;  Granulocyte%ofMNCProduct|32|NCT01292486|February 2011
3309|Completed|A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas||Drug:MEDI-565|Interventional|Phase 1|Industry|Determine the maximum tolerable dose (MTD) or optimal biological dose (OBD) of MEDI-565 in subjects with gastrointestinal (GI) adenocarcinomas for which no standard or curative treatments are available.;  Evaluate the safety profile in adult subjects with advanced gastrointestinal (GI) adenocarcinomas who have no available standard or curative treatments.;  Assess the safety and antitumor activity of MEDI-565 in the dose-expansion phase.;  PharmacokineticsofMEDI-565;  ImmunogenicityofMED-565|78|NCT01284231|December 2010
3310|Active not recruiting|Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma||Drug:Bendamustine;  Drug:Rituximab;  Radiation:Y-90ibritumomab|Interventional|Phase 2|Other / Industry|CompleteResponseRate|39|NCT01234766|October 2010
3311|Completed|A Study in Participants With Acute Leukemia||Drug:LY2090314|Interventional|Phase 2|Industry|Number of Participants with one or more drug related Adverse Events (AEs) or any Serious AE&apos;s;  Number of Participants with Best Response of Partial Response or Complete Response;  Pharmacokinetics: Area Under the Concentration-Time Curve (AUC);  Pharmacokinetics:MaximumConcentration(Cmax);  Percentage of Participants with Best Response of Partial Response or Complete Response;  Changein&#946;-cateninlevelsovertime|38|NCT01214603|November 2010
3312|Active not recruiting|Oxidative Stress Markers In Inherited Homocystinuria And The Impact Of Taurine||Drug:taurine|Interventional|Phase 1 / Phase 2|Other|Change in Biomarkers associated with oxidative stress and inflammation;tumor necrosis factor (TNF)-alpha and thiobarbituric acid reactive substances (TBARS);  ChangeinPharmacokineticsofTaurine;  Evaluation of Biochemical and Clinical Safety Data;  Evaluationofbloodvesselsandplateletfunction;  ChangeinTaurinePharmacokinetics;  Evaluation of Multiple Biomarkers of Inflammation and Oxidative Stress;  Relation to Biochemical Parameters of Homocystinuria;  ChangeinBoneMineralDensity|15|NCT01192828|January 2010
3313|Completed|A Study of RO4989991 in Patients With Allergic Rhinitis||Drug:Placebo;  Drug:RO4989991|Interventional|Phase 1|Industry|Assessment of the safety and tolerability of RO4989991;  Assessmentofpharmacokinetics|24|NCT01152619|July 2010
3314|Terminated|RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer||Drug:Exemestane;  Drug:Gamma-SecretaseInhibitorRO4929097;  Drug:GoserelinAcetate|Interventional|Phase 1|NIH|Incidence of treatment emergent adverse events (TEAEs) based on CTCAE version 3 grade;  Timetorelapse;  Overallsurvival|15|NCT01149356|October 2010
3315|Completed|Utility of Routine Cervical Mediastinoscopy in Clinical Stage I Non-Small Cell Lung Cancer (NSCLC)|||Observational||Other|Prevalence of occult N2/3 metastases in the study population;  Sensitivity of cervical mediastinoscopy for clinically occult N2 metastases|111|NCT01146366|January 2008
3316|Completed                  Has Results|Alignment Comparison Between TruMatch&#8482; Personalized Solutions and Conventional Total Knee Replacement Instrumentation||Other:TruMatch&#8482;PersonalizedSolutions;  Device: Total Knee Arthroplasty with Conventional Instrumentation.|Interventional||Industry|Mechanical Axis Alignment(Absolute Value Measured in Degrees)Using 51 Inch Long Leg Films;  Compare Intraoperative Time Data (Skin-to-skin Tourniquet Tourniquet to Bone);  CompareAPTibial/FemoralComponentAlignment;  SagittalComponentAlignment|78|NCT01108237|October 2009
3317|Completed|Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors||Drug:TKI258(dovitinib)|Interventional|Phase 1|Industry|Determine the relative bioavailability of the final market image form of TKI258 (monohydrate capsules) as compared to the clinical service form of TKI258 (anhydrate capsules);  Determine the effect of food on the bioavailability of TKI258;  Characterize the safety and tolerability of TKI258 including acute and chronic toxicities;  Evaluate preliminary evidence of anti-tumor activity of TKI258 in patients with advanced solid tumors.|60|NCT01030055|February 2010
3318|Terminated|Efficacy 2 Part Study of Identification of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence||Drug:QAX576;  Drug:QAX576placebo|Interventional|Phase 2|Industry / Other|Recurrenceofkeloidsaftershaveremoval.;  To assess the mechanism biomarker responses post-shave removal of keloids for confirmation in Part I and application in Part II|3|NCT00987545|June 2009
3319|Completed|Patient-Reported Outcomes Version of Common Terminology Criteria (CTCPRO) Cognitive Debriefing||Behavioral:Interview|Observational||Other / NIH|Comprehension of Patient Reported Outcome (PRO) Criteria|20|NCT00909207|July 2009
3320|Completed                  Has Results|Safety Trial of Single Versus Multiple Dose Thymoglobulin Induction in Kidney Transplantation||Biological: Single-dose rabbit Anti-thymocyte Globulin induction;  Biological: Divided-dose rabbit Anti-thymocyte Globulin induction|Interventional|Phase 2|Other / Industry|Composite Endpoint of 5 Components: Fever Hypoxia Hypotension Cardiac Events and Delayed Graft Function;  PatientSurvival;  GraftSurvival;  AcuteKidneyRejection;  IncompleteThymoglobulinInfusion;  KidneyFunction|99|NCT00906204|March 2010
3321|Completed                  Has Results|Patient-Centered Adherence Intervention After Acute Coronary Syndrome (ACS) Hospitalization||Behavioral:Intervention;  Behavioral:Usualcare|Interventional||U.S. Fed|Adherence to Cardioprotective Medications (Clopidogrel Statins Beta Blockers ACE-inhibitor/ARB)|253|NCT00903032|July 2010
3322|Completed|Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema||Drug:iCo-007IntravitrealInjection|Interventional|Phase 1|Industry|Safety and tolerability of 4 dose levels of intravitreal administration of iCo-007.;  To assess the systemic pharmacokinetics of iCo-007 after intravitreal administration. To assess change in retinal thickness relative to baseline as determined by OCT. To assess change in best corrected visual acuity relative to baseline.|15|NCT00886808|February 2008
3323|Completed|A Study of KRN23 in X-linked Hypophosphatemia||Drug:Placebo;  Drug:KRN23|Interventional|Phase 1|Industry|Safetyandtolerability;  Effecttopharmacodynamicparameter|42|NCT00830674|December 2008
3324|Terminated|Safety &amp; Efficacy of ALT-711 (Alagebrium) in Chronic Heart Failure||Drug:ALT-711;  Drug:Placebo|Interventional|Phase 2|Industry|The primary end-point of the study will be aerobic capacity (VO2 max) measured at exercise testing. An improvement of 15% in VO2 max will be considered as a clinically significant increase.|100|NCT00739687|August 2008
3325|Completed|AREDS 2 Ancillary Spectral Domain Optical Coherence Tomography Study|||Observational||Other / Industry|Primary outcome measures are the percent of eyes developing CNV mean change in visual acuity and change in drusen volume area of GA and photoreceptor layer thickness from SDOCT centered on the fovea.;  Drusen area measured from SDOCT versus from color fundus photographs. Mean change in drusen area reproducibility of measurements using these techniques.;  Grading of drusen type presence or absence of fluid photoreceptor loss or retinal thickening from SDOCT versus from color fundus photographs at each timepoint.;  Correlation between SDOCT imaging and autofluorescence imaging and onset of geographic atrophy.;  Measurement of area of GA from SDOCT images versus color fundus photos versus AF images.;  To evaluate whether the SDOCT outcome measures differ significantly between AREDS 2 patients randomized to different oral supplements in the AREDS2.|470|NCT00734487|June 2008
3326|Completed|Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma||Biological:MDX-010|Interventional|Phase 1|Industry|To determine the safety and pharmacokinetic profile of single and multiple doses of MDX-010.;  Determine the clinical activity profile of single and multiple doses of MDX-010|92|NCT00729950|July 2003
3327|Completed                  Has Results|Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients||Drug:pegloticase8mgi.v.|Interventional|Phase 3|Industry|AdverseEventProfile;  MeanPlasmaUricAcid|7|NCT00675103|May 2008
3328|Terminated|Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia||Drug:gemtuzumabozogamicin;  Drug:vorinostat;  Other:laboratorybiomarkeranalysis|Interventional|Phase 2|Other / NIH|Probability of achieving CR or CRi with induction therapy (Good-risk group);  Probabilityofsurvival(Poor-riskgroup);  Relapse-freesurvival(Good-andPoor-riskgroup);  Probability of achieving CR or CRi with induction therapy (Poor-risk group);  Probabilityofsurvival(Good-riskgroup)|107|NCT00673153|March 2008
3329|Completed                  Has Results|Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors||Drug:5-fluorouracil;  Drug:Oxaliplatin;  Drug:Leucovorin|Interventional|Phase 2|Other / NIH|OverallResponseRate(ORR);  OverallSurvival;  Progression-freeSurvival(PFS);  DiseaseControlRate(DCR);  Tumor Specific Changes That May Alter Treatment Outcomes;  Genetic Polymorphisms That May Alter Treatment Outcomes (Partial Response);  Genetic Polymorphisms That May Alter Treatment Outcomes (Stable Disease)|26|NCT00515216|August 2007
3330|Terminated                  Has Results|A Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528||Other:PLACEBO;  Biological:MEDI5289mg/kg|Interventional|Phase 2|Industry|Listing of Total Interleukin-9 (IL-9) Counts by Enzyme-linked Immunosorbent Assay in Bronchoalveolar Lavage Fluid (BAL);  IncidenceofAdverseEvents;  IncidenceofSeriousAdverseEvents;  Incidence of Anti-drug Antibodies (ADA) to MEDI-528;  TimetoPeakConcentration(Tmax);  PeakConcentration(Cmax);  Area Under the Concentration Curve From Time Zero to Last Measurable Concentration [AUC(0-t)];  Area Under the Concentration Curve From Time Zero to Infinity [AUC(0-infinity)];  Percent of Total Area Under the Concentration Curve Extrapolated From Last Measurable Time to Infinity [AUC(Ext)];  Clearance(CL);  TerminalHalf-life(T1/2);  VolumeatSteadyState(Vss);  VolumeatDistribution(Vz)|11|NCT00483041|July 2007
3331|Terminated|Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin||Drug:Infergenandribavirin|Interventional|Phase 4|Industry|To evaluate the proportion of patients with a sustained viral response (SVR) defined as undetectable serum HCV RNA at the end of the 24 week post-treatment follow-up period.;  Compare proportion of patients with SVR after switching treatment with Infergen/Ribavirin for 48 weeks versus those treated for 36 weeks|5|NCT00456248|February 2007
3332|Completed                  Has Results|Testing the Helpfulness of 2 Decision Aids for Prostate Cancer||Behavioral:typeofdecisionaid|Interventional||U.S. Fed|Knowledge|1028|NCT00432601|August 2008
3333|Completed|A Study of R547 in Patients With Advanced Solid Tumors.||Drug:RG547|Interventional|Phase 1|Industry|AEslaboratoryparameters.;  Pharmacokinetic and pharmacodynamic profiles of R547|58|NCT00400296|May 2005
3334|Completed|H5 Vaccine Alone or With Adjuvant in Healthy Adults||Drug:Aluminumhydroxide;  Biological: Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur pre-adsorbed)|Interventional|Phase 1 / Phase 2|NIH|Adverse event (AE) or serious adverse event (SAE) information (solicited in the clinic and via memory aids concomitant medications and periodic targeted physical assessments).;  Proportion of subjects in each group achieving a serum neutralizing antibody titer of greater than or equal to 1:40 against the influenza A/H5N1 virus.;  Proportion of subjects in each dose group achieving a serum Hemagglutination Inhibition (HAI) antibody titer of greater than or equal to 1:40 against the influenza A/H5N1 virus.;  Geometric mean titer (GMT) and frequency of 4-fold or greater increases in neutralizing antibody titers in each group.;  Geometric mean titer (GMT) and frequency of 4-fold or greater increases in serum HAI antibody titers in each group.;  1 month after receipt of each dose and 7 months after receipt of the first dose of vaccine.;  Geometric mean titer (GMT) and the frequency of 4-fold or greater increases in serum HAI antibody titers.;  Development of serum antibody responses against antigenically drifted variants of H5N1 influenza virus.|600|NCT00296634|March 2006
3335|Completed                  Has Results|Use of Infliximab for the Treatment of Pemphigus Vulgaris||Drug:Infliximab;  Drug:Prednisone;  Other:Placebo|Interventional|Phase 2|NIH / Other|ParticipantResponsetoTreatmentatWeek18;  Treatment-Related Adverse Events &gt;= Grade 3 On or Before Week 18;  ParticipantModifiedResponseStatusatWeek18;  ParticipantTimetoCessationofNewBlisters;  Timeto80%LesionHealing;  Total Prednisone Dosage Required for Participants to Achieve Cessation of New Blisters;  Total Prednisone Dosage Required for Participants to Achieve 80% Healing of Existing Erosions;  Participant Health Related Quality of Life (Medical Outcome Study Short Form 36) Score Changes From Baseline to Week 18;  Participant Dermatology-Related Quality of Life Changes From Baseline to Week 18;  ParticipantDurationofClinicalResponse;  Participants Who Experienced Severe Infusion Reactions;  Participants Who Experienced Severe Infectious Complications;  Adverse Events Resulting in Treatment Discontinuation;  Participant Pemphigus Vulgaris Disease Activity Score|20|NCT00283712|March 2006
3336|Terminated                  Has Results|A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation||Drug: Leuprolide acetate depot (LAD) 11.25 mg 3 Month;  Drug:Matchedplacebo|Interventional|Phase 2|Industry / Other|Mean Change From Baseline in IgM Response (Mcg/mL) Before Keyhole Limpet Hemocyanin (KLH) Vaccination at Month 6 and After KLH Vaccination at Month 7 in Patients Who Received LAD or Placebo;  Mean Change From Baseline in IgG1 Response (Mcg/mL) Before KLH Vaccination at Month 6 and After KLH Vaccination at Month 7 in Patients Who Received LAD or Placebo;  Mean Change From Baseline in Interferon Gamma Response (Spots/1 Million Cells) Before KLH Vaccination at Month 6 and After KLH Vaccination at Month 7 in Patients Who Received LAD or Placebo;  Mean Change From Baseline in T Cell Excision Circles (TREC) Per 100000 CD4+ Cells to Final Visit in Patients Treated With LAD (11.25 mg) or Placebo After Transplant;  Mean Change From Baseline in TREC Per 100000 CD8+ Cells to Final Visit in Patients Treated With LAD (11.25 mg) or Placebo After Transplant|25|NCT00275262|February 2006
3337|Completed|Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test||Biological:RagweedMATAMPL|Interventional|Phase 2|Industry|To assess immunological differences between three Ragweed MATA MPL treatment arms compared to placebo with respect to immunoglobulin levels (ragweed spec. IgG IgG1 IgG4IgE).;  Residual allergenicity of modified Ragweed pollen in RagweedMATAMPL compared to unmodified native allergen using Skin Prick Test;;  Tolerability of native modified allergens and tyrosine adsorbents with and without MPL&#174; using Skin Prick Test;;  Tolerabilityofdifferentsubcutaneousdoses;;  Tolerability of the cumulative subcutaneous doses;;  Clinicalchemistryhematologyandurinalysis;;  NumberofAdverseEvents(AEs);;  NumberofAdverseReactions;|69|NCT00258635|November 2005
3338|Completed|Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC||Drug:SNS-595Injection|Interventional|Phase 2|Industry|Efficacy;  Safety;  Tumorresponse;  Overallsurvival;  Biomarkercorrelationtoclinicalresponse|50|NCT00252382|November 2005
3339|Completed|Paroxetine-CR to Treat Post-Traumatic Stress Disorder (PTSD) Symptomatic After Initial Exposure Therapy||Drug: Cognitive-behavioral therapy and paroxetine-CR|Interventional|Phase 2 / Phase 3|Other / Industry|ShortPTSDRatingInterview(SPRINT);  DavidsonTraumaScale(DTS);  Clinical Global Impressions Severity Scale (CGI-S);  Clinical Global Impressions Improvement Scale (CGI-I);  PosttraumaticDiagnosticScale(PDS);  BeckDepressionInventory(BDI);  Quality of Life Enjoyment and Satisfaction Questionnaire/General Activities Subscale (Q-LES-Q/GA);  SheehanDisabilityScale(SDS);  Connor-DavidsonResilienceScale(CD-RISC);  Post-TraumaticCognitionsInventory(PTCI);  SeverityofSymptomsScale(SOSS);  PittsburghSleepQualityIndex(PSQI);  WorldAssumptionsScale(WAS);  Mood-SRLifetime|17|NCT00215163|December 2002
3340|Completed|Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme||Radiation: iodine I 131 monoclonal antibody TNT-1/B|Interventional|Phase 1|Other / NIH|Maximum tolerated dose based on CTCAE v3.0 weekly for 8 weeks then every 8 weeks;  Biodistribution and radiation dosimetry by blood urine and whole body scans daily for 10 days;  Toxicity by CTCAE v3.0 weekly for 12 weeks then every 8 weeks;  Overall survival median time of survival and percent alive at 6 months|22|NCT00128635|October 2005
3341|Completed|Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)||Drug:AEE788|Interventional|Phase 1 / Phase 2|Industry|Maximumtolerateddose;  Doselimitingtoxicity;  Safety tolerability pharmacokinetic profiles change in plasma markers of angiogenesis tumor PK levels|64|NCT00116376|January 2004
3342|Completed|Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors||Drug:SB-485232|Interventional|Phase 1|Industry|- Safety and tolerability endpoints will include evaluation of adverse events and changes in laboratory values and clinical variables from pre-dose values.;  - Biologically effective dose based. - Pharmacokinetic endpoints: AUC Adverse Events cmax tmax and t1/2. - Presence or absence of anti-SB-485232 antibodies. - Pharmacodynamic endpoints. - Radiographic tumor assessments.|25|NCT00085878|January 2003
3343|Completed|MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer||Drug: MLN2704 (DM1 conjugated monoclonal antibody MLN591)|Interventional|Phase 1 / Phase 2|Industry||46|NCT00070837|October 2003
3344|Completed|Donepezil or EGb761 in Improving Neurocognitive Function in Patients Who Have Previously Undergone Radiation Therapy for Primary Brain Tumor or Brain Metastases||DietarySupplement:EGb761;  Drug:donepezilhydrochloride;  Procedure:cognitiveassessment|Interventional|Phase 2|Other / NIH|||NCT00070161|March 2004
3345|Completed|Omega-3 Fatty Acids That Affect the Immune System in Kidney Transplant Patients||DietarySupplement:Canolaoil;  DietarySupplement:Arginine;  DietarySupplement:Fishoilemulsion|Interventional|Phase 0|NIH|Increases in omega-3 fatty acid levels in plasma and red blood cell membranes observed in each of the three omega-3 supplements used in this study;  Compliance rates observed in each of the three study groups|75|NCT00047983|
3346|Completed|Optimizing Electroconvulsive Therapy for Depression||Procedure:Highdosageelectroconvulsivetherapy;  Drug:Nortriptyline;  Drug:Venlafaxine;  Drug:Lithium;  Procedure:Lowdosageelectroconvulsivetherapy|Interventional|Phase 4|Other / NIH|Neurocognitivebattery;  Clinical evaluations side effect evaluations and blood level determinations;  Memoryfunction|340|NCT00045916|February 2001
3347|Completed|Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients||Drug:INGAPPeptide|Interventional|Phase 1 / Phase 2|Industry||62|NCT00034255|December 2001
3348|Completed|EQUIC-CC: Enhancing Quality of Informed Consent - Customized Consent|||Observational||U.S. Fed|improve method of disclosing information to patients in the informed consent process|240|NCT00032539|April 1999
3349|Completed|Improving Diabetes Care Via Telephone Assessment and Patient Education|||Observational||U.S. Fed||480|NCT00012649|
3350|Completed|Amifostine Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer||Drug:amifostinetrihydrate;  Drug:cisplatin;  Drug:etoposide;  Radiation:radiationtherapy|Interventional|Phase 2|Other / NIH||34|NCT00004176|October 1998
3351|Completed|A Pilot Randomized Double-Blind Placebo-Controlled Parallel Design Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3||Drug:Ranitidinehydrochloride|Interventional|Phase 2|Industry||104|NCT00002106|
3352|Completed|Trial of Nonpharmacologic Interventions in Elderly (TONE)||Behavioral:dietreducing;  Behavioral:dietsodium-restricted|Interventional|Phase 3|NIH|||NCT00000535|April 1992
3353|Recruiting|Safety Tolerability Pharmacokinetics and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer||Drug:GS-5829;  Drug:Enzalutamide|Interventional|Phase 1 / Phase 2|Industry|For dose escalation incidence of dose limiting toxicities (DLT);  For dose expansion efficacy assessed as non-progression/progression rate at Week 24 according to prostate cancer working group (PCWG2) criteria;  For dose escalation PK parameter: Cmax of GS-5829;  For dose escalation PK parameter: Ctau of GS-5829;  For dose escalation PK parameter: AUClast of GS-5829;  For dose escalation PK parameter: AUCtau of GS-5829;  For dose escalation PK parameter: Tmax of GS-5829;  Prostate-specific antigen (PSA) response defined as &#8805; 30% decline in PSA from baseline at 12 weeks for Groups 1 2 and 3;  Progressionfreesurvival(PFS);  Overallsurvival(OS)|132|NCT02607228|December 2015
3354|Recruiting|A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson&apos;s Disease (PD) to Determine the Safety Tolerability and Pharmacokinetic (PK) Profile of SER-214||Drug:SER-214|Interventional|Phase 1|Industry|Safety - Adverse Events and Serious Adverse Events;  Percentage of patients in each cohort who discontinued therapy due to any adverse events {Tolerability};  Safety-VitalSigns;  Safety-AbnormalLaboratoryResults;  Safety-Treatment-EmergentAdverseEvents;  Safety-ECGChanges;  Fluctuationindex;  Maximumplasmaconcentration[C(max)];  Timetomaximumconcentration[T(max)];  Dose-adjustedareaunderthecurve(AUC);  UnifiedParkinson&apos;sDiseaseRatingScale;  Unified Parkinson&apos;s Disease Rating Scale - Motor Part III Only;  EpworthSleepinessScale(ESS);  ColumbiaSuicideSeverityRatingScale(C-SSRS);  Questionnaire for Impulsive-Compulsive Disorders in Parkinson&apos;s disease (QUIP)|20|NCT02579473|December 2015
3355|Enrolling by invitation|Diagnosing Bacterial Vaginosis/Vaginitis (BV) Using the Gynecologene Test Method|||Observational||Industry|Evidence of Confirmed BV Through Next Generation Sequencing Gynecologene Assay;  Comparison of Sensitivity of Gynecologene to Clinical Diagnosis of BV by Nugent Score (Gold Standard);  Comparison of Specificity of Gynecologene to Clinical Diagnosis of BV by Nugent Score (Gold Standard)|300|NCT02558179|September 2015
3356|Recruiting|A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer||Drug:CombinationofVarlilumabandAtezolizumab|Interventional|Phase 1 / Phase 2|Industry|Phase l: Safety and tolerability of varlilumab in combination with atezolizumab as measured by incidence of drug related adverse events (AEs) serious drug related AEs dose-limiting toxicities and laboratory test abnormalities.;  Phasell:ObjectiveResponseRate|55|NCT02543645|October 2015
3357|Active not recruiting|Performance of the ePrime System for Cellulite||Device:ePrime|Interventional||Industry|Improvement in cellulite compared to baseline for the upper thighs and buttocks as assessed by blinded evaluation of clinical photographs;  NumberofParticipantswithAdverseEvents;  Improvementincellulitecomparedtobaseline;  Investigatorsatisfaction-byquestionnaire;  Subjectsatisfaction-byquestionnaire|51|NCT02489994|October 2014
3358|Recruiting|INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function||Drug:INC280|Interventional|Phase 1|Industry|AUClastofINC280;  AUCinfofINC280;  CmaxofINC280;  TmaxofINC280;  T1/2ofINC280;  CL/FofINC280;  Vz/FofINC280;  Adverse events based on the CTCAE v4.03 grade (severity) and frequency and other safety data (e.g. ECG laboratory results);  Unbound fraction and AUClast based on unbound concentration in plasma;  Unbound fraction and AUCinf based on unbound concentration in plasma;  Unbound fraction and Cmax based on unbound concentration in plasma;  Unbound fraction and Tmax based on unbound concentration in plasma;  Unbound fraction and T1/2 based on unbound concentration in plasma;  Unbound fraction and CL/F based on unbound concentration in plasma;  Unbound fraction and Vz/F based on unbound concentration in plasma|36|NCT02474537|June 2015
3359|Recruiting|Safety Study of Inhaled Carbon Monoxide to Treat Acute Respiratory Distress Syndrome (ARDS)||Drug:InhaledCarbonMonoxideat100ppm;  Drug: Placebo for Inhaled Carbon Monoxide at 100ppm;  Drug:InhaledCarbonMonoxideat200ppm;  Drug: Algorthim Specified dose of iCO to achieve COHb of 6-8%;  Drug: Placebo for Inhaled Carbon Monoxide at 200ppm;  Drug: iCO to achieve COHb of 6-8% w/muscle biopsies;  Drug:PlaceboforCohort3|Interventional|Phase 1|Other|Number of administration associated adverse events.;  Comparison between the calculated COHb level at 90 minutes using CFK equation and measured COHb level at 90 minutes;  Mean daily Sequential Organ Failure Assessment (SOFA) score;  PaO2/FiO2ratioandOxygenationIndex;  Acutelunginjury(ALI)score;  Vasopressor-freedays;  ICU-freedays;  Hospital-freedays;  Plasma biomarkers of inflammation lung epithelial injuryendothelial injury markers of change in other end-organ function;  Skeletal muscle biomarkers of mitochondrial biogenesis|48|NCT02425579|April 2015
3360|Completed|A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD||Drug:HLD200|Interventional|Phase 3|Other|Swanson Kotkin Agler M-Flynn and Pelham (SKAMP) combined scores across 8 hours;  Before School Function Questionnaire (BSFQ) total score during early morning|48|NCT02255513|May 2014
3361|Terminated|Trial of High Dose Vitamin D in Patient&apos;s With Crohn&apos;s Disease||Drug:Cholecalciferol10000IU;  Drug:Cholecalciferol400IU|Interventional|Phase 4|Other|PrimaryCompositeOutcome;  Hypercalcemia;  Incidenceofnephrolithiasis;  Crohn&apos;srelatedhospitalizations;  Steroidprescriptions;  Crohn&apos;srelatedsurgeries;  change in modified Harvey-Bradshaw Index (HBI without examination);  ChangeinC-reactiveprotein;  Changesinfecalcalprotectin;  Percentwithescalationoftherapy;  QualityofLifemeasurechanges;  Changeinfatiguemeasurements;  Crohn&apos;srelatedEmergencyDepartment(ED)visits|11|NCT02208310|April 2015
3362|Recruiting|Trial of a Mammography Decision Aid for Women Aged 75 and Older||Other:Mammographydecisionaid;  Other:Homesafetypamphlet|Interventional||Other|Receiptofmammographyscreening;  Screeningintentions;  Knowledge of the pros and cons of mammography screening;  DecisionalConflictScale(DCS);  Decision-makingrole;  PreparationforDecision-Making;  Acceptability;  Anxiety;  Homesafety;  Screeningdiscussions;  Homesafetydiscussions|550|NCT02198690|September 2014
3363|Withdrawn|Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors||Drug:dovitiniblactate;  Other:pharmacologicalstudy;  Other:laboratorybiomarkeranalysis|Interventional|Phase 2|Other / NIH|Progression-freesurvival;  Timetotreatmentfailure;  Timetoprogression;  Overallsurvival;  Durationofresponse;  Biochemical response classified according to RECIST v1.1;  Radiographic response classified according to RECIST v1.1;  Incidence of adverse events graded according to National Cancer Institute (NCI) CTCAE version 4.0|0|NCT02108782|October 2014
3364|Recruiting|A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma||Drug:Panobinostat;  Drug:Dexamethasone;  Drug:Lenalidomide;  Drug:Bortezomib|Interventional|Phase 1|Other / Industry|MTD (Maximum Tolerated Dose) of panobinostat in combination with RVD;  Recommended dose of the combination for Phase 2 studies in participants with relapsed and relapsed/refractory multiple myeloma (MM) with SC bortezomib.;  Responsetopan-RVD(minimalresponseorbetter;  Progression-freesurvival(PFS);  Durationofresponse|28|NCT01965353|October 2013
3365|Completed|NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)||Drug:NT0102;  Drug:Placebo|Interventional|Phase 3|Industry|SKAMP;  PERMP|87|NCT01835548|July 2013
3366|Active not recruiting|Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia||Device:DignicapSystem|Interventional||Industry|Hairloss;  Tolerability;  Adverseevents;  Hairregrowth;  QualityofLife|110|NCT01831024|July 2013
3367|Recruiting|Modifiers of Disease Severity in Cerebral Cavernous Malformations|||Observational||Other / NIH|TotalCCMlesionnumberperpatient;  Changeinlesionnumber;  ModifiedRankinscoreperpatient|800|NCT01764529|July 2009
3368|Completed|Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents||Drug:Latuda&#169;|Interventional|Phase 2|Other|ChangeinWeight;  ProportionofParticipantsCompletingTreatment;  ChangesinEfficacyMeasures;  SideEffects;  OverallClinicalImprovement|10|NCT01731119|December 2012
3369|Recruiting|Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer||Drug:Carboplatin;  Drug:Cisplatin;  Drug:Fluorouracil;  Drug:Hydroxyurea;  Other:LaboratoryBiomarkerAnalysis;  Drug:Paclitaxel;  Other:Placebo;  Radiation:RadiationTherapy;  Drug:Veliparib|Interventional|Phase 1 / Phase 2|NIH|MTD of veliparib graded according to the Common Terminology Criteria for Adverse Events (Phase I);  Relative change in tumor size as measured by RECIST (Phase II);  Disease-freesurvival;  DSS;  OS;  PFS;  Timetolocalordistantprogression;  Toxicityratesduringinductionandoverall|110|NCT01711541|October 2012
3370|Completed|Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years||Biological:C.difficilevaccine;  Biological:C.difficilevaccine+adjuvant|Interventional|Phase 1|Industry|Number subjects reporting local reactions (pain erythema and induration) and their severity as self reported on eDiaries for 7 days following each vaccination.;  Number of subjects reporting systemic reactions (fever vomiting diarrhea headache fatigue new or worsening muscle pain and new or worsening joint pain) and their severity as self reported on eDiaries for 7 days following each vaccination.;  Number of subjects reporting AEs from day 1 (at the time of vaccination) up to 28 days post Dose 3 (visit 9 month 7) and SAEs throughout the study period.;  Number of subjects with abnormal hematology and blood chemistry laboratory assessments after each vaccination dose.;  NeutralizingantibodylevelsatMonth2.;  Neutralizing antibody levels after each vaccination dose.;  Number of subjects in each treatment group with 4 and higher fold-rises in neutralizing antibody levels after each vaccination dose.;  Number of subjects in each treatment group with neutralizing antibody levels &#8805; a specified threshold after each vaccination dose.|192|NCT01706367|September 2012
3371|Recruiting|Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura||Biological:rituximab|Interventional|Phase 2|Other / NIH|Incidence of the composite primary outcome of exacerbation or refractory TTP;  IncidenceofDurableTreatmentResponse;  NumberofdaystoDurableTreatmentResponse;  IncidenceofRelapse;  NumberofdaystoRelapse;  Incidenceofdeath;  Treatment-relatedadverseevents|20|NCT01554514|August 2012
3372|Completed|Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS)||Other:ResistanceExercise;  Other:EnduranceExercise;  Other:Stretching/Range-of-Motion|Interventional||Other|ResistanceExerciseTolerability;  EnduranceExerciseTolerability;  VitalCapacity;  ALSFunctionalRatingScores;  MuscleStrength;  Spasticity;  Fatigue;  QualityofLife|60|NCT01521728|January 2012
3373|Unknown&nbsp;&#8224;|Cardiovascular Effects of Exposure to Ozone|||Observational||Other|Changeinendothelialfunction;  Changeinheartratevariability;  Changeinprothromboticvascularstate;  Changeincardiacrepolarization;  Changeinmarkersofsystemicinflammation;  Changeinlungfunction;  Lunginflammation|90|NCT01487005|January 2012
3374|Completed|A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors||Biological: ALT-836 in combination with gemcitabine|Interventional|Phase 1|Industry|Maximum Tolerated Dose (MTD) of ALT-836 in combination with gemcitabine;  SafetyProfile;  ClinicalBenefit;  ProgressionFreeSurvival;  OverallSurvival;  Pharmacokinetics|30|NCT01325558|May 2011
3375|Completed|Impact of Blood Storage Duration on Physiologic Measures|||Observational|Phase 3|Other / NIH|Changeinthenaroxygenationsaturation;  Changeindownslopeofthenaroxygensaturation;  Changeinupslopeofthenaroxygensaturation;  Changeincerebraloxygenation;  Changeinmicrovascularmeanflowindex;  Changeinpercentperfusedvessels;  Changeincapillarydensityindex;  Changeinthenaroxygensaturation;  Changeinmulti-organdysfunctionscore;  All-causemortality;  Compositeofmajorcardiacevents;  Compositeofmajorpulmonaryevents|390|NCT01274390|January 2011
3376|Completed|Randomized Study of PH-10 for Psoriasis||Drug:PH-10(0.002%RoseBengal);  Drug:PH-10(0.005%RoseBengal);  Drug:PH-10(0.01%RoseBengal);  Drug:Vehicle|Interventional|Phase 2|Industry|The primary efficacy endpoint is &quot;Treatment Success&quot; a static endpoint assessed at Day 29 after initial PH-10 treatment and defined as 0 or 1 on all Psoriasis Severity Index (PSI) components and 0 or 1 on the Plaque Response scale.;  The primary safety endpoint is incidence of adverse experiences including pain and dermatologic/skin toxicity (incidence severity frequency duration and causality).;  Psoriasis Severity Index (PSI) score changes at each visit from Day 1 pre-treatment.;  Plaque Response score changes at each visit from Day 1 pre-treatment.;  Pruritus Self-Assessment score changes at each visit from Day 1 pre-treatment.|99|NCT01247818|December 2010
3377|Terminated|Determination of Safety Efficacy and Pharmacokinetics of &quot;Regorafenib&quot; Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer||Drug: Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed;  Drug: Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed|Interventional|Phase 1|Industry|Number of participants with treatment related toxicities and adverse events and change from baseline in vitals signs and laboratory parameters;  Pharmacokinetics assessments of Alimta Cisplatin and regorafenib in Cycle 1 and 2;  Biomarkers (includes but not limited to plasma protein analysis of angiogenesis-related proteins DNA mutational anaylsis of tumor tissue and plasma);  Tumor Assessments according to Response Evaluation Criteria in Solid Tumors (RECIST) every second cycle|9|NCT01187615|August 2010
3378|Completed|A Study of Safety and Tolerability of Fipamezole in Adult Subjects With Parkinson&apos;s Disease Who Are Receiving Levodopa||Drug:FipamezoleODT;  Drug:Placebo|Observational|Phase 1|Industry|To determine the Maximum Tolerated Dose (MTD) of Fipamezole orally disintegrating tablets (ODT) in adult patients with Parkinson&apos;s disease.;  To assess cardiovascular safety of ascending doses of Fipamezole ODT in adult patients with Parkinson&apos;s disease.;  To evaluate pharmacokinetics (PK) of ascending doses of Fipamezole ODT in adult patients with Parkinson&apos;s disease.;  To assess incidence and severity of Adverse Events|40|NCT01140841|June 2010
3379|Completed                  Has Results|Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade Dysplasia||Drug:Ursodiol;  Other:LaboratoryBiomarkerAnalysis|Interventional|Phase 2|NIH|Reversal of Oxidative DNA Damage as Assessed by Changes in 8-hydroxy-2&apos; -Deoxyguanosine (8OHdG) Immunostaining;  Changes in Gastric Bile Acid Composition Measured by Liquid Chromatography-tandem Mass Spectrometry From Baseline to Post-intervention;  Changes in Cell Proliferation in BE Epithelium From Baseline to Post-intervention as Assessed by Proliferation-related Ki-67 Antigen (Ki67) Immunostaining Percentage of Positively Stained Nuclei in BE Tissue Sections|36|NCT01097304|April 2010
3380|Unknown&nbsp;&#8224;|Ofatumumab Pentostatin and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma||Drug:pentostatin;  Drug:cyclophosphamide;  Biological:ofatumumab;  Procedure:laboratorybiomarkeranalysis;  Other:flowcytometry;  Genetic:proteinexpressionanalysis|Interventional|Phase 2|Other|ArmA:Proportionofcompleteresponses;  ArmB:Treatment-freeSurvivalat18months;  Overallresponserate;  Completeresponserate;  Depthofresponseafterofatumumabconsolidation;  Progression-freesurvival;  Treatment-freesurvival;  Durationofresponse;  Differences in the distributions of risk factors (VH gene mutation CD38 CD49d ZAP-70 and FISH status) by clinical outcome (responders vs nonresponders);  Adverseevents|82|NCT01024010|August 2010
3381|Completed|Evaluating an Emergency Department Observation Syncope Protocol for Older Adults||Other:EmergencyDepartmentObservationProtocol;  Other:Unstructuredinpatientevaluation|Interventional||Other / NIH|AdmissionRate;  30dayclinicaloutcomes;  Qualityoflife;  Cost|123|NCT01003262|March 2010
3382|Completed|Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors||Drug:I-131-CLR1404|Interventional|Phase 1|Industry|Calculate whole body and organ radiation dosimetry of I-131-CLR1404 to determine the millicurie dose which is expected to deliver 35-40 centigray of radiation to bone marrow;  To determine the safety and pharmacokinetic profile of I-131-CLR1404|9|NCT00925275|June 2009
3383|Completed|Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)||Drug:GSK1265744;  Drug:Placebo|Interventional|Phase 2|Industry|Change from plasma HIV-1 ribonucleic acid (RNA) to Day 1;  GSK1265744 PK parameters following dose administration on Day 1 and 10: AUC(0-24);  GSK1265744 PK parameters following last repeat administration on Day 10:AUC(0-tau);  Safetyandtolerability:adverseevents(AEs);  Safety and tolerability: clinical laboratory results;  Safetyandtolerability:vitalsigns;  Safety and tolerability: electrocardiogram (ECG) assessments;  GSK1265744 PK parameters following dose administration on Day 1 and 10: Cmax;  GSK1265744 PK parameters following dose administration on Day 1 and 10: tmax;  GSK1265744 PK parameters following dose administration on Day 1 and 10: concentration at 24 hrs post dose(C24);  GSK1265744 PK parameters following dose administration on Day 1 and 10: terminal half-life(t1/2);  GSK1265744 PK parameters following dose administration on Day 1 and 10: absorption lag time(tlag);  GSK1265744 PK parameters following last repeat administration on Day 10: predose concentration(C0);  GSK1265744 PK parameters following last repeat administration on Day 10: concentration at end of dosing interval(Ctau);  GSK1265744 PK parameters following last repeat administration on Day 10: minimum observed concentration during one dosing interval(Cmin);  GSK1265744 PK parameters following last repeat administration on Day 10: Cmax;  GSK1265744 PK parameters following last repeat administration on Day 10: tmax;  GSK1265744 PK parameters following last repeat administration on Day 10: t1/2;  GSK1265744 PK parameters following last repeat administration on Day 10: Apparent clearance following oral dosing (CL/F);  ChangefrombaselineinplasmaHIV-1RNA;  Change from baseline in plasma HIV-1 RNA to nadir (maximum change) over 11 days;  PlasmaHIV-1RNArateofdecline(slope);  Proportion of subjects with HIV-1 RNA&lt;400 copies/mL;  Proportion of subjects with HIV-1 RNA&lt;50 copies/mL;  ChangefrombaselineinCD4+cellcounttoDay11;  Emergence of drug resistance mutations if appropriate;  GSK1265744 Day 10 AUC(0-tau) compared to Day 1 AUC(0-24) to estimate accumulation ratios (R) for AUC;  Pre-morning dose concentrations (C0) on Day 2 through 10 to assess the achievement of steady state of GSK1265744 following repeat administration;  GSK1265744 Day 10 Cmax compared to Day 1 Cmax to estimate accumulation ratios (R) for Cmax;  GSK1265744 Day 10 Ctau compared to Day 1 C24 to estimate accumulation ratios (R) for Ctau|9|NCT00920426|June 2009
3384|Completed|DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer||Genetic:DNAmethylationanalysis;  Genetic:microarrayanalysis;  Genetic:polymerasechainreaction;  Other:laboratorybiomarkeranalysis|Observational||Other / NIH|Correlation of changes in gene marker methylation with progression at 9-12 weeks;  Changes in methylated gene markers from baseline after 3-4 weeks and after 9-12 weeks;  Effects of common exposures (i.e. alcohol smoking medications and dietary factors) on patterns of serum methylation;  Creation of a predictive model of DNA methylation profiles;  Correlation of gene marker methlyation with survival;  Correlation of gene marker methlyation with time to progression;  Correlation of circulating tumor cells (CTCs) with clinical outcome;  CorrelationofCTCswithserummethylation;  Determination if the addition of CTCs to serum methylation results in an improved predictive model|249|NCT00899548|September 2006
3385|Completed|Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors||Drug:ABT-263;  Drug:paclitaxel|Interventional|Phase 1|Industry|SafetyAssessment;  EfficacyAssessment|19|NCT00891605|July 2009
3386|Completed                  Has Results|Pharmacokinetics and Safety of Piperacillin-tazobactam in Neonates||Drug:piperacillin-tazobactam|Interventional|Phase 1|Other|PiperacillinPharmacokinetics(PK)|32|NCT00873327|October 2009
3387|Completed|Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics||Drug:AripiprazoleorPerphenazine;  Drug:Metformin;  Drug: Olanzapine quetiapine risperidone ziprasidone aripiprazole asenapine iloperidone lurasidone paliperidone or olanzapine/fluoxetine|Interventional|Phase 4|Other / NIH|Bodymassindex(BMI)z-scorechange;  Bodyfatmass;  Wholebodyinsulinsensitivityindex;  Triglyceridelevels;  Lowdensitylipoprotein(LDL)-cholesterollevel;  Metabolicsyndrome|127|NCT00806234|January 2009
3388|Completed                  Has Results|Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel Dacarbazine||Drug:Ipilimumab;  Drug:Carboplatin;  Drug:Paclitaxel;  Drug:Dacarbazine|Interventional|Phase 1|Industry|Pharmacokinetic Parameter Maximum Observed Serum Concentration (Cmax) for Ipilimumab Paclitaxel Dacarbazine and the Active Metabolite for Dacarbazine 5-aminoimidazole-4carboxamide (AIC)- Pharmacokinetic Analysis Population;  Area Under the Concentration Time Curve (AUC) From Time Zero to 21 Days [AUC(0-21d)] for Ipilimumab and AUC Time Zero Extrapolated to Infinity [AUC(INF)] for Paclitaxel Dacarbazine and the Active Metabolite AIC - Pharmacokinetic Analysis Population;  Pharmacokinetic Parameter of Time of Maximum Observed Concentration (Tmax) for Ipilimumab Paclitaxel Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population;  Pharmacokinetic Parameter of Terminal Elimination Half Life (T-HALF) for Ipilimumab Paclitaxel Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population;  Pharmacokinetic Parameter of Clearance (CLT) for Ipilimumab Paclitaxel Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population;  Pharmacokinetic Parameter Volume of Distribution at Steady State (Vss) for Ipilimumab Paclitaxel Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population;  Number of Participants in Best Overall Response Categories Based on Modified World Health Organization (mWHO) Criteria - All Treated Participants;  Number of Participants in Best Overall Response Categories Based on Immune Related (ir) Response Criteria (RC) - All Treated Participants;  Number of Participants With Objective Response to Treatment and Disease Control Using mWHO Criteria - All Randomized Participants;  Number of Participants With Adverse Events Serious Adverse Events Deaths and Discontinuation Due to Adverse Events From Day 1 to Week 48 - All Treated Population;  Mean Absolute Lymphocyte Count (ALC) at Each Nominal Ipilimumab Induction Dose and at End of the Induction Period - Pharmacodynamic Population;  Mean Change From Baseline at Weeks 16 and 48 in Diastolic and Systolic Blood Pressure - All Treated Population;  Mean Change From Baseline in Pulse Rate at Weeks 16 and 48 - All Treated Population;  Mean Change From Baseline in Respiration Rate at Weeks 16 and 48 - All Treated Population;  Mean Baseline Change in Body Temperature at Weeks 16 and 48 - All Treated Population;  Number of Participants on Treatment With Toxicity Changes From Baseline by Worst Common Terminology Criteria (CTC) Grade for Hemoglobin - All Treated Population;  Number of Participants on Treatment With Toxicity Changes From Baseline by Worst Common Terminology Criteria (CTC) Grade for Leukocytes - All Treated Population;  Number of Participants on Treatment With Toxicity Changes From Baseline by Worst Common Terminology Criteria (CTC) Grade for Lymphocytes - All Treated Population;  Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Neutrophils - All Treated Population;  Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Neutrophils Plus Bands - All Treated Population;  Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Platelet Count - All Treated Population;  Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Alanine Aminotransferase (ALT) - All Treated Population;  Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Aspartate Aminotransferase (AST) - All Treated Population;  Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Albumin - All Treated Population;  Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Alkaline Phosphatase - All Treated Population;  Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Bilirubin - All Treated Population;  Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Serum Potassium (High) - All Treated Population;  Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Amylase - All Treated Population;  Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Calcium (High) - All Treated Population;  Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Lipase - All Treated Population;  Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Uric Acid - All Treated Population|72|NCT00796991|February 2009
3389|Terminated|Comparative Evaluation of Albumin and Starch Effects in Acute Lung Injury (ALI)||Drug:5%humanalbumin;  Drug:6%hetastarch|Interventional|Phase 3|Other|Changeinextravascularlungwater(EVLW);  Changeinoxygenation(PaO2/FiO2ratio);  Duration of mechanical ventilation (ventilator-free days)|31|NCT00796419|January 2009
3390|Unknown&nbsp;&#8224;|Safety and Efficacy Study of an Ophthalmic Solution in Patients With Age-Related Cataract||Drug:C-KADOphthalmicSolution;  Drug:Placebo|Interventional|Phase 2|Industry|Best-correctedvisualacuitybyETDRS|80|NCT00793091|November 2008
3391|Completed|Patient Outcomes Evaluation of the EBI Vuelock&#8482; Anterior Cervical Plate System||Device:VueLock&#8482;AnteriorCervicalPlate|Observational||Industry|ProportionofPatientswithradiographicfusion;  Neck Disability Index and SF-36 scores change from baseline|371|NCT00726128|August 1998
3392|Completed|Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer||Drug:TRC105chimericanti-CD105antibody|Interventional|Phase 1|Industry|SafetyandTolerabilitywillbeevaluated;  DoseLimitingToxicities;  PharmacokineticsofTRC105monoclonalantibody;  Numberofresponsesbytumortype|51|NCT00582985|December 2007
3393|Completed|Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin&apos;s Lymphoma||Drug:IDEC-114|Interventional|Phase 1 / Phase 2|Industry|To characterize the safety profile of IDEC-114 and to define their duration and reversibility;  ToevaluatePK;  To monitor presence of human anti galiximab antibody;  Toevaluateefficacy;  To identify Nk functional assays that may predict galiximab efficacy|42|NCT00575068|January 2002
3394|Completed                  Has Results|DePuy Trochanteric (ATN) Nailing Clinical Outcomes Trial||Device:Intramedullarynailing|Interventional|Phase 4|Industry|SuccessinTermsoftheMerleD&apos;AubigneScore;  LowerExtremityMeasure(LEM);  MedicalImaging;  SixItemScreenerandAmbulatoryStatus;  SF-12;  Merled&apos;AubigneandPostel|62|NCT00546429|September 2006
3395|Terminated|Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies||Drug:XL228|Interventional|Phase 1|Industry|To assess the safety and tolerability of XL228 administered as a once-weekly or twice-weekly 1-hour intravenous (IV) infusion in subjects with advanced malignancies.;  To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of XL228 administered as a once- or twice-weekly 1-hour IV infusion in subjects with advanced malignancies.;  To evaluate plasma pharmacokinetics of XL228 administered as a once- or twice-weekly 1-hour IV infusion in subjects with advanced malignancies.;  To evaluate preliminary safety and efficacy of XL228 when administered at the once-weekly MTD|84|NCT00526838|September 2007
3396|Completed|Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors||Drug:SNS-314|Interventional|Phase 1|Industry|ToassessthesafetyandtolerabilityofSNS-314|50|NCT00519662|August 2007
3397|Completed|A Study to Evaluate the Effects of Pharmacological Chaperones in Cells From Patients With Pompe Disease||Other:Observation|Observational||Industry|To evaluate and characterize the effects of pharmacological chaperones on enzyme activity and other markers of disease in cell lines derived from patients with Pompe disease;  To study biomarkers associated with Pompe Disease and study the correlation between biomarkers and clinical disease state of patients with Pompe disease|30|NCT00515398|August 2007
3398|Completed                  Has Results|Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma||Drug:Avastin;  Drug:Docetaxel|Interventional|Phase 2|Other / NIH / Industry|SixMonthProgressionFreeSurvival(PFS);  MedianProgressionFreeSurvival;  OverallResponseRate(RR);  OccurrenceofGrade3or4Toxicity;  OverallSurvival(OS)|45|NCT00504257|March 2007
3399|Completed                  Has Results|Safety Study of Ziprasidone (Geodon) for the Depressive Mixed State||Drug:ziprasidone(Geodon);  Drug:placebo|Interventional|Phase 2|Other / Industry|The Primary Outcome Measure Was Change in Montgomery-Asberg Depression Rating Scale (MADRS) Scores Over Weeks Between Groups.|73|NCT00490542|December 2006
3400|Completed|Multi-Center Pre-Bariatric Weight Loss Study||Device: GI Sleeve Implantable weight loss device (EndoBarrier);  Procedure:ShamProcedure|Interventional|Phase 2|Industry|WeightLoss|69|NCT00469391|June 2007
3401|Completed                  Has Results|A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies||Biological:MDX-1106|Interventional|Phase 1|Industry|Number of Participants With Severe Adverse Events (AEs) Serious Adverse Events (SAEs) Drug-Related AEs Deaths Discontinuation of Study Drug Due to AE Dose-Limiting Toxicity (DLT) AE and Immune-related AEs (irAEs) in Safety Population;  Geometric Mean Maximum Serum Concentration (Cmax) Observed Post-Single Dose;  Median Time at Which the Maximum Serum Concentration Occurred (Tmax) Post-Single Dose;  Geometric Mean Area Under the Curve (AUC) From Time of Dosing to Time of Last Observation (0-T) and Extrapolated to Infinity (INF) Observed Post-Single Dose;  Mean Elimination Half-life (T-HALF) Post-Single Dose;  Geometric Mean Total Body Clearance of Drug From Serum (CLT) Post-Single Dose;  MeanVolumeofDistribution(Vz)Post-SingleDose;  Percent of Participants With Best Overall Response Rate in Safety Population and in Tumor Evaluable Population;  Percent of Participants With Prostate-Specific Antigen (PSA) Response After the First Dose by Day 85 In Participants With Hormone-Refractory Prostate Adenocarcinoma (HRPC);  Number of Participants With Best Overall Response (BOR) by Category in Safety Population;  Percentage of Participants With Disease Control and Major Durable Disease Control;  Median Time to Tumor Response and Duration of Tumor Response;  Time to Tumor Progression and Tumor Progression Free Survival;  Median Time to PSA Progression in Days and Median PSA Progression Free Survival in Days in PSA Evaluable Population;  Mean Change From Baseline in PSA Relative Velocity at Days 29 57 and 85 With Cycle 1 in PSA Evaluable Population;  Mean Change From Baseline in Electrocardiogram Parameters PR QRS and QT in Safety Population;  Mean Diastolic Blood Pressure at Baseline and Post-Infusion Day 1 (Cycle 1) in 0.3 mg Cohort - Safety Population;  Mean Systolic Blood Pressure at Baseline and Post-Infusion Day 1 (Cycle 1) in 0.3 mg Cohort - Safety Population;  Mean Diastolic Blood Pressure at Baseline and Post-Infusion Day 1 (Cycle 1) in 1mg 3mg and 10 mg Cohorts - Safety Population;  Mean Systolic Blood Pressure at Baseline and Post-Infusion Day 1 (Cycle 1) in in 1mg 3mg and 10 mg Cohorts - Safety Population|39|NCT00441337|August 2006
3402|Completed|Educational Program for Various Health Literacy Levels to Improve the Health of Individuals With Heart Failure||Behavioral:TeachtoGoal(TTG);  Behavioral:BriefEducationalIntervention(BEI)|Interventional||Other / NIH|Allcausehospitalization;  Allcausemortality;  Heartfailurequality-of-life;  Heartfailure-relatedhospitalizations;  Difference between groups for adoption of appropriate self-management knowledge and behaviors|605|NCT00378950|March 2007
3403|Completed                  Has Results|NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)||Drug:Tinidazole;  Other:Placebo;  Drug:Doxycycline;  Drug:Azithromycin|Interventional|Phase 2|NIH|Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Nausea;  Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Vomiting;  Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Stomach Upset;  Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting of Abdominal Pain;  Safety and Tolerability of Doxycycline/Tinidazole and Azithromycin/Tinidazole: Number of Participants Reporting Diarrhea;  Percentage of Participants Achieving Clinical Cure of Non-gonococcal Urethritis (NGU) With Doxycycline Versus Doxycycline With Tinidazole; and Azithromycin Versus Azithromycin With Tinidazole;  Percentage of Participants Achieving Clinical Cure of NGU With (Doxycycline Plus Doxycycline/Tinidazole) Versus (Azithromycin Plus Azithromycin/Tinidazole);  Percentage of Participants Achieving Microbiological Cure of Chlamydia Trachomatis With Doxycycline Versus Doxycycline With Tinidazole; and Azithromycin Versus Azithromycin With Tinidazole;  Percentage of Participants Achieving Microbiological Cure of Trichomonas Vaginalis With Doxycycline Versus Doxycycline With Tinidazole; and Azithromycin Versus Azithromycin With Tinidazole;  Percentage of Participants Achieving Microbiological Cure of Mycoplasma Genitalium With Doxycycline Versus Doxycycline With Tinidazole; and Azithromycin Versus Azithromycin With Tinidazole;  Prevalence of Chlamydia Trachomatis in Men With Non-gonococcal Urethritis;  Prevalence of Trichomonas Vaginalis (Swab or Urine Specimen) in Men With Non-gonococcal Urethritis;  Prevalence of Mycoplasma Genitalium in Men With Non-gonococcal Urethritis;  Clinical Behavioral and Demographic Predictors of Chlamydia Trachomatis in Men With Non-gonococcal Urethritis;  Clinical Behavioral and Demographic Predictors of Trichomonas Vaginalis in Men With Non-gonococcal Urethritis;  Clinical Behavioral and Demographic Predictors of Mycoplasma Genitalium in Men With Non-gonococcal Urethritis;  Specimens for Future Studies to Determine the Role of Unique and Novel Pathogens in the Etiology of Non-gonococcal Urethritis|305|NCT00322465|November 2006
3404|Active not recruiting|Phase II Trial of Bevacizumab in Combination With Pemetrexed as 2nd Line Therapy in Patients With Stable Brain Metastases From Non-small Cell Lung Cancer||Drug:Bevacizumab;  Drug:Pemetrexed;  Drug:VitaminB12;  Drug:folate;  Drug:dexamethasone|Interventional|Phase 2|Other / Industry|Safety of combining bevacizumab and pemetrexed in non-small cell lung cancer (NSCLC) patients with stable brain metastases;  Progression free survival (PFS) and overall survival;  tumorcontamination|40|NCT00227019|March 2006
3405|Completed|Comparison of PolyethyleneGlycol and Placebo for Relief of Constipation From Constipating Medications||Drug:polyethyleneglycol3350|Interventional|Phase 4|Industry|A successful outcome is defined as no longer meeting the definition of constipation using ROME I criteria;  AnalysisofindividualROMEIcriteria;  Safety(adverseeventandlaboratorytesting)|100|NCT00153127|November 2001
3406|Completed|Letrozole Herceptin in Her2neu + Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive MBC||Drug:Letrozole;  Drug:Trastuzumab|Interventional|Phase 2|Other / Industry|To determine the proportion of patients with ER and/or PR positive ErbB2 positive tamoxifen resistant metastatic breast cancer who achieve complete remission (CR);  orpartialremission(PR);  or no significant change in lesion size for greater than 24 weeks;  To determine duration of response and median time to progression with letrozole plus trastuzumab treatment;  To evaluate the clinical adverse experience during treatment with letrozole plus trastuzumab treatment;  To generate a tumor and serum bank from patients receiving combination trastuzumab and letrozole treatment;  To analyze ErbB2 expression on circulating malignant cells during treatment with letrozole and trastuzumab|33|NCT00134680|January 2000
3407|Completed|A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy||Drug:Abacavirsulfate;  Drug:Emtricitabine;  Drug:Lamivudine;  Drug:Lopinavir/ritonavir;  Drug:Saquinavir;  Drug:Tenofovirdisoproxilfumarate;  Drug:Zidovudine|Interventional|Phase 2|NIH|Tolerability of dual PI-based HAART versus multi-NRTI HAART salvage regimens (time to first intolerant event);  95% confidence interval (CI) for change in CD4% computed for PI-containing groups versus PI-sparing group;  95% CI for change in BMD (both percent change in BMD and change in z-score from baseline) for each treatment group;  HIV-1RNA;  growthanddevelopmentmarkers;  toxicity;  adherence;  pharmacokinetics;  specialvirologicandimmunologicparameters|6|NCT00102206|
3408|Completed|Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors||Drug:SNS-595|Interventional|Phase 1|Industry|||NCT00094159|October 2004
3409|Completed|Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.||Drug:SNS-595|Interventional|Phase 1|Industry|||NCT00091585|June 2004
3410|Completed|Buprenorphine/Naloxone - Facilitated Rehabilitation for Opioid Dependent Adolescents - 1||Drug:Buprenorphine/naloxone|Interventional|Phase 3|Other|Opiateabstinence|223|NCT00078130|July 2003
3411|Completed|Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small Cell Lung Cancer||Drug:celecoxib;  Procedure:adjuvanttherapy|Interventional|Phase 2|Other / NIH|||NCT00058006|September 2002
3412|Completed|NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma Multiforme||Biological:interleukin-4PE38KDELcytotoxin;  Procedure:conventionalsurgery|Interventional|Phase 2|Industry|||NCT00014677|March 2001
3413|Completed|Patient Education in Preventing Nausea and Vomiting in Cancer Patients Receiving Chemotherapy||Drug:ondansetron|Interventional||Other / NIH|||NCT00005994|August 2000
3414|Completed|Etoposide in Treating Patients With Relapsed Non-Hodgkin&apos;s Lymphoma||Drug:Etoposidephosphate|Interventional|Phase 2|Other / NIH|Pharmacodynamicsofetoposide;  Response|53|NCT00002880|November 1996
3415|Completed|The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS||Drug:Zidovudine;  Drug:Sargramostim;  Drug:Ganciclovir|Interventional||NIH / Industry||50|NCT00000989|
3416|Completed|A Phase I Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected Persons||Drug:Alvirceptsudotox;  Drug:Zidovudine|Interventional|Phase 1|NIH / Industry||64|NCT00000743|
3417|Completed|Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer||Drug:carboplatin;  Drug:etoposide;  Drug:topotecanhydrochloride;  Radiation:radiationtherapy|Interventional|Phase 2|Other / NIH|Responserate;  Durationofresponse;  Failure-freeandoverallsurvival;  Pharmacokinetics and pharmacodynamics of topotecan and etoposide||NCT00025272|November 2001
3418|Unknown&nbsp;&#8224;|Safety Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma||Drug:PRLX93936|Interventional|Phase 1 / Phase 2|Industry|MaximumToleratedDose;  Responsetotreatment;  Timetoresponse;  Durationofresponse;  Timetoprogression|40|NCT01695590|March 2012
3419|Completed|Validation of PROMIS Banks With COPD Exacerbations|||Observational||Other||188|NCT00784342|July 2008
3420|Completed|The MIND Study: Modifying the INcidence of Delirium||Drug:Ziprasidone;  Drug:Haloperidol;  Other:Placebo|Interventional|Phase 2|Other|Days alive and free of delirium and coma (delirium and coma free days);  Severity of neuropsychological dysfunction at hospital discharge;  aliveandfreeofdelirium(deliriumfreedays);  Lengthofstayonmechanicalventilation;  Mechanicalventilationfreedays;  lengthofstayintheICU;  Lengthofstayinthehospital;  hospitalmortality;  mortalityat1year|102|NCT00096863|December 2004
3421|Completed|Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma||Drug:procarbazinehydrochloride;  Drug:thalidomide|Interventional|Phase 2|Other / NIH|Response rate by CT scan and MRI at baseline pre-odd cycles and study completion;  Progression-free survival by CT scan MRI and follow up form at baseline pre-odd cycles and study completion;  Overall survival by follow-up form at study completion;  Quality of life by FACT-Br FACIT-F and Karnofsky performance status (PS) at baseline pre-odd cycles and study completion;  Toxicity by evaluation form at baseline pre-odd cycles and study completion|55|NCT00079092|January 2004
3422|Completed|Radiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases||Drug:temozolomide;  Drug:thalidomide;  Radiation:radiationtherapy|Interventional|Phase 2|Other / NIH|Overallmediansurvival;  Radiographic response rate as assessed by MRI and RECIST one-dimensional criterion at 1 month 3 months and every 3 months thereafter;  Mediantimetotumorprogression;  Median time to neurologic response and progression;  Causeofdeathatmediantime;  Quality of life as assessed by FACT-BT FACT-F and Beck Depression Inventory at 1 month 3 months and every 3 months thereafter;  Toxicity as assessed by NCI Common Toxicity Criteria (CTC) version 2.0 for up to 90 days||NCT00049361|January 2004
3423|Completed|Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer||Drug:carboplatin;  Drug:irinotecanhydrochloride;  Drug:thalidomide|Interventional|Phase 2|Other / NIH|||NCT00025285|November 2001
3424|Completed|Open-Label Study of OTO-201 for Treatment of AOMT||Drug:OTO-201|Interventional|Phase 2|Industry|Safety as assessed by adverse events and otoscopic exams;  Feasibilityofadministration;  Clinical effect as assessed by the Absence of otorrhea|39|NCT02408796|March 2015
3425|Completed|A Study of the Efficacy and Safety of ETC-1002 in Subjects With Statin Intolerance||Drug:ETC-1002;  Drug:Placebo|Interventional|Phase 2|Industry|PercentchangefrombaselineinLDL-C;  Percent change from baseline in other lipids and cardio-metabolic risk factors;  PercentachievingLDL-Cgoal;  Numberofsubjectswithadverseevents;  Number of subjects with muscle related adverse events|56|NCT01751984|October 2012
3426|Active not recruiting|Knee Arthroplasty Pain Coping Skills Training (KASTPain): A Randomized Trial||Behavioral:PainCopingSkillsTraining;  Behavioral:ArthritisEducation;  Other:UsualCare|Interventional|Phase 3|Other / NIH|Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Scale;  WOMACPhysicalFunctionScale;  0to10verbalpainratingscale;  PainCatastrophizingScale;  GlobalRatingofChangeScale;  Patient Health Questionnaire (PHQ-8) Depression Scale;  EuroQol(EQ-5D-5L);  Healthcarerelatedcostdiary;  WOMACPainScale;  Six-minuteWalkTest;  ShortPhysicalPerformanceBattery|402|NCT01620983|December 2012
3427|Completed                  Has Results|Randomized Single Blind Placebo Controlled to Evaluate Efficacy and Safety of Polidocanol Injectable Foam for Treatment of Symptomatic Visible Varicose Veins With SFJ Incompetence||Drug: Varisolve (Polidocanol Endovenous Microfoam);  Drug:AgitatedSaline|Interventional|Phase 2 / Phase 3|Other|The Absolute Change From Baseline Score for the VVSymQ (Total Score) at 8 Weeks|77|NCT00758420|October 2008
3428|Completed|Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma||Drug:OT-730ophthalmicsolution;  Drug:timololmaleateophthalmicsolution;  Drug:OT-730placebo|Interventional|Phase 1 / Phase 2|Industry|AssessthesafetyprofileofOT-730;  Changefrombaselineinintraocularpressure|48|NCT00753168|September 2008
3429|Completed|Tolerability Safety and Efficacy of RKI983 Eye Drops in Subjects With Primary Open Angle Glaucoma and Ocular Hypertension||Drug:RKI983|Interventional|Phase 1|Industry|Rates of adverse events and serious adverse events as well as changes in ophthalmic evaluations laboratory values ECGs and vital signs over period of 7 days treatment.;  Change in ocular hypertension from Baseline to Day 7.|90|NCT00515424|July 2007
3430|Completed|Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer||Drug:paclitaxel|Interventional|Phase 2|Other / NIH|ResponseRate;  Progression-freesurvival;  Overallsurvival;  Overallresponse;  Toxicity|36|NCT00005646|April 2000
3431|Completed                  Has Results|The Esteem&#174; Hearing Implant Post Approval Study||Device:TheEsteemHearingImplant|Observational|Phase 4|Industry|Change From Baseline (Pre-implant Aided Condition) at Year 5 in Speech Reception Threshold (SRT);  Change From Baseline (Pre-implant Aided Condition) at Year 5 in Word Recognition Score (WRS) at 50 dB HL;  Incidence of Serious Adverse Device Events (SADEs) and Device Failures and Replacements at Each Follow-up.;  BoneConductionStability;  Improvement in Quality of Life as Reflected by Abbreviated Profile of Hearing Aid Benefit (APHAB) Questionnaire|51|NCT02666222|August 2010
3432|Completed                  Has Results|Esteem Totally Implantable Hearing System||Device:EsteemTotallyImplantableHearingSystem|Interventional||Industry|SRTImprovement;  WordRecognitionScoreImprovement;  SADEs;  AssessmentofCochlearFunction;  PTAImprovement;  QuickSIN;  APHAB;  EsteemQuestionnaire|57|NCT01092910|January 2008
3433|Terminated|An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn&apos;s Disease||Drug:AIN457|Interventional|Phase 2|Industry|To assess the long-term safety and tolerability of AIN457 in patients with moderate to severe Crohn&apos;s disease who participated in the core CAIN457A2202 phase II proof-of-concept study.;  ToassessthelongtermimmunogenicityofAIN457;  To assess the long term concentration of IL-17 in blood;  To assess markers of disease activity CRP calprotectin and lactoferrin in the long term;  To assess the pharmacokinetics of AIN457 at steady-state|7|NCT01009281|October 2009
3434|Completed|A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer Severe Infection Related to Bone Marrow Transplantation||Drug:DrotrecoginAlfa(activated)|Interventional|Phase 4|Industry|Safety;  Mortality;  Bleedingincidence|7|NCT00067730|March 2003
3435|Active not recruiting|Effectiveness of an mHealth Colorectal Cancer Screening Intervention||Behavioral:mCRCintervention;  Behavioral:HealthyLifestylesvideo|Interventional||Other / NIH|CompletionofCRCScreening;  CRCScreeningAttitudesandBeliefs;  IntentiontoreceiveCRCscreening;  Self-efficacy;  Abilitytomakeascreeningdecision;  CRCscreeningdiscussions;  Satisfactionwithscreeningdecision;  CRCscreeningtestorder;  CostofthemCRCintervention;  UsabilityofthemCRCsystem|450|NCT02088333|June 2014
3436|Active not recruiting|Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment|||Observational||Other|Therapeuticresponsetoisotretinoin;  Adversereacciontoisotretinoin|250|NCT01727440|September 2011
3437|Active not recruiting|The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort|||Observational||Other|Serum-based proteomic biomarkers associated with disease initiation and progression in MS|1000|NCT01723709|June 2010
3438|Active not recruiting|Implementing a Physical and Cognitive Performance Assessment Cohort in the MURDOCK Study Community Registry and Biorepository||Genetic:Biomarkerstudies|Observational||Other|Implementing a Physical and Cognitive Performance Assessment Cohort in the MURDOCK Study Community Registry and Biorepository|1000|NCT01720472|May 2012
3439|Completed|The Weight-Wise Weight Loss Translation Study||Behavioral:SpecialIntervention;  Behavioral:DelayedIntervention|Interventional||Other / U.S. Fed|Weight Change difference between baseline and 4 month follow-up;  Change in blood pressure dietary intake physical activity and quality of life between baseline and 4 month follow-up|189|NCT01141348|January 2009
3440|Completed|Hormonal and Environmental Risk Factors for Developing Systemic Lupus Erythematosus: The Carolina Lupus (CLU) Study|||Observational||NIH||640|NCT00342095|December 1996
3441|Completed|Reducing Symptoms of Depression in Low-Income Mothers||Behavioral:ModifiedInterpersonalTherapy;  Behavioral:Attentioncontrol/usualcare|Interventional|Phase 2|Other / NIH|Levelofdepressivesymptoms;  Motherchildinteractions|226|NCT00074789|June 2003
3442|Recruiting|Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer||Drug:5-Fluorouracil;  Drug:Leucovorin;  Drug:Irinotecan;  Drug:Bevacizumab|Interventional|Phase 2|Other|ProgressionFreeSurvival;  Toxicity;  OverallResponse;  OverallSurvival|100|NCT02138617|May 2014
3443|Completed|Combination Chemotherapy in Treating Women With Breast Cancer That is Metastatic or Cannot be Treated With Surgery||Drug:docetaxel;  Drug:fluorouracil|Interventional|Phase 2|Other / NIH|To determine the response rate to this combination after two to four courses of Docetaxel (Taxotere) And 5-Fluorouracil;  To evaluate toxicities of Docetaxel (Taxotere) And 5-Fluorouracil|25|NCT00015886|January 1997
3444|Completed|A Non-Invasive Neuromodulation Device for Treatment of Migraine Headache||Device: neuromodulation for episodic migraine headache|Interventional||Industry|Numberofmonthlymigraineheadachedays;  Number of monthly migraine headache days (reduction by by 50% or more);  Totalmonthlypainscore;  Mood and cognition measures - Change in mood scores;  Verifytheabsenceofmaterialdizziness;  Mood and cognition measures - Change in cognitive speed scores;  Mood and cognition measures - Change in memory scores|81|NCT01899040|August 2013
3445|Active not recruiting|Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed Non-Bulky Stage I/II Hodgkin Lymphoma||Drug:Brentuximabvedotin;  Drug:ABVD|Interventional||Other / Industry|Feasibility;  ResponseRate;  ProgressionFreeSurvival;  TimetoProgression;  Toxicity|41|NCT01578967|April 2012
3446|Completed|Sertraline Compared With Hypericum Perforatum (St.John&apos;s Wort) in Treating Depression||Drug:Zoloft50mg;  DietarySupplement:St.John&apos;sWort600mg|Interventional|Phase 3|Other / NIH|Depression severity as measured by Hamilton Depression rating scale.;  Somnolence nausea and insomnia as assessed by the NCI Common Toxicity Criteria. The Epworth Sleepiness Scale will also be used to assess somnolence.;  Fatigue as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue Scale.|2|NCT00066859|March 2004
3447|Recruiting|Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Children||Drug:Amoxicillin;  Drug:Amoxicillin-clavulanate;  Drug:Cefdinir;  Other:Placebo|Interventional|Phase 4|NIH|DesirabilityofOutcomeRanking(DOOR);  Adequate clinical response rates (a component of DOOR);  Frequencyofsolicitedevents;  Receipt of non-study systemic antibiotics for all causes during medically attended visits;  Receipt of non-study systemic antibiotics for persistent or worsening pneumonia during medically attended visits;  Resolutionofsymptoms(acomponentofDOOR)|400|NCT02891915|October 2016
3448|Active not recruiting|A Smoking Cessation Study to Understand the Biological and Functional Changes After One Year of Smoking Cessation|||Observational||Industry|LevelsofhighdensitylipoproteinC(HDL-C).;  Levelsofwhitebloodcells(WBC).;  Post-bronchodilator forced expiratory volume in 1 second (FEV1).;  Concentrations of soluble intercellular adhesion molecule 1 (sICAM-1).;  Concentrations of 11-dehydrothromboxane B2 (11-DTXB2).;  Concentrations of 8-epi-prostaglandin F2&#945; (8-epi-PGF2&#945;).;  Concentrations of total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (total NNAL).;  Levelsofcarboxyhemoglobin(COHb).|1020|NCT02432729|May 2015
3449|Completed|Zenapro&#8482; Hybrid Hernia Repair Device for Ventral Hernia Repair||Device:HybridGraft|Observational||Industry|Rateofherniarecurrence|63|NCT01784822|February 2013
3450|Unknown&nbsp;&#8224;|A Pharmacogenomic Exploration of Lacosamide Response|||Observational||Other|Seizurefrequency;  Maintenancedose;  Adversedrugreactions|660|NCT01399528|September 2011
3451|Unknown&nbsp;&#8224;|CT Coronary Angiogram Versus Traditional Care in Emergency Department Assessment of Potential ACS||Procedure:CTCoronaryAngiography;  Procedure:TraditionalStandardofCare|Interventional|Phase 4|Other|To estimate the rate of major cardiac events (AMI or cardiac death) within 30 days in participants in Group B who were found not to have stenosis of the main or first order coronary branches greater than or equal to 50% by CT coronary angiography.;  To estimate and compare the rates of significant CAD detected within the index visit in participants across the two study arms.;  To compare hospital length of stay across the two study groups.;  To compare health care utilization and cost incurred by participants in the two study groups during the index hospitalization.;  To compare cardiac health care utilization and cost incurred by participants in the two study groups during 1 year post triage/presentation.;  To compare rates of major cardiac events (cardiac death AMI and revascularization for participants who were not found to have significant CAD at the index visit) among participants in the two study groups within 1 year post triage/presentation.|1365|NCT00933400|July 2009
3452|Completed|Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma||Drug:MGCD0103|Interventional|Phase 2|Industry|Responserate;  Progression-freesurvival;  Durationofobjectiveresponse;  Safetyprofile;  Pharmacokinetics;  Pharmacodynamics|74|NCT00359086|August 2006
3453|Completed|SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS||Drug:SB-681323Intravenous3mg;  Drug:SB-681323Intravenous7.5mg;  Drug:SB-681323Intravenous7.5mg;  Drug:SB-681323Intravenous10mg;  Other:Placebo|Interventional|Phase 2|Industry|Safety and tolerability of intravenous SB-681323 repeated for three days in patients at risk for developing ALI or ARDS;  Evaluation of the pharmacokinetics of intravenous SB-681323 infused over 4 or 24 hours for three days in patients at risk for developing ALI or ARDS;  Evaluate the effects of intravenous SB-681323 infused over 4 or 24 hours for three days compared with placebo in this population on biomarkers.;  Evaluate the effects of intravenous SB-681323 infused over 4 or 24 hours for three days compared with placebo in this population on acute kidney injury scales.|90|NCT00996840|October 2009
3454|Completed|Lidocaine and Tetracaine Cream to Treat Postherpetic Neuralgia (PHN)||Drug:lidocaineandtetracainecream7%/7%;  Drug:Placebo|Interventional|Phase 2|Industry|Pain will be rated using the Numeric Pain Rating Scale (NPRS). Patients will rate: Worst pain over the last 24 hours Least pain over the last 24 hours Average pain over the last 24 hours Present pain intensity.;  Area of allodynia will be mapped at baseline and at the treatment sessions.;  Intensityofallodynia;  Patientglobalimpressionofchange.|23|NCT00609323|January 2008
3455|Completed|IL13-PE38QQR Infusion After Tumor Resection Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma||Drug:IL13-PE38QQR;  Procedure:Surgeryforplacement;  Procedure:Radiationtherapy;  Drug:Temozolomidewithradiationtherapy|Interventional|Phase 1|Industry||24|NCT00089427|July 2004
3456|Recruiting|Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer||Drug:Sym004;  Drug:Nivolumab|Interventional|Phase 1 / Phase 2|Industry|Phase 1b: Determination of the Dose-Limiting Toxicities (DLT) and the MTD and/or RP2D of escalating doses of Sym004 in combination with a standard dose of nivolumab;  Phase 2b: Evaluation of the antitumor effects of the RP2D of Sym004 when administered in combination with a standard dose of nivolumab as measured by Response Rate;  Number of participants with treatment-related adverse events (AEs) as assessed by NCI-CTCAE v4.03;  Evaluation of the occurrence of anti-drug antibodies (ADAs) to Sym004 measured in serum at selected timepoints from baseline to end of trial participation;  Areaundertheconcentration-timecurve(AUC);  Dose-normalized AUC from End-of-Infusion to 336 hours (AUCnorm 0-336h);  ConcentrationatEnd-of-Infusion;  Clearance(CL);  MaximumConcentration(Cmax);  TroughConcentration(Ctrough);  EliminationHalf-Life(T&#189;);  Timetoreachmaximumconcentration(Tmax);  VolumeofDistribution(VD);  Evaluation of the antitumor effects of Sym004 in combination with nivolumab as measured by progression-free survival (PFS);  Evaluation of the antitumor effects of Sym004 in combination with nivolumab as measured by overall survival (OS);  Evaluation of the antitumor effects of Sym004 in combination with nivolumab as measured by 12-month OS;  Evaluation of the antitumor effects of Sym004 in combination with nivolumab as measured by duration of response (DOR)|93|NCT02924233|November 2016
3457|Terminated|Trial Comparing Peripheral I.V. Catheter Complication Rates of Two Different Catheter Dressings||Device: 3M&#8482; Tegaderm&#8482; I.V. Advanced Securement Dressing Cat #1683;  Device: 3M&#8482; Tegaderm&#8482; IV Transparent Film Dressing Cat #1624W|Interventional||Industry|Dressingweartime;  Peripheral I.V. (PIV) catheter-related complications;  Overall and specific Peripheral I.V. (PIV) catheter-related complication rates;  Incidence of unscheduled Peripheral I.V. (PIV) catheter restarts;  Cost effectiveness of Tegaderm&#8482; 1683 securement dressing to a flat film dressing|247|NCT02725788|September 2014
3458|Active not recruiting|NIOX VERO Nasal Application in Primary Ciliary Dyskinesia|||Observational||Industry|The primary endpoint will be the analysis of the means of the successful nNO measurements in Subjects with PCD as compared with Healthy Subjects in the Evaluable Population.|163|NCT02622061|May 2016
3459|Active not recruiting|Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity||Drug:Bevacizumab|Interventional|Phase 1|Other / NIH|SuccessfulTreatmentofROP;  DistributionofVEGFLevels;  DistributionofAvastinLevels;  Number of study eye and fellow eyes requiring additional treatment/s for ROP and if retreated type of treatment;  Any adverse events or complications since the 4-week exam;  Assessmentofvision;  Proportion of infants for whom at least one event was reported;  Proportion of infants with an adverse event thought by investigator to be related to study drug;  Proportion of infants for whom at least one serious adverse event was reported;  Proportionofinfantdeaths|112|NCT02390531|April 2015
3460|Completed|Ultherapy&#174; for the Treatment of Erythematotelangiectatic Rosacea||Device:UltheraSystemTreatment|Interventional||Industry|Clinician Erythema Assessment at 90 days post-treatment compared to baseline;  CEA scale at 180 days post-treatment compared to baseline.;  CEA scale at 365 days post-treatment compared to baseline.;  Patient Self-Assessment (PSA) of erythema at 90 Days compared to baseline.;  Patient Self-Assessment (PSA) of erythema at 180 Days compared to baseline.;  Patient Self-Assessment (PSA) of erythema at 365 Days compared to baseline.;  Dermatology Life Quality Index (DLQI) Assessment at 90 Days post-treatment;  Dermatology Life Quality Index (DLQI) Assessment at 180 Days post-treatment;  Dermatology Life Quality Index (DLQI) Assessment at 365 Days post-treatment;  Colorimeterat90Dayspost-treatment;  Colorimeterat180Dayspost-treatment;  Colorimeterat365Dayspost-treatment|88|NCT02144181|May 2014
3461|Active not recruiting|Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)||Drug:Sunitinib;  Behavioral:Questionnaire|Interventional|Phase 2|Other / Industry|RateofToxicity;  Progression-FreeSurvival(PFS)|60|NCT02060370|August 2014
3462|Completed|Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women||Biological:GBSvaccine;  Biological:Placebo|Interventional|Phase 2|Industry|Concentration of GBS IgG levels in infant serum at Delivery and Days 42 and 90 of age;  Concentration of GBS IgG levels in maternal serum at prevaccination Study Day 31 at Delivery and at Days 42 and 90 postpartum;  Ratio relative to prevaccination levels of maternal serum GBS IgG antibody levels as measured at Study Day 31 Delivery and at Days 42 and 90 postpartum;  Ratio of GBS antibody levels in infant serum relative to maternal serum at the time of Delivery|75|NCT02046148|March 2014
3463|Completed|Clinical Evaluation of BD NEXT Pen Needle||Device:BDNEXT31Gx5mmpenneedle;  Device:BDNEXT31Gx8mmpenneedle;  Device:BDNEXT32Gx4mmpenneedle|Interventional||Industry|OverallPenNeedlePreference;  Relativeperceivedthumbforce;  Confidenceinfulldosedeliveryofinsulin;  Perceived injection time to deliver full dose of insulin;  Penusergroupsubsetcomparisons|217|NCT01852136|September 2012
3464|Completed|Seprafilm in Open Abdomens: a Study of Wound and Adhesion Characteristics in Trauma Damage Control Patients||Biological:Seprafilm|Interventional||Other|Woundhealingcharacteristics;  Adhesioncharacteristics|30|NCT01594385|April 2010
3465|Terminated                  Has Results|Pilot Study of Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator||Drug:amiodarone;  Drug:sotalol;  Device:BiosenseWebster&apos;sNAVI-STARThermo-Cool|Interventional||Other|Number of Participants Completed Month 3 Follow-Up;  Number of Participants Completed Month 6 Follow-Up;  Number of Participants Had at Least One of the Efficacy Outcome Measurement;  CardiovascularHospitalizations;  Number of Participants Remained on Randomized Treatment Assignment;  NumberofParticipantsSwitchedtoOtherArm;  TimetoFirstRecurrentICDTherapyforVT;  Number of Participants Received Treatment Assigned|27|NCT01576042|May 2012
3466|Completed                  Has Results|Safety Study of Replagal&#174; Therapy in Children With Fabry Disease||Biological:Replagal(agalsidasealfa)|Interventional|Phase 2|Industry|NumberofSeriousAdverseEvent(SAE);  NumberofTreatmentEmergentAdverseEvent(TEAE);  DevelopmentofIgGAnti-AgalsidaseAlfaAntibody;  Change From Baseline in Heart Rate Variability Parameter SDNN;  Change From Baseline in Heart Rate Variability Parameter rMSSD;  Change From Baseline in Heart Rate Variability Parameter pNN50;  ChangeFromBaselineinLVMI;  ChangeFromBaselineinMFS;  ChangeFromBaselineinPlasmaGb3;  ChangeFromBaselineinUrineGb3|15|NCT01363492|May 2011
3467|Completed                  Has Results|Tolerance to Target Doses of Thiazides in Actual Practice: A Feasibility Study||Other: Favor one of two thiazides for new prescriptions &amp; attempt target dose|Interventional|Phase 4|U.S. Fed|PrescriptionRates;  FactorsAssociatedWithPrescribingPatterns|20|NCT01235377|September 2011
3468|Completed                  Has Results|2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women||Biological: Trivalent inactivated influenza vaccine|Interventional|Phase 2|NIH|Number of Participants Reporting Vaccine-associated Unsolicited Non-serious Adverse Events;  Number of Participants Reporting Maternal Complications of Pregnancy Labor and Delivery;  Number of Participants Reporting Neonatal Complications;  Number of Participants Reporting Vaccine-associated Serious Adverse Events (SAEs);  Number of Participants Reporting Solicited Subjective Local Reactions After Vaccination;  Number of Participants Reporting Solicited Quantitative Local Reactions After Vaccination;  Number of Participants Reporting Solicited Subjective Systemic Reactions After Vaccination;  Number of Participants Reporting Fever After Vaccination;  Hemagglutination Inhibition Assay (HAI) Geometric Mean Titer (GMT) Against Each Antigen in the 2010-2011 Seasonal Influenza Trivalent Influenza Vaccine;  Number of Participants With 4-fold or Greater Serum HAI Antibody Titer Increases Against Each Antigen in the 2010-2011 Seasonal Influenza Trivalent Influenza Vaccine;  Number of Participants With HAI Antibody Titer of 40 or Greater Against Each Antigen in the 2010-2011 Seasonal Influenza Trivalent Influenza Vaccine;  Hemagglutination Inhibition Assay (HAI) Geometric Mean Titer (GMT) Against Each Antigen in the 2010-2011 Seasonal Influenza Trivalent Influenza Vaccine at 6 Months After Vaccination;  Number of Participants With 4-fold or Greater Serum HAI Antibody Titer Increases Against Each Antigen in the 2010-2011 Seasonal Influenza Trivalent Influenza Vaccine at 6 Months After Vaccination;  Number of Participants With HAI Antibody Titer of 40 or Greater Against Each Antigen in the 2010-2011 Seasonal Influenza Trivalent Influenza Vaccine at 6 Months After Vaccination;  Maternal HAI GMT Against Each Antigen in the 2010-2011 Seasonal Influenza Trivalent Influenza Vaccine at Time of Delivery;  Number of Participants With 4-fold or Greater Maternal Serum HAI Antibody Titer Increases Against Each Antigen in the 2010-2011 Seasonal Influenza Trivalent Influenza Vaccine at Time of Delivery;  Number of Participants With a Maternal Serum HAI Antibody Titer Greater Than or Equal to 40 Against Each Antigen Included in the 2010-2011 Inactivated TIV at Time of Delivery.;  HAI GMT Against Each Antigen in the 2010-2011 Seasonal Influenza Trivalent Influenza Vaccine in Cord Blood Collected at Time of Delivery;  Number of Participants With HAI Antibody Titer Greater Than or Equal to 40 Against Each Antigen Included in the 2010-2011 Inactivated TIV in Cord Blood Collected at Time of Delivery.|183|NCT01173211|September 2010
3469|Terminated|Sinus Augmentation With Dental Implant||Device:INFUSE&#174;BoneGraft|Observational||Industry|Clinical stability and osseointegration of endosseous dental implants;  Evidence of successful INFUSE&#174; Bone Graft placement as well as the safety of INFUSE&#174; when used in sinus augmentation which will be confirmed by CT scans.|23|NCT00991393|October 2009
3470|Completed|Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy||Drug:CMX-2043;  Drug:Placebocontrol|Interventional|Phase 2|Industry|SafetyasmeasuredbychangesinCK-MB;  Cardiacbiomarkers;  STsegmentchanges|142|NCT00984802|February 2010
3471|Terminated|A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer||Drug:MGCD265+erlotinib;  Drug:MGCD265+docetaxel|Interventional|Phase 1|Industry|Phase I: Safety profile (including maximum tolerated dose and dose limiting toxicities);  Phase II: Antitumor activity of MGCD265+erlotinib and MGCD265+docetaxel;  Phase I: Pharmacokinetic profiles of MGCD265+erlotinib and MGCD265+docetaxel;  Phase I and Phase II: Pharmacodynamic profiles of MGCD265+erlotinib and MGCD265+docetaxel;  Phase I: Antitumor activity of MGCD265+erlotinib and MGCD265+docetaxel.;  Phase II: Safety profile of MGCD265+erlotinib and MGCD265+docetaxel;|126|NCT00975767|August 2009
3472|Completed                  Has Results|H1N1 Vaccine in Pregnant Women||Biological:InactivatedH1N1Vaccine|Interventional|Phase 2|NIH|Number of Participants Reporting Solicited Subjective Local Reactions After First Vaccination;  Number of Participants Reporting Solicited Subjective Local Reactions After Second Vaccination;  Number of Participants Reporting Solicited Quantitative Local Reactions After First Vaccination;  Number of Participants Reporting Solicited Quantitative Local Reactions After Second Vaccination;  Number of Participants Reporting Solicited Subjective Systemic Reactions After First Vaccination;  Number of Participants Reporting Solicited Subjective Systemic Reactions After Second Vaccination;  Number of Participants Reporting Fever After First Vaccination;  Number of Participants Reporting Fever After Second Vaccination;  Number of Participants With 4-fold or Greater Serum Hemagglutination Inhibition (HAI) Antibody Titer Increases Against Influenza H1N1 2009 Virus Following a Single Dose of H1N1 Vaccine;  Number of Participants With a Serum Hemagglutination Inhibition (HAI) Antibody Titer of 1:40 or Greater Against Influenza H1N1 2009 Virus Following a Single Dose of H1N1 Vaccine;  Number of Participants Reporting Maternal Complications of Pregnancy Labor and Delivery;  Number of Participants Reporting Neonatal Complications;  Number of Participants Reporting Vaccine-associated Serious Adverse Events (SAEs);  Number of Participants With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer Greater Than or Equal to 40 Against the Novel Influenza H1N1 2009 Virus in the Maternal Blood at the Time of Delivery;  Number of Participants With a Serum Hemagglutination Inhibition Assay (HAI) Antibody Titer Greater Than or Equal to 40 Against the Novel Influenza H1N1 2009 Virus in Cord Blood;  Number of Participants With 4-fold or Greater Serum Hemagglutination Inhibition (HAI) Antibody Titer Increases Against Influenza H1N1 2009 Virus Following 2 Doses of H1N1 Vaccine;  Number of Participants With a Serum Hemagglutination Inhibition (HAI) Antibody Titer of 1:40 or Greater Against Influenza H1N1 2009 Virus Following 2 Doses of H1N1 Vaccine|120|NCT00963430|September 2009
3473|Terminated|Combination Study of BMS-754807 and Erbitux&#174; in Subjects With Advanced or Metastatic Solid Tumors||Drug:BMS-754807;  Drug:cetuximab(Erbitux&#174;)|Interventional|Phase 1 / Phase 2|Industry|Maximum tolerated dose of BMS-754807 administered orally (daily schedule) in combination with cetuximab administered standard doses IV (weekly basis) will be determined by observation of dose limiting toxicities during the first 33 days of administration;  To assess anti-tumor activity as measured by objective responses;  To evaluate the safety and tolerability of the BMS-754807/cetuximab combination regimen;  To assess the effects of the BMS-754807/cetuximab combination regimen on glucose homeostasis;  Dose Expansion only: To identify biomarkers that are predictive of a response to BMS-754807/cetuximab combination therapy in advanced or metastatic CRC and SCCHN subjects with cetuximab resistance|54|NCT00908024|October 2009
3474|Completed|Littlears Auditory Questionnaire: Validation Study in CI Children|||Observational||Industry|To validate the LittlEARS Auditory Questionnaire in hearing impaired children. The item analyses scale analysis analysis of expected values and minimal values have to be calculated as it was performed with the US validation study.;  To determine if there are differences in statistical parameters between normal hearing children and hearing impaired children;  Longitudinal assessment of cochlear implanted children over 24 months after first CI fitting;  To establish the first words understood by a child with a cochlear implant;  To establish the first words spoken by a child with a cochlear implant;  Toestablishasequenceofworddevelopment;  To compare words and word categories in different languages|31|NCT00785707|May 2008
3475|Terminated                  Has Results|Minimally Invasive Total Knee Replacement - Navigated Versus Non-navigated Study||Device: Either P.F.C. Sigma or L.C.S. Complete knee replacement using the conventional surgical approach and manual surgical technique;  Device: Either P.F.C. Sigma or L.C.S. Complete knee replacement using minimally invasive surgical approach and computer navigation|Interventional|Phase 4|Industry|To Compare the Precision of the Long Leg Alignment Between the Between Subjects Who Have Undergone Minimally Invasive vs. Conventional Total Knee Arthroplasty.;  To Compare the Proportion of Procedures That Fall Within a Satisfactory Alignment Window Between Subjects Who Have Undergone Minimally Invasive vs. Conventional Total Knee Arthroplasty.;  To Compare the Number of Optimal Implantations Achieved From Pre-op to 6-12 Weeks Between Subjects Who Have Undergone Minimally Invasive vs. Conventional Total Knee Arthroplasty.;  To Compare American Knee Society Knee Score Between Subjects Who Have Undergone Minimally Invasive vs. Conventional Total Knee Arthroplasty.;  To Compare Oxford Knee Scores Between Subjects Who Have Undergone Minimally Invasive vs. Conventional Total Knee Arthroplasty.;  To Compare WOMAC Scores Between Subjects Who Have Undergone Minimally Invasive vs. Conventional Total Knee Arthroplasty.;  To Compare VAS Pain Scores Between Subjects Who Have Undergone Minimally Invasive vs. Conventional Total Knee Arthroplasty.;  To Compare Interface Radiographic Appearance Between Subjects Who Have Undergone Minimally Invasive vs. Conventional Total Knee Arthroplasty.;  To Compare the Change From 6-12 Weeks &amp; 5 Years on Long Leg Alignment.;  To Compare 6 Minute Walk Test Scores Between Subjects Who Have Undergone Minimally Invasive vs. Conventional Total Knee Arthroplasty.|86|NCT00733330|January 2005
3476|Completed|Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus||Drug:SBI-087|Interventional|Phase 1|Industry|Safety (physical examinations laboratory tests adverse events) and tolerability (dose-limiting toxicities) of ascending single doses of SBI-087 in subjects with Systemic Lupus Erythematosus (SLE);  Initial pharmacokinetic and pharmacodynamic profiles of SBI-087 in subjects with Systemic Lupus Erythematosus (SLE)|30|NCT00714116|February 2009
3477|Recruiting|Immune Tolerance Induction Study||Biological:Myozyme(alglucosidasealfa)|Interventional|Phase 4|Industry|Evaluate the efficacy of ITI regimens as assessed by anti-recombinant human acid &#945;-glucosidase (anti-rhGAA) antibody titers and antibodies that inhibit the enzymatic activity and/or uptake of Myozyme;  Evaluate Pompe disease activity in patients receiving the 2 ITI regimens as measured by overall survival.;  Evaluate Pompe disease activity in patients receiving the 2 ITI regimens as measured by respiratory function.;  Evaluate Pompe disease activity in patients receiving the 2 ITI regimens as measured by Left ventricular mass index (LVMI).;  Evaluate Pompe disease activity in patients receiving the 2 ITI regimens as measured by motor function.;  Evaluate Pompe disease activity in patients receiving the 2 ITI regimens as measured by disability index.;  Evaluate the safety of the 2 ITI regimens as assessed by the incidence of adverse events (AEs) serious adverse events (SAEs) and clinical laboratory abnormalities.|9|NCT00701701|December 2008
3478|Completed|Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment||Drug:Silymarin;  Other:Placebo|Interventional|Phase 2|NIH / Other|Efficacy - whether or not serum ALT (mg/dl) is less than or equal to 45 IU/L (approximate normal range) or achieves at least 50% decline to less than 65 IU/L (approximately 1.5 times the upper limit of normal);  Safety-occurenceofadose-limitingtoxicity;  Adherence - summary of missed dose information obtained from patient diaries and dose counts;  Biomarkers - the following relationships will be explored: dose and change in biomarkers changes in biomarkers and rate of treatment success change in biomarkers and rate of toxicity|154|NCT00680342|April 2008
3479|Completed|Vibration Response Imaging (VRI) in Patients That Are Undergoing Pulmonary Interventional Procedure||Other:VibrationResponseImaging|Observational||Industry|The principal objective is to determine the ability of the VRI to assess changes in the lungs before and after pulmonary intervention in patients suffering from airway obstruction.;  The secondary objective is to assess the contribution of the VRI in aiding in identification of the pulmonary obstruction as compared to the standard methods prior the intervention procedure.|200|NCT00672893|February 2006
3480|Completed                  Has Results|Efficacy and Safety Study of Caldolor (Intravenous Ibuprofen) in Hospitalized Adult and Pediatric Burn Patients||Drug:Caldolor;  Drug:Placebo|Interventional|Phase 3|Industry|Temperature|61|NCT00606489|November 2007
3481|Completed                  Has Results|Fluorouracil Oxaliplatin and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer||Drug:fluorouracil;  Drug:leucovorincalcium;  Drug:oxaliplatin;  Genetic:geneexpressionanalysis;  Genetic:polymorphismanalysis;  Genetic:proteinexpressionanalysis;  Other:pharmacologicalstudy|Interventional|Phase 2|Other / NIH|Number of Patients With Each Response in &quot;Good Risk&quot; Genotype (Thymidylate Synthase Promoter Enhancer Region [TSER]*2/*2 or TSER*2/*3 Genotype [Low TS Expression])|33|NCT00514020|August 2007
3482|Completed|Phase I Trial of Silymarin for Chronic Liver Diseases||Drug:Placebo;  Drug:Silymarin|Interventional|Phase 1|NIH|Adverseevents|56|NCT00389376|November 2006
3483|Completed                  Has Results|Intensive Glycemic Control and Skeletal Health Study||Drug: hypoglycemic agents hydroxymethylglutaryl-CoA Reductase inhibitors hypertensive agents|Interventional|Phase 3|Other / NIH|Number of Participants With at Least One Non-vertebral Fracture;  NumberofParticipantsWithatLeastOneFall;  NumberofParticipantsWith&gt;2cmofHeightLoss|7287|NCT00324350|October 2003
3484|Completed|Risperidone Pharmacokinetics in Children With Pervasive Developmental Disorder (PDD)||Drug:Risperidone|Interventional|Phase 1|Other|Quantify the variability of clearance and volume of distribution among AE rating weight gain and ABC responder status.;  Exploratory analysis will be performed to examine the relationship of other factors to risperidone and metabolite concentrations for PK/PD assessment.|100|NCT00147394|December 2001
3485|Completed|VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia||Drug:hydroxyurea;  Drug:laromustine|Interventional|Phase 2|Industry|Completeresponserate;  Toxiceffects;  Pharmacokinetics|230|NCT00083187|November 2005
3486|Enrolling by invitation|Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)||Biological:Neo-KidneyAugment|Interventional|Phase 2|Industry / Other|Procedure and/or product related adverse events (AE&apos;s) through 12 months following the final NKA implantation as measured by AE reporting.;  Serial estimation of glomerular filtration rate (GFR) through 6 months following the final cell implantation as measured by serial Serum Creatinine.;  Renal-specific laboratory assessments through 12 months following the last NKA implantation under this protocol whether first or second as measured by renal specific biomarkers.|30|NCT02525263|July 2016
3487|Terminated|Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett&apos;s Esophagus With Radiofrequency Ablation||Drug:Dexlansoprazole;  Drug:DexlansoprazolePlacebo|Interventional|Phase 4|Industry|Percentage of Participants with Recurrence of Intestinal Metaplasia (IM) at 12 months;  Percentage of Participants with Recurrence of Intestinal Metaplasia (IM) with Dysplasia at 12 months;  The percentage of participants demonstrating Erosive Esophagitis (EE) during the 12 month treatment phase of the study.;  Mean change from baseline in quality of life (GERD-HRQL) at 12 months|6|NCT02162758|July 2014
3488|Completed                  Has Results|Indacaterol 75 &#956;g Compared to Placebo Assessing Time to Patient&apos;s Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease||Drug:indacaterol;  Drug:placebo|Interventional|Phase 4|Industry|Time (in Minutes) to Patient&apos;s Perception of Onset of Effect|40|NCT01543828|January 2012
3489|Active not recruiting|Treovance Stent-Graft With Navitel Delivery System for Patients With Infrarenal Abdominal Aortic Aneurysms||Device: Treovance Abdominal Aortic Stent-Graft with Navitel Delivery System|Interventional|Phase 1|Industry|majormorbidityandmortality;  Deviceperformance|30|NCT01328197|June 2011
3490|Completed                  Has Results|A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition||Drug:Oxybutynintransdermalsystem|Interventional|Phase 4|Industry|Average Number of Catheterizations Without Leaking Per Day;  PatchAdhesion;  UrodynamicMeasurements;  UrinaryLeakageandCatheterizationData|24|NCT00224029|December 2004
3491|Withdrawn|Rapid Assessment of Cardiac Markers for the Evaluation of Acute Coronary Syndrome (RACE-ACS)||Device: Triage CardioProfilER (Troponin I Myoglobin CK-MB BNP)|Interventional|Phase 4|Other|Sensitivity and specificity of the three-marker versus the four-marker panelDetermine the added benefit of BNP in the diagnosis of patients with ACS;  Determine the economic and resource utilization benefit of the POC platform vs. standard lab testing|0|NCT00206817|October 2003
3492|Completed                  Has Results|Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer||Biological:falimarev;  Biological:inalimarev;  Biological:sargramostim;  Biological: therapeutic autologous dendritic cells|Interventional|Phase 2|Other / NIH|Recurrence-freeSurvivalat2Years;  Positive Immune Response as Measured by (Enzyme-linked Immunosorbent Spot) ELISpot Assay|74|NCT00103142|February 2005
3493|Completed|A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)||Drug:Lenalidomide|Interventional|Phase 2|Industry|Safety;  Change in CRPS pain rating in index limb compared to baseline|40|NCT00067743|August 2003
3494|Recruiting|Oral Iron for Erythropoietic Protoporphyrias||Drug:OralIron|Interventional||Other / NIH|Changeinerythrocyteprotoporphyrinlevels;  EPP-specificQualityofLifeQuestionnaire|20|NCT02979249|December 2016
3495|Recruiting|A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction||Drug:MYK-461|Interventional|Phase 2|Industry|Change in post-exercise peak LVOT gradient from baseline to Week 12||NCT02842242|August 2016
3496|Recruiting|Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS||Drug:RPC1063|Interventional|Phase 1|Industry|Maximumplasmaconcentration(Cmax);  Area under the plasma concentration-time curve (AUC);  AdverseEvents;  EDSS(ExpandedDisabilityStatusScale);  Pharmacodynamic response measured in change from baseline in Absolute Lymphocyte Count|24|NCT02797015|July 2016
3497|Recruiting|Collection of Samples From Pregnant Women for the Evaluation of Preeclampsia (Pre-E) Biomarkers|||Observational||Industry|Suspected and Pre-E cases determined by institutional standards|1791|NCT02780414|January 2016
3498|Recruiting|One Stage Versus Two Stage For Periprosthetic Hip And Knee Infection||Procedure: One-stage exchange joint replacement surgery;  Procedure: Two-stage exchange joint replacement surgery|Interventional||Other|Recurrenceofinfection;  HealthRelatedQualityofHealth;  Patient-ReportedFunctionalOutcomes|308|NCT02734134|June 2016
3499|Recruiting|CLAD Phenotype Specific Risk Factors and Mechanisms.||Procedure:BloodDraw;  Procedure:Bronchoscopy|Observational||NIH / Other|Time from transplant to Restrictive Chronic Lung Allograft Dysfunction (RCLAD) or Bronchiolitis Obliterans Syndrome (BOS).;  Chemokine/cytokine Quantification of Type 1 and Type 17 immune profile proteins;  LongitudinalQualityoflife(QOL)trajectory;  Timefromtransplanttodeathorretransplant;  Time from CLAD onset to the occurrence of death or retransplant;  Longitudinal Pulmonary function test (PFT) trajectory|800|NCT02631720|December 2015
3500|Enrolling by invitation|The Capillary Index Score Trial||Procedure:EndovascularTreatment(EVT)|Observational|Phase 1|Other / Industry|Modified Rankin score (mRS) between favorable CIS group versus poor CIS group.;  Complication rate between favorable CIS group versus poor CIS group;  Modified Rankin score (mRS) between favorable CIS with good revascularization versus poor CIS with good revascularization.|54|NCT02618031|March 2016
3501|Completed|Phase IV O2 Consumption Study in COPD Patients||Drug: Budesonide 160 mcg and formoterol fumarate dehydrate 4.5 mcg Inhalation aerosol;  Drug:MatchingPlacebopMDI160/4.5&#956;g|Interventional|Phase 4|Industry|Change from pre-dose (Visit 2) to post-dose (Visit 5) assessment in oxygen consumption (VO2; obtained via a metabolic cart);  Change from pre-dose (Visit 2) to post-dose (Visit 5) assessment in oxygen pulse (defined as VO2/heart rate [HR]; VO2 is obtained via a metabolic cart; used as a surrogate for stroke volume);  Change from pre-dose (Visit 2) to post-dose (Visit 5) assessment in gas exchange parameters (HR VCO2 and SaO2);  Change from pre-dose (Visit 2)to post-dose (Visit 5) assessment in spirometry.;  Change from pre-dose (Visit 2) to post-dose (Visit 5) assessment in mean inspiratory flow (tidal volume [Vt]/inspiratory time [Ti]);  Change from pre-dose (Visit 2) to post-dose (Visit 5) assessment in the Modified Borg Scale for dyspnea|122|NCT02533505|August 2015
3502|Completed|A Study of the Safety and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee||Drug:CR8450.25mg;  Drug:CR8450.50mg;  Drug:CR8451mg;  Drug:CR8455mg|Interventional|Phase 2|Industry|To assess the Safety and Tolerability of orally-administered CR845 in patients with osteoarthritis of the hip or the knee in sequentially escalating doses (0.25 mg 0.50 mg 1 mg and 5 mg).;  To characterize the pharmacokinetic (pk) profile of orally-administered CR845 with twice a day (b.i.d) dosing;  To explore the effectiveness of orally administered CR845 in this patient population|81|NCT02524197|August 2015
3503|Suspended|Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain||Drug:Resiniferatoxin|Interventional|Phase 1 / Phase 2|NIH|The primary outcome is to achieve a dose-response relationship for safety;  substantially reduced pain; improved pain relief; substantially reduced concomitant opioid analgesic consumption; improved quality of life|30|NCT02522611|August 2015
3504|Recruiting|Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed With Attention-deficit/Hyperactivity Disorder||Drug:SPD489|Interventional|Phase 3|Industry|Number of patients with treatment-emergent adverse events (TEAEs) in subjects in Group A;  Number of patients with treatment-emergent adverse events (TEAEs) in subjects in Group B;  Change in sleep patterns assessed by questionnaire in subjects in group A;  Change in sleep patterns assessed by questionnaire in subjects in group B;  Change in Electrocardiogram (ECG) Results in subjects in Group A;  Change in Electrocardiogram (ECG) Results in subjects in Group B;  Change in suicide related behavior assessed by questionnaire in subjects in Group A;  Change in suicide related behavior assessed by questionnaire in subjects in Group B;  Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) in subjects in Group A;  Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) in subjects in Group B;  Change in the clinician-administered Attention Deficit/Hyperactivity Disorder Rating Scale (ADHD-RS-IV) Preschool Version total score in subjects in Group A;  Change in the clinician-administered Attention Deficit/Hyperactivity Disorder Rating Scale (ADHD-RS-IV) Preschool Version total score in subjects in Group B|100|NCT02466386|July 2015
3505|Completed|Study of Diclofenac Capsules to Treat Pain Following Surgery in Children Ages 6 to &lt;17 Years of Age||Drug:DiclofenacCapsuleslowdose;  Drug:DiclofenacCapsuleshighdose|Interventional|Phase 2|Industry|Plasmaconcentrationsofdiclofenac;  Safety of Diclofenac Capsules low dose and high dose as Assessed by the Incidence of Adverse Events from Baseline to Day 3 or Early Termination|30|NCT02424578|May 2015
3506|Active not recruiting|A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer||Drug: VT-464: given orally once daily in 28 day cycles|Interventional|Phase 1 / Phase 2|Industry|The safety and tolerability of VT-464 by evaluating adverse events vital signs physical examination findings concomitant medications and laboratory tests.;  PeakPlasmaConcentration(Cmax)ofVT-464;  Area under the plasma concentration versus time curve (AUC) of VT-464;  Time to maximum plasma concentration (Tmax) of VT-464|21|NCT02361086|June 2014
3507|Terminated|Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors||Drug:CC-90003|Interventional|Phase 1|Industry|Summary of the adverse events (type severity and incidence) related to CC-;  DoseLimitingToxicitiesofCC-90003;  MaximumToleratedDose(MTD)ofCC-90003;  Pharmacokinetics (PK) observed maximum concentration (Cmax);  PK-Area under the plasma concentration time curve (AUC);  PK-Timetomaximalplasmaconcentration(Tmax);  PK-terminalhalf-life;t1/2;  PK-Apparenttotalbodyclearance(CL/F);  PK-ApparentTotalVolumeofDistribution(Vz/F);  AccumulationindexofCC-90003;  ResponseRatebasedonRECIST1.1;  DurationofResponse;  DiseaseControl;  ProgressionFreeSurvival;  OverallSurvival|19|NCT02313012|January 2015
3508|Recruiting|Craniofacial Microsomia: Longitudinal Outcomes in Children Pre-Kindergarten (CLOCK)|||Observational||Other / NIH|NeurodevelopmentalOutcomeMeasures;  PhenotypicAssessments;  Phenotypic Assessments Phenotypic Assessments Phenotypic Assessments|685|NCT02224677|November 2013
3509|Active not recruiting|Ceramic On Ceramic (COC) 36mm PAS IDE Rollover Subjects; Ceramic Acetabular Bearing With Ceramic Femoral Head in Total Hip Replacement|||Observational||Industry|Devicesurvivorshipat10-yearspost-operatively;  HarrisHipscores;  SubjectHipOutcomes;  Radiographic;  AdverseEvents;  Devicesurvivorship|80|NCT02096198|January 2014
3510|Completed|TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)||Drug:TRI102;  Other:Placebo|Interventional|Phase 3|Industry|SKAMP (Swanson Kotkin Agler M-Flynn and Pelham Scale);  PERMP(PermanentProductMeasureofPerformance)|108|NCT02083783|March 2014
3511|Completed|Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy||Drug:BMS-936559;  Drug:PlaceboforBMS-936559|Interventional|Phase 1|NIH|Occurrence of a Grade 3 or greater adverse event (AE) including sign/symptom lab toxicity or clinical event that is definitely probably or possibly related to study treatment;  Occurrence of a Grade 1 or &gt; AE of all incident adrenal insufficiency or adrenal crisis (confirmed) myocarditis pneumonitis uveitis immune-mediated hyperthyroidism or hypothyroidism that is definitely probably or possibly related to study;  Frequency of HIV-1 Gag-specific CD8 T-cells by intracellular staining for interferon (IFN)-gamma at baseline and after treatment (through Day 28);  HIV-1 RNA by single copy assay (SCA) at baseline and after treatment (through Day 28);  PK parameters from non-compartmental analysis (area under curve [AUC] Cmax V Tmax CL/F t1/2);  Exploratory pharmacodynamic parameters (Emax EC50);  HIV-1DNAatbaselineandaftertreatment;  Programmed cell death 1 ligand 1 (PD-L1) receptor occupancy;  Proportion of total and HIV-1 gag-specific CD8 T-cells expressing programmed cell death 1 (PD-1) PD-L1 and other exhaustion markers;  CD107a mobilization and carboxyfluorescein diacetate succinimidyl ester (CFSE) dilution of HIV-1 gag-specific CD8 T-cells;  Polyfunctionality of HIV-1 specific CD8 and CD4 T-cells;  CD38 and human leukocyte antigen-DR (HLA-DR) expression on CD8 T-cells;  Geneexpressionprofilesinwholeblood;  Detection of antibody to study treatment in plasma;  Occurrence of a Grade 3 or greater AE including sign/symptom lab toxicity or clinical event that is definitely probably or possibly related to study treatment;  Occurrence of a Grade 1 or &gt; AE of all incident adrenal insufficiency or adrenal crisis (confirmed) myocarditis pneumonitis uveitis immune mediated hyperthyroidism or hypothyroidism that is definitely probably or possibly related to study;  2-long terminal repeat (2LTR) circle DNA at baseline and after treatment;  Cell-associated HIV-1 RNA at baseline and after treatment;  RNA/DNA ratios in total CD4 cells at baseline and after treatment;  Expression of programmed cell death 1 ligand 2 (PD-L2) on dendritic cells and monocyte-derived macrophages|8|NCT02028403|June 2014
3512|Recruiting|A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia||Drug:AMG232;  Drug:Trametinib|Interventional|Phase 1|Industry|To evaluate the safety and tolerability of AMG 232;  Characterize the pharmacokinetics of AMG 232 alone and in combination with trametinib when administered orally.;  Determine the maximum tolerated dose of AMG 232 alone and in combination with trametinib if possible.;  TreatmentResponse|130|NCT02016729|April 2014
3513|Recruiting|Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma||Drug:Epacadostat;  Other:LaboratoryBiomarkerAnalysis;  Biological:MELITAC12.1PeptideVaccine|Interventional|Phase 2|Other / Industry / NIH|Changes in the concentration and number of CD8+ cells infiltrating tumor by IHC;  ChangeinPBMCtranscriptome;  Change in the number and character of PBMC populations including T and NK cells as evaluated by multiparameter flow cytometry;  Changes in expression of IDO1 protein by IHC in tumor or tumor-infiltrating cells;  Changes in the level or character of the vaccine-induced CD8+ and CD4+ specific T-cell immune responses by IFN-gamma ELISPOT;  Incidence of adverse events using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0;  Overall response rate using the RECIST or Immune-Related Response Criteria (irRC);  Overallsurvival;  TimetotumorprogressionusingRECISTorirRC|12|NCT01961115|September 2013
3514|Recruiting|Family Health History in Diverse Care Settings||Other:MeTree|Interventional||Other|Increasing uptake of risk-management evidence based preventive strategies for the clinical decision support conditions;  Measure patient-related outcomes associated with using the MeTree tool;  MeasurephysicianexperiencewithMeTree;  ImplementationparametersforMeTree;  uptakeofMeTreebyclinicalpractices|7000|NCT01956773|April 2014
3515|Recruiting|L-asparaginase Encapsulated in Red Blood Cells for Frontline Therapy of Patients With Phi-neg ALL Older Than 18 yo||Drug:L-asparaginaseencapsulatedinRBC|Interventional|Phase 1|Industry|Determination of the Maximal Total Dosage (MTD) based on number of patients presenting with related DLT;  Overallsafetyandtolerability;  Plasma levels of asparagineaspartateglutamine glutamate and asparaginase and blood levels of asparaginase;  OptionalsamplesforCSFlevelsofaminoacids;  Red blood cell 24-hour recovery analysis  total free and encapsulated L-asparaginase;  Immunogenicity|12|NCT01910428|October 2013
3516|Recruiting|Treatment for Advanced B-Cell Lymphoma||Drug:Rituximab;  Drug:ITCytarabine|Interventional|Phase 2|Other|To determine if disease response rate will improve with this combination of therapy.;  To determine if the combination of IT Depocyte&#174; Rituximab and FAB Chemotherapy is safe.|24|NCT01859819|January 2013
3517|Recruiting|Genetic Studies of Non-Alcoholic Fatty Liver Disease|||Observational||NIH||1000|NCT01629095|June 2012
3518|Active not recruiting|mTBI Mechanisms of Action of HBO2 for Persistent Post-Concussive Symptoms||Drug:Hyperbaricoxygen(HBO2)at1.5atms;  Drug:Shamcontrol1.2atms|Interventional||U.S. Fed|Battery of symptom and quality of life assessments|72|NCT01611194|September 2012
3519|Active not recruiting|Study of ACY-1215 in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma||Drug:ACY-1215;  Drug:lenalidomide;  Drug:Dexamethasone|Interventional|Phase 1|Industry|Establish optimal dose of ACY-1215 in combination with lenalidomide and dexamethasone;  Evaluatesafetybyassessingtoxicities;  Determine the preliminary anti-tumor activity of ACY-1215 in combination with lenalidomide and dexamethasone;  Area under the plasma concentration versus time curve (AUC);  Changes in acetylated tubulin and acetylated histone levels|38|NCT01583283|April 2012
3520|Active not recruiting|Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer||Drug:GoserelinAcetate;  Other:LaboratoryBiomarkerAnalysis;  Drug:LeuprolideAcetate;  Drug:Vismodegib|Interventional|Phase 1 / Phase 2|NIH|Proportion of patients with =&lt; 5% tumor involvement;  Differences in relapse rates by bone scan/computed tomography scan (objective);  Differences in relapse rates by PSA levels (biochemical);  Differences in the rate of positive surgical margins between the two groups;  Proportion of patients expressing differences in hedgehog androgen signaling and related genes markers;  ProportionofpatientswithPSA=&lt;0.2ng/mL;  Time to PSA (biochemical) progression defined as PSA recurrence;  Time to PSA (clinical) progression defined as a serial rise in PSA concentration in the presence of castrate serum testosterone concentration or radiographic evidence of progression|66|NCT01163084|July 2010
3521|Completed                  Has Results|Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies||Drug:EribulinMesylate|Interventional||Industry|Safety|9|NCT01142661|August 2010
3522|Completed                  Has Results|A Study in Subjects With Recurrent Malignant Glioma||Drug:Lenvatinib;  Drug:Bevacizumab|Interventional|Phase 2|Industry|ProgressionFreeSurvival(PFS)RateatMonth6;  ObjectiveResponseRate(ORR);  ProgressionFreeSurvival;  OverallSurvival(OS);  DiseaseControlRate(DCR);  ClinicalBenefitRate(CBR);  Number of Participants With Adverse Events (AEs)/Serious Adverse Events (SAEs) as a Measure of Safety;  Pharmacokinetic (PK) Profile and Pharmacodynamics (PD) of Lenvatinib|151|NCT01137604|November 2010
3523|Completed|Comparative Study of Clinical Endpoint in DMD: Handheld Myometry (HHM) Versus CINRG Quantitative Measurement System (CQMS)|||Observational||Other|Compare the inter and intra rater reliability of HHM and CQMS by measuring Elbow and Knee Flexor/Extensor Strength in children ages 6-18 diagnosed with DMD tested by experienced clinical evaluators in both HHM and CQMS.|30|NCT01125709|January 2010
3524|Completed|A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian Breast and Prostate Cancer||Biological: DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides a universal T Helper peptide a polynucleotide adjuvant a liposome and Montanide ISA51 VG|Interventional|Phase 1|Industry|To determine the safety profile of two different doses of subcutaneously administered DPX-0907. Safety assessments will be based on reported adverse events and the results of vital sign measurements physical examinations and clinical laboratory tests.;  To determine the levels of CMI (cell mediated immunity) to the 7 cancer epitopes induced by vaccination with DPX-0907;  To establish a recommended dose based on safety and immune response for phase 2 studies.|23|NCT01095848|March 2010
3525|Completed|Erlotinib Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer||Drug:erlotinib;  Drug:gemcitabine;  Drug:nab-paclitaxel|Interventional|Phase 1|Industry|MaximumToleratedDose;  Safety of drug combination assessed through dose limiting toxicities (DLTs);  Safety of drug combination assessed through Adverse Events (AEs);  Evaluate erlotinib Pharmacokinetic (PK) trough concentrations (C24h);  ObjectiveResponseRate;  ProgressionFreeSurvival(PFS);  OverallSurvival|19|NCT01010945|December 2009
3526|Completed|Safety Tolerability and Effect of TMC207 and Efavirenz in Healthy Volunteers||Drug:Efavirenz(EFV);  Drug:TMC207|Interventional|Phase 1|NIH|Area under curve (AUC) over 336 hours of TMC207 measured when dosed alone and when dosed together with efavirenz (EFV) 600 mg daily;  Signs or symptoms of toxicity ranked Grade 2 or higher according to the DAIDS adverse event (AE) grading table;  Maximum observed plasma or serum concentration (Cmax) and oral clearance (CL/F) of TMC207 and AUC Cmax and CL/F of the M2 metabolite of TMC207 when dosed alone and when dosed together with EFV 600 mg daily;  AUC over 24 hours Cmax Cmin CL/F and elimination half-life (T1/2) of EFV and host EFV metabolism genotype status (CYP2B6) obtained from whole blood samples taken at screening;  Correlation between AUC over 24 hours of EFV and AUC over 336 hours of TMC207|37|NCT00992069|December 2009
3527|Active not recruiting|Bortezomib and Romidepsin in Treating Patients With Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Indolent B-cell Lymphoma Peripheral T-cell Lymphoma or Cutaneous T-Cell Lymphoma||Drug:Bortezomib;  Drug:Romidepsin|Interventional|Phase 1|Other / NIH|Maximumtolerateddose;  Pharmacodynamicresponses|24|NCT00963274|April 2010
3528|Completed                  Has Results|36 mm Ceramic-on-Ceramic Acetabular Cup Total Hip Replacement||Device: 36 mm ceramic head on a ceramic acetabular liner;  Device: 28 mm ceramic head on a polyethylene acetabular liner|Interventional||Industry|TotalHarrisHipScore;  HarrisHipSubscaleScore:Pain;  HarrisHipSubscaleScore:Function;  HarrisHipSubscaleScore:Activities;  HarrisHipSubscaleScore:Deformity;  HarrisHipSubscaleScore:RangeofMotion;  HarrisHipScoreLongitudinalAnalysis;  ProportionofCompositeSuccesses|243|NCT00953719|April 2003
3529|Completed                  Has Results|A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retinoid Used in a Combined Regimen With a BPO Wash||Drug:CTGel/BPOWash;  Drug:SoapFreeCleanserandCTGel|Interventional|Phase 3|Industry|LocalTolerability-SkinDryness;  LocalTolerability-SkinScaling;  LocalTolerability-Erythema(Redness);  SubjectAssessmentofBurning/Stinging;  SubjectAssessmentofItching|61|NCT00891982|April 2009
3530|Completed                  Has Results|Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis||Device:EpiCeramSkinBarrierEmulsion;  Drug:DesonideCream0.05%|Interventional|Phase 4|Industry|ChangeFromBaselineinThreeItemSeverityScore|100|NCT00828412|March 2009
3531|Completed                  Has Results|A Clinical Demonstration of EEG Brain-computer Interface for ALS Patients||Device:BCIDevice|Observational||U.S. Fed / Other|BCISystemUsagebytheALSPatient;  BCIUsagebyandImpactontheALSPatient;  Time of BCI Impact on the Significant Other and Systems Operator;  FacilitySupportSpeedofSolution|27|NCT00786032|September 2011
3532|Completed                  Has Results|Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis||Biological:AIN457;  Biological:Placebo|Interventional|Phase 2|Industry|Change From Baseline in Psoriasis Area and Severity Index (PASI) Scores;  ChangeFromBaselineinPASI;  InvestigatorGlobalAssessment(IGA)Scores|80|NCT00770965|September 2008
3533|Unknown&nbsp;&#8224;|Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer||Drug:Talactoferrin;  Drug:Placebo|Interventional|Phase 3|Industry|OverallSurvival;  Progressionfreesurvival;  Objectiveresponseanddiseasestabilizationrate;  Safetyandtolerability|1100|NCT00706862|February 2009
3534|Completed|FLU A+B Nasal Swab Clinical Study||Other:Non-invasivediagnostictesting|Observational||Industry|Support the addition of nasal swab sample type to labeling for the FLU A+B Test. The nasal swab sample data will be analyzed for the FLU A+B Test versus standard laboratory culture identification to determine the sensitivity and specificity.|800|NCT00636662|February 2008
3535|Completed                  Has Results|Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery||Drug:erlotinibhydrochloride;  Genetic:TUNELassay;  Genetic:proteinexpressionanalysis;  Other:immunohistochemistrystainingmethod;  Other:laboratorybiomarkeranalysis;  Other:liquidchromatography;  Other:massspectrometry;  Other: matrix-assisted laser desorption ionization mass spectrometry;  Procedure:therapeuticconventionalsurgery|Interventional|Phase 2|Other / NIH|Number of Participants Experiencing in Situ Anti-tumor Effect of Tarceva;  Molecular Profile of Participants Who Are Responsive to Tarceva;  Average Post-treatment Plasma Level of Erlotinib Hydrochloride|50|NCT00633750|August 2002
3536|Completed                  Has Results|Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults||Drug:VI-0521;  Drug:Placebomatchedphentermine/topiramate|Interventional|Phase 3|Industry|PercentWeightLossFromBaselinetoWeek56;  Percentage of Subjects With at Least 5% Weight Loss at Week 56|1267|NCT00554216|November 2007
3537|Active not recruiting|Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma||Drug:Lenalidomide|Interventional|Phase 2|Other / Industry|To assess the overall response rate (RR) in relapsed or refractory cHL.;  To assess the safety and tolerability of lenalidomide therapy in relapsed or refractory cHL.;  To assess the complete response rate (CR) partial response (PR) and stable disease (SD) rate in relapsed or refractory cHL.;  Toassesstimetoprogression(TTP).;  Toassessoverallsurvival(OS);  Toassessrelapsefreesurvival(RFS);  To evaluate changes in NK cell number and function plasma cytokines gene expression profiles of peripheral blood and plasma proteins via proteomics before during and after lenalidomide therapy (correlative studies).;  Toassesseventfreesurvival(EFS).;  Toassessdurationofresponse.|80|NCT00540007|September 2007
3538|Completed                  Has Results|Safety and Pharmacokinetic (PK) Study of Intravenous (IV) Acetaminophen Administration in Pediatric Inpatients||Drug:IVAcetaminophen|Interventional|Phase 1|Industry|Single-dose Maximum Plasma Concentration (Cmax)  Micrograms Per Milliliter (&#181;g/mL) Pharmacokinetics of IV Acetaminophen;  Single-dose Time to Reach Maximum Plasma Concentration [Tmax(h)] Pharmacokinetics of IV Acetaminophen;  Multiple-dose Area Und the Curve (AUC) From Time 0 (Predose) to the Time of the Dosing Interval at Steady-state (0-t (&#181;g*h/ml) Pharmacokinetics of IV Acetaminophen;  Multiple-dose Terminal Elimination Half-life [t1/2(h)] Pharmacokinetics of IV Acetaminophen;  Number of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE);  Subjects Who Experience at Least One Serious Treatment-Emergent Adverse Event (TEAE)|75|NCT00493246|June 2007
3539|Terminated|High Dose Oral 4-Aminosalicylic Acid (PASER&#174;) to Control Acute Flares of Mild to Moderate Crohn&apos;s Disease||Drug:4-Aminosalicylicacid;  Drug:PASERplacebogranules|Interventional|Phase 2|Industry|Response as defined by a reduction of the CDAI score of &gt;70 points by 4 weeks compared with baseline;  Rate of remission as defined by the decrease in CDAI &gt; 100 points and total CDAI &lt; 150 by 4 weeks;  Rate of response as defined by a reduction in HBI to less than 5 by 4 weeks;  Rate of remission as defined by the decrease in HBI to less than 3 by 4 weeks;  Time to response and/or remission including time to change in HBI according to elements of the daily patient diary;  Increase in IBDQ to greater than 170 and the time to score above 170;  The change from baseline in the patient&apos;s general sense of disease activity as recorded in the individual daily diary;  Absence of night time stools if they were present on entry and time to disappearance;  Time to normalization of all other components in the diary;  Change in Hgb ESR CRP platelet count calprotectin from baseline and time to normalization;  Change in global physician assessment of disease activity from baseline to study completion|54|NCT00417690|January 2007
3540|Completed|A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer||Drug:CNTO328;  Drug:Docetaxel|Interventional|Phase 1|Industry|Number of Patients With Adverse Events as a Measure of Safety and Tolerability;  PlasmaConcentrationofDocetaxel;  Serum Concentration of Docetaxel in Combination With CNTO 328;  Number of Patients with Prostate-Specific Antigen (PSA) Response;  Number of Patients With PSA Reduced Within 3 Months;  PSAProgressioninPatients;  DurationofTumorResponse;  DurationofPSAresponse;  ObjectiveTumorResponse;  Pharmacodynamics of CNTO 328 administered in combination with docetaxel;  SerumconcentrationofCNTO328;  Serum concentration of CNTO 328 in combination with docetaxel|40|NCT00401765|September 2005
3541|Completed                  Has Results|A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.||Drug:valganciclovir[Valcyte]|Interventional|Phase 1|Industry|Area Under The Observed Plasma Concentration-Time Curve Between Dosing Intervals AUC(0-tau);  Maximum Observed Plasma Concentration (Cmax) of Ganciclovir;  Time to Maximum Observed Plasma Concentration (Tmax) of Ganciclovir;  ApparentEliminationRate(Kelim)ofGanciclovir;  PlasmaHalf-Life(T1/2)ofGanciclovir|31|NCT00377741|December 2004
3542|Unknown&nbsp;&#8224;|The Effects of the MME Procedure on Chronic Low Back Pain||Procedure:MMEProcedure|Interventional|Phase 3|Industry|reductioninpain;  improvedabilitytofunction;  tolerabilitytoprocedure;  neurologicstability;  reductioninpainmedication|100|NCT00325377|April 2006
3543|Unknown&nbsp;&#8224;|Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection||Drug:XTL6865|Interventional|Phase 1|Industry|logchangeinserumconcentrationsofHCVRNA;  changeinserumanti-E2concentrations|36|NCT00300807|October 2005
3544|Unknown&nbsp;&#8224;|The Effects of the Magnetic Molecular Energizer (MME) on Diabetic Peripheral Neuropathy||Procedure:MMEprocedure|Interventional|Phase 3|Industry|Improvement in neurologic function following procedure;  Improvement in DPN related pain following procedure;  SubjecttolerancetotheMMEprocedure;  Neurologicfunctionat6monthfollow-up;  Painlevelat6monthfollow-up;  Quality of Life assessments at baseline post-procedure and 6 month follow-up|100|NCT00134524|July 2005
3545|Completed|Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)||Drug:TRAIL-R1mAb(TRM-1;HGS-ETR1)|Interventional|Phase 2|Industry|||NCT00092924|
3546|Completed|RNA-Loaded Dendritic Cell Cancer Vaccine||Biological:MB-002|Interventional|Phase 1 / Phase 2|Industry|To examine the safety of multiple administrations of MB-002 in patients with newly diagnosed metastatic renal cell carcinoma.;  To measure clinical antitumor activity including objective tumor response and an estimate of time to tumor progression (or progression-free interval).|26|NCT00087984|January 2004
3547|Completed|The Maternal Lifestyle Study (MLS)|||Observational|Phase 4|Other / NIH / U.S. Fed|Neurodevelopmentalimpairment|11811|NCT00059540|May 1993
3548|Completed                  Has Results|Ginkgo Biloba Prevention Trial in Older Individuals||Drug:Ginkgobiloba;  Drug:Placebo|Interventional|Phase 3|NIH|NumberofParticipantsWithIncidentDementia;  Number of Participants With the Indicated Cardiovascular Disease or Mortality;  Progression of Cognitive Decline in Standardized Z-score Scale. Higher Z-scores Indicate Worse Performance.|3069|NCT00010803|October 2000
3549|Completed|A Study of Zidovudine in HIV-Infected Patients With Liver Disease||Drug:Zidovudine|Interventional||NIH||39|NCT00001001|
3550|Completed|Coping Strategies Used by Food Insecure Households||Behavioral:CopingStrategies|Observational||Other|Identify participants who have used at least one target coping strategy|320|NCT02767141|May 2012
3551|Recruiting|Registry of Older Patients With Cancer|||Observational|Phase 1|Other / NIH|Creation of a registry of older patients within the University of North Carolina&apos;s healthcare system;  CompletionoftheGeriatricAssessment(GA);  Information that would lend support for future research;  Response rates of Geriatric Assessments of Carolina Senior patients and their satisfaction with the GA|150|NCT01137825|September 2009
3552|Suspended|A Study of Regorafenib in Advanced Pancreatic Cancer Patients||Drug:regorafenib|Interventional|Phase 2|Other / Industry|ProgressionFreeSurvival;  Overallsurvival|32|NCT02080260|June 2014
3553|Completed|Comparison of Hand Feeding Techniques for Persons With Dementia||Behavioral:Handfeedingtechniques|Interventional||Other|Changeinfrequencyofaversivefeedingbehaviors;  Changes in time spent providing feeding assistance;  Changesinmealintake;  Functional ability and feeding behaviors exhibited by person with dementia;  Characterize feeding assistant responses to functional ability and feeding behaviors;  Develop decision-making algorithm of adaptive approaches used by feeding assistant|30|NCT01780402|March 2012
3554|Completed|Effectiveness of Enhanced Terminal Room Disinfection to Prevent Healthcare-associated Infections (HAIs)||Other:Quaternaryammonium;  Other:Bleach;  Other:QuaternaryammoniumandUV-Clight;  Other:BleachandUV-Clight|Interventional||Other|Clinical incidence rate of four target organisms among patients admitted to a study room;  Clinical incidence rate of C. difficile among patients admitted to a study room;  Clinical incidence rate of target vegetative bacteria (MRSA VRE Acinetobacter) among patients admitted to a seed room.;  Clinical incidence rate of target organisms among all patients admitted to the hospital;  Clinical incidence rate of MRSA among all patients admitted to the hospital;  Clinical incidence rate of VRE among all patients admitted to the hospital;  Clinical incidence rate of MDR-Acinetobacter among all patients admitted to the hospital;  Clinical incidence rate of C. difficile among all patients admitted to the hospital;  Incidence rate of healthcare-associated infections caused by target bacteria (MRSA VRE C. difficile and MDR-Acinetobacter) among patients admitted to a seed room.;  Incidence rate of healthcare-associated infections caused by MRSA among patients admitted to a seed room.;  Incidence rate of healthcare-associated infections caused by VRE among patients admitted to a seed room.;  Incidence rate of healthcare-associated infections caused by MDR-Acinetobacter among patients admitted to a seed room.;  Incidence rate of healthcare-associated infections caused by MDR-Acinetobacter among all hospitalized patients.;  Incidence rate of healthcare-associated infections caused by MRSA among all hospitalized patients.;  Incidence rate of healthcare-associated infections caused by VRE among all hospitalized patients.;  Incidence rate of healthcare-associated infections caused by target vegetative bacteria (MRSA VRE MDR-Acinetobacter) among all hospitalized patients.;  MissedOpportunities;  TimeonDiversion;  RoomTurnoverTime;  EDtofloorwaittime;  Clinical incidence of MRSA VRE C. difficile and MDR-Acinetobacter during UV-C light versus No UV-C light|21395|NCT01579370|April 2012
3555|Active not recruiting|Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma||Drug:Bendamustine;  Drug:Rituximab|Interventional|Phase 2|Other / Industry|Complete response (CR) rate as defined by The International Harmonization Project for Response Criteria;  Overallresponserate(ORRCR+PR);  Estimate the disease-free survival (DFS) progression-free and overall survival;  Evaluate the toxicity and tolerability of bendamustine in combination with rituximab|37|NCT01234467|November 2010
3556|Completed|Safety Tolerability and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia||Drug:ISISapoC-IIIRx;  Drug:Placebo|Interventional|Phase 2|Industry|VLDLapoC-III|89|NCT01529424|February 2012
3557|Unknown&nbsp;&#8224;|Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen||Drug:tamoxifencitrate;  Genetic:geneexpressionanalysis;  Other:pharmacogenomicstudies;  Other:questionnaireadministration;  Procedure:quality-of-lifeassessment|Interventional||Other / NIH|Change in endoxifen levels after an increase in the tamoxifen citrate dose from 20 mg to 40 mg in patients with intermediate-metabolizing (IM) CYP2D6 genotypes;  Tolerability of increasing the dose of tamoxifen citrate from 20 to 40 mg per day in patients with IM CYP2D6 genotypes;  Feasibility of obtaining pharmacogenomic information from patients in the clinical setting and using it to guide changes in therapy;  CYP2D6 allele frequencies and endoxifen levels among African-American women taking tamoxifen citrate;  Change in plasma endoxifen levels after an increase in tamoxifen citrate dose from 20 mg to 40 mg daily in patients with poor-metabolizing genotypes|501|NCT00764322|June 2008
3558|Recruiting|Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis||Drug:Tradipitant;  Drug:Placebo|Interventional|Phase 2|Industry|Efficacy of tradipitant relative to placebo in reducing chronic pruritus as measured by the Visual Analogue Scale (VAS).|150|NCT02651714|January 2016
3559|Completed|Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD||Device:GFFMDI(PT003)withAerochamber;  Device:GFFMDI(PT003)withoutAerochamber|Interventional|Phase 3|Industry|Change from morning pre-dose trough FEV1 GFF 36/9.6 with Aerochamber Plus VHC relative to GFF 36/9.6 w/o Aerochamber Plus VHC on Day 8;  CompositeMeasureofPharmacokineticsonDay8|60|NCT02454959|May 2015
3560|Recruiting|Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma||Drug:MGD007|Interventional|Phase 1|Industry|Characterize dose limiting toxicity and establish a maximum tolerated dose and schedule;  CharacterizethePKandImmunogenicityofMGD07;  Describeanyevidenceofanti-tumoractivity|158|NCT02248805|September 2014
3561|Recruiting|Observational Study of Dental Outcomes in Head and Neck Cancer Patients|||Observational||Other / NIH|Toothloss;  Incidenceofexposedintraoralbone;  Extractioncomplications;  DecayedMissingorFilledSurfaces(DMFS)Index;  PeriodontalMeasures;  StimulatedSalivaryFlowRate;  Trismusmeasure;  Topicalfluorideuseforcariesprevention;  ChronicOralMucositisIncidence;  QualityofLifeafterRadiationTherapy;  OralCancerPainScale|756|NCT02057510|February 2014
3562|Completed|Pharmacokinetic Study of Makena&#174; (Hydroxyprogesterone Caproate Injection 250 mg/mL) and Its Metabolites in Blood||Drug:Hydroxyprogesteronecaproate250mg/ml|Interventional|Phase 1|Industry|Plasma concentrations of hydroxyprogesterone caproate and metabolites|30|NCT01899846|July 2013
3563|Completed|Safety Tolerability and PK of AN2728 in Adolescents With Atopic Dermatitis||Drug:AN2728TopicalOintment2%|Interventional|Phase 1 / Phase 2|Industry|Assessmentofsafetyandtolerability;  Profile of pharmacokinetics on Days 2469 at timepoints 012468 hrs post-dose (only timepoint 0 on Day 9);  Achievementoftreatmentsuccess;  Improvement in the signs and symptoms of atopic dermatitis|23|NCT01652885|July 2012
3564|Completed|Flexible Composite Next Generation Tissue Separating Mesh in Laparoscopic Incisional/Ventral Hernia Repair||Device:NG-TSM|Observational||Industry||48|NCT01162564|June 2010
3565|Completed                  Has Results|Bacterial Vaginosis Home Screening to Prevent STDs||Drug:Metronidazole|Interventional|Phase 3|NIH|One-year Incidence of Chlamydial and Gonococcal Infections in Women Who Receive Screening (Every 2 Months) and Treatment for Asymptomatic Bacterial Vaginosis as Compared to a Control Group With Regular Monitoring (Every 2 Months) But no Treatment;  Percentage of Women Testing Positive for Bacterial Vaginosis (BV) Through 12 Months|1370|NCT00667368|July 2008
3566|Withdrawn|A Study to Evaluate PT-523 in Patients With Refractory Leukemia||Drug:PT-523forInjection|Interventional|Phase 1 / Phase 2|Industry||0|NCT00129558|July 2005
3567|Not yet recruiting|Subcutaneous Furosemide in Acute Decompensated Heart Failure Pilot||Drug:Furosemide|Interventional|Phase 1|Other|the overall safety of a strategy based on subcutaneous delivery of furosemide in inpatients.;  the overall safety of a strategy based on subcutaneous delivery of furosemide in outpatients.;  the overall feasibility of an outpatient strategy based on subcutaneous delivery of furosemide.|40|NCT02877095|October 2016
3568|Not yet recruiting|Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer||Other:LaboratoryBiomarkerAnalysis;  Drug:Retinoid9cUAB30;  Procedure:TherapeuticConventionalSurgery|Interventional|Phase 1|NIH|Absolute change in Ki-67 expression in breast epithelial cells of patients treated with 9cUAB30 assessed by immunohistochemistry;  Change in apoptosis in breast epithelial cells of patients treated with 9cUAB30 assessed by TUNEL assay and immunohistochemistry;  Change in gene expression of breast cancer samples using a custom gene panel from Nanostring Technologies|40|NCT02876640|November 2016
3569|Not yet recruiting|A Feasibility Registry of Actigraphy Monitoring in Degenerative Mitral Regurgitation Subjects Receiving the MitraClip&#174; Device|||Observational||Industry|Observational change in daily reported activity levels (counts/min) as assessed by actigraphy from baseline to 30 days post MitraClip implantation;  Levels of daily and weekly activity as assessed by actigraphy;  PatternsofdailySleep/Wakebyactigraphy;  NYHAFunctionalClass;  MitralRegurgitationseverity;  Echocardiographicassessment;  Distancewalked6minutewalktest(6MWT);  Health-relatedqualityoflife(QoL)|36|NCT02858245|August 2016
3570|Available|Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin&apos;s B-Cell Lymphoma||Drug:MT-3724|Expanded Access|Phase 1|Industry|||NCT02715843|December 2015
3571|Completed|A Multi-Reader Multi-Case Pivotal Trial||Device:FFDMPlusDBT;  Device:FFDMAlone|Interventional|Phase 2|Industry|Correct Lesion Localization: Area under the receiver operating characteristic (ROC) curve (AUC) for FFDM + DBT versus FFDM alone based on probability of malignancy (POM) scores and requiring correct lesion localization.|300|NCT02692209|December 2015
3572|Completed|Multi-Reader Multi-Case Controlled Clinical Trial to Assess the Fujifilm FFDM and DBT Reader Training Program||Device:FFDMPlusDBT;  Device:FFDM|Interventional|Phase 2|Industry|PerSubjectAreaUnderCurve(AUC)|100|NCT02685566|August 2015
3573|Recruiting|The ENRGISE Pilot Study||DietarySupplement:Omega-3fishoil;  Drug:Losartan;  Other:Placebo|Interventional|Phase 2|Other / NIH|Changes in the Interleukin-6 level between the groups performed at baseline months 3 6 9 and 12.;  Changes to the 400 meter walk for major mobility disability will be performed at baseline months 3 6 9 and 12 between the groups;  Changes in the Short Physical Performance Battery (SPPB) will be performed at baseline months 3 6 9 and 12 between the groups;  Changes in frailty will be performed at baseline months 3 6 9 and 12 between the groups;  Changes in the isometric hand grip strength will be performed at baseline months 3 6 9 and 12 between the groups;  Changes in the isokinetic dynamometry of the knee extensors and flexors will be performed at baseline and month 12 between the groups;  Changes in the Short Form Health Survey (SF-36) will be performed at baseline months 3 6 9 and 12 between the groups|300|NCT02676466|February 2016
3574|Recruiting|SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma||Drug:SL-401/Pomalidomide/Dexamethasone|Interventional|Phase 1 / Phase 2|Other|The percentage of patients with treatment-related and treatment-emergent adverse events;  SL-401 plasma concentration at multiple time points;  SL-401maximumplasmaconcentration;  Overallresponserate;  Progressionfreesurvival|32|NCT02661022|January 2016
3575|Recruiting|Study of Indomethacin Capsules to Treat Pain Following Surgery in Children Ages 6 to &lt;17 Years of Age||Drug:IndomethacinCapsuleslowdose;  Drug:IndomethacinCapsuleshighdose|Interventional|Phase 2|Industry|PlasmaConcentrationsofindomethacin;  Safety of Indomethacin Capsules low dose and high dose as assessed by the incidence of adverse events from baseline to Day 3 or early termination|30|NCT02633969|December 2015
3576|Recruiting|A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.||Biological:MEDI4276|Interventional|Phase 1 / Phase 2|Industry|Number and percentage of subjects with adverse events (AEs) serious adverse events (SAEs) and dose-limiting (DLTs).;  ObjectiveResponseRate(ORR);  PeakPlasmaConcentration(Cmax);  Progression-freesurvival(PFS);  Overallsurvival(OS);  Area under the plasma concentration versus time curve (AUC)|216|NCT02576548|September 2015
3577|Recruiting|PK PD Safety Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Non-Hodgkin&apos;s B-Cell Lymphoma and B-Cell Chronic Lymphocytic Leukemia||Drug:MT-3724|Interventional|Phase 1|Industry|Tolerability as measured by number of subjects with dose limiting toxicities;  Safety as measured by number of subjects with Adverse Events using CTCAE;  Tolerability as measured by adverse events using CTCAE and clinical laboratory parameters;  PK as measured by concentrations of free MT-3724 (Cmax AUC tmax Cinf);  PD as measured by clinical symptoms tumor response immunogenicity;  TumorResponseasmeasuredbyPETorCTscan|40|NCT02361346|February 2015
3578|Withdrawn|A Phase 2 Extension of Study GCS-100-CS-4003||Drug:GCS-100|Interventional|Phase 2|Industry|Determine the safety and tolerability of extended dosing with a fixed dose of GCS-100 3 mg IV push in patients with CKD (side effects)|0|NCT02333955|January 2015
3579|Recruiting|Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone||Drug:MRZ;  Drug:BEV|Interventional|Phase 1 / Phase 2|Industry|Phase 1: Maximum Tolerated Dose (MTD) / Maximum Administered Dose (MAD);  Phase1:RecommendedPhase2Dose(RP2D);  Phase2:MRZsingleagenttumoractivity;  Phase1:Tumoractivity;  Phase1andPhase2:Assesssafetyandtolerance;  Phase1:MRZpharmacokinetics;  Phase 1: Proteasome Activity in Packed Whole Blood (PWB);  Phase 1 and Phase 2: Neurological Coordination Assessment;  Phase1andPhase2:QualityofLifeAssessment|66|NCT02330562|March 2015
3580|Enrolling by invitation|Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)||Drug:KRN23|Interventional|Phase 2|Industry|Incidence frequency and severity of adverse events and serious adverse events;  ChangefromBaselineinserumFGF23;  ChangefromBaselineinserumALP;  ChangefromBaselineinserum125(OH)2D;  ChangefromBaselineinserumiPTH;  Change from Baseline in serum and urine phosphorus;  ChangefromBaselineinserumTRPandTMP/GFR;  ChangefromBaselineinserumBALP;  ChangefromBaselineinserumCTx;  ChangefromBaselineinserumP1NP|25|NCT02312687|December 2014
3581|Recruiting|Autologous Cell Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery||Biological: autologous muscle-derived cells (AMDC)|Interventional|Phase 1 / Phase 2|Industry|Rateofproduct-relatedseriousadverseevents;  Rate of product-related biopsy procedure-related and injection procedure-related adverse events;  Volumeofpost-voidresidualurine;  Amountofurineleakage;  Change is patient-reported quality of life assessed by a questionnaire|30|NCT02291432|December 2014
3582|Completed|A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults||Biological:MEDI7510;  Biological:IIV;  Biological:Placebo|Interventional|Phase 1|Industry|Theoccurrenceallsolicitedsymptoms;  The occurrence of treatment-emergent adverse events and serious adverse events;  The occurrence of treatment-emergent serious adverse events new onset chronic disease and adverse events of special interest;  Humoralimmunogenicityassessments;  Cellularimmunogenicityassessments|363|NCT02289820|January 2015
3583|Completed|Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study||Drug:fosbretabulin|Interventional|Phase 2|Industry|Changeinbiomarkersfrombaseline|7|NCT02279602|December 2014
3584|Completed|Randomized Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea||Drug:AZD0914;  Drug:Ceftriaxone|Interventional|Phase 2|NIH|The proportion of subjects with microbiological cure rate at urethral or cervical sites in each study arm;  The proportion of subjects reporting Adverse Events (AEs) and Serious Adverse Events (SAEs) considered product-related.;  The proportion of subjects with microbiological cure rate at rectal sites in each study arm;  The proportion of subjects with clinical cure in each study arm;  The proportion of subjects with microbiological cure at pharyngeal sites in each study arm;  The proportion of subjects with no detectable N. gonorrhoeae nucleic acid in urethral cervical rectum and pharynx specimen in each study arm;  The in vitro minimum inhibitory concentrations against AZD0914 and ceftriaxone of gonococcal isolates from culture|180|NCT02257918|November 2014
3585|Completed|Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)|||Observational||Industry|List Primary Sclerosing Cholangitis (PSC) Symptoms for inclusion in patient questionnaire|26|NCT02247934|October 2014
3586|Terminated|Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga BAY73-4506) in Patients With Advanced or Metastatic Cancer||Drug:Refametinib(BAY86-9766);  Drug:Regorafenib(StivargaBAY73-4506)|Interventional|Phase 1|Industry|Maximum drug concentration in plasma after multiple dose (Cmaxmd) for Refametinib;  Maximum drug concentration in plasma after multiple dose (Cmaxmd) for Refametinib metabolite M-11;  Area under the plasma concentration-time curve from 0 to 12 h after multiple dose (AUC(0-12)md) for Refametinib;  Area under the plasma concentration-time curve from 0 to 12 h after multiple dose (AUC(0-12)md) for Refametinib metabolite M-11;  Maximum drug concentration in plasma after multiple dose (Cmaxmd) for Regorafenib;  Maximum drug concentration in plasma after multiple dose (Cmaxmd) for Regorafenib metabolite M-2;  Maximum drug concentration in plasma after multiple dose (Cmaxmd) for Regorafenib metabolite M-5;  Area under the plasma concentration-time curve from 0 to 24 h after multiple dose (AUC(0-24)md) for Regorafenib;  Area under the plasma concentration-time curve from 0 to 24 h after multiple dose (AUC(0-24)md) for Regorafenib metabolite M-2;  Area under the plasma concentration-time curve from 0 to 24 h after multiple dose (AUC(0-24)md) for Regorafenib metabolite M-5;  Tumor response during Phase 2 as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1;  Maximum drug concentration in plasma (Cmax) for Refametinib and its metabolite M-11;  Time to reach maximum drug concentration in plasma after single (first) dose (tmax) for Refametinib and its metabolite M-11;  Area under the plasma concentration-time curve from 0 to 8 h (AUC(0-8)) for Refametinib and its metabolite M-11;  Time to reach maximum drug concentration in plasma after multiple dose (tmaxmd) for Refametinib and its metabolite M-11;  Maximum drug concentration in plasma (Cmax) for Regorafenib and its metabolites M-2 and M-5;  Time to reach maximum drug concentration in plasma after single (first) dose (tmax) for Regorafenib and its metabolites M-2 and M-5;  Area under the plasma concentration-time curve from 0 to 24 h (AUC(0-24)) for Regorafenib and its metabolites M-2 and M-5;  Time to reach maximum drug concentration in plasma after multiple dose (tmaxmd) for Regorafenib and its metabolites M-2 and M-5;  Tumor response during Phase 1b as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1;  OverallsurvivalduringPhase2;  TimetoprogressionduringPhase2;  Progression-freesurvivalduringPhase2|20|NCT02168777|June 2014
3587|Active not recruiting|Acquisition of Breast Mammography Images||Device:FFDMMammography;  Device:DBTMammography|Observational|Phase 3|Industry|Case Collection of Mammography Images with Breast Cancer;  Case Collection of Mammography Images that Required Recall with No Cancer;  Case Collection of Mammography Images with No Cancer|1232|NCT02156258|June 2014
3588|Active not recruiting|A Phase 2 Extension Study of Study GCS-100-CS-4002||Drug:GCS-100|Interventional|Phase 2|Industry|EvaluationofSafety|116|NCT02155673|January 2014
3589|Completed|Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC|||Observational||Industry|TumorSpecimen|11|NCT02143492|August 2013
3590|Active not recruiting|A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers||Drug:fosbretabulintromethamine|Interventional|Phase 2|Industry|Change from one or more baseline biomarker values for each patient to each study visit and study end|18|NCT02132468|September 2014
3591|Recruiting|A Multi-Site Clinical Evaluation of the ARIES Norovirus Assay|||Observational||Industry|Diagnostic accuracy will be expressed in terms of clinical sensitivity (or positive agreement) and specificity (or negative agreement).|500|NCT02092259|January 2014
3592|Recruiting|Case Review of the Penumbra and Indigo Systems for Mechanical Thrombectomy in the Periphery||Device: Mechanical Thrombectomy by the Indigo System|Interventional|Phase 4|Industry|Angiographic assessment of vessel patency at immediate post-procedure as measured by TIMI scores;  Proceduralseriousadverseevents|100|NCT02085551|March 2014
3593|Completed|A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults||Drug:RXI-109;  Drug:Placebo|Interventional|Phase 2|Industry|Reduction in recurrence of hypertrophic scarring after scar revision surgery;  SafetyofRXI-109|25|NCT02030275|November 2013
3594|Terminated|A Phase 1 Open-label Safety Study of NKA in Patients With Type 2 Diabetes||Biological:Neo-kidneyaugment|Interventional|Phase 1|Industry|Number of adverse events related to study procedures or investigational product;  Numberofrenal-specificadverseevents|1|NCT02008851|December 2013
3595|Completed|Pharmacokinetics of Multiple Dose Methadone in Children Treated for Opiate Withdrawal||Drug:Methadone|Observational|Phase 1|Other / NIH|PK Parameters after multiple doses of enteral methadone;  PKofmethadone&apos;sprimarymetaboliteEDDP;  PKofR-andS-enantiomersofmethadone;  CorrelationbetweenplasmaandDBSsamples;  Correlationbetweenplasmaandscavengesamples;  Influence of CYP3A4 and CYP3B6 genetic polymorphisms on methadone PK;  MethadonepharmacodynamicsusingtheWAT-1;  Adverseevents|26|NCT01945736|January 2014
3596|Completed|Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis||Drug:AM001Cream7.5%;  Drug:PlaceboofAM001Cream|Interventional|Phase 2|Industry|Investigator&apos;s Global Assessment of Disease Severity (IGA);  Target Lesion Psoriasis Area Severity Index (PASI);  BodySurfaceArea(BSA);  TargetLesionArea;  DermatologyLifeQualityIndex(DLQI);  Pharmacokinetics|92|NCT01938599|August 2013
3597|Active not recruiting|A First-in-Human Double Blind Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.||Drug:AMG282;  Drug:AMG282MatchingPlacebo|Interventional|Phase 1|Industry|Incidenceoftreatmentemergentadverseevents;  Incidence of abnormal clinically significant vital signs;  Incidence of abnormal clinically significant chemistry hematology and urinalysis test results;  Incidence of abnormal clinically significant ECG results;  Incidenceofanti-AMG282antibodies;  Determination of various PK parameters including tmax AUClast and Cmax|70|NCT01928368|August 2013
3598|Completed|Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen||Biological:PurifiedVeroRabiesVaccine(VRVg);  Biological: Imovax&#174; Rabies: inactivated rabies vaccine|Interventional|Phase 2|Industry|Number of participants with rabies virus neutralizing antibody (RVNA) titer &#8805; 0.5 IU/mL at Day 42 (14 days after the last vaccination of primary vaccination series).;  Number of Participants Reporting Solicited Injection Site Reactions Solicited Systemic Reactions Unsolicited Systemic Reactions and Serious Adverse Events Occurring Throughout the Trial;  Geometric mean titer ratio (GMTR) following vaccination with either Purified Vero Rabies Vaccine Serum Free or Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post exposure Regimen|342|NCT01877395|June 2013
3599|Recruiting|Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab Pertuzumab Combination Trastuzumab +Pertuzumab or Combination Trastuzumab + Lapatinib||Drug:Trastuzumab;  Drug:pertuzumab;  Drug:lapatinib|Interventional|Phase 0|Other / Industry|difference in kinome activation pre and post treatment;  predictabilityinkinomeactivation|40|NCT01875666|September 2013
3600|Suspended|Electrical Stimulation for the Treatment of Chronic Post-Stroke Shoulder Pain Using the Smartpatch System||Device: Smartpatch Peripheral Nerve Stimulation (PNS) System|Interventional||Industry|Change from Baseline Shoulder Pain Intensity at End of Treatment (EOT);  Device related adverse event rates in treatment and control groups;  Change from Baseline Shoulder Pain Interference at End of Treatment;  Durability of change from baseline Shoulder Pain Intensity at 12-weeks beyond Treatment;  Change from Baseline Quality of Life at End of Treatment;  Change from Baseline Average Pain Intensity at End of Treatment;  Patient Global Impression of Change at End of Treatment;  Change in Pain Medication Usage at End of Treatment;  Clinical Global Impression of Improvement at End of Treatment|180|NCT01847885|April 2013
3601|Active not recruiting|An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors||Drug:ruxolitinib;  Drug:gemcitabine;  Drug:nab-paclitaxel;  Drug:filgrastim|Interventional|Phase 1|Industry|Adverse events that are defined as dose limiting toxicities occurring in the first 28 days of treatment.;  Plasma concentrations will be used to estimate peak plasma concentration (cmax) and area under the plasma concentration curve (AUC).;  Plasma concentration of tumor specific biomarkers and cytokines before and during treatment.;  Clinical activity as measured by the greatest decrease in tumor burden compared to baseline.|75|NCT01822756|April 2013
3602|Terminated|Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson&apos;s Disease||Drug:Topiramate;  Drug:Placebo|Interventional|Phase 2|Other|TheUnifiedDyskinesiaRatingScale(UDysRS);  ClinicalGlobalImpression-Changescore|44|NCT01789047|March 2013
3603|Recruiting|First-line Pomalidomide Bortezomib and Dexamethasone For AL Amyloidosis or LCDD||Drug:pomalidomide;  Drug:bortezomib;  Drug:dexamethasone;  Other:LaboratoryBiomarkerAnalysis|Interventional|Phase 1|Other / NIH|Maximum tolerated dose defined as the dose level before 2 of 6 patients experience dose-limiting toxicity (DLT) using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;  Completehematologicresponserate(hCR);  Overall hematologic response rate (partial response [PR] + complete response [CR]);  Organresponserates(heartliverkidney);  Overallsurvival;  Progressionfreesurvival|36|NCT01728259|March 2013
3604|Completed|Blepharospasm Patient Survey for Patients With Blepharospasm||Other:Nointervention-onlyonetimesurvey|Observational||Industry|BotulinumToxinTreatmentInformation|124|NCT01686061|September 2012
3605|Completed|Laser Vision Correction Use of an Eye Shield for Maintaining Vision and Mitigating Pain||Device:EyeShield|Interventional||Industry|Evidence of maintaining vision and mitigating pain post Laser Vision Correction using an Eye Shield|125|NCT01675375|March 2012
3606|Terminated|Gastric Restriction Using the EndoSurgical Operating System||Device:UsingtheEOSforgastricrestriction|Interventional||Industry|ClinicalEvaluationinregardstoWeightLoss|32|NCT01661608|December 2008
3607|Completed|A Safety Study of Carfilzomib Cyclophosphamide &amp; Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma||Drug:Carfilzomib;  Drug:Cyclophosphamide;  Drug:Dexamethasone|Interventional|Phase 1|Other / Industry|Adverse Events as a measure of safety and tolerability;  OverallResponseafterinductiontherapy;  OverallResponsepostASCT;  TimetoProgression;  ProgressionFreeSurvival;  TimetoNextTherapy|29|NCT01660750|January 2013
3608|Active not recruiting|Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies||Drug:SNX-5422|Interventional|Phase 1|Industry|Numberofpatientswithdoselimitingtoxicities;  Number of patients with adverse events as a measure of tolerability;  Tumorprogression|10|NCT01635712|February 2014
3609|Completed|CDC Prevention Epicenters Wake Up and Breathe Collaborative||Procedure:DailySAT&amp;SBT|Interventional||Other / U.S. Fed|ChangeinVACrate.;  ICU-specificoutcomes;  Hospital-specificoutcomes;  Patient-specificoutcomes|3342|NCT01583413|May 2012
3610|Active not recruiting|Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer||Drug:Veliparib;  Radiation:Standardradiationtreatment|Interventional|Phase 1|Other|To determine the maximum tolerated dose of veliparib that can be administered concurrently with standard doses of radiotherapy to the chest wall and regional nodes.;  To describe the nature of toxicity that develops when PARP inhibitors are administered concurrently with chest wall radiotherapy.|30|NCT01477489|January 2012
3611|Completed|Parents of Pediatric Solid Organ Transplant Recipients: Transition to Home and Chronic Illness Care|||Observational||Other|Determine if discharge preparation has an effect on parent readiness for hospital discharge and if readiness for hospital discharge effects post-discharge outcomes following hospital discharge in parents of solid organ transplant recipients;  Posttransplantoutcomes|51|NCT01389804|July 2010
3612|Completed                  Has Results|Hyperbaric Oxygen Therapy (HBO2) for Persistent Post-concussive Symptoms After Mild Traumatic Brain Injury (mTBI)||Drug:hyperbaricoxygen;  Other:shamhyperbaricair|Interventional|Phase 2|U.S. Fed|Post-Intervation Post-concussion Symptom Scores Using RPQ - Intent to Treat;  Change in Post-concussion Symptom Scores Using RPQ - Intent to Treat;  Post-Intervation Post-concussion Symptom Scores Using RPQ - Per Protocol Population;  Change in Post-concussion Symptom Scores Using RPQ - Per Protocol Population|79|NCT01306968|February 2011
3613|Completed                  Has Results|Collection and Testing of Respiratory Samples||Device:artusInfluenzaA/BRT-PCRTest|Observational||Industry|DetectionofRespiratoryViruses|272|NCT01302418|February 2011
3614|Completed|1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors||Drug:1-methyl-d-tryptophan;  Drug:docetaxel;  Other:diagnosticlaboratorybiomarkeranalysis;  Other:pharmacologicalstudy|Interventional|Phase 1|NIH|MTD defined as the dose level in which 1 of 6 patients experiences DLT assessed using CTCAE version 4.0;  PKdata;  Overall objective response rate per RECIST criteria|27|NCT01191216|September 2010
3615|Completed|Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy||Biological:Wholepeanutextract;  Biological:Placeboformulation|Interventional|Phase 1|Industry|Safetyevaluation;  Systemic reactions evaluation and treatment; treatment adherence|100|NCT01170286|July 2010
3616|Completed                  Has Results|Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis||Drug:HalobetasolProprionateLotion0.05%;  Drug:HalobetasolProprionateCream0.05%|Interventional|Phase 2|Industry|AdrenalSuppressionPotential;  PharmacokineticProperties(Cmax);  PharmacokineticProperties(Tmax);  PharmacokineticProperties(AUC);  ChangesinDiseaseSeverity(Success);  Number of Subjects Whose Signs of Psoriasis Was Designated &quot;Success&quot;|43|NCT01166646|July 2010
3617|Completed|A Study Evaluating the Efficacy of SAR 1118 (0.1% 1.0% 5.0%) Ophthalmic Solution in Subjects With Dry Eye||Drug:Lifitegrast;  Drug:Placebo|Interventional|Phase 2|Industry|Sign: Corneal fluorescein staining before CAE exposure;  Symptoms:Ocularsymptomspre-andpost-chamber;  Signs: Ocular Signs pre- &amp; post-chamber; Additional evaluations of dry eye including fluorescein staining lissamine green staining conjunctival redness TFBUT blink rate OPI STT &amp; corneal sensitivity;  Safetyacrosstreatmentgroups|230|NCT00926185|June 2009
3618|Completed|Comparison of Fetal Fibronectin (fFN) Specimen Collection Methodologies: With Speculum Versus Without Speculum|||Observational||Industry||329|NCT00883324|March 2009
3619|Completed                  Has Results|A Phase 2a Study to Evaluate the Safety and Efficacy of AZX100 in Trocar Sites of Arthroscopic Shoulder Surgery Patients||Drug:Placebo;  Drug:AZX100|Interventional|Phase 2|Industry|Differences Among the 3 Dosage Groups in the Patient (PSAS) and Observer (OSAS) Scar Assessment Scale (POSAS) Scores;  Between-group Mean Differences in Visual Analog Scale Scores Rated by Independent Blinded Raters Using 3D Photography;  Between-group Mean Differences in Objective Measures Via 3D Photography (Elevation Length Width);  Between-group Mean Differences in Objective Measures Via 3D Photography (Volume);  HistologicalEvaluationofCollagen;  Histological Evaluation of Number of Alpha Smooth Muscle Actin Cells|150|NCT00811577|January 2009
3620|Completed|Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control|||Observational||Other / Industry||16|NCT00806520|April 2008
3621|Completed|Gene Transfer for Cancer Pain||Biological:NP2|Interventional|Phase 1|Industry|Safety measured by vital signs physical exam findings clinical laboratory analyses and treatment related Adverse Events (AE).;  Evaluatechangesincancer-relatedpain|10|NCT00804076|February 2008
3622|Terminated|Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma||Drug:BIW-8962|Interventional|Phase 1|Industry|SerumMproteinlevels;  Timetoprogressionordeath|23|NCT00775502|October 2008
3623|Unknown&nbsp;&#8224;|An Observational Study of Pruritus Amongst Hemodialysis Patients|||Observational||Industry||80|NCT00715260|December 2007
3624|Terminated                  Has Results|Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer||Drug:etaracizumab;  Biological:bevacizumab|Interventional|Phase 1 / Phase 2|NIH|Maximum Tolerated Dose of Bevacizumab  Based on Incidence of Dose-limiting Toxicity (DLT) Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (Phase I);  Progression-freeSurvival(PhaseII);  Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug Graded According to NCI CTCAE Version 3.0 (Phase II);  OverallSurvival(PhaseII);  Response Rate According to Response Evaluation Criteria in Solid Tumors (RECIST) Including Confirmed and Unconfirmed Complete and Partial Responses (Phase II);  Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug|5|NCT00684996|June 2008
3625|Completed|A Healthy Volunteer And Patient Study To Assess The Safety Tolerability And Pharmacokinetics Of GSK1265744||Drug:GSK1265744|Interventional|Phase 1|Industry|Safety evaluations (labs ECG blood pressure) and blood sampling for PK Continuous AE monitoring through study conclusion and follow up 7-14 days after last dose. For Part C only: anti-viral activity through study conclusion and follow-up.;  GSK1265744 blood levels to determine PK parameters;  PlasmaHIV-1RNAlevels;  To assess the development of genotypic viral resistance if appropriate in HIV cohort.|58|NCT00659191|February 2008
3626|Completed|Phase 2 Study of the Safety of Diannexin in Kidney Transplant Recipients||Drug:Diannexin;  Drug:Placebo|Interventional|Phase 2|Industry / Other|Safety assessments -- physical examinations vital signs clinical safety laboratory tests ECGs immunogenicity testing adverse events;  Populationpharmacokinetics|58|NCT00615966|February 2008
3627|Completed|Study of the Scandinavian Total Ankle Replacement (STAR) for the Treatment of Bilateral Degenerative Ankle Disease||Device: Scandinavian Total Ankle Replacement (STAR)|Interventional|Phase 3|Industry|Safety endpoints to be measured are: &#8226; Device failure or device removal/revision &#8226; Radiographically confirmed loosening and migration &#8226; Complications|21|NCT00586781|September 2001
3628|Completed                  Has Results|Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy||Drug:IntravenousRituximab;  Drug:ACE/ARB;  Dietary Supplement: Omega-3 Fatty Acid Fish Oil Supplement|Interventional|Phase 4|Other / Industry|ChangeinProteinuriaat12Months;  BiochemicalMarkerIgAat12Months;  Biochemical Marker Gd-Immunoglobulin A Subclass 1 (IgA1) at 12 Months;  Biochemical Marker Immunoglobulin G (IgG) AutoAb at 12 Months|34|NCT00498368|February 2009
3629|Active not recruiting|Phase II Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy||Drug:Lapatinib;  Procedure:Radiotherapy;  Device: G.E. Healthcare 1.5T MR systems revision 12.0 M5;  Procedure:Pet/CT|Interventional|Phase 2|Other / Industry|Efficacy of combining lapatinib and radiotherapy in terms of time to progression (TTP) in patients with locally advanced HNSCC who cannot tolerate concurrent chemoradiotherapy;  2-year locoregional control progression free survival and over all survival rates in these patients;  Rate and pattern of late-treatment related toxicity in these patients;  Role of DCE MRI in predicting treatment outcomes in treated patients Outcome Time Frame:;  Changes in the expression of relevant tumoral and circulating biomarkers;  Change in quality of life status relative to baseline|60|NCT00490061|July 2007
3630|Terminated                  Has Results|A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel&#8482; in Subjects With Recurrent Glioma||Drug:OncoGel(ReGel/Paclitaxel)|Interventional|Phase 1 / Phase 2|Other|OccurenceofDose-limitingToxicities(DLTs)|4|NCT00479765|March 2007
3631|Completed|Influenza Vaccine in Premature Infants||Biological: Trivalent Inactivated Influenza Vaccine|Observational|Phase 4|Other||66|NCT00455169|October 2007
3632|Completed                  Has Results|Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer||Drug:Dasatinib;  Drug:Docetaxel|Interventional|Phase 1 / Phase 2|Industry|Maximum Tolerated Dose (MTD) of Dasatinib Administered With Docetaxel;  Recommended Phase 2 Dose of Dasatinib Administered With Docetaxel 75 mg/m^2;  Percentage of Participants With a Prostate Specific Antigen (PSA) Response;  Duration of Prostate Specific Antigen (PSA) Response;  Number of Months of Progression-free Survival (PFS);  Percentage of Participants With an Objective Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST);  Number of Participants by Best On-study Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST);  Number of Participants by Best On-study Bone Scan Assessment From Baseline;  Percentage of Participants With Improvement on Bone Scan;  Baseline Scores and Changes in Pain Intensity From Baseline on the Brief Pain Inventory Short Form (BPI-sf) Scores Through Cycle 6;  Number of Participants With Death as Outcome Serious Adverse Events (SAEs) Drug-related SAEs Drug-related Adverse Events (AEs) Drug-related AEs Leading to Discontinuation and Drug-related Grade 3 or 4 AEs in the Overall Population;  Number of Participants With Death as Outcome Drug-related Serious Adverse Events (SAEs) Drug-related Adverse Events (AEs) Drug-related AEs Leading to Discontinuation and Drug-related Grade 3 or 4 AEs in the Phase 2 Cohort;  Area Under the Concentration-time Curve (AUC) From 0 to 10 Hours Postdose (AUC [0-10])and AUC in 1 Dosing Interval From Time 0 to 24 Hours (AUC[Tau])of Dasatinib Coadministered With Docetaxel;  Maximum Observed Plasma Concentration (Cmax) of Dasatinib and of Docetaxel;  Area Under the Concentration-time Curve (AUC) From Time 0 to Infinity (AUC[Inf]) of Docetaxel;  Number of Participants Meeting the Criteria for On-study Abnormal Results Grade 3-4 of Clinical Laboratory Tests|49|NCT00439270|July 2007
3633|Unknown&nbsp;&#8224;|AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme||Drug:AQ4N;  Drug:Temozolomide;  Procedure:Radiotherapy|Interventional|Phase 1 / Phase 2|Industry|Phase 1b: Evaluation of the safety and tolerability of AQ4N in combination with radiation therapy and temozolomide (TEMODAR&#174;)for the treatment of glioblastoma multiforme (GBM). Dose levels for the Phase 2a will be selected.;  Phase 2a: Rate of progression-free survival at 6 months.;  Phase 2a: Rate of progression-free survival at 12 months;  Percentofsubjectsaliveat12months;  Durationofprogression-freesurvival;  Timetoprogression;  Durationofoverallsurvival|60|NCT00394628|October 2006
3634|Completed|ALD-301 for Critical Limb Ischemia Randomized Trial||Procedure: ALDH-br bone marrow cells vs. mononuclear bone marrow cells|Interventional|Phase 1 / Phase 2|Industry|adverseevents;  ankle-brachialsystolicpressureindex;  transcutaneousoxygenvalue(mmTorr);  qualityoflife(questionnaires);  sizeoflowerextremityulcer(s);  peripheralnerveconductionexam;  levelofpainatrest(questionnaire);  limbclinicalstatus|20|NCT00392509|October 2006
3635|Terminated|Safety Toleration and Efficacy of CP-741952 for the Treatment of Obesity||Drug:CP-741952|Interventional|Phase 2|Industry|WeightLosstolerationsafety;  WaistCircumferenceserumlipids|100|NCT00367783|June 2006
3636|Completed|Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis||Drug:R89674(genericnamenotyetestablished)|Interventional|Phase 3|Industry|Ocular itching and conjunctival redness post challenge;  Ciliary and episcieral redness; chemosis; lid swelling; tearing; ocular mucous discharge; and nasal symptoms. All measured postchallenge|150|NCT00241319|October 2005
3637|Completed|A Study in Type 1 Diabetic Patients With Repeated Doses of E1 in Combination With G1||Drug:E1andG1|Interventional|Phase 1|Industry|To evaluate the safety and tolerability of repeated subcutaneous doses of E1 in combination with G1 in patients with type 1 diabetes;  To evaluate the pharmacokinetic (PK) profile and clinical effects of repeated subcutaneous doses of E1 in combination with G1 in patients with type 1 diabetes|20|NCT00239148|June 2005
3638|Completed|Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation||Drug:repertaxin|Interventional|Phase 2|Industry|PaO2/inspired oxygen fraction ratio on ICU admission and at 24 hours after ICU admission;  PGDscore;  Timeofmechanicalventilation;  DurationofICUstay;  ICUmortality;  Acuterejectionepisodes;  Patientsurvivalrate;  Pharmacokineticprofile|100|NCT00224406|May 2005
3639|Completed|SHORTness of Breath In the Emergency Department (SHORTIE)||Device:TriageProfilerS.O.B.Panel|Interventional|Phase 2 / Phase 3|Other|Timetospecifictreatmentforfinaldiagnosis;  Lengthofstayintheemergencydepartment(ED);  EDandtotalhospitalcosts;  Outcome at 30 days (Phase I and II) and 90 days (Phase II);  Diagnostic accuracy of the Triage&#174; Profiler S.O.B. panel for acute myocardial infarction (AMI) heart failure (HF) and pulmonary embolism (PE) in patients presenting with S.O.B.|306|NCT00206830|April 2005
3640|Completed|Registry for African Americans With Early Rheumatoid Arthritis|||Observational||NIH|Radiographic severity of rheumatoid arthritis in African Americans|357|NCT00074555|January 2001
3641|Completed|A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer||Drug:EMD72000|Interventional|Phase 2|Industry||38|NCT00073541|April 2003
3642|Completed|Anidulafungin in Treating Immunocompromised Children With Neutropenia||Drug:anidulafungin|Interventional|Phase 1 / Phase 2|NIH|||NCT00068471|July 2003
3643|Completed|Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients||Drug:Entecavir|Interventional|Phase 2 / Phase 3|Industry|||NCT00051038|September 2002
3644|Completed|Soy Protein Supplement in Preventing Prostate Cancer in Patients With Elevated Prostate-Specific Antigen Levels||DietarySupplement:soyproteinisolate;  DietarySupplement:caseinproteins|Interventional|Phase 2|Other / NIH|Reduction of prostatic cellular proliferation rates by 50% as measured by Ki-67|26|NCT00031746|February 2000
3645|Unknown&nbsp;&#8224;|Video Support Program For Families With a Parent Newly Diagnosed With Cancer||Procedure:psychosocialassessmentandcare|Interventional||Industry / NIH|||NCT00020553|August 2000
3646|Terminated                  Has Results|Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer||Drug:Cisplatin&amp;Gemcitabine;  Drug:Cisplatin&amp;Pemetrexed;  Drug:Docetaxel&amp;Gemcitabine;  Drug:Pemetrexed&amp;Gemcitabine|Interventional|Phase 2|Other / Industry|1-year Progression Free Survival Rate in Chemo-naive Select Stage IIIB or Stage IV NSCLC Patients;  MedianTimetoProgressiveDisease;  Mean Change From Baseline to Follow-up Cycle in Quality of Life - Functional Assessment of Cancer Therapy-Lung (FACT-L);  Drug Sensitivity Quartiles for Cisplatin and Pemetrexed|101|NCT00509366|May 2007
3647|Active not recruiting|Cardiovascular Risk and Preventive Care in Prostate Cancer Patients Receiving Radiation and Hormone Therapy|||Observational||Other|Proportion of prostate cancer patients with controlled blood sugars blood pressure and cholesterol profile.;  Proportion of prostate cancer patients with guideline-recommended cardiovascular preventive care (glucose testing cholesterol testing and blood pressure measurement).;  Proportion of prostate cancer patients who receive other (non-cardiovascular) guideline-recommended primary and preventive care (flu vaccination colorectal cancer screening and healthy lifestyle counseling).;  Patient-reportedqualityoflife.;  Patient-reportedcoordinationofcare.;  Patient-reportedsatisfactionwithcare.|101|NCT02003417|June 2012
3648|Completed|Open Label Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)||Drug:Dupilumab;  Drug:Midazolam;  Drug:Omeprazole;  Drug:Warfarin;  Drug:Caffeine;  Drug:Metoprolol|Interventional|Phase 1|Industry|Ratio of Area Under Curve last (AUClast) and maximum concentration (Cmax) for Cytochrome P450 substrates from pre-dupilumab administration at baseline (period 1 day 1);  Ratio of AUClast and Cmax for CYP substrates 4 weeks after initiating a weekly regimen of dupilumab (period 2 day 36);  Incidence of treatment-emergent adverse events (TEAEs) from day of first administration of dupilumab to end of study (day 50 for patients who enroll in the OLE study; day 134 for patients who decline participation in the OLE).|14|NCT02647086|December 2015
3649|Recruiting|Intra-Arterial Treatment of Pancreatic Cancer Using the RenovoCath&#8482; RC120 Catheter||Device:RenovoCath&#8482;R120Catheter|Observational||Industry|Survival in patients diagnosed with pancreatic cancer who undergo intra-arterial delivery of chemotherapeutic agents to the pancreas;  Tumor response in the primary site of application as assessed by imaging|100|NCT02591082|December 2015
3650|Completed|Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)||Drug:CTNSR;  Drug:Placebo|Interventional|Phase 2|Industry|Total Attention-Deficit Hyperactivity Disorder Rating Scale IV (ADHD-RS-IV) Score;  Total Attention-Deficit Hyperactivity Disorder Rating Scale IV (ADHD-RS-IV) Score for subgroup of participants with target CTN SR dose of 400 mg/day;  ADHD-RS-IV Score total score after 1 and 2 weeks of treatment;  ADHD-RS-IVInattentionsubscalescore;  ADHD-RS-IV Hyperactivity/Impulsivity subscale score;  Permanent Product Measure of Performance (PERMP) Score;  Clinical Global Impressions of Severity (CGI-S) Score;  Evaluate global impressions of ADHD severity as measured by the Clinical Global Impressions of Improvement (CGI-I);  The Number of participants with treatment-emergent adverse events (TEAEs);  Maximumconcentration(Cmax);  Timetomaximumconcentration(tmax);  Area under the concentration-time curve during the steady-state 24-hour dosing interval (AUC0-t);  Eliminationphasehalf-life(t&#189;);  Lastmeasurableconcentration(Clast);  Time point of the last measurable concentration (tlast);  Eliminationphaserateconstant(ke)|85|NCT02547428|August 2015
3651|Completed|Single Dose Manufacturing Site (Pfizer vs. BIP) And Device (Prefilled Syringe vs. Prefilled Pen) Comparability Study For Bococizumab In Healthy Volunteers||Biological:bococizumabPFS:Pfizer;  Biological:bococizumabPFS:BIP;  Biological:bococizumabPFP|Interventional|Phase 1|Industry|Cmax;  AUCinf;  Cmax for bococizumab using DS from Pfizer as comapred to DS from BIP;  AUCinf for bococizumab using DS from Pfizer as comapred to DS from BIP;  CmaxforbococizumabusingPFSascomapredtoPFP;  AUCinf for bococizumab using PFS as comapred to PFP;  MaxELDL-C;  AUEClast;  TmaxLDL-C;  Tmax;  CL/F;  Vz/F;  T1/2;  AUClast;  IncidenceofADAsandneutralizingantibodies;  TiterforADAsandneutralizingantibodies;  Incidence severity and causal relationship of treatment emergent AEs;  IncidenceandseverityofISRs;  Incidence of abnormal and clinically relevant safety laboratory parameters;  MaxELDL-C using DS from Pfizer as compared to BIP if applicable;  AUEClast using DS from Pfizer as compared to BIP if applicable;  MaxELDL-C using PFS as compared to PFP if applicable;  AUEClast using PFS as compared to PFP if applicable|470|NCT02458209|May 2015
3652|Recruiting|Development of Circulating Molecular Predictors of Chemotherapy and Novel Hormonal Therapy Benefit in Men With Metastatic Castration Resistant Prostate Cancer (mCRPC) (PCF)||Device:AR-v7assays|Observational||Other / Industry|Comparison of median progression free survival (PFS) and overall survival (OS) to AR-v7 status;  Determine the prevalence of defined categories of a molecular taxonomy of mCRPC using CTC biomarkers and correlate each to clinical benefit (PSA response PFS);  Compare levels of circulating epithelial to mesenchymal transition (EMT) and other epithelial plasticity (EP) biomarkers with mCRPC taxonomic categories and clinical outcomes (PSA decline rates PFS);  Determine molecular lesions in CTCs and ctDNA that consistently emerge during enzalutamide and taxane chemotherapy progression in men with mCRPC;  Correlate specific AR-v7 assays with clinical outcomes (PSA decline rates PFS);  Correlatate other AR-variants with clinical outcomes (PSA decline rates PFS);  Change in neuroendocrine biomarkers during enzalutamide and taxane progression in men with mCRPC;  Associate high CTC heterogeneity with PFS OS and CTC genotype/phenotypes|120|NCT02269982|April 2015
3653|Active not recruiting|A Phase II Study of Ibrutinib Plus FCR in Previously Untreated Younger Patients With Chronic Lymphocytic Leukemia||Drug:Ibrutinib;  Drug:Fludarabine;  Drug:Cyclophosphamide;  Drug:Rituximab|Interventional|Phase 2|Other / Industry|RateofMRDNegativeCompleteResponse;  RateofMRD-negativeCR;  PercentageofOverallResponseRate;  PercentageofCompleteResponseRate;  PercentageRateofPartialResponse;  RateofProgressionFreeofSurvival;  RateofOverallSurvival;  TimetoMRD-negativity;  Number of Participants with Serious and Non-Serious Adverse Events;  Association of established CLL prognostic factors including FISH cytogenetics IGHV mutation status and TP53 mutation with clinical response|35|NCT02251548|October 2014
3654|Recruiting|A Randomized Trial to Assess Patient Quality of Life and Function After Alternative Surgeries for Pathologic Fractures of the Femur||Procedure: long-stem cemented hemiarthroplasty (LSCH);  Procedure:intramedullarynailing(IMN);  Behavioral:questionnaires|Interventional||Other / U.S. Fed|differencesinpostoperativefunctionaloutcomes;  postoperativecomplications;  differencesintransfusionvolume|114|NCT02164019|June 2014
3655|Recruiting|Oropharyngeal Administration of Mother&apos;s Colostrum for Premature Infants||Other:oropharyngealmother&apos;smilk;  Other:oropharyngealsterilewater|Interventional||Other|Incidenceofoflate-onsetsepsis;  Incidenceofnecrotizingenterocolitis;  Incidenceofventilator-associatedpneumonia;  Timetoreachfullenteralfeeds;  Lengthofhospitalstay;  Concentrationsoflactoferrininurine;  Changesinstoolmicrobiome;  Changesinurinarybiomarkersofoxidativestress|622|NCT02116699|November 2013
3656|Completed                  Has Results|An Evaluation of Innerview&#8482; a Web-based Tool to Support the Integration of Mental Health in the Primary Care Setting|||Observational||Industry|AccuracyoftheNarrativeModule;  ReliabilityoftheNarrativeModule;  Standard Error of Measure for the Individualized Rating Scale (Rating Module);  ProviderSurvey(Question1);  ProviderSurvey(Question2);  ProviderSurvey(Question3);  ProviderSurvey(Question4);  ProviderSurvey(Question5);  ProviderSurvey(Question6);  ProviderSurvey(Question7);  ProviderSurvey(Question8);  ProviderSurvey(Question9);  ProviderSurvey(Question10);  ProviderSurvey(Question11);  SubjectSurvey(Question1);  SubjectSurvey(Question2);  SubjectSurvey(Question3);  SubjectSurvey(Question4);  SubjectSurvey(Question5);  SubjectSurvey(Question6);  SubjectSurvey(Question7);  SubjectSurvey(Question8);  SubjectSurvey(Question9);  SubjectSurvey(Question10)|139|NCT02025647|January 2014
3657|Completed|Efficacy Safety And Tolerability Study In Subjects With Parkinson&apos;s Disease||Drug:PF-06412562;  Drug:Placebo|Interventional|Phase 1|Industry|Fingertappingspeed;  MaximumObservedPlasmaConcentration(Cmax);  Time to Reach Maximum Observed Plasma Concentration (Tmax);  Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast);  ApparentOralClearance(CL/F);  ApparentVolumeofDistribution(Vz/F);  PlasmaDecayHalf-Life(t1/2);  MeanResidenceTime(MRT);  Number of Participants with categorical scores on the Columbia Suicide Severity Rating Scale (C-SSRS)|19|NCT02006290|March 2014
3658|Active not recruiting                  Has Results|Peanut Epicutaneous Phase II Immunotherapy Clinical Trial||Biological:PlaceboViaskin&#174;Patch;  Biological:Low-doseDBV712Viaskin&#174;Patch;  Biological:High-doseDBV712Viaskin&#174;Patch|Interventional|Phase 2|NIH / Other|Percentage of Subjects With a Successful Treatment Response;  Percentage of Subjects Desensitized to Peanut Protein;  Percentage of Subjects Who Can Successfully Consume 1044 mg or 5044 mg Peanut Protein;  Percentage of Desensitized Subjects in the Active Treatment Arms as Measured by 5044 mg Peanut Protein Oral Food Challenge (OFC);  Average Successfully Consumed Dose as Measured by 5044 mg Peanut Protein Oral Food Challenge (OFC);  Percentage of Subjects Who Pass an OFC to 5044 mg of Peanut Protein Followed by an Open Feeding of Peanut Butter After 8 Weeks or 20 Weeks of Discontinuation of Dosing Subsequent to Passing the Week 130 Oral Food Challenge (OFC);  Percentage of Subjects With Adverse Events Related to Therapy Through Week 52 and Through 30 Months;  Percentage of Subjects Who Successfully Complete the Dosing Regimen With no More Than Mild Symptoms Related to Peanut Patch Dosing After 30 Months of Therapy|75|NCT01904604|September 2013
3659|Active not recruiting|Peanut Oral Immunotherapy in Children||Biological: Peanut Oral Immunotherapy - Liquid Extract;  Biological: Placebo for Peanut Oral Immunotherapy - Liquid Extract form;  Biological: Peanut Oral Immunotherapy - Peanut Flour;  Biological: Placebo for Peanut Oral Immunotherapy - Peanut Flour|Interventional|Phase 2|NIH / Other|ProportionofDesensitizedSubjects;  ToleranceEndpoint;  TransientDesensitization;  HighestToleratedCumulativeDose;  Theincidenceofalladverseevents;  RatesofWithdrawalfromOITorPlacebo|146|NCT01867671|August 2013
3660|Active not recruiting|Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy||Drug:EggOralImmunotherapy;  Drug:BakedEgg|Interventional|Phase 2|Other / NIH|The development of sustained unresponsiveness to egg consumption at 2 years.;  The development of desensitization to &gt;= 5 grams egg white solid.;  Incidence of all serious adverse events during the study.;  Changes in egg-specific mechanistic measures and prick skin test results.|92|NCT01846208|July 2013
3661|Recruiting|Adoption-specific Treatment Prevention Pilot Trial||Behavioral:ADAPT|Interventional|Phase 1|Other|ParentWeeklyReport;  Number of child participants whose internalizing and externalizing behaviors improve|60|NCT01744951|October 2012
3662|Active not recruiting|Fulvestrant With or Without Ganetespib in HR+ Breast Cancer||Drug:Fulvestrant;  Drug:Ganetespib|Interventional|Phase 2|Other|EffectofAddingGanetespibtoFulvestrant;  Number of participants with adverse events after treatment with Ganetespib Plus Fulvestrant;  ObjectiveResponseRateBetweenArmsbyRECIST;  ComparisonofClinicalBenefitRateBetweenArms;  ComparisonofOverallSurvivalBetweenArms|50|NCT01560416|May 2012
3663|Completed|Thoratec&apos;s Reduce Driveline Trauma Through Stabilization and Exit Site Management Study||Other:PercutaneousLeadManagementKit|Observational||Industry|Demonstration of the wearability and usability of the Percutaneous Lead Management Kit;  Incidence of adverse reactions to any Percutaneous Lead Management Kit components;  Evidenceofdrivelineinfection;  Durability of the Percutaneous Lead Management Kit&apos;s infection mitigation and stabilization|50|NCT01485666|May 2012
3664|Terminated|Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer||Drug:kanglaitegelcap;  Drug:Kanglaitegelcap|Interventional|Phase 2|Industry|prostatespecificantigendoublingtime(PSADT);  PSAobjectiveresponse;  KLTcintakecompliance|90|NCT01483586|November 2011
3665|Terminated                  Has Results|Comparison of HP011-101 to Standard Care for Stage I-II Pressure Ulcers in Subjects With Spinal Cord Injury||Drug:HP011-101(XenadermOintment);  Drug:StandardCare|Interventional|Phase 2|Industry|Change From Baseline in Composite PUSH (Pressure Ulcer Scale for Healing) Score|19|NCT01433159|September 2011
3666|Recruiting|Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor||Biological:TTRNA-xALT;  Biological:TTRNA-DCs|Interventional|Phase 1 / Phase 2|Other / U.S. Fed|EvaluatesafetyofTTRNA-DCsandTTRNA-xALT;  Determineprogression-freesurvival;  DetermineObjectiveRadiographicResponseRate;  Correlate magnitude and persistence of anti-tumor humoral or cellular immunity with clinical outcome;  Evaluate changes in cytokine profile and Toll-Like Receptor activation status;  Characterize the immunologic phenotype of lymphocyte subsets (na&#239;ve effector memory regulatory) and natural killer cells;  Identify potential tumor specific antigens as vaccine candidates;  Determine the progression-free survival and overall survival rate|50|NCT01326104|April 2010
3667|Completed|Eosinophilic Esophagitis Databank|||Observational||NIH|Elucidate the genetic components of EoE focusing on a candidate gene approach the TSLP/WDR36 locus and through GWAS analysis|709|NCT01323803|April 2011
3668|Enrolling by invitation|Post-Approval Study to Investigate the Long Term (8 Year) Survivorship of STAR Ankle Among Continued Access Study Patients||Device: Scandinavian Total Ankle Replacement System (STAR Ankle)|Observational||Industry|The primary objective for this study is to examine the long-term survivorship of the STAR Ankle;  American Orthopaedic Foot and Ankle Society questionnaire will be used to evaluate and monitor the progress of patients following foot and ankle surgery.|125|NCT01288586|January 2011
3669|Completed|Safety Tolerability Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness||Drug:ABT-652;  Drug:Placebo|Interventional|Phase 1|Industry|LaboratoryTests;  ECG;  AdverseEvents;  VitalSigns;  MaintenanceWakefulnessTest|36|NCT01124851|August 2010
3670|Completed|Comparative Sedation Study of the MyoSure Hysteroscopic Tissue Removal System||Device:HysteroscopicMorcellator|Interventional||Industry|Subject tolerance of procedure-related pain rated on an 11 point scale (0-10);  Subject assessment of most severe post-procedural pain rated on an 11 point scale;  Subject assessment of most severe pain experienced during 48 hours post procedure rated on an 11 point scale|40|NCT00979342|November 2009
3671|Completed|Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors||Drug:ABT-263;  Drug:gemcitabine|Interventional|Phase 1|Industry|Assess the safety profile of ABT-263 in combination with gemcitabine.;  Study the pharmacokinetic interaction between ABT-263 and gemcitabine.;  Determine the maximum tolerated dose (MTD) of ABT-263 in combination with gemcitabine.;  Evaluate safety at the defined recommended Phase 2 dose (RPTD) and schedule in combination with a standard and weekly regimen of gemcitabine.;  Evaluate preliminary data regarding progression free survival (PFS);  Evaluate preliminary data regarding objective response rate (ORR);  Evaluate preliminary data regarding time to tumor progression (TTP);  Evaluate preliminary data regarding overall survival (OS);  Evaluate preliminary data regarding duration of overall response;  Evaluate preliminary data with Eastern Cooperative Oncology Group (ECOG) performance status;  Evaluatebiomarkersto|46|NCT00887757|September 2009
3672|Completed|An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy||Drug:metreleptin|Interventional||Industry|To provide metreleptin an investigational medication under a treatment protocol to subjects with lipodystrophy that is associated with diabetes mellitus and/or hypertriglyceridemia;  To monitor the safety and tolerability of metreleptin in subjects with lipodystrophy that is associated with diabetes mellitus and/or hypertriglyceridemia;  Information on the efficacy of metreleptin as assessed by its effects on fasting triglyceride concentrations HbA1c and fasting glucose concentrations in subjects with lipodystrophy that is associated with diabetes mellitus and/or hypertriglyceridemia|41|NCT00677313|March 2009
3673|Completed                  Has Results|Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Facial Wrinkles and Creases||Biological: Autologous Human Fibroblasts (azficel-T)|Interventional|Phase 2|Industry|Change in Subject Assessment of Wrinkles Compared to Baseline on Subject Wrinkle Assessment;  Independent Panel Global Improvement Assessment Compared to Baseline|50|NCT00654654|March 2007
3674|Completed|Safety and Dose Ranging Study of ALXN6000 to Treat Relapsing or Refractory CLL or MM||Drug:ALXN6000|Interventional|Phase 1 / Phase 2|Industry|Obtain dose safety PK and PD information about ALXN6000.;  Obtain biological information on ALXN6000 including binding to CD200 on B CLL cells; describe the effect of ALXN6000 in B-CLL patients on ORR and its components of CR PR nPR and SD; and in MM patients on response as defined in the protocol|26|NCT00648739|June 2008
3675|Terminated                  Has Results|A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds||Drug:ThymosinBeta4(T&#946;4);  Other:Placebo|Interventional|Phase 2|Industry|Number of Participants With Treatment Emergent Adverse Events (TEAEs) After Treatment With Thymosin Beta 4 in the Target Eye of Diabetic Patients During Vitrectomy;  Number of Participants With Corneal Epithelial Wound Healing at Day 14 (End of Treatment)|12|NCT00598871|December 2007
3676|Completed                  Has Results|A Randomized Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial||Drug:Glycerinatedpeanutallergenicextract;  Drug:Placeboforpeanutextract(glycerin)|Interventional|Phase 1 / Phase 2|NIH / Other|Percent of Participants Who Successfully Consumed 5000 mg of Peanut Powder or at Least a 10-fold Increase in the Amount of Peanut Powder Compared to Their Baseline Oral Food Challenge;  Percent of Participants Who Achieved a Maintenance Dose of 1386 mcg;  Percent of Crossover Participants Who Successfully Consumed 5000 mg of Peanut Powder or at Least a 10-fold Increase in the Amount of Peanut Powder Compared to Their Baseline Oral Food Challenge After 44 Weeks of Open Label Peanut Protein Consumption;  Percent of Crossover Participants Who Achieved an Open Label Peanut Protein Consumption Maintenance Dose of 3696 mcg;  Number of Participants With Serious Adverse Events (SAEs);  Number of Crossover Participants With Serious Adverse Events (SAEs) During 44 Weeks of Open Label Peanut Protein Consumption;  Percent of Participants Who Successfully Consumed 10000 mg of Peanut Powder|40|NCT00580606|December 2007
3677|Completed|Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer||Drug:RAD001|Interventional|Phase 2|Other / Industry|to determine whether high uptake on FDG-PET is associated with tumor shrinkage;  to determine whether a change in FDG-PET in the context of RAD001 therapy is associated with tumor shrinkage|60|NCT00529802|September 2007
3678|Terminated|Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone||Drug:LBH589|Interventional|Phase 1|Industry|&#8226; To determine the maximum-tolerated dose (MTD) and dose-limiting toxicity (DLT) of esca-lating doses of LBH589 in adult men with HRPC.;  &#8226; To determine the MTD and DLT of escalating doses of LBH589 in combination with a stan-dard dose of docetaxel q3wks and daily Prednisone&#174; in adult men with HRPC.;  &#8226; To characterize the safety and tolerability of LBH589 alone and in combination with do-cetaxel and Prednisone&#174; including acute and chronic toxicities;  &#8226; To characterize the single-dose and multidose pharmacokinetic (PK) profiles of LBH589 alone and in combination with docetaxel and Prednisone&#174;. To characterize the PK profiles of docetaxel alone and in combination with LBH589.|16|NCT00493766|May 2006
3679|Completed                  Has Results|Oral Immunotherapy for Childhood Egg Allergy||Drug:Eggoralimmunotherapy;  Drug:ControlGroup|Interventional|Phase 2|NIH / Other|Percent of Participants Who Successfully Consumed 10000 mg of Egg White Solid Followed by Open Feeding of Egg;  Percent of Participants Who Successfully Consumed 5000 mg of Egg White Solid;  Percent of Participants Who Successfully Consumed a 50 mg Dose at Initial Escalation;  Percent of Participants Who Achieved a Maintenance Dose of 2000 mg;  Number of Participants With Serious Adverse Events (SAEs);  Percent of Participants in the Egg OIT Treatment Arm Who Successfully Consumed 10000 mg of Egg White Solid|55|NCT00461097|May 2007
3680|Completed|Efficacy and Safety of Single Doses of Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) Compared to Placebo in Patients With Persistent Asthma||Drug:indacaterolmaleate|Interventional|Phase 2 / Phase 3|Industry|Lung function measured 24 hours after having taken medication by a special test called &quot;forced expiratory volume in 1 second &quot;(FEV1);  FEV1 at time points 30 min 1 2 and 4 h post-dose;  Percent change in FEV1 at time points 30 min 1 2 and 4 h 23 h 10 min and 23 h 45 min post dose;  Forced vital capacity (FVC) at time points 30 min 1 2 and 4 h 23 h 10 min and 23 h 45 min post dose|45|NCT00403637|November 2006
3681|Completed|An Observational Study of Childhood Food Allergy|||Observational||NIH / Other|Peanutallergyaftertheageofthreeyears;  Resolution of milk allergy after the age of three years;  Resolution of egg allergy after the age of three years;  Resolution of peanut allergy after the age of three years;  Resolution of a positive test to peanut after the age of three years (suspected allergy category);  Development/persistence of milk allergy after the age of three years;  Development/persistenceofeggallergy|515|NCT00356174|July 2006
3682|Completed|D2-EPG Study: Evaluation of New Sensing Circuitry and Capture Management||Device:ImplantableCardioverterDefibrillator|Interventional||Industry|Ventricularfibrillation(VF)detectiontime;  VentricularCaptureManagementaccuracy|65|NCT00328705|May 2006
3683|Completed                  Has Results|Study to Assess Steady-State Trough Concentrations Safety and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)||Drug: Abatacept or Placebo (both as IV &amp; SC Solution);  Drug: Abatacept or Placebo (both as IV &amp; SC solution);  Drug:Abatacept|Interventional|Phase 1 / Phase 2|Industry|Short Term Period: Steady-state Trough Serum Concentration (Cmin) of Abatacept Following Weekly Subcutaneous Dosing in Participants With Active Rheumatoid Arthritis Receiving Disease Modifying Anti-rheumatic Drugs (DMARDS);  Number of Participants With Adverse Events (AEs) Serious Adverse Events (SAEs) Deaths Discontinuations Due to Adverse Events Reported During the Variable Dosing Phase of the Long Term Period (LTE);  Number of Participants With Pre-specified AEs of Special Interest in the Variable Dosing Phase of Long Term Extension (LTE);  Number of Participants With Adverse Events (AEs) Serious Adverse Events (SAEs) Deaths Discontinuations Due to Adverse Events Summarized Over the Entire Long Term Extension (LTE) Period (Both Variable and Fixed Dosing);  Short Term Period: Peak Serum Concentration (Cmax) of Abatacept at Steady State in Participants With Rheumatoid Arthritis Receiving DMARDS;  Short Term Period: Area Under the Curve (AUC) in Time Interval of 7 Days [AUC(TAU)] of Abatacept in Participants With Rheumatoid Arthritis Receiving DMARDS;  Short Term Period: Summary of Adverse Events (AEs) Serious AEs Deaths and Discontinuations Due to AEs During 12 Weeks of Treatment With Either Abatacept or Placebo;  Short Term Period: Number of Participants With Pre-specified Adverse Events (AEs) of Special Interest After Administration of Abatacept or Placebo Over 12 Weeks;  Short Term Period: Mean Percent Change From Baseline on Day 85 in Participants Positive for Serum Rheumatoid Factor During Abatacept or Placebo Administration;  Short Term Period: Number of Participants With Laboratory Abnormalities in Hematology at Baseline (Day 1) to End of Period (Day 85);  Short Term Period: Number of Participants With Laboratory Abnormalities in Serum Chemistry at Baseline and on Treatment up to Day 85;  Short Term Period: Mean Change From Baseline at Day 85 in Blood Pressure After SC Administration of Abatacept or Placebo in Participants With Rheumatoid Arthritis Receiving DMARDS;  Short Term Period: Mean Change From Baseline at Day 85 in Pulse Rate After SC Administration of Abatacept or Placebo in Participants With Rheumatoid Arthritis Receiving DMARDS;  Short Term Period: Mean Change From Screening to Day 85 in Electrocardiogram (QT PR Intervals QRS Width) After SC Administration of Abatacept or Placebo in Participants With Rheumatoid Arthritis Receiving DMARDS;  Short Term Period: Mean Change From Screening at Day 85 in ECG (Heart Rate) After SC Administration of Abatacept or Placebo in Participants With Rheumatoid Arthritis Receiving DMARDS;  Overall Study ST and LTE Periods: Number of Participants With Anti-abatacept Antibodies and/or Anti-cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Antibodies|87|NCT00254293|January 2006
3684|Withdrawn|Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)||Procedure:Leukapheresis;  Procedure: Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT);  Procedure: Autologous CD34+HPC transplantation (HSCT);  Procedure:Plasmapheresis;  Drug:Rabbitanti-thymocyteglobulin;  Drug:Methylprednisolone;  Drug:Growthcolonystimulatingfactor(G-CSF);  Drug:Corticosteroids;  Drug:Mycophenolatemofetil;  Drug:Azathioprine;  Drug:Intravenousimmunoglobulin;  Drug:Methotrexate;  Drug:Rituximab;  Drug:Leflunomide|Interventional|Phase 2|NIH|Mortality resulting from treatment underlying disease or unrelated causes|0|NCT00230035|September 2005
3685|Completed                  Has Results|Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer||Drug:Bevacizumab;  Drug:Cyclophosphamide;  Drug:Methotrexate;  Drug:Capecitabine|Interventional||Other / Industry|The Completion Rate of 1 Year of Bevacizumab Therapy for All Four Cohorts|164|NCT00121134|June 2005
3686|Completed                  Has Results|Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects||Drug:Emtricitabine(FTC);  Drug:TenofovirDisoproxilFumarate(TDF);  Drug:Efavirenz(EFV);  Drug:FTC/TDF;  Drug:FTC/TDF/EFV;  Drug:Lamivudine/zidovudine|Interventional|Phase 3|Industry|Percentage of Participants With Confirmed Plasma HIV-1 RNA &lt; 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm;  Percentage of Participants With Confirmed Plasma HIV-1 RNA &lt; 50 c/mL at Week 48 (Defined by FDA TLOVR Algorithm);  Percentage of Participants With Plasma HIV-1 RNA &lt; 400 c/mL at Week 48.;  Percentage of Participants With HIV-1 RNA &lt; 50 c/mL at Week 48;  Percentage of Participants With Loss of Virologic Response (HIV-1 RNA &lt; 400 c/mL) at Week 48;  Percentage of Participants With Loss of Virologic Response (HIV-1 RNA &lt; 50 c/mL) at Week 48;  Percentage of Participants With Pure Virologic Failure (HIV-1 RNA &lt; 400 c/mL) at Week 48;  Percentage of Participants With Pure Virologic Failure (HIV-1 RNA &lt; 50 c/mL) at Week 48;  Change From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 48;  Change From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 48;  Percentage of Participants With Confirmed Plasma HIV-1 RNA &lt; 400 c/mL at Week 96 (Defined by FDA TLOVR Algorithm);  Percentage of Participants With Confirmed Plasma HIV-1 RNA &lt; 50 c/mL at Week 96 (Defined by FDA TLOVR Algorithm);  Percentage of Participants With Loss of Virologic Response (HIV-1 RNA &lt; 400 c/mL) at Week 96;  Percentage of Participants With Loss of Virologic Response (HIV-1 RNA &lt; 50 c/mL) at Week 96;  Percentage of Participants With Pure Virologic Failure (HIV-1 RNA &lt; 400 c/mL) at Week 96;  Percentage of Participants With Pure Virologic Failure (HIV-1 RNA &lt; 50 c/mL) at Week 96;  Change From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 96;  Change From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 96;  ChangeinLimbFat(kg)FromWeek48toWeek96;  ChangeinTrunkFat(kg)FromWeek48toWeek96;  Change in Total Body Fat (kg) From Week 48 to Week 96;  Percentage of Participants With Confirmed Plasma HIV-1 RNA &lt; 400 c/mL at Week 144 (Defined by FDA TLOVR Algorithm);  Percentage of Participants With Confirmed Plasma HIV-1 RNA &lt; 50 c/mL at Week 144 (Defined by FDA TLOVR Algorithm);  Percentage of Participants With Plasma HIV-1 RNA &lt; 400 c/mL at Week 144;  Percentage of Participants With Plasma HIV-1 RNA &lt; 50 c/mL at Week 144;  Percentage of Participants With Loss of Virologic Response (HIV-1 RNA &lt; 400 c/mL) at Week 144;  Percentage of Participants With Loss of Virologic Response (HIV-1 RNA &lt; 50 c/mL) at Week 144;  Percentage of Participants With Pure Virological Failure (HIV-1 RNA &lt; 400 c/mL) at Week 144;  Percentage of Participants With Pure Virological Failure (HIV-1 RNA &lt; 50 c/mL) at Week 144;  Change From Study Baseline in HIV-1 RNA (Log10 c/mL) at Week 144;  Change From Study Baseline in CD4 Cell Count (Cells/mm^3) at Week 144;  ChangeinLimbFat(kg)FromWeek48toWeek144;  ChangeinTrunkFat(kg)FromWeek48toWeek144;  Change in Total Body Fat (kg) From Week 48 to Week 144;  Percentage of Participants With Confirmed Plasma HIV-1 RNA &lt; 400 c/mL at Week 240 (Atripla Week 96) Defined by the FDA TLOVR Algorithm;  Percentage of Participants With Confirmed Plasma HIV-1 RNA &lt; 50 c/mL at Week 240 (Atripla Week 96) Defined by the FDA TLOVR Algorithm;  Percentage of Participants With Plasma HIV-1 RNA &lt; 400 c/mL at Week 240 (Atripla Week 96);  Percentage of Participants With Plasma HIV-1 RNA &lt; 50 c/mL at Week 240 (Atripla Week 96);  Percentage of Participants With Loss of Virologic Response (HIV-1 RNA &lt; 400 c/mL) From Week 144 (Atripla Baseline) Through Week 240 (Atripla Week 96);  Percentage of Participants With Loss of Virologic Response (HIV-1 RNA &lt; 50 c/mL) From Week 144 (Atripla Baseline) Through Week 240 (Atripla Week 96);  Percentage of Participants With Pure Virological Failure (HIV-1 RNA &lt; 400 c/mL) Through Week 240 (Atripla Week 96);  Percentage of Participants With Pure Virological Failure (HIV-1 RNA &lt; 50 c/mL) Through Week 240 (Atripla Week 96);  Change From Baseline in CD4 Cell Count (Cells/mm^3) at Week 240 (Atripla Week 96);  Change in Limb Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96);  Change in Trunk Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96);  Change in Total Body Fat (kg) From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96);  Treatment Satisfaction Questionnaire (Satisfaction With Convenience and Simplicity of Current Treatment Regimen): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.;  Treatment Satisfaction Questionnaire (Satisfaction With Current Treatment Regimen to Control HIV): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.;  Treatment Satisfaction Questionnaire (Satisfaction With Tolerability of Current Treatment Regimen) Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.;  Treatment Satisfaction Questionnaire (General Satisfaction With Current Treatment Regimen): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.;  Treatment Satisfaction Questionnaire (Bothered With the Side Effects of Current Treatment Regimen): Change From Week 144 to Week 240 in the Category Shift From Atripla Baseline.;  Quality of Life (SF-12v2 Health Survey: Physical Component Summary) Change From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96);  Quality of Life (SF-12v2 Health Survey: Mental Component Summary) Change From Week 144 (Atripla Baseline) to Week 240 (Atripla Week 96)|517|NCT00112047|July 2003
3687|Completed|Alanosine in Treating Patients With Progressive or Recurrent Malignant Gliomas||Drug:L-alanosine|Interventional|Phase 1|NIH||18|NCT00075894|March 2004
3688|Unknown&nbsp;&#8224;|Autologous Cultured Myoblasts (BioWhittaker) Transplanted Via Myocardial Injection||Drug:MyoCell&#8482;AutologousMyoblasts|Interventional|Phase 1|Industry||15|NCT00050765|August 2006
3689|Active not recruiting|Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery||Procedure:biopsy;  Procedure:magneticresonanceimaging;  Procedure:radiomammography;  Procedure:ultrasoundimaging;  Radiation:gadopentetatedimeglumine;  Drug:chemotherapy|Interventional||Other / NIH|response|384|NCT00033397|February 2002
3690|Completed|Treatment of Youth With ADHD and Anxiety||Drug:methylphenidate;  Drug:fluvoxamine|Interventional||NIH||120|NCT00012584|November 2000
3691|Withdrawn|Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication||Drug:Ritonavir;  Drug:Abacavirsulfate;  Drug:Amprenavir;  Drug:Lamivudine;  Drug:Filgrastim|Interventional||NIH||0|NCT00006578|
3692|Completed|Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss||DietarySupplement:omega-3fattyacid|Interventional|Phase 1 / Phase 2|Other / NIH|survival|63|NCT00003077|October 1995
3693|Completed|A Study of Efavirenz in Combination With Stavudine and Didanosine||Drug:Efavirenz;  Drug:Stavudine;  Drug:Didanosine|Interventional|Phase 2|Industry||60|NCT00002225|
3694|Completed|A Study of Ribavirin in the Treatment of Patients With AIDS and AIDS-Related Problems||Drug:Ribavirin|Interventional|Phase 1|NIH||96|NCT00001015|
3695|Completed|Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer||Drug:gemcitabinehydrochloride;  Drug:irinotecanhydrochloride;  Radiation:radiationtherapy|Interventional|Phase 2|Other / NIH|||NCT00025168|November 2001
3696|Terminated                  Has Results|Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer||Drug:VinorelbinefollowedbyCisplatin;  Drug:PemetrexedfollowedbyCisplatin|Interventional|Phase 2|Other / Industry|2-Year Progression-Free Survival Rate in Patients With Completely Resected Stage IB II or IIIA NSCLC;  Percentage of Patients With Completely Resected NSCLC Tumors That Can Be Analyzed and Used to Direct Adjuvant Chemotherapy;  2-Year Overall Survival in Patients Treated for NSCLC;  Patient Understanding and Perceptions of Participating in a Clinical Trial Evaluating Cancer Genomics for Adjuvant Treatment of Early Stage Lung Cancer;  Compare Drug Sensitivity Patterns of Cisplatin and Pemetrexed in Both Treatment Arms|31|NCT00545948|December 2007
3697|Active not recruiting|Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer||Drug:Abirateroneacetate;  Drug:Prednisone|Interventional|Phase 2|Other|Median radiographic progression free survival (PFS);  Changeinradiologicresponserates;  ChangeinPSAresponse;  TimetoPSAnadir;  PercentofmenwhoachieveaPSA&lt;0.1;  Numberofadverseevents|100|NCT01940276|October 2013
3698|Completed                  Has Results|Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects||Drug:NB;  Behavioral:CLI;  Behavioral:UsualCare|Interventional|Phase 3|Industry|Percent Change in Body Weight From Baseline (Day 1) to Week 26;  Percentage of Subjects Achieving a Loss of at Least 5% of Baseline Body Weight at Week 26;  Percentage of Subjects Achieving a Loss of at Least 10% of Baseline Body Weight at Week 26;  Percentage of Subjects Achieving a Loss of at Least 15% of Baseline Body Weight at Week 26;  Absolute Change in Body Weight From Baseline to Week 26;  Change in Waist Circumference From Baseline to Week 26;  Change in Fasting Triglycerides From Baseline to Week 26;  Change in Fasting Low-density Lipoprotein Cholesterol From Baseline to Week 26;  Change in Fasting High-density Lipoprotein Cholesterol From Baseline to Week 26;  Change in Systolic Blood Pressure From Baseline to Week 26;  Change in Diastolic Blood Pressure From Baseline to Week 26;  ChangeinHeartRateFromBaselinetoWeek26;  Change in Fasting Plasma Glucose From Baseline to Week 26;  ChangeFastingInsulinFromBaselinetoWeek26;  Change in Homeostasis Model Assessment-insulin Resistance (HOMA-IR) From Baseline to Week 26;  Change in Patient-reported Binge Eating Scale (BES) Total Scores From Baseline to Week 26;  Change in Patient-reported Arizona Sexual Experiences Scale (ASEX) Total Scores From Baseline to Week 26;  Change in Patient-reported Impact of Weight on Quality of Life-Lite Questionnaire (IWQOL-Lite) Total Score From Baseline to Week 26|242|NCT01764386|February 2013
3699|Terminated|RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases||Drug:berubicinhydrochloride(RTA744)|Interventional|Phase 2|Industry|To evaluate the efficacy of RTA 744 in reducing intracranial tumor on contrast-enhanced MRI of breast cancer patients with progression of brain metastases following whole brain radiotherapy (WBRT).;  To evaluate the efficacy of RTA 744 on intracranial tumor as measured by intracranial objective response rate (Intracranial ORR) determined by modified RECIST criteria and by volumetric analysis.;  To evaluate overall objective response rate after administration of RTA 744.;  To evaluate the efficacy of RTA 744 on intracranial tumor as measured by intracranial Time To Progression.;  To evaluate progression free survival (PFS) after administration of RTA 744.;  To evaluate overall survival (OS) after administration of RTA 744.;  To evaluate the safety and tolerability of RTA 744 administered at 7.5 mg/m2/day for 3 consecutive days on a 21-day cycle.;  To evaluate the impact of RTA 744 on quality of life through the FACT-B and modified FACT-Br questionnaires.|14|NCT00538343|October 2007
3700|Active not recruiting|Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients||Drug:Mepolizumab;  Drug:Placebo|Interventional|Phase 3|Industry|Frequencyofmoderate/severeexacerbations;  Frequency of COPD exacerbations requiring emergency department (ED) visits;  Change from baseline in mean total St. George&apos;s Respiratory Questionnaire-COPD;  Change from baseline in COPD assessment test (CAT) score;  Timetofirstmoderate/severeexacerbation|800|NCT02105948|April 2014
3701|Terminated|The Mechanism of Action of the Unite Biomatrix in Diabetic Foot Ulcer||Device:UniteBiomatrix;  Other:SalineandGauze|Interventional||Industry|timetocompletehealing;  percentofwoundshealedat12weeks;  woundhealingpathwaymarkers;  bacterialburden;  1) mean &amp; median of % wound size changes 2) ulcer recurrence 3) adverse events|90|NCT00958711|January 2009
3702|Completed|Oxandrolone Compared With Megestrol in Preventing Weight Loss in Patients Receiving Chemotherapy for Cancer||Drug:MegestrolAcetate;  Drug:Oxandrolone20mg|Interventional|Phase 3|Other / NIH|Lean body mass as measured by the Bioelectrical Impedance Analysis monthly;  Weight;  Body fat as measured by the Bioelectrical Impedance Analysis monthly;  Health-related quality of life as measured by the Functional Assessment of Cancer Therapy with subscales for anorexia/cachexia and fatigue;  PerformancestatusasmeasuredbyECOGcriteria;  Toxicity as measured by standard NCI toxicity criteria|155|NCT00070148|March 2004
3703|Active not recruiting|Lung-MAP: AZD4547 as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches||Drug:FGFRInhibitorAZD4547;  Other:LaboratoryBiomarkerAnalysis|Interventional|Phase 2 / Phase 3|Other / NIH|Objective Response Rate (ORR) (confirmed and unconfirmed complete and partial) (Design #2 Phase II);  DoR among patients who achieve a CR or PR by RECIST 1.1 (Design #2 Phase II);  OS with investigational therapy (Design #2 Phase II);  PFS with investigational therapy (Design #2 Phase II);  Severity of toxicities associated with investigational therapy (Design #2 Phase II)|42|NCT02965378|June 2014
3704|Active not recruiting|Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches||Drug:ErlotinibHydrochloride;  Other:LaboratoryBiomarkerAnalysis;  Biological:Rilotumumab|Interventional|Phase 2 / Phase 3|Other / NIH|IA-PFS as defined by RECIST 1.1 (Design #1 Phase II);  IA-PFS in patients with advanced stage refractory squamous cell carcinoma (SCCA) of the lung randomized to receive investigational therapy versus standard of care (SoC) (Design #2 Phase III);  Less than 33% improvement in median IA-PFS as defined as RECIST 1.1 (Design #1 Phase III);  Objective Response Rate (ORR) (confirmed and unconfirmed complete and partial) (Design #2 Phase II);  OS(Design#1PhaseIII);  OS in patients with advanced stage refractory SCCA of the lung randomized to receive investigational therapy versus SoC (Design #2 Phase III);  DoR among patients who achieve a CR or PR by RECIST 1.1 (Design #2 Phase II);  Frequency and severity of toxicities associated with investigational therapy versus SoC (Design #2 Phase III);  IA-PFS censoring patients with symptomatic deterioration (SD) at the time of SD (Design #1 Phase III);  OS with investigational therapy (Design #2 Phase II);  PFS with investigational therapy (Design #2 Phase II);  Response rate (confirmed and unconfirmed) in patients with measurable disease as defined by RECIST 1.1 (Design #1 Phase II and III);  Response rates (confirmed and unconfirmed complete and partial) among patients randomized to receive investigational therapy versus SoC (Design #2 Phase III);  Severity of toxicities associated with investigational therapy versus SoC (Design #2 Phase II);  Toxicity frequencies monitored using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Design #1 Phase II and III)|310|NCT02926638|June 2014
3705|Recruiting|Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers||Biological:Ipilimumab;  Other:LaboratoryBiomarkerAnalysis;  Biological:Nivolumab|Interventional|Phase 3|Other / NIH|IA-PFS as defined by RECIST 1.1 (Design #1 Phase II);  Less than 33% improvement in median IA-PFS as defined as RECIST 1.1 (Design #1 Phase III);  OS(Design#1PhaseIII);  Overallsurvival;  IA-PFS censoring patients with symptomatic deterioration (SD) at the time of SD (Design #1 Phase III);  Response rate (confirmed and unconfirmed) in patients with measurable disease as defined by RECIST 1.1 (Design #1 Phase II and III);  Toxicity frequencies monitored using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Design #1 Phase II and III)|350|NCT02785952|December 2015
3706|Recruiting|Lung-MAP: Palbociclib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches||Other:LaboratoryBiomarkerAnalysis;  Drug:Palbociclib|Interventional|Phase 2 / Phase 3|Other / NIH|Objective Response Rate (ORR) (confirmed and unconfirmed complete and partial) (Design #2 Phase II);  DoR among patients who achieve a CR or PR by RECIST 1.1 (Design #2 Phase II);  OS with investigational therapy (Design #2 Phase II);  PFS with investigational therapy (Design #2 Phase II);  Severity of toxicities associated with investigational therapy (Design #2 Phase II)|42|NCT02785939|June 2014
3707|Recruiting|Lung-MAP: Taselisib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches||Other:LaboratoryBiomarkerAnalysis;  Drug:Taselisib|Interventional|Phase 2|Other / NIH|Objective Response Rate (ORR) (confirmed and unconfirmed complete and partial) (Design #2 Phase II);  DoR among patients who achieve a CR or PR by RECIST 1.1 (Design #2 Phase II);  OS with investigational therapy (Design #2 Phase II);  PFS with investigational therapy (Design #2 Phase II);  Severity of toxicities associated with investigational therapy (Design #2 Phase II)|59|NCT02785913|June 2014
3708|Active not recruiting|Lung-Map: MEDI4736 as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers||Drug:Docetaxel;  Biological:Durvalumab;  Other:LaboratoryBiomarkerAnalysis|Interventional|Phase 2|Other / NIH|Response rate (confirmed and unconfirmed complete and partial) as defined by RECIST 1.1;  IA-PFS all patients and the subset of PD-L1 positive patients as defined by RECIST criteria;  IA-PFS assessed using a modified response criteria adapted for immunotherapy (irRC-IA-PFS);  OS;  Toxicity frequencies monitored using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|100|NCT02766335|June 2014
3709|Recruiting|Breast Cancer WEight Loss Study (BWEL Study)||Other:HealthEducationProgram;  Other:WeightLossIntervention|Interventional|Phase 3|Other / NIH|Invasivedisease-freesurvival;  Overallsurvival;  Distantdisease-freesurvival;  Changeinweight(definedas%change);  Measures of physical activity (self report and objective);  Dietaryintake(totalcalorieconsumption);  Occurrence of insulin resistance syndrome complications (diabetes hospitalizations for cardiovascular disease);  Changes in biomarker (insulin) associated with breast cancer risk and outcomes;  Changes in biomarker (glucose) associated with breast cancer risk and outcomes;  Changes in biomarker (HOMA) associated with breast cancer risk and outcomes;  Changes in biomarker (leptin) associated with breast cancer risk and outcomes;  Changes in biomarker (adiponectin) associated with breast cancer risk and outcomes;  Changes in biomarker (IGF-1) associated with breast cancer risk and outcomes;  Changes in biomarker (IGFBP3) associated with breast cancer risk and outcomes;  Changes in biomarker (IL-6) associated with breast cancer risk and outcomes;  Changes in biomarker (CRP) associated with breast cancer risk and outcomes;  Changes in biomarker (TNF-a) associated with breast cancer risk and outcomes;  Patientreportedoutcomes-physicalfunctioning;  Patientreportedoutcomes-fatigue;  Patient reported outcomes - depression and anxiety;  Patientreportedoutcomes-sleepdisturbance;  Patient reported outcomes - incidence of breast cancer treatment related symptoms;  Patientreportedoutcomes-bodyimage|3136|NCT02750826|August 2016
3710|Recruiting|S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery||Drug:Fluorouracil;  Drug:GemcitabineHydrochloride;  Drug:IrinotecanHydrochloride;  Drug:Oxaliplatin;  Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;  Procedure:Pancreatectomy|Interventional|Phase 2|Other / NIH|Overallsurvival;  Disease-freesurvival(DFS);  Incidence of toxicity by National Cancer Institute Common Terminology Criteria for Adverse Events version 4;  Overallresectionrate;  OverallresponserateperRECIST1.1;  Pathologicalresponserates;  Patternsofrecurrence;  R0resectionrate|112|NCT02562716|October 2015
3711|Recruiting|Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer||Drug:Carboplatin;  Drug:Cyclophosphamide;  Drug:DoxorubicinHydrochloride;  Other:LaboratoryBiomarkerAnalysis;  Drug:Paclitaxel|Interventional|Phase 3|Other / NIH|IDFS;  BCFS;  DRFI;  Frequencies of adverse events categorized using the National Cancer Institute CTCAE v4.0;  OS;  RFI|990|NCT02488967|July 2015
3712|Recruiting|NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas||Drug:Afatinib;  Drug:AktinhibitorAZD5363;  Drug:Binimetinib;  Drug:Crizotinib;  Other:CytologySpecimenCollectionProcedure;  Drug:Dabrafenib;  Drug:Dasatinib;  Drug:Defactinib;  Drug:FGFRInhibitorAZD4547;  Other:LaboratoryBiomarkerAnalysis;  Biological:Nivolumab;  Drug:Osimertinib;  Drug:Palbociclib;  Drug:PI3K-betaInhibitorGSK2636771;  Drug:SunitinibMalate;  Drug:Taselisib;  Drug:Trametinib;  Biological:TrastuzumabEmtansine;  Drug:Vismodegib|Interventional|Phase 2|NIH|Objective response rate (ORR) defined as the percentage of patients whose tumors have a complete or partial response to treatment;  Overall survival (OS) evaluated specifically for each drug (or step);  Progressionfreesurvival(PFS);  Timetoprogression(TTP)|3000|NCT02465060|August 2015
3713|Recruiting|A &quot;Real World&quot; Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)||Drug:INSULINGLARGINE(U300);  Drug:INSULINGLARGINE(U100);  Drug:Insulindetemir(Levemir)|Interventional|Phase 4|Industry|- Proportion of patients with individualized HbA1c target attainment per HEDIS criteria (&lt;8% if age &#8805;65 years or with defined comorbidities or otherwise &lt;7%) at 6 months without documented symptomatic (BG &#8804;70 mg/dL) hypoglycemia;  Change in HbA1c from baseline (obtained at screening visit within one week of study initiation);  Proportion of patients with documented symptomatic (BG &#8804;70 mg/dL) nocturnal (midnight to 5:59 am) hypoglycemia;  Proportion of patients with documented symptomatic (BG &#8804;70 mg/dL) 24-hour hypoglycemia|3270|NCT02451137|June 2015
3714|Recruiting|Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic Estrogen Receptor-Positive HER2-Negative Breast Cancer||Other:LaboratoryBiomarkerAnalysis;  Other:PharmacologicalStudy;  Drug:TamoxifenCitrate;  Drug:Z-EndoxifenHydrochloride|Interventional|Phase 2|NIH|PFS;  Incidence of adverse events per CTCAE version 4.0;  Overallsurvivaldistributionbystudyarm;  Tumor response rate by study arm defined as the number of patients with a complete or partial response as defined by RECIST on 2 consecutive evaluations at least 6 weeks apart divided by the total number of eligible patients who began study treatment|94|NCT02311933|March 2015
3715|Completed|Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy||Drug:doxepinhydrochlorideoralsolution;  Drug: DLA (diphenhydramine lidocaine and antacids) rinse;  Other:Placebo|Interventional|Phase 3|Other / NIH|Total pain reduction as measured by numerical analogue scale of mouth pain in the questionnaires taken at baseline 5 15 30 60 120 and 240 minutes after assigned treatment;  The total unpleasant taste of the oral rinse as measured by the numerical analogue scale of taste of the oral rinse in the questionnaires;  The total stinging or burning from the oral rinse as measured by the numerical analogue scale of stinging or burning from the oral rinse in the questionnaires;  The total drowsiness increase as measured by the numerical analogue scale of drowsiness questionnaires;  The incidence of using alternative analgesics between 1 and 4 hours after initial mouthwash;  Patient preference for continued therapy with oral rinse after initial test rinse phase as measured by Item 9 in the patient-reported questionnaire after 4 hours;  ThelengthoftimeintheContinuationPhase;  PainscoreintheContinuationPhase;  Alternative analgesics use in the Continuation Phase|275|NCT02229539|November 2014
3716|Recruiting|Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)||Drug:Crizotinib;  Other:LaboratoryBiomarkerAnalysis;  Other:Placebo|Interventional|Phase 3|Other / NIH|OS;  DFS;  Toxicity rates determined using the CTCAE version 4.0|378|NCT02201992|August 2014
3717|Recruiting|Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery||Drug:Dabrafenib;  Other:LaboratoryBiomarkerAnalysis;  Drug:Trametinib|Interventional|Phase 2|NIH|Progression-freesurvival;  Overallsurvival;  Ratesoffever;  Responserates|280|NCT02196181|July 2014
3718|Recruiting|Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)||Other:CytologySpecimenCollectionProcedure;  Other:LaboratoryBiomarkerAnalysis|Observational||NIH|Central clinical genotyping to facilitate accrual to the adjuvant Intergroup studies E4512 and A081105 as measured by rate of accrual;  Feasibility of research grade formalin-fixed paraffin-embedded tissue collection for CCG analysis as measured by adequate specimens collected per month;  Agreement of local genotyping methods (direct sequencing of EGFR ALK FISH) with central Clinical Laboratory Improvement Amendments genotyping;  Disease free survival (DFS) rate for lung cancers which are wild-type for EGFR and ALK|8300|NCT02194738|August 2014
3719|Recruiting|Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)||Drug:ErlotinibHydrochloride;  Other:LaboratoryBiomarkerAnalysis;  Other:Placebo|Interventional|Phase 3|NIH|OS;  DFS rate defined as the proportion of patients alive and disease free at 2 years from the date of randomization;  Incidence of adverse events associated with each treatment arm;  OS rate defined as the proportion of patients alive at 10 years from date of randomization;  OS rate defined as the proportion of patients alive at 5 years from date of randomization;  Overall DFS between the erlotinib hydrochloride and placebo arms|450|NCT02193282|August 2014
3720|Active not recruiting|S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer||Biological:cetuximab;  Drug:irinotecanhydrochloride;  Drug:vemurafenib|Interventional|Phase 2|Other / NIH|PFS(ArmsIandII);  PFS(Crossover);  Overallsurvival(ArmsIandII);  Overallresponserate;  Incidence of adverse events graded according to the National Cancer Institute CTCAE v4.0|106|NCT02164916|November 2014
3721|Active not recruiting|A Study Comparing the Efficacy Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||Drug:fluticasonefuroate(FF);  Drug:vilanterol(VI);  Drug:umeclidiniumbromide(UMEC)|Interventional|Phase 3|Industry|Annual rate of on-treatment moderate and severe exacerbations comparing FF/UMEC/VI with UMEC/VI;  Annual rate of on-treatment moderate and severe exacerbations comparing FF/UMEC/VI with FF/VI;  Change from baseline trough FEV1 at Week 52 comparing FF/UMEC/VI with FF/VI;  Change from baseline St George&apos;s Respiratory Questionnaire (SGRQ) total score at Week 52 comparing FF/UMEC/VI with FF/VI;  Time to first on-treatment moderate or severe exacerbation comparing FF/UMEC/VI with FF/VI and with UMEC/VI;  Annual rate of on-treatment moderate and severe exacerbations comparing FF/UMEC/VI with UMEC/VI in the subset of subjects with a blood eosinophil count &gt;=150cells/ MicroLitre (mcl);  Time to first on-treatment moderate or severe exacerbation comparing FF/UMEC/VI with UMEC/VI in the subset of subjects with a blood eosinophil count&gt;=150cells/mcl;  Annual rate of on-treatment severe exacerbations comparing FF/UMEC/VI with FF/VI and with UMEC/VI|10000|NCT02164513|June 2014
3722|Recruiting|Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer||Drug:Docetaxel;  Biological:Durvalumab;  Drug:ErlotinibHydrochloride;  Drug:FGFRInhibitorAZD4547;  Biological:Ipilimumab;  Other:LaboratoryBiomarkerAnalysis;  Biological:Nivolumab;  Drug:Palbociclib;  Biological:Rilotumumab;  Drug:Taselisib|Interventional|Phase 2 / Phase 3|Other / NIH|IA-PFS as defined by RECIST 1.1 (Design #1 Phase II);  IA-PFS in patients with advanced stage refractory SCCA of the lung randomized to receive investigational therapy versus SoC (Design #2 Phase III);  Less than 33% improvement in median IA-PFS as defined as RECIST 1.1 (Design #1 Phase III);  Objective Response Rate (ORR) (confirmed and unconfirmed complete and partial) (Design #2 Phase II);  OS(Design#1PhaseIII);  OS in patients with advanced stage refractory SCCA of the lung randomized to receive investigational therapy versus SoC (Design #2 Phase III);  DoR among patients who achieve a CR or PR by RECIST 1.1 (Design #2 Phase II);  Frequency and severity of toxicities associated with investigational therapy versus SoC (Design #2 Phase III);  IA-PFS censoring patients with symptomatic deterioration (SD) at the time of SD (Design #1 Phase III);  OS with investigational therapy (Design #2 Phase II);  PFS with investigational therapy (Design #2 Phase II);  Response rate (confirmed and unconfirmed) in patients with measurable disease as defined by RECIST 1.1 (Design #1 Phase II and III);  Response rates (confirmed and unconfirmed complete and partial) among patients randomized to receive investigational therapy versus SoC (Design #2 Phase III);  Severity of toxicities associated with investigational therapy versus SoC (Design #2 Phase II);  Toxicity frequencies monitored using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Design #1 Phase II and III)|10000|NCT02154490|June 2014
3723|Recruiting|Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic||Drug:Entinostat;  Drug:Exemestane;  Drug:GoserelinAcetate;  Other:LaboratoryBiomarkerAnalysis;  Other:PharmacologicalStudy;  Other:Placebo;  Other:Quality-of-LifeAssessment|Interventional|Phase 3|NIH|OS;  PFS defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1);  Incidence of toxicity graded according to National Cancer Institute CTCAE version 4.0;  Objective response defined as the proportion of patients with complete response (CR) or partial response (PR) among all patients assessed per RESIST v1.1;  Time to treatment deterioration (TTD) assessed per RECIST v1.1|600|NCT02115282|March 2014
3724|Recruiting|Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy||Drug:Canagliflozin;  Drug:Placebo|Interventional|Phase 3|Industry / Other|Time to the first occurrence of an event in the primary composite endpoint;  Time to the First Occurrence of an Event in the CV Composite Endpoint of CV Death And Hospitalized Congestive Heart Failure;  TimetoCVDeath;  Timetoall-causedeath;  Time to the first occurrence of an event in the renal composite endpoint;  Time to the first occurrence of an event in the CV composite endpoint|4200|NCT02065791|February 2014
3725|Suspended|Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III IV or Recurrent Endometrial Cancer||Drug:Carboplatin;  Other:LaboratoryBiomarkerAnalysis;  Drug:MetforminHydrochloride;  Drug:Paclitaxel;  Other:Placebo;  Other:Quality-of-LifeAssessment;  Other:QuestionnaireAdministration|Interventional|Phase 2 / Phase 3|Other / NIH|Overallsurvival(PhaseIIandIII);  Progression-freesurvival(PhaseII);  Durationofresponsebytreatment;  Incidence of adverse events as assessed by CTCAE version 4 within each arm;  Levelofobesity;  Overallsurvival(PhaseII);  PFS(PhaseIII);  Proportionofpatientsrespondingtotherapy|540|NCT02065687|March 2014
3726|Active not recruiting|Ibrutinib and Rituximab Compared With Fludarabine Phosphate Cyclophosphamide and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma||Drug:Cyclophosphamide;  Drug:FludarabinePhosphate;  Drug:Ibrutinib;  Other:LaboratoryBiomarkerAnalysis;  Other:PharmacogenomicStudy;  Other:Quality-of-LifeAssessment;  Biological:Rituximab|Interventional|Phase 3|NIH|Change in quality of life assessed using Functional Assessment of Cancer Therapy -Leukemia (FACT-Leu) Trial Outcome Index (TOI);  PFS;  Adherence to prescription assessed by the Moriskey Adherence Scale (Arm A only);  ChangeinFACT-LeuTOIscore;  ImpactofCLLonQOL;  Incidence of toxicity defined as adverse events that are classified as either possibly probably or definitely related to study treatment graded according to NCI Common Terminology for Adverse Events version 4.0;  OS|519|NCT02048813|February 2014
3727|Recruiting|Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer||Drug:Olaparib;  Drug:Placebo|Interventional|Phase 3|Industry / Other|InvasiveDiseaseFreeSurvival(IDFS);  Overallsurvival(OS);  DistantDiseaseFreeSurvival(DDFS);  Effect on the incidence of new primary contralateral breast cancers new primary ovarian cancer new primary fallopian tube cancer and new primary peritoneal cancer;  Effect in patients identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays.;  Exposure to Olaparib (in plasma) in patients receiving Olaparib as adjuvant therapy;  FACIT-Fatiure symptoms and EORTC QLQ-C30 Questionnaires|330|NCT02032823|April 2014
3728|Active not recruiting|A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors||Drug:APD356-Lorcaserinhydrochloride;  Drug:Placebo|Interventional|Phase 4|Industry / Other|Time from randomization to first occurrence of Major Adverse Cardiovascular Events (MACE);  Time from randomization to conversion to type 2 diabetes mellitus (T2DM) for subjects without any type of diabetes at Baseline;  Time from randomization to first occurrence of MACE+;  Time from randomization to event of each component of MACE+;  Time from randomization to event of all-cause mortality;  Time from randomization to event of new onset renal impairment or worsening existing renal impairment in subjects with T2DM at Baseline;  Time from randomization to event of improvement in renal function;  Change from Baseline in HbA[1c] at 6 months in subjects with T2DM at Baseline;  The proportion of subjects who meet FDA-defined valvulopathy in echocardiographically determined heart valve changes;  The percent change from Baseline in echocardiographically-determined pulmonary arterial systolic pressure;  Timetoconversiontonormalglucosehomeostasis|12000|NCT02019264|January 2014
3729|Active not recruiting|Docetaxel Carboplatin Trastuzumab and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive HER2-Positive Operable or Locally Advanced Breast Cancer||Drug:AromataseInhibitionTherapy;  Drug:Carboplatin;  Other:CytologySpecimenCollectionProcedure;  Drug:Docetaxel;  Drug:GoserelinAcetate;  Other:LaboratoryBiomarkerAnalysis;  Biological:Pertuzumab;  Other:Quality-of-LifeAssessment;  Procedure:TherapeuticConventionalSurgery;  Biological:Trastuzumab;  Radiation:WholeBreastIrradiation|Interventional|Phase 3|NIH|Rate of pCR in the breast and post therapy lymph nodes;  Change in endocrine-related symptoms using Breast Cancer Prevention Trial (BCPT) symptom checklist;  Change in greater vasomotor symptoms musculoskeletal complaints and vaginal problems as measured by the subscale scores from the BCPT symptom checklist;  Change in QOL as measured by the Functional Assessment of Cancer Therapy-Breast Trial Outcome Index (FACT-B TOI) and the 12-item Short Form (SF-12) Physical Component Scale (PCS);  Incidence of cardiac toxicity categorized according to National Cancer Institute CTCAE version 4.0;  Levelsoftumor-infiltratinglymphocytes;  OS;  PatternsofOSbymenopausalstatus;  PatternsofpCRbymenopausalstatus;  PatternsofRFIbymenopausalstatus;  RateofpCRinthebreast;  Rate of second primary invasive cancer of any type;  RFI|312|NCT02003209|January 2014
3730|Active not recruiting|The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects||Drug:bococizumab(PF-04950615);  Drug:Placebo|Interventional|Phase 3|Industry|The primary endpoint is the time from randomization to the first occurrence of a major cardiovascular (CV) event a composite endpoint of CV death non-fatal MI non-fatal stroke and hospitalization for unstable angina needing urgent revascularization.;  Key secondary endpoint: The time from randomization to the first adjudicated and confirmed occurrence of a composite endpoint of CV death non-fatal MI and non-fatal stroke.;  Key secondary endpoint: The time from randomization to the first adjudicated and confirmed occurrence of a composite endpoint of all-cause death non-fatal MI non-fatal stroke and hospitalization for unstable angina needing urgent revascularization.;  Key secondary endpoint: The time from randomization to the first adjudicated and confirmed occurrence of a composite endpoint of all-cause death non-fatal MI and non-fatal stroke.;  Key secondary endpoint: The time from randomization to the first adjudicated and confirmed occurrence of hospitalization for unstable angina needing urgent revascularization.;  Time to first occurrence of a composite endpoint of CV death non-fatal MI and non-fatal stroke and hospitalization for unstable angina; and each component of every composite endpoint and an endpoint of hospitalization for congestive heart failure.;  Changes in levels of circulating biomarkers (lipids and hs-CRP)|17000|NCT01975376|October 2013
3731|Active not recruiting|Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.||Drug:AclidiniumBromide;  Drug:Placebo|Interventional|Phase 4|Industry|Time to first Major Adverse Cardiovascular Event (MACE);  Rate of moderate or severe COPD exacerbations per patient per year during the first year of treatment;  Rate of hospitalizations due to COPD exacerbation per patient per year during the first year of treatment;  Time to first Major Adverse Cardiovascular Event (MACE) or other serious cardiovascular events of interest|4000|NCT01966107|October 2013
3732|Recruiting|Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery||Drug:fulvestrant;  Drug:anastrozole|Interventional|Phase 3|Other / NIH|Rateofendocrineresistantdisease-(FirstPhase);  Pathologiccompleteresponserate-(pCRrate);  Recurrence-freesurvival(RFS)-(SecondPhase)|2820|NCT01953588|December 2013
3733|Active not recruiting|Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer||Drug:enzalutamide;  Drug:abiraterone;  Drug:prednisone|Interventional|Phase 3|Other / NIH / Industry|Overallsurvival(OS);  Grade 3 or higher toxicity profile using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;  DeclineinProstateSpecificAntigen(PSA);  ProgressionFreeSurvival(PFS);  Objectiveresponserate;  RadiographicProgressionFreeSurvival(rPFS);  Tumorburdenandboneactivity|1311|NCT01949337|January 2014
3734|Active not recruiting|S1304 Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma||Drug:Carfilzomib;  Drug:Dexamethasone;  Other:LaboratoryBiomarkerAnalysis|Interventional|Phase 2|Other / NIH|Progression-freesurvival;  Overallsurvival;  Response rate (stringent complete response [sCR] complete response [CR] very good partial response [VGPR] partial response [PR])|143|NCT01903811|October 2013
3735|Recruiting|Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy||Procedure:AxillaryLymphNodeDissection(ALND);  Radiation:NodalRadiationTherapy;  Radiation:AxillaryRadiationTherapy|Interventional|Phase 3|Other / NIH|Invasive breast cancer recurrence-free interval (IBC-RFI);  Overallsurvival;  Ipsilateral/local/regional invasive breast cancer recurrence (ILR-REC)|2918|NCT01901094|February 2014
3736|Active not recruiting|Rituximab and Bendamustine Hydrochloride Rituximab and Ibrutinib or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia||Drug:BendamustineHydrochloride;  Drug:Ibrutinib;  Other:LaboratoryBiomarkerAnalysis;  Other:Quality-of-LifeAssessment;  Biological:Rituximab|Interventional|Phase 3|NIH|PFS;  CompleteandnPRrate;  Durationofresponse(CRnPRandPR);  Geriatricfunctionalstatus(optional);  OS;  Proportion of patients achieving a biopsy-proven CR;  Proportion of patients achieving any response to treatment (ORR [PR +nPR+ CR]);  Proportion of patients who attain MRD negative status;  Proportion of patients who experience grade 3 or higher non-hematologic toxicities;  Proportion of patients who go off treatment due to adverse reactions or refuse further treatment for lesser toxicities that inhibit their willingness to continue participation;  Qualityoflife;  Timetoprogression;  Tolerability assessed by the number of patients requiring dose modifications and/or dose delays;  Toxicity calculated according to the frequency and severity of adverse events per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|523|NCT01886872|December 2013
3737|Recruiting|Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma||Drug:bortezomib;  Drug:lenalidomide;  Drug:dexamethasone;  Drug:carfilzomib;  Procedure:quality-of-lifeassessment;  Other:laboratorybiomarkeranalysis|Interventional|Phase 3|Other / NIH|Overallsurvivalforthemaintenanceanalysis;  Progression-free survival for the maintenance analysis;  Progression-free survival for the induction analysis;  Overallsurvivalfortheinductionanalysis;  Response rates including partial response (PR) very good partial response (VGPR) immunofixation negative complete response (IF-CR) and complete response (CR);  ResponseratesincludingPRVGPRIF-CRandCR;  Time to progression (TTP) for the induction analysis;  Duration of response (DOR) for the induction analysis;  Incidence of overall grade 3 or higher non-hematologic toxicity and grade 3 or higher toxicity by type during induction active maintenance and observation phases using CTCAE version 4.0;  Incidence of grade 2 or higher peripheral neuropathy and cardiac toxicity during induction phase assessed using CTCAE version 4.0;  Change in the Functional Assessment of Cancer Therapy-Neurotoxicity Trial Outcome Index (FACT-Ntx TOI) for the transition to maintenance analysis;  Change in the FACT-Ntx TOI for the short-term maintenance analysis;  Change in the FACT-Ntx TOI for the long-term maintenance analysis;  Change in the FACT-Ntx TOI for the end of induction analysis;  Change in the FACT-Ntx TOI for the early induction analysis;  Levels and changes from related start of induction active maintenance and observation phases;  Time to worsening of FACT-Ntx TOI for the induction analysis;  Time to worsening of Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) for the maintenance analysis|756|NCT01863550|November 2013
3738|Completed|Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk||Biological:Evolocumab(AMG145);  Other:Placebo;  Drug:Effectivestatintherapy|Interventional|Phase 3|Industry|The primary endpoint is the time to cardiovascular death myocardial infarction hospitalization for unstable angina stroke or coronary revascularization whichever occurs first.;  Time to cardiovascular death myocardial infarction or stroke whichever occurs first;  Timetocardiovasculardeath;  Timetodeathbyanycause;  Timetofirstmyocardialinfarction;  Timetofirststroke;  Timetofirstcoronaryrevascularization;  Time to cardiovascular death or first hospitalization for worsening heart failure whichever occurs first;  Time to ischemic fatal or non-fatal stroke or TIA whichever occurs first|27564|NCT01764633|February 2013
3739|Recruiting|S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer||Drug:anastrozole;  Drug:everolimus;  Drug:exemestane;  Drug:goserelinacetate;  Drug:letrozole;  Drug:leuprolideacetate;  Drug:tamoxifencitrate;  Other:placebo|Interventional|Phase 3|Other / NIH|IDFS using a stratified log-rank test assessed up to 10 years;  OS estimates will be based on Kaplan-Meier procedures assessed up to 10 years;  DRFSassessedupto10years;  Toxicity based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 assessed up to 10 years|1900|NCT01674140|April 2013
3740|Completed                  Has Results|Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating||Drug:Linaclotide290micrograms;  Drug:Linaclotide145micrograms;  Drug:Matchingplacebo|Interventional|Phase 3|Industry|9/12 Week Complete Spontaneous Bowel Movement (CSBM) 3+1 Responder;  Change From Baseline in 12-Week Abdominal Bloating;  Percent Change From Baseline in 12-week Abdominal Bloating;  Percent Change From Baseline in Abdominal Bloating at Week 12;  6/12WeekAbdominalBloating30%Responder;  Change From Baseline in 12-week CSBM Frequency Rate;  Change From Baseline in CSBM Frequency Rate at Week 1.;  Change From Baseline in CSBM Frequency Rate at Week 4.;  Change From Baseline in CSBM Frequency Rate at Week 8;  Change From Baseline in CSBM Frequency Rate at Week 12;  Change From Baseline in 12-Week SBM Frequency Rate;  Change From Baseline in SBM Frequency Rate at Week 1;  Change From Baseline in SBM Frequency Rate at Week 4;  Change From Baseline in SBM Frequency Rate at Week 8;  Change From Baseline in SBM Frequency Rate at Week 12;  Change From Baseline in the Number of Days With a Spontaneous Bowel Movement (SBM);  SBM Within 24 Hours After the First Dose of Investigational Product;  Time to Spontaneous Bowel Movement (SBM) After the First Dose of Investigational Product;  ChangeFromBaselinein12-weekStoolConsistency;  Change From Baseline in Stool Consistency at Week 12;  Change From Baseline in 12-week Severity of Straining;  Change From Baseline in Severity of Straining at Week 12;  9/12 Week Mild Straining and Diarrhea-free Responder|487|NCT01642914|August 2012
3741|Active not recruiting|S1202: Duloxetine Hydrochloride to Treat Muscle Bone and Joint Pain in Pts W/Early-Stage Breast Cancer Receiving Hormone Therapy||Drug:duloxetinehydrochloride;  Other:placebo|Interventional|Phase 3|Other / NIH|Reduction in average joint pain according to BPI-SF assessed up to 12 weeks;  Reduction in worst joint pain according to the BPI-SF worst pain score assessed up to 12 weeks;  Reduction in pain interference according to the BPI-SF worst pain score assessed up to 12 weeks|294|NCT01598298|May 2013
3742|Recruiting|Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery||Drug:PazopanibHydrochloride;  Other:PharmacologicalStudy;  Other:Placebo;  Other:Quality-of-LifeAssessment;  Other:QuestionnaireAdministration|Interventional|Phase 3|NIH|Disease-freesurvival(DFS);  Change in fatigue as assessed by Patient Reported Outcome Measurement Information System Fatigue and Functional Assessment of Chronic Illness Therapy Fatigue subscales;  Change in kidney cancer-related symptoms as assessed by the Functional Assessment of Cancer Therapy-Kidney Cancer Symptom Index;  Change in Q-TWiST between the two arms as assessed by the European Quality of Life 5-Dimensions;  Overallsurvival;  Plasmatroughlevelsofpazopanibhydrochloride;  Prospective banking of preserved tissue from primary tumors and associated metastatic sites;  Toxicity defined as time spent with grade 3 or 4 adverse events prior to disease recurrence as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|128|NCT01575548|August 2012
3743|Recruiting|Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment||Drug:testosterone;  Other:placebo|Interventional|Phase 3|Other / NIH|Intra-patient change in joint pain at 3 months from baseline as measured by item #3 (average) of the Brief Pain Inventory;  Proportion of women with changes in pain at least 10 points on a converted 0-100 scale at 3 months from baseline;  The intra-patient change in joint pain at 6 months from baseline as measured by item #3 (average) of the Brief Pain Inventory for aromatase inhibitor arthralgias (BPI-AIA).;  The intra-patient changes in joint pain at each month from baseline as measured by the BPI-AIA.;  Incidence of toxicities assessed using the Common Terminology Criteria for Adverse Events (CTCAE) 4.0.;  Alopecia as reported by the patient using CTCAE 4.0;  AcneasreportedbythepatientusingCTCAE4.0;  Hirsutism as reported by the patient using CTCAE 4.0;  The change of hot flashes during the first two months from baseline as measured by hot flash diary;  The change of libido from baseline as measured by POMS monthly.;  The change of menopause specific quality of life from baseline as measured by MENQOL monthly.;  The intrapatient change in joint pain for each month from baseline as measured by item#1 (worst) of the BPI-AIA.;  The intrapatient change in joint pain for each month from baseline as measured by item#2 (least) of the BPI-AIA.;  The intrapatient change in joint pain for each month from baseline as measured by item#4 (right now) of the BPI-AIA.;  The intrapatient change in joint pain for each month from baseline as measured by item#5 (stiffness) of the BPI-AIA.;  The intrapatient change in activity level (interference of activity) for each month from baseline as measured by item#6 (interference) of the BPI-AIA.|224|NCT01573442|August 2013
3744|Active not recruiting|Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer||Procedure:therapeuticconventionalsurgery;  Radiation:wholebreastirradiation|Interventional|Phase 2|Other / NIH|Local recurrence defined as histologic evidence of ductal carcinoma in situ or invasive breast cancer in the ipsilateral breast or chest wall assessed up to 5 years;  Conversion rate to mastectomy secondary to persistent positive margins assessed;  Type and severity of adverse effects of breast-conserving surgery and radiation as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;  Radiation-related side effects of whole-breast radiation with a boost to 1 large or &gt; 1 lumpectomy site as assessed by NCI CTCAE version 4.0;  Patient&apos;s perception of cosmesis assessed up to 24 months after WBI using the BREAST-Q&#169; scoring module|230|NCT01556243|July 2012
3745|Active not recruiting|Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer||Drug:Doxorubicin;  Drug:Cyclophosphamide;  Drug:Docetaxel;  Drug:Paclitaxel|Interventional|Phase 3|Other / NIH|Invasivedisease-freesurvival(IDFS);  Disease-freesurvival(DFS-DCIS);  Overallsurvival(OS);  Recurrence-freeinterval(RFI);  Toxicityofeachregimen;  Molecularpredictorsofefficacy|1871|NCT01547741|April 2012
3746|Recruiting|Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery||Other:ClinicalObservation;  Drug:Docetaxel;  Drug:DoxorubicinHydrochloride;  Biological:Filgrastim;  Drug:GemcitabineHydrochloride;  Biological:Pegfilgrastim|Interventional|Phase 3|Other / NIH|Overallsurvival;  Incidence of adverse events as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0;  Recurrence-freesurvival|216|NCT01533207|June 2012
3747|Recruiting|PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery||Drug:FOLFOX(chemotherapy);  Other:5FUCMT(chemoradiation);  Procedure:surgery;  Procedure: magnetic resonance imaging or endorectal ultrasound|Interventional|Phase 2 / Phase 3|Other / NIH|PelvicR0resectionrate(PhaseII);  DFS(PhaseIII);  Timetolocalrecurrence(TLR);  Pathologiccompleteresponse;  Overallsurvival;  Adverseevent(AE)profiles;  Ratesofreceivingpre-orpost-operative5FUCMT|1060|NCT01515787|January 2012
3748|Completed|Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension||Drug:NebivololandValsartan1;  Drug:NebivololandValsartan2;  Drug:NebivololandValsartan3;  Drug:Nebivolol1;  Drug:Nebivolol2;  Drug:Valsartan1;  Drug:Valsartan2;  Drug:Placebo|Interventional|Phase 3|Industry|ChangeinSittingDiastolicBloodPressure(DBP);  ChangeinSittingSystolicBloodPressure(SBP)|4161|NCT01508026|January 2012
3749|Active not recruiting|S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal Gastric or Gastroesophageal Junction Cancer||Drug:FOLFOXregimen;  Drug:docetaxel;  Drug:fluorouracil;  Drug:irinotecanhydrochloride;  Drug:leucovorincalcium;  Drug:oxaliplatin|Interventional|Phase 2|Other / NIH|Progression-free survival (PFS) between high-ERCC1 and low-ERCC1 patients treated with FOLFOX versus irinotecan hydrochloride plus docetaxel;  PFS between low-ERCC1 and high-ERCC1 patients treated with FOLFOX;  PFS between low-ERCC1 and high-ERCC1 patients treated with irinotecan hydrochloride plus docetaxel;  Overallsurvival;  Responserate;  Toxicity|213|NCT01498289|February 2012
3750|Recruiting|S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab Panitumumab or Erlotinib Hydrochloride||Procedure:assessmentoftherapycomplications;  Procedure:psychosocialassessmentandcare;  Procedure:quality-of-lifeassessment|Observational||Other / NIH|PsychometricpropertiesoftheFACT-EGFRI18;  Changeinseverityandimpactofskinsymptoms;  Agreement between site physician ratings with the CTCAE Version 4 and patient ratings for the FACT-EGFRI 18 items;  Associations between toxicity profile and treatment profiles;  Feasibility as measured by accrual time to specified accrual time to complete forms|140|NCT01416688|November 2011
3751|Recruiting|S0820 Adenoma and Second Primary Prevention Trial||Drug:Eflornithineplacebo&amp;sulindacplacebo;  Drug:eflornithine&amp;sulindacplacebo;  Drug:Eflornithineplacebo&amp;sulindac;  Drug:Eflornithineplussulindac|Interventional|Phase 3|Other / NIH / Industry|3-year event rate after registration among Stage 0-III colon cancer patients. (An event is defined as high-risk adenoma or second primary colorectal cancer.);  Incidence of colorectal lesions with respect to high-grade dysplasia adenomas with villous features adenomas 1 cm or greater multiple adenomas polyps &gt;/= 0.3 cm total advanced colorectal events or total colorectal events at 3 years.;  ToxicitybyCTCAEv.4.0at3years;  Examine interaction of treatment arm and genotype expression with respect to different outcomes.;  Interaction of intervention arm and baseline statin use with respect to 3-year event rate.;  Evaluate SNPs associated with decreased adenoma/second primary CRC risk and AEs|1340|NCT01349881|March 2013
3752|Completed                  Has Results|Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease||Drug:fluticasonefuroate/vilanterol;  Drug:fluticasonefuroate;  Drug:vilanterol;  Other:Placebo|Interventional|Phase 3|Industry|Number of Participants With Death (Both on and Off Treatment) Due to Any Cause Time up to or on the Pre-determined Common End Date;  Decline in Forced Expiratory Volume in 1 Second (FEV1);  Number of Participants With First On-treatment Cardiovascular (CV) Composite Events Occured on or Before Common End Date|16568|NCT01313676|January 2011
3753|Active not recruiting|Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer||Drug:Cyclophosphamide;  Drug:Docetaxel;  Drug:DoxorubicinHydrochloride;  Other:LaboratoryBiomarkerAnalysis;  Drug:Paclitaxel;  Other:Quality-of-LifeAssessment;  Biological:Trastuzumab|Interventional|Phase 3|NIH|IDFS;  BCFS;  ChangeinHER2mRNAlevel;  DFS-DCIS;  DRFI;  Fcgammareceptorpolymorphism;  Incidence of adverse events using the National Cancer Institute CTCAE v4.0;  OS;  RFI|3260|NCT01275677|January 2011
3754|Active not recruiting|Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery||Biological:Ipilimumab;  Other:Quality-of-LifeAssessment;  Biological:RecombinantInterferonAlfa-2b|Interventional|Phase 3|NIH|OS;  RFS;  Change in global quality of life assessed using the FACT-G (patients age &gt;= 18 only);  Change in health-related domains of quality of life assessed using symptom and functioning subscales (patients age &gt;= 18 only);  Incidence of toxicity assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|1500|NCT01274338|May 2011
3755|Recruiting|Tamoxifen Citrate Letrozole Anastrozole or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer||Drug:Anastrozole;  Drug:Exemestane;  Other:LaboratoryBiomarkerAnalysis;  Drug:Letrozole;  Other:Quality-of-LifeAssessment;  Drug:SystemicChemotherapy;  Drug:TamoxifenCitrate|Interventional|Phase 3|NIH|RSasmeasuredbyOncotypeDX;  DDFS;  Localdisease-freeinterval;  OS;  Toxicities using standard National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.0|10000|NCT01272037|January 2011
3756|Active not recruiting|Oxaliplatin Leucovorin Calcium and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery||Drug:celecoxib;  Drug:5-fluorouracil;  Other:placebo;  Drug:oxaliplatin;  Drug:leucovorin|Interventional|Phase 3|Other / NIH|Disease-freesurvival;  Overallsurvival|2500|NCT01150045|June 2010
3757|Completed|Efficacy Safety and Tolerability of JNJ-27018966 in the Treatment of Irritable Bowel Syndrome With Diarrhea||Drug:JNJ-27018966;  Drug:Placebo|Interventional|Phase 2|Industry|Clinical response to treatment based upon improvement from baseline in both of the following co-primary endpoints: pain intensity as assessed by average daily pain scores; and stool consistency as assessed by Bristol Stool Scores.;  Averagedailypainscores;  Stoolconsistency;  Stoolfrequency|807|NCT01130272|May 2010
3758|Completed                  Has Results|Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease||Drug:tiotropium18mcg;  Drug:tiotropium1.25mcg(2actuations/day);  Drug:tiotropium2.5mcg(2actuations/day)|Interventional|Phase 3|Industry|TimetoAll-CauseMortality;  TimetoFirstCOPDExacerbation;  Trough FEV1 Over 120 Weeks (in a Substudy of 1370 Patients);  NumberofCOPDExacerbations;  Time to First Hospitalization Associated With COPD Exacerbation;  Number of Hospitalizations Associated With COPD Exacerbation;  Time to First Moderate to Severe COPD Exacerbation;  Time to Onset of First Major Adverse Cardiovascular Event (MACE);  Time to Death From Major Adverse Cardiovascular Event (MACE)|17183|NCT01126437|May 2010
3759|Active not recruiting|S0931 Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery||Drug:everolimus;  Other:placebo|Interventional|Phase 3|Other / NIH|Compare Recurrence-free survival in those patients randomized to everolimus versus those randomized to placebo.;  Compare Overall survival in those patients randomized to everolimus versus those randomized to placebo.;  CompareToxicitybetweenthetwostudyarms|1545|NCT01120249|April 2011
3760|Recruiting|Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery||Drug:Cisplatin;  Radiation:ExternalBeamRadiationTherapy;  Radiation:Intensity-ModulatedRadiationTherapy;  Other:LaboratoryBiomarkerAnalysis;  Other:Quality-of-LifeAssessment|Interventional|Phase 3|Other / NIH|RFS;  Incidence of adverse events graded according to the active version of CTCAE;  Localcontrol;  OS;  Patientrisk-benefit;  Quality of life assessed using the FACT-Cx TOI FACT-GOG/neurotoxicity 4 subscale and the Brief Pain Inventory (BPI);  Site(s)ofrecurrence;  Treatmentcompliance|534|NCT01101451|April 2010
3761|Completed|JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab||Drug:natalizumab|Observational||Industry|Demonstrate that the incidence of PML in natalizumab-treated participants who do not have detectable antibodies to JC virus (JCV) (antibody negative) is lower than in patents who have detectable antibodies to JCV (antibody positive);  Estimate the incidence of PML in natalizumab-treated participants who are anti-JCV antibody negative and anti-JCV antibody positive based on a meta-analysis of data obtained from this study and other data sources;  Define the prevalence of anti-JCV antibody in relapsing MS participants receiving natalizumab within the TOUCH Prescribing Program;  Determine changes in anti-JCV antibody status over time|35895|NCT01070836|March 2010
3762|Active not recruiting|Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer||Drug:DoxorubicinHydrochloride;  Other:LaboratoryBiomarkerAnalysis;  Other:PharmacologicalStudy;  Drug:SorafenibTosylate|Interventional|Phase 3|NIH|Overallsurvival;  Incidence of adverse events as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0;  Progressionfreesurvival|480|NCT01015833|February 2010
3763|Active not recruiting|Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer||Biological:Bevacizumab;  Drug:Cisplatin;  Drug:GemcitabineHydrochloride;  Other:LaboratoryBiomarkerAnalysis;  Other:Placebo|Interventional|Phase 3|NIH|Overallsurvival(OS);  Grade 3 or greater treatment-related toxicity using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0;  Objective response rate (defined as confirmed complete and partial responses) using Response Evaluation Criteria in Solid Tumors criteria;  Progression-freesurvival(PFS)|500|NCT00942331|July 2009
3764|Unknown&nbsp;&#8224;|Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer Fallopian Tube Cancer or Primary Peritoneal Cancer||Drug:ElesclomolSodium;  Drug:Paclitaxel|Interventional|Phase 2|Other / NIH|Frequencyofobjectiveresponse;  Durationofobjectiveresponse;  Frequency of observed adverse effects defined as any unfavorable and unintended sign symptom or disease that occurs in a patient administered a medical treatment whether the event is considered related or unrelated to the medical treatment;  Severity of observed adverse effects graded using the NCI CTCAE version 4.0;  Progression-freesurvival;  Overallsurvival|55|NCT00888615|December 2010
3765|Active not recruiting|A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative HER2-Negative Breast Cancer||Drug:bevacizumab;  Drug:docetaxel;  Drug:doxorubicin;  Drug:cyclophosphamide;  Drug:pegfilgrastim|Interventional|Phase 3|Other / Industry|Invasive disease-free survival(IDFS)relative to the TAC chemotherapy regimen alone;  Invasive disease-free survival (IDFS) relative to the TAC chemotherapy regimen;  Disease-free survival (DFS-DCIS) relative to the TC alone regimen;  Overall survival (OS) relative to the TC alone regimen;  OSrelativetotheTACregimen;  Recurrence-free interval (RFI) relative to the TC alone regimen;  RFIrelativetotheTACregimen;  Develop molecular predictive markers for the degree of benefit from TCB over TC or TAC;  Provide the efficacy data from Group 1 patients and Group 2 patients enrolled in B-46-I/07132 to US Oncology Research Inc. (USOR) for a planned combined analysis with efficacy data from patients receiving the same regimens in the USOR 06-090 trial;  Toxicityassociatedwitheachoftheregimens;  Determine the role of topoisomerase II alpha (TOP2A) in prognosis and prediction of degree of benefit from TAC over TC;  Develop predictive markers for benefit from doxorubicin|3900|NCT00887536|May 2009
3766|Active not recruiting                  Has Results|Paclitaxel Nab-paclitaxel or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer||Drug:Paclitaxel;  Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;  Drug:Ixabepilone;  Biological:Bevacizumab;  Other:QuestionnaireAdministration;  Other:LaboratoryBiomarkerAnalysis|Interventional|Phase 3|NIH|ProgressionFreeSurvival;  ObjectiveTumorResponseRate;  TimetoTreatmentFailure;  12MonthProgressionFreeSurvival;  OverallSurvival|799|NCT00785291|October 2008
3767|Active not recruiting|Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy||Other:LaboratoryBiomarkerAnalysis;  Biological:Trastuzumab;  Radiation:WholeBreastIrradiation|Interventional|Phase 3|NIH|Time from randomization to ipsilateral invasive breast cancer ipsilateral skin cancer recurrence or ipsilateral DCIS;  Contralateralbreastcancer(invasiveorDCIS);  Incidence of post-treatment amenorrhea (absence of menstrual period for at least 12 months) in women who were premenopausal at the time of study entry;  InvasiveorDCISdisease-freesurvival;  InvasiveorDCISrecurrence-freeinterval;  Invasiveregionalordistantrecurrence;  Overallsurvival|2000|NCT00769379|November 2008
3768|Recruiting|Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II III or IV Ovarian Fallopian Tube or Primary Peritoneal Cancer||Behavioral:BehavioralDietaryIntervention;  Behavioral:ComplianceMonitoring;  Other:Counseling;  Other:EducationalIntervention;  Behavioral:ExerciseIntervention;  Other:LaboratoryBiomarkerAnalysis;  Other:Quality-of-LifeAssessment;  Other:QuestionnaireAdministration|Interventional|Phase 3|Other / NIH|Progression-freesurvival;  Change in irritable bowel syndrome-specific symptoms measured using GSRS-IBS;  Change in self-reported quality of life measured using RAND-36|1070|NCT00719303|June 2012
3769|Recruiting|Carboplatin Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Primary Peritoneal or Fallopian Tube Cancer||Biological:Bevacizumab;  Drug:Carboplatin;  Drug:Docetaxel;  Drug:GemcitabineHydrochloride;  Other:LaboratoryBiomarkerAnalysis;  Drug:Paclitaxel;  Other:Quality-of-LifeAssessment|Interventional|Phase 3|NIH|Overallsurvival;  ChangeinQOLasmeasuredbyFACT-OandRAND-SF36;  Frequency and severity of adverse events assessed by Common Terminology Criteria for Adverse Events version 3.0;  Molecularand/orbiochemicalprofiles;  Progression-freesurvival|1038|NCT00565851|December 2007
3770|Recruiting|Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms|||Observational||Industry|Risk rates of adverse events of high clinical interest (eg cancers neurological diseases connective tissue diseases) assessed by the investigator;  Risk rates of common complications of breast surgery (eg capsular contracture implant rupture/deflation) assessed by the subject and investigator;  Re-operations|57000|NCT00443274|November 2006
3771|Active not recruiting|Doxorubicin Hydrochloride Cyclophosphamide and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk Lymph Node-Negative Breast Cancer||Biological:Bevacizumab;  Drug:Cyclophosphamide;  Drug:DoxorubicinHydrochloride;  Other:LaboratoryBiomarkerAnalysis;  Drug:Paclitaxel;  Other:Placebo;  Other:Quality-of-LifeAssessment|Interventional|Phase 3|NIH / Other|Disease-freesurvival;  Incidence of adverse events graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0;  Overallsurvival;  Quality of life measured by average total score for the Functional Assessment of Cancer Therapy-Breast|4950|NCT00433511|December 2009
3772|Active not recruiting|Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer||Drug:Letrozole;  Other:Placebo|Interventional|Phase 3|Other / NIH / Industry|Disease-freesurvival;  Overallsurvival;  Breastcancer-freeinterval;  Distantrecurrence;  Osteoporotic-relatedfractures;  Arterialthromboticevents|3966|NCT00382070|August 2006
3773|Completed                  Has Results|GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS)||Drug:Celecoxib;  Drug: Any commercially available NSAID with the indication for osteoarthritis|Interventional|Phase 4|Industry|Percentage of Participants With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs);  Percentage of Participants With Moderate to Severe Abdominal Symptoms;  Percentage of Participants Who Withdrew Due to GI Adverse Events (AEs);  Hemoglobin(Hb)atBaseline;  ChangeFromBaselineHbatWeek24;  Hematocrit(Hct)atBaseline;  ChangeFromBaselineHctatWeek24;  Percentage of Participants With Clinically Significant Decrease in Hct and/or Hb From Baseline;  Percentage of Participants Satisfied With Efficacy of Current Pain Medication Overall;  Percentage of Participants Satisfied With Efficacy of Current Pain Medication - Time to Pain Relief;  Percentage of Participants Satisfied With Efficacy of Current Pain Medication - Amount of Pain Relief;  Percentage of Participants Satisfied With Efficacy of Current Pain Medication - Duration of Pain Relief|8067|NCT00373685|October 2006
3774|Completed|Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen||Drug:celecoxib;  Drug:Ibuprofen;  Drug:Naproxen|Interventional|Phase 4|Industry / Other|The first occurrence of cardiovascular death (including hemorrhagic death) non-fatal myocardial infarction or non-fatal stroke (APTC composite endpoint).;  The occurrence of Clinical Significant Gastrointestinal Events (CSGIEs);  Patient&apos;sAssessmentofArthritisPain(VAS);  The first occurrence of a MACE defined as the composite of cardiovascular death (including hemorrhagic death) non-fatal MI non-fatal stroke hospitalization for UA revascularization or hospitalization for TIA|24222|NCT00346216|October 2006
3775|Active not recruiting|Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB Stage II or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery||Biological:Bevacizumab;  Drug:Cisplatin;  Drug:Docetaxel;  Drug:GemcitabineHydrochloride;  Other:LaboratoryBiomarkerAnalysis;  Drug:PemetrexedDisodium;  Other:QuestionnaireAdministration;  Drug:VinorelbineTartrate|Interventional|Phase 3|NIH / Other|Overallsurvival;  Disease-freesurvival(DFS);  Expression of intracellular adhesion molecule (ICAM);  Expression of vascular endothelial growth factor (VEGF);  Toxicity rates as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|1500|NCT00324805|June 2007
3776|Active not recruiting|Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)||Drug:Anastrozole;  Drug:Exemestane;  Other:LaboratoryBiomarkerAnalysis;  Drug:Letrozole;  Other:Quality-of-LifeAssessment;  Radiation:RadiationTherapy;  Drug:TamoxifenCitrate|Interventional|Phase 3|NIH / Other|Disease-freesurvival;  Distantrecurrence-freeinterval;  Overallsurvival;  Perceived cognitive function evaluated using the Functional Assessment of Cancer Therapy - Cognitive Function (FACT-COG) version 3;  Quality of life measured using FACT-COG fatigue (FACT-Fatigue and Patient Reported Outcomes Measurement Information System Fatigue SF) fear of recurrence (Assessment of Survivor Concerns) endocrine symptoms (FACT-ES) and HRQL (FACT-General);  Recurrence-freeinterval|11248|NCT00310180|April 2006
3777|Active not recruiting|Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer||Biological:bevacizumab;  Biological:cetuximab;  Drug:FOLFOXor;  Drug:FOLFIRI|Interventional|Phase 3|Other / NIH / Industry|Overallsurvival;  Progression-freesurvival;  Timetotreatmentfailure;  Durationoftumorresponse|2334|NCT00265850|November 2005
3778|Completed|Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes||Drug:insulindetemir|Interventional|Phase 4|Industry|Comparison of the change from baseline to end of treatment;  Spontaneously reported adverse events during the trial;  Incidence of severe hypoglycaemic during the trial nocturnal (11 pm - 6 am);  FPG during the trial (central laboratory) at Visit 2 and Visit 3;  Proportion of subjects achieving HbA1C &lt;= 7.0% at Visit 2 and Visit 3;  InsulindetemirdosesatVisit2andVisit3;  Within-subject variation of before-breakfast SMPG values at Visit 2 and Visit 3|5652|NCT00264901|October 2005
3779|Completed                  Has Results|Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial Primary Peritoneal or Fallopian Tube Cancer||Biological:Bevacizumab;  Drug:Carboplatin;  Other:LaboratoryBiomarkerAnalysis;  Drug:Paclitaxel;  Other:Placebo;  Other:Quality-of-LifeAssessment|Interventional|Phase 3|NIH|Progression-freeSurvival;  OverallSurvival;  Frequency and Severity of Adverse Events Assessed by Common Terminology Criteria for Adverse Events Version 3.0;  Impact on Quality of Life Measured by the Functional Assessment of Cancer Therapy-Ovary Trial Outcome Index (FACT-O TOI)|1873|NCT00262847|September 2005
3780|Active not recruiting|Oxaliplatin Leucovorin Calcium and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer||Biological:Bevacizumab;  Drug:Fluorouracil;  Other:LaboratoryBiomarkerAnalysis;  Drug:LeucovorinCalcium;  Drug:Oxaliplatin|Interventional|Phase 3|NIH|Disease-freesurvival;  Impact of tumor biologic characteristics and their relationship to overall survival;  Incidence of adverse events graded by NCI CTCAE 4.0;  Overallsurvival|3610|NCT00217737|August 2005
3781|Completed|Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)||Biological:bevacizumab;  Biological:recombinantinterferonalfa|Interventional|Phase 3|Other / NIH|OverallSurvival;  Timetoprogression;  Toxicity|732|NCT00072046|October 2003
3782|Completed|Bipolar Study in Adults at Least 18 Years of Age||Drug:lamotrigine|Interventional|Phase 4|Industry|The primary endpoint will be the rate of rash during 12 weeks.;  Change from baseline in Week 5 and Week 12 Clinical Global Impression-Bipolar version (CGI-BP) Severityand Improvement scores.|1200|NCT00067938|August 2003
3783|Completed|Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy||Drug:anastrozole;  Drug:tamoxifencitrate;  Radiation:RadiationTherapy|Interventional|Phase 3|Other / NIH|Timetooccurrenceoffirstbreastcancerevent;  Time to invasive breast cancer at occurrence of first cancer event;  Ipsilateral recurrence at occurrence of first cancer event;  Contralateral breast cancer at occurrence of first cancer event;  Non-breast second primary malignancies at occurrence of first cancer event;  Osteoporoticfractures;  Disease-freesurvival;  Overallsurvival;  Qualityoflifeandsymptoms;  Quality-adjustedsurvivaltime|3104|NCT00053898|January 2003
3784|Active not recruiting|Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer||Drug:ACregimen;  Drug:cyclophosphamide;  Drug:doxorubicinhydrochloride;  Drug:paclitaxel|Interventional|Phase 3|Other / NIH|DurationofDFS;  Overallsurvival;  Incidence of adverse events graded according to the revised National Cancer Institute Common Terminology Criteria for Adverse Events 4.0;  Timetodistantmetastases;  Localcontrol|4646|NCT00041119|May 2002
3785|Completed|Iressa Expanded Access Program (EAP)||Drug:ZD1839(Gefitinib)|Interventional|Phase 3|Industry|||NCT00034879|August 2000
3786|Completed|Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women||Drug:Raloxifene;  Drug:Tamoxifen|Interventional|Phase 3|Other / NIH / Industry|Incidence of invasive breast cancer; superiority of one of the therapies.;  Effect of the study therapies on the incidence of intraductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS).;  Effect of the study therapies on the incidence of endometrial cancer.;  Effect of the study therapies on the incidence of ischemic heart disease.;  Effect of the study therapies on the incidence of fractures of the hip spine or Colles&apos; fractures of the wrist.;  Effect of the study therapies on the toxicity and side effects of each therapy.;  Effect of the study therapies on participants&apos; quality of life.|19747|NCT00003906|May 1999
3787|Recruiting|Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia||Drug:Epanova&#174;(omega-3carboxylicacids);  Drug:cornoilcontrol|Interventional|Phase 3|Industry / Other|The primary outcome measure is the time to the first occurrence of any component of the composite of MACE.;  The composite measure of CV events that include the first occurrence of cardiovascular death non-fatal MI and non-fatal stroke.;  The composite measure of coronary events that include the first occurrence of cardiac death.;  The first occurrence of individual components of MACE: cardiovascular death non-fatal myocardial infarction non-fatal stroke emergent/elective coronary revascularization or hospitalization for unstable angina.;  TimetoCVdeath|13000|NCT02104817|October 2014
3788|Active not recruiting|The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects||Drug:bococizumab(PF-04950615);  Drug:Placebo|Interventional|Phase 3|Industry|The primary endpoint is the time from randomization to the first occurrence of a major cardiovascular (CV) event a composite endpoint of CV death non-fatal MI non-fatal stroke and hospitalization for unstable angina needing urgent revascularization.;  Key secondary endpoint: The time from randomization to the first adjudicated and confirmed occurrence of a composite endpoint of CV death non-fatal MI and non-fatal stroke.;  Key secondary endpoint: The time from randomization to the first adjudicated and confirmed occurrence of a composite endpoint of all-cause death non-fatal MI non-fatal stroke and hospitalization for unstable angina needing urgent revascularization.;  Key secondary endpoint: The time from randomization to the first adjudicated and confirmed occurrence of a composite endpoint of all-cause death non-fatal MI and non-fatal stroke.;  Key secondary endpoint: The time from randomization to the first adjudicated and confirmed occurrence of hospitalization for unstable angina needing urgent revascularization;  Time to first occurrence of a composite endpoint of CV death non-fatal MI and non-fatal stroke and hospitalization for unstable angina; and each component of every composite endpoint and an endpoint of hospitalization for congestive heart failure.;  Changes in levels of circulating biomarkers (lipids and hs-CRP)|10653|NCT01975389|October 2013
3789|Recruiting|Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma||Drug:Cyclophosphamide;  Drug:DoxorubicinHydrochloride;  Other:LaboratoryBiomarkerAnalysis;  Drug:Lenalidomide;  Drug:Prednisone;  Biological:Rituximab;  Drug:VincristineSulfate|Interventional|Phase 2|NIH|PFS;  CRratebasedonPET-CTscan;  OS;  OverallRRbasedonPET-CTscan|345|NCT01856192|August 2013
3790|Active not recruiting|Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer||Drug:CabozantinibS-malate;  Other:LaboratoryBiomarkerAnalysis;  Drug:SunitinibMalate|Interventional|Phase 2|NIH|Overallsurvival(OS);  Progressionfreesurvival(PFS);  Objectiveresponserates;  Proportion of patients with unacceptable treatment related grade 3 or higher toxicity for all patients assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|150|NCT01835158|July 2013
3791|Active not recruiting|Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer||Drug:Cisplatin;  Drug:Etoposide;  Other:LaboratoryBiomarkerAnalysis;  Other:Placebo;  Other:Quality-of-LifeAssessment;  Other:QuestionnaireAdministration;  Drug:Veliparib|Interventional|Phase 1 / Phase 2|NIH|Maximum-tolerated dose of veliparib based on the incidence of dose-limiting toxicity as assessed by the Common Terminology Criteria for Adverse Events version 4.0 (Phase I);  PFS(PhaseII);  Best objective response evaluated via RECIST 1.1 (Phase II);  OS(PhaseII);  Toxicity will be determined using the CTCAE version 4.0 criteria (Phase II)|168|NCT01642251|September 2012
3792|Completed|The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial||Drug:Darapladib160mg;  Drug:Placebo;  Other:StandardTherapy|Interventional|Phase 3|Industry / Other|Time to the first occurrence of any component of the composite of major coronary events (i.e. Coronary Heart Disease (CHD) death non-fatal myocardial infarction (MI) or urgent coronary revascularization for myocardial ischemia).;  The composite measure of Major Adverse Cardiovascular Event (MACE) that includes cardiovascular (CV) death (death due to a cardiovascular cause) non-fatal MI or non-fatal stroke.;  Individual components of MACE (CV death MI (fatal and non-fatal) stroke (fatal and non-fatal)).;  Individual components of major coronary events (CHD death MI (fatal and non-fatal) urgent coronary revascularization for myocardial ischemia).;  Composite measure of total coronary events that incl. first occurrence of CHD death non-fatal MI hosp. for unstable angina(UA) or any coronary revasc. proc.(excl. percutaneous coronary intervention(PCI) planned prior to but performed after rand.).;  Any coronary revascularization procedures (excluding PCI planned prior to randomization but performed after randomization).;  The first occurrence of any component of the composite of all-cause mortality non-fatal MI or non-fatal stroke.;  ThecompositeofCHDdeathandnon-fatalMI.;  Allcausemortality.|13026|NCT01000727|December 2009
3793|Completed                  Has Results|Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery||Biological:Bevacizumab;  Drug:Carboplatin;  Drug:Cyclophosphamide;  Drug:DoxorubicinHydrochloride;  Other:LaboratoryBiomarkerAnalysis;  Drug:Paclitaxel|Interventional|Phase 2|NIH|Pathologic Complete Response (pCR) in the Breast. Defined as the Absence of Residual Invasive Carcinoma in the Breast (ypT0/is).;  Pathologic Complete Response (pCR) in the Breast and Axilla. Defined as the Absence of Residual Invasive Carcinoma in the Breast (ypT0/is) Plus the Absence of Any Tumor Deposit &gt;0.2 mm in Sampled Axillary Nodes (ypT0/isN0).;  Pathologic Stage in the Breast and in the Breast Plus Axilla as Measured by American Joint Committee on Cancer (AJCC) Tumor Node Metastasis (TNM) Staging Criteria (Version 6);  Radiographic Response Assessed by Tumor Measurement;  ClinicalResponseAssessedbyTumorMeasurement;  OverallSurvival;  Recurrence-freeSurvival;  Time to First Failure Defined as First Instance of Ipsilateral Invasive Breast Tumor Recurrence Local/Regional Invasive Breast Cancer Recurrence Distant Recurrence or Death From Any Cause;  Incidence and Severity of Post-op Complications Namely Excessive Bleeding Delayed Wound Healing and Wound Dehiscence.|454|NCT00861705|May 2009
3794|Recruiting|Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy||Drug:darbepoetinalfa500mcgQ3W;  Drug:placebo|Interventional|Phase 3|Industry|Overallsurvival(OS);  Incidence of neutralizing antibody formation to darbepoetin alfa;  Incidence of at least 1 Red Blood Cell (RBC) transfusion or hemoglobin less than or equal to 8.0 g/dL from study day 1 to end of efficacy treatment period;  Incidence of at least 1 Red Blood Cell (RBC) transfusion or hemoglobin less than or equal to 8.0 g/dL from week 5 (day 29) to end of efficacy treatment period;  Incidence of adverse events (AEs) such as thrombovascular events (TVE) venous thromboembolic events (VTE) and AEs associated with Red Blood Cell (RBC) transfusions;  Change in hemoglobin from baseline to end of efficacy treatment period;  Objectivetumorresponse;  Progression-freesurvival(PFS)|3000|NCT00858364|July 2009
3795|Completed                  Has Results|Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes||Biological:albiglutide;  Drug:sitagliptin;  Drug:glimepiride;  Drug:metformin;  Biological:placeboalbiglutide;  Drug:placebositagliptin;  Drug:placeboglimepiride|Interventional|Phase 3|Industry|Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 104;  ChangeFromBaselineinHbA1catWeek156;  Change From Baseline in Fasting Plasma Glucose (FPG) at Week 104;  ChangeFromBaselineinFPGatWeek156;  Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of &lt;6.5% &lt;7% and &lt;7.5% at Week 104;  Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of &lt;6.5% &lt;7% and &lt;7.5% at Week 156;  TimetoHyperglycemiaRescue;  ChangeFromBaselineinBodyWeightatWeek104;  ChangeFromBaselineinBodyWeightatWeek156|1049|NCT00838903|February 2009
3796|Active not recruiting|Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy Paclitaxel and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer||Radiation: 3-Dimensional Conformal Radiation Therapy;  Drug:Carboplatin;  Radiation:Intensity-ModulatedRadiationTherapy;  Radiation:InternalRadiationTherapy;  Other:LaboratoryBiomarkerAnalysis;  Drug:Paclitaxel;  Other:Quality-of-LifeAssessment;  Other:QuestionnaireAdministration|Interventional|Phase 3|Other / NIH|Durationofrecurrence-freesurvival;  Contributingcauseofdeath;  Cumulativeincidenceofextra-pelvicrecurrence;  Cumulativeincidenceofpelvic/vaginalrecurrence;  Durationofoverallsurvival|555|NCT00807768|March 2009
3797|Completed|Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy||Other:LaboratoryBiomarkerAnalysis;  Other:Placebo;  Other:Quality-of-LifeAssessment;  Drug:SunitinibMalate|Interventional|Phase 3|NIH|PFS;  Overallsurvival(OS);  Responserate(RR);  Time to deterioration in QOL and symptom progression using the EORTC QLQ-C30 and LC13;  Time to quality of life or symptom deterioration as assessed by continuous quality of life (QOL) scores including QLQ-C30 and LC13 subscales;  VEGF levels and correlation with clinical outcomes including RR PFS and OS|210|NCT00693992|June 2008
3798|Completed|A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome||Drug:Dalcetrapib(RO4607381);  Drug: Evidence-based medical care for Acute Coronary Syndrome;  Drug:Placebo|Interventional|Phase 3|Industry|Time to first occurrence of any component of the composite cardiovascular event (cardiovascular mortality and morbidity);  Compositeendpoint:allcausemortality;  Change from baseline in blood lipids and lipoprotein levels;  AdverseeventslabparametersvitalsignsECG|15865|NCT00658515|April 2008
3799|Completed                  Has Results|A Study to Describe Pediatric Influenza Vaccine Coverage||Biological:Influenzavaccination|Observational|Phase 4|Industry|Influenza Vaccine Coverage in Participants &lt;18 Years of Age by Age Group in Pediatric Practices;  Compliance With the Recommended Two-dose Regimen in Vaccinated Participants;  Correlation of Office Vaccination-related Attitudes and Activities With Actual Vaccine Coverage|147494|NCT00639418|August 2007
3800|Active not recruiting|Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma||Biological:Bevacizumab;  Drug:Carboplatin;  Drug:Cisplatin;  Drug:Docetaxel;  Drug:Fluorouracil;  Other:LaboratoryBiomarkerAnalysis|Interventional|Phase 3|NIH|Overallsurvival;  Comorbidities;  Incidence of toxicity as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0;  Objectiveresponserates;  Progression-freesurvival|400|NCT00588770|August 2008
3801|Completed                  Has Results|A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer||Drug:Sunitinib;  Drug:paclitaxel;  Drug:bevacizumab|Interventional|Phase 3|Industry|Progression-FreeSurvival(PFS);  NumberofParticipantsWithObjectiveResponse;  DurationofResponse(DR);  OverallSurvival(OS);  Percentage of Participants Surviving at 1 and 2 Years;  European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30);  EORTCQLQBreastCancerModule(BR23);  EuroQualityofLife-5Dimension(EQ-5D);  EQ-VisualAnalogScale(EQ-VAS);  Biomarkers|488|NCT00373256|November 2006
3802|Completed|Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery||Other:LaboratoryBiomarkerAnalysis;  Other:Placebo;  Other:Quality-of-LifeAssessment;  Drug:SorafenibTosylate;  Drug:SunitinibMalate|Interventional|Phase 3|NIH / Other|Disease-freesurvival(DFS);  Changes in left ventricular ejection fraction (LVEF) decline in patients treated with sunitinib malate or sorafenib tosylate;  DFSamongpatientswithclearcellhistology;  Differences in fatigue assessed by FACIT Fatigue Subscale;  Frequency of clinically significant congestive heart failure (CHF) grade 3 or higher using the Common Terminology Criteria for Adverse Events version 4.0;  Overallsurvival;  Psychometric properties assessed by the PROMIS Fatigue-SF1 measure;  ScanfrequencyinpreventingCHF|1877|NCT00326898|April 2006
3803|Completed                  Has Results|Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer||Drug:irinotecanhydrochloride;  Drug:oxaliplatin;  Drug:leucovorincalcium;  Drug:fluorouracil;  Biological:cetuximab;  Drug:LocallyDirectedTherapy|Interventional|Phase 3|NIH / Other|Disease-free Survival (Arms A and D: Wild-type KRAS Patients);  Disease-free Survival (Arms A and D: Mutant KRAS Patients);  Disease-freeSurvival;  OverallSurvival;  Toxicity|3397|NCT00079274|February 2004
3804|Recruiting|Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer||Other:LaboratoryBiomarkerAnalysis;  Biological:Nivolumab|Interventional|Phase 3|NIH|Disease-freesurvival;  Overallsurvival;  Incidence of toxicity graded according to Common Terminology Criteria for Adverse Events version 4.0|714|NCT02595944|May 2016
3805|Recruiting|Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy||Drug:Capecitabine;  Drug:Carboplatin;  Drug:Cisplatin;  Other:LaboratoryBiomarkerAnalysis|Interventional|Phase 3|Other / NIH|IDFSofpatientswithbasal-likeTNBC;  Incidence of toxicity graded using the National Cancer Institute CTCAE v. 4.0;  OS of patients with basal-like TNBC with residual disease after neoadjuvant chemotherapy;  Rate of basal-like gene expression using PAM50 analysis by digital mRNA quantification;  RFS|562|NCT02445391|April 2015
3806|Recruiting|Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History||Drug:BenralizumabArmA;  Drug:BenralizumabArmB;  Drug:Placebo|Interventional|Phase 3|Industry|Evaluation of the effect of benralizumab on COPD exacerbations in subjects with moderate to very severe COPD;  Evaluation of the effect of benralizumab on health status/health-related quality of life;  Evaluation of the effect of benralizumab on pulmonary function;  Evaluation of the effect of benralizumab on respiratory symptoms;  Evaluation of the effect of benralizumab on rescue medication use;  Evaluation of the effect of benralizumab on nocturnal awakenings;  Evaluation of the effect of benralizumab on the severity frequency and duration of Exacerbations of Chronic Pulmonary Disease Tool (EXACT-PRO) - Patient-reported Outcome questionnaire defined events;  Evaluation of the effect of benralizumab on healthcare resource utilization due to COPD;  Evaluation of the pharmacokinetics parameters of benralizumab.;  Assessment of the safety and tolerability of benralizumab;  Evaluationoftheimmunogenicityofbenralizumab|1626|NCT02138916|June 2014
3807|Active not recruiting|A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus||Drug:Ticagrelor60mg;  Drug:Ticagrelorplacebo|Interventional|Phase 3|Industry|Time from randomisation to first occurrence of any event from the composite of CV death MI or stroke;  Prevention of CV death. The efficacy variable is time from randomisation to death of CV cause;  Prevention of MI. The efficacy variable is time from randomisation to first occurrence of MI;  Prevention of ischaemic stroke. The efficacy variable is time from randomisation to first occurrence of ischaemic stroke;  Prevention of all-cause death. The efficacy variable is time from randomisation to death of any cause|19000|NCT01991795|February 2014
3808|Completed|A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events||Drug:insulindegludec;  Drug:insulinglargine|Interventional|Phase 3|Industry|Time from randomisation to first occurrence of a major adverse cardiovascular event (MACE): cardiovascular death non-fatal myocardial infarction or non-fatal stroke;  Numberofseverehypoglycaemicepisodes;  ChangeinGlycosylatedhaemoglobin(HbA1c)|7637|NCT01959529|October 2013
3809|Recruiting|Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery||Radiation:regionalnodalXRT;  Radiation:chestwallXRT;  Radiation:WBI|Interventional|Phase 3|Other / NIH|IBC-RFI;  OS;  LRRFI;  DRFI;  DFS-DCIS;  TimetoSPC;  Effect of radiation therapy on cosmetic outcome in mastectomy and lumpectomy patients as assessed by quality of life questionnaire;  Frequencies of adverse events graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;  Molecularpredictorsofrecurrence|1636|NCT01872975|August 2013
3810|Active not recruiting|Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia||Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;  Drug:Cytarabine;  Drug:DaunorubicinHydrochloride;  Drug:Idarubicin;  Other:LaboratoryBiomarkerAnalysis;  Drug:Vorinostat|Interventional|Phase 3|NIH|EFS;  RateofallogeneicHCT;  EFSof7+3comparedtoIA;  EFSrate;  OSrate|784|NCT01802333|February 2013
3811|Recruiting|Cardiovascular Inflammation Reduction Trial||Drug:Methotrexate;  Drug:Placebo|Interventional|Phase 3|Other / NIH|Rateofmajorcardiovascularevents;  Rateofall-causemortality;  Rate of the primary endpoint plus coronary revascularization;  Rate of hospitalization for congestive heart failure;  Rate of primary endpoint plus all-cause mortality plus coronary revascularization plus congestive heart failure;  Rate of new onset type 2 diabetes among those with metabolic syndrome but not diabetes at study entry|7000|NCT01594333|April 2013
3812|Completed|Efficacy Safety and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3001)||Drug:JNJ-27018966;  Drug:Placebo|Interventional|Phase 3|Industry|Composite response based on improvements from baseline in daily abdominal pain and daily stool consistency scores.;  Pain response based on improvement from baseline in daily abdominal pain scores;  Stool consistency response based on improvement from baseline in daily stool consistency scores.;  Abdominalbloating;  Bowelmovementfrequency;  Urgencyepisodes;  Incontinenceepisodes;  Irritable Bowel Syndrome global symptom severity response;  Durability of treatment based on composite response in daily abdominal pain scores.;  Durability of treatment based on composite response in daily stool consistency scores.;  Durability of treatment based on composite response in Irritable Bowel Syndrome Global symptom severity.|1282|NCT01553591|May 2012
3813|Completed                  Has Results|Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study||Drug:open-labelrifaximin;  Drug:double-blindplacebo;  Drug:double-blindrifaximin|Interventional|Phase 3|Industry|RepeatTreatmentResponders|2583|NCT01543178|February 2012
3814|Completed                  Has Results|Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer|||Observational||Industry|Sensitivity and Specificity of the Exact CRC Screening Test With Comparison to Colonoscopy Both With Respect to Cancer.|12776|NCT01397747|June 2011
3815|Active not recruiting|A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer||Biological:sipuleucel-T|Observational||Industry|To further quantify the risk of cerebrovascular events following sipuleucel-T therapy for all subjects;  Survival|1500|NCT01306890|January 2011
3816|Active not recruiting|Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I Stage II Stage III or Stage IVA Endometrial Cancer||Drug:Carboplatin;  Drug:Cisplatin;  Radiation:InternalRadiationTherapy;  Drug:Paclitaxel;  Other:Quality-of-LifeAssessment;  Radiation:RadiationTherapy|Interventional|Phase 3|Other / NIH|Recurrence-freesurvival(RFS);  Cumulative incidence of distant metastases (beyond the pelvis and vagina);  Cumulative incidence of grade 3 or higher bowel-related gastrointestinal adverse events graded by the NCI CTCAE version 3.0;  Cumulative incidence of local recurrence (limited to the pelvis or vagina);  Incidence of acute and adverse effects as graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version (CTCAE) version 3.0;  Incidence of late adverse events as graded by the NCI CTCAE version 3.0;  Overallsurvival;  Patient-reportedqualityoflife(QOL)|804|NCT00942357|June 2009
3817|Active not recruiting|Collecting and Storing Blood Bone Marrow and Other Samples From Patients With Acute Leukemia Chronic Leukemia or Myelodysplastic Syndromes||Other:biologicsamplepreservationprocedure|Observational||Other / NIH|Collection and storage of specimens from newly diagnosed patients with acute or chronic leukemia or myelodysplastic syndromes enrolled on a CALGB protocol|1500|NCT00899223|May 1996
3818|Completed                  Has Results|Safety and Efficacy of Albiglutide in Type 2 Diabetes||Biological:albiglutide;  Drug:placebo|Interventional|Phase 3|Industry|Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52;  Change From Baseline in HbA1c at Weeks 104 and 156;  TimetoHyperglycemiaRescue;  Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52;  Change From Baseline in Fasting Plasma Glucose (FPG) at Week 156;  Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of &lt;6.5% &lt;7% and &lt;7.5% at Week 52;  Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of &lt;6.5% &lt;7% and &lt;7.5% at Week 156;  ChangeFromBaselineinBodyWeightatWeek52;  ChangeFromBaselineinBodyWeightatWeek156|310|NCT00849056|January 2009
3819|Completed                  Has Results|A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes||Drug:placebotomatchalbiglutide;  Biological:albiglutide;  Drug:metformin;  Drug:glimepiride;  Drug:pioglitazone;  Drug:placebotomatchpioglitazone|Interventional|Phase 3|Industry|Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52;  Change From Baseline in HbA1c at Week 104 and Week 156;  Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52;  Change From Baseline in FPG at Week 104 and Week 156;  TimetoHyperglycemiaRescue;  Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of &lt;6.5% &lt;7% and &lt;7.5% at Week 52;  Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of &lt;6.5% &lt;7% and &lt;7.5% at Week 156;  ChangeFromBaselineinBodyWeightatWeek52;  Change From Baseline in Body Weight at Week 104 and Week 156|685|NCT00839527|February 2009
3820|Active not recruiting|Chronic Plaque Psoriasis (Ps) Registry|||Observational||Industry|IncidenceofSeriousAdverseEvents;  IncidenceofAdverseEventsofSpecialInterest;  Adverse Events that lead to permanent discontinuation of HUMIRA&#174;;  Patient reported outcome - Dermatology Life Quality Index;  PatientHealthQuestion-9;  HealthCareUtilization;  Work Productivity and Activity Impairment Questionnaire: Specific Health Problem;  RosenbergSelf-EsteemScale;  Census;  MedicalOutcomesSocialActivitiesScale;  PsoriasisImpactandExperience;  IllnessCognition;  InsuranceStatus;  PatientGlobalAssessment;  Physician&apos;sGlobalAssessment|6000|NCT00799877|September 2008
3821|Completed|An Open-label Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation||Drug:Linaclotide|Interventional|Phase 3|Industry|Safety will be assessed descriptively by summarizing AEs clinical laboratory test results vital sign measurements and ECG measurements.;  TreatmentSatisfaction|1743|NCT00730171|September 2008
3822|Terminated|BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab||Drug:Docetaxel;  Drug:Trastuzumab;  Drug:Carboplatin;  Drug:Bevacizumab;  Drug:5-Fluorouracil;  Drug:Epirubicin;  Drug:Cyclophosphamide|Interventional|Phase 3|Other / Industry|InvasiveDisease-freeSurvival(IDFS);  Invasive disease-free survival (IDFS) within chemotherapy cohorts;  Disease-freesurvival(DFS);  Overallsurvival(OS);  Recurrence-freeinterval(RFI);  Distantrecurrence-freeinterval(DRFI);  Cardiac toxicity. Cumulative incidence of severe cardiac events defined as definite or probable cardiac death or NYHA Class III or IV CHF;  Non-cardiac toxicity. Frequencies of adverse events categorized using the NCI CTCAE v3.0.;  Identification of biomarkers (from tumor and serum/plasma) predictive for the level of benefit from the addition of bevacizumab to standard adjuvant systemic treatment for HER2-positive breast cancer as well as for cardiac toxicity|3509|NCT00625898|April 2008
3823|Active not recruiting|Chemotherapy With or Without Bevacizumab in Treating Women With Stage I Stage II or Stage IIIA Breast Cancer That Can Be Removed By Surgery||Biological:bevacizumab;  Drug:capecitabine;  Drug:cyclophosphamide;  Drug:docetaxel;  Drug:doxorubicinhydrochloride(Adriamycin);  Drug:gemcitabinehydrochloride|Interventional|Phase 3|Other / NIH|Pathologic complete response (pCR) of the primary tumor in the breast;  pCRinthebreastandnodes;  Clinical overall response (cOR) following docetaxel alone docetaxel/capecitabine and docetaxel/gemcitabine hydrochloride with or without bevacizumab as assessed by physical exam at the completion of the docetaxel-based portion of chemotherapy;  cOR as assessed by physical exam at the completion of the sequential chemotherapy regimens;  Clinical complete response (cCR) following docetaxel alone docetaxel/capecitabine and docetaxel/gemcitabine hydrochloride with or without bevacizumab as assessed by physical exam at completion of therapy;  cCR as assessed by physical exam at the completion of the sequential chemotherapy regimens physical exam at the completion of the sequential chemotherapy regimens;  Percentageofcardiacevents;  Percentageofsurgicalcomplications;  Toxicities including events other than congestive heart failure of chemotherapy alone bevacizumab with chemotherapy and bevacizumab alone;  Disease-freesurvival(DFS)|1206|NCT00408408|November 2006
3824|Active not recruiting                  Has Results|Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive||Drug:Fulvestrant;  Other:LaboratoryBiomarkerAnalysis;  Drug:LapatinibDitosylate;  Other:Placebo|Interventional|Phase 3|NIH|Progression-freeSurvival(PFS);  ObjectiveTumorResponseRate;  OverallSurvival(OS)|295|NCT00390455|September 2006
3825|Completed|Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer||Drug:cyclophosphamide;  Drug:adriamycin;  Drug:epirubicin;  Drug:fluorouracil|Interventional|Phase 3|Other / NIH|Disease free survival or no breast cancer (BC) at time of local recurrence (LR) after mastectomy LR in the ipsilateral breast following lumpectomy regional or distant recurrence contralateral BC 2nd primary cancer or death;  Survival;  Adverseevents;  QualityofLife;  Postchemotherapyamenorrhea;  ChangeinLVEFatthe12-monthevaluation;  HER-2andTopoIIgeneamplification;  Recurrence-freeinterval;  Distantrecurrence-freeinterval|2722|NCT00087178|May 2004
3826|Completed|S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer||Biological:cetuximab;  Drug:gemcitabinehydrochloride|Interventional|Phase 3|Other / NIH|Overall survival comparison between treatment groups;  Response rate comparison between treatment groups as measured by RECIST and radiological evaluation at every other course;  Time to treatment failure comparison between groups from registration to first observation of progressive disease symptomatic deterioration or death;  Percentage of patients with EGFR tumor expression and compare overall survival of patients in the EGFR subset;  Toxicity profile comparison of patients treated with 2 regimens and measured until 30 days after completion of study treatment;  Total response rate comparison between treatment groups in the subset of patients with measurable disease by RECIST at every other course;  Pain and quality of life comparison between treatment groups as measured by patient questionnaire at baseline before each course and then completion of study treatment|766|NCT00075686|January 2004
3827|Active not recruiting|Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ||Drug:tamoxifencitrate;  Procedure:adjuvanttherapy;  Radiation:radiationtherapy|Interventional|Phase 3|Other / NIH|Local recurrence (e.g. invasive or noninvasive recurrence);  Overallsurvival;  Timetodistantmetastasis;  Invasivelocalrecurrence;  Salvagemastectomyrate|636|NCT00003857|December 1999
3828|Recruiting|Long Term Safety Study of Plecanatide||Drug:Plecanatide|Interventional|Phase 3|Industry|Number of participants with treatment related adverse events.|1500|NCT02706483|January 2016
3829|Active not recruiting|Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)|||Observational||Industry|Description of patterns of the disease Polycythemia Vera (PV) and associations of such patterns with patients&apos; exposures or treatments;  Incidence(frequency)ofdiseaseprogression;  Incidence (frequency) of healthcare resources utilization;  Incidence(frequency)ofcomplicationsduetoPV;  Incidence (frequency) and description of PV-related symptoms;  Incidence (frequency) of adverse events (for those patients on active therapies including PHL);  Patient-reported outcomes as assessed by Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) for assessment of the severity of symptoms;  Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP) score for assessment of work productivity and activity impairment;  European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) for Health Related Quality of Life (HRQoL);  Caregiverburden;  Burdenofphlebotomy(PHL)|2544|NCT02252159|July 2014
3830|Recruiting|S1314 Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer||Drug:Gemcitabine;  Drug:Cisplatin;  Drug:Methotrexate;  Drug:Vinblastine;  Drug:Doxorubicin;  Drug:Filgrastim|Interventional|Phase 2|Other / NIH|The relationship of dose-dense methotrexate vinblastin doxorubicin and cisplatin (DDMVAC)- and gemcitabine+cisplatin (GC)- specific CO-eXpression ExtrapolatioN (COXEN) scores.;  Predictability of the CO-eXpression ExtrapolatioN (COXEN) score to direct which of the two regimens the patient should receive: gemcitabine+cisplatin (GC) versus dose-dense methotrexate vinblastin doxorubicin and cisplatin (DDMVAC);  Overallsurvival;  Pathologic T0 rate evaluation: gemcitabine+cisplatin (GC) versus dose-dense methotrexate vinblastin doxorubicin and cisplatin (DDMVAC);  Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug|184|NCT02177695|July 2014
3831|Recruiting|A Long-Term Registry of Humira&#174; (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)|||Observational||Industry|Evaluation of long term safety of Adalimumab in patients with moderately to severely active UC;  Evaluation of long term effectiveness of Adalimumab in patients with moderately to severely active UC who have had an inadequate response to conventional therapy|8250|NCT01848561|April 2013
3832|Active not recruiting|Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)||Drug:Canakinumab;  Drug:Placebo|Interventional|Phase 3|Industry|Main:Time to first occurrence of major adverse cardiovascular event which is a composite of CV death non-fatal MI and stroke.;  Substudy 1; Change from baseline in carotid plaque burden in the bifurcation region of the index carotid artery;  Substudy 2; Change from baseline of the insulin secretion rate (ISR) relative to glucose 0-30 min defined as &#934;30 = AUCISR 0-30 / AUCGluc 0-30 averaged across the yearly visits.;  Main:Time to first occurrence of the composite cardiovascular endpoint consisting of cardiovascular death non-fatal MI stroke and hospitalization for unstable angina requiring unplanned revascularization.;  Main:Time to new onset type 2 diabetes among patients with pre-diabetes at randomization.;  Main:Time to first occurrence of non-fatal MI stroke and all-cause mortality composite.;  Main:Timetoall-causemortality.;  Substudy 1; Change from baseline of the total vessel wall area at Month 3 of the index carotid artery.;  Substudy 1; Mean total vessel wall area across the left and right carotid artery at Month 3 and Month 24.;  Substudy 1; Change from baseline in corresponding total vessel wall area in the left and right carotid arteries.;  Substudy 1; The existence of a baseline total vessel wall area by treatment interaction as well as the consistency of the treatment effect across subgroups.;  Substudy 2; Change from baseline in insulin sensitivity index.;  Substudy 2; Change from baseline in OGTT stimulated area under curve (AUC) 0-120 min of glucose concentration insulin concentration pro-insulin concentration and insulin concentration/glucose concentration ratio.;  Substudy 2; Change from baseline in fasting pro-insulin concentration /insulin concentration ratio.;  Substudy 2; Change from baseline in OGTT stimulated area under the curve (AUC) 0-120 min of C-peptide concentration.|10066|NCT01327846|April 2011
3833|Completed                  Has Results|Prevention of Cardiovascular Events (eg Death From Heart or Vascular Disease Heart Attack or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin||Drug:Ticagrelor90mg;  Drug:Ticagrelor60mg;  Drug:TicagrelorPlacebo|Interventional|Phase 3|Industry|Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death) Myocardial Infarction (MI) or Stroke Within 3 Years From Randomization;  Kaplan-Meier Estimate of the Percentage of Patients Who Experienced a TIMI Major Bleeding Within 3 Years From First Dose of Study Drug Units: Percentage of Patients;  Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death) Within 3 Years From Randomization;  Kaplan-Meier Estimate of the Percentage of Patients Who Died From Any Cause Within 3 Years From Randomization|21379|NCT01225562|October 2010
3834|Active not recruiting|Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities||Drug:Febuxostat;  Drug:Allopurinol|Interventional|Phase 3|Industry|First occurrence of any event in the predefined Major Adverse Cardiovascular Events Composite.;  First occurrence of any Antiplatelet Trialists&apos; Collaborative Event.;  FirstoccurrenceofCardiovascularDeathdeath.;  First occurrence of Non-fatal Myocardial Infarction.;  FirstoccurrenceofNon-fatalstroke.;  First occurrence of Unstable Angina with Urgent Coronary Revascularization.|6198|NCT01101035|April 2010
3835|Active not recruiting|Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma||Drug:CediranibMaleate;  Drug:Cisplatin;  Drug:PemetrexedDisodium;  Other:Placebo|Interventional|Phase 1 / Phase 2|NIH|Maximum tolerated dose determined if the dose-limiting toxicity rate is less than or equal to 33% according to NCI CTCAE version 4.0 (Phase I);  Progression-freesurvival(PhaseII);  Overallsurvival(PhaseII);  Response(PhaseII);  Toxicity assessed using NCI CTCAE version 4.0 (Phase II)|116|NCT01064648|March 2010
3836|Terminated|Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery||Drug:rosuvastatin;  Other:placebo|Interventional|Phase 3|Other / NIH|Occurrence of &#8805; 1 adenomatous polyp of the colon or rectum metachronous colorectal carcinoma or colon cancer recurrence (APMC+R);  Size number and features of colorectal adenomas including advanced adenomas;  Disease-freesurvival;  Overall Survival: Time from randomization to death from any cause;  Recurrence-free interval: Time from randomization to first recurrence of colon cancer;  Second non-colorectal primary cancer-free interval;  Behavioral and Health Outcomes as measured by SF-12 component scores global quality-of-life scale and symptom checklist;  Occurrenceandgradeofreportedtoxicities;  Measurementsofrelevanttumorandbloodmarkers|406|NCT01011478|March 2010
3837|Completed                  Has Results|Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)||Drug:LinaclotideorMatchingPlacebo|Interventional|Phase 3|Industry|Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder 9 Out of 12 Weeks;  Complete Spontaneous Bowel Movement (CSBM) 3+1 Responder 9 Out of 12 Weeks;  AbdominalPainResponder9Outof12Weeks;  Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder 6 Out of 12 Weeks;  12-Week Complete Spontaneous Bowel Movement (CSBM) Frequency;  12-WeekSpontaneousBowlMovement(SBM)Frequency;  12-WeekChangeinStoolConsistency;  12-WeekChangeinSeverityofStraining;  12-WeekChangeinAbdominalPainScore;  12-WeekChangeinAbdominalDiscomfort;  12-WeekChangeinBloating;  Complete Spontaneous Bowl Movement (CSBM) Responder for 6 Weeks Out of 12 Weeks of Treatment;  AbdominalPainResponderfor6Outof12Weeks;  12-WeekPercentofAbdominalPain-freeDays|805|NCT00938717|July 2009
3838|Completed                  Has Results|Trial of Linaclotide in Patients With Chronic Constipation||Drug:MatchingPlacebo;  Drug:Linaclotide|Interventional|Phase 3|Industry|Complete Spontaneous Bowel Movement (CSBM) Overall Responder;  12-Week Complete Spontaneous Bowel Movement (CSBM) Frequency;  12-WeekSpontaneousBowlMovement(SBM)Frequency;  12-weekChangeinStoolConsistency;  12-weekChangeinSeverityofStraining;  12-weekChangeinAbdominalDiscomfort;  12-weekChangeinBloating;  12-weekChangeinConstipationSeverity|643|NCT00730015|August 2008
3839|Active not recruiting|FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer||Drug:Systemicchemotherapy(FOLFOX);  Device:SIR-Spheresyttrium-90microspheres|Interventional||Industry|progressionfreesurvival|518|NCT00724503|August 2006
3840|Completed                  Has Results|A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects||Drug:Clopidogrel;  Drug:Prasugrel;  Drug:Commercially-availableAspirin|Interventional|Phase 3|Industry / Other|Percentage of Participants With a Composite Endpoint of Cardiovascular (CV) Death Myocardial Infarction (MI) or Stroke;  Percentage of Participants With a Composite Endpoint of CV Death and MI;  Percentage of Participants With a Composite Endpoint of CV Death MI Stroke or Re-hospitalization for Recurrent Unstable Angina (UA);  Percentage of Participants With a Composite Endpoint of All-cause Death MI or Stroke;  PlateletAggregationMeasures;  Biomarker Measurements of Inflammation/Hemodynamic Stress: Brain Natriuretic Peptide (BNP);  Biomarker Measurements of Inflammation/Hemodynamic Stress: C-Reactive Protein (CRP);  GenotypingRelatedtoDrugMetabolism;  EconomicandQualityofLifeOutcomes;  SummaryofAllDeaths|9326|NCT00699998|June 2008
3841|Active not recruiting|Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer||Drug:bicalutamide;  Drug:flutamide;  Radiation:radiationtherapy|Interventional|Phase 3|Other / NIH|Freedomfromprogression(FFP);  Secondarybiochemicalfailure;  Hormone-refractorydisease;  Localfailure;  Distantmetastasis;  Cause-specificmortality;  Overallmortality;  Incidence of acute adverse events &#8804; 90 days of the completion of radiotherapy (RT);  Time to late grade 2+ and 3+ adverse events assessed &gt; 90 days from the completion of RT;  Comparison of disease-specific health related quality of life (HRQOL) change by EPIC Hopkins Verbal Learning Test Revised (HVLT-R) Trail Making Test parts A &amp; B and Controlled Oral Word Association Test (COWAT);  Assessment of mood and depression change using QOL measured by the Hopkins Symptom Checklist (HSCL-25);  Assessment and comparison of Quality Adjusted Life Year (QALY) and Quality Adjusted FFP Year (QAFFPY);  Evaluation and comparison of the cost-utility using EuroQoL - 5 Dimensions (EQ-5D);  Association between serum levels of beta-amyloid (Abeta) and measures of HSCL-25 the HVLT-R Trail Making Test parts A &amp; B or the COWAT;  Prognostic value of genomic and proteomic markers for the primary and secondary clinical endpoints;  Assessment of the relationship(s) between the American Urological Association Symptom Index (AUA SI) and urinary morbidity (Adverse Event terms: Urinary frequency/urgency) using the CTCAE v. 3.0 grading system|1792|NCT00567580|February 2008
3842|Completed|Asimadoline for the Treatment of Subjects With Irritable Bowel Syndrome||Drug:Asimadoline;  Drug:Placebo|Interventional|Phase 2|Industry / Other|ReliefofIBSPain-totalmonths;  ReliefofIBSPain-percentofpatients;  ReliefofIBSSymptoms;  LowerGIfunction-changefrombaseline;  AbdominalPainScore-changefrombaseline;  AbdominalDiscomfortScore-changefrombaseline|596|NCT00454688|August 2006
3843|Completed                  Has Results|Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate||Drug:warfarin;  Drug:Dabigatrandose1;  Drug:Dabigatrandose2|Interventional|Phase 3|Industry / Other|Yearly Event Rate for Composite Endpoint of Stroke/SEE;  Yearly Event Rate for Composite Endpoint of Stroke/SEE/All Cause Death;  Yearly Event Rate: Composite of Stroke/SEE/PE/MI/Vascular Death;  BleedingEvents(MajorandMinor);  Clinical Relevant Abnormalities for Intracerebral Hemorrhage and Other Intracranial Hemorrhage (ICH);  AbnormalLiverFunctionTest|18113|NCT00262600|November 2005
3844|Completed                  Has Results|&quot;REDUCE&quot; - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk||Drug:Dutasteride;  Drug:Placebo|Interventional|Phase 3|Industry|Number of Participants With Biopsy-detectable Prostate Cancer at Years 2 and 4 (Crude Rate Approach);  Number of Participants With Biopsy-detectable Prostate Cancer at Years 2 and 4 (Modified Crude Rate Approach);  Number of Participants With Biopsy-detectable Prostate Cancer at Years 2 and 4 (Restricted Crude Rate Approach);  Number of Participants With the Indicated Gleason Score at Diagnosis;  Number of Participants With HGPIN ASAP and Prostate Cancer at Biopsy;  VolumeofHGPINatBiopsy;  PercentageofCoreInvolvedatDiagnosis;  NumberofCancer-positiveCores;  TreatmentAlterationScore;  Number of Participants Undergoing Intervention (Surgical and Non-surgical) for Prostate Cancer Treatment;  Adjusted Mean Change From Baseline in the International Prostate Symptom Score (IPSS) at Month 48;  Adjusted Mean Percentage Change From Baseline in Prostate Volume at Months 24 and 48;  Adjusted Mean Change From Baseline in Maximum Urinary Flow (Qmax) at Months 12 24 36 and 48;  Number of Participants Starting Alpha Blockers to Control Benign Prostatic Hyperplasia (BPH) Symptoms;  Number of Participants With at Least One Event of Acute Urinary Retention (AUR);  Number of Participants With at Least One Urinary Tract Infection (UTI);  Number of Participants With Post-biopsy Macroscopic Hematuria;  Number of Participants With Post-biopsy Macroscopic Hematospermia;  OverallSurvival;  Adjusted Mean Change From Baseline in the Benign Prostatic Hypertrophy (BPH) Impact Index (BII) at Month 48;  Adjusted Mean Change From Baseline in The Medical Outcomes Study Sleep Problems Index 6-item Standard Version (MOS Sleep-6S) at Month 48;  Adjusted Mean Change From Baseline in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH CPSI) at Month 48;  Adjusted Mean Change From Baseline in Quality of Life Question 8 (QOL Q8) at Month 48;  Adjusted Mean Change From Baseline in the Problem Assessment Scale of the Sexual Function Index (PASSFI) at Month 48;  Number of Participants With the Indicated Serum Dihydrotestosterone (DHT) Concentration at Month 48;  Mean Change From Baseline in Testosterone at Month 48|8231|NCT00056407|March 2003
3845|Active not recruiting|Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study||Other:Studyvouchercard|Interventional|Phase 4|Industry / Other|MajorAdverseCardiovascularEvents;  LongTermPersistencetoP2Y12receptorinhibitor;  P2Y12receptorinhibitorselection;  HealthcareResourceUtilization|11000|NCT02406677|June 2015
3846|Recruiting|Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)|||Observational||Industry|NumberofCRPCTreatmentPatterns;  Health-related Quality of Life (HRQoL) as assessed by Modified Total Illness Burden Index (TIBI-CaP);  HRQoLasassessedbySF-12v2HealthSurvey;  HRQoL as assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P);  HRQoL as assessed by Brief Pain Inventory - Short Form (BPI-SF);  HRQoL as assessed by Memorial Anxiety Scale for Prostate Cancer (MAX-PC);  HRQoL as assessed by Work Productivity and Activity Questionnaire: Specific Health Problem (WPAI-SHP);  HRQoL as assessed by Service Satisfaction Scale for Cancer Care (SCA);  Number of patients with Physician Factors for Treatment Decisions;  Number of patients with Clinical outcomes including PSA values clinical and/or radiologic evidence of disease progression and overall survival;  Number of patients with Prognostic factors (e.g. patient and disease characteristics) potentially related to select clinical outcomes and HRQoL|1200|NCT02380274|March 2015
3847|Recruiting|S1313 PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer||Drug:PEGPH20;  Drug:Oxaliplatin;  Drug:Leucovorin;  Drug:Irinotecan;  Drug:5-fluorouracil|Interventional|Phase 1 / Phase 2|Other / NIH / Industry|Phase I: Maximum tolerated dose of PEGPH20 determined according to incidence of dose-limiting toxicity graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4;  PhaseII:OverallSurvival;  ProgressionFreeSurvival(PFS)(PhaseII);  Objective Tumor Response (confirmed and unconfirmed complete and partial);  Frequencyofadverseevents;  Severityofadverseevents;  Tolerabilityofadverseevents|172|NCT01959139|January 2014
3848|Active not recruiting|Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)||Drug:Placebo;  Drug:Linagliptin|Interventional|Phase 4|Industry|Time to the first occurence of any of the following adjudicated components of the primary composite endpoint: cardiovascular death non fatal myocardial infarction non fatal stroke and hospitalization for unstable angina pectoris;  Time to first occurence of any of the following adjudicated components: cardiovascular death non fatal myocardial infarction and non fatal stroke;  Time to first occurence of any of the following adjudicated composite renal endpoint: renal death end stage renal disease and a sustained decrease of 50% or more in estimated glomerular filtration rate|8300|NCT01897532|July 2013
3849|Recruiting|Study Of Diabetic Nephropathy With Atrasentan||Drug:Atrasentan;  Drug:Placebo|Interventional|Phase 3|Industry|Time to the first occurrence of a component of the composite renal endpoint.;  Time to a 50% estimated glomerular filtration rate reduction.;  Time to cardio-renal composite endpoint: confirmed doubling of serum creatinine end stage renal disease cardiovascular death nonfatal myocardial infarction nonfatal stroke.;  Time to the cardiovascular composite endpoint: cardiovascular death nonfatal myocardial infarction and nonfatal stroke.;  Time to first occurrence of a component of composite renal endpoint: confirmed doubling of serum creatinine or the onset of end stage renal disease for all randomized subjects (pooled).|4148|NCT01858532|May 2013
3850|Completed|A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease||Drug:Ticagrelor;  Drug:Clopidogrel|Interventional|Phase 3|Industry|Time from randomization to first occurrence of any event in the composite of cardiovascular death myocardial infarction and ischemic stroke;  Time from randomisation to first occurrence of any event in the composite of CV death MI ischemic stroke and ALI;  Time from randomization to occurrence of cardiovascular death;  Time from randomization to occurrence of myocardial infarction;  Time from randomization to occurrence of all-cause mortality;  Time from randomization to occurrence of composite of cardiovascular death myocardial infarction and all-cause stroke (ischaemic or haemorrhagic);  TimefromrandomisationtooccurrenceofALI;  Time from randomisation to occurrence of lower extremity revascularization;  Time from randomisation to occurrence of any revascularisation (coronary peripheral [limb mesenteric renal carotid and other])|16415|NCT01732822|December 2012
3851|Active not recruiting|Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease||Biological:Darbepoetinalfa|Interventional|Phase 3|Industry|Receiptof1ormoreRBCtransfusion;  Total number of units of red blood cells (RBC) transfused. Time to first red blood cell transfusion.;  Average achieved hemoglobin (Hb) concentration while receiving investigational product.;  Cumulativedoseofdarbepoetinalfa;  TimetofirstRBCtransfusion|756|NCT01652872|July 2012
3852|Terminated                  Has Results|Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease||Drug:TAK-875;  Drug:TAK-875Placebo|Interventional|Phase 3|Industry|Time to First Occurrence of Any Component of Primary Major Adverse Cardiovascular Event (MACE) Composite;  Time to First Occurrence of Any Component of Secondary Major Adverse Cardiovascular Event (MACE) Composite|3207|NCT01609582|June 2012
3853|Terminated|Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)||Drug:NB32;  Drug:PBO;  Behavioral:WeightManagementProgram|Interventional|Phase 3|Industry|Time from treatment period randomization to the first confirmed occurrence of MACE;  Time from treatment period randomization to the first confirmed occurrence of cardiovascular death nonfatal myocardial infarction nonfatal stroke or nonfatal unstable angina requiring hospitalization;  Time from treatment period randomization to the confirmed occurrence of cardiovascular death (including fatal myocardial infarction fatal stroke);  Time from treatment period randomization to the first confirmed occurrence of myocardial infarction (nonfatal or fatal);  Time from treatment period randomization to the first confirmed occurrence of stroke (nonfatal or fatal)|8910|NCT01601704|June 2012
3854|Completed                  Has Results|SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.||Drug:ADVAIR100/50mcg;  Drug:ADVAIR250/50mcg;  Drug:ADVAIR500/50mcg;  Drug:FLOVENT100mcg;  Drug:FLOVENT250mcg;  Drug:FLOVENT500mcg|Interventional|Phase 4|Industry|Number of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization Asthma-related Endotracheal Intubation or Asthma-related Death);  Number of Participants Experiencing at Least One Asthma Exacerbation;  Number of Participants Experiencing at Least One Asthma Related Hospitalization  Endotracheal Intubation and Death;  Number of Participant Withdrawals From Study Treatment Due to Asthma Exacerbation;  Mean Rescue Medication (Albuterol/Salbutamol) Use as Puffs Per 24 Hours|11751|NCT01475721|November 2011
3855|Active not recruiting|Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II Stage III or Stage IV Ovarian Epithelial Cancer Primary Peritoneal Cancer or Fallopian Tube Cancer||Biological:Bevacizumab;  Drug:Carboplatin;  Procedure:ComputedTomography;  Drug:Paclitaxel;  Procedure:TherapeuticConventionalSurgery|Interventional|Phase 3|NIH|Progression-freesurvival;  Incidence of adverse effects using the National Cancer Institute CTCAE version 4.0;  Overallsurvival;  QOL assessed using the FACT-O TOI (as of 02/08/2012 the QOL portion of this study is complete; patients enrolled after this date will not have QOL assessments);  ResponserateaccordingtoRECIST|773|NCT01167712|September 2010
3856|Terminated|A Long Term Study To Evaluate The Safety And Tolerability Of CP-690550 For Patients With Moderate To Severe Chronic Plaque Psoriasis||Drug:CP-690550|Interventional|Phase 3|Industry|Incidence and severity of adverse events during treatment.;  Incidence of clinical laboratory abnormalities and change from baseline (in this and/or prior study) in clinical laboratory values during treatment.;  Incidence of investigator-reported clinically significant changes in physical examination from baseline (in this and/or prior study) during treatment.;  Incidence of vital sign (blood pressure and heart rate) abnormalities and change from baseline (in this and/or prior study) in vital sign measures during treatment.;  Summary of adjudicated cardiovascular endpoints. Summary of malignancies confirmed by central laboratory pathologist over read of biopsies.;  Incidence of electrocardiogram (ECG) abnormalities and change from baseline (in this and/or prior study) in ECG measurements during treatment.;  Physician&apos;s Global Assessment (PGA) response ie the proportion of participants achieving a PGA of &quot;clear&quot; or &quot;almost clear&quot; at various time points.;  Psoriasis Area and Severity Index 75 (PASI75) response ie the proportion of participants achieving at least a 75% reduction in PASI relative to baseline (in this and/or prior study) at various time points.;  Actual and change from baseline (in this and/or prior study) in PASI and PASI component scores at various time points.;  Proportion of participants achieving at least a 50% and 90% reduction in PASI relative to baseline (in this and/or prior study) (ie PASI50 and PASI90 respectively) at various time points.;  Proportion of participants with a PASI score &gt;= 125% of the baseline PASI score (in this and/or prior study) at any time point.;  Actual and change from baseline (in this and/or prior study) in the Itch Severity Item (ISI) score;  Actual and change from baseline (in this and/or prior study) on the Dermatology Life Quality Index (DLQI) score.;  Short Form-36 Health Survey (SF-36) - (Version 2 Acute);  PatientGlobalAssessment(PtGA);  Euro-Qol5Dimensions(EQ-5D);  Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU)|2873|NCT01163253|September 2010
3857|Completed                  Has Results|Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)||Drug:Lixisenatide(AVE0010);  Drug:Placebo|Interventional|Phase 3|Industry|Time to First Occurence of Primary CV Event: CV Death Non-Fatal MI Non-Fatal Stroke or Hospitalization for Unstable Angina;  Time to First Occurence of CV Event: CV Death Non-Fatal MI Non-Fatal Stroke Hospitalization for Unstable Angina or Hospitalization For Heart Failure;  Time to First Occurence of CV Event: CV Death Non-Fatal MI Non-Fatal Stroke Hospitalization for Unstable Angina Hospitalization For Heart Failure or Coronary Revascularization Procedure;  Percent Change From Baseline in the Urinary Albumin/Creatinine Ratio (UACR) at Week 108|6068|NCT01147250|June 2010
3858|Active not recruiting|Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus||Drug:ExenatideOnceWeekly;  Drug:Placebo|Interventional|Phase 3|Industry|The primary efficacy outcome variable is defined as the composite endpoint of cardiovascular death nonfatal MI or nonfatal stroke;  The primary safety outcome variable is defined as the composite endpoint of cardiovascular death nonfatal MI or nonfatal stroke.;  All-causemortality;  Components of the primary composite endpoint (cardiovascular death fatal or nonfatal MI fatal or nonfatal stroke).;  Hospitalizationforacutecoronarysyndrome;  Hospitalizationforheartfailure|14000|NCT01144338|June 2010
3859|Active not recruiting|S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer||DietarySupplement:cholecalciferol;  Other:placebo|Interventional|Phase 2|Other / NIH|Change in mammographic density at 12 months compared to baseline;  Ki-67 as assessed in tissue obtained in breast biopsies at baseline and at 12 months|200|NCT01097278|November 2011
3860|Active not recruiting|Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer||Drug:carboplatin;  Drug:celecoxib;  Drug:gemcitabinehydrochloride;  Drug:pemetrexeddisodium;  Other:placebo|Interventional|Phase 3|Other / NIH|Progression-freesurvival;  Overallsurvival;  Responserate;  Toxicity;  Comparison of survival benefit between patients with COX-2 index &#8805; 2 treated with different treatment regimens;  AdverseprognosticvalueofCOX-2expression|792|NCT01041781|February 2010
3861|Active not recruiting|Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer Fallopian Tube Cancer or Primary Peritoneal Cancer||Biological:Bevacizumab;  Drug:Carboplatin;  Drug:Cisplatin;  Other:LaboratoryBiomarkerAnalysis;  Drug:Paclitaxel;  Other:Quality-of-LifeAssessment|Interventional|Phase 3|NIH|Progression-freesurvival;  Frequency and severity of adverse events as defined by NCI CTCAE version 3.0;  Overallsurvival;  Quality of life and other patient-reported outcomes (e.g. neuropathy abdominal discomfort fatigue and nausea) as assessed by FACT-O-TOI FACT-GOG/NTX4 FACT-GOG/AD FACIT-Fatigue and FACT-Nausea questionnaires|1526|NCT00951496|July 2009
3862|Active not recruiting|S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer||Biological:Bevacizumab;  Drug:Carboplatin;  Biological:Cetuximab;  Other:LaboratoryBiomarkerAnalysis;  Drug:Paclitaxel|Interventional|Phase 3|Other / NIH|Overallsurvival(OS);  Progression-free survival (PFS) of EGFR FISH-positive patients by institutional review;  Incidence of toxicity as assessed by NCI CTCAE version 4.0;  OS of EGFR FISH-positive patients by centralized review;  PFS of EGFR FISH-positive patients by centralized review;  PFS of the entire study population by centralized review and by institutional review;  Response|1546|NCT00946712|July 2009
3863|Active not recruiting|Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer||Drug:bicalutamide;  Drug:buserelin;  Drug:flutamide;  Drug:goserelinacetate;  Drug:leuprolideacetate;  Drug:triptorelin;  Radiation: 3-dimensional conformal radiation therapy;  Radiation:intensity-modulatedradiationtherapy|Interventional|Phase 3|Other / NIH|Overallsurvival(OS);  Biochemical failure according to the Phoenix (nadir + 2) definition;  Localrecurrence;  Regionalrecurrence;  Distantmetastasis;  Prostatecancer-specificmortality;  Non-prostatecancer-specificmortality;  Rateofsalvageandrogen-deprivationtherapy;  Rates of OS for patients treated with the 3 different radiotherapy modalities in each arm;  Incidence of &quot;acute&quot; adverse events as assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v. 4.0;  Time to &quot;late&quot; grade 3+ adverse events as assessed by NCI CTCAE v. 4.0;  FreedomfromFailure;  Comparison of prostate cancer-specific health related quality of life (HRQOL) change as measured by EPIC;  Comparison of fatigue status as measured by the Patient Reported Outcome Measurement Information System (PROMIS) fatigue domain;  Assessment and comparison of Quality Adjusted Life Years (QALYs);  Correlation between the fatigue PROMIS score change and plasma cytokine change|1538|NCT00936390|September 2009
3864|Completed|S9925: Collecting and Storing Samples From Patients With Lung Cancer||Other:biologicsamplepreservationprocedure|Observational||Other / NIH|Establishment of a central lung cancer specimen repository to serve as a resource for current and future scientific studies;  Correlation of clinicopathologic information in the Southwest Oncology Group clinical data base with results of studies using the repository;  Test of new hypotheses with the specimens in the repository|2264|NCT00920010|September 2000
3865|Completed                  Has Results|Comparing the Efficacy Safety and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)||Drug:rabeprazolesodium;  Drug:Placebo|Interventional|Phase 3|Industry|Mean Percentage of Diary-Recorded Heartburn-Free Days at Week 4;  Change From Baseline in Average Daily Severity Score of Gastroesophageal Reflux Disease (GERD)-Related Symptoms at Week 4|305|NCT00911534|January 2009
3866|Completed                  Has Results|Safety and Efficacy Study of Albiglutide in Type 2 Diabetes||Biological:albiglutide;  Biological:albiglutideuptitration;  Biological:placebo|Interventional|Phase 3|Industry|Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52;  Change From Baseline in HbA1c at Weeks 104 and 156;  TimetoHyperglycemiaRescue;  Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52;  Change From Baseline in Fasting Plasma Glucose (FPG) at Week 156;  Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of &lt;6.5% &lt;7% and &lt;7.5% at Week 52;  Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of &lt;6.5% &lt;7% and &lt;7.5% at Week 156;  ChangeFromBaselineinBodyWeightatWeek52;  ChangeFromBaselineinBodyWeightatWeek156;  Change From Baseline in Postprandial Blood Glucose Profile Parameter-4 Hour C-peptide AUC;  Change From Baseline in Postprandial Blood Glucose Profile Parameter- 4 Hour Blood Glucose AUC;  Change From Baseline in Postprandial Blood Glucose Profile Parameters-4 Hour Insulin AUC and 4 Hour Proinsulin AUC;  Albiglutide Plasma Concentration at Weeks 8 and 24|309|NCT00849017|January 2009
3867|Completed                  Has Results|S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer||Biological:ziv-aflibercept;  Drug:topotecanhydrochloride|Interventional|Phase 2|NIH|Progression-freeSurvival(PFS);  OverallSurvival;  Response Rate (Confirmed and Unconfirmed Complete and Partial Responses);  Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs|189|NCT00828139|May 2009
3868|Completed                  Has Results|Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB Recurrent or Persistent Cervical Cancer||Biological:Bevacizumab;  Drug:Cisplatin;  Other:LaboratoryBiomarkerAnalysis;  Drug:Paclitaxel;  Other:Quality-of-LifeAssessment;  Other:QuestionnaireAdministration;  Drug:TopotecanHydrochloride|Interventional|Phase 3|NIH|OverallSurvival;  Progression-freeSurvival;  TumorResponse;  Incidence of Adverse Events Assessed by National Cancer Institute CTCAE Version 3.0.|452|NCT00803062|April 2009
3869|Completed                  Has Results|Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation||Drug:warfarintablets;  Drug:Edoxabantablets(highdoseregimen-60mg);  Drug:Edoxabantablets(lowdoseregimen-30mg);  Drug:placebowarfarin;  Drug:placeboedoxaban|Interventional|Phase 3|Industry / Other|Compare Edoxaban to Warfarin for Composite of Stroke and Systemic Embolic Events (SEE).;  Compare Edoxaban to Warfarin for Superiority for Composite of Stroke and Systemic Embolic Events (SEE).;  Compare Edoxaban to Warfarin for Composite of Stroke Systemic Embolic Event (SEE) and Cardiovascular (CV) Mortality;  Compare Edoxaban to Warfarin for Major Adverse Cardiac Event (MACE): a Composite of Non-fatal MI Non-fatal Stroke Non-fatal SEE and Death Due to CV Cause or Bleeding;  Compare Edoxaban to Warfarin for Composite of Stroke SEE and All-cause Mortality;  AdjudicatedBleedingEvents|21105|NCT00781391|November 2008
3870|Active not recruiting                  Has Results|Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery||Drug:LapatinibDitosylate;  Biological:Trastuzumab;  Drug:Paclitaxel;  Other:LaboratoryBiomarkerAnalysis|Interventional|Phase 3|NIH|pCRRate;  PathologicStageintheBreastandAxilla;  Radiographic Response Rate (at Completion of Neoadjuvant Therapy);  OverallSurvival;  Relapse-freeSurvival(RFS);  TimetoFirstFailure;  Incidence of Adverse Events as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3|305|NCT00770809|December 2008
3871|Terminated|Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)||Drug:Renzapride|Interventional|Phase 3|Industry|Adverseevents;  Vital signs routine clinical laboratory data 12-lead ECG|939|NCT00607971|April 2006
3872|Completed                  Has Results|A Comparison of Once a Day Dose Compared to 2 Doses/Day||Drug:MesalamineOnce-Daily;  Drug:MesalamineTwice-Daily|Interventional|Phase 3|Industry|Percentage of Patients Remaining in Remission at Month 6 ITT Population Determined by the Simple Clinical Colitis Activity Index (SCCAI);  Percentage of Patients Remaining in Remission at Month 3 ITT Population;  Percentage of Patients Remaining in Remission at Month 12 ITT Population;  Number of Subjects Who Relapse/Flare Within 6 Months ITT Population;  Total MARS (Medication Adherence Report Scale) Questionnaire Scores ITT Population Month 6;  Percentage of Participants Indicating Ulcerative Colitis in Remission (Patient Defined Remission Index) ITT Population Month 6|1027|NCT00505778|July 2007
3873|Completed                  Has Results|Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn||Drug:DexlansoprazoleMR|Interventional|Phase 3|Industry|Mean Change From Baseline to Month 12 for Hemoglobin Values;  Mean Change From Baseline to Month 12 for Hematocrit Values;  Mean Change From Baseline to Month 12 for Red Blood Cell Count Values;  Mean Change From Baseline to Month 12 for Mean Corpuscular Hemoglobin Concentration Values;  Mean Change From Baseline to Month 12 for Platelet Count Values;  Mean Change From Baseline to Month 12 for White Blood Cell Count Values;  Mean Change From Baseline to Month 12 for Blood Urea Nitrogen Values;  Mean Change From Baseline to Month 12 for Creatinine Values;  Mean Change From Baseline to Month 12 for Calcium Values;  Mean Change From Baseline to Month 12 for Inorganic Phosphorus Values;  Mean Change From Baseline to Month 12 for Total Bilirubin Values;  Mean Change From Baseline to Month 12 for Alkaline Phosphatase Values;  Mean Change From Baseline to Month 12 for Aspartate Aminotransferase Values;  Mean Change From Baseline to Month 12 for Alanine Aminotransferase Values;  Mean Change From Baseline to Month 12 for Serum Gastrin Levels;  Mean Change From Baseline to Month 12 for Systolic Blood Pressure;  Mean Change From Baseline to Month 12 for Diastolic Blood Pressure;  Mean Change From Baseline to Month 12 for Pulse Rate;  Changes From Baseline to Final Visit in Antrum Biopsy Results;  Changes From Baseline to Final Visit in Fundus Biopsy Results;  Mean Change From Baseline to Month 1 for PAGI-QOL Total Score;  Mean Change From Baseline to Month 3 for PAGI-QOL Total Score;  Mean Change From Baseline to Month 6 for PAGI-QOL Total Score;  Mean Change From Baseline to Month 9 for PAGI-QOL Total Score;  Mean Change From Baseline to Month 12 for PAGI-QOL Total Score;  Mean Change From Baseline to Month 1 for PAGI-SYM Total Score;  Mean Change From Baseline to Month 3 for PAGI-SYM Total Score;  Mean Change From Baseline to Month 6 for PAGI-SYM Total Score;  Mean Change From Baseline to Month 9 for PAGI-SYM Total Score;  Mean Change From Baseline to Month 12 for PAGI-SYM Total Score|591|NCT00255190|January 2006
3874|Terminated                  Has Results|JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events||Drug:Rosuvastatin;  Other:Placebo|Interventional|Phase 3|Industry|Time to Major Cardiac Event (Cardiovascular Death Stroke Myocardial Infarction Hospitalization Due to Unstable Angina or Arterial Revascularization);  TimetoDeathDuetoAnyCause;  TimetoNon-cardiovascularDeath;  TimetoDevelopmentofDiabetesMellitus;  TimetoVenousThromboembolicEvent;  TimetoBoneFracture|17802|NCT00239681|February 2003
3875|Completed|S0421 Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy||Drug:atrasentanhydrochloride;  Drug:docetaxel;  Drug:prednisone;  Other:placebo|Interventional|Phase 3|Other / NIH|Compare survival between a control or standard therapy arm of docetaxel + placebo + prednisone with docetaxel + atrasentan + prednisone in patients with hormone refractory prostate cancer.;  Compare progression-free survival between a control or standard therapy arm of docetaxel + placebo + prednisone with docetaxel + atrasentan + prednisone in patients with hormone refractory prostate cancer.;  Compare pain progression between the two study arms.;  Compare qualitative and quantitative toxicity between the two study arms;  Compare prostate specific antigen (PSA) response rates between the experimental arm and the standard arm.;  Compare objective responses between the two treatment groups in patients with measurable disease as defined by RECIST criteria.;  Compare elements of Quality of Life between treatment arms: pain palliation response as measured by the Brief Pain Inventory (BPI);  Compare elements of Quality of Life between treatment arms: change in functional status as measured by the Trial Outcome Index score from the FACT-P|1038|NCT00134056|August 2006
3876|Completed|Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer||Drug:TLK286(Telcyta)HClforInjection;  Drug:gefitinib(Iressa)|Interventional|Phase 3|Industry||520|NCT00080340|
3877|Active not recruiting|Doxorubicin Hydrochloride Cisplatin and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer||Drug:Carboplatin;  Drug:Cisplatin;  Drug:DoxorubicinHydrochloride;  Biological:Filgrastim;  Other:LaboratoryBiomarkerAnalysis;  Drug:Paclitaxel;  Biological:Pegfilgrastim;  Other:Quality-of-LifeAssessment|Interventional|Phase 3|Other / NIH|Durationofoverallsurvival;  Change in functional well-being assessed using the FACT/GOG Neurotoxicity subscale;  Change in physical well-being assessed using the Functional Assessment of Cancer Therapy (FACT)-Endometrial subscale;  Durationofprogression-freesurvival;  Estrogen and progesterone receptor status (positive or negative);  Incidenceofadverseevents;  Number of courses of study therapy administered (for those not completing the prescribed study therapy);  Sitesofdiseaseandtumorgrade|1331|NCT00063999|August 2003
3878|Completed|Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer||Drug:cisplatin;  Drug:fluorouracil;  Drug:mitomycinC;  Radiation:radiationtherapy|Interventional|Phase 3|Other / NIH||650|NCT00003596|October 1998
3879|Terminated|Naltrexone/Bupropion Cardiovascular Outcomes Study||Drug:NaltrexoneHCl/BupropionHClER;  Drug:Placebo|Interventional|Phase 4|Industry|Time from Treatment Period Randomization to the First Confirmed Major Adverse Cardiovascular Events (MACE);  Time from Treatment Period Randomization to the First Confirmed Extended MACE;  Time from Treatment Period Randomization to the Occurrence of All-Cause Death;  Time from Treatment Period Randomization to the Occurrence of Cardiovascular (CV) Death|67|NCT02638129|January 2016
3880|Recruiting|The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)||Drug:Plecanatide;  Drug:Placebo|Interventional|Phase 3|Industry|The primary efficacy endpoint is Overall Responder;  AbdominalPainIntensityWeeklyResponder;  StoolFrequencyResponder;  CompleteSpontaneousBowelMovement;  SpontaneousBowelMovement;  Stool Consistency based upon the Bristol Stool Form Scale;  SustainedEfficacyResponder;  TimetofirstSBMandCSBM;  Change and Percent Change from baseline in abdominal pain;  Stool Frequency Responder for at least 6 of the 12 treatment weeks;  TimetofirstuseofRescueMedication(RM);  Overall Responder for at least 9 of the 12 treatment weeks;  SBMs and CSBMs within 24 hours after first dose of study medication;  SymptomsassociatedwithIBS-C;  PatientGlobalQuestionnaires|1050|NCT02387359|December 2014
3881|Recruiting|A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients||Drug:Rivaroxaban10mg;  Drug:Rivaroxaban7.5mg;  Drug:Placebo|Interventional|Phase 3|Industry|Time from randomization to the first occurrence of symptomatic venous thromboembolism event (VTE) and VTE-related death;  Time from randomization to the first occurrence of major bleeding;  Time from randomization to an occurrence of VTE-related death;  Time from randomization to the first occurrence of a symptomatic VTE;  Time from randomization to the first occurrence of a composite of symptomatic VTE and all-cause mortality (ACM);  TimefromrandomizationtoanoccurrenceofACM;  Time from randomization to an occurrence of myocardial infarction;  Time from randomization to an occurrence of non-hemorrhagic stroke;  Time from randomization to an occurrence of cardiovascular death|8000|NCT02111564|June 2014
3882|Recruiting|Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer||Other:LaboratoryBiomarkerAnalysis;  Drug:Letrozole;  Drug:Paclitaxel;  Drug: Pegylated Liposomal Doxorubicin Hydrochloride;  Other:PharmacologicalStudy;  Other:Quality-of-LifeAssessment;  Drug:TamoxifenCitrate;  Drug:TopotecanHydrochloride;  Drug:Trametinib|Interventional|Phase 2 / Phase 3|NIH|Progression-freesurvival(PFS);  Incidence of adverse events (AEs) assessed using the National Cancer Institute CTCAE version 4;  Objective tumor response rate (complete response and partial response) using the RECIST 1.1;  Overallsurvival;  QualityoflifeasmeasuredbyFACT-GOG-NTX;  QualityoflifeasmeasuredbyFACT-O-TOI|250|NCT02101788|February 2014
3883|Recruiting|NSABP Patient Registry and Biospecimen Profiling Repository|||Observational||Other|To characterize common genetic/molecular profiles associated with colorectal cancer (CRC);  To identify subpopulations of registry patients on the basis of their molecular profiles that may be eligible for participation in available NSABP clinical trials involving novel agents;  To conduct further analysis of tumor samples for the discovery of new potential targets and mechanisms of drug resistance|2000|NCT01793805|February 2013
3884|Completed|The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)||Drug:Plecanatide;  Drug:Placebo|Interventional|Phase 2|Industry|Change from baseline in the mean number of Complete Spontaneous Bowel Movement (CSBM) over the 12 week treatment period;  Proportion of patients who are overall responders during the 12 week Treatment period|350|NCT01722318|November 2012
3885|Recruiting|Bortezomib Dexamethasone and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma||Drug:Bortezomib;  Drug:Dexamethasone;  Biological:Elotuzumab;  Other:LaboratoryBiomarkerAnalysis;  Drug:Lenalidomide|Interventional|Phase 1 / Phase 2|Other / NIH|PFS;  Incidence of toxicity assessed by the NCI CTCAE version 4.0;  Overallsurvival;  Response(partialresponse[PR]orbetter)rate|122|NCT01668719|November 2012
3886|Completed|The Plecanatide Chronic Idiopathic Constipation (CIC) Study||Drug:plecanatide|Interventional|Phase 2 / Phase 3|Industry|CompleteSpontaneousBowelMovement(CSBM);  Reduction in straining and abdominal symptoms such as pain discomfort and bloating.|951|NCT01429987|October 2011
3887|Recruiting|Rituximab Bendamustine Hydrochloride and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma||Biological:rituximab;  Drug:bendamustinehydrochloride;  Drug:bortezomib;  Drug:lenalidomide|Interventional|Phase 2|Other / NIH|2-year PFS rate of patients treated with RBV to an induction regimen of RB compared to RB alone;  PFS improvement of patients treated with lenalidomide added to a consolidation regimen;  PET-documentedCRrate;  ResponseratetoRBandRBV;  Toxicity;  Qualityoflife|332|NCT01415752|May 2012
3888|Completed                  Has Results|A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine||Drug:Fesoterodine8mg;  Drug:Fesoterodine4mg;  Drug:Placebo|Interventional|Phase 4|Industry|Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12.;  Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 4.;  Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12.;  Change From Baseline in Percentage of Micturitions Per 24 Hours at Week 4.;  Change From Baseline in Percentage of Micturitions Per 24 Hours at Week 12.;  Change From Baseline in Mean Number of UUI Episodes Per 24 Hours at Week 4.;  Change From Baseline in Percentage of UUI Episodes Per 24 Hours at Week 4.;  Change From Baseline in Percentage of UUI Episodes Per 24 Hours at Week 12.;  Change From Baseline in Mean Number of Micturition-Related Urgency Episodes Per 24 Hours at Week 4.;  Change From Baseline in Mean Number of Micturition-Related Urgency Episodes Per 24 Hours at Week 12.;  Change From Baseline in Percentage of Micturition-Related Urgency Episodes Per 24 Hours at Week 4.;  Change From Baseline in Percentage of Micturition-Related Urgency Episodes Per 24 Hours at Week 12.;  Number of Participants With Change From Baseline in Patient Perception of Bladder Condition (PPBC) at Week 12.;  Number of Participants With Change From Baseline in Urgency Perception Scale (UPS) at Week 12.;  Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score at Week 12.;  Change From Baseline in Health Related Quality of Life (HRQL)-Coping Domain and Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 12.;  Change From Baseline in Health Related Quality of Life (HRQL)-Concern Domain and Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 12.;  Change From Baseline in Health Related Quality of Life (HRQL)-Sleep Domain and Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 12.;  Change From Baseline in Health Related Quality of Life (HRQL)-Social Interaction Domain and Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 12.;  Change From Baseline in Health Related Quality of Life (HRQL)-Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 12.;  Percentage of Participants Who Became Dry at Week 4.;  Percentage of Participants Who Became Dry at Week 12.|2012|NCT01302067|May 2011
3889|Active not recruiting|CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes||Drug:linagliptin;  Drug:glimepiride;  Drug:linagliptinplacebo;  Drug:glimeprideplacebo|Interventional|Phase 3|Industry|Time to first occurence of any of the following adjudicated components of the primary composite endpoint: CV death non-fatal MI (excluding silent MI) non-fatal stroke and hospitalisation for unstable angina pectoris;  Time to first occurrence of any of the following adjudicated components of the composite endpoint: CV death (including fatal stroke and fatal MI) non-fatal stroke non-fatal MI (excluding silent MI);  Proportion of patients on study treatment at study end that at Final Visit maintain glycemic control (HbA1c &lt;= 7.0%) without need for rescue medication without any moderate/severe hypoglycaemic episodes and without &gt; 2% weight gain (from V6 on);  Occurence of any of the adjudicated components of the composite primary and composite first key secondary endpoint.;  Transitions in albuminuria classes between baseline and Final visit.;  Proportion of patients on study treatment at study end that at Final Visit maintain glycaemic control (HbA1c &lt;= 7.0%) without need for rescue medication and without &gt; 2% weight gain (from V6 on);  Occurence of and time to composite endpoint of all CEC confirmed adjudicated events;  Change from baseline to Final Visit in diabetes related laboratory parameters: HbA1c fasting plasma glucose Total cholesterol LDL cholesterol HDL cholesterol Triglycerides Creatinine eGFR (MDRD formula) Albumin|6115|NCT01243424|October 2010
3890|Recruiting|Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery||Radiation: 3-Dimensional Conformal Radiation Therapy;  Drug:Capecitabine;  Drug:Chemotherapy;  Drug:ErlotinibHydrochloride;  Drug:Fluorouracil;  Drug:GemcitabineHydrochloride;  Radiation:Intensity-ModulatedRadiationTherapy;  Other:LaboratoryBiomarkerAnalysis;  Other:Quality-of-LifeAssessment|Interventional|Phase 3|NIH|Overallsurvival(PhaseII);  Overallsurvival(PhaseIII);  Changes in fatigue as measured by the FACIT-F (primary) and the PROMIS derived short form (exploratory);  Disease-freesurvival;  Frequency of objective criteria of resectability as measured by preoperative imaging;  Incidence of adverse events assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|950|NCT01013649|November 2009
3891|Active not recruiting|Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial||Genetic:DNAanalysis;  Genetic:Southernblotting;  Genetic:cytogeneticanalysis;  Genetic:polymerasechainreaction|Observational||Other / NIH|Distributionresponse;  Distributionofcytogeneticresponse;  Distribution of RT-PCR response or Southern blot response;  Frequency of residual disease in patients who have achieved a complete response|60|NCT01004640|December 1998
3892|Completed                  Has Results|Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome||Drug:Alogliptin;  Drug:Placebo|Interventional|Phase 3|Industry|Percentage of Participants With Primary Major Adverse Cardiac Events (MACE);  Percentage of Participants With Secondary Major Adverse Cardiac Events (MACE)|5380|NCT00968708|September 2009
3893|Completed                  Has Results|Treatment With Pazopanib for Neoadjuvant Breast Cancer||Drug:doxorubicin+cyclophosphamide;  Drug:paclitaxel+pazopanib;  Procedure:surgery;  Drug:pazopanibmonotherapy|Interventional|Phase 2|Industry / Other|Number of Participants With Pathologic Complete Response (pCR) in the Breast and Nodes;  Number of Participants With Pathologic Complete Response (pCR) in the Breast;  Number of Participants With Clinical Complete Response (cCR) in the Breast and Nodes at the Completion of the Doxorubicin and Cyclophosphamide (AC) Period;  Number of Participants With Clinical CR (cCR) in the Breast and Nodes at the Completion of the AC and Weekly Paclitaxel (WP) + Pazopanib Preoperative Periods;  InvasiveRecurrence-freeInterval(IRFI);  Number of Participants With Cardiac Toxicity (Per Common Terminology Criteria for Adverse Events Version 3) at the Completion of the AC Period;  Number of Participants With Cardiac Toxicity (Per CTCAE Version 3) at the Completion of the AC and Weekly Paclitaxel (WP) + Pazopanib Preoperative Periods;  Number of Participants With Cardiac Toxicity (Per CTCAE Version 3.0) During the Postoperative Pazopanib Period;  Participants With Normal Thyroid Stimulating Hormone (TSH) Levels at Baseline Who Had an Elevated TSH Level at Least Once During the Study and During the Individual Study Periods;  Number of Participants With the Indicated Radiotherapy-related Complications;  NumberofParticipantsWithRecurrenceEvents|101|NCT00849472|July 2009
3894|Enrolling by invitation|SECURE the Cimzia &#174; Crohn&apos;s Disease Post-Marketing Registry||Drug:Cimzia|Observational||Industry|Incidence rate of Adverse Events (AEs) of interest during the study (approximately 10 years);  Recurrence of Adverse Events (AEs) of interest during the study (approximately 10 years);  Time to Adverse Event (AE) of interest during the study (approximately 10 years);  Change from Baseline in Harvey Bradshaw Index (HBI) total score yearly (up to 10 years);  Change from Baseline in Physician&apos;s assessment of disease yearly (up to 10 years);  Change from Baseline in Patient&apos;s assessment of disease yearly (up to 10 years)|4000|NCT00844285|January 2009
3895|Completed                  Has Results|A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes||Biological:albiglutide;  Drug:insulinglargine|Interventional|Phase 3|Industry|Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52;  ChangeFromBaselineinHbA1catWeek156;  Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52;  Change From Baseline in Fasting Plasma Glucose (FPG) at Week 156;  Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of &lt;6.5% &lt;7% and &lt;7.5% at Week 52;  Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of &lt;6.5% &lt;7% and &lt;7.5% at Week 156;  TimetoHyperglycemiaRescue;  ChangeFromBaselineinBodyWeightatWeek52;  ChangeFromBaselineinBodyWeightatWeek156;  Change From Baseline in Glucose Profile Measured by 24-hour Area Under Curve (AUC) at Week 52;  Albiglutide Plasma Concentrations at Week 8 and Week 24|779|NCT00838916|February 2009
3896|Completed                  Has Results|Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol (&quot;Bad Cholesterol&quot;) and Triglycerides||Drug:ABT-143;  Drug:simvastatin|Interventional|Phase 3|Industry|Mean Percent Change From Baseline to the Final Visit in Low-density Lipoprotein Cholesterol (LDL-C) (Full Analysis Set);  Mean Percent Change From Baseline to the Final Visit in Low-density Lipoprotein Cholesterol (LDL-C) With ABT-143 Capsules 10/135 Milligrams Versus Simvastatin Capsules 40 Milligrams (Full Analysis Set);  Mean Percent Change From Baseline to the Final Visit in Low-density Lipoprotein Cholesterol (LDL-C) With ABT-143 Capsules 5/135 Milligrams Versus Simvastatin Capsules 40 Milligrams (Full Analysis Set)|474|NCT00812955|November 2008
3897|Active not recruiting|Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery||Drug:carboplatin;  Drug:erlotinibhydrochloride;  Drug: paclitaxel albumin-stabilized nanoparticle formulation;  Radiation:radiationtherapy|Interventional|Phase 2|Other / NIH|Overallsurvivalat12months;  Responserate;  Progression-freesurvival|76|NCT00553462|March 2008
3898|Completed|A Long-Term Registry of Humira&#174; (Adalimumab) in Subjects With Moderately to Severely Active Crohn&apos;s Disease (CD)|||Observational||Industry|The primary objective of this Registry study is to evaluate the long-term safety of adalimumab in CD subjects who are treated as recommended in the local product label.;  The secondary objective is to evaluate long-term effectiveness of adalimumab in CD subjects who are treated as recommended in the local product label.|5067|NCT00524537|September 2007
3899|Completed                  Has Results|Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine||Biological: 13 valent pneumococcal conjugate vaccine|Interventional|Phase 3|Industry|Percentage of Participants Achieving at Least 4-fold Increase in Titer for Concomitant Trivalent Inactivated Influenza Vaccine (TIV) Antigens 1 Month After Dose 1;  Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose|1116|NCT00521586|September 2007
3900|Active not recruiting                  Has Results|ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D||Drug:Lapatinib;  Biological:Trastuzumab|Interventional|Phase 3|Industry / Other / NIH|Disease-freeSurvival(DFS);  OverallSurvival(OS);  TimetoRecurrence;  TimetoDistantRecurrence;  TimetoCentralNervousSystemRecurrence;  DFS Ignoring Non-breast Second Primary Malignancies|8381|NCT00490139|May 2007
3901|Completed|Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer||Drug:duloxetinehydrochloride;  Other:placebo|Interventional|Phase 3|Other / NIH|AveragepainasmeasuredbytheBPI-SF;  Peripheralneuropathy-relatedfunctionalstatus;  Quality of life as measured by FACT/COG-NTX and EORTC QLQ-C30 questionnaires in weeks 1 6 8 and 13|242|NCT00489411|April 2008
3902|Completed                  Has Results|An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation||Drug:Rivaroxaban;  Drug:Warfarin;  Drug: Matching placebo for Rivaroxaban arm (Warfarin placebo);  Drug: Matching placebo for Warfarin arm (Rivaroxaban placebo)|Interventional|Phase 3|Industry|The Composite Event of Stroke/Non-CNS Systemic Embolism: Primary Efficacy (Non-Inferiority);  The Composite of Event of Stroke/Non-CNS Systemic Embolism: Primary Efficacy (Superiority);  The Composite Event of Major/Non-major Clinically Relevant Bleeding Events: Primary Safety;  The Composite Event of Stroke/Non-CNS Systemic Embolism/Vascular Death;  The Composite Event of Stroke/Non-CNS Systemic Embolism/Myocardial Infarction/Vascular Death;  The Individual Components of the Composite Primary and Major Secondary Efficacy Outcome Measures: Stroke;  The Individual Components of the Composite Primary and Major Secondary Efficacy Outcome Measures: Non-CNS Systemic Embolism;  The Individual Components of the Composite Primary and Major Secondary Efficacy Outcome Measures: Myocardial Infarction;  The Individual Components of the Composite Primary and Major Secondary Efficacy Outcome Measures: Vascular Death;  All-causeMortality|14269|NCT00403767|December 2006
3903|Completed                  Has Results|IMPROVE HF: Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting|||Observational||Industry|To Observe Over the Aggregate IMPROVE-HF Practice Sites a Relative 20% or Greater Improvement in at Least 2 of the 7 Performance Measures at 24 Months Compared With Baseline.;  Evaluate the Proportion of Sites That Demonstrate a Relative 20% or Greater Improvement in 2 or More of the 7 Performance Measures at 24 Months as Compared to Baseline.;  Observe the Relative Improvement From Baseline to 24M in Composite Score for the Aggregate Practices.;  Observe the Relative Improvement From Baseline to 6M in Composite Score for the Aggregate Practices.;  Observe the Relative Improvement From Baseline to 18M in Composite Score for the Aggregate Practices.|34810|NCT00303979|May 2005
3904|Active not recruiting|Paclitaxel Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Peritoneal Cancer or Fallopian Tube Cancer||Other:ClinicalObservation;  Other:LaboratoryBiomarkerAnalysis;  Drug:Paclitaxel;  Drug:PaclitaxelPoliglumex;  Procedure:Quality-of-LifeAssessment|Interventional|Phase 3|Other / NIH|Overallsurvival;  Frequency and severity of adverse effects assessed by CTCAE v3.0;  Progression-freesurvival;  Quality of life assessed by Functional Assessment of Cancer Therapy-Ovarian-Trial Outcome Index and Functional Assessment of Cancer Therapy-Gynecologic Oncology Group/Neurotoxicity version 4|1100|NCT00108745|March 2005
3905|Completed                  Has Results|S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer||Biological:cetuximab|Interventional|Phase 2|Other / NIH|OverallSurvivalat6Months;  TimetoTreatmentFailure;  TimetoProgression|63|NCT00096031|October 2004
3906|Completed|Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy||Drug:Alosetron|Interventional|Phase 3|Industry|Subject self assessment of improvement between treatment groups using the IBS Global Improvement Scale; comparison of safety and tolerability between treatment groups with respect to adverse events &amp; laboratory abnormalities.;  Comparison of treatment groups with respect to subject relief of IBS pain &amp; discomfort.|702|NCT00067561|June 2003
3907|Completed|PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma||Drug:PTK787/ZK222584|Interventional|Phase 2|Other / NIH|Survival;  Failurefreesurvival|47|NCT00053885|July 2003
3908|Completed|Docetaxel Estramustine and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy||Drug:docetaxel;  Drug:estramustinephosphatesodium;  Drug:exisulind|Interventional|Phase 2|Other / NIH|Timetoprogression;  Toxicity;  ChangesinPSA;  OverallSurvival|80|NCT00052845|November 2002
3909|Completed|Genetic Trial to Study Diarrhea in Patients With Stage III Colon Cancer Who Are Receiving Chemotherapy||Genetic:mutationanalysis;  Genetic: polymorphic microsatellite marker analysis|Observational||Other / NIH|response|308|NCT00048971|April 2002
3910|Active not recruiting|Cytogenetic Studies in Acute Leukemia and Multiple Myeloma||Genetic:cytogeneticanalysis|Observational||Other / NIH|Determine the incidence of specific less common primary as well as common secondary chromosome abnormalities in adult AML ALL MDS and MM;  Correlate specific (normal or various primary and secondary chromosomal abnormalities) with clinical and laboratory parameters;  Correlate specific karyotype groups with response rates response duration survival and cure in patients treated with various induction and post-induction regimens;  Correlate specific karyotype groups with selected molecular abnormalities as studied in CALGB leukemia protocols;  To correlate specific karyotype groups with multidrug resistance data;  To correlate specific karyotype groups with epidemiologic data (toxic exposure and family history);  To determine karyotype changes at relapse and the influence of the type of change (or no change) in karyotype at relapse on subsequent clinical course;  To identify new chromosome abnormalities important in leukemogenesis|9000|NCT00048958|June 1984
3911|Completed|Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer||Drug:celecoxib;  Drug:Celecoxib|Interventional|Phase 2|Other / NIH|Progressionfreesurvival|39|NCT00045591|February 2003
3912|Completed|Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer||Drug:carboplatin;  Drug:etoposide;  Drug:exisulind|Interventional|Phase 2|Other / NIH|percentage of patients with extensive stage small cell lung cancer who live more than 12 months after treatment;  responserate|41|NCT00041054|June 2002
3913|Completed                  Has Results|Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane||Drug:exemestane(Aromasin);  Drug:tamoxifen+exemestane|Interventional|Phase 3|Industry|Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 2.75 Years;  Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 5 Years;  NumberofEventsforOverallSurvival(OS);  TimetoNewPrimaryBreastCancers;  NumberofEventsforTimetoRelapse;  Number of Participants With New Primary Non-breast Cancers|9779|NCT00036270|August 2001
3914|Completed|Vaccine Therapy in Treating Patients With Colorectal Cancer Metastatic to the Liver||Biological: monoclonal antibody 11D10 anti-idiotype;  Biological:monoclonalantibody3H1AluGel|Interventional|Phase 2|Other / NIH|Recurrencefreesurvival;  Toxicity|56|NCT00033748|December 2001
3915|Completed|Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer||Drug:carboplatin;  Drug:gemcitabinehydrochloride;  Drug:paclitaxel;  Radiation:radiationtherapy|Interventional|Phase 2|Other / NIH|Response;  OverallSurvival;  Toxicity|69|NCT00033553|March 2002
3916|Terminated|S0002 - A Program to Quit Smoking With or Without Bupropion in Treating Patients With Stage I or II Non-Small Cell Lung Cancer Who Have Undergone Surgery||Behavioral:smokingcessationintervention;  Drug:bupropionhydrochloride;  Drug:nicotine;  Procedure:psychosocialassessmentandcare|Interventional|Phase 3|Other / NIH|To compare the effect on 12 month quit rates of adding an anti-depressant versus placebo in a double blind to an intervention and nicotine replacement in complete resected Stage I and II non-small cell lung cancer patients who are current smokers;  To assess predictors of successful cessation in male and female patients.;  To explore the relationship between smoking cessation and standard outcome measures.;  To compare the effect on emotional functioning of adding bupropion to a behavioral intervention plus nicotine replacement in this patient population.|10|NCT00032084|January 2002
3917|Completed|Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin&apos;s Lymphoma||Biological:filgrastim;  Biological:rituximab;  Drug:cyclophosphamide;  Drug:doxorubicinhydrochloride;  Drug:etoposide;  Drug:prednisone;  Drug:vincristinesulfate|Interventional|Phase 2|Other / NIH|Response;  ProgressionfreeSurvival;  Overallsurvival;  Toxicity|78|NCT00032019|February 2002
3918|Completed|Combination Chemotherapy and Radiation Therapy in Treating Patients With Pancreatic Cancer||Drug:fluorouracil;  Drug:gemcitabinehydrochloride;  Radiation:radiationtherapy|Interventional|Phase 2|Other / NIH|OverallSurvival;  Timetoprogression;  ClinicalResponse;  CA19-9Levels;  Toxicity|81|NCT00026130|September 2001
3919|Completed|Surgery With or Without Chemotherapy and Radiation Therapy in TreatingPatients With Stage I Rectal Cancer||Drug:fluorouracil;  Drug:leucovorincalcium;  Procedure:conventionalsurgery;  Radiation:radiationtherapy|Interventional|Phase 2|Other / NIH|disease-freesurvival;  overallsurvival;  colostomy-freesurvival|320|NCT00023751|July 2001
3920|Completed|Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma||Biological:filgrastim;  Biological:rituximab;  Drug:carmustine;  Drug:cyclophosphamide;  Drug:cytarabine;  Drug:doxorubicinhydrochloride;  Drug:etoposide;  Drug:leucovorincalcium;  Drug:methotrexate;  Drug:prednisone;  Drug:vincristinesulfate;  Procedure: peripheral blood stem cell transplantation|Interventional|Phase 2|Other / NIH|ProgressionFreeSurvival;  Response;  Survival|79|NCT00020943|June 2001
3921|Completed|Combination Chemotherapy in Treating Patients With Bladder Cancer||Biological:filgrastim;  Drug:cisplatin;  Drug:doxorubicinhydrochloride;  Drug:gemcitabinehydrochloride|Interventional|Phase 3|Other / NIH|Overallsurvival|42|NCT00014534|March 2004
3922|Completed|Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas||Drug:cisplatin;  Drug:docetaxel;  Drug:gemcitabinehydrochloride;  Drug:irinotecanhydrochloride|Interventional|Phase 2|Other / NIH|OverallSurvival;  Timetodiseaseprogression;  Toxicity|259|NCT00012220|January 2001
3923|Completed|Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia||Drug:ara-C;  Biological:gemtuzumabozogamicin|Interventional|Phase 2|Other / NIH|Completeremissionrate;  Toxicity|60|NCT00006265|March 2001
3924|Completed|Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin&apos;s Lymphoma||Drug:doxorubicinhydrochloride;  Drug:topotecanhydrochloride|Interventional|Phase 2|Other / NIH|Responserate;  Timetoprogression||NCT00006125|July 2000
3925|Completed|Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin&apos;s Lymphoma||Drug:gemcitabinehydrochloride;  Drug: pegylated liposomal doxorubicin hydrochloride;  Drug:vinorelbinetartrate|Interventional|Phase 1 / Phase 2|Other / NIH|Overallresponserate;  Overallsurvival|91|NCT00006029|July 2000
3926|Completed|Diagnostic Study of Patients With Aggressive Non-Hodgkin&apos;s Lymphoma||Genetic:comparativegenomichybridization;  Genetic:cytogeneticanalysis;  Genetic:fluorescenceinsituhybridization;  Genetic:generearrangementanalysis|Observational||Other / NIH|responsetotherapy;  failure-freesurvival;  overallsurvival|391|NCT00003863|June 1999
3927|Completed|Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia||Drug:cyclophosphamide;  Drug:fludarabinephosphate|Interventional|Phase 3|Other / NIH||280|NCT00003764|December 1999
3928|Completed|Thoracoscopy in Patients With Stage IIIA Non-Small Cell Lung Cancer||Procedure:videothoracoscopy|Interventional||Other / NIH||75|NCT00003566|September 1998
3929|Completed|Docetaxel in Treating Patients With Solid Tumors||Drug:docetaxel|Interventional|Phase 2|Other / NIH||109|NCT00003565|September 1998
3930|Active not recruiting                  Has Results|Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin&apos;s Lymphoma||Drug:Doxorubicin;  Drug:Bleomycin;  Drug:Vinblastine;  Drug:Dacarbazine;  Drug:Vincristine;  Drug:Mechlorethamine;  Drug:Etoposide;  Drug:Prednisone;  Drug:Cyclophosphamide;  Radiation:Radiotherapy|Interventional|Phase 3|Other / NIH|Failure-freeSurvivalat5Years;  5-yearOverallSurvival;  IncidenceofSecondCancers|854|NCT00003389|April 1999
3931|Completed|Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors||Biological:bleomycinsulfate;  Biological:filgrastim;  Drug:carboplatin;  Drug:cisplatin;  Drug:cyclophosphamide;  Drug:etoposide;  Procedure:autologousbonemarrowtransplantation;  Procedure: bone marrow ablation with stem cell support;  Procedure:conventionalsurgery;  Procedure: peripheral blood stem cell transplantation;  Radiation:radiationtherapy|Interventional|Phase 3|Other / NIH||270|NCT00002596|September 1994
3932|Recruiting|Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension||Biological:Evolocumab|Interventional|Phase 3|Industry|Subjectincidenceofadverseevents;  Percent change of LDL-C from baseline at each scheduled yearly visit;  Achieve an LDL-C &lt; 40 mg/dL (1.03 mmol/L) at each scheduled yearly visit|5000|NCT02867813|September 2016
3933|Suspended|Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery||Biological:Ipilimumab;  Other:LaboratoryBiomarkerAnalysis;  Biological:Nivolumab;  Other:Quality-of-LifeAssessment|Interventional|Phase 2|NIH|Confirmed response rate estimated as the number of patients having a best objective tumor status of complete response (CR) or partial response (PR) lasting at least 4 weeks divided by the number of evaluable patients;  Adverse event (AE) rates graded using the NCI CTCAE v4.0;  Clinicalbenefitrate;  Durationofresponse;  Overallsurvival(OS);  Progression-freesurvival(PFS)|84|NCT02500797|July 2015
3934|Recruiting|A Randomized Double-Blind Parallel-Group 24-Week Chronic-Dosing Multi-Center Study to Assess the Efficacy and Safety of PT010 PT003 and PT009 Compared With Symbicort&#174; Turbuhaler&#174; (Kronos)||Drug:BGFMDI320/14.4/9.6&#956;g;  Drug:GFFMDI(PT003)14.4/9.6&#956;g;  Drug:BFFMDI(PT009)320/9.6&#956;g;  Drug: Symbicort&#174; Turbuhaler&#174; (TBH) Inhalation Powder|Interventional|Phase 3|Industry|Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1);  FEV1 area under the curve from 0 to 4 hours (AUC0-4);  Transitiondyspneaindex(TDI)focalscore;  St.GeorgeRespiratoryQuestionnaire(SGRQ);  RescueVentolinHFAuse;  PeakFEV1within4hourspost-dosing;  The EXAcerbations of Chronic pulmonary disease Tool (EXACT) total score;  TimetoonsetofactiononDay1|1800|NCT02497001|July 2015
3935|Recruiting|S1403 Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent EGFR Mutation Positive Non-small Cell Lung Cancer||Drug:AfatinibDimaleate;  Biological:Cetuximab;  Other:LaboratoryBiomarkerAnalysis|Interventional|Phase 2 / Phase 3|Other / NIH|OS(phaseIII);  PFS(phaseII);  PFS;  Responserates;  Timetotreatmentdiscontinuation;  Timetotreatmentfailure;  Toxicity rates assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|605|NCT02438722|March 2015
3936|Completed|Safety and Contraceptive Efficacy of an Intravaginal Ring With LNG (Levonorgestrel) Over One Year in Healthy Women||Drug:Levonorgestrel(BAY98-7196)|Interventional|Phase 3|Industry|Pregnancyrate(PearlIndex)|1471|NCT02403401|May 2015
3937|Recruiting|Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery||Biological:Ipilimumab;  Other:LaboratoryBiomarkerAnalysis;  Biological:Nivolumab;  Biological:Sargramostim|Interventional|Phase 2 / Phase 3|NIH|OS;  Clinical response assessed using the utility of irRC;  Immune response assessed using the utility of Immune related response criteria (irRC);  Incidence of toxicities defined using the Common Terminology Criteria for Adverse Events version 4.0 criteria;  PFS evaluated based on international criteria proposed by the revised RECIST guideline (version 1.1)|400|NCT02339571|September 2015
3938|Active not recruiting|Comparing the Efficacy of Tiotropium + Olodaterol (5/5 &#181;g) Fixed Dose Combination (FDC) Over Tiotropium 5&#181;g in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.||Drug:olodaterol;  Drug:tiotropium|Interventional|Phase 3|Industry|Primary endpoint: annualised rate of moderate to severe COPD exacerbation during the treatment period (within 1 day after the last drug administration date).;  Key secondary endpoint: time to first moderate to severe COPD exacerbation during the treatment period (within 1 day after the last drug administration date).;  Annualised rate of exacerbation leading to hospitalisation during the treatment period (within 1 day after the last drug administration date).;  Time to first COPD exacerbations leading to hospitalisation during the treatment period (within 1 day after the last drug administration date).;  Time to all-cause mortality (within 1 day after the last drug administration date).|7910|NCT02296138|January 2015
3939|Completed|Trial of Linaclotide in Patients With Chronic Idiopathic Constipation||Drug:Linaclotide;  Drug:MatchingPlacebo|Interventional|Phase 3|Industry|Complete Spontaneous Bowel Movement (CSBM) Overall Responder|1223|NCT02291679|October 2014
3940|Recruiting|Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis||Drug:tofacitinib;  Biological:adalimumab;  Biological:etanercept|Interventional|Phase 4|Industry|Malignancies excluding non-menlanoma skin cancer (NMSC);  Incidence of major adverse cardiovascular events (MACE);  Opportunisticinfections;  Hepaticevents;  CardiovasculareventsotherthanMACE;  Allcausemortality;  Disease Activity Score Based on 28-joints Count (DAS28);  Number of Participants With an American College of Rheumatology 20% (ACR20) Response;  ClinicalDiseaseActivityIndex(CDAI);  SimplifiedDiseaseActivityIndex(SDAI);  ACR-EULARBooleanremission;  Number of Participants Achieving American College of Rheumatology 50% (ACR50) Response;  Number of Participants Achieving American College of Rheumatology 70% (ACR70) Response;  Health Assessment Questionnaire-Disability Index (HAQ-DI)|4000|NCT02092467|March 2014
3941|Active not recruiting|Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery||Drug:Capecitabine;  Drug:Fluorouracil;  Other:LaboratoryBiomarkerAnalysis;  Drug:LeucovorinCalcium;  Drug:Trametinib|Interventional|Phase 2|NIH|OS;  Objective response (complete response unconfirmed complete response partial response unconfirmed partial response) using the RECIST 1.1;  Rate of toxicities using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|89|NCT02042443|February 2014
3942|Completed|12-Week Study of Plecanatide for CIC (The CIC3 Study)||Drug:Plecanatide;  Drug:Placebo|Interventional|Phase 3|Industry|Proportionofpatientswhoareoverallresponders|1394|NCT01982240|November 2013
3943|Completed|Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)||Drug:Plecanatide|Interventional|Phase 3|Industry / Other|SafetyandTolerability;  Patient-ReportedOutcomes|2370|NCT01919697|August 2013
3944|Terminated                  Has Results|Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence||Drug:afatinib;  Other:placebo|Interventional|Phase 2|Other / NIH|Disease-freeSurvival(DFS)|3|NCT01824823|July 2013
3945|Recruiting|S1216 Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer||Drug:TAK-700;  Drug:Bicalutamide|Interventional|Phase 3|Other / Industry / NIH|Overallsurvival|1304|NCT01809691|March 2013
3946|Completed|A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes||Drug:ITCA650;  Other:ITCAplacebo|Interventional|Phase 3|Industry|ChangeinHbA1c|460|NCT01455857|March 2013
3947|Completed|Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting &#946;2-agonist (LABA) and Inhaled Corticosteroid (ICS)||Drug:Roflumilast;  Drug:Placebo|Interventional|Phase 4|Industry|Rate of moderate or severe COPD exacerbations per subject per year;  Prebronchodilator Forced Expiratory Volume in 1 second (FEV1) in Liters|2354|NCT01443845|September 2011
3948|Completed|Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes||Drug:insulindegludec/liraglutide;  Drug:insulindegludec;  Drug:liraglutide|Interventional|Phase 3|Industry|Mean change from baseline in HbA1c (glycosylated haemoglobin) at week 26;  Mean change from baseline in body weight at week 26;  Numberofhypoglycaemicepisodes;  Change from baseline in incremental area under the curve 0-4h (iAUC0-4h) derived from the glucose concentration profile during meal test;  Meanactualdailyinsulindose|1663|NCT01336023|May 2011
3949|Completed|Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)||Drug:PPD10558;  Drug:Atorvastatin;  Drug:Placebo|Interventional|Phase 2|Industry|Incidence of stopping treatment with double-blinded study drug due to statin-associated myalgia.;  Change from Baseline in fasting lipid profile components (low density lipoprotein-cholesterol(LDL-C) high density lipoprotein-cholesterol(HDL-C) triglyceride(TG) total cholesterol(TC) Apolipoprotein B(ApoB) HDL-TG LDL/HDL ratio and TC/HDL ratio);  Change from baseline in muscle strength measurements (Sit-to-stand(STS) performance and hand grip strength by Jamar Hydraulic Hand Dynamometer);  Frequencyofpainrescuemedication;  Change from Baseline in inflammatory markers (Tumor necrosis factor &#945; (TNF-&#945;) C-reactive protein (CRP) and lipoprotein-associated phospholipase A2 (Lp-PLA2));  Change in patients&apos; functional health and well-being as measured by the Short Form-36v2 Health Survey (SF-36);  Timetoonsetofstatin-associatedmyalgia(SAM);  Time to stopping treatment with study drug due to SAM|282|NCT01279590|March 2011
3950|Completed                  Has Results|Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension||Drug:nebivololandlisinopril(freecombination);  Drug:nebivololmonotherapy;  Drug:lisinoprilmonotherapy;  Drug:placebo|Interventional|Phase 4|Industry|The Change From Baseline in Trough Seated Diastolic Blood Pressure at Week 6.;  The Change From Baseline in Trough Seated Systolic Blood Pressure at Week 6.|664|NCT01218100|October 2010
3951|Completed                  Has Results|A 6-month Randomized Open-label Patient OutComes Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis||Drug:Fingolimod;  Drug:StandardMSDMTs|Interventional|Phase 4|Industry|Change From Baseline in the Global Satisfaction Subscale of the Treatment Satisfaction Questionnaire for Medication (TSQM) at Month 6;  Number of Patients Who Experienced Adverse Events Serious Adverse Events and Death;  Change From Baseline in Patient-reported Activities of Daily Living (ADL) Using the Multiple Sclerosis Activities Scale (PRIMUS-Activities) at Month 6;  Change From Baseline in Patient-reported Fatigue Using the Fatigue Severity Scale (FSS);  Change From Baseline in the Patient-reported Effectiveness Subscale Using the TSQM v1.4;  Change From Baseline in the Patient-reported Side Effects Subscale Using the TSQM v1.4;  Change From Baseline in the Patient-reported Convenience Subscale Using the TSQM v1.4;  Change From Baseline in Patient-reported Health-related Quality-of-life Using the Short Form Health Survey v2 Standard (SF-36 v2);  Change From Baseline in Patient-reported Depression Using the Beck Depression Inventory (BDI-II);  Physician-reported Clinical Global Impression of Improvement (CGI-I)|1053|NCT01216072|August 2010
3952|Completed|Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)||Other:PatientswithAtrialFibrillation(AF)|Observational|Phase 4|Industry / Other|The primary outcome is stroke or non-CNS (systemic) embolism. Key primary objective is: characterize &amp; describe the AF patient population as a whole with emphasis on demographics comorbidities and risk profiles.;  Thenumberofmajoradversecardiacevents.|10179|NCT01165710|June 2010
3953|Recruiting|Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer||Biological:bevacizumab;  Drug:pemetrexeddisodium|Interventional|Phase 3|Other / NIH|Overallsurvival;  Progression-freesurvival;  ObjectiveresponseasmeasuredbyRECIST;  Toxicity;  Association between bevacizumab and pemetrexed disodium population pharmacokinetics;  Association between proteomic profiles and ICAM VEGF and FGF-beta with the clinical outcomes (Closed as of 04/01/2010)|1282|NCT01107626|August 2010
3954|Active not recruiting|A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer||Drug:metforminhydrochloride;  Other:placebo|Interventional|Phase 3|Other / NIH|Invasive disease-free survival in hormone receptor (ER and PgR) negative and positive (ER and/or PgR) sub-groups;  Overallsurvival;  Distantrelapse-freesurvival;  Breastcancer-freeinterval;  Long-termclinicalandlaboratorysafety;  Relevant medical endpoints (new diabetes new cardiovascular hospitalizations);  Health-related quality of life physical activity and diet;  Changeinbodymassindex;  Correlativescienceoutcomes|3649|NCT01101438|July 2010
3955|Unknown&nbsp;&#8224;|Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine Ovarian Fallopian Tube or Peritoneal Cavity Cancer||Drug:Paclitaxel;  Drug:Carboplatin;  Drug:Ifosfamide;  Other:Quality-of-LifeAssessment|Interventional|Phase 3|Other / NIH|Overallsurvival;  Durationofprogression-freesurvival;  Incidence of adverse events as assessed by CTCAE version 3.0;  Quality of life measured using the Functional Assessment of Cancer Therapy (FACT)-general Physical Well-being and Functional Well-being subscales FACT-endometrial and FACT/GOG-NTtx subscale|603|NCT00954174|August 2009
3956|Completed                  Has Results|A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)||Drug:tocilizumab[RoActemra/Actemra];  Drug:NonbiologicDMARDsofinvestigator&apos;schoice|Interventional|Phase 3|Industry|Percentage of Participants Experiencing at Least One Serious Adverse Event (SAE) During the 24 Week Treatment Period;  Percentage of Participants Experiencing Serious Adverse Events of Special Interest;  Percentage of Participants Experiencing Non-serious Adverse Events of Special Interest;  Percentage of Participants Achieving Clinical Remission at Weeks 8 16 and 24;  Change From Baseline in DAS28 Score at Weeks 8 16 and 24;  Percentage of Participants Achieving American College of Rheumatology (ACR) (ACR20/50/70) Responses at Weeks 8 16 and 24;  Percentage of Participants With Tocilizumab Dose Increased From 4 mg/kg to 8 mg/kg at Week 8;  Number of Participants Having Their Tocilizumab Dose Increased From 4 mg/kg to 8 mg/kg at Weeks 12 16 and 20;  Change From Baseline in Routine Assessment Patient Index Data (RAPID3) Score at Weeks 8 16 and 24;  Change From Baseline in Fatigue Visual Analogue Scale (VAS) at Weeks 8 16 and 24|886|NCT00891020|May 2009
3957|Active not recruiting|Zoledronic Acid in Treating Patients With Metastatic Breast Cancer Metastatic Prostate Cancer or Multiple Myeloma With Bone Involvement||Drug:zoledronicacid|Interventional|Phase 3|Other / NIH|Proportion of patients with at least one skeletal-related event (SRE) within 2 years after randomization;  Pain intensity score as assessed by the Brief Pain Inventory (BPI) questionnaire;  ECOGperformancestatus;  Incidenceofosteonecrosisofthejaw;  Incidenceofrenaldysfunction;  Skeletalmorbidityrate;  Bone turnover assessed by serum N-telopeptide (NTX) levels;  Proportion of patients having at least one SRE within 24 months after randomization for the subgroups of patients with breast cancer prostate cancer and multiple myeloma|1758|NCT00869206|March 2009
3958|Completed                  Has Results|Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)||Drug:Rifaximin;  Drug:Placebo|Interventional|Phase 3|Industry|Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie Weeks 3 Through 6).;  Proportion of Subjects Who Had Adequate Relief of IBS-related Bloating for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie Weeks 3 Through 6).|623|NCT00731679|July 2008
3959|Completed|Cognition in the Study of Tamoxifen and Raloxifene||Drug:tamoxifen;  Drug:raloxifene|Interventional|Phase 3|Other / NIH|CaliforniaVerbalLearningTest(CVLT);  BentonVisualRetentionTest(BVRT)FormD;  ModifiedMini-MentalStateExam;  ProspectiveMemoryTest;  PrimaryMentalAbilitiesVocabularyTest;  CardRotationsTest;  FingerTappingTest;  CVLTLongDelayRecallandRecognitionTrials;  Letter (FAS) and Semantic (fruits vegetables) Fluency Tests;  DigitSpan;  PositiveandNegativeAffectScale(PANAS);  GeriatricDepressionScale(GDS);  Women&apos;s Health Initiative (WHI) Sleep Disturbance Measure Version 5;  MenopausalSymptomsChecklistVersion5|1498|NCT00687102|October 2001
3960|Completed                  Has Results|Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension||Drug:Olmesartanmedoxomil;  Drug:Amlodipine;  Drug:Hydrochlorothiazide|Interventional|Phase 3|Industry|Change From Baseline to Week 12 in Seated Diastolic Blood Pressure (SeDBP).;  Percentage of Subjects Who Reached Blood Pressure Goal (&lt;140/90 mmHg; &lt;130/80 mmHg for Subjects With Diabetes Chronic Renal Disease or Chronic Cardiovascular Disease)by 12 Weeks;  Change in Mean 24-hour Ambulatory Blood Pressure From Baseline to Week 12 or Early Termination;  Change in Seated Systolic Blood Pressure From Baseline to Week 12|2500|NCT00649389|May 2008
3961|Active not recruiting                  Has Results|Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer||Biological:Bevacizumab;  Other:LaboratoryBiomarkerAnalysis;  Drug:Letrozole;  Other:QuestionnaireAdministration;  Drug:TamoxifenCitrate|Interventional|Phase 3|NIH|Progression-freeSurvival;  12MonthProgressionFreeSurvivalRate;  6MonthProgression-FreeSurvivalRate;  ObjectiveResponseRate;  OverallSurvival(OS);  DurationofTumorResponse;  ProbabilityofSurvivingUntil36Months;  SiteofProgression;  Time-to-treatmentFailure;  TreatmentRelatedToxicity|394|NCT00601900|May 2008
3962|Completed|Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonate (Fosrenol)|||Observational||Industry|Compare all-cause mortality and bone fractures among three groups of subjects with end stage renal disease (ESRD);  Compare the incidence of selected morbidities among three groups of patients with ESRD|2105|NCT00567723|April 2006
3963|Completed                  Has Results|An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis||Biological:Placebo;  Biological:Golimumab50mg;  Biological:Golimumab100mg;  Biological:Golimumab200mg|Interventional|Phase 3|Industry|Number of Participants in Clinical Response Through Week 54;  Number of Participants With Clinical Remission at Both Week 30 and Week 54;  Number of Participants With Mucosal Healing at Both Week 30 and Week 54;  Number of Participants With Clinical Remission at Both Week 30 and 54 Among Participants With Clinical Remission at Week 0 of Maintenance Study;  Number of Participants With Clinical Remission at Week 54 and Not Receiving Concomitant Corticosteroids Among Participants on Corticosteroids at Week 0 of Maintenance Study|1228|NCT00488631|September 2007
3964|Active not recruiting|Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer||Drug:docetaxel;  Drug:LHRHagonist;  Procedure:surgery|Interventional|Phase 3|Other / NIH|3-year biochemical progression-free survival (bPFS) rate;  5-yearbPFSrateandbPFS;  Time to clinical local recurrence (The time from randomization to the first biopsy-proven recurrence in the prostatic bed or new mass.);  Time to metastatic disease progression (The date of randomization to date of evidence of systemic disease on bone scan or cross sectional imaging.);  Unacceptable toxicity (grade 3 or higher toxicity);  Prostate cancer-specific-free survival (The time from randomization to the time of death due to prostate cancer.);  Diseaseprogression;  Overall survival (The date of randomization to the time of death due to prostate cancer.)|788|NCT00430183|December 2006
3965|Completed|Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis||Drug:Balsalazidedisodium|Interventional|Phase 3|Industry|The primary efficacy endpoint is the proportion of subjects that achieve clinical improvement and improvement in the rectal bleeding subscale of the MMDAI at the end of six weeks of therapy.|400|NCT00408174|May 2006
3966|Completed                  Has Results|RED-HF&#8482; Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial||Drug:Darbepoetinalfa;  Drug:Placebo|Interventional|Phase 3|Industry|Time to All Cause Death or First Hospitalization for Worsening Heart Failure;  TimetoDeathFromAnyCause;  Time to Cardiovascular Death or First Hospital Admission for Worsening Heart Failure;  Change From Baseline to Month 6 in Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score;  Change From Baseline to Month 6 in KCCQ Symptom Frequency Score|2278|NCT00358215|June 2006
3967|Completed|Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome||Drug:Rifaximin|Interventional|Phase 2|Industry|The primary objective of this trial is to evaluate the efficacy of a 14-day course of oral rifaximin at 550 mg BID versus placebo in providing adequate relief from Diarrhea-associated IBS (DIBS) symptoms.;  To evaluate the dose-response relationship of placebo administered for 28 days and rifaximin administered at 275 mg BID 550 mg BID or 1100 mg BID for 14 days;;  to evaluate the efficacy of 550 mg BID for 4 weeks to determine if there are any differences when treatment is extended for an additional 2-week period when compared to a similar dosing regimen for 2 weeks;;  to evaluate the durability of response over a 12-week Post-treatment Phase in subjects with DIBS who achieved a response during the acute Treatment Phase of the study.|525|NCT00269412|December 2005
3968|Active not recruiting|Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer||Biological:cetuximab;  Drug:cisplatin|Interventional|Phase 3|Other / NIH|Disease-freesurvival(DFS);  Overallsurvival(OS);  Local-regionalcontrol(LRC);  Mucositistoxicity&#8805;grade3;  Othertoxicity&#8805;grade3;  Protocoltreatmentdelivery;  Death &#8804; 30 days after discontinuation of protocol treatment;  Quality of life as measured by Performance Status Scale for Head and Neck Cancer and the European Quality of Life questionnaire (EQ-5D);  Quality of life as measured by Functional Assessment of Cancer Therapy-General version;  Correlation of expression of epidermal growth factor receptor or its down-stream molecules (e.g. MAPK AKT Stat-3 PKC) with DFS OS and LRC;  Correlation of pre-treatment positron emission tomography (PET)/CT scan findings with DFS OS and LRC;  Correlation of post-treatment PET/CT scan findings with pathologic nodal complete response and nodal relapse rate at 2 years in clinical N2-3 patients|720|NCT00265941|November 2005
3969|Completed|PPAR - Combination With Metformin||Drug:Muraglitazar|Interventional|Phase 3|Industry|compare change from baseline in HbA1c after 24 weeks of treatment with muraglitazar + metformin vs placebo + metformin;  change in FPG from basline to W24 proportion of subjects receiving therapeutic response at W24 percent change of fasting lipid levels from baseline to W11/12 change in hs-CRP from baseline to W24|534|NCT00162240|June 2003
3970|Active not recruiting|Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer||Radiation: 3-dimensional conformal accelerated partial breast irradiation;  Radiation:brachytherapy;  Radiation:wholebreastirradiation;  Radiation: MammoSite or other single-entry intracavitary device|Interventional|Phase 3|Other / NIH|In-breasttumorrecurrence(IBTR);  Overallsurvival;  Recurrence-freesurvival;  Distantdisease-freesurvival;  Quality of life and patient-reported cosmesis by Breast Cancer Treatment Outcome Scale MOS SF-36 Vitality Convenience of Care scale and symptoms;  Toxicity as assessed by adverse events during treatment|4216|NCT00103181|March 2005
3971|Completed|FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum||Drug:cetuximab;  Drug:5-FU;  Drug:irinotecan;  Drug:leucovorin;  Drug:oxaliplatin|Interventional|Phase 2|Other / NIH / Industry|Overallsurvival;  Progression-freesurvival;  Completeresponse;  Partialresponse;  Proportion of patients experiencing &#8805; Grade 3 diarrhea;  Proportionofpatientsexperiencing&#8805;Grade3ANC;  Percentoftotaldoseadministered;  Proportion of patients experiencing &#8805; Grade 4 toxicity on each cetuximab treatment arm|238|NCT00077233|December 2003
3972|Terminated|Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors||Drug:cisplatin;  Drug:ifosfamide;  Drug:paclitaxel;  Drug:vinblastine|Interventional|Phase 3|Other / NIH|Overallsurvival|1|NCT00072215|April 2004
3973|Completed|Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer||Drug:carboplatin;  Drug:celecoxib;  Drug:gemcitabinehydrochloride;  Drug:zileuton|Interventional|Phase 2|Other / NIH|Diseasefreesurvival|140|NCT00070486|December 2003
3974|Active not recruiting|Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer||Procedure:psychosocialassessmentandcare;  Procedure:quality-of-lifeassessment|Observational||Other / NIH|qualityoflife;  diseasefreesurvival;  mortalityrate|1360|NCT00068328|August 2003
3975|Completed|Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy||Drug:alosetron|Interventional|Phase 3|Industry|Subject self assessment of improvement between treatment groups using the IBS Global Improvement Scale; comparison of safety and tolerability between treatment groups with respect to adverse events &amp; laboratory abnormalities.;  Comparison of treatment groups with respect to subject relief of IBS pain &amp; discomfort; lower GI symptoms changes in quality of life lost workplace productivity &amp; lost household/leisure activity &amp; subject satisfaction with assigned study drug.|700|NCT00067457|June 2003
3976|Active not recruiting                  Has Results|Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer||Drug:Exemestane;  Other:LaboratoryBiomarkerAnalysis;  Procedure:Oophorectomy;  Other:Quality-of-LifeAssessment;  Radiation:RadiationTherapy;  Drug:Tamoxifen;  Drug:Triptorelin|Interventional|Phase 3|Other / NIH|Disease-freeSurvival;  BreastCancer-freeInterval;  DistantRecurrence-freeInterval;  OverallSurvival|3066|NCT00066690|August 2003
3977|Active not recruiting|Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer||Drug:cisplatin;  Drug:epirubicinhydrochloride;  Drug:fluorouracil;  Drug:leucovorincalcium;  Radiation:radiationtherapy|Interventional|Phase 3|Other / NIH|Overallsurvival;  Diseasefreesurvival|546|NCT00052910|December 2002
3978|Completed                  Has Results|Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer||Drug:StandardTreatment;  Drug:capecitabine|Interventional|Phase 3|Other / NIH|Relapse-freeSurvivalRatesat2.4Years;  OverallSurvivalRateat2.4Years;  Number of Participants With Grade 3 4 or 5 Adverse Event at Least Possibly Related to Treatment.|633|NCT00024102|September 2001
3979|Completed|Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer||Drug:carboplatin;  Drug:paclitaxel|Interventional|Phase 3|Other / NIH|Recurrence-freeinterval;  Overallsurvival;  Frequencyandseverityofadverseevents|571|NCT00003644|October 1998
3980|Completed|Surgery in Treating Patients With Prostate Cancer||Procedure:conventionalsurgery|Interventional|Phase 2|Other / NIH|Survivalcharacteristics;  QOLassessment|49|NCT00002938|May 1997
3981|Recruiting|FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer||Drug:Fluorouracil;  Drug:IrinotecanHydrochloride;  Other:LaboratoryBiomarkerAnalysis;  Drug:LeucovorinCalcium;  Drug:Veliparib|Interventional|Phase 2|NIH|OS;  Diseasecontrolrate;  Durationofresponse(DoR);  Incidence of adverse events associated with each treatment arm using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0;  Overallresponserate;  PFS|143|NCT02890355|September 2016
3982|Recruiting|Efficacy in Controlling Glycaemia With Victoza&#174; (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes||Drug:liraglutide;  Drug:alpha-glucosidaseinhibitors;  Drug:DPP-4inhibitors;  Drug:meglitinides;  Drug:SGLT-2inhibitors;  Drug:sulfonylurea;  Drug:thiazolidinediones|Interventional|Phase 4|Industry|Time to inadequate glycaemic control defined as HbA1c above 7.0% (53 mmol/mol);  Number of subjects who achieve HbA1c below or equal to 6.5% (48 mmol/mol);  Number of subjects who achieve HbA1c below or equal to 7.0% (53 mmol/mol) without weight gain;  Changeinfastingplasmaglucose(FPG);  ChangeinBodyweight|1994|NCT02730377|March 2016
3983|Recruiting|Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV Non-small Cell Lung Cancer||Drug:Docetaxel;  Other:LaboratoryBiomarkerAnalysis;  Drug:Trametinib|Interventional|Phase 2|NIH|Response rate (confirmed and unconfirmed complete and partial responses) in all KRAS mutant patients (both those with G12C mutations and those with non-G12C mutations);  Incidence of toxicity graded according to the National Cancer Institute CTCAE version 4.0;  Overallsurvival;  Progressionfreesurvival;  ResponserateinpatientswithaG12Cmutation|53|NCT02642042|July 2016
3984|Completed|A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia||Drug:Ibandronate|Interventional|Phase 4|Industry|Part A: Number of participants who currently use weekly biphosphonate who answer &quot;yes&quot; to any of the questions in Candidate Identification Questionnaire (CIQ);  Part B: Number of participants who demonstrate improvement from their baseline satisfaction score after 6 months of ibandronate;  Part B: Percentage of participants who demonstrate improvement from their baseline satisfaction score after 6 months of ibandronate;  Part B: Percentage of eligible weekly biphosphonate users at screening who elect to enter Part B;  Part B: Percentage of participants who report an improved satisfaction score with monthly ibandronate compared to weekly alendronate or risendronate;  Part B: Percentage of participants who report preference to monthly ibandronate or weekly alendronate or risedronate;  Part B: Percentage of participants who have greater than or equal to (&gt;=) 80 percent (%) compliance;  Part B: Percentage of participants who report an improvement in the gastrointestinal (GI) symptoms;  Part B: Percentage of participants by age and activity level who report high satisfaction according to Osteoporosis Patient Survey satisfaction Questionnaire (OPSAT-Q);  Part B: Individual Domain scores from Osteoporosis Patient Survey satisfaction Questionnaire (OPSAT-Q);  Part B: Number of eligible weekly biphosphonate users at screening who elect to enter Part B;  Part B: Number of participants who report an improved satisfaction score with monthly ibandronate compared to weekly alendronate or risendronate;  Part B: Number of participants who report preference to monthly ibandronate or weekly alendronate or risedronate;  Part B: Number of participants who have &gt;= 80% compliance;  Part B: Number of participants who report an improvement in the GI symptoms;  Part B: Number of participants by age and activity level who report high satisfaction according to Osteoporosis Patient Survey satisfaction Questionnaire (OPSAT-Q)|1711|NCT02604836|June 2004
3985|Suspended|Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma||Other:LaboratoryBiomarkerAnalysis;  Drug:PazopanibHydrochloride;  Drug:Sapanisertib|Interventional|Phase 1 / Phase 2|NIH|Maximum tolerated dose of sapanisertib defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients) (Phase I);  PFS defined as either disease progression or death (in cases where patients have died without evidence of disease progression) (Phase II);  CBR defined as the number of patients having either CR PR or stable disease for at least 6 months after starting treatment;  Durationofresponse;  Incidence of adverse events graded according to NCI CTCAE version 4.0;  OS;  TTP;  Tumor response (complete response [CR] partial response [PR] stable disease [SD] and progressive disease [PD])|148|NCT02601209|November 2015
3986|Recruiting|Cisplatin With or Without Veliparib in Treating Patients With Stage IV Triple-Negative and/or BRCA Mutation-Associated Breast Cancer||Drug:Cisplatin;  Other:LaboratoryBiomarkerAnalysis;  Other:Placebo;  Drug:Veliparib|Interventional|Phase 2|NIH|Progression-free survival defined as radiologic progression of disease by Response Evaluation Criteria in Solid Tumors or unequivocal progression of non-measurable disease in the opinion of the treating physician;  Clinicalbenefitrate;  Overallsurvival;  Responserate(measurablediseaseonly)|235|NCT02595905|July 2016
3987|Recruiting|Study to Assess the Safety and Tolerability of PT010 PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease||Drug:BGFMDI(PT010)320/14.4/9.6&#956;g;  Drug:GFFMDI(PT003)14.4/9.6&#956;g;  Drug:BFFMDI(PT009)320/9.6&#956;g|Interventional|Phase 3|Industry|Bone Mineral Density (BMD) measurement of the lumbar spine;  Lens Opacities Classification System III (LOCS III) Posterior sub capsular (P) Score;  BoneMineralDensity(BMD)measurementofthehip;  LOCS III Nuclear Opalescence (NO) Nuclear Color (NC) and Cortical;  Logarithm of the Minimum Angle of Resolution (LogMAR);  Horizontalcup-to-discratio;  Adverseevents(AEs);  12-leadelectrocardiograms(ECGs);  Clinicallaboratorytesting;  Intraocularpressuremeasurement|500|NCT02536508|August 2015
3988|Recruiting|Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS||Drug:dalcetrapib;  Drug:Placebo|Interventional|Phase 3|Industry / Other|Composite of Major Cardiovascular Adverse Events (MACE) death MI and stroke|5000|NCT02525939|April 2016
3989|Recruiting|High-Dose Recombinant Interferon Alfa-2B Ipilimumab or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery||Biological:Ipilimumab;  Other:LaboratoryBiomarkerAnalysis;  Biological:Pembrolizumab;  Other:PharmacologicalStudy;  Other:Quality-of-LifeAssessment;  Biological:RecombinantInterferonAlfa-2b|Interventional|Phase 3|NIH|OS;  PD-L1status;  RFS;  B-Raf proto-oncogene serine/threonine kinase (BRAF) mutation status;  Changeinqualityoflife;  Incidence of toxicity assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0;  Long-termsurvival;  Post-relapsetherapy|1378|NCT02506153|October 2015
3990|Recruiting|Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease||Drug:Rivipansel;  Other:Placebo|Interventional|Phase 3|Industry|Timetoreadiness-for-discharge.;  Timetodischarge.;  Cumulative IV opioid consumption from the time of the loading dose of study drug to discharge.;  TimetodiscontinuationofIVopioids.;  Cumulative IV opioid consumption within the first 24 hours post-loading dose of study drug.;  Percent of subjects re-hospitalized for VOC within 3 days of discharge.|350|NCT02187003|June 2015
3991|Active not recruiting|S1222 Trial (Everolimus Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer||Drug:Fulvestrant;  Drug:Anastrozole;  Drug:Everolimus;  Drug:Placebo-Anastrozole;  Drug:Placebo-Everolimus|Interventional|Phase 3|Other / Industry|progression-freesurvival;  overallsurvival;  Number of Participants with Serious and Non-Serious Adverse Events;  responserate;  clinicalbenefitrate;  molecular determinants of response in circulating tumor cells|825|NCT02137837|May 2014
3992|Completed|Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults||Drug:favipiravir;  Drug:placebo|Interventional|Phase 3|Industry|Time to alleviation of all primary influenza symptoms and fever;  Time to alleviation of each of the primary influenza symptoms and fever;  To characterize the PK of favipiravir when used under clinical conditions|1161|NCT02008344|December 2013
3993|Recruiting|Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Refractory Multiple Myeloma||Drug:pomalidomide;  Drug:ixazomib;  Drug:dexamethasone|Interventional|Phase 1 / Phase 2|Other / NIH / Industry|Maximum Tolerated Dose (MTD) of pomalidomide and ixazomib determined according to incidence of dose limiting toxicity (DLT) graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I);  Progressionfreesurvival(PFS)(PhaseII);  Incidence and type of dose limiting toxicities (DLTs) serious adverse events and adverse events graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I);  Incidenceofdosereductions/delays(PhaseI);  Overall response rate (ORR) defined as partial response (PR) very good partial response (VGPR) complete response (CR) or stringent complete response (sCR) according to International Myeloma Working Group (IMWG) Uniform Response Criteria (Phase II);  Clinical benefit rate (CBR) defined as minimal response (MR) and better according to International Myeloma Working Group (IMWG) Uniform Response Criteria (Phase II);  Disease control rate (DCR) defined as stable disease (SD) and better according to International Myeloma Working Group (IMWG) Uniform Response Criteria (Phase II);  Duration of response (DOR) calculated for all patients achieving an objective response partial response (PR) or better (Phase II);  Overallsurvival(OS)(PhaseII);  Timetonexttreatment(TNT)(PhaseII);  Incidence type and severity of adverse events graded according to National Cancer Institute (NCI) Common Terminology Criteria Adverse Events (CTCAE) version 4.0 (Phase II);  Response rates (overall response rate (ORR) clinical benefit rate (CBR) disease control rate (DCR) for all patients on the pomalidomide/dexamethasone arm at the time of cross-over to pomalidomide/dexamethasone/ixazomib (Phase II);  Progression free survival (PFS) for all patients on the pomalidomide/dexamethasone arm at the time of cross-over to pomalidomide/dexamethasone/ixazomib (Phase II);  Baseline level of perceived fatigue and QOL assessed using the Registration Fatigue/Uniscale Assessment form (Phase II)|132|NCT02004275|February 2014
3994|Recruiting|Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery||Biological:Bevacizumab;  Biological:Ipilimumab;  Other:LaboratoryBiomarkerAnalysis|Interventional|Phase 2|NIH|Overallsurvival(OS);  Immune response assessed using the utility of irRC;  Incidence of adverse events (AE) defined using the Common Terminology Criteria for Adverse Events version 4.0 criteria;  Progression-free survival (PFS) evaluated based on international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)|168|NCT01950390|December 2013
3995|Completed|Assess Safety &amp; Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia||Drug:WC3055;  Other:Placebo|Interventional|Phase 2|Industry|Change from Baseline in Total IPSS (International Prostate Symptom Score);  ChangefromBaselineTotalIPSS;  Change from Baseline IIEF-EF (International Index of Erectile Function-Erectile Function) Domain Score;  ChangefromBaselineIIEF-EFDomainScore|796|NCT01939184|August 2013
3996|Active not recruiting|Study of a Candidate Clostridium Difficile Toxoid Vaccine (Cdiffense) in Subjects at Risk for C. Difficile Infection||Biological:C.difficileToxoidVaccine;  Biological:Placebo:0.9%normalsaline|Interventional|Phase 3|Industry|Number of participants with symptomatic PCR-confirmed primary CDI cases;  The number of participants with symptomatic PCR confirmed primary CDI cases after 3 injections;  The number of participants with symptomatic PCR-confirmed primary CDI cases after 2 injections;  The number of symptomatic PCR-confirmed primary CDI cases after 3 injections as a function of time since enrollment and within 3.0 years or 2.5 years in Stage 1 or Stage 2 respectively after the third injection;  Serum antibody concentrations against toxins A and B;  Number of Participants Reporting Solicited Injection Site Reactions Solicited Systemic Reactions Unsolicited Systemic Reactions and Serious Adverse Events Occurring Throughout the Trial|15000|NCT01887912|July 2013
3997|Active not recruiting|Lesinurad and Allopurinol Combination Extension Study in Gout||Drug:Lesinurad|Interventional|Phase 3|Industry|Proportion of subjects with an sUA level that is &lt; 6.0 mg/dL;  Resolutionofatleast1targettophi|717|NCT01808131|February 2013
3998|Active not recruiting|Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events||Drug:Dapagliflozin10mg;  Drug:Placebotablet|Interventional|Phase 3|Industry / Other|Time to first event included in the composite endpoint of CV death MI or ischemic stroke;  Time to first event of Hospitalization for Congestive Heart Failure;  Time to first event included in the composite endpoint of CV death MI ischemic stroke hospitalization for heart failure hospitalization for unstable angina pectoris or hospitalization for any revascularization;  TimetoAll-causemortality;  Bodyweightchangefrombaseline|17276|NCT01730534|April 2013
3999|Recruiting|Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)||Other:PatientswithAtrialFibrillation|Observational|Phase 4|Industry / Other|Numberofmajorbleedingevents;  Numberofmajoradversecardiacevents|15000|NCT01701817|February 2013
4000|Active not recruiting|TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer||Drug:AMG386;  Drug:Paclitaxel;  Drug:AMG386Placebo;  Drug:Carboplatin|Interventional|Phase 3|Industry|Progressionfreesurvival;  Overallsurvival(OS);  Incidence of adverse events and significant laboratory abnormalities;  PharmacokineticsofAMG386(CmaxandCmin);  Incidenceofanti-AMG386antibodyformation;  Patient reported ovarian cancer-specific symptoms and health related quality of life;  Patient reported status as measured by the EuroQOL (EQ-5D);  AMG 386 exposure-response relationships for PFS and OS;  Correlation of serum biomarkers with measures of response|1015|NCT01493505|January 2012
4001|Recruiting|GLORIA-AF Registry Program - Second and Third Phases|||Observational||Industry|Myocardialinfarction;  Life-threateningbleedingevents;  Allcausedeath;  Vasculardeath;  composite endpoint: Stroke systemic embolism myocardial infarction and vascular death (vascular composite endpoint);  Stroke (hemorrhagic and ischemic uncertain classification);  TransientIschemicattack(TIA);  Systemicembolism;  Pulmonaryembolism;  composite endpoint: stroke systemic embolism myocardial infarction life-threatening bleeding events and vascular death;  Major bleeding events (including life-threatening bleeding events)|19000|NCT01468701|November 2011
4002|Enrolling by invitation|Gilead Sustained Virologic Response (SVR) Registry|||Observational||Industry|Proportion of participants maintaining SVR at Week 144 by treatment regimen;  Proportion of participants with detectable HCV RNA due to reemergence of preexisting virus through Week 144 by treatment regimen;  Proportion of participants with detectable HCV resistance mutations through Week 144 by treatment regimen;  Proportion of participants with detectable HCV RNA due to reinfection through Week 144 by treatment regimen;  Liverdiseaseprogression;  Proportion of participants who develop hepatocellular carcinoma (HCC) through Week 144 by treatment regimen|7000|NCT01457755|April 2012
4003|Completed                  Has Results|[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL||Drug:Oliveoil4g;  Drug:omega-3-carboxylicacids2g;  Drug:omega-3-carboxylicacids4g|Interventional|Phase 3|Industry|SerumNon-HDLCholesterol|646|NCT01408303|August 2011
4004|Active not recruiting|Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I Stage II Stage III or Stage IV Ovarian Epithelial Primary Peritoneal Cavity or Fallopian Tube Cancer||Procedure:AssessmentofTherapyComplications;  Drug:Carboplatin;  Biological:Filgrastim;  Drug:Paclitaxel;  Other:PharmacologicalStudy;  Other:Quality-of-LifeAssessment;  Other:QuestionnaireAdministration|Observational||Other / NIH|Percent of women who are 70 years or older able to complete at least 4 cycles of treatment regardless of dose reduction and delays;  Tolerance to study treatment defined as completing four cycles of study treatment without dose reductions or treatment delays of over seven days;  Changes in comorbidity index measured by the Charlson scale;  Changesinnutritionalstatusmeasuredbyweight;  Changes in quality-of-life measured by FACT-O FACT/GOG-Ntx-4 subscale IADL and ADL;  Clinical response of elderly patients with ovarian primary peritoneal cavity or fallopian tube cancer;  Percent of patients reporting adverse events as assessed by the National Cancer Institute&apos;s Common Terminology Criteria for Adverse Events|290|NCT01366183|August 2011
4005|Completed                  Has Results|Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients||Drug:Canakinumabpre-filledsyringe;  Drug:Canakinumablyophilizedpowder;  Drug:TriamcinoloneAcetonide;  Drug:Placebo|Interventional|Phase 3|Industry|Pain Intensity on a 0-100 mm Visual Analog Scale (VAS) Between the Canakinumab 150 mg PFS and Triamcinolone Acetonide 40 mg Groups;  Pain Intensity on a 0 - 100 mm VAS Between the Canakinumab 150 mg PFS and Canakinumab 150 mg LYO Groups;  Patient&apos;s Assessment of Pain Intensity on a 0-100mm VAS;  Patient&apos;s Assessment of Pain Intensity on a 5-point Likert Scale;  Number of Patients With at Least One New Gouty Arthritis Flare After Baseline;  TimetotheFirstNewGoutyArthritisFlare;  Time to 50% Reduction in Baseline Pain on a 0 - 100 VAS;  Time to Resolution of Gouty Arthritis Flare as Reported by Patient;  Patient&apos;s Global Assessment of Response to Treatment on a 5-point Likert Scale;  Physician&apos;s Global Assessment of Response to Treatment on a 5 Point Likert Scale;  Physician&apos;sAssessmentofTenderness;  Physician&apos;sAssessmentofSwelling;  Physician&apos;sAssessmentofErythema;  Physician&apos;s Assessment of Range of Motion of the Most Affected Joint;  Proportion of Patients With Rescue Medication Intake;  TimetoFirstRescueMedicationIntake;  AmountofRescueMedicationTaken(mg);  C-reactiveProteinLevel|397|NCT01356602|May 2011
4006|Active not recruiting|Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery||Radiation: Whole breast irradiation delivered by 3-dimensional conformal radiation therapy or intensity modulated radiation therapy;  Radiation:Higherperdailyradiationtherapy;  Radiation:Concurrentboostradiotherapy;  Radiation:Standardperdailyradiationtherapy;  Radiation:Sequentialboostradiotherapy|Interventional|Phase 3|Other / NIH|Localcontrol;  Overallsurvival;  Disease-freesurvival;  Distantdisease-freesurvival;  Changes in breast-related symptoms and side effects and cosmesis;  Correlation between dose-volume data and both adverse events and efficacy;  Treatment cost of accelerated course of hypofractionated WBI versus standard WBI with a sequential boost|2312|NCT01349322|May 2011
4007|Active not recruiting|Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer||Drug:Regorafenib(BAY73-4506);  Drug:FOLFIRI;  Drug:Placebo|Interventional|Phase 2|Other / Industry|ProgressionFreeSurvival(PFS);  OverallResponse(OR)rate;  diseasecontrol(DC)rate;  OverallSurvival(OS);  DrugMetabolism;  Toxicity Assessments According to NCI CTCAE v. 4.0|181|NCT01298570|February 2011
4008|Active not recruiting|Radiation Therapy Paclitaxel and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer||Drug:Carboplatin;  Other:LaboratoryBiomarkerAnalysis;  Drug:Paclitaxel;  Other:Quality-of-LifeAssessment;  Radiation:RadiationTherapy;  Procedure:TherapeuticConventionalSurgery;  Biological:Trastuzumab|Interventional|Phase 3|NIH|Disease-freesurvival(DFS);  Health-related quality of life (QOL) as measured by FACT-E;  Incidence of adverse events assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0;  Molecularcorrelatesofefficacy;  Overallsurvival(OS);  Pathologiccompleteresponse;  Predictorsofcardiotoxicity;  Quality-adjustedsurvivalassessedbytheEQ-5D|591|NCT01196390|December 2010
4009|Completed                  Has Results|A Study To Evaluate The Effects And Safety Of Treatment Treatment Withdrawal Followed By Re-Treatment With CP-690550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis||Drug:CP-690550|Interventional|Phase 3|Industry|Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B);  Percentage of Participants Maintaining a Physician&apos;s Global Assessment (PGA) Response During the Double-Blind Treatment Withdrawal (Period B);  Percentage of Participants Achieving a PASI75 Response During CP-690550 Re-Treatment (Period C) Among Those Who Had a Greater Than (&gt;)50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B);  Percentage of Participants Achieving a PGA Response of Clear or Almost Clear During CP-690550 Re-treatment (Period C) Among Participants Who Had a PGA of Mild Moderate or Severe During Double-Blind Treatment Withdrawal (Period B);  Median Time to PASI75 Response During Initial CP-690550 Treatment (Period A);  Median Time to PGA Response of Clear or Almost Clear During Initial CP-690550 Treatment (Period A);  Percentage of Participants Achieving Both a PASI50-75 Response and Dermatology Life Quality Index (DLQI) &#8804;5 Response During Initial CP-690550 Treatment (Period A);  Percentage of Participant Maintaining an Adequate Response During the Double-Blind Treatment Withdrawal (Period B);  Median Time to Loss of Adequate Response During the Double-Blind Treatment Withdrawal (Period B);  Percentage of Participants With PASI Score &#8805;125% of Baseline-A or New Type of Psoriasis (Pustular Erythrodermic) During the Period Between Week 24 and Week 32 (Period B);  Percentage of Participants With PASI Score &#8805;125% of Baseline-A or New Type of Psoriasis (Pustular Erythrodermic) During the Double-Blind Treatment Withdrawal (Period B);  Percentage of Participants Maintaining Adequate PASI Response and Maintaining PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B);  Median Time to Loss of &gt;50% of the Visit A4/Week 24 PASI Response and Loss of PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B);  Percentage of Participants Regaining PASI75 and PGA Response (Clear or Almost Clear) During CP-690550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C;  Median Time to Regain PASI75 and PGA Response (Clear or Almost Clear) During CP-690550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C;  Percentage of Participants Regaining PASI75 and PGA Response (PGA of Clear or Almost Clear) During CP-690550 Re-Treatment (Period C) Who Had Lost Both PASI75 Response and PGA Response at the Beginning of Period C;  Median Time to PASI75 Response During CP-690550 Re-Treatment (Period C) For Those Who Had a &gt;50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B);  Median Time to PGA Response of Clear or Almost Clear During CP-690550 Re-Treatment (Period C) Among Participants Who Had a PGA of Mild Moderate or Severe at the Beginning of Period C;  Percentage of Participants With a PASI75 Response During the Initial CP-690550 Treatment (Period A);  Percentage of Participants With a PASI75 Response During Double-Blind Withdrawal Treatment (Period B);  Percentage of Participants With a PASI75 Response During the CP-690550 Re-Treatment (Period C);  Percentage of Participants With PGA Response of Clear or Almost Clear During the Initial CP-690550 Treatment (Period A);  Percentage of Participants With PGA Response of Clear or Almost Clear During Double-Blind Withdrawal Treatment (Period B);  Percentage of Participants With PGA Response of Clear or Almost Clear During the CP-690550 Re-Treatment (Period C);  Mean Total Percent of Psoriatic Body Surface Area (BSA) During Initial CP-690550 Treatment (Period A);  Mean Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B);  Mean Total Percent of Psoriatic BSA During CP-690550 Re-Treatment (Period C);  Mean Change From Baseline in Total Percent of Psoriatic BSA During Initial CP-690550 Treatment (Period A);  Mean Change From Baseline in Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B);  Mean Change From Baseline in Total Percent of Psoriatic BSA During CP-690550 Re-Treatment (Period C);  Mean Percent of Psoriatic BSA by Body Region During Initial CP-690550 Treatment (Period A);  Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B);  Mean Percent of Psoriatic BSA by Body Region During CP-690550 Re-Treatment (Period C);  Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690550 Treatment (Period A);  Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B);  Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690550 Re-Treatment (Period C);  Mean PASI Score During Initial CP-690550 Treatment (Period A);  Mean PASI Score During Double-Blind Treatment Withdrawal (Period B);  Mean PASI Score During the CP-690550 Re-Treatment (Period C);  Mean Change From Baseline-A in PASI Score During Initial CP-690550 Treatment (Period A);  Mean Change From Baseline-B in PASI Score During Double-Blind Treatment Withdrawal (Period B);  Mean Change From Baseline-C in PASI Score During the CP-690550 Re-Treatment (Period C);  Mean PASI Component Scores During Initial CP-690550 Treatment (Period A);  Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B);  Mean PASI Component Scores During the CP-690550 Re-Treatment (Period C);  Mean Change From Baseline in PASI Component Scores During Initial CP-690550 Treatment (Period A);  Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B);  Mean Change From Baseline in PASI Component Scores During the CP-690550 Re-Treatment (Period C);  Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During Period A;  Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During Period A;  Percentage of Participants Achieving at Least a 100% Reduction in PASI Relative to Baseline-A (PASI100) During Period A;  Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During the CP-690550 Re-Treatment (Period C);  Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During the CP-690550 Re-Treatment (Period C);  Percentage of Participants Achieving 100% Reduction in PASI Relative to Baseline-A (PASI100) During the CP-690550 Re-Treatment (Period C);  Percentage of Participants With a PASI Score &#8805;125% of the Baseline-A PASI Score During Initial CP-690550 Treatment (Period A);  Percentage of Participants With a PASI Score &#8805;125% of the Baseline-A PASI Score During Double-Blind Treatment Withdrawal (Period B);  Percentage of Participants With a PASI Score &#8805;125% of the Baseline-A PASI Score During the CP-690550 Re-Treatment (Period C);  Mean Itch Severity Item (ISI) Score During the Initial CP-690550 Treatment (Period A);  Mean ISI Score During the Double-Blind Treatment Withdrawal (Period B);  Mean ISI Score During the CP-690550 Re-Treatment (Period C);  Mean Change From Baseline-A in ISI Score During the Initial CP-690550 Treatment (Period A);  Mean Change From Baseline-B in ISI Score During the Double-Blind Treatment Withdrawal (Period B);  Mean Change From Baseline-C in ISI Score During the CP-690550 Re-Treatment (Period C);  Percentage of Participants With ISI Score of 0 During the Initial CP-690550 Treatment (Period A);  Percentage of Participants With ISI Score of 0 During CP-690550 Re-Treatment (Period C);  Percentage of Participants Achieving ISI Score of &#8804;1 During the Initial CP-690550 Treatment (Period A);  Percentage of Participants Achieving an ISI Score of &#8804;1 During CP-690550 Re-Treatment (Period C);  Percentage of Participants Achieving ISI &#8805;2-Point Reduction During the Initial CP-690550 Treatment (Period A);  Percentage of Participants Achieving ISI &#8805;2-Point Reduction During the CP-690550 Re-Treatment (Period C);  ISI Score of &#8804;1 During the Initial CP-690550 Treatment (Period A) - Percentage of Participants With a Response;  Median Time to ISI Score of &#8804;1 During the Initial CP-690550 Treatment (Period A);  ISI Score of &#8804;1 During CP-690550 Re-Treatment (Period C) - Percentage of Participants With a Response;  Median Time to ISI Score of &#8804;1 During the CP-690550 Re-Treatment (Period C);  ISI Reduction (2-point Decrease in ISI Score) During the Initial CP-690550 Treatment (Period A) - Percentage of Participants With a Response;  Median Time to ISI Reduction (2-point Decrease in ISI Score) During the Initial CP-690550 Treatment (Period A);  ISI Reduction (2-point Decrease in ISI Score) During the CP-690550 Re-Treatment (Period C) - Percentage of Participant With a Response;  Median Time to ISI Reduction (2-point Decrease in ISI Score) During the CP-690550 Re-Treatment (Period C);  Mean Dermatology Life Quality Index (DLQI) Score During the Initial CP-690550 Treatment (Period A);  Mean DLQI Score During the CP-690550 Re-Treatment (Period C);  Mean DLQI Score During the Double-Blind Treatment Withdrawal (Period B);  Mean Change From Baseline-A in DLQI Score During the Initial CP-690550 Treatment (Period A);  Mean Change From Baseline-B in DLQI Score During the Double-Blind Treatment Withdrawal (Period B);  Mean Change From Baseline-C in DLQI Score During the CP-690550 Re-Treatment (Period C);  Mean DLQI Subscale Scores During the Initial CP-690550 Treatment (Period A);  Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B);  Mean DLQI Subscale Scores During the CP-690550 Re-Treatment (Period C);  Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690550 Treatment (Period A);  Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B);  Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690550 Re-Treatment (Period C);  Percentage of Participants Achieving DLQI &#8805;5 Point Reduction From Baseline-A Response During Initial CP-690550 Treatment (Period A);  Percentage of Participants Achieving DLQI &#8805;5 Point Reduction From Baseline-B Response During Double-Blind Treatment Withdrawal (Period B);  Percentage of Participants Achieving DLQI &#8805;5 Point Reduction From Baseline-C Response During CP-690550 Re-Treatment (Period C);  Percentage of Participants Achieving DLQI &#8804;1 Response During the Initial CP-690550 Treatment (Period A);  Percentage of Participants Achieving DLQI &#8804;1 Response During Double-Blind Treatment Withdrawal (Period B);  Percentage of Participants Achieving DLQI &#8804;1 Response During CP-690550 Re-Treatment (Period C);  Percentage of Participants by DLQI Severity Category During the Initial CP-690550 Treatment (Period A);  Percentage of Participants With DLQI &#8805;5-Point Reduction From Baseline-A Response During Initial CP-690550 Treatment (Period A);  Median Time to DLQI &#8805;5-Point Reduction From Baseline-A Response During Initial CP-690550 Treatment (Period A);  Percentage of Participants With DLQI &#8805;5-Point Reduction From Baseline-A Response During CP-690550 Re-Treatment (Period C);  Median Time to DLQI &#8805;5-Point Reduction From Baseline-A Response During CP-690550 Re-Treatment (Period C);  Mean Short-Form 36 (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores During the Initial CP-690550 Treatment (Period A);  Mean SF-36 PCS and MCS Scores During CP-690550 Re-Treatment (Period C);  Mean Change From Baseline-A in SF-36 PCS and MCS Scores During the Initial CP-690550 Treatment (Period A);  Mean Change From Baseline-C in SF-36 PCS and MCS Scores During CP-690550 Re-Treatment (Period C);  Mean SF-36 Domain Scores During the Initial CP-690550 Treatment (Period A);  Mean SF-36 Domain Scores During CP-690550 Re-Treatment (Period C);  Mean Change From Baseline-A in SF-36 Domain Scores During the Initial CP-690550 Treatment (Period A);  Mean Change From Baseline-C in SF-36 Domain Scores During CP-690550 Re-Treatment (Period C);  Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690550 Treatment (Period A);  Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B);  Percentage of Participants in Each PtGA of Psoriasis Category During CP-690550 Re-Treatment (Period C);  Percentage of Participants With PtGA Response of Clear or Almost Clear During the Initial CP-690550 Treatment (Period A);  Percentage of Participants With PtGA Response of Clear or Almost Clear During CP-690550 Re-Treatment (Period C) Among Participants Who Had a PtGA of Mild Moderate or Severe During CP-690550 Treatment Withdrawal (Period B);  Percentage of Participants Maintaining PtGA Response of Clear or Almost Clear During the Double-Blind Treatment Withdrawal (Period B) Among Participants Who Had a Response of Clear or Almost Clear at Beginning of Period B;  Mean EuroQol 5 Dimensions (EQ-5D) Health State Profile Utility Score and VAS Scores During the Initial CP-690550 Treatment Period (Period A);  Mean EQ-5D Utility Score and VAS Scores During CP-690550 Re-Treatment (Period C);  Mean Change From Baseline-A in EQ-5D Utility Score and VAS Scores During the Initial CP-690550 Treatment Period (Period A);  Mean Change From Baseline-C in EQ-5D Utility Score and VAS Scores During CP-690550 Re-Treatment (Period C);  Mean EQ-5D Domain Scores During the Initial CP-690550 Treatment Period (Period A);  Mean EQ-5D Domain Scores During CP-690550 Re-Treatment (Period C);  Mean Change From Baseline-A in EQ-5D Domain Scores During the Initial CP-690550 Treatment Period (Period A);  Mean Change From Baseline-C in EQ-5D Domain Scores During CP-690550 Re-Treatment (Period C);  Percentage of Participants With Pustular Erythrodermic or Guttate Psoriasis During the Initial CP-690550 Treatment (Period A);  Percentage of Participants With Pustular Erythrodermic or Guttate Psoriasis During Double-Blind Treatment Withdrawal (Period B);  Percentage of Participants With Pustular Erythrodermic or Guttate Psoriasis During CP-690550 Re-Treatment (Period C)|666|NCT01186744|September 2010
4010|Completed|Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A Long Term Evaluation||Drug:liraglutide;  Drug:placebo|Interventional|Phase 3|Industry|Time from randomisation to first occurrence of cardiovascular death non-fatal myocardial infarction or non-fatal stroke (a composite cardiovascular outcome);  Time from rand. to first occurrence of an expanded composite cardiovascular outcome defined as either cardiovascular death non-fatal myocardial infarction non-fatal stroke revascularisation hospitalisation for unstable angina or for heart failure;  Timefromrandomisationtoallcausedeath;  Time from randomisation to each individual component of the expanded composite cardiovascular outcome|9340|NCT01179048|August 2010
4011|Recruiting|Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma||Other:ClinicalObservation;  Other:LaboratoryBiomarkerAnalysis;  Drug:Lenalidomide;  Other:Quality-of-LifeAssessment|Interventional|Phase 3|NIH|Incidence of grade 3 or higher toxicities based on Cancer Therapy Evaluation Program-Adverse Event Reporting System expedited reporting (Phase II);  PFS(PhaseIII);  Durationofresponse;  Incidence of adverse events graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0;  Overallsurvival(OS);  Responserate(completeandpartialresponse)|180|NCT01169337|October 2010
4012|Completed                  Has Results|XIENCE V&#174; USA Dual Antiplatelet Therapy (DAPT) Cohort||Drug:placebo+aspirin;  Drug: clopidogrel + aspirin OR prasugrel + aspirin;  Device: XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)|Interventional|Phase 4|Industry / Other|Incidence of Composite of All Death MI and Stroke (Defined as MACE);  IncidenceofARCDefiniteorProbableST;  Major Bleeding (GUSTO Classification Severe and Moderate Bleeding Combined);  MACEforITTPopulation;  STforITTPopulation;  MajorBleedingforITTPopulation;  MACEforTreatmentPopulation;  STforTreatmentPopulation;  MajorBleedingforTreatmentPopulation|870|NCT01106534|August 2009
4013|Completed|Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)||Drug:Asimadoline;  Drug:Placebo|Interventional|Phase 3|Industry / Other|12 Week Abdominal Pain and Stool (APS) Frequency Responder;  Compare the two treatment groups with respect to IBS-related abdominal pain;  Compare the two treatment groups with respect to stool frequency;  Compare the two treatment groups with respect to stool urgency;  Compare the two treatment groups with respect to IBS symptoms;  Compare the two treatment groups with respect to stool consistency scores;  Incidence of adverse events as a measure of tolerability;  Abnormalities of laboratory tests as a measure of tolerability|611|NCT01100684|May 2010
4014|Completed|Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy||Drug:calciumgluconate;  Drug:magnesiumsulfate;  Other:placebo;  Drug:oxaliplatin|Interventional|Phase 3|Other / NIH|Oxaliplatin-induced sensory neuropathy as repeatedly measured by the EORTC QLQ-CIPN20 sensory subscale during chemotherapy;  Area under the curve (AUC) of EORTC QLQ-CIPN20 motor subscale and autonomic subscale;  Percentage of patients experiencing grade 2+ and grade 3+ chronic cumulative neurotoxicity (NCI CTCAE version 4.0 and oxaliplatin-specific neurotoxicity scale) during and after chemotherapy;  Time to onset of grade 2+ and grade 3+ chronic cumulative neurotoxicity and the duration of the chronic cumulative neurotoxicity during and after chemotherapy;  Cumulative oxaliplatin doses that can be administered without dose-limiting chronic neurotoxicity and the percentage of patients discontinuing oxaliplatin-based chemotherapy because of neurotoxicity;  Percentage of acute neuropathy associated with oxaliplatin as measured by daily Side Effect Questionnaire during and after oxaliplatin-based chemotherapy (at 1 3 6 12 and 18 months);  Incidence of calcium gluconate and magnesium sulfate-induced adverse events as measured by CTCAE version 4.0;  AUC of patient-reported quality of life (QOL) as measured by the supplemental QOL questionnaire;  Incidence and expression of GSTP1 or other gene polymorphism with early onset of oxaliplatin-induced neurotoxicity|362|NCT01099449|June 2010
4015|Terminated|Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone||Drug:Dutogliptin;  Drug:Sitagliptin|Interventional|Phase 3|Industry|To demonstrate safety and tolerability of dutogliptin as assessed by vital signs adverse event reporting routine clinical laboratory assessments and ECG;  To demonstrate maintenance or lowering of HbA1c and fasting plasma glucose.|141|NCT01089790|March 2010
4016|Completed|Treatment of Erectile Dysfunction - Long Term Safety and Efficacy||Drug:Udenafil50mg;  Drug:Udenafil100mg;  Drug:Udenafil150mg;  Drug:PlaceboMatching50mgUdenafil;  Drug:PlaceboMatching100mgUdenafil;  Drug:PlaceboMatching150mgUdenafil|Interventional|Phase 3|Industry|International Index of Erectile Function (IIEF) score;  Changes in the satisfaction of intercourse orgasmic function sexual desire and overall satisfaction|1027|NCT01065012|January 2010
4017|Completed|An Observational Study to Assess Respiratory Syncytial Virus (RSV) Respiratory Events Among Premature Infants|||Observational||Industry|The primary endpoint is the incidence rate of outpatient RSV LRI during the RSV season with RSV LRI determined by real time RT-PCR;  Rate of RSV-associated emergency department (ED) visits during the RSV season;  Rate of RSV-associated hospitalization during the RSV season;  Rate of risk factors for RSV-associated outpatient LRI hospitalization and ED visits;  RateofriskfactorsforRSVinfection|3000|NCT00983606|September 2009
4018|Completed                  Has Results|Long-Term Safety and Efficacy Study of Avanafil in Men With Erectile Dysfunction||Drug:avanafil|Interventional|Phase 3|Industry|Change in Percentage of Sexual Attempts in Which Subjects Were Able to Maintain an Erection of Sufficient Duration to Have Successful Intercourse.;  Change in Percentage of Sexual Attempts in Which Subjects Were Able to Insert the Penis Into the Partner&apos;s Vagina;  Change in International Index of Erectile Function - Erectile Function Domain (IIEF-EF) Score|712|NCT00853606|March 2009
4019|Completed|Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes||Drug:Vildagliptin;  Drug:Placebo|Interventional|Phase 2 / Phase 3|Industry|Measure: To evaluate the efficacy of vildagliptin as monotherapy in patients with T2DM by assessing changes in HbA1c from baseline to 24 weeks.;  Measure: To evaluate the efficacy of vildagliptin as monotherapy in patients with T2DM as measured by changes in fasting plasma glucose from baseline to 24 weeks;  Measure: To evaluate the safety and tolerability of vildagliptin compared to placebo over 24 weeks of treatment as monotherapy in patients with T2DM;  Measure: To evaluate the long-term safety and tolerability of vildagliptin over the entire study duration as monotherapy in patients with T2DM;  Measure: To evaluate the body weight change from baseline with vildagliptin compared to placebo after 24 weeks of treatment as monotherapy in patients with T2DM|338|NCT00821977|November 2008
4020|Completed                  Has Results|Research Evaluating an Investigational Medication for Erectile Dysfunction - General ED||Drug:placebo;  Drug:avanafil|Interventional|Phase 3|Industry|Change in Percentage of Sexual Attempts in Which Subjects Were Able to Maintain an Erection of Sufficient Duration to Have Successful Intercourse;  Change in Percentage of Sexual Attempts in Which Subjects Were Able to Insert the Penis Into the Partner&apos;s Vagina;  Change in International Index of Erectile Function - Erectile Function Domain (IIEF-EF) Score|646|NCT00790751|November 2008
4021|Terminated                  Has Results|Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy||Drug:Prednisone;  Drug:sunitinib;  Drug:Placebo|Interventional|Phase 3|Industry|OverallSurvival(OS);  Progression-FreeSurvival(PFS);  Percent of Participants With Objective Response (OR);  DurationofResponse(DR);  ChangeFromBaselineinPainSeverity;  Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P);  Change From Baseline in Euro Quality of Life (EQ-5D)- Health State Profile Utility Score|873|NCT00676650|July 2008
4022|Unknown&nbsp;&#8224;|Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia||Drug:Cyclophosphamide;  Drug:FludarabinePhosphate;  Other:LaboratoryBiomarkerAnalysis;  Drug:Lenalidomide;  Biological:Rituximab|Interventional|Phase 2|NIH / Other|2-YearProgressionFreeSurvivalRate;  Inductionresponserate;  Induction response rates in patients with del(11q22.3);  PFSrateofpatientswithdel(11q22.3);  Time-to-progression;  Time-to-progressioninpatientswithdel(11q22.3)|418|NCT00602459|January 2008
4023|Terminated|Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia||Drug: Lapaquistat acetate and stable statin therapy;  Drug:Stablestatintherapy|Interventional|Phase 3|Industry|Change from Baseline in fasting plasma Low Density Lipoprotein cholesterol;  ChangefromBaselineinTriglycerides;  ChangefromBaselineinTotalCholesterol;  Change from Baseline in High Density Lipoprotein cholesterol;  Change from Baseline in Very Low Density Lipoprotein cholesterol;  ChangefromBaselineinapolipoproteinA1;  ChangefromBaselineinapolipoproteinB;  Change from Baseline in non- High Density Lipoprotein cholesterol;  Change from Baseline in the ratio of Low Density Lipoprotein cholesterol/High Density Lipoprotein cholesterol;  Change from Baseline in the ratio of Total Cholesterol/High Density Lipoprotein cholesterol;  Change from Baseline in the ratio of apolipoprotein A1/apolipoprotein B;  Change from Baseline in high-sensitivity C-reactive protein;  Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 1.81 mmol/L (70 mg/dL);  Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 2.59 mmol/L (100 mg/dL);  Percentage of subjects who achieve Low Density Lipoprotein cholesterol concentrations less than 3.37 mmol/L (130 mg/dL)|411|NCT00532311|July 2007
4024|Completed                  Has Results|Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only||Drug:Albiglutide(GSK716155)orexenatide|Interventional|Phase 2|Industry|Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16;  Change From Baseline in HbA1c at Weeks 4 5 7 8 9 12 15 and 16;  Number of Participants Who Achieved Target Values for HbA1c &lt;6.5% and &gt;=6.5% to &lt;7% at Weeks 4 5 7 8 9 12 15 and 16;  Change From Baseline in Waist Circumference at Week 16;  ChangeFromBaselineinBodyWeightatWeek16;  Percent Change From Baseline in Body Weight at Week 16;  Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 4 5 7 8 9 12 15 and 16;  Change From Baseline in Fasting Fructosamine at Weeks 5 8 12 and 16;  Change From Baseline in Fasting C-peptide at Weeks 5 8 12 and 16;  Change From Baseline in Fasting Glucagon at Weeks 5 8 12 and 16;  Change From Baseline in Fasting Insulin at Weeks 5 8 12 and 16;  Change From Baseline in Triglycerides Free Fatty Acids Total Cholesterol Low-density Lipoprotein Cholesterol and High-density Lipoprotein Cholesterol at Weeks 5 8 12 and 16;  Change From Baseline in Functional Living Index - Emesis (FLIE) Scores at Week 16;  Number of Participants With the Indicated Response to Questions on the Hunger Craving and Fullness Questionnaire (HCFQ) at Week 16;  MeanClearanceofAlbiglutide;  MeanVolumeofDistributionofAlbiglutide;  MeanAbsorptionRateofAlbiglutide;  Mean Half-maximal Effective Concentration (EC50) of Albiglutide for HbA1c and FPG|361|NCT00518115|April 2007
4025|Completed|Open-Label Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study||Drug:BalsalazideDisodium|Interventional|Phase 3|Industry|Incidence of adverse events and serious adverse eventsrelationship to study medication and severity;  Timetoonsetofadverseevents|500|NCT00486031|October 2006
4026|Active not recruiting|A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis|||Observational||Industry|The endpoint is the occurrence of serious adverse events including the observation of systemic and cutaneous malignancies|8037|NCT00475605|May 2005
4027|Completed                  Has Results|A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia||Drug:ABT-335androsuvastatincalcium;  Drug:ABT-335;  Drug:rosuvastatincalcium|Interventional|Phase 3|Industry|Mean Percent Change From Baseline to the Final Visit in High-density Lipoprotein Cholesterol (HDL-C) (Full Analysis Set);  Mean Percent Change From Baseline to the Final Visit in Triglycerides (Full Analysis Set);  Mean Percent Change From Baseline to the Final Visit in Low-density Lipoprotein Cholesterol (LDL-C) (Full Analysis Set);  Mean Percent Change From Baseline to the Final Visit in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) With ABT-335 135 mg in Combination With Rosuvastatin 5 mg Versus ABT-335 135 mg Monotherapy (Full Analysis Set);  Mean Percent Change From Baseline to the Final Visit in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) With ABT-335 135 mg in Combination With Rosuvastatin 5 mg Versus Rosuvastatin 5 mg Monotherapy (Full Analysis Set);  Mean Percent Change From Baseline to the Final Visit in Very-low-density Lipoprotein Cholesterol (VLDL-C) (Full Analysis Set);  Mean Percent Change From Baseline to the Final Visit in Apolipoprotein B (ApoB) (Full Analysis Set);  Median Percent Change From Baseline to the Final Visit in High Sensitivity C-reactive Protein (hsCRP) (Full Analysis Set);  Mean Percent Change From Baseline to the Final Visit in Total Cholesterol (Full Analysis Set)|760|NCT00463606|April 2007
4028|Completed                  Has Results|Randomized Double-blind Dose-range-finding Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)||Drug:LinaclotideAcetate;  Drug:Matchingplacebo|Interventional|Phase 2|Industry|Change From Baseline in the Weekly Normalized Complete Spontaneous Bowel Movement (CSBM) Rate During Weeks 1 Through 12 of the Treatment Period;  CSBM 75% Responder for the Treatment Period (Based on the Normalized Rate);  Change From Baseline in the Weekly Normalized SBM Rate for the Treatment Period;  Change From Baseline in Stool Consistency (7-point Ordinal BSFS) for the Treatment Period;  Change From Baseline in Straining (5-point Ordinal Scale) for the Treatment Period;  Change From Baseline in Degree of Relief of Irritable Bowel Syndrome (IBS) Symptoms (7-point Balanced Scale) for the Treatment Period;  Change From Baseline in Abdominal Pain (5-point Ordinal Scale) for the Treatment Period|420|NCT00460811|April 2007
4029|Active not recruiting                  Has Results|Bevacizumab Sorafenib Tosylate and Temsirolimus in Treating Patients With Metastatic Kidney Cancer||Biological:Bevacizumab;  Other:LaboratoryBiomarkerAnalysis;  Other:PharmacologicalStudy;  Drug:SorafenibTosylate;  Drug:Temsirolimus|Interventional|Phase 2|NIH|Progression-freeSurvival(PFS);  Proportion of Patients With Stable Disease at 6 Months;  OverallSurvival;  ObjectiveResponseRate|361|NCT00378703|September 2007
4030|Completed|Thyroid Dysfunction in Women With Newly Diagnosed Breast Cancer Compared to Healthy Volunteers||Other:physiologictesting;  Procedure:fatigueassessmentandmanagement;  Procedure:managementoftherapycomplications|Observational||Other / NIH|Compare proportion of hypothyroidism in women with newly diagnosed stage I-IIIB breast cancer prior to chemotherapy vs in age-matched healthy volunteers;  Compare change in thyroid function from baseline to 24 months after enrollment;  Correlate variation in thyroid function with fatigue symptom scores and anthropometric measurements at baseline and 24 months after enrollment|541|NCT00336102|April 2006
4031|Active not recruiting|Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer||Drug:bicalutamide;  Drug:buserelin;  Drug:docetaxel;  Drug:flutamide;  Drug:goserelinacetate;  Drug:leuprolideacetate;  Drug:prednisone;  Drug:triptorelin;  Radiation:radiationtherapy|Interventional|Phase 3|Other / NIH|OverallSurvival;  BiochemicalControl;  LocalControl;  DistantMetastasis;  Disease-freeSurvival;  IncidenceofAdverseEvents;  The time interval between biochemical failure and distant metastases with respect to testosterone level;  Validity of PSA-defined endpoints as a surrogate for overall survival|612|NCT00288080|December 2005
4032|Completed                  Has Results|Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer||Drug:Paclitaxel(Taxane);  Drug:Docetaxel(Taxane);  Drug:Carboplatin;  Drug:Cetuximab|Interventional|Phase 3|Industry|Median Number of Months of Progression-free Survival (PFS);  Number of Participants With Complete Response (CR) or Partial Response (PR);  Number of Participants With Complete Response (CR) Partial Response (PR) or Stable Disease (SD);  MedianNumberofMonthsofResponse;  MedianNumberofMonthstoResponse;  MedianNumberofMonthsofSurvival;  Number of Participants With Improvement of Symptoms;  Median Number of Months Until Symptomatic Progression (Worsening of Symptoms);  Number of Participants Who Died or Experienced Other Serious Adverse Events (SAEs) and Adverse Events (AEs);  Number of Participants Experiencing AEs Leading to Study Drug Discontinuation;  Number of Participants Experiencing Other Significant AEs: Acneform Rash;  Number of Participants Experiencing Other Significant AEs: Infusion Reaction;  Number of Participants Experiencing Other Significant AEs: Cardiac AEs;  Number of Participants Who Exprienced the Most Frequent Grade 3-4 Hematology Abnormalities Occurring in &gt;=5% Participants;  Number of Participants Who Experienced the Most Frequent Grade 3-4 Serum Chemistry Abnormalities Occurring in &gt;=5% Participants;  Number of Participants Who Had Unscheduled Visits to Physicians Clinics Hospitals and Other Unscheduled Major Medicinal Procedures|755|NCT00112294|December 2004
4033|Completed|TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer||Drug:TLK286inCombinationwithCarboplatin;  Drug:DoxorubicinHClLiposomeInjection|Interventional|Phase 3|Industry|StudyObjectives|244|NCT00102973|December 2004
4034|Active not recruiting                  Has Results|Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin&apos;s Lymphoma||Biological:rituximab|Interventional|Phase 3|Other / NIH|TimetoRituximabFailure(TTRF);  TimetoFirstCytotoxicTherapy(TTFC);  Overall Health-related Quality of Life (HRQL) at 6 Month After Randomization|545|NCT00075946|November 2003
4035|Completed|Cisplatin and Irinotecan Followed by Carboplatin Etoposide and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer||Drug:carboplatin;  Drug:cisplatin;  Drug:etoposide;  Drug:irinotecanhydrochloride;  Radiation:radiationtherapy|Interventional|Phase 2|Other / NIH|Efficacy in terms of survival at 2 years after initiation of study treatment;  Overall response rate as measured by RECIST at completion of study treatment;  Overallsurvival;  Failure-freesurvival;  Response rate as measured by RECIST after completion of 2 courses of induction chemotherapy;  Toxicity as measured by NCI CTCAE v.30 after completion of 2 courses of chemotherapy;  Tolerability as measured by chemotherapy dose-delivered dose delays after completion of study treatment|78|NCT00072527|November 2003
4036|Active not recruiting                  Has Results|Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia||Drug:Dasatinib;  Drug:ImatinibMesylate;  Other:LaboratoryBiomarkerAnalysis|Interventional|Phase 2|NIH|MolecularResponseRateat12Months;  HematologicResponse;  2-yearOverallSurvival(OS);  TwoYearRelapse-freeSurvival;  Toxicity|406|NCT00070499|August 2004
4037|Active not recruiting                  Has Results|Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer||Drug:cisplatin;  Radiation:StandardfractionationRT;  Radiation: Accelerated fractionation radiation therapy;  Procedure: Conventional surgery for select patients|Interventional|Phase 3|Other / NIH|OverallSurvival(3-yearRate);  Local-regionalControl;  Disease-freeSurvival;  RateofGrade3-5Toxicity;  QualityofLife;  Correlation of Epidermal Growth Factor Receptor(EGFR) With Outcomes;  CorrelationofCOX-2WithOutcomes|743|NCT00047008|July 2002
4038|Completed|Prevention of Autogenous Vein Graft Failure in Coronary Artery Bypass Procedures||Drug:CGT003(E2FDuplexDecoy)|Interventional|Phase 3|Industry||3000|NCT00042081|July 2002
4039|Recruiting|Cabozantinib-S-Malate Crizotinib Volitinib or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer||Drug:CabozantinibS-malate;  Drug:Crizotinib;  Other:LaboratoryBiomarkerAnalysis;  Drug:SunitinibMalate;  Drug:Volitinib|Interventional|Phase 2|NIH|PFS;  Incidence of toxicity graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0;  OS;  RR|180|NCT02761057|April 2016
4040|Recruiting|Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn&apos;s Disease||Drug:GED-0301;  Drug:Placebo|Interventional|Phase 3|Industry|Clincial remission defined by Crohn&apos;s Disease Activity Index (CDAI);  Endoscopic improvement by the Simple Endoscopic Score for Crohn&apos;s Disease (SES-CD);  Clinical remission by Crohn&apos;s Disease Activity Index (CDAI);  Corticosteroid-free clinical remission by Crohn&apos;s Disease Activity Index (CDAI);  AdverseEvents(AEs)|1064|NCT02596893|December 2015
4041|Recruiting|Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment||Drug:ObeticholicAcid;  Drug:Placebo|Interventional|Phase 3|Industry|To evaluate the effect of Obeticholic Acid compared to placebo on liver histology in non-cirrhotic nonalcoholic steatohepatitis (NASH) subjects with stage 2 or 3 fibrosis by assessing the following co-primary endpoints;  To evaluate the effect of Obeticholic Acid compared to placebo on all-cause mortality and liver-related clinical outcomes as measured by the time to first occurrence of any of the listed adjudicated events (clinical outcomes composite endpoint);  To evaluate the effect of Obeticholic Acid compared to placebo on liver histology in NASH|2000|NCT02548351|September 2015
4042|Recruiting|Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian Fallopian Tube or Primary Peritoneal Cancer||Drug:CediranibMaleate;  Other:LaboratoryBiomarkerAnalysis;  Drug:Olaparib;  Drug:Paclitaxel;  Drug: Pegylated Liposomal Doxorubicin Hydrochloride;  Other:QuestionnaireAdministration;  Drug:TopotecanHydrochloride|Interventional|Phase 2 / Phase 3|NIH|OS(PhaseIII);  PFS(PhaseIIandPhaseIII);  Frequency and severity of adverse events by CTCAE v.4.0 (Phase II and Phase III);  Frequency and severity of adverse events by CTCAE v.4.0 (Phase III);  ORR (partial or complete response) defined by RECIST v1.1 criteria (Phase II and Phase III)|680|NCT02502266|February 2016
4043|Recruiting|Effect of Albiglutide When Added to Standard Blood Glucose Lowering Therapies on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus||Biological:Albiglutide30mg;  Biological:Albiglutide50mg;  Biological:Albiglutidematchingplacebo|Interventional|Phase 4|Industry / Other|Time to first occurrence of major adverse cardiovascular events (MACE; cardiovascular death myocardial infarction or stroke) [Non-inferiority];  TimetofirstoccurrenceofMACE[Superiority];  Time to first occurrence of MACE or urgent revascularisation for unstable angina;  Time to first occurrence of the individual components of the primary endpoint;  Time to first occurrence of cardiovascular death or hospitalization due to heart failure;  Allcausemortality;  Time to initiation of insulin of more than 3 months duration for those subjects not treated with insulin at study start;  The proportion of subjects achieving glycemic control (HbA1c &lt;=7.0% at final assessment) with no severe hypoglycemic incidents and weight gain &lt;5% of body weight|9400|NCT02465515|July 2015
4044|Recruiting|Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation||Biological: Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine;  Other:Placebo|Interventional|Phase 2|Industry|Subjects in each vaccine group with postoperative S aureus BSI and/or deep incisional or organ/space SSI occurring within 90 days of elective open posterior spinal fusion procedures with multilevel instrumentation;  Safety and tolerability of a single vaccination of SA4Ag in adults aged 18 to &lt;86 years undergoing elective open posterior spinal fusion procedures with multilevel instrumentation by measuring local reactions systemic events and AEs.;  Subjects in each vaccine group with postoperative S. aureus BSI and/or deep incisional or organ/space surgical site infections occurring within 180 days of elective open posterior spinal fusion procedures with multilevel instrumentation;  Subjects in each vaccine group with postoperative S. aureus surgical site infections occurring within 90 days of elective open posterior spinal fusion procedures with multilevel instrumentation.;  Subjects in each vaccine group with postoperative S. aureus surgical site infections occurring within 180 days of elective open posterior spinal fusion procedures with multilevel instrumentation.|2600|NCT02388165|July 2015
4045|Active not recruiting|Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian Fallopian Tube or Primary Peritoneal Cancer||Drug:CabozantinibS-malate;  Other:LaboratoryBiomarkerAnalysis|Interventional|Phase 2|NIH|Complete or partial objective tumor response evaluated using the RECIST v1.1;  Progression-freesurvival;  IncidenceoftoxicityasassessedbyCTCAEv4;  Overallsurvival|34|NCT02315430|April 2015
4046|Active not recruiting|The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia||Drug:volanesorsen;  Drug:Placebo|Interventional|Phase 3|Industry|The percent change in fasting triglycerides (TG) from baseline|114|NCT02300233|December 2014
4047|Active not recruiting|Nivolumab in Treating Patients With Persistent Recurrent or Metastatic Cervical Cancer||Other:LaboratoryBiomarkerAnalysis;  Biological:Nivolumab|Interventional|Phase 2|NIH|Frequency of objective tumor response as assessed by RECIST 1.1 criteria;  Incidence of adverse events as assessed by CTCAE version 4;  OS;  PFS|25|NCT02257528|May 2015
4048|Active not recruiting|Non-inferiority Study to Compare the Efficacy and Safety of Mylan&apos;s Insulin Glargine With Lantus&#174; in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)||Drug:Mylan&apos;sinsulinglargine;  Drug:Lantus&#174;|Interventional|Phase 3|Industry|ChangeinHbA1cfrombaselineto24weeks;  Rate of hypoglycemic events per 30 days and hypoglycemia occurrence;  Immunogenicity:Changeinantibodytiter|600|NCT02227875|August 2014
4049|Completed|Extension Study to Evaluate the Safety and Efficacy of PT003 PT001 and PT005 in Subjects With Moderate to Very Severe COPD With Spiriva&#174; Handihaler&#174; (PINNACLE 3)||Drug:GFFMDI(PT003);  Drug:GPMDI(PT001);  Drug:FFMDI(PT005);  Drug: Open-label tiotropium bromide inhalation (Spiriva&#174; Handihaler&#174;)|Interventional|Phase 3|Industry|Overall safety and tolerability will be evaluated using adverse events vital sign measurements 12-lead ECG parameters and clinical laboratory parameters.;  Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1);  TransitionDyspneaIndex(TDI)score;  PeakchangefrombaselineinFEV1;  Change from baseline in St. George Respiratory Questionnaire (SGRQ) total score;  Change from baseline in Daily rescue Ventolin hydrofluoroalkane (HFA) use|893|NCT01970878|November 2013
4050|Completed|A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms||Drug:Estradiol;  Drug:Progesterone;  Drug:Placebo|Interventional|Phase 3|Industry|Primary Efficacy Endpoints: Vasomotor Symptoms (VMS Substudy);  Endometrialprotection;  VMSSubstudy|1847|NCT01942668|September 2013
4051|Recruiting|ABSORB III Randomized Controlled Trial (RCT)||Device:AbsorbBVS;  Device:XIENCE|Interventional||Industry|Target Lesion Failure (TLF) at 1 year non-inferiority (NI) against the control.;  Powered Imaging Cohort Secondary Endpoint: The in-stent/scaffold mean lumen diameter change between pre- and post-nitrate infusion at 3 years by angiography;  Powered Imaging Cohort Secondary Endpoint: The in-stent/scaffold mean lumen area change from post-procedure to 3 years by intravascular ultrasound (IVUS);  Powered Imaging Cohort Secondary Endpoint: The in-stent/scaffold mean lumen area change from post-procedure to 3 years by IVUS;  PoweredSecondaryEndpoint:Angina;  PoweredSecondaryEndpoint:DiabeticIndication;  Acute Success- Device success (Lesion level analysis);  Acute Success- Procedural success (Subject level analysis);  Death(CardiacVascularNon-cardiovascular);  MyocardialInfarction(MI);  Ischemia driven-Target Lesion Revascularization (ID-TLR);  NonID-TLR(NID-TLR);  Ischemia driven-Target Vessel Revascularization (ID-TVR);  NonID-TVR(NID-TVR);  Allcoronaryrevascularization;  Death/AllMI;  CardiacDeath/AllMI;  CardiacDeath/TV-MI/ID-TLR(TLF);  Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Events-MACE);  CardiacDeath/AllMI/ID-TLR(MACE);  Cardiac Death/All MI/ID-TLR/ID-TVR non TL (Target Vessel Failure TVF);  CardiacDeath/AllMI/ID-TLR/ID-TVRnonTL(TVF);  Death/AllMI/Allrevascularization;  Scaffold/StentThrombosis(perARCdefinition);  LandmarkanalysisonTLFandcomponents;  Landmark analysis on scaffold thrombosis/stent thrombosis (per ARC definition definite and probable);  OpticalCoherenceTomography(OCT)endpoint|2250|NCT01751906|December 2012
4052|Completed|The Management of Schizophrenia in Clinical Practice (MOSAIC)|||Observational||Industry|Positive and Negative Symptoms of Schizophrenia (PANSS);  Clinical Global Impression Schizophrenia Scale (CGI-SCH);  Cognitive function (Fluency Digit Symbol-Coding Trail Making Test);  NegativeSymptomAssessmentScale(NSA4);  Pharmacologic/behavioural treatments used in usual care settings: intervention;  Pharmacologic/behavioural treatments used in usual care settings: dose;  Pharmacologic/behavioural treatments used in usual care settings: duration;  PersonalandSocialPerformance(PSP);  SchizophreniaQualityofLifeScale(SQLS);  SchizophreniaCaregiverQuestionnaire;  MaslachBurnoutInventory(MBI)|557|NCT01746134|December 2012
4053|Completed|A Study of Evacetrapib in High-Risk Vascular Disease||Drug:Evacetrapib;  Drug:Placebo|Interventional|Phase 3|Industry / Other|Time to First Occurence of the Composite Endpoint of Cardiovascular (CV) Death Myocardial Infarction (MI) Stroke Coronary Revascularization or Hospitalization for Unstable Angina (UA);  Mean Percent Change from Baseline to 3 Months in Low-Density (LDL-C) and High-Density Lipoprotein Cholesterol (HDL-C) levels;  Time to First Occurrence of the Composite Endpoint of All-Cause Mortality MI Stroke Coronary Revascularization or Hospitalization for UA;  Time to First Occurrence of the Composite Endpoint of CV Death MI or Coronary Revascularization;  Time to First Occurrence of the Composite Endpoint of CV Death MI Stroke or Hospitalization for UA;  Time to First Occurrence of Composite Endpoint of CV Death MI or Stroke|12116|NCT01687998|October 2012
4054|Recruiting|ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab||Drug:alirocumab;  Drug:Placebo|Interventional|Phase 3|Industry|Time from randomization to first occurrence of one of the following clinical events: CHD death any non-fatal MI fatal and non-fatal ischemic stroke unstable angina requiring hospitalization;  Time to the first occurrence of any CHD event major CHD event any CV event composite of all cause mortality/non-fatal MI/non-fatal ischemic stroke all cause mortality;  Change from baseline in blood lipids and lipoprotein levels|18600|NCT01663402|October 2012
4055|Completed                  Has Results|Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy||Drug:AktInhibitorMK2206;  Drug:Fluorouracil;  Drug:Oxaliplatin;  Drug:Selumetinib|Interventional|Phase 2|NIH|OverallSurvival;  Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug|137|NCT01658943|August 2012
4056|Completed|Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.||Drug:Fingolimod;  Drug:DiseaseModifyingtherapy|Interventional|Phase 4|Industry|Retentionontreatment;  ReasonsforDiscontinuation;  Adverseevents;  Cognitiveimpairment;  Percentchangeinbrainvolume;  Treatmentsatisfaction|881|NCT01623596|June 2012
4057|Completed|Efficacy Safety and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3002)||Drug:JNJ-27018966;  Other:PlaceboComparator|Interventional|Phase 3|Industry|Composite response based on improvements from baseline in daily abdominal pain and daily stool consistency scores.;  Pain response based on improvement from baseline in daily abdominal pain scores.;  Stool consistency response based on improvement from baseline in daily stool consistency scores.;  Abdominalbloating;  Bowelmovementfrequency;  Urgencyepisodes;  Incontinenceepisodes;  Irritable Bowel Syndrome global symptom severity response;  Durability of treatment based on composite response in daily abdominal pain scores.;  Durability of treatment based on the composite response in daily stool consistency scores.;  Durability of treatment based on the composite response in Irritable Bowel Syndrome global symptom severity.|1150|NCT01553747|May 2012
4058|Completed|A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease||Other:Backgroundcare;  Drug:Placebo;  Drug:dalcetrapib|Interventional|Phase 3|Industry|Time to first occurrence of any component of the composite cardiovascular event (cardiovascular mortality and morbidity);  Allcausemortality;  Safety:Incidenceofadverseevents;  Changeinbloodlipidandlipoproteinlevels|2220|NCT01516541|January 2012
4059|Completed                  Has Results|A Clinical Trial to Study the Safety Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17||Biological:rLP2086andGardasil;  Biological:rLP2086;  Biological:Gardasil|Interventional|Phase 2|Industry|Geometric Mean Titer (GMT) of Human Papillomavirus (HPV) Antigens;  Serum Bactericidal Assay Using Human Complement (hSBA) GMTs of PMB80 [A22] and PMB2948 [B24];  Percentage of Participants With at Least One Adverse Event (AE);  Percentage of Participants Achieving Seroconversion for Human Papillomavirus (HPV);  Percentage of Baseline Seropositive Participants: Group 1 and 3 Participants;  Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ);  Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer &gt;= Prespecified Titer Level;  Serum Bactericidal Assay Using Human Complement (hSBA) Geometric Mean Titer (GMT)|2499|NCT01461993|September 2011
4060|Completed|Evaluation of Clinical Endpoints of Two Diclofenac Sodium Gel 1%||Drug:Diclofenac;  Drug:Placebo|Interventional|Phase 3|Industry|MeanChangefromBaselineinWOMACPainScale;  Superiority of Test and Reference against Placebo in the Mean Change from baseline in the total WOMAC pain score.|749|NCT01456611|September 2011
4061|Completed                  Has Results|A Study of Fluzone&#174; High-Dose Vaccine Compared With Fluzone&#174; Vaccine In Elderly Adults||Biological: High Dose Trivalent Inactivated Influenza Vaccine;  Biological: Trivalent Inactivated Influenza Vaccine|Interventional|Phase 4|Industry|Occurrences of Culture- or Polymerase Chain Reaction (PCR)-Confirmed Influenza Caused by Any Influenza Viral Types/Subtypes in Association With a Protocol-defined Influenza-like Illness (ILI).;  Occurrences of Culture-confirmed Influenza Caused by Influenza Viral Types/Subtypes That Are Antigenically Similar to Those Contained in the Vaccine Formulations in Association With a Protocol-defined Influenza-like Illness (ILI);  Occurrences of Culture-confirmed Influenza Caused by Any Influenza Viral Types/Subtypes in Association With a Protocol-defined Influenza-like Illness;  Occurrences of Culture-confirmed Influenza Caused by Influenza Viral Types/Subtypes That Are Antigenically Similar to Those Contained in the Vaccine Formulations in Association With a Modified CDC-defined Influenza-like Illness.;  Occurrences of Culture-confirmed Influenza Caused by Any Influenza Viral Types/Subtypes in Association With a Modified CDC-defined Influenza-like Illness;  Occurrences of Culture-confirmed Influenza Caused by Influenza Viral Types/Subtypes That Are Antigenically Similar to Those Contained in the Vaccine Formulations in Association With a Respiratory Illness;  Occurrences of Culture-confirmed Influenza Caused by Any Influenza Viral Types/Subtypes in Association With a Respiratory Illness|31989|NCT01427309|September 2011
4062|Completed|Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension||Drug: Nebivolol Valsartan and Hydrochlorothiazide|Interventional|Phase 3|Industry|AdverseEventRecording;  DiastolicBloodPressure(DBP).;  SystolicBloodPressure(SBP)|812|NCT01415505|August 2011
4063|Completed|S0927: Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Pts W/Stage I II or III Breast Cancer Receiving Hormone Therapy||DietarySupplement:omega-3fattyacid;  Other:placebo|Interventional|Phase 3|Other / NIH|Reductioninworstjointpainand/orstiffness;  Proportion of joint pain and stiffness improvement versus deterioration with omega-3-fatty acid versus placebo;  AdverseeventsasassessedbyNCICTCAEvs4.0;  Frequencyofnewpainmedicationsused;  Changes in serum-free and total estradiol levels as measured by liquid chromatography and mass spectrometry;  Changes in hormonal and inflammatory serum biomarkers;  Changesinfastingcholesterollevels|262|NCT01385137|February 2012
4064|Recruiting|Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer||Radiation:radiationtherapy;  Radiation:Whole-pelvicradiotherapy(WPRT)|Interventional|Phase 3|Other / NIH|OverallSurvival;  Cause-specificsurvival;  Distantmetastasis-freesurvival;  Biochemical failure by the Phoenix definition (PSA &#8805; 2 ng/mL over the nadir PSA);  Incidence of &quot;acute&quot; adverse events as assessed by the Common Toxicity Criteria for Adverse Effects (CTCAE) current version;  Time to &quot;late&quot; grade 3+ adverse events as assessed by CTCAE current version;  Prostate cancer-specific HRQOL change as measured by the EPIC-26 (bowel or urinary domain);  Fatigue status as measured by the Patient-Reported Outcome Measurement Information System (PROMIS) fatigue-domain change score;  Assessment and comparison of Quality Adjusted Life Years (QALYs)|2580|NCT01368588|July 2011
4065|Completed                  Has Results|Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation||Drug:NKTR-118;  Drug:Usualcare|Interventional|Phase 3|Industry|Incidence of Patients Experiencing at Least One Adverse Event (AE);  Incidence of Patients Experiencing AEs That Resulted in Discontinuation of Investigational Product (IP);  Incidence of Patients Experiencing Severe Adverse Events (SAEs)|844|NCT01336205|April 2011
4066|Completed|A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors||Drug:Etanercept;  Drug:Tocilizumab|Interventional|Phase 4|Industry|Time to First Occurrence of Cardiovascular (CV) Events Adjudication Committee (EAC) (CV-EAC) Adjudicated Event Defined as a Composite of CV Death Non-Fatal Myocardial Infarction and Non-Fatal Stroke;  Time to First Occurrence of Expanded Composite Endpoint Defined as a Composite of CV Death Non-Fatal Myocardial Infarction Non-Fatal Stroke Non-Elective Coronary Revascularization Procedures and Hospitalization for Unstable Angina;  Percentage of Participants with Adverse Events (AEs) and Serious AEs (SAEs)|3080|NCT01331837|August 2011
4067|Completed                  Has Results|A Clinical Study in Patients With Overactive Bladder With Leakage of Urine to Find Out if the Medicine Fesoterodine Works in Those Patients Who Did Not Have Enough Response to the Medicine Tolterodine.||Drug:Fesoterodine8mg;  Drug:Placebo|Interventional|Phase 4|Industry|Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours;  Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12;  Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 12;  Change From Baseline in Mean Number of Micturition-Related Urgency Episodes Per 24 Hours at Week 12;  Number of Participants With Change From Baseline in Patient Perception of Bladder Condition (PPBC) at Week 12;  Number of Participants With Change From Baseline in Urgency Perception Scale (UPS) at Week 12;  Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score at Week 12;  Change From Baseline in Health Related Quality of Life (HRQL) Domains and Total HRQL Score of Overactive Bladder Questionnaire (OAB-q) at Week 12;  Percentage of Participants With More Than (&gt;) 50 Percent (%) Reduction in UUI Episodes at Week 12 as Compared to Week -2;  Percentage of Participants With More Than (&gt;) 50 Percent (%) Reduction in UUI Episodes at Week 12 as Compared to Baseline;  Percentage of Participants With No UUI Episodes (Diary Dry Rate)|990|NCT01302054|May 2011
4068|Active not recruiting|Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma||Drug:BendamustineHydrochloride;  Drug:Bortezomib;  Radiation:FludeoxyglucoseF-18;  Other:LaboratoryBiomarkerAnalysis;  Biological:Ofatumumab;  Procedure: Positron Emission Tomography with Radiolabeled Targeting Agent|Interventional|Phase 2|NIH|CRrate;  Grade 3 or higher toxicities assessed according to NCI Common Terminology Criteria for Adverse Events version 4.0;  Immunohistochemical(IHC)markers;  PFS;  Pre-treatment single nucleotide polymorphisms (SNP);  PredictivevalueofFDG-PET|130|NCT01286272|April 2011
4069|Active not recruiting|Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32||Drug:Metformin;  Drug:Placebo|Observational||Other / NIH|Questionnaire scores from patient reported outcome battery regarding fatigue stress sleep depression and general quality of life;  Questionnaire scores from patient reported comorbid conditions and behavioral risks;  Biological correlates of fatigue (medical and demographic characteristics of pts.);  DNApolymorphisms;  ChangesinRNAgeneexpression|394|NCT01286233|July 2011
4070|Completed                  Has Results|Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE&#8482; - Diabetes||Drug:liraglutide;  Drug:placebo|Interventional|Phase 3|Industry|Change(%)FromBaselineinBodyWeight(Fasting);  Proportion of Subjects Losing at Least 5% of Baseline Body Weight;  Proportion of Subjects Losing More Than 10% of Baseline Body Weight;  Change (%-Points) From Baseline in HbA1c (Glycosylated Haemoglobin A1c);  Proportion of Subjects Reaching Target HbA1c Below 7%;  Proportion of Subjects Reaching Target HbA1c Below or Equal to 6.5%;  ChangeFromBaselineinWaistCircumference;  Change (%) From Week 56 to 68 in Body Weight (Fasting);  ChangeFromWeek56to68inWaistCircumference;  IncidenceofHypoglycaemicEpisodes|846|NCT01272232|June 2011
4071|Active not recruiting|Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy||Biological:Bevacizumab;  Drug:Everolimus;  Other:LaboratoryBiomarkerAnalysis;  Other:PharmacologicalStudy|Interventional|Phase 3|NIH|Overallsurvival(OS);  Objective response rate (defined as confirmed complete response plus partial response);  Progression-freesurvival(PFS);  Toxicities graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|700|NCT01198158|September 2010
4072|Active not recruiting|Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy||Drug:sulfasalazine;  Other:placebo|Interventional|Phase 3|Other / NIH|Maximum severity of diarrhea toxicity as measured by the CTCAE v4.0 during and after radiotherapy (RT);  Maximum severity and the duration of maximum severity of each outcome variable (i.e. rectal bleeding abdominal cramping tenesmus constipation and diarrhea) measured during and after RT;  Area under the curve that combines the individual severity of diarrhea toxicity as measured by the CTCAE v4.0 during and after RT;  Averagescoreforeachoutcomevariable;  Percentage of patients in each arm that experience each outcome variable during and after RT;  Long-termdiarrheaseveritygrade;  Long-termbowelfunctionscore;  Percent of patients in each arm that recorded &quot;yes&quot; to each of questions 2-12 on the bowel function questionnaire;  Percentage of patients in each arm that require any and each type of antidiarrheal medications;  Percentage of patients in each arm that experience clinically significant deficits in overall quality of life and fatigue|140|NCT01198145|April 2011
4073|Completed                  Has Results|Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study||Drug:Linagliptin;  Drug:Placebo|Interventional|Phase 3|Industry|Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 24 Weeks;  Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 6 Weeks;  Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 12 Weeks;  Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 18 Weeks;  Occurrence of Absolute Efficacy Response (HbA1c &lt; 7%) After 24 Weeks;  Occurrence of Absolute Efficacy Response (HbA1c &lt; 6.5%) After 24 Weeks;  Occurrence of Relative Efficacy Response (Reduction in HbA1c &gt;= 0.5%) After 24 Weeks;  Change From Baseline in Fasting Plasma Glucose (FPG) After 24 Weeks;  Change From Baseline in 2-hour Post-prandial Glucose (PPG) After 24 Weeks|234|NCT01194830|September 2010
4074|Active not recruiting                  Has Results|Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II Stage III or Stage IV Follicular Non-Hodgkin Lymphoma||Other:LaboratoryBiomarkerAnalysis;  Drug:Lenalidomide;  Biological:Rituximab|Interventional|Phase 2|NIH|Number of Participants Who Achieved a Complete Response;  Toxicity of Study Treatment Assessed by the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0;  TimetoDiseaseProgression;  TimetoBestResponse|63|NCT01145495|June 2010
4075|Completed                  Has Results|Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications||Drug:Saxagliptin;  Drug:Placebo|Interventional|Phase 4|Industry|Participants With Any Event From the Composite of Cardiovascular Death (CV Death) Non-fatal Myocardial Infarction (MI) or Non-fatal Ischaemic Stroke;  Participants With Any Event From the Composite of CV Death Non-fatal MI Non-fatal Ischaemic Stroke Hospitalisation for Heart Failure Hospitalisation for Unstable Angina Pectoris or Hospitalisation for Coronary Revascularisation;  ParticipantsWithEventofDeath|18206|NCT01107886|May 2010
4076|Completed|A Study of LY2484595 in Patients With High LDL-C or Low HDL-C||Drug:LY2484595;  Drug:Atorvastatin;  Drug:Simvastatin;  Drug:Rosuvastatin;  Drug:PlaceboforLY2484595;  Drug:PlaceboforStatins|Interventional|Phase 2|Industry|Percent change from baseline to 12 week endpoint in high density lipoprotein cholesterol (HDL-C) with LY2484595 in combination with atorvastatin and atorvastatin monotherapy;  Percent change from baseline to 12 week endpoint in low density lipoprotein cholesterol (LDL-C) with LY2484595 in combination with atorvastatin and atorvastatin monotherapy;  Percent change from baseline to 12 weeks in HDL-C with LY2484595 and Placebo;  Percent change from baseline to 12 weeks in LDL-C with LY2484595 and Placebo;  Percent change from baseline to 12 week endpoint in HDL-C with LY2484595 in combination with simvastatin or rosuvastatin and simvastatin/rosuvastatin monotherapy;  Percent change from baseline to 12 week endpoint in LDL-C with LY2484595 in combination with simvastatin or rosuvastatin and simvastatin/rosuvastatin monotherapy;  Pharmacokinetics-AreaUndertheCurve(AUC);  Percent change in plasma Cholesteryl Ester Transfer Protein (CETP) activity;  Percent change in plasma Cholesteryl Ester Transfer Protein (CETP) mass;  Incidenceandseverityofrashes;  Change from baseline to 12 week endpoint in blood pressure;  Change from baseline to 12 week endpoint in serum aldosterone;  Change from baseline to 12 week endpoint in plasma renin activity;  Change from baseline to 12 week endpoint in plasma potassium;  Change from baseline to 12 week endpoint in serum sodium;  Change from baseline to 12 week endpoint in serum bicarbonate;  Change from baseline to 6 week follow-up in EuroQol-5 dimensions (EQ-5D) score|430|NCT01105975|April 2010
4077|Active not recruiting|Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer||Drug:letrozole;  Drug:panobinostat;  Genetic:RNAanalysis;  Genetic:microarrayanalysis;  Genetic: reverse transcriptase-polymerase chain reaction;  Other:enzyme-linkedimmunosorbentassay;  Other:immunohistochemistrystainingmethod;  Other:laboratorybiomarkeranalysis|Interventional|Phase 1 / Phase 2|Other / NIH|Maximum-tolerateddose(phaseI);  Adverseevents;  Responserate(phaseII);  Survivaltime(phaseII);  Time-to-diseaseprogression(phaseII);  Progression-freesurvival(phaseII);  Durationofresponse(phaseII);  Clinicalbenefitrate;  Timetotreatmentfailure|48|NCT01105312|September 2010
4078|Terminated                  Has Results|A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain||Drug:Oseltamivir;  Drug:Placebo|Interventional|Phase 4|Industry|TimetoCessationofViralShedding;  Percentage of Participants With Viral Shedding by Clinic Visit as Measured by Viral Culture;  Percentage of Participants With Viral Shedding by Clinic Visit as Measured by Reverse Transcriptase Polymerase Chain Reaction;  Change From Baseline in Influenza Titer Measured by Viral Culture;  Number of Participants With Development of Oseltamivir-Resistant Influenza Virus;  TimetoResolutionofFever;  Time to Alleviation of All Clinical Symptoms - Children;  Time to Alleviation of All Clinical Symptoms - Adults;  Number of Participants Who Developed Secondary Illnesses During the Study;  Number of Participants Who Developed Secondary Illnesses That Were Treated With Antibiotics|102|NCT01032837|November 2009
4079|Completed|Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis||Drug:Budesonide;  Drug:Placebo|Interventional|Phase 3|Industry|Theproportionofsubjectswhoachieveremission.|281|NCT01008423|November 2009
4080|Completed                  Has Results|A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of Pregnancy||Drug:DR-103|Interventional|Phase 3|Industry|All Users Pregnancy Rates Based on Pearl Index (PI) Analyses for 91-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight;  Typical-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 91-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight;  Compliant-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 91-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight;  All Users Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycle-Equivalents and Broken Out by Subpopulations Defined by Participant Weight;  Typical-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycle-Equivalents and Broken Out by Subpopulations Defined by Participant Weight;  Compliant-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycle-Equivalents and Broken Out by Subpopulations Defined by Participant Weight;  Summary of Participants With Treatment-emergent Adverse Events;  All Users Life-Table Estimates of Pregnancy Rates Based on 91-day Cycles and Broken Out by Subpopulations Defined by Participant Weight;  Compliant-Use Life-Table Estimates of Pregnancy Rates Based on 91-day Cycles and Broken Out by Subpopulations Defined by Participant Weight|3597|NCT00996580|October 2009
4081|Active not recruiting|Carboplatin Paclitaxel and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma||Biological:bevacizumab;  Drug:carboplatin;  Drug:everolimus;  Drug:paclitaxel|Interventional|Phase 2|Other / NIH|Progression-freesurvival;  Incidence of adverse events as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0;  Confirmed tumor response rate (complete response [CR] or partial response [PR]) according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria;  Overallsurvivaltime|149|NCT00976573|April 2010
4082|Terminated                  Has Results|Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone&#174; Vaccine in Adults Aged 65 Years and Older||Biological: Trivalent inactivated influenza vaccine High Dose;  Biological: Trivalent inactivated influenza vaccine|Interventional|Phase 3|Industry|Efficacy of Fluzone High Dose Relative to Fluzone in the Prevention of Laboratory Confirmed Influenza Caused by Viral Types and Subtypes That Are Antigenically Similar to Those Contained in the Respective Annual Vaccine Formulations.|9172|NCT00976027|September 2009
4083|Completed                  Has Results|Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy||Drug:Tadalafil;  Other:Placebo|Interventional|Phase 3|Other / NIH|Spontaneous (Off-drug) Erectile Function (EF) as Measured by International Index of Erectile Function (IIEF) at Weeks 28-30 After Initiation of Radiation Therapy (RT);  Spontaneous (Off-drug) EF at Years 1 and 2 After Initiation of RT;  Overall Sexual Function as Measured by the IIEF at Weeks 28-30 and Years 1 and 2 After Initiation of RT;  Patient and Partner Overall Sexual Satisfaction as Measured by the Sexual Adjustment Questionnaire (SAQ) at Weeks 28-30 and Years 1 and 2 After Initiation of RT;  Patient and Partner Marital Adjustment as Measured by the Locke&apos;s Marital Adjustment Test at Weeks 28-30 and Years 1 and 2 After Initiation of RT;  Patient-related Predictors of EF at Weeks 28-30 and Years 1 and 2 After Initiation of RT;  Patient Follow-up Treatment for Erectile Dysfunction at Weeks 28-30 and Years 1 and 2 After Initiation of RT;  Radiotherapy Factors Associated With Spontaneous (Off-drug) EF at Weeks 28-30 and Years 1 and 2 After Initiation of RT|242|NCT00931528|November 2009
4084|Completed                  Has Results|Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence||Drug:Oxybutynin;  Drug:Placebo|Interventional|Phase 3|Industry|Change From Baseline in Mean Weekly Frequency of Urinary Incontinence Episodes at Week 12|626|NCT00909181|March 2009
4085|Completed|Collecting Tumor Samples From Patients With Gynecological Tumors||Other:LaboratoryBiomarkerAnalysis|Observational||Other / NIH|Collection of gynecological tumor specimens and serum from patients at GOG institutions;  Create a repository for long-term storage of these specimens;  Make available tissue and blood for proposed projects|275|NCT00897442|June 1992
4086|Active not recruiting                  Has Results|Temozolomide (TMZ) and Radiation Therapy (RT) With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (GBM)||Radiation:Radiationtherapypre-randomization;  Biological:Bevacizumab;  Drug:Placebo;  Drug:Temozolomidepre-randomization;  Drug:Temozolomidepost-randomization;  Radiation:Radiationtherapypost-randomization|Interventional|Phase 3|NIH|OverallSurvival(OS);  Progression-freeSurvival(PFS);  Incidence of Grade 3 and Higher Treatment-related Toxicity as Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (AEs) Version 3.0|637|NCT00884741|April 2009
4087|Active not recruiting|S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases||Procedure:assessmentoftherapycomplications|Observational||Other / NIH / Industry|Diagnosis of confirmed osteonecrosis of the jaw (ONJ);  Disease-specific estimates of the confirmed cumulative incidence at 3 years of ONJ;  ClinicalpresentationandnaturalhistoryofONJ;  Overallanddisease-specificcumulativeincidence;  Association of baseline factors with cumulative incidence of confirmed ONJ;  Association between patient-related outcomes and confirmed incidence|3500|NCT00874211|December 2008
4088|Active not recruiting|Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia||Biological:EpoetinAlfa;  Other:LaboratoryBiomarkerAnalysis;  Drug:Lenalidomide|Interventional|Phase 3|NIH|MER defined as sustained transfusion independence in transfusion-dependent patients or a rise in hemoglobin &gt; 2 g/dL in transfusion-independent patients with anemia for a minimum of 8 consecutive weeks;  Bone marrow response (complete response and partial response) rate;  Cytogeneticresponserate;  Duration of MER defined as the time interval between the documented date of MER and the earliest date of resumption of RBC transfusions &gt;= 2 units a reduction in hemoglobin concentration &gt;= 2 g/dL;  Minorerythroidresponserate;  RateofMER;  TimetoMER|252|NCT00843882|January 2009
4089|Completed                  Has Results|Research Evaluating an Investigational Medication for Erectile Dysfunction - Diabetic ED (REVIVE-D)||Drug:placebo;  Drug:avanafil|Interventional|Phase 3|Industry|Change in Percentage of Sexual Attempts in Which Subjects Were Able to Maintain an Erection of Sufficient Duration to Have Successful Intercourse;  Change in Percentage of Sexual Attempts in Which Subjects Were Able to Insert the Penis Into the Partner&apos;s Vagina;  Change in International Index of Erectile Function - Erectile Function Domain (IIEF-EF) Score|390|NCT00809471|December 2008
4090|Completed                  Has Results|A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure||Drug:amlodipineandolmesartanmedoxomiltablets;  Drug:hydrochlorothiazidetablets|Interventional|Phase 4|Industry|The Percentage of Patients Who Achieve Seated Systolic Blood Pressure Goal (&lt;140 mm Hg for Non-diabetics and &lt;130 mm Hg for Diabetics) From Baseline to 12 Weeks;  The Percentage of Subjects Achieving Seated Diastolic BP Goal (&lt;90 mmHg for Non-diabetics or &lt; 80 mmHg for Subjects With Diabetes) From Baseline to 12 Weeks;  The Percentage of Subjects Who Achieve BP Goal (&lt;140/90 mmHg for Non-diabetics or &lt;130/80 mmHg for Diabetics) From Baseline to 12 and 20 Weeks;  Change in Mean Seated Systolic Blood Pressure From Baseline to 4 8 12 16 20 Weeks;  Change in Mean Seated Diastolic Blood Pressure From Baseline to 4 8 12 16 20 Weeks;  Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals as Measured by Ambulatory Blood Pressure Monitor From Baseline to 12 Weeks;  Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals as Measured by Ambulatory Blood Pressure Monitor From Baseline to 20 Weeks;  Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals as Measured by Ambulatory Blood Pressure Monitor From Baseline to 12 Weeks;  Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals as Measured by Ambulatory Blood Pressure Monitor From Baseline to 20 Weeks;  Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals as Measured by Ambulatory Blood Pressure Monitor From Baseline to 12 Weeks;  Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals as Measured by Ambulatory Blood Pressure Monitor From Baseline to 20 Weeks;  Change From Baseline to Week 12 in Ambulatory Systolic and Diastolic Blood Pressure Values;  Change From Baseline to Week 20 in Ambulatory Systolic and Diastolic Blood Pressure Values;  Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4 8 12 16 20 Weeks;  Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4 8 12 16 20 Weeks;  Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks;  Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks;  Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 12 Weeks;  Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 20 Weeks;  Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 12 Weeks;  Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 20 Weeks;  Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks;  Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks;  Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks;  Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks;  Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks;  Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks|999|NCT00791258|November 2008
4091|Completed                  Has Results|Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)||Drug:Rifaximin;  Drug:Placebo|Interventional|Phase 3|Industry|Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie Weeks 3 Through 6).;  Proportion of Subjects Who Had Adequate Relief of IBS-related Bloating for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie Weeks 3 Through 6)|637|NCT00724126|July 2008
4092|Completed                  Has Results|Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms||Drug:AZD3355;  Drug:Placebo;  Drug:Gelusil&#174;|Interventional|Phase 2|Industry|Symptom Intensity Rated by Participants Twice Daily Using an Electronic Reflux Symptom Questionnaire Diary|478|NCT00703534|May 2008
4093|Terminated                  Has Results|Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients||Drug:bapineuzumab;  Drug:placebo|Interventional|Phase 3|Industry|The Change From Baseline in the Alzheimer&apos;s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)/11 Total Score at Week 78;  The Change From Baseline in the Disability Assessment for Demential (DAD) Total Score at Week 78;  The Change From Baseline in Brain Amyloid Burden at Week 71.;  The Change From Baseline in Phospho-tau Levels in the Cerebrospinal Fluid (CSF) at Week 71.;  The Change From Baseline in Brain Volume at Week 71;  Divergence of Effect on the ADAS-Cog/11 Total Scores From Week 39 to Week 78;  Divergence of Effect on the DAD Total Scores From Week 39 to Week 78;  Time to Median Placebo Deterioration on ADAS-Cog/11 Total Score (European Union [EU] Analysis Plan);  Time to First Clinically Meaningful Deterioration on ADAS-Cog/11 Total Score (United States [US] Analysis Plan);  Time to Median Placebo Deterioration on DAD Total Score;  Time to First Clinically Meaningful Deterioration on DAD Total Score (US Analysis Plan);  Percentage of Participants With Worsening From Baseline in ADAS-Cog/11 Total Score at Week 78 (European Union Analysis Plan);  Percentage of Participants With Worsening From Baseline in ADAS-Cog/11 Total Score at Week 78 (US Analysis Plan);  Percentage of Participants With Worsening From Baseline in DAD Total Score at Week 78 (European Union Analysis Plan);  Percentage of Participants With Worsening From Baseline in DAD Total Score at Week 78 (US Analysis Plan);  Change From Baseline in Dependence Scale Total Score at Week 78;  Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SOB) Total Score at Week 78|901|NCT00667810|June 2008
4094|Completed                  Has Results|A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension||Drug:irbesartan;  Drug:placebo;  Drug:PS433540|Interventional|Phase 2|Industry|Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) Following 12 Weeks of Treatment With PS433540 200 mg 400 mg 800 mg and Placebo.;  Change From Baseline in Mean Seated Diastolic Blood Pressure (DBP) Following 12 Weeks of Treatment With PS433540 200 mg 400 mg 800 mg and Placebo.;  The Percentage of Patients Treated With Each Dose of PS433540 Who Achieved Blood Pressure Control Defined as &lt;140/90 mmHg After 12 Weeks of Treatment.|261|NCT00635232|March 2008
4095|Completed                  Has Results|Study Evaluating The Safety Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)||Biological: 13 valent Pneumococcal Conjugate Vaccine;  Biological:23vPS|Interventional|Phase 3|Industry|Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC Relative to 23vPS (Vax 1 / Year 0);  Percentage of Participants Achieving a &#8805; 4-fold Rise for Serotype 6A OPA Titer for 13vPnC Relative to 23vPS (Vax 1 / Year 0);  Pneumococcal OPA Geometric Mean Titer (GMT) for Serotype 6A for 13vPnC Relative to 23vPS (Vax 1 / Year 0);  Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 13vPnC (Vax 1 / Year 0);  Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0);  Pneumococcal OPA Geometric Mean Titer (GMT) for Serotype 6A for 13vPnC / 13vPnC (Vax 2 / Year 1) Relative to 23vPS (Vax 1 / Year 0)|938|NCT00546572|November 2007
4096|Completed                  Has Results|A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis||Drug:Tocilizumab;  Drug:Placebo;  Drug:PermittedDMARDs|Interventional|Phase 3|Industry|Percentage of Patients With an Improvement of at Least 50% in American College of Rheumatology (ACR) Score (ACR50) From Baseline at Week 24;  Percentage of Patients With an Improvement of at Least 20% 50% or 70% in American College of Rheumatology (ACR) Score (ACR20 ACR50 ACR70) From Baseline at Weeks 4 8 12 16 20 and 24;  Mean Change From Baseline in Disease Activity Score 28 (DAS28) at Weeks 4 8 12 16 20 and 24;  Percentage of Patients With European League Against Rheumatism (EULAR) Good Moderate or no Response at Weeks 4 8 12 16 20 and 24;  Mean Change From Baseline in the Routine Assessment Patient Index Data (RAPID) Score at Weeks 4 8 12 16 20 and 24;  Mean Change From Baseline in 12-Item Short Form Health Survey v2 (SF-12) Scores at Weeks 4 8 12 16 20 and 24;  Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Weeks 4 8 12 16 20 and 24;  Mean Change From Baseline in the Medical Outcomes Study (MOS) Sleep Scale Score at Weeks 4 8 12 16 20 and 24;  Mean Change From Baseline in Individual Components of the Routine Assessment Patient Index Data (RAPID) at Each Day During the First 7 Days of Treatment;  Percentage of Patients With an Improvement of at Least 20% 50% or 70% in American College of Rheumatology (ACR) Score (ACR20 ACR50 ACR70) From Baseline at Day 7;  Mean Change From Baseline in C-reactive Protein (CRP) at Days 3 and 7|619|NCT00531817|October 2007
4097|Completed                  Has Results|VelcadeThalidomide and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade Melphalan and Prednisone||Drug:Bortezomib;  Drug:Dexamethasone;  Drug:Melphalan;  Drug:Prednisone;  Drug:Thalidomide|Interventional|Phase 3|Industry|ProgressionFreeSurvival(PFS);  Percentage of Participants With an Overall Response;  Percentage of Participants With a Complete Response;  Percentage of Participants With a Complete Response or a Very Good Partial Response;  DurationofResponse;  OverallSurvival;  TimetoAlternativeTherapy;  Change From Baseline in EORTC QLQ-C30 - Global Health Status|502|NCT00507416|June 2007
4098|Completed|Open-label Study of the Efficacy and Safety of VESIcare&#174; in Patients With Overactive Bladder Symptoms||Drug:solifenacinsuccinate|Interventional|Phase 3|Industry|To evaluate the efficacy of 5 and 10mg solifenacin succinate in patients with OAB symptoms;  Percentage of patients satisfied with 5mg treatment;  Percentage of patients obtaining additional benefit with increase to 10mg dose|2225|NCT00463541|June 2004
4099|Completed                  Has Results|Efficacy and Safety of Oral Febuxostat in Participants With Gout||Drug:Febuxostat;  Drug:Allopurinol|Interventional|Phase 3|Industry|Percentage of Subjects Whose Serum Urate Level is &lt;6.0 Milligrams Per Deciliter (mg/dL) at the Final Visit.;  Percentage of Renal Impairment Subjects Whose Final Visit Serum Urate Level is &lt;6.0 mg/dl;  Percentage of Subjects Whose Serum Urate Levels Are &lt;6.0 mg/dL at Month 2 Visit.;  Percentage of Subjects Whose Serum Urate Levels Are &lt;6.0 mg/dL at Month 4 Visit.;  Percentage of Subjects Whose Serum Urate Levels Are &lt;6.0 mg/dL at Month 6 Visit.;  Percentage of Subjects Whose Serum Urate Levels Are &lt;5.0 mg/dL at Month 2 Visit.;  Percentage of Subjects Whose Serum Urate Levels Are &lt;5.0 mg/dL at Month 4 Visit.;  Percentage of Subjects Whose Serum Urate Levels Are &lt;5.0 mg/dL at Month 6 Visit.;  Percentage of Subjects Whose Serum Urate Levels Are &lt;5.0 mg/dL at Final Visit.;  Percentage of Subjects Whose Serum Urate Levels Are &lt;4.0 mg/dL at Month 2 Visit;  Percentage of Subjects Whose Serum Urate Levels Are &lt;4.0 mg/dL at Month 4 Visit;  Percentage of Subjects Whose Serum Urate Levels Are &lt;4.0 mg/dL at Month 6 Visit;  Percentage of Subjects Whose Serum Urate Levels Are &lt;4.0 mg/dL at Final Visit;  Mean Percent Change From Baseline in Serum Urate Levels at Month 2 Visit.;  Mean Percent Change From Baseline in Serum Urate Levels at Month 4 Visit;  Mean Percent Change From Baseline in Serum Urate Levels at Month 6 Visit.;  Mean Percent Change From Baseline in Serum Urate Levels at Final Visit.|2269|NCT00430248|February 2007
4100|Active not recruiting|S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells in Women With Metastatic Breast Cancer Receiving Chemotherapy||Drug:chemotherapy|Interventional|Phase 3|Other / NIH|Overallsurvival;  Progression-freesurvival;  Prognostic value of sequentially collected circulating tumor cell (CTC) values;  Toxicity;  Correlation of CTC levels with breast cancer tumor markers|651|NCT00382018|October 2006
4101|Completed                  Has Results|Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety||Drug: Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care|Interventional|Phase 4|Industry|Number of Subjects With Decline in Forced Expiratory Volume (FEV1) Exceeding 20% From Baseline;  Supplemental Definition of Decline in Forced Expiratory Volume in One Second (FEV1): Number of Subjects;  Time to Persistent Decline in FEV1 Exceeding 20% From Baseline;  Change From Baseline in Forced Expiratory Volume in One Second (FEV1);  Pulmonary Serious Adverse Event (SAE) Composite: SAEs of Asthma Chronic Obstructive Pulmonary Disease (COPD) Pneumonia or Acute Bronchitis;  Time to Event for Pulmonary Serious Adverse Event (SAE) Composite: SAEs of Asthma Chronic Obstructive Pulmonary Disease (COPD) Pneumonia or Acute Bronchitis;  All-causeMortality:NumberofDeaths;  TimetoEvent:All-causeMortality;  Cardiovascular SAE Composite: SAEs of Cardiovascular Mortality Non-fatal Myocardial Infarction (MI) or Non-fatal Stroke;  Time to Event for Cardiovascular Serious Adverse Event (SAE) Composite: SAEs of Cardiovascular Mortality Non-fatal Myocardial Infarction or Non-fatal Stroke;  Allergic Response Serious Adverse Event (SAE) Composite: SAEs of Anaphylaxis Angioedema Generalized Allergic Reaction or Allergic Bronchospasm;  Time to Event for Allergic Response Serious Adverse Event (SAE) Composite Including: SAEs of Anaphylaxis Angioedema Generalized Allergic Reaction or Allergic Bronchospasm;  Change in Glycosylated Hemoglobin (HbA1c) From Baseline|1976|NCT00359801|July 2006
4102|Terminated                  Has Results|Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer||Drug:oxaliplatin;  Drug:fluorouracil;  Drug:leucovorincalcium;  Drug:bevacizumab|Interventional|Phase 3|Other / NIH|5-yearOverallSurvivalRate;  5-yearDisease-freeSurvivalRate;  PatternsofFailure;  Proportion of Patients Who Completed 12 Cycles of Treatment|355|NCT00303628|February 2006
4103|Completed                  Has Results|Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension||Drug:Amlodipine5mg;  Drug:Placebo;  Drug:Telmisartan20mg;  Drug:Telmisartan40mg;  Drug:Amlodipine10mg;  Drug:Telmisartan80mg;  Drug:Amlodipine2.5mg|Interventional|Phase 3|Industry|Change From Baseline at 8 Weeks in Seated Trough Cuff Mean Diastolic Blood Pressure (DBP) (Observed Telmisartan Effect);  Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Telmisartan Effects);  Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Observed Amlodipine Effects);  Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Amlodipine Effects);  Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Observed Treatment Effects);  Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects);  Change From Baseline at 8 Weeks in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects Excluding Pl);  Change From Baseline in Seated Trough Cuff Mean DBP (Observed Telmisartan Effect);  Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Telmisartan Effects);  Change From Baseline in Seated Trough Cuff Mean DBP (Observed Amlodipine Effects);  Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Amlodipine Effects);  Change From Baseline in Seated Trough Cuff Mean DBP (Observed Treatment Effects);  Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects);  Change From Baseline in Seated Trough Cuff Mean DBP (Adjusted Treatment Effects Excluding Pl);  Change From Baseline at 8 Weeks in Seated Trough Cuff Mean Systolic Blood Pressure (SBP);  Change From Baseline at 8 Weeks in Standing Trough Cuff Mean DBP;  Change From Baseline at 8 Weeks in Standing Trough Cuff Mean SBP;  DBPControl;  DBPResponse;  SBPResponse;  BPNormality;  Change From Baseline in ABPM Hourly Mean (Relative to Dosing) DBP;  Change From Baseline in ABPM Hourly Mean (Relative to Dosing) SBP;  ChangeFromBaselineinABPM24-hourMeanDBP;  ChangeFromBaselineinABPM24-hourMeanSBP;  OrthostaticChangeinTroughCuffMeanDBP;  OrthostaticChangeinTroughCuffMeanSBP;  ChangeFromBaselineinSeatedTroughPulseRate;  Change From Baseline in Seated Trough Cuff Mean SBP;  Change From Baseline in Standing Trough Cuff Mean DBP;  Change From Baseline in Standing Trough Cuff Mean SBP;  Clinical Relevant Abnormalities for Laboratory Parameters and Electrocardiogram (ECG)|1461|NCT00281580|April 2006
4104|Completed|Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)||Drug: Salmeterol 50mcg/ Fluticasone Propionate 500mcg|Interventional|Phase 3|Industry|Allcausemortalityat3years;  Rate of moderate and severe COPD exacerbations and health status assessed by the St. George&apos;s Respiratory Questionnaire.|6228|NCT00268216|September 2000
4105|Completed                  Has Results|Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)||Drug:SunitinibMalateContinuousDailyDosing;  Drug:SunitinibMalateSchedule4/2|Interventional|Phase 2|Industry|Time to Tumor Progression (TTP) Assessed Using Memorial Sloan-Kettering Cancer Center (MSKCC) Prognostic Factors Model;  Percentage of Participants With Objective Response (OR);  DurationofResponse(DR);  Overall Survival (OS) Assessed Using MSKCC Prognostic Factors Model|317|NCT00267748|December 2005
4106|Terminated|A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.||Drug:torcetrapib/atorvastatin;  Drug:ezetimibe/simvastatin|Interventional|Phase 3|Industry|Percent change in LDL-C and HDL-C from baseline after six weeks of treatment.;  Changes in other lipid parameters and other biomarkers.|1784|NCT00267267|January 2006
4107|Completed                  Has Results|Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis||Drug:DexlansoprazoleMR;  Drug:Lansoprazole|Interventional|Phase 3|Industry|Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Crude Rate Analysis.;  Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Life Table Method;  Percentage of Subjects With Baseline Erosive Esophagitis Grade C or D Combined Who Have Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Crude Rate Analysis.;  Percentage of Subjects With Baseline Erosive Esophagitis Grade C or D Combined Who Have Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Life Table Method.;  Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 4 as Assessed by Endoscopy - Crude Rate Analysis.;  Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 4 as Assessed by Endoscopy - Life Table Method|2054|NCT00251719|December 2005
4108|Approved for marketing|TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.||Drug:TMC-114|Expanded Access|Phase 3|Industry|||NCT00245739|
4109|Completed|Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain||Drug:Alvimopan;  Drug:Placebo|Interventional|Phase 3|Industry|To compare alvimopan with placebo for long-term safety and tolerability;  Quality of life pharmacokinetics pharmacogenetics (dependent on results from other data)|805|NCT00241722|August 2005
4110|Completed|Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma||Drug:Sorafenib(NexavarBAY43-9006)|Interventional|Phase 3|Industry|Safetyparameters;  Limitedradiologicalevaluations|2567|NCT00111020|June 2005
4111|Completed                  Has Results|Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.||Drug:ModifiedBolus5-FU/LVwithIrinotecan;  Drug:FOLFIRI+bevacizumab;  Drug:miFL+bevacizumab;  Drug:Infusional5-FU/LVwithIrinotecan;  Drug:OralCapecitabinewithIrinotecan|Interventional|Phase 3|Industry|Time to Progression (TTP) at Primary Completion: FOLFIRI and mIFL;  TimetoProgression:FOLFIRImIFLandCapeIRI;  OverallResponse:FOLFIRImIFLandCapeIRI;  SurvivalTime:FOLFIRImIFLandCapeIRI;  1YearSurvival:FOLFIRImIFLandCapeIRI;  TimetoProgression:CelecoxibandPlacebo;  OverallResponse:CelecoxibandPlacebo;  SurvivalTime:CelecoxibandPlacebo;  Time to Progression: Bevacizumab With FOLFIRI mIFL;  OverallResponse:BevacizumabWithFOLFIRImIFL;  1YearSurvival:BevacizumabWithFOLFIRImIFL;  Survival Time at Last Follow-Up Visit: Bevacizumab With FOLFIRI mIFL;  Dose Reduction Due to Treatment Emergent Adverse Events;  OverallRelativeDoseIntensityofIrinotecan|547|NCT00101686|February 2003
4112|Completed|Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension||Drug:Irbesartan/HCTZ;  Drug:Irbesartanmonotherapy|Interventional|Phase 3|Industry|Proportion of subjects whose seated diastolic blood pressure is controlled (SeDBP &lt; 90 mmHg) at Week 5;  Frequency of discontinuation due to AE frequencies of hypotension dizziness syncope headaches hypokalemia and hyperkalemia after 17 weeks of therapy.|645|NCT00095394|September 2004
4113|Completed|EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan||Drug:Tolvaptan|Interventional|Phase 3|Industry||3600|NCT00071331|September 2003
4114|Terminated                  Has Results|Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer||Other:placebo;  Drug:selenium|Interventional|Phase 3|Other / NIH|IncidenceRateofSecondPrimaryLungTumor;  5-yearProgression-freeSurvivalRate;  5-yearOverallSurvivalRate|1772|NCT00008385|October 2000
4115|Active not recruiting|Doxorubicin Hydrochloride Cyclophosphamide and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer||Drug:AromataseInhibitionTherapy;  Drug:Cyclophosphamide;  Drug:DoxorubicinHydrochloride;  Other:LaboratoryBiomarkerAnalysis;  Drug:Paclitaxel;  Drug:TamoxifenCitrate;  Biological:Trastuzumab|Interventional|Phase 3|NIH / Other|DurationofDFS;  Overallsurvival|3000|NCT00005970|May 2000
4116|Terminated                  Has Results|High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma||Biological:interferonalfa-2b;  Other:observation|Interventional|Phase 3|Other / NIH|5-yearRelapse-freeSurvivalRate;  5-yearOverallSurvivalRate|1150|NCT00003641|December 1998
4117|Recruiting|Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations||Drug:Clofarabine;  Drug:Cyclophosphamide;  Drug:Cytarabine;  Drug:Dasatinib;  Drug:Dexamethasone;  Drug:DoxorubicinHydrochloride;  Drug:Etoposide;  Drug:HydrocortisoneSodiumSuccinate;  Other:LaboratoryBiomarkerAnalysis;  Drug:LeucovorinCalcium;  Drug:Mercaptopurine;  Drug:Methotrexate;  Drug:Pegaspargase;  Drug:Prednisone;  Radiation:RadiationTherapy;  Drug:Thioguanine;  Drug:VincristineSulfate|Interventional|Phase 3|NIH|Comparison of DFS of children with HR B-ALL receiving post-Induction age adjusted ITT on an MBFM-IMHDM backbone compared to age adjusted IT MTX;  DFS of children adolescents and young adults with VHR B-ALL between arms;  Children and young adults with Ph-like B-ALL and a predicted TKI-sensitive mutation treated with dasatinib plus MBFM-IMHDM;  Increase of greater than or equal to 65% of 5-year DFS and less than 10% induction mortality in patients with DS and HR B-ALL treated with modified Induction and post-Induction therapy regimen with MBFM-IMIDM;  OSrateforHRB-ALLpatients;  OSrateforVHRB-ALLpatients;  Percentage of VHR-ALL patients randomized to control versus experimental arms that attain MRD less than or equal to 0.01% upon recovery from consolidation;  Toxicity and tolerability of Experimental arm and Control arm in patients with VHR B-ALL;  Toxicity and tolerability of MBFM-IMIDM in children with Down syndrome;  Toxicity and tolerability of post-induction age-adjusted ITT compared to age-adjusted IT MTX in children with HR B-ALL|5437|NCT02883049|February 2012
4118|Recruiting|Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities||Drug:Rivaroxaban(XareltoBAY59-7939);  Drug:Rivaroxaban-Placebo|Interventional|Phase 3|Industry / Other|Time from randomization to the first occurrence of any of the following major thrombotic vascular events: MI (Myocardial infarction) ischemic stroke CV (Cardiovascular) death ALI (Acute limb ischemia) and major amputation;  Time from randomization to first occurrence of major bleeding events according to the Thrombolysis in Myocardial Infarction (TIMI) classification;  Time from randomization to first occurrence of an index limb revascularization;  Time from randomization to first occurrence of myocardial infarction ischemic stroke coronary heart disease mortality acute limb ischemia and major amputation of a vascular etiology;  Time from randomization to first occurrence of myocardial infarction ischemic stroke all-cause mortalityacute limb ischemia and major amputation of a vascular etiology;  Time from randomization to first occurrence of hospitalization for a coronary or peripheral cause (either lower limb) of a thrombotic nature;  Time from randomization to first occurrence of myocardial infarction all-cause stroke cardiovascular death acute limb ischemia and major amputation of a vascular etiology;  Time from randomization to first occurrence of venous thromboembolic (VTE) events;  Timefromrandomizationtoall-causemortality|6500|NCT02504216|August 2015
4119|Completed|Efficacy and Safety Study of QVA149 in COPD Patients||Drug:QVA149;  Drug:Umeclidinium/vilanterol;  Drug:Placebo(umeclidinium/vilanterol);  Drug:Placebo(QVA149)|Interventional|Phase 3|Industry|To demonstrate non-inferiority of QVA149 compared to umeclidinium/vilanterol in terms of FEV1 AUC 0-24h;  To demonstrate the superiority of QVA149 compared to umeclidinium/vilanterol in terms of FEV1 AUC 0-24h;  To demonstrate the superiority of QVA149 compared to umeclidinium/vilanterol in terms of trough FEV1 (mean of 23h 15 min and 23 h 45 min post previous morning dose);  To demonstrate the superiority of QVA149 compared to umeclidinium/vilanterol in terms of FEV1 AUC 12-24h|356|NCT02487446|July 2015
4120|Recruiting|Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)||Drug:BGFMDI320/14.4/9.6&#956;g;  Drug:GFFMDI14.4/9.6&#956;g;  Drug:BGFMDI160/14.4/9.6&#956;g;  Drug:BFFMDI320/9.6&#956;g|Interventional|Phase 3|Industry|Rateofmoderateorsevereexacerbations;  Time to first moderate or severe COPD exacerbation;  Change from baseline in average daily rescue Ventolin HFA use over 52 weeks;  Timetodeath(allcause)|8000|NCT02465567|June 2015
4121|Recruiting|Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian Fallopian Tube or Primary Peritoneal Cancer||Drug:Carboplatin;  Drug:CediranibMaleate;  Drug:GemcitabineHydrochloride;  Other:LaboratoryBiomarkerAnalysis;  Drug:Olaparib;  Drug:Paclitaxel;  Drug: Pegylated Liposomal Doxorubicin Hydrochloride;  Other:PharmacologicalStudy;  Other:Quality-of-LifeAssessment|Interventional|Phase 3|NIH / Industry|PFSdeterminedusingRECIST1.1criteria;  Frequency and severity of adverse effects as defined by CTCAE version 4.0;  Overallsurvival;  Patient reported scores of disease-related symptoms as measured by the NFOSI-18 DRS-P|450|NCT02446600|February 2016
4122|Completed|Phase 2 Randomized Double-Blind Placebo-Controlled Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain||Drug:Linaclotide145micrograms;  Drug:Linaclotide290micrograms;  Drug:Placebo|Interventional|Phase 2|Industry|Change from baseline in the 8-week Spontaneous Bowel Movement (SBM) frequency rate (SBMs/week) during the Treatment Period;  Time to first Spontaneous Bowel Movement (SBM) after the first dose of investigational product;  6/8 Week Spontaneous Bowel Movement (SBM) 3 + 1 responder;  Change from baseline in 8-week stool consistency (Bristol Stool Form Scale);  Changefrombaselinein8-weekstraining;  Changefrombaselinein8-weekabdominalbloating|254|NCT02270983|October 2014
4123|Active not recruiting|Non-inferiority Study to Compare the Efficacy and Safety of Mylan&apos;s Insulin Glargine With Lantus&#174; in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)||Drug:Mylan&apos;sinsulinglargine;  Drug:Lantus&#174;|Interventional|Phase 3|Industry|ChangeinHbA1cfrombaselineto24weeks;  Immunogenicity: Change from baseline in titer and incidence of ADA;  Rateper30daysofhypoglycemicevents;  Insulindoseperbodyweight(U/kg)|500|NCT02227862|August 2014
4124|Recruiting|Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma||Drug:Dabrafenib;  Biological:Ipilimumab;  Other:LaboratoryBiomarkerAnalysis;  Biological:Nivolumab;  Other:Quality-of-LifeAssessment;  Drug:Trametinib|Interventional|Phase 3|NIH|OS rate defined as the proportion of patients alive after 2 years of follow-up time;  PFSevaluatedbasedonRECISTversion1.1;  ResponserateaccordingtoRECISTversion1.1;  ToxicityrateforcategorizedAEs;  Toxicityrateforindividualadverseevents(AEs);  ToxicityrateforworstdegreeAEs|300|NCT02224781|July 2015
4125|Completed|Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects||Biological:Evolocumab(AMG145);  Other:Placebo;  Drug:Effectivestatintherapy|Interventional|Phase 3|Industry|Mean Change from baseline over time in Spatial Working Memory (SWM) index of executive function;  Mean Change from baseline over time in Spatial Working Memory (SWM) between-errors score;  Mean Change from baseline over time in Paired Associated Learning (PAL) total errors adjusted.;  Mean Change from baseline over time in Reaction Time (RTI) median 5-choice reaction time|1972|NCT02207634|September 2014
4126|Recruiting|Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD) Not on Dialysis||Drug:Roxadustat;  Drug:Placebo|Interventional|Phase 3|Industry|Major adverse cardiovascular (CV) events (MACE): Time to first occurrence of all cause mortality non-fatal myocardial infarction or non-fatal stroke.;  Mean change in hemoglobin (Hb) from baseline to the end of treatment period (event-driven anticipate 1-2 years).;  Proportion of total time of Hb measurements within the interval of 11&#177;1 g/dL from week 28 until end of treatment visit (event-driven anticipate 1-2 years).;  MACE+: Time to first occurrence of all cause mortality non-fatal myocardial infarction (MI) or non-fatal stroke heart failure requiring hospitalization or unstable angina leading to hospitalization.;  Time to first occurrence of all cause mortality MI stroke heart failure requiring hospitalization unstable angina leading to hospitalization deep vein thrombosis pulmonary embolism vascular access thrombosis or hypertensive emergency.;  Time-to-first instance of receiving intravenous (IV) iron red blood cell (RBC) transfusions or erythropoietin analogue as rescue therapy.;  Change in estimated glomerular filtration rate (eGFR) from baseline to the end of treatment period (event-driven anticipate 1-2 years).;  Changes in anemia symptoms and four disease-specific Health Related Quality of Life (HRQoL) domains as measured by the Functional Assessment of Cancer Therapy-Anemia (FACT-An).;  Changes in generic HRQoL as measured by the Short Form 36 (SF-36) (vers 2 standard).;  Changes in self-reported health status as measured by the EuroQol Health Utility Index-5-dimensional-5-level (EQ-5D-5L) and Patients&apos; Global Impression of Change (PGIC).;  Adverse events (AEs) serious adverse events (SAEs) and changes in vital signs electrocardiogram (ECG) and laboratory values. Measured from first screening visit to end of study (event-driven anticipate 1-2 years).|2600|NCT02174627|June 2014
4127|Recruiting|Absorb IV Randomized Controlled Trial||Device:AbsorbBVS;  Device:XIENCE|Interventional||Industry|Landmark TLF Primary Endpoint: TLF between 1 and 5 years tested first for non-inferiority (NI) of Absorb BVS to XIENCE with reflex testing to superiority.;  Powered Primary Outcome: TLF tested for non-inferiority of Absorb BVS to XIENCE.;  Angina Powered Secondary Endpoint: The percentage of patients who experienced angina within 1 year tested first for non-inferiority of Absorb BVS to XIENCE with reflex testing to superiority against the control.;  Acute Success- Device success (Lesion level analysis);  Acute Success- Procedural success (Subject level analysis);  Death(CardiacVascularNon-cardiovascular);  MyocardialInfarction(MI);  Ischemia driven-Target Lesion Revascularization (ID-TLR);  NonID-TLR(NID-TLR);  Ischemia driven-Target Vessel Revascularization (ID-TVR);  NonID-TVR(NID-TVR);  Allcoronaryrevascularization;  Death/AllMI;  CardiacDeath/AllMI;  CardiacDeath/TV-MI/ID-TLR(TLF);  Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Events-MACE);  CardiacDeath/AllMI/ID-TLR(MACE);  Cardiac Death/All MI/ID-TLR/ID-TVR non TL (Target Vessel Failure TVF);  CardiacDeath/AllMI/ID-TLR/ID-TVRnonTL(TVF);  Death/AllMI/Allrevascularization;  Scaffold/Stent Thrombosis (per Academic Research Consortium (ARC) definition);  Scaffold/StentThrombosis(perARCdefinition);  Rehospitalization;  Repeatcoronaryarteriography;  LandmarkanalysisonTLFandcomponents;  Landmark analysis on MACE and TVF and their components;  Landmark analysis on scaffold thrombosis/stent thrombosis (per ARC definition definite and probable);  TLFthrough1year;  TLFthrough5years|3000|NCT02173379|July 2014
4128|Recruiting|Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma||Biological:BleomycinSulfate;  Drug:BrentuximabVedotin;  Drug:Cyclophosphamide;  Drug:DoxorubicinHydrochloride;  Drug:Etoposide;  Other:LaboratoryBiomarkerAnalysis;  Drug:Prednisone;  Other:Quality-of-LifeAssessment;  Other:QuestionnaireAdministration;  Drug:VincristineSulfate|Interventional|Phase 3|NIH|EFS where events include disease progression or relapse second malignancy or death;  Proportion of patients experiencing grade 3+ peripheral neuropathy assessed by modified Balis scale;  Proportion of patients needing protocol-directed RT defined as patients with SRL or PD;  Proportion of patients with early response defined as no slow responding lesions (SRL) and no progressive disease (PD) at all sites determined by PET per Deauville criteria through central review|600|NCT02166463|March 2015
4129|Recruiting|Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History||Drug:BenralizumabArmA;  Drug:BenralizumabArmB;  Drug:BenralizumabArmC;  Drug:Placebo|Interventional|Phase 3|Industry|Evaluation of the effect of benralizumab on COPD exacerbations in subjects with moderate to very severe COPD;  Effect of benralizumab on health status/health-related quality of life;  Effectofbenralizumabonpulmonaryfunction;  Effectofbenralizumabonrespiratorysymptoms;  Effectofbenralizumabonrescuemedicationuse;  Effectofbenralizumabonnocturnalawakenings;  Effect of benralizumab on the severity frequency and duration of exacerbations of COPD;  Effect of benralizumab on healthcare resource utilization;  Benralizumabconcentrationinserum;  Safetyandtolerabilityofbenralizumab;  Immunogenicityofbenralizumab|2168|NCT02155660|June 2014
4130|Completed                  Has Results|Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout||Drug:FebuxostatIR;  Drug:FebuxostatXR;  Drug:Febuxostatplacebo;  Drug:Colchicine;  Drug:Naproxen;  Drug:Lansoprazole|Interventional|Phase 3|Industry|Percentage of Participants With Serum Urate &lt;5.0 mg/dL at Month 3;  Percentage of Participants With at Least One Gout Flare Requiring Treatment;  Percentage of Participants With Serum Urate &lt;6.0 mg/dL at Month 3|1790|NCT02139046|April 2014
4131|Recruiting|Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma||Drug:Bortezomib;  Drug:Cyclophosphamide;  Drug:Cytarabine;  Drug:DaunorubicinHydrochloride;  Drug:Dexamethasone;  Drug:DoxorubicinHydrochloride;  Drug:Etoposide;  Drug:HydrocortisoneSodiumSuccinate;  Drug:Ifosfamide;  Other:LaboratoryBiomarkerAnalysis;  Drug:LeucovorinCalcium;  Drug:Mercaptopurine;  Drug:Methotrexate;  Drug:Pegaspargase;  Radiation:RadiationTherapy;  Drug:Thioguanine;  Drug:VincristineSulfate|Interventional|Phase 3|NIH|EFS between modified ABFM backbone with or without bortezomib in all randomized patients;  Cumulativeincidencerates;  EFS;  EFS between very high risk (VHR) T-ALL patients treated with HR BFM intensification blocks who become MRD negative and those who remain MRD positive at the end of HR Block 3;  EFS between VHR T-LLy patients treated with HR BFM intensification blocks who have partial remission or complete remission with those who do not respond;  Incidence of toxicity associated with modified standard therapy including dexamethasone and additional pegaspargase as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|1400|NCT02112916|September 2014
4132|Completed|Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events||Drug:Bococizumab(PF-04950615;RN316);  Other:Placebo|Interventional|Phase 3|Industry|Percent Change from Baseline in fasting LDL-C at week 12.;  Change from baseline in fasting Lipid Parameters at Week 12.;  Change from baseline in fasting Lipid Parameters at Week 24.;  Change from baseline in fasting Lipid Parameters at Week 52.;  Proportion of subjects achieving fasting LDL-C &lt;=100 mg/dL and &lt;=70 mg/dL at week 12.;  Proportion of subjects achieving fasting LDL-C &lt;=100 mg/dL and &lt;=70 mg/dL at week 24.;  Proportion of subjects achieving fasting LDL-C &lt;=100 mg/dL and &lt;=70 mg/dL at week 52.;  PlasmaPF-04950615concentrationatweek12.;  PlasmaPF-04950615concentrationatweek24.;  PlasmaPF-04950615concentrationatweek52.|690|NCT02100514|October 2014
4133|Completed|Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes||Drug: Insulin glargine/lixisenatide (HOE901/AVE0010);  Drug:Insulinglargine(HOE901);  Drug:Metformin|Interventional|Phase 3|Industry|ChangeinHbA1cfrombaseline;  PercentageofpatientsreachingHbA1ctargets;  Change in 2-hour Post Prandial Glucose and in blood glucose excursion during standardized meal test from baseline to week 30;  Changeinbodyweightfrombaseline;  Change in 7-point Self-Monitoring Plasma Glucose profiles from baseline;  Change in daily dose of insulin glargine from baseline;  ChangeinFastingPlasmaGlucosefrombaseline;  Documented (plasma glucose less than or equal to 70 mg/dl) symptomatic hypoglycemia;  Severesymptomatichypoglycemia|736|NCT02058160|January 2014
4134|Completed|Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM||Drug: Insulin glargine/lixisenatide (HOE901/AVE0010);  Drug:Insulinglargine(HOE901);  Drug:Lixisenatide(AVE0010);  Drug:Metformin|Interventional|Phase 3|Industry|ChangeinHbA1cfrombaseline;  PercentageofpatientsreachingHbA1ctargets;  Change in 2-hour Post Prandial Glucose and in blood glucose excursion during standardized meal test from baseline;  Changeinbodyweightfrombaseline;  Change in 7-point Self Measured Plasma Glucose profiles from baseline;  Dailydoseofinsulinglargine;  ChangeinFastingPlasmaGlucosefrombaseline;  Documented (plasma glucose less than or equal to 70 mg/dl) symptomatic hypoglycemia;  Severesymptomatichypoglycemia|1170|NCT02058147|February 2014
4135|Recruiting|Antibiotic Safety (SCAMP)||Drug:ampicillinandmetronidazoleandgentamicin;  Drug:ampicillinandgentamicinandclindamycin;  Drug:gentamicinandPiperacillin-tazobactam;  Drug: standard of care antibiotics and metronidazole;  Drug: metronidazole clindamycin or peracillin-tazobactam|Interventional|Phase 2 / Phase 3|Other / Industry|Death;  Number of participants with therapeutic success at Day 30 and Day 90|284|NCT01994993|December 2013
4136|Completed|Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis||Drug:Placebo;  Drug:RifaximinSSD40mgIRtablet;  Drug:RifaximinSSD80mgIRtablet;  Drug:RifaximinSSD40mgSERtablet;  Drug:RifaximinSSD80mgSERtablet;  Drug: Rifaximin SSD 80 mg IR tablet + rifaximin SSD 80 mg SER tablet|Interventional|Phase 2|Industry|Time to all-cause mortality or hospitalization that is attributable to complications of liver disease.;  Overall hospitalization rate due to each complication of liver disease or all-cause mortality over the 24-week treatment period.;  Pharmacokineticsofrifaximinanditsmetabolite.;  Incidenceoftreatment-emergentadverseevents.;  Changeinclinicallaboratoryparameters.;  Changesinelectrocardiogrammeasurements;  Changesinindicesofhealthoutcomes|420|NCT01904409|June 2013
4137|Completed|A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate in Participants With Moderate to Severe Active Rheumatoid Arthritis||Drug:Placebo;  Drug:Tocilizumab;  Drug:methotrexate|Interventional|Phase 3|Industry|Change from Week 24 in disease activity score based on 28 joints count (DAS28) score at Week 40;  Percentage of participants achieving American college of rheumatology 50% improvement (ACR50) responses;  Percentage of participants with &gt;/= 1.2 points worsening (increase) in DAS28 Score;  Percentage of participants achieving DAS28 score &lt;2.6;  Percentage of participants achieving DAS 28 score &lt;/= 3.2;  Percentage of participants achieving American college of rheumatology 20% improvement (ACR20) responses;  Percentage of participants achieving American college of rheumatology 70% improvement (ACR70) responses;  Number of participants with adverse events (AEs) and serious adverse events (SAEs);  Change from Week 24 in bone erosion score (as measured by magnetic resonance imaging [MRI]) for participants in the MRI substudy;  Percentage of participants with anti-tocilizumab (TCZ) antibodies;  MeanTCZconcentration;  Mean soluble interleukin-6 (IL-6) receptor concentration|718|NCT01855789|November 2013
4138|Completed|Efficacy and Safety of PT003 PT005 and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)||Drug:GFFMDI;  Drug:GPMDI;  Drug:FFMDI;  Drug: Open-label tiotropium bromide inhalation powder (Spiriva&#174; Handihaler&#174;);  Drug:PlaceboMDI|Interventional|Phase 3|Industry|Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1);  TransitionDyspneaIndex(TDI)focalscore;  St.GeorgeRespiratoryQuestionnaire(SGRQ)score;  RescueVentolinhydrofluoroalkane(HFA)use;  Timetoonsetofaction;  PeakFEV1;  Change in trough FEV1 for GFF MDI and GP MDI vs. open-label tiotropium bromide inhalation powder|2103|NCT01854645|May 2013
4139|Completed|Study of Safety of Foradil in Patients With Persistent Asthma||Drug:Formoterol;  Drug:Fluticasonepropionate100mcg;  Drug:Fluticasonepropionate250mcg;  Drug:Fluticasonepropionate500mcg;  Drug:Placebo|Interventional|Phase 4|Industry|Combinedseriousasthmarelatedevents;  Asthma-relatedhospitalization;  Asthma-relatedintubation;  Asthma-relateddeaths;  Rescuemedicationuse;  Symptomandrescue-freedays;  Nighttimeawakenings;  AsthmacontrolQuestionnaire(ACQ-6)score|827|NCT01845025|May 2013
4140|Active not recruiting                  Has Results|Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya&#174;) Versus E/C/F/TDF (Stribild&#174;) in HIV-1 Positive Antiretroviral Treatment-Naive Adults||Drug:E/C/F/TAF;  Drug:E/C/F/TDF;  Drug:E/C/F/TDFPlacebo;  Drug:E/C/F/TAFPlacebo|Interventional|Phase 3|Industry|Percentage of Participants Achieving HIV-1 RNA &lt; 50 Copies/mL at Week 48;  Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 96;  Percentage of Participants With HIV-1 RNA &lt; 20 Copies/mL at Weeks 48 and 96;  Change From Baseline in CD4+ Cell Count at Week 48;  Change From Baseline in CD4+ Cell Count at Week 96;  Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48;  Percent Change From Baseline in Hip BMD at Week 96;  Percent Change From Baseline in Spine BMD at Week 48;  Percent Change From Baseline in Spine BMD at Week 96;  Change From Baseline in Serum Creatinine at Week 48;  Change From Baseline in Serum Creatinine at Week 96;  Percentage of Participants With Treatment-emergent Proteinuria Through Week 48;  Percentage of Participants With Treatment-emergent Proteinuria Through Week 96;  Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48;  Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96;  Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 48;  Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 96|872|NCT01797445|January 2013
4141|Recruiting|Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma||Drug:armodafinil150mg;  Other:Placebo;  Drug:armodafinil250mg|Interventional|Phase 3|Other / NIH|Response rate in terms of a clinically meaningful improvement in patient-reported fatigue at 8 weeks. A response is defined as an improvement of 2 points on the 0-10 scale of the usual fatigue on the Brief Fatigue Inventory (BFI).;  Fatigue: Brief Fatigue Inventory (BFI) Patient Reported Outcomes - Common Terminology Criteria for Adverse Events (PRO-CTCAE) and the summated score from the Patient Reported Outcomes Measurement Information System (PROMIS);  Cognitive function: As Assessed by Symbol Digit Modalities Test (SDMT) Controlled Oral Word Association Trail Making Test and the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog);  Quality of Life as measured by Linear Analogue Self Assessment (LASA);  Proportion of patients reporting adverse events via the CTCAE version 4.0 items|330|NCT01781468|June 2013
4142|Completed|Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain||Drug:Elagolix;  Other:Placebo|Interventional|Phase 3|Industry|EndometriosisAssociatedPain;  BoneMineralDensity(DXAScan);  EndometrialBiopsy;  TransvaginalUltrasound(TVU);  Clinical Laboratory Tests (standard laboratory values including hormones);  NumberofstudysubjectswithAdverseEvents|507|NCT01760954|December 2012
4143|Recruiting|Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry||Biological:BENLYSTA;  Other:SLEtreatment|Observational||Industry|Incidenceofadverseeventsofspecialinterest;  Changeinorgandamage;  ChangeinconcomitantSLEmedicationuse;  Changeindiseaseactivity;  Changeinsevereflares;  Changeinqualityoflife;  Changeinfatigue;  Rateofhospitalizations|3000|NCT01729455|February 2013
4144|Completed|Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes||Drug:semaglutide;  Drug:placebo|Interventional|Phase 3|Industry|Time from randomisation to first occurrence of a MACE defined as cardiovascular death non-fatal myocardial infarction or non-fatal stroke;  Time from randomisation to first occurrence of an expanded composite cardiovascular outcome;  Time from randomisation to each individual component of the expanded composite cardiovascular outcome;  Time from randomisation to first occurrence of all-cause death non-fatal MI or non-fatal stroke;  Change from baseline to last assessment during the treatment period in other treatment outcomes: glycosylated haemoglobin (HbA1c);  Change from baseline to last assessment during the treatment period in other treatment outcomes: fasting plasma glucose;  Change from baseline to last assessment during the treatment period in other treatment outcomes: body weight;  Change from baseline to last assessment during the treatment period in other treatment outcomes: lipid profile;  Change from baseline to last assessment during the treatment period in other treatment outcomes: urinary albumin to creatinine ratio;  Change from baseline to last assessment during the treatment period in other treatment outcomes: vital signs;  Incidence during the treatment period in other treatment outcomes: hypoglycaemic events;  Incidence during the treatment period in other treatment outcomes: adverse events;  Occurrence during the treatment period in other treatment outcomes: anti-semaglutide antibodies;  Change from baseline to last assessment during the treatment period in other treatment outcomes: patient reported outcome (PRO)|3297|NCT01720446|February 2013
4145|Completed                  Has Results|Co-administration of Olodaterol Respimat&#174; and Tiotropium Handihaler&#174;||Drug:Tiotropium;  Drug:PlacebomatchingOlodaterol;  Drug:Olodaterol|Interventional|Phase 3|Industry|FEV1 AUC0-3h Response at 12 Weeks; Defined as Change From Baseline to Week 12;  Trough FEV1 Response at 12 Weeks; Defined as Change From Baseline to Week 12;  Saint George Respiratory Questionnaire - (Total Score) Based on Combined 1222.51 and 1222.52 Data;  Peak FEV1 Response at 12 Weeks - Defined as Change From Baseline;  FVC AUC0-3h Response at 12 Weeks; Defined as Change From Baseline;  Peak FVC Response at 12 Weeks; Defined as Change From Baseline;  Trough FVC Response at 12 Weeks; Defined as Change From Baseline;  Rescue Medication Usage - Percentage of Rescue Free Days;  Rescue Medication Usage - Mean Weekly Rescue Usage (Total Daily);  Rescue Medication Usage - Mean Weekly Rescue Usage (Daytime);  Rescue Medication Usage - Mean Weekly Rescue Usage (Nighttime)|1137|NCT01696058|September 2012
4146|Completed|Phase 2b Multicenter Randomized Double-Blind Placebo- and Active-Controlled Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM||Drug:50mgPB1023;  Drug:70mgPB1023;  Drug:100mgPB1023;  Drug:Placebo(0.9%SodiumChloride);  Drug:Victoza&#174;;  Other:DietandExercise;  Drug:Metformin;  Drug:Sulfonylurea;  Drug:MetforminandSulfonylurea|Interventional|Phase 2|Industry|Evaluation of dose response of Glymera as measured as the change from baseline in HbA1c after 20 weeks of dosing with Glymera compared to placebo and active comparator;  Description of the incidence severity and duration of reported gastrointestinal side effects of Glymera compared to active comparator;  Compare change from baseline in weekly fasting plasma glucose (FPG) following 20 weeks of dosing compared to placebo and active comparator;  Describe the frequencies of adverse events in the treatment groups;  Proportion of subjects reaching HbA1c targets (&lt;7.0%) after 20 weeks of dosing|593|NCT01658501|July 2012
4147|Completed|A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain||Drug:Elagolix;  Other:placebo|Interventional|Phase 3|Industry|EndometriosisAssociatedPain;  BoneMineralDensity(DXAScan);  Endometrial Biopsy; Assessment of significant endometrial biopsy findings at baseline;  Endometrial Biopsy; Changes from baseline to final treatment in biopsy findings;  Transvaginal Ultrasound (TVU); Assessment of significant TVU findings at baseline;  Transvaginal Ultrasound (TVU); Changes from baseline to final treatment in TVU findings;  Clinical Laboratory Tests (Hematology Chemistry Urinalysis and Endocrine Panel);  NumberofstudysubjectswithAdverseEvents|872|NCT01620528|May 2012
4148|Active not recruiting|Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors||Biological:Bevacizumab;  Other:LaboratoryBiomarkerAnalysis;  Other:PharmacologicalStudy;  Other:Placebo;  Biological:Trebananib|Interventional|Phase 2|NIH|Incidenceofdose-limitingtoxicity(Cohort1);  PFS(Cohort2);  Feasibility of trebananib weekly in combination with bevacizumab every 2 weeks measured by the percentage of patients requiring dose reduction/interruption or discontinuation in the first 2 and subsequent courses (Cohort 1);  Incidence of treatment-related toxicity measured by CTCAE v. 4;  OS(Cohort2);  PFS;  Radiographic RR as measured by Revised Assessment in Neuro-Oncology response criteria (Cohort 2);  Tumor genotype expression profile and circulating angiogenesis biomarkers (Cohort 2)|75|NCT01609790|June 2012
4149|Completed                  Has Results|Combining Lesinurad With Allopurinol in Inadequate Responders||Drug:Lesinurad;  Drug:Placebo;  Drug:Allopurinol|Interventional|Phase 3|Industry|Proportion of Subjects With an sUA Level That is &lt; 6.0 mg/dL;  GoutFlares;  Tophus|607|NCT01510158|January 2012
4150|Terminated                  Has Results|Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes||Drug:Placebo;  Drug:Azilsartanmedoxomil|Interventional|Phase 3|Industry|Change From Baseline in Trough Sitting Clinic Systolic Blood Pressure;  Change From Baseline in Glycosylated Hemoglobin (HbA1c);  Change From Baseline in Trough Sitting Clinic Diastolic Blood Pressure;  Change From Baseline in the 24-hour Mean Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring;  Change From Baseline in the 24-hour Mean Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring;  Change From Baseline in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring;  Change From Baseline in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring;  Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring;  Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring;  Change From Baseline in the 12-hr Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring;  Change From Baseline in the 12-hr Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring;  Change From Baseline in the Trough (22 to 24 Hours After Dosing) Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring;  Change From Baseline in the Trough (22 to 24 Hours After Dosing) Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring;  Percentage of Participants Requiring Rescue Glycemic Therapy;  TimetoFirstGlycemicRescue;  ChangeFromBaselineinHbA1c;  ChangeFromBaselineinFastingPlasmaGlucose;  Change From Baseline to Week 6 and Week 24 in 2h Glucose During Oral Glucose Tolerance Testing (OGTT);  Change From Baseline to Week 6 and Week 24 in the Area Under the Plasma Concentration-time Curve (AUC) for Glucose During OGTT;  Change From Baseline to Week 6 and Week 24 in AUC for Insulin During OGTT;  Change From Baseline to Week 6 and Week 24 in AUC for C-peptide During OGTT;  Change From Baseline to Week 6 and Week 24 in AUC for Insulin/Glucose Ratio During OGTT;  Change From Baseline to Week 6 and Week 24 in AUC for Glucagon During OGTT|105|NCT01496430|January 2012
4151|Completed|A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome||Drug:250mgLX1033tablets;  Drug:Placebotablet|Interventional|Phase 2|Industry|Changefrombaselineinstoolconsistency;  Changefrombaselineinplasma5-HIAAlevels;  Change from baseline in worst abdominal pain in past 24 hours|373|NCT01494233|February 2012
4152|Completed                  Has Results|Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)||Drug:SSP-002358(0.1mg)+PPI;  Drug:SSP-002358(0.5mg)+PPI;  Drug:SSP-002358(2.0mg)+PPI;  Drug:Placebo+PPI|Interventional|Phase 2|Industry|Change From Baseline in Percent Regurgitation-Free Days Over Weeks 5-8;  Change From Baseline in Heartburn-Free Days Over Weeks 5-8;  Change From Baseline in the Persistent Reflux Integrated Symptom Measurement (PRISM) Liquid and Food Domain Scores Over Weeks 5-8;  Area Under the Steady-state Plasma Concentration-time Curve (AUC) of SSP-002358;  Steady State Maximum Plasma Concentration (Cmax) of SSP-002358;  Time to Maximum Plasma Concentration (Tmax) of SSP-002358|480|NCT01472939|February 2012
4153|Terminated                  Has Results|Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder||Drug:RamelteonSL;  Drug:Placebo|Interventional|Phase 3|Industry|TimeFromRandomizationtoAnyRelapse;  Time From Randomization to Relapse Due to Depression;  Time From Randomization to Relapse Due to Mania/Hypomania or Mixed Episode;  Time From Randomization to Relapse Due to Depression From PI Judgement and/or MADRS &#8805;16;  Time From Randomization to Relapse Due to Mania/Hypomania;  Time From Randomization to Relapse Due to Mixed Episode;  Time From Randomization to Relapse Due to Psychiatric Hospitalization for Bipolar Disorder;  Time From Randomization to Relapse Due to Electroconvulsive Therapy (ECT) Administration;  Time From Randomization to Relapse Due to Psychotropic Medication Change Prescribed for the Treatment of Depression Mania/Hypomania or Mixed Episodes;  Time From Randomization to Study Withdrawal for Any Reason;  Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) Total Score|642|NCT01467713|December 2011
4154|Terminated                  Has Results|Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder||Drug:RamelteonSL;  Drug:Placebo|Interventional|Phase 3|Industry|Change From Baseline in the Montgomery-&#197;sberg Depression Rating Scale (MADRS) Total Score at Week 6;  Change From Baseline in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-SF) Short Form Total Score at Week 6;  Percentage of Participants With MADRS Response at Week 6 With Response Defined as a &#8805; 50% Decrease in the MADRS Total Score From Baseline;  Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Week 6;  Clinical Global Impression Scale-Improvement (CGI-I) Score at Week 6;  Change From Baseline in Clinical Global Impression Scale-Severity (CGI-S) at Week 6;  Percentage of Participants With MADRS Remission at Week 6 With Remission Defined as a MADRS Total Score &#8804;10;  Change From Baseline in the Quick Inventory of Depressive Symptomatology - Self-Rated16 (QIDS-SR16) Total Score at Week 6;  Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 6|490|NCT01467700|December 2011
4155|Terminated|Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares||Drug:Rilonacept;  Drug:Placebo;  Drug:Allopurinol|Interventional|Phase 3|Industry|Summary of TEAEs (Treatment-Emergent Adverse Events);  Proportion of patients with 1 or more gout flares from day 1 to week 24;  Proportion of patients with 1 or more gout flares from day 1 to wk 52;  Proportion of patients with 2 or more gout flares from day 1 to wk 52.;  Proportion of patients with 2 or more gout flares from day 1 to week 24|219|NCT01459796|November 2011
4156|Completed|Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients||Drug:Canakinumab150mginprefilledsyringe|Interventional|Phase 3|Industry|Safety and tolerability of repeated dosing of canakinumab 150mg s.c. PFS;  Immunogenicity of repeated dosing of canakinumab 150mg s.c. PFS;  The time to the first new gouty arthritis flare since the entry into the core study;  Frequencyofnewgoutyarthritisflares;  Signsandsymptomsofnewgoutyarthritisflares;  Pharmacokinetics (PK) of canakinumab 150mg s.c. PFS|233|NCT01431638|August 2011
4157|Active not recruiting                  Has Results|Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia||Drug:Bortezomib;  Drug:Decitabine;  Other:LaboratoryBiomarkerAnalysis;  Other:PharmacologicalStudy;  Other:Quality-of-LifeAssessment;  Other:QuestionnaireAdministration|Interventional|Phase 2|NIH|OverallSurvival(OS)Time;  CompleteRemissionRate(CRandCRi);  Disease-freeSurvival(DFS);  Progression-freeSurvival;  AdverseEvents|165|NCT01420926|November 2011
4158|Completed|Evaluation of Clinical Equivalence Between Two Lubiprostone Products||Drug:Lubiprostone;  Drug:Placebo|Interventional|Phase 3|Industry|PrimaryAnalysis;  SafetyAnalysis|808|NCT01372423|May 2011
4159|Recruiting|Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy||Drug:caspofunginacetate;  Drug:fluconazole;  Other:laboratorybiomarkeranalysis|Interventional|Phase 3|Other / NIH|Time to development of proven or probable IFI defined according to criteria developed by the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG);  Time to development of proven or probably invasive aspergillosis (IA) defined according to the criteria developed by the EORTC/MSG;  Timetodeathduetoanycause;  Total days of empiric antifungal therapy while a patient is receiving prophylaxis;  Sensitivity specificity positive predictive value and negative predictive value of the galactomannan and beta-D glucan assays for the diagnosis of IFI or IA alone;  Results of the genotyping assays for single nucleotide polymorphism analysis|575|NCT01307579|April 2011
4160|Active not recruiting|Vitamin D and Breast Cancer Biomarkers in Female Patients||DietarySupplement:vitaminD;  Other:placebo|Interventional|Phase 3|Other / NIH|Change (between baseline and year 1) in mammographic density by the Boyd method compared between arms;  Change (between baseline and year 1) in serum biomarker (IGF1) compared between arms;  Change (between baseline and year 1) in tissue biomarker (atypia) compared between arms;  Change (between baseline and year 1) in tissue biomarker (Ki67) compared between arms;  Change (between baseline and year 1) in breast cancer biomarker (density) compared between arms;  Change (between baseline and year 1) in breast cancer biomarker (IGF1) compared between arms;  Change (between baseline and year 1) in breast cancer biomarkers (atypia) compared between arms;  Change (between baseline and year 1) in breast cancer biomarkers (Ki67) compared between arms;  Reported time spent outside as assessed using the Sunlight Questionnaire;  Change (between baseline and year 1) in breast density measurements|250|NCT01224678|October 2010
4161|Recruiting|Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma||Drug:Cyclophosphamide;  Drug:Cytarabine;  Drug:Dexamethasone;  Drug:DoxorubicinHydrochloride;  Other:LaboratoryBiomarkerAnalysis;  Drug:LeucovorinCalcium;  Drug:Mercaptopurine;  Drug:Methotrexate;  Drug:Pegaspargase;  Other:Quality-of-LifeAssessment;  Other:QuestionnaireAdministration;  Drug:Thioguanine;  Drug:VincristineSulfate|Interventional|Phase 3|Other / NIH|Determination of whether less intensive therapy will maintain DFS &gt;= 95% for LR patients randomized to 1 of 2 low-intensity regimens;  Determination of whether the 5-year DFS in AR patients is adversely affected by the reduced pulses in maintenance;  DFSforB-LLypatients;  DFSforDownsyndromepatients;  Improvement in DFS from 93% to 96% in AR patients based on the methotrexate randomization;  Burden of therapy in AR patients overall at different time points during and at the end of therapy;  Burden of therapy in AR patients randomized to every 4-week vs every 12-week pulses during maintenance therapy|9022|NCT01190930|August 2010
4162|Active not recruiting|Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma||Radiation: 3-Dimensional Conformal Radiation Therapy;  Radiation:Intensity-ModulatedRadiationTherapy;  Other:LaboratoryBiomarkerAnalysis;  Drug:Vorinostat|Interventional|Phase 1 / Phase 2|NIH|EFS(PhaseII);  Incidenceoftoxicities(PhaseII);  MTD of vorinostat defined as the maximum dose at which fewer than one-third of patients experience dose-limiting toxicity (DLT) during chemoradiation graded using Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0) (Phase I);  ChangeinH3andH4acetylationlevelsinPBMCs;  ChangeinNHEJactivityinPBMCs;  Levels of DNA repair proteins in paraffin-embedded blocks measured via immunohistochemistry or Western analysis;  OS(PhaseII)|80|NCT01189266|August 2010
4163|Completed|Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System||Drug:AG200-15transdermalpatch;  Drug:OralContraceptive|Interventional|Phase 3|Industry|Pregnancy|1504|NCT01181479|August 2010
4164|Recruiting|Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia||Other:CytologySpecimenCollectionProcedure;  Other:LaboratoryBiomarkerAnalysis|Observational||Other / NIH|Classificationdataforcorrelativestudies;  Development of a central reference guide for required and research ALL studies;  Development of a risk classification system to be used to assign patients to treatment on COG frontline ALL treatment studies;  Development of mechanism for optional leukemia and germline specimens for current and future research|14250|NCT01142427|August 2010
4165|Completed                  Has Results|A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.||Biological:albiglutide;  Drug:liraglutide|Interventional|Phase 3|Industry|Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 32;  Mean Change From Baseline in HbA1c at Weeks 4 6 12 18 and 26;  Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 32;  Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 1 2 3 4 6 12 18 and 26;  Number of Participants Who Achieved HbA1c Response Level of &lt;6.5% and &lt;7.0% at Week 32;  TimetoHyperglycemiaRescueatWeek32;  Mean Change From Baseline in Body Weight at Week 32|841|NCT01128894|May 2010
4166|Terminated                  Has Results|Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015||Drug:Buprenorphinetransdermalpatch|Interventional|Phase 3|Industry|Number of Participants With Adverse Events (AEs) as a Measure of Safety|354|NCT01125917|June 2004
4167|Recruiting|Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma||Drug:ABVD;  Drug:BEACOPP;  Radiation:radiationtherapy|Interventional|Phase 2|Other / NIH|Progression-free survival at 36 months from enrollment;  Completeresponserate;  Standard uptake values (SUVs) for target sites measured at baseline after course 2 and after completion of therapy;  Determination of the optimal cutoff for absolute decrease in maximum SUV body weight (SUVbw) and SUV lean body mass (SUVlbm) relative uptake in tumor vs various reference anatomic sites IHP criteria as well as various cutoffs for post-therapy maxim ...;  Volumetric vs 2-dimensional (2-D) measurement changes for target lesions between baseline and after course 2 at the end of chemotherapy and after IFRT;  Comparison of qualitative and semiquantitative fludeoxyglucose-PET findings/changes 2-D and volumetric CT changes and combinatorial analyses (PET + dedicated CT data) with molecular parameters and conventional parameters|123|NCT01118026|September 2010
4168|Completed                  Has Results|A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children||Biological:Q/LAIV(MEDI3250);  Biological:FluMist/B/Yamagata;  Biological:FluMist/B/Victoria|Interventional|Phase 3|Industry|The 4 Post-dose Strain-specific Serum Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titers (GMT) in the Q/LAIV (MEDI3250) Arm Are Noninferior to Those in the Comparator FluMist Group.;  The Percent of Participants (Regardless of Serostatus) Within Each Treatment Arm Who Experienced a Seroresponse to the A/H1N1 Strain Post Immunogenicity Dose;  Percent of Participants (Regardless of Serostatus) Within Each Treatment Arm Who Experienced a Seroresponse to the A/H3N2 Strain Post Immunogenicity Dose;  Percent of Participants (Regardless of Serostatus) Within Each Treatment Arm Who Experienced a Seroresponse to the B/Yamagata Strain Post Immunogenicity Dose;  Percent of Participants (Regardless of Serostatus) Within Each Treatment Arm Who Experienced a Seroresponse to the B/Victoria Strain Post Immunogenicity Dose;  Percent of Serosusceptible Participants Within Each Treatment Arm Who Experienced a Seroresponse to the A/H1N1 Strain Post Immunogenicity Dose;  Percent of Serosusceptible Participants Within Each Treatment Arm Who Experience Seroresponse to the A/H3N2 Strain Post Immunogenicity Dose;  Percent of Serosusceptible Participants Within Each Treatment Arm Who Experience Seroresponse to the B/Yamagata Strain Post Immunogenicity Dose;  Percent of Serosusceptible Participants Within Each Treatment Arm Who Experience Seroresponse to the B/Victoria Strain Post Immunogenicity Dose;  Percent of Seronegative Participants Within Each Treatment Arm Who Experienced a Seroresponse to the A/H1N1 Strain Post Immunogenicity Dose;  Percent of Seronegative Participants Within Each Treatment Arm Who Experienced a Seroresponse to the A/H3N2 Strain Post Immunogenicity Dose;  Percent of Seronegative Participants Within Each Treatment Arm Who Experienced a Seroresponse to the B/Yamagata Strain Post Immunogenicity Dose;  Percent of Seronegative Participants Within Each Treatment Arm Who Experienced a Seroresponse to the B/Victoria Strain Post Immunogenicity Dose;  Percent of Participants (Regardless of Serostatus) Who Achieved an A/H1N1 or A/H3N2 Strain-specific HAI Antibody Titer &#8805; 32 Post Immunogenicity Dose;  Percent of Participants (Regardless of Serostatus) Who Achieved a B/Yamagata HAI Antibody Titer &#8805; 32 Post Immunogenicity Dose;  Percent of Participants (Regardless of Serostatus) Who Achieved a B/Victoria HAI Antibody Titer &#8805; 32 Post Immunogenicity Dose;  Percent of Serosusceptible Participants Who Achieved an A/H1N1 HAI Antibody Titer &#8805; 32 Post Immunogenicity Dose;  Percent of Serosusceptible Participants Who Achieved an A/H3N2 HAI Antibody Titer &#8805; 32 Post Immunogenicity Dose;  Percent of Serosusceptible Participants Who Achieved a B/Yamagata HAI Antibody Titer &#8805; 32 Post Immunogenicity Dose;  Percent of Serosusceptible Participants Who Achieved a B/Victoria HAI Antibody Titer &#8805; 32 Post Immunogenicity Dose;  Percent of Seronegative Participants Who Achieved an A/H1N1 HAI Antibody Titer &#8805; 32 Post Immunogenicity Dose;  Percent of Seronegative Participants Who Achieved an A/H3N2 HAI Antibody Titer &#8805; 32 Post Immunogenicity Dose;  Percent of Seronegative Participants Who Achieved a B/Yamagata HAI Antibody Titer &#8805; 32 Post Immunogenicity Dose;  Percent of Seronegative Participants Who Achieved a B/Victoria HAI Antibody Titer &#8805; 32 Post Immunogenicity Dose;  Percent of All Participants Experiencing Each Solicited Symptom From Administration of Investigational Product Through 14 Days Post Dose 1;  Percent of Two-dose Participants Experiencing Each Solicited Symptom From Administration of Investigational Product Through 14 Days Post Dose 1;  Percent of Two-dose Participants Experiencing Each Solicited Symptom From Administration of Dose 2 During Days 0-14 Post Dose 2;  Percent of All Participants Experiencing Any Adverse Event From Administration of Investigational Product Through Day 28 Post Dose 1;  Percent of Two-dose Participants Experiencing Any Adverse Event From Administration of Investigational Product Through Day 28 Post Dose 1;  Percent of Two-dose Participants Experiencing Any Adverse Event From Administration of Dose 2 Through 28 Days Post Dose 2;  Percent of All Participants Reporting Any Serious Adverse Event (SAE) From Administration of Investigational Product Through Day 28 Post Dose 1;  Percent of Two-dose Participants Reporting Any SAE From Administration of Dose 2 During Days 0-28 Post Dose 2;  Percent of All Participants Reporting Any SAE From Administration of Investigational Product Through 180 Days Post Last Dose;  Percent of All Participants Reporting Any New Onset Chronic Disease (NOCD) From Administration of Investigational Product Through 180 Days Post Last Dose|2312|NCT01091246|March 2010
4169|Completed                  Has Results|PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-na&#239;ve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b||Drug:Peginterferonalfa-2a[Pegasys];  Drug:Peginterferonalfa-2b[PegIntron&#174;]|Observational||Industry|Percentage of Participants With Sustained Virological Response by Type of Peginterferon and Genotype in Modified All Treated Population;  Percentage of Participants With Sustained Virological Response by Type of Peginterferon and Genotype in Per Protocol Population;  Percentage of Participants With Modified Sustained Virological Response Over Time by Type of Peginterferon and Genotype in Modified All Treated Population;  Percentage of Participants With Modified Sustained Virological Response by Type of Peginterferon and Genotype in Per Protocol Population;  Percentage of Participants With Predictive Values of Virological Response by Week 4 and 12 on Modified Sustained Virological Response After Treatment Initiation in Modified All Treated Population;  Percentage of Participants With Predictive Values of Virological Response by Week 4 and 12 on Modified Sustained Virological Response After Treatment Initiation in Per Protocol Population;  Percentage of Participants With Virological Response by Type of Peginterferon and Genotype in Modified All Treated Population Over Time;  Percentage of Participants With Virological Response by Type of Peginterferon and Genotype in Per Protocol Population Over Time;  Percentage of Participants With Modified Virological Response by Type of Peginterferon and Genotype in Modified All Treated Population Over Time;  Percentage of Participants With Modified Virological Response by Type of Peginterferon and Genotype in Per Protocol Population Over Time;  Percentage of Participants With at Least a 2-log10 Drop in Hepatitis C Virus Ribonucleic Acid in Modified All Treated Population at Week 2 Week 4 and Week 12;  Percentage of Participants With at Least a 2-log10 Drop in Hepatitis C Virus Ribonucleic Acid in Per Protocol Population at Week 2 Week 4 and Week 12;  Percentage of Participants With at Least a 1-log10 Drop in Hepatitis C Virus Ribonucleic Acid in Modified All Treated Population at Week 2 Week 4 and Week 12;  Percentage of Participants With at Least a 1-log10 Drop in Hepatitis C Virus Ribonucleic Acid in Per-Protocol Population at Week 2 Week 4 and Week 12;  Percentage of Participants With Predictive Values of Virological Response on Modified Sustained Virological Response After Treatment Initiation in Modified All Treated Population;  Percentage of Participants With Predictive Values of Virological Response on Modified Sustained Virological Response After Treatment Initiation in Per Protocol Population;  Number of Participants With Response by Disjoint Categories in Modified All-Treated Population at Week 4 and Week 12;  Number of Participants With Response by Disjoint Categories in Per-Protocol Population at Week 4 and Week 12;  Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Modified All-Treated Population at 12 Weeks After End of Treatment;  Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Modified All-Treated Population at 24 Weeks After End of Treatment;  Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Per-Protocol Population at 12 Weeks After End of Treatment;  Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Per-Protocol Population at 24 Weeks After End of Treatment|1656|NCT01066819|January 2008
4170|Completed|Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy||Drug:XOMA052;  Drug:Placebo|Interventional|Phase 2|Industry|Mean change from baseline (Day 0 pre-dose) in HbA1c at Day 182;  Safety assessed by pre- and post-treatment serial measurements of vital signs clinical laboratory assessments daily fasting blood glucose measured by the subject using a glucose monitor and treatment-emergent adverse events.;  Diabetic parameters: mean change from baseline (Day 0 pre-dose) at measured time points;  Inflammatory markers: mean change from baseline (Day 0 pre-dose) at measured time points;  Markers of cardiovascular disease: mean change from baseline (Day 0 pre-dose) at measured time points;  SerumlevelsofXOMA052(selectsitesonly)|421|NCT01066715|January 2010
4171|Completed|Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (&#8805; 200 and &lt; 500 mg/dL)||Drug:AMR101(ethylicosapentate);  Drug:Placebo|Interventional|Phase 3|Other|Difference between AMR101 (ethyl icosapentate) and placebo treatment groups in triglyceride lowering effect;  Difference between AMR101 (ethyl icosapentate) and placebo treatment groups in other lipid and biomarker levels|702|NCT01047501|December 2009
4172|Completed|Novel Influenza A (H1N1) Surveillance Registry|||Observational||NIH||894|NCT01046331|October 2009
4173|Completed|A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease||Drug:placebo;  Drug:taspoglutide|Interventional|Phase 3|Industry|Time to cardiovascular composite primary endpoints;  Secondarycardiovascularcompositeendpoints;  Individual components of primary cardiovascular composite endpoints;  Totalmortality;  Metabolic and renal function parameters: HbA1c fasting plasma glucose body weight lipid profile albumin/creatinine ratio (ACR) albuminuria glomerular filtration rate (GFR)|2118|NCT01018173|January 2010
4174|Terminated                  Has Results|Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia||Biological:alemtuzumab;  Biological:rituximab|Interventional|Phase 2|Other / NIH|Proportion of Patients With Complete Response (CR);  ProportionofPatientsWithOverallResponse(OR);  OverallSurvival(OS);  Progression-freeSurvival(PFS);  TimetoResponse;  DurationofResponse|31|NCT01013961|October 2010
4175|Completed|S9007 Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers||Genetic:cytogeneticanalysis;  Genetic:fluorescenceinsituhybridization|Observational||Other / NIH|Maintain and expand a database of cytogenetic information on leukemia patients.|3341|NCT00996047|July 1991
4176|Recruiting|Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer||Drug:Cisplatin;  Drug:DoxorubicinHydrochloride;  Drug:Fluorouracil;  Drug:IrinotecanHydrochloride;  Other:LaboratoryBiomarkerAnalysis;  Procedure:LiverTransplantation;  Drug:Temsirolimus;  Procedure:TherapeuticConventionalSurgery;  Drug:VincristineSulfate|Interventional|Phase 3|NIH|Diseasestatusattheendof2coursesoftherapy;  Event-freesurvival;  Incidence of adverse events graded according to Common Terminology Criteria for Adverse Events version 4.0;  Rateofdeath;  Feasibilityofreferralforlivertransplantation|253|NCT00980460|September 2009
4177|Completed                  Has Results|The Dual Antiplatelet Therapy Study (DAPT Study)||Drug:Placebo&amp;Aspirin;  Drug:Clopidogrel&amp;AspirinPrasugrel&amp;Aspirin|Interventional|Phase 4|Other / Industry|MACCE (Death Myocardial Infarction or Stroke) - Randomized DES ITT;  Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT;  GUSTO Severe or Moderate Bleeding - Randomized DES ITT;  MACCE (Death Myocardial Infarction or Stroke) - Propensity Matched DES vs. BMS;  Definite or Probable Stent Thrombosis (ST) - Propensity Matched DES vs. BMS;  MACCE (Death Myocardial Infarction or Stroke) - Randomized BMS ITT;  Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT;  GUSTO Severe or Moderate Bleeding - Randomized BMS ITT|25682|NCT00977938|October 2009
4178|Terminated                  Has Results|A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751871) In Patients With Extensive-Stage Small Cell Lung Cancer||Drug:figitumumab;  Drug:Cisplatin(OrCarboplatin);  Drug:Etoposide|Interventional|Phase 2|Industry|Progression-FreeSurvival(PFS);  NumberofParticipantsWithObjectiveResponse;  OverallSurvival(OS);  Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs);  Maximum Observed Plasma Concentration (Cmax) of Figitumumab;  Minimum Observed Plasma Trough Concentration (Cmin) of Figitumumab;  Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Etoposide;  Maximum Observed Plasma Concentration (Cmax) of Etoposide;  Percentage of Participants Reporting Positive Anti-Drug Antibodies (ADA) Response for Figitumumab;  CancerDyspneaScale(CDS)Score;  NumericRatingScale(NRS)Score;  Pre-treatment Levels of Tumor Biomarkers Involved in Insulin-Like Growth Factor 1 (IGF-I) Signaling Pathway;  Levels of Serum Circulating Insulin-like Growth Factor (IGF) Pathway Related Markers;  Number of Total Circulating Tumor-Related Cells (CTCs) and Insulin-Like Growth Factor 1 Receptor (IGF-IR)-Expressing CTCs|9|NCT00977561|April 2010
4179|Completed|Study of Blood Samples From Newborns With Down Syndrome||Genetic:DNAanalysis;  Genetic:RNAanalysis;  Genetic:cytogeneticanalysis;  Genetic:fluorescenceinsituhybridization;  Genetic:geneexpressionanalysis;  Genetic:microarrayanalysis;  Genetic:mutationanalysis;  Genetic:polymerasechainreaction;  Genetic:polymorphismanalysis;  Other:flowcytometry;  Other:laboratorybiomarkeranalysis;  Other:pharmacologicalstudy|Observational||Other / NIH|Event-freesurvival;  Overallsurvival;  Transient myeloproliferative disorder (TMD)-related mortality;  Incidence of subsequent leukemia for patients with resolved TMD|180|NCT00959283|February 2009
4180|Completed                  Has Results|Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation||Drug:Linaclotide290micrograms;  Drug:Matchingplacebo|Interventional|Phase 3|Industry|Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder 9 Out of 12 Weeks;  Complete Spontaneous Bowel Movement (CSBM) 3+1 Responder 9 Out of 12 Weeks;  AbdominalPainResponder9Outof12Weeks;  Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder 6 Out of 12 Weeks.;  12-Week Complete Spontaneous Bowel Movement (CSBM) Frequency Rate;  12-Week Spontaneous Bowl Movement (SBM) Frequency Rate;  12-WeekStoolConsistency;  12-WeekSeverityofStraining;  12-WeekChangeinAbdominalPainScore;  12-WeekChangeinAbdominalDiscomfort;  12-WeekChangeinBloating;  Complete Spontaneous Bowl Movement (CSBM) Responder for 6 Weeks Out of 12 Weeks of Treatment;  AbdominalPainResponderfor6Outof12Weeks;  12-WeekPercentofAbdominalPain-free(APF)Days|803|NCT00948818|July 2009
4181|Completed|A Phase 3 Multi-Center Study of Gemcitabine/Carboplatin With or Without BSI-201 in Patients With ER- PR- and Her2-Negative Metastatic Breast Cancer||Drug:gemcitabine/carboplatin;  Drug:Iniparib|Interventional|Phase 3|Industry|progressionfreesurvival;  Overallsurvival;  Bestoverallresponse;  Objectiveresponserate|519|NCT00938652|July 2009
4182|Completed|S9910 Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer||Other:biologicsamplepreservationprocedure|Observational||Other / NIH|Maintenance and expansion of tissue repositories of highly characterized samples from patients with ALL CLL AML CML or myelodysplastic syndromes|1294|NCT00919425|April 1999
4183|Recruiting|Collecting and Storing Tissue Blood and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma||Other:biologicsamplepreservationprocedure;  Other:laboratorybiomarkeranalysis|Observational||Other / NIH|Collection of human tumor tissue and other biological specimens (blood serum and bone marrow) from patients with rhabdomyosarcoma or non-rhabdomyosarcoma soft tissue sarcoma;  Collection of clinical data on patients who are not being treated on a COG therapeutic study|1500|NCT00919269|March 1999
4184|Recruiting|Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma||Other:laboratorybiomarkeranalysis;  Other:cytologyspecimencollectionprocedure|Observational||Other / NIH|Factors currently used for risk-group assignment (DNA content MYCN copy number and tumor histology);  Prevalence of 1p 11q 14q and 17q allelic status;  MYCNcopynumberbyquantitativePCR;  Expression pattern of neurotrophin-related genes in diagnostic neuroblastoma tumors;  Presence of rare tumor cells in biological specimens by RT-PCR;  Database of the known biologic prognostic factors for patients on therapeutic studies;  MYCNstatuspertumor;  MYCNstatusperblood;  IncidenceofOMA;  Incidenceofspinalcordcompression;  Presentationwithmultifocalprimarytumors|10000|NCT00904241|November 2000
4185|Active not recruiting|Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia||Genetic:DNAanalysis;  Genetic:DNAmethylationanalysis;  Genetic:geneexpressionanalysis;  Genetic:mutationanalysis;  Genetic:polymerasechainreaction;  Genetic: reverse transcriptase-polymerase chain reaction;  Other:highperformanceliquidchromatography;  Other:laboratorybiomarkeranalysis|Observational||Other / NIH|Presence of molecular markers that fulfill eligibility criteria in diagnostic samples from AML patients considered for CALGB therapeutic protocols;  Frequency of specific single-gene markers over-expression and levels of promoter methylation of specific genes;  Predictivevalueofspecificsingle-genemarkers;  Microarray multi-gene and multi-miR expression signatures|529|NCT00900224|June 2008
4186|Recruiting|Study of Kidney Tumors in Younger Patients||Other:laboratorybiomarkeranalysis;  Other:cytologyspecimencollectionprocedure|Observational||Other / NIH|Disease-freesurvival;  Overallsurvival;  Loss of heterozygosity (LOH testing discontinued as of April 2014)|5000|NCT00898365|February 2006
4187|Recruiting|Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma||Other:CytologySpecimenCollectionProcedure;  Other:LaboratoryBiomarkerAnalysis|Observational||Other / NIH|BankingoftumorcellsandgermlineDNA|528|NCT00897325|September 2006
4188|Active not recruiting|Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer||Drug:neratinib;  Other:placebo|Interventional|Phase 3|Industry|diseasefreesurvival(DFS);  TimetoDistantRecurrence(TTDR);  Disease free survival including ductal carcinoma in situ (DFS-DCIS);  Distantdiseasefreesurvival(DDFS);  Incidenceofcentralnervoussystemrecurrence;  Overallsurvival;  Shortandlongtermsafetyofneratinib|2840|NCT00878709|July 2009
4189|Completed                  Has Results|Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease||Drug:Indacaterol150&#956;g;  Drug:Tiotropium18&#956;g;  Drug:Placebotoindacaterol|Interventional|Phase 3|Industry|Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 8 Hours Post-dose at the End of the Study (Week 12 Day 84);  Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at the End of the Study (Week 12 + 1 Day Day 85);  Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 8 Hours Post-dose on Day 1;  Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose on Day 2;  Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 4 Hours Post-dose on Day 1;  Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 4 Hours Post-dose at the End of the Study (Week 12 Day 84)|1142|NCT00877383|April 2009
4190|Terminated                  Has Results|Phase III Acute Coronary Syndrome||Drug:Apixaban;  Drug:Placebo|Interventional|Phase 3|Industry / Other|Event Rate of Cardiovascular Death Myocardial Infarction or Ischemic Stroke During the Intended Treatment Period - Randomized Participants;  Event Rate of Confirmed Major Bleeding Using Thrombolysis in Myocardial Infarction (TIMI) Criteria During the Treatment Period - Treated Participants;  Event Rate of Unstable Angina (UA) During the Intended Treatment Period - Randomized Participants;  Event Rate of Stroke During the Intended Treatment Period - Randomized Participants;  Event Rate of Myocardial Infarction (MI) During the Intended Treatment Period - Randomized Participants;  Event Rate of Stent Thrombosis During the Intended Treatment Period - Randomized Participants;  Event Rate of Composite of Cardiovascular Death Myocardial Infarction Unstable Angina or Ischemic Stroke During the Intended Treatment Period - Randomized Participants;  Event Rate of Composite of Cardiovascular Death Fatal Bleed Myocardial Infarction or Stroke During the Intended Treatment Period - Randomized Participants;  Event Rate of Composite of All-Cause Death Myocardial Infarction or Stroke During the Intended Treatment Period - Randomized Participants;  Event Rate of Confirmed Major Bleeding Using International Society on Thrombosis and Hemostasis (ISTH) Criteria During the Treatment Period - Treated Participants;  Event Rate of Confirmed Major Bleeding or Clinically Relevant Non-Major Bleeding (CRNM) Using ISTH Criteria During the Treatment Period - Treated Participants;  Event Rate of All Bleeding Reported by the Investigator During the Treatment Period - Treated Participants|7484|NCT00831441|March 2009
4191|Completed                  Has Results|RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial||Drug:dabigatrandose1;  Drug:dabigatrandose2|Interventional|Phase 3|Industry|Major Bleeding Annualized Rate of Subjects With Major Bleeds;  StrokeAnnualizedRateofSubjectsWithStroke;  Non CNS Systemic Embolism (SEE) Annualized Rate of Subjects With Non-CNS SEE;  Pulmonary Embolism (PE) Annualized Rate of Subjects With PE;  Acute Myocardial Infarction (MI) Annualized Rate of Subjects With MI;  Deep Vein Thrombosis Annualized Rate of Subjects With DVT;  DeathAnnualizedRateofSubjectDeath;  Annualized Rate of Subjects With Composite Incidence of Stroke Non CNS Systemic Embolism (SEE);  Annualized Rate of Subjects With Composite Incidence of Stroke Non CNS Systemic Embolism (SEE) and All Cause Death;  Annualized Rate of Subjects With Composite Incidence of Stroke Non CNS Systemic Embolism (SEE) Pulmonary Embolism (PE) Myocardial Infarction Vascular Death;  Annualized Rate of Subjects With Composite Incidence of Stroke Non CNS Systemic Embolism (SEE) Pulmonary Embolism (PE) Myocardial Infarction (MI) All Cause Death and Major Bleed;  AnnualizedRateofSubjectsWithMinorBleeds;  Annualized Rate of Subjects With Any Bleeds (Major Plus Minor);  Annualized Rate of Subjects With Intra-Cranial Hemorrhage (ICH)|5897|NCT00808067|November 2008
4192|Completed                  Has Results|Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants||Biological:MenACWY-CRM197;  Biological: DTaP (Diptheria Tetanus Pertussis) Vaccine;  Biological:Hib(Haemophilusinfluenzab)Vaccine;  Biological: IPV (Inactivated Polio Vaccine) Vaccine;  Biological:PneumococcalconjugateVaccine;  Biological: MMR (Measles Mumps and Rubella) Vaccine;  Biological:VaricellaVaccine;  Biological:HepatitisAVirus|Interventional|Phase 3|Industry|Percentages of Subjects With At Least One Severe Systemic Reaction After Any Vaccination;  Percentages of Subjects With At Least One Serious Adverse Event During the Entire Study Period;  Percentages of Subjects Reporting Solicited Adverse Events After Each Vaccination;  Number of Subjects Who Reported Unsolicited Adverse Events After Any Vaccination|7744|NCT00806195|December 2008
4193|Completed|The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial||Drug:Darapladib;  Drug:Placebo|Interventional|Phase 3|Industry|Time to the first occurrence of any component of the composite of Major Adverse Cardiovascular Events [MACE: CV death (death due to a cardiovasacular cause) non-fatal myocardial infarction non-fatal stroke];  The composite measure of major coronary events that include the time to first occurrence of coronary heart disease death non-fatal myocardial infarction or urgent coronary revascularization for myocardial ischemia;  The composite measure of total coronary events that include the time to first occurrence of coronary heart disease death non-fatal myocardial infarction hospitalization for unstable angina  or any coronary revascularization procedure;  The time to individual components of MACE [cardiovascular death myocardial infarction (fatal and non-fatal) stroke (fatal and non-fatal) ];  The time to the first occurrence of any component of the composite of all-cause mortality non-fatal myocardial infarction or non-fatal stroke;  Allcausemortality|15828|NCT00799903|December 2008
4194|Completed                  Has Results|A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet Sumatriptan Tablet and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period||Drug: sumatriptan and naproxen sodium combination tablet;  Drug:sumatriptantablet;  Drug:naproxensodiumtablet|Interventional|Phase 4|Industry|Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen;  Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan and Naproxen;  Treatment Difference in Systolic and Diastolic Blood Pressure Mean Changes From Baseline at 6 Months Between Sumatriptan/Naproxen and Sumatriptan;  Treatment Difference in Systolic and Diastolic Blood Pressure Mean Changes From Baseline at 6 Months Between Sumatriptan/Naproxen and Naproxen;  Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating on Average &lt;4 Migraines 4-6 Migraines &gt;=4 Migraines and &gt;6 Migraines Per Month;  Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating on Average &lt;1.3 Times Per Migraine 1.3-1.7 Times Per Migraine and &gt;1.7 Times Per Migraine;  Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating on Average With &lt;6 6-10 &gt;=6 10-14 and &gt;14 Doses Per Month;  Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating With &lt;30 Total Doses 30-60 Total Doses &gt;=30 60-90 Total Doses and &gt;90 Total Doses;  Number of Participants With an Increase of &gt;=5 mmHg From the Baseline Systolic Blood Pressure for the Average of Any Given Two-day Consecutive Collection of Blood Pressure Measurements;  Number of Participants With an Increase of &gt;=3 mmHg From the Baseline Diastolic Blood Pressure for the Average of Any Given Two-day Consecutive Collection of Blood Pressure Measurements;  Number of Participants With a Consecutive 2-day Average Systolic Blood Pressure of &gt;=140 mmHg During the Study;  Number of Participants With a Consecutive 2-day Average Diastolic Blood Pressure of &gt;=90 mmHg;  Time to the First Day With an Average Systolic Blood Pressure Increase of &gt;=5 mmHg From the Baseline Systolic Blood Pressure;  Time to the First Day With an Average Diastolic Blood Pressure Increase of &gt;=3 mmHg From the Baseline Diastolic Blood Pressure;  Number of Participants Withdrawn From the Study Due to Blood Pressure Changes|407|NCT00792636|November 2008
4195|Completed|An Open-Label Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation||Drug:Linaclotide300micrograms|Interventional|Phase 3|Industry|Safety will be assessed descriptively by summarizing AEs clinical laboratory test results vital sign measurements and ECG measurements.|1557|NCT00765999|October 2008
4196|Completed                  Has Results|Trial to Evaluate the Efficacy of GSK Biologicals&apos; Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older||Biological: GSK Bio&apos;s influenza vaccine GSK2186877A;  Biological:FluarixTM|Interventional|Phase 3|Industry|Number of Subjects Reporting Polymerase Chain Reaction (PCR)-Confirmed Influenza A and/or B Infection.;  Serum Hemagglutination-inhibition (HI) Antibody Titers Against Each of the 3 Vaccine Influenza Strains in the FluNG Groups.;  Number of Subjects Reporting Culture-confirmed Influenza A and/or B Infection.;  Number of Subjects Reporting Pneumonia or Clinical Influenza After the First Dose of Vaccine.;  Number of Subjects Reporting All-cause Death After the First Dose of Vaccine.;  Number of Subjects Reporting Hospitalization Due to Respiratory Diseases After the First Dose of Vaccine;  Number of Subjects Reporting Any Severe (Grade 3) and Related to Vaccination Adverse Events (AEs) of Specific Interest Including Autoimmune Disease (AID).;  Number of Subjects Reporting Any and Related to Vaccination Serious Adverse Events (SAEs).;  Number of Subjects Reporting Any and Severe (Grade 3) Solicited Local Symptoms.;  Number of Days With Any Grade of Solicited Local Symptoms;  Number of Subjects Reporting Any and Severe (Grade 3) Solicited Local Symptoms;  Number of Days With Any Grade of Solicited Local Symptoms.;  Number of Subjects Reporting Any Severe (Grade 3) and Related to Vaccination Solicited General Symptoms;  Number of Days With Any Grade of Solicited General Symptoms;  Number of Subjects Reporting Any Severe (Grade 3) and Related Solicited General Symptoms.;  Number of Days With Any Grade of Solicited General Symptoms.;  Number of Subjects Reporting Any Severe (Grade 3) and Related to Vaccination Unsolicited Adverse Events (AEs).;  Number of Subjects Reporting Any Severe (Grade 3) and Related to Vaccination Unsolicited AEs With Medically Attended Visit;  Number of Subjects Reporting Any Severe (Grade 3) and Related to Vaccination Unsolicited AEs With Medically Attended Visit.;  Serum Hemagglutination-inhibition (HI) Antibody Titer Against Each of the 3 Vaccine Influenza Strains.;  Serum Hemagglutination-inhibition (HI) Antibody Titer Against Each of the 3 Vaccine Influenza Strains;  Number of Seroconverted Subjects for HI Antibodies Against Each of the 3 Vaccine Influenza Strains|43695|NCT00753272|September 2008
4197|Recruiting|Long-Term Follow-Up of Patients Who Have Participated in Children&apos;s Oncology Group Studies||Procedure:AssessmentofTherapyComplications;  Other:QuestionnaireAdministration|Observational||Other / NIH|Collection of cumulative therapeutic exposure data;  Collectionofprotocol-specificoutcomedata;  Percentage of eligible patients located who were lost to follow-up;  Percentageoflocatedpatientsenrolled;  Percentageofpatientsenrolled;  Percentage of patients in which long-term (20+ years) contact is maintained|4485|NCT00736749|May 2008
4198|Completed                  Has Results|Follow-Up Study for Exubera||Drug:Exubera;  Other:Randomizeddiabetestherapy|Observational||Industry|RateofPrimaryLungCancerMortality;  Rate of Primary Lung Cancer Mortality Among Former Smokers;  RateofAll-causeMortality;  RateofPrimaryLungCancerDiagnosis|7439|NCT00734591|August 2008
4199|Completed|A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Thiazolidinedione or a Combination of Both.||Drug:exenatide;  Drug:taspoglutide|Interventional|Phase 3|Industry|ChangeinHbA1c;  Fastingbodyweight;  Proportion of patients reaching target HbA1c &lt;=7.0% &lt;=6.5%;  Relative change in glucose insulin C-peptide and glucagon values during a meal tolerance test in a subset of patients.;  Betacellfunction(proinsulin/insulinratio)|1189|NCT00717457|July 2008
4200|Completed                  Has Results|Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension||Drug:Azilsartanmedoxomilandolmesartan;  Drug:Olmesartan;  Drug:Placebo|Interventional|Phase 3|Industry|Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.;  Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure;  Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.;  Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure;  Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.;  Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.;  Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.;  Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.;  Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring;  Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring;  Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.;  Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.;  Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response Defined as &lt; 140 mm Hg and/or Reduction From Baseline &#8805; 20 mm Hg;  Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response Defined as &lt; 90 mm Hg and/or Reduction From Baseline &#8805; 10 mm Hg;  Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response|1275|NCT00696241|June 2007
4201|Active not recruiting|Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma||Drug:Bortezomib;  Drug:Dexamethasone;  Other:LaboratoryBiomarkerAnalysis;  Drug:Lenalidomide|Interventional|Phase 3|NIH|Progression-freesurvival;  Overallsurvival;  Response rates (stringent complete response a complete response a very good partial response or partial response)|525|NCT00644228|April 2008
4202|Completed                  Has Results|Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood||Drug:ABT-335;  Drug:placebo;  Drug:atorvastatin;  Drug:ezetimibe|Interventional|Phase 3|Industry|Median Percent Change in Triglycerides From Baseline to Final Visit;  Mean Percent Change in High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Final Visit;  Mean Percent Change in Apolipoprotein AI (apoAI) From Baseline to Final Visit;  Mean Percent Change in Very Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Final Visit;  Mean Percent Change in Apolipoprotein CIII (apoCIII) From Baseline to Final Visit;  Mean Percent Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Final Visit;  Mean Percent Change in Apolipoprotein B (apoB) From Baseline to Final Visit;  Median Percent Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Final Visit|543|NCT00639158|February 2008
4203|Completed                  Has Results|S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery||Biological:cixutumumab;  Drug:erlotinibhydrochloride;  Drug:gemcitabinehydrochloride|Interventional|Phase 1 / Phase 2|NIH|MaximumToleratedDoseDetermination;  Progression-FreeSurvival;  OverallSurvival;  Response;  Toxicity|134|NCT00617708|March 2008
4204|Completed|Safety and Efficacy of LibiGel&#174; for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women||Drug:testosteronegel;  Drug:placebogel|Interventional|Phase 3|Industry|The rate of adjudicated predefined cardiovascular events in LibiGel-treated subjects compared to that of placebo-treated subjects.|3656|NCT00612742|January 2008
4205|Completed                  Has Results|Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone||Drug:Lubiprostone;  Drug:Placebo|Interventional|Phase 3|Industry|Change From Baseline in Mean Weekly Spontaneous Bowel Movement (SBM) Frequency in Subjects Without Dose Reduction Prior to Week 8;  ChangeFromBaselineinMeanWeeklySBMFrequency;  FirstPost-doseSBM;  ResponderRate;  Mean Changes From Baseline in Straining Stool Consistency Constipation Severity Abdominal Bloating Abdominal Discomfort and Bowel Habit Regularity;  TreatmentEffectiveness|437|NCT00597428|August 2007
4206|Completed|A Long-Term Placebo-Controlled X-Ray Study Investigating the Safety and Efficacy of SD-6010 in Subjects With Osteoarthritis of the Knee||Drug:SD-6010;  Drug:Placebo|Interventional|Phase 2 / Phase 3|Industry|Assessing the progression rate of joint space narrowing in the study knee of subjects diagnosed with knee OA over a 24-month period.;  Assessing the safety and tolerability of multiple doses of SD-6010 administered long-term in subjects diagnosed with knee OA;;  Assessing the clinical benefit of multiple doses of SD-6010 in subjects diagnosed with knee OA|5077|NCT00565812|November 2007
4207|Active not recruiting|Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia||Drug:vincristinesulfate;  Drug:daunorubicinhydrochloride;  Drug:cyclophosphamide;  Drug:pegaspargase;  Drug:asparaginase;  Drug:prednisone;  Drug:methylprednisolone;  Drug:dexamethasone;  Drug:cytarabine;  Drug:methotrexate;  Drug:therapeutichydrocortisone;  Biological:filgrastim;  Drug:leucovorincalcium;  Drug:etoposide;  Drug:mercaptopurine;  Drug:lestaurtinib;  Other:laboratorybiomarkeranalysis;  Other:pharmacologicalstudy|Interventional|Phase 3|Other / NIH|Lestaurtinib-related dose limiting toxicity as graded by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;  Event-free survival (EFS) of MLL-R infants randomized to combination chemotherapy with or without lestaurtinib;  EFSofpatientstreatedonArmC;  EFS;  Incidence of grade 3/4 non-hematologic adverse events as assessed by the NCI CTCAE version 4.0;  Incidenceoftoxicdeath;  Proportion of infants who received prophylactic treatment for prevention of fungal infections;  Minimal residual disease (MRD) assessed by multiparameter flow cytometry and by quantitative reverse transcriptase-polymerase chain reaction|242|NCT00557193|January 2008
4208|Active not recruiting|High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery||Biological:cetuximab;  Drug:carboplatin;  Drug:paclitaxel;  Radiation: 3-dimensional conformal radiation therapy|Interventional|Phase 3|Other / NIH|Overall(Failure:deathfromanycause)survival;  Progression-free survival (Failure: occurrence of local or regional progression distant metastases or death from any cause);  Local-regional failure (Failure: occurrence of local or regional progression);  Grade 3-5 esophagitis and pneumonitis adverse events as assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0;  Other grade 3-5 adverse events as assessed by NCI CTCAE v3.0;  Death during or within 30 days of discontinuation of protocol treatment;  Quality of life (QOL) as measured by the Functional Assessment of Cancer Therapy-Trial Outcome Index (FACT-TOI) and lung cancer subscale (LCS);  Patient-reportedswallowingability;  Quality-adjusted survival based on EuroQoL (EQ5D)-derived health utility score;  Correlation of tumor markers with overall survival local-regional failure and QOL;  Prognostic and predictive effects of gross tumor volume on overall survival;  Prognostic value of pre-treatment standardized uptake value (SUV) of PET scan in predicting survival distant metastasis and local-regional control|500|NCT00533949|November 2007
4209|Active not recruiting|Radiation Therapy Androgen Suppression and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy||Drug:bicalutamide;  Drug:docetaxel;  Drug:flutamide;  Drug:goserelinacetate;  Drug:leuprolideacetate;  Procedure:adjuvanttherapy;  Radiation: 3-dimensional conformal radiation therapy;  Radiation:intensity-modulatedradiationtherapy|Interventional|Phase 2|Other / NIH|Freedomfromprogressionat3years;  Local-regionalprogression;  Distantmetastasis;  Prostatecancerspecificsurvival;  Non-prostatecancerspecificsurvival;  Overallsurvival;  Timetobiochemical(PSA)failure;  Grade3andlateadverseevents|80|NCT00528866|April 2008
4210|Completed                  Has Results|Galiximab in Treating Patients With Relapsed or Refractory Hodgkin&apos;s Lymphoma||Biological:galiximab|Interventional|Phase 2|Other / NIH|OverallResponse;  12MonthOverallSurvivalRate;  6MonthProgressionFreeSurvivalRate|30|NCT00516217|June 2008
4211|Recruiting|Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer||Procedure:lobectomy;  Procedure:segmentectomyorwedgeresection|Interventional|Phase 3|Other / NIH|disease-freesurvival;  overallsurvival;  rateofloco-regionalandsystemicrecurrence;  pulmonary function as measured by expiratory flow rate 6 months postoperatively|1258|NCT00499330|June 2007
4212|Recruiting|Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer||Radiation: 3-Dimensional Conformal Radiation Therapy;  Drug:Cisplatin;  Radiation:Intensity-ModulatedRadiationTherapy;  Radiation:InternalRadiationTherapy|Interventional|Phase 2|Other / NIH|Durationofprogression-freesurvival;  Durationofoverallsurvival;  Incidence of adverse effects graded by CTCAE version 3.0;  Prognostic significance of tumor size tumor location (vaginal only vs. all others) and histology|164|NCT00492778|February 2008
4213|Completed                  Has Results|An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis||Biological:Placebo;  Biological:Golimumab100mg;  Biological:Golimumab200mg;  Biological:Golimumab400mg;  Biological:Golimumab50mg|Interventional|Phase 2 / Phase 3|Industry|Number of Participants With Clinical Response at Week 6;  Number of Participants With Clinical Remission at Week 6;  Number of Participants With Mucosal Healing at Week 6;  Change From Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) Score at Week 6|1065|NCT00487539|August 2007
4214|Completed|Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia||Other:laboratorybiomarkeranalysis|Observational||Other / NIH|Development of a classification guide to help determine patient assignment to a specific treatment clinical trial for newly diagnosed acute lymphoblastic leukemia (ALL);  Development of a classification database for correlative studies;  Development of a central reference guide for all required and research only ALL studies;  Development of a leukemia and germline specimen bank for current and future research|11196|NCT00482352|December 2003
4215|Completed                  Has Results|A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure||Drug:Nesiritide;  Drug:Placebo|Interventional|Phase 3|Industry|Composite of Rehospitalization Due to Heart Failure and All-Cause Mortality;  Dyspnea Self-Assessment at 6 Hours After Initiation of Study Drug;  Dyspnea Self-Assessment at 24 Hours After Initiation of Study Drug;  Overall Well-Being Self-Assessment at 6 Hours After Initiation of Study Drug;  Overall Well-Being Self-Assessment at 24 Hours After Initiation of Study Drug;  Composite of Persistent or Worsening Heart Failure and All-Cause Mortality;  NumberofDaysAliveandOutsidetheHospital;  Composite of Cardiovascular Rehospitalization and Cardiovascular Mortality|7141|NCT00475852|May 2007
4216|Completed                  Has Results|A Comparison of SYMBICORT&#174; pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.||Drug:Budesonide/formoterol(SYMBICORT)pMDI;  Drug:BudesonideHFApMDI|Interventional|Phase 3|Industry|TotalNumberofAsthmaExacerbations;  AsthmaExacerbations;  QT Interval Corrected Using the Fridericia Formula Measured Via Electrocardiogram (ECG);  Number of Patients With Shift From Normal to High Rate of Total Ectopic Ventricular Beats as Measured by 24-hour Holter Monitor Assessment;  Number of Patients With Shift From Normal to High Rate of Total Ectopic Supraventricular Beats as Measured by 24-hour Holter Monitor Assessment;  Total Number of Ventricular Runs as Measured by 24-hour Holter Monitor Assessment;  DiaryAssessments-Rescue-freeDay;  DiaryAssessments-Symptom-freeDay;  DiaryAssessments-Asthma-controlDay;  OnsetofEffectQuestionnaire(OEQ);  PeakExpiratoryFlow(PEF)inMorning;  ForcedExpiratoryVolumeinOneSecond(FEV1);  AsthmaTreatmentSatisfactionMeasure(ATSM)|742|NCT00419952|February 2007
4217|Active not recruiting|Collection of Patient-Reported Symptoms and Performance Status Via the Internet||Other:internet-basedintervention;  Other:assessmentoftherapycomplications;  Other:QuestionnaireAdministration|Interventional||Other / NIH|Willingness of approached patients to participate in this study this study;  Proportion of enrolled patients who submit an online questionnaire at any given follow-up visit any given follow-up visit;  Proportion of total attended visits during the study period at which a questionnaire was completed (completers:visits) which a questionnaire was completed (completers:visits);  Patient-reported CTCAE symptoms using symptom severity data;  Clinician-reported CTCAE symptoms using symptom severity data clinician reporting at day 43 (when patients report before clinicians; clinicians view those reports) vs at day 22 (patients report symptoms after the clinical encounter);  Mean severity scores for patient reporting at day 43|300|NCT00417040|December 2006
4218|Active not recruiting|Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma||Drug:Asparaginase;  Drug:Cyclophosphamide;  Drug:Cytarabine;  Drug:DaunorubicinHydrochloride;  Drug:Dexamethasone;  Drug:DoxorubicinHydrochloride;  Other:LaboratoryBiomarkerAnalysis;  Drug:LeucovorinCalcium;  Drug:Mercaptopurine;  Drug:Methotrexate;  Drug:Nelarabine;  Drug:Pegaspargase;  Drug:Prednisone;  Radiation:RadiationTherapy;  Drug:Thioguanine;  Drug:VincristineSulfate|Interventional|Phase 3|NIH|Efficacy of combination chemotherapy with vs without nelarabine;  Efficacy of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine vs escalating-dose methotrexate (without leucovorin calcium rescue) and pegaspargase;  Event-freesurvival(EFS)afterinitialremission;  Incidence of toxicities of combination chemotherapy with vs without nelarabine as assessed by NCI CTCAE version 4.0;  Incidence of toxicities of high-dose methotrexate (with leucovorin calcium rescue) and mercaptopurine vs escalating-dose methotrexate (without leucovorin calcium rescue) and pegaspargase;  Nelarabine toxicity assessment by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;  IncidenceofCNSrelapse;  Overallsurvival|1900|NCT00408005|January 2007
4219|Completed                  Has Results|Dose-range-finding Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation||Drug:linaclotideacetate;  Drug:Matchingplacebo|Interventional|Phase 2|Industry|Change From Pretreatment in Weekly Normalized Spontaneous Bowel Movement (SBM) Frequency;  SBM 75% Responder for the Treatment Period (Based on the Normalized Rate);  CSBM 75% Responder for the Treatment Period (Based on the Normalized Rate);  Change From Baseline in the Weekly Normalized CSBM Rate for the Treatment Period;  Change From Baseline in Stool Consistency (BSFS) Score for the Treatment Period;  Change From Baseline in Straining Score for the Treatment Period|310|NCT00402337|November 2006
4220|Active not recruiting|Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia||Drug:vincristinesulfate;  Drug:prednisone;  Drug:doxorubicinhydrochloride;  Drug:pegaspargase;  Drug:cytarabine;  Drug:methotrexate;  Drug:dexamethasone;  Drug:etoposide;  Drug:cyclophosphamide;  Drug:leucovorincalcium;  Biological:filgrastim;  Drug:asparaginase;  Drug:mercaptopurine|Interventional|Phase 3|Other / NIH|EFS;  Frequency and severity of adverse effects assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;  Gene expression profile of early versus late marrow relapse by DNA microarray;  RateofMRD&lt;0.01%atEndBlock1;  RateofMRD&lt;0.01%atEndBlock3;  EFSonStandardArmtreatedwithchemotherapy;  EFS on Standard Arm treated with matched sibling HSCT|275|NCT00381680|March 2007
4221|Active not recruiting|Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms&apos; Tumor||Drug:doxorubicinhydrochloride;  Drug:liposomalvincristinesulfate;  Procedure:conventionalsurgery;  Radiation: 3-dimensional conformal radiation therapy;  Biological:dactinomycin;  Drug:cyclophosphamide;  Drug:etoposide|Interventional|Phase 3|Other / NIH|EFS of patients with stage IV and rapid complete response (RCR) of lung metastases;  EFS of patients with stage IV and slow incomplete response (SIR) of lung metastases;  EFS of patients with stage IV non lung disease only and stage III with LOH 1p and 16q;  Correlate between the burden of pulmonary metastatic disease with outcome in patients with stage IV FH Wilms&apos; tumor|395|NCT00379340|February 2007
4222|Completed|Stress Management Therapy in Patients Receiving Chemotherapy for Cancer||Other:SelfAdministeredStressManagement|Interventional||Other / NIH|Qualityoflife;  Anxiety;  Depression;  Degreeofacculturation|442|NCT00377130|December 2006
4223|Active not recruiting                  Has Results|Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia||Drug:asparaginase;  Drug:cytarabine;  Drug:daunorubicinhydrochloride;  Drug:etoposide;  Drug:gemtuzumabozogamicin;  Drug:mitoxantronehydrochloride|Interventional|Phase 3|Other / NIH|Event-freeSurvivalat3Years;  OverallSurvivalat3Years;  Remission Induction Rate After 2 Courses of Induction Therapy;  Disease-freeSurvival;  Mortality;  TimetoMarrowRecovery;  ToxicitiesIncludingInfectiousComplications|1070|NCT00372593|August 2006
4224|Completed|Patient&apos;s Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder||Drug:Darifenacin|Interventional|Phase 4|Industry|Change from baseline in the patient&apos;s perception of outcome at Week 13 using the Patient Perception Bladder Condition questionnaire (PPBC).;  Patient&apos;s perception of outcome using the PPBC questionnaire at Week 7.;  Patient&apos;s satisfaction by using the Patient Satisfaction Treatment Benefits questionnaire (PSTB Part I) at Week 13.;  Assessment of efficacy of darifenacin with respect to change from baseline in:;  NumberofmicturitionsperdayatWeeks7and13;  Number of urgency episodes per day at Weeks 7 and 13;  Number of urge urinary incontinence episodes (UUIE) per week at Weeks 7 and 13;  Assessmentofsafetyandtolerability|500|NCT00366002|June 2006
4225|Completed|Vincristine Dactinomycin and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I Stage II or Stage III Wilms&apos; Tumor||Procedure:therapeuticconventionalsurgery;  Drug:vincristinesulfate;  Biological:dactinomycin;  Drug:doxorubicinhydrochloride;  Radiation: 3-dimensional conformal radiation therapy|Interventional|Phase 3|Other / NIH|Event-freesurvival;  Overallsurvival;  Incidence of contralateral kidney lesions in patients with very low-risk disease;  Incidence of renal failure in patients with very low-risk disease|808|NCT00352534|October 2006
4226|Recruiting|Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo||Drug:Lyrica(pregabalin);  Drug:placebo|Interventional|Phase 4|Industry|Changes in vision from baseline to end of study assessed by the Humphrey Visual Field Analzyer.;  Visual acuity will be assessed at the baseline and end of the study.;  Change in mean deviation score on the Humphrey Visual Field at baseline and end of the study.|284|NCT00351611|July 2006
4227|Completed|Combination Chemotherapy Radiation Therapy and/or Surgery in Treating Patients With High-Risk Kidney Tumors||Drug:DoxorubicinHydrochloride;  Drug:IrinotecanHydrochloride;  Procedure:ConventionalSurgery;  Drug:Cyclophosphamide;  Drug:Etoposide;  Drug:Carboplatin;  Biological:Dactinomycin;  Drug:VincristineSulfate;  Radiation:RadiationTherapy;  Other:LaboratoryBiomarkerAnalysis|Interventional|Phase 2|Other / NIH|Event-free survival of patients with diffuse anaplastic Wilms&apos; tumor (DAWT) treated with HU-1;  Long-term survival of patients with Stage I-IV malignant rhabdoid tumors;  Efficacy of vincristine/irinotecan when delivered in an 6-week window;  Event-freesurvival;  Toxicity as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;  Frequency of INI1 mutations in renal and extrarenal malignant rhabdoid tumor by fluorescent in situ hybridization;  Frequency of TP53 mutations in patients with anaplastic Wilms&apos; tumor by immunohistochemistry|294|NCT00335556|June 2006
4228|Completed|Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin||Drug:rosiglitazone|Interventional|Phase 4|Industry|HbA1cateachvisit;  FPG at each visit C-peptide at each visit lipids at each visit BNP at each visit CRP at each visit PAI-1 at each visit MMP-9 at each visit|630|NCT00329225|September 2002
4229|Terminated                  Has Results|Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain||Drug:Buprenorphine;  Drug:OxycodoneImmediate-Release|Interventional|Phase 3|Industry|Average Pain Over the Last 24 Hours Score at Weeks 4 8 and 12.;  Mean Daily Number of Supplemental Analgesic Tablets;  OswestryDisabilityIndex(ODI)Score(V2.0);  The Sleep Disturbance Subscale in the MOS-Sleep Scale at Weeks 4 8 and 12.|660|NCT00313014|February 2004
4230|Completed                  Has Results|Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus||Drug:Alogliptinandpioglitazone;  Drug:Pioglitazone|Interventional|Phase 3|Industry|Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.;  Change From Baseline in Glycosylated Hemoglobin (Week 4).;  Change From Baseline in Glycosylated Hemoglobin (Week 8).;  Change From Baseline in Glycosylated Hemoglobin (Week 12).;  Change From Baseline in Glycosylated Hemoglobin (Week 16).;  Change From Baseline in Glycosylated Hemoglobin (Week 20).;  Change From Baseline in Fasting Plasma Glucose (Week 1).;  Change From Baseline in Fasting Plasma Glucose (Week 2).;  Change From Baseline in Fasting Plasma Glucose (Week 4).;  Change From Baseline in Fasting Plasma Glucose (Week 8).;  Change From Baseline in Fasting Plasma Glucose (Week 12).;  Change From Baseline in Fasting Plasma Glucose (Week 16).;  Change From Baseline in Fasting Plasma Glucose (Week 20).;  Change From Baseline in Fasting Plasma Glucose (Week 26).;  Number of Participants With Marked Hyperglycemia (Fasting Plasma Glucose &#8805; 200 mg Per dL).;  NumberofParticipantsRequiringRescue.;  Change From Baseline in Fasting Proinsulin (Week 4).;  Change From Baseline in Fasting Proinsulin (Week 8).;  Change From Baseline in Fasting Proinsulin (Week 12).;  Change From Baseline in Fasting Proinsulin (Week 16).;  Change From Baseline in Fasting Proinsulin (Week 20).;  Change From Baseline in Fasting Proinsulin (Week 26).;  ChangeFromBaselineinInsulin(Week4).;  ChangeFromBaselineinInsulin(Week8).;  ChangeFromBaselineinInsulin(Week12).;  ChangeFromBaselineinInsulin(Week16).;  ChangeFromBaselineinInsulin(Week20).;  ChangeFromBaselineinInsulin(Week26).;  Change From Baseline in Proinsulin/Insulin Ratio (Week 4).;  Change From Baseline in Proinsulin/Insulin Ratio (Week 8).;  Change From Baseline in Proinsulin/Insulin Ratio (Week 12).;  Change From Baseline in Proinsulin/Insulin Ratio (Week 16).;  Change From Baseline in Proinsulin/Insulin Ratio (Week 20).;  Change From Baseline in Proinsulin/Insulin Ratio (Week 26).;  ChangeFromBaselineinC-peptide(Week4).;  ChangeFromBaselineinC-peptide(Week8).;  ChangeFromBaselineinC-peptide(Week12).;  ChangeFromBaselineinC-peptide(Week16).;  ChangeFromBaselineinC-peptide(Week20).;  ChangeFromBaselineinC-peptide(Week26).;  Number of Participants With Glycosylated Hemoglobin &#8804; 6.5%.;  Number of Participants With Glycosylated Hemoglobin &#8804; 7.0%.;  Number of Participants With Glycosylated Hemoglobin &#8804; 7.5%.;  Number of Participants With Glycosylated Hemoglobin Decrease From Baseline &#8805; 0.5%.;  Number of Participants With Glycosylated Hemoglobin Decrease From Baseline &#8805; 1.0%.;  Number of Participants With Glycosylated Hemoglobin Decrease From Baseline &#8805; 1.5%.;  Number of Participants With Glycosylated Hemoglobin Decrease From Baseline &#8805; 2.0%.;  ChangeFromBaselineinBodyWeight(Week8).;  ChangeFromBaselineinBodyWeight(Week12).;  ChangeFromBaselineinBodyWeight(Week20).;  ChangeFromBaselineinBodyWeight(Week26).|493|NCT00286494|February 2006
4231|Completed|PROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide (HCT) (40/12.5 or 80/12.5) With Losartan/HCT (50/12.5) Using Ambulatory Blood Pressure Monitoring (ABPM)||Drug:Telmisartan&amp;Hydrochlorothiazide;  Drug:Losartan&amp;Hydrochlorothiazide;  Procedure:ABPM|Interventional|Phase 4|Industry|Change from baseline in the last 6-hour mean (relative to dose time) diastolic blood pressure (DBP) as measured by ABPM (Ambulatory Blood Pressure Monitoring);  Change in the last 6-hour ABPM mean (relative to dosing time) for systolic blood pressure (SBP);  Change in the 24-hour ABPM mean (relative to dosing time) for DBP and SBP;  Change in the ABPM mean DBP and SBP during the morning daytime and night-time periods of the 24-hour dosing interval;  Change in systolic and diastolic blood pressure load during the 24-hour dosing interval of the 24-hour dosing interval;  Change in mean seated trough DBP and SBP as measured by manual in-clinic cuff sphygmomanometer;  Responder rates based on both the 24-hour ABPM mean (relative to dose time) blood pressures and the in-clinic trough cuff measurements|805|NCT00274638|July 2002
4232|Completed|Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer||Biological:bevacizumab;  Drug:pemetrexeddisodium|Interventional|Phase 2|Other / NIH|Proportion of progression-free patients at 3 months;  Response (complete and partial) as assessed by RECIST criteria;  Overallsurvival;  Progression-freesurvival;  Durationofresponse;  Timetotreatmentfailure|48|NCT00268489|May 2006
4233|Completed                  Has Results|A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)||Drug:bevacizumab;  Drug:placebo;  Drug:erlotinibHCl|Interventional|Phase 3|Industry|Progression-freeSurvival(PFS);  Number of Participants With Prospectively Identified Treatment Emergent Adverse Events (TEAE) During Chemotherapy Phase;  Number of Participants With Prospectively Identified Treatment Emergent Adverse Events (TEAE) During Post-Chemotherapy Phase;  Number of Participants With Any Adverse Events During Post-Chemotherapy Phase;  Incidence of Study Treatment Discontinuation for Reasons Other Than Disease Progression in Chemotherapy Phase;  IncidenceofStudyTreatmentDiscontinuation;  OverallSurvival|1145|NCT00257608|January 2006
4234|Completed|Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain||Drug:alvimopan;  Drug:Placebo|Interventional|Phase 3|Industry|to compare alvimopan with placebo for efficacy in the treatment of OBD;  Safety and tolerability quality of life pharmacokinetics pharmacogenetics (dependent on results from other data)|518|NCT00256932|August 2005
4235|Completed                  Has Results|Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis||Drug:DexlansoprazoleMR;  Drug:Placebo|Interventional|Phase 3|Industry|Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Crude Rate Analysis.;  Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Life Table Method;  Percentage of Days Without Daytime or Nighttime Heartburn as Assessed by Daily Diary-Median.;  Percentage of Days Without Daytime or Nighttime Heartburn as Assessed by Daily Diary-Mean.;  Percentage of Days Without Nighttime Heartburn as Assessed by Daily Diary-Median.;  Percentage of Days Without Nighttime Heartburn as Assessed by Daily Diary-Mean.|451|NCT00255164|January 2006
4236|Completed                  Has Results|Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis||Drug:DexlansoprazoleMR;  Drug:Placebo|Interventional|Phase 3|Industry|Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Crude Rate Analysis.;  Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Life Table Method;  Percentage of Days Without Daytime or Nighttime Heartburn as Assessed by Daily Diary-Median.;  Percentage of Days Without Daytime or Nighttime Heartburn as Assessed by Daily Diary-Mean.;  Percentage of Days Without Nighttime Heartburn as Assessed by Daily Diary-Median.;  Percentage of Days Without Nighttime Heartburn as Assessed by Daily Diary-Mean.|451|NCT00255151|January 2006
4237|Completed                  Has Results|Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn||Drug:DexlansoprazoleMR;  Drug:Placebo|Interventional|Phase 3|Industry|Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Median;  Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Mean;  Percentage of Days Without Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Median;  Percentage of Days Without Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Mean|908|NCT00251745|December 2005
4238|Completed                  Has Results|Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis||Drug:DexlansoprazoleMR;  Drug:Lansoprazole|Interventional|Phase 3|Industry|Percentage of Subjects With Complete Healing of Erosive Esophagitis (EE) by Week 8 as Assessed by Endoscopy - Crude Rate Analysis.;  Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Life Table Method.;  Percentage of Subjects With Baseline Erosive Esophagitis Grade C or D Combined Who Have Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Crude Rate Analysis.;  Percentage of Subjects With Baseline Erosive Esophagitis Grade C or D Combined Who Have Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Life Table Method.;  Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 4 as Assessed by Endoscopy - Crude Rate Analyses.;  Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 4 as Assessed by Endoscopy - Life Table Method.|2038|NCT00251693|December 2005
4239|Completed|A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 Diabetics||Drug:Muraglitazar|Interventional|Phase 3|Industry|Compare change from basline in HbA1c after 24 weeks and 50 weeks of treatment with muraglitazar + metformin vs. pioglitazone + metformin;  Change in FPG from basline to W24 proportion of subjects receiving therapeutic response at W24 percent change of fasting lipid levels from baseline to W11/12 change in;  hs-CRPfrombaselinetoW24|1159|NCT00240370|October 2003
4240|Terminated|Open-label Trial of Leukine in Active Crohn&apos;s Disease||Drug:Sargramostim(Leukine)|Interventional|Phase 2|Industry|To establish a safety profile for long-term repeated cycles of sargramostim administered to subjects with Crohn&apos;s disease.;  Crohn&apos;sdiseaseactivity;  Duration of clinical remission and time to disease flare;  Patientcompliance|378|NCT00206700|February 2003
4241|Completed|A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.||Drug:AZD0865|Interventional|Phase 2|Industry|Time to sustained absence of patient-reported heartburn.;  The Quality of Life in Reflux and Dyspepsia (QOLRAD).;  Patient-reportedsymptoms.;  Investigator-reportedsymptoms.;  Population pharmacokinetics (PK). Area under the concentration-time curve (AUC) and the oral clearance calculated by dose/AUC (CL/F).;  pHmonitoring.;  Histology.;  Safety (Adverse events Laboratory variables BP pulse ECG and physical examination).|1400|NCT00206284|May 2004
4242|Completed|A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.||Drug:AZD0865|Interventional|Phase 2|Industry|Healingoferosiveesophagitisat4weeks.;  Healingoferosiveesophagitisat2and8weeks.;  The Quality of Life in Reflux and Dyspepsia (QOLRAD).;  Patient-reportedsymptoms.;  Investigator-reportedsymptoms.;  Population pharmacokinetics (PK). Area under the concentration-time curve (AUC) and the oral clearance calculated by dose/AUC (CL/F).;  pHmonitoring.;  Histology.;  Safety (Adverse events Laboratory variables BP pulse ECG and physical examination).|1400|NCT00206245|May 2004
4243|Completed                  Has Results|PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes||Drug:Aggrenox;  Drug:Clopidogrelplacebo;  Drug:Micardis;  Drug:Aggrenoxplacebo;  Drug:Clopidogrel;  Drug:Micardisplacebo|Interventional|Phase 4|Industry|Number of Patients With First Recurrent Stroke of Any Type Fatal or Nonfatal (Antiplatelet Comparison Only);  Number of Patients With First Recurrent Stroke of Any Type Fatal or Nonfatal (Telmisartan vs. Placebo Only);  Composite Outcome of Stroke Myocardial Infarction (MI) or Vascular Death (Antiplatelet Comparison Only);  Composite Outcome of Stroke Myocardial Infarction Vascular Death or New or Worsening Congestive Heart Failure (CHF) (Telmisartan vs. Placebo Only);  Number of Patients With New Onset of Diabetes (Telmisartan vs. Placebo Only)|20332|NCT00153062|August 2003
4244|Completed|Safety and Efficacy Study of Pregabalin in Fibromyalgia||Drug:pregabalin;  Drug:placebo|Interventional|Phase 3|Industry|To evaluate the efficacy of pregabalin (BID) compared with placebo in assessing the durability of effect for the treatment of pain associated with fibromyalgia among patients who initially respond to open-label pregabalin using Pain Visual Analog Scale;  To evaluate the efficacy of pregabalin (BID) compared with placebo treatment to relieve pain and to improve global assessment functional status sleep and fatigue associated with fibromyalgia using questionnaires. To evaluate the longterm safety|1020|NCT00151489|April 2005
4245|Active not recruiting|Combination Chemotherapy PEG-Interferon Alfa-2b and Surgery in Treating Patients With Osteosarcoma||Drug:doxorubicinhydrochloride;  Drug:cisplatin;  Drug:methotrexate;  Procedure:therapeuticconventionalsurgery;  Biological:peginterferonalfa-2b;  Drug:ifosfamide;  Drug:etoposide;  Procedure:quality-of-lifeassessment;  Other:questionnaireadministration|Interventional|Phase 3|Other / NIH|Event-freesurvival;  Overallsurvival;  ToxicityasmeasuredbyCTCAEv3.0;  Qualityoflife|1164|NCT00134030|November 2005
4246|Completed                  Has Results|Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone||Drug:Saxagliptin+Metformin;  Drug:Placebo+Metformin;  Drug:Pioglitazone|Interventional|Phase 3|Industry|Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24;  Baseline and Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24;  Percentage of Participants Achieving Therapeutic Glycemic Response (A1C &lt; 7.0%) at Week 24;  Baseline and Change From Baseline at Week 24 in Postprandial Glucose (PPG) Area Under the Curve (AUC)|1462|NCT00121667|August 2005
4247|Completed|Rituximab and Galiximab in Treating Patients With Stage II Stage III or Stage IV Non-Hodgkin&apos;s Lymphoma||Biological:galiximab;  Biological:rituximab|Interventional|Phase 2|Other / NIH|Overallresponse|62|NCT00117975|June 2005
4248|Completed                  Has Results|Pemetrexed Disodium Carboplatin and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer||Biological:cetuximab;  Drug:carboplatin;  Drug:pemetrexeddisodium;  Radiation:radiationtherapy|Interventional|Phase 2|Other / NIH / Industry|18MonthSurvival;  Failure-freeSurvival;  Number of Participants With Overall Tumor Response|109|NCT00117962|September 2005
4249|Active not recruiting|Quality of Life Employment and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer||Other:quality-of-lifeassessment;  Other:QuestionnaireAdministration|Observational||Other / NIH|Degree that symptoms interfere with patient functioning according to the National Cancer Institute (NCI) Common Toxicity Criteria;  Relative duration that symptoms interfere with patient functioning according to the NCI Common Toxicity Criteria|684|NCT00115505|October 2005
4250|Completed                  Has Results|Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer||Drug:carboplatin;  Drug:paclitaxel|Interventional|Phase 2|Other / NIH|NatureandDegreeofToxicity;  Response Evaluation Criteria in Solid Tumors Criteria (RECIST) 1.0 Best Response|55|NCT00112489|May 2005
4251|Active not recruiting|Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia||Drug:doxorubicinhydrochloride;  Radiation: 3-dimensional conformal radiation therapy;  Drug:cytarabine;  Drug:dexamethasone;  Drug:pegaspargase;  Drug:methotrexate;  Drug:leucovorincalcium;  Drug:mercaptopurine;  Drug:cyclophosphamide;  Drug:thioguanine;  Drug:vincristinesulfate|Interventional|Phase 3|Other / NIH|Event-freesurvival(EFS)forSR-averagepatients;  Health-relatedqualityoflife;  Correlation of minimal residual disease (MRD) with EFS;  Correlation of minimal residual disease (MRD) and overall survival;  Correlation of early marrow response status with MRD|5377|NCT00103285|April 2005
4252|Completed                  Has Results|Coenzyme Q10 in Relieving Treatment-Related Fatigue in Women With Breast Cancer||DietarySupplement:CoQ10&amp;VitaminE;  DietarySupplement:Placebo&amp;VitaminE|Interventional|Phase 3|Other / NIH|Effects of Coenzyme Q10 on Fatigue (as Measured by POMS-F) 24 Weeks Following Randomization;  Effects of Coenzyme Q10 on Quality of Life (as Measured by FACT-B) 24 Weeks Following Randomization;  Effects of Coenzyme Q10 on Depression (as Measured by CES-D Short-form) 24 Weeks Following Randomization|236|NCT00096356|August 2004
4253|Completed|Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone||Drug:muraglitazar|Interventional|Phase 3|Industry|ChangeinbaselineHbA1cafter52weeks;  Change in lipids after 52 weeks; safety and efficacy when administered with metformin after 52 weeks|1752|NCT00095030|February 2004
4254|Unknown&nbsp;&#8224;|Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I Stage II or Stage IIIA Primary Breast Cancer||Procedure:quality-of-lifeassessment|Observational||Other / NIH|||NCT00090974|December 2004
4255|Completed                  Has Results|Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment||Drug:dutasteride0.5mgoncedailyfor4years;  Drug:tamsulosin0.4mgoncedailyfor4years|Interventional|Phase 3|Industry|Number of Events of Acute Urinary Retention (AUR) or Benign Prostatic Hyperplasia (BPH)-Related Prostatic Surgery at the Indicated Time Periods.;  Number of Participants With AUR or BPH-related Surgery;  Number of Events of First BPH Clinical Progression at Years 1 2 3 and 4;  The Number of Participants With Each of the Five Components of BPH Clinical Progression;  Number of Events of Symptom Deterioration at the Indicated Time Periods;  Number of Participants With an Event of Post-baseline BPH-related Macroscopic Hematuria;  Number of Participants With an Event of Post-baseline BPH-related Hematospermia;  Adjusted Mean Change From Baseline in International Prostate Symptom Score (IPSS) at Months 12 24 36 and 48;  Adjusted Mean Change From Baseline in Urinary Flow Rate (Qmax) at Months 12 24 36 and 48;  Adjusted Mean Percent Change From Baseline in Prostate Volume at Months 12 24 36 and 48;  Adjusted Mean Change From Baseline in Transition Zone (Portion of the Prostate That Surrounds the Proximal Urethra) Volume at Months 12 24 36 and 48;  Number of Unscheduled Visits to GP/Urologist Regarding AUR Symptoms Since the Last Study Visit;  Number of &quot;Yes&quot; Responses to the Question: &quot;Would the Participant Have Paid a Visit to His GP/Urologist Regarding AUR Symptoms if the Study Visit Had Not Been Planned&quot;?.;  Number of Visits to GP/Urologist Regarding BPH-related Surgery Since the Last Study Visit;  Number of &quot;Yes&quot; Responses to the Question: &quot;Would the Participant Have Paid a Visit to His GP/Urologist Regarding BPH-related Surgery Since the Last Study Visit?&quot;;  Number of Unplanned Visits to GP/Urologist That Would Have Taken Place if a Scheduled Study Visit Had Not Been Planned (Including Visits Resulting From UTI UI Macroscopic Haematuria Etc.);  Number of Unscheduled Visits to GP/Urologist (Outpatient) Planned Not Relating to the Study (Including Visits Resulting From UTI UI Macroscopic Haematuria Etc.);  Adjusted Mean Change From Baseline in BPH Impact Index (BII) at Months 12 24 36 and 48;  Adjusted Mean Change From Baseline in BPH-Related Health Status (BHS) at Months 12 24 36 and 48;  Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 1 (LOCF);  Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 2 (LOCF);  Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 3 (LOCF);  Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 4 (LOCF);  Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 5 (LOCF);  Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 6 (LOCF);  Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 7 (LOCF);  Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 8 (LOCF);  Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 9 (LOCF);  Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 10 (LOCF);  Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 11 (LOCF);  Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 12 (LOCF)|4844|NCT00090103|November 2003
4256|Completed|DNA Variations in the Gene in Young Patients With Wilms&apos; Tumor||Genetic:moleculargenetictechnique;  Genetic:polymerasechainreaction;  Genetic:polymorphismanalysis|Observational||Other / NIH|Presence of the A133S polymorphism of the RASSF1A tumor suppressor gene in germline DNAs of children with Wilms&apos; tumor;  Inheritance pattern of the A133S polymorphism in the parents of children who carry this polymorphism;  Differences in age at diagnosis stage histology site of primary tumor and outcome between patients with vs without the A133S polymorphism;  Whether the S131F RASSF1A variant is a true polymorphism;  Polymorphic differences in this gene based on ethnicity and sex|471|NCT00088803|August 2004
4257|Completed|Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin&apos;s Lymphoma||Drug:doxorubicinhydrochloride;  Drug:gemcitabinehydrochloride;  Drug:vinblastine;  Procedure: fludeoxyglucose F 18 positron-emission tomography (PET) scan;  Procedure:CTscan|Interventional|Phase 2|Other / NIH|Response|104|NCT00086801|May 2004
4258|Completed|A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients||Drug:Exisulind|Interventional|Phase 3|Industry||600|NCT00085826|April 2001
4259|Completed|Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer||Drug:larotaxel(RPR109881XRP9881);  Drug:capecitabine|Interventional|Phase 3|Industry|Timetotumorprogression.;  Overallsurvival.|438|NCT00081796|April 2004
4260|Unknown&nbsp;&#8224;|S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer||Drug:anastrozole;  Drug:fulvestrant|Interventional|Phase 3|Other / NIH|Timetotumorprogression;  Clinicalresponserates;  Overallsurvival|690|NCT00075764|April 2004
4261|Active not recruiting                  Has Results|Dexamethasone Compared With Prednisone During Induction Therapy and MTX With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia||Drug:cyclophosphamide;  Drug:cytarabine;  Drug:daunorubicinhydrochloride;  Drug:dexamethasone;  Drug:doxorubicinhydrochloride;  Drug:leucovorincalcium;  Drug:mercaptopurine;  Drug:methotrexate;  Drug:pegaspargase;  Drug:prednisone;  Drug:thioguanine;  Drug:vincristinesulfate;  Radiation:radiationtherapy|Interventional|Phase 3|Other / NIH|Comparison of the Increase in Cure Rate of High Risk ALL Without Causing More Serious Side Effects Between Interventions;  Correlation of Minimal Residual Disease (MRD) Positive With Overall Survival (OS);  Correlation of Minimal Residual Disease (MRD) Negative With Overall Survival (OS).;  Correlation of Early Marrow Response Status With MRD Positive.;  Correlation of Early Marrow Response Status With MRD Negative.;  Correlation of Minimal Residual Disease (MRD) Positive With Event Free Survival (EFS);  Correlation of Minimal Residual Disease (MRD) Negative With Event Free Survival (EFS).|3154|NCT00075725|December 2003
4262|Completed                  Has Results|Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes||Drug:vatalanib|Interventional|Phase 2|Other / NIH|NumberofParticipantsWithResponse;  TimetoTransformationtoAML;  DurationofResponse;  OverallSurvival;  Progression-freeSurvival|155|NCT00072475|December 2003
4263|Active not recruiting                  Has Results|Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer||Drug:exemestane;  Drug:tamoxifen;  Drug:triptorelin|Interventional|Phase 3|Other / NIH|Disease-freeSurvival;  BreastCancer-freeInterval;  DistantRecurrence-freeInterval;  OverallSurvival|2672|NCT00066703|August 2003
4264|Completed|Fruit and Vegetable Extracts in Treating Patients With Stage I-IV Stage IVA/IVB Head and Neck Cancer||DietarySupplement:fruitandvegetableextracts;  DietarySupplement:placebo|Interventional|Phase 3|Other / NIH|Expression of p27 cell cycle regulatory protein associated with disease-free survival as measured by blood sample at baseline and week 12;  Cell proliferation (Ki-67) DNA damage (strand breaks) and immune function (T-cell function) as measured by biopsy at baseline and week 12;  Tobacco and alcohol use as measured by head and neck baseline questionnaire and food frequency questionnaire at baseline and week 12;  Depression as measured by Center for Epidemiologic Depression scale and positive symptom subscale at baseline and week 12;  Serum carotenoids and antioxidant levels (vitamins A C and E) as measured by blood tests at baseline and week 12|132|NCT00064298|January 2004
4265|Completed|Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke||Drug:NXY-059|Interventional|Phase 3|Industry|Global disability on modified Rankin scale at 90 days.;  NIHstrokescale;  BarthelIndex;  StrokeImpactScale;  EQ-5Dallat90days;  Safetyoutcomes|3200|NCT00061022|May 2003
4266|Completed|S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia||Drug:cytarabine;  Drug:gemtuzumabozogamicin|Interventional|Phase 2|Other / NIH|CR|33|NCT00049179|April 2003
4267|Completed|Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma Glioblastoma Multiforme Gliosarcoma or Diffuse Intrinsic Pontine Glioma||Drug:temozolomide;  Procedure:adjuvanttherapy;  Radiation:radiationtherapy|Interventional|Phase 2|Other / NIH|Improvedoutcome;  ToxicityasassessedbyNCICTCAEv.2.0|170|NCT00028795|December 2002
4268|Completed|Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin&apos;s Disease||Biological:BleomycinSulfate;  Drug:Cisplatin;  Drug:Cyclophosphamide;  Drug:Cytarabine;  Drug:Dexamethasone;  Drug:DoxorubicinHydrochloride;  Drug:Etoposide;  Biological:Filgrastim;  Radiation:Involved-FieldRadiationTherapy;  Drug:Prednisone;  Drug:VincristineSulfateLiposome|Interventional|Phase 3|Other / NIH|Event-free survival defined as the time to treatment failure (disease progression disease recurrence biopsy positive residual after completion of all protocol therapy) occurrence of a second malignant neoplasm or death from any cause;  Disease response assessed by modified RECIST criteria;  Incidence of Grade 3 or 4 non-hematologic toxicity that doesn&apos;t respond to treatment within 7 days despite recommended therapy modification assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;  Overallsurvival|1734|NCT00025259|September 2002
4269|Completed|Lobradimil and Carboplatin in Treating Children With Brain Tumors||Drug:carboplatin;  Drug:lobradimil|Interventional|Phase 2|NIH / Other|||NCT00019422|March 1998
4270|Completed|S0012 Doxorubicin Cyclophosphamide and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer||Biological:filgrastim;  Drug:cyclophosphamide;  Drug:doxorubicin;  Drug:paclitaxel;  Procedure:surgery|Interventional|Phase 3|Other / NIH|Comparison of microscopic pathologic response rates;  Toxicity;  Comparisonofdelivereddoseintensity;  Correlation of microscopic pathologic complete response with clinical complete response at the primary tumor site|399|NCT00016406|May 2001
4271|Completed|External-Beam Radiation Therapy Plus Implanted Radiation Therapy in Treating Patients With Prostate Cancer||Radiation:brachytherapy;  Radiation:iodineI125;  Radiation:radiationtherapy|Interventional|Phase 2|Other / NIH|RateoflatesevereGUandGItoxicity;  RateofacutesevereGUandGItoxicity;  BiochemicalFailure;  Overallfailure;  Failure rate of clinical progression including local-regional/distant failure|138|NCT00006365|November 2000
4272|Active not recruiting|Paclitaxel in Treating Patients With Ovarian Stromal Cancer||Drug:Paclitaxel|Interventional|Phase 2|Other / NIH|Frequency of complete clinical response assessed using GOG RECIST criteria;  Durationofprogression-freesurvival;  Overallsurvival|31|NCT00006227|November 2000
4273|Completed|Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma||Drug:lomustine;  Drug:temozolomide|Interventional|Phase 1|Other / NIH|ProgressionFreeSurvival|32|NCT00006024|November 2000
4274|Completed|Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer||Drug:cisplatin;  Drug:fluoxetine;  Drug:gemcitabinehydrochloride|Interventional|Phase 2|Other / NIH|Change in the MHI-17 global psychological distress subscale;  Overallsurvival;  Failure-freesurvival|21|NCT00005850|August 2001
4275|Completed|STI571 in Treating Patients With Recurrent Leukemia||Drug:imatinibmesylate|Interventional|Phase 1|Other / NIH|Survival;  Dose-limitingtoxicities;  Characterizethepharmacokineticbehavior;  Definetheanti-leukemicactivityofSTI571|31|NCT00004932|January 2002
4276|Completed|Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma||Biological:dactinomycin;  Biological:filgrastim;  Biological:pegfilgrastim;  Biological:sargramostim;  Drug:cyclophosphamide;  Drug:irinotecanhydrochloride;  Drug:vincristinesulfate;  Radiation:radiationtherapy|Interventional|Phase 2|Other / NIH|EventFreeSurvival|77|NCT00003955|September 1999
4277|Completed|Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma||Drug:cisplatin;  Drug:dexrazoxanehydrochloride;  Drug:doxorubicinhydrochloride;  Drug:etoposide;  Drug:ifosfamide;  Drug:methotrexate;  Procedure:conventionalsurgery|Interventional|Phase 3|Other / NIH|EventFreeSurvival|253|NCT00003937|September 1999
4278|Completed|Chemotherapy in Treating Children With Recurrent or Refractory Sarcomas||Drug:topotecanhydrochloride|Interventional|Phase 2|NIH||125|NCT00003745|May 1999
4279|Completed|Antibiotic Therapy With or Without G-CSF in Treating Children With Neutropenia and Fever Caused by Chemotherapy||Biological:filgrastim|Interventional|Phase 3|Other / NIH|TimetoResolutionofFebrileNeutropenia;  Incidence of Change of the Initial Empiric Antibiotic Treatment|67|NCT00003739|March 1999
4280|Completed|Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder Acute Myelogenous Leukemia or Myelodysplastic Syndrome||Drug:asparaginase;  Drug:cytarabine;  Drug:daunorubicinhydrochloride;  Drug:methotrexate;  Drug:therapeutichydrocortisone;  Drug:thioguanine|Interventional|Phase 3|Other / NIH|EventFreeSurvival|254|NCT00003593|June 1999
4281|Completed|Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia||Biological:filgrastim;  Drug:cladribine;  Drug:idarubicin|Interventional|Phase 2|Other / NIH|EventFreeSurvival|120|NCT00003178|March 1998
4282|Active not recruiting|Surgery in Treating Children With Neuroblastoma||Biological:filgrastim;  Biological:sargramostim;  Drug:carboplatin;  Drug:cyclophosphamide;  Drug:doxorubicinhydrochloride;  Drug:etoposide;  Procedure:adjuvanttherapy;  Procedure:conventionalsurgery;  Radiation:radiationtherapy|Interventional|Phase 3|Other / NIH|Estimate the 3 year survival rate for low risk asymptomatic stage 2A/2B patients who are treated with surgery alone|968|NCT00003119|March 1998
4283|Completed|Combination Chemotherapy in Treating Children With Neuroblastoma||Biological:filgrastim;  Biological:sargramostim;  Drug:carboplatin;  Drug:cyclophosphamide;  Drug:doxorubicinhydrochloride;  Drug:etoposide;  Procedure:conventionalsurgery;  Procedure:neoadjuvanttherapy|Interventional|Phase 3|Other / NIH|EventFreeSurvival|573|NCT00003093|March 1988
4284|Completed|Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma||Biological:dactinomycin;  Biological:filgrastim;  Biological:sargramostim;  Drug:cyclophosphamide;  Drug:vincristinesulfate;  Radiation:radiationtherapy|Interventional|Phase 3|Other / NIH|Failure-freesurvival|483|NCT00002995|August 1997
4285|Completed|Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin&apos;s or Non-Hodgkin&apos;s Lymphoma||Drug:carmustine;  Drug:cyclophosphamide;  Drug:etoposide;  Drug:mesna;  Procedure: peripheral blood stem cell transplantation|Interventional|Phase 2|Other / NIH|Failure-freesurvivalrate;  Estimating parameters relevant to recovery of normal bone marrow function;  PredictivevalueofMRDassessment|69|NCT00002941|April 1998
4286|Completed|Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer||Biological:dactinomycin;  Biological:filgrastim;  Drug:cyclophosphamide;  Drug:doxorubicinhydrochloride;  Drug:etoposide;  Drug:vincristinesulfate;  Procedure:conventionalsurgery;  Radiation:radiationtherapy|Interventional|Phase 3|Other / NIH|Progressionfreesurvival|3031|NCT00002611|July 1995
4287|Completed|Chemotherapy With or Without Surgery Radiation Therapy or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors||Biological:dactinomycin;  Biological:filgrastim;  Drug:carboplatin;  Drug:cyclophosphamide;  Drug:doxorubicinhydrochloride;  Drug:etoposide;  Drug:vincristinesulfate;  Procedure:conventionalsurgery;  Radiation:radiationtherapy|Interventional|Phase 3|Other / NIH|Eventfreesurvival;  EventFreeSurvival;  Post-relapsesurvival;  Responserate|203|NCT00002610|January 1996
4288|Recruiting|Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer||Drug:CRLX101;  Drug:Capecitabine;  Radiation:Radiotherapy;  Procedure:Surgery|Interventional|Phase 1 / Phase 2|Other / Industry|Maximumtolerateddose(MTD);  Pathologicalcompleteresponse(pCR);  Pathologicalresponserate;  Numberofsubjectswithadverseevents;  Disease-freesurvival(DFS);  Overallsurvival(OS);  Disease-free survival (DFS) and overall survival (OS) based on pathological complete response (pCR).|71|NCT02010567|December 2013
4289|Recruiting|Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery||Drug:Cisplatin;  Radiation:Intensity-ModulatedRadiationTherapy;  Other:LaboratoryBiomarkerAnalysis|Interventional|Phase 2|Other / NIH|DFSinpatientswithdisruptivep53mutation;  DFSinpatientswithnon-disruptivep53mutation;  DFSinpatientswithwildtypep53mutation;  Incidence of adverse events graded using Common Terminology Criteria for Adverse Events version 4;  p53asapredictivemarkerofrecurrence|345|NCT02734537|March 2016
4290|Recruiting|A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy Safety and Immunogenicity Persistence of GSK Biologicals&apos; Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults||Biological:HerpesZosterVaccineGSK1437173A|Interventional|Phase 3|Industry|Number of subjects with confirmed herpes zoster (HZ).;  Number of subjects with confirmed post herpetic neuralgia (PHN).;  Antigen-glicoprotein E (gE) humoral immunogenicity.;  Cell mediated immunity (CMI) in terms of frequencies of antigen-specific CD4+ T cells.;  Solicited local and general symptoms in subjects administered with 1 or 2 additional doses of HZ/su vaccine.;  Unsolicited Adverse Events (AEs) in subjects administered with 1 or 2 additional doses of HZ/su vaccine.;  Occurrence and relationship to vaccination of all Serious Adverse Events (SAEs).;  Occurrence of SAEs related to investigational vaccine related to study participation or to GSK concomitant medication/vaccine.;  Occurrence of AEs of specific interest: Potential immune mediated diseases (pIMDs).|12500|NCT02723773|April 2016
4291|Recruiting|Cross-vaccination Study of GSK Biologicals&apos; Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.||Biological:HerpesZosterVaccineGSK1437173A|Interventional|Phase 3|Industry|Occurrence intensity and relationship to vaccination of unsolicited AEs according to the Medical Dictionary for Regulatory Activities (MedDRA) classification in all subjects;  Occurrence and relationship to vaccination of all SAEs;  Occurrence and relationship to vaccination of any potential Immune Mediated Diseases (pIMDs);  OccurrenceofsuspectedHerpesZoster(HZ)cases|14535|NCT02690207|March 2016
4292|Recruiting|A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)||Drug:Avelumab(MSB0010718C);  Drug:Axitinib(AG-013736);  Drug:Sunitinib|Interventional|Phase 3|Industry|ProgressionFreeSurvival(PFS);  OverallSurvival(OS);  Number of participants with Objective Response (OR);  DiseaseControl(DC);  TimetoTumorResponse(TTR);  Durationofresponse(DR);  Progression Free Survival (PFS) by Investigator assessment;  Troughplasmaconcentration(Ctrough)ofavelumab;  Troughplasmaconcentration(Ctrough)ofaxitinib;  Maximumplasmaconcentration(Cmax)ofaxitinib;  Anti-Drug Antibody (ADA) levels of avelumab/Neutralizing antibodies titers for MSB0010718C;  Tumortissuebiomarkerstatus;  Overall Survival (OS) in biomarker-positive and biomarker-negative subgroups;  Change From Baseline in FACT-Kidney Symptom Index (FKSI)-19;  Change from Baseline in European Quality of Life Questionnaire (EQ-5D) - Health State Profile;  Progression Free Survival (PFS) in biomarker-positive and biomarker-negative subgroups;  Objective Response (OR) in biomarker-positive and biomarker-negative subgroups;  Disease Control (DC) in biomarker-positive and biomarker-negative subgroups;  Time To Response (TTR) in biomarker-positive and biomarker-negative subgroups;  Duration of Response (DR) in biomarker-positive and biomarker-negative subgroups;  Change from Baseline in European Quality of Life Questionnaire (EQ-5D) - Visual Analogic Scale|583|NCT02684006|March 2016
4293|Recruiting|A Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate||Drug:ABT-494;  Drug:PlaceboforABT-494;  Drug:Adalimumab;  Drug:PlaceboforAdalimumab|Interventional|Phase 3|Industry|Proportion of participants achieving American College of Rheumatology (ACR) 20 Response;  Proportion of subjects achieving Clinical remission (CR) based on Disease Activity 28 (DAS28) C-Reactive Protein (CRP);  ChangeinDiseaseActivityScore(DAS)28(CRP).;  ChangeinmodifiedTotalSharpScore(mTSS);  Change in Health Assessment Questionnaire (HAQ-DI);  Proportion of participants achieving American College of Rheumatology (ACR) 50;  Proportion of participants achieving American College of Rheumatology (ACR) 70;  Change in Short Form 36 (SF-36) Physical Component Score (PCS);  Change in Functional Assessment of Chronic Illness Therapy (FACIT-F);  Change in Work Instability Score for Rheumatoid Arthritis (RA-WIS);  ChangeinMorningStiffnessseverity;  Proportion of subjects achieving Low Disease Activity (LDA);  Proportion of subjects with no radiographic progression;  Proportion of subjects achieving Low Disease Activity (LDA) based on Disease Activity 28 (DAS28) C-Reactive Protein (CRP)|1500|NCT02629159|December 2015
4294|Recruiting|A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C||Drug:Tenapanor;  Drug:Placebo|Interventional|Phase 3|Industry|6of12WeekOverallResponderRate;  6 of 12 Week Overall Complete Spontaneous Bowel Movement (CSBM)Responder Rate;  6 of 12 Week Overall Abdominal Pain Responder Rate;  9of12WeekOverallResponderRate;  9of12WeekOverallCSBMResponderRate;  9 of 12 Week Overall Abdominal Pain Responder Rate|600|NCT02621892|October 2015
4295|Recruiting|Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Untreated and Previously Treated Chronic Lymphocytic Leukemia||Biological:Obinutuzumab;  Biological:Ublituximab;  Drug:TGR-1202;  Drug:Chlorambucil|Interventional|Phase 3|Industry|Progression-FreeSurvival;  OverallResponseRate|450|NCT02612311|January 2016
4296|Active not recruiting|Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Antiretroviral Treatment-Naive Adults||Drug:DTG;  Drug:F/TAF;  Drug:B/F/TAF;  Drug:DTGPlacebo;  Drug:F/TAFPlacebo;  Drug:B/F/TAFPlacebo|Interventional|Phase 3|Industry|Proportion of Participants who Achieve HIV-1 RNA &lt; 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm;  Proportion of Participants who Achieve HIV-1 RNA &lt; 50 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm;  Proportion of Participants who Achieve HIV-1 RNA &lt; 50 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm;  Proportion of Participants who Achieve HIV-1 RNA &lt; 20 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm;  Proportion of Participants who Achieve HIV-1 RNA &lt; 20 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm;  Proportion of Participants who Achieve HIV-1 RNA &lt; 20 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm;  Change from Baseline in log10 HIV-1 RNA at Week 48;  Change from Baseline in log10 HIV-1 RNA at Week 96;  Change from Baseline in log10 HIV-1 RNA at Week 144;  Change from Baseline in CD4+ Cell Count at Week 48;  Change from Baseline in CD4+ Cell Count at Week 96;  Change from Baseline in CD4+ Cell Count at Week 144|645|NCT02607956|November 2015
4297|Active not recruiting|Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected Antiretroviral Treatment-Na&#239;ve Adults||Drug:ABC/DTG/3TC;  Drug:B/F/TAF;  Drug:ABC/DTG/3TCPlacebo;  Drug:B/F/TAFPlacebo|Interventional|Phase 3|Industry|Proportion of Participants who Achieve HIV-1 RNA &lt; 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm;  Proportion of Participants who Achieve HIV-1 RNA &lt; 50 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm;  Proportion of Participants who Achieve HIV-1 RNA &lt; 50 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm;  Proportion of Participants who Achieve HIV-1 RNA &lt; 20 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm;  Proportion of Participants who Achieve HIV-1 RNA &lt; 20 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm;  Proportion of Participants who Achieve HIV-1 RNA &lt; 20 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm;  Change from Baseline in log10 HIV-1 RNA at Week 48;  Change from Baseline in log10 HIV-1 RNA at Week 96;  Change from Baseline in log10 HIV-1 RNA at Week 144;  Change from Baseline in CD4+ Cell Count at Week 48;  Change from Baseline in CD4+ Cell Count at Week 96;  Change from Baseline in CD4+ Cell Count at Week 144;  Percentage Change from Baseline in Hip Bone Mineral Density (BMD) at Week 48;  Percentage Change from Baseline in Hip BMD at Week 96;  Percentage Change from Baseline in Hip BMD at Week 144;  Percentage Change from Baseline in Spine BMD at Week 48;  Percentage Change from Baseline in Spine BMD at Week 96;  Percentage Change from Baseline in Spine BMD at Week 144|629|NCT02607930|November 2015
4298|Recruiting|Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL||Biological:TVGV-1;  Biological:GPI-0100;  Biological:Placebo|Interventional|Phase 2|Industry|Absence of histologic HSIL (CIN2/3) as assessed by biopsy at last study Visit 11 Day 270.;  Assessment of cutaneous toxicities (i.e. size induration and time to resolution of skin reactions to vaccine).;  Absence of HPV16 in cervical cytological specimen. Absence of cervical dysplasia 6 months and 8 months after last dose of TVGV-1.;  Assessment of clinical or laboratory findings and other safety variables.|51|NCT02576561|November 2015
4299|Active not recruiting|Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)||Drug:Linaclotide;  Drug:MatchingPlacebo|Interventional|Phase 2|Industry|TheWeeklyChangefromBaselineinAbdominalPain;  The Weekly Change from Baseline Complete Spontaneous Bowel Movement (CSBM) Frequency;  6/12 Week Abdominal Pain and Constipation (APC) +1 Responder;  6/12WeekCSBM+1Responder;  6/12WeekAbdominalPainResponder;  WeeklyCSBM+1Responder;  WeeklyAbdominalPainResponder;  WeeklyAPC+1Responder;  ChangefromBaselinein12-weekAbdominalPain|532|NCT02559206|October 2015
4300|Recruiting|Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee||Drug:NSAID;  Biological:Tanezumab2.5mg;  Biological:Tanezumab5mg|Interventional|Phase 3|Industry|Incidenceofapredefinedcompositeendpoint;  ChangefromBaselineinWOMACPainSubscaleScore;  Change from Baseline in WOMAC Physical Function Subscale Score;  Change from Baseline in Patient&apos;s Global Assessment of Osteoarthritis;  Incidenceofindividualadjudicationoutcomes;  Incidenceofallcausetotaljointreplacements;  Change from Baseline in Minimum Joint Space Width of the index knee;  Change from Baseline in Minimum Joint Space Width of the index hip;  Incidence of subjects with progression of osteoarthritis in the index knee according to Bland and Altman method;  Incidence of subjects with progression of osteoarthritis in the index hip according to Bland and Altman method;  WOMACPainsubscalechangefromBaseline;  WOMAC Physical Function subscale change from Baseline;  Patient&apos;s Global Assessment of Osteoarthritis change from Baseline;  OMERACTOARSIresponderindex;  Treatment Response: Reduction in the WOMAC Pain subscale of 30% 50% 70% and 90%;  Cumulative distribution of percent change from Baseline in the WOMAC Pain subscale score;  Treatment Response: Reduction in the WOMAC Physical Function subscale of 30% 50% 70% and 90%.;  Cumulative distribution of percent change from Baseline in the WOMAC Physical Function subscale score;  Treatment Response: Improvement of 2 points in Patient&apos;s Global Assessment of Osteoarthritis;  Average pain score in the index joint change from Baseline;  WOMACStiffnesssubscalechangefromBaseline;  WOMACAveragechangefromBaseline;  WOMAC Pain Subscale Item: Pain When Walking on a Flat Surface change from Baseline;  WOMAC Pain Subscale Item: Pain When Going Up or Down Stairs change from Baseline;  Work Productivity and Activity Impairment Questionnaire for Osteoarthritis (WPAI:OA) impairment scores change from Baseline;  EuroQol 5 Dimension (EQ 5D 5L) dimensions and overall health utility score;  Treatment Satisfaction Questionnaire Medicine v.II (TSQM v.II) satisfaction with effectiveness side effects and convenience and overall satisfaction;  Patient Reported Treatment Impact Assessment Modified (mPRTI);  Incidence and Time to discontinuation due to Lack of Efficacy;  IncidenceofRescueMedicationUse;  AmountofRescueMedicationTaken;  HealthCareResourceUtilization;  Lower Extremity Activity Scale: change from Baseline;  Change from Baseline in average daily minutes of physical activity;  Change from Baseline in average daily physical activity counts;  Change from Baseline in average daily minutes of moderate to vigorous physical activity;  Change from Baseline in average daily minutes of bouted (sustained) moderate to vigorous physical activity;  ChangefromBaselineinaveragedailystepcount;  IncidenceofSubjectswithAdverseEvents;  Orthostatic(supine/standing)bloodpressure;  SurveyofAutonomicSymptomscores;  Neurologicexaminations;  Antitanezumabantibodylevels;  IncidenceofPhysicalExaminationFindings;  Incidence of Subjects with Clinical Laboratory Test Abnormalities;  ChangefromBaselineSittingBloodPressure;  ChangefromBaselineSittingHeartRate;  ChangefromBaseline12-leadElectrocardiogram;  NumberofDaysofRescueMedicationUse|3000|NCT02528188|July 2015
4301|Recruiting|Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)||Drug:Plecanatide;  Drug:Placebo|Interventional|Phase 3|Industry|The primary efficacy endpoint is Overall Responder;  AbdominalPainIntensityWeeklyResponder;  StoolFrequencyResponder;  CompleteSpontaneousBowelMovement;  SpontaneousBowelMovement;  Stool Consistency based upon the Bristol Stool Form Scale;  SustainedEfficacyResponder;  TimetofirstSBMandCSBM;  Change and Percent Change from baseline in abdominal pain;  Stool Frequency Responder for at least 6 of the 12 treatment weeks;  TimetofirstuseofRescueMedication(RM);  Overall Responder for at least 9 of the 12 treatment weeks;  SBMs and CSBMs within 24 hours after first dose of study medication;  SymptomsassociatedwithIBS-C;  PatientGlobalQuestionnaires|1050|NCT02493452|June 2015
4302|Recruiting|Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.||Drug:QVA149;  Drug:Umeclidinium/vilanterol;  Drug:Placebo(umeclidinium/vilanterol);  Drug:Placebo(QVA149)|Interventional|Phase 3|Industry|To demonstrate non-inferiority of QVA149 compared to umeclidinium/vilanterol in terms of FEV1 AUC 0-24h;  To demonstrate the superiority of QVA149 compared to umeclidinium/vilanterol in terms of FEV1 AUC 0-24h;  To demonstrate the superiority of QVA149 compared to umeclidinium/vilanterol in terms of trough FEV1 (mean of 23h 15 min and 23 h 45 min post previous morning dose) after 12 weeks of treatment;  To demonstrate the superiority of QVA149 compared to umeclidinium/vilanterol in terms of FEV1 AUC 12-24h|354|NCT02487498|July 2015
4303|Recruiting|Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV High-grade Serous Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer||Other:Placebo;  Drug:Veliparib;  Drug:Carboplatin;  Drug:Paclitaxel|Interventional|Phase 3|Industry / Other|Progression-Freesurvival(PFS);  OverallSurvival(OS);  DiseaseRelatedSymptom(DRS)scores|1100|NCT02470585|July 2015
4304|Active not recruiting|Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma||Drug:GlycopyrroniumMDI;  Drug:SereventDiskus50&#956;g;  Drug:Placebo|Interventional|Phase 2|Industry|Primary Efficacy Endpoint (Peak change from baseline in FEV1);  Secondary Efficacy Endpoints: (Change from baseline in morning pre-dose trough FEV1);  Secondary Efficacy Endpoints: (Forced expiratory volume);  Secondary Efficacy Endpoints: (Change from baseline in average daily pre-dose peak expiratory flow rate (PEFR);  Secondary Efficacy Endpoints: (Change from baseline in average daily post-dose PEFR);  Secondary Efficacy Endpoints: Change from baseline in average daily rescue medication use;  Secondary Efficacy Endpoints: Change from baseline in Asthma Control Questionnaire-5;  SafetyEndpointsAdverseEvents;  SafetyEndpoints12-Leadelectrocardiograms;  SafetyEndpointsClinicallaboratorytesting;  SafetyEndpointsVitalsignmeasurements|249|NCT02433834|April 2015
4305|Recruiting|A Study of Apixaban in Patients With Atrial Fibrillation Not Caused by a Heart Valve Problem Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event Such as a Heart Attack or a Procedure to Open the Vessels of the Heart||Drug:Apixaban;  Drug:vitaminKantagonist;  Drug:Acetylsalicylicacid;  Other:Acetylsalicylicacidplacebo|Interventional|Phase 4|Industry / Other|Time to first occurrence of International Society on Thrombosis and Haemostasis (ISTH) major or Clinically Relevant Non-Major (CRNM) bleeding during the treatment period between Apixaban and VKA;  Time to first occurrence of major or CRNM bleeding during the treatment period between No aspirin and aspirin;  Superiority on major + CRNM bleeding between Apixaban versus VKA;  The composite endpoints of death and ischemic events (stroke myocardial infarction stent thrombosis urgent revascularization) between Apixaban versus VKA;  First re-hospitalization for any cause between Apixaban versus VKA;  The composite endpoints of death and ischemic events (stroke myocardial infarction stent thrombosis urgent revascularization) between aspirin versus placebo;  First re-hospitalization for any cause between aspirin versus placebo|4600|NCT02415400|June 2015
4306|Completed|A Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis||Drug:RM-131;  Drug:Placebo|Interventional|Phase 2|Industry|Effect of RM-131 on vomiting episodes as assessed in the Diabetic Gastroparesis Symptom Severity Diary (DGSSD);  Effect of RM-131 on key symptoms of gastroparesis assessed with a composite score derived from the Diabetic Gastroparesis Symptom Severity Diary (DGSSD);  Effect of RM-131 on vomiting severity as assessed in the DGSSD;  Effect of RM-131 on gastric emptying as assessed in a Gastric Emptying Breath Test (GEBT)|393|NCT02357420|January 2015
4307|Completed|Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications||Drug:InsulinglargineU300HOE901;  Drug:InsulinglargineHOE901|Interventional|Phase 3|Industry|ChangeinHbA1cfrombaseline;  Incidence (% of patients) of severe and/or confirmed (by plasma glucose &#8804;70mg/dL [3.9mmol/L]) hypoglycemia event (symptomatic or asymptomatic) from 22:00 to 08:59 next morning over 26 weeks of treatment;  Incidence (% of patients) of nocturnal (from 00:00 to 05:59) severe and/or confirmed (&#8804;70 mg/dL [3.9mmol/L]) hypoglycemia (symptomatic or asymptomatic) over 26 weeks of treatment;  Incidence (% of patients) of severe and/or confirmed (by plasma glucose &#8804;70mg/dL [3.9mmol/L]) hypoglycemia (symptomatic or asymptomatic) occurring at any time of day over 26 weeks of treatment;  Percentage of patients with HbA1c (a) &lt;7.5% (b) &lt;7.0% at Week 26;  Percentage of eligible patients with HbA1c (a) &lt;7.5% (b) &lt;7.0% at Week 26 with no severe and/or confirmed (by plasma glucose &#8804;70mg/dL [3.9mmol/L]) hypoglycemia event over 26 weeks of treatment;  Change in fasting plasma glucose (FPG) from baseline to Week 26;  Change in Patient Report Outmcome (PRO) instruments scores from baseline to Week 26;  Percentage of patients requiring rescue therapy over the 26 weeks of treatment|1014|NCT02320721|January 2015
4308|Completed|Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer Fallopian Tube Cancer and/or Primary Peritoneal Cancer||Drug:Carboplatin;  Drug:Glutathione;  Other:LaboratoryBiomarkerAnalysis;  Drug:Paclitaxel;  Other:Placebo;  Other:Quality-of-LifeAssessment|Interventional|Phase 3|NIH|Paclitaxel/carboplatin (PC) induced peripheral neuropathy as assessed by EORTC QLQ-CIPN20;  Antitumor activity of PC as defined by recurrence-free (for patients without clinical evidence of disease) or progression-free (for patients with clinical evidence of disease) survival;  Association between genetic variations and grade 2+ PCI PN;  Change in patient reported quality of life as assessed by FACT-O and patient daily-symptom questionnaires over time;  Paclitaxel acute pain syndrome incidence and severity between GSH and placebo arms;  Percentage of patients discontinuing PC chemotherapy secondary to PN;  Percentage of patients undergoing dose reductions secondary to PCI PN;  Percentage of patients with grade 2+ and grade 3+ paclitaxel/carboplatin-induced (PCI) peripheral neuropathy (PN) according to the CTCAE neuropathy scale;  TimestoonsetofCTCAEgrade2+andgrade3+PN;  Toxicity profile of glutathione as assessed by CTCAE v4.0|282|NCT02311907|December 2009
4309|Recruiting|World-wide Randomized Antibiotic Envelope Infection Prevention Trial||Device:TYRXAbsorbableAntibacterialEnvelope|Interventional|Phase 4|Industry / Other|ThefirstoccurrenceofamajorCIEDinfection.;  The first occurrence of a major or minor CIED infection;  The first occurrence of a CIED procedure related or system related complication|7764|NCT02277990|January 2015
4310|Completed|A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD||Drug:SUN-10150mcgBIDeFlow(CS)nebulizer;  Drug:Spiriva&#174;18mcgQDHandihaler|Interventional|Phase 3|Industry|Number of subjects with treatment-emergent adverse events (TEAE);  Number of subjects with treatment-emergent serious adverse events (SAE);  Number of subjects who discontinue the study due to TEAE;  Percentage of subjects with treatment-emergent adverse events;  Percentage of subjects with treatment-emergent serious adverse;  Percentage of subjects who discontinue the study due to TEAE;  Number of subjects with major adverse cardiac events (MACE) including cardiovascular death ischemia/infarction and stroke;  Mean change from baseline over 48 weeks in trough FEV1 for all subjects;  Percentage of subjects with major adverse cardiac events (MACE) including cardiovascular death ischemia/infarction and stroke|1087|NCT02276222|October 2014
4311|Recruiting|Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)||Drug:optionalASAascomedication;  Drug:placebotoASA;  Drug:placebotooptionalASAascomedication;  Drug:placebotodabigatranetexilate;  Drug:ASA100mg;  Drug:dabigatranetexilate|Interventional|Phase 3|Industry|Time to first recurrent stroke (ischemic hemorrhagic or unspecified);  TimetoIschemicStroke;  Composite endpoint of (time to) nonfatal stroke nonfatal myocardial infarction (MI) and cardiovascular death;  Time to Disabling stroke (modified Rankin Scale greater than or equal to 4 as determined 3 months after recurrent stroke);  TimetoAll-causedeath;  Timetofirstmajorbleed;  Timetofirstintracranialhemorrhage;  Timetolife-threateningbleed;  Fatalbleed;  Timetoanybleed(allseverities)|6000|NCT02239120|November 2014
4312|Recruiting|24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension||Drug:Empagliflizonlowdose;  Drug:placebo;  Drug:Empagliflizonhighdose|Interventional|Phase 3|Industry|ChangefrombaselineinHbA1c;  Change from baseline in mean 24-hour ambulatory systolic blood pressure (SBP);  Change from baseline in mean trough ambulatory SBP;  ChangefrombaselineintroughseatedSBP;  Change from baseline in mean 24-hour ambulatory diastolic blood pressure (DBP);  ChangefrombaselineintroughseatedDBP;  Changefrombaselineinbodyweight|154|NCT02182830|July 2014
4313|Recruiting|Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery||Drug:DoxorubicinHydrochloride;  Drug:Ifosfamide;  Other:LaboratoryBiomarkerAnalysis;  Drug:PazopanibHydrochloride;  Other:PharmacologicalStudy;  Radiation:RadiationTherapy;  Procedure:TherapeuticConventionalSurgery|Interventional|Phase 2 / Phase 3|NIH|EFS(PhaseIII);  Potential benefit for chemoradiotherapy plus pazopanib hydrochloride defined as protocol week 13 pathologic response (Phase II);  Potential benefit for radiotherapy plus pazopanib hydrochloride defined as protocol week 10 pathologic response (Phase II/III);  Adverse event profile of the treatments delivered (chemo-radiotherapy; radiotherapy) characterized using the current Common Terminology Criteria for Adverse Events version;  Distant failure defined as disease recurrence at sites other than the primary site and diagnosis and nodes regional to that site (metastatic disease whether or not present at diagnosis) with or without loco-regional failure;  Local failure defined as disease recurrence only at the primary site of disease at diagnosis;  Regional failure defined as disease recurrence at lymph nodes regional to the primary disease site with or without local failure but without distant failure|340|NCT02180867|July 2014
4314|Active not recruiting|A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma||Biological:Tralokinumab;  Other:Placebo|Interventional|Phase 3|Industry|Asthmaexacerbationratereduction(AERR);  Percent change from baseline to Week 52 in pre-dose/pre-bronchodilator forced expiratory volume in 1 second;  Change from baseline to Week 52 in daily asthma symptom score;  Change from baseline to Week 52 in Asthma Quality of Life Questionnaire for 12 Years and Older total score;  Change from baseline to Week 52 in Asthma Control Questionnaire-6 defined asthma control;  Annualised asthma exacerbation rate that is associated with an ER or urgent care visit or a hospitalization;  European Quality of Life - 5 Dimension 5 Level Daily Living Questionnaire;  Rescuemedicationuse;  Homepeakexpiratoryflow(morningandevening);  Night-timeawakeningduetoasthma;  Timetofirstasthmaexacerbation;  Proportion of subjects with &#8805;1 asthma exacerbation;  Work Productivity and Activity Impairment Questionnaire plus Classroom Impairment Questions;  Asthmaspecificresourceutilization;  Pharmacokinetic parameters (Ctrough at steady state);  Incidence rate of positive anti-drug antibodies including the characterization of their neutralizing potential;  Asthmaexacerbationratereduction|1140|NCT02161757|June 2014
4315|Active not recruiting|Treatment of Pain Associated With Fibromyalgia||Drug:DS-556515mgtablet;  Drug:150mgpregabalincapsule;  Drug:placebotablet;  Drug:placebocapsule;  Drug:75mgpregabalincapsule|Interventional|Phase 3|Industry / Other|change in weekly average daily pain score (ADPS) DS-5565 versus placebo;  change in ADPS from baseline to Week 13 DS-5565 versus pregabalin;  proportion of responders at week 13 DS-5565 versus placebo;  change in patient global impression measure DS-5565 versus placebo;  changeinFIQmeasureDS-5565versusplacebo;  changeinMFI-20measureDS-5565versusplacebo;  changeinHADSmeasureDS-5565versusplacebo;  changeinSF-36measureDS-5565versusplacebo;  changeinEQ-5DmeasureDS-5565versusplacebo;  change in pain-associated sleep interference DS-5565 versus placebo;  changeinBPI-SFmeasureDS-5565versusplacebo;  numberandseverityofadverseevents;  proportionofdaysarescuemedicationwasused|1294|NCT02146430|October 2014
4316|Active not recruiting|Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-associated Pain||Drug:Elagolix|Interventional|Phase 3|Industry|Endometriosis-AssociatedPain;  BoneMineralDensity(DXAscan);  TransvaginalUltrasound(TVU);  Clinical Laboratory Tests (standard laboratory values including hormones);  NumberofstudysubjectswithAdverseEvents|500|NCT02143713|May 2014
4317|Completed|Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-na&#239;ve Subjects With Type 2 Diabetes||Drug:semaglutide;  Drug:insulinglargine|Interventional|Phase 3|Industry|ChangeinHbA1cfrombaseline;  Changeinbodyweightfrombaseline;  Changeinfastingplasmaglucosefrombaseline;  Change in systolic and diastolic blood pressure from baseline;  Change in patient reported outcome (PRO) questionnaire SF-36v2&#8482; from baseline;  Change in patient reported outcome (PRO) questionnaire DTSQs (diabetes treatment satisfaction questionnaire) from baseline;  Subjects who achieve HbA1c equal to or below 6.5% (48 mmol/mol) American Association of Clinical Endocrinologists (AACE) target: (yes/no)|1082|NCT02128932|August 2014
4318|Completed|12-Week Study of Plecanatide for CIC (The National CIC3 Study)||Drug:Plecanatide;  Drug:Placebo|Interventional|Phase 3|Industry|Proportionofpatientswhoareoverallresponders|1410|NCT02122471|April 2014
4319|Recruiting|Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia||Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;  Drug:Asparaginase;  Biological:Blinatumomab;  Drug:Cyclophosphamide;  Drug:Cytarabine;  Drug:Dexamethasone;  Drug:Etoposide;  Other:LaboratoryBiomarkerAnalysis;  Drug:LeucovorinCalcium;  Drug:Mercaptopurine;  Drug:Methotrexate;  Drug:MitoxantroneHydrochloride;  Drug:Pegaspargase;  Other:PharmacologicalStudy;  Drug:TherapeuticHydrocortisone;  Drug:Thioguanine;  Drug:VincristineSulfate|Interventional|Phase 3|NIH|DFSofHRandIRrelapsepatients;  DFSofLRrelapsepatients;  OSofHRandIRrelapsepatients;  OSofLRrelapsepatients|598|NCT02101853|December 2014
4320|Completed|Ocriplasmin Research to Better Inform Treatment (ORBIT)|||Observational||Industry|Resolution of VMA by Spectral-domain optical coherence tomography (SD-OCT) as determined by the treating physician.;  Full thickness macular hole (FTMH) closure by SD-OCT as determined by the treating physician;  Mean change in visual acuity (VA) from baseline across time;  Occurrenceandtimetovitrectomy|540|NCT02079883|May 2014
4321|Active not recruiting|A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen||Drug:Nivolumab|Interventional|Phase 3|Industry|Incidence for high grade (Grade 3-4 and Grade 5) treatment related select adverse events (AEs);  Incidence for high grade (Grade 3-4 and Grade 5) select AEs;  Median time to onset and median time to resolution (Grade 3-4);  Percentage of subjects who received immune modulating medication or hormonal replacement therapy percentage of subjects who received &#8805;40 mg Prednisone equivalents total duration of all immune modulating medications given for select event|1380|NCT02066636|February 2014
4322|Completed|Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients||Drug:Arhalofenate600mg;  Drug:Allopurinol300mg;  Drug:Colchicine0.6mg;  Drug:Placebo;  Drug:Arhalofenate800mg|Interventional|Phase 2|Industry|The incidence of flares (mean number of flares per patient) from baseline through Week 12 in the arhalofenate 800 mg group compared to the allopurinol 300 mg group.;  Percent sUA reduction from baseline to Week 12 in the arhalofenate 800 mg group compared to the placebo group;  Percent sUA reduction from baseline to Week 12 in the arhalofenate 600 mg group compared to the placebo group;  Proportion of patients with sUA &lt; 6 mg/dL at Week 12 in the arhalofenate 800 mg group compared to the placebo group;  The incidence of flares from baseline through Week 12 in the arhalofenate 600 mg group compared to the allopurinol 300 mg group;  Proportion of patients with sUA &lt; 6 mg/dL at Week 12 in the arhalofenate 600 mg group compared to placebo group;  Time from baseline to onset of first flare for the arhalofenate 800 mg group compared to the allopurinol 300 mg group;  Time from baseline to onset of first flare for the arhalofenate 600 mg group compared to the allopurinol 300 mg group|248|NCT02063997|March 2014
4323|Recruiting|A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer||Drug:Eribulin;  Drug:Paclitaxel|Interventional|Phase 3|Other|Overall Survival (OS) of subjects from Baseline taking eribulin mesylate vs. subjects taking paclitaxel;  ObjectivetumorresponseasdefinedbyRECIST1.1;  Durationoftumorresponse;  Time-to-treatment-failureoferibulinmesylate;  Treatment-relatedtoxicityoferibulinmesylate;  Progression-Free Survival (PFS) defined as the time from randomization to progression (under RECIST 1.1 criteria) or death due to any cause whichever occurs first|910|NCT02037529|March 2014
4324|Active not recruiting|Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis||Drug:MetoclopramideNasalSpray;  Drug:PlaceboNasalSpray|Interventional|Phase 3|Industry|PatientReportedOutcome(PRO)SymptomDiary;  PopulationPharmacokinetics|53|NCT02025751|April 2014
4325|Completed|Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis||Drug:MetoclopramideNasalSpray;  Drug:PlaceboNasalSpray|Interventional|Phase 3|Industry|PatientReportedOutcome(PRO)SymptomDiary;  PopulationPharmacokinetics|205|NCT02025725|April 2014
4326|Completed|Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events||Drug:Bococizumab(PF-04950615;RN316);  Other:Placebo|Interventional|Phase 3|Industry|PercentChangefromBaselineinLDL-CatWeek12;  Change from Baseline in Lipid Parameters at Week 12;  Change from Baseline in Lipid Parameters at Week 24;  Change from Baseline in Lipid Parameters at Week 52;  Proportion of Subjects Achieving Fasting LDL-C &lt;= 100 mg/dL and &lt;=70 mg/dL;  PlasmaPF-04950615concentration|2139|NCT01968967|October 2013
4327|Recruiting|A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer||Drug:Apalutamide;  Drug:Placebo|Interventional|Phase 3|Industry|Metastasis-freesurvival;  Overallsurvival;  Timetosymptomaticprogression;  Timetoinitiationofcytotoxicchemotherapy;  ProgressionFreeSurvival;  Timetometastasis;  Participants with change in FACT-P and EQ-5D questionnaire scores;  Numberofparticipantsaffectedbyadverseevents;  Plasma concentrations of apalutamide and metabolite ARN000308|1200|NCT01946204|October 2013
4328|Active not recruiting|A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain||Drug:Elagolix;  Other:placebo|Interventional|Phase 3|Industry|Proportion of responders with Endometriosis Associated Pain assessed using modified Biberoglu and Behrman (B&amp;B) scale;  ChangefromBaselineinBoneMineralDensity;  Change in Endometrial Thickness assessed by Transvaginal Ultrasound (TVU);  Change in percentage of subjects with significant Transvaginal Ultrasound (TVU) findings;  ChangeinClinicalLaboratoryTests;  ProportionofsubjectswithAdverseEvents|788|NCT01931670|May 2013
4329|Completed|RDEA3170 Monotherapy in Subjects With Gout||Drug:Placebo;  Drug:RDEA31705mg;  Drug:RDEA317010mg;  Drug:RDEA317012.5mg|Interventional|Phase 2|Industry|EfficacyofRDEA3170monotherapyatWeek12;  Incidence of treatment-emergent adverse events and change from baseline in laboratory values vital signs and electrocardiograms;  EfficacyofRDEA3170monotherapyatWeek24|172|NCT01927198|August 2013
4330|Completed|Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients||Drug:TERIFLUNOMIDEHMR1726|Interventional|Phase 4|Industry|Assessment at 48 weeks of global satisfaction with teriflunomide treatment measured by the Treatment Satisfaction Questionnaire for Medicine (TSQM) version 1.4 score;  Change in Treatment Satisfaction Questionnaire for Medicine (TSQM) from baseline to week 4 (W4) and to week 48 (W48) in patients switching from another Disease Modifying Therapy (DMT);  Change in Treatment Satisfaction Questionnaire for Medicine (TSQM) from W4 to W48 in na&#239;ve patients;  Change in disease progression from baseline to week 24 (W24) and to W48 of teriflunomide treatment measured by the Patient Determined Disease Steps (PDDS);  Change in disease progression from baseline to W24 and to W48 of teriflunomide treatment measured by the Multiple Sclerosis Performance Scale (MSPS) score;  Clinical outcomes: treated relapses time to first treated relapse;  Change in cognition from baseline to W48 of teriflunomide treatment measured by the Symbol Digit Modalities Test (SDMT) score;  Overview of adverse events (AEs) based on AE reporting at each visit;  Adherence (ie compliance) and persistence (ie duration of exposure) to teriflunomide treatment;  Quality of life: change from baseline to W48 of teriflunomide treatment measured by the Multiple Sclerosis International Quality of Life (MusiQoL) score and Stern Leisure Activity Scale;  ExpandedDisabilityStatusScale(EDSS)score|1001|NCT01895335|June 2013
4331|Active not recruiting|Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors||Other:LaboratoryBiomarkerAnalysis;  Drug:PazopanibHydrochloride;  Other:Placebo;  Other:Quality-of-LifeAssessment|Interventional|Phase 2|NIH|Progression-freesurvival;  Duration of response (DR) for the subset of patients with a confirmed CR or PR;  Objective response rate (ORR) defined as the percentage of patients with a confirmed complete response (CR) or partial response (PR) per RECIST 1.1 criteria;  Overallsurvival(OS);  Time to second progression for patients who crossover from placebo to active therapy;  Timetotreatmentfailure|165|NCT01841736|June 2013
4332|Completed|Extension Study for 2993-112||Drug:AC2993|Interventional|Phase 3|Industry|Change in HbA1c from Day 1 of Protocol 2993-112 to Week 52 (or termination);  Change in body weight from Day 1 of Protocol 2993-112 to Week 52 (or termination)|225|NCT01789957|September 2002
4333|Completed                  Has Results|Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination &#177; Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection||Drug:LDV/SOF;  Drug:RBV|Interventional|Phase 3|Industry|Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12);  Incidence of Adverse Events Leading to Permanent Discontinuation From Any Study Drug;  Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24);  Percentage of Participants With HCV RNA &lt; LLOQ at Week 1;  Percentage of Participants With HCV RNA &lt; LLOQ at Week 2;  Percentage of Participants With HCV RNA &lt; LLOQ at Week 4;  Percentage of Participants With HCV RNA &lt; LLOQ at Week 8;  Percentage of Participants With HCV RNA &lt; LLOQ at Week 12;  Percentage of Participants With HCV RNA &lt; LLOQ at Week 24;  ChangeFromBaselineinHCVRNAatWeek1;  ChangeFromBaselineinHCVRNAatWeek2;  ChangeFromBaselineinHCVRNAatWeek4;  ChangeFromBaselineinHCVRNAatWeek8;  PercentageofParticipantsWithVirologicFailure|441|NCT01768286|January 2013
4334|Completed|ADenosine Vasodilator Independent Stenosis Evaluation II - ADVISE II|||Observational||Industry|HemodynamicSeverity;  Specificity|818|NCT01740895|December 2012
4335|Completed                  Has Results|Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV||Drug:LDV/SOF;  Drug:RBV|Interventional|Phase 3|Industry|Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Study Drug (SVR12);  Incidence of Adverse Events Leading to Permanent Discontinuation From Any Study Drug;  Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Study Drug;  Percentage of Participants With HCV RNA &lt; LLOQ at Week 2;  Percentage of Participants With HCV RNA &lt; LLOQ at Week 4;  Percentage of Participants With HCV RNA &lt; LLOQ at Week 8;  ChangeFromBaselineinHCVRNAatWeek2;  ChangeFromBaselineinHCVRNAatWeek4;  ChangeFromBaselineinHCVRNAatWeek8;  PercentageofParticipantsWithVirologicFailure|870|NCT01701401|September 2012
4336|Completed|Efficacy and Safety Study With Diltiazem Hydrochloride Cream to Treat Anal Fissures||Drug:VEN307;  Drug:Placebo|Interventional|Phase 3|Industry|Change from baseline (average NRS during the last 3 days in which subject had a defecation during the 7 day screening period) in average of worst AF-related pain associated with or following defecation for Days 22-28 (Week 4).|434|NCT01690221|October 2012
4337|Completed                  Has Results|Comparison Study of the Glycemic Effects Safety and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus||Drug:Exenatideonceweeklysuspension;  Drug:Sitagliptin;  Drug:Placebo|Interventional|Phase 3|Industry|Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28;  Percentage of Subjects Achieving HbA1c &lt;7% at Week 28;  Change in Fasting Plasma Glucose Concentrations From Baseline to Week 28;  Change in Body Weight (kg) From Baseline to Week 28;  Change in 2-hour Postprandial Glucose Concentrations From Baseline to Week 16 (Visit 8)|365|NCT01652729|February 2013
4338|Recruiting|Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)||Biological:Placeboplusstandardtherapy;  Biological: Belimumab 10 mg/kg plus standard therapy;  Drug:Standardtherapy|Interventional|Phase 4|Industry|Response rate at 52 weeks measured by the SLE Responder Index (SRI);  Timetofirstsevereflare(SLEFlareIndex);  Reductioninprednisonedose;  Number of participants who experienced adverse events|816|NCT01632241|February 2013
4339|Terminated|Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients||Drug:BMS-823778;  Drug:PlacebomatchingwithBMS-823778|Interventional|Phase 2|Industry|The dose-dependent trend among doses of BMS-823778 and placebo by assessing the change from baseline in 24-hour ambulatory diastolic blood pressure following 12 weeks of double-blind treatment;  Change in 24-hour ambulatory systolic blood pressure (SBP)(evaluation of the dose-dependent trend);  Change in 24-hour ambulatory diastolic blood pressure (DBP);  Changein24-hourambulatorySBP;  ChangeinambulatorydaytimeandnighttimeDBP;  ChangeinambulatorydaytimeandnighttimeSBP;  ChangeinseatedDBP;  ChangeinseatedSBP|7|NCT01602367|July 2012
4340|Recruiting|Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy||Drug:ART-123;  Drug:Placebo|Interventional|Phase 3|Industry|PrimaryEfficacyOutcomeMeasure;  PrimarySafetyOutcomeMeasure;  SecondaryEfficacyOutcomeMeasure;  SecondarySafetyOutcomeMeasure|800|NCT01598831|August 2012
4341|Active not recruiting|Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia||Biological:Rituximab;  Drug:Prednisone;  Drug:Etoposide;  Drug:DoxorubicinHydrochloride;  Drug:Cytarabine;  Drug:VincristineSulfate;  Drug:Cyclophosphamide;  Drug:Methotrexate;  Drug:Methylprednisolone;  Drug:LeucovorinCalcium;  Drug:TherapeuticHydrocortisone;  Other:LaboratoryBiomarkerAnalysis|Interventional|Phase 2 / Phase 3|Other / NIH|EFS;  Survival;  Complete remission rate compared between arms by logistic regression;  Acute and long-term toxicity as assessed by the National Cancer Institute Common Terminology Criteria version 4.0;  Immune reconstitution as assessed by Ig (G A and M) levels and lymphocyte counts|640|NCT01595048|June 2012
4342|Completed|Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin||Drug:PBO;  Drug:200mgPF-04950615(RN316);  Drug:300mgPF-04950615(RN316);  Drug:PF-04950615|Interventional|Phase 2|Industry|The absolute change from baseline in Low Density Lipoprotein-cholesterol at the end of week 12 following randomization;  Low Density Lipoprotein-Cholesterol (LDL-C) will be assessed as change and % change from baseline at the end of week 12 following randomization;  Safety endpoints will include incidence of anti-drug antibody (ADA) injection site;  Plasma steady-state PF-04950615 pharmacokinetic parameters what PK measurements are being done?;  Proportion of subjects having LDL-C less than particular limits (&lt;100mg/dL &lt;70 mg/dL &lt;40mg/L &lt;25mg/dL);  Total cholesterol will be assessed as change and % change from baseline at the end of week 12 following randomization;  Apolipoprotein B (ApoB) will be assessed as change and % change from baseline at the end of week 12 following randomization;  Apolipoprotein A1 (ApoA1) Apolipoprotein AII (ApoAII) will be assessed as change and % change from baseline at the end of week 12 following randomization;  Lipoprotein (a) (Lp(a)) will be assessed as change and % change from baseline at the end of week 12 following randomization;  High Density Lipoprotein (HDL)-cholesterol will be assessed as change and % change from baseline at the end of week 12 following randomization;  Very Low Density Lipoprotein (VLDL)-cholesterol will be assessed as change and % change from baseline at the end of week 12 following randomization;  Triglycerides will be assessed as change and % change from baseline at the end of week 12 following randomization;  non-HDL-cholesterol will be assessed as change and % change from baseline at the end of week 12 following randomization|356|NCT01592240|July 2012
4343|Completed|Head to Head Study Epi proColon and FIT|||Observational||Industry|Non-inferiority of Epi proColon test result compared to FIT result using a 95% confidence interval for difference in sensitivities and differences in specificities below a strictly defined margin.|336|NCT01580540|March 2012
4344|Terminated                  Has Results|An Efficacy Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)||Drug:GlatiramerAcetate;  Drug:Placebo|Interventional|Phase 3|Industry|The Annualized Relapse Rate During the Placebo Controlled Period;  The Cumulative Number of New or Enlarging T2 Lesions Measured at Months 6 and 12 (End of Placebo Controlled Period);  The Cumulative Number of Gadolinium-enhancing Lesions on T1-weighted Images Measured at Months 6 and 12 (End of Placebo Controlled Period);  Percent Change From Baseline to Month 12 (End of Placebo Controlled Period) in Brain Volume|178|NCT01578785|March 2012
4345|Completed                  Has Results|8-week Randomized Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension||Drug:Aliskiren|Interventional|Phase 4|Industry|Change From Baseline (Visit 3) to End of Study (Week 8) in Mean 24 Hour Ambulatory Systolic Blood Pressure (maSBP);  Change From Baseline (Visit 3) to End of Study (Week 8) in Mean 24 Hour Ambulatory Diastolic Blood Pressure (maDBP);  Percentage of Patients Achieving Blood Pressure Control;  Change From Baseline (Visit 3) to End of Study (8 Weeks) in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP);  Percentage of Patients Achieving a Successful Response in Systolic Blood Pressure Reduction;  Pharmacokinetic (PK) of Aliskiren: The Observed Maximum Plasma Concentration (Cmax) Following Drug Administration in Fasted vs. Fed;  Pharmacokinetic of Aliskiren: The Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau (AUCtau) in Fasted vs. Fed;  Pharmacokinetic of Aliskiren: Time to Reach the Maximum Concentration (Tmax) After Drug Administration in Fasted vs. Fed;  Change From Baseline to Week 8 in Plasma Renin Activity (PRA);  Change From Baseline to Week 8 in Plasma Renin Concentration (PRC);  Number of Patients With Adverse Events Serious Adverse Events and Death|589|NCT01570686|April 2012
4346|Withdrawn|Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine Leiomyoma||Drug:UlipristalAcetate;  Drug:Iron|Interventional|Phase 3|Industry|Changefrombaselineinhemoglobinlevels(g/dL)|0|NCT01553123|April 2012
4347|Active not recruiting                  Has Results|Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia||Drug:Azacitidine;  Drug:Lenalidomide;  Drug:Vorinostat|Interventional|Phase 2|NIH|ResponseRate(PhaseII);  OverallSurvival(PhaseIII);  Relapse-freeSurvival;  OverallSurvival;  Pre-studyCytogeneticAbnormalities;  ToxicityRate|282|NCT01522976|March 2012
4348|Completed                  Has Results|Combining Lesinurad With Allopurinol in Inadequate Responders||Drug:Lesinurad;  Drug:Placebo;  Drug:Allopurinol|Interventional|Phase 3|Industry|Subjects With a Serum Urate (sUA) &lt; 6.0 mg/dL by Month 6.;  GoutFlares;  Subjects With &#8805; 1 Target Tophus at Baseline Who Experience Complete Resolution of at Least 1 Target Tophus by Month 12|610|NCT01493531|December 2011
4349|Active not recruiting|A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.||Drug:AMR101;  Drug:Placebo|Interventional|Phase 3|Other|Composite endpoint of CV death MI stroke coronary revascularization and hospitalization for unstable angina.;  Incidence of additional cardiovascular events lipid and lipoprotein levels subgroup analyses such as: diabetics etc.|8000|NCT01492361|November 2011
4350|Terminated                  Has Results|Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes||Drug:TAK-875;  Drug:Glimepiride|Interventional|Phase 3|Industry|ChangeFromBaselineinHbA1catWeeks78and104;  PercentageofParticipantsWithHypoglycemia;  Change From Baseline in Body Weight at Weeks 78 and 104;  ChangeFromBaselineinHbA1catWeeks26and52;  PercentageofParticipantsWithHbA1c&lt;7%;  Percentage of Participants With HbA1c &lt;7% for Participants Who Did Not Report Hypoglycemia;  Change From Baseline in Fasting Plasma Glucose at Weeks 26 52 78 and 104|2454|NCT01481116|January 2012
4351|Completed                  Has Results|A Clinical Trial to Study the Safety Tolerance and Immunogenic Response to MCV4 Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age||Biological:rLP2086+MCV4+Tdap;  Biological:MCV4+Tdap+saline;  Biological:rLP2086+saline|Interventional|Phase 2|Industry|Geometric Mean Concentrations (GMC) for Diphtheria and Tetanus Antigens;  Geometric Mean Concentrations (GMC) for Acellular Pertussis Antigens;  Geometric Mean Titer (GMT) for Meningococcal Conjugate Vaccine (MCV4) Antigens;  Serum Bactericidal Assay Using Human Complement (hSBA) GMTs of PMB80 [A22] and PMB2948 [B24] 1 Month After Vaccination 3;  Percentage of Participants With Seroresponse for Tetanus Diphtheria and Acellular Pertussis (Tdap) and Meningococcal Conjugate Vaccine (MCV4) Antigens;  Percentage of Participants Achieving Predefined Antibody Level for Diphtheria and Tetanus Antigens;  Serum Bactericidal Assay Using Human Complement (hSBA) GMTs of PMB80 [A22] and PMB2948 [B24] Before Vaccination 1 and 1 Month After Vaccination 2;  Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer &gt;= Lower Limit of Quantitation (LLOQ);  Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer &gt;= Prespecified Titer Level|2648|NCT01461980|September 2011
4352|Enrolling by invitation|A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response|||Observational||Industry|Proportion of participants with at least one drug resistant mutation (DRM) loss from enrollment to end of study by treatment regimen;  Proportion of participants with DRM loss by unit category 1 2 3&#8230;n by treatment regimen;  AveragenumberofDRMlossbytreatmentregimen;  Liverdiseaseprogression;  Proportion of participants who develop hepatocellular carcinoma (HCC) through Week 144 by treatment regimen|650|NCT01457768|December 2011
4353|Completed|A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents||Drug:SymbicortpMDI;  Drug:budesonidepMDI|Interventional|Phase 3|Industry|Time to first event in composite endpoint (asthma-related death asthma-related intubation or asthma-related hospitalization);  Time to first event included in the definition of asthma exacerbation;  Percentofdayswithnoasthmasymptoms;  Percent of days with no activity limitation due to asthma;  Meannumberofpuffsofrescuemedicationperday;  AsthmaControlQuestionnaire(ACQ6)|12463|NCT01444430|December 2011
4354|Completed                  Has Results|Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)||Drug:Nebivolol;  Drug:Placebo|Interventional|Phase 4|Industry|TroughSeatedDiastolicBloodPressure(DBP);  TroughSeatedSystolicBloodPressure(SBP)|641|NCT01415531|August 2011
4355|Recruiting|Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer||Drug:Carboplatin;  Drug:Cisplatin;  Radiation:ExternalBeamRadiationTherapy;  Radiation:InternalRadiationTherapy;  Drug:Paclitaxel;  Other:Quality-of-LifeAssessment|Interventional|Phase 3|Other / NIH|Overallsurvivalrate;  Patternsofdiseaserecurrence;  Progression-freesurvivalrate;  Qualityoflifeincludingpsychosexualhealth;  Radiationprotocolcompliance;  Rateofacuteandlong-termtoxicities|780|NCT01414608|January 2012
4356|Completed                  Has Results|Allopurinol Outcome Study||Drug:Allopurinol|Interventional|Phase 4|Industry|SafetyofAllopurinol;  Proportion of Subjects With Serum Urate (sUA) Less Than 6.0 mg/dL;  IncidenceofGoutFlares;  Mean Change From Baseline to Month 6 in SF-36 PCS+MCS|1735|NCT01391325|July 2011
4357|Recruiting|Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia||Drug:Asparaginase;  Drug:Bortezomib;  Drug:Cytarabine;  Drug:DaunorubicinHydrochloride;  Drug:Etoposide;  Other:LaboratoryBiomarkerAnalysis;  Drug:MitoxantroneHydrochloride;  Other:PharmacologicalStudy;  Other:Quality-of-LifeAssessment;  Other:QuestionnaireAdministration;  Drug:SorafenibTosylate|Interventional|Phase 3|NIH|EFS;  EFS(ArmCCohort1);  EFS(ArmCCohort2);  EFS(ArmCCohort3);  Bortezomib pharmacokinetic plasma concentration-time profiles;  Change in parent-reported outcomes over time in recipients of SCT or chemotherapy;  Courseduration;  Incidenceoftreatment-relatedmortality;  Lengthofhospitalization;  OS;  OS(ArmCCohort1);  OS(ArmCCohort2);  OS(ArmCCohort3);  Parent-reportedquestionnairescores;  Proportion of high risk children without HR FLT3/ITD+ converting from positive MRD at end of Induction I to negative MRD at the end of Induction II;  Proportion of patients dying in each course of therapy;  Proportion of patients experiencing grade 3 or higher non-hematologic toxicities and infections assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0);  Relapse rate assessed by bone marrow analysis for leukemic blasts;  Remissionrateafter1courseoftherapy;  Remissionrateafter2coursesoftherapy;  SerumconcentrationsofGVHDbiomarkers;  Shortening fraction/ejection fraction percentages and change over time;  Systemic exposure of sorafenib tosylate and N-oxide metabolite for each course of induction and intensification (CL Vd time to maximum concentration [Tmax]&#189; area under curve [AUC]);  Timetobloodcountrecovery|1750|NCT01371981|June 2011
4358|Terminated                  Has Results|Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes||Drug:Valturna;  Drug:Amlodipine;  Drug:Chlorthalidone;  Drug:PlaceboofValturnaTablet;  Drug:PlaceboCapsule|Interventional|Phase 4|Industry|Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) After 12 Weeks of Treatment Ending With the Combination of Valturna and Amlodipine Versus Valturna Alone;  Change From Baseline in MSSBP After 12 Weeks of Treatment Ending With Between the Valturna + Chlorthalidone Combination and Valturna Alone;  Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) After 12 Weeks of Treatment;  PercentageofRespondersAfterTreatment;  Percentage of Patients Achieving Blood Pressure Control After Treatment;  Number of Patients With Adverse Events Serious Adverse Events and Death to Assess Safety and Tolerability of Treatment With Valturna and Chlorthalidone or Valturna and Amlodipine Versus Valturna Alone|975|NCT01368536|May 2011
4359|Terminated|Efficacy and Safety Study to Treat Subjects With Symptomatic Internal Hemorrhoids||Drug:Iferanserin;  Drug:Placebo;  Drug:Iferanserin+Placebo|Interventional|Phase 3|Industry|Proportion of subjects with cessation of bleeding by the end of Day 7 that persists for the remainder of the treatment period (through Day 14) will be analyzed as the primary endpoint;  Proportion of subjects with cessation of pain by the end of Day 7 that persists for the remainder of the treatment period (through Day 14).|403|NCT01355874|July 2011
4360|Completed                  Has Results|Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected Antiretroviral Treatment-Naive Adults||Drug:FTC/RPV/TDF;  Drug:EFV/FTC/TDF|Interventional|Phase 3|Industry|Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 48;  Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 96;  ChangeFromBaselineinCD4CellCountatWeek48;  ChangeFromBaselineinCD4CellCountatWeek96;  Change From Baseline in Fasting Total Cholesterol at Week 48;  Change From Baseline in Fasting High-density Lipoprotein (HDL) Cholesterol at Week 48;  Change From Baseline in Fasting Low-density Lipoprotein (LDL) Cholesterol at Week 48;  Change From Baseline in Fasting Triglycerides at Week 48;  Development of HIV-1 Drug Resistance Through Week 96 All Participants;  Development of HIV-1 Drug Resistance Through Week 96 Participants With Viral Resistance|799|NCT01309243|February 2011
4361|Terminated                  Has Results|A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor||Drug:tocilizumab[RoActemra/Actemra];  Drug:adalimumab;  Drug:placebototocilizumab;  Drug:placebotoadalimumab;  Drug:methotrexate;  Drug:folate|Interventional|Phase 4|Industry|Percentage of Participants With Disease Activity Score 28 Joints (DAS28) Remission at Week 24;  Percentage of Participants With American College of Rheumatology (ACR20) Response at Week 24;  Percentage of Participants With ACR50 Response at Week 24;  Percentage of Participants With ACR70 Response at Week 24;  Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) DAS28 Responses at Week 24;  Percentage of Participants With DAS28 Low Disease Activity (LDAS) at Week 24;  ChangeFromBaselineinDAS28ScoreatWeek24;  Change From Baseline in Swollen Joint Count (SJC) at Week 24;  Change From Baseline in Tender Joint Count (TJC) at Week 24;  Change From Baseline in Patient Assessment of Pain Visual Analog Scale (VAS) at Week 24;  Change From Baseline in the Patient Global Assessment of Disease Activity VAS at Week 24;  Change From Baseline in the Physician Global Assessment of Disease Activity VAS at Week 24;  Change From Baseline in High Sensitivity C-Reactive Protein (hsCRP) at Week 24;  Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Week 24;  Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24;  Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-Fatigue) Score at Week 24;  Change From Baseline in Quality of Life Short Form (SF-36) Score at Week 24;  Change From Baseline in Routine Assessment of Patient Index Data 3 (RAPID3) Score at Week 24;  ChangeFromBaselineinHemoglobinatWeek24;  Number of Participants With Serious Adverse Events (SAEs) Adverse Events (AEs) Discontinuation Due to AEs and Deaths|96|NCT01283971|May 2011
4362|Completed|Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer||Drug:Manukahoney;  Drug: Viscous lidocaine and magnesium aluminum oxide (Maalox&#174;); Liquid or solid oxycodone|Interventional|Phase 2|Other / NIH|Radiation esophagitis-related pain 4 weeks from the start of treatment as measured by the Numerical Rating Pain Scale for pain on swallowing (NRPS);  Radiation esophagitis during treatment as measured weekly during treatment and 12 weeks from the start of treatment by the NRPS;  Dysphagiaviadailypatientlog;  Quality of life and pain as measured by the EORTC QLQ-30 global QOL score and pain symptom subscale at 4 and 12 weeks;  Radiationesophagitisgrade3-4(CTCAEv.4);  Weight loss (percent change from baseline to 4 weeks);  Nutritional status (change in serum prealbumin levels from baseline to 4 weeks);  Opioiduse;  Adverse events associated with Manuka honey using CTCAE v. 4;  Patient reported adverse events associated with Manuka honey using the PRO-CTCAE|163|NCT01262560|February 2012
4363|Completed                  Has Results|Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer||Drug:AktInhibitorMK2206|Interventional|Phase 2|NIH|OverallSurvival(OS);  ProgressionFreeSurvival(PFS);  Response Rate (Complete and Partial Confirmed and Unconfirmed);  Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug|75|NCT01260701|January 2011
4364|Suspended|Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma||Drug:vincristinesulfate;  Drug:doxorubicinhydrochloride;  Drug:cyclophosphamide;  Drug:ifosfamide;  Drug:etoposide;  Drug:topotecanhydrochloride;  Other:laboratorybiomarkeranalysis|Interventional|Phase 3|Other / NIH|EFS;  Overallsurvival;  Relativeriskfordeath;  Histological response in terms of event free survival after local control in patients who received local control therapy;  Positron emission tomography (PET)-determined response in terms of event free survival after local control;  Probabilities of identifying tumors of at least 200 ml;  Extent of tumor necrosis according to the necrosis grading criteria in patients who have surgical resection of tumor;  Radiological response of soft tissue component of mass by PET;  Differences associated with local control modality on risk for EFS event according to surgery only v. radiation therapy only v. surgery and radiation therapy;  Number and proportion of patients who experience any grade 2 or higher musculoskeletal event (ME) or surgery required to treat a complication of local therapy;  Proportion of patients who have tumor present at the margin of resection on risk for EFS event in patients undergoing surgery|693|NCT01231906|November 2010
4365|Completed|Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma||Biological:Bevacizumab;  Drug:Cyclophosphamide;  Other:LaboratoryBiomarkerAnalysis;  Drug:Temsirolimus;  Drug:VinorelbineTartrate|Interventional|Phase 2|NIH|Event-freesurvival;  Feasibility assessed by rate of grade 3+ non-hematologic toxicity graded using Common Terminology Criteria for Adverse Events version 4.0;  Responserate(CR+PR)|85|NCT01222715|October 2010
4366|Terminated                  Has Results|Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery||Procedure:Postoperativechemotherapy;  Procedure:Perioperativechemotherapy|Interventional|Phase 3|Other / NIH|Recurrence-freeSurvival(RFS);  RFSofPatientsEvent-free;  OverallSurvival;  The Difference in R0 and Combined R0 + R1 Resection Rates Between the Two Arms.;  Frequencies of Selected Postoperative Surgical Complications and Other Adverse Events Within 30 Days of Surgery;  Frequencies of Adverse Events as Assessed by the NCI CTCAE v4.0|9|NCT01189227|August 2010
4367|Terminated                  Has Results|Conversion to Embeda With Rescue Trial||Drug: morphine sulfate and naltrexone hydrochloride (EMBEDA)|Interventional|Phase 4|Industry|Percentage of Participants Achieving Stable Dose of EMBEDA Within 6 Weeks Titration Phase;  Percentage of Participants Achieving Stable Dose of EMBEDA Within 6 Weeks Titration Phase Stratified by Prior Opioid Therapy;  DurationtoTitrateParticipantstoStableDose;  Duration to Titrate Participants to Stable Dose Stratified by Prior Opioid Therapy;  NumberofTitrationStepstoAchieveStableDose;  Number of Titration Steps to Achieve Stable Dose Stratified by Prior Opioid Therapy;  Percentage of Participants With Rescue Medications Usage During Titration;  Change From Baseline in Brief Pain Inventory (BPI) at Visit 3 (First Visit After Successful Titration);  Investigator&apos;s Level of Satisfaction With the EMBEDA Conversion Guide|684|NCT01179191|August 2010
4368|Completed|Study to Evaluate Efficacy Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals&apos; Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older||Biological:HerpesZosterVaccineGSK1437173A;  Biological:Placebo|Interventional|Phase 3|Industry|Number of subjects with First or only episode of herpes zoster (HZ);  Outcome measure for the pooled analysis of combined data from studies ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229): Number of subjects with post-herpetic neuralgia (PHN);  Outcome measure for the pooled analysis of combined data from studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of subjects with confirmed HZ;  Number of subjects with post-herpetic neuralgia (PHN);  Number of days with severe &apos;worst&apos; HZ-associated pain;  Number of subjects with confirmed HZ episode related mortality and hospitalizations;  Number of subjects with overall mortality and HZ-related mortality;  Number of subjects with confirmed HZ episode related hospitalizations;  NumberofsubjectswithHZrelatedcomplications;  Number of subjects receiving pain medication associated with HZ;  Number of days with pain medication associated with HZ;  Numberofsubjectswithsolicitedlocalsymptoms;  Number of subjects with solicited general symptoms;  Number of subjects with unsolicited adverse events (AEs);  Number of subjects with any related and fatal serious adverse events (SAEs);  Number of subjects with potential immune mediated diseases (pIMDs);  Number of subjects with Medically Attended events (MAEs);  Outcome measure for the pooled analysis of combined data from studies Zoster-006 (NCT01165177)and Zoster-022 (NCT01165229): Overall number of subjects with PHN in subjects &#8805; 50 YOA;  Outcome measure for the pooled analysis of combined data from studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of subjects with a reduction of PHN incidence in subjects &#8805; 50 YOA with confirmed HZ;  Outcome measure for the pooled analysis of combined data from studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of days with severe &apos;worst&apos; HZ-associated pain in subjects &#8805; 70 YOA with confirmed HZ.;  Outcome measure for the pooled analysis of combined data from studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of subjects with any and Grade 3 solicited local symptoms;  Outcome measure for the pooled analysis of combined data from studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of subjects with any Grade 3 and related solicited general symptoms;  Outcome measure for the pooled analysis of combined data from studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of subjects with unsolicited AEs in subjects &#8805; 70 YOA;  Outcome measure for the pooled analysis of combined data from studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): number of subjects with any related and fatal SAEs;  Outcome measure for the pooled analysis of combined data from studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of subjects with any pIMDs;  Outcome measure for the pooled analysis of combined data from studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of subjects with Medically Attended events (MAEs)|14819|NCT01165229|August 2010
4369|Completed|Study to Evaluate Efficacy Safety and Immunogenicity of GSK Biologicals&apos; Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older||Biological:HerpesZosterVaccineGSK1437173A;  Biological:Placebo|Interventional|Phase 3|Industry|Number of subjects with confirmed Herpes zoster (HZ) cases;  Number of subjects with any episodes of Post-Herpetic Neuralgia (PHN);  Number of subjects with a reduction of duration of severe &apos;worst&apos; HZ-associated pain;  Number of subjects with confirmed HZ episode related mortality;  Number of subjects with confirmed HZ episode related hospitalizations;  NumberofsubjectswithHZrelatedcomplications;  Number of subjects with a confirmed HZ episode taking pain medication associated with HZ;  Number of subjects with a confirmed HZ episode with a reduction on duration of pain medication associated with HZ;  Number of days with severe &apos;worst&apos; HZ-associated pain;  Number of subjects with confirmed HZ episode related mortality and hospitalizations;  Number of subjects with HZ related complications by complication type;  Distribution of pain medication associated with HZ;  Number of days of pain medication associated with HZ in subjects with a confirmed HZ episode;  Number of subjects with any and grade 3 solicited local symptoms;  Number of subjects with any grade 3 and related solicited general symptoms;  Number of subjects with any and Grade 3 symptoms (solicited and unsolicited);  Number of subjects with any and related potential Immune mediated diseases (pIMDs);  Number of subjects with AEs with any and related medically attended visit (MAEs);  Number of subjects with unsolicited adverse events (AEs);  Number of subjects with serious adverse events (SAEs)|16166|NCT01165177|August 2010
4370|Terminated|VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome||Drug:A-002varespladibmethyl;  Drug:Placebo|Interventional|Phase 3|Industry|PrimaryObjectiveoftheStudy;  SecondaryObjectiveoftheStudy|5189|NCT01130246|May 2010
4371|Active not recruiting|PRE-DETERMINE Cohort Study|||Observational||Other / NIH / Industry|To identify a series of genetic markers and biomarkers that specifically predict risk of arrhythmic death as compared to other causes of mortality among CAD patients with preserved left ventricular ejection fraction (LVEF &gt; 35%).;  To determine whether these genetic markers and biomarkers advance SCD risk prediction when combined with advanced substrate imaging by CE-MRI.|5763|NCT01114269|June 2007
4372|Completed                  Has Results|Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study||Drug:ADVAIRDISKUS250/50mgBID;  Drug:SEREVENT50mcgBID|Interventional|Phase 4|Industry|Number of Par. With Chronic Obstructive Pulmonary Disease (COPD) EXs Requiring Hospitalization That Occurred &gt;21 Days Post-discharge/Physician&apos;s Office Visit for a COPD EX Requiring Treatment With Oral Corticosteroids (OCSs) or OCSs and Antibiotics (ABs);  Number of Participants With the Indicated Number of EXs of COPD Requiring Hospitalization That Occurred More Than 21 Days Post-discharge or Physician&apos;s Office Visit for an EX of COPD Requiring Treatment With OCSs or OCSs and ABs;  Number of EXs of COPD Requiring Hospitalization That Occurred More Than 21 Days Post-discharge or Physician&apos;s Office Visit for an EX of COPD Requiring Treatment With OCSs or OCSs and ABs;  Number of Participants With an EX of COPD Requiring Treatment With OCSs Treatment With ABs and/or Hospitalization;  Number of EXs of COPD Requiring Treatment With OCSs Treatment With ABs and/or Hospitalization (Alone and in Combination)|639|NCT01110200|April 2010
4373|Completed                  Has Results|A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.||Biological:albiglutide;  Drug:sitagliptin|Interventional|Phase 3|Industry|Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26;  Mean Change From Baseline in HbA1c at Weeks 4 8 12 16 and 20: LOCF;  Mean Change From Baseline in HbA1c at Weeks 4 8 12 16 20 26 36 48 and Week 52: Observed Cases;  Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26;  Mean Change From Baseline in FPG at Weeks 4 8 12 16 20 and 26: LOCF;  Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 1 2 3 4 8 12 16 20 26 36 48 and Week 52: OC;  Number of Participants Who Achieved Clinically Meaningful HbA1c Response Levels of &lt;6.5% and &lt;7.0% at Week 26: LOCF;  Number of Participants Who Achieved a Clinically Meaningful Improvement in the HbA1c Response Level of &gt;=1.0% &gt;=1.5% and &gt;=2.0% at Week 26: LOCF;  Number of Participants Who Achieved a Clinically Meaningful HbA1c Response Level of &lt;6.5% and &lt;7.0% at Week 52: OC;  Number of Participants Who Achieved a Clinically Meaningful Improvement in the HbA1c Response Level of &gt;=1.0% &gt;=1.5% and &gt;=2.0% at Week 52: OC;  Number of Participants With the Indicated Time to Hyperglycemic Rescue Through Week 52;  TimetoHyperglycemicRescueThroughWeek52;  Change From Baseline in Body Weight at Week 26: LOCF;  Change From Baseline in Body Weight Through Week 26: LOCF;  Change From Baseline in Body Weight Through Week 52: OC;  Plasma Concentrations (Conc.) of Albiglutide at Week 8 and Week 16|507|NCT01098539|May 2010
4374|Completed                  Has Results|Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Antiretroviral Treatment-Naive Adults||Drug:Stribild;  Drug:Atripla;  Drug:StribildPlacebo;  Drug:AtriplaPlacebo|Interventional|Phase 3|Industry|The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) &lt; 50 Copies/mL at Week 48;  The Percentage of Participants With Virologic Success Using the FDA-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 RNA &lt; 50 Copies/mL at Week 96;  The Percentage of Participants With Virologic Success Using the FDA-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 RNA &lt; 50 Copies/mL at Week 144;  The Percentage of Participants With Virologic Success Using the FDA-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 RNA &lt; 50 Copies/mL at Week 192;  The Percentage of Participants Achieving and Maintaining Confirmed HIV-1 RNA &lt; 50 Copies/mL at Week 48 Using the FDA-defined Time to Loss of Virologic Response (TLOVR) Algorithm;  The Change From Baseline in Cluster Determinant 4 (CD4) Cell Count at Weeks 48 96 144 and 192;  The Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 48|707|NCT01095796|March 2010
4375|Terminated                  Has Results|Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America||Drug:Flibanserin;  Drug:Placebo|Interventional|Phase 3|Industry|Change From Baseline in the Number of Satisfying Sexual Events;  Change From Baseline in the Score on the Female Sexual Function Index (FSFI) Desire Domain|748|NCT01057901|January 2010
4376|Completed|A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus||Drug:Aleglitazar;  Drug:Placebo|Interventional|Phase 3|Industry|Effect on cardiovascular death non-fatal myocardial infarction and non-fatal stroke;  Effectsonothercardiovascularendpoints;  Glycemic control lipoprotein profile blood pressure biomarkers of cardiovascular risk;  Tolerabilityandlong-termsafetyprofile|7226|NCT01042769|February 2010
4377|Terminated                  Has Results|This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure||Drug:LCZ696200mgBID;  Drug:Enalapril10mgBID|Interventional|Phase 3|Industry|Number of Participants That Had First Occurrence of the Composite Endpoint Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization;  NumberofPatients-All-causeMortality;  Number of Patients Reported With Adjudicated Primary Causes of Death;  Change From Baseline to Month 8 for the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score;  Number of Patients With First Confirmed Renal Dysfunction;  Percentage of Participants With New Onset of Atrial Fibrillation (AF)|8442|NCT01035255|December 2009
4378|Active not recruiting|Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma||Biological:bleomycinsulfate;  Drug:doxorubicinhydrochloride;  Drug:liposomalvincristinesulfate;  Drug:vinorelbinetartrate;  Drug:cyclophosphamide;  Drug:etoposidephosphate;  Drug:prednisone;  Biological:filgrastim;  Drug:ifosfamide|Interventional|Phase 3|Other / NIH|Second-event-freesurvival;  Safetyanalysisandmonitoringoftoxicdeath;  EFSof93%;  Achieve a similar outcome for patients with RER and SER through intensification of therapy for SER patients;  Prognostic significance of &quot;very early response&quot; as assessed by PET scan;  Patterns of relapse after ABVE-PC and risk-adapted RT;  Grade3and4non-hematologictoxicities;  Overallsurvival|166|NCT01026220|December 2009
4379|Completed                  Has Results|Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes||Drug:BI10773placebo;  Drug:BI10773lowdose;  Drug:BI10773highdose|Interventional|Phase 2|Industry|Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) After 18 Weeks of Treatment;  Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5%) After 18 54 and 78 Weeks of Treatment;  Change From Baseline in Fasting Plasma Glucose (FPG) After 18 54 and 78 Weeks of Treatment;  Percent Change From Baseline in Fasting Plasma Glucose (FPG) After 18 54 and 78 Weeks of Treatment;  Change From Baseline in Basal Insulin Dose/Day After 54 and 78 Weeks of Treatment;  Change From Baseline in Body Weight After 18 54 and 78 Weeks of Treatment;  ChangeFromBaselineinBodyWeightatFollow-up;  Change From Baseline in HbA1c After 54 and 78 Weeks of Treatment;  The Occurrence of Treat to Target Efficacy Response That is an HbA1c Under Treatment of &lt;7.0% After 18 54 and 78 Weeks of Treatment|494|NCT01011868|November 2009
4380|Completed|Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis||Drug:Budesonide;  Drug:Placebo|Interventional|Phase 3|Industry|Theproportionofsubjectswhoachieveremission.|265|NCT01008410|November 2009
4381|Completed|Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus||Drug:TAK-875;  Drug:Glimepiride;  Drug:Placebo|Interventional|Phase 2|Industry|Change from Baseline in Glycosylated Hemoglobin at Week 12.;  Change from Baseline in Fasting Plasma Glucose at Week 12.;  ChangefromBaselineinBodyWeightatWeek12.;  Incidence of Hypoglycemia During Double-Blind Treatment Period.|426|NCT01007097|December 2009
4382|Active not recruiting|Paclitaxel Carboplatin and Bevacizumab or Paclitaxel Carboplatin and Temsirolimus or Ixabepilone Carboplatin and Bevacizumab in Treating Patients With Stage III Stage IV or Recurrent Endometrial Cancer||Biological:Bevacizumab;  Drug:Carboplatin;  Drug:Ixabepilone;  Other:LaboratoryBiomarkerAnalysis;  Drug:Paclitaxel;  Drug:Temsirolimus|Interventional|Phase 2|NIH|Progression-freesurvivalassessedbyRECIST;  BestconfirmedresponseassessedbyRECIST;  Overallsurvival|330|NCT00977574|September 2009
4383|Completed                  Has Results|A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine||Biological:albiglutide+insulinglargine;  Drug: insulin glargine + preprandial lispro insulin|Interventional|Phase 3|Industry|Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 26;  Change From Baseline in HbA1c at Weeks 36 48 and 52;  Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26;  Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 36 48 and 52;  Number of Participants Who Achieved HbA1c Response Level of &lt;6.5% and &lt;7.0% at Week 26;  TimetoHyperglycemiaRescue;  ChangeFromBaselineinBodyWeightatWeek26;  Change From Baseline in Body Weight at Weeks 36 48 and 52|586|NCT00976391|September 2009
4384|Terminated|Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Pioglitazone||Drug:Placebo;  Drug:Dutogliptin|Interventional|Phase 3|Industry|HemoglobinA1cLevel(HbA1c);  FastingPlasmaGlucoseLevel(FPG)|252|NCT00970424|August 2009
4385|Active not recruiting|Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone||Drug:Lapatinib;  Biological:Trastuzumab|Interventional|Phase 3|Industry|Progression-freesurvival;  Overallsurvival;  Clinical benefit response rate (CR PR or SD &#8805;24 weeks);  Determine the qualitative and quantitative adverse event profile of the 2 treatment arms|280|NCT00968968|January 2010
4386|Recruiting|Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer||Biological:cetuximab;  Radiation:intensity-modulatedradiationtherapy|Interventional|Phase 3|Other / NIH|Overallsurvival;  Adverse events (dysphagia xerostomia and skin toxicity) according to CTCAE v. 4 and their relationships with patient-reported outcomes at 3 12 and 24 months;  Other acute adverse events (&#8804; 90 days from start of radiotherapy [RT]) according to CTCAE v. 4;  Other late adverse events (&gt; 90 days from start of RT) according to CTCAE v. 4;  Disease-freesurvival;  Loco-regionalcontrol;  Quality of life as measured by Functional Assessment of Cancer Therapy-Head &amp; Neck (FACT-HN) and EuroQol (EQ-5D) at baseline and at 3 12 and 24 months;  Xerostomia as measured by University of Michigan Xerostomia-Related Quality of Life Scale (XeQOLS) at baseline and at 3 12 and 24 months;  Swallowing as measured by the normalcy of diet subscale of the Performance Status Scale for Head and Neck Cancer (PSS-HN) at baseline and at 3 12 and 24 months;  Skin toxicity as measured by the Dermatology Life Quality Index (DLQI) at baseline and at 3 12 and 24 months|700|NCT00956007|November 2009
4387|Terminated|Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin||Drug:Dutogliptin;  Drug:Placebo|Interventional|Phase 3|Industry|HemoglobinA1c(HbA1c);  FastingPlasmaGlucose(FPG)|677|NCT00947557|July 2009
4388|Active not recruiting|Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor||Biological:Dactinomycin;  Drug:DoxorubicinHydrochloride;  Drug:VincristineSulfate;  Drug:Carboplatin;  Drug:Cyclophosphamide;  Drug:EtoposidePhosphate;  Radiation:RadiationTherapy;  Procedure:TherapeuticConventionalSurgery;  Procedure:AdjuvantTherapy;  Procedure:NeoadjuvantTherapy|Interventional|Phase 3|Other / NIH|Event-freesurvival;  Prevention of complete removal of at least one kidney in 50% of patients with bilateral Wilms tumor (BWT);  Efficacy of chemotherapy in preserving renal units and preventing Wilms tumor development in patients with diffuse hyperplastic perilobular nephrogenic rests;  Facilitation of partial nephrectomy in lieu of total nephrectomy in 25% of patients with unilateral Wilms tumor;  Percentage of patients with bilateral Wilms tumor (BWT) undergoing definitive surgical treatment by week 12|249|NCT00945009|July 2009
4389|Completed                  Has Results|An Investigational Drug PF-02341066 Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene||Drug:PF-02341066|Interventional|Phase 2|Industry|ObjectiveResponseRate;  PercentageofParticipantsWithAdverseEvents;  DurationofResponse(DR);  TimetoTumorResponse(TTR);  DiseaseControlRate(DCR);  ProgressionFreeSurvival(PFS);  Mean Change From Baseline in QLQ-C30 Global Quality of Life Scores.;  Patient Reported Outcomes (PROs) of Health-related Quality of Life (HRQoL): Mean Change From Baseline of EQ-5D Visual Analog Score (VAS) Scale;  Percentage of Participants With Visual Symptom Assessment Questionnaire (VSAQ-ALK);  Plasma Concentrations of Crizotinib (PF-02341066) and Its Metabolite PF-06260182;  Molecular Profiling (ALK Status) Descriptive Statistics for ALK Percentage of Positive Cells by Central Laboratory Test (SA [ALK Positive by IUO] Population);  Genotypes of Alleles Possibly Associated With Adverse Hepatic Drug Reactions (Pharmacogenomic Evaluable Population);  QTcProlongationinParticipants;  OverallSurvival(OS);  ProbabilityofSurvival;  Mean Change From Baseline of EORTC QLQ-C30 Functional and Symptom Scale Scores;  Mean Change From Baseline of QLQ-LC13 Scale Scores|1068|NCT00932451|January 2010
4390|Completed                  Has Results|A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency||Drug:Fesoterodine;  Drug:Placebo|Interventional|Phase 4|Industry|Mean Number of Micturition-related Nocturnal Urgency Episodes Per 24 Hours;  Change From Baseline in Mean Number of Micturition-related Nocturnal Urgency Episodes Per 24 Hours at Week 12;  Change From Baseline in Mean Number of Micturition-related Nocturnal Urgency Episodes Per 24 Hours at Week 4;  Percent Change From Baseline in Micturition-related Nocturnal Urgency Episodes Per 24 Hours at Week 4 and 12;  NumberofNocturnalMicturitionsPer24Hours;  Change From Baseline in Number of Nocturnal Micturitions Per 24 Hours at Week 4 and 12;  Percent Change From Baseline in Nocturnal Micturitions Per 24 Hours at Week 4 and 12;  MeanNumberofMicturitionsPer24Hours;  Change From Baseline in Mean Number of Micturitions Per 24 Hours at Week 4 and 12;  Percent Change From Baseline in Micturitions Per 24 Hours at Week 4 and 12;  Number of Micturition-related Urgency Episodes Per 24 Hours;  Change From Baseline in Number of Micturition-related Urgency Episodes Per 24 Hours at Week 4 and 12;  Percent Change From Baseline in Micturition-related Urgency Episodes Per 24 Hours at Week 4 and 12;  Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours;  Change From Baseline in Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 4 and 12;  Percent Change From Baseline in of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 4 and 12;  Nocturnal Frequency-urgency Sum Rating Per 24 Hours;  Change From Baseline in Nocturnal Frequency-urgency Sum Rating Per 24 Hours at Week 4 and 12;  Frequency-urgencySumRatingPer24Hours;  Change From Baseline in Frequency-urgency Sum Rating Per 24 Hours at Week 4 and 12;  MeanVoidedVolumePerNocturnalMicturition;  Change From Baseline in Mean Voided Volume Per Nocturnal Micturition at Week 12;  MeanVoidedVolumePerMicturition;  Change From Baseline in Mean Voided Volume Per Micturition at Week 12;  Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score;  Change From Baseline in Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score at Week 4 and 12;  Health Related Quality of Life (HRQL) Domain and Total Score of Overactive Bladder Questionnaire (OAB-q);  Change From Baseline in Health Related Quality of Life (HRQL) Domain and Total Score of Overactive Bladder Questionnaire (OAB-q) at Week 4 and 12|963|NCT00911937|August 2009
4391|Completed                  Has Results|Open-Label Extension of a Randomized Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza&#174; and Simvastatin Therapy in Hypertriglyceridemic Subjects||Drug: Simvastatin + Lovaza&#174; (omega-3-acid ethyl esters)|Interventional|Phase 3|Industry|Median Percent Change of Non-HDL-C (High Density Lipoprotein-Cholesterol) in Switchers vs. Non-Switchers Subjects From LOV111858 End-of-Treatment (Week 8) to Month 4 of Extension Study (LOV111818);  Median Percent Change of Lipid Measurements From LOV111858 End-of-Treatment Week 8 to Months 4 12 and 24 of the Open-Label Extension Study (LOV111818) in &quot;Switchers&quot; vs. Non-switchers;  Median Percent Change of Lipid Measurements From LOV111858 End-of-Treatment Week 8 to LOV111818 Months 4 12 and 24 of the Open-Label Extension Trial|188|NCT00903409|November 2005
4392|Active not recruiting|Collecting and Storing Biological Samples From Young Patients With Hodgkin&apos;s Lymphoma||Other:CytologySpecimenCollectionProcedure|Observational||Other / NIH|Biologicspecimenrepositoryanddatabase|1272|NCT00900250|October 2006
4393|Recruiting|Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma||Other:biologicsamplepreservationprocedure|Observational||Other / NIH|Collect biological specimens from patients with osteosarcoma;  Provide a repository for long-term storage of osteosarcoma-related biological materials;  Make these specimens available to qualified researchers to understand the biology of osteosarcoma;  Correlate these results with the patients&apos; clinical data|1000|NCT00899275|February 2008
4394|Recruiting|Collecting and Storing Malignant Borderline Malignant Neoplasms and Related Samples From Young Patients With Cancer||Other:cytologyspecimencollectionprocedure|Observational||Other / NIH|Repository of malignant borderline malignant neoplasms and related biological specimens|3000|NCT00898079|March 2003
4395|Unknown&nbsp;&#8224;|Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma||Drug:asparaginase;  Drug:doxorubicinhydrochloride;  Drug:therapeutichydrocortisone;  Drug:liposomalvincristinesulfate;  Drug:cytarabine;  Drug:prednisone;  Drug:bortezomib;  Drug:pegaspargase;  Drug:methotrexate;  Drug:etoposidephosphate;  Drug:cyclophosphamide;  Biological:filgrastim;  Drug:leucovorincalcium;  Other:laboratorybiomarkeranalysis|Interventional|Phase 2|NIH|Second complete remission rate at the end of block 1 reinduction chemotherapy;  PK of bortezomib in patients receiving multi-agent combination therapy;  Toxicity according to NCI Common Terminology Criteria for Adverse Events version 4.0;  Minimalresidualdisease|151|NCT00873093|March 2009
4396|Completed|PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1||Drug:rilonacept|Interventional|Phase 3|Industry|numberofflaresduringthetreatmentperiod;  number of modified gout flares per subject from Day 1 to Week 16;  proportion of subjects with at least one flare from Day 1 to Week 16;  proportion of subjects with at least two flares from Day 1 to Week 16;  mean number of gout flare days per subject assessed from Day 1 to Week 16;  mean number of days with the subject&apos;s pain score of 5 or more (daily diary) per subject from Day 1 to Week 16|241|NCT00829829|February 2009
4397|Completed                  Has Results|Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn&apos;s Disease||Drug:vedolizumab;  Other:Placebo|Interventional|Phase 3|Industry|Induction Phase: Percentage of Participants Achieving Clinical Remission at Week 6;  Induction Phase: Percentage of Participants With Enhanced Clinical Response at Week 6;  Maintenance Phase: Percentage of Participants Achieving Clinical Remission at Week 52;  Induction Phase: Change From Baseline in C-Reactive Protein (CRP) Levels at Week 6;  Maintenance Phase: Percentage of Participants With Enhanced Clinical Response at Week 52;  Maintenance Phase: Percentage of Participants in Corticosteroid-free Clinical Remission at Week 52;  Maintenance Phase: Percentage of Participants With Durable Clinical Remission|1116|NCT00783692|December 2008
4398|Completed|S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I Stage II or Stage IIIA Breast Cancer Undergoing Chemotherapy||Dietary Supplement: acetyl-L-carnitine hydrochloride;  Other:placebo|Interventional|Phase 3|Other / NIH|Neurotoxicity as measured by the 11-item neurotoxicity component of the FACT-Taxane Questionnaire at baseline and at 12 weeks;  Functional status as measured by the FACT-Taxane Trial Outcome Index at baseline and at 12 24 and 36 weeks;  Fatigue as measured by the FACIT-Fatigue Symptom Module at baseline and at 12 24 and 36 weeks;  Proportion of patients experiencing grade 2 or 3 neuropathy as measured by NCI CTCAE v3.0 criteria at 12 24 and 36 weeks;  Nerve growth factor levels at baseline and 12 weeks;  Total dose of taxane received and treatment delays compliance with therapy and use of concurrent medications dietary supplements (e.g. glutamine) vitamin E and complementary and alternative medicines;  Relationship between nerve growth factor levels and the degree of neuropathy and functional status;  Relationship between genetic markers responsible for taxane metabolism and clearance and degree of neuropathy|437|NCT00775645|September 2009
4399|Completed                  Has Results|A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn&apos;s Disease Who Have Been Previously Treated With Anti-TNF Therapy||Drug:Placebo(IP);  Drug:Ustekinumab1mg/kg(IP);  Drug:Ustekinumab3mg/kg(IP);  Drug:Ustekinumab6mg/kg(IP);  Drug:PlaceboIV-Responder-PlaceboSC(MP);  Drug: Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP);  Drug: Ustekinumab IV - Responder - Placebo SC (MP);  Drug: Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP);  Drug: Ustekinumab IV - Nonresponder - Placebo SC (MP);  Drug: Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)|Interventional|Phase 2|Industry|Number of Participants With Clinical Response at Week 6;  Number of Participants With Clinical Remission at Week 6;  Number of Participants With Clinical Response at Week 4;  Number of Participants With Clinical Response at Week 8;  Number of Participants With Clinical Remission at Week 8;  Number of Participants With Clinical Remission at Week 22 (Among Responders From Week 6);  Number of Participants With Clinical Response at Week 22 (Among Responders From Week 6)|526|NCT00771667|December 2008
4400|Completed                  Has Results|Phase III Randomized Double-Blind Placebo-Controlled Trial of Linaclotide Administered to Patients With Chronic Constipation||Drug:Linaclotide290micrograms;  Drug:Linaclotide145micrograms;  Drug:Placebo|Interventional|Phase 3|Industry|Complete Spontaneous Bowel Movement (CSBM) Overall Responder;  12-week Complete Spontaneous Bowel Movement (CSBM) Frequency Rate;  12-Week Spontaneous Bowel Movement (SBM) Frequency Rate;  12-WeekStoolConsistency;  12-WeekSeverityofStraining;  12-WeekAbdominalDiscomfort;  12-WeekBloating;  12-WeekConstipationSeverity|633|NCT00765882|September 2008
4401|Completed                  Has Results|Multicenter Randomized Double-Blind Double-Dummy Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir||Drug:Elvitegravir;  Drug:Raltegravir;  Drug:EVGplacebo;  Drug:RALplacebo;  Drug:Backgroundregimen|Interventional|Phase 3|Industry|Percentage of Participants Achieving and Maintaining Confirmed HIV-1 RNA &lt; 50 Copies/mL at Week 48;  Percentage of Participants Achieving and Maintaining Confirmed HIV-1 RNA &lt; 50 Copies/mL at Week 96;  Percentage of Participants Achieving and Maintaining Confirmed HIV-1 RNA &lt; 400 Copies/mL at Week 48;  Percentage of Participants Achieving and Maintaining Confirmed HIV-1 RNA &lt; 400 Copies/mL at Week 96;  Virologic Response at Week 48 (HIV-1 RNA &lt; 50 Copies/mL);  Virologic Response at Week 96 (HIV-1 RNA &lt; 50 Copies/mL);  Percentage of Participants With Pure Virologic Failure (HIV-1 RNA Cutoff at 50 Copies/mL) up to Week 48;  Percentage of Participants With Pure Virologic Failure (HIV-1 RNA Cutoff at 50 Copies/mL) up to Week 96;  Percentage of Participants With Pure Virologic Failure (HIV-1 RNA Cutoff at 400 Copies/mL) up to Week 48;  Percentage of Participants With Pure Virologic Failure (HIV-1 RNA Cutoff at 400 Copies/mL) up to Week 96;  Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 48;  Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 96;  Percentage of Participants With HIV-1 RNA &lt; 400 Copies/mL at Week 48;  Percentage of Participants With HIV-1 RNA &lt; 400 Copies/mL at Week 96;  ChangeFromBaselineinHIV-1RNAatWeek48;  ChangeFromBaselineinHIV-1RNAatWeek96;  ChangeFromBaselineinCD4CellCountatWeek48;  ChangeFromBaselineinCD4CellCountatWeek96|724|NCT00708162|July 2008
4402|Active not recruiting|Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer||Drug:neratinib;  Drug:vinorelbine|Interventional|Phase 1 / Phase 2|Industry|Safety of the combination of neratinib with vinorelbine.;  Overall Response Rate (ORR) in subjects without prior lapatinib exposure.;  Clinical benefit (Complete Response [CR]+Partial Response [PR]+ Stable Disease [SD] &gt; 24 weeks) for subjects without prior lapatinib exposure.;  Progression-Free Survival [PFS] rate for subjects without prior lapatinib exposure.;  Duration of response for subjects without prior lapatinib exposure.|92|NCT00706030|April 2008
4403|Active not recruiting                  Has Results|Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer||Biological:ramucirumab(IMC-1121B);  Drug:docetaxel;  Other:Placebo|Interventional|Phase 3|Industry|Progression-FreeSurvival(PFS);  OverallSurvival(OS);  TimetoProgression(TTP);  Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate);  DurationofResponse;  Total Functional Assessment of Cancer Therapy-Breast (FACT-B): Change From Baseline to End of Therapy;  NumberofParticipantsWithAdverseEvents|1144|NCT00703326|August 2008
4404|Completed                  Has Results|Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer||Drug:Axitinib(AG-013736);  Drug:Sorafenib|Interventional|Phase 3|Industry|Progression-FreeSurvival(PFS);  OverallSurvival(OS);  Percentage of Participants With Objective Response (OR);  DurationofResponse(DR);  Functional Assessment of Cancer Therapy Kidney Symptom Index-15 (FKSI-15) Score;  FKSI-DiseaseRelatedSymptoms(FKSI-DRS)Score;  Euro Quality of Life Questionnaires- 5 Dimension (EQ-5D) Index Score;  EQ-5DVisualAnalogScale(EQ-5DVAS)|723|NCT00678392|September 2008
4405|Completed|The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose||Drug:Nebivolol;  Drug:HCTZ;  Drug:Placebo|Interventional|Phase 4|Industry|Troughseateddiastolicbloodpressure(DBP);  Plasma glucose level after an oral glucose tolerance test;  Homeostasis Model Assessment of Insulin Resistance;  Troughseatedsystolicbloodpressure(SBP);  FastingBloodGlucose|543|NCT00673790|May 2008
4406|Completed|Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia||Drug:Ramelteon;  Drug:Placebo|Interventional|Phase 3|Industry|Mean Subjective Sleep Latency per subject diary from Nights 1 through 7 of double-blind Treatment;  SubjectiveTotalSleepTime.;  SubjectiveNumberofAwakenings.;  Subjective Ease of Falling Back to Sleep after Awakening.;  SubjectiveSleepQuality.;  ClinicalGlobalImpressionChangeofCondition.;  ClinicalGlobalImpressionSeverityofIllness.;  ClinicalGlobalImpressionTherapeuticEffect.;  ClinicalGlobalImpressionSideEffects.;  Average Subjective Sleep Latency over the week preceding the Day 15 Day 22 Day 29 and Day 36 Visits.|829|NCT00671255|December 2002
4407|Completed                  Has Results|Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)||Drug:Rabeprazolesodium;  Drug:Esomeprazole|Interventional|Phase 3|Industry|Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks;  Percentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 4 Weeks;  Percentage of Participants Who Achieved Diary-recorded Sustained Resolution of Heartburn by Week 4|1397|NCT00658632|February 2008
4408|Completed|A Double-blind Parallel Group Placebo-Controlled Outpatient Trial of PD 00200390 in Adults With Nonrestorative Sleep||Drug:PD0200390;  Drug:Placebo|Interventional|Phase 2|Industry|Total score of how an individual rates the restorative value of his/her sleep in the morning using the weekly version of the Restorative Sleep Questionnaire (RSQ-Weekly);  Measure sleep and early morning behavior during treatment using the Leeds Sleep Evaluation Questionnaire;  Total score of the Daily Restorative Sleep Questionnaire;  Total score of the Multidimensional Assessment of Fatigue (MAF);  Total score of the Sheehan Disability Scale to measure functional impairment;  Measure of health status using the Medical Outcomes Study Short Form-36 (SF-36v2-Acute);  Total mood disturbance score using the Profile of Mood State-Short Form Questionnaire (POMS-SF);  Total score of the Endicott Work Productivity Scale (EWPS) measuring work productivity.;  Disease severity and change using the Clinical Global Impression of Severity (CGI-S) as rated by the Clinician.;  Disease change (patient rated) measure using the Patient Global Impression of Change (PGIC).|306|NCT00655369|April 2008
4409|Active not recruiting|Daunorubicin Cytarabine and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia||Drug:cytarabine;  Drug:daunorubicin;  Drug:midostaurin;  Other:placebo;  Drug:dexamethasoneacetate|Interventional|Phase 3|Other / NIH / Industry|Overallsurvival(OS);  OS where patients who receive a stem cell transplant are censored at the time of the transplant;  Complete response rate in the remission induction stage of the study;  Event-freesurvival;  Disease-freesurvival(DFS);  DFS rate one year after completing the planned continuation phase|717|NCT00651261|April 2008
4410|Completed|A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.||Drug:tolterodineextendedrelease|Interventional|Phase 4|Industry|Change from baseline to Week 12 in the micturition bladder diary variable related to the primary symptom of the patient at the time of study entry;  OABBotherRatingScaleatbaseline;  Change from baseline to Week 4 and 12 in micturition bladder diary variables;  Change from baseline to Week 4 and 12 in Patient&apos;s Perception of Bladder Condition;  Change from baseline to Week 4 and 12 in AUA Symptom Index;  Change from baseline to Week 4 and 12 in OAB questionnaire;  ClinicalGlobalImpression-ImprovementatWeek12;  Overall Treatment Effect Scale of Overactive Bladder Control at Week 4 and 12;  To asses the safety of tolterodine in patients with OAB|896|NCT00645281|March 2004
4411|Completed                  Has Results|Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism||Drug:Enoxaparin;  Drug:warfarin;  Drug:Placeboforapixaban;  Drug:Placeboforenoxaparin;  Drug:Placeboforwarfarin;  Drug:apixaban|Interventional|Phase 3|Industry|Incidence of Adjudicated Composite of Symptomatic Recurrent Venous Thromboembolism (VTE) or VTE-Related Death During 6 Months of Treatment;  Incidence of Adjudicated Composite of Recurrent Symptomatic Venous Thromboembolism (VTE) or All-Cause Death;  Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or Cardiovascular (CV)-Related Death;  Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or VTE-related Death or Major Bleeding;  Incidence of Adjudicated Composite of Recurrent Symptomatic VTE Myocardial Infarction Stroke CV-related Death Clinically Relevant Non-major (CRNM) Bleeding or Major Bleeding;  Incidence of Adjudicated Symptomatic Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period;  Incidence of Adjudicated Symptomatic Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period;  Incidence of Adjudicated Venous Thromboembolism (VTE)-Related Death During the Intended Treatment Period;  Incidence of Cardiovascular (CV)-Related Death Including VTE-related Death During the Intended Treatment Period;  Incidence of All-Cause Death During the Intended Treatment Period;  Incidence of Adjudicated Major Bleeding During the Treatment Period in Treated Participants;  Incidence of Adjudicated Major/CRNM Bleeding During the Treatment Period in Treated Participants;  Incidence of Adjudicated Clinically Relevant Non Major (CRNM) Bleeding During the Treatment Period in Treated Participants;  Incidence of Adjudicated Minor Bleeding During the Treatment Period in Treated Participants;  Incidence of Adjudicated Total Bleeding During the Treatment Period in Treated Participants;  Number of Participants With Adverse Events (AEs) Serious AEs (SAEs) Bleeding AEs Discontinuations Due to AEs and Death During the Treatment Period in Treated Participants;  Number of Treated Participants With Marked Abnormalities in Hematology Laboratory Tests;  Number of Treated Participants With Marked Abnormalities in Electrolyte Laboratory Tests;  Number of Treated Participants With Marked Abnormalities in Kidney and Liver Function Laboratory Tests;  Number of Treated Participants With Marked Abnormalities in Creatine Kinase Uric Acid and Total Protein Laboratory Tests;  Number of Treated Participants With Marked Abnormalities in Urinalysis Laboratory Tests|5614|NCT00643201|July 2008
4412|Completed                  Has Results|Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism||Drug:Apixaban;  Drug:Placebo|Interventional|Phase 3|Industry|Adjudicated Composite of Symptomatic Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population With Imputation;  Adjudicated Composite of Symptomatic Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population Without Imputation;  Adjudicated Composite of Recurrent Symptomatic Venous Thromboembolism (VTE) or VTE-related Death During the Intended Treatment Period - Randomized Population With Imputation;  Adjudicated Composite of Recurrent Symptomatic Venous Thromboembolism (VTE) or Cardio Vascular (CV) -Related Death During the Intended Treatment Period - Randomized Population With Imputation;  Adjudicated Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period - Randomized Population With Imputation;  Adjudicated Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period - Randomized Population With Imputation;  Adjudicated Venous Thromboembolism (VTE) - Related Death During the Intended Treatment Period - Randomized Population With Imputation;  Adjudicated Cardiovascular (CV)-Related Death During the Intended Treatment Period - Randomized Population With Imputation;  Adjudicated All-Cause Death During the Intended Treatment Period - Randomized Population With Imputation;  Number of Participants With an Adjudicated Symptomatic Nonfatal Venous Thromboembolism (VTE) Recurrence or Death (All Cause) During the Intended Treatment Period - Randomized Participants Without Imputation;  Adjudicated Major Bleeding During the Treatment Period - Treated Population;  Adjudicated Composite of Major/Clinically Relevant Non-major Bleeding During the Treatment Period - Treated Participants;  Adjudicated Clinically Relevant Non-major Bleeding During the Treatment Period - Treated Participants;  Adjudicated Clinically Relevant Minor Bleeding During the Treatment Period - Treated Participants;  Adjudicated Total Bleeding During the Treatment Period - Treated Participants;  Adjudicated Composite of Recurrent Symptomatic Venous Thromboembolism (VTE) or Venous Thromboembolism-related Death During the Intended Treatment Period - Randomized Population Without Imputation;  Adjudicated Composite of Recurrent Symptomatic Venous Thromboembolism (VTE) or Cardio Vascular (CV) - Related Death During the Intended Treatment Period - Randomized Population Without Imputation;  Adjudicated Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period - Randomized Population Without Imputation;  Adjudicated Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period - Randomized Population Without Imputation;  Adjudicated Venous Thromboembolism (VTE)- Related Death During the Intended Treatment Period - Randomized Population Without Imputation;  Adjudicated Cardio Vascular (CV)-Related Death During the Intended Treatment Period - Randomized Population Without Imputation;  Adjudicated All-Cause Death During the Intended Treatment Period - Randomized Population Without Imputation|2711|NCT00633893|May 2008
4413|Completed                  Has Results|A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)||Drug:GEn1200mg/day;  Drug:GEn2400mg/day;  Drug:GEn3600mg/day;  Drug:Placebo|Interventional|Phase 2|Industry|Change From Baseline in the Mean 24-hour Average Pain Intensity (API) Score at the End of Maintenance Treatment (EOMT) Using Last Observation Carried Forward (LOCF) Data;  Change From Baseline in the Mean Night-time Average Pain Intensity (API) Score at EOMT Using LOCF Data;  Change From Baseline in the Mean Current Morning Pain Intensity Score at EOMT Using LOCF Data;  Change From Baseline in the Mean Night-time Worst Pain Intensity Score at EOMT Using LOCF Data;  Change From Baseline in the Mean Sleep Interference Score at EOMT Using LOCF Data;  Change From Baseline in the Mean Day-time Average Pain Intensity(API) Score at EOMT Using LOCF Data;  Change From Baseline in the Mean Current Evening Pain Intensity Score at EOMT Using LOCF Data;  Change From Baseline in the Mean Day-time Worst Pain Intensity Score at EOMT Using LOCF Data;  Change From Baseline in Pain Quality as Assessed by the Neuropathic Pain Scale (NPS) Summary Scores at EOMT Using LOCF Data;  Change From Baseline in Pain Characteristics and Intensity as Assessed by the Short Form-McGill Pain Questionnaire (SF-MPQ) at EOMT Using LOCF Data;  Change From Baseline in Dynamic Allodynia at EOMT Using LOCF Data;  Number of Participants Who Are Responders on the Patient Global Impression of Change (PGIC) Questionnaire at EOMT Using LOCF Data;  Number of Participants Achieving Various Levels of Percent Reduction From Baseline in the Mean 24-hour Average Pain Intensity Score at EOMT Using LOCF Data;  Time to Onset of Sustained Improvement in the 24-hour Average Pain Intensity Score;  Change From Baseline in the Mean Daily Dose in Milligrams of Rescue Medication at EOMT Using LOCF Data;  Change From Baseline in Severity of Pain and the Impact of Pain as Assessed by the Brief Pain Inventory (BPI) at EOMT Using LOCF Data;  Change From Baseline in Quality of Life as Assessed by the SF-36 at EOMT Using LOCF Data;  Change From Baseline in Emotional Functioning as Assessed by the POMS-B at EOMT Using LOCF Data;  Number of Participants Who Are Responders on the Clinician Global Impression of Change (CGIC) Questionnaire at EOMT Using LOCF Data|376|NCT00619476|February 2008
4414|Terminated|Early Versus Delayed Enteral Feeding and Omega-3 Fatty Acid/Antioxidant Supplementation for Treating People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN-Omega Study)||Behavioral:Minimal(Trophic)Feeding;  Behavioral:FullFeeding;  Dietary Supplement: Omega-3 Fatty Acids and Antioxidant Supplements;  DietarySupplement:Placebo|Interventional|Phase 3|NIH|Numberofventilator-freedays(VFD);  Mortality before hospital discharge with unassisted breathing;  Numberofintensivecareunit-freedays;  Number of organ failure-free days (liver kidney heart central nervous system and hematologic);  Incidenceofventilator-associatedpneumonia;  Number of days from first meeting criteria for weaning readiness to Day 28;  VFDs and mortality in participants with a partial pressure of oxygen in arterial blood (PaO2)/fraction of inspired oxygen (FIO2) less than or equal to 200 or with shock at the time of study entry;  Change in plasma and mini-bronchoalveolar lavage (BAL) levels of interleukin (IL)-6 IL-8 von Willebrand factor (VWF) surfactant protein D (SPD) and total protein concentrations;  Health-related quality of life; healthcare utilization; and psychological neurocognitive and physical activity outcomes;  Duration of survival after hospital discharge using the National Death Index|272|NCT00609180|December 2007
4415|Active not recruiting                  Has Results|Melphalan Prednisone and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma||Drug:melphalan;  Drug:prednisone;  Drug:thalidomide;  Drug:lenalidomide|Interventional|Phase 3|NIH|Progression-FreeSurvival(PFS);  OverallSurvival;  VeryGoodPartialResponse(VGPR)Rate;  Change in Functional Assessment of Cancer Therapy-Neurotoxicity Trial Outcome Index (FACT-Ntx TOI) Score From Baseline to Cycle 12|306|NCT00602641|February 2008
4416|Completed|Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection||Drug:gentamicin-collagenspongedippedinsaline|Interventional|Phase 3|Industry / Other|Efficacy will be evaluated by a comparison between the 2 study groups of the incidence of surgical wound infections that occur within the period from surgery through postop day 90.;  Proportion of patients with surgically treated surgical wound infection adjudicated by an independent blinded committee.;  Proportion of patients with deep surgical wound infections based on Centers for Disease Control criteria adjudicated by an independent blinded committee.;  Proportion of patients with superficial surgical wound infections based on Centers for Disease Control criteria adjudicated by an independent blinded committee.;  Efficacybytypeofpathogen/bacteriology;  ASEPSISscore;  RehospitalizationforSternalWoundInfection;  Costanalysiscomparisonbetweenstudygroups;  Serum gentamicin levels and changes in serum creatinine level;  Bone and wound healing questionnaire including Emergency Room and surgical office visits secondary to wound complaints;  Pain assessments from surgery through 7 days postoperatively (see section 4.2.) and amount of pain medication administered in the first 3 days postoperatively.;  Reporting of serious and nonserious AEs including reexploration for bleeding and renal failure;  All-cause mortality at 30 days 60 days and 90 days postop|1502|NCT00600483|December 2007
4417|Completed|Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin Fluoropyrimidine and Bevacizumab||Drug:cediranibmaleate;  Drug:irinotecanhydrochloride|Interventional|Phase 2|Other / NIH|The proportion of patients who are progression-free at 12 weeks from the start of second-line therapy;  Radiographicresponserate;  Overallsurvival|5|NCT00588900|March 2008
4418|Completed                  Has Results|TREXIMET&#174; Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults||Drug:TREXIMET&#174;;  Drug: Butalbital-containing Combination Medications (BCM);  Drug:placebo|Interventional|Phase 3|Industry|Number of Participants With a Sustained Pain-free (SPF) Response From 2 to 24 Hours Post-dose;  Number of Participants With a Pain-free Response From 2 to 48 Hours Post-dose;  Number of Participants Using Rescue Medication Within 48 Hours Post Dose;  Mean Time to First Use of Rescue Medication for the First Attack Treated With Study Medication (Attack 1);  Mean Time to First Use of Rescue Medication for the Second Attack Treated With Study Medication (Attack 2);  Mean Time to First Use of Rescue Medication for the Third Attack Treated With Study Medication (Attack 3);  Number of Participants With a Migraine-free Response 2-48 Hours After Dosing;  Number of Participants With Pain-freedom and Relief of Nausea at 2 4 6 8 24 and 48 Post-dose Time Points;  Number of Participants With Pain-freedom and Relief of Photophobia at 2 4 6 8 24 and 48 Post-dose Time Points;  Number of Participants With Pain-freedom and Relief of Phonophobia at 2 4 6 8 24 and 48 Post-dose Time Points;  Number of Participants With Pain-freedom and Relief of Vomiting at 2 4 6 8 24 and 48 Hours Post-dose;  Number of Participants With Relief From Sinus/Facial Pain at 2 4 6 8 24 and 48 Hours After Dosing in Those Who Also Had the Symptom at Dosing;  Number of Participants With Relief From Neck Pain at 2 4 6 8 24 and 48 Hours After Dosing Who Also Had the Symptom at Baseline;  Number of Participants With Pain Relief at 2 4 6 8 24 and 48 Hours After Dosing Moderate or Severe Baseline Pain;  Number of Participants Who Reported a Complete Symptom-Free Response at 2 4 6 8 24 and 48 Hours After Dosing;  Mean Performance Index (PI) Scores at Time of Dosing and at 2 4 6 8 24 and 48 Hours After Dosing;  Mean Stanford Sleepiness (SS) Scale Scores at Time of Dosing and at 2 4 6 8 24 and 48 Hours After Dosing;  Efficacy Subscore as Measured by the Revised Patient Perception of Migraine (PPMQ-R) Questionnaire 24 Hours After Treating a Migraine;  Functionality Subscore as Measured by the Revised Patient Perception of Migraine (PPMQ-R) Questionnaire 24 Hours After Taking Study Medication;  Ease-of-Use Subscore as Measured by the Revised Patient Perception of Migraine (PPMQ-R) Questionnaire 24 Hours After Taking Study Medication;  Bothersomeness-of-side Effect Subscore as Measured by the Revised Patient Perception of Migraine (PPMQ-R) Questionnaire 24 Hours After Taking Study Medication;  Total PPMQ-R Score as Measured With the Revised Patient Perception of Migraine (PPMQ-R) Questionnaire 24 Hours After Taking Study Medication;  Numbers of Participants Able to &quot;Engage in Normal Activities Not Impaired&quot; at Time of Dosing and 2 4 6 and 8 Hours After Dosing as Assessed by the CDQ (Clinical Disability Questionnaire)|375|NCT00573170|February 2008
4419|Active not recruiting|Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma||Procedure: Autologous Hematopoietic Stem Cell Transplantation;  Drug:Carboplatin;  Drug:Cisplatin;  Drug:Cyclophosphamide;  Drug:DoxorubicinHydrochloride;  Drug:Etoposide;  Radiation:ExternalBeamRadiationTherapy;  Biological:Filgrastim;  Drug:Isotretinoin;  Other:LaboratoryBiomarkerAnalysis;  Drug:Melphalan;  Procedure: Peripheral Blood Stem Cell Transplantation;  Other:PharmacologicalStudy;  Drug:Thiotepa;  Drug:TopotecanHydrochloride;  Drug:VincristineSulfateLiposome|Interventional|Phase 3|Other / NIH|Event-freesurvivalrate;  Incidencerateoflocalrecurrence;  Responseafterinductiontherapy;  Duration of greater than or equal to grade 3 neutropenia;  Duration of greater than or equal to grade 3 thrombocytopenia;  EFS in patients 12-18 months stage 4 MYCN nonamplified tumor/unfavorable histopathology/diploid DNA content/indeterminant histology/ploidy and patients &gt; 547 days stage 3 MYCN nonamplified tumor AND unfavorable histopathology/indeterminant histology;  Enumeration of peripheral blood cluster of differentiation (CD)3 CD4 and CD8 cells;  Neurologic symptom resolution in patients with primary tumors with intraspinal extension;  OS in patients 12-18 months stage 4 MYCN nonamplified tumor/unfavorable histopathology/diploid DNA content/indeterminant histology/ploidy and patients &gt; 547 days stage 3 MYCN nonamplified tumor AND unfavorable histopathology/indeterminant histology;  Peak serum concentration of isotretinoin in patients enrolled on either A3973 ANBL0032 ANBL0931 ANBL0532 and future high risk studies;  Pharmacogenetic variants in patients enrolled on either A3973 ANBL0032 ANBL0931 ANBL0532 and future high risk studies;  Presence and function of T cells capable of recognizing neuroblastoma;  Proportion of patients with neuroblastoma detected in bone marrow and peripheral blood using RT-PCR technique;  Responserate;  Surgicalresponse;  Topotecansystemicclearance;  Typeofradiotherapycomplication;  Typeofsurgicalcomplication|665|NCT00567567|November 2007
4420|Completed                  Has Results|Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen||Drug:Placebo;  Drug: Aflibercept (ziv-aflibercept AVE0005 VEGF trap ZALTRAP&#174;);  Drug: FOLFIRI (Irinotecan 5-Fluorouracil and Leucovorin)|Interventional|Phase 3|Industry / Other|OverallSurvival(OS);  Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC);  Overall Objective Response Rate (ORR) Based on the Tumor Assessment by the Independent Review Committee (IRC) as Per Response Evaluation Criteria in Solid Tumours (RECIST) Criteria;  NumberofParticipantsWithAdverseEvents(AE);  Immunogenicity Assessment: Number of Participants With Positive Sample(s) in the Anti-drug Antibodies (ADA) Assay and in the Neutralizing Anti-drug Antibodies (NAb) Assay|1226|NCT00561470|November 2007
4421|Completed                  Has Results|Methotrexate-Inadequate Response Study||Drug:Subcutaneous(SC)Abatacept;  Drug:Intravenous(IV)Abatacept|Interventional|Phase 3|Industry|Double-blind Period: Number of Participants Achieving American College of Rheumatology (ACR) 20 Response at Day 169;  Anti-TNF Failure Sub-Study Double Blind Period : Number of Participants With Positive Anti-abatacept or Anti-Cytotoxic T Lymphocyte Antigen 4-T Cell (CTLA4-T) Response in Anti-TNF Failure Population;  Double-blind Period: Number of Participants Achieving ACR 50 and ACR 70 Responses at Day 169;  Double-blind Period: Mean Baseline Health Assessment Questionnaire Disability Index (HAQ-DI) for Participants With Assessments at Day 169;  Double-blind Period: Adjusted Mean Change From Baseline to Day 169 in HAQ-DI;  Double-blind Period: Number of Participants Achieving Clinically Meaningful HAQ-DI Response at Day 169;  Double-blind Period: Number of Participants With Death As Outcome Serious Adverse Events (SAEs) Treatment-related SAEs SAEs Leading to Discontinuation Adverse Events (AEs) Treatment-related AEs or AEs Leading to Discontinuation;  Anti-TNF Failure Sub-study Double-blind Period: Number of Participants With SAEs AEs Leading to Discontinuation or Who Died;  Double-blind Period: Number of Participants With AEs of Special Interest;  Double-blind Period: Number of Participants With Clinically Significant Abnormalities in Vital Sign Measurements;  Double-blind Period: Number of Participants With Hematology Laboratory Test Results Meeting the Criteria for Marked Abnormality;  Double-blind Period: Number of Participants With Liver Function Laboratory Test Results Meeting the Criteria for Marked Abnormality;  Double-blind Period: Number of Participants With Electrolyte Laboratory Test Results Meeting the Criteria for Marked Abnormality;  Double-blind Period: Minimum Observed Serum Concentration of Abatacept;  Anti-TNF Failure Sub-study Double-blind Period: Minimum Observed Serum Concentration (Cmin) of Abatacept;  Double-blind Period: Maximum Observed Serum Concentration of Abatacept;  Anti-TNF Failure Substudy Double Blind Period: Geometric Mean Maximum Observed Serum Concentration of Abatacept;  Double-blind Period: Area Under The Curve In A Dose Interval (AUC TAU) of Abatacept;  Anti-TNF Failure Sub-study Double Blind Period: Area Under The Curve In A Dose Interval (AUC TAU) of Abatacept;  Double-blind Period: Number of Participants With Positive Anti-abatacept or Anti-Cytotoxic T Lymphocyte Antigen 4-T Cell (CTLA4-T) Responses Over Time by Enzyme Linked Immunoabsorbant Assay (ELISA);  Double-blind Period: Time-matched Median Percent Change From Baseline in Levels of Serum C-reactive Protein Over the Short-term Period;  Double-blind Period: Number of Participants With Positive Anti-abatacept Responses Over Time by Electrochemiluminescence Immunoassay Among the First 10% of Participants Randomized;  Double-blind Period: Number of Participants Seroconverting by Day 169 According to Status (Negative or Positive) at Baseline;  Open-Label LT Period: Number of Participants Achieving ACR 20 Response at Days 169 729 1261 and 1821;  Open-Label LT Period: Number of Participants Achieving ACR 50 and ACR 70 Responses at Days 169 729 1261 1821;  Open-Label LT Period: Mean Change From Baseline in Disease Activity Score in 28 Joints (DAS28) Using C-reactive Protein (CRP) at Days 169 729 1261 1821;  Open-Label LT Period: Number of Participants Achieving DAS 28 Remission at Days 169 729 1261 1821;  Open-Label LT Period: Number of Participants Achieving DAS 28 Low Disease Activity (LDA) at Days 169 729 1261 1821;  Open-Label LT Period: Number of Participants With HAQ-DI Response at Days 169 729 1261 1821;  Open-Label LT Period: Number of Participants With Death As Outcome Serious Adverse Events (SAEs) Treatment-related SAEs SAEs Leading to Discontinuation Adverse Events (AEs) Treatment-related AEs or AEs Leading to Discontinuation;  Open-Label LT Period: Number of Participants With AEs of Special Interest;  Open-Label LT Period: Number of Participants With Clinically Significant Abnormalities in Vital Sign Measurements;  Open-Label LT Period: Number of Participants With Clinically Significant Laboratory Abnormalities|2492|NCT00559585|January 2008
4422|Terminated|Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)||Drug: CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin;  Drug:Plavix(clopidogrel75mg)andaspirin|Interventional|Phase 3|Industry|Composite of upper gastrointestinal clinical events including gastroduodenal bleeding symptomatic gastroduodenal ulcer persistent pain with multiple gastric erosions obstruction or perforation;  Composite of gastroduodenal bleeding symptomatic gastroduodenal ulcer obstruction or perforation;  Composite of gastroduodenal bleeding obstruction or perforation;  Discontinuation of study medication attributed to gastrointestinal signs or symptoms;  Gastroesophageal reflux disease as evidenced by symptomatic endoscopically-confirmed erosive esophagitis;  Dyspepsia defined as an increase of at least ten points on the &quot;pain intensity&quot; component of the SODA instrument from baseline;  Occurrence of a cardiovascular event (cardiovascular death nonfatal myocardial infarction CABG or PCI or confirmed ischemic stroke|5000|NCT00557921|December 2007
4423|Completed                  Has Results|Asacol Acute Diverticulitis(DIVA)Study||Drug:Mesalamine;  Drug:Probiotic;  Drug:Placebo;  Other:DietaryAdvice;  Drug:AntibioticforDiverticulitis|Interventional|Phase 2|Industry|Global Symptom Score (GSS) at Week 12 Primary Efficacy Population;  Percentage of Responders at Week 12 - ITT Population;  Percentage of Responders at Week 52 - ITT Population;  Change in GSS From Baseline to Week 12 - ITT Population;  Change in GSS From Baseline to Week 52 - ITT Population;  Withdrawal Due to Surgery for Diverticulitis Percentage ITT Population Week 12;  Recurrent Diverticulitis Percentage ITT Population Week 12;  Recurrent Diverticulitis Percentage ITT Population Week 52|117|NCT00554099|November 2007
4424|Terminated|Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma||Drug:Elesclomol(STA-4783);  Drug:Paclitaxel|Interventional|Phase 3|Industry|Progressionfreesurvival;  OverallSurvival;  Objectiveresponserate;  Clinicalbenefitrate;  Durationofobjectiveresponse;  Safety;  Pharmacokinetics|630|NCT00522834|August 2007
4425|Active not recruiting|Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia||Biological:rituximab;  Drug:fludarabinephosphate|Interventional|Phase 3|Other / NIH|Timetosecondtreatment;  Proportion of patients with mutated and unmutated IgVH genes|84|NCT00513747|January 2008
4426|Completed|Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee||Drug:Naproxcinod375mgbid;  Drug:Naproxcinod750mgbid;  Drug:Naproxen500mgbid;  Drug:placebo|Interventional|Phase 3|Industry|To show that both doses of Naproxcinod (375 mg twice daily [bid] and 750 mg bid) were superior to placebo in relieving osteoarthritis (OA) signs and symptoms in subjects with OA of the knee at Week 13.;  To assess the efficacy of naproxcinod compared to naproxen 500 mg bid in relieving OA signs and symptoms in subjects with OA of the knee;  To evaluate the effect on blood pressure (BP) of both doses of naproxcinod placebo and naproxen 500 mg bid as measured by the office BP monitoring in a population of OA subjects;  To obtain information regarding the pharmacokinetics/exposure of both doses of naproxcinod through a population pharmacokinetics (PK) approach;  To assess if there were any radiological changes at Week 52 in naproxcinod compared with naproxen subjects (target joint radiographs were taken at Screening and after 52 weeks of treatment or if early termination occurred after Week 26);  To compare the general safety and tolerability of both doses of naproxcinod versus naproxen 500 mg bid up to 52 weeks and with one Week post treatment follow up (Week 53)|1020|NCT00504127|April 2007
4427|Unknown&nbsp;&#8224;|Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma||Drug:carboplatin;  Drug:cyclophosphamide;  Drug:doxorubicinhydrochloride;  Drug:etoposide;  Drug:topotecanhydrochloride;  Drug:Isotretinoin|Interventional|Phase 3|Other / NIH|Overallsurvival(OS)rates;  Event-freesurvival(EFS)rate;  Second-event-free survival (E2FS) of intermediate risk patients;  Overallsurvivaltime;  Definitive determination of the prognostic ability of 1p and 11q;  Comparison between reduce intensity of therapy for patients with stage 4 neuroblastoma and favorable biological features and patients &lt; 1 year of age with stage 4 neuroblastoma treated on COG-A3961;  Comparison between reduce intensity of therapy for patients with unfavorable histology neuroblastoma and patients unfavorable histology neuroblastoma treated on COG-A3961;  Reduced surgical morbidity for patients with stage 4S neuroblastoma;  Outcome of patients with stage 4S neuroblastoma who are unable to undergo biopsy for biology-based risk assignment;  Correlation between extent of surgical resection with the maintenance of local control EFS and/or OS rates and surgical complication rate;  Biologicalsurrogatemarkers;  Proportion of patients with neurologic symptoms overall and type of symptom;  Association between surgical biopsy technique with adequacy of tissue acquisition for biologic studies and with complications associated with the biopsy procedure;  Prognostic ability of the INRG image-defined risk factor (IDRF) system|464|NCT00499616|October 2007
4428|Terminated|GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer||Biological: GSK1572932A Antigen-Specific Cancer Immunotherapeutic;  Biological:PlaceboControl|Interventional|Phase 3|Industry|Disease-freesurvival;  Overallsurvival;  Lung-cancer-specificsurvival;  Disease-freesurvivalat234and5year;  Disease-freespecificsurvival;  Anti-MAGE-A3 and anti-protein D seropositivity rate. Seropositivity will be assessed at baseline after 2 4 6 7 and 9 administrations;  Occurrence of adverse events including abnormal hematological and biochemical parameters;  Occurrenceofseriousadverseevents|2278|NCT00480025|October 2007
4429|Completed                  Has Results|Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer||Drug:sunitinib|Interventional|Phase 2|Industry|NumberofParticipantsWithObjectiveResponse;  NumberofParticipantsWithClinicalBenefit;  Number of Participants With Objective Response of Superficial Lesions;  Progression-FreeSurvival(PFS);  DurationofResponse(DR);  OverallSurvival(OS);  Number of Participants With Objective Response for Subgroup of Participants Whom Sunitinib Was at Least a Third Line Therapy;  Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionaire-C30 (EORTC- QLQ-C30) Score;  Change From Baseline in EORTC-QLQ Companion Breast Cancer Module (EORTC-QLQ-BR23) Score: Body Image;  Change From Baseline in EORTC-QLQ-BR23 Score: Future Perspective;  Change From Baseline in EORTC-QLQ-BR23 Score: Sexual Enjoyment;  Change From Baseline in EORTC-QLQ-BR23 Score: Sexual Functioning;  Change From Baseline in EORTC-QLQ-BR23 Score: Arm Symptoms;  Change From Baseline in EORTC-QLQ-BR23 Score: Breast Symptoms;  Change From Baseline in EORTC-QLQ-BR23 Score: Systemic Therapy Side Effects;  Change From Baseline in EORTC-QLQ-BR23 Score: Upset by Hair Loss;  Change From Baseline in Cancer Therapy Satisfaction Questionnaire (CTSQ) Score: Expectation of Therapy;  Change From Baseline in CTSQ Score: Feelings About Side Effects;  Change From Baseline in CTSQ Score: Satisfaction With Therapy|83|NCT00471276|August 2007
4430|Completed|Safety and Efficacy of Ilaprazole 5 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis||Drug:Ilaprazole;  Drug:Lansoprazole|Interventional|Phase 2|Industry|The crude healing rate of Erosive Esophagitis at week 4 of treatment as assessed by endoscopy.;  The crude healing rate of Erosive Esophagitis at week 8 of treatment as assessed by endoscopy.|831|NCT00471094|May 2007
4431|Completed                  Has Results|Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer||Drug:bevacizumab;  Drug:AG-013726;  Drug:AG-013736(axitinib)|Interventional|Phase 1 / Phase 2|Industry|Percentage of Participants With Objective Response: Phase 2;  Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Axitinib: Phase 1;  Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - &#8734;)] For Axitinib: Phase 1;  Maximum Observed Plasma Concentration (Cmax) For Axitinib: Phase 1;  Minimum Observed Plasma Trough Concentration (Cmin) For Axitinib: Phase 1;  Apparent Oral Clearance (CL/F) For Axitinib: Phase 1;  Plasma Decay Half-Life (t1/2) For Axitinib: Phase 1;  Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Oxaliplatin: Phase 1;  Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - &#8734;)] For Oxaliplatin: Phase 1;  Maximum Observed Plasma Concentration (Cmax) For Oxaliplatin: Phase 1;  Minimum Observed Plasma Trough Concentration (Cmin) For Oxaliplatin: Phase 1;  Clearance(CL)ForOxaliplatin:Phase1;  Plasma Decay Half-Life (t1/2) For Oxaliplatin: Phase 1;  Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For 5-Fluorouracil: Phase 1;  Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - &#8734;)] For 5-Fluorouracil: Phase 1;  Maximum Observed Plasma Concentration (Cmax) For 5-Fluorouracil: Phase 1;  Minimum Observed Plasma Trough Concentration (Cmin) For 5-Fluorouracil: Phase 1;  Clearance(CL)For5-Fluorouracil:Phase1;  Plasma Decay Half-Life (t1/2) For 5-Fluorouracil: Phase 1;  Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Irinotecan: Phase 1;  Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - &#8734;)] For Irinotecan: Phase 1;  Maximum Observed Plasma Concentration (Cmax) For Irinotecan: Phase 1;  Minimum Observed Plasma Trough Concentration (Cmin) For Irinotecan: Phase 1;  Clearance(CL)ForIrinotecan:Phase1;  Plasma Decay Half-Life (t1/2) For Irinotecan: Phase 1;  Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Bevacizumab: Phase 1;  Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - &#8734;)] For Bevacizumab: Phase 1;  Maximum Observed Plasma Concentration (Cmax) For Bevacizumab: Phase 1;  Minimum Observed Plasma Trough Concentration (Cmin) For Bevacizumab: Phase 1;  Clearance(CL)ForBevacizumab:Phase1;  Plasma Decay Half-Life (t1/2) For Bevacizumab: Phase 1;  DurationofResponse(DR):Phase2;  Progression-FreeSurvival(PFS):Phase2;  TimetoTreatmentFailure(TTF):Phase2;  OverallSurvival(OS):Phase2;  Change From Baseline in M.D. Anderson Symptom Assessment Inventory - Diarrhea (MDASI-D) Symptom Severity and Interference Subscale Scores at Day 1 of Cycle 2 Through Day 1 Cycle 42 and Follow-up: Phase 2|187|NCT00460603|January 2006
4432|Completed|A Study to Evaluate Daily Pravastatin Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia||Drug: Pravafen (combination of Pravastatin and Fenofibrate)|Interventional|Phase 3|Industry|Primary endpoints will assess differences in change from baseline in non-HDL-C for the patients receiving Pravafen versus the patients receiving Pravastatin or Fenofibrate at the end of the 12-week portion of the study.;  Secondary endpoints will assess differences in change from baseline in TC TG LDL-C HDL-C and TC/HDL-C for the pts receiving the combo therapy vs the pts receiving Pravastatin or Fenofibrate;  Differences in change from baseline in ALT AST and CK as well as overall safety for the pts receiving the combo therapy vs the pts receiving Pravastatin or Fenofibrate at the end of the 12-week of the study|481|NCT00459745|April 2007
4433|Terminated|Assessment and Tracking of Long-term Alefacept Safety||Drug:Alefaceptexposure|Observational|Phase 4|Industry|To measure the rates of non-Hodgkin&apos;s lymphoma (NHL) and infections that require hospitalization occurring in psoriasis patients treated with alefacept;  To estimate the rates of lung cancer breast cancer (female) prostate cancer colorectal cancer melanoma and active tuberculosis within a population of patients with psoriasis treated with alefacept.|1897|NCT00454701|June 2003
4434|Active not recruiting                  Has Results|Cisplatin or Carboplatin and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer||Drug:sunitinibmalate;  Drug:cisplatin;  Drug:carboplatin;  Drug:etoposide;  Other:placebo;  Other:laboratorybiomarkeranalysis|Interventional|Phase 1 / Phase 2|NIH|Maximum Tolerated of Sunitinib Combined With Cisplatin and Etoposide (Phase I);  Progression-freeSurvival(PhaseII);  OverallSurvival;  Number of Participants With Overall Tumor Response|156|NCT00453154|March 2007
4435|Completed|S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I Stage II or Stage III Non-Small Cell Lung Cancer||Genetic:chromogenicinsituhybridization;  Genetic:geneexpressionanalysis;  Genetic:mutationanalysis;  Genetic:polymerasechainreaction;  Genetic:polymorphismanalysis;  Other:fluorescentantibodytechnique;  Other:immunohistochemistrystainingmethod;  Other:laboratorybiomarkeranalysis;  Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry;  Other: study of socioeconomic and demographic variables;  Procedure:studyofhighriskfactors|Observational||Other / NIH|DNAadductlevels;  Tumortissuealterations|981|NCT00450281|October 2005
4436|Completed|A Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE)|||Observational|Phase 4|Industry||1026|NCT00443443|January 2007
4437|Completed                  Has Results|Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness Of Breath||Other:Non-interventionalstudy.|Observational||Industry|Number of Participants With a Post-bronchodilator FEV1/FVC &lt;=70% Versus Participants With a Postbronchodilator FEV1/FVC &gt;70%;  Number of Participants With the Indicated Scores on the MRC (Medical Research Council) Dyspnea Scale;  Number of Participants With an Affirmative Response to Specific Categories on the Modified American Thoracic Society (ATS) Respiratory Questionnaire;  Number of Participants With the Indicated Responses to the Question of How They&apos;d Rate Their General Health a Question on the 12-item Short Form Health Survey;  Number of Participants With the Indicated Responses to the Question of Whether Their Health is Limited in Moderate Activities a Question on the 12-item Short Form Health Survey;  Number of Participants With the Indicated Responses to the Question of Whether Their Health is Limited in Climbing Stairs a Question on the 12-item Short Form Health Survey;  Number of Participants With the Indicated Responses to the Question of Whether They Had Accomplished Less Than They Would Like a Question on the 12-item Short Form Health Survey;  Number of Participants With the Indicated Responses to the Question of How Often They Were Limited in the Kind of Work/Activities a Question on the 12-item Short Form Health Survey;  Number of Participants With the Indicated Responses to the Question of How Often They Accomplished Less Due to Emotional Problems a Question on the 12-item Short Form Health Survey;  Number of Participants With the Indicated Responses to the Question of How Often They Did Work Less Carefully Due to Emotional Problems a Question on the 12-item Short Form Health Survey;  Number of Participants With the Indicated Responses to the Question of to What Degree Does Pain Interfere With Normal Work a Question on the 12-item Short Form Health Survey;  Number of Participants With the Indicated Responses to the Question of How Often They Felt Calm and Peaceful a Question on the 12-item Short Form Health Survey;  Number of Participants With the Indicated Responses to the Question of How Often They Have a Lot of Energy a Question on the 12-item Short Form Health Survey;  Number of Participants With the Indicated Responses to the Question of How Often They Felt Downhearted and Depressed a Question on the 12-item Short Form Health Survey;  Number of Participants With the Indicated Responses to the Question of How Often They Experience Interference With Social Activities a Question on the 12-item Short Form Health Survey;  FEV1 and FVC Pre-bronchodilator Spirometry Measures;  FEV1 Percent Predicted and FEV1/FVC Percent Predicted Pre-bronchodilator Spirometry Measures;  FEV1 and FVC Post-bronchodilator Spirometry Measures;  FEV1 Percent Predicted and FEV1/FVC Percent Predicted Post-bronchodilator Spirometry Measures;  Post-bronchodilatorReversibilityMeasures;  Number of Participants Who Responded &quot;Yes&quot; to Respective Questions Regarding Past Illness;  Number of Participants Who Responded &quot;Yes&quot; to Respective Questions Regarding Occupational History and Socioeconomic Status;  Number of Participants Who Completed the Highest Indicated Education Level or Grade;  Number of Participants With the Indicated Experience With Tobacco Smoking;  Number of Participants Who Responded &quot;Yes&quot; When Asked Indicated Questions Regarding Medical History|1283|NCT00442468|April 2007
4438|Terminated                  Has Results|Drug Study of Albuterol to Treat Acute Lung Injury||Drug:AlbuterolSulfate;  Procedure:Mini-BronchoalveolarLavage(BAL);  Drug:Placebo|Interventional|Phase 2 / Phase 3|NIH|NumberofVentilatorFreeDays(VFD);  Mortality Prior to Hospital Discharge With Unassisted Breathing to Day 60;  Mortality Prior to Hospital Discharge With Unassisted Breathing to Day 90;  Number of ICU-free Days at 28 Days After Randomization;  Number of Organ Failure-free Days at Day 28 Following Randomization;  Ventilator Free Days to Day 28 in the Subset of Participants With ARDS;  Hospital Mortality to Day 60 in the Subset of Participants With ARDS;  Ventilator Free Days to Day 28 in the Subset of Patients With Baseline Shock;  Hospital Mortality up to Day 60 in Subjects With Baseline Shock;  PlasmaLevelsofIL-6andIL-8onStudyDay3|282|NCT00434993|August 2007
4439|Active not recruiting|Long-Term Effectiveness And Safety Of CP-690550 For The Treatment Of Rheumatoid Arthritis||Drug:CP-690550|Interventional|Phase 3|Industry|Primary endpoints will be standard laboratory safety data (chemistry hematology etc.) and adverse event (AE) reports;  The long-term safety and tolerability of CP-690550 5 mg BID and 10 mg BID for the treatment of rheumatoid arthritis;  Percent of patients with ACR 20 50 and 70 responses;  AreaunderACRncurve;  DAS 28 (CRP) and DAS 28 (ESR)as well as incidence of Disease Activity Score &lt;2.6 and &lt;3.2;  HAQDIscore;  SF36score;  FACIT Fatigue Scale EuroQol EQ 5D Work Limitations Questionnaire and RA Healthcare Resource Utilization Questionnaire;  Preservation of joint structure in patients who had baseline radiographs obtained in their qualifying index study;  Vaccine sub-study endpoints: 1. % achieving a satisfactory humoral response to the pneumococcal vaccine as defined by &#8805; 2-fold increase in antibody concentrations;  Vaccine sub-study 2. % achieving a satisfactory humoral response to the seasonal influenza vaccine as defined by &#8805; 4-fold increase in antibody titers;  1. Percentage of subjects achieving protective antibody titers to the seasonal influenza vaccine as measured by a hemagglutination inhibition (HI) assay titer of &#8805; 1:40 in &#8805; 2 of 3 influenza antigens measured at vaccine sub-study;  2. Percentage of subjects who respond to each of the 12 pneumococcal antigens as defined by &#8805; 2-fold increase in antibody concentrations from vaccine sub-study visit 2 (vaccination baseline) measured at vaccine sub-study visit 4;  3. Percentage of subjects who respond to each of the 3 influenza antigens as defined by &#8805; 4-fold increase in antibody titers from vaccine sub-study visit 2 (vaccination baseline) measured at vaccine sub-study visit 4;  4. Fold increase of anti-pneumococcal antibody levels to each of the 12 pneumococcal antigens above vaccination baseline values (vaccine sub-study visit 2) at vaccine sub-study visit 4;  5. Fold increase of anti-influenza antibody levels to each of the 3 influenza antigens above vaccination baseline values (vaccine sub-study visit 2) at vaccine sub-study visit 4;  6. Concentrations of anti-pneumococcal antibodies at vaccine sub-study visit 3 and 4;  7. Titers of anti-influenza antibodies at vaccine sub-study visit 3 and 4|4500|NCT00413699|February 2007
4440|Completed|Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes||Drug: repaglinide and metformin combination tablet;  Drug: rosiglitazone and metformin combination tablet|Interventional|Phase 3|Industry|HbA1c;  Changein8-pointGlucoseProfiles;  ChangeinLipidProfile;  Eventsofhypoglycemia;  Safetyparameters;  ChangeinFastingPlasmaGlucose;  Waist/hipratiochange;  Changeinbodyweight;  Percentage of subjects achieving sudden levels of HbA1c|560|NCT00399711|November 2006
4441|Completed                  Has Results|A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome||Drug:Ticagrelor;  Drug:Clopidogrel|Interventional|Phase 3|Industry|Participants With Any Event From the Composite of Death From Vascular Causes Myocardial Infarction (MI) and Stroke;  ParticipantsWithAnyMajorBleedingEvent;  Participants With Any Event From the Composite of Death From Vascular Causes MI and Stroke for the Subgroup of Patients With Intent for Invasive Management at Randomization;  Participants With Any Event From the Composite of All-cause Mortality MI and Stroke;  Participants With Any Event From the Composite of Death From Vascular Causes MI (Including Silent) Stroke Recurrent Ischemia Transient Ischemic Attack (TIA) and Other Arterial Thrombotic Events.;  ParticipantsWithMIEvent;  ParticipantsWithDeathFromVascularCauses;  ParticipantsWithStroke;  ParticipantsWithDeathFromAnyCause;  Participants With Non-CABG (Coronary Artery Bypass Graft) Related Major Bleeding;  ParticipantsWithMajororMinorBleeding;  ParticipantsWithNon-proceduralMajorBleeding;  Participants With Coronary Artery Bypass Graft (CABG) Major Bleeding;  Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding;  Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24-hour ECG Recorders for 1 Week Following Randomization;  Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24 Hour ECG Recorders for 1 Week at 1 Month Following Randomization|18624|NCT00391872|October 2006
4442|Terminated                  Has Results|Study Of CP-751871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer||Drug:CP-751871;  Drug:exemestane;  Drug:Fulvestrant|Interventional|Phase 2|Industry|Progression-FreeSurvival(PFS);  PFS in Participants With Hemoglobin A1c (HbA1c) Less Than (&lt;) 5.7% at Baseline;  Percentage of Participants Achieving Complete Response (CR) Partial Response (PR) or Stable Disease (SD) Maintained for at Least 6 Months;  MaximumPlasmaConcentrationofCP-751871;  MinimumPlasmaConcentrationofCP-751871;  Area Under the Concentration Time Curve From Time 0 to the Last Time Point With Quantifiable Concentration;  Number of Participants With Negative Human Anti-Human Antibodies (HAHAs);  Percentage of Participants With Circulating Tumor Cells Expressing Insulin-Like Growth Factor 1 Receptor (IGF-IR);  Percentage of Participants With Serum Markers Relevant to the IGF-1R Pathway;  European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire 30 (QLQ-C30) Scores;  EORTCQLQBreastCancerModule(BR23)Scores|219|NCT00372996|February 2007
4443|Completed                  Has Results|Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension||Drug:AzilsartanMedoxomil;  Drug:Olmesartan;  Drug:Placebo|Interventional|Phase 2|Industry|Change From Baseline in Sitting Clinic Diastolic Blood Pressure.;  Change From Baseline in Sitting Clinic Systolic Blood Pressure.;  Change From Baseline in Standing Clinic Systolic Blood Pressure.;  Change From Baseline in Standing Clinic Diastolic Blood Pressure.;  Change From Baseline in 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.;  Change From Baseline in 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.;  Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.;  Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.;  Change From Baseline in the 10-12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.;  Change From Baseline in the 10-12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.;  Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.;  Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.;  Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.;  Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.;  Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.;  Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.;  Change From Baseline in the 24-36-Hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.;  Change From Baseline in the 24-36-Hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.;  Change From Baseline in the 34-36-Hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.;  Change From Baseline in the 34-36-Hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.|449|NCT00362115|May 2006
4444|Completed|Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension||Drug:Ramiprilandhydrochlorothiazide|Interventional|Phase 3|Industry|Compare the effects on sitting diastolic blood pressure of two antihypertensive drugs in combination against each antihypertensive alone after an eight week treatment period.;  Compare the effect on sitting diastolic blood pressure of two antihypertensive drugs in combination taken once daily against one antihypertensive drug taken twice daily.;  Compare the effect on sitting diastolic blood pressure of a dose of an antihypertensive drug taken once daily against half of the same dose taken twice daily.;  Compare the effect on the sitting and standing blood pressure among all treatment groups.;  Compare the safety of each medication regimen stated above.;  Compare the effect on mean 24-hour diastolic blood pressure (ABPM) of the medication regimens stated above.||NCT00355589|July 2006
4445|Active not recruiting|Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma||Drug:IrinotecanHydrochloride;  Biological:Dactinomycin;  Drug:Cyclophosphamide;  Drug:VincristineSulfate;  Radiation:RadiationTherapy;  Other:LaboratoryBiomarkerAnalysis;  Other:QuestionnaireAdministration|Interventional|Phase 3|Other / NIH|Failure-freesurvival(FFS);  Responserate(RR)(completeorpartialresponse);  Overallsurvival(OAS);  Long-term FFS of patients with intermediate-risk RMS treated with VAC and early (Week 4) radiotherapy compared to delayed (Week 10) radiotherapy using IRSIV for historic comparison;  Local control of patients with intermediate-risk RMS treated with VAC and early (Week 4) radiotherapy compared to delayed (Week 10) radiotherapy using IRSIV for historic comparison;  Overall survival of patients with intermediate-risk RMS treated with VAC and early (Week 4) radiotherapy compared to delayed (Week 10) radiotherapy using IRSIV for historic comparison;  Incidence of toxicity associated with concurrent VI and radiotherapy;  Acute and late effects of VAC as delivered on this study to D9803 VAC;  Change in FDG PET maximum standard uptake value (SUVmax);  Incidence of toxicity related to VI treatment in patients with UGT1A1 genotype;  Incidence of toxicity related to VAC treatment in patients with CYP2B6 genotypes;  Incidence of toxicity related to VAC treatment in patients with CYP2C9 genotypes;  Incidence of toxicity related to VAC treatment in patients with GSTA1 genotypes;  Geneexpressionanalysis;  Bladder function by disease-free patient/parent self report using a 14 point questionnaire|481|NCT00354835|December 2006
4446|Active not recruiting                  Has Results|High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma||Biological:dactinomycin;  Drug:cyclophosphamide;  Drug:doxorubicinhydrochloride;  Drug:etoposide;  Drug:ifosfamide;  Drug:irinotecanhydrochloride;  Drug:vincristinesulfate;  Procedure:conventionalsurgery;  Radiation:radiationtherapy;  Biological:filgrastim|Interventional|Phase 3|Other / NIH|TumorResponseRate;  Estimate of the Percent of Patients Event Free at 4 Years Following Study Entry;  EarlyDiseaseControl;  Feasibility;  Toxicity|109|NCT00354744|July 2006
4447|Terminated|Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer||Drug:Telcyta;  Drug:LiposomalDoxorubicin|Interventional|Phase 3|Industry|To demonstrate superiority in progression-free survival of TLK286 in combination with liposomal doxorubicin as compared with the active control arm liposomal doxorubicin;  To evaluate and compare the safety profile of each treatment arm|244|NCT00350948|May 2006
4448|Unknown&nbsp;&#8224;|Observation Radiation Therapy Combination Chemotherapy and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma||Drug:doxorubicinhydrochloride;  Other:clinicalobservation;  Procedure:therapeuticconventionalsurgery;  Radiation: 3-dimensional conformal radiation therapy;  Drug:ifosfamide|Interventional|Phase 3|Other / NIH|Long-termsurvivalforlow-riskpatients;  Event-free and overall survival for patients in the intermediate risk group;  Localfailurerate;  Toxicityofneoadjuvantchemoradiotherapy|588|NCT00346164|February 2007
4449|Completed|Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn&apos;s Disease With Previous Exposure to Infliximab (CHOICE)||Drug:adalimumab|Interventional|Phase 3|Industry|AEs laboratory data physical examinations and vital signs;  Efficacy variables will be assessed from Outcomes Questionnaires|1000|NCT00338650|June 2006
4450|Completed|Study of 2 Doses of HRV Vaccine Given Concomitantly or Separately With Routine Vaccinations in Healthy Infants in USA||Biological: 2-dose oral live attenuated G1P[8] human rotavirus vaccine|Interventional|Phase 3|Industry|Demonstrate that coadministration with HRV vaccine does not impair the immune response to all antigens contained in each of the routine infant vaccines.;  AssessimmunogenicityandsafetyofHRVvaccine.|484|NCT00334607|June 2006
4451|Completed                  Has Results|Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease||Drug:DexlansoprazoleMR;  Drug:Placebo|Interventional|Phase 3|Industry|Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Median;  Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Mean;  Percentage of Days Without Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Median;  Percentage of Days Without Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Mean|947|NCT00321984|June 2006
4452|Completed                  Has Results|Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.||Drug:Alogliptinandinsulin;  Drug:Insulin|Interventional|Phase 3|Industry|Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.;  Change From Baseline in Glycosylated Hemoglobin (Week 4).;  Change From Baseline in Glycosylated Hemoglobin (Week 8).;  Change From Baseline in Glycosylated Hemoglobin (Week 12).;  Change From Baseline in Glycosylated Hemoglobin (Week 16).;  Change From Baseline in Glycosylated Hemoglobin (Week 20).;  Change From Baseline in Fasting Plasma Glucose (Week 1).;  Change From Baseline in Fasting Plasma Glucose (Week 2).;  Change From Baseline in Fasting Plasma Glucose (Week 4).;  Change From Baseline in Fasting Plasma Glucose (Week 8).;  Change From Baseline in Fasting Plasma Glucose (Week 12).;  Change From Baseline in Fasting Plasma Glucose (Week 16).;  Change From Baseline in Fasting Plasma Glucose (Week 20).;  Change From Baseline in Fasting Plasma Glucose (Week 26).;  Number of Participants With Marked Hyperglycemia (Fasting Plasma Glucose &#8805; 200 mg Per dL).;  NumberofParticipantsRequiringRescue.;  ChangeFromBaselineinC-peptide(Week4).;  ChangeFromBaselineinC-peptide(Week8).;  ChangeFromBaselineinC-peptide(Week12).;  ChangeFromBaselineinC-peptide(Week16).;  ChangeFromBaselineinC-peptide(Week20).;  ChangeFromBaselineinC-peptide(Week26).;  Number of Participants With Glycosylated Hemoglobin &#8804; 6.5%.;  Number of Participants With Glycosylated Hemoglobin &#8804; 7.0%.;  Number of Participants With Glycosylated Hemoglobin &#8804; 7.5%.;  Number of Participants With Glycosylated Hemoglobin Decrease From Baseline &#8805; 0.5%.;  Number of Participants With Glycosylated Hemoglobin Decrease From Baseline &#8805; 1.0%.;  Number of Participants With Glycosylated Hemoglobin Decrease From Baseline &#8805; 1.5%.;  Number of Participants With Glycosylated Hemoglobin Decrease From Baseline &#8805; 2.0%.;  ChangeFromBaselineinBodyWeight(Week8).;  ChangeFromBaselineinBodyWeight(Week12).;  ChangeFromBaselineinBodyWeight(Week20).;  ChangeFromBaselineinBodyWeight(Week26).|390|NCT00286429|February 2006
4453|Completed                  Has Results|The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)||Drug:Insulinglargine;  Drug:LisproLowMix;  Drug:LisproMidMix;  Drug:Lispro|Interventional|Phase 4|Industry|INITIATION: 24-Week Endpoint Glycosylated Hemoglobin (HbA1c);  MAINTENANCE: Duration of Time HbA1c Maintained at Goal by Initiation Regimen (Insulin Glargine or Lispro Low Mix);  ADDENDUM:24-WeekEndpointHbA1c;  INITIATION: Change in HbA1c From Baseline to 24 Weeks;  INITIATION: Percentage of Participants With HbA1c &lt; or = 7.0% HbA1c &lt;7.0% and HbA1c &lt; or = 6.5% at Endpoint;  INITIATION:HbA1c;  INITIATION: 7-point Self-monitored Plasma Glucose (SMPG) Profiles and Postprandial Excursions;  INITIATION: Change From Baseline to Endpoint in 15 Anhydroglucitol (15 AG);  INITIATION: Incremental Change From Baseline in Body Weight;  INITIATION:BodyWeight;  INITIATION: Percentage of Participants With Self-reported Hypoglycemic Episodes;  INITIATION: Rate of Self-reported Hypoglycemic Episodes;  INITIATION:InsulinDose;  INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Age;  INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Origin;  INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Homeostasis Model Assessment of Insulin Resistance (HOMA-IR);  INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - HbA1c;  INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Baseline HbA1c Percentage Group;  INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - 15 AG;  INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal at Week 24 - Pre Meals Blood Glucose Post Meals Blood Glucose Average of All Blood Glucose and Fasting Blood Glucose;  INITIATION: Participant Demographics of Participants Who Did Versus Did Not Achieve HbA1c Goal - Oral Diabetes Medication at Baseline;  MAINTENANCE: HbA1c at Specified Visits and Endpoint;  MAINTENANCE: 7-point SMPG Profiles and Postprandial Excursions;  MAINTENANCE:RateofIncreaseinHbA1c;  MAINTENANCE: Percentage of Participants With HbA1c &lt; or = 7.0% HbA1c &lt;7.0 and HbA1c &lt; or = 6.5%;  MAINTENANCE: Incremental Change From Baseline in Body Weight;  MAINTENANCE:BodyWeight;  MAINTENANCE:InsulinDose;  MAINTENANCE: Percentage of Participants With Self-reported Hypoglycemic Episodes;  MAINTENANCE: Rate of Self-reported Hypoglycemic Episodes;  MAINTENANCE: Change From Baseline in 15-Anhydroglucitol;  MAINTENANCE: Change From Baseline to Endpoint in HbA1c;  MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Duration of Diabetes;  MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Duration of Diabetes;  MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Duration of Diabetes Group;  MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Duration of Diabetes Group;  MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Baseline HbA1c;  MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Baseline HbA1c;  MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Baseline HbA1c Group;  MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Baseline HbA1c Group;  MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Oral Diabetes Medicine at Baseline;  MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Oral Diabetes Medicine at Baseline;  MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - 15 AG;  MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - 15 AG;  MAINTENANCE: Participant Demographics of Insulin Glargine Participants Who Did Versus Did Not Maintain HbA1c Goal - Mean of Post Meals Blood Glucose and Average of All Blood Glucose;  MAINTENANCE: Participant Demographics of Lispro LM Participants Who Did Versus Did Not Maintain HbA1c Goal - Mean of Post Meals Blood Glucose and Average of All Blood Glucose;  ADDENDUM: Change in HbA1c From Point of Second Randomization (Addendum Baseline) to Endpoint;  ADDENDUM: Percentage of Participants With HbA1c &lt; or = 7.0% HbA1c &lt; 7.0% and &lt; or = 6.5%;  ADDENDUM:7-pointSMPGProfiles;  ADDENDUM: Incremental Change From Baseline in Body Weight;  ADDENDUM:BodyWeight;  ADDENDUM:InsulinDose;  ADDENDUM: Percentage of Participants With Self-reported Hypoglycemic Episodes;  ADDENDUM: Rate of Self-reported Hypoglycemic Episodes;  ADDENDUM: Change From Baseline in 15-Anhydroglucitol to Week 24;  ADDENDUM:HbA1catSpecifiedVisitsandEndpoint|2091|NCT00279201|December 2005
4454|Terminated                  Has Results|OMNI Study--Assessing Therapies in Medtronic Pacemaker Defibrillator and Cardiac Resynchronization Therapy Devices.|||Observational||Industry|ImplantedSystemsFrequencies;  Implantable Pulse Generator (IPG) Device Baseline Programming Frequencies.;  ICD/CRT-DDeviceBaselineProgrammingFrequencies;  ICD/CRT-D Device Baseline Programming Measurements;  AV Block Status by Device Type at 6 and 12 Months.;  AV Block Status by Severity of Historical AV Block;  Summary of ATP Episodes Within All Treated Episodes;  Compare First Shock Rate Between Medtronic &quot;PainFREE&quot; Programming and &quot;SCD-HeFT&quot; Programming in Primary Prevention Study Participants.;  Frequencies of Subjects With OptiVol Trends and Disease Progression.|3032|NCT00277524|August 2005
4455|Completed|Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer||Drug:cisplatin;  Drug:tirapazamine|Interventional|Phase 3|NIH / Other|Progression-freesurvival;  Frequency and severity of adverse events assessed by Common Terminology Criteria for Adverse Events version 3.0;  Overallsurvival|402|NCT00262821|February 2006
4456|Completed                  Has Results|Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn||Drug:DexlansoprazoleMR;  Drug:Placebo|Interventional|Phase 3|Industry|Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Median;  Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Mean;  Percentage of Days Without Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Median;  Percentage of Days Without Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Mean|908|NCT00251758|December 2005
4457|Completed|A Randomized Double-blind Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients||Drug:telmisartan80mg/hydrochlorothiazide25mg;  Drug:valsartan160mg/hydrochlorothiazide25mg;  Drug:placebo|Interventional|Phase 4|Industry|Change from baseline in mean seated trough cuff diastolic and systolic blood pressure measurements at the end of an 8-week treatment period;  Percentage of responders based on change from baseline in cuff diastolic and systolic blood pressure measurements at the end of an 8-week treatment period|1109|NCT00240448|September 2003
4458|Completed|Dose Ranging Study With LT Monotherapy PPAR||Drug:Muraglitazar|Interventional|Phase 2 / Phase 3|Industry|To compare after 24 weeks of oral administration of double-blind treatment the change from baseline in hemoglobin A1c (HbA1c) achieved with the highest dose and subsequent doses of BMS-298585 versus the lowest dose of BMS-298585 in subjects with Type 2;  To assess after 12 and 24 weeks of oral administration of double-blind therapy the percent change from baseline in fasting lipids (total cholesterollow density lipoprotein cholesterolHDL-C TG non-HDL chol|1260|NCT00240383|May 2002
4459|Unknown&nbsp;&#8224;|Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass||Genetic:proteomicprofiling;  Other: surface-enhanced laser desorption/ionization-time of flight mass spectrometry;  Procedure:biopsy|Interventional||Other / NIH|Proteomic proflie (i.e. discrimination of tumor from nontumor in pelvic mass)|2000|NCT00238342|October 2005
4460|Completed|A Controlled Pregabalin Trial In Fibromyalgia||Drug:pregabalin;  Drug:placebo|Interventional|Phase 3|Industry|To evaluate the efficacy of pregabalin for pain relief by comparing the mean pain score between treatment groups and placebo.;  To evaluate the efficacy of pregabalin for improvement in sleep fatigue health-related quality of life functioning and mood disturbance associated with fibromyalgia. To evaluate safety and tolerability.|740|NCT00230776|October 2005
4461|Completed                  Has Results|Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness||Drug:Armodafinil100to250mg/day|Interventional|Phase 3|Industry|Safety and Tolerability in This Patient Population (Narcolepsy OSAHS SWSD) Over Time (up to 2 Years)|743|NCT00228553|May 2004
4462|Completed                  Has Results|Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.||Biological:Adalimumab;  Drug:Placebo|Interventional|Phase 3|Industry|Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 24;  Change From Baseline in Modified Total Sharp X-ray Score at Week 52;  Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 52;  Number of Participants Meeting ACR20 Response Criteria at Week 52;  Change From Baseline in Modified Total Sharp X-ray Score at Week 24;  Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 24;  Maintenance of the Disability Index of the HAQ at Week 52 for Participants Who Were Responders at Week 12 or Week 24;  Maintenance of ACR20 Response at Week 52 for Participants Who Were ACR20 Responders at Week 24;  Number of Participants With a Continuous ACR70 Response for 6 Months During 52 Weeks of Treatment;  Time to First Response According to ACR20 Criteria - Number of Participants Meeting ACR20 Criteria for the First Time at Each Time Point;  Time to First Response According to ACR50 Criteria - Number of Participants Meeting ACR50 Criteria for the First Time at Each Time Point;  Time to First Response According to ACR70 Criteria - Number of Participants Meeting ACR70 Criteria for the First Time at Each Time Point;  Estimated Yearly Progression of Rheumatoid Arthritis|619|NCT00195702|February 2000
4463|Completed|Study of co-Administration of Olmesartan Medoxomil Plus Amlodipine in Patients With Mild to Severe Hypertension||Drug:Olmesartanmedoxomil;  Drug:Amlodipine|Interventional|Phase 3|Industry|Change from baseline in trough seated systolic blood pressure and seated diastolic blood pressure for each treatment arm;  To evaluate the number (%) of patients achieving BP goal.;  To characterize the pharmacokinetic interactions and the corresponding pharmacodynamic (BP) correlation|1900|NCT00185133|May 2005
4464|Completed|PPAR-COMBO With Sulfonylurea||Drug:Muraglitazar|Interventional|Phase 3|Industry|Compare change from baseline in HbA1c after 24 weeks of treatment with muraglitazar + glyburide vs placebo + glyburide;  Change in FPG from basline to W24 proportion of subjects receiving therapeutic response at W24 percent change of fasting lipid levels from baseline to W11/12 change in hs-CRP from baseline to W24|534|NCT00162175|July 2003
4465|Completed|Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy||Drug:Estradiol|Interventional|Phase 4|Industry|||NCT00160173|
4466|Completed|Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population||Drug:Amlodipine/Atorvastatin|Interventional|Phase 4|Industry|To evaluate the efficacy of Caduet therapy by assessing the percentage of intent-to-treat subjects achieving both BP and lipid treatment goals (JNC VII and NCEP ATP III);  To assess the percentage of subjects achieving treatment goals(JNC VII and NCEP) stratified by the final BP and lipid therapy doses respectively the change from baseline in lipid profile SBP and DBP|500|NCT00150384|July 2004
4467|Completed|A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol||Drug:torcetrapib/atorvastatin;  Drug:atorvastatin;  Drug:placebo|Interventional|Phase 3|Industry|LDLandHDLlevels;  otherlipidparameters|3800|NCT00138762|July 2004
4468|Completed|A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease||Drug:torcetrapib/atorvastatin;  Drug:atorvastatin|Interventional|Phase 3|Industry|Change coronary artery atheroma volume as measured by intravascular ultrasound.;  Changesinlevelsoflipidsandotherbiomarkers.|1100|NCT00134173|October 2003
4469|Completed                  Has Results|Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children||Biological:motavizumab(MEDI-524);  Biological:palivizumab|Interventional|Phase 3|Industry|Incidence of RSV Hospitalization (Includes Deaths by RSV);  Number of Participants Reporting Any Adverse Events (AEs);  NumberofParticipantsReportingAnyRelatedAEs;  Number of Participants Reporting Any Serious Adverse Events (SAEs);  NumberofParticipantsReportingAnyRelatedSAEs;  Number of Participants Reporting AEs by Highest Severity Grade;  Number of Participants Who Discontinued Study Drug Due to AEs;  NumberofParticipantsWhoDied;  Number of Participants Reporting Changes in Vital Signs From Baseline;  The Incidence of Outpatient Medically-attended Lower Respiratory Illness (LRI);  The Incidence of RSV-specific Medically-attended Outpatient Lower Respiratory Illnesses (LRIs) Between Treatment Groups;  The Incidence of Medically-attended Otitis Media (OM) Infections;  The Frequency of Prescribed Antibiotics for Medically-attended LRI;  The Frequency of Prescribed Antibiotics for Medically-attended OM Infections;  The Number of Participants With Anti-motavizumab Antibodies;  TheSerumConcentrationsofMotavizumabatDay0;  The Trough Serum Concentrations of Motavizumab at 30 Days Post Dose 1;  The Trough Serum Concentrations of Motavizumab at 30 Days Post Dose 2;  The Trough Serum Concentrations of Motavizumab at 30 Days Post Dose 3;  The Trough Serum Concentrations of Motavizumab at 30 Days Post Dose 4|6635|NCT00129766|November 2004
4470|Completed|Trivalent Live Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6&#8211;59 Months of Age||Drug:LiquidCAIV-T|Interventional|Phase 3|Industry|The primary efficacy endpoint of this study is the relative efficacy of CAIV-T;  compared to TIV against the incidence of culture-confirmed symptomatic influenza infection caused by community-acquired wild-type strains antigenically similar to those contained in the vaccine occurring during the;  influenza surveillance period and at least 14 days after the last required vaccination;  Culture-confirmed symptomatic influenza infection regardless of antigenic match;  Febrile acute otitis media (AOM) with antibiotic use associated with culture-confirmed influenza infection antigenically similar to vaccine strains;  Febrile acute otitis media (AOM) with antibiotic use associated with culture-confirmed influenza infection regardless of antigenic match;  Lower respiratory illness (LRI) with culture-confirmed influenza infection antigenically similar to vaccine strains and;  Lower respiratory illness (LRI) with culture-confirmed influenza infection regardless of antigenic match|8500|NCT00128167|October 2004
4471|Active not recruiting                  Has Results|Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer||Drug:Carboplatin;  Drug:ErlotinibHydrochloride;  Other:LaboratoryBiomarkerAnalysis;  Drug:Paclitaxel|Interventional|Phase 2|NIH|18WeeksProgressionFreeSurvival(PFS)Rate;  OverallResponseRate;  Number of Participants With Grade 3 4 or 5 Adverse Event at Least Possibly Related to Treatment.|188|NCT00126581|August 2005
4472|Completed|A Study in People With Abnormal Fat Levels in the Blood||Drug:PPARalpha;  Drug:placebo|Interventional|Phase 2|Industry|EffectsonHDL-CandTriglyceridesafter12weeks;  Safetyafter12weeks;  EffectsonLDL-Cafter12weeks;  Effects on biomarkers of atherosclerosis after 12 weeks;  Effects on factors of metabolic syndrome after 12 weeks|300|NCT00116519|July 2005
4473|Completed|Advair&#174; DISKUS&#174; Versus Serevent&#174; DISKUS&#174; For Chronic Obstructive Pulmonary Disease Exacerbations||Drug: Fluticasone Propionate/Salmeterol Combination Product;  Drug:Salmeterol|Interventional|Phase 4|Industry|Rate of moderate/severe exacerbations over a 52 week treatment period;  The time until the first moderate/severe exacerbation; the annual rate of exacerbations requiring oral corticosteroid treatment and breathing tests conducted over one year|797|NCT00115492|December 2004
4474|Terminated|A Study of the Safety and Efficacy of Nitric Oxide Reduction in Patients With Cardiogenic Shock After a Heart Attack||Drug: Tilarginine Acetate Injection intravenous infusion|Interventional|Phase 3|Industry|Allcausemortalityat30dayspostrandomization;  Number of patients demonstrating resolution of cardiogenic shock compared to placebo;  The duration of cardiogenic shock compared to placebo|658|NCT00112281|May 2005
4475|Completed|Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes||Drug:Muraglitazar;  Drug:Pioglitazone|Interventional|Phase 3|Industry|ChangeinHBA1cfrombaselinetoWeek24;  ChangeforbaselineinTGandHDL-CatWeek24;  Change from baseline in FPG fasting insulin fasting c-peptide body mass index body weight waist circumferance SBP and DBP.;  To assess safety and tolerability of both Muraglitazar regimens relative to pioglitazone regimen when administered for up to 24 weeks|1440|NCT00106808|August 2005
4476|Completed|Study Of Asthma In Patients Of African Descent||Drug:fluticasonepropionate/salmeterolpowder;  Drug:fluticasonepropionatepowder|Interventional|Phase 4|Industry|Asthmaexacerbationrateperpatientperyear;  Morning peak flow measurement percent of asthma symptom-free days percent of albuterol-free days|479|NCT00102765|November 2004
4477|Completed|Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication||Drug:alvimopan;  Drug:placebo|Interventional|Phase 2|Industry|Change in weekly SCBM frequency. A SCBM is a spontaneous and complete bowel movement which means a bowel movement that occurs with no laxative use in the prior 24 hours and leaves the subject with the feeling of complete evacuation of the rectum.;  Additional measures of Bowel movement (BM) frequency and symptoms safety profile of the treatment regimens and any changes in pain intensity or opioid use.|233|NCT00101998|October 2003
4478|Completed|Radiation Therapy Temozolomide and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme||Drug:irinotecanhydrochloride;  Drug:temozolomide;  Procedure:adjuvanttherapy;  Radiation:radiationtherapy|Interventional|Phase 2|Other / NIH|Overallsurvival;  Progression-freesurvival|170|NCT00099125|November 2004
4479|Completed|Study of Milnacipran for the Treatment of Fibromyalgia||Drug:milnacipranhydrochloride|Interventional|Phase 3|Industry|Composite responder analysis based on pain and patient global status with or without physical function.;  QualityofLife;  Health Assessment Questionnaire (HAQ) Disability Index;  Fatiguesleepandcognitiveassessments|1200|NCT00098124|November 2004
4480|Completed|A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)|||Observational|Phase 4|Industry||1846|NCT00096928|March 2005
4481|Completed|Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma||Drug:Cisplatin;  Radiation:CraniospinalIrradiation;  Drug:Cyclophosphamide;  Radiation:Involved-FieldRadiationTherapy;  Other:LaboratoryBiomarkerAnalysis;  Drug:Lomustine;  Other:Quality-of-LifeAssessment;  Radiation:RadiationTherapy;  Drug:VincristineSulfate|Interventional|Phase 3|Other / NIH|Timetoevent-freesurvival(EFS);  Incidence of grade 3 and grade 4 toxicities in any body system as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events v 4.0;  Localposteriorfossa(LPF)failure;  Non-localposteriorfossa(NLPF)failure;  Non-posteriorfossa(NPF)failure;  Post-treatment endocrine function (e.g. growth sexual maturation and need for hormone replacement) by laboratory assessment clinical history and exam;  Post-treatment hearing loss as measure by audiogram or brainstem auditory evoked response (BAER);  Post-treatment neurocognitive function as measured by neuropsychometric battery;  Timetodeathfromanycause;  Time to recurrence progression or death due to cancer|528|NCT00085735|April 2004
4482|Active not recruiting                  Has Results|Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck||Biological:cetuximab;  Drug:cisplatin;  Drug:docetaxel;  Radiation:radiationtherapy|Interventional|Phase 2|Other / NIH|Disease-freeSurvival;  OverallSurvival;  TreatmentTolerance;  Frequency of Toxicity (Grade 5 and Acute Non-hematologic Grade 4);  FrequencyofOtherAcuteandLateToxicity;  Local-regionalControl;  Correlation of EGFR (Total and Phosphorylated) pMAPK pAKT Stat-3 KI-67 COX-2 and Cyclin B1 Expression With Local-regional Control and Overall and Disease-free Survival|238|NCT00084318|April 2004
4483|Completed                  Has Results|Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases||Drug:zoledronicacid;  Other:placebo;  Drug:androgendeprivationtherapy;  Drug:GnRHagonist;  DietarySupplement:Calciumsupplement;  DietarySupplement:VitaminD|Interventional|Phase 3|Other / NIH / Industry|TimetoFirstSkeletalRelatedEvent;  OverallSurvival;  Progression-freeSurvival|645|NCT00079001|January 2004
4484|Active not recruiting|Captopril in Treating Patients With Non-Small Cell Lung Cancer or Limited-Stage Small Cell Lung Cancer That Has Been Previously Treated With Radiation Therapy With or Without Chemotherapy||Drug:captopril|Interventional|Phase 2|Other / NIH|Incidenceoftherapy-inducedlungtoxicity;  Correlation of lung toxicities with biochemical markers;  Correlation of quality of life with late effects as measured by European Organization for Research and Treatment of Cancer (EORTC) C-30 or LC-13;  Pulmonary toxicity at 2 years after completion of study treatment|81|NCT00077064|June 2003
4485|Active not recruiting                  Has Results|Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer||Drug:chemotherapy;  Radiation:radiationtherapy|Interventional|Phase 3|Other|Disease-freeSurvival;  OverallSurvival;  SitesofFirstFailures|162|NCT00074152|July 2002
4486|Completed|Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy||Drug:asparaginase;  Drug:busulfan;  Drug:cyclophosphamide;  Drug:cyclosporine;  Drug:cytarabine;  Drug:daunorubicinhydrochloride;  Drug:etoposide;  Drug:gemtuzumabozogamicin;  Drug:methotrexate;  Drug:mitoxantronehydrochloride;  Procedure:allogeneicbonemarrowtransplantation|Interventional|Phase 2|Other / NIH|Safety;  Completeremissionrate;  Feasibility;  Effectofkaryotypicabnormalities|350|NCT00070174|December 2003
4487|Completed|Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic EGFR-Positive Colorectal Cancer||Drug:cetuximab;  Drug:Irinotecan|Interventional|Phase 3|Industry|OverallSurvival;  ProgressionFreeSurvival;  Response;  DurationofResponse;  TimetoResponse;  DiseaseControlRate;  Safety;  QualityofLife;  HealthEconomics|1302|NCT00063141|April 2003
4488|Completed|Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin&apos;s Lymphoma||Biological:rituximab;  Radiation:yttriumY90ibritumomabtiuxetan|Interventional|Phase 2|Other / NIH|Overallresponserate;  Durationofresponse;  Complete response (CR) unconfirmed CR and partial response;  Event-freesurvival;  Timetoprogression;  Timetonextlymphomatreatment|84|NCT00062114|April 2004
4489|Completed|Effect Of Carvedilol Versus Metoprolol On Glycemic Control In Patients With Type II Diabetes And Hypertension||Drug:carvedilol;  Drug:metoprolol|Interventional|Phase 4|Industry|ChangefrombaselineinHbA1cat5months;  Blood pressure at 3 and 5 months Body weight at 3 and 5 months Lab levels (glucose insulin triglycerides cholesterol and albumin:creatinine ratio) at 3 and 5 months.|501|NCT00060931|June 2001
4490|Completed                  Has Results|Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma||Drug:doxorubicinhydrochloride;  Drug:mercaptopurine;  Drug:methotrexate;  Drug:prednisone;  Drug:vinblastinesulfate;  Drug:vincristinesulfate|Interventional|Phase 3|Other / NIH|Event-freeSurvival(EFS)|129|NCT00059839|November 2003
4491|Completed                  Has Results|Brain Irradiation in Treating Patients With Limited-Stage Small Cell Lung Cancer||Radiation: Prophylactic cranial irradiation 2.5 Gy fx;  Radiation: Prophylactic cranial irradiation 2.0 Gy fx;  Radiation: Prophylactic cranial irradiation 1.5 Gy fx|Interventional|Phase 2|Other / NIH|IncidenceofChronicNeurotoxicity|265|NCT00057746|February 2003
4492|Completed|TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer||Drug:TLK286HClforinjection;  Drug:topotecanhydrochlorideforinjection;  Drug:doxorubicinHClliposomeinjection|Interventional|Phase 3|Industry||440|NCT00057720|June 2003
4493|Completed|Study of the Physical and Emotional Needs of Parents Caring for Children Receiving Chemotherapy for Acute Lymphoblastic Leukemia||Other:questionnaireadministration|Interventional||Other / NIH|EventFreeSurvival;  Determine whether caregivers whose child is randomized to receive the 24-hour methotrexate infusion will report lower caregiving demand than will caregivers whose child is randomized to receive the 4-hour infusion;  TotalscorefromtheCMCC|172|NCT00056069|December 2002
4494|No longer available|Atazanavir for HIV Infected Individuals: An Early Access Program||Drug:Atazanavir(BMS-232632)|Expanded Access||Industry|||NCT00046345|May 2002
4495|Completed|Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea||Drug:AC2993;  Drug:Placebo|Interventional|Phase 3|Industry|ChangeinHbA1cfromBaselinetoWeek30;  Change in HbA1c from baseline (Day 1) to each of the intermediate visits;  The number of subjects achieving HbA1c target values of &lt; 7% and &lt; 8% by Week 30;  The number of subjects achieving HbA1c reductions of &gt; 0.5% and &gt; 1.0% by Week 30;  The time to achieve HbA1c reductions of 0.5% or more and &gt;1.0% or more;  The time to achieve specific HbA1c target values of &lt; 7% and &lt; 8%;  Change in body weight from Baseline to each intermediate visit and Week 30|377|NCT00039026|February 2002
4496|Completed|Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin||Drug:AC2993;  Drug:Placebo|Interventional|Phase 3|Industry|Change in HbA1c (glycosylated hemoglobin) from baseline to study termination (Week 30);  Change in HbA1c from baseline (Day 1) to each of the intermediate visits;  The number of subjects achieving HbA1c target values of &lt; 7% and &lt; 8% by Week 30;  The number of subjects achieving HbA1c reductions of &gt; 0.5% and &gt; 1.0% by Week 30;  The time to achieve specific HbA1c target values of &lt; 7% and &lt; 8%;  The time to achieve HbA1c reductions of 0.5% or more and &gt;1.0% or more;  Change in body weight from Baseline to each intermediate visit and Week 30|336|NCT00039013|March 2002
4497|Completed                  Has Results|S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma||Drug:capecitabine;  Drug:gemcitabinehydrochloride|Interventional|Phase 2|Other / NIH|Response;  OverallSurvival;  Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug;  AccrualofPatientsWithThisDiseaseSite;  Median Survival Time for Participants With Relevant Biologic Markers|57|NCT00033540|September 2003
4498|Completed|Isotretinoin With or Without Dinutuximab Aldesleukin and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma||Biological:Aldesleukin;  Biological:Dinutuximab;  Drug:Isotretinoin;  Other:LaboratoryBiomarkerAnalysis;  Other:PharmacologicalStudy;  Other:Quality-of-LifeAssessment;  Biological:Sargramostim|Interventional|Phase 3|NIH|EFS;  EFS of patients from the non-randomized portion of the trial;  Incidence of toxicities assessed using Common Terminology Criteria for Adverse Events version 4.0;  Numberofcoursesoftherapydelivered;  OS;  OS of patients from the non-randomized portion of the trial|1449|NCT00026312|October 2001
4499|Completed|Zoledronate Calcium and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer||DietarySupplement:calciumsalts;  DietarySupplement:cholecalciferol;  Drug:zoledronicacid|Interventional|Phase 3|Other / NIH|Bonemineraldensityinthelumbarspine|439|NCT00022087|December 2001
4500|Completed|Docetaxel in Treating Children With Relapsed or Refractory Acute Lymphoblastic or Acute Myeloid Leukemia||Drug:docetaxel|Interventional|Phase 2|Other / NIH|Responsetotherapy|12|NCT00021242|August 2002
4501|Completed|Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia||Biological:aldesleukin|Interventional|Phase 1|Other / NIH|To determine the maximum tolerated dose (MTD) of IL-2|1|NCT00009698|March 1998
4502|Completed|Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer||Biological:sargramostim;  Procedure:quality-of-lifeassessment;  Radiation:radiationtherapy|Interventional|Phase 3|Other / NIH|||NCT00008398|October 2000
4503|Completed|Evaluation of Memory Skills in Patients Receiving Radiation Therapy for Brain Metastases||Procedure:managementoftherapycomplications;  Procedure:quality-of-lifeassessment|Interventional||Other / NIH|Feasibility of performing a test battery of neurocognitive and quality of life measures|59|NCT00007007|November 2000
4504|Completed|Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing&apos;s Sarcoma or Neuroectodermal Tumor||Biological:filgrastim;  Drug:cyclophosphamide;  Drug:doxorubicinhydrochloride;  Drug:etoposide;  Drug:ifosfamide;  Drug:vincristinesulfate;  Procedure:adjuvanttherapy;  Procedure:conventionalsurgery;  Procedure:neoadjuvanttherapy;  Radiation:brachytherapy;  Radiation:radiationtherapy|Interventional|Phase 3|Other / NIH|Event-freesurvival|587|NCT00006734|May 2001
4505|Completed|Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer||Drug:Biafinecream;  Procedure:quality-of-lifeassessment;  Radiation:radiationtherapy|Interventional|Phase 3|Other / NIH|||NCT00006481|October 2000
4506|Completed|Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia||Drug:gemcitabinehydrochloride|Interventional|Phase 2|Other / NIH|DeterminetheresponseratetoGemcitabine|32|NCT00006462|April 2001
4507|Completed|Radiation Therapy and Tamoxifen in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme||Drug:tamoxifencitrate;  Radiation:radiationtherapy|Interventional|Phase 2|Other / NIH|OverallSurvival|77|NCT00006388|December 2000
4508|Completed|Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin&apos;s Lymphoma||Drug:becatecarin|Interventional|Phase 2|NIH||200|NCT00006102|July 2000
4509|Completed|Combination Chemotherapy in Treating Patients With Non-Hodgkin&apos;s Lymphoma or Acute Lymphocytic Leukemia||Biological:filgrastim;  Drug:cyclophosphamide;  Drug:cytarabine;  Drug:dexamethasone;  Drug:doxorubicinhydrochloride;  Drug:etoposide;  Drug:ifosfamide;  Drug:leucovorincalcium;  Drug:methotrexate;  Drug:vincristinesulfate|Interventional|Phase 3|Other / NIH|Event-freesurvival|83|NCT00005977|September 2000
4510|Completed|Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia||Drug:cyclophosphamide;  Drug:cytarabine;  Drug:daunorubicinhydrochloride;  Drug:dexamethasone;  Drug:leucovorincalcium;  Drug:mercaptopurine;  Drug:methotrexate;  Drug:pegaspargase;  Drug:thioguanine;  Drug:vincristinesulfate|Interventional|Phase 3|Other / NIH|Improvement in outcome in children receiving multidrug delayed-intensification therapy;  Event-free survival minimal residual disease and early response;  Occurrenceofanticipatedfailures;  Total grade 3+ central nervous system (CNS) toxicity rates based on the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0|1076|NCT00005596|April 2000
4511|Completed|Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia||Drug:cyclophosphamide;  Drug:cytarabine;  Drug:daunorubicinhydrochloride;  Drug:dexamethasone;  Drug:leucovorincalcium;  Drug:mercaptopurine;  Drug:methotrexate;  Drug:pegaspargase;  Drug:thioguanine;  Drug:vincristinesulfate|Interventional|Phase 3|Other / NIH|Event-freesurvival;  Occurrenceofanticipatedfailures;  Grade 3 or greater CNS toxicity rates assessed using NCI CTC version 2.0;  Measuresoflaboratoryfactors(otherthanMRD);  Homocysteinelevels|838|NCT00005585|April 2000
4512|Completed|Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin&apos;s Disease||Biological:bleomycinsulfate;  Biological:filgrastim;  Drug:cyclophosphamide;  Drug:dexrazoxanehydrochloride;  Drug:doxorubicinhydrochloride;  Drug:etoposide;  Drug:prednisone;  Drug:vincristinesulfate;  Radiation:radiationtherapy|Interventional|Phase 3|Other / NIH|Diffusing capacity of the lungs for carbon monoxide (DLCO)|219|NCT00005578|March 1997
4513|Completed|Radiation Therapy and Cisplatin in Treating Patients With Advanced Head and Neck Cancer||Drug:cisplatin;  Radiation:radiationtherapy|Interventional|Phase 2|Other / NIH|||NCT00005088|April 2000
4514|Completed|Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer||Drug:cisplatin;  Drug:etoposide;  Radiation:radiationtherapy|Interventional|Phase 1|Other / NIH|Frequency of patients developing unacceptable (grade 3 or higher) acute toxicities attributable to thoracic irradiation with concurrent chemotherapy;  Compare baseline and follow-up Mini Mental Status Examinations|64|NCT00005022|February 1998
4515|Active not recruiting                  Has Results|Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma||Drug:asparaginase;  Drug:cyclophosphamide;  Drug:cytarabine;  Drug:daunorubicinhydrochloride;  Drug:dexamethasone;  Drug:doxorubicinhydrochloride;  Drug:leucovorincalcium;  Drug:mercaptopurine;  Drug:methotrexate;  Drug:prednisone;  Drug:thioguanine;  Drug:vincristinesulfate;  Radiation:radiationtherapy|Interventional|Phase 3|Other / NIH|Event-freeSurvival;  Percentage of Patients With Overall Survival as Assessed by Time to Death|393|NCT00004228|June 2000
4516|Completed|Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma||Drug:etoposide;  Drug:vincristinesulfate;  Radiation:radiationtherapy|Interventional|Phase 1|Other / NIH|Survival;  Monitorthetoxicity|31|NCT00003935|September 1999
4517|Active not recruiting|Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia||Other:laboratorybiomarkeranalysis|Observational||Other / NIH|Disease-freesurvival;  Overallsurvival;  Association of novel genes or micorRNAs with other biomarkers;  Clinical significance of minimal residual disease (MRD) as defined by BCR-ABL;  ClinicalsignificanceofMRDasdefinedbyWT-1|840|NCT00003861|April 1999
4518|Completed|Pentosan Polysulfate in Treating Patients With Gastrointestinal Disturbance Caused by Radiation Therapy||Drug:pentosanpolysulfatesodium;  Procedure:quality-of-lifeassessment|Interventional|Phase 3|Other / NIH||174|NCT00003825|June 1999
4519|Completed|Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors||Biological:bleomycinsulfate;  Drug:amifostinetrihydrate;  Drug:cisplatin;  Drug:etoposide;  Procedure:conventionalsurgery|Interventional|Phase 2|Other / NIH|FeasibilityfromEfficacyStandpoint;  AssessmentofReductioninToxicity|27|NCT00003811|April 2000
4520|Completed|Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma||Biological:filgrastim;  Drug:cisplatin;  Drug:cyclophosphamide;  Drug:etoposide;  Drug:vincristinesulfate;  Radiation:radiationtherapy|Interventional|Phase 2|Other / NIH|Assess the efficacy of oral etoposide at 50 mg/m2/day given concurrently with radiotherapy followed with dose intensive adjuvant chemotherapy in children with newly diagnosed high stage medulloblastoma|53|NCT00003573|November 1998
4521|Completed|Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer||Biological:filgrastim;  Drug:amifostinetrihydrate;  Drug:carboplatin;  Drug:paclitaxel;  Radiation:radiationtherapy|Interventional|Phase 3|Other / NIH||243|NCT00003313|September 1998
4522|Completed|Brachytherapy in Treating Patients With Prostate Cancer||Radiation:iodineI125|Interventional|Phase 2|Other / NIH||95|NCT00003312|September 1998
4523|Completed|Vinorelbine in Treating Children With Recurrent or Refractory Cancers||Drug:vinorelbinetartrate|Interventional|Phase 2|Other / NIH|Diseaseprogression|50|NCT00003234|May 1998
4524|Completed|Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer||Procedure:paintherapy;  Radiation:radiationtherapy|Interventional|Phase 3|Other / NIH||949|NCT00003162|February 1998
4525|Completed|Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer||Drug:enalaprilmaleate;  Procedure:quality-of-lifeassessment|Interventional|Phase 3|Other / NIH|Cardiacfunctionalstatusandqualityoflife|13|NCT00003070|September 2000
4526|Terminated|Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer||Drug:conjugatedestrogens|Interventional|Phase 3|Other / NIH||2108|NCT00002976|June 1997
4527|Completed|S9630 Medroxyprogesterone in Treating Women With Breast Cancer||Drug:medroxyprogesterone;  Drug:tamoxifencitrate;  Procedure:adjuvanttherapy|Interventional|Phase 3|Other / NIH|Endometrialpathologicdiagnosis|313|NCT00002920|March 1997
4528|Completed|Radiation Therapy With or Without Radiosurgery in Treating Patients With Brain Metastases||Procedure:surgicalprocedure;  Radiation:radiationtherapy;  Radiation:stereotacticradiosurgery|Interventional|Phase 3|Other / NIH||333|NCT00002708|January 1996
4529|Completed|Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia||Biological:filgrastim;  Drug:asparaginase;  Drug:cyclophosphamide;  Drug:daunorubicinhydrochloride;  Drug:dexamethasone;  Drug:etoposide;  Drug:leucovorincalcium;  Drug:liposomalcytarabine;  Drug:mercaptopurine;  Drug:mesna;  Drug:methotrexate;  Drug:therapeutichydrocortisone;  Drug:thiotepa;  Drug:vincristinesulfate;  Radiation:low-LETelectrontherapy;  Radiation:low-LETphotontherapy|Interventional|Phase 2|NIH||156|NCT00002704|January 1996
4530|Completed|Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer||Radiation:3D-CRT|Interventional|Phase 1 / Phase 2|Other / NIH|To establish the maximum tolerated dose (MTD) of radiation that can be delivered to the prostate gland and immediate surrounding tissues in patients with carcinoma of the prostate using three dimensional conformal radiation therapy (3D-CRT).;  To quantify the normal tissue toxicity rate (normal tissue complication probability (NTCP)) for rectum and bladder using 3D-CRT;  To evaluate local control by clinical pathologic and PSA (stable in normal range) determinations;  Distantmetastasisandsurvival|1084|NCT00002602|May 1994
4531|Completed|Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer||Drug:flutamide;  Drug:goserelinacetate;  Drug:leuprolideacetate;  Radiation:radiationtherapy|Interventional|Phase 3|Other / NIH|Overallsurvival|2028|NCT00002597|October 1994
4532|Completed|Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors||Biological:Sargramostim;  Drug:cyclophosphamide;  Drug:melphalan;  Procedure:autologousbonemarrowtransplantation;  Procedure: bone marrow ablation with stem cell support;  Procedure: peripheral blood stem cell transplantation|Interventional|Phase 2|Other / NIH|Progression-freesurvival|31|NCT00002594|September 1994
4533|Completed|Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer||Radiation:radiationtherapy|Interventional|Phase 1 / Phase 2|Other / NIH||36|NCT00002577|July 1995
4534|Completed|Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme||Drug:carmustine;  Radiation:low-LETphotontherapy|Interventional|Phase 3|Other / NIH||200|NCT00002545|February 1994
4535|Completed|Gemcitabine and/or Erlotinib as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer||Drug:erlotinibhydrochloride;  Drug:gemcitabinehydrochloride|Interventional|Phase 2|Other / NIH|Progression-freesurvival;  Responserate;  Overallsurvivalrate;  Toxicity;  Qualityoflife|147|NCT00283244|March 2006
4536|Completed|Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer||Drug:Sunitinib|Interventional|Phase 2|Industry|Overallconfirmedobjectiveresponserate(ORR);  Progression-freesurvival(PFS);  Timetoprogression(TTP);  Durationofresponse(DR);  Overallsurvival(OS);  Probabilityofsurvivalat1year|111|NCT00092001|January 2005
4537|Recruiting|Study to Evaluate BIIB059 in CLE With or Without SLE||Drug:BIIB059;  Drug:Placebo|Interventional|Phase 2|Industry|Percent change from baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index - Activity (CLASI-A) score;  CLASI-50response;  Percent change from baseline over time in CLASI-A score;  A&#8805;4-pointreductioninCLASI-Ascore;  Composite of Systemic Lupus Erythematosus Responder Index response of &#8805; 4 (SRI-4) at Week 24;  Change from baseline to Week 24 in Physician&apos;s Global Assessment (PGA) visual analog scale (VAS) score;  Change from baseline to Week 24 in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-2K score;  No new British Isles Lupus Activity Group (BILAG)-2004 A or &#8804; 2B to Week 24;  Number of participants experiencing Adverse Events (AEs and Serious Adverse Events (SAEs);  BIIB059clearance;  BIIB059volumeofdistribution;  BIIB059absorptionrate;  Number of participants with clinically significant laboratory assessment abnormalities;  Number of participants with clinically significant Vital sign abnormalities;  Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities;  Number of participants with positive serum BIIB059 antibodies;  Absolute change from baseline over time in immunoglobulin levels;  Absolute change from baseline over time in vaccine titers;  Percent change from baseline over time in immunoglobulin levels;  Percent change from baseline over time in vaccine titers|290|NCT02847598|August 2016
4538|Recruiting|AMPLIFY - D6571C00001 Duaklir USA Phase III Study||Drug: Aclidinium bromide 400 &#956;g/Formoterol Fumarate 12 &#956;g (AB/FF 400/12 &#956;g);  Drug:Aclidiniumbromide400&#956;g(AB400&#956;g);  Drug:Formoterolfumarate12&#956;g(FF12&#956;g);  Drug: Placebo to AB/FF 400/12 &#956;g AB 400 &#956;g and FF 12 &#956;g;  Drug:Tiotropium18&#956;g(TIO18&#956;g);  Drug:PlacebotoTIO18&#956;g|Interventional|Phase 3|Industry|Change from baseline in 1-hour morning post-dose dose FEV1 of AB/FF 400/12 &#956;g compared to AB 400 &#956;g at week 24.;  Change from baseline in morning predose (trough) FEV1 of AB/FF 400/12 &#956;g compared to FF 12 &#956;g at week 24.;  Change from baseline in morning predose (trough) FEV1 at week 24 comparing AB 400 &#956;g versus TIO 18 &#956;g to demonstrate non-inferiority.;  Change from baseline in normalized AUC0-3/3h FEV1 of AB/FF 400/12 &#956;g compared to AB 400 &#956;g at Week 24.;  Change from baseline in normalized AUC0-3/3h FEV1 of AB/FF 400/12 &#956;g compared to FF 12 &#956;g at Week 24.;  Responder analysis of St. George&apos;s Respiratory Questionnaire (SGRQ) total score with AB/FF 400/12 &#956;g versus AB 400 &#956;g.;  Responder analysis of SGRQ total score with AB/FF 400/12 &#956;g versus FF 12 &#956;g.|1500|NCT02796677|July 2016
4539|Recruiting|Study to Assess Efficacy and Safety of PT009 Compared to PT005 PT008 and Symbicort&#174; Turbuhaler&#174; on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD||Drug:BFFMDI320/9.6&#956;g;  Drug:BFFMDI160/9.6&#956;g;  Drug:FFMDI9.6&#956;g;  Drug:BDMDI320&#956;g;  Drug:Symbicort&#174;TBH400/12&#956;gBID|Interventional|Phase 3|Industry|Change from baseline in morning pre-dose trough FEV1;  ChangefrombaselineinFEV1AUC0-4;  Percentage of subjects achieving an MCID of 4 units or more in SGRQ;  PeakchangefrombaselineinFEV1;  Change from baseline in average daily rescue Ventolin HFA use;  Timetoonsetofaction|2420|NCT02766608|May 2016
4540|Recruiting|A Study to Compare ABT-494 to Placebo in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs||Drug:ABT-494;  Drug:Placebo|Interventional|Phase 3|Industry|Proportion of participants achieving American College Rheumatology (ACR) 20 response rate;  Proportion of participants achieving low disease activity (LDA);  Change in Disease Activity Score (DAS)28 C-Reactive Protein (CRP);  ACR50responserate;  Change in Health Assessment Questionnaire Disability Index (HAQ-DI);  ACR70responserate;  Change in Short-Form 36 (SF-36) Physical Component Score (PCS);  ACR20responserate|450|NCT02706847|March 2016
4541|Recruiting|Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)||Drug:Placebo;  Drug:Elagolix;  Drug:Estradiol/NorethindroneAcetate|Interventional|Phase 3|Industry|Percentage of Responders based on menstrual blood loss (MBL) volume reduction at Final Month;  ChangeinMBLvolume;  MonthlyChangeinMBLVolume;  Percentage of Subjects with Suppression of Bleeding;  Percentage of Subjects with Increase in Hemoglobin|400|NCT02691494|June 2014
4542|Recruiting|An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)||Drug:Tenapanor;  Drug:Placebo|Interventional|Phase 2|Industry|ChangeinSerumPhosphatefromBaseline;  Change in Serum Phosphate during Randomized Withdrawal Period;  ChangeinSerumPhosphate|150|NCT02675998|January 2016
4543|Recruiting|Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee Hip or Shoulder Replacement||Drug: Investigational Medical Product (IMP) administered in parent study|Interventional|Phase 3|Industry|Surgeon&apos;sAssessmentofProceduralDifficulty;  Subject&apos;s overall satisfaction with surgery as assessed by the Self-Administered Patient Satisfaction (SAPS) Scale;  Post-surgicalcomplications;  AdditionalorCorrectiveProcedures;  PhysicalRehabilitationActivities;  AveragePain;  Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC);  ShoulderPainandDisabilityIndex(SPADI);  ConcomitantAnalgesicUse|250|NCT02674386|July 2016
4544|Active not recruiting|Extension Study to Assess Safety and Efficacy of Mylan&apos;s Insulin Glargine and Lantus&#174; in Type 1 Diabetes Mellitus Patients||Drug:Mylan&apos;sinsulinglargine;  Drug:Lantus&#174;|Interventional|Phase 3|Industry|Change in HbA1c from baseline between two periods at 12 weeks;  Change in basal insulin dose per unit body weight (U/Kg/day);  Changeinimmunogenicity;  Rate of hypoglycemic events per 30 days; and occurrence of hypoglycemia;  Occurrence of local reactions systemic reactions and other adverse events;  Changeinfastingplasmaglucose|138|NCT02666430|December 2015
4545|Recruiting|Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women||Drug:Placebo;  Drug:Elagolix;  Drug:Elagolix+Estradiol/NorethindroneAcetate|Interventional|Phase 3|Industry|Percentage of Responders based on menstrual blood loss (MBL) volume reduction at Final Month;  ChangeinMBLVolume;  MonthlyChangeinMBLVolume;  Percentage of Subjects with Suppression of Bleeding;  Percentage of Subjects with Increase in Hemoglobin|400|NCT02654054|December 2015
4546|Recruiting|A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn&apos;s Disease||Drug:GED-0301;  Other:Placebo|Interventional|Phase 3|Industry|AdverseEvents(AEs)|1400|NCT02641392|July 2016
4547|Recruiting|Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)||Drug:Fedovapagon2mg;  Drug:Placebo|Interventional|Phase 2 / Phase 3|Industry|Changeinthemeannumberofnight-timevoids;  Change in mean patient reported nocturia bother score;  Change in mean night-time urine production absolute and as a proportion of 24 hour urine production;  Changeinmeanfunctionalbladdercapacity;  Change in International Prostate Symptom Score (IPSS);  ChangeinN-QOLScore;  NumberandtypeofAdverseEvents|425|NCT02637960|March 2016
4548|Active not recruiting|A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain||Drug:Fasinumab;  Drug:placebo|Interventional|Phase 2 / Phase 3|Industry|Change from baseline at week 16 in the average daily LBPI NRS;  Change from baseline at week 16 in the RMDQ total score;  Change from baseline at week 16 in the PGA of LBP score;  Change from baseline at weeks 2 4 8 and 12 in the LBPI NRS;  Percent of patients reporting TEAEs (Treatment Emergent Adverse Events);  Incidenceofanti-fasinumabantibodyformation|563|NCT02620020|February 2016
4549|Recruiting|A Study to Evaluate the Safety Tolerability and Microbiome Dynamics of SER-287 in Subjects With Ulcerative Colitis||Drug: Eubacterial Spores Purified Suspension Encapsulated;  Drug:Placebo;  Drug:PlaceboPre-Treat;  Drug:VancomycinPre-Treat|Interventional|Phase 1|Industry|Safety and tolerability of SER-287 vs. placebo in adult subjects by analysis of AE&apos;s lab values vital sign physical exam findings medical history and ECG.;  Examination of baseline composition of the intestinal microbiome to the composition;  Engraftment of SER-287 bacteria into the intestinal microbial community in each of the SER-287 arms compared to the placebo arm|55|NCT02618187|December 2015
4550|Active not recruiting|Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes||Drug:semaglutide;  Drug:sitagliptin;  Drug:placebo|Interventional|Phase 3|Industry|ChangeinHbA1c(glycosylatedhaemoglobin);  Changeinbodyweight(kg);  ChangeinFPG(fastingplasmaglucose);  Subjects who achieve HbA1c below 7.0% (53 mmol/mol) American Diabetes Association (ADA) target (yes/no);  ChangeinHbA1c;  ChangeinFPG|1860|NCT02607865|February 2016
4551|Recruiting|A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)||Drug:Nivolumab;  Drug:Bevacizumab;  Drug:Pemetrexed;  Other:BestSupportiveCare;  Drug:nab-Paclitaxel;  Drug:Paclitaxel;  Drug:Docetaxel;  Drug:Gemcitabine;  Drug:Erlotinib;  Drug:Crizotinib;  Drug:Carboplatin|Interventional|Phase 1 / Phase 2|Industry|GroupA:Progression-freesurvival(PFS);  GroupA:Overallsurvival(OS);  GroupB:Progression-freesurvival(PFS);  GroupB:Overallsurvival(OS);  GroupC:Progression-freesurvival(PFS);  GroupC:Overallsurvival(OS);  GroupD:Progression-freesurvival(PFS);  Group E: Number of Incidence of treatment-related Adverse events (AEs) leading to both study drugs discontinuation;  GroupA:Durationofresponse(DOR);  GroupA:ObjectiveResponserate(ORR);  GroupB:Durationofresponse(DOR);  GroupB:ObjectiveResponserate(ORR);  GroupC:Durationofresponse(DOR);  GroupC:ObjectiveResponserate(ORR);  GroupD:Overallsurvival(OS);  GroupD:Durationofresponse(DOR);  GroupD:ObjectiveResponserate(ORR);  GroupE:PFS;  GroupE:ORR|1953|NCT02574078|November 2015
4552|Recruiting|An Efficacy and Safety Study of JNJ-56021927 (ARN-509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS||Drug:JNJ-56021927;  Drug:Bicalutamide;  Drug:BicalutamidePlacebo;  Drug:JNJ-56021927Placebo;  Drug:GnRH(agonist);  Radiation:74-80Grays(unitsofradiation)|Interventional|Phase 3|Industry|Metastasis-freesurvival;  TimetoLocal-regionalRecurrence;  Time to Castration-resistant Prostate Cancer (CRPC);  TimetoDistantMetastasis;  OverallSurvival(OS)|1500|NCT02531516|November 2015
4553|Completed|Dose-Ranging Study to Evaluate the Glycemic Effects Safety and Tolerability of Metformin Delayed Release in Subjects With T2DM||Drug:MetDR;  Drug:MetIR;  Drug:Placebo|Interventional|Phase 2|Industry|ChangeinHbA1c(%)at16Weeks|552|NCT02526524|September 2015
4554|Recruiting|A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas||Drug:vismodegib;  Drug:GSK2256098|Interventional|Phase 2|Other / NIH / Industry|Progressionfreesurvivalrateat6-months;  Responserate;  Overallsurvival;  Adverse events will be summarized as the number and frequency of patients who experience any AE AEs of grade 3+ and AEs of grade 4+.|56|NCT02523014|August 2015
4555|Recruiting|PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer||Drug:Palbociclib;  Drug:StandardAdjuvantEndocrineTherapy|Interventional|Phase 3|Other / Industry|InvasiveDiseaseFreeSurvival(iDFS);  To compare the safety of 2 years of palbociclib with adjuvant endocrine therapy versus adjuvant endocrine therapy alone. (distant recurrence-free survival (DRFS) locoregional recurrences-free survival (LRRFS) and overall survival (OS)|4600|NCT02513394|August 2015
4556|Active not recruiting|A Study to Evaluate the Efficacy of MEDI7510 in Older Adults||Biological:MEDI7510;  Biological:IIV;  Other:Placebo|Interventional|Phase 2|Industry|The incidence of the first episode of acute RSV associated respiratory illness (ARA-RI) observed during the surveillance period in Season 1.;  Theoccurrenceofallsolicitedsymptoms;  The incidence of RSV PCR-positive respiratory illness during the RSV surveillance period in Season 1.;  The post-dose geometric mean titers (GMTs) and geometric mean fold rises (GMFRs) from baseline of strain-specific hemagglutination inhibition (HAI) antibodies to influenza antigens contained in the seasonal influenza vaccine.;  Measuring the immune response to MEDI7510 in Seasons 1 and 2 in the RSV immunogenicity subset.;  The occurrence of treatment-emergent adverse events;  The occurrence of treatment-emergent serious adverse events new onset chronic disease and adverse events of special interest|1900|NCT02508194|September 2015
4557|Completed|A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis||Drug:EpoetinHospiraArm;  Other:StandardofCareArm;  Drug:IVIron|Interventional|Phase 3|Industry|For each group the proportions of time subjects&apos; hemoglobin levels are between 9-11 g/dL using FMCNA analogous dosing algorithms Epogen cMAB 5 [inclusive of versions 5.0 5.1] and Epoetin Hospira cMAB 1 [inclusive of version 1.0 1.1]) for each ESA.;  For each group the change from baseline in the mean ESA dose per patient per week using analogous dosing algorithms (Epogen cMAB 5 [inclusive of versions 5.0 5.1] and Epoetin Hospira cMAB 1 [inclusive of version 1.0 1.1]) for each ESA.|432|NCT02504294|July 2015
4558|Completed|COL-1077 (Lidocaine Bioadhesive Gel 10%) in Women Undergoing Transvaginal Pipelle-Directed Endometrial Biopsy||Drug:COL-1077;  Drug:Placebo|Interventional|Phase 2|Industry|Pain Intensity recorded on the 11-point Numerical Pain Rating Scale (NPRS);  Painintensity(using11-pointNPRS);  Time-WeightedAveragePainIntensity(TWAPI);  SumPainIntensityDifference(SPID);  Rescuemedicationusage;  Proportion of responders vs. non-responders to COL-1077.|187|NCT02465320|May 2015
4559|Recruiting|Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis||Drug:RPC1063;  Drug:Placebo|Interventional|Phase 3|Industry|Clinical remission assessed by Mayo component sub-scores|900|NCT02435992|May 2015
4560|Recruiting|Safety Of Rivipansel (GMI-1070) In The Treatment Of One or More Vaso-occlusive Crises In Hospitalized Subjects With Sickle Cell Disease||Drug:Rivipansel|Interventional|Phase 3|Industry|Number (%) of subjects with treatment emergent adverse events (TEAEs) over the study.;  Number (%) of subjects with adjudicated Acute Chest Syndrome (ACS) over the study.;  Number (%) of subjects with adjudicated severe and/or generalized cutaneous manifestations over the study;  Number (%) of subjects with serious adverse events (SAEs) over the study.;  Subjectrehospitalization|250|NCT02433158|December 2015
4561|Active not recruiting|An Extension Study to Evaluate the Long-Term Safety Tolerability and Efficacy of Dalfampridine Extended-Release Tablets for the Treatment of Chronic Post-Ischemic Stroke Walking Deficits in Subjects Who Participated in the DALF-PS-1016 Study||Drug:dalfampridine-ER7.5mg;  Drug:dalfampridine-ER10mg|Interventional|Phase 3|Industry|Number of participants with Serious and Non-Serious Adverse Events (AEs) as a measure of Safety and Tolerability;  Change from baseline on the Two-Minute Walk Test (2MinWT);  Change from baseline on the 10 Meter Walk Test (10MWT);  Change from baseline on the Timed up and Go (TUG) Test;  Change from baseline on the Walking Impact Scale (Walk-12);  Change from baseline on the Stroke Impact Scale (SIS);  SubjectGlobalImpression(SGI);  Change from baseline on the 12-item health survey (SF-12)|296|NCT02422940|April 2015
4562|Active not recruiting|Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)||Drug:dupilumabSAR231893(REGN668);  Drug:placebo|Interventional|Phase 3|Industry|Annualizedrateofsevereexacerbationevents;  Absolute change from baseline in pre-bronchodilator forced expiratory volume in one second (FEV1);  Percent change from baseline in pre-bronchodilator FEV1;  Absolute change from baseline in pre-bronchodilator FEV1;  Annualized rate of loss of asthma control (LOAC) event;  Annualized rate of severe exacerbation events resulting in hospitalization or emergency room visit;  Timetofirstsevereexacerbationevent;  Timetofirstlossofasthmacontrolevent|1858|NCT02414854|April 2015
4563|Enrolling by invitation|&quot;A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA&quot;||Drug:JZP-110|Interventional|Phase 3|Industry|The number and percent of subjects who experienced treatment emergent adverse events.;  Changes in Epworth Sleepiness Scale scores Patient Global Impression of Change ratings and Clinical Global Impression of Change ratings.|600|NCT02348632|May 2015
4564|Active not recruiting|&quot;Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy&quot;||Drug:JZP-110|Interventional|Phase 3|Industry|Maintenance of Wakefulness Test (MWT): Change in the mean sleep latency time (in minutes) as determined from the first four trials of a 40-minute MWT from Baseline to Week 12;  Epworth Sleepiness Scale (ESS): Change in ESS score from Baseline to Week 12;  Patient Global Impression of change (PGIc): Percentage of subjects reported as improved (minimally much or very much) on the PGIc at Week 12|240|NCT02348593|May 2015
4565|Recruiting|Altis&#174; 522 Trial - Treatment of Female Stress Urinary Incontinence||Device:AltisSling;  Device:TransobturatororRetropubicSling|Observational|Phase 4|Industry|Observed device and/or procedure-related serious adverse events;  Observed effectiveness defined as a reduction from baseline in 24-hour pad weight of at least 50%;  Observed rates for the following: organ perforation bleeding mesh exposure in the vagina mesh erosion into the bladder pelvic pain infection de novo dyspareunia urinary retention recurrent incontinence other urinary or neuromuscular problems;  Observed effectiveness defined as a reduction from baseline in 24 hour pad weight of at least 50%.;  QualityofLife;  Observedadverseeventsoftheindexprocedure;  Observedrevision/re-surgeryattheindexlevel;  Observed effectiveness for subjects considered dry (pad weight less than or equal to 4.0 grams)|356|NCT02348112|January 2015
4566|Completed|Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4)||Drug:SUN-10150mcgBIDeFlow(CS)nebulizer;  Drug:SUN-10125mcgBIDeFlow(CS)nebulizer;  Drug:PlaceboeFlow(CS)nebulizer|Interventional|Phase 3|Industry|Change from baseline in trough forced expiratory volume in 1 second (FEV1) at Week 12;  Change from baseline in trough forced vital capacity (FVC) at Week 12;  Change from baseline in health status measured by St. George&apos;s Respiratory Questionnaire (SGRQ) at Week 12/End of Study;  Change in number of rescue medication puffs per day over the 12-week double-blind treatment period;  Number and percentage of subjects with treatment emergent adverse events (TEAE);  Number and percentage of subjects with treatment emergent serious adverse events (SAE);  Number and percentage of subjects who discontinue treatment due to TEAE;  Number and percentage of subjects with major adverse cardiac events (MACE)|641|NCT02347774|February 2015
4567|Active not recruiting|Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)||Drug:FTC/RPV/TAF;  Drug:FTC/RPV/TDFPlacebo;  Drug:FTC/RPV/TDF;  Drug:FTC/RPV/TAFPlacebo|Interventional|Phase 3|Industry|Proportion of Participants with HIV-1 RNA &lt; 50 copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm;  Proportion of Participants with HIV-1 RNA &#8805; 50 copies/mL at Weeks 48 and 96 as Defined by the US FDA-Defined Snapshot Algorithm;  Proportion of Participants with HIV-1 RNA &lt; 50 copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm;  Change From Baseline in CD4+ Cell Count at Weeks 48 and 96;  Percent Change From Baseline in hip and spine Bone Mineral Density (BMD) at Weeks 48 and 96|632|NCT02345252|January 2015
4568|Active not recruiting|Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed HIV-1 Infected Adults||Drug:FTC/RPV/TAF;  Drug:EFV/FTC/TDFPlacebo;  Drug:EFV/FTC/TDF;  Drug:FTC/RPV/TAFPlacebo|Interventional|Phase 3|Industry|Proportion of participants with HIV-1 RNA &lt; 50 copies/mL as defined by the US FDA-defined snapshot algorithm;  Proportion of participants with HIV-1 RNA &#8805; 50 copies/mL at Weeks 48 and 96 as defined by the US FDA-defined snapshot algorithm;  Proportion of participants with HIV-1 RNA &lt; 50 copies/mL at Week 96 as defined by the US FDA-defined snapshot algorithm;  Change from baseline in CD4+ cell count at Weeks 48 and 96;  Percent change from baseline in hip and spine bone mineral density (BMD) at Weeks 48 and 96;  ChangefrombaselineinHIVsymptomindexscore|877|NCT02345226|January 2015
4569|Active not recruiting|A Phase 3 Randomized Double-blind Placebo-controlled Parallel-group Trial With an Open-label Extension||Drug:Bremelanotide;  Drug:Placebo|Interventional|Phase 3|Industry|Efficacy of a fixed dose of bremelanotide as measured by FSFI (Question Q1 and Q2) 28-day recall.;  Efficacy of a fixed dose of bremelanotide as measured by FSDS-DAO (item 13);  Efficacy of a fixed dose of bremelanotide as measured by the change in baseline to End of Study in the number of satisfying sexual events (SSEs) associated with study drug administration;  Efficacy of a fixed dose of bremelanotide as measured by the change in baseline to End of Study in mean desire score (Q3) from the FSEP-R;  Efficacy of a fixed dose of bremelanotide as measured by the change in baseline to End of Study in mean satisfaction with desire score (Q4) from FSEP-R;  Efficacy of a fixed dose of bremelanotide as measured by the change in baseline to End of Study in the FSDS-DAO total score;  Efficacy of a fixed dose of bremelanotide as measured by the change in baseline to End of Study in the FSFI total score;  Efficacy of a fixed dose of bremelanotide as measured by the change in baseline to End of Study in the mean level of sexual arousal (Q6) from the FSEP-R;  Efficacy of a fixed dose of bremelanotide as measured by the change in baseline to End of Study in the mean satisfaction with sexual arousal (Q7) from the FSEP-R;  Efficacy of a fixed dose of bremelanotide as measured by the change in baseline to End of Study in the scored time spent being concerned by difficulty with sexual arousal (Q14) from the FSDS-DAO;  Efficacy of a fixed dose of bremelanotide as measured by the change in baseline to End of Study in the arousal domain of the FSFI (Q3 to Q6);  Efficacy of a fixed dose of bremelanotide as measured by the change in baseline to End of Study in the total number of SSEs;  Efficacy of a fixed dose of bremelanotide as measured by the change in baseline to End of Study in the desire domain of the FSFI (Q1 to Q2) throughout the entirety of the double-blind phase;  Efficacy of a fixed dose of bremelanotide as measured by the change in baseline to End of Study in the score for feeling bothered by low sexual desire as measured by the FSDS-DAO (item 13) throughout the entirety of the double-blind phase;  Efficacy of a fixed dose of bremelanotide as measured by the change in baseline to End of Study in the number of SSEs associated with study drug administration throughout the entirety of the double-blind phase|714|NCT02338960|January 2015
4570|Suspended|Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma||Drug:Cyclophosphamide;  Drug:DoxorubicinHydrochloride;  Drug:Etoposide;  Radiation:ExternalBeamRadiationTherapy;  Biological:Ganitumab;  Drug:Ifosfamide;  Other:LaboratoryBiomarkerAnalysis;  Other:PharmacologicalStudy;  Radiation:StereotacticRadiosurgery;  Procedure:TherapeuticSurgicalProcedure;  Drug:VincristineSulfate|Interventional|Phase 2|NIH|Time to adverse analytic event (EFS) defined to be disease-related event diagnosis of a second malignant neoplasm or death;  Bonemarrowresponserates;  Feasibility of SBRT defined as an individual that has SBRT planned for at least one site starts the treatment of metastatic disease phase of the protocol and has at least 85% of tumor sites planned to be treated with SBRT receive successful SBRT;  Ganitumabpharmacokinetics(PK);  OverallSurvival;  Overall toxicity of the addition of ganitumab to VDC/IE chemotherapy using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0;  Riskofdeath;  Sinusoidal obstructive disease (SOS) associated with the addition of ganitumab to VDC/IE;  Tolerabilityofmaintenanceganitumab|140|NCT02306161|December 2014
4571|Terminated|A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects||Drug:Arformoteroltartrateinhalationsolution;  Drug:Tiotropium|Interventional|Phase 4|Industry|The rate of all-cause hospitalization or Emergency Department visit within 90-days of initiating treatment.|66|NCT02275481|November 2014
4572|Recruiting|Evaluation of Efficacy and Safety of Roxadustat in the Treatment of Anemia in Stable Dialysis Subjects||Drug:EpoetinAlfa;  Drug:FG-4592|Interventional|Phase 3|Industry|US (FDA) submission: Hemoglobin (Hb) change from baseline to the average Hb level during the evaluation period defined as Week 28 until Week 52. Ex-US submission: Hb change from baseline to the average Hb level of Weeks 28 to 36.;  US (FDA) submission: The proportion of subjects with a mean Hb level &#8805;10.0 g/dL during the evaluation period;  Ex-US submissions: Hemoglobin response (mean Hb 10.0 to 12.0 g/dL) during Weeks 28 to 36 without having received rescue therapy;  AveragemonthlyIVIronusepersubject;  Change from baseline in low density lipoprotein (LDL);  Change from baseline in SF-36 Physical Functioning (PF) sub-score;  Change from baseline in SF-36 Vitality (VT) sub-score;  Effectonpredialysisbloodpressure(BP)|600|NCT02273726|December 2014
4573|Completed|A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets for Treatment of Stable Walking Deficits in Post-Ischemic Stroke||Drug:Placebo;  Drug:dalfampridine-ER7.5mg;  Drug:dalfampridine-ER10mg|Interventional|Phase 3|Industry|Proportion of subjects who show at least a 20% improvement on the Two Minute Walk Test (2MinWT) at week 12;  Change from baseline on the Walking Impact Scale (Walk-12) at week 12 (key secondary);  Proportion of subjects who show at least a 20% improvement on the 2MinWT;  Changefrombaselineonthe2MinWT;  ChangefrombaselineontheWalk-12;  Change from baseline on the 10 Meter Walk Test (10MWT);  Change from baseline on the Timed Up and Go Test (TUG);  Change from baseline on the Stroke Impact Scale (SIS);  Change from baseline on the 12-item Health Survey (SF-12);  Shift in projected community ambulation based on the 10MWT;  Number of participants with Serious and Non-Serious Adverse Events (AEs)|377|NCT02271217|December 2014
4574|Completed|Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women||Drug:Estradiol;  Drug:Placebo|Interventional|Phase 3|Industry|Co-Primary Efficacy Endpoint - Vaginal Superficial Cells;  Co-Primary Efficacy Endpoint - Vaginal Parabasal Cells;  Co-PrimaryEfficacyEndpoint-VaginalpH;  Co-Primary Efficacy Endpoint - Severity of Most Bothersome Symptom (Dyspareunia);  Secondary Efficacy Endpoints - Vaginal Superficial and Parabasal Cells Vaginal pH and Severity of MBS (dyspareunia);  Secondary Efficacy Endpoints - Severity of other VVA symptoms and visual evaluation of vaginal mucosa;  Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI);  Secondary Efficacy Endpoints - Hormone Concentration Assessments (serum estradiol estrone and estrone conjugates; SHBG) - PK Substudy|764|NCT02253173|September 2014
4575|Recruiting|Study Comparing Daratumumab Lenalidomide and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma||Drug:Daratumumab;  Drug:Lenalidomide;  Drug:Dexamethasone|Interventional|Phase 3|Industry|Progression-FreeSurvival(PFS)Time;  TimetoDiseaseProgression(TTP);  Percentage of Participants With Complete response (CR);  MinimalResidualDisease(MRD)NegativityRate;  Progression-Free Survival on Next Line of Therapy (PFS2);  OverallSurvival(OS)Time;  Percentage of Participants With Stringent Complete Response (sCR);  TimeToNextTreatment;  Percentage of Participants With Overall Response (OR);  Percentage of Participants With Very Good Partial Response (VGPR) or Better Response;  TimetoResponse;  DurationofResponse(DR);  European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score;  Euro Quality of Life (EQ-5D-5L) Health State Profile Utility Score|730|NCT02252172|February 2015
4576|Recruiting|One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn&apos;s Disease||Drug:RifaximinDR;  Drug:Placebo|Interventional|Phase 3|Industry|Clinicalsymptomremission;  Endoscopicresponse;  Endoscopicremission|660|NCT02240121|July 2014
4577|Active not recruiting|An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia||Drug:15mgDS-5565|Interventional|Phase 3|Industry|Number of subjects experiencing adverse events as a measure of safety;  number of subjects experiencing an abnormal value of a clinical laboratory test;  Changes from baseline to scheduled timepoint in Average Daily Pain Score (ADPS).;  Changes from baseline to scheduled timepoint in Average Daily Sleep Interference Score (ADSIS).;  Proportion of subjects with improvement in overall status at Week 52 as assessed by Patient Global Impression of Change (PGIC).;  Changes from baseline to Week 52 in Hospital Anxiety Depression Scale (HADS) depression and anxiety scores;  Changes in EuroQol-Instrument 5 Dimensions (EQ-5D).;  ChangesinShortForm36(SF-36)parameters;  number of subjects experiencing changes in physical examinations;  numberofsubjectsexperiencingabnormalECGs;  number of subjects experiencing suicidal ideation or behavior as identified using the C-SSRS;  number of subjects experiencing a withdrawal symptom as identified in the PWC.|2091|NCT02234583|January 2015
4578|Active not recruiting|Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo||Drug:ExantidewithDapagliflozin;  Drug:Exentide;  Drug:Dapagliflozin|Interventional|Phase 3|Industry|Efficacy of exenatide in terms of change in glycosylated hemoglobin (HbA1c);  Efficacy of exenatide in terms of change in total body weight;  Efficacy of exenatide in terms of change in fasting plasma glucose (FPG) from baseline to Week 28.;  Efficacy of exenatide in terms of change in 2-hour postprandial glucose (PPG) after a standardized meal tolerance test;  Efficacy of exenatide in terms of proportion of patients achieving HbA1c &lt;7.0%;  Efficacy of exenatide in terms of proportion of patients achieving weight loss &#8805;5.0%;  EfficacyofexenatideintermsofchangeinFPG;  Efficacy of exenatide in terms of change in seated systolic Blood Pressure|1375|NCT02229396|September 2014
4579|Terminated|A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol||Drug:Evacetrapib;  Drug:Atorvastatin;  Drug:Ezetimibe;  Drug:Placebo|Interventional|Phase 3|Industry|Percent Change from Baseline to 3 Months in Low-Density Lipoprotein Cholesterol (LDL-C);  Percent Change from Baseline to 3 Months in High-Density Lipoprotein Cholesterol (HDL-C);  Percent Change from Baseline to 3 Months in Apolipoprotein AI (apoAI);  Percent Change from Baseline to 3 Months in Non-HDL-C;  Percent Change from Baseline to 3 Months in Apolipoprotein B (apoB);  Percent Change from Baseline to 3 Months in Cholesterol Efflux Capacity;  Percent Change from Baseline to 3 Months in Lipoprotein(a) (Lp[a])|366|NCT02227784|October 2014
4580|Recruiting|Study to Evaluate the Efficacy Safety and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)||Drug:Mirabegron;  Drug:Placebo|Interventional|Phase 4|Industry|Change from baseline to the end of treatment in mean number of micturitions/24 hour based on a 3-day micturition diary;  Change from baseline to end of treatment in mean number of incontinence episodes/24 hour based on a 3-day micturition diary;  Change from baseline to the end of treatment in mean volume voided per micturition;  Change from baseline to the end of treatment in symptom bother and total health related quality of life scores as assessed by OAB-q questionnaire;  Change from baseline to the end of treatment in PPBC;  Safety profile assessed by adverse events (AE) and vital signs;  Safety profile assessed by laboratory parameters (serum chemistry hematology and urinalysis);  Change from baseline to end of treatment in Montreal Cognitive Assessment (MoCA) score|800|NCT02216214|September 2014
4581|Recruiting|BGJ398 for Patients With Tumors With FGFR Genetic Alterations||Drug:BGJ398|Interventional|Phase 2|Industry|Clinical benefit rate associated with BGJ398 treatment;  Overall Response (OR) or Partial Response (PR) or greater;  Progression-FreeSurvival;  Overallsurvival;  DurationofResponse;  SafetyandTolerability|90|NCT02160041|July 2014
4582|Completed|Comparing the Efficacy of Symbicort&#174; pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease||Drug:Symbicort;  Drug:Formoterolturbohaler;  Other:PlaceboforSymbicortpMDI;  Other:PlaceboforFormoterolTurbohaler|Interventional|Phase 3|Industry|The rate of moderate and severe COPD exacerbations defined as: Worsening of &#8805;2 major symptoms or worsening of 1 major symptom together with &#8805;1 minor symptom for &#8805;2 consecutive days;  Time to first moderate or severe COPD exacerbation;  St.George&apos;sRespiratoryQuestionnaire(SGRQ);  Pre-dose/pre-bronchodilator FEV1 at the study site;  Totalrescuemedicationuse(averagepuffs/day);  NightswithawakeningduetoCOPD|2026|NCT02157935|June 2014
4583|Terminated|Pyridorin in Diabetic Nephropathy||Drug:Pyridorin;  Drug:Placebo|Interventional|Phase 3|Industry / Other|Time to composite endpoint of &gt;=50% SCr increase from baseline or ESRD;  Time to the composite endpoint &gt;=100% SCr increase or ESRD|328|NCT02156843|June 2014
4584|Active not recruiting|A Study of the Safety and Efficacy of Intermittent Ulipristal Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas||Drug:Ulipristalacetate(UPA)5mg;  Drug:Ulipristalacetate(UPA)10mg;  Drug:Placebo|Interventional|Phase 3|Industry|Absenceofbleeding;  Timetoabsenceofbleeding|432|NCT02147158|January 2014
4585|Recruiting|Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer||Drug:sorafenib;  Drug:everolimus|Interventional|Phase 2|Other / NIH / Industry|ProgressionFreeSurvival;  Confirmedresponserate;  Overallsurvival;  Incidence of adverse events graded according to Common Terminology Criteria for Adverse Events|34|NCT02143726|October 2014
4586|Completed                  Has Results|Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.||Biological: 13-valent pneumococcal conjugate vaccine;  Biological: Seasonal Inactivated Influenza Vaccine;  Other:Placebo|Interventional|Phase 4|Industry|Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 13 Pneumococcal Serotypes;  Hemagglutination Inhibition Assay (HAI) Geometric Mean Titers (GMTs) for Each Influenza Virus Strain in Quadrivalent Influenza Vaccine (QIV);  Percentage of Participants With Treatment--Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) After Vaccination 1;  Percentage of Participants With Treatment--Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) After Vaccination 2;  Percentage of Participants With Treatment--Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) After 13vPnC Vaccination;  Percentage of Participants With Treatment--Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) at the 6-Month Follow-up;  Percentage of Participants Achieving Pneumococcal Serotype-specific Opsonophagocytic Activity (OPA) Antibody Titer Greater Than or Equal to (&gt;=) Lower Limit of Quantitation (LLOQ);  Geometric Mean Fold Rise (GMFR) for Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) Titers 1 Month After 13vPnC Vaccination 1 to Immediately Before 13vPnC Vaccination 1;  Geometric Mean Fold Rise (GMFR) for Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) Titers 1 Month After 13vPnC Vaccination 2 to Immediately Before 13vPnC Vaccination 2;  Percentage of Participants Achieving Seroconversion in Hemagglutination Inhibition Assay (HAI) Titers;  Geometric Mean Fold Rise (GMFR) in Hemagglutination Inhibition Assay (HAI) 1 Month After Vaccination 1 to Immediately Before Vaccination 1|882|NCT02124161|September 2014
4587|Terminated|52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)||Drug:Ibodutant10mg;  Drug:Placebo|Interventional|Phase 3|Industry|Weekly response for abdominal pain intensity AND stool consistency over the first 24 weeks of treatment in at least 50% of the weeks of treatment (12 out of 24 weeks).;  Weekly response for abdominal pain intensity over the first 24 weeks of treatment in at least 50% of the weeks of treatment (12 out of 24 weeks).;  Weekly response for stool consistency over the first 24 weeks of treatment in at least 50% of the weeks of treatment (12 out of 24 weeks).;  Weekly response for relief of overall IBS signs and symptoms over the first 24 weeks of treatment in at least 50% of the weeks (12 out of 24);  Sustainedefficacy|500|NCT02120027|March 2014
4588|Active not recruiting|Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy||Drug:Olanzapine;  Drug: Chemotherapy (cisplatin or cyclophosphamide and doxorubicin);  Drug: Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant);  Other:Placebo|Interventional|Phase 3|Other / NIH|Proportion of patients with no nausea defined as a response of 0 in the nausea item of Nausea and Vomiting Daily Diary/Questionnaire;  Nausea scores measured by the Nausea and Vomiting Daily Diary/Questionnaire;  Complete response defined as no emetic episodes and no use of rescue medication measured by the Nausea and Vomiting Daily Diary/Questionnaire;  Incidence of potential toxicities related to olanzapine as measured by the Nausea and Vomiting Daily Diary/Questionnaire;  Frequency of rescue medication repeatedly measured by the Nausea and Vomiting Daily Diary/Questionnaire|372|NCT02116530|August 2014
4589|Completed|A Study to Examine Patient Characteristics Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir||Drug:Nointervention|Observational|Phase 4|Industry|Number of Patients who Achieve Sustained Virologic Response(SVR);  Determination of Prognostic Factors of Virologic Response;  Totaldurationoftherapy;  Number of Patients who Discontinue Therapy by reason;  Number of Patients who Achieve Rapid Virologic Response (RVR);  Number of Patients who Achieve Sustained Virologic Response(SVR) Among Participants who Achieve Rapid Virologic Response (RVR);  Number of Patients who Achieve Sustained Virologic Response(SVR) According to Patient Demographics Baseline Disease Characteristics Treatment Paradigm and Select Practice Setting Features;  Number of Patients With On-treatment Virologic Failure;  NumberofPatientsWithViralRelapse;  Number of Patients With Adverse Events by Grade and Causality;  Number of Patients With Changes in Clinical Laboratory Parameters by Grade and Causality;  Number of Patients With Adverse Event Determined to be Related to Simeprevir;  NumberofPatientsWithSeriousAdverseEvent;  Number of Patients who Develop Mutations at the Time of Virologic Failure|315|NCT02103699|February 2014
4590|Recruiting|A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Participants Who Are Refractory to or Intolerant of Tumor Necrosis Factor (TNF) Inhibitors||Drug:Etrozulimab;  Drug:Placebo|Interventional|Phase 3|Industry|Percentage of Participants With Remission as Determined by the Mayo Clinic Score (MCS);  Percentage of Participants With Remission at Week 66 Among Randomized Participants in Clinical Remission at Week 14 as Determined by the MCS;  Percentage of Participants With Clinical Remission at Week 14 (Induction Phase) and Week 66 (Maintenance Phase) as Determined by MCS;  Percentage of Participants With Clinical Response at Week 14 (Induction Phase) and Week 66 (Maintenance Phase);  Percentage of Participants With Improvement From Baseline in Endoscopic Appearance of the Mucosa at Week 14 (Induction Phase) and Week 66 (Maintenance Phase);  Percentage of Participants With Endoscopic Remission at Week 14 (Induction Phase) and Week 66 (Maintenance Phase);  Change From Baseline to Week 14 and Week 66 in UC Bowel Movement Signs and Symptoms as assessed by Ulcerative Colitis Patient-Reported Bowel Movement Signs and Symptoms (UC-PRO/SS);  Change From Baseline to Week 14 and Week 66 in UC Abdominal Symptoms as assessed by UC-PRO/SS;  Change From Baseline to Week 14 and Week 66 in Health Related Quality of Life (QoL) as assessed by the Overall Score of Inflammatory Bowel Disease Questionnaire (IBDQ);  Percentage of Participants With Corticosteroid-Free Clinical Remission at Week 66 Among Participants who Were Receiving Corticosteroids at Baseline;  Percentage of Participants With Corticosteroid-Free Remission at Week 66 Among Participants who Were Receiving Corticosteroids at Baseline;  Area Under the Serum Concentration-Time Curve (AUC);  MaximumObservedSerumConcentration(Cmax);  Minimum Observed Serum Trough Concentration at Steady State (Ctroughss);  Percentage of Participants With Anti-therapeutic Antibodies to Etrolizumab|800|NCT02100696|May 2014
4591|Recruiting|Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer&apos;s Disease||Drug:Azeliragon;  Drug:Placebo|Interventional|Phase 3|Industry|Change from Baseline in Alzheimer&apos;s Disease Assessment Scale - Cognitive (ADAS-cog) total score;  Change from Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-sb);  Change from Baseline in Magnetic Resonance Imaging (MRI) brain volumetric measures;  Change from Baseline in Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography Scan;  Change from Baseline in Neuropsychiatric Inventory (NPI);  Change from Baseline in Mini-Mental State Examination (MMSE);  Change from Baseline in Alzheimer&apos;s Disease Cooperative Study- Activities of Daily Living Inventory (ADCS-ADL);  Change from Baseline in Continuous Oral Word Association Task (COWAT);  Change from Baseline in Category Fluency Test (CFT);  Change from Baseline in Resource Utilization in Dementia (RUD);  Change from Baseline in Dementia Quality of Life (DEMQOL);  ChangefromBaselineinPlasmaAmyloidBeta;  ProportionofRespondersbasedonADAS-cog;  ProportionofRespondersbasedonCDR-SB;  AdverseEvents|800|NCT02080364|April 2015
4592|Recruiting|Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia||Procedure:Opensurgicalrevascularization;  Device:Endovascularrevascularization|Interventional||Other / NIH|Time to major adverse limb event or death whichever occurs first in subjects with Single-Segment Great Saphenous Vein (SSGSV) available;  Time to major adverse limb event or death whichever occurs first in subjects without available SSGSV;  Time to re-intervention of the index leg amputation of the index leg or death whichever occurs first in subjects with SSGSV available;  Time to re-intervention of the index leg amputation of the index leg or death whichever occurs first in subjects without available SSGSV;  Number of re-interventions in the index leg in subjects with SSGSV available;  Number of re-interventions in the index leg in subjects without available SSGSV;  Time to all-cause mortality in subjects with SSGSV available;  Time to all-cause mortality in subjects without available SSGSV;  Change in VascuQoL score in subjects with SSGSV available;  Change in VascuQoL score in subjects without available SSGSV;  Change in EuroQoL EQ-5D score in subjects with SSGSV available;  Change in EuroQoL EQ-5D score in subjects without available SSGSV;  Treatment associated costs in subjects with SSGSV available;  Treatment associated costs in subjects without available SSGSV;  Major adverse cardiovascular events in subjects with SSGSV available;  Major adverse cardiovascular events in subjects without available SSGSV;  Proportion of subjects with at least one peri-operative complication in subjects with SSGSV available;  Proportion of subjects with at least one peri-operative complication in subjects without available SSGSV|2100|NCT02060630|August 2014
4593|Recruiting|Dimethyl Fumarate (DMF) Observational Study||Drug:dimethylfumarate|Observational||Industry|The number of participants that experience Adverse Events (AEs) that lead to discontinuation of dimethyl fumarate (DMF);  The number of participants that experience Serious Adverse Events (SAEs);  Durationofdimethylfumarate(DMF)use;  dimethylfumarate(DMF)dosingfrequency;  Primary reasons for discontinuation of dimethyl fumarate (DMF) use;  Frequencyofrelapsesovertime;  Disease progression as measured by Expanded Disability Status Scale (EDSS) over time;  Multiple Sclerosis Impact Scale-29 Items (MSIS-29) physical multiple sclerosis (MS) impact score;  Multiple Sclerosis Impact Scale-29 Items (MSIS-29) psychological multiple sclerosis (MS) impact score;  EuroQol-5 Dimensions (5 Level) (EQ-5D-5L) index score;  EuroQol Visual Analogue Scale (EQ VAS) (0-100 scale);  Modified Fatigue Impact Scale-5 (MFIS-5) total score;  Work Productivity and Activity Impairment questionnaire: Multiple Sclerosis Version 2.0 (WPAI-MS) impairment percentages;  HealthCareResourceConsumptionQuestionnaire|5000|NCT02047097|November 2013
4594|Active not recruiting|A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer||Drug:Veliparib;  Drug:Carboplatin;  Drug:Paclitaxel;  Drug:Doxorubicin;  Drug:Cyclophosphamide;  Drug:Placebo|Interventional|Phase 3|Industry / Other|PathologicalCompleteResponse(pCR).;  Rate of eligibility for breast conservation after therapy (BCR).;  EventFreeSurvival(EFS);  OverallSurvival(OS)|624|NCT02032277|April 2014
4595|Completed|A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine||Biological:LBR-101HighDose;  Biological:LBR-101LowDose;  Biological:Placebo|Interventional|Phase 2|Industry|Efficacy of two distinct doses of subcutaneous LBR-101 in the preventive treatment of HFEM measured by mean change from baseline in the monthly migraine days during the 28-day post treatment period ending with week 12;  Evaluate the safety and tolerability (ie: by measuring the change from baseline in the frequency and severity of adverse events) of LBR-101 in the preventive treatment of HFEM.;  Efficacy of two distinct doses of subcutaneous LBR-101 in the preventive treatment of HFEM measured by mean change from baseline on the number of days with headache of any severity during the 28-day post treatment period ending with week 12|319|NCT02025556|January 2014
4596|Recruiting|Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia||Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;  Biological:Blinatumomab;  Drug:Cyclophosphamide;  Drug:Cytarabine;  Drug:DaunorubicinHydrochloride;  Drug:Dexamethasone;  Drug:Etoposide;  Other:LaboratoryBiomarkerAnalysis;  Drug:Mercaptopurine;  Drug:Methotrexate;  Drug:Pegaspargase;  Drug:Prednisone;  Drug:VincristineSulfate|Interventional|Phase 3|NIH|OS;  Incidence of adverse events per the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0;  MRDstatus;  RFS|360|NCT02003222|December 2013
4597|Completed|[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]||Drug:ticagrelor;  Drug:Acetylsalicylicacid(ASA)|Interventional|Phase 3|Industry|CompositeofstrokeMIanddeath.;  Preventionofsubsequentischaemicstroke.;  Netclinicaloutcome.;  Time to discontinuation of study medication due to any bleeding event.;  CompositeofischaemicstrokeMIandCVdeath.|13307|NCT01994720|January 2014
4598|Recruiting|Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease The VERTIS CV Study (MK-8835-004)||Drug:Ertugliflozin;  Drug:Placebo|Interventional|Phase 3|Industry|Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death Non-fatal Myocardial Infarction or Non-fatal Stroke]);  Time to First Occurrence of Cardiovascular Death or Hospitalization for Heart Failure;  TimetoOccurrenceofCardiovascularDeath;  Time to First Occurrence of the Composite of Renal Death Renal Dialysis/Transplant or &#8805;2x Increase in Baseline Serum Creatinine;  Time to First Occurrence of Mace Plus (Composite Endpoint of Cardiovascular Death Non-fatal Myocardial Infarction Non-fatal Stroke or Hospitalization for Unstable Angina);  Time to First Occurrence of Fatal or Non-fatal Stroke;  Time to First Occurrence of Hospitalization for Heart Failure;  Time to First Occurrence of Individual Components of MACE (Cardiovascular Death Non-fatal Myocardial Infarction Non-fatal Stroke);  TimetoOccurrenceofAll-causeMortality;  Time to Occurrence of All MACE Events (not censored at the time of the first event);  Time to Occurrence of All Cardiovascular Death or Hospitalizations for Heart Failure (Not Censored at the Time of the First Event);  ChangefromBaselineinHemoglobinA1C(HbA1C);  Change from Baseline in Fasting Plasma Glucose (FPG);  Time to the first Occurrence of a Participant Receiving Glycemic Rescue Therapy (Up to 18 weeks);  Time to Initiation of Insulin for Participants Not on Insulin at Randomization;  Change from Baseline in Insulin Dose at the End of Study (up to 6.1 years);  ChangefromBaselineinBodyWeight;  NumberofParticipantswithaHbA1C&lt;7%;  ChangefromBaselineinSystolicBloodPressure;  ChangefromBaselineinDiastolicBloodPressure;  Number of Participants Experiencing and Adverse Event (AE);  Number of Participants Discontinuing Study Treatment Due to An AE;  Time to First Occurrence of any of the Components of the Composite Endpoint of Cardiovascular Death Non-fatal Myocardial Infarction Non-fatal Stroke or Hosptialization for Unstable Angina;  ChangefromBaselineinHbA1CatWeek18;  ChangefromBaselineinBodyWeightatWeek18;  Number of Participants with a HbA1C &lt;7% at Week 18;  Change from Baseline in Systolic Blood Pressure at Week 18;  Change from Baseline in Diastolic Blood Pressure at Week 18;  Time to First Occurrence of Fatal or Non-fatal Myocardial Infarction|8000|NCT01986881|November 2013
4599|Terminated                  Has Results|Fasiglifam 25 mg BID vs 50 mg QD||Drug:Fasiglifam;  Drug:Placebotofasiglifam|Interventional|Phase 2|Industry|ChangeFromBaselineinHbA1catWeek12.;  Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12|10|NCT01982253|October 2013
4600|Completed|UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects||Drug:DCV/ASV/BMS-791325|Interventional|Phase 3|Industry|Proportion of treated subjects in the naive cohort with sustained virologic response (SVR) 12;  Proportion of subjects in the experienced cohort with SVR12;  Proportion of subjects in each cohort who achieve HCV RNA &lt;LOQ TD/TND;  Proportion of subjects in each cohort who achieve HCV RNA &lt;LOQ TND;  Safety measured by frequency of serious AEs (SAEs) and discontinuations due to adverse events (AEs) through the end of treatment in each cohort;  Proportion of anemia defined as Hg &lt;10 g/dL on-treatment and Hg &#8805;10 g/dL at baseline  in each cohort;  Rates of selected grade 3-4 lab abnormalities (hematologic and liver function) in each cohort;  Proportion of subjects in each cohort achieving SVR12 associated with HCV geno subtype 1a vs 1b;  Proportion of subjects in each cohort achieving SVR12 associated with IL28B rs12979860 single nucleotide polymorphism (SNP) status (CC genotype or non-CC genotype);  Proportion of subjects in each cohort achieving SVR12 associated with stage of liver fibrosis|416|NCT01979939|December 2013
4601|Recruiting|Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma||Drug:BrentuximabVedotin;  Drug:Crizotinib;  Drug:Cyclophosphamide;  Drug:Cytarabine;  Drug:Dexamethasone;  Drug:DoxorubicinHydrochloride;  Drug:Etoposide;  Drug:Ifosfamide;  Other:LaboratoryBiomarkerAnalysis;  Drug:Methotrexate|Interventional|Phase 2|NIH|EFS;  Occurrence of grade 3+ non-hematologic adverse events using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0;  ChangesonlevelsofMRD|140|NCT01979536|November 2013
4602|Completed                  Has Results|Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults||Drug:E/C/F/TAF;  Drug:DRV;  Drug:Pre-existingARVregimen|Interventional|Phase 3|Industry|Percentage of Participants in Each Treatment Arm in Cohort 2 With HIV-1 RNA &lt; 50 Copies/mL at Week 24;  Percentage of Participants in Each Treatment Arm in Cohort 2 With HIV-1 RNA &lt; 50 Copies/mL at Week 48;  Change From Baseline in CD4+ Cell Count at Week 24;  Change From Baseline in CD4+ Cell Count at Week 48|158|NCT01968551|September 2013
4603|Terminated                  Has Results|Efficacy Safety and Tolerability of Plovamer Acetate (Pathway 1)||Drug:Plovameracetate0.5milligram(mg);  Drug:Copaxone20mg;  Drug:Plovameracetate3mg;  Drug:Plovameracetate10mg;  Drug:Plovameracetate20mg|Interventional|Phase 2|Industry|Mean Number of Time Constant 1 (T1) Gadolinium (Gd)-Enhancing Lesions Per Subject and Scan;  MeanAnnualizedRelapseRate(ARR);  PercentageofSubjectsRemainingRelapse-Free;  Mean Number of New T1 Gadolinium (Gd)-Enhancing Lesions Per Subject and Scan;  Mean Number of New or Enlarging Time Constant 2 (T2) Lesions Per Subject and Scan;  Mean Number of New Unenhancing T1 Lesions (Black Holes) Per Subject and Scan;  Mean Change From Baseline in Volume of T1 Gadolinium (Gd)-Enhancing Lesions Per Subject and Scan;  Mean Change From Baseline in Volume of T2 Gadolinium (Gd)-Enhancing Lesions Per Subject and Scan;  TimetoFirstRelapse;  Mean Change From Baseline in Brain Volume Per Subject|255|NCT01963611|October 2013
4604|Terminated|A Golimumab Phase 3b Multicenter Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE&#174;)||Biological:Golimumab2mg/kgIV|Interventional|Phase 3|Industry|American College of Rheumatology 20 (ACR20) response at Week 24;  For subjects who have a confirmed presence of antibodies to infliximab (ie the level of antibodies to infliximab detected in the sample is not equivocal per the LLOQ) the proportion who achieve an ACR20 response at Week 24|11|NCT01962974|October 2013
4605|Active not recruiting                  Has Results|A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Na&#239;ve Women (ARIA)||Drug:Dolutegravir/abacavir/lamivudineFDC;  Drug:Atazanavir;  Drug:Ritonavir;  Drug:Tenofovir/emtricitabineFDC|Interventional|Phase 3|Industry|Percentage of Participants With Plasma HIV-1 RNA &lt;50 Copies/mL at Week 48;  Percentage of Participants With Plasma HIV-1 RNA &lt;50 and &lt;400 c/mL Over Time;  Change From Baseline in Plasma HIV-1 RNA at Indicated Time Points;  Change From Baseline in CD4+ Cell Count at Indicated Timepoints;  Change From Baseline in Carbon Dioxide Electrolytes Lipids Glucose Urea at Indicated Time Points;  Change From Baseline in Bilirubin and Creatinine at Indicated Timepoints.;  Change From Baseline in Albumin at Indicated Timepoints.;  Change From Baseline in Alanine Aminotransferase Alkaline Phosphatase Aspartate Aminotransferase Creatine Kinase at Indicated Time Points;  Change From Baseline in Creatinine Clearance at Indicated Time Points;  Change From Baseline in Lipase at Indicated Timepoints.;  Change From Baseline in Total CHLS/HDL CHLS Ratio at Indicated Timepoints.;  Change From Baseline in Basophils Eosinophils Lymphocytes Monocytes at Indicated Time Points;  Change From Baseline in Erythrocytes at Indicated Time Points.;  Change From Baseline in Hematocrit Count at Indicated Time Points.;  Change From Baseline in Erythrocyte Mean Corpuscular Volume at Indicated Time Points.;  ChangeFromBaselineinTriglyceridesatWeek48;  ChangeFromBaselineinTC/HDLRatioatWeek48;  Change From Baseline in Urine Albumin Creatinine Ratio at Indicated Time Points;  Summary of AEs by Maximum Toxicity as Per DAIDS AE Grading Table.;  Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs);  Summary of Maximum Post-Baseline Emergent Chemistry Toxicities;  Summary of Maximum Post-Baseline Emergent Hematology Toxicities;  Number of Participants Who Withdrew From Treatment Due to AEs;  Change From Baseline in Bone Specific Alkaline Phosphatase Osteocalcin and Procollagen 1 N-terminal Propeptide at Indicated Timepoints;  Change From Baseline in Type I Collagen C-telopeptides at Indicated Timepoints;  Change From Baseline in Vitamin D Vitamin D2 and Vitamin D3 at Week 24 and Week 48;  Bone Specific Alkaline Phosphatase Osteocalcin Procollagen 1 N-terminal Propeptide Type 1 Collagen C-Telopeptide Vitamin D Ratio of Week 48 Results Over Baseline;  Change From Baseline at Week 48 in SF-12 Total Score MCS and PCS;  Assessment of HIVTSQs Total Score at Indicated Timepoints.;  Percentage of Participants With Plasma HIV-1 RNA &lt;50 Copies/mL at Week 48 by Subgroups;  Number of Participants With Post-Baseline HIV-1 Disease Progression;  Number of Participants With Treatment Emergent Resistances|499|NCT01910402|August 2013
4606|Active not recruiting|Progress of Mild Alzheimer&apos;s Disease in Participants on Solanezumab Versus Placebo||Drug:Solanezumab;  Drug:Placebo|Interventional|Phase 3|Industry|Change from Baseline in Alzheimer&apos;s Disease Assessment Scale-Cognitive 14 Item Subscore (ADAS-Cog14);  Change from Baseline in Alzheimer&apos;s Disease Cooperative Study- Instrumental Activities of Daily Living (ADCS-iADL);  Change from Baseline in Alzheimer&apos;s Disease Assessment Scale-Cognitive 11 Item Subscore (ADAS-Cog11);  Change from Baseline in Mini-Mental State Examination (MMSE);  Change from Baseline in Alzheimer&apos;s Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL);  Change from Baseline in Functional Activities Questionnaire (FAQ);  Change from Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB);  Change from Baseline in Neuropsychiatric Inventory (NPI);  Change from Baseline in Resource Utilization in Dementia-Lite (RUD-Lite);  Change from Baseline in Quality of Life in Alzheimer&apos;s Disease (QoL-AD);  Change from Baseline in 5-Dimensional EuroQol Quality of Life Scale Proxy Version (EQ-5D Proxy);  Change from Baseline in Integrated Alzheimer&apos;s Disease Rating Scale (iADRS);  ProportionofCognitiveandFunctionalResponders;  Change from Baseline in Plasma Amyloid-Beta (A&#946;) Species;  Change from Baseline in volumetric Magnetic Resonance Imaging (vMRI);  Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of Solanezumab (LY2062430);  Change from Baseline in Florbetapir Positron Emission Tomography (PET) Scan;  Change from Baseline in Cerebrospinal Fluid (CSF) A&#946; Levels|2100|NCT01900665|July 2013
4607|Completed                  Has Results|Study of Intra-articular Injections vs Placebo in Patients With Pain From Osteoarthritis of the Knee||Drug:Traumeel&#174;/Zeel&#174;InjectableSolution;  Drug:Placebo|Interventional|Phase 3|Industry|Change in Knee Pain as Measured by the WOMAC Osteoarthritis (OA) Index Pain Subscale (Section A Items #1-5) Measured by 100 mm VAS;  Pain Subscore (WOMAC Section A Items #1-5) Measured by 100 mm VAS;  Stiffness Subscore (WOMAC Section B Items #6-7) Measured by 100 mm VAS;  Physical Function Bubscore (WOMAC Section C Items #8-24) Recorded on 100 mm VAS;  Total WOMAC Score (All Subscales) Recorded on 100 mm VAS;  PatientGlobalAssessment(PGA);  PhysicianGlobalAssessment(PhGA);  Pain Immediately Following the 50-foot Walk (100 mm VAS);  TimetoWalking(50-footWalkTest);  Time to 50% Pain Relief (Study Population Measure Statistically Derived);  PatientsAchieving100%PainRelief;  Time to and Use of Rescue Medication (Acetaminophen up to 3000 mg Per Day for Breakthrough Pain) (Study Population Measure Statistically Derived) - Patients Use;  Time to and Use of Rescue Medication (Acetaminophen up to 3000 mg Per Day for Breakthrough Pain) (Study Population Measure Statistically Derived). Tablets Taken.|287|NCT01887678|June 2013
4608|Completed|Multi-Center Study to Assess the Efficacy and Safety of PT003 PT005 and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)||Drug:GFFMDI(PT003);  Drug:GPMDI(PT001);  Drug:FFMDI(PT005);  Drug:Placebo|Interventional|Phase 3|Industry|Change from baseline in morning pre-dose trough FEV1;  TransitionDyspneaIndex(TDI)focalscore;  PeakFEV1;  St.GeorgeRespiratoryQuestionnaire(SGRQ)score;  RescueVentolinHFAuse;  Timetoonsetofaction|1618|NCT01854658|July 2013
4609|Terminated                  Has Results|Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation||Drug:Elobixibat10mg/day;  Drug:Elobixibat5mg/day;  Drug:Placebo|Interventional|Phase 3|Industry|Overall Complete Spontaneous Bowel Movement (CSBM) Response;  OccurrenceofCSBMResponse;  Change From Baseline in Weekly Frequency of Spontaneous Bowel Movement (SBMs);  Change From Baseline in Weekly Stool Consistency of SBMs;  Total Patient Assessment of Constipation - Quality of Life (PAC-QOL) Score Responder;  Change From Baseline in Weekly Degree of Straining of SBMs;  Change From Baseline in Weekly Abdominal Bloating Score;  Change From Baseline in Weekly Abdominal Discomfort Score|314|NCT01833065|April 2013
4610|Terminated                  Has Results|TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes||Drug:Placebo;  Drug:TAK-875|Interventional|Phase 3|Industry|ChangeFromBaselineinHbA1catWeek24;  PercentageofParticipantsWithHbA1c&lt;7%;  Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24|90|NCT01829464|May 2013
4611|Active not recruiting                  Has Results|Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Positive Participants||Drug:E/C/F/TAF;  Drug:E/C/F/TDF;  Drug:EFV/FTC/TDF;  Drug:RTV;  Drug:ATV;  Drug:FTC/TDF;  Drug:COBI|Interventional|Phase 3|Industry|Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 48;  Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48;  Percent Change From Baseline in Spine BMD at Week 48;  Change From Baseline in Serum Creatinine at Week 48;  Change From Baseline in Overall EFV-related Symptom Assessment Score at Week 48|1443|NCT01815736|March 2013
4612|Active not recruiting                  Has Results|Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya&#174;) Versus E/C/F/TDF (Stribild&#174;) in HIV-1 Positive Antiretroviral Treatment-Naive Adults||Drug:E/C/F/TAF;  Drug:E/C/F/TDF;  Drug:E/C/F/TDFPlacebo;  Drug:E/C/F/TAFPlacebo|Interventional|Phase 3|Industry|Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 48;  Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 96;  Percentage of Participants With HIV-1 RNA &lt; 20 Copies/mL at Weeks 48 and 96;  Change From Baseline in CD4+ Cell Count at Week 48;  Change From Baseline in CD4+ Cell Count at Week 96;  Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48;  Percent Change From Baseline in Hip BMD at Week 96;  Percent Change From Baseline in Spine BMD at Week 48;  Percent Change From Baseline in Spine BMD at Week 96;  Change From Baseline in Serum Creatinine at Week 48;  Change From Baseline in Serum Creatinine at Week 96;  Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 48;  Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 96;  Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48;  Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96;  Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 48;  Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 96|872|NCT01780506|December 2012
4613|Completed                  Has Results|Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim||Other:GeneralEducationDVD;  Other:BonePainEducationDVD|Interventional|Phase 2|Industry|MaximumPatient-reportedBonePaininCycle1;  Maximum Patient-reported Bone Pain by Cycle and Across All Cycles;  Mean Patient-reported Bone Pain by Cycle and Across All Cycles;  Patient-reported Bone Pain Area Under the Curve (AUC) by Cycle and Across All Cycles;  Percentage of Participants With Any Grade Bone Pain as Captured in Standard Adverse Event Reporting;  Percentage of Participants With Grade 3 or 4 Bone Pain Captured in Standard Adverse Event Reporting;  Percentage of Participants Who Used Analgesics for the Treatment of Bone Pain by Cycle and Across Cycles|304|NCT01752907|January 2013
4614|Completed                  Has Results|Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer&apos;s Disease||Drug:ELND005;  Drug:Placebo|Interventional|Phase 2|Industry|Change From Baseline in NPI-C Combined Agitation and Aggression Subscores (NPI-C A+A).;  Change From Baseline in Modified-ADCS-CGIC Agitation Scores;  ChangeFromBaselineinNPITotalScores;  ChangeFromBaselineinMMSEScores;  ChangeFromBaselineinADCS-ADLScores|350|NCT01735630|November 2012
4615|Completed|A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities||Drug:Placebo;  Drug:aleglitazar|Interventional|Phase 3|Industry|Time to first occurrence of any component of the composite event (cardiovascular death non-fatal myocardial infarction (MI) non-fatal stroke) as adjudicated by the Clinical Events Committee (CEC);  Time to first occurrence of a composite with components as adjudicated by the CEC: cardiovascular death non-fatal MI and non-fatal stroke (in each of the subgroups with or without evidence of T2D at baseline);  Time to first occurrence of a composite with components as adjudicated by the CEC: all-cause mortality non-fatal MI and non-fatal stroke (in each of the subgroups with or without evidence of T2D at baseline)|1999|NCT01715818|December 2012
4616|Completed                  Has Results|A 12-week Treatment Multi-center Randomized Double-blind Parallel-group Placebo and Active Controlled Study to Assess the Efficacy Safety and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation||Drug:QVA149;  Drug:QAB149;  Drug:NVA237;  Drug:Placebo|Interventional|Phase 3|Industry|Primary: Change From Baseline in Standardized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) (0-12 Hours (h));  Change From Baseline in St. George&apos;s Respiratory Questionnaire (SGRQ) Total Score;  Percentage of Participants With a Clinically Important Improvement of at Least 4 Units in the SGRQ Total Score;  ChangeFromBaselineinTroughFEV1;  ChangeFromBaselineinPre-doseTroughFEV1;  ChangeFromBaselineinFEV1;  ChangeFromBaselineinFVC;  Secondary: Change From Baseline in Standardized FEV1 AUC (0-4 h) FEV1 AUC (4-8h) FEV1 AUC (8-12h) and FEV1 AUC (0-12 h);  TransitionalDyspneaIndex(TDI)FocalScore;  Secondary: Change From Baseline in Mean Daily Number of Puffs of Rescue Medication;  Secondary: Change From Baseline in Mean Total Daily Symptom Score Mean Daytime Total Symptom Score and Mean Nighttime Total Symptom Score|1001|NCT01712516|December 2012
4617|Completed                  Has Results|A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy||Drug:PF-04634817;  Drug:Placebo|Interventional|Phase 2|Industry|Percent Reduction From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12;  ChangeFromBaselineinUACRatWeeks48and16;  Change From Baseline in Urinary Protein to Creatinine Ratio (UPCR) at Weeks 4 8 12 and 16;  Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) Using the Abbreviated Modified Diet in Renal Disease (MDRD) Formula at Weeks 1 4 8 12 and 16;  Change From Baseline in eGFR Using Cystatin Formula at Weeks 12 and 16;  Change From Baseline in Serum Creatinine at Weeks 1 4 8 12 and 16;  Change From Baseline in Serum Cystatin C at Weeks 12 and 16;  Change From Baseline in Plasma Glycosylated Hemoglobin (HbA1c) at Weeks 4 8 12 and 16;  Summary of Plasma PF-04634817 Pharmacokinetic (PK) Concentrations at Day 1 and Weeks 1 4 8 and 12|226|NCT01712061|December 2012
4618|Completed|Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic Constipation||Drug:Lubiprostone;  Drug:Placebo|Interventional|Phase 3|Industry|PrimaryAnalysis|909|NCT01674530|October 2012
4619|Active not recruiting|VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer||Drug:pegylatedliposomaldoxorubicin(PLD);  Drug:VTX-2337;  Drug:Placebo|Interventional|Phase 2|Industry / Other|Overall survival (OS) of patients treated with VTX-2337 + PLD versus those treated with PLD alone;  Progression-free survival (PFS) of patients treated with VTX-2337 + PLD versus those treated with PLD alone using Immune-Related Response Evaluation Criteria In Solid Tumors (irRECIST).;  Frequency and severity of drug-related adverse events (AEs) of patients treated with VTX-2337 + PLD versus those treated with PLD alone.|290|NCT01666444|October 2012
4620|Terminated|A Trial of NNC0109-0012 an Anti-IL-20 Biologic in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics||Drug:NNC0109-0012;  Drug:placebo|Interventional|Phase 2|Industry|ACR20 (defined as 20% improvement in American College of Rheumatology criteria measures);  20%/50%/or 70% improvement of ACR score from baseline;  Change in DAS28-CRP (defined as Disease Activity Score for 28 joints with C-reactive protein measure) from baseline;  Simplified Disease Activity Index (SDAI) remission (SDAI of 3.3 or below);  European League Against Rheumatism (EULAR) criteria response;  Change from baseline in the overall scores of Health Assessment Questionnaire - Disability Index (HAQ-DI);  Change from baseline in the overall scores of Short Form Health Survey (SF-36v2);  Incidenceandtypeofadverseevents(AEs);  Change from baseline in van der Heijde modified sharp score;  ACR20/50/70 (20% 50% or 70% improvement of ACR (American College of Rheumatology) score from baseline)|239|NCT01636817|August 2012
4621|Completed                  Has Results|Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies||Drug:SOF;  Drug:RBV;  Drug:Peg-IFN|Interventional|Phase 3|Industry|Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12);  Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event;  Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24);  Percentage of Participants With On-treatment Virologic Failure;  PercentageofParticipantsWithViralRelapse|534|NCT01625338|June 2012
4622|Active not recruiting|An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)|||Observational||Industry|Distribution of patients receiving unique treatment regimen/sequence of treatment regimens;  Progression-freesurvival(PFS);  Overallsurvival(OS);  Post-progressionsurvival(PPS);  Time-to-treatmentfailure(TTF);  Responserate(RR);  Safety:Incidenceofadverseevents;  Patient-reportedoutcomeassessment(PRO)|1017|NCT01615068|June 2012
4623|Completed|Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza||Drug:Nitazoxanide;  Drug:Oseltamivir|Interventional|Phase 3|Industry|Time to resolution of all clinical symptoms of influenza as reported by the subjects;  Time to resolution of each individual symptom of influenza|1941|NCT01610245|March 2013
4624|Completed|Efficacy Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate Aclidinium Bromide Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)||Drug: Aclidinium bromide/formoterol Fixed-Dose Combination (FDC);  Drug:Aclidiniumbromide;  Drug:FormoterolFumarate;  Drug:Placebo|Interventional|Phase 3|Industry|Safetyandtolerability|909|NCT01572792|April 2012
4625|Completed                  Has Results|Safety and Efficacy of Azelaic Acid Foam 15 % in Papulopustular Rosacea||Drug:Azelaicacidfoam15%(BAY39-6251);  Drug:Vehiclefoam|Interventional|Phase 3|Industry|Percentage of Participants With Investigator&apos;s Global Assessment (IGA) Based Therapeutic Success at End of Treatment (LOCF: Last Observation Carried Forward);  Nominal Change From Baseline in Inflammatory Lesion (IL) Count at End of Treatment (LOCF);  Percent Change From Baseline in Inflammatory Lesion Count at End of Treatment (LOCF);  Percentage of Participants With Investigator&apos;s Global Assessment (IGA) Based Therapeutic Response at End of Treatment (LOCF);  Grouped Changes From Baseline in Erythema Intensity Score at End of Treatment (LOCF);  Percentage of Participants With Investigator&apos;s Global Assessment (IGA) Scores at End of Treatment (LOCF);  Nominal Value of Inflammatory Lesion Count at End of Treatment (LOCF);  Percentage of Participants With Erythema Intensity Score at End of Treatment (LOCF);  Grouped Changes From Baseline in Telangiectasia Intensity Score at End of Treatment (LOCF);  Percentage of Participants With Facial Skin Color Rating at End of Treatment (LOCF);  Participants&apos; Global Assessment of Treatment Response at End of Treatment;  Participants&apos; Global Assessment of Tolerability at End of Treatment;  Participants&apos; Opinion on Cosmetic Acceptability at End of Treatment;  Participants&apos; Opinion on Practicability of Product Use in Facial Areas Next to the Hairline at End of Treatment;  Change From Baseline in Rosacea Quality of Life (RosaQoL) Questionnaire at End of Treatment - Overall Quality of Life Score;  Number of Participants With Change From Baseline in Dermatology Life Quality Index (DLQI) Questionnaire at End of Treatment - Overall Score;  Change From Baseline in EuroQol Group Questionnaire-Visual Analogue Scale (EQ-VAS) at End of Treatment;  Change From Baseline in Index Value at End of Treatment|961|NCT01555463|September 2012
4626|Completed                  Has Results|A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone||Drug:Ranolazine;  Drug:Placebotomatchranolazine;  Drug:Metformin;  Drug:Placebotomatchmetformin;  Behavioral:Diet;  Behavioral:Exercise|Interventional|Phase 3|Industry|Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24;  Change From Baseline in Fasting Serum Glucose at Week 24;  Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24|442|NCT01555164|June 2012
4627|Terminated                  Has Results|Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes||Drug:Fasiglifam(TAK-875);  Drug:Sitagliptin;  Drug:Placebo|Interventional|Phase 3|Industry|Change From Baseline in Glycosylated Hemoglobin (HbA1c);  IncidenceofHbA1c&lt;7%;  Change From Baseline in Fasting Plasma Glucose (FPG)|916|NCT01549964|April 2012
4628|Active not recruiting|Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian Fallopian Tube or Primary Peritoneal Cancer||Other:LaboratoryBiomarkerAnalysis;  Drug:Veliparib|Interventional|Phase 2|NIH|Incidence of adverse effects as assessed by CTCAE v 4.0;  The frequency of patients who have objective tumor response;  DurationofOS;  DurationofPFS;  The proportion of patients who survive progression-free for at least 6 months|51|NCT01540565|April 2012
4629|Active not recruiting|S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer||Behavioral:Textmessagereminder|Interventional||Other / NIH|Time to first evidence of adherence failure (discontinuation);  Adherence effect of text message compared to usual care using the patient self-report responses to AI Usage form;  Relationship between randomized arm and various participant site and health insurance characteristics;  Reasons for early discontinuation of AI therapy among intervention arm and control arm as assessed by quality-of-life questionnaires;  Timetolastevidenceofadherence|692|NCT01515800|May 2012
4630|Completed                  Has Results|Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat||Drug:Lesinurad;  Drug:Placebo;  Drug:Febuxostat|Interventional|Phase 3|Industry|Subjects With a Serum Urate (sUA) Level That is &lt; 5.0 mg/dL by Month 6;  CompleteResolutionofatLeastOneTargetTophus;  Complete or Partial Response of at Least One Tophus;  QualityofLife|330|NCT01510769|January 2012
4631|Completed                  Has Results|Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy||Drug:Lantus(Insulinglargine);  Drug: HOE901-U300 (new formulation of insulin glargine)|Interventional|Phase 3|Industry|ChangeinHbA1cFromBaselinetoMonth6Endpoint;  Percentage of Participants With At Least One Severe and/or Confirmed Nocturnal Hypoglycemia From Start of Week 9 to Month 6 Endpoint;  Change in Average Preinjection Self-Monitored Plasma Glucose (SMPG) From Baseline to Month 6 Endpoint;  Change in Variability of Preinjection SMPG From Baseline to Month 6 Endpoint;  Percentage of Participants With HbA1c &lt;7% at Month 6 Endpoint;  Change in Fasting Plasma Glucose (FPG) From Baseline to Month 6 Endpoint;  Percentage of Participants With FPG &lt;5.6 mmol/L (&lt;100 mg/dL) at Month 6 Endpoint;  Change in 8-Point SMPG Profiles Per Time Point From Baseline to Month 6 Endpoint;  Change in Daily Basal Insulin Dose From Baseline to Month 6 Endpoint;  Change in Treatment Satisfaction Score Using The Diabetes Treatment Satisfaction Questionnaire (DTSQs) From Baseline to Month 6 Endpoint;  Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline to Month 12|811|NCT01499095|December 2011
4632|Completed|A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)||Biological:Placebo;  Biological:Belimumab200mgSC;  Drug:Standardtherapy|Interventional|Phase 3|Industry|SLEResponderIndex(SRI)responserate;  Timetofirstsevereflare(SLEFlareIndex);  Reductioninprednisonedose|839|NCT01484496|November 2011
4633|Recruiting|HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network|||Observational||Other|Sustainedvirologicalresponse(SVR);  Treatmentpersistence;  Virologicalbreakthrough;  Managementofadverseevents|4500|NCT01474811|November 2011
4634|Recruiting|Observational Study of the Use of KRYSTEXXA&#174; in Refractory Chronic Gout||Biological:pegloticase|Observational||Industry|Number of participants with pre-specified adverse events;  Serumuricacidresponse;  Change from Baseline in Number of Swollen Joints at 25 weeks;  Change from Baseline in Number of Swollen Joints at 51 weeks;  Change from Baseline in Number of Tender Joints at 25 weeks;  Change from Baseline in Number of Tender Joints at 51 weeks;  Change from Baseline in Number of Tophi at 25 weeks;  Change from Baseline in Number of Tophi at 51 weeks;  Change from Baseline in Number of Swollen Joints at Early Discontinuation;  Change from Baseline in Number of Tender Joints at Early Discontinuation;  Change from Baseline in Number of Tophi at Early Discontinuation;  Change from Baseline in Number of Gout Flares at 6 weeks;  Change from Baseline in Number of Gout Flares in weeks 6-12;  Change from Baseline in Number of Gout Flares in Months 3-6;  Change from Baseline in Number of Gout Flares in Months 6-9;  Change from Baseline in Number of Gout Flares in Months 9-12;  Change from Baseline in Number of Gout Flares in Months 12-15|1500|NCT01466166|October 2011
4635|Completed                  Has Results|6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old||Drug:ADVAIR100/50mcg;  Drug:ADVAIR250/50mcg;  Drug:FLOVENT100mcg;  Drug:FLOVENT250mcg|Interventional|Phase 4|Industry|Number of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization Asthma-related Endotracheal Intubation or Asthma-related Death);  Number of Participants With at Least One Asthma Exacerbation Over the 6-month Study Treatment Period;  Number of Participants Experiencing Asthma-related Deaths Over the 6-month Study Treatment Period.;  Number of Participants Experiencing Asthma-related Endotracheal Intubations Over the 6-month Study Treatment Period;  Number of Participants Experiencing Asthma-related Hospitalizations Over the 6-month Study Treatment Period;  Number of Participants Withdrawn From Study Treatment Due to Asthma Exacerbation Over the 6-month Study Treatment Period;  Percentage of Rescue-free Days Over the 6-month Study Treatment Period;  Percentage of Asthma Control Days Over the 6-month Study Treatment Period|6250|NCT01462344|November 2011
4636|Completed                  Has Results|Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes||Drug:Placebo;  Drug:Fasiglifam|Interventional|Phase 3|Industry|Change From Baseline in Glycosylated Hemoglobin (HbA1c);  IncidenceofHbA1c&lt;7%;  ChangeFromBaselineinFastingPlasmaGlucose;  Change From Baseline in 2-hour Postprandial Glucose (PPG) Following a Meal Tolerance Test (MTT)|421|NCT01456195|November 2011
4637|Active not recruiting|Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile|||Observational||Other|Molecular profiles and clinical characteristics that define subsets of myeloma patients at initial diagnosis and at relapse of disease.;  Responserates;  Survivalrates;  Bonediseaseassessedradiographically;  Health-relatedqualityoflife;  Resourceutilization;  Severeadverseevents|1154|NCT01454297|July 2011
4638|Completed                  Has Results|Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)||Drug:Ranolazine;  Drug:Placebo|Interventional|Phase 3|Industry|Kaplan-Meier Estimates for Time From Randomization to First Occurrence of Ischemia-driven Revascularization or Ischemia-driven Hospitalization Without Revascularization;  Kaplan-Meier Estimates for Time From Randomization to Sudden Cardiac Death;  Kaplan-Meier Estimates for Time From Randomization to Cardiovascular Death;  Kaplan-Meier Estimates for Time From Randomization to Myocardial Infarction|2651|NCT01442038|October 2011
4639|Completed|Efficacy Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)||Drug:AclidiniumBromide/FormoterolFumarate;  Drug:AclidiniumBromide;  Drug:FormoterolFumarate;  Drug:placebo|Interventional|Phase 3|Industry|Morning pre-dose (trough) Forced Expiratory Volume in one second (FEV1) at Week 24;  Morningone-hourpost-doseFEV1atWeek24;  Change from baseline in George&apos;s Respiratory Questionnaire (SGRQ) total score;  Improvement in Transition Dyspnea Index (TDI) score|1692|NCT01437397|September 2011
4640|Completed|A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain||Drug:Oxycodone/Naloxonecontrolled-release;  Drug:OxycodoneHClcontrolled-release;  Drug:Placebo|Interventional|Phase 3|Industry|Overall complete spontaneous bowel movement (CSBM) responder rates;  CSBM Responder at least 50% of the weeks in the double-blind period;  Laxative-free Responder at least 50% of the weeks in the double-blind period|450|NCT01427283|August 2011
4641|Completed|Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus||Biological:PF-04236921|Interventional|Phase 2|Industry|The primary endpoint of the study is the proportion of subjects achieving the SLE Responder Index (SRI).;  Percentage of subjects with an improvement of greater than or equal to 4 in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-2K score.;  Percentage of subjects with no new British Isles Lupus Assessment Group (BILAG) A organ domain scores or 2 new BILAG B organ domain scores;  Percentage of subjects with No worsening of Physician&apos;s Global Assessment (PhGA) score.;  Percentage of subjects who develop anti-drug antibodies (ADAs) and neutralizing antibodies (Nabs) if observed.;  Mean change from baseline in patient reported outcome measures using Short Form-36 European Quality of Life-5 Dimensional questionnaire Functional Assessment of Chronic Illness Therapy-Fatigue and Visual Analog Scale scores.;  Proportion of subjects achieving SRI at all timepoints except Week 24;  Proportion of subjects achieving modified SRI at all timepoints;  Proportion of subjects achieving BILAG based Combined Lupus Assessment (BICLA) response at all timepoints;  Percentage of subjects with abnormal immunoglobulins anti-dsDNA C3 or C4 at baseline that become normal.;  Percentage of subjects receiving corticosteroids greater than 7.5 mg per day whose dose has been reduced by both &gt;= 25% from baseline and to &lt;= 7.5 mg per day during Week 12 through Week 24.;  Evaluate the safety and tolerability of PF-04236921 at the different dose levels compared to placebo for adverse events laboratory changes ECGs and vital signs.;  BloodconcentrationofPF-04236921|183|NCT01405196|December 2011
4642|Completed|Safety &amp; Efficacy WC3011 in the Treatment of Vulvovaginal Atrophy in Postmenopausal Women||Drug:WC3011VaginalGel;  Drug:Vehicle|Interventional|Phase 3|Industry|Change in Vaginal Cytology (Maturation Index; Percentage of Basal and Superficial Cells) from Baseline to Week 12/Final Visit;  Change in Vaginal pH from Baseline to Week 12/Final Visit;  Change in Subject&apos;s Self-Assessment of Intensity of Vaginal Dryness from Baseline to Week 12/Final Visit;  Change in Investigator Assessment of Vulvovaginal Atrophy (VVA) from Baseline to Week 12;  Change in Subjects&apos; Self-Assessment of Intensity of Vaginal Dryness from Baseline to Week 4;  Change in Subjects&apos; Self-Assessment of Intensity of Vaginal Dryness from Baseline to Week 8;  Change in Subjects&apos; Self-Assessment of Vaginal and/or Vulvar Irritation/Itching from Baseline to Week 4;  Change in Subjects&apos; Self-Assessment of Vaginal and/or Vulvar Irritation/Itching from Baseline to Week 8;  Change in Subjects&apos; Self-Assessment of Vaginal and/or Vulvar Irritation/Itching from Baseline to Week 12;  Change in Subjects&apos; Self-Assessment of Dysuria (painful or difficult urination) from Baseline to Week 4;  Change in Subjects&apos; Self-Assessment of Dysuria (painful or difficult urination) from Baseline to Week 8;  Change in Subjects&apos; Self-Assessment of Dysuria (painful or difficult urination) from Baseline to Week 12;  Change in Subjects&apos; Self-Assessment of Dyspareunia (pain associated with sexual activity) from Baseline to Week 4;  Change in Subjects&apos; Self-Assessment of Dyspareunia (pain associated with sexual activity) from Baseline to Week 8;  Change in Subjects&apos; Self-Assessment of Dyspareunia (pain associated with sexual activity) from Baseline to Week 12;  Change in Subjects&apos; Self-Assessment of Vaginal Bleeding associated with sexual activity from Baseline to Week 4;  Change in Subjects&apos; Self-Assessment of Vaginal Bleeding associated with sexual activity from Baseline to Week 8;  Change in Subjects&apos; Self-Assessment of Vaginal Bleeding associated with sexual activity from Baseline to Week 12|722|NCT01400776|July 2011
4643|Completed                  Has Results|A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation||Drug:NKTR-118;  Drug:Placebo|Interventional|Phase 3|Industry|Incidence of Patients Experiencing at Least One Adverse Event (AE);  Incidence of Patients Experiencing AEs That Resulted in Discontinuation of Investigational Product (IP);  Incidence of Patients Experiencing Severe Adverse Events (SAEs);  Change From Baseline in Patient Assessment of Constipation Symptoms Questionnaire (PAC-SYM);  Change From Baseline in Patient Assessment of Constipation Quality of Life (PAC-QOL)|302|NCT01395524|July 2011
4644|Terminated                  Has Results|Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain||Drug:NKTR-118;  Drug:Placebo|Interventional|Phase 3|Industry|Response(Responder/Non-responder)toStudyDrug|14|NCT01384292|June 2011
4645|Completed                  Has Results|Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)||Drug:5-Fluorouracil;  Drug:Bevacizumab;  Drug:Irinotecan;  Drug:Leucovorin;  Drug:Oxaliplatin;  Drug:Capecitabine|Interventional|Phase 2|Industry|Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1;  PFS According to RECIST Version 1.1 in Participants With High ERCC-1 Levels;  PFS According to RECIST Version 1.1 in Participants With Low ERCC-1 Levels;  PFS According to RECIST Version 1.1 in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels;  PFS According to RECIST Version 1.1 in Participants With High Vascular Endothelial Growth Factor (VEGF)-A Levels Versus Participants With Low VEGF-A Levels;  PFS According to RECIST Version 1.1 in Participants With High ERCC-1 and High VEGF-A Levels;  PFS According to RECIST Version 1.1 in Participants With High ERCC-1 and Low VEGF-A Levels;  PFS According to RECIST Version 1.1 in Participants With Low ERCC-1 and High VEGF-A Levels;  PFS According to RECIST Version 1.1 in Participants With Low ERCC-1 and Low VEGF-A Levels;  OverallSurvival(OS);  OSinParticipantsWithHighERCC-1Levels;  OSinParticipantsWithLowERCC-1Levels;  OS in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels;  Percentage of Participants With Objective Response According to RECIST Version 1.1;  Percentage of Participants With Objective Response According to RECIST Version 1.1 in Participants With High ERCC-1 Levels;  Percentage of Participants With Objective Response According to RECIST Version 1.1 in Participants With Low ERCC-1 Levels;  Percentage of Participants With Objective Response According to RECIST Version 1.1 in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels;  Percentage of Participants With Disease Control According to RECIST Version 1.1;  Percentage of Participants With Disease Control According to RECIST Version 1.1 in Participants With High ERCC-1 Levels;  Percentage of Participants With Disease Control According to RECIST Version 1.1 in Participants With Low ERCC-1 Levels;  Percentage of Participants With Disease Control According to RECIST Version 1.1 in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels;  Percentage of Participants With Liver Metastasis Resection;  Percentage of Participants With Complete Liver Metastasis Resection;  Percentage of Participants With Liver Metastasis Resection in Participants With High ERCC-1 Levels;  Percentage of Participants With Complete Liver Metastasis Resection in Participants With High ERCC-1 Levels;  Percentage of Participants With Liver Metastasis Resection in Participants With Low ERCC-1 Levels;  Percentage of Participants With Complete Liver Metastasis Resection in Participants With Low ERCC-1 Levels;  Percentage of Participants With Liver Metastasis Resection in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels;  Percentage of Participants With Complete Liver Metastasis Resection in Participants With High ERCC-1 Levels Versus Participants With Low ERCC-1 Levels;  PFS According to RECIST Version 1.1 in Participants With Wild-Type V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Versus Participants With Mutant KRAS;  OS in Participants With High VEGF-A Levels Versus Participants With Low VEGF-A Levels;  OS in Participants With Wild-Type KRAS Versus Participants With Mutant KRAS;  Percentage of Participants With Objective Response According to RECIST Version 1.1 in Participants With High VEGF-A Levels Versus Participants With Low VEGF-A Levels;  Percentage of Participants With Objective Response According to RECIST Version 1.1 in Participants With Wild-Type KRAS Versus Participants With Mutant KRAS;  Percentage of Participants With Disease Control According to RECIST Version 1.1 in Participants With High VEGF-A Levels Versus Participants With Low VEGF-A Levels;  Percentage of Participants With Liver Metastasis Resection in Participants With High VEGF-A Levels Versus Participants With Low VEGF-A Levels;  Percentage of Participants With Complete Liver Metastasis Resection in Participants With High VEGF-A Levels Versus Participants With Low VEGF-A Levels|376|NCT01374425|August 2011
4646|Completed|Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer||Drug:ON01910.Na;  Drug:Gemcitabine|Interventional|Phase 3|Industry / Other|Survival;  Progression-freesurvival;  Tumorsize;  Safety/tolerability;  QOLquestionnaire;  Biomarkers;  PopulationPharmacokinetics;  FullPharmacokinetics|160|NCT01360853|May 2011
4647|Completed                  Has Results|Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis||Drug:Dalfampridine-ER5mg;  Drug:Dalfampridine-ER10mg;  Other:Placebo|Interventional|Phase 3|Industry|Change From Baseline in Walking Speed Near Maximum Plasma Concentration at Steady State (CmaxSS) of Placebo and Dalfampridine-ER (5mg and 10mg) Using the Timed 25 Foot Walk (T25FW).;  Change From Baseline in Walking Speed Near Minimum Plasma Concentration at Steady State (CminSS) of Placebo Dalfampridine-ER (5mg and 10mg) Using the Timed 25 Foot Walk (T25FW).;  Change From Baseline in 12-item MS Walking Scale (MSWS-12) at Visit 3;  ChangeFromBaselineinMSWS-12atVisit2;  Change From Baseline in Six-Minute Walk Distance at Visit 2;  Change From Baseline in EuroQol Group 5 Dimensions (EQ-5D) Scores at Visit 3.;  Change From Baseline in EQ-5D Visual Analogue Self-rating (VAS) Score at Visit 3.|430|NCT01328379|March 2011
4648|Active not recruiting|A Randomized Double-blind Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer||Biological:PROSTVAC-V;  Biological:PROSTVAC-F;  Drug:GM-CSF;  Other:GM-CSFPlacebo;  Biological:Placebo|Interventional|Phase 3|Industry|Overallsurvival;  Proportion of event-free patients compared with placebo|1298|NCT01322490|December 2011
4649|Terminated|Open-Label Extension Study of GSK1605786A||Drug:GSK1605786A|Interventional|Phase 3|Industry|Number of subjects with adverse events and serious adverse events;  Change from baseline in vital signs haematology and clinical chemistry parameters electrocardiogram measurements;  ChangefrombaselineinCDAIscore;  Proportionofsubjectsinclinicalremission;  Proportion of subjects achieving clinical response;  Change from baseline in health outcome measures (IBDQ SF-36v2 EQ-5D Work and Productivity Activity Impairment-Crohn&apos;s disease and disability)|400|NCT01318993|April 2011
4650|Terminated|GSK1605786A in the Maintenance of Remission in Subjects With Crohn&apos;s Disease||Drug:GSK1605786A;  Drug:Placebo|Interventional|Phase 3|Industry|Remission(CDAIscorelessthan150points);  Corticosteroid-freeremission;  Remission in subjects who were in remission at baseline;  Remissionatendoftreatment;  Clinical response (CDAI decrease of at least 100 points);  Induction of remission in subjects who were not in remission at baseline;  ChangefrombaselineinCDAIscore;  Safetyoutcomes;  Healthoutcomes;  Biomarkers|229|NCT01316939|May 2011
4651|Completed                  Has Results|Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation||Drug:NKTR-118;  Drug:Placebo|Interventional|Phase 3|Industry|Response (Responder/Non-responder) to Study Drug During Weeks 1 to 12;  Response (Responder/Non-responder) to Study Drug in the LIR Subgroup During Weeks 1 to 12;  Time (in Hours) to First Post-dose Laxation Without the Use of Rescue Laxatives Within the Previous 24 Hours;  Change From Baseline in Mean Number of Days Per Week With at Least 1 SBM During Weeks 1 to 12;  ChangeFromBaselineinDegreeofStraining;  Change From Baseline in Stool Consistency (Bristol Stool Scale);  Change From Baseline in Percent Numbers of Days With a CSBM (Complete Spontaneous Bowel Movement);  Change From Baseline in Mean Spontaneous Bowel Movements/Week;  Time (in Hours) to First Post-dose Laxation Without the Use of Rescue Laxatives Within the Previous 24 Hours in the Laxative Inadequate Response (LIR) Subgroup;  Change From Baseline in Patient Assessment of Constipation Symptoms Questionnaire (PAC-SYM);  Change From Baseline in Patient Assessment of Constipation Quality of Life (PAC-QOL) Satisfaction Domain|652|NCT01309841|March 2011
4652|Active not recruiting|Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer||Biological:cetuximab;  Drug:cisplatin|Interventional|Phase 3|Other / NIH|Overallsurvival;  Progression-freesurvival;  Local-regionalfailure;  Distantmetastasis;  Acute toxicities (CTCAE v. 4) and overall toxicity burden at end of treatment and at 1 3 and 6 months after completion of treatment;  Latetoxicities(CTCAEv.4)at12and5years;  Secondprimarycancers;  Patternoffailure;  Earlydeaths;  Feedingtuberateat1year;  EORTC QLC-C30 at baseline end of treatment 3 6 and 12 months from end of treatment.;  EORTC QLQ-H&amp;N35 at baseline end of treatment 3 6 and 12 months from end of treatment.;  PRO-CTCAE-H&amp;N at baseline end of treatment 3 6 and 12 months from end of treatment.;  EQ-5D at baseline end of treatment 3 6 and 12 months from end of treatment.;  Work Status Questionnaire at baseline end of treatment 3 6 and 12 months.;  Dental status at baseline 12 24 60 and 120 months from end of treatment.;  Hearing quality of life outcomes as measured by the HHIA-S at baseline end of treatment and at 3 6 and 12 months from end of treatment.;  Behavioral Risk Assessment Survey (BRASS) at baseline.;  Translationalresearchanalysis|706|NCT01302834|June 2011
4653|Completed|A Study To Monitor Long-Term Treatment With PF-00547659||Drug:PF-00547659|Interventional|Phase 2|Industry|Frequency of on-treatment AEs AEs leading to withdrawal and SAEs.;  Frequency of the development of Anti-drug Antibodies;  Plasma trough concentrations of PF-00547659 will be analyzed using population Pharmacokinetic (PK) methodology.|268|NCT01298492|July 2011
4654|Completed|Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn&apos;s Disease||Drug:PF-00547659SCinjection|Interventional|Phase 2|Industry|Crohn&apos;s Disease Activity Index (CDAI) 70 response rate at week 8 or week 12 (between the investigational product group and the placebo group).;  Safety and tolerability of PF-00547659 dose levels versus placebo: the frequency of treatment adverse events withdrawal due to adverse events and serious adverse events (SAEs) will be reported.;  Percent of subjects with a CDAI remission (CDAI &lt;150) CDAI 70 and CDAI 100 responses Weeks 2 through 12.;  Immunogenicity assessments of antidrug antibodies (ADAs).;  The PK of total PF-00547659 will be characterized using a population PK approach. PK parameters including but not limited to AUC CL and half life will be estimated using data pooled from both typical and additional PK groups.|265|NCT01276509|April 2011
4655|Completed|Study to Evaluate sUA Lowering Activity Safety and Efficacy of Oral Ulodesine Added to Allopurinol||Drug:ulodesine;  Drug:Placebo|Interventional|Phase 2|Industry|To evaluate the dose response of ulodesine when combined with Allopurinol on sUA.|279|NCT01265264|December 2010
4656|Active not recruiting|Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting|||Observational||Industry|TherateofCompleteCytogeneticResponse;  ThedurationofinitialTKItreatment;  The rate of discontinuation and treatment changes after initial TKI treatment;  The rate of best response to therapy (i.e. hematologic cytogenetic molecular response);  Theadherencetotreatment;  Impact of first-line treatment options on quality of life;  Non-hematologic side effects from treatment affecting patient quality of life and outcomes;  PatientsatisfactionwithCMLtreatment;  Patterns of disease monitoring as observed in a real-world setting;  Resource utilization associated with CML management|1494|NCT01244750|December 2010
4657|Recruiting|Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer||Procedure:palliativesurgery;  Procedure:therapeuticconventionalsurgery;  Radiation:palliativeradiationtherapy;  Radiation:radiationtherapy|Interventional|Phase 3|Other / NIH|Overallsurvival;  Uncontrolledchestwalldisease;  Health-relatedqualityoflife|880|NCT01242800|February 2011
4658|Terminated                  Has Results|Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)||Drug:Fostamatinib|Interventional|Phase 3|Industry|Percentage of Patients Who Had at Least 1 Adverse Event in Any Category;  MeanDAS28-CRPScore;  MeanmTSSScore;  MeanHAQ-DIScore|1917|NCT01242514|January 2011
4659|Unknown&nbsp;&#8224;                  Has Results|A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced Integrase Inhibitor-Naive Adults||Drug:GSK1349572;  Drug:Raltegravir;  Drug:GSK1349572Placebo;  Drug:RaltegravirPlacebo|Interventional|Phase 3|Industry|Percentage of Participants With HIV-1 RNA &lt;50 Copies/Milliliter (c/mL) at Week 48;  Number of Participants (Par.) With Detectable Virus That Has Genotypic or Phenotypic Evidence of Treatment-emergent INI Resistance at Time of Protocol Defined Virology Failure (PDVF);  Number of Participants With Plasma HIV-1 RNA &lt;50 c/mL at Week 24;  Number of Participants With Plasma HIV-1 RNA &lt;400 c/mL at Week 24 and Week 48;  Absolute Values and Change From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Counts at Weeks 4 8 12 16 24 32 40 and 48;  Number of Participants With Indicated Post-Baseline HIV-associated Conditions Excluding Recurrences and Disease Progressions;  Number of Participants With the Indicated Post-Baseline Emergent Grade 1 to 4 Clinical Chemistry and Hematology Toxicities/Laboratory Adverse Events (AEs);  DTG PK Parameters Including Cmax Cmin C0 and C0_avg;  DTGPKParametersIncludingAUC(0-tau)|724|NCT01231516|October 2010
4660|Completed|Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer||Drug:AbirateroneAcetate;  Drug:Prednisone\Prednisolone|Interventional|Phase 3|Industry|The number and type of adverse events reported by the investigator or the patient.|2334|NCT01217697|November 2010
4661|Completed                  Has Results|A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis||Drug: ferric citrate ca acetate sevelamer carbonate placebo|Interventional|Phase 3|Industry|Change in Mean Serum Phosphorus From Baseline (Week 52) to the End of the Efficacy Assessment Period (EAP; Week 56);  Change in Mean Serum Ferritin From Baseline to Week 52;  Change in Mean Serum Transferrin Saturation (TSAT) From Baseline to the End of the Safety Assessment Period (Week 52);  IVIronAnalysis;  ESAAnalysis|441|NCT01191255|October 2010
4662|Terminated                  Has Results|A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn&apos;s Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence||Biological:Infliximab;  Drug:Placebo|Interventional|Phase 3|Industry|Percentage of Participants With Clinical Recurrence (CR) of Crohn&apos;s Disease (CD) Prior to or at Week 76;  Percentage of Participants With Endoscopic Recurrence of CD Prior to or at Week 76;  Percentage of Participants With Clinical Recurrence (CR) of Crohn&apos;s Disease (CD) Prior to or at Week 104|297|NCT01190839|November 2010
4663|Completed                  Has Results|A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy||Drug:DR-102|Interventional|Phase 3|Industry|All Users Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight Using the 7-Day Rule;  Typical-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight Using the 7-Day Rule;  Compliant-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight Using the 7-Day Rule;  All Users Life-Table Estimates of Pregnancy Rates Based on 28-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight;  Compliant-Use Life-Table Estimates of Pregnancy Rates Based on 28-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight;  Percentage of On-Drug Pregnancies in All Users by Body Weight Decile Groups Using the 7-Day Rule;  Percentage of On-Drug Pregnancies in Typical-Use by Body Weight Decile Groups Using the 7-Day Rule;  Percentage of On-Drug Pregnancies in Compliant-Use by Body Weight Decile Groups Using the 7-Day Rule;  Percentage of On-Drug Pregnancies in All Users by Body Mass Index (BMI) Decile Groups Using the 7-Day Rule;  Percentage of On-Drug Pregnancies in Typical-Use by Body Mass Index (BMI) Decile Groups Using the 7-Day Rule;  Percentage of On-Drug Pregnancies in Compliant-Use by Body Mass Index (BMI) Decile Groups Using the 7-Day Rule|2858|NCT01178125|August 2010
4664|Terminated|Antihypertensive Treatment of Acute Cerebral Hemorrhage-II||Drug:Nicardipinehydrochloride|Interventional|Phase 3|Other / NIH|A pragmatic streamlined randomized design to evaluate the efficacy of intensive SBP reduction and its effect on outcomes measures at 24 h 30 d and at 3 m from randomization in subjects with ICH;  Secondaryoutcomes;  SecondaryOutcomes|1000|NCT01176565|May 2011
4665|Completed|Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma||Drug:Gemzar(Gemcitabine);  Drug:TH-302|Interventional|Phase 2|Industry|Progression-freesurvival(PFS);  Objective response rate (confirmed and unconfirmed);  Durationofresponse;  StableDiseaserate;  Overall survival (OS) including 6- and 12-month survival;  Event-freesurvival;  SerumCA19-9responserate;  ChangeinpainintensityasmeasuredbyVASscore;  Changeinperformancestatus|165|NCT01144455|June 2010
4666|Terminated                  Has Results|Safety of Buprenorphine Transdermal Patch (BTDS) in Osteoarthritis Pain: a 52-Week Extension Phase||Drug:Buprenorphinetransdermalpatch|Interventional|Phase 3|Industry|The Number of Participants With Adverse Events as a Measure of Safety and Tolerability|196|NCT01135524|April 2004
4667|Active not recruiting|Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma||Biological:BleomycinSulfate;  Drug:DoxorubicinHydrochloride;  Drug:ProcarbazineHydrochloride;  Drug:VinblastineSulfate;  Drug:Dacarbazine;  Drug:Cyclophosphamide;  Drug:Etoposidephosphate;  Drug:prednisone;  Drug:RadiationTherapy;  Radiation:FludeoxyglucoseF-18;  Procedure:computedtomography;  Procedure:PositronEmissionTomography|Interventional|Phase 2|Other / NIH|Progression-freesurvival(PFS)at36months;  completeresponserate|149|NCT01132807|May 2010
4668|Terminated                  Has Results|Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma||Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;  Other:laboratorybiomarkeranalysis|Interventional|Phase 2|NIH|Progression-free Survival According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1;  OverallSurvival;  Percentage of Participants With Confirmed and Unconfirmed Complete or Partial Response;  Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs|36|NCT01120275|October 2010
4669|Terminated|A Study in Participants With Diabetic Kidney Disease||Drug:LY2382770;  Drug:Placebo|Interventional|Phase 2|Industry|Change in Serum Creatinine from baseline to 12 month endpoint;  Change in Urine Protein/Creatinine Ratio from baseline to 12 month endpoint;  PopulationPK;  Serum creatinine slope of change from baseline through 12 months|417|NCT01113801|July 2010
4670|Completed                  Has Results|Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected Antiretroviral Treatment-Naive Adults||Drug:COBI;  Drug:RTV;  Drug:ATV;  Drug:FTC/TDF;  Drug:COBIplacebo;  Drug:RTVplacebo|Interventional|Phase 3|Industry|Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 48;  Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 96;  Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 144;  Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 192;  ChangeFromBaselineinCD4CellCountatWeek48;  ChangeFromBaselineinCD4CellCountatWeek96;  Change From Baseline in CD4 Cell Count at Week 144;  Change From Baseline in CD4 Cell Count at Week 192|698|NCT01108510|April 2010
4671|Completed                  Has Results|Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Antiretroviral Treatment-Naive Adults||Drug:Stribild;  Drug:ATV;  Drug:Ritonavir;  Drug:FTC/TDF;  Drug:StribildPlacebo;  Drug:ATVPlacebo;  Drug:RTVPlacebo;  Drug:FTC/TDFPlacebo|Interventional|Phase 3|Industry|The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) &lt; 50 Copies/mL at Week 48;  The Percentage of Participants With Virologic Success Using the FDA-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 RNA &lt; 50 Copies/mL at Week 96;  The Percentage of Participants With Virologic Success Using the FDA-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 RNA &lt; 50 Copies/mL at Week 144;  The Percentage of Participants With Virologic Success Using the FDA-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 RNA &lt; 50 Copies/mL at Week 192;  The Percentage of Participants Achieving and Maintaining Confirmed HIV-1 RNA &lt; 50 Copies/mL at Week 48 Using the FDA-defined Time to Loss of Virologic Response (TLOVR) Algorithm;  The Change From Baseline in Cluster Determinant 4 (CD4) Cell Count at Weeks 48 96 144 and 192;  The Percentage of Participants With HIV-1 RNA &lt; 50 Copies/mL at Week 48|708|NCT01106586|April 2010
4672|Completed                  Has Results|Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome||Drug:ADPreceptorinhibitors|Observational||Industry|Percentage of Participants With Major Adverse Cardiovascular Events (MACE);  Factors Associated With Initial Adenosine Diphosphate (ADP) Receptor Inhibitor Selection at Enrollment;  Factors Associated With Initial ADP Receptor Inhibitor Selection at Enrollment: Pre-Procedure Hemoglobin;  Factors Associated With Initial ADP Receptor Inhibitor Selection at Enrollment: Duke Coronary Artery Disease (CAD) Index;  Percentage of Participants With Cumulative Severe or Moderate Bleeding Events;  Percentage of Participants With MACE and Who Had No Prior History of Transient Ischemic Attack (TIA)/Stroke Weigh &#8805;60 Kilograms (kg) and Are Age &lt;75 Years;  Percentage of Participants With MACE Over 1 6 and 15 Months;  Percentage of Participants With Definite or Probable Stent Thrombosis (ST) Events;  Resource Use Patterns Cumulative Total Medical Costs and Cost Effectiveness|12227|NCT01088503|March 2010
4673|Active not recruiting|Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer||Biological:Bevacizumab;  Drug:Capecitabine;  Drug:Carboplatin;  Other:LaboratoryBiomarkerAnalysis;  Drug:Oxaliplatin;  Drug:Paclitaxel;  Other:Quality-of-LifeAssessment|Interventional|Phase 3|NIH|Overallsurvival;  Incidence of adverse effects assessed by CTCAE version 4.0;  Progression-freesurvival;  QOL scores assessed using FACT-O TOI and FACT-GOG/Neurotoxicity 4;  ResponseratesassessedbyRECIST1.1|332|NCT01081262|October 2010
4674|Active not recruiting|Connect&#174; MM- The Multiple Myeloma Disease Registry|||Observational||Industry|Identify and summarize patterns in therapeutic regimens;  Identify and summarize patterns in therapeutic regimens and patient outcomes;  SummarizeEffectivenessofTreatmentRegimens;  Summarize health-related quality of life (HRQoL) relation to treatment regimens/sequence and clinical outcomes|3011|NCT01081028|September 2009
4675|Completed                  Has Results|Treatment of Erectile Dysfunction I||Drug:Udenafil;  Drug:Placebo|Interventional|Phase 3|Industry|Change in Erectile Function Domain Assessed by International Index of Erectile Function (IIEF) Baseline to Final Visit/Week 12 mITT (Modified Intent-to-Treat) LOCF (Last Observation Carried Forward);  Change in Sexual Encounter Profile (SEP) Question 2 Change From Baseline to Overall Study/Weeks 1-12 mITT;  Change in SEP Question 3 Change From Baseline to Overall Study/Weeks 1-12 mITT;  Global Assessment Questionnaire (GAQ) While Using the Study Medication Did You Feel That Your Erections Improved? (Yes Responders) Week 12/Final Visit mITT Population;  Change From Baseline to Week 12/Final Visit in Mean Patient Self-Assessment of Erection (PSAE) mITT Population;  Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Derived Score Subject Version Week 12/ Final Visit LOCF mITT Population;  Change in Satisfaction of Intercourse Domain Score Assessed by IIEF Baseline to Week 12/Final Visit mITT LOCF;  Change in Orgasmic Function Domain Score Assessed by IIEF Baseline to Week 12/Final Visit mITT LOCF;  Change in Sexual Desire Domain Score Assessed by IIEF Baseline to Week 12/Final Visit mITT LOCF;  Change in Overall Satisfaction Domain Score Assessed by IIEF Baseline to Week 12/Final Visit mITT LOCF;  Change in SEP Question 1 Change From Baseline to Overall/Weeks 1-12 mITT;  Change in SEP Question 4 Change From Baseline to Overall Study/Weeks 1-12 mITT;  Change in SEP Question 5 Change From Baseline to Overall/Weeks 1-12 mITT|618|NCT01037244|September 2009
4676|Completed                  Has Results|A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)||Drug:FF/GW642444InhalationPowder;  Drug:GW642444InhalationPowder|Interventional|Phase 3|Industry|Annual Rate of Moderate and Severe COPD Exacerbations Expressed as Least Square Mean;  Time to First Occurrence of Moderate or Severe COPD Exacerbation;  Annual Rate of Exacerbations Requiring Systemic/Oral Corticosteroids Expressed as Least Square Mean;  Change From Baseline in Trough FEV1 at Week 52 (Visit 11)|1635|NCT01017952|September 2009
4677|Completed                  Has Results|Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia||Drug:Placebo;  Drug:Milnacipran|Interventional|Phase 4|Industry|TimetoLossofTherapeuticResponse(LTR);  Time to Worsening in Patient Global Impression of Change (PGIC);  Time to Worsening in Multidimensional Assessment of Fatigue (MAF)|340|NCT01014585|November 2009
4678|Completed|Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma||Biological:Bevacizumab;  Drug:Docetaxel;  Biological:Filgrastim;  Drug:GemcitabineHydrochloride;  Biological:Pegfilgrastim;  Other:Placebo|Interventional|Phase 3|NIH|Durationofprogression-freesurvival;  Durationofoverallsurvival;  Frequency and severity of adverse effects as assessed by the CTCAE version 4.0;  ResponseasmeasuredbyRECIST1.1criteria|106|NCT01012297|November 2009
4679|Completed|Study of A3309 in Patients With Chronic Idiopathic Constipation||Drug:A3309|Interventional|Phase 2|Industry|Change from baseline in frequency of spontaneous bowel movements;  Responder analyses for complete spontaneous bowel movements;  Timetofirstbowelmovement|190|NCT01007123|November 2009
4680|Active not recruiting|Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia||Genetic:fluorescenceinsituhybridization;  Genetic:mutationanalysis;  Genetic:nucleicacidsequencing;  Genetic:polymerasechainreaction;  Genetic:westernblotting;  Other:flowcytometry;  Other:laboratorybiomarkeranalysis|Observational||Other / NIH|completeresponse;  prolongedprogression-freesurvival;  overallsurvival|600|NCT01005368|October 2009
